[
    {
        "id": "doc_0",
        "document": "Rapid communication on updated guidance on the management of tuberculosis in children and adolescents\n\nRapid communication on updated guidance on the management of tuberculosis in children and adolescents\n\nISBN 978-92-4-003345-0 (electronic version) ISBN 978-92-4-003346-7 (print version)"
    },
    {
        "id": "doc_1",
        "document": "\u00a9 World Health Organization 2021\n\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo)."
    },
    {
        "id": "doc_2",
        "document": "Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add"
    },
    {
        "id": "doc_3",
        "document": "the following disclaimer along with the suggested citation: \u201cThis translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition\u201d."
    },
    {
        "id": "doc_4",
        "document": "Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).\n\nSuggested citation. Rapid communication on updated guidance on the management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.\n\nCataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris."
    },
    {
        "id": "doc_5",
        "document": "Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing."
    },
    {
        "id": "doc_6",
        "document": "Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party- owned component in the work rests solely with the user."
    },
    {
        "id": "doc_7",
        "document": "General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement."
    },
    {
        "id": "doc_8",
        "document": "The mention of specific companies or of certain manufacturers\u2019 products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters."
    },
    {
        "id": "doc_9",
        "document": "All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\nBackground"
    },
    {
        "id": "doc_10",
        "document": "Children and young adolescents (aged from 0 - 14 years; for monitoring and evaluation purposes collectively referred to as children1) represent approximately 12% of all tuberculosis (TB) patients globally, with 1.2 million children becoming ill with TB every year, and 230,000 estimated to have died of TB in 2019.2 Between 25,000 and 32,000 children are estimated to develop multi-drug resistant TB (MDR-TB) every year.3, 4 Over half of the children with TB are not diagnosed or are not reported."
    },
    {
        "id": "doc_11",
        "document": "This case detection gap is largest in young children; 65% of children aged below 5 years of age are not detected. As well, only one third of household contacts aged below 5 who were eligible for TB preventive treatment (TPT) in 2019 received it.2"
    },
    {
        "id": "doc_12",
        "document": "The political declaration of the 2018 United Nations General Assembly High Level Meeting on the Fight Against TB commits, among others, to diagnosing and treating 40 million people with TB, including 3.5 million children, and 1.5 million people with drug-resistant TB, including 115,000 children.5 It also commits to providing at least 30 million people - including 4 million children under 5 years of age, 20 million other household contacts (including children over the age of 5 years) and 6"
    },
    {
        "id": "doc_13",
        "document": "million people living with HIV (including children) - with TB preventive treatment by 2022.5 In order to achieve these ambitious targets, there is an urgent need to improve prevention, diagnosis, treatment and care for children and adolescents with TB or at risk of developing it."
    },
    {
        "id": "doc_14",
        "document": "To support countries in responding to the challenges of TB, WHO\u2019s Global Tuberculosis Programme develops guidance on prevention, diagnosis, treatment, and care of people with TB, including for children and adolescents. The first edition of Guidance for national tuberculosis programmes on the management of tuberculosis in children was published in 2006, after which a Rapid Advice on the treatment of tuberculosis in children was released in 2010. In 2014, WHO published the second edition of the"
    },
    {
        "id": "doc_15",
        "document": "Guidance for national tuberculosis programmes on the management of tuberculosis in children. Since 2014, several recommendations pertaining to the management of TB in children and adolescents have been published in guidelines issued by WHO\u2019s Global Tuberculosis Programme."
    },
    {
        "id": "doc_16",
        "document": "Since the publication of the previous guidelines, critical gaps have been identified in diagnostic approaches for TB in children, the optimal duration of treatment for children with non-severe, drug- susceptible TB, treatment regimens for drug-resistant TB and TB meningitis, as well as optimal models of care for the delivery of child and adolescent TB services. In light of new evidence on these topics available to WHO\u2019s Global Tuberculosis Programme in 2021, and aligned with requests from Member"
    },
    {
        "id": "doc_17",
        "document": "States, WHO convened a Guideline Development Group (GDG) to examine the evidence in order to"
    },
    {
        "id": "doc_18",
        "document": "1 Children (aged 0-9 years) and young adolescents (aged 10-14 years) are referred to as children in this section based on historical surveillance definitions. However, in 2020, WHO\u2019s Global Tuberculosis Programme asked countries to report data on national notifications for more disaggregated age groups (0\u20134, 5\u20139, 10\u201314 and 15\u201319 years, compared with the previous groupings of 0\u20134 and 5\u201314 years."
    },
    {
        "id": "doc_19",
        "document": "2 Global Tuberculosis Report 2020. 2020. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/tb/publications/global_report/en/\n\n3 Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. The Lancet Infectious Diseases. 2016;16(10):1193-201 (http://dx.doi.org/10.1016/S1473-3099(16)30132-3.\n\nAW, Yuen CM, Parr JB, Keshavjee S,\n\nmultidrug-resistant\n\nHE,"
    },
    {
        "id": "doc_20",
        "document": "CM et\n\ndisease in children: systematic review and global estimates. The Lancet. 2014;383(9928):1572-9.\n\n5 Political declaration of the UN General-Assembly High-Level Meeting on the Fight Against Tuberculosis.\n\nhttps://www.who.int/publications/m/item/political-declaration-of-the-un-general-assembly-high-level-meeting-on-the-fight- against-tuberculosis\n\n1"
    },
    {
        "id": "doc_21",
        "document": "update the 2014 Guidance for national tuberculosis programmes on the management of tuberculosis in children. The GDG met in virtual sessions from 31 May to 17 June 2021 and proposed several new recommendations related to the management of TB in children and adolescents.6"
    },
    {
        "id": "doc_22",
        "document": "Following on from the GDG meeting, the preparation of consolidated WHO guidelines on the management of TB in children and adolescents, including the new recommendations as well as existing recommendations and a related operational handbook are underway. Both documents are expected to be released by the end of the year and will become available on the WHO Global Tuberculosis Programme\u2019s knowledge sharing platform in Module 5: Co-morbidities, vulnerable populations and people-centred care:"
    },
    {
        "id": "doc_23",
        "document": "Management of tuberculosis in children and adolescents."
    },
    {
        "id": "doc_24",
        "document": "This Rapid Communication is being issued to help national TB programmes and other stakeholders prepare for the changes that will be introduced in the new consolidated WHO guidelines on the management of TB in children and adolescents. Full implementation of the recommendations will only be possible after the new guidance is published by WHO, as the guidelines and operational handbook will address a range of implementation considerations.\n\nKey findings"
    },
    {
        "id": "doc_25",
        "document": "Diagnostic approaches in children aged below 10 years\n\nIntegrated treatment decision algorithms"
    },
    {
        "id": "doc_26",
        "document": "Various algorithms and scoring systems for the diagnosis of TB in children are currently in use, but these have not been systematically evaluated. To overcome the large case detection gap, especially in children under 10 years of age, evidence-based, pragmatic treatment decision algorithms are needed, ideally for different settings with varying access to diagnostic tests and chest radiography, as well as for children with co-morbidities, such as HIV infection. A review of individual patient data"
    },
    {
        "id": "doc_27",
        "document": "(IPD) from diagnostic evaluation studies (comprising 14 cohorts from 13 countries, with 4811 participants) was conducted to assess the sensitivity and specificity of existing treatment decision algorithms designed to detect pulmonary TB, which was defined according to a pre-specified clinical case definition.7 Each of these algorithms was compared to an algorithm considered to align closest to the current standard of care for diagnosing TB in children.8 The sensitivity of the algorithms ranged"
    },
    {
        "id": "doc_28",
        "document": "from 16% (95% CI: 9-27%) to 95% (95% CI: 88-98%) and specificity ranged from 9% (95% CI: 3-24%) to 89% (95% CI: 80-95%). Algorithms with a high sensitivity had a low specificity and vice versa. The standard of care algorithm had a sensitivity of 65% (95% CI: 52-76%) and a specificity of 64% (95% CI: 44-80%)."
    },
    {
        "id": "doc_29",
        "document": "The use of Xpert Ultra in gastric aspirate and stool samples\n\nThe Xpert MTB/RIF Ultra cartridge (Cepheid, Sunnyvale, USA), hereafter referred to as Xpert Ultra, was developed as the next-generation assay to overcome the suboptimal sensitivity in smear-negative TB patients when using the Xpert MTB/RIF assay. Existing WHO recommendations support the use of the"
    },
    {
        "id": "doc_30",
        "document": "6The focus population for this guideline is children and adolescents, defined as: A child is a person under 10 years of age (0-9 years); An adolescent is a person 10-19 years of age (inclusive).\n\n7 Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S179-87. doi: 10.1093/cid/civ581"
    },
    {
        "id": "doc_31",
        "document": "8 The International Union Against Tuberculosis and Lung Disease. The Union\u2019s desk guide for diagnosis and management of TB in children. Third edition. 2016. Paris, France: The International Union Against Tuberculosis and Lung Disease.\n\n2"
    },
    {
        "id": "doc_32",
        "document": "Xpert Ultra assay in sputum and naso-pharyngeal aspirate samples in children for the diagnosis of TB and rifampicin resistance, in addition to the use of Xpert MTB/RIF cartridge (Cepheid, Sunnyvale, USA) in sputum, gastric aspirate, naso-pharyngeal aspirate and stool.9 The diagnostic accuracy of Xpert Ultra in gastric aspirate and stool samples for the diagnosis of pulmonary TB and rifampicin resistance against a microbiological reference standard (solid or liquid culture) was assessed in a"
    },
    {
        "id": "doc_33",
        "document": "systematic review and meta-analysis. The review included six studies involving 659 participants for gastric aspirate samples and six studies involving 1278 participants for stool samples. Studies were from nine countries (including four high TB and five high TB-HIV burden countries). The sensitivity of Xpert Ultra for detection of Mycobacterium tuberculosis was 64% (95% CI: 48 to 77%) in gastric aspirate samples and 53% (95% CI: 35 to 70%) in stool samples. The specificity was 95% in gastric"
    },
    {
        "id": "doc_34",
        "document": "aspirate samples (95% CI: 84 to 99%) and 98% in stool (CI: 93 to 99%). The benefit of detecting rifampicin resistance using Xpert Ultra was extrapolated from adult data."
    },
    {
        "id": "doc_35",
        "document": "Treatment shortening in children and adolescents with non-severe tuberculosis"
    },
    {
        "id": "doc_36",
        "document": "Evidence from the SHINE trial (Shorter Treatment for Minimal Tuberculosis in Children)10 was reviewed by the GDG. The SHINE trial was an open-label treatment-shortening trial in children with non-severe, symptomatic, presumed drug-susceptible, smear-negative TB, conducted in Uganda, Zambia, South Africa and India. Children aged below 16 years were randomised to 16- versus 24-weeks of standard first-line anti-tuberculosis treatment, using WHO pre-qualified paediatric fixed-dose combination"
    },
    {
        "id": "doc_37",
        "document": "formulations composed of TB medicines in ratios that are aligned with WHO-recommended dosing for children. The primary efficacy outcomes reviewed by the GDG were death by 72 weeks, treatment failure and loss-to-follow-up. The primary safety outcome was grade \u22653 adverse events observed during treatment. The 4-month treatment regimen was non-inferior to the 6-month regimen for children treated for non-severe, smear-negative TB, presumed to be drug susceptible. Non-inferiority was consistent across"
    },
    {
        "id": "doc_38",
        "document": "all key analyses (including age groups, HIV status, type of TB and adherence)."
    },
    {
        "id": "doc_39",
        "document": "The use of bedaquiline and delamanid for the treatment of rifampicin-resistant and multi-drug resistant TB in children\n\nThe use of bedaquiline in children aged below six years"
    },
    {
        "id": "doc_40",
        "document": "Bedaquiline is a core component of both shorter all-oral regimens as well as longer regimens recommended by WHO for the treatment of multidrug- or rifampicin-resistant tuberculosis (MDR/RR- TB) for children aged 6 years and above.11 The recommendations that apply to children are conditional and based on extrapolation of efficacy data in adults, in combination with pharmacokinetic (PK) and safety data from phase II trials for children aged 6-17 years."
    },
    {
        "id": "doc_41",
        "document": "9 WHO consolidated guidelines on tuberculosis. Module 3: diagnosis \u2013 rapid diagnostics for tuberculosis detection. 2021 update. Geneva, Switzerland: World Health Organization. Available at:\n\nhttps://apps.who.int/iris/rest/bitstreams/1354562/retrieve"
    },
    {
        "id": "doc_42",
        "document": "10 Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018 Apr 19;19(1):237. doi: 10.1186/s13063-018-2608-5. 11 WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. 2020. Geneva: World Health Organization. Available at: https://apps.who.int/iris/rest/bitstreams/1280998/retrieve\n\n3"
    },
    {
        "id": "doc_43",
        "document": "Data from two phase II trials (TMC207-C21112 and IMPAACT P110813) were reviewed by the GDG. Data from TMC207-C211 corresponded to children aged 5 to 18 years and IMPAACT P1108 included children aged 0-6 years; therefore, the review of PK and safety data focused mainly on data from IMPAACT P1108. Although the sample size was small (N= 12), the GDG concluded that in children 0-6 years of age, there were no cardiac safety signals distinct from those reported in adults. Population PK models from"
    },
    {
        "id": "doc_44",
        "document": "both studies suggest that drug exposures observed in adults can be reached in most children receiving bedaquiline, although some dose modification may be necessary depending on the age and weight of the child."
    },
    {
        "id": "doc_45",
        "document": "In addition, data from a paediatric drug resistant (DR)-TB IPD were analysed descriptively (24,231 records from all six WHO regions, the majority from India and South Africa). Just under twenty thousand of these records were used for a matched analysis of treatment outcomes in children being treated for DR-TB. The analysis included 40 children aged below 6 years and 68 children aged 6-12 years who received bedaquiline. In the matched analysis, bedaquiline was significantly associated with"
    },
    {
        "id": "doc_46",
        "document": "shorter treatment duration and lower odds of injectable TB drug use. Although children aged less than six years receiving a bedaquiline based regimen had a lower proportion of successful treatment outcomes (75%) than those not receiving bedaquiline (84.1%), residual confounding (including confounding by indication) was thought to be likely."
    },
    {
        "id": "doc_47",
        "document": "The use of delamanid in children aged below three years\n\nSince 2018, WHO has conditionally recommended the use of delamanid for the treatment of MDR/RR- TB patients aged 3 years or more on longer regimens, based on extrapolation of efficacy data in adults, and trial data on PK and safety in children."
    },
    {
        "id": "doc_48",
        "document": "Data were reviewed by the GDG from a phase I, open-label, age de-escalation trial designed to assess the PK, safety, and tolerability of delamanid administered twice daily for 10 days in children with MDR/RR-TB on treatment with an optimized background regimen (protocol 242-12-232) and from the corresponding open-label extension study (protocol 242-12-233).14 Data from cohorts 1 (age 12-17 years), 2 (age 6-11 years), 3 (age 3-5 years) and 4 (age 0-2 years) for both protocols were reviewed."
    },
    {
        "id": "doc_49",
        "document": "Exposures in the 0-2 year age group were lower than those of patients aged 3 years and older, necessitating a modelling/simulation approach to dosing. No cardiac safety signals distinct from those reported in adults were observed in children 0-2 years of age. However, these findings were based on the fact that children received lower drug exposures comparable to adults. Pharmacodynamic simulations suggested that clinically meaningful changes in QT (i.e., prolongation) would be unlikely in"
    },
    {
        "id": "doc_50",
        "document": "children under 3 years of age, even if higher doses were used to reach drug exposures comparable to"
    },
    {
        "id": "doc_51",
        "document": "12 A Phase II, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti- mycobacterial Activity of TMC207 in Combination With a Background Regimen of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the Treatment of Children and Adolescents 0 Months to <18 Years of Age Who Have Confirmed or Probable Pulmonary MDR-TB. Available at: https://clinicaltrials.gov/ct2/show/NCT02354014"
    },
    {
        "id": "doc_52",
        "document": "13 Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability, of Bedaquiline in Combination with optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) on in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease. Available at: https://www.impaactnetwork.org/studies/p1108 14 A Phase I, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC"
    },
    {
        "id": "doc_53",
        "document": "67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background"
    },
    {
        "id": "doc_54",
        "document": "Regimen of Anti-tuberculosis Drugs. Available at: https://clinicaltrials.gov/ct2/show/NCT01856634\n\nA Phase II, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC- 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti- tuberculosis Drugs Over a 6-Month Treatment Period. Available at: https://clinicaltrials.gov/ct2/show/NCT01859923\n\n4"
    },
    {
        "id": "doc_55",
        "document": "those achieved in adults. The paediatric DR-TB IPD included only 7 children aged below 3 years treated with delamanid, 14 children aged 3-6 years, and 69 children aged 6-12 years. All 7 children aged below 3 years were successfully treated. The number of patients was insufficient for a matched analysis.\n\nTreatment of TB meningitis in children and adolescents"
    },
    {
        "id": "doc_56",
        "document": "TB meningitis (TBM) is the most serious and the second most common form of extrapulmonary TB in children and adolescents. Without timely diagnosis and treatment, TBM is fatal and treatment outcomes are often poor even when treatment is provided.15 For children aged 0 to 10 years, WHO currently recommends a treatment regimen of twelve months, consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol given daily for the first two months, followed by isoniazid and rifampicin given daily for"
    },
    {
        "id": "doc_57",
        "document": "ten additional months (2HRZE/10HR). The recommendation on the use of the 12-month regimen was based on a literature review conducted in 2009, largely based on non-randomized, non-comparative studies, which were not entered into GRADE (Grading of Recommendations, Assessment Development and Evaluation), given the lack of comparative data.16"
    },
    {
        "id": "doc_58",
        "document": "A systematic review and meta-analysis was conducted to compare the effectiveness of a shorter, intensive regimen (using daily isoniazid, rifampicin, pyrazinamide, and ethionamide throughout for six months - 6HRZEto) versus the WHO-recommended twelve-month regimen. Dosing of isoniazid and rifampicin in the intervention regimen was slightly higher compared to the comparator regimen.17 The shorter intensive regimen (3 studies, involving 724 participants) had a death rate of 8.0% (95% CI: 2- 13%)"
    },
    {
        "id": "doc_59",
        "document": "versus 24.0% (95% CI: 18-32%) for the 12-month regimen (3 studies, 282 participants). Treatment success for the shorter intensive regimen was 83% (95% CI: 74-99%) versus 75% for the 12-month regimen (95% CI: 69-81%). Neurological sequelae occurred in 66% of survivors (95% CI: 55-75%) who received the shorter intensive regimen versus 36% (95% CI: 30-43%) in the 12-month regimen. Survival without neurological sequelae was 28% (95% CI: 20-41%) versus 48% (95% CI: 42-54%) for patients who received"
    },
    {
        "id": "doc_60",
        "document": "the shorter intensive regimen and the 12-month regimen, respectively. The GDG members noted the small number of studies and the potential for residual confounding."
    },
    {
        "id": "doc_61",
        "document": "Models of care for case detection and provision of TB preventive treatment in children and adolescents"
    },
    {
        "id": "doc_62",
        "document": "Capacity for paediatric TB care is often highly centralized at the secondary or tertiary levels of the health care system, and children may present seriously ill at these services, after delays in accessing other services. Healthcare workers at the primary health care (PHC) level may have limited capacity and confidence in managing paediatric TB, although this is where most children with TB or at risk of TB initially seek care. In addition, TB screening is often not part of clinical algorithms"
    },
    {
        "id": "doc_63",
        "document": "for child health. There"
    },
    {
        "id": "doc_64",
        "document": "15 Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Oct;14(10):947-57. doi: 10.1016/S1473-3099(14)70852-7. Epub 2014 Aug 6. 16 WHO Rapid advice: Treatment of tuberculosis in children. Annex 1 - Evidence summary tables. 2010. Geneva, Switzerland: World Health Organization."
    },
    {
        "id": "doc_65",
        "document": "17 Daily dosages used in the 6 month intensive regimen were: isoniazid 20 mg/kg (maximum 400 mg), rifampicin 20 mg/kg (maximum 600 mg), pyrazinamide 40 mg/kg (maximum 2000 mg), ethionamide 20mg/kg (maximum 750mg). Daily dosages used in the 12 month standard regimen are: isoniazid 7-15 mg/kg, rifampicin 10-20 mg/kg, pyrazinamide 30-40 mg/kg, ethambutol 15-25 mg/kg.\n\n5"
    },
    {
        "id": "doc_66",
        "document": "are many missed opportunities for contact tracing, TB prevention, TB detection and TB care and management, often because of weak integration of child and adolescent TB services with other programmes and services. Decentralization and family-centred, integrated care are highlighted as one of ten key actions in the 2018 Roadmap Towards Ending TB in Children and Adolescents.18"
    },
    {
        "id": "doc_67",
        "document": "A systematic review was conducted to assess evidence on the impact of decentralized and family- centred, integrated approaches on case detection and the provision of TB preventive treatment (TPT). The evidence showed that combined health facility and community approaches (including improved diagnostic capacity in primary care and community outreach or screening services) increased the number of children and adolescents diagnosed with TB and decentralized services can increase the levels of TPT"
    },
    {
        "id": "doc_68",
        "document": "initiation. There was positive but limited evidence showing that different types of service integration increase TB case notifications in children and adolescents. Socio-economic support for families affected by TB was shown to improve TPT coverage and completion among children and adolescents as well."
    },
    {
        "id": "doc_69",
        "document": "Key updates\n\nBased on the evidence reviewed and considering the discussions, deliberations and decisions of the GDG, the key updates for the upcoming TB guidelines will include the following points:"
    },
    {
        "id": "doc_70",
        "document": "\u2022 In children aged below 10 years with presumptive pulmonary TB, treatment decision algorithms may be used to diagnose pulmonary TB. Bacteriological confirmation needs to be sought whenever possible, using available and recommended diagnostic tests and appropriate paediatric specimens. The choice of the treatment decision algorithm will depend on the specific population and available diagnostic tests. Practical guidance on treatment decision algorithms for different settings and populations will"
    },
    {
        "id": "doc_71",
        "document": "be included in the operational handbook which will be published alongside the guidelines."
    },
    {
        "id": "doc_72",
        "document": "\u2022 In children aged below 10 years with signs and symptoms of pulmonary TB, the latest evidence reviewed supports the use of Xpert MTB/ RIF Ultra in gastric aspirate or stool specimens as the initial diagnostic test for TB and the detection of rifampicin resistance, rather than smear microscopy/culture and phenotypic drug susceptibility testing (DST). This is in addition to sputum or naso-pharyngeal aspirate specimens, which are already recommended by WHO for Xpert Ultra testing, in the same"
    },
    {
        "id": "doc_73",
        "document": "population.19"
    },
    {
        "id": "doc_74",
        "document": "In children and adolescents under 16 years of age with non-severe, presumed drug-susceptible TB, a 4-month regimen (2HRZ(E)/2HR) should be used rather than the standard 6-month regimen (2HRZ(E)/4HR). Important implementation considerations were noted to determine eligibility for the shorter treatment regimen and will be described in the consolidated guidelines and in the operational handbook.\n\n\u2022 In children with MDR/ RR-TB of all ages:"
    },
    {
        "id": "doc_75",
        "document": "18 Roadmap towards ending TB in children and adolescents: second edition. 2018. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/iris/bitstream/handle/10665/274374/9789241514668-eng.pdf 19 WHO consolidated guidelines on tuberculosis. Module 3: diagnosis \u2013 rapid diagnostics for tuberculosis detection. . 2021. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/publications/i/item/9789240029415\n\n6"
    },
    {
        "id": "doc_76",
        "document": "o Bedaquiline may be used as part of the shorter, all oral bedaquiline-containing regimen (conditionally recommended by WHO in 202020) or as part of longer treatment regimens. o Delamanid may be used as part of longer treatment regimens.\n\no These recommendations make it possible to design all-oral regimens for children of all ages."
    },
    {
        "id": "doc_77",
        "document": "In children and adolescents with microbiologically confirmed or clinically diagnosed TB meningitis, presumed to be drug susceptible, a 6-month intensive regimen composed of 6HRZEto may be used as an alternative option to the WHO recommended 12-month regimen composed of 2HRZE/10HR. The existing strong recommendation for the 12-month regimen composed of 2HRZE/10HR remains in place."
    },
    {
        "id": "doc_78",
        "document": "\u2022 In high TB burden settings, decentralized and family-centred, integrated services may be implemented to improve TB case detection and the uptake of TB preventive treatment. In this context, decentralized services do not replace centralized or specialized child and adolescent TB services, rather, they complement them.\n\nNext steps"
    },
    {
        "id": "doc_79",
        "document": "\u2022 The updated recommendations will be released as the WHO consolidated guidelines on tuberculosis: Module 5: Co-morbidities, vulnerable populations and people-centred care: Management of tuberculosis in children and adolescents by the end of 2021. These guidelines will consolidate the updated recommendations and all relevant WHO guidance on the management of TB in children and adolescents and will include detailed results of the evidence that was reviewed, as well as GDG processes. The summary"
    },
    {
        "id": "doc_80",
        "document": "of findings and evidence to decision tables will be produced in conformity with the GRADE method and will be made available on the WHO Global Tuberculosis Programme website. The guidelines will be translated into French, Spanish and Russian."
    },
    {
        "id": "doc_81",
        "document": "\u2022 The guidelines will be accompanied by an operational handbook. This document will provide operational guidance on the new recommendations, including treatment decision algorithms for use in various settings and populations, eligibility criteria for shorter treatment regimens for children with non-severe, drug-susceptible TB, practical advice on building treatment regimens for children with MDR/RR- TB who are not eligible for shorter all-oral bedaquiline-containing regimens, and examples of"
    },
    {
        "id": "doc_82",
        "document": "models of care from various settings, among other topics. The content and structure of the operational handbook, as well as the preferred methods for dissemination of both the guidelines and the operational handbook will be informed by feedback collected by WHO\u2019s Global Tuberculosis Programme from National TB Programmes, technical partners and other key stakeholders through an online survey conducted between April and June 2021."
    },
    {
        "id": "doc_83",
        "document": "\u2022 WHO\u2019s Global Tuberculosis Programme will also undertake the following additional consultations to further inform the guidelines and operational handbook:\n\no on dosing of bedaquiline and delamanid in younger age groups (0-6 and 0-3 years, respectively, taking into account the availability of child-friendly formulations), as well as the shorter intensive regimen for TB meningitis"
    },
    {
        "id": "doc_84",
        "document": "20 WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. 2020. Geneva, Switzerland: World Health Organization. Available at: https://apps.who.int/iris/rest/bitstreams/1280998/retrieve\n\n7\n\no the classification of intrathoracic TB in children (currently intrathoracic lymphadenopathy is classified as extra-pulmonary TB)."
    },
    {
        "id": "doc_85",
        "document": "\u2022 The release of the new guidelines and operational handbook will be followed by a series of WHO webinars for different regions to communicate the recommendations and implementation considerations. The new recommendations on the management of TB in children and adolescents will be included in the online knowledge sharing platform that WHO\u2019s Global Tuberculosis Programme has launched in June 2021, which provides access to all WHO guidelines, operational handbooks and eLearning tools.21 The"
    },
    {
        "id": "doc_86",
        "document": "webinars and the online knowledge sharing platform will support countries to update their national guidelines, train staff, inform programme budgets and facilitate rapid transition to scale up interventions to improve the prevention, diagnosis and management of TB in children and adolescents."
    },
    {
        "id": "doc_87",
        "document": "Acknowledgements\n\nWHO gratefully acknowledges the work of the GDG members, the evidence reviewers, national TB programmes, WHO staff, technical and funding partners, community and civil society representatives, patients and their care-givers, as well as all others who contributed to the data to inform this guideline update.\n\n21 WHO Global Tuberculosis Programme\u2019s knowledge sharing platform is accessible at: https://tbksp.org/en/home\n\n8\n\n\u00a2 /) = Y v 74 N \u2018\\. > V N"
    },
    {
        "id": "doc_88",
        "document": "World Health Organization\n\nWorld Health Organization Global Tuberculosis Programme Avenue Appia 20, CH-1211 Geneva-27, Switzerland\n\n9789240033450 I\n\nglobal TUBERCULOSIS REPORT\n\n\u00a3 ENDTB,\n\nGlobal tuberculosis report 2023\n\n4 Word Health & Organization\n\ni\n\nGlobal tuberculosis report 2023\n\nISBN 978-92-4-008385-1 (electronic version) ISBN 978-92-4-008386-8 (print version)"
    },
    {
        "id": "doc_89",
        "document": "\u00a9 World Health Organization 2023\n\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC- SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo)."
    },
    {
        "id": "doc_90",
        "document": "Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropri- ately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Crea- tive Commons licence. If you create a translation of this work, you should"
    },
    {
        "id": "doc_91",
        "document": "add the following disclaimer along with the suggested citation: \u201cThis translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition\u201d."
    },
    {
        "id": "doc_92",
        "document": "Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).\n\nSuggested citation. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.\n\nCataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/."
    },
    {
        "id": "doc_93",
        "document": "Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders. To submit requests for com- mercial use and queries on rights and licensing, see https://www.who.int/copyright."
    },
    {
        "id": "doc_94",
        "document": "Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user."
    },
    {
        "id": "doc_95",
        "document": "General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement."
    },
    {
        "id": "doc_96",
        "document": "The mention of specific companies or of certain manufacturers\u2019 products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters."
    },
    {
        "id": "doc_97",
        "document": "All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\nDesigned by minimum graphics\n\nCover design by Irwin Law"
    },
    {
        "id": "doc_98",
        "document": "Contents\n\nAcknowledgements Abbreviations 1. Introduction 2. Global TB commitments, strategy and targets 3. Main findings and messages 4. Conclusions References Annex 1. Basic facts about TB Annex 2. Data sources and access Annex 3. WHO global lists of high TB burden countries Annex 4. Country, regional and global profiles Annex 5. Updates to estimates of TB disease burden Annex 6. The WHO TB-SDG monitoring framework vii xiii 1 3 6 39 40 43 45 47 50 51 55\n\niii\n\n3; W& -, T"
    },
    {
        "id": "doc_99",
        "document": "Dr Tedros Adhanom Ghebreyesus Director-General World Health Organization\n\n\u201c For millennia, our ancestors have suffered and died with tuberculosis, without knowing what it was, what caused it, or how to stop it. Today, we have knowledge and tools they could only have dreamed of. We have political commitment, and we have an opportunity that no generation in the history of humanity has had: the opportunity to write the final chapter\n\n= \u00a2 < 7"
    },
    {
        "id": "doc_100",
        "document": "Dr Tereza Kasaeva Director WHO Global Tuberculosis Programme\n\n\u201c We have strong commitments with concrete targets, made by world leaders in the political declaration of the second UN high-level meeting on TB, which provide a strong impetus to accelerate the TB response. This report provides key data and evidence about the status of the TB epidemic and a review of progress, which can inform the translation of these commitments and targets into action in countries. We need all\n\nv"
    },
    {
        "id": "doc_101",
        "document": "Acknowledgements\n\nThe Global tuberculosis report 2023 was produced by a core team of 13 people in the WHO Global Tubercu- losis Programme: Taghreed Adam, Annabel Baddeley, Mathieu Bastard, Saskia den Boon, Anna Dean, Dennis Falzon, Katherine Floyd, Nebiat Gebreselassie, Marek Lalli, Irwin Law, Peter Nguhiu, Hazim Timimi and Takuya Yamanaka. The team was led by Katherine Floyd. Over- all oversight was provided by the Director of the Global TB Programme, Tereza Kasaeva."
    },
    {
        "id": "doc_102",
        "document": "The data collection forms were developed by Haz- im Timimi, with input from staff throughout the WHO Global Tuberculosis Programme. Hazim Timimi led and organized all aspects of data and code management, including the preparation and implementation of the web system used for the 2023 round of global tubercu- losis (TB) data collection from 215 countries and areas, with support from Simone Gigli and Veemalla Thevi."
    },
    {
        "id": "doc_103",
        "document": "Data were reviewed by the following people at WHO headquarters: Annabel Baddeley, Mathieu Bastard, Saskia den Boon, Annemieke Brands, Anna Dean, Den- nis Falzon, Medea Gegia, Lic\u00e9 Gonzalez Angulo, Avinash Kanchar, Alexei Korobitsyn, Marek Lalli, Cecily Miller, Francis Mhimbira, Carl-Michael Nathanson, Peter Ngu- hiu, Linh Nguyen, Liana Oganezova, Cicilia Gita Parwati, Samuel Schumacher, Lana Syed, Hazim Timimi, Sabine Verkuijl and Takuya Yamanaka. Financing data were also reviewed by Andrew"
    },
    {
        "id": "doc_104",
        "document": "Siroka (independent consult- ant). Data for the European Region were collected and validated jointly by the WHO Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC)."
    },
    {
        "id": "doc_105",
        "document": "The joint United Nations Programme on HIV/AIDS (UNAIDS) managed the process of data collection from national AIDS programmes and provided access to their TB/HIV dataset. Review and validation of TB/HIV data were both undertaken in collaboration with UNAIDS staff."
    },
    {
        "id": "doc_106",
        "document": "Doris Ma Fat from the WHO Mortality and Burden of Disease team provided data from the WHO Mortali- ty Database that were used to estimate TB mortality among HIV-negative people; and Juliana Daher and Mary Mahy (UNAIDS) provided epidemiological data that were used to estimate TB incidence and mortality among people with HIV.\n\nThe report is designed to optimize web or app-based access and use and has three major components: a core report document that focuses on the main findings and"
    },
    {
        "id": "doc_107",
        "document": "messages; webpages containing more detailed and digitized content, which are organized by topic area (comprising six standard topics and six featured top- ics); and a mobile app containing country, regional and global profiles as well as two slide-sets. Many people contributed to these three report components. Unless specified, those named below work in the WHO Global Tuberculosis Programme."
    },
    {
        "id": "doc_108",
        "document": "The production of the core report document was coordinated by Katherine Floyd and Irwin Law. The main text was written by Katherine Floyd, with contributions from Taghreed Adam, Mathieu Bastard, Nebiat Gebre- selassie and Takuya Yamanaka. Irwin Law organized the preparation of all figures and tables, which were produced by Taghreed Adam, Mathieu Bastard, Saskia den Boon, Anna Dean, Peter Dodd (Sheffield University, United Kingdom of Great Britain and Northern Ireland), Dennis Falzon, Irwin Law,"
    },
    {
        "id": "doc_109",
        "document": "Peter Nguhiu, Andrew Siroka (independent consultant), Hazim Timimi and Takuya Yamanaka. Annexes 1, 3 and 6 were prepared by Kather- ine Floyd; Annexes 2 and 4 by Hazim Timimi; and Annex 5 by Mathieu Bastard, Anna Dean and Katherine Floyd, with inputs from Nimalan Arinaminpathy (Imperial Col- lege London, United Kingdom)."
    },
    {
        "id": "doc_110",
        "document": "The report webpages include content for six standard topics. These are: 1) TB disease burden, comprising TB incidence (prepared by Mathieu Bastard and Katherine Floyd), TB mortality (prepared by Mathieu Bastard and Katherine Floyd), drug-resistant TB (prepared by Anna Dean, Peter Dodd and Hazim Timimi) and national TB prevalence surveys (prepared by Katherine Floyd and Irwin Law); 2) TB diagnosis and treatment, prepared by Katherine Floyd and Takuya Yamanaka, with contribu- tions from Nazir"
    },
    {
        "id": "doc_111",
        "document": "Ismail and Fuad Mirzayev; 3) TB pre- vention and screening, prepared by Annabel Baddeley, Saskia den Boon, Dennis Falzon and Hazim Timimi, with contributions from Avinash Kanchar and Cecily Miller; 4) Financing for TB prevention, diagnostic and treatment services, prepared by Taghreed Adam, Peter Nguhiu, Andrew Siroka (independent consultant) and Takuya Yamanaka, with contributions from Katherine Floyd; 5) Universal health coverage (UHC) and TB determinants, prepared by Takuya Yamanaka with"
    },
    {
        "id": "doc_112",
        "document": "contributions from Taghreed Adam, Delia Boccia (London School of Hygiene and Tropical Medicine, United Kingdom), Kath- erine Floyd and Ernesto Jaramillo; and 6) TB research and innovation, prepared by Nebiat Gebreselassie and"
    },
    {
        "id": "doc_113",
        "document": "vii\n\nIrwin Law, with contributions from Saskia den Boon, Dennis Falzon, Katherine Floyd, Medea Gegia, Nazir Ismail, Alexei Korobitsyn, Cecily Miller, Fuad Mirzayev and Matteo Zignol. The interactive graphics that appear in the webpages, which allow users to visualize data values by hovering over data points, were prepared by Mathieu Bastard, Irwin Law, Peter Nguhiu, Hazim Timi- mi and Takuya Yamanaka."
    },
    {
        "id": "doc_114",
        "document": "The report team is very grateful to Nimalan Arinam- inpathy and Peter Dodd for their key contributions to the estimates of TB disease burden that are included in the core report document and the standard set of report webpages. Nimalan Arinaminpathy produced all estimates of TB incidence and mortality for the period 2020\u20132022 that were based on country or region-spe- cific dynamic models (26 and 23 countries, respective- ly). Peter Dodd produced global, regional and national estimates of the"
    },
    {
        "id": "doc_115",
        "document": "incidence of rifampicin-resistant TB (RR-TB) in the period 2015\u20132022, a global estimate of the incidence of isoniazid-resistant TB in 2022, a global estimate of the number of deaths caused by RR-TB in 2022 and age-sex disaggregated estimates for TB inci- dence and mortality at global, regional and country lev- els in 2022. The report team is also grateful to Philippe Glaziou (who led WHO\u2019s work related to TB disease burden estimation from 2008\u20132022) for his advice on the use, implementation and"
    },
    {
        "id": "doc_116",
        "document": "updating (as appropriate) of previous methods and codes; and to Sandip Mandal (John Snow India Private Limited) for his key role in the production of estimates of TB incidence and mortality for India."
    },
    {
        "id": "doc_117",
        "document": "The report webpages include content for six featured topics. These are: 1) the political declaration from the United Nations (UN) high-level meeting on TB that was held in September 2023, prepared by Nebiat Gebrese- lassie; 2) new treatment for drug-resistant TB, prepared by Fuad Mirzayev; 3) international donor funding for TB, prepared by Peter Nguhiu, with contributions from Taghreed Adam and Katherine Floyd; 4) TB in prisons, prepared by Kerri Viney, with contributions from Pedro Avedillo,"
    },
    {
        "id": "doc_118",
        "document": "Annabel Baddeley, Andrei Dadu, Katherine Floyd, Christian Gunneberg, Ernesto Jaramillo, Farai Mavhunga, Hazim Timimi and Askar Yedilbayev; 5) find- ings from recent TB epidemiological reviews in Nigeria and the United Republic of Tanzania, prepared by Marek Lalli and Charalambos Sismanidis, with contributions from Mathieu Bastard and Peter Nguhiu; and 6) multi- sectoral accountability in the TB response, prepared by Hannah Monica Dias, Tereza Kasaeva and Liana Ogan- ezova."
    },
    {
        "id": "doc_119",
        "document": "The report landing page and all of the other report webpages were prepared by Olivier Beauvais, Irwin Law, Hazim Timimi and Takuya Yamanaka, with overall guidance and oversight provided by Hazim Timimi and Patrick Tissot.\n\nThe technical appendix that explains the methods"
    },
    {
        "id": "doc_120",
        "document": "used to produce estimates of TB disease burden was prepared by Mathieu Bastard, Anna Dean, Hazim Timi- mi, Nimalan Arinaminpathy (Imperial College, London, United Kingdom) and Peter Dodd (University of Shef- field, United Kingdom)."
    },
    {
        "id": "doc_121",
        "document": "The data and other content provided in the mobile app were prepared by Katherine Floyd, Irwin Law and Hazim Timimi. The app was first developed by the WHO Global Tuberculosis Programme in collaboration with Adappt in 2019 and has subsequently been maintained by Adappt throughout the year and then updated on an annual basis. The report team is very appreciative of the excellent work done by Adappt."
    },
    {
        "id": "doc_122",
        "document": "The web-based versions of global, regional and coun- try profiles that are available via the report landing page were prepared by Hazim Timimi. Simplified versions for a more general audience were prepared by Hannah Monica Dias and Yi Wang."
    },
    {
        "id": "doc_123",
        "document": "The report team is grateful to various WHO staff outside the WHO Global Tuberculosis Programme for their useful comments and advice on advanced drafts of report content. Particular thanks are due to Bochen Cao and Wahyu Retno (Annet) Mahanani for their review of content related to estimates of TB disease burden; to Bochen Cao and Stephen MacFeely for their advice related to the methods used to produce estimates of TB mortality in India; to Elena Vovc for her review of content related to TB and"
    },
    {
        "id": "doc_124",
        "document": "HIV; and to Gabriela Flores Pentzke Saint-Germain for her review of material relat- ed to TB financing and UHC. The team is also grateful to various contributors outside WHO; in particular, Sophia Georghiou, Sandra Kik, Mikashmi Kohli, Morten Ruhwald, Zaid Tanvir, Margaretha de Vos and Jennifer Woolley for their contributions to and reviews of con- tent related to TB research and innovation."
    },
    {
        "id": "doc_125",
        "document": "The principal source of financial support for the report was the United States Agency for Internation- al Development (USAID). Data collection and analysis were also supported by the government of the Republic of Korea."
    },
    {
        "id": "doc_126",
        "document": "In addition to the core report team and those men- tioned above, the report benefited from inputs from many staff working in WHO regional and country offices and hundreds of people working for national TB pro- grammes or within national surveillance systems who contributed to the reporting of data and to the review of report material prior to publication. These people are listed below, organized by WHO region."
    },
    {
        "id": "doc_127",
        "document": "Among the WHO staff listed below, the report team is particularly grateful to Pedro Avedillo, Kenza Bennani, Vineet Bhatia, Martin Van Den Boom, Michel Gasana, Giorgi Kuchukhidze, Ernesto Montoro, Fukushi Morish- ita, Kalpeshsinh Rahevar, Md Kamar Rezwan, Manami Yanagawa and Askar Yedilbayev for their contribution to data collection and validation.\n\nviii\n\nGlobal tuberculosis report 2023\n\nWHO staff in regional and country offices\n\nWHO African Region"
    },
    {
        "id": "doc_128",
        "document": "Jean Louis Abena Foe, Jean de Dieu Iragena, Casimir Mingiedi Manzengo, Inacio Alvarenga, Nicole Anshambi, Claudina Augusto Da Cruz, Fekadeselassie Mikru Asfaw, Nay\u00e9 Bah, Nurbai Calu, Lastone Chitembo, Ndella Diakhate, Noel Djemadji-Oudjiel, Angelie Serge Patrick Dzabatou Babeaux, Ismael Endris, Zahra Fall Fatimetou, Louisa Ganda, Michel Gasana, Carolina Cardosa Da Silva Leite, Sirak Hailu Bantiewalu, Telesphore Houansou, Moses Jeuronlon, Y\u00e9ba Laconi Kaaga Epse Doleagbenou, Victoria Katawera,"
    },
    {
        "id": "doc_129",
        "document": "Nzuzi Katondi, Houria Khelifi, D\u00e9sir\u00e9 Aristide Komangoya- Nzonzo, Angela Katherine Lao Seoane, Sharmila Lareef-Jah, Winnie Low-Wah, Nomthandazo Lukhele, David Lukudu, Frank Lule, Johnson Lyimo, Tebogo Madidimalo, Abdoulaye Mariama Ba\u00efssa, Richard Mbumba Ngimbi, Tamba Jacques Millimouno, Nkateko Mkhondo, Laurent Moyenga, Ribakare Muhayimpundu, Francis Mupeta, Ahamada Nassuri, Andre Ndongosieme, Moses Mutebi Nganda, Mkhokheli Ngwenya, Denise Nkezimana, Ghislaine Nkone Asseko, Ajoy Nundoochan,"
    },
    {
        "id": "doc_130",
        "document": "Ishmael Nyasulu, Eunice Omesa, Amos Omoniyi Fadare, Mainuka Paul, Henintsoa Rabarijaona, Kafui Senya, Dani\u00e8le Simnoue, Evelyne Tibananuka, Siaka Toure, Hubert Wang, Addisalem Yilma, Assefash Zehai Kassahun."
    },
    {
        "id": "doc_131",
        "document": "WHO Region of the Americas"
    },
    {
        "id": "doc_132",
        "document": "Zohra Abaakouk, Monica Alonso, Angel Alvarez, Kleydson Alves, Miguel Angel Arag\u00f3n, Fiona Elizabeth Anthony, Pedro Avedillo, Valerie Beach-Horne, Edwin Bolastig, Susana Borroto, Ana Botello, Olivia Brathwaite, Gemma Chery, Rainier Escalada, Gloria Figueroa, Ingrid Garcia, Izola Garcia, Harry Geffrard, Guillermo Gonzalvez, Monica Guardo, Franklin Hernandez, Percy Halkyer, Reynold Hewitt, Ana Maria Jimenez, Sandra Jones, Job Joseph, Serene Joseph, Francisco Le\u00f3n, Rub\u00e9n Mayorga, Ernesto Montoro,"
    },
    {
        "id": "doc_133",
        "document": "Romeo Montoya, Jean Marie Reangabwoda, Oscar Martin Mesones, M\u00f3nica Rond\u00f3n, Enrique Perez Flores, Elizabeth Rodriguez, Grisel Rodriguez, Hans Salas, Maria Esther Salazar, Maria Jesus Sanchez, Prabhjot Singh, Nicole Helene Slack-Liburd, Katrina Smith, Aida Soto, Valeska Stempliuk, Jorge Victoria, Franka des Vignes, Marcelo Vila, Zerabruk Weres, Anneke Wilson."
    },
    {
        "id": "doc_134",
        "document": "WHO Eastern Mediterranean Region\n\nJaylan Abdeen, Mohamed Abukalish, Chinara Aidyralieva, Muhammad Akhtar, Ziad Aljarad, Mohammad Reza Aloudal, Kenza Bennani, Martin van den Boom, Gabriel Brun-Rambaud, Sally Elhawary, Nahla Gamaleldin, Salma Gouda, Hania Husseiny, Sindani Ireneaus Sebit, Santosha Kelamane, Adnan Khamisi, Khawaja Laeeq Ahmad, Ramzi Ouhichi, Fatouma Salem, Najib Thabet, Soumia Triki, Omid Zamani."
    },
    {
        "id": "doc_135",
        "document": "WHO European Region\n\nAndrei Dadu, Jamshid Gadoev, Gayane Ghukasyan, Tom Hiatt, Araksya Hovhannesyan, Giorgi Kuchukhidze, Artan Mesi, Andreea Teodora Popescu, Javahir Suleymanova, Sona Valiyeva, Askar Yedilbayev, Saltanat Yegeubayeva."
    },
    {
        "id": "doc_136",
        "document": "WHO South-East Asia Region\n\nVineet Bhatia, Maria Regina Christian, Anupama Hazarika, Faiha Ibrahim, Debashish Kundu, Jonathan Marbun, Khin Pa Pa Naing, O Nam Ju, Md Thet Naing Oo, Shushil Dev Pant, Malik Parmar, Kiran Rade, Ranjani Ramachandran, Jewel Rana, Md Kamar Rezwan, Nazis Arefin Saki, Preshila Samaraweera, Aye Thida, Khine Thet Su, Barsha Thapa, Sonam Wangdi, Ye Win Thein."
    },
    {
        "id": "doc_137",
        "document": "WHO Western Pacific Region\n\nNadhir Adi Azahar, Tsolmon Boldoo, Zhongdan Chen, Serongkea Deng, Philippe Guyant, Clarissa Blanca Halum, Lepaitai Hansell, Vibol Iem, Narantuya Jadambaa, Inthalaphone Keovichith, Fukushi Morishita, Anuzaya Purevdagva, Kalpeshsinh Rahevar, Challa Negeri Ruda, Joanne Saimon, Jacques Sebert, Chun Paul Soo, Somdeth Souksanh, Lia Tanabose, Subhash Yadav, Manami Yanagawa.\n\nNational respondents who contributed to reporting and verification of data\n\nWHO African Region"
    },
    {
        "id": "doc_138",
        "document": "Abderramane Abdelrahim Barka, Yaw Adusi-Poku, Dissou Affolabi, Felix Kwami Afutu, Arnaud Baurel Akiera, Sofiane Alihalassa, Soumana Alphazazi, Chukwuma Anyaike, Moses Arinaitwe, Robert Balama, Mamadou Pathe Balde, Ball\u00e9 Boubakar, Adama Marie Bangoura, Jorge Noel Barreto, Jos\u00e9 Benedita, Annie Prudence Bisso Ngono, Miguel Camara, Obioma Chijioke-Akaniro, Rhehab Chimzizi, Adjima Combary, Fatou Ti\u00e9p\u00e9 Coulibaly, Abdoul Karim Coulibaly, Muhammed Lamin Darboe, John Deng, Youssouf Diallo, Adama Diallo,"
    },
    {
        "id": "doc_139",
        "document": "Yacine Mar Diop, Ambr\u00f3sio Disadidi, Sicelo Dlamini, Themba Dlamini, Mohammed Fall Dogo, Antoine Etoundi Evouna, Juan Eyene Acuresila, Yakhokh Fall,"
    },
    {
        "id": "doc_140",
        "document": "Acknowledgements\n\nix"
    },
    {
        "id": "doc_141",
        "document": "Marta Freire, Herv\u00e9 Gildas Gando, Juach Philip Garang, Evariste Gasana, Belaineh Girma, Amanuel Hadgu Mebrahtu, Santiago Izco, Vincent Kamara, Elhadj Malick Kane, Clara Chola Kasapo, Michel Kaswa Kayomo, Immaculate Kathure, Fungai Kavenga, Mariam Keita, Colette Kinkela Bedi, David Korboi, Jacquemin Kouakou Kouakou, Taye Letta, Apal Toby Maduot, Llang Bridget Maama Maime, Raimundo Machava, Mariama Mahmoud, Jocelyn Mahoumbou, Dorothy Maloboka, Bheki Mamba, Str\u00e9dice Manguinga Guitouka, Olivia"
    },
    {
        "id": "doc_142",
        "document": "Mbitikon, Patrick Migambi, Tuduetso Molefi, Louine Morel, James Mpunga, Angel Mubanga, Lindiwe Mvusi, Judith Mzyece, Euphrasie Ndihokubwayo, Norbert Ndjeka, Peter Neema, Winnie Estelle Marie Nkana Yiki, Emmanuel Nkiligi, Tendai Nkomo, Jos\u00e9lyne Nsanzerugeze, Hiwet Nuguse, Franck-Hardain Okemba-Okombi, Abdelhadi Oumar, Emile Rakotondramanana, Harolalaina Rakotondrazanany, Thato Raleting Letsie, Reesual Ramprakash, Adulai Rodrigues, Aiban Ronoh, Wandifa Samateh, Agbenyegan Samey, Rufus Saye, Alzira"
    },
    {
        "id": "doc_143",
        "document": "Segunda Silva do Rosario, Pascal Selemani, Hilarius Shilomboleni, Siene Tienabe, Bakary Sirageou, Nicholas Siziba, Daniel Tollo, Andriamampilantohery Finarimahefa Tonimihamina, Abdallahi Traor\u00e9, Thusoyaone Titi Tsholofelo, Turyahabwe Stavia, Justine Zlahn."
    },
    {
        "id": "doc_144",
        "document": "WHO Region of the Americas"
    },
    {
        "id": "doc_145",
        "document": "Sarita Aguirre, Shalauddin Ahmed, Edwin Alexis Aizpurua, Xochil Alem\u00e1n de Cruz, Gabriela Amaya, Aisha Andrewin, Norma Leticia Artiles Milla, Carlos Alberto Marcos Ayala Luna, Carla Ayala Reyes, Patricia Bartholomay, Jose Calderon-Squiabro, Sandy Sorayda Cano Lemus, Shawn Charles, Karolyn April Chong Castillo, Angel Colon-Semidey, Eric Commiesie, Mariela Contrera, Yaren Cruz, Oscar Andres Cruz Martinez, Tracy Dalton, Jose Davy, Clara De la Cruz, Carlos Andres De la Rocha Guerra, Vladimir D\u00edaz,"
    },
    {
        "id": "doc_146",
        "document": "Fernanda Dockhorn Costa Johansen, Nadia Escobar Salinas, Mercedes Espa\u00f1a Cede\u00f1o, Hugo Fern\u00e1ndez, Cecilia Ruth Figueroa Benites, Clara Freile Gachet, Gail Gajadhar, Julio Garay Ramos, Anyeli Garcia, Neela Goswami, Claudia Guti\u00e9rrez, Patrice Hanna, Maria Henry, Jenny Hern\u00e1ndez, Ana Loyda Hesse, Ir\u00e1lice Jansen, Glenise Johnson, Diana Khan, Adam Langer, Diana Lawrence, F\u00e1tima Leticia Luna L\u00f3pez, Eug\u00e8ne Maduro, Andrea Yvette Maldonado Saavedra, Mar\u00eda de Lourdes Mart\u00ednez Olivares, Timothy McLaughlin-"
    },
    {
        "id": "doc_147",
        "document": "Munroe, Ang\u00e9lica Medina, Erin Miller, Richard Milo, Jeetendra Mohanlall, Francis Morey, Willy Morose, Pilar Mu\u00f1oz, Franchina Murillo Picado, Marcela Natiello, Jacqueline Newbold, Ayoola Oyinloye, Claudia Llerana Polo, Daniele Maria Pelissari, Tomasa Portillo Esquivel, Robert Pratt, Julia Rosa Maria Rios Vidal, Tyrone Roberts, Myrian Rom\u00e1n, Samanta Rosas, Arelisabel Ruiz Guido, Sateesh Sakhamuri, Wilmer Salazar, Pel\u00e1ez Maritza Samayoa, Karla Mar\u00eda S\u00e1nchez Mendoza, Julie Self, Natalia Sosa, Angela"
    },
    {
        "id": "doc_148",
        "document": "Starks, Alvarez Lourdes Suarez, Neil Trotman, Michelle Trotman, Aspiro Urbina, Melissa Valdez, Daniel V\u00e1zquez, Samuel Williams, Jennifer Wilson, Lorna Wilson, Oritta Zachariah."
    },
    {
        "id": "doc_149",
        "document": "WHO Eastern Mediterranean Region"
    },
    {
        "id": "doc_150",
        "document": "Idil Abdirahim Abdillahi, Suhaib Abu Failat, Shahnaz Ahmadi, Abdullatif Al Khal, Muna Yahya Alabed, Maha Alalawi, Abeer Albalawi, Mahmoud AlBaour, Qatmeer AlDolabi, Abdulbari Al-Hammadi, Nada Almarzouqi, Ehab Al-Sakkaf, Layth Al-Salihi, Haya Alsenan, Haleema Alserehi, Awatef Alshammeri, Kifah Alshaqeldi, Khalsa Al-Thulhli, Fatma Alyaquobi, Ghada Alzayani, Wagdy Amin, Mohamed Belkahla, Laila Bouhamidi, Imane Chelloufi, Joanne Daghfal, Driss Daoudi, Hend Farhat, Mohamed Furjani, Dia Hjaija, Arslan"
    },
    {
        "id": "doc_151",
        "document": "Hyder, Basharat Javed Khan, Ibrahim Maia, Khan Mohamad Mangal, Ahmed Mankhi, Badeeha Mansoor, Abderraouf Mansouri, Mahshid Nasehi, Yassir Piro, Radia Sabouni, Zia Samad, Eman Samir, Saeed Sharafi, Hiam Yaacoub, Moiah Zafari."
    },
    {
        "id": "doc_152",
        "document": "WHO European Region"
    },
    {
        "id": "doc_153",
        "document": "Malik Adenov, Irada Akhundova, Salihjan Alimov, Thomas Althaus, Ekkehardt Altpeter, Elena Arbuzova, Trude Arnesen, Zaza Avaliani, Emine Avci, \u00c1gnes Bakos, Snje\u017eana Br\u010dkalo, Isabel Carvalho, Mamuka Chincharauli, Nicoleta Valentina Cioran, Andrei Corloteanu, Valeriu Crudu, Edita Davidaviciene, Gerard de Vries, Ir\u00e8ne Demuth, Jelena Djakovic Devic, Anka Djuric, Camille Dorin, Mladen Duronjic, Margaret Fitzgibbon, Majlinda Gjocaj, Marta Gomes, Biljana Grbav\u010devi\u0107, Irina Gubankova, Gennady Gurevich,"
    },
    {
        "id": "doc_154",
        "document": "Jean-Paul Guthmann, Henrik Hansen, Ejebai Ishanova, Sarah Jackson, Gulnora Jalilova, Jerker Jonsson, Rovshen Jumaev, Olim Kabirov, Abdullaat Kadyrov, Anush Khachatryan, Naira Khachatryan, Dmitry Klimuk, Maria Korzeniewska-Kose\u0142a, Mitja Ko\u0161nik, Stefan Kr\u00f6ger, Nino Lomtadze, Stevan Lucic, Donika Mema, Zorica Nanovic, Edibe Nurzen Namli Bozkurt, Anne Negre, Rustam Nurov, Mihaela Obrovac, Joan O\u2019Donnell, Mary O\u2019Meara, Analita Pace Asciak, Nargiza Parpiyeva, Belma Paralija, Sivan Haia Perl, Ludin"
    },
    {
        "id": "doc_155",
        "document": "Philipp, Karolina Pilovska, Georgeta Gilda Popescu, Liudmyla Prylepina, Ieva Rimsane, Jerome Robert, Gerard Scheiden, Anita Seglina, Firuza Sharipova, Erika Slump, Hanna Soini, Ivan Solovic, Sergey Sterlikov, Maja Sto\u0161i\u0107, Ase Strand, Petra Svetina, Silva Tafaj, Danina Dohranovic Tafro, Sevinj Taghiyeva, Mariona Yana Terleyeva, Mariya Tyufekchieva, Shahnoza Usmonova, Tuneu Valls, Ruzica Vasiljevic, Irina Vasilyeva, Anne Vergison, Piret Viiklepp, Valentina Vilc, Ji\u0159\u00ed Wallenfels, Stefan Weso\u0142owski,"
    },
    {
        "id": "doc_156",
        "document": "Angelina Yaneva, Sead Zeynel, Dmitry Zhurkin."
    },
    {
        "id": "doc_157",
        "document": "Global tuberculosis report 2023"
    },
    {
        "id": "doc_158",
        "document": "WHO South-East Asia Region\n\nJunaina Ahmed, Rupali Sisir Banu, Mizaya Cader, Choe Kum Song, Gracinda de Orleans Tilman, Monirul Haque, Rajendra Joshi, Lok Joshi, Phalin Kamolwat, Ahmadul Hasan Khan, Ravinder Kumar, Constantino Lopes, Than Than Lwin, Tiffany Tiara Pakasi, Nirupa Pallewatta, Fathmath Nazla Rafeeq, Naveen Prakash Shah, Mahfuzer Rahman Sharkar, Sharad Kumar Sharma, Antonio Soares, Wilawan Somsong, SKM Sulistyo, Janaka Thilakarathne, Karchung Tshering, Tandin Wangmo."
    },
    {
        "id": "doc_159",
        "document": "WHO Western Pacific Region"
    },
    {
        "id": "doc_160",
        "document": "Zirwatul Adilah binti Abdul Aziz, Siti Hafsah Abdul Halim, Renata Amos, Samantha Anuntak, Marvin Apas, Metua Bates, Emosi Bayanivalu, Jose Gerard Belimac, Uranchimeg Borgil, Chang Kwok Chiu, Wei Chen, Hoyong Choi, Kuok Hei Chou, Alice Cuenca, Jeffery Lawrence Cutter, Jagdagsuren Davaalkham, J\u00e9r\u00f4me D\u00e9bacre, Van Luong Dinh, Jack Ekiek Mayleen, Suria Elisala, Takeshi Enami, Angela Fineanganofo, Kyla Galan, Donna Mae Gaviola, Ben Gwali, Nor Azian binti Haji Hafneh, Chanyuda Huot, Donekham Inthavong,"
    },
    {
        "id": "doc_161",
        "document": "Khalifah Ismail, Henry Kako, Margaret Kal, Seiya Kato, Martina Kifrawi, Jin-Sun Kim, Koay Teng Khoon, Phonesavanh Kommanivanh, Win Mar Kyaw, Wing Sze Law, Hyewon Lee, Liza Lopez, Mohd Ihsani bin Mahmood, Chima Mbakwem, Shouhei Nagae, Binh Hoa Nguyen, Chanly Nou, Juan Ogarto, Connie Olikong, Mere Prasad, Asmah Razali, Geoffrey Roche, Evonne Sablan, Vaimaila Laurica Salele, Anousone Sisouvanh, Lai Bun Tai, Joseph Takai, Edwina Tangaroa, Aaone Tanumafili, Annie Teannaki, Dharshi Thangarajah, Tieng"
    },
    {
        "id": "doc_162",
        "document": "Sivanna, Marou Tikataake, Vivian Toaniso, U Ka In, Kazuhiro Uchimura, Frank Underwood, Zhao Yanlin."
    },
    {
        "id": "doc_163",
        "document": "Acknowledgements\n\nxi\n\nAbbreviations"
    },
    {
        "id": "doc_164",
        "document": "AIDS acquired immune deficiency syndrome ART antiretroviral therapy BCG bacille Calmette-Gu\u00e9rin BPaLM bedaquiline, pretomanid, linezolid and moxifloxacin BRICS Brazil, the Russian Federation, India, China and South Africa csv comma separated value Cl confidence interval COVID-19 coronavirus disease 2019 DST drug susceptibility testing ECDC European Centre for Disease Prevention and Control GDP gross domestic product GHO Global health observatory HBC high burden country"
    },
    {
        "id": "doc_165",
        "document": "HIV human immunodeficiency virus IGRA interferon-gamma release assay IHME Institute for Health Metrics and Evaluation LMICs low- and middle-income countries MAF-TB multisectoral accountability framework for TB MDR-TB multidrug-resistant TB TB NTP national TB programme OECD Organization for Economic Co-operation and Development PPP purchasing power parity PPPR pandemic preparedness, prevention and response RR-TB rifampicin-resistant TB TB SCl service coverage index"
    },
    {
        "id": "doc_166",
        "document": "SDG Sustainable Development Goal SHA System of Health Accounts SRS sample registration system TB tuberculosis UHC universal health coverage ul uncertainty interval UN United Nations UNAIDS Joint United Nations Programme on HIV/AIDS UNPD UN Population Division VR vital registration USAID United States Agency for International Development WHO World Health Organization WRD WHO-recommended rapid diagnostic test XDR-TB extensively drug-resistant TB"
    },
    {
        "id": "doc_167",
        "document": "XDR-TB extensively drug-resistant TB\n\nxiii\n\nWHO End TB Strategy: 2025 milestones\n\nPERCENTAGE OF TB INCIDENCE RATE NUMBER OF TB DEATHS PEOPLE WITH TB FACING CATASTROPHIC TOTAL COSTSa Milestone: 50% reduction 2015\u20132025 8.7% reduction 2015\u20132022 Milestone: 75% reduction 2015\u20132025 19% reduction 2015\u20132022 Milestone: Zero in 2025 49% of people with TB face catastrophic total costs"
    },
    {
        "id": "doc_168",
        "document": "2018 UN high-level meeting on TB: treatment targets\n\nTB TREATMENT TB TREATMENT MDR/RR-TB TREATMENT MDR/RR-TB TREATMENT (ALL AGES) (CHILDREN) (ALL AGES) (CHILDREN) Target: 40 million 2018\u20132022 34 million (84%) treated in Target: 3.5 million 2018\u20132022 2.5million (71%) treated in Target: 1.5 million 2018\u20132022 825 000 (55%) treated in Target: 115 000 2018\u20132022 2018\u20132022 2018\u20132022 2018\u20132022 21 600 (19%) treated in 2018\u20132022"
    },
    {
        "id": "doc_169",
        "document": "2018 UN high-level meeting on TB: TB preventive treatment targets\n\nALL AGES PEOPLE LIVING WIH HIV HOUSEHOLD CONTACTS AGED <5 YEARS HOUSEHOLD CONTACTS AGED \u22655 YEARS Target: 30 million 15.5 million (52%) Target: 6 million 11.3 million (>100%) Target: 4 million 2.2 million (55%) Target: 20 million 2018\u20132022 treated in 2018\u20132022 treated in 2018\u20132022 treated in 2018\u20132022 2018\u20132022 2018\u20132022 2018\u20132022 2.0 million (10%) treated in 2018\u20132022\n\n2018 UN high-level meeting on TB: funding targets"
    },
    {
        "id": "doc_170",
        "document": "UNIVERSAL ACCESS TOTB\n\nPREVENTION, DIAGNOSIS, TREATMENT AND CARE TB RESEARCH US$ US$ Target: US$ 13 billion annually 5.8 billion (44%) in 2022 Target: US$ 2 billion annually 1.0 billion (50%) in 2021 by 2022 2018\u20132022\n\nMDR/RR-TB, multidrug-resistant TB/rifampicin-resistant TB.\n\na Total costs includes direct medical expenditures, non-medical expenditures and income losses. This indicator is not the same as the SDG indicator for catastrophic health expenditures. See Box 5 for further explanation."
    },
    {
        "id": "doc_171",
        "document": "1. Introduction"
    },
    {
        "id": "doc_172",
        "document": "Tuberculosis (TB) is a preventable and usually curable disease. Yet in 2022, TB was the world\u2019s second leading cause of death from a single infectious agent, after coro- navirus disease (COVID-19), and caused almost twice as many deaths as HIV/AIDS. More than 10 million people continue to fall ill with TB every year. Urgent action is required to end the global TB epidemic by 2030, a goal that has been adopted by all Member States of the United Nations (UN) and the World Health Organization (WHO)"
    },
    {
        "id": "doc_173",
        "document": "(1, 2)."
    },
    {
        "id": "doc_174",
        "document": "TB is caused by the bacillus Mycobacterium tubercu- losis, which is spread when people who are sick with TB expel bacteria into the air (e.g. by coughing). About a quarter of the global population is estimated to have been infected with TB (3). Following infection, the risk of developing TB disease is highest in the first 2 years (approximately 5%), after which it is much lower (4).1 Some people will clear the infection (5, 6). Of the total number of people who develop TB disease each year,"
    },
    {
        "id": "doc_175",
        "document": "about 90% are adults, with more cases among men than women. The disease typically affects the lungs (pulmonary TB) but can affect other sites as well."
    },
    {
        "id": "doc_176",
        "document": "Basic facts about TB are provided in Annex 1."
    },
    {
        "id": "doc_177",
        "document": "Without treatment, the death rate from TB disease is high (about 50%) (7). With treatments currently rec- ommended by WHO (a 4\u20136 months course of anti-TB drugs), about 85% of people with TB can be cured. Reg- imens of 1\u20136 months are available to treat TB infection. Universal health coverage (UHC) is necessary to ensure that all people who need treatment for TB disease or infection can access these treatments. The number of people acquiring infection and developing disease (and in turn the number"
    },
    {
        "id": "doc_178",
        "document": "of deaths caused by TB) can also be reduced through multisectoral action to address TB determinants such as poverty, undernourishment, HIV infection, smoking and diabetes."
    },
    {
        "id": "doc_179",
        "document": "Some countries have already reduced their burden of TB disease to fewer than 10 cases and less than one death per 100 000 population per year. Research breakthroughs (e.g. a new vaccine) are needed to rap- idly reduce the number of new cases each year (i.e. TB incidence) worldwide to the levels already achieved in these low-burden countries.\n\nPolitical commitment to ending the TB epidemic has stepped up in recent years. The UN held its first-ever"
    },
    {
        "id": "doc_180",
        "document": "1 For people with a long-established infection, empirical data suggest an annual risk of about 10\u201320 per 100 000 individuals.\n\nhigh-level meeting on TB in 2018 (8). With global pro- gress off track and in the wake of setbacks during the COVID-19 pandemic, a second UN high-level meeting on TB was held on 22 September 2023. The resulting politi- cal declaration reaffirms existing commitments and tar- gets and includes new ones for the period 2023\u20132027 (9)."
    },
    {
        "id": "doc_181",
        "document": "This WHO global TB report follows just over 1 month later. It provides a comprehensive and up-to-date assess ment of the status of the TB epidemic and pro- gress in the response at global, regional and national levels, in the context of global commitments, strategies and targets."
    },
    {
        "id": "doc_182",
        "document": "As with previous WHO global TB reports, the 2023 edition is based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection.2 In 2023, 192 countries and areas (out of 215) with more than 99% of the world\u2019s population and TB cases reported data (Annex 2), including all high TB burden countries (Annex 3). The report also draws on monthly or quarterly national TB case notification data, which have been collected since the start of the COVID-19 pandemic"
    },
    {
        "id": "doc_183",
        "document": "(10, 11), and databases maintained by other UN agencies and the World Bank."
    },
    {
        "id": "doc_184",
        "document": "The report has three main components. There is a short main report that focuses on key findings and mes- sages (this document); webpages that provide more detailed and digitized information, including many interactive graphics;3 and an app that contains coun- try, regional and global profiles as well as two slide sets (Annex 4). All components can be accessed from the report landing page on the WHO website, and all data can be downloaded from WHO\u2019s online global TB data- base (11). The report"
    },
    {
        "id": "doc_185",
        "document": "format ensures web or app-based availability of all content in relatively small and \u201cbite- sized\u201d chunks, which facilitates navigation, reading and use."
    },
    {
        "id": "doc_186",
        "document": "The top findings and messages of the 2023 report are highlighted in Box 1.\n\n2 WHO has published a global TB report every year since 1997. Annual data are reported by national TB programmes (NTPs) or the national entity responsible for TB surveillance."
    },
    {
        "id": "doc_187",
        "document": "3 The webpages cover six standard topics: TB disease burden; TB diagnosis and treatment; TB prevention and screening; TB financing; UHC and TB determinants; and TB research and innovation. There are also webpages on \u201cfeatured topics\u201d, which this year are: new treatments for drug-resistant TB; TB in prisons; international donor funding for TB; the 2023 UN high-level meeting on TB; multisectoral accountability for the TB response; and national TB epidemiological reviews.\n\n1"
    },
    {
        "id": "doc_188",
        "document": "Box 1. Top findings and messages in the 2023 report"
    },
    {
        "id": "doc_189",
        "document": "n There was a major global recovery in the number of people diagnosed with TB and treated in 2022, after 2 years of COVID-related disruptions. This has started to reverse or moderate the damaging impact of the pandemic on the number of people dying from or falling ill with TB. However, TB remained the world\u2019s second leading cause of death from a single infectious agent in 2022, after COVID-19, and global TB targets have either been missed or remain off track."
    },
    {
        "id": "doc_190",
        "document": "The reported global number of people newly diagnosed with TB was 7.5 million in 2022. This is the highest number since WHO began global TB monitoring in 1995, above the pre-COVID baseline (and previous historical peak) of 7.1 million in 2019, and up from 5.8 million in 2020 and 6.4 million in 2021. The number in 2022 probably includes a sizeable backlog of people who developed TB in previous years, but whose diagnosis and treatment was delayed by COVID-related disruptions that affected access to"
    },
    {
        "id": "doc_191",
        "document": "and provision of health services."
    },
    {
        "id": "doc_192",
        "document": "India, Indonesia and the Philippines, which collectively accounted for a large share (\u226560%) of the global reductions in the number of people newly diagnosed with TB in 2020 and 2021, all recovered to above 2019 levels in 2022.\n\nGlobally in 2022, TB caused an estimated 1.30 million deathsa (95% UI: 1.18\u20131.43 million). This was down from best estimates of 1.4 million in both 2020 and 2021 and almost back to the level of 2019.b"
    },
    {
        "id": "doc_193",
        "document": "COVID-related disruptions are estimated to have resulted in almost half a million excess deaths from TB in the three years 2020\u20132022, compared with the number that would have occurred if pre-pandemic trends had been maintained."
    },
    {
        "id": "doc_194",
        "document": "The net reduction in the global number of deaths caused by TB from 2015 to 2022 was 19%, far from the WHO End TB Strategy milestone of a 75% reduction by 2025. Progress is much better in the WHO African and European regions, and 47 countries achieved reductions of at least 35%.c"
    },
    {
        "id": "doc_195",
        "document": "Worldwide, an estimated 10.6 million people (95% UI: 9.9\u201311.4 million) developed TB in 2022, up from best estimates of 10.3 million in 2021 and 10.0 million in 2020. A return to the pre-pandemic downward trend may occur in 2023 or 2024."
    },
    {
        "id": "doc_196",
        "document": "The global gap between the estimated number of people developing TB (incident cases) and the reported number of people newly diagnosed with TB (notified cases) narrowed to a best estimate of 3.1 million in 2022, down from around 4 million in both 2020 and 2021 and back to the pre-pandemic level of 2019."
    },
    {
        "id": "doc_197",
        "document": "Globally, the estimated TB incidence rate (new cases per 100 000 population per year) was 133 (95% UI: 124\u2013143) in 2022. The net reduction from 2015 to 2022 was 8.7%, far from the WHO End TB Strategy milestone of a 50%\n\nreduction by 2025. Progress is much better in the WHO African and European regions, and 83 countries achieved reductions of at least 20%.c"
    },
    {
        "id": "doc_198",
        "document": "Thirty high TB burden countries accounted for 87% of the world\u2019s TB cases in 2022 and two-thirds of the global total was in eight countries: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%).\n\nIn 2022, 55% of people who developed TB were men, 33% were women and 12% were children (aged 0\u201314 years)."
    },
    {
        "id": "doc_199",
        "document": "Globally, an estimated 410 000 people (95% UI: 370 000\u2013 450 000) developed multidrug-resistant or rifampicin- resistantd TB (MDR/RR-TB) in 2022. The number of people diagnosed and started on treatment was much lower: 175 650 people in 2022, equivalent to about two in five of those in need and still below the pre-pandemic level of 181 533 people in 2019."
    },
    {
        "id": "doc_200",
        "document": "New national surveys of TB disease and up-to-date cause-of-death data from national or sample vital registration systems of high quality and coverage are needed for more accurate estimation of TB disease burden in the post-COVID period.\n\nGlobal targets set at the first UN high-level meeting on TB for the 5-year period 2018\u20132022 were not achieved.\n\n\u25b6 34 million people were treated for TB, 84% of the 5-year target of 40 million."
    },
    {
        "id": "doc_201",
        "document": "\u25b6 15.5 million people were initiated on TB preventive treatment, 52% of the 5-year target of 30 million. This included 3.8 million people in 2022, above the pre- pandemic level of 3.6 million in 2019.\n\n\u25b6 US$ 5.8 billione was available for provision of TB diagnosis, treatment and prevention services in 2022, below pre-COVID levels and less than half of the target of at least US$ 13 billion per year by 2022."
    },
    {
        "id": "doc_202",
        "document": "\u25b6 investment in TB research averaged just under US$ 1 billion per year, less than half of the US$ 2 billion target.f"
    },
    {
        "id": "doc_203",
        "document": "About 50% of TB patients and their households face total costs (direct medical expenditures, non-medical expenditures and indirect costs such as income losses) that are catastrophic (>20% of annual household income),g far from the WHO End TB Strategy target of zero. This shows that there are major economic and financial barriers to accessing and completing TB treatment, which need to be addressed through faster progress towards UHC and better levels of social protection."
    },
    {
        "id": "doc_204",
        "document": "Treatment success rates have improved: to 88% for people treated for drug-susceptible TB and 63% for people with MDR/RR-TB.\n\nEnding the global TB epidemic requires translating the commitments made at the 2023 UN high-level meeting on TB into action.\n\na This total includes 167 000 deaths from TB among people with HIV, which are officially classified as deaths from HIV/AIDS."
    },
    {
        "id": "doc_205",
        "document": "Estimates for 2010-2021 have been revised downwards compared with those published in 2022, mainly due to revisions for India (Box 4) oo\n\nc This reduction corresponds to the first (2020) milestone of the End TB Strategy (Box 2).\n\nd Rifampicin is the most powerful first-line anti-TB drug. MDR-TB is defined as resistance to rifampicin and isoniazid.\n\ne In constant US$ values for 2022.\n\nf The source of these data is reports published by Treatment Action Group."
    },
    {
        "id": "doc_206",
        "document": "g This indicator is not the same as the SDG indicator for catastrophic health expenditures (Box 5).\n\nGlobal tuberculosis report 2023\n\n2. Global TB commitments, strategy and targets"
    },
    {
        "id": "doc_207",
        "document": "In 2014 and 2015, all WHO and UN Member States committed to ending the TB epidemic, through their adoption of WHO\u2019s End TB Strategy (Box 2) and the UN Sustainable Development Goals (SDGs) (1, 2). The strat- egy included milestones (for 2020 and 2025) and targets (for 2030 and 2035) for large reductions in the TB inci- dence rate (new cases per 100 000 population per year), the absolute number of deaths caused by TB, and costs faced by TB patients and their households."
    },
    {
        "id": "doc_208",
        "document": "Reaching the milestones and targets for reductions in TB incidence required an annual decline in the TB incidence rate of 4\u20135% per year by 2020, accelerating to 10% per year by 2025 and then to an average of 17% per year from 2025 to 2035. Reaching the milestones and targets for reductions in the number of deaths caused by TB required not only these declines in TB incidence, but also reductions in the case fatality ratio (the percentage of people with TB who die from the disease). The global"
    },
    {
        "id": "doc_209",
        "document": "VISION GOAL INDICATORS AWORLD FREE OF TB \u2014 zero deaths, sease and suffering due to TB END THE GLOBAL TB EPIDEMIC MILESTONES TARGETS 2020 2025 2030 2035 Percentage reduction in the absolute number of TB deaths\u00ae (compared with 2015 baseline) 5% 5% 0% 5% Percentage reduction in the TB incidence rate (compared with 2015 baseline) 20% 50% 80% 90% Percentage of TB-affected households facing catastrophic total costs due to TB\u00ae (level in 2015 unknown) 0% 0% 0% 0%"
    },
    {
        "id": "doc_210",
        "document": "PRINCIPLES\n\n1. Government stewardship and accountability, with monitoring and evaluation\n\n2. Strong coalition with civil society organizations and communities\n\n;;\n\n3. Protection and promotion of human rights, ethics and equity\n\n4. Adaptation of the strategy and targets at country level, with global collaboration"
    },
    {
        "id": "doc_211",
        "document": "PILLARS AND COMPONENTS\n\n1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION\n\nA. Early diagnosis of TB including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups\n\nB. Treatment of all people with TB including drug-resistant TB, and patient support\n\nC. Collaborative TB/HIV activities, and management of comorbidities\n\nD. Preventive treatment of persons at high risk, and vaccination against TB"
    },
    {
        "id": "doc_212",
        "document": "2. BOLD POLICIES AND SUPPORTIVE SYSTEMS\n\nE. Political commitment with adequate resources for TB care and prevention\n\nF. Engagement of communities, civil society organizations, and public and private care providers\n\nG. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control\n\nH. Social protection, poverty alleviation and actions on other determinants of TB"
    },
    {
        "id": "doc_213",
        "document": "3. INTENSIFIED RESEARCH AND INNOVATION\n\nI. Discovery, development and rapid uptake of new tools, interventions and strategies\n\nJ. Research to optimize implementation and impact, and promote innovations\n\na This indicator is for the combined total of TB deaths in HIV-negative and HIV-positive people. Deaths from TB among HIV-positive people are officially classified as deaths caused by HIV/AIDS, with TB as a contributory cause."
    },
    {
        "id": "doc_214",
        "document": "b This indicator is not the same as the SDG indicator for catastrophic health expenditures. See Box 5 for further explanation.\n\n3\n\nTAblE 1\n\nGlobal targets set in 2018 at the first UN high-level meeting on TB"
    },
    {
        "id": "doc_215",
        "document": "INDICATOR | TARgET Number of people with TB disease treated in the five years 2018-2022 40 million people, including: 3.5 million children \u00a9 1.5 million people with drug-resistant TB, including 115 000 children"
    },
    {
        "id": "doc_216",
        "document": "Number of people provided with TB preventive treatment in the five years 2018-2022 At least 30 million people, including: * 4 million children under 5 years of age who are household contacts of people diagnosed with B \u00a9 20 million people in older age groups who are household contacts of people diagnosed with TB \u00a9 6 million people living with HIV Annual funding for universal access to quality prevention, diagnosis, treatment and care of TB At least US$ 13 billion per year by 2022"
    },
    {
        "id": "doc_217",
        "document": "Annual funding for TB research USS$ 2 billion annually in the five years 2018-2022"
    },
    {
        "id": "doc_218",
        "document": "case fatality ratio needed to fall to 10% by 2020 and then to 6.5% (a level already achieved in high-income coun- tries) by 2025. Key requirements to reach the milestones and targets were defined within the three pillars of the End TB Strategy (Box 2). They included provision of TB prevention, diagnostic and treatment services within the context of progress towards UHC and social pro- tection; multisectoral actions to address broader social and economic determinants of TB; and technological"
    },
    {
        "id": "doc_219",
        "document": "breakthroughs, such as a new TB vaccine by 2025."
    },
    {
        "id": "doc_220",
        "document": "The third target of the End TB Strategy, that no TB patients and their households face catastrophic total costs1 as a result of the disease, was set in recognition of the fact that removal of financial and economic barriers to accessing TB diagnosis and treatment is a prerequi- site for achieving the milestones and targets for reduc- tions in TB incidence and TB mortality. \u201cCatastrophic\u201d is"
    },
    {
        "id": "doc_221",
        "document": "defined as direct medical expenditures, direct non-med- ical expenditures and indirect costs (e.g. income losses) that sum to more than 20% of household income.\n\nFurther details about the rationale for the milestones and targets and how they were defined is available else- where (12)."
    },
    {
        "id": "doc_222",
        "document": "In 2018, the UN General Assembly held its first-ever high-level meeting on TB. Commitments to the SDGs and End TB Strategy were reaffirmed and new global targets, for mobilization of funding and provision of treatment (Table 1), were agreed upon (8).2 A second high-level meeting was held in September 2023, along- side high-level meetings about UHC and pandemic prevention, preparedness and response (PPPR). The political declaration (9) includes new commitments and targets for the period 2023\u20132027"
    },
    {
        "id": "doc_223",
        "document": "(Table 2, Table 3)."
    },
    {
        "id": "doc_224",
        "document": "TAblE 2\n\nGlobal targets set in 2023 at the second UN high-level meeting on TB"
    },
    {
        "id": "doc_225",
        "document": "INDICATOR { GLOBAL TARGET TB treatment coverage (percentage of the estimated number of people who develop TB disease each year who are provided with quality-assured diagnosis and treatment) 90% by 2027 (equivalent to up to 45 million people globally in the 5-year period 2023-2027, including up to 4.5 million children and up to 1.5 million people with drug-resistant TB)"
    },
    {
        "id": "doc_226",
        "document": "Coverage of TB preventive treatment (percentage of people at high risk of developing TB disease who are provided with TB preventive treatment) 90% by 2027 (equivalent to up to 45 million people globally in the 5-year period 2023-2027, including 30 million household contacts of people with TB and 15 million people living with HIV) Coverage of rapid diagnostic testing for TB (percentage of those diagnosed with TB who were initially tested with a WHO-recommended rapid molecular test) 100% by 2027"
    },
    {
        "id": "doc_227",
        "document": "Coverage of health and social benefits package for people with TB 100% by 2027 Availability of new TB vaccines that are safe and effective Rollout initiated, preferably within 5 years Annual funding for universal access to quality prevention, diagnosis, treatment and care for TB US$ 22 billion by 2027, US$ 35 billion by 2030 Annual funding for TB research USS$ 5 billion by 2027"
    },
    {
        "id": "doc_228",
        "document": "1 This indicator is not the same as the SDG indicator for catastrophic health expenditures (see Box 5).\n\n4\n\n2 The meeting followed a WHO global ministerial conference in 2017 (13).\n\nGlobal tuberculosis report 2023\n\nTAblE 3\n\nHighlights of commitments and requests at the second UN high-level meeting on TB in 2023\n\na) commitments"
    },
    {
        "id": "doc_229",
        "document": "TOPIc OR THEME cOMMITMEnT"
    },
    {
        "id": "doc_230",
        "document": "Provide comprehensive care to all people with TB"
    },
    {
        "id": "doc_231",
        "document": "Strengthen the provision of comprehensive care for all people with TB, with particular attention to people who are vulnerable or in vulnerable situations (e.g. people with HIV, people with TB-associated disabilities, older people, migrants, refugees, internally displaced people, and pregnant and lactating women), using specific models of care such as nutritional, mental health and psychosocial support, social protection, rehabilitation and palliative care"
    },
    {
        "id": "doc_232",
        "document": "Scale-up comprehensive efforts to close longstanding gaps in the prevention, diagnosis, treatment and care of children Address the crisis of drug- resistant TB Work towards the achievement of universal, equitable and affordable access to WHO-recommended diagnostics and drug susceptibility tests, and all-oral shorter-duration treatment regimens for people with drug-resistant TB, complemented by monitoring and management of side-effects, together with care and support to improve treatment outcomes"
    },
    {
        "id": "doc_233",
        "document": "Build on interlinkages across the global health agendas of TB, UHC and PPPR, to strengthen the TB response Establish TB services as essential elements of national and global strategies to advance UHC, address antimicrobial resistance and strengthen PPPR Integrate systematic screening, prevention, treatment and care of TB, and related health conditions, within primary health care, including community-based health services Invest in public health infrastructure and the health workforce"
    },
    {
        "id": "doc_234",
        "document": "Address TB during health and humanitarian emergencies Safeguard TB services as essential health services during humanitarian and health emergencies Strengthen the engagement of civil society and communities affected by TB Intensify national efforts to create enabling legal and social policy frameworks to combat inequalities, and to eliminate all forms of TB-related stigma, discrimination and other human rights barriers and violations"
    },
    {
        "id": "doc_235",
        "document": "Strengthen the meaningful engagement of parliaments, civil society, and TB-affected local communities, including young people and women, in all aspects of the TB response, to ensure equitable and people- centred access to TB services, with increased and sustained investments, especially in community initiatives Enable and strengthen TB research Create an enabling environment for TB research and innovation across Member States and partners"
    },
    {
        "id": "doc_236",
        "document": "Strengthen research capacity and collaboration through TB research platforms and networks across the public and private sectors, academia and civil society Accelerate the research, development and roll-out of safe, effective, affordable and accessible vaccines, preferably within the next 5 years, including through leveraging global collaboration mechanisms and WHO initiatives such as the accelerator council for new TB vaccines"
    },
    {
        "id": "doc_237",
        "document": "Promote access to affordable medicines Promote equitable access to affordable, safe, effective and quality medicines, such as generics, vaccines, diagnostics and health technologies, including through the Stop TB Partnership/Global Drug Facility, to ensure availability and access to quality-assured and affordable commodities recommended by WHO"
    },
    {
        "id": "doc_238",
        "document": "Strengthen multisectoral accountability Support the WHO multisectoral accountability framework for TB by strengthening high-level multisectoral accountability and review mechanisms, in line with national contexts, defining the roles and responsibilities of relevant sectors and stakeholders with the meaningful engagement of people and communities affected by TB Develop and implement ambitious, costed national TB strategic plans or health strategies with a multisectoral approach b) Requests"
    },
    {
        "id": "doc_239",
        "document": "TOPIc OR THEME REquEST"
    },
    {
        "id": "doc_240",
        "document": "Role of WHO"
    },
    {
        "id": "doc_241",
        "document": "WHO is requested to continue providing global leadership to support Member States to build a resilient response to TB as an integral part of the UHC agenda, and to also address the drivers and determinants of the epidemic, including in the context of health and humanitarian emergencies, with multisectoral engagement, the provision of normative guidance and technical support, and through monitoring, reporting and review of progress, and by advancing the TB research and innovation agenda"
    },
    {
        "id": "doc_242",
        "document": "Tf\\e U!\\l Secret\u00e9ry\u2014Ge ner: a,lf With,r, he support of WHO, is requested to report, as part of his annual SDG"
    },
    {
        "id": "doc_243",
        "document": "Secretary-General, support WHO, requested report, as part\n\nreport, on the global effort to end TB\n\nReport and review\n\nprogress\n\nThe UN Secretary-General, with the support of WHO, is requested to present a report to the UN General\n\nAssembly in 2027, on the progress achieved towards realizing the commitments made in the 2023 political\n\ndeclaration on TB\n\nHeads of state and government are requested to undertake a comprehensive review of progress at a UN"
    },
    {
        "id": "doc_244",
        "document": "high-level meeting on TB in 2028\n\nHIV: human immunodeficiency virus; PPPR: pandemic preparedness, prevention and response; UHC: universal health coverage; UN: United Nations; WHO: World Health Organization\n\n2. Global TB commitments, strategy and targets\n\n5"
    },
    {
        "id": "doc_245",
        "document": "3. Main findings and messages\n\nThere was a major global recovery in the number of people diagnosed with TB and treated in 2022, after 2 years of COVID-related disruptions. This has started to reverse or moderate the damaging impact of the pan- demic on the number of people dying from or falling ill with TB."
    },
    {
        "id": "doc_246",
        "document": "However, TB remained the world\u2019s second leading cause of death from a single infectious agent in 2022, after COVID-19, and caused almost twice as many deaths as HIV/AIDS. Global targets for improvements in TB treatment, TB preventive treatment and funding set at the first UN-high-level meeting on TB in 2018 have been missed and global TB targets for reductions in TB disease burden remain off track."
    },
    {
        "id": "doc_247",
        "document": "Ending the global TB epidemic requires translating the commitments made at the 2023 UN high-level meet- ing on TB into action.\n\nTB case notifications"
    },
    {
        "id": "doc_248",
        "document": "Rebound to beyond pre-cOVId levels in 2022\n\nThe most obvious and immediate impact on TB of dis- ruptions caused by the COVID-19 pandemic was a large global fall in the number of people newly diagnosed with TB and reported (i.e. officially notified). Following large increases between 2017 and 2019, there was a reduction of 18% between 2019 and 2020, from 7.1 mil- lion to 5.8 million, with a partial recovery to 6.4 million in 2021."
    },
    {
        "id": "doc_249",
        "document": "Globally in 2022, 7.5 million people were newly diagnosed with TB and officially notified as a TB case (Fig. 1). This was a rebound to above the pre-COVID lev- el (7.1 million in 2019), 16% above the level of 2021, 28% above the level of 2020, and the highest number for a single year since WHO started global TB monitoring in the mid-1990s. The substantial increase in 2022 shows that there has been a good recovery in access to and provision of health services in many (but not all) coun- tries. It"
    },
    {
        "id": "doc_250",
        "document": "also probably reflects diagnosis of a sizeable backlog of people who developed TB in previous years but whose diagnosis was delayed due to COVID-related disruptions, and an increase in the number of people falling ill with TB."
    },
    {
        "id": "doc_251",
        "document": "At regional level, trends in case notifications before, during and in the aftermath of the COVID-19 pandemic vary (Fig. 2).\n\nThe pattern in the WHO South-East Asia Region was very similar to the global trend, with a large reduction\n\n(-24%) between 2019 and 2020 followed by a partial recovery in 2021 and then a rebound to above the pre-COVID level in 2022; indeed, it is this region that drove the trend at global level. There was a comparable pattern in the WHO Region of the Americas."
    },
    {
        "id": "doc_252",
        "document": "Notifications in the WHO Eastern Mediterranean Region had already recovered to 2019 levels in 2021, with a further increase in 2022 (mostly influenced by\n\nFIg. 1\n\nGlobal trend in case notifications of people newly diagnosed with TB, 2010\u20132022\n\n) 8.0 s n o i l l i m 7.5 ( r a e y 7.0 r e p s n 6.5 o i t a c i f i t o 6.0 N 5.5 2010 2012 2014 2016 2018 2020 2022\n\ntrends in Pakistan, the country with the highest burden of TB in the region)."
    },
    {
        "id": "doc_253",
        "document": "In the WHO European Region, notifications fell at a rate above the historical trend in 2020, increased in 2021 (likely representing some backlog from 2020) and then resumed a decline similar to the historical trend in 2022."
    },
    {
        "id": "doc_254",
        "document": "In the WHO Western Pacific Region, there was a big drop in case notifications in 2020, a further fall in 2021 and a partial recovery (increase) in 2022. However, trends among countries in this region varied. In China, which accounts for about half of total notifications in the region, notifications have been declining consistently for more than 10 years (Fig. 3). In most other countries in the region, including three high TB burden countries (Cambodia, the Philippines and Viet Nam), case notifi-"
    },
    {
        "id": "doc_255",
        "document": "cations fell in either 2020 or 2021 but then recovered to 2019 levels (or beyond) in 2022 (Fig. 3)."
    },
    {
        "id": "doc_256",
        "document": "It was striking that notifications in the WHO African Region increased throughout the pandemic, suggesting that any COVID-related disruptions had a limited impact on TB case detection.\n\nAt country level, the 30 high TB burden and three\n\n6\n\nFIg. 2\n\nTrends in case notifications of people newly diagnosed with TB by WHO region, 2010\u20132022\n\n)\n\nNotifications per year (millions)\n\nN\n\n)\n\nNotifications per year (millions)\n\n1.8\n\n1.7\n\n1.6\n\n1.5\n\n1.4\n\n1.3\n\n1.2\n\n0.35\n\n0.30\n\n0.25\n\n0.20"
    },
    {
        "id": "doc_257",
        "document": "African\n\nRegion of the Americas 0.25 3.6 0.24 0.23 3.2 0.22 2.8 0.21 2.4 0.20 0.19 2.0 2010 2012 2014 2016 2018 2020 2022 Eastern Mediterranean Region 0.60 1.5 0.55 1.4 1.3 0.50 1.2 0.45 1.1 0.40 1.0\n\nRegion\n\n2010 2012 2014 2016 2018 2020 2022\n\n2010\n\nRegion\n\nEuropean"
    },
    {
        "id": "doc_258",
        "document": "N\n\n0.15\n\n2010 2012 2014 2016 2018 2020 2022\n\n2010 2012 2014 2016 2018 2020 2022\n\n2010 2012 2014 2016 2018 2020 2022\n\nglobal TB watchlist countries1 can be categorized into six groups, according to the timing and degree of disrup- tions to TB notifications during the COVID-19 pandemic and subsequent patterns of recovery in its aftermath (Fig. 3)."
    },
    {
        "id": "doc_259",
        "document": "The largest group consists of 13 countries in which there were major reductions in TB case notifications in 2020 or 2021, followed by a rebound to 2019 levels or beyond in 2022 (Fig. 3a). This included the three coun- tries that accounted for a large share (\u226560%) of the glob- al reductions in 2020 and 2021: India, Indonesia and the Philippines. In a further six countries, there were reductions between 2019 and 2021, followed by a par- tial recovery in 2022 (Fig. 3b)."
    },
    {
        "id": "doc_260",
        "document": "Nine countries reported either increased notifica- tions throughout the pandemic and its aftermath or declines that were consistent with historical trends, suggesting no or only limited COVID-related disruptions to TB case detection (Fig. 3c, Fig. 3d). The countries"
    },
    {
        "id": "doc_261",
        "document": "1 In 2021, WHO updated its three lists of high burden countries for TB, MDR/RR-TB and HIV-associated TB. The lists are for 2021\u20132025, replacing the previous lists for 2016\u20132020, and are explained in Annex 3. The three countries that exited the TB list (Cambodia, the Russian Federation and Zimbabwe) were defined as global TB watchlist countries.\n\nin these two groups were mostly in the WHO African Region, consistent with regional data (Fig. 2)."
    },
    {
        "id": "doc_262",
        "document": "Five countries had unusual patterns that are diffi- cult to explain: either a reduction in 2020, an apparent recovery in 2021 and then a reduction in 2022 (Fig. 3e); or a decline consistent with historical trends during the main years of the pandemic (2020 and 2021) followed by an increase in 2022 that was in stark contrast to pre-2022 trends (Fig. 3f). To better understand these patterns, further assessment of surveillance, epidemi- ological and programmatic data is required."
    },
    {
        "id": "doc_263",
        "document": "Patterns of impact and recovery in 2020, 2021 and 2022, in percentage terms and relative to the baseline of 2019, are shown for the 30 high TB burden and three global TB watchlist countries in Fig. 4. As highlight- ed in previous global TB reports (14, 15), the countries with the largest relative reductions in either 2020 or 2021 were (ordered according to the size of the relative reduction) Myanmar, the Philippines, Mongolia, Leso- tho, Indonesia, Cambodia, Zimbabwe, India, Viet Nam and"
    },
    {
        "id": "doc_264",
        "document": "Bangladesh (all >20%)."
    },
    {
        "id": "doc_265",
        "document": "Reasons for region and country variation in TB noti- fication trends between 2019 and 2022 include differ- ences in when they were first affected by the COVID-19 pandemic and the timing of subsequent waves of\n\n3. Main findings and messages\n\n7\n\nFIg. 3\n\nCase notifications of people newly diagnosed with TB in the 30 high TB burden and 3 global TB watchlist countries, categorized according to the timing and degree of disruptions during the COVID-19 pandemic and its aftermath, 2020\u20132022"
    },
    {
        "id": "doc_266",
        "document": "(a) negative impact in 2020a or 2021, recovery to 2019 levels or beyond in 2022"
    },
    {
        "id": "doc_267",
        "document": "r 500 000 Philippines 800 000 Indonesia 2 500 000 India 500 000 Pakistan a e y r e 400 000 600 000 2 000 000 400 000 p s 300 000 1 500 000 300 000 n o i t a 200 000 400 000 1 000 000 200 000 c i f i t o 100 000 200 000 500 000 100 000 N 0 0 0 0 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 r a 100 000 Kenya 20 000 Sierra Leone 100 000 Brazil 8 000 Gabon e y r e 75 000 15 000 75 000 6 000 p s n o 50 000 10 000 50 000 4 000 i t a c i f i t 25 000 5 000 25 000 2 000 o N"
    },
    {
        "id": "doc_268",
        "document": "0 0 0 0 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 r a e 40 000 Papua New Guinea 100 000 Uganda 15 000 Congo 40 000 Cambodia y r e p 30 000 75 000 10 000 30 000 s n o i 20 000 50 000 20 000 t a c i f i t o 10 000 25 000 5 000 10 000 N 0 0 0 0 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 Viet Nam r 125 000 a e y 100 000 r e p s 75 000 n o i t a 50 000 c i f i t o 25 000 N 0 a Countries are shown in descending order of the relative"
    },
    {
        "id": "doc_269",
        "document": "decline (%) between 2019 and 2020, which 2016 2018 2020 2022 ranged from 37% to 2.6%."
    },
    {
        "id": "doc_270",
        "document": "2022\n\n2022\n\n2022\n\n(b) negative impact in 2020a\u20132021, partial recovery in 2022\n\n8 000 Lesotho 6 000 4 000 2 000 0 2016 2018 2020 2022 5 000 Mongolia 4 000 3 000 2 000 1 000 0 2016 2018 2020 2022\n\nNotifications per year"
    },
    {
        "id": "doc_271",
        "document": "Notifications per year\n\n30 000 20 000 10 000 0 2016 2018 2020 2022 100 000 Thailand 75 000 50 000 25 000 0 2016 2018 2020 2022\n\n150 000 Myanmar 100 000 50 000 0 2016 2018 2020 2022\n\nAngola 0 2016 2018 2020 2022\n\na Countries are shown in descending order of the relative decline (%) between 2019 and 2020, which ranged from 35% to 2.2%.\n\n8\n\nGlobal tuberculosis report 2023"
    },
    {
        "id": "doc_272",
        "document": "(c) Year-on-year increases in notifications in 2020\u20132022\n\nr 15 000 Central African Republic 250 000 of the Congo a e y r e p s 10 000 200 000 150 000 n o i t a c i f i t o 5 000 100 000 50 000 N 0 0 2016 2018 2020 2022 2016 2018 2020 2022 United Republic of Tanzania 60 000 Zambia r a e 100 000 y r e p 75 000 40 000 s n o i 50 000 t a c i f i t 25 000 20 000 o N 0 0 2016 2018 2020 2022 2016 2018 2020 2022"
    },
    {
        "id": "doc_273",
        "document": "120 000 Mozambique 90 000 60 000 30 000 0 2016 2018 2020 2022\n\nNigeria 0 2016 2018 2020 2022\n\n(d) no or limited departure from pre-2020 downward trend\n\nNotifications per year\n\nr\n\na\n\ne\n\ny\n\nr\n\ne\n\np\n\ns\n\nn\n\no\n\ni\n\nt\n\na\n\nc\n\ni\n\nf\n\ni\n\nt\n\no\n\nN\n\nDemocratic People\u2019s 800 000 600 000 China 125 000 100 000 75 000 Republic of Korea 100 000 75 000 Russian Federation 400 000 50 000 50 000 200 000 25 000 25 000 0 0 0 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 2022\n\n2016 2018 2020 2022"
    },
    {
        "id": "doc_274",
        "document": "(e) negative impact in 2020,a recovery in 2021, decrease in 2022\n\nBangladesh Liberia 300 000 8 000 200 000 6 000 4 000 100 000 2 000 0 0 2016 2018 2020 2022 2016 2018 2020 2022\n\na Countries are shown in descending order of the relative decline (%) between 2019 and 2020, which ranged from 21% to 16%.\n\n(f) no or limited departure from pre-2020 downward trend in 2020 and 2021, but a marked reversal of this trend in 2022\n\nNotifications per year\n\nr\n\na\n\ne\n\ny\n\nr\n\ne\n\np\n\ns\n\nn\n\no\n\ni\n\nt\n\na\n\nc\n\ni\n\nf\n\ni\n\nt"
    },
    {
        "id": "doc_275",
        "document": "o\n\nN\n\n150 000 Ethiopia 10 000 Namibia 300 000 South Africa 100 000 7 500 200 000 5 000 50 000 2 500 100 000 0 0 0 2016 2018 2020 2022 2016 2018 2020 2022 2016 2018 2020 2022\n\n3. Main findings and messages\n\n9\n\nFIg. 4\n\nCase notifications of people newly diagnosed with TB in 2020, 2021 and 2022 compared with 2019, 30 high TB burden and 3 global TB watchlist countriesa\n\nThe vertical dashed line marks the level of 2019."
    },
    {
        "id": "doc_276",
        "document": "Philippines Lesotho Indonesia Zimbabwe India Myanmar Bangladesh Russian Federation Pakistan Namibia Liberia Kenya Angola China Sierra Leone Brazil Mongolia Gabon South Africa Papua New Guinea Uganda Democratic People's Republic of Korea Congo Cambodia Viet Nam Ethiopia Thailand Mozambique United Republic of Tanzania Central African Republic Zambia Democratic Republic of the Congo Nigeria 40 60 80 100 120 140 160 180 200 220 240 Number in 2020, 2021 and 2022 as a percentage of 2019"
    },
    {
        "id": "doc_277",
        "document": "2020 2021 2022\n\na The three global TB watchlist countries are Cambodia, the Russian Federation and Zimbabwe (see Annex 3 for further explanation).\n\nFIg. 5\n\nGlobal trends in the estimated number of deaths caused by TB (left) and the TB mortality rate (right),a 2010\u20132022\n\nThe horizontal dashed line shows the 2025 milestone of the End TB strategy, which is a 75% reduction in the total number of TB deaths between 2015 and 2025. Shaded areas represent 95% uncertainty intervals."
    },
    {
        "id": "doc_278",
        "document": "2.5 r a e y 2.0 Total r e p n o i t 30 Total 1.5 1.0 HIV-negative people a l u p o p 0 0 0 0 0 20 10 HIV-negative people 0.5 2025 milestone 1 r e People with HIV p e People with HIV 0 t a R 0 2010 2012 2014 2016 2018 2020 2022 2010 2012 2014 2016 2018 2020 2022"
    },
    {
        "id": "doc_279",
        "document": "Millions\n\na Deaths from TB among people with HIV are officially classified as deaths caused by HIV/AIDS, with TB as a contributory cause.\n\n10\n\nGlobal tuberculosis report 2023\n\ninfection, the severity of the impact of the pandemic, the extent to which restrictions were put in place and adhered to, the capacity and resilience of health sys- tems, trends in the years leading up to the pandemic, and the extent and intensity of recovery efforts in 2021 and 2022.\n\nDeaths caused by TB"
    },
    {
        "id": "doc_280",
        "document": "cOVId-related increases reversed in 2022"
    },
    {
        "id": "doc_281",
        "document": "Global reductions in the reported number of people newly diagnosed with TB in 2020 and 2021 suggest- ed that the number of people with undiagnosed and untreated TB had grown, resulting first in an increased number of deaths from TB and more community trans- mission of infection and then, with some lag-time, increased numbers of people developing TB (Box 3).1 The global recovery in TB case notifications is 2022, to beyond pre-COVID levels, is now estimated to have reversed the upward trend in the"
    },
    {
        "id": "doc_282",
        "document": "number of deaths caused by TB between 2019 and 2021."
    },
    {
        "id": "doc_283",
        "document": "Globally in 2022, the total number of deaths caused by TB (including those among people with HIV)2 was 1.30 million (95% uncertainty interval [UI]: 1.18\u20131.43 million), down from best estimates of 1.4 million in both 2020 and 2021 and almost back to the level of 2019 (Fig. 5)."
    },
    {
        "id": "doc_284",
        "document": "Global estimates of the number of deaths caused by TB since 2010 have been revised downwards, compared with those published in 2022 (15). The main reason is revisions to estimates for India, based on recently pub- lished cause-of-death data for 2014\u20132019 (Box 4).3"
    },
    {
        "id": "doc_285",
        "document": "Global trends in the number of deaths caused by TB differ by HIV status (Fig. 5). In 2022, TB caused an esti- mated 1.13 million deaths among HIV-negative people (95% UI: 1.02\u20131.26 million), almost back to the level of 2019 after 2 years of estimated increases in 2020 and 2021.4 Deaths from TB among people with HIV have been falling steadily for many years; in 2022, the esti- mated number was 167 000 (95% UI: 139 000\u2013198 000)."
    },
    {
        "id": "doc_286",
        "document": "1 Disruptions to TB diagnosis and treatment affect those who already have TB disease first; people who remain undiagnosed and untreated have a higher risk of death compared with those started on treatment. Most people infected through increased community transmission will not go on to develop TB disease (4); for those who do, the time between acquisition of infection and development of TB disease ranges from weeks to decades. Disruptions to diagnosis and treatment therefore have a more immediate"
    },
    {
        "id": "doc_287",
        "document": "impact on TB mortality and a more delayed impact on TB incidence. Similarly, recoveries in access to TB diagnosis and treatment have a more immediate effect on TB mortality and a more delayed impact on TB incidence."
    },
    {
        "id": "doc_288",
        "document": "2 Deaths from TB among people with HIV are officially classified as deaths from HIV/AIDS. For this reason, a clear distinction between deaths among HIV-negative people and those among people with HIV is made in Fig. 5, Fig. 6 and Fig. 7.\n\n3 Other updates are explained in Annex 5."
    },
    {
        "id": "doc_289",
        "document": "4 The estimated number of deaths caused by TB among HIV- negative people was 1.10 million (95% UI: 0.99\u20131.22 million) in 2019, 1.14 million (95% UI: 1.02\u20131.26 million) in 2020 and 1.19 million (95% UI: 1.07\u20131.32 million) in 2021.\n\n3. Main findings and messages\n\nFIg. 6"
    },
    {
        "id": "doc_290",
        "document": "Estimated number of excess TB deaths during the COVID-19 pandemic and its aftermath\n\nThe blue shaded area represents the 95% uncertainty interval of the actual number of deaths estimated to have been caused by TB; the red line shows the estimated number of deaths that would have been caused by TB in the absence of the COVID-19 pandemic; the red shaded area shows the excess number of deaths caused by TB due to disruptions associated with the COVID-19 pandemic."
    },
    {
        "id": "doc_291",
        "document": "2 500 000 s 2 000 000 h t a e d 1 500 000 f o r e b m 1 000 000 u N 500 000 0 2010 2012 2014 2016 2018 2020 2022\n\nFIg. 7\n\nGlobal trends in the estimated number of deaths caused by TB and HIV (in millions),a,b 2000\u20132022\n\nShaded areas represent 95% uncertainty intervals.\n\nr HIV deaths a e y 2.0 r e p s h t 1.5 TB deaths in HIV-negative people a e d f o 1.0 s n o i l l i M 0.5 TB deaths in people with HIV 0 2000 2004 2008 2012 2016 2022"
    },
    {
        "id": "doc_292",
        "document": "a For HIV/AIDS, the latest estimates of the number of deaths in 2022 that have been published by UNAIDS are available at http://www.unaids.org/en/ (accessed 15 August 2023). For TB, the estimates for 2022 are those published in this report.\n\nb Deaths from TB among people with HIV are officially classified as deaths caused by HIV/AIDS in the International Classification of Diseases.\n\n11\n\nBox 3. Estimating TB incidence and mortality during the COVID-19 pandemic"
    },
    {
        "id": "doc_293",
        "document": "n The most obvious and immediate impact on TB of disruptions caused by the COVID-19 pandemic was a large global fall in the number of people newly diagnosed with TB and reported, in both 2020 and 2021 (Fig. 1\u2013Fig. 4). In countries where reductions departed from pre-2020 trends, their impact on the numbers of people dying from TB and falling ill with TB was estimated using country- or region-specific dynamic models (14, 15)."
    },
    {
        "id": "doc_294",
        "document": "The main assumption used in the modelling was that all or most of the reduction in the reported number of people newly diagnosed reflected real reductions in diagnosis (rather than underreporting or a reduction in TB incidence). This results in an increase in the number of people in the community with undiagnosed and untreated TB, which in turn increases the transmission of infection, and subsequently the number of people infected with TB and at risk of developing TB disease."
    },
    {
        "id": "doc_295",
        "document": "The most immediate impact on TB disease burden of growing numbers of people with undiagnosed and untreated TB is an increase in the number of deaths from TB. The impact of a consequent increase in transmission on TB incidence (new cases) is more delayed, because of the time lag (from months to many years) between acquisition of infection and progression to TB disease (4). Similarly, the most immediate impact of a recovery in the numbers of people newly diagnosed and treated for TB is a reduction"
    },
    {
        "id": "doc_296",
        "document": "in the number of people dying from TB. Reversals in TB incidence happen with a longer lag-time."
    },
    {
        "id": "doc_297",
        "document": "Restrictions during the COVID-19 pandemic (e.g. lockdowns) and adjustments to behaviour (e.g. use of masks) might have reduced TB transmission in 2020 and 2021. The models assumed that transmission was reduced by 50% (UI: 25\u201375%) during periods of official lockdowns.a"
    },
    {
        "id": "doc_298",
        "document": "In 2023, country-specific dynamic models were used to estimate TB incidence and mortality in the period 2020\u20132022 for 26 countries that reported large absolute reductions in TB notifications in 2020 or 2021 that departed significantly from pre-2020 trends. The 26 countries were Afghanistan, Angola, Azerbaijan, Bangladesh, Brazil, Cambodia, Colombia, India, Indonesia, Kazakhstan, Kenya, Kyrgyzstan, Lesotho, Malaysia, Mexico, Mongolia, Myanmar, Nepal, Pakistan, Peru, the Philippines, Thailand,"
    },
    {
        "id": "doc_299",
        "document": "Ukraine, Uzbekistan, Viet Nam and Zimbabwe.b The models were fitted to monthly or quarterly TB case notification data reported to WHO for the period since January 2020 (10) and calibrated to pre-2020 estimates of TB incidence and mortality.c Region-specific models were used for 23 other low- and middle-income countries (LMICs) that had reductions in TB notifications in the period 2020\u20132021 that departed from pre-2020 trends."
    },
    {
        "id": "doc_300",
        "document": "Other influential assumptions used in the models, drawing on the scientific literature, include the number\n\nof secondary infections per case per year (estimated by model calibration) and the rate of breakdown from TB infection to active TB disease, which was informed by a recent (2018) review of TB models (4)."
    },
    {
        "id": "doc_301",
        "document": "An important limitation is that the models do not account for the negative impact of the COVID-19 pandemic on broader TB determinants (e.g. undernourishment, poverty and income per capita), which could have influenced both TB incidence and mortality. Impacts on TB incidence and mortality in the modelled countries may thus be underestimated.\n\nThe modelling methods have been extensively discussed and reviewed. This included:"
    },
    {
        "id": "doc_302",
        "document": "\u25b6 a review by WHO\u2019s Strategic and Technical Advisory Group for TB in June 2021 (17);\n\n\u25b6 a 2-day meeting of a subgroup of the WHO Global Task Force on TB Impact Measurement (the Task Force) in May 2022 (18), which brought together 32 global experts in mathematical modelling, epidemiology and statistics as well as representatives from national TB programmes (NTPs) and partner agencies; and"
    },
    {
        "id": "doc_303",
        "document": "\u25b6 in an immediate follow-up to the Task Force meeting, a further detailed review of model documentation by several global experts in TB modelling, following which comments and suggestions were addressed."
    },
    {
        "id": "doc_304",
        "document": "From February to June 2023, the models were further informed by a series of in-depth bilateral discussions with 13 countries: Afghanistan, Brazil, Cambodia, Indonesia, Kazakhstan, Kyrgyzstan, Lesotho, Malaysia, Pakistan, the Philippines, Thailand, Uzbekistan and Viet Nam. These discussions were used to identify any new information that could be used to inform model inputs and resulted in some model adjustments (e.g. to the level of underreporting during COVID-19 disruptions)."
    },
    {
        "id": "doc_305",
        "document": "Further details about the methods used to estimate TB incidence and mortality in the period 2020\u20132022 (including methods used for non-modelled countries) and the methods used to produce estimates for 2010\u2013 2019 are provided in the report webpages (section 1.1 and section 1.2) and a technical appendix."
    },
    {
        "id": "doc_306",
        "document": "Estimates in this report are consistent with those published in 2022 (15). In countries with the biggest reductions in TB notifications compared with pre-2020 trends, the estimates show an increase in the number of TB deaths from 2019 to 2020 and again from 2020 to 2021. The pre-COVID decline in TB incidence is estimated to have slowed in 2020, followed by an increase from 2020 to 2021. Also, as suggested by the projections included in the 2021 report (14), the estimates in this report show a"
    },
    {
        "id": "doc_307",
        "document": "further increase in TB incidence in 2022 and a reversal (from a 2021 peak) in the number of deaths caused by TB."
    },
    {
        "id": "doc_308",
        "document": "a In addition, for India specifically, Google mobility data were used to include a second period of reduced transmission, during the COVID-19 \u201cDelta\u201d wave of 2021 (when there was no official \u201clockdown\u201d). Such data were not available for other countries."
    },
    {
        "id": "doc_309",
        "document": "b For four of the modelled countries (Azerbaijan, Brazil, Kazakhstan and Ukraine), national vital registration (VR) data were used for mortality estimates, instead of model-based estimates. For Bangladesh, the estimate of the incidence rate for 2010\u20132019 (unchanged throughout this period, with considerable uncertainty) was retained for 2020\u20132022, to avoid an odd discontinuity, and given the absence of evidence about trends in the period 2010\u20132019."
    },
    {
        "id": "doc_310",
        "document": "c Generally, these were estimates previously published by WHO, either for 2019 or for a combination of 2014 and 2019. For India, the calibration was to more recent estimates of TB incidence derived from the 2020 national TB prevalence survey and programmatic data, and updated estimates of the number of TB deaths in 2015 and 2019 (Box 4).\n\n12\n\nGlobal tuberculosis report 2023\n\nBox 4. Estimates of the number of deaths caused by TB in India revised downwards"
    },
    {
        "id": "doc_311",
        "document": "n WHO estimates of the annual number of deaths caused by TB in India have been revised downwards, following the availability of new cause-of-death data from the country\u2019s sample registration system (SRS) for the period 2014\u20132019. The updated estimates were extensively discussed with the Ministry of Health and Family Welfare in India and also informed by communications with the Institute for Health Metrics and Evaluation (IHME)."
    },
    {
        "id": "doc_312",
        "document": "The SRS provides data about vital events (births and deaths) that are nationally representative, based on a sample population of about 8 million people. Collection of SRS data on causes of death, based on verbal autopsy, was first piloted in 1998 and then expanded; the initial goal was to cover 1 million deaths between 1998 and 2014 (19). The SRS is an interim solution until the national vital registration (VR) system, which includes medical certification of causes of death, can achieve"
    },
    {
        "id": "doc_313",
        "document": "sufficient national coverage and quality. Coverage of the national VR system ranged from 16 to 22% in the period 2008\u2013 2020 (20)."
    },
    {
        "id": "doc_314",
        "document": "Between February and April 2023, the Office of the Registrar-General and Census Commissioner of India published official reports of SRS cause-of-death data for 2015\u20132017, 2016\u20132018 and 2017\u20132019 (21\u201323). A report for 2014\u20132016 was published in May 2022 (24). Reports for 2004\u20132006, 2007\u20132009 and 2010\u20132013 were first published in September 2021 (25\u201327). Previously, there were no official reports in the public domain that included SRS cause-of-death data."
    },
    {
        "id": "doc_315",
        "document": "In 2022, WHO estimates of the number of deaths caused by TB in India for the period 2000\u20132019 (15) were based on those produced as part of IHME\u2019s Global Burden of Disease study 2019 (GBD 2019) (28). WHO first used IHME estimates in 2016, in recognition of IHME\u2019s access to unpublished SRS datasets (for 2005, 2008 and 2012) and extensive analyses of TB mortality data for India (29). IHME methods include redistribution of causes of death, recognizing challenges in accurate assignment of cause of"
    },
    {
        "id": "doc_316",
        "document": "death based on verbal autopsy."
    },
    {
        "id": "doc_317",
        "document": "Estimates of the percentage of total deaths in India that were caused by TB in the official SRS reports are lower than those in GBD 2019, with increasing divergence over time (Fig. B4.1). A quasi-binomial model was used to produce a complete time series for 2000\u20132019, based on the SRS raw values for multi-year time periods (with the raw value assigned to the mid-year). As shown in Fig. B4.1, the SRS-based estimates are consistent with the values reported from the national VR system (which has"
    },
    {
        "id": "doc_318",
        "document": "the strength of being based on medical certification of the cause of death rather than verbal autopsy, but the weakness of low national coverage), in terms of absolute values and trends."
    },
    {
        "id": "doc_319",
        "document": "Estimates of the total number of deaths caused by TB for each year 2000\u20132019 were then produced in two steps. First, the SRS-based estimates of the percentage of total deaths caused by TB (shown in the red curve in Fig. B4.1) were upward adjusted for all years, to allow for possible inaccuracies in the cause of death assigned using verbal autopsy, and ill-defined causes. The upward adjustment was informed by the values of SRS \u201craw\u201d data as a\n\nFIg. b4.1"
    },
    {
        "id": "doc_320",
        "document": "Estimates of the percentage of deaths in India caused by TB, alternative sources\n\nB T y b d e s u 7 6 5 SRS-based estimates, 2000-2019 IHME estimates (GBD 2019) a c s h t a e d f o e g a t n e c r e P 4 3 2 1 0 2000 National VR data SRS data (raw values) 2005 2010 2015 2019"
    },
    {
        "id": "doc_321",
        "document": "proportion of GBD 2019 estimates in the three years for which IHME has unpublished, detailed SRS datasets i.e. 2005, 2008 and 2012. Based on these values, the upward adjustment for all years was approximated as a uniform distribution with bounds of 0.70 and 0.85. The second step was to multiply the upward-adjusted SRS values by WHO estimates of the total number of deaths in India."
    },
    {
        "id": "doc_322",
        "document": "The resulting estimates of the number of deaths caused by TB between 2000 and 2019 are considerably lower than the \u201cinterim\u201d estimates published in 2022 (15). For example, the revised estimate for 2019 is about 120 000 lower.\n\nEstimates for 2020\u20132022 were produced using a country- specific dynamic model that accounts for disruptions to TB diagnosis and treatment during the COVID-19 pandemic (Box 3), with the model calibrated to the new SRS-based estimates for 2015 and 2019."
    },
    {
        "id": "doc_323",
        "document": "The updated estimates of the number of deaths caused by TB in India between 2000 and 2022 are shown in Fig. B4.2.\n\nFurther details are provided in the online technical appendix.\n\nFIg. b4.2\n\nUpdated WHO estimates of the number of deaths caused by TB in India, 2000\u20132022\n\n1 000 000 s h t a e d 800 000 600 000 f o r e b m u 400 000 N 200 000 0 2000 2005 2010 2015 2019 2022\n\n3. Main findings and messages\n\n13\n\nFIg. 8"
    },
    {
        "id": "doc_324",
        "document": "Top causes of death worldwide in 2019a,b\n\nDeaths from TB among people with HIV are shown in grey."
    },
    {
        "id": "doc_325",
        "document": "Ischaemic heart disease Stroke Chronic obstructive pulmonary disease Lower respiratory infections Neonatal conditions Trachea, bronchus, lung cancers Alzheimer disease and other dementias Diarrhoeal diseases Diabetes mellitus Kidney diseases Cirrhosis of the liver Road injury Tuberculosis Hypertensive heart disease Colon and rectum cancers Stomach cancer Self-harm Falls HIV/AIDS Breast cancer 0 2 4 6 8 10 Number of deaths (millions)"
    },
    {
        "id": "doc_326",
        "document": "a This is the latest year for which estimates for all causes are currently available. See WHO estimates, available at\n\nhttps://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death\n\nb Deaths from TB among people with HIV are officially classified as deaths caused by HIV/AIDS in the International Classification of Diseases."
    },
    {
        "id": "doc_327",
        "document": "COVID-related disruptions are estimated to have resulted in almost half a million excess deaths from TB in the three years 2020\u20132022,1 compared with the num- ber that would have occurred if pre-pandemic trends had been maintained (Fig. 6)."
    },
    {
        "id": "doc_328",
        "document": "TB was the world\u2019s second leading cause of death from a single infectious agent in 2022, after COVID-19 (30).2 The global number of deaths officially classified as caused by TB in 2022 (1.13 million) was almost double the number caused by HIV/AIDS (0.63 million), and TB mortality has been much more severely impacted by the COVID-19 pandemic than HIV/AIDS (Fig. 7). In con- trast to TB, deaths from HIV/AIDS continued to decline between 2019 and 2022 (31)."
    },
    {
        "id": "doc_329",
        "document": "The latest year for which WHO has published esti- mates of global deaths by cause is 2019 (Fig. 8). In that year, TB was the 13th leading cause of death worldwide and the top cause from a single infectious agent."
    },
    {
        "id": "doc_330",
        "document": "The global pattern of a fall in the absolute number of deaths caused by TB (including those among people with HIV) until 2019, followed by increases in 2020\u20132021 and then a reversal in 2022, was also evident in the WHO Eastern Mediterranean and European regions (Fig. 9). In the South-East Asia and Western Pacific regions, the estimated number of deaths caused by TB was rela- tively stable between 2021 and 2022. In the Region of"
    },
    {
        "id": "doc_331",
        "document": "1 The best estimate is a cumulative total of 475 680 in these 3 years. This is consistent with a previous WHO projection (16).\n\n2 The officially reported number of deaths caused by COVID-19 in 2022 was 1.24 million (30). Since the reported number of deaths does not capture all deaths caused by COVID-19, the actual number was higher.\n\n14"
    },
    {
        "id": "doc_332",
        "document": "the Americas, the estimated number of deaths caused by TB continued to rise in 2022. In the African Region, the estimated number of deaths caused by TB fell up to 2019, was stable from 2019 to 2020 and then started to fall again.\n\nPatterns in the 30 high TB burden countries vary; some have estimated reductions in 2022, some have estimated increases and in a few the trend was relative- ly stable.3"
    },
    {
        "id": "doc_333",
        "document": "In 2022, 81% of the global number of deaths caused by TB among HIV-negative people occurred in the WHO African and South-East Asia regions; India alone accounted for 29% of such deaths. The WHO African and South-East Asia regions also accounted for 81% of the combined total number of deaths caused by TB among people with and without HIV; India accounted for 26% of such deaths."
    },
    {
        "id": "doc_334",
        "document": "Of the global number of deaths caused by TB among HIV-negative people in 2022, an estimated 587 000 (95% UI: 528 000\u2013649 000) were adult men (aged \u226515 years) equivalent to 52% of the total; 365 000 (95% UI: 328 000\u2013 404 000) were adult women (aged \u226515 years), equivalent to 32% of the total; and 183 000 (95% UI: 164 000\u2013 202 000) were children (aged <15 years), equivalent to 16% of the total."
    },
    {
        "id": "doc_335",
        "document": "Of the global deaths from TB among people with HIV, an estimated 78 000 (95% UI: 65 000\u201392 000) were adult men (47% of the total), 58 000 (95% UI: 48 000\u2013 69 000) were adult women (35% of the total) and 31 000 (95% UI: 26 000\u201337 000) were children (18% of the total).\n\n3 Time series for each of the 30 high TB burden countries are displayed in the report webpages and mobile app.\n\nGlobal tuberculosis report 2023\n\nFIg. 9"
    },
    {
        "id": "doc_336",
        "document": "Trends in the estimated absolute number of TB deaths (in thousands, including deaths among people with HIV)a by WHO region, 2010\u20132022\n\nThe horizontal dashed line shows the 2025 milestone of the End TB strategy, which is a 75% reduction in the total number of TB deaths between 2015 and 2025. Shaded areas represent 95% uncertainty intervals."
    },
    {
        "id": "doc_337",
        "document": "African Region Region of the Americas South-East Asia Region 1000 40 1200 800 30 1000 800 600 20 600 ) s d n 400 400 a s u o h 200 10 200 t ( r a e y 0 0 0 r e p s European Region Eastern Mediterranean Region Western Pacific Region h t a 60 120 150 e d B T l 50 100 125 a t o T 40 80 100 30 60 75 20 40 50 10 20 25 0 0 0 2010 2012 2014 2016 2018 2020 2022 2010 2012 2014 2016 2018 2020 2022 2010 2012 2014 2016 2018 2020 2022"
    },
    {
        "id": "doc_338",
        "document": "a Deaths from TB among people with HIV are officially classified as deaths caused by HIV/AIDS, with TB as a contributory cause.\n\nNumber of people developing TB"
    },
    {
        "id": "doc_339",
        "document": "global rise continued in 2022\n\nAn estimated 10.6 million people (95% UI: 9.9\u201311.4 mil- lion) fell ill with TB worldwide in 2022, up from 10.3 mil- lion (95% UI: 9.6\u201311.0 million) in 2021 and 10.0 million (95% UI: 9.4\u201310.7 million) in 2020, continuing the rever- sal of the downward trend that had been sustained for many years up to 2020 (Fig. 10).1,2"
    },
    {
        "id": "doc_340",
        "document": "The TB incidence rate (new cases per 100 000 popu- lation per year)3 is estimated to have increased by 3.9% between 2020 and 2022,4 from 128 (95% UI: 120\u2013137) in\n\n1 Estimates of TB incidence in 2020 and 2021 have been revised downwards for several countries, compared with those published in 2022 (15), resulting in downward revisions to the global estimates. Further details are provided in Annex 5."
    },
    {
        "id": "doc_341",
        "document": "2 The major contributors to the global increase between 2020 and 2022 were Indonesia, Myanmar and the Philippines. Collectively, TB incidence is estimated to have risen by about 0.4 million in these three countries.\n\n3 The report uses the latest population estimates published by the UN Population Division (see Annex 2).\n\n4 The estimated increase was 1.9% from 2020 to 2021 and also 1.9% from 2021 to 2022.\n\n3. Main findings and messages"
    },
    {
        "id": "doc_342",
        "document": "2020 to 133 (95% UI: 124\u2013143) in 2022, following declines of about 2% per year between 2010 and 2020 (Fig. 10, right panel).5"
    },
    {
        "id": "doc_343",
        "document": "This reversal of progress made up to 2020 is consist- ent with previous projections (14) and estimates (15), and reflects the estimated impact of disruptions to essential TB services during the COVID-19 pandemic (Fig. 1\u2013Fig. 4, Box 3). The impact of these disruptions on TB incidence globally in 2021 and 2022, compared with a continued decline from 2019 to 2020, can be explained by time lags between increases in TB trans- mission (caused by more people having undiagnosed and untreated TB) and"
    },
    {
        "id": "doc_344",
        "document": "subsequent development of dis- ease among a proportion of those newly infected."
    },
    {
        "id": "doc_345",
        "document": "At regional level, the TB incidence rate continued to increase in 2022 in three of the six WHO regions: the Region of the Americas, South-East Asia and the West- ern Pacific (Fig. 11). An upward trend between 2020 and 2021 was reversed in 2022 in two regions: the Eastern Mediterranean Region (back to the level of 2020) and the\n\n5 Globally, the TB incidence rate is estimated to have fallen by 21% between 2010 and 2020.\n\n15\n\nFIg. 10"
    },
    {
        "id": "doc_346",
        "document": "Global trends in the estimated number of incident TB cases (left) and the incidence rate (right), 2010\u20132022\n\nThe horizontal dashed line shows the 2025 milestone of the End TB strategy, which is a 50% reduction in the TB incidence rate between 2015 and 2025. Shaded areas represent 95% uncertainty intervals."
    },
    {
        "id": "doc_347",
        "document": "15 Total r a e y r e p 250 200 Total 10 n o i t a l u 150 5 Case notifications of people newly diagnosed with TB People living with HIV p o p 0 0 0 0 0 1 r e 100 50 Case notifications of people newly diagnosed with TB People living with HIV 2025 milestone p 0 e t a 0 R 2010 2012 2014 2016 2018 2020 2022 2010 2012 2014 2016 2018 2020 2022\n\nMillions per\n\nTrends in estimated TB incidence rates by WHO region, 2010\u20132022"
    },
    {
        "id": "doc_348",
        "document": "The overall TB incidence rate is shown in blue and the incidence rate among people living with HIV is shown in light blue. The black solid lines show case notifications of people newly diagnosed with TB, for comparison with estimates of the overall incidence rate. The horizontal dashed line shows the 2025 milestone of the End TB strategy, which is a 50% reduction in the TB incidence rate between 2015 and 2025. Shaded areas represent 95% uncertainty intervals."
    },
    {
        "id": "doc_349",
        "document": "African Region 400 300 r a e y 200 r e p n o i t 100 a l u p o p 0 0 0 0 0 0 1 European Region r e p e t a r e 45 c n e d i c n I 30 15 0 2010 2012 2014 2016 2018 2020 2022\n\nRegion of the Americas\n\n30v/\n\n20\n\nT \\S\n\nL e e o\n\n10\n\n0\n\nEastern Mediterranean Region\n\n150\n\n100\n\ne\n\n50\n\n0\n\n2010 2012 2014 2016 2018 2020 2022\n\nSouth-East Asia Region\n\n400 300 200 | == - - - 100\n\nWestern Pacific Region\n\n80 40 0 2010 2012 2014 2016 2018 2020 2022\n\n16\n\nGlobal tuberculosis report 2023\n\nFIg. 12"
    },
    {
        "id": "doc_350",
        "document": "Estimated number of incident TB cases in 2022, for countries with at least 100 000 incident casesa\n\nChina Bangladesh Philippines Pakistan Number of incident cases Nigeria India 100 000 Indonesia 500 000 Democratic Republic of the Congo 1 000 000 2 000 000"
    },
    {
        "id": "doc_351",
        "document": "a The eight countries ranked in order from first to last in terms of numbers of cases, and that accounted for about two thirds of global cases in 2022, are India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and the Democratic Republic of the Congo."
    },
    {
        "id": "doc_352",
        "document": "European Region (almost back to the level of 2020). In the African Region, the decline that has been sustained for many years was maintained in 2022, consistent with evidence that disruptions related to the COVID-19 pandemic had limited impact on the number of people diagnosed and officially notified with TB in either 2020 or 2021 (Fig. 2)."
    },
    {
        "id": "doc_353",
        "document": "Geographically, in 2022, most people who developed TB were in the WHO regions of South-East Asia (46%), Africa (23%) and the Western Pacific (18%), with small- er proportions in the Eastern Mediterranean (8.1%), the Americas (3.1%) and Europe (2.2%). The 30 high TB burden countries accounted for 87% of all estimated incident cases worldwide, and eight of these countries (Fig. 12) accounted for more than two thirds of the global total: India (27%), Indonesia (10%), China (7.1%), the Philippines"
    },
    {
        "id": "doc_354",
        "document": "(7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%)."
    },
    {
        "id": "doc_355",
        "document": "TB can affect anyone, regardless of age or sex (Fig. 13). The highest burden is in adult men (aged \u226515 years), with an estimated 5.8 million cases (95% UI: 5.4\u20136.2 million) in 2022, equivalent to 55% of the esti- mated total. There were an estimated 3.5 million cases (95% UI: 3.3\u20133.8 million) among adult women (aged \u226515 years), equivalent to 33% of the estimated total; and 1.3 million cases (95% UI: 1.2\u20131.3 million) among children (aged 0\u201314 years), equivalent to 12% of the estimated"
    },
    {
        "id": "doc_356",
        "document": "3. Main findings and messages\n\nFIg. 13\n\nGlobal estimates of TB incidence (black outline) and case notifications of people newly diagnosed with TB disaggregated by age and sex (female in purple; male in orange), 2022\n\n\u226565 55\u201364 ) s r 45\u201354 a e y ( p u 35\u201344 o r g 25\u201334 e g A 15\u201324 5\u201314 0\u20134 1 000 000 500 000 0 500 000 1 000 000 Number of TB cases\n\n17\n\nFIg. 14"
    },
    {
        "id": "doc_357",
        "document": "Estimated TB incidence rates, 2022\n\nIncidence per 100 000 population per year 0\u20139.9 10\u201349 50\u201399 100\u2013299 300\u2013499 \u2265500 No data Not applicable\n\ntotal. The higher share of TB cases among men is con- sistent with evidence from national TB prevalence sur- veys, which show that TB disease affects men more than women, and that gaps in case detection and reporting are higher among men.1"
    },
    {
        "id": "doc_358",
        "document": "Among all incident cases of TB in 2022, 6.3% were people living with HIV; this proportion has been steadi- ly declining for several years. The proportion of people with a new episode of TB who were living with HIV was highest in countries in the WHO African Region, exceed- ing 50% in parts of southern Africa."
    },
    {
        "id": "doc_359",
        "document": "The severity of national TB epidemics, in terms of the number of incident TB cases per 100 000 population per year, varies widely among countries, from less than 10 to more than 500 new and relapse cases per 100 000 population per year (Fig. 14). In 2022, 57 countries had a low incidence of TB (<10 cases per 100 000 population per year), mostly in the WHO Region of the Americas and the WHO European Region, plus a few countries in the WHO Eastern Mediterranean and Western Pacific regions. There"
    },
    {
        "id": "doc_360",
        "document": "were 150\u2012400 cases per 100 000 popu- lation in most of the 30 high TB burden countries, and more than 500 cases per 100 000 population in the Cen- tral African Republic, the Democratic People\u2019s Republic of Korea, Gabon, Lesotho and the Philippines."
    },
    {
        "id": "doc_361",
        "document": "Drug-resistant TB continues to be a public health threat. Resistance to rifampicin \u2013 the most effective first- line drug \u2013 is of greatest concern. TB that is resistant to\n\n1 For further details, see Section 1.4 of the report webpages.\n\n18\n\nrifampicin and isoniazid is defined as multidrug-resist- ant TB (MDR-TB). Both MDR-TB and rifampicin-resistant TB (RR-TB) require treatment with second-line drugs."
    },
    {
        "id": "doc_362",
        "document": "Globally, the estimated annual number of people who developed MDR-TB or RR-TB (MDR/RR-TB) was rela- tively flat between 2020 and 2022 (Fig. 15), after a slow downward trend between 2015 and 2019. The estimated number in 2022 was 410 000 (95% UI: 370 000\u2013450 000).2 The reason why the number of people developing MDR/ RR-TB was relatively stable from 2020\u20132022, in contrast to an estimated rise in the number of people develop- ing TB overall (Fig. 10), is that increases in the overall number of"
    },
    {
        "id": "doc_363",
        "document": "people developing TB have been compensat- ed for by an estimated downward trend (since 2015) in the proportion of people with TB who have MDR/RR-TB, particularly among those with a previous history of treatment (Fig. 16)."
    },
    {
        "id": "doc_364",
        "document": "In 2022, the estimated proportion of people with TB who had MDR/RR-TB was 3.3% (95% UI: 2.6\u20134.0%) among new cases and 17% (95% UI: 11\u201323%) among those previously treated; the figures in 2015 were 4.0% (95% UI: 3.1\u20134.9%) and 25% (95% UI: 15\u201336%), respec-"
    },
    {
        "id": "doc_365",
        "document": "2 Estimates for 2015\u20132021 are lower than those published in 2022 (15), although with widely overlapping uncertainty intervals. Estimates for the entire period 2015\u20132022 have been revised based on new or updated data (including corrections to data previously reported to WHO). The country revision that had the biggest impact on global estimates was for Pakistan. Further details are provided in Annex 5 and the online technical appendix.\n\nGlobal tuberculosis report 2023\n\nFIg. 15"
    },
    {
        "id": "doc_366",
        "document": "Global trend in the estimated number of people who developed MDR/RR-TB (incident cases), 2015\u20132022\n\nThe shaded area represents the 95% uncertainty interval.\n\n600 r a e y r e p 400 s d n a s u o h 200 T 0 2015 2016 2017 2018 2019 2020 2021 2022\n\nFIg. 16"
    },
    {
        "id": "doc_367",
        "document": "Global trend in the estimated percentage of people with TB who had MDR/RR-TB, 2015\u20132022\n\nThe shaded areas represent 95% uncertainty intervals.\n\nPeople with no previous history of TB treatment\n\n) % ( B T - R 8 R / R D M 6 h t i w n 4 o i t r o p 2 o r P 0\n\nPeople previously treated for TB\n\n40\n\n) % ( B T - R 30 R / R D M h t 20 i w n o i t r 10 o p o r P 0 2015 2016 2017 2018 2019 2020 2021 2022"
    },
    {
        "id": "doc_368",
        "document": "tively; in 2020, the figures were 3.4% (95% UI: 2.7\u20134.1%) and 20% (95% UI: 13\u201327%), respectively (Fig. 16).\n\nThree countries accounted for 42% of the estimated global number of people who developed MDR/RR-TB in 2022 (Fig. 17): India (27%), the Philippines (7.5%) and the Russian Federation (7.5%). The highest proportions (>50% of previously treated cases with MDR/RR-TB) are found in the Russian Federation and in several countries in Eastern Europe and Central Asia."
    },
    {
        "id": "doc_369",
        "document": "Milestones for reducing TB disease burden Mostly off track, some success stories"
    },
    {
        "id": "doc_370",
        "document": "The first End TB Strategy milestones for reductions in TB disease burden were a 35% reduction in the total number of deaths caused by TB (including those among people with HIV1) and a 20% reduction in the TB inci- dence rate by 2020, compared with levels in 2015; the second milestones, for 2025, were a 75% reduction in deaths from TB and a 50% reduction in TB incidence (Box 2). The first milestones set for 2020 have not yet been reached either globally or in most WHO regions and countries, and"
    },
    {
        "id": "doc_371",
        "document": "the second milestones are far away in most parts of the world. Reversals of progress dur- ing the COVID-19 pandemic have made both milestones much harder to achieve."
    },
    {
        "id": "doc_372",
        "document": "Globally, the net reduction in the total number of deaths caused by TB between 2015 and 2022 was 19%. Progress achieved up to 2019 (a 19% reduction from 2015 to 2019 and a 33% reduction from 2010 to 2019) was compromised by increases in the number of deaths caused by TB in 2020 and 2021 (Fig. 5, left panel)."
    },
    {
        "id": "doc_373",
        "document": "At regional level, reductions in the number of deaths caused by TB since 2015 vary (Fig. 9). The biggest reductions were in the WHO African Region, with a 38% decline by 2022, followed by the WHO European Region with a decline of 32%. These two regions are the only ones that have surpassed the first milestone of the End TB Strategy. Following major reversals of progress in 2020 and 2021, the net decline by 2022 compared with 2015 was modest in three WHO regions: the Eastern Mediterranean (7.8%),"
    },
    {
        "id": "doc_374",
        "document": "South-East Asia (6.3%) and the Western Pacific (3.3%). In the Region of the Americas, the estimated number of deaths caused by TB in 2022 was much higher than in 2015 (+41%)."
    },
    {
        "id": "doc_375",
        "document": "Progress in reducing the number of deaths caused by TB at country level is highly variable (Fig. 18). By 2022, a total of 47 countries had reached or surpassed the first milestone of the End TB Strategy, with an estimat- ed reduction of at least 35% since 2015. This included at least one country in every WHO region. Some coun- tries are estimated to have achieved reductions of 50% or more between 2015 and 2022, including five high TB burden countries (Kenya, Mozambique, Uganda, the"
    },
    {
        "id": "doc_376",
        "document": "3. Main findings and messages\n\n1 Officially classified as deaths from HIV/AIDS, with TB as a contributory cause.\n\n19\n\nFIg. 17"
    },
    {
        "id": "doc_377",
        "document": "Estimated number of people who developed MDR/RR-TB (incident cases) in 2022, for countries with at least 1000 incident casesa\n\nRussian Federation China Philippines Pakistan Myanmar Nigeria India Number of cases Indonesia 1 000 10 000 100 000\n\na The eight countries ranked in descending order of the total number of RR-TB incident cases in 2022 are India, the Philippines, the Russian Federation, Indonesia, China, Pakistan, Myanmar and Nigeria."
    },
    {
        "id": "doc_378",
        "document": "United Republic of Tanzania and Zambia) and one of the three global TB watchlist countries (the Russian Fed- eration).1 At the other extreme, there are 71 countries where the number of deaths caused by TB in 2022 was more than 5% above the level of 2015, most noticeably in the WHO Region of the Americas.\n\nGlobally, the cumulative reduction in the TB inci- dence rate from 2015 to 2022 was 8.7%, far from the End TB Strategy milestone of a 50% reduction by 2025 (Fig. 10, right panel)."
    },
    {
        "id": "doc_379",
        "document": "At regional level, as with reductions in deaths caused by TB, reductions in the TB incidence rate since 2015 vary (Fig. 11). The biggest reduction was in the WHO European Region, with a net reduction of 25% by 2022, even though progress was reversed by COVID-related disruptions in 2021 and the incidence rate remained above the 2019 level in 2022. A similar reduction was achieved in the African Region, with a 23% decline by 2022. These are the only regions to have surpassed the first milestone of"
    },
    {
        "id": "doc_380",
        "document": "the End TB Strategy. The net decline by 2022 compared with 2015 was relatively small in three of the remaining WHO regions: the Eastern Med-"
    },
    {
        "id": "doc_381",
        "document": "1 Alongside the list of 30 high TB burden countries for 2021\u20132025, WHO established a global TB watchlist (Annex 3). The watchlist comprises the three countries that transitioned out of the previous list for 2016\u20132020, which warrant continued global attention: Cambodia, the Russian Federation and Zimbabwe.\n\n20"
    },
    {
        "id": "doc_382",
        "document": "iterranean Region (7.4%), South-East Asia (6.6%) and the Western Pacific (3.7%). Increases in TB incidence in 2021 and 2022 in the WHO South-East Asia and West- ern Pacific regions were a major setback to progress made up to 2019, while the WHO Eastern Mediterranean Region suffered a setback in 2020 that was reversed in 2022. The most concerning trend is in the WHO Region of the Americas, where there was a net increase of 14% between 2015 and 2022."
    },
    {
        "id": "doc_383",
        "document": "Progress in reducing the TB incidence rate at coun- try level is highly variable (Fig. 19). By 2022, a total of 83 countries, mostly in the WHO European and African regions, had achieved estimated reductions of more than 20% since 2015, thus surpassing the first mile- stone of the End TB Strategy. A total of 21 countries are estimated to have achieved reductions of at least 50% between 2015 and 2022, including one high TB burden country (South Africa). At the other extreme, there are 39"
    },
    {
        "id": "doc_384",
        "document": "countries where TB incidence in 2022 was estimated to be more than 5% higher than in 2015. These are most noticeably in the WHO Region of the Americas, but also include four high TB burden countries in Asia: Indone- sia, Mongolia, Myanmar and the Philippines."
    },
    {
        "id": "doc_385",
        "document": "Global tuberculosis report 2023\n\nFIg. 18\n\nChange (%) in the estimated number of deaths caused by TB, 2022 compared with 2015\n\nChange (2022 vs 2015,%) Increase (>5%) Stable (\u20135% to +5%) Decrease (6\u201319%) Decrease (20\u201334%) Decrease (35\u201349%) Decrease (\u226550%) No data Not applicable\n\nFIg. 19\n\nChange (%) in estimated TB incidence (new cases per 100 000 population), 2022 compared with 2015"
    },
    {
        "id": "doc_386",
        "document": "Change (2022 vs 2015,%) Increase (>5%) Stable (\u20135% to +5%) Decrease (6\u20139%) Decrease (10\u201319%) Decrease (20\u201349%) Decrease (\u226550%) No data Not applicable\n\n3. Main findings and messages\n\n21\n\nFIg. 20\n\nThe relationship between GDP per capita and the prevalence of undernourishment,a and TB incidence per 100 000 population, 2022b\n\nEach dot represents a country or area."
    },
    {
        "id": "doc_387",
        "document": "1000 1000 ) e l a c s g o 100 l ( n o 100 i t a l u p o p 0 0 0 0 0 1 10 r e p 10 e c n e d i c n I 1 1 1 10 100 3 10 30 GDP per capita (US$ thousands) Prevalence of undernourishment (% of population)"
    },
    {
        "id": "doc_388",
        "document": "Incidence per 100 000 population (log scale)\n\na Prevalence of undernourishment is the percentage of the population whose habitual food consumption is insufficient to provide the dietary energy levels that are required to maintain a normal active and healthy life.\n\nb The year of data used for GDP per capita and undernourishment is the latest year for which data are available in the World Bank\n\n(https://data.worldbank.org) and SDG (https://unstats.un.org/sdgs/dataportal) databases, respectively."
    },
    {
        "id": "doc_389",
        "document": "TB deaths and incidence beyond 2022\n\nglobal rise in incidence may reverse in 2023 or 2024"
    },
    {
        "id": "doc_390",
        "document": "The country-specific models developed for 26 coun- tries (Box 3) to estimate TB incidence and mortality in the period 2020\u20132022 also allow projections for subse- quent years, for different scenarios of recovery in the numbers of people newly diagnosed and treated for TB in the period 2023\u20132025. If the recoveries in 2022 are sustained, then at the global level the number of deaths caused by TB should continue to decline. Reversal of the upward trend in TB incidence may occur in 2023 but could"
    },
    {
        "id": "doc_391",
        "document": "take until 2024."
    },
    {
        "id": "doc_392",
        "document": "At country level, returning to pre-COVID downward trends is most challenging in the countries that experi- enced the biggest reductions in the number of people newly diagnosed and treated for TB in 2020 and 2021; of these, the two that have the biggest influence on global trends are Indonesia and the Philippines. Both countries achieved impressive recoveries in 2022, which have already moderated upward trends in the number of people developing TB and the number of deaths caused by TB."
    },
    {
        "id": "doc_393",
        "document": "Maintaining these recoveries should be a top priority in both countries, and elsewhere, in 2023 and beyond."
    },
    {
        "id": "doc_394",
        "document": "The current models might understate the impact of the COVID-19 pandemic on TB disease burden in 2020\u20132022, because they do not account for negative\n\n22"
    },
    {
        "id": "doc_395",
        "document": "effects on broader TB determinants (Box 3). These include average income (measured as gross domestic product [GDP] per capita) and the prevalence of under- nourishment, both of which are closely associated with TB incidence (Fig. 20). Worsening trends in these two indicators, and other determinants such as levels of poverty, could increase the probability of developing TB disease among people already infected with M. tubercu- losis as well as their subsequent risk of dying from TB. Declines in"
    },
    {
        "id": "doc_396",
        "document": "income may also affect health care seeking behaviour when people become unwell, making delays in TB diagnosis and treatment more likely."
    },
    {
        "id": "doc_397",
        "document": "Estimation of TB disease burden\n\nnew direct measurements needed"
    },
    {
        "id": "doc_398",
        "document": "Estimating TB disease burden during the COVID-19 pan- demic and its aftermath is difficult and currently relies on country- and region-specific dynamic models for many low and middle-income countries (LMICs) (Box 3). This is in contrast to the methods used for the period 2000\u20132019.1 These included use of results from popula- tion-based surveys of the prevalence of TB disease that were implemented between 2000 and 2019 to inform estimates of TB incidence in 29 countries that account- ed for about"
    },
    {
        "id": "doc_399",
        "document": "two-thirds of global TB incidence; and use"
    },
    {
        "id": "doc_400",
        "document": "1 For further details, see Section 1.1 and Section 1.2 of the report webpages.\n\nGlobal tuberculosis report 2023\n\nof data from national vital registration (VR) systems or mortality surveys for the period 2000\u20132019 to inform estimates of the number of deaths caused by TB in 123 countries that accounted for about 60% of the global number of deaths caused by TB among HIV-negative people."
    },
    {
        "id": "doc_401",
        "document": "For this report, there were only three high TB bur- den or global TB watchlist countries for which data on the number of TB deaths in the period 2020\u20132022 were available from national VR systems and shared with WHO: Brazil, China and the Russian Federation. Among the modelled countries, in addition to Brazil, national VR data were used to produce the mortality estimates for Azerbaijan, Kazakhstan and Ukraine (Box 3).1"
    },
    {
        "id": "doc_402",
        "document": "The only country in which a national TB prevalence survey has been completed since 2019 is India; the sur- vey was started in 2019, interrupted for several months in 2020 and then completed in 2021. Results from this survey were a key input to the estimates of TB incidence in India published in this report.2"
    },
    {
        "id": "doc_403",
        "document": "New national population-based surveys of TB dis- ease and up-to-date cause-of-death data from national or sample VR systems of high quality and coverage are needed for more accurate estimation in the wake of the pandemic. Inventory studies to assess the level of underreporting of people diagnosed with TB would also be helpful."
    },
    {
        "id": "doc_404",
        "document": "A repeat national TB prevalence survey in Cambo- dia started in July 2023 (following previous surveys in 2002 and 2011) and 11 additional countries are actively interested in implementing a repeat survey in the next 1\u20133 years: Ethiopia, Ghana, Indonesia, Malawi, Nigeria, Pakistan, Thailand, Uganda, the United Republic of Tan- zania, Zambia and Zimbabwe.3 In Indonesia, a national inventory study is also being planned, to be implement- ed before the repeat national TB prevalence survey."
    },
    {
        "id": "doc_405",
        "document": "The recently published cause-of death data from the sample registration system (SRS) in India (Box 4) clearly demonstrate the value of up-to-date cause of death data from sample and national VR systems, for more reliable tracking of trends in the number of deaths caused by TB.\n\nTB diagnosis and treatment"
    },
    {
        "id": "doc_406",
        "document": "global recovery in 2022, but targets not achieved\n\nThere are still wide gaps between the estimated num- ber of people who develop TB each year (incident cases) and the number of people newly diagnosed and official- ly reported as a TB case (Fig. 21), reflecting a mixture of underdiagnosis of people with TB as well as underre- porting of people diagnosed with TB to national author-\n\n1 i.e. the models were used only for estimates of TB incidence in these countries."
    },
    {
        "id": "doc_407",
        "document": "2 Further details are provided in Annex 5 and the online technical appendix.\n\n3 For further details, see Section 1.4 of the report webpages.\n\n3. Main findings and messages\n\nFIg. 21\n\nGlobal trend in case notifications of people newly diagnosed with TB (black) and the estimated number of incident TB cases (green), 2010\u20132022\n\nThe shaded area represents the 95% uncertainty interval.\n\n15 r a e y 10 r e p s n o i l l i M 5 0 2010 2012 2014 2016 2018 2020 2022"
    },
    {
        "id": "doc_408",
        "document": "ities (Fig. 21). Disruptions associated with the COVID-19 pandemic caused a major widening of the global gap in 2020 and 2021, to best estimates of around 4 million in both years. The major rebound in global notifications of people newly diagnosed with TB in 2022 (Fig. 1) has narrowed the gap back to the pre-pandemic level, with best estimates of 3.1 million in both 2019 and 2022. However, it is important to highlight that some of the rebound in the number of people newly diagnosed with TB and"
    },
    {
        "id": "doc_409",
        "document": "reported as a \u201cnew case\u201d in 2021 and 2022 probably reflects a sizeable backlog of people who developed TB in previous years; they were not \u201cincident cases\u201d, but rather people whose diagnosis was delayed by COVID-related disruptions."
    },
    {
        "id": "doc_410",
        "document": "The two countries that made the biggest contribu- tions to the global rebound in the reported number of people newly diagnosed with TB in 2022 were India and Indonesia, together accounting for 56% of the increase between 2021 and 2022. Previously, they were also the main contributors to the large global increase in TB case notifications that occurred between 2013 and 2019. The two other countries that made major contributions to the global increase between 2021 and 2022 were the Philippines and"
    },
    {
        "id": "doc_411",
        "document": "Pakistan (11% and 8.4% of the global increase, respectively)."
    },
    {
        "id": "doc_412",
        "document": "In 2022, TB treatment coverage (approximated as the reported number of people newly diagnosed with TB divided by incidence)4 appears to have recovered to the pre-pandemic level of 70% (95% UI: 66\u201375%), up from 62% (95% UI: 58\u201367%) in 2021 and 58% (95% UI: 55\u201362%) in 2020. However, as already highlighted above, some of the people newly diagnosed with TB in 2022 (and 2021)"
    },
    {
        "id": "doc_413",
        "document": "4 Some people who are newly diagnosed and reported may not be started on treatment, and some people may be diagnosed and treated but not reported (and thus not included in the number of case notifications).\n\n23\n\nFIg. 22\n\nThe global number of people reported to have been treated for TB disease, 2010\u20132022\n\n8 6 s n o i l l 4 i M 2 0 2010 2012 2014 2016 2018 2020 2022 Adults (aged \u226515 years) Children (aged 0\u201314 years)\n\ntral African Republic, Lesotho, Liberia, Mongolia and Myanmar."
    },
    {
        "id": "doc_414",
        "document": "The major reversals of progress in increasing the number of people newly diagnosed with TB each year (Fig. 1) in 2020 and 2021 badly impacted progress towards global TB treatment targets (Fig. 22). Despite the global recovery in 2022, none of the treatment targets set for the period 2018\u20132022 at the first UN high-level meeting on TB were achieved (Fig. 23). The cumulative number of people treated for TB between 2018 and 2022 was 34 million,1 equivalent to 84% of the 5-year (2018\u20132022) target of"
    },
    {
        "id": "doc_415",
        "document": "40 million. This number included 2.5 million children, 71% of the 5-year target of 3.5 million."
    },
    {
        "id": "doc_416",
        "document": "In 2022, 10 countries collectively accounted for 71% of the global gap between estimated TB incidence and the reported number of people newly diagnosed with\n\nFIg. 23\n\nThe global numbers of people treated for TB between 2018 and 2022, compared with targets set at the 2018 UN high-level meeting on TB"
    },
    {
        "id": "doc_417",
        "document": "TB TREATMENT TB TREATMENT (ALL AGES) (CHILDREN) Target: 40 million 34million (84%) Target: 3.5 million 2.5million (71%) 2018\u20132022 treated in 2018\u20132022 treated in 2018\u20132022 2018\u20132022 MDR/RR-TB TREATMENT MDR/RR-TB TREATMENT (ALL AGES) (CHILDREN) Target: 1.5 million 825 000 (55%) Target: 115 000 21 600 (19%) 2018\u20132022 treated in 2018\u20132022 treated in 2018\u20132022 2018\u20132022"
    },
    {
        "id": "doc_418",
        "document": "were part of a backlog of people who developed TB in previous years (and were thus not \u201cincident\u201d cases), whose diagnosis was delayed by COVID-related disrup- tions. This distorts estimates of treatment coverage in 2021 and 2022."
    },
    {
        "id": "doc_419",
        "document": "Among the six WHO regions, best estimates of treat- ment coverage in 2022 ranged from 63% in the Western Pacific Region to 74% in the Region of the Americas. Of the 30 high TB burden countries, those with the highest levels (\u226580%) of treatment coverage in 2022 included Brazil, India, Uganda and Zambia. Five high TB burden countries had worryingly low levels of treatment cover- age in 2022, with best estimates of below 50%: the Cen-\n\n24"
    },
    {
        "id": "doc_420",
        "document": "TB (Fig. 24). The top five contributors (collectively accounting for more than 50% of the global gap) were India (18%), Indonesia (11%), the Philippines (9.6%), Nigeria (6.2%) and Pakistan (5.8%). From a global per- spective, efforts to increase levels of case detection are of particular importance in these countries.\n\nIn many countries, there is also a need to increase the percentage of cases confirmed bacteriologically by scal- ing up the use of recommended diagnostics, in line with"
    },
    {
        "id": "doc_421",
        "document": "1 This number assumes that all those diagnosed and reported were treated.\n\nGlobal tuberculosis report 2023\n\nFIg. 24\n\nThe ten countries with the largest gaps between notifications of people with a new or relapse episode of TB and the best estimates of TB incidence,a 2022\n\nChina Bangladesh Viet Nam Philippines Pakistan Myanmar Size of gap Nigeria India 50 000 Indonesia 250 000 Democratic Republic of the Congo 500 000"
    },
    {
        "id": "doc_422",
        "document": "a The ten countries ranked in order of the size of the gap between notified cases and the best estimates of TB incidence in 2022 are India, Indonesia, the Philippines, China, Nigeria, Pakistan, Myanmar, Bangladesh, Viet Nam and the Democratic Republic of the Congo."
    },
    {
        "id": "doc_423",
        "document": "WHO guidelines (32).1 The microbiological detection of TB using WHO-recommended tests is critical because it allows people to be correctly diagnosed, is necessary to test for drug resistance and ensures that the most effective treatment regimen (depending on the pattern of drug resistance) can be selected as early as possible."
    },
    {
        "id": "doc_424",
        "document": "Of the 6.2 million people diagnosed with pulmonary TB worldwide in 2022, 63% were bacteriologically con- firmed (Fig. 25). This was the same level as in 2021. There was some variation among the six WHO regions, with the highest percentage achieved in the Region of the Americas (79%) and the lowest in the Eastern Med- iterranean Region (56%). There was also considerable variation among countries. In general, levels of confir- mation were lowest in low-income countries (median, 71%), and highest"
    },
    {
        "id": "doc_425",
        "document": "in high-income countries (median, 91%) where there is wide access to the most sensitive diagnostic tests."
    },
    {
        "id": "doc_426",
        "document": "The use of rapid tests is growing, although it remains far too limited (Fig. 26). A WHO-recommended rapid"
    },
    {
        "id": "doc_427",
        "document": "1 To facilitate implementation of WHO guidelines, WHO also publishes operational handbooks. More recently, WHO has developed online courses that are designed for health care workers and people working with NTPs. To date, these cover TB prevention, diagnostics, treatment, and use of data for decision making. The courses are free of charge and can be accessed via the End TB channel in OpenWHO (openwho.org) and the WHO Academy.\n\n3. Main findings and messages"
    },
    {
        "id": "doc_428",
        "document": "diagnostic test (WRD) was used as the initial test for 47% (3.5 million) of the 7.5 million people newly diagnosed with TB in 2022, up from 38% (2.5/6.4 million) in 2021 and 33% (1.9/5.8 million) in 2020. Coverage will need to more than double to reach the new target set at the 2023 UN high-level meeting on TB, which is 100% by 2027 (Table 2)."
    },
    {
        "id": "doc_429",
        "document": "There was substantial variation in the coverage of rapid testing among regions and countries in 2022 (Fig. 26, Fig. 27). Among WHO regions, the highest lev- els of coverage were in the European Region (77%) and the Western Pacific Region (65%) and the lowest was in the South-East Asia Region (39%). At country level, 55 countries achieved levels of at least 80% in 2022, but it was less than 20% in 50 countries. Among the 49 countries in one of the three global lists of high burden countries (for"
    },
    {
        "id": "doc_430",
        "document": "TB, HIV-associated TB and MDR/RR-TB),2 31 reported that a WRD had been used as the initial test for more than half of their notified TB cases in 2022, up from 27 in 2021 and 21 in 2020."
    },
    {
        "id": "doc_431",
        "document": "The global coverage of HIV testing among people diagnosed with TB remained high in 2022, at 80% (up from 76% in 2021 and 73% in 2020). At regional level, the highest coverage in 2022 was achieved in the WHO African Region (89%) and the European Region (93%). In\n\n2 See Annex 3.\n\n25\n\nFIg. 25\n\nPercentage of people newly diagnosed with pulmonary TB who were bacteriologically confirmed, globally and for WHO regions,a 2010\u20132022"
    },
    {
        "id": "doc_432",
        "document": "100 Global African Region Region of the Americas South-East Asia Region 80 d 60 e m r i f 40 n o c y 20 l l a c i g o 0 l o i 2010 2013 2016 2019 2022 r e t c a 100 European Region Eastern Mediterranean Region Western Pacific Region b e g a 80 t n e c r e 60 P 40 20 0 2010 2013 2016 2019 2022 2010 2013 2016 2019 2022 2010 2013 2016 2019 2022"
    },
    {
        "id": "doc_433",
        "document": "a Data are for notified cases. The calculation for years prior to 2013 is based on smear results, except for the European Region where data on confirmation by culture were also available for the period 2010\u20132012.\n\nFIg. 26\n\nPercentage of people newly diagnosed with TB who were initially tested with a WHO-recommended rapid diagnostic test (WRD), globally and for WHO regions, 2015\u20132022\n\ne\n\nPercentage"
    },
    {
        "id": "doc_434",
        "document": "P\n\n100\n\n80\n\n60\n\n40\n\n20\n\n0\n\n100\n\n80\n\n60\n\n40\n\n20\n\nAfrican Region Region of the Americas Eastern Mediterranean Region Western Pacific Region\n\nGlobal\n\nEuropean"
    },
    {
        "id": "doc_435",
        "document": "South-East Asia\n\nRegion\n\n2016 2018 2020 2022\n\n0\n\n2016\n\n2016 2018 2020 2022\n\n2016 2018 2020 2022\n\n26\n\nGlobal tuberculosis report 2023\n\nFIg. 27\n\nPercentage of people newly diagnosed with TB who were initially tested with a WHO-recommended rapid diagnostic test (WRD), by country, 2022\n\nPercentage (%) <20 20\u201339 40\u201359 60\u201379 \u226580 No data Not applicable"
    },
    {
        "id": "doc_436",
        "document": "97 countries or areas, at least 90% of people diagnosed with TB knew their HIV status; this included 32 of the 47 countries in the African Region, where the burden of HIV-associated TB is highest."
    },
    {
        "id": "doc_437",
        "document": "Among people living with HIV who develop TB, both TB treatment and antiretroviral therapy (ART) for HIV are required to prevent unnecessary deaths from TB and HIV. The global coverage of ART for people living with HIV who were newly diagnosed and reported with TB was 85% in 2022, the same as in 2021. However, when compared with the total number of people liv- ing with HIV estimated to have developed TB in 2022, coverage was only 54% (up from 46% in 2021). This was far below the overall level of"
    },
    {
        "id": "doc_438",
        "document": "coverage of ART for people living with HIV, which was 76% at the end of 2022 (33). The main reason for the relatively low coverage was the big gap between the estimated number of people living with HIV who developed TB in 2022 (a best estimate of 671 000) and the reported number of people living with HIV who were diagnosed with TB in 2022 (426 958)."
    },
    {
        "id": "doc_439",
        "document": "A very positive finding from both 2020 and 2021 was that treatment outcomes for people treated for TB were maintained or improved (Fig. 28). Among people newly diagnosed with TB and enrolled on first-line treatment,1 the treatment success rate was 86% for those enrolled\n\n1 The latest WHO guidelines on treatment for drug-susceptible TB were published in 2022 (34). Annex 1 provides a summary of recommended treatments.\n\n3. Main findings and messages"
    },
    {
        "id": "doc_440",
        "document": "in 2020 (the same level as in 2019) and 88% for those enrolled in 2021. This shows that, despite the many dis- ruptions caused by the COVID-19 pandemic, the quality of treatment for those diagnosed with TB was main- tained in 2020 and 2021. Treatment success rates remain lower among people living with HIV (79% globally in 2021), although there have been steady improvements over time. The treatment success rate for children (aged 0\u201314 years) was 91% in 2021, an increase from 88% in both 2020 and"
    },
    {
        "id": "doc_441",
        "document": "2019. Among 26 high burden countries2 that reported treatment outcome data disaggregated by sex, the treatment success rate was slightly higher in"
    },
    {
        "id": "doc_442",
        "document": "Provision of TB treatment to HIV-negative people is estimated to have averted 38 million deaths between 2010 and 2022; among people living with HIV who were diagnosed with TB, the combination of TB treatment and ART is estimated to have averted 6.4 million deaths between 2010 and 2022 (Table 4)."
    },
    {
        "id": "doc_443",
        "document": "2 Since 2021, WHO has requested data on treatment outcomes disaggregated by sex from the 49 countries in one of the three lists of high burden countries (Annex 3). The countries from which such data are requested may be expanded in future (for example, to include all countries with case-based digital surveillance systems for TB).\n\n27"
    },
    {
        "id": "doc_444",
        "document": "TAblE 4\n\nCumulative number of deaths averted by a) TB treatment as well as b) antiretroviral treatment for people diagnosed with TB who were also living with HIV, 2010\u20132022 (in millions), globally and by WHO region"
    },
    {
        "id": "doc_445",
        "document": "R T bEST ESTIMATE ooy uncERTAInTY InTERVAl | pomewmae bEST ESTIMATE uncERTAInTY InTERVAl | ow bEST ESTIMATE | uncERTAInTY InTERVAl African Region 5.2 4.3-6.2 4.8 4.1-5.5 10 8.9-11 Region of the Americas 12 1.0-1.3 0.23 0.21-0.24 14 1.3-1.5 South-East Asia Region 18 15-21 0.85 0.53-1.2 19 16-22 European Region Il 0.95-1.2 0.21 0.18-0.25 13 1.2-14 Eastern Mediterranean Region 3.4 2.9-3.9 0.062 0.047-0.078 45 3.0-4.0 Western Pacific Region 9.0 8.0-10 0.32 0.26-0.37 9.3 8.3-10"
    },
    {
        "id": "doc_446",
        "document": "Global 38 33-43 6.4 5.5-7.3 44 39-49"
    },
    {
        "id": "doc_447",
        "document": "a Deaths from TB among people with HIV are officially classified as deaths caused by HIV/AIDS (with TB as a contributory cause). This is the reason why the estimates make a clear distinction between people with and without HIV.\n\nFIg. 28"
    },
    {
        "id": "doc_448",
        "document": "Global success rates for people treated for TB, 2012\u20132021a\n\n100 ) % ( e t a r s s e c c u s 90 80 70 People newly diagnosed with TB (new and relapse cases) and enrolled on first-line treatment t n e m t a 60 e r T 50 People diagnosed with MDR/RR-TB and enrolled 40 on an MDR/RR-TB treatment regimen 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Year started on treatment\n\na 2012 is the first year for which WHO collected data about treatment outcomes for MDR/RR-TB."
    },
    {
        "id": "doc_449",
        "document": "Drug-resistant TB: diagnosis and treatment Slow recovery, targets not achieved"
    },
    {
        "id": "doc_450",
        "document": "WHO uses five categories to classify cases of drug-re- sistant TB: isoniazid-resistant TB; RR-TB and MDR-TB (defined above); extensively drug-resistant TB (XDR- TB); and pre-XDR-TB. Pre-XDR-TB is TB that is resistant to rifampicin and any fluoroquinolone (a class of sec- ond-line anti-TB drug). XDR-TB is TB that is resistant to rifampicin, plus any fluoroquinolone, plus at least one of either bedaquiline or linezolid."
    },
    {
        "id": "doc_451",
        "document": "Detection of drug resistance requires bacteriological confirmation of TB and testing for drug resistance using rapid molecular diagnostic tests, culture methods or sequencing technologies.\n\nSince 2018, WHO has recommended all-oral regi- mens for the treatment of MDR/RR-TB, marking a major advance compared with previous regimens that includ-\n\n28"
    },
    {
        "id": "doc_452",
        "document": "ed injectable agents (35). The latest guidelines for treat- ment of DR-TB, updated in 2022, include three major categories of regimen (36). The first is a short 6-month all-oral regimen for people with MDR/RR-TB (which may be extended by 3 months if necessary) consisting of bedaquiline, pretomanid, linezolid and moxifloxa- cin, referred to as BPaLM; for people with pre-XDR-TB, the regimen can be used without moxifloxacin and is referred to as BPaL.1 The second category is all-oral short regimens"
    },
    {
        "id": "doc_453",
        "document": "of 9 months for people with MDR/RR-TB (which may be extended by 2 months if necessary). The third category is longer regimens of 18\u201320 months that may include an injectable drug (amikacin). The short 6-month regimen is prioritized for use and is recom- mended for people aged 14 years and older who have MDR/RR-TB or pre-XDR-TB."
    },
    {
        "id": "doc_454",
        "document": "Globally in 2022, 73% of people (2.9/4.0 million) diagnosed with bacteriologically confirmed pulmonary TB were tested for rifampicin resistance, up from 69% (2.4/3.5 million) in 2021 and above the pre-pandem- ic level of 62% (2.2/3.6 million) in 2019. Among those tested, 149 511 people with MDR/RR-TB and 27 075 people with pre-XDR-TB or XDR-TB were detected, giv- ing a combined total of 176 586 (4.4% of those tested). Despite increased testing coverage and an increase in the absolute number of"
    },
    {
        "id": "doc_455",
        "document": "people tested, the number of people detected with MDR/RR-TB was lower in 2022 than in 2019 (when the total was 202 009, 5.6% of those tested). This is consistent with the estimated decline in the proportion of people with TB who have MDR/RR-TB (Fig. 16)."
    },
    {
        "id": "doc_456",
        "document": "Worldwide, 175 650 people with MDR/RR-TB were enrolled on treatment in 2022, up 8.5% from 161 843 in 2021 and up 17% from 150 510 in 2020 but still below the pre-pandemic level of 181 533 in 2019 (Fig. 29, Fig. 30).\n\n1 The BPaLM/BPaL regimen is one of the featured topics of this report.\n\nGlobal tuberculosis report 2023\n\nFIg. 29"
    },
    {
        "id": "doc_457",
        "document": "Global number of people diagnosed with MDR/RR-TB (blue) and number enrolled on an MDR-TB treatment regimen (red), compared with estimates of the global number of incident cases of MDR/RR-TB (95% uncertainty interval shown in green), 2015\u20132022a\n\n600 000 r a e y r e p 400 000 r e b m u N 200 000 0 2015 2016 2017 2018 2019 2020 2021 2022\n\na The time period corresponds to the period for which estimates of the incidence of MDR/RR-TB are available.\n\nFIg. 30"
    },
    {
        "id": "doc_458",
        "document": "The global number of people reported to have been enrolled on treatment for MDR/RR-TB, 2010\u20132022a\n\n200 150 s d n a s u o 100 h T 50 0 2010 2012 2014 2016 2018 2020 All ages People aged \u226515 years or age not reported People aged 0\u201314 years 2022\n\na Global data disaggregated by age are not available for the years before 2018.\n\nThis level of enrolment is equivalent to about 43% of the estimated number of people who develop MDR/RR-TB each year (Fig. 15, Fig. 29)."
    },
    {
        "id": "doc_459",
        "document": "The global targets set at the UN high-level meeting in 2018 for the number of people to be treated for drug-re- sistant TB were not reached (Fig. 23). The cumulative number of people with MDR/RR-TB who were reported as being enrolled on treatment from 2018 to 2022 was 825 000, only 55% of the 5-year target (2018\u20132022) of 1.5 million. For children specifically, the cumulative number was 21 600, only 19% of the 5-year target of 115 000."
    },
    {
        "id": "doc_460",
        "document": "Ten countries account for about 70% of the global gap between the estimated global number of people who develop MDR/RR-TB each year (incident cases of MDR/RR-TB) and the global number of people enrolled on treatment in 2022: China, the Democratic People\u2019s Republic of Korea, India, Indonesia, Myanmar, Nigeria, Pakistan, the Philippines, Ukraine and Viet Nam. To make substantial progress in closing this gap, improve- ments in the coverage of testing for drug resistance and access to treatment are"
    },
    {
        "id": "doc_461",
        "document": "needed in these countries."
    },
    {
        "id": "doc_462",
        "document": "There have been steady improvements in the treat- ment success rate for people diagnosed with MDR/ RR-TB (Fig. 28). Globally in 2020 (the latest patient cohort for which data are available), the treatment suc- cess rate was 63%, up from 60% in 2019 and much bet- ter than the level of 50% in 2012.1 Among WHO regions, the treatment success rate in 2020 ranged from 55% in the European Region to 73% in the Eastern Mediterra- nean Region."
    },
    {
        "id": "doc_463",
        "document": "1 2012 is the first year for which WHO collected data on outcomes for people enrolled on treatment for MDR/RR-TB.\n\n3. Main findings and messages\n\nBy the end of 2022, 40 countries had started to use the new 6-month BPaLM/BPaL regimen to treat people with MDR/RR-TB or pre-XDR-TB. A total of 92 countries were using the shorter 9-month oral regimens for the treatment of MDR/RR-TB, almost the same as in 20212 and up from 65 in 2020.\n\nTB prevention"
    },
    {
        "id": "doc_464",
        "document": "global recovery, but most targets missed\n\nThe main health care intervention available to reduce the risk of TB infection progressing to active TB disease is TB preventive treatment. Other preventive interven- tions are TB infection prevention and control, and vac- cination of children with the bacille Calmette-Gu\u00e9rin (BCG) vaccine, which can confer protection, especially from severe forms of TB in children."
    },
    {
        "id": "doc_465",
        "document": "WHO recommends TB preventive treatment for peo- ple living with HIV, household contacts of people diag- nosed with bacteriologically confirmed pulmonary TB and clinical risk groups (e.g. those receiving dialysis) (37).3 Options include: a weekly dose of isoniazid and rifapentine for 3 months; a daily dose of isoniazid and rifampicin for 3 months; a daily dose of isoniazid and rifapentine for 1 month; a daily dose of rifampicin for 4 months; and a daily dose of isoniazid for 6 months or longer."
    },
    {
        "id": "doc_466",
        "document": "The global number of people provided with TB pre- ventive treatment in 2022 was 3.8 million, up from 2.9 million in both 2020 and 2021 and above the pre-COVID\n\n2 The total was 93 in 2021.\n\n3 Addressing broader determinants that influence TB epidemics can also help to prevent TB infection and disease. These are discussed below.\n\n29\n\nFIg. 31\n\nThe global number of people provided with TB preventive treatment, 2015\u20132022\n\n4 3 s n o i l l i M 2 1 0 2015 2016 2017 2018 2019 2020 2021 2022"
    },
    {
        "id": "doc_467",
        "document": "I B Il\n\nPeople living with HIV\n\nHousehold contacts aged <5 years\n\nHousehold contacts aged \u22655 years\n\nlevel of 3.6 million in 2019 (Fig. 31). There was a particu- larly noticeable increase in the number of household contacts enrolled on TB preventive treatment: from 0.76 million in 2021 to 1.9 million in 2022. In contrast, the number of people living with HIV who were enrolled on TB preventive treatment fell slightly, from 2.2 million in 2021 to 1.9 million in 2022."
    },
    {
        "id": "doc_468",
        "document": "Despite progress to beyond pre-pandemic levels in 2022, the global target set at the UN high-level meeting in 2018 was missed by a considerable margin (Fig. 32). A cumulative total of 15.5 million people were provid- ed with TB preventive treatment in the 5-year period 2018\u20132022, equivalent to 52% of the target of 30 million.\n\nMore positively, the subtarget for people living with HIV was far surpassed; the total of 11.3 million was almost double the target of 6 million."
    },
    {
        "id": "doc_469",
        "document": "The cumulative total for household contacts was 4.2 million, equivalent to 17% of the 5-year target of 24 million for the period 2018\u20132022; this number includ- ed 2.2 million children aged under 5 years (55% of the 5-year subtarget of 4 million) and 2.0 million people in older age groups (10% of the 5-year subtarget of 20 mil- lion) (Fig. 32)."
    },
    {
        "id": "doc_470",
        "document": "In 83 countries that reported outcomes, the median completion rate for household contacts who started treatment in 2021 was 89%, up from 86% in both 2019 and 2020. For people living with HIV, the median com- pletion rate in 31 countries that reported data was 81%, compared with 87% in 20 countries that reported data for 2020.\n\nSubstantial intensification and expansion of efforts and investment are needed to improve the provision of TB preventive treatment. This includes providing more\n\nFIg. 32"
    },
    {
        "id": "doc_471",
        "document": "The global numbers of people provided with TB preventive treatment between 2018 and 2022, compared with targets set at the 2018 UN high-level meeting on TB"
    },
    {
        "id": "doc_472",
        "document": "ALL AGES PEOPLE LIVING WITH HIV Target: 30 million 15.5 million (52%) Target: 6 million 11.3million (>100%) 2018\u20132022 treated in 2018\u20132022 treated in 2018\u20132022 2018\u20132022 HOUSEHOLD CONTACTS HOUSEHOLD CONTACTS AGED <5 YEARS AGED \u22655 YEARS Target: 4 million 2.2 million (55%) Target: 20 million 2.0million (10%) 2018\u20132022 treated in 2018\u20132022 treated in 2018\u20132022 2018\u20132022\n\n30\n\nGlobal tuberculosis report 2023"
    },
    {
        "id": "doc_473",
        "document": "TB screening at household level, improving the fol- low-up to TB screening at household level and among people living with HIV, and increasing access to short- er (1\u20133 months) rifamycin-based regimens. Treatment using these shorter regimens is expanding: in 2022, 0.60 million people were reported to have been treated in 74 countries, a three-fold increase from 0.19 million people in 52 countries in 2021."
    },
    {
        "id": "doc_474",
        "document": "The ratio of the TB notification rate among health care workers to the TB notification rate in the general adult population reflects the effectiveness of TB infec- tion control in health facilities; the ratio should be about 1. However, in 2022 it was greater than 1 in 14 countries that reported five or more TB cases among health care workers (unchanged from 2021)."
    },
    {
        "id": "doc_475",
        "document": "Following concerning declines in the global coverage of BCG vaccination during the COVID-19 pandemic, from 89% in 2019 to 84% in 2021, there was a recovery to 87% in 2022 (38).\n\nFunding for essential TB services"
    },
    {
        "id": "doc_476",
        "document": "Funding down since 2019, far below target\n\nProgress in reducing the burden of TB disease requires adequate funding for TB diagnostic, treatment and prevention services, sustained over many years. How- ever, funding in LMICs \u2013 which account for 99% of the reported number of people newly diagnosed with TB each year \u2013 falls far short of what is needed and remains below pre-pandemic levels."
    },
    {
        "id": "doc_477",
        "document": "In 2022, the funding available for TB diagnostic, treat- ment and prevention services in LMICs was US$ 5.8 bil- lion (in constant 2022 US$).1 This level of funding was similar to that of 2020 and 2021 but down more than 10% from US$ 6.5 billion in 2019 (Fig. 33).23 The total of US$ 5.8 billion was only 44% of the global target of US$ 13 billion annually by 2022 (Table 1) and only 38% of the US$ 15.0 billion that was estimated to be required in 2022 in the Stop TB Partnership\u2019s Global Plan to End"
    },
    {
        "id": "doc_478",
        "document": "TB, 2018\u20132022 (39). It is far below the new targets of US$ 22 billion by 2027 and US$ 35 billion by 2030 set at the second UN high-level meeting on TB in September 2023 (Table 2); both targets were informed by the Glob- al Plan to End TB, 2023\u20132030 (40)."
    },
    {
        "id": "doc_479",
        "document": "1 All amounts quoted in this subsection are in constant 2022 US$. Numbers should not be directly compared with those in previous reports, given adjustments to the whole time series that are made for each new report, to account for inflation.\n\n2 These amounts include funding reported to WHO by NTPs and estimates (produced by the WHO Global Tuberculosis Programme) of the resources used to provide inpatient and outpatient care to the reported number of people newly diagnosed with TB (Fig. 1)."
    },
    {
        "id": "doc_480",
        "document": "3 The data sources, boundaries, accounting rules, and estimation methods used in this report differ from those of the System of Health Accounts 2011 (SHA2011). The data on available funding for TB are not comparable with the disease expenditure data, including for TB, that are reported in WHO\u2019s Global Health Expenditure Database.\n\n3. Main findings and messages"
    },
    {
        "id": "doc_481",
        "document": "FIg. 33\n\nFunding available for TB prevention, diagnostic and treatment services in 134 low- and middle-income countries compared with the global target set at the 2018 UN high-level meeting on TB of at least US$ 13 billion per year,a,b,c,d 2018\u20132022\n\n15 ) $ S U Target set at 2018 UN high-level meeting on TB 2 2 0 2 10 t n a t s n o c ( s 5 n o i l l i B 0 2018 2019 2020 2021 2022 Domestic funding International donor funding"
    },
    {
        "id": "doc_482",
        "document": "a Sources: data reported by NTPs and estimates produced by the WHO Global Tuberculosis Programme.\n\nb The data sources, boundaries, accounting rules, and estimation methods used in this report are different from those of the system of Health Accounts 2011 (SHA2011). The TB funding data reported here are thus not comparable with the disease expenditure data, including for TB, that are reported in WHO\u2019s Global Health Expenditure Database."
    },
    {
        "id": "doc_483",
        "document": "c The 134 countries accounted for 99% of the world\u2019s officially reported TB cases in 2022.\n\nd Values for 2018\u20132021 are higher than those shown in the Global Tuberculosis Report 2022, since they have been inflated (for comparability with data for 2022) to constant US$ values for 2022."
    },
    {
        "id": "doc_484",
        "document": "Of the total available funding of US$ 5.8 billion in 2022, US$ 3.5 billion was for diagnosis and treatment of drug-susceptible TB and US$ 2.1 billion was for treat- ment and management of drug-resistant TB.4,5 Both these amounts are less than half of the requirements for 2022 that were estimated in the Global Plan (39). The remaining amount included spending on TB preventive treatment (covering drugs only) and interventions spe- cifically related to HIV-associated TB."
    },
    {
        "id": "doc_485",
        "document": "4 The category of drug-susceptible TB includes funding reported by NTPs for the following items: laboratory equipment and supplies; anti-TB drugs; programme management (including staff and activities); operational research and surveys; patient support; and miscellaneous items. It also includes WHO estimates of funding for inpatient and outpatient care for people treated for drug-susceptible TB, which are based on WHO estimates of the unit costs of bed-days and visits combined with the average"
    },
    {
        "id": "doc_486",
        "document": "number of outpatient visits and bed-days per TB patient as reported by NTPs. The category of drug-resistant TB includes anti-TB drugs required for treatment of MDR/RR-TB (including pre-XDR-TB and XDR-TB), any programme management (staff and activity) costs specifically required for the provision of care to people with drug-resistant TB, and WHO estimates of funding for inpatient and outpatient care. Further details are provided in Section 4 of the report webpages."
    },
    {
        "id": "doc_487",
        "document": "5 The categories for which funding is reported to WHO do not allow for funding for the diagnosis of drug-resistant TB specifically to be distinguished. In data analysis, the category of laboratory supplies and equipment is allocated to drug-susceptible TB. Rapid tests recommended by WHO can detect TB and RR-TB simultaneously.\n\n31\n\nFIg. 34\n\nFunding available for TB prevention, diagnostic and treatment services in 134 low- and middle-income countries and 3 other country groups,a,b 2013\u20132022"
    },
    {
        "id": "doc_488",
        "document": "All low and middle-income countriesc (n=134) BRICS (n=5) 8 5 ) $ 6 S U 2 2 4 0 2 t n 3 4 a t s n o c 2 ( 2 s n o i l l 1 i B 0 0 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 High TB burden and global TB watchlist countries 0.9 outside BRICSd (n=28) 2.0 Other low and middle-income countries (n=101) 0.8 0.7 0.6 0.5 0.4 ) $ S U 2 2 0 2 t n a t s n o c ( s n o i l l i B 1.5 1.0 0.5 0.3 0 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2013"
    },
    {
        "id": "doc_489",
        "document": "2014 2015 2016 2017 2018 2019 2020 2021 2022 Domestic funding International donor funding"
    },
    {
        "id": "doc_490",
        "document": "BRICS: Brazil, Russian Federation, India, China, South Africa.\n\na Sources: data reported by NTPs and estimates produced by the WHO Global Tuberculosis Programme."
    },
    {
        "id": "doc_491",
        "document": "b The data sources, boundaries, accounting rules, and estimation methods used in this report are different from those of the System of Health Accounts 2011 (SHA2011). The TB funding data reported here are thus not comparable with the disease expenditure data, including for TB, that are reported in WHO\u2019s Global Health Expenditure Database.\n\nc The 134 countries accounted for 99% of the world\u2019s officially reported TB cases in 2022."
    },
    {
        "id": "doc_492",
        "document": "d The two global TB watchlist countries included are Cambodia and Zimbabwe.\n\nAs in previous years, most of the funding available in LMICs in 2022 (US$ 4.7 billion out of a total of US$ 5.8 bil- lion; i.e. 80%) was from domestic sources (Fig. 33). Between 2019 and 2022, there was a decline of US$ 0.8 billion in funding from domestic sources and a slight increase (of US$ 0.1 billion) in funding from internation- al donors."
    },
    {
        "id": "doc_493",
        "document": "The aggregate figure for the share of funding pro- vided from domestic sources in LMICs continues to be strongly influenced by Brazil, the Russian Federation, India, China and South Africa (BRICS). Together, these five countries accounted for US$ 3.0 billion (65%) of the total of US$ 4.7 billion that was provided from domes- tic sources in 2022 (Fig. 34). Overall, domestic sources accounted for 94% of the funding for TB diagnostic, treatment and prevention services in BRICS and all of the"
    },
    {
        "id": "doc_494",
        "document": "funding used in Brazil, China and the Russian Fed- eration."
    },
    {
        "id": "doc_495",
        "document": "In other LMICs, international donor funding remains\n\n32\n\ncrucial (Fig. 33). For example, in 2022, it accounted for 52% of the funding available for TB services in the 26 high TB burden and the two global TB watchlist coun- tries (Cambodia and Zimbabwe) outside BRICS, and 61% of the funding available in low-income countries."
    },
    {
        "id": "doc_496",
        "document": "The total amount of international donor funding reported to WHO by NTPs in LMICs has been around US$ 1.1 billion per year since 2013 (Fig. 34).1 The main source for many years has been the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund); its contribution in 2022 was 75%, slightly less than the level of 76% in 2021. The United States government is the largest contributor of funding to the Global Fund"
    },
    {
        "id": "doc_497",
        "document": "1 Data on TB expenditures and funding that are reported to WHO by NTPs do not include all the international donor funding that is provided to LMICs (e.g. funding channelled to entities outside the NTP). A comprehensive analysis of international donor funding for TB, based on donor reports to the Organisation for Economic Co-operation and Development (OECD), is one of the \u201cfeatured topics\u201d on the report webpages.\n\nGlobal tuberculosis report 2023"
    },
    {
        "id": "doc_498",
        "document": "(about one-third) and is also the largest bilateral donor; overall, it contributes about 50% of international donor funding for TB (for details, see the featured topic on international donor funding).\n\nSubstantial increases in both domestic and interna- tional funding for TB are urgently required."
    },
    {
        "id": "doc_499",
        "document": "Variation in the share of funding from domestic sourc- es within a given income group suggests that there is scope to increase domestic funding in some high TB burden and global TB watchlist countries."
    },
    {
        "id": "doc_500",
        "document": "Mobilization of increased levels of funding will require the development of strong national strategic plans for TB that are properly costed, to which countries have committed at the 2023 UN high-level meeting on TB (Table 3). WHO has recently updated its guidance on national strategic planning (41); the TB module of the Integrated Health Tool for planning and costing (IHT) has also been recently upgraded by WHO and is now available for use by countries.1"
    },
    {
        "id": "doc_501",
        "document": "UHC, TB determinants and multisectoral accountability\n\nFaster progress required, Tb target off track"
    },
    {
        "id": "doc_502",
        "document": "Global TB targets for reductions in TB disease burden can only be achieved if TB diagnostic, treatment and prevention services are provided within the context of progress towards UHC, and if there is multisectoral action to address the broader determinants that influ- ence TB epidemics. For example, the 2025 milestone of the End TB Strategy \u2013 a 75% reduction in the number of deaths caused by TB (compared with 2015) \u2013 requires that not more than 6.5% of people who develop TB dis- ease die from"
    },
    {
        "id": "doc_503",
        "document": "it;2 this is only feasible if everyone with TB can promptly access diagnostic and treatment services."
    },
    {
        "id": "doc_504",
        "document": "UHC means that everyone can obtain the health services they need without suffering financial hardship (42). Through their adoption of the SDGs, all countries have committed to achieving UHC by 2030: Target 3.8 is \u201cAchieve universal health coverage, including finan- cial risk protection, access to quality essential health- care services and access to safe, effective, quality and affordable essential medicines and vaccines for all\u201d (1). The two indicators to monitor progress towards this target"
    },
    {
        "id": "doc_505",
        "document": "are a UHC service coverage index (SCI) (Indica- tor 3.8.1), and the percentage of the population experi- encing household expenditures on health care that are \u201clarge\u201d in relation to household expenditures or income (Indicator 3.8.2).3 The SCI can take values from 0 (worst) to 100 (best) and is calculated using 16 tracer indica- tors, one of which is the coverage of TB treatment. In"
    },
    {
        "id": "doc_506",
        "document": "1 The tool is available at https://tb.integratedhealthtool.org/.\n\n2 See also Section 2 of this report. The estimated percentage in 2022 was 12%.\n\n3 Indicator 3.8.2 is a measure of financial hardship rather than financial barriers to accessing health care. The need for out-of- pocket payments may deter many people from seeking care.\n\n3. Main findings and messages"
    },
    {
        "id": "doc_507",
        "document": "the monitoring of Indicator 3.8.2 by WHO and the World Bank, direct medical expenditures that account for 10% or more of household expenditure or income are classi- fied as \u201ccatastrophic\u201d (43).\n\nThe latest published data for the two UHC indicators are for 2021 (SCI) and 2019 (catastrophic out-of-pocket expenditures on health) (43, 44)."
    },
    {
        "id": "doc_508",
        "document": "Worldwide, the SCI increased from a score of 45 (out of 100) in 2000 to 68 in 2019. Most of this progress occurred between 2000 and 2015 and was primarily due to improvements in service coverage for infectious diseases (with only limited changes for other areas of service provision). At regional level, the SCI increased in all six WHO regions between 2000 and 2019; the biggest gains were in the South-East Asia and Western Pacific regions. There were also increases in all four World Bank income"
    },
    {
        "id": "doc_509",
        "document": "groups. In 2020 and 2021, during the COVID-19 pandemic, progress stalled globally (at a value of 68 in 2021) and in most WHO regions and World Bank income groups. In 2021, the WHO regions with the highest val- ues were the European Region (81) and the Region of the Americas (80); the African Region had the lowest value (44)."
    },
    {
        "id": "doc_510",
        "document": "Among the 30 high TB burden countries, most made progress in service coverage between 2000 and 2019. The largest gains in absolute terms (+30 index points or more) were in China, India, Myanmar, Thailand and Viet Nam. During the COVID-19 pandemic, progress stalled or reversed in most countries. In 2021, the high TB burden countries with the highest SCI values (around 80) were Brazil, China and Thailand; most other coun- tries had values between about 40 and 60."
    },
    {
        "id": "doc_511",
        "document": "In contrast to improvements in the SCI, the global level of financial protection for health expenditures worsened continuously between 2010 and 2019 (esti- mates for later years are not currently available). World- wide, the proportion of the general population facing catastrophic expenditure on health (using a threshold of >10% annual household income or expenditure) rose from 11.4% (794 million people) in 2010 to 13.5% (1.04 billion people) in 2019 (43). At regional level, higher pro- portions"
    },
    {
        "id": "doc_512",
        "document": "in 2019 compared with 2010 were estimated for all WHO regions except the Region of the Americas."
    },
    {
        "id": "doc_513",
        "document": "National values for the level of financial protection are available for different years and there is more geo- graphical variability compared with the SCI, including within regions. Of the 30 high TB burden countries, estimates of the percentage of the population facing catastrophic health expenditures are particularly high (\u226515% of the population) for Angola, Bangladesh, China, India, Nigeria, Sierra Leone and Uganda."
    },
    {
        "id": "doc_514",
        "document": "Values for both indicators in the 30 high TB burden countries show that there is a long way to go before the SDG targets for UHC are achieved in most of these countries (Fig. 35). Only Thailand stands out as having a high SCI (82 in 2021) and a low level of catastrophic\n\n33\n\nFIg. 35\n\nUHC service coverage index (SDG 3.8.1)a and percentage of the general population facing catastrophic health expenditure (SDG 3.8.2),b 30 high TB burden countries,c stratified by income groupd\n\nLow-income"
    },
    {
        "id": "doc_515",
        "document": "40 ) 2 . 8 . 3 G D S ( e r u t i d n e p x e 30 20 10 0 Central African Republic Sierra Leone Democratic Republic of the Congo Liberia Uganda United Republic of Tanzania Ethiopia Mozambique h t l 20 40 60 80 a e h c i h 40 Lower-middle-income p o Angola r t s a 30 t a c g n i c a f n o i t a l u 20 10 0 Congo Nigeria Pakistan Lesotho Bangladesh India Kenya Myanmar Zambia Philippines Indonesia Mongolia Viet Nam p o 20 40 60 80 p l a r Upper-middle-income e n 40 e g e h t 30 f o China e g 20 a t n"
    },
    {
        "id": "doc_516",
        "document": "e c 10 Brazil r e P 0 Gabon Namibia South Africa Thailand 20 40 60 80 UHC service coverage index (SDG 3.8.1)"
    },
    {
        "id": "doc_517",
        "document": "a The SCI can take values from 0 (worst) to 100 (best) and is calculated using 16 tracer indicators, one of which is the coverage of TB treatment. Values shown for the SCI are estimates for the latest year for which data for SDG 3.8.2 are available. Values are based on interpolated points between available years over the 2000-2021 period.\n\nb Defined as \u226510% of total household consumption or income. The latest available year ranges from 2007 to 2021 for the 30 high TB burden countries."
    },
    {
        "id": "doc_518",
        "document": "c Data were not available for Democratic People\u2019s Republic of Korea and Papua New Guinea.\n\nd The classification is for the latest year for which data for SDG 3.8.2 are available.\n\nSource: Global Health Observatory (https://www.who.int/data/gho)"
    },
    {
        "id": "doc_519",
        "document": "health expenditures (2.0% of households). A Universal Coverage Scheme was established in 2002 to provide an explicit benefit to all citizens of Thailand not already covered by a health insurance scheme in the formal sec- tor, supported by domestic funding and a strong prima- ry health care system (45)."
    },
    {
        "id": "doc_520",
        "document": "To achieve UHC, substantial increases in investment in health care are critical. From 2000 to 2020, there were striking increases in health expenditure (from all sources) per capita in a small number of high TB burden countries, notably the upper-middle-income countries of Brazil, China, South Africa and Thailand. A steady upward trend was evident in Bangladesh, Cambodia, Ethiopia, India, Indonesia, Lesotho, Mongolia, Mozam- bique, the Philippines and Viet Nam, and there was a noticeable rise"
    },
    {
        "id": "doc_521",
        "document": "from 2012 to 2017 in Myanmar. Else-"
    },
    {
        "id": "doc_522",
        "document": "34\n\nwhere, however, levels of spending have been relatively stable, and at generally much lower levels."
    },
    {
        "id": "doc_523",
        "document": "Given the importance of UHC to targets for reduc- tions in TB incidence and mortality, the End TB Strategy included a third target: that no TB patients and their households face total costs that are catastrophic (2, 12). The definition of catastrophic used for this TB-specif- ic indicator is total costs (comprising direct medical expenditures, nonmedical expenditures and indirect costs such as income losses) above 20% of annual household income. The key differences between this indicator and the"
    },
    {
        "id": "doc_524",
        "document": "SDG indicator for catastrophic health expenditures (Indicator 3.8.2) are explained in Box 5."
    },
    {
        "id": "doc_525",
        "document": "Since 2015, a total of 31 countries have completed a national survey of costs faced by TB patients and their households, of which 29 (including 17 of the 30 high TB\n\nGlobal tuberculosis report 2023\n\nBox 5. The difference between \u201ccatastrophic total costs\u201d for TB patients and their households, and the SDG indicator of catastrophic expenditures on health care"
    },
    {
        "id": "doc_526",
        "document": "n It is important to distinguish between the indicator of \u201cthe proportion of the population with large household expenditures on health as a share of total household expenditure or income\u201d, which is used within the SDG monitoring framework (SDG Indicator 3.8.2), and the indicator of \u201cthe percentage of TB patients and their households facing catastrophic total costs due to TB\u201d, which is part of the WHO End TB Strategy."
    },
    {
        "id": "doc_527",
        "document": "The SDG indicator is for the general population. Household expenditures on health are defined as direct expenditures on health by all household members who seek any type of care (preventive, curative, rehabilitative, long-term) for any type of disease, illness or health condition, in any type of setting (outpatient, inpatient, at home). They include both formal and informal expenditures. The indicator attempts to capture the"
    },
    {
        "id": "doc_528",
        "document": "impact of household expenditures on health on household ability to spend on other basic needs. The denominator of the total population includes many people who had no contact with the health system and thus had zero expenditures on health. Although these people did not experience financial hardship because of direct expenditures on health care, they may nonetheless have faced financial barriers to accessing health services that they needed. Hence, the SDG indicator cannot be used as a measure of"
    },
    {
        "id": "doc_529",
        "document": "financial barriers to access to health care."
    },
    {
        "id": "doc_530",
        "document": "Due to the nature of the illness, TB patients and their households can face severe direct and indirect financial and economic costs. These pose barriers that can greatly affect their ability to access diagnosis and treatment, and to complete treatment successfully. Costs included in the TB-specific"
    },
    {
        "id": "doc_531",
        "document": "indicator include not only direct medical payments for diagnosis and treatment, but also direct nonmedical payments (e.g. for transport and lodging) and indirect costs (e.g. lost income). In contrast to SDG Indicator 3.8.2, the TB- specific indicator is restricted to a particular population: people diagnosed with TB who are users of health services that are part of NTP networks."
    },
    {
        "id": "doc_532",
        "document": "Given these conceptual differences, the percentage of TB patients facing \u201ccatastrophic total costs\u201d (defined as direct and indirect costs that account for >20% of their annual household income) is expected to be much higher than the percentage of the general population facing catastrophic expenditures on health care. Hence, the two indicators cannot and should not be compared directly."
    },
    {
        "id": "doc_533",
        "document": "burden countries and one of the three global TB watch- list countries)1 have reported results. The percentage facing catastrophic total costs ranged from 13% (95% confidence interval [CI]: 10\u201317%) in El Salvador to 92% (95% CI: 86\u201397%) in Solomon Islands; the pooled aver- age, weighted for each country\u2019s number of notified cases, was 49% (95% CI: 37\u201361%) (Fig. 36). Among 25 countries that reported disaggregated data, the percentage facing catastrophic total costs was much higher for people with"
    },
    {
        "id": "doc_534",
        "document": "drug-resistant TB, with a pooled average of 83% (95% CI: 75\u201390%)."
    },
    {
        "id": "doc_535",
        "document": "Survey results have been used to inform approaches to health financing, service delivery and social protec- tion that will reduce these costs (46). They have also been used to produce model-based estimates of costs faced by TB patients and their households in other countries (47)."
    },
    {
        "id": "doc_536",
        "document": "Many new cases of TB are attributable to five risk factors: undernourishment, HIV infection, alcohol use disorders, smoking (especially among men) and diabe- tes (Fig. 37). In the context of the COVID-19 pandemic and its aftermath, as well as war in Ukraine, ongoing conflicts in other parts of the world and global challeng- es with energy and food security, multisectoral action to address these and other determinants of TB, such as\n\n1 See Annex 3.\n\n3. Main findings and messages"
    },
    {
        "id": "doc_537",
        "document": "GDP per capita (Fig. 20) and poverty, is more important than ever.2"
    },
    {
        "id": "doc_538",
        "document": "The political declaration from the 2023 UN high-lev- el meeting on TB includes commitments to strength- en multisectoral action and accountability (Table 3), including through use of the WHO multisectoral accountability framework (MAF-TB) (48). The framework has two major parts: one for the global/regional level; and one for the national level. Each part has four major, inter-related components: commitments; actions; mon- itoring and reporting; and review. To illustrate how the MAF-TB can be"
    },
    {
        "id": "doc_539",
        "document": "used at national level, WHO has pub- lished a checklist that can be used for an initial, base- line assessment, as well as an operational guide and a compendium of country examples (49\u201351)."
    },
    {
        "id": "doc_540",
        "document": "Data reported to WHO by NTPs for indicators relat- ed to multisectoral accountability show that at coun- try level, there is considerable scope to enhance the engagement of most sectors of government (e.g. agri- culture, education, labour, justice, finance and social development) as well the private sector, communities and civil society; and a need for more high-level review of progress, informed by national reports.3"
    },
    {
        "id": "doc_541",
        "document": "2 SDG targets and indicators that are associated with TB incidence are described in Annex 6.\n\n3 For further information, see the \u201cfeatured topics\u201d component of this report.\n\n35\n\nFIg. 36\n\nEstimates of the percentage of TB patients and their households facing catastrophic total costs,a national surveys completed 2015\u20132022\n\nTB (first-line treatment)b\n\nDrug-resistant TB\u00ae"
    },
    {
        "id": "doc_542",
        "document": "Solomon Islands Solomon Islands NA Namibia Namibia Timor-Leste Timor-Leste NA Zimbabwe Zimbabwe Niger Niger Nigeria Nigeria Mongolia Mongolia Ghana Ghana Lao People's Democratic Republic Lao People's Democratic Republic Viet Nam Viet Nam Myanmar Myanmar Zambia Zambia Democratic Republic of the Congo Democratic Republic of the Congo South Africa South Africa Burkina Faso Burkina Faso Uganda Uganda Colombia Colombia Mali Mali Brazil Brazil United Republic of Tanzania United Republic of Tanzania"
    },
    {
        "id": "doc_543",
        "document": "Philippines Philippines Fiji Fiji NA Indonesia Indonesia Benin Benin Papua New Guinea Papua New Guinea Thailand Thailand Kenya Kenya Lesotho Lesotho El Salvador El Salvador NA Pooled average Pooled average 0 25 50 75 100 0 25 50 75 100 Percentage Percentage"
    },
    {
        "id": "doc_544",
        "document": "NA \u2013 not available."
    },
    {
        "id": "doc_545",
        "document": "a Defined as direct medical expenditures, direct nonmedical expenditures and indirect costs (e.g. income losses) that sum to >20% of annual household expenditure or income. This indicator is not the same as the SDG indicator for catastrophic health expenditures; see Box 5 for further explanation. b Disaggregated estimates for TB (first-line treatment) and drug-resistant TB were available for only 25 countries. The calculation of confidence intervals for Mali and Uganda did not account for"
    },
    {
        "id": "doc_546",
        "document": "sampling design."
    },
    {
        "id": "doc_547",
        "document": "FIg. 37\n\nGlobal estimates of the number of TB cases attributable to selected risk factors,a 2022\n\nUndernourishment HIV infection Alcohol use disorders Smoking Diabetes 0 0.5 1.0 1.5 2.0 2.5"
    },
    {
        "id": "doc_548",
        "document": "a Sources of data used to produce estimates were: Imtiaz s et al. Eur Resp Jour (2017) (https://pubmed.ncbi.nlm.nih.gov/28705945/); Hayashi S et al. Trop Med Int Health (2018) (https://pubmed.ncbi.nlm.nih.gov/30062731/); L\u00f6nnroth K et al. Lancet (2010) (https://pubmed.ncbi.nlm.nih.gov/20488524/); World bank sustainable Development Goals Database (http://datatopics.worldbank.org/sdgs/); WHO Global Health Observatory (https://www.who.int/data/gho); and the WHO Global Tuberculosis Programme.\n\n36"
    },
    {
        "id": "doc_549",
        "document": "Global tuberculosis report 2023\n\nIn line with the global part of the MAF-TB and the requests at the 2023 UN high-level meeting on TB (Table 3), WHO will continue to lead the coordination of global monitoring, reporting and review, and provide technical support and guidance to countries and partners. WHO\u2019s work will also continue to be informed by the WHO Civil Society Task Force on TB.1\n\nTB research and innovation"
    },
    {
        "id": "doc_550",
        "document": "Slow progress, much more investment needed, new vaccine initiatives hold promise\n\nThe End TB Strategy targets set for 2030 and 2035 (Box 2) cannot be met without intensified research and innovation. When these targets were first established, it was highlighted that technological breakthroughs would be needed by 2025, so that the annual decline in the global TB incidence rate could be accelerated to an average of 17% per year between 2025 and 2035 (2, 12)."
    },
    {
        "id": "doc_551",
        "document": "Reductions in TB incidence achieved between 2015 and 2022 fall far short of the 2025 milestone of the strat- egy (8.7% compared with 50%). This means that an even faster rate of decline will now be required to reach the targets for 2030 and 2035."
    },
    {
        "id": "doc_552",
        "document": "Priorities include a vaccine to reduce the risk of infec- tion, a vaccine or new drug treatment to cut the risk of TB disease in people already infected, rapid diagnostic tests for accurate detection of TB disease at the point of care, and simpler, shorter treatments for TB disease. WHO has developed a global strategy for TB research and innovation, which was adopted by all Member States in 2020 (52). This aims to support accelerated TB research and innovation and improve equitable access to the"
    },
    {
        "id": "doc_553",
        "document": "benefits of research."
    },
    {
        "id": "doc_554",
        "document": "There is progress in the development of new TB diagnostics, drugs and vaccines.2 However, this is con- strained by the overall level of investment. Although there have been modest increases in funding in recent years (Fig. 38); the most recently published data show a total of US$ 1.0 billion in 2021 (53). This is only half of the global target of US$ 2 billion per year that was set for the period 2018\u20132022 at the first UN high-level meeting on TB (Table 1) and one fifth of the new target of US$"
    },
    {
        "id": "doc_555",
        "document": "5 billion per year by 2027 that was set at the second UN high-level meeting in 2023 (Table 2)."
    },
    {
        "id": "doc_556",
        "document": "The diagnostic pipeline has expanded considerably in terms of the number of tests, products or methods in development. These include molecular tests for the detection of TB disease and drug resistance, interfer-\n\n1 For further information, see\n\nhttps://www.who.int/groups/civil-society-task-force-on-tb."
    },
    {
        "id": "doc_557",
        "document": "2 A high-level summary of the status of the pipelines for new TB diagnostics, drugs and vaccines is provided in this subsection. The report webpages (Section 6) provide more details, including graphics showing the products in each pipeline and links to websites that provide information about the clinical trials that are underway."
    },
    {
        "id": "doc_558",
        "document": "FIg. 38\n\nFunding for TB research, 2015\u20132021 2.0 Target set at 2018 UN high-level meeting on TB ) $ S U 1.5 t n e r r u c 1.0 ( s n o i l l i B 0.5 0 2015 2016 2017 2018 2019 2020 2021\n\nSource: Treatment Action Group, Stop TB Partnership. Tuberculosis research funding trends 2005\u20132021. New York: Treatment Action Group; 2022 (https://www.treatmentactiongroup.org/resources/tbrd-report/tbrd- report-2022)"
    },
    {
        "id": "doc_559",
        "document": "on-gamma release assays (IGRAs) for detection of TB infection, biomarker-based assays for detection of TB infection and disease, computer-aided detection for TB screening using digital chest radiography, and a new class of aerosol-capture technologies for detection of TB disease."
    },
    {
        "id": "doc_560",
        "document": "In 2023, WHO convened a guideline development group that assessed the use of targeted next-genera- tion sequencing for detecting drug-resistant TB directly from sputum specimens, and issued a rapid commu- nication to highlight the key findings (54). This class of tests is a major step towards comprehensive drug sus- ceptibility testing (DST)."
    },
    {
        "id": "doc_561",
        "document": "In the near future, WHO plans to review evidence on nucleic acid amplification tests to detect TB, including use of alternative sample types and testing for resist- ance to drugs used to treat drug-susceptible TB, MDR/ RR-TB, pre-XDR and XDR-TB. Additional products under consideration for review include point-of-care TB tests, near point-of-care molecular tests, culture-based DST, broth microdilution methods for DST, new IGRAs to test for TB infection and computer-aided detection for dig- ital"
    },
    {
        "id": "doc_562",
        "document": "chest radiography in individuals under 15 years of age (as well as other use cases)."
    },
    {
        "id": "doc_563",
        "document": "As of August 2023, there were 28 drugs for the treat- ment of TB disease in Phase I, Phase II or Phase III trials\n\n(55). This is an increase from 26 in 2022 and eight in 2015. The 28 drugs comprise:\n\n\" 18 new chemical entities. These are BVL-GSK098, BTZ-043, delpazolid, GSK-286 (GSK 2556286), GSK- 3036656, macozinone, OPC-167832, TBAJ-587, TBAJ- 876, TBI-223, TBI-166, TBA-7371, telacebec-(Q203), sanfetrinem, SQ109, SPR720 (fobrepodacin), sutezol- id, and sudapyridine (WX-081);"
    },
    {
        "id": "doc_564",
        "document": "\" three drugs that have already been approved by WHO for use in treatment. These are bedaquiline, delama- nid and pretomanid;\n\n3. Main findings and messages\n\n37\n\n\" seven repurposed drugs. These are clofazimine, lev- ofloxacin, linezolid, moxifloxacin, rifampicin (high dose), rifapentine and tedizolid."
    },
    {
        "id": "doc_565",
        "document": "Various combination regimens with new or repur- posed drugs, as well as host-directed therapies, are also in Phase II or Phase III/IV trials or being evaluated as part of operational research projects."
    },
    {
        "id": "doc_566",
        "document": "In August 2023, there were at least 29 clinical tri- als and implementation research studies underway to evaluate drug regimens and models of delivery for TB preventive treatment. Examples include a trial for the prevention of MDR-TB using delamanid, studies to assess how to optimize treatment administration in\n\nvery young children and people with HIV, and trials of rifamycin monotherapies for durations of 6 or 8 weeks."
    },
    {
        "id": "doc_567",
        "document": "In August 2023, there were 16 vaccine candidates in clinical trials (unchanged from 2022): four in Phase I, eight in Phase II and four in Phase III. They included can- didates to prevent TB infection and TB disease, and to help improve the outcomes of treatment for TB disease."
    },
    {
        "id": "doc_568",
        "document": "Effective vaccines are critical to achieve annual glob- al and national reductions in TB incidence and mortali- ty that are much faster than those achieved historically. Recent high-level actions by WHO to support the devel- opment and implementation of new TB vaccines are summarized in Box 6."
    },
    {
        "id": "doc_569",
        "document": "Box 6. WHO actions to support TB vaccine development and implementation\n\nn Recognizing the critical role of TB vaccines in achieving rapid reductions in TB incidence and mortality, WHO has given considerable attention to high- level actions aimed at accelerating vaccine development and use.\n\nIn 2022, an investment case that sets out the economic and health impact arguments for TB vaccine development and uptake was developed and published (56). Key findings included the following estimates:"
    },
    {
        "id": "doc_570",
        "document": "\u25b6 over 25 years, a vaccine that is 50% effective in preventing disease among adolescents and adults could avert up to 76 million people developing TB disease, 8.5 million deaths from TB, 42 million courses of antibiotic treatment and US$ 41.5 billion in costs faced by TB-affected households;\n\n\u25b6 over 25 years, a vaccine that is 75% effective could avert up to 110 million new TB cases and 12.3 million deaths;"
    },
    {
        "id": "doc_571",
        "document": "\u25b6 for every US$ 1 invested, a vaccine with 50% efficacy could generate an economic return of US$ 7 in terms of averted health costs and increased productivity."
    },
    {
        "id": "doc_572",
        "document": "In January 2023, WHO convened a high-level event during the World Economic Forum, to highlight the role of new TB vaccines in the fight against TB (57). The importance of strategic partnerships and investments to boost the development, testing and manufacturing of safe and effective TB vaccines and equitable access to their use once available was highlighted, drawing on lessons learned during the COVID-19 pandemic. At the meeting, the WHO Director-General announced plans to establish an"
    },
    {
        "id": "doc_573",
        "document": "\u201caccelerator council\u201d on new TB vaccines (58)."
    },
    {
        "id": "doc_574",
        "document": "In March 2023, the WHO Director-General launched a new 5-year (2023\u20132027) flagship initiative to accelerate progress towards ending TB (59). This included a call for the licensing of at least one new vaccine by 2027."
    },
    {
        "id": "doc_575",
        "document": "In September 2023, in association with the second UN high-level meeting on TB, the WHO Director-General launched the \u201cTB vaccine accelerator council\u201d (60, 61). The council aims to boost the TB vaccine pipeline and facilitate the licensing and use of safe TB vaccines that will have a substantial impact on the TB epidemic, by catalysing high-level alignment among national governments, funding agencies, global agencies and communities on both the important challenges in TB vaccine development and"
    },
    {
        "id": "doc_576",
        "document": "the actions required to address them."
    },
    {
        "id": "doc_577",
        "document": "38\n\nGlobal tuberculosis report 2023\n\n4. Conclusions\n\nIn 2014 and 2015, all WHO and UN Member States com- mitted to ending the global TB epidemic, through their adoption of the WHO End TB Strategy and UN SDGs. The 2030 targets of the End TB Strategy are a 90% reduc- tion in the number of deaths caused by TB and an 80% reduction in the TB incidence rate, compared with lev- els in 2015; the 2025 milestones are reductions of 75% and 50%, respectively."
    },
    {
        "id": "doc_578",
        "document": "These commitments have been reaffirmed at two UN high-level meetings on TB, in 2018 and most recently September 2023, and reinforced with additional targets related to funding, the provision of treatment to people with TB disease or TB infection, and the availability of new TB vaccines.\n\nProgress in reducing the burden of TB disease was made up to 2019, but the COVID-19 pandemic was a major setback that reversed previous gains. The num- ber of people accessing TB care fell substantially in"
    },
    {
        "id": "doc_579",
        "document": "2020 and recovered only partially in 2021, resulting in increases in both the number of people dying from TB and the number of people falling ill with the disease, for the first time in many years."
    },
    {
        "id": "doc_580",
        "document": "In 2022, there was an encouraging recovery in the number of people being diagnosed with TB and treated, which has started to reverse or mitigate the damaging impact of the pandemic. However, the world as a whole and most regions and countries are far from reaching End TB Strategy milestones and targets. Despite being preventable and usually curable, TB remained the world\u2019s second leading cause of death from a single infectious agent in 2022, after COVID-19, and caused almost twice as many deaths"
    },
    {
        "id": "doc_581",
        "document": "as HIV/AIDS."
    },
    {
        "id": "doc_582",
        "document": "Ending the global TB epidemic requires that the new and reaffirmed commitments made at the second UN high-level meeting on TB in September 2023 are urgent- ly translated into action.\n\n39"
    },
    {
        "id": "doc_583",
        "document": "References\n\n1. Sustainable Development Goals [website]. New York: United Nations; 2022 (https://sdgs.un.org/).\n\nGlobal strategy and targets for tuberculosis prevention, care and control after 2015 (Resolution WHA67.1, Agenda item 12.1). Geneva: World Health Assembly; 2014 (http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R1-en.pdf)."
    },
    {
        "id": "doc_584",
        "document": "3. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152 (https://doi.org/10.1371/journal.pmed.1002152)."
    },
    {
        "id": "doc_585",
        "document": "4. Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect Dis. 2018;18(8):e228\u2013e38 (https://doi.org/10.1016/S1473-3099(18)30134-8)."
    },
    {
        "id": "doc_586",
        "document": "5. Emery JC, Richards AS, Dale KD, McQuaid CF, White RG, Denholm JT, Houben RM. Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease. Proc Biol Sci. 2021;288(1943):20201635. (https://doi.org/10.1098/rspb.2020.1635).\n\n6. Behr MA, Edelstein PH, Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ. 2019;367:l5770 (https://doi.org/10.1136/bmj.l5770)."
    },
    {
        "id": "doc_587",
        "document": "7. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601. (https://doi.org/10.1371/journal.pone.0017601).\n\n8. Resolution 73/3: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations General Assembly; 2018"
    },
    {
        "id": "doc_588",
        "document": "(https://www.who.int/publications/m/item/political-declaration-of-the-un-general-assembly-high-level-meeting-on- the-fight-against-tuberculosis).\n\n9. Resolution 78/L.4. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations; 2023 (https://digitallibrary.un.org/record/4022582)."
    },
    {
        "id": "doc_589",
        "document": "10. Provisional tuberculosis (TB) notifications [website]. Geneva: World Health Organization; 2023 (https://worldhealthorg.shinyapps.io/tb_pronto/).\n\n11. Tuberculosis data [website]. Geneva: World Health Organization; 2023 (https://www.who.int/tb/data/en/).\n\n12. Floyd K, Glaziou P, Houben R, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016\u20132035: definition and rationale. Int J Tuberc Lung Dis. 2018;22(7):723\u201330. doi: https://doi.org/10.5588/ijtld.17.0835."
    },
    {
        "id": "doc_590",
        "document": "13. Moscow Declaration to End TB; First WHO global ministerial conference on ending TB in the sustainable development era: a multisectoral response. Geneva: World Health Organization and the Ministry of Health of the Russian Federation; 2017 (https://iris.who.int/handle/10665/345527).\n\n14. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/346387)."
    },
    {
        "id": "doc_591",
        "document": "15. Global tuberculosis report 2022. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/363752).\n\n16. Impact of the COVID-19 pandemic on TB detection and mortality in 2020. Geneva: World Health Organization; 2021 (https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020)."
    },
    {
        "id": "doc_592",
        "document": "17. Strategic and Technical Advisory Group for Tuberculosis (STAG-TB): report of the 21st meeting, 21\u201323 June 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/351132).\n\n18. Report of a subgroup meeting of the WHO Task Force on TB Impact Measurement: methods used by WHO to estimate TB disease burden. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/363428)."
    },
    {
        "id": "doc_593",
        "document": "19. Krishnan A, Gupta V, Nongkynrih B, Kumar R, Kaur R, Malhotra S et al. Mortality in India established through verbal autopsies (MINErVA): Strengthening national mortality surveillance system in India. J Glob Health. 2020;10(2):020431. doi: https://doi.org/10.7189/jogh.10.020431.\n\n20. MCCD \u2013 annual report [website]. Office of the Registrar-General and Census Commissioner of India, 2023 (https://censusindia.gov.in/census.website/data/MCCDREP)."
    },
    {
        "id": "doc_594",
        "document": "21. Sample Registration System (SRS) \u2013 cause of death in India 2015\u20132017. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2023 (https://censusindia.gov.in/census.website/data/SRSCOD).\n\n40\n\n22. Sample Registration System (SRS) \u2013 cause of death in India 2016\u20132018. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2022 (https://censusindia.gov.in/census.website/data/SRSCOD)."
    },
    {
        "id": "doc_595",
        "document": "23. Sample Registration System (SRS) \u2013 cause of death in India 2017\u20132019. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2023 (https://censusindia.gov.in/census.website/data/SRSCOD).\n\n24. Sample Registration System (SRS) \u2013 cause of death in India 2014\u20132016. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2022 (https://censusindia.gov.in/census.website/data/SRSCOD)."
    },
    {
        "id": "doc_596",
        "document": "25. Sample Registration System (SRS) \u2013 cause of death in India 2004\u20132006. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2022 (https://censusindia.gov.in/census.website/data/SRSCOD).\n\n26. Sample Registration System (SRS) \u2013 cause of death in India 2007\u20132009. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2023 (https://censusindia.gov.in/census.website/data/SRSCOD)."
    },
    {
        "id": "doc_597",
        "document": "27. Sample Registration System (SRS) \u2013 cause of death in India 2010\u20132013. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2022 (https://censusindia.gov.in/census.website/data/SRSCOD).\n\n28. GBD results tool [website]. Washington: Institute for Health Metrics and Evaluation, Global Health Data Exchange; 2019 (ghdx.healthdata.org/gbd-results-tool)."
    },
    {
        "id": "doc_598",
        "document": "29. Global tuberculosis report 2016. Geneva: World Health Organization; 2016 (pp20) (https://iris.who.int/handle/10665/250441).\n\n30. Coronavirus (COVID-19) dashboard [website]. Geneva: World Health Organization; 2022 (https://covid19.who.int/).\n\n31. AIDS info [website]. Geneva: UNAIDS; 2023 (https://aidsinfo.unaids.org/)."
    },
    {
        "id": "doc_599",
        "document": "32. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis \u2013 rapid diagnostics for tuberculosis detection 2021 update. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342331).\n\n33. Global HIV & AIDS statistics \u2013 fact sheet [website]. Geneva: UNAIDS; 2023"
    },
    {
        "id": "doc_600",
        "document": "(https://www.unaids.org/en/resources/fact-sheet).\n\n34. WHO consolidated guidelines on tuberculosis. Module 4: Treatment \u2013 drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/353829)\n\n35. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/275383)."
    },
    {
        "id": "doc_601",
        "document": "36. WHO consolidated guidelines on tuberculosis. Module 4: Treatment \u2013 drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365308).\n\n37. WHO consolidated guidelines on tuberculosis. Module 1: Prevention \u2013 tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/331170).\n\n38. The Global Health Observatory [website]. Geneva: World Health Organization; 2023"
    },
    {
        "id": "doc_602",
        "document": "(https://www.who.int/data/gho/data/indicators/indicator-details/GHO/bcg-immunization-coverage-among-1-year- olds-(-)).\n\n39. The Global Plan to End TB, 2018\u20132022. Geneva: Stop TB Partnership; 2019 (https://www.stoptb.org/advocate-to-endtb/global-plan-to-end-tb).\n\n40. The Global Plan to End TB, 2023\u20132030. Geneva: Stop TB Partnership; 2019"
    },
    {
        "id": "doc_603",
        "document": "(https://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030).\n\n41. Guidance for national strategic planning for tuberculosis. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/361418).\n\n42. World Health Organization/World Bank. Tracking Universal Health Coverage: 2017 Global monitoring report. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/259817)."
    },
    {
        "id": "doc_604",
        "document": "43. World Health Organization/World Bank. Global monitoring report on financial protection in health 2021. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/350240).\n\n44. World Health Organization/World Bank. Tracking Universal Health Coverage: 2023 Global monitoring report. Geneva:World Health Organization; 2023 (https://www.who.int/publications/i/item/9789240080379)."
    },
    {
        "id": "doc_605",
        "document": "45. Tangcharoensathien V, Witthayapipopsakul W, Panichkriangkrai W, Patcharanarumol W, Mills A. Health systems development in Thailand: a solid platform for successful implementation of universal health coverage. Lancet. 2018;391(10126):1205\u201323. doi: https://doi.org/10.1016/S0140-6736(18)30198-3.\n\n46. National surveys of costs faced by TB patients and their households, 2015\u20132021. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/366277)."
    },
    {
        "id": "doc_606",
        "document": "47. Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Garcia Baena I, Floyd K, Menzies N. Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis. Lancet Glob Health. 2023; 11(10):e1640-e1647 (https://pubmed.ncbi.nlm.nih.gov/37734806).\n\nReferences\n\n41"
    },
    {
        "id": "doc_607",
        "document": "48. Multisectoral accountability framework to accelerate progress to end tuberculosis by 2030. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/331934)."
    },
    {
        "id": "doc_608",
        "document": "49. WHO Multisectoral accountability framework for TB (MAF-TB): baseline assessment checklist for country use in pursuing a national MAF-TB. Geneva: World Health Organization; 2020 (https://www.who.int/publications/m/item/who-multisectoral-accountability-framework-for-tb-(maf-tb)-baseline- assessment-checklist-for-country-use-in-pursuing-a-national-maf-tb)."
    },
    {
        "id": "doc_609",
        "document": "50. Adaptation and implementation of the WHO Multisectoral Accountability Framework to end TB: Operational guidance. Geneva: World Health Organization; 2023\n\n(https://www.who.int/publications/m/item/operational-guidance-adaptation-and-implementation-of-the-who- multisectoral-accountability-framework-to-end-tb)."
    },
    {
        "id": "doc_610",
        "document": "51. Adaptation and implementation of WHO\u2019s multisectoral accountability framework to end TB (MAF-TB): best practices. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365806).\n\n52. Global Strategy for Tuberculosis Research and Innovation (WHA73.3). Seventy-third World Health Assembly. Geneva: World Health Organization; 2020 (https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R3-en.pdf)."
    },
    {
        "id": "doc_611",
        "document": "53. Treatment Action Group, Stop TB Partnership. Tuberculosis research funding trends 2005\u20132021. New York: Treatment Action Group; 2022 (https://www.treatmentactiongroup.org/resources/tbrd-report/tbrd-report-2022/).\n\n54. Use of targeted next-generation sequencing to detect drug-resistant tuberculosis. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/371687)."
    },
    {
        "id": "doc_612",
        "document": "55. WHO launches the TB research tracker, an online platform to track progress in TB research. Geneva: World Health Organization; 2023\n\n(https://www.who.int/news/item/05-06-2023-who-launches-the-tb-research-tracker--an-online-platform-to-track- progress-in-tb-research).\n\n56. An investment case for new tuberculosis vaccines. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365230)."
    },
    {
        "id": "doc_613",
        "document": "57. Davos AM23 \u2013 Ending tuberculosis: how do we get there? [website]. Geneva: World Economic Forum; 2023 (https://www.weforum.org/events/world-economic-forum-annual-meeting-2023/sessions/ending-tuberculosis-how-do- we-get-there)."
    },
    {
        "id": "doc_614",
        "document": "58. WHO announces plans to establish a TB Vaccine Accelerator council. Geneva: World Health Organization; 2023 (https://www.who.int/news/item/17-01-2023-who-announces-plans-to-establish-a-tb-vaccine-accelerator- council#:~:text=Speaking%20earlier%20today%20at%20a,new%20TB%20Vaccine%20Accelerator%20Council)."
    },
    {
        "id": "doc_615",
        "document": "59. World Health Organization Director-General Flagship Initiative to #ENDTB 2023\u20132027 [website]. Geneva: World Health Organization; 2023 (https://www.who.int/publications/m/item/who-director-general-flagship-initiative-to-endtb).\n\n60. Ghebreyesus TA, Lima NT. The TB Vaccine Accelerator Council: harnessing the power of vaccines to end the tuberculosis epidemic. Lancet Infect Dis. 2023; S1473-3099(23)00589-3 (https://pubmed.ncbi.nlm.nih.gov/37742697)."
    },
    {
        "id": "doc_616",
        "document": "61. Tuberculosis Vaccine Accelerator Council [website]. Geneva: World Health Organization; 2023 (https://www.who.int/initiatives/tuberculosis-vaccine-accelerator-council).\n\n42\n\nGlobal tuberculosis report 2023\n\nANNEx 1 Basic facts about TB"
    },
    {
        "id": "doc_617",
        "document": "Tuberculosis (TB) is an old disease. Studies of human skeletons show that it has affected humans for thou- sands of years (1). Its cause remained unknown until 24 March 1882, when Dr Robert Koch announced his dis- covery of the bacillus responsible, subsequently named Mycobacterium tuberculosis (2). The disease is spread when people who are sick with TB expel bacteria into the air (e.g. by coughing). TB typically affects the lungs (pulmonary TB) but can also affect other sites (extrapul- monary"
    },
    {
        "id": "doc_618",
        "document": "TB). Most people who develop the disease (about 90%) are adults and there are more cases among men than women."
    },
    {
        "id": "doc_619",
        "document": "Diagnostic tests for TB disease have improved sub- stantially in recent years. There are now several rapid molecular tests recommended by WHO as the initial diagnostic test for TB, some of which can detect drug resistance simultaneously (3). These tests can be used at the lower levels of the health system. A point-of-care lateral-flow test performed on urine is also recommend- ed by WHO; its main use is to assist with diagnosis of TB in people with advanced HIV disease, in combination with rapid"
    },
    {
        "id": "doc_620",
        "document": "molecular tests. There are additional rapid molecular tests specifically for the detection of resist- ance to a variety of first- and second-line anti-TB drugs, while sequencing technologies can be used to provide a comprehensive individual profile of drug resistance. The older method of sputum smear microscopy (devel- oped >100 years ago) is still widely used for TB diagnosis in low and middle-income countries but is increasingly being replaced with rapid tests."
    },
    {
        "id": "doc_621",
        "document": "Culture testing remains the reference standard for TB diagnosis. In addition, culture is required for the detec- tion of resistance to newer anti-TB drugs and may also be used as a confirmatory test in settings and situations in which people have a low pre-test probability of hav- ing TB disease. Following diagnosis, culture or smear (as opposed to rapid molecular tests) are necessary to monitor an individual\u2019s response to treatment."
    },
    {
        "id": "doc_622",
        "document": "Without treatment, the death rate from TB is high. Studies of the natural history of TB disease in the absence of treatment with anti-TB drugs (conducted before drug treatments became available) found that about 70% of individuals with sputum smear-positive pulmonary TB died within 10 years of being diagnosed, as did about 20% of people with culture-positive (but smear-negative) pulmonary TB (4).\n\nEffective drug treatments were first developed"
    },
    {
        "id": "doc_623",
        "document": "in the 1940s. The latest WHO guidelines (5) include a strong recommendation for a 6-month regimen of isoniazid (H), rifampicin (R), ethambutol (E) and pyrazinamide (Z) for people with drug-susceptible TB (both pulmonary and extrapulmonary): all four drugs for the first two months, followed by H and R for the remaining 4 months. They also include newer recom- mendations that people aged 12 years and older with drug-susceptible pulmonary TB may be treated with a 4-month regimen of rifapentine (P),"
    },
    {
        "id": "doc_624",
        "document": "H, Z and moxiflox- acin (M), and that children and adolescents between 3 months and 16 years of age with non-severe TB (and without suspicion or evidence of resistance to R and H) may be treated with a 4-month regimen (2 months of H, R, Z and sometimes also E, followed by 2 months of H and R). Treatment success rates of at least 85% for people enrolled on the 6-month regimen are regu- larly reported to WHO by its 194 Member States."
    },
    {
        "id": "doc_625",
        "document": "Treatment for people diagnosed with R-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB, defined as resistance to H and R) requires other regimens. The latest WHO guidelines (6) prioritize a new 6-month regimen consisting of bedaquiline (B), pretomanid (Pa), linezolid (L) and moxifloxacin (M), referred to as BPaLM; for people who have pre-extensively drug-resistant TB (pre-XDR-TB, defined as TB that is resistant to R and any fluoroquinolone), the regimen can be used with- out moxifloxacin"
    },
    {
        "id": "doc_626",
        "document": "(BPaL). Based on currently available safety data, this regimen is recommended only for people aged 14 years and above. For people not eligi- ble for the 6-month regimen, other 9-month or longer regimens can be used (6). Nationally, treatment suc- cess rates for RR-TB reported to date have typically been in the range of 50\u201375%; the global average has been improving in recent years, reaching 63% in the most recent patient cohort for which data are availa- ble. This may further improve with"
    },
    {
        "id": "doc_627",
        "document": "expanded use of BPaLM, for which clinical trial data showed a treat- ment success rate of 89% (7). Treatment for XDR-TB (resistance to R, any fluoroquinolone and at least one of bedaquiline or linezolid) remains much more dif- ficult and treatment success rates are typically low."
    },
    {
        "id": "doc_628",
        "document": "A global modelling study published in 2016 estimated that about a quarter of the world\u2019s population had been infected with M. tuberculosis (8). Recent analyses and commentary suggest that the number of those current- ly infected is lower, given that some people will clear\n\n43"
    },
    {
        "id": "doc_629",
        "document": "the infection (9, 10). An older modelling study published in 2000 estimated that about 5\u201310% of people infected with TB will go on to develop TB disease at some point during their lifetime (11). The probability of developing TB disease is much higher among people living with HIV, and among people affected by risk factors such as undernutrition, diabetes, smoking and alcohol con- sumption."
    },
    {
        "id": "doc_630",
        "document": "Preventive treatment is available for people with TB infection. Recommended options include: a weekly dose of H and P for 3 months (3HP), a daily dose of H and\n\nR for 3 months (3HR), a daily dose of H and P for 1 month (1HP), a daily dose of R for 4 months (4R), and a daily dose of H for 6 months (6H) or longer (12)."
    },
    {
        "id": "doc_631",
        "document": "The only licensed vaccine for prevention of TB dis- ease is the bacille Calmette-Gu\u00e9rin (BCG) vaccine. The BCG vaccine was developed almost 100 years ago, pre- vents severe forms of TB in children and is widely used. There is currently no licenced vaccine that is effective in preventing TB disease in adults, either before or after exposure to TB infection; however, results from a Phase II trial of the M72/AS01E candidate are promising (13)."
    },
    {
        "id": "doc_632",
        "document": "References\n\n1. Hershkovitz I, Donoghue HD, Minnikin DE, May H, Lee OY, Feldman M, et al. Tuberculosis origin: the Neolithic scenario. Tuberculosis. 2015;95 Suppl 1:S122\u20136 (https://www.ncbi.nlm.nih.gov/pubmed/25726364).\n\n2. Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax. 1982;37(4):246\u201351 (https://www.ncbi.nlm.nih.gov/pubmed/6180494)."
    },
    {
        "id": "doc_633",
        "document": "3. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis \u2013 rapid diagnostics for tuberculosis detection 2021 update. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342331)."
    },
    {
        "id": "doc_634",
        "document": "4. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601 (https://www.ncbi.nlm.nih.gov/pubmed/21483732).\n\n5. WHO consolidated guidelines on tuberculosis. Module 4: Treatment \u2013 drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/353829)"
    },
    {
        "id": "doc_635",
        "document": "6. WHO consolidated guidelines on tuberculosis. Module 4: Treatment \u2013 drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2022 update (https://iris.who.int/handle/10665/365308).\n\n7. Nyang\u2019wa BT et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Eng J Med. 2022;387(25):2331-2343 (https://pubmed.ncbi.nlm.nih.gov/36546625/)."
    },
    {
        "id": "doc_636",
        "document": "8. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PloS Med. 2016 (https://doi.org/10.1371/journal.pmed.1002152).\n\n9. Emery JC, Richards AS, Dale KD, McQuaid FC, White RG, Denholm JT and Houben RMGJ. Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease. Proc Biol Sci. 2021 (https://royalsocietypublishing.org/doi/full/10.1098/rspb.2020.1635)."
    },
    {
        "id": "doc_637",
        "document": "10. Behr MA, Edelstein PH, Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ 2019;367:l5770 (https://www.bmj.com/content/367/bmj.l5770).\n\n11. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. American journal of epidemiology. 2000;152(3):247-63."
    },
    {
        "id": "doc_638",
        "document": "12. WHO consolidated guidelines on tuberculosis. Module 1: Prevention \u2013 tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/331170).\n\n13. Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Eng J Med. 2019;381(25):2429\u201339 (https://pubmed.ncbi.nlm.nih.gov/31661198/).\n\n44\n\nGlobal tuberculosis report 2023\n\nANNEX 2\n\nData sources and access"
    },
    {
        "id": "doc_639",
        "document": "A2.1 Database contents\n\nThe Global tuberculosis report 2023 is based on data requested annually from 215 countries and areas, including all 194 World Health Organization Member States. Data are stored in the global TB database which is managed by the TB Monitoring, Evaluation and Stra- tegic Information unit of the Global Tuberculosis Pro- gramme, at WHO headquarters."
    },
    {
        "id": "doc_640",
        "document": "The Global Tuberculosis Programme has implement- ed annual rounds of data collection since 1995. The main round of data collection for this report took place in April 2023. As in previous years, data were collected on the following: TB case notifications and treatment outcomes, including breakdowns by TB case type, age, sex, HIV status and drug resistance; laboratory diag- nostic services; monitoring and evaluation, including surveillance and surveys specifically related to drug-re- sistant TB;"
    },
    {
        "id": "doc_641",
        "document": "contact screening and TB preventive treat- ment; digital systems; TB infection control; engagement of all public and private care providers in TB prevention and care; community engagement; specific elements of the WHO multisectoral accountability framework for TB; budgets of national TB programmes (NTPs); use of general health services (hospitalization and outpa- tient visits) during treatment; and NTP expenditures. A shortened version of the questionnaire was used for high-income countries as"
    },
    {
        "id": "doc_642",
        "document": "defined by the World Bank1 or low-incidence countries, defined as countries with an incidence rate of <20 cases per 100 000 population or <10 cases in total in 2021."
    },
    {
        "id": "doc_643",
        "document": "High TB burden countries and selected other regional priority countries were also asked to continue reporting monthly or quarterly provisional notification data. This process started in 2020 to monitor trends in the context of the COVID-19 pandemic."
    },
    {
        "id": "doc_644",
        "document": "Countries and areas reported data via a dedicated website.2 Countries in the European Union submitted data on notifications and treatment outcomes to the TESSy system managed by the European Centre for Dis- ease Prevention and Control (ECDC). Data from TESSy were uploaded into the WHO global TB database.\n\nAdditional data about the provision and completion of TB preventive treatment to people newly or current- ly enrolled in HIV care, detection of TB among people"
    },
    {
        "id": "doc_645",
        "document": "1 https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519-world-bank-country-and-lending-groups\n\n2 https://extranet.who.int/tme\n\nTAblE A2.1"
    },
    {
        "id": "doc_646",
        "document": "Reporting of data in the 2023 round of global TB data collection\n\ncOunTRIES And AREAS WHO MEMbER STATES nuMbER nuMbER nuMbER THAT REPORTEd nuMbER THAT REPORTEd dATA dATA African Region 47 46 47 46 Region of the Americas 45 39 35 32 South-East Asia Region 11 11 11 11 European Region 54 44 53 43 Eastern Mediterranean Region 22 21 21 20 Western Pacific Region 36 31 27 26 Global 215 192 194 178"
    },
    {
        "id": "doc_647",
        "document": "newly enrolled in HIV care, and provision of antiretrovi- ral therapy for TB patients living with HIV were collect- ed by the Joint United Nations Programme on HIV/AIDS (UNAIDS). These data were jointly validated by WHO and UNAIDS, and then uploaded into the WHO global TB database."
    },
    {
        "id": "doc_648",
        "document": "Following review and follow-up with countries, the data used for the main part of this report were those that were available on 21 July 2023. Table A2.1 shows the number of countries and territories that had report- ed data by 21 July 2023.\n\nIndicators in the Sustainable Development Goals (SDGs) associated with TB incidence were imported into the global TB database on 4 July 2023. Table A2.2 shows the data sources used."
    },
    {
        "id": "doc_649",
        "document": "Population estimates from the United Nations Popu- lation Division\u2019s 2022 revision of World Population Pros- pects3 were imported into the global TB database on 2 August 2022 and used in the analyses for this report."
    },
    {
        "id": "doc_650",
        "document": "A2.2 Accessing TB data using the WHO website\n\nMost of the data held in the WHO global TB database can be accessed via the WHO TB data web page.4 This page provides comma-separated value (CSV) data files and data visualizations, as well as country, regional and global profiles (Annex 4).\n\nData reported by countries, such as time series for\n\n3 https://population.un.org/wpp/\n\n4 https://www.who.int/teams/global-tuberculosis-programme/ data\n\n45\n\nTAblE A2.2"
    },
    {
        "id": "doc_651",
        "document": "Data sources for indicators in the Sustainable Development Goals associated with TB incidence"
    },
    {
        "id": "doc_652",
        "document": "Sdg IndIcATOR dISPlAY nAME In PROFIlE dATA SOuRcE nAME AT SOuRcE SOuRcE uRl Ll Population living below the international poverty line (% of population) UN SDG database Proportion of population below the international poverty line of US$1.90 per day https://unstats.un.org/SDGAPI/v1/sdg/Series/ Data?seriesCode=SI_POV_DAY1"
    },
    {
        "id": "doc_653",
        "document": "40 Population covered by social protection floors/ systems (% of population) World Bank Coverage of social protection and labor programs (% of population) http://data.worldbank.org/indicator/per_allsp. cov_pop_tot ZALIL Prevalence of undernourishment (% of population) World Bank Prevalence of undernourishment (% of population) http://data.worldbank.org/indicator/SN.ITK. DEFC.ZS"
    },
    {
        "id": "doc_654",
        "document": "3.3.1 (alternative) HIV prevalence (% of population aged 15-49 years) WHO-GHO Prevalence of HIV among adults aged 15 to 49 (%) https://ghoapi.azureedge.net/api/ MDG_0000000029 3.4.1 (alternative) Diabetes prevalence (% of population aged = 18 years) WHO-GHO Raised fasting blood glucose (=7.0 mmol/L or on medication) (age-standardized estimate) https://ghoapi.azureedge.net/api/NCD_GLUC_04"
    },
    {
        "id": "doc_655",
        "document": "852 (alternative) Alcohol use disorders, 12 month prevalence (% of population aged = 15 years) WHO-GHO Alcohol use disorders (15+), 12 month prevalence (%) with 95% https://ghoapi.azureedge.net/api/ SA_0000001462 3al (alternative) Smoking prevalence (% of population aged = 15 years) WHO-GHO Estimate of current tobacco smoking prevalence (%) (age-standardized rate) https://ghoapi.azureedge.net/api/M_Est_smk_ curr_std"
    },
    {
        "id": "doc_656",
        "document": "3.8.1 UHC index of essential service coverage (based on 14 tracer indicators including TB treatment) WHO-GHO UHC index of essential service coverage https://ghoapi.azureedge.net/api/UHC_INDEX_ REPORTED 3.8.2 Greater than 10% of total household expenditure orincome on health (% of population) WHO-GHO Catastrophic out-of-pocket health spending (SDG indicator 3.8.2) https://ghoapi.azureedge.net/api/ FINPROTECTION_CATA_TOT_10_POP"
    },
    {
        "id": "doc_657",
        "document": "3.8.2 (alternative) Health expenditure per capita, PPP (current international \u00a7) World Bank Current health expenditure per capita, PPP (current international \u00a7) http://data.worldbank.org/indicator/SH.XPD. CHEX.PP.CD 712 Access to clean fuels and technologies for cooking (% of population) World Bank Access to clean fuels and technologies for cooking (% of population) http://data.worldbank.org/indicator/EG.CFT. ACCS.ZS"
    },
    {
        "id": "doc_658",
        "document": "811 (alternative) GDP per capita, PPP (constant 2011 international \u00a7) World Bank GDP per capita, PPP (constant 2011 international $) http://data.worldbank.org/indicator/NY.GDP. PCAP.PP.KD 10.1.1 (alternative) GINlindex (0=perfect equality, 100=perfect inequality) World Bank GINlindex (World Bank estimate) http://data.worldbank.org/indicator/SI.POV.GINI"
    },
    {
        "id": "doc_659",
        "document": "ikl Population living in slums (% of urban population) UN SDG database Proportion of urban population living in slums (%) https://unstats.un.org/SDGAPI/v1/sdg/Series/ Data?seriesCode=EN_LND_SLUM"
    },
    {
        "id": "doc_660",
        "document": "case notifications and treatment outcomes, and WHO\u2019s estimates of TB disease burden, can be downloaded as CSV files covering all years for which data are available. They can be imported into many applications such as spreadsheets, databases and statistical analysis soft- ware. These files are the primary resource for anyone interested in conducting their own analyses of the records in the global TB database. A data dictionary that defines each of the variables available in the CSV files is also"
    },
    {
        "id": "doc_661",
        "document": "available."
    },
    {
        "id": "doc_662",
        "document": "The CSV files are generated on demand directly from the WHO global TB database, and may therefore include updates received after publication of the Global tuber- culosis report 2023."
    },
    {
        "id": "doc_663",
        "document": "A2.3 Accessing TB data using the WHO Global Health Observatory\n\nThe WHO Global Health Observatory (GHO)1 is a portal that provides access to data and analyses for monitor- ing the global health situation; it includes a data repos- itory.\n\nData from WHO\u2019s global TB database can be viewed, filtered, aggregated and downloaded from within the GHO data repository.2"
    },
    {
        "id": "doc_664",
        "document": "There is also an application programme interface (API)3 using the open data protocol. The API allows ana- lysts and programmers to use GHO data directly in their software applications.\n\n1 https://www.who.int/data/gho\n\n2 https://www.who.int/data/gho/data/themes/tuberculosis\n\n3 https://www.who.int/data/gho/info/gho-odata-api\n\n46\n\nGlobal tuberculosis report 2023\n\nANNEx 3\n\nWHO global lists of high TB burden countries"
    },
    {
        "id": "doc_665",
        "document": "A3.1 Background\n\nDuring the period 1998 to 2015, the concept of a \u201chigh burden country\u201d (HBC) became familiar and widely used in the context of tuberculosis (TB). The first global list developed by the World Health Organization (WHO) consisted of 22 HBCs with approximately 80% of the world\u2019s TB cases; this was established in 1998. Subsequently two other HBC lists, for HIV-associated TB and multidrug-resistant TB (MDR-TB), were defined."
    },
    {
        "id": "doc_666",
        "document": "In 2015, three WHO global lists of HBCs \u2013 for TB, TB/ HIV and MDR-TB \u2013 were in use. With a new era of the United Nations (UN) Sustainable Development Goals (SDGs) and the WHO End TB Strategy starting in 2016, a thorough review of the three lists was undertaken by the WHO Global Tuberculosis Programme in 2015 (1). This included consideration of whether the lists should be modified (and if so how) or whether they should be discontinued. The outcome of the review was the definition of three new"
    },
    {
        "id": "doc_667",
        "document": "global HBC lists, of 30 countries each, for the period 2016\u20132020: one for TB, one for TB/HIV and one for MDR-TB."
    },
    {
        "id": "doc_668",
        "document": "WHO conducted a consultation process in 2020 and early 2021, as the basis for defining updated global HBC lists for 2021\u20132025.\n\nA3.2 Global HBC lists to be used by WHO, 2021\u20132025"
    },
    {
        "id": "doc_669",
        "document": "Three global HBC lists for 2021\u20132025 have been estab- lished: one for TB, one for HIV-associated TB and one for MDR/rifampicin-resistant TB (MDR/RR-TB). The lists were defined using the same criteria as those agreed for the 2016\u20132020 lists, in combination with the WHO esti- mates (for 2019) of the incidence of TB, HIV-associated TB and rifampicin-resistant TB that were published in WHO\u2019s Global Tuberculosis Report 2020. Full details are available in a background document (2)."
    },
    {
        "id": "doc_670",
        "document": "The criteria for all three lists are the same:\n\n\" the top 20 countries in terms of their estimated abso- lute number of new (incident) cases in 2019; plus\n\n\" the 10 countries with the most severe burden in terms of the incidence rate (new cases per 100 000 popula-\n\nFIg. A3.1\n\nThe three global lists of high-burden countries for TB, HIV-associated TB and MDR/RR-TB to be used by WHO in the period 2021\u20132025, and their areas of overlap"
    },
    {
        "id": "doc_671",
        "document": "Brazil Central African Republic Congo Ethiopia Gabon Kenya Lesotho Liberia Namibia Thailand Uganda United Republic of Tanzania China Democratic Republic of the Congo India Indonesia Mozambique Myanmar Nigeria Philippines South Africa Zambia Angola Bangladesh Democratic People\u2019s Republic of Korea Mongolia Pakistan Papua New Guinea Viet Nam MDR/RR-TB TB/HIV Botswana Azerbaijan Belarus Kazakhstan Cameroon Nepal Eswatini Peru Guinea Guinea-Bissau Sierra Leone Republic of Moldova Russian Federation"
    },
    {
        "id": "doc_672",
        "document": "Malawi Somalia Russian Federation Tajikistan Zimbabwe Ukraine Uzbekistan Zimbabwe"
    },
    {
        "id": "doc_673",
        "document": "47\n\ntion in 2019) that are not already in the top 20, and that meet a minimum threshold in terms of their absolute number of cases. The thresholds are 10 000 new cases per year for TB; and 1000 new cases per year for HIV-associated TB and rifampicin-resistant TB."
    },
    {
        "id": "doc_674",
        "document": "The 30 countries that are in each of the three lists are shown in Fig. A3.1 and Table A3.1. There is overlap among the three lists, but 49 countries are in at least one of them. Each list accounted for 86\u201390% of the estimated global incidence in 2019.\n\nThe main changes compared with the previous lists for 2016\u20132020 are:\n\n\" The 30 high TB burden countries. Cambodia, the Russian Federation and Zimbabwe transi- tioned out of the list; Gabon, Mongolia and Ugan- da joined the list."
    },
    {
        "id": "doc_675",
        "document": "\" The 30 high TB/HIV burden countries. Ango- la, Chad, Ghana and Papua New Guinea transi- tioned out of the list; Gabon, Guinea, Philippines and the Russian Federation joined the list.\n\n\" The 30 high MDR/RR-TB burden countries. Ethiopia, Kenya and Thailand transitioned out of the list; Mongolia, Nepal and Zambia joined the list."
    },
    {
        "id": "doc_676",
        "document": "The lists provide a focus for global action on TB, HIV-associated TB and drug-resistant TB in the countries where progress is most needed to achieve the targets set in WHO\u2019s End TB Strategy, the polit- ical declaration of the UN high-level meeting on TB held in 2018 and the UN SDGs (Table 1). They also help to build and sustain national political commit- ment and funding in the countries with the highest burden in terms of absolute numbers or severity and promote global monitoring of progress in"
    },
    {
        "id": "doc_677",
        "document": "a well-defined set of countries."
    },
    {
        "id": "doc_678",
        "document": "The 30 high TB burden countries are given par- ticular attention in the report. Where estimates of disease burden and assessment of progress in the response are for HIV-associated TB or MDR/RR-TB specifically, the countries in the other two lists are given particular attention. Country profiles for all countries are available online, including in the mobile app that accompanies the report (Annex 4)."
    },
    {
        "id": "doc_679",
        "document": "A3.3 Global TB watchlist\n\nAlongside the three updated global HBC lists, WHO has established a \u201cglobal TB watchlist\u201d. This con- sists of the three countries that exited the global list of 30 high TB burden countries in 2021, but which nonetheless warrant continued attention and will remain a priority in terms of support from WHO. The three countries in the watchlist are Cambodia, the Russian Federation and Zimbabwe.\n\n48\n\nTAblE A3.1"
    },
    {
        "id": "doc_680",
        "document": "Countries in the three global lists of high-burden countries for TB, HIV-associated TB and MDR/RR- TB to be used by WHO in the period 2021\u20132025.\n\nThe red square indicates that a country is in a list."
    },
    {
        "id": "doc_681",
        "document": "cOunTRY Tb Tb/HIV MdR/ RR-Tb Angola \ue04c Azerbaijan EENR Bangladesh \ue04c \ue04c Belarus H Botswana Brazil u Cameroon EEEEN Central African Republic China HEEEN \ue04c \ue04c Congo H Democratic People\u2019s Republic of Korea \ue04c Democratic Republic of the Congo \ue04c \ue04c Eswatini Ethiopia u Gabon \ue04c Guinea Guinea-Bissau EEEEEEN India \ue04c \ue04c \ue04c Indonesia \ue04c H \ue04c Kazakhstan \ue04c Kenya u \ue04c Kyrgyzstan \ue04c Lesotho \ue04c \ue04c Liberia u \ue04c Malawi \ue04c Mongolia \ue04c Mozambique EEE \ue04c u Myanmar \ue04c \ue04c u Namibia H \ue04c Nepal Nigeria u \ue04c Pakistan u"
    },
    {
        "id": "doc_682",
        "document": "Papua New Guinea \ue04c EEEENENERN Peru Philippines \ue04c \ue04c Republic of Moldova of Moldova \ue04c Russian Federation H Sierra Leone \ue04c \ue04c Somalia u South Africa \ue04c \ue04c u Tajikistan \ue04c Thailand \ue04c \ue04c Uganda \ue04c \ue04c Ukraine \ue04c United Republic of Tanzania \ue04c \ue04c Uzbekistan Viet Nam \ue04c EEN Zambia \ue04c \ue04c \ue04c Zimbabwe \ue04c o"
    },
    {
        "id": "doc_683",
        "document": "Zimbabwe\n\no\n\nGlobal tuberculosis report 2023\n\nReferences\n\n1. World Health Organization. Use of high burden country lists for TB by WHO in the post-2015 era (discussion paper). Geneva: World Health Organization; 2015\n\n(https://www.who.int/publications/m/item/who-htm-tb-2015-29)."
    },
    {
        "id": "doc_684",
        "document": "2. World Health Organization. WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/ rifampicin-resistant TB (MDR/RR-TB), 2021\u20132025: background document. Geneva. World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/341980).\n\nAnnex 3. WHO global lists of high TB burden countries\n\n49\n\nANNEX 4"
    },
    {
        "id": "doc_685",
        "document": "Country, regional and global profiles\n\nCountry, regional and global profiles as well as data for all key indicators for all countries and areas are availa- ble in the WHO Global Tuberculosis Report mobile app and on the tuberculosis (TB) Data web page.1\n\nA4.1 The WHO Global TB Report mobile app"
    },
    {
        "id": "doc_686",
        "document": "The free WHO Global TB Report mobile app includes country, regional and global profiles from the WHO global TB database, as well as a summary of the key facts and messages from the report and an overview of progress towards global TB targets. The app allows users to easily view, query and visualize data, and to define queries, including those for specific country groups. Once installed, the app works offline so that data can be accessed without an ongoing internet connection. The app is"
    },
    {
        "id": "doc_687",
        "document": "available for Android devices through Google Play and for iOS devices, such as iPhones and iPads, through the Apple Store.2,3 It is available in English, French, Spanish and Russian."
    },
    {
        "id": "doc_688",
        "document": "DEMOCRATIC REPUBLIC OF THE I DEMOCRATIC REPUBLIC OF THE oz CONGO e e CONGO @ Africa a - - = Numbr @ e (. par 100 000 populaion per you] = o s om o 8 So0e 00840 - e Maraly = 34K 9om o0 ~O\u2014 Vole: 317 2 Estimates of TB Burden Lou\u201d g 205454 Notifications e 10000 UHC and social protection Rt patients TB/HIV care in new and relapse TB Drug-resistant TB Yeur Treatment suceess rate Number T8 preventive treatment (PT) T8 financing Cases atiributable o five risk factors SDG indicators associated with T8"
    },
    {
        "id": "doc_689",
        "document": "incidence 1] o % 1] w A"
    },
    {
        "id": "doc_690",
        "document": "A4.2 Online country profiles and other reports"
    },
    {
        "id": "doc_691",
        "document": "TB data profiles are available online for all 215 coun- tries and areas that report TB data to WHO each year, as are aggregate profiles for WHO regions and globally.1 The profiles are available in English, French, Spanish and Russian. They are generated on-demand directly from the WHO global TB database (Annex 2) and may therefore include updates received after publication of the global TB report. Estimates of TB cases attributa- ble to five risk factors and indicators in the Sustainable"
    },
    {
        "id": "doc_692",
        "document": "Development Goals (SDGs) that are associated with TB incidence are available for all 215 countries and territo- ries. TB financial profiles are available for more than 100 countries and territories that report detailed TB finan- cial data to WHO."
    },
    {
        "id": "doc_693",
        "document": "1 https://www.who.int/teams/global-tuberculosis-programme/ data\n\n2 https://play.google.com/store/apps/details?id=uk.co.adappt. whotbreport\n\n3 https://apps.apple.com/us/app/tb-report/id1483112411\n\n50\n\nANNEx 5\n\nUpdates to estimates of TB disease burden"
    },
    {
        "id": "doc_694",
        "document": "The report includes estimates of tuberculosis (TB) incidence and mortality for the period 2010\u20132022; estimates of TB incidence and mortality, disaggregat- ed by age and sex, for 2022; and estimates of the inci- dence of rifampicin-resistant TB (RR-TB) for the period 2015\u20132022. This annex summarizes the main updates to the methods used to produce these estimates and the resulting estimates that are presented in the report, compared with the Global tuberculosis report 2022 (1, 2). Details are"
    },
    {
        "id": "doc_695",
        "document": "provided in the technical appendix."
    },
    {
        "id": "doc_696",
        "document": "There were four major updates to estimates for this report:\n\n\" Time period for which estimates are presented. The start year for the time series of TB incidence and mortality estimates was changed from 2000 to 2010.\n\n\" Estimates for India. Estimates of TB incidence and mortality were updated for the period 2010\u20132019, with a major revision to estimates of TB mortality. These updates led in turn to updates to previously published estimates for 2020\u20132021 (1)."
    },
    {
        "id": "doc_697",
        "document": "\" Country-specific dynamic models. Use of such models to estimate TB incidence and mortality dur- ing the COVID-19 pandemic (and its aftermath) was expanded to include three additional countries and dropped for one country."
    },
    {
        "id": "doc_698",
        "document": "\" Estimates of the incidence of RR-TB. Estimates of the proportion of new and previously treated TB cas- es with RR-TB in the period 2015\u20132021 were updated for some countries, based on new or corrected data. For all countries, the time series was extended to cover 2015\u20132022 rather than 2015\u20132021.\n\nA5.1 Time period for which estimates are presented"
    },
    {
        "id": "doc_699",
        "document": "The report presents estimates of TB incidence and mor- tality for the period 2010\u20132022. The first year of the time series was changed to 2010 (instead of 2000). Thus, the estimates cover a shorter period before the start of the World Health Organization (WHO) End TB Strategy and United Nations (UN) Sustainable Development Goals (SDGs) and give greater emphasis to the periods covered by the strategy (2016\u20132035) and the SDGs (2016\u20132030), up to the most recent complete calendar year. The base- line"
    },
    {
        "id": "doc_700",
        "document": "year for the milestones and targets set in the End TB Strategy is 2015.1"
    },
    {
        "id": "doc_701",
        "document": "1 See Box 2 in the main report.\n\nA5.2 Estimates for India"
    },
    {
        "id": "doc_702",
        "document": "There was a major revision to estimates of TB mortality in the period 2010\u20132019, following the recent publication of cause-of-death data from the country\u2019s Sample Reg- istration System (SRS) for the period 2014\u20132019 (3\u20136). There was a minor revision (a slight upward adjustment) to TB incidence estimates, following a thorough review of the country-specific model that was used in 2022 to produce \u201cinterim\u201d estimates and the incorporation of new data in this model. Both revisions followed several"
    },
    {
        "id": "doc_703",
        "document": "months of joint work by WHO, India\u2019s Ministry of Health & Family Welfare and modelling experts from academic institutions (within and outside India)."
    },
    {
        "id": "doc_704",
        "document": "The country-specific model used for TB incidence estimates in the period 2010\u20132019 was developed as a collaboration between the National TB Elimination Pro- gramme in the Ministry of Health & Family Welfare, the WHO Country Office for India and the Indian Council for Medical Research. This model was used in combination with the WHO country-specific dynamic model that was developed to estimate TB incidence and mortality in India during the COVID-19 pandemic and its aftermath (see also Section"
    },
    {
        "id": "doc_705",
        "document": "A5.3)."
    },
    {
        "id": "doc_706",
        "document": "The revisions to TB mortality estimates are highlight- ed and explained in more detail in Box 4 in the main report. Further details about updates to TB incidence estimates are provided in the technical appendix.\n\nA5.3 Country-specific dynamic models"
    },
    {
        "id": "doc_707",
        "document": "Country-specific models were first developed in 2021. This was necessary to ensure that estimates of TB inci- dence and mortality in 2020 accounted for the impact of COVID-related disruptions on TB diagnosis and treat- ment. Such impacts were evident in large absolute reductions in TB case notifications (relative to pre-pan- demic trends) in some countries. These reductions were interpreted as being due to reduced detection of peo- ple with TB, which in turn resulted in an increase in the number"
    },
    {
        "id": "doc_708",
        "document": "of people in the community with undiagnosed and untreated TB."
    },
    {
        "id": "doc_709",
        "document": "In 2022, to produce estimates of TB incidence and mortality in 2020 and 2021, country-specific models were used for 24 countries. In 2023, to produce esti- mates in the period 2020\u20132022, these models were retained for use in 23 countries, no longer used for Papua New Guinea and expanded to cover Afghanistan,\n\n51\n\nUkraine and Uzbekistan.1 Thus, in 2023, country-specif- ic models were used for a total of 26 countries."
    },
    {
        "id": "doc_710",
        "document": "The model-based estimates of TB mortality were not used for four countries that reported national vital reg- istration (VR) data on causes of death (including for TB specifically) for the period 2020\u20132022 to WHO: Azerbai- jan, Brazil, Kazakhstan and Ukraine."
    },
    {
        "id": "doc_711",
        "document": "The country-specific models were extensively reviewed in 2021 and 2022; details about both the models and the reviews are available elsewhere (7, 8). From February to June 2023, the models were further informed by a series of in-depth bilateral discussions with 13 countries: Afghanistan, Brazil, Cambodia, Indonesia, Kazakhstan, Kyrgyzstan, Lesotho, Malaysia, Pakistan, the Philippines, Thailand, Uzbekistan and Viet Nam. These discussions were used to identify any new information available at"
    },
    {
        "id": "doc_712",
        "document": "country level to inform model inputs and to make associated model adjust- ments (e.g. to the estimated level of underreporting during COVID-19 disruptions). Generally, these adjust- ments resulted in downward revisions to estimates of TB incidence in the period 2020\u20132021."
    },
    {
        "id": "doc_713",
        "document": "A5.4 RR-TB incidence estimates\n\nIn 2022, new methods were developed to produce time series of estimates at country, regional and global levels for the first time, covering the period 2015\u20132021 (1, 2). These methods have been described in detail elsewhere and were extensively discussed and reviewed. For this report, the same methods were used to produce time series for 2015\u20132022."
    },
    {
        "id": "doc_714",
        "document": "Two of the key inputs to RR-TB incidence estimates are estimates of a) the proportion of new TB cases that have RR-TB and b) the proportion of previously treated TB cases that have RR-TB (1, 2, 7). For this report, esti- mates of these proportions in 2022 and in previous years were used, and estimates for years before 2022 were revised for some countries based on updated or cor- rected data. These revisions included a major update to estimates of the proportion of people in Pakistan newly"
    },
    {
        "id": "doc_715",
        "document": "diagnosed with TB (and with no previous history of TB treatment) who have RR-TB, for which there was a large downward revision (from 5.9% in 2021 to 2.3% in 2022), based on updated subnational surveillance data report- ed to WHO. This update resulted in a downward revision to the estimated annual incidence of RR-TB in Pakistan of about 20 000."
    },
    {
        "id": "doc_716",
        "document": "A third key input to RR-TB incidence estimates is the estimated level of TB incidence overall (1, 2, 7). Down- ward revisions to overall estimates of TB incidence in some of the countries for which country-specific mod- els were used for the period 2020\u20132022 (Section A5.3 above) resulted in lower estimates of RR-TB incidence in these countries."
    },
    {
        "id": "doc_717",
        "document": "As a result of the downward revision to the estimated proportion of new TB cases in Pakistan that have RR-TB and the downward revisions to overall estimates of TB incidence in some countries, current global estimates of RR-TB incidence in 2020\u20132021 are lower than those published in 2022 (1)."
    },
    {
        "id": "doc_718",
        "document": "A5.5 Other miscellaneous updates\n\nNew data on TB mortality were reported to WHO between mid-2020 and mid-2021. Several countries either reported historical data that were previously missing or corrected previously reported data. Updat- ed estimates of HIV prevalence and mortality were obtained from the Joint UN Programme on HIV/AIDS (UNAIDS) in July 2023."
    },
    {
        "id": "doc_719",
        "document": "A new inventory study was completed in China in 2022. Results from this study were shared with WHO in July 2023 and used to estimate TB incidence in China in 2022."
    },
    {
        "id": "doc_720",
        "document": "A5.6 More information about methods used for all countries\n\nDetails about the methods used for all countries, with a clear distinction between the time periods 2010\u20132019 and 2020\u20132022, are provided in the report webpages (Section 1.1 and Section 1.2)2 and in the technical appendix.\n\nThe main data sources currently available to inform estimates of TB disease burden in the 30 high TB bur- den countries and three global TB watchlist countries (Annex 3) are summarized in Table A5.1."
    },
    {
        "id": "doc_721",
        "document": "1 A country model was no longer used in Papua New Guinea to avoid a discontinuity with the previous (flat) trend estimated for the period 2010\u20132019. Development of country-specific models for the three new countries followed a careful review of their case notification data for 2020\u22122022, which showed reductions during the COVID-19 pandemic (compared with pre-pandemic trends).\n\n52\n\n2 In particular, see Box 1.1.1 in Section 1.1 and Box 1.2.1 in Section 1.2.\n\nGlobal tuberculosis report 2023"
    },
    {
        "id": "doc_722",
        "document": "References\n\nGlobal tuberculosis report 2022. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/363752).\n\n2. Methods used by WHO to estimate the global burden of TB disease. Geneva: World Health Organization; 2021 (https://www.who.int/publications/m/item/methods-used-by-who-to-estimate-the-global-burden-of-tb-disease)."
    },
    {
        "id": "doc_723",
        "document": "3. Sample Registration System (SRS) \u2013 cause of death in India 2014\u20132016. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2022 (https://censusindia.gov.in/census.website/data/SRSCOD).\n\n4. Sample Registration System (SRS) \u2013 cause of death in India 2015\u20132017. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2023 (https://censusindia.gov.in/census.website/data/SRSCOD)."
    },
    {
        "id": "doc_724",
        "document": "5. Sample Registration System (SRS) \u2013 cause of death in India 2016\u20132018. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2022 (https://censusindia.gov.in/census.website/data/SRSCOD).\n\n6. Sample Registration System (SRS) \u2013 cause of death in India 2017\u20132019. New Delhi: Office of the Registrar-General and Census Commissioner of India; 2023 (https://censusindia.gov.in/census.website/data/SRSCOD)."
    },
    {
        "id": "doc_725",
        "document": "7. Report of a subgroup meeting of the WHO Task Force on TB Impact Measurement: methods used by WHO to estimate TB disease burden. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/363428).\n\n8. Strategic and Technical Advisory Group for Tuberculosis (STAG-TB): report of the 21st meeting, 21\u201323 June 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/351132).\n\nAnnex 5. Updates to estimates of TB disease burden\n\n53\n\nTAblE A5.1"
    },
    {
        "id": "doc_726",
        "document": "Sources of data available to inform estimates of TB disease burden in the 30 high TB burden countries and the 3 global TB watchlist countries, 2010-2022.a Blue indicates that a source is available, orange indicates it will be available in the near future, and red indicates that a source is not available."
    },
    {
        "id": "doc_727",
        "document": "COUNTRY NOTIFICATION DATA STANDARDS AND BENCHMARK ASSESSMENT\u00ae NATIONAL INVENTORY STUDY* NATIONALTB PREVALENCE SURVEY! NATIONAL DRUG RESISTANCE SURVEY OR SURVEILLANCE\u00ae NATIONAL VR DATA OR MORTALITY SURVEY\" Angola 2000-2022 2019, 2023 \u2013 \u2013 2022 \u2013 Bangladesh 2000-2022 2019, 2023 \u2013 2015 2011, 2019 = Brazil 2000-2022 2018 \u2013 NA 2008 2000-2022 Cambodia 2000-2022 2018, 2022 \u2013 2002, 2011 2001,2008, 2017 g Central African Republic 2000-2022 2019, 2022 \u2013 \u2013 2009 \u2013"
    },
    {
        "id": "doc_728",
        "document": "China 2000-2022 - 2018, 2022 2000, 2010 2007, 2013, 2020, 2022 2004-2021 Congo 2000-2022 2019, 2022 = = = Democratic People\u2019s Republic of Korea 2000-2022 2017 \u2013 2016 2014 Democratic Republic of the Congo 2000-2022 2019, 2022 \u2013 \u2013 2017 \u2013 Ethiopia 2000-2022 2016, 2023 = 2011 2005, 2018, 2018, 2020 = Gabon 2000-2022 2018, 2020 = = = = India 2000-2022 2019 2016 2019-2021 2016, 2020 2000-2019 Indonesia 2000-2022 2019, 2022 2017 2023 2013-2014 2018 2006\u20132007, 2009\u20132015"
    },
    {
        "id": "doc_729",
        "document": "Kenya 2000-2022 2017, 2021 2013 2015 2014, 2020 = Lesotho 2000-2022 2017, 2022 \u2013 2019 2014, 2019-2022 \u2013 Liberia 2000-2022 2015, 2019 \u2013 = = = Mongolia 2000-2022 2015, 2018 2023 2014-2015 2007, 2016, 2018-2022 2016-2019 Mozambique 2000-2022 2013 \u2013 2017-2019 2007, 2022, 2021-2022 = Myanmar 2000-2022 2017, 2023 \u2013 2009, 2018 2003, 2008, 2013, 2018, 2020 \u2013 Namibia 2000-2022 2019, 2022 \u2013 2017-2018 2008, 2015, 2018, 2020-2022 Nigeria 2000-2022 2020, 2023 = 2012 2010, 2022 ="
    },
    {
        "id": "doc_730",
        "document": "Pakistan 2000-2022 2019, 2022 2012, 2017 2011 2013, 2019-2020 2006, 2007, 2010 Papua New Guinea 2000-2022 2017 \u2013 = 2014, 2019-2020 = Philippines 2000-2022 2016, 2019 2023 2007, 2016 2004, 2012, 2019, 2021-2022 2000-2014, 2016-2019 Russian Federation 2000-2022 2017 \u2013 NA 2016-2022 2000-2022 Sierra Leone 2000-2022 2015, 2020 \u2013 = = = South Africa 2000-2022 2019, 2022 2022 2017-2019 2002, 2014, 2021-2022 2000-2017 Thailand 2000-2022 2013 \u2013 2012 2001, 2006, 2012, 2018 2000, 2002\u20132019"
    },
    {
        "id": "doc_731",
        "document": "Uganda 2000-2022 2019, 2022 \u2013 2014-2015 2011, 2018-2019 = United Republic of Tanzania 2000-2022 2018, 2023 \u2013 2012 2007, 2018, 2021-2022 \u2013 Viet Nam 2000-2022 2019, 2023 2017 2007, 2017-2018 2006, 2012, 2018, 2020-2022 \u2013 Zambia 2000-2022 2016, 2020 \u2013 2014 2000, 2008, 2020, 2018-2021 \u2013 Zimbabwe 2000-2022 2019, 2022 \u2013 2014 2016, 2018-2020, 2022 \u2013"
    },
    {
        "id": "doc_732",
        "document": "NA, not applicable; VR, vital registration\n\na Data for the period 2000\u20132009 can inform estimates for the period 2010\u20132022 and are shown for this reason. The 3 global TB watchlist countries are Cambodia, Russian Federation and Zimbabwe."
    },
    {
        "id": "doc_733",
        "document": "b The WHO TB surveillance checklist of standards and benchmarks is designed to assess the quality and coverage of notification data (based on 9 core standards), VR data (1 standard) and drug-resistant TB, HIV co-infection and childhood TB (3 supplementary standards). A partial assessment has been done in China. If more than two assessments have been done, the years of the last two only are shown."
    },
    {
        "id": "doc_734",
        "document": "c An inventory study is currently underway in Indonesia and South Africa. Studies are planned in Mongolia in 2023 and the Philippines for 2023\u20132024. Prioritization of TB inventory studies is recommended in countries where a large share of TB care is provided to people with TB outside the existing NTP network."
    },
    {
        "id": "doc_735",
        "document": "d Brazil does not meet the following criteria recommended by the WHO Global Task Force on TB Impact Measurement for implementing a national prevalence survey: TB incidence \u2265150 per 100 000 population per year, no vital registration system and under-5 mortality rate (probability of dying by age of 5 per 1000 live births) is >10."
    },
    {
        "id": "doc_736",
        "document": "e Data points are shown for people without history of previous TB treatment only. Data are available from continuous surveillance (indicated by italics in blue cell) based on routine diagnostic testing in Angola, China, Ethiopia, India, Kenya, Lesotho, Mongolia, Mozambique, Myanmar, Namibia, Pakistan (subnational only), Philippines, South Africa, Uganda, United Republic of Tanzania, Viet Nam, Zambia and Zimbabwe."
    },
    {
        "id": "doc_737",
        "document": "f Years of data availability for Indonesia, Mongolia, Pakistan and South Africa were provided to WHO by IHME."
    },
    {
        "id": "doc_738",
        "document": "g Input data used to inform the covariates for estimating TB mortality in Cambodia available here: Ma, J., Vongpradith, A., Ledesma, J.R. et al. Progress towards the 2020 milestones of the end TB strategy in Cambodia: estimates of age and sex specific TB incidence and mortality from the Global Burden of Disease Study 2019. BMC Infect Dis 22, 904 (2022). https://doi.org/10.1186/s12879-022-07891-5.\n\n54\n\nGlobal tuberculosis report 2023\n\nANNEx 6\n\nThe WHO TB-SDG monitoring framework"
    },
    {
        "id": "doc_739",
        "document": "In 2017, the World Health Organization (WHO) developed a framework for monitoring of indicators in the United Nations (UN) Sustainable Development Goals (SDGs) that are strongly associated with tuberculosis (TB) inci- dence. This was done as part of the preparations for the first global ministerial conference on TB (1), building on previously published work that identified clear linkages between a range of social, economic and health-related indicators and TB incidence (2\u20135)."
    },
    {
        "id": "doc_740",
        "document": "The TB-SDG monitoring framework comprises 14 indicators under seven SDGs (Table A6.1).\n\nFor SDG 3, the framework includes seven indicators:\n\n\" coverage of essential health services;\n\n\" proportion of the population with large household expenditures on health as a share of total household expenditure or income;\n\n\" current health expenditure per capita;\n\n\" HIV prevalence;\n\n\" prevalence of smoking;\n\n\" prevalence of diabetes; and\n\n\" prevalence of alcohol use disorders."
    },
    {
        "id": "doc_741",
        "document": "For SDGs 1, 2, 7, 8, 10 and 11, the seven indicators select- ed for monitoring are:\n\n\" proportion of the population living below the inter- national poverty line;\n\n\" proportion of the population covered by social pro- tection floors or systems;"
    },
    {
        "id": "doc_742",
        "document": "References\n\n\" prevalence of undernourishment;\n\n\" proportion of the population with primary reliance on clean fuels and technology;\n\n\" gross domestic product (GDP) per capita;\n\n\" Gini index for income inequality; and\n\n\" proportion of the urban population living in slums."
    },
    {
        "id": "doc_743",
        "document": "Collection and reporting of data for the 14 indicators does not require any additional data collection and reporting efforts by national TB programmes (NTPs). Nor does it require data collection and reporting efforts that go beyond those to which countries have already committed in the context of the SDGs. At the global level, the UN has established a monitoring system for SDG indicators, and countries are expected to report data on an annual basis via the appropriate UN agen- cies (including"
    },
    {
        "id": "doc_744",
        "document": "WHO). Therefore, analysis of the status of, and trends in, the 14 indicators related to TB can be based primarily on data held in the UN\u2019s SDG database."
    },
    {
        "id": "doc_745",
        "document": "In some cases, the official SDG indicator was not considered the best metric, and a better (but closely related) alternative was identified and justified (five indicators under SDG 3, one under SDG 8 and one under SDG 10). In such cases, the data sources are one of the following: WHO, the Organisation for Economic Co-operation and Development (OECD), the Joint United Nations Programme on HIV/AIDS (UNAIDS) or the World Bank."
    },
    {
        "id": "doc_746",
        "document": "1. Monitoring and evaluation of TB in the context of the Sustainable Development Goals in Policy Briefs: WHO Global Ministerial Conference Ending TB in the Sustainable Development Era: Multisectoral Response. Geneva: World Health Organization; 2017. (https://www.who.int/publications/m/item/moscow-conference---policy-brief)."
    },
    {
        "id": "doc_747",
        "document": "2. Lienhardt C, Glaziou P, Uplekar M, L\u00f6nnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol. 2012;10(6):407 (https://www.ncbi.nlm.nih.gov/pubmed/22580364).\n\n3. L\u00f6nnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P et al. Tuberculosis control and elimination 2010\u201350: cure, care, and social development. Lancet. 2010;375(9728):1814\u201329 (https://www.ncbi.nlm.nih.gov/pubmed/20488524)."
    },
    {
        "id": "doc_748",
        "document": "4. L\u00f6nnroth K, Jaramillo E, Williams B, Dye C, Raviglione M. Tuberculosis: the role of risk factors and social determinants. In: Blas E & Kurup A (eds.), Equity, social determinants and public health programmes. 2010 (https://apps.who.int/iris/bitstream/handle/10665/44289/9789241563970_eng."
    },
    {
        "id": "doc_749",
        "document": "5. L\u00f6nnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68(12):2240\u20136 (https://www.ncbi.nlm.nih.gov/pubmed/19394122).\n\n55\n\nTAblE A6.1\n\nTB-SDG monitoring framework: indicators to monitor within SDG 3\n\nSDG 3: Ensure healthy lives and promote well-being for all at all ages"
    },
    {
        "id": "doc_750",
        "document": "SDG TARGETS FOR 2030 SDG INDICATORS ALTERNATIVE INDICATORS TO MONITOR RATIONALE DATA SOURCE COLLECT DATA FORTB PATIENTS SPECIFICALLY?"
    },
    {
        "id": "doc_751",
        "document": "3.3 End the epidemics of AIDS, TB, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases 3.3.1 Number of new HIV infections per 1000 uninfected population 3.3.2 TBincidence per 100 000 population HIV prevalence HIV is a strong risk factor for development of TB disease and is associated with poorer treatment outcomes. HIV prevalence is selected in preference to HIV incidence because itis directly measured. UNAIDS WHO"
    },
    {
        "id": "doc_752",
        "document": "Yes, already routinely collected. NA"
    },
    {
        "id": "doc_753",
        "document": "3.4 Reduce premature mortality by one third from non-communicable diseases and promote mental health and well- being 3.4.1 Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease Prevalence of diabetes"
    },
    {
        "id": "doc_754",
        "document": "Diabetes is a strong risk factor for development of TB disease, although a link with TB incidence at the national (as opposed to individual) level has been difficult to establish due to confounding. Diabetes prevalence is more relevant than mortality for TB since it directly influences the risk of developing TB. WHO Could be considered at country level, to inform planning of care for comorbidities."
    },
    {
        "id": "doc_755",
        "document": "3.5 Strengthen prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol 3.5.2 Alcohol consumption per capita per year (in litres of pure alcohol) among those aged 215 years (harmful level defined nationally) Prevalence of alcohol use disorders"
    },
    {
        "id": "doc_756",
        "document": "Alcohol use is a strong risk factor for TB disease and poorer treatment outcomes at the individual level, although a link with TB incidence at the national (as opposed to individual) level has been hard to establish due to confounding. The prevalence of alcohol use disorders is the most relevantindicatorin the context of TB. WHO Could be considered at country level, to inform planning of care for comorbidities."
    },
    {
        "id": "doc_757",
        "document": "3.8 Achieve Universal Health Coverage (UHC), including financial risk protection, access to quality essential health- care services and access to safe, effective, quality and affordable essential medicines and vaccines forall 3.8.1 Coverage of essential health services (defined as the average coverage of essential services based on 16 tracer interventions). 3.8.2 Proportion of population with large household expenditures on health as a share of total household expenditure or income NA NA"
    },
    {
        "id": "doc_758",
        "document": "Achieving UHC is required to achieve the three high-level targets of the End TB Strategy for reductions in the TB incidence rate, reductions in the number of TB deaths and elimination of catastrophic costs for TB patients and their households. TB treatment coverage has been monitored for years and is one of the 16 tracer indicators that have been selected to measure SDG indicator3.8.1. WHO No"
    },
    {
        "id": "doc_759",
        "document": "3.a Strengthen implementation of the WHO Framework Convention on Tobacco Control 3.a.1 Age-standardized prevalence of current tobacco use among those aged 215 years Prevalence of smoking among those aged 215 years (%) Smoking is a strong risk factor for TB disease at the individual level, although a link with TB incidence at the national (as opposed to individual) level has been difficult to establish due to confounding. WHO"
    },
    {
        "id": "doc_760",
        "document": "Could be considered (e.g. to inform access to smoking cessation interventions). smoking cessation"
    },
    {
        "id": "doc_761",
        "document": "3.c Substantially increase health financing and and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and smallisland developing States 3.c.1 Health worker density and distribution Current health expenditure per capita Health expenditure per capita is negatively correlated with TB incidence. WHO No"
    },
    {
        "id": "doc_762",
        "document": "AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus; NA, not applicable; SDG, Sustainable Development Goal; TB, tuberculosis; UHC, universal health coverage; UNAIDS, Joint United Nations Programme on HIV/AIDS; WHO, World Health Organization\n\n56\n\nGlobal tuberculosis report 2023\n\nTABLE 8.2B\n\nTB-SDG monitoring framework: indicators to monitor beyond SDG 3"
    },
    {
        "id": "doc_763",
        "document": "SDG TARGETS FOR 2030 SDG INDICATORS ALTERNATIVE INDICATORS TO MONITOR RATIONALE DATA SOURCE COLLECT DATA FOR TB PATIENTS SPECIFICALLY?"
    },
    {
        "id": "doc_764",
        "document": "1.1 Eradicate extreme poverty for all people everywhere, currently measured as people living on less than $1.25 a day 1.3 Implement nationally appropriate social protection systems and measures forall, including floors, and achieve substantial coverage of the poor and vulnerable 1.1.1 Proportion of population living below the international poverty line 1.3.1 Proportion of population covered by social protection floors/systems NA NA"
    },
    {
        "id": "doc_765",
        "document": "Poverty is a strong risk factor for TB, operating through several pathways. Reducing poverty should also facilitate prompt health-care seeking. Countries with higher levels of social protection have lower TB burden. Progress on both indicators will help to achieve the End TB Strategy target to eliminate catastrophic costs for TB patients and their households. UN SDG database, World Bank No Could be considered (e.g. to facilitate access to social protection)."
    },
    {
        "id": "doc_766",
        "document": "SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture |"
    },
    {
        "id": "doc_767",
        "document": "2.1 End hunger and ensure access by all people, in particular the poor and people in vulnerable situations, including infants, to safe, nutritious and sufficient food year- round 2.1.1 Prevalence of undernourishment NA Undernutrition weakens the body\u2019s defence against infections and is a strong risk factor for TB at the national and individual level. UN SDG database Could be considered (e.g. to plan food support)."
    },
    {
        "id": "doc_768",
        "document": "| SDG T7: Ensure access to affordable, reliable, sustainable, and modern energy for all 7.1 Ensure universal access to affordable, reliable and modern energy services 7.1.2 Proportion of population with primary reliance on clean fuels and technology NA Indoor air pollution is a risk factor for TB disease at the individual level. There has been limited study of ambient air pollution but itis plausible thatitis linked to TBincidence. WHO No"
    },
    {
        "id": "doc_769",
        "document": "SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all 8.1 Sustain per capita growth in accordance with national circumstances and, in particular, at least 7% GDP growth per year in the least developed countries 8.1.1 Annual growth rate of real GDP per capita GDP per capita Historic trends in TB incidence are closely correlated with changes in the absolute level of GDP per capita (but not with the growth rate). World Bank No"
    },
    {
        "id": "doc_770",
        "document": "SDG 10: Reduce inequality within and among countries | 10.1 Achieve and sustain income growth of the bottom 40% of the population at a rate higher than the national average 10.1.1 Growth rates of household expenditure orincome per capita, overall and for the bottom 40% of the population Gini index forincome inequality TBis a disease of poverty. Decreasing income inequalities combined with economic growth should have an effect on the TB epidemic. World Bank OECD No"
    },
    {
        "id": "doc_771",
        "document": "SDG1 ake ies and human settlements inclusive, safe, resilient and sustainable 11.1 Ensure access for allto adequate, safe and affordable housing and basic services and upgrade slums 11.1.1 Proportion of urban population living in slums, informal settlements or inadequate housing NA Living in a slum is a risk factor for TB transmission due to its link with overcrowding. It is also a risk factor for developing TB disease, due to links with air pollution and undernutrition. UN SDG database No"
    },
    {
        "id": "doc_772",
        "document": "GDP, gross domestic product; NA, not applicable; OECD, Organisation for Economic Co-operation and Development; SDG, Sustainable Development Goal; TB, tuberculosis; UN, United Nations; WHO, World Health Organization.\n\nAnnex 6. The WHO TB-SDG monitoring framework\n\n57\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n356\n\nTREATMENT LOC Note Cough mixtures, sedatives, mucolytics, and antihistamines are USELESS in pertussis and should NOT be given"
    },
    {
        "id": "doc_773",
        "document": "Prevention\n\n~ Educate parents on the importance of following the routine childhood immunisation schedule:\n\n~ Ensure good nutrition\n\n~ Avoid overcrowding\n\n~ Booster doses of vaccine in exposed infants"
    },
    {
        "id": "doc_774",
        "document": "5.2.9 Pneumonia ICD10 CODE: J13-18\n\nAcute infection and inflammation of the lungs alveoli. There are two major types:\n\n~ Bronchopneumonia: involves both the lung parenchyma and the bronchi. Common in children and the elderly\n\n~ Lobar pneumonia: involves one or more lobes of the lung. Common in young people"
    },
    {
        "id": "doc_775",
        "document": "Causes\n\nCausative agents can be viral, bacterial or parasitic. Pathogens vary according to age, patient\u2019s condition and whether infection was ac- quired in the community or hospital (Gram negative are more common in hospital).\n\n~ Neonates: group B streptococcus, Klebsiella, E.coli, Chla- mydia and S. aureus\n\n~ Children <5 years: Pneumococcus, Haemophilus influen- zae, less frequently: S. aureus, M. catarrhalis, M. Pneumo- niae, viruses (RSV, influenza, measles)"
    },
    {
        "id": "doc_776",
        "document": "~ Adults and children >5 years: most commonly S.pneumo-\n\nniae, followed by atypical bacteria, e.g. Mycloplasma pneu- moniae, viruses\n\n~ Immunosuppressed: Pneumocystis (in HIV infected)\n\nPredisposing factors\n\n~ Malnutrition\n\n~ Old age\n\n000\n\n~ Immunosuppression (HIV, cancer, alcohol dependence)\n\n~ Measles, pertussis\n\n~ Pre-existing lung or heart diseases, diabetes\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nInvestigations\n\nIf facilities are available\n\nDo a chest X-ray and look for complications, e.g."
    },
    {
        "id": "doc_777",
        "document": "- Pneumothorax, pyothorax\n\n- Pneumonitis suggestive of pneumocystis jiroveci pneumonia (PCP)\n\n- Pneumatocoeles (cavities filled with air) suggestive of staphylococcal pneumonia\n\nSputum: For Gram stain, Ziehl-Neelsen (ZN) stain, culture for AFB\n\nBlood: Complete blood count"
    },
    {
        "id": "doc_778",
        "document": "5.2.9.1 Pneumonia in an Infant (up to 2 months)\n\nIn infants, not all respiratory distress is due to infection. But as pneumonia may be rapidly fatal in this age group,\n\nsuspected cases should be treated promptly and referred for parenteral treatment with antimicrobials. Consider all children < 2 months with pneumonia as SEVERE disease.\n\nClinical features\n\n~ Rapid breathing ( 60 breaths/minute)\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n357\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn"
    },
    {
        "id": "doc_779",
        "document": "~ Severe chest in drawing, grunting respiration\n\n[OJOJONOJONOXO]\n\n~ Inability to breastfeed\n\n~ Convulsions\n\n~ Drowsiness\n\n~ Stridor in a calm child, wheezing\n\n~ Fever may or may not be present\n\n~ Cyanosis and apnoeic attacks (SpO2 less than 90%)\n\nManagement\n\nInfants with suspected pneumonia should be referred to hospital after pre-referral dose of antibiotics.\n\nWALAVHD\n\nsasess|g A103e1dsay 1\u00a7\n\nManagement"
    },
    {
        "id": "doc_780",
        "document": "TREATMENT LOC Q Admit H Q Keep baby warm Q Prevent hypoglycaemia by breastfeeding/giving expressed breast milk/NGT f child is lethargic, do not give oral feeds. Use IV fluids with care (see section 1.1.4) Give oxygen to keep SpO2 >94% f Ampicillin 50 mg/ g IV every 6 hours f Plus gentamicin 7.5 mg/kg IV once daily Q Neonates < 7 days old: 5 mg/kg IV once daily Q n premature babies, the doses may need to be reduced (specialist only) In severely ill infants O Ceftriaxone 100 mg/kg IV once daily"
    },
    {
        "id": "doc_781",
        "document": "Alternative (only use if above not available) O Chloramphenicol 25 mg/kg IV every 6 hours (contrain- dicated in premature babies and neonates < 7 days old)"
    },
    {
        "id": "doc_782",
        "document": "dicated in premature babies and neonates < 7 days old)\n\n358\n\nManagement\n\nTREATMENT Continue treatment for at least 5 days, and for 3 days after the child is well If meningitis is suspected, continue for 21 days If septicaemia is suspected, continue for 10 days LOC H"
    },
    {
        "id": "doc_783",
        "document": "5.2.9.2 Pneumonia in a Child of 2 months-5 years\n\nClinical features\n\n~ Fever - may be high, low grade or absent (in severe illness)\n\nPneumonia\n\n~ Cough\n\n~ Fast breathing (2-12 months: 50 bpm, 1-5 years: 40 bpm)\n\n~ Mild chest wall in-drawing"
    },
    {
        "id": "doc_784",
        "document": "Severe pneumonia\n\n~ As above plus at least one of the following\n\n~ Central cyanosis (blue lips, oral mucosa, finger nails or ox- ygen saturation < 90% using a pulse oximeter)\n\n~ Inability to feed, vomiting everything\n\n~ Convulsions, lethargy, decreased level of consciousness\n\n~ Severe respiratory distress (severe chest indrawing, grunt- ing, nasal flaring)"
    },
    {
        "id": "doc_785",
        "document": "~ Extrapulmonary features, e.g. confusion or disorientation, may predominate and may be the only signs of pneumonia in malnourished or immunosuppressed children\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n359\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nManagement of pneumonia"
    },
    {
        "id": "doc_786",
        "document": "TREATMENT LOC Non-severe pneumonia HC2 O Give oral amoxicillin dispersible tabs (DT) 40 mg/kg every 12 hours for 5 days O 5 days 1-3 years 500 mg (2 tabs) every 12 hours for 5 days 3-5 years 750 mg (3 tabs) every 12 hours for 5 days HC3 O wheezing present Salbutamol inhaler 1-2 puffs every 4-6 hours until wheezing stops O Reassess child for progress after 3 days Severe pneumonia HC4 Q Refer to hospital after 1st dose of antibiotic Q Admit"
    },
    {
        "id": "doc_787",
        "document": "Q Give Oxygen if SpO2 < 90% with nasal prongs and monitor through pulse oximetry HC4 Give ampicillin 50 mg/kg IV every 6 hours or benzyl penicillin 50,000 1U/kg IM or IV Plus gentamicin 7.5 mg/kg IM or IV once daily Continue treatment for at least 5 days, up to 10 days"
    },
    {
        "id": "doc_788",
        "document": "If not better after 48 hours, use second line f Ceftriax- one 80 mg/kg IM or IV once daily f If staphylococcus is suspected (empyema, pneumatocele at X ray) , give gentamicin 7.5 mg/ kg once daily plus cloxacillin 50 mg/kg IM or IV every 6 hours"
    },
    {
        "id": "doc_789",
        "document": "360"
    },
    {
        "id": "doc_790",
        "document": "TREATMENT LOC Once the patient improves Switch to oral amoxicillin 40 mg/kg every 12 hours for 5 days to complete a total of at least 5 days of antibiotics Alternative (if above not available/not working) Chloramphenicol 25 mg/kg IV every 6 hours Other treatments Give Paracetamol 10 mg/kg every 4-6 hours for fever If wheezing, give salbutamol 1-2 puffs every 4-6 hours Gentle suction of thick secretions from upper airway"
    },
    {
        "id": "doc_791",
        "document": "Daily maintenance fluids \u2014 careful to avoid overload especially in small and malnourished children (see section 1.1.4) If convulsions, give diazepam 0.5 mg/kg rectally or 0.2 mg/kg IV convulsions are continuous Give a long-acting anticonvulsant, e.g., phenobarbital 10-15 mg/kg IM as a loading dose. Depending on response, repeat this dose after 12 hours or switch to oral maintenance dose of 3-5 8-12 hours"
    },
    {
        "id": "doc_792",
        "document": "mg/kg every Monitor and record Respiratory rate (every 2 hours) Body temperature (every 6 hours) Oxygen saturation (every 12 hours) Improvement in appetite and playing Use of accessory muscles of respiration Ability to breastfeed, drink and eat -"
    },
    {
        "id": "doc_793",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n361\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nWALAVHD\n\nsasess|g A103e1dsay 1\u00a7\n\n362\n\n5.2.9.3 Pneumonia in Children > 5 years and adults\n\nClinical features\n\nModerate\n\n~ Fever, chest pain, cough (with or without sputum), rapid breathing (> 30 bpm), no chest indrawing\n\nSevere\n\n~ As above plus\n\ng\n\n~ Chest indrawing\n\n~ Pulse >120/minute\n\n~ Temperature > 39.5 o C\n\n~ Low BP < 90/60 mmHg\n\n~ Oxygen saturation less than 90%"
    },
    {
        "id": "doc_794",
        "document": "Note\n\nExtrapulmonary features, e.g. confusion or disorientation, may predominate and may be the only signs of pneumonia in elderly or immunosuppressed patients\n\nManagement of pneumonia"
    },
    {
        "id": "doc_795",
        "document": "TREATMENT Moderate pneumonia (ambulatory patients) Amoxicillin 500 mg-1 g every 8 hours for 5 days Children: 40 mg/kg every 12 hours for 5 days. Preferably use dispersible tablets in younger children If penicillin allergy or poor response after 48 hours (possible atypical pneumonia), give: Doxycycline 100 mg every 12 hours for 7-10 days Child > 8 years only: 2 mg/kg per dose Or Erythromycin 500 mg every 6 hours for 5 days LOC"
    },
    {
        "id": "doc_796",
        "document": "TREATMENT LOC - 14 days in cases of atypical pneumonia HC3 Child: 10-15 mg/kg per dose O Give oxygen and monitor SpO2 saturation with pulse O Benzylpenicillin 2 MU IV or IM daily every 4-6 hours Child: 50,000-100,000 IU/kg per dose If better 48 hours:"
    },
    {
        "id": "doc_797",
        "document": "O Ceftriaxone 1 g IV or IM every 24 hours Child: 50 mg/kg per dose (max: 1 g) If S. Aureus is suspected O Cloxacillin 500 mg IV every 6 hours If other options are not available O Chloramphenicol 1 g IV every 6 hours for 7 days Child: 25 mg/kg per dose (max: 750 mg)"
    },
    {
        "id": "doc_798",
        "document": "5.2.9.4 Pneumonia by Specific Organisms\n\nManagement of pneumonia\n\nTREATMENT Stapylococcus pneumonia This form is especially common following a recent influenza infection. It can cause empyema and pneu- matocele. Adults and children >5 years: Cloxacillin 1-2 g IV or IM every 6 hours for 10-14 days Child >5 years: 50 mg/kg per dose (max: 2 g) Child 2 months-5 years LOC"
    },
    {
        "id": "doc_799",
        "document": "epuebn -\n\n\u00a320Z S3UIIBPIND [ed1Ul])\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n363\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nManagement of pneumonia"
    },
    {
        "id": "doc_800",
        "document": "TREAjI'MENT TREATMENT LOC O Cloxacillin 25-50 mg/kg IV or IM every 6 hours ? mg/kg daily O Or ciprofloxacin 500 mg every 12 hours Child: chloramphenicol 25 mg/kg every 6 hours - Give a 5-day course - Amend therapy as guided by C&S results Pneumococcal pneumonia H O Benzylpenicillin 50,000 1U/kg IV or IM every 6 hours for 2-3 days then switch to oral Amoxicillin 500 mg-1 g every 8 hours for 5 days Children: 40 mg/kg every 12 hours for 5 days."
    },
    {
        "id": "doc_801",
        "document": "Preferably use dispersible tablets in younger children\n\n5.2.9.5 Pneumocystis jirovecii Pneumonia\n\nRefer to section 3.1.10.2\n\n364\n\nICD10 CODE: J85.0-1\n\n5.2.9.6 Lung Abscess\n\nLocalised inflammation and\n\nof"
    },
    {
        "id": "doc_802",
        "document": "to Localised inflammation and necrosis (destruction) of lung tissue leading pus formation. It is most commonly - . [e1ul] caused by aspiration of oral secretions by patients who have impaired SauljapIng consciousness. Cause \u00ae Infection of lungs with pus forming organisms: e.g. \u20ac20z \u00ae Klebsiella pneumoniae, Staphylococcus aureus Clinical features Onset is acute or gradual 0000 Malaise, loss of appetite, sweating with chills and fever"
    },
    {
        "id": "doc_803",
        "document": "Cough with purulent sputum, foul-smelling breath (halitosis) YyILdAVHD Chest pain indicates pleurisy :\u00a7 Complications A1o3eJ1dsay \u00ae Pus in the pleural cavity (empyema) \u00ae Coughing out blood (haemoptysis) saseasiq \u00ae Septic emboli to various parts of the body, e.g. brain (caus- ing brain abscess) \u00ae Bronchiectasis (pus in the bronchi) Differential diagnosis Bronchogenic carcinoma Bronchiectasis [OONONO! Primary empyema communicating with a bronchus TB of the lungs"
    },
    {
        "id": "doc_804",
        "document": "~ Liver abscess communicating into the lung\n\nepuebn -\n\n365\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nInvestigations\n\nChest X-ray\n\nEarly stages: Signs of consolidation\n\nLater stages: A cavity with a fluid level\n\nSputum: For microscopy and culture and sensitivity\n\nManagement of pneumonia"
    },
    {
        "id": "doc_805",
        "document": "TREATMENT LOC O Benzylpenicillin 1-2 MU IV or IM every 4-6 hours HC4 O Child: 50,000-100,000 IU/kg per dose (max: 2 MU) Q Plus metronidazole 500 mg IV every 8-12 hours Child: 12.5 mg/kg per dose Once improvement occurs, change to oral medication and continue for 4-8 weeks f Metronidazole 400 mg every 12 hours Child: 10 mg/kg per dose Plus Amoxicillin 500 mg-1 g 8 hourly Child: 25-50 mg/kg per dose for 4-6 weeks Postural drainage/physiotherapy Surgical drainage may be necessary"
    },
    {
        "id": "doc_806",
        "document": "Prevention\n\n~ Early detection and treatment of pneumonia\n\n5.3 TUBERCULOSIS (TB) ICD11 CODE: A15-A19"
    },
    {
        "id": "doc_807",
        "document": "5.3.1Definition, Clinical Features and Diagnosis of TB\n\nA chronic infection caused by Mycobacterium tuberculosis complex. It commonly affects lungs but can affect any organ (lymph nodes, bones, meninges, abdomen, kidney).\n\n366\n\nFor more information on the management of TB see:\n\nManual of the National TB/Leprosy Programme (NTLP) in Uganda 4th Edition, 2022\n\nNTLP desk guide\n\n00O\n\nLatent TB guidelines\n\nNational drug resistant TB guidelines\n\nCauses"
    },
    {
        "id": "doc_808",
        "document": "~ Mycobacterium tuberculosis complex (e.g. M. tuberculosis,\n\n~ M. bovis, M. avium, M. africanum and M. Microti)\n\n(ONONNO]\n\n~ M. tuberculosis is the commonest cause of tuberculosis\n\n~ Transmission by droplet inhalation (cough from a patient with open pulmonary TB); can also be through drinking unpasteurised milk, especially M.bovis\n\nClinical features\n\nGeneral symptoms\n\n~ Fevers especially in the evening,\n\n~ excessive night sweats\n\n~ Weight loss and loss of appetite"
    },
    {
        "id": "doc_809",
        "document": "Pulmonary TB\n\n~ Chronic cough of >2 weeks (however, in HIV settings, cough of any duration)\n\n~ Chest pain, purulent sputum occasionally blood-stained, shortness of breath\n\nExtrapulmonary TB\n\n~ Lymphnode TB: Localized enlargement of lymph nodes de- pending on the site affected (commonly neck)\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsasess|g A103e1dsay 1\u00a7 WALAVHD\n\n367\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn"
    },
    {
        "id": "doc_810",
        "document": "WALAVHD\n\nsasess|g A103e1dsay 1\u00a7\n\n~ Pleural or pericardial effusion\n\n(ONONO}\n\n~ Abdominal TB: ascites and abdominal pain\n\n~ TB meningitis: subacute meningitis (headache, alteration of consciousness)\n\n~ Bone or joint TB: swelling and deformity"
    },
    {
        "id": "doc_811",
        "document": "Complications\n\n~ Massive haemoptysis - coughing up >250 mL blood per episode\n\n~ Spontaneous pneumothorax and pleural effusion\n\n000\n\n~ TB pericarditis, TB meningitis, TB peritonitis\n\n~ Bone TB: can be TB spine with gibbus, TB joints with deformity)\n\n~ Respiratory failure\n\nTB Case Definitions"
    },
    {
        "id": "doc_812",
        "document": "CASE DEFINITION DESCRIPTION Presumptive TB patient Any patient who presents with symptoms and signs suggestive of TB or found to have chest X-ray suggestive of active TB disease Bacteriologically confirmed TB patient Patient in whom biological specimen is positive by smear microscopy, culture or molecular WHO Recommended Diagnostic (mWRD) test like GeneXpert Truenat or TB LAMP. All such cases should be notified (regis- tered in the unit TB register)"
    },
    {
        "id": "doc_813",
        "document": "Clinically diagnosed TB patient Patient who does not fulfil the criteria for bacteriological confir- mation but has been diagnosed with active TB by a clinician on the basis of clinical signs and symptoms supported by relevant investigations"
    },
    {
        "id": "doc_814",
        "document": "368"
    },
    {
        "id": "doc_815",
        "document": "Classification of TB Disease CASE DEFINITION Site of the disease DESCRIPTION Pulmonary TB: bacteriologically confirmed or clinically diagnosed case, affecting lung parenchyma or tracheobronchial tree. Extrapulmonary TB: Any other case of TB. Isolated TB pleural effusion and mediastinal lymphadenopathy without lung tissue involvement is considered extrapulmonary TB If the patient has pulmonary and extrapulmonary involvement, he/ she will be classified as pulmonary B"
    },
    {
        "id": "doc_816",
        "document": "History of treatment New: no previous TB treatment (or treatment less < 1 month) Relapse: patient who completed a previous course of treatment, was declared cured or treatment completed, and is now diagnosed with a recurrent episode of TB Treatment after failure: those who have previously been treated for TB and whose treatment failed at the end of their most recent course of treatment"
    },
    {
        "id": "doc_817",
        "document": "Treatment after loss to follow-up: Patient has been previously treated for TB and were declared lost to follow-up at the end of their most recent course of treatment."
    },
    {
        "id": "doc_818",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n369\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD"
    },
    {
        "id": "doc_819",
        "document": "CASE DEFINITION DESCRIPTION Treatment history unknown: Those who have previously been treated for TB but whose Outcome after their most recent course of treatment is unknown or undocu- mented Drug susceptibility status (based on drug susceptibility Tests) Drug Sensitive TB (DS-TB): These are sensitive to 1st line anti-TB drugs Drug resistant TB (DR-TB): Resis- tant to any anti-TB drug. Can be classified as follows."
    },
    {
        "id": "doc_820",
        "document": "Rifampicin resistant: any case of rifampicin resistance (isolated or in combination with other resistance) (RR-TB) Monoresistant: resistant to only one first line anti-TB drug Poly drug resistant: resistant to more than one first line anti TB other than both rifampicin and isoniazid Multi drug resistant: resistant to ri- fampicin and isoniazid (MDR -TB)"
    },
    {
        "id": "doc_821",
        "document": "Extensive drug resistance (XDR- TB): resistant to rifampicin, isoniazid (MDR TB) and any fluoroquinolone and at least one of either bedaquiline or Linezolid ) HIV status Positive: patients who tested HIV-positive at time of diagnosis or already enrolled in HIV care"
    },
    {
        "id": "doc_822",
        "document": "370\n\nCASE DEFINITION DESCRIPTION HIV status Negative: patients who tested neg- ative at the moment of diagnosis Unknown: If testing is then performed at any moment during treatment, patient should be re classified\n\nDifferential diagnosis\n\n~ Histoplasma pneumonia, trypanosomiasis, brucellosis\n\n\u00a9O\u00ae0 00060606\n\n~ Pneumonia\n\n~ COVID-19\n\n~ HIV/AIDS\n\n~ Malignancy\n\n~ COPD, asthma, bronchiectasis, emphysema etc.\n\n~ Post TB lung disease\n\n~ Fungal infection of the lungs e.g. Aspergillosis"
    },
    {
        "id": "doc_823",
        "document": "Screening and diagnosis of TB disease\n\nTB screening: is defined as the systematic identification of peo- ple at risk for TB disease, in a predetermined target group, by assessing using tests, examinations or other procedures that can be applied rapidly\n\nTB screening approaches:\n\n\u2022 Symptom screening or CXR\n\n\u2022 All individuals seeking health care should be screened for TB at each visit"
    },
    {
        "id": "doc_824",
        "document": "Investigations for TB\n\nObtain sputum sample or other relevant samples from presumptive TB patients for diagnosis\n\n\u2022 Xpert MTB/RIF is the recommended diagnostic test for TB diagnosis\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n371\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsasess|g A103e1dsay 1\u00a7 WALAVHD\n\n\u2022 Where Xpert MTB/RIF test is not available, do\n\nSputum smear microscopy for AAFBs (ZN stain) but send the sample for Xpert MTB/RIF test."
    },
    {
        "id": "doc_825",
        "document": "GeneXpert MTB/Rif: automated DNA test on body samples (sputum, lymphonodes tissue, pleural fluid, CSF etc) which can diagnose pulmonary TB and determine susceptibility to Rifampicin. It is superior to microscopy. Other investigations\n\nX- ray, abdominal ultrasound, biopsies etc. can be used for sputum and GeneXpert negative patients or in case of extrapulmonary TB according to clinical judgement\n\nTST can be used as a supportive test to guide decision to treat for TB in children"
    },
    {
        "id": "doc_826",
        "document": "putum culture and Drug susceptibility test: is a confirmatory test for TB and also provides resistance pattern to TB medicines. Do this test for:\n\nPatients with Rifampicin resistance reported with GeneXpert\n\nAlso patients on first-line treatment who remain positive at 2 months and are reported Rifampicin sensitive on GeneXpert\n\nPatients suspected to be failing on first-line treatment\n\nNote: All presumed and diagnosed TB patients should be offered an HIV test"
    },
    {
        "id": "doc_827",
        "document": "5.3.1.1Tuberculosis in Children and adolescents\n\nTB may present at any age in children though the risk is highest below the age of two years. When compared to adults, children are more prone to TB infection, TB disease, and severe forms of TB disease."
    },
    {
        "id": "doc_828",
        "document": "Risk factors\n\n~ Contact with infectious (pulmonary) case of TB\n\n~ Age < 5 years\n\n372\n\n~ Immunosuppression (HIV, malnutrition, diabetes, etc).\n\n~ Age < 1 year and lack of BCG vaccination are risk factors for severe disease\n\nClinical features\n\n~ Suspect TB in all children with\n\n- Fever > 2 weeks\n\n- Cough >2 weeks\n\n- Poor weight gain for one month\n\n- Close (home) contact of pulmonary TB case.\n\n- In young children, reduced playfulness, poor feeding, decreased activity"
    },
    {
        "id": "doc_829",
        "document": "- Other signs include swollen lymph nodes in the neck, groin region etc.\n\nInvestigations\n\nBacteriological confirmation of TB is more difficult in children. The diagnosis of TB in children is dependent on conducting a detailed clinical assessment combined with available tests\n\nWhenever possible, geneXpert should be performed Management\n\nThe principles and objectives of TB treatment are similar to those of adults. In addition, effective treatment of TB in children promotes growth and development."
    },
    {
        "id": "doc_830",
        "document": "5.3.1.2 Drug-Resistant TB\n\nDrug resistance is said to occur when TB organisms continue to grow in the presence of one or more anti-TB medicines.\n\n~ Although several factors can contribute to the development of drug-resistant TB, inadequate anti-TB treatment is prob- ably the most important. Inadequate anti-TB treatment leads to mutation in drug-susceptibility bacilli making them drug resistant."
    },
    {
        "id": "doc_831",
        "document": "epuebn -\n\n\u00a320Z S3UIIBPIND [ed1Ul])\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n373\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\nWho is at risk for drug-resistant TB:\n\nContact with known drug-resistant tuberculosis\n\nRetreatments (relapses, treatment after failures, return after loss to follow-up)\n\nHistory of frequent interruption of drug treatment\n\nPatients who remain sputum smear-positive at month 2 or 3 of first-line anti-TB treatment"
    },
    {
        "id": "doc_832",
        "document": "~ Patients presumed to have DR-TB should be screened using rapid drug susceptibility testing (DST) of rifampicin (Xpert MTB/RIF, Truenat)\n\nAll patients who are drug-resistant TB suspects should therefore have sputum/other specimens taken for culture and DST.\n\n~ Patients with drug-resistant TB should be linked to desi na- ted MDR TB treatment initiation centers in the respective regions\n\nDRUG RESISTANT TB IS A MAJOR PUBLIC HEALTH PROBLEM. INADE- QUATE TB TREATMENT IS THE MAJOR CONTRIBUTING FACTOR"
    },
    {
        "id": "doc_833",
        "document": "5.3.1.3 Post-TB patient management\n\nA post-TB patient is one who was successfully treated for TB but presents with respiratory symptoms (chest pain, shortness of breath, cough).\n\n~ Re-do standard TB diagnostic evaluation (sputum geneX- pert and Chest X ray)\n\n~ If negative, evaluate for post-TB lung disease e.g., bronchi- ectasias, COPD, pulmonary hypertension."
    },
    {
        "id": "doc_834",
        "document": "~ In most cases these patients have residual lung damage on Chest X-ray from previous TB, BUT they do not need retreatment if bacteriologically negative\n\n~ Counsel the patient and give supportive treatment e.g., Pulmonary rehabilitation, etc.\n\n374"
    },
    {
        "id": "doc_835",
        "document": "5.3.2 Management of TB\n\nGeneral principles\n\n~ The country has adopted patient centered care. It is rec- ommended that all TB medicines are taken under direct observation by a treatment supporter (DOT). Digital Adher- ence Technologies (DAT) have been introduced to support treatment adherence.\n\n~ Anti-TB drugs are given in fixed dose combination (FDC) regimens according to the patient\u2019s TB classification"
    },
    {
        "id": "doc_836",
        "document": "\u2022 Treatment is divided into two phases: an initial (intensive) phase of 2 months and a continuation phase of 4 months (longer in severe forms of TB particularly TB meningitis and osteoarticular TB)TB treatment regimens are expressed in a standard format, e.g. 2RHZE/4RH where:\n\n- Letters represent abbreviated drug names\n\n- Numbers show the duration in months\n\n- shows the division between treatment phases\n\n~ Other shorter term (4-months) treatment regimen recently adopted"
    },
    {
        "id": "doc_837",
        "document": "\u2022 2 HRE(Z)/2RH for children 2 months to 16 years\n\n\u2022 2 HPMZ/2HPM for adults\n\n~ Anti-TB drugs have side effects and they should be man- aged appropriately (see section 5.3.2.1)\n\n~ TB treatment monitoring should be done by clinical, spu- tum and where possible radiological\n\n~ A conclusion of \u201ctreatment outcome\u201d status should be done for every patient treated for TB.\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n375\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn"
    },
    {
        "id": "doc_838",
        "document": "YILAVHD\n\nsaseasiq A103e1d50Y 1\u00a7\n\nFirst line anti-TB medication"
    },
    {
        "id": "doc_839",
        "document": "Drug Adult Dose Children | Dose Contraindications (C) / Interactions (I) Isoniazid (H) oral | 5 mg/kg (max 300 mg) 10 mg/ kg (range 7-15 mg/ kg) C: Liver disease, known hypersensitivity I: I: carbamazepine, phenytoin Rifampicin (R) oral 10 mg/kg (max 600 mg) 15 mg/ kg (range 10-20 mg/kg) C: Liver disease, known hypersensitivity I: Oral contraceptives, nevirap- ine, warfarin, phenytoin, glibenclamide"
    },
    {
        "id": "doc_840",
        "document": "Pyrazina- mide (Z) oral 30-40 mg/kg (max 2500 mg) 35 mg/ kg (range 30\u201340 mg/kg) C: Liver disease, known Hypersensitivity Etham- butol (E) oral 15 mg/kg 20 mg/ kg (range 15-25 mg/kg) C: Pre existing optic neu- ritis, established kidney failure Moxifloxacin (M) oral 10-15mg / Kg Resistance to a fluoro- quinolone"
    },
    {
        "id": "doc_841",
        "document": "Note\n\nRifampicin interacts with oestrogen-containing contraceptives and reduces the protective efficacy of the contraceptives. Use high dose contraceptive or use an additional barrier method.\n\n376\n\nImportant: The choice of regimen now depends on rifampicin sensitivity and not on the previous history of treatment:\n\nAll patients without rifampicin resistance (either new or re-treat- ments) are treated with 1st line regimen."
    },
    {
        "id": "doc_842",
        "document": "Patients with rifampicin resistance (either new or re- treatments) are treated with second line medication in a designated MDR-TB treatment facility.\n\nSusceptible TB: 1st line treatment regimens\n\nFor patients without rifampicin resistance to Gene Xpert MTB/Rif (both new and re-treatment cases).\n\nNew cases not belonging to priority (risk) groups and in which diagnosis was done by sputum examination will also be treated with this regimen."
    },
    {
        "id": "doc_843",
        "document": "Type Of TB Disease Regimen For Susceptible TB TB LOC Intensive Phase | Continuation Phase All forms of TB in adults and children of all ages but excluding TB meningitis and Bone TB) 2RHZE 4RH HC3 TB meningitis Bone (Osteo- articular) TB 2RHZE 10RH HC4and above Alternative 1st-line treat- ment regimen All forms of TB in children (2 months to 16 years) with non-severe disease 2 HRE(Z) 2RH General Hospital and above"
    },
    {
        "id": "doc_844",
        "document": "All forms of TB in adults above 12 years, weight >40 Kags, if HIV positive CD4>100 cells/L 2 HPMZ 2HPM"
    },
    {
        "id": "doc_845",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n377\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n378\n\nDrug -resistant TB\n\nPatients with drug-resistant TB should undergo culture and Drug Sen- sitivity testing, and be treated with second line regimens according to national guidelines.\n\nNotify the relevant TB focal persons and organize referral to MDR-TB treatment initiation center for appropriate management."
    },
    {
        "id": "doc_846",
        "document": "Type Of TB Regimen For Drug LOC Disease Resistant TB INH mono-resist- 6(H)REZ\u2013levoflox- DTUS ance acin) RR/MDR TB Treatment at des- Hospital and above ignated MDR TB treatment initiation centers as per the national guidelines Pre XDR, XDR Treatment at des- Hospital and above in ignated MDR TB consultation with national treatment initiation panel centers as per the national guidelines\n\nAdjunctive treatment"
    },
    {
        "id": "doc_847",
        "document": "TREATMENT LOC Vitamin B6 (pyridoxine): 25 mg per day; given con- HC3H comitantly with isoniazid for the duration of therapy, to prevent peripheral neuropathy Prednisolone in TB patients in whom complications of fibrosis are anticipated because of severe inflammation such as TB meningitis. - Prednisolone is given in a dose of 1-2 mg/kg body weight (not more than 60 mg/day) as a single dose for 4 weeks, and then tapered off over 2 weeks\n\nTREATMENT\n\nLaboratory Monitoring (For Pulmonary Tb)"
    },
    {
        "id": "doc_848",
        "document": "At the end of the initial 2 months:\n\n- Sputum smear-negative; start continuation phase\n\n- Sputum smear-positive; do GeneXpert to rule out rifampicin resistance, start continuation phase and Xpert MTB/XDR where accessible, to rule out resistance to other drugs\n\nIf Rifampicin-resistant, refer for MDR-TB treatment and\n\nIf Rifampicin-sensitive, continue with first-line\n\ntreatment, explore adherence issues but repeat smear at\n\nAt the beginning of 5 months:"
    },
    {
        "id": "doc_849",
        "document": "- Sputum smear-negative, continue with continuation treatment\n\n- Sputum smear-positive, diagnose Treatment Failure\n\n- Take sputum for GeneXpert to rule out Rifampicin Resistance and Xpert MTB/XDR where accessible, to rule out resistance to other drugs\n\nIf Rifampicin Resistant, refer for DR treatment\n\n- If INH resistant manage as INH mono-resistant TB as above\n\n- If TB detected but not Rifampicin Resistant, restart first line regimen but explore adherence issues\n\nMonitoring of susceptible TB"
    },
    {
        "id": "doc_850",
        "document": "During the 6th month:\n\n- Sputum smear-negative, complete treatment and declare cured or treatment completed\n\n- Sputum smear-positive, diagnose treatment failure\n\n- Take sputum for GeneXpert to rule out rifampicin resistance and Xpert MTB/XDR where accessible, to rule out resistance to other drugs\n\nIf Rifampicin-resistant, refer for MDR-TB treatment\n\n- If Rifampicin-sensitive, restart first-line treatment, explore adherence issues\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD"
    },
    {
        "id": "doc_851",
        "document": "379\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nClinical Monitoring (For All Tb Cases)\n\n- Monitor wellbeing and weight gain\n\n- Assess and reinforce treatment adherence\n\n- Assess and manage side effects\n\nNote\n\nRadiological monitoring\u2013 this method should not be used as the sole monitoring tool.\n\nManagement of treatment interruptions\n\nRefer to NTLP manual"
    },
    {
        "id": "doc_852",
        "document": "Treatment outcomes\n\nA conclusion should be made regarding treatment outcome of EVERY TB patient who has been started on anti-TB treatment."
    },
    {
        "id": "doc_853",
        "document": "OUTCOME DESCRIPTION Cure A pulmonary TB patient with bacteri- ologically confirmed TB at the begin- ning of treatment who was smear- or culture-negative in the last month of treatment and on at least one previous occasion"
    },
    {
        "id": "doc_854",
        "document": "Treatment completed A TB patient who completed treatment without evidence of failure BUT with no record to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were negative, either because tests were not done or because results are unavailable Lost to fol- low-up A TB patient who did not start treat- ment, or completed more than one month of treatment and whose treatment was interrupted for two or more consecutive months"
    },
    {
        "id": "doc_855",
        "document": "380"
    },
    {
        "id": "doc_856",
        "document": "OUTCOME DESCRIPTION Died A TB patient who dies for any reason before starting or during the course of treatment Treatment failure A TB patient whose sputum smear or culture is positive at month five or later during treatment Not evaluated A patient for whom no treatment out- come is assigned. This includes cases \u201ctransferred out\u201d to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit Treatment success The sum of cured and treatment completed"
    },
    {
        "id": "doc_857",
        "document": "5.3.2.1 Anti-TB Drugs Side Effects\n\nCommon side effects"
    },
    {
        "id": "doc_858",
        "document": "Drug Side-Effects Isoniazid Hepatitis, peripheral neuropathy Rifampicin Flu-like syndrome, dermatitis, hepatitis, reddish-brown colouration of urine Pyrazin- amide Joint pains, hepatitis Ethambutol Impaired visual acuity and colour vision Moxifloacin Tendonitis, arthralgia, GI disturbance, heamaturia"
    },
    {
        "id": "doc_859",
        "document": "Treatment completed A TB patient who completed treatment without evidence of failure BUT with no re- cord to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were neg- ative, either because tests were not done or because results are unavailable"
    },
    {
        "id": "doc_860",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n381\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nManagement of side effects"
    },
    {
        "id": "doc_861",
        "document": "Side-Effects Drug(S) Likely To Cause Management Low appe- tite, nausea, abdominal pain Pyrazinamide, Ri- fampicin Give drugs with small meal or just before going to bed Joint pains Pyrazinamide Give an analgesic e.g. ibuprofen or Paracetamol Burning sensation in the feet Isoniazid Pyridoxine 25-100 mg daily Orange/red urine Rifampicin Reassure the patient that it is not harmful Skin rash (hyper- sensitivity reaction) Any anti-TB drug Depending on degree, see guidelines below"
    },
    {
        "id": "doc_862",
        "document": "Deafness (no wax on auroscopy) Dizziness, vertigo, and nystagmus Streptomycin Stop streptomycin. Use Eth- ambutol Jaundice (other caus- es es excluded) Pyrazinamide, Ri- fampicin and Iso- niazid Stop anti-TB drugs see guide- lines below Mental con- fusion Isoniazid, Rifampicin and Pyrazinamide 1. If jaundiced, suspect liver failure, stop drugs (see below) 2. If no jaundice, suspect Isoniazid, increase dose of pyridoxine"
    },
    {
        "id": "doc_863",
        "document": "382\n\nSide-Effects Drug(S) Likely Management To Cause Visual Ethambutol Stop Ethambutol. Use impairment streptomycin (other causes excluded)\n\nHypersensitivity reaction\n\nMost anti-TB drugs can cause hypersensitisation between week 3 and week 8 of treatment in order of frequency: ethambutol, pyrazinamide, rifampicin and isoniazid.\n\nIf mild (simple itchy rash), give antihistamine (e.g. chlorpheniramine) and moisturizer and continue treatment.\n\nSevere reactions are characterised by"
    },
    {
        "id": "doc_864",
        "document": "- Fever, headache, vomiting\n\n- Macular dark erythematous rash which can progress to a Steven Johnson-Toxic Epidermal Necrolysis syndrome\n\nAdjunctive treatment\n\nTREATMENT LOC Stop all drugs immediately H Manage supportively Refer for specialised management RR"
    },
    {
        "id": "doc_865",
        "document": "Drug-induced hepatitis\n\nSevere hepatic damage, presenting with jaundice, vomiting, severe malaise. In order of frequency, the implicated drugs are Isoniazid, Pyrazinamide, Rifampicin and Ethambutol.\n\nAdjunctive treatment\n\nTREATMENT LOC Stop all drugs immediately H Manage supportively When jaundice has resolved, re-introduce single drugs at RR 3-7 days interval, starting from the least likely involved\n\nManage supportively\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n383"
    },
    {
        "id": "doc_866",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\nAdjunctive treatment\n\nTREATMENT If reaction very severe, do not try to restart pyrazina- mide. If RH tolerated, do not try pyrazinamide Use alternative regimen avoiding the causative drug LOC H RR"
    },
    {
        "id": "doc_867",
        "document": "5.3.2.2 Prevention and Infection Control of TB\n\nCase diagnosis and management\n\nA TB patient is more infectious before they start TB treatment.\n\n~ Provide PPE to sputum-positive patients\n\n~ Early detection of cases and initiation of appropriate TB treatment\n\n~ Treatment under directly observed treatment (DOT) and fol- low up to ensure adherence and cure\n\nContact tracing\n\n~ Tracing of contacts of TB patients\n\n~ Routine screening of health workers for latent & active TB"
    },
    {
        "id": "doc_868",
        "document": "High Priority Patients For Contact Tracing\n\n~ Bacteriologically confirmed PTB (Smear positive or Xpert positive or Culture positive)\n\n~ Cavitation of chest x-ray\n\nOO0\n\n~ Age < 5 years\n\n~ MDR TB \u2022 PLHIV\n\nOther preventive measures\n\n~ BCG vaccination at birth to prevent severe forms of TB\n\n~ TB Preventive Treatment for categories at risk"
    },
    {
        "id": "doc_869",
        "document": "General hygiene\n\n~ Avoidance of overcrowding\n\n~ Avoid drinking unboiled milk\n\n384\n\n~ Cough hygiene (cover cough with pieces of cloth, washing hands with soap, proper disposal of sputum)\n\n~ Good nutrition\n\n~ Promote good ventilation in housing & transport\n\n\u2022 Open ventilators, windows & doors that allow air exchange"
    },
    {
        "id": "doc_870",
        "document": "5.3.2.3 Tuberculosis Preventive Treatment\n\nTuberculosis preventive treatment is recommended to prevent the development of active TB disease in an individual who has latent TB infection (LTBI).\n\nUganda guidelines for programmatic management of Latent TB infection recommend TB preventive treatment (TPT ) in the following categories of people:\n\n- Persons living with HIV\n\n- Child & adult contacts of pulmonary TB patients\n\nDo not use TPT in cases of active TB"
    },
    {
        "id": "doc_871",
        "document": "TREATMENT LOC Exclude active TB Hc3 - Assess for cough, fever, weight loss and nights sweats (Children: cough, fever, poor weight gain) - If any of the TB symptoms are present, do clinical - evaluation for TB - If none is present, TB is unlikely, then rule out contra-indications for TPT medicines. If none, then give Give TPT as per dosing chart below. Note HIV-positive children < 1 year should receive TPT only if they\n\nexcluded\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD"
    },
    {
        "id": "doc_872",
        "document": "385\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n5.3.2.5 TB Preventive Treatment Dosing Chart"
    },
    {
        "id": "doc_873",
        "document": "Medicine frequency & duration Formulation Dose of TPT medicine (mgs) | Dose/ weight Reco 3HP (once weekly rifapentine plus isoni- azid for 3 months) 6H (daily isoniazid Fixed Doze Combination (FDC) Tablet Rifapentine 300mg/ Iso- niazid 300mg 3-5 Single medicine tablet Pyridoxine 25mg/day 3-5 Single medicine tablet Isoniazid 100 mg <10 years 10mg/kg 0.5 > 10 years 5mg/kg Isoniazid 300 mg > 10 years 5mg/kg Single medicine tablet Pyridoxine 25 mg 0.5"
    },
    {
        "id": "doc_874",
        "document": "3RH (daily Rifampic- Fixed Doze in Isoniazid for 3 Combination months) (FDC) Tablet\n\n386\n\n\u00a3207 S2UII3PIND (21Ul epuebn\n\nsasess|g A103e1dsay 1\u00a7 WALAVHD\n\nRecommended number of tablets per body weight in kilograms\n\nDose of TPT\n\nFormulation\n\nMedicine frequency\n\nDose/\n\nmedicine\n\n& duration"
    },
    {
        "id": "doc_875",
        "document": "weight\n\n10\u2013 16\u2013 24\u2013 31- 35- >45kgs 15kgs 23kgs 30kgs 34kgs 45kgs 1 1.5 2 2.5 3 3 1 1 1 1 1 1 6\u20139.9 1 0 \u2013 1 4 \u2013 2 0 \u2013 2 5 - 3 5 - 4 5 - >50 kgs 1 3 . 9 19.9 24.9 3 4 . 5 44.5 49.9 Kgs kgs kgs kgs kgs kgs kgs 1 1.5 2 2.5 1.5 2 2.5 1 0.5 1 1 1 1 1 1 1 4-7 kgs 8-11 12-15 16\u201324 25- 33- 40-54\n\n(mgs)\n\n3HP (once weekly\n\nFixed Doze\n\nRifapentine\n\nrifapentine plus isoni-\n\nCombination\n\n300mg/ Iso-\n\n(FDC) Tablet\n\nazid for 3 months)\n\nniazid 300mg\n\nSingle medicine\n\nPyridoxine\n\n25mg/day\n\ntablet"
    },
    {
        "id": "doc_876",
        "document": "6H (daily isoniazid\n\n3\u20135.9\n\nfor 6 months)\n\nkgs\n\nIsoniazid 100\n\n<10 years\n\n0.5\n\nSingle medicine\n\nmg\n\n10mg/kg\n\ntablet\n\n> 10 years\n\n5mg/kg\n\nIsoniazid 300\n\n> 10 years\n\nmg\n\n5mg/kg\n\n0.5\n\nSingle medicine\n\nPyridoxine 25\n\nmg\n\ntablet\n\nin Isoniazid for 3\n\nCombination\n\nkgs\n\nkgs\n\n(FDC) Tablet\n\nmonths)\n\nkgs\n\nkgs\n\nkgs\n\nkgs\n\n387\n\nepuebn [\n\n207 saulapING [ea1uip>\n\nSingle medicine\n\ntablet\n\nSingle medicine\n\ntablet\n\nRH\n\n75mg/50mg\n\nRH\n\n150mg/75mg\n\nPyridoxine\n\n25mg/day\n\n< 10 years\n\nR-15mg/kg\n\nH-10mg/kg\n\n>10 years"
    },
    {
        "id": "doc_877",
        "document": "R-10mg/kg\n\nH-5 mg/kg\n\n0.5\n\n0.5\n\nsasesas|g A103e1ds oy 1\u00a7 WALAVHD\n\nMedicine frequency & duration 1HP (once daily rifapentine plus isoni- azid for 1 month - 28 days) for adolescents >13 years & adults Formulation Single medicine tablets Dose of TPT medicine (mgs) ne Isoniazid (H) 300mg tablet 4 Rifapentine (P) 150mg tablets / day Pyridoxine 25mg/day Dose/ weight Regardless o f we i g h t band\n\n388\n\n1 2 3 4 4 2 3 1 1 1 1 1 1 1\n\nRH\n\n< 10 years\n\n0.5\n\n75mg/50mg\n\nR-15mg/kg\n\nH-10mg/kg\n\nSingle medicine"
    },
    {
        "id": "doc_878",
        "document": "tablet\n\n>10 years\n\nRH\n\n150mg/75mg\n\nR-10mg/kg\n\nH-5 mg/kg\n\nPyridoxine\n\nSingle medicine\n\n0.5\n\n\u00e9\n\nRecommended number of tablets per body weight in kilograms\n\nFormulation\n\nDose/\n\nDose of TPT\n\nMedicine frequency\n\n(mgs)\n\n10\u2013 16\u2013 24\u2013 31- 35- >45kgs 15kgs 23kgs 30kgs 34kgs 45kgs 1 1.5 2 2.5 1 1 1 1 1 1 4 4 1 1 1 1 1 1\n\n1HP (once daily\n\nrifapentine plus isoni-\n\nazid for 1 month - 28\n\nRegardless\n\ndays) for adolescents\n\no f we i g h t\n\n>13 years & adults\n\nband\n\nne Isoniazid\n\nSingle medicine"
    },
    {
        "id": "doc_879",
        "document": "tablets\n\n(H) 300mg\n\ntablet\n\n4 Rifapentine\n\n(P) 150mg\n\ntablets / day\n\nPyridoxine\n\nsaseas|q A103ex1dsaY 1S HILAVHD\n\n389\n\n[\n\n|\n\n$20Z S3UIAPING e3ju> epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nPreferred options for Ti\n\nTPT medicine option Isoniazid monotherapy Isoniazid/co-trimoxazole/pyridoxine (Q-TIB) 3 months of Rifapentine/Isoniazid 1 month of Rifapentine/Isoniazid\n\n(-\n\n390"
    },
    {
        "id": "doc_880",
        "document": "[ N\n\n|\n\nB Preventive Treatment >t population (active TB ruled out) cts of PBC TB patients < 2 years of age J on protease inhibitors gnant women living with HIV with; ory of contact with a TB patient 4 < 200 cells/ml O stage 3 or 4 /; <12 months) in care <200 cells/ml stage 3 or 4 J > 2 years of age (not on protease inhibitors (PI) cts of PBC TB patients > 2 years ers workers\n\nTPT medicine option\n\nIsoniazid monotherapy"
    },
    {
        "id": "doc_881",
        "document": "Isoniazid/co-trimoxazole/pyridoxine (Q-TIB)\n\n1\n\n|\n\n\u00a3202 59UNI9PING [\u20ac21U11D epUCE\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n[ N\n\n391\n\n|\n\ndiseases\n\nReview"
    },
    {
        "id": "doc_882",
        "document": "Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches\n\nGuilherme Bartolomeu-Gon\u00e7alves 1 , Joyce Marinho de Souza 2,3 , Bruna Terci Fernandes 2,4, La\u00eds Fernanda Almeida Spoladori 2, Guilherme Ferreira Correia 2 , Isabela Madeira de Castro 2, Paulo Henrique Guilherme Borges 2 , Gislaine Silva-Rodrigues 2, Eliandro Reis Tavares 2,5, Lucy Megumi Yamauchi 2 , Marsileni Pelisson 1 , Marcia Regina Eches Perugini 1 and Sueli Fumie Yamada-Ogatta 1,2,*"
    },
    {
        "id": "doc_883",
        "document": "check for v updates\n\nCitation: Bartolomeu-Gon\u00e7alves, G.; Souza, J.M.d.; Fernandes, B.T.; Spoladori, L.F.A.; Correia, G.F.; Castro, I.M.d.; Borges, P.H.G.; Silva- Rodrigues, G.; Tavares, E.R.; Yamauchi, L.M.; et al. Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches. Diseases 2024, 12, 202. https://doi.org/10.3390/ diseases12090202\n\nAcademic Editor: Fernando Monroy\n\nReceived: 28 June 2024 Revised: 31 August 2024 Accepted: 31 August 2024 Published: 3 September 2024"
    },
    {
        "id": "doc_884",
        "document": "Copyright: \u00a9 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).\n\n1 Programa de P\u00f3s-Gradua\u00e7\u00e3o em Fisiopatologia Cl\u00ednica e Laboratorial, Universidade Estadual de Londrina, Londrina CEP 86038-350, Paran\u00e1, Brazil; guilherme.bartolomeu@uel.br (G.B.-G.); marsileni@uel.br (M.P.); marciaperugini@uel.br (M.R.E.P.)"
    },
    {
        "id": "doc_885",
        "document": "2 Programa de P\u00f3s-Gradua\u00e7\u00e3o em Microbiologia, Universidade Estadual de Londrina, Londrina CEP 86057-970, Paran\u00e1, Brazil; joycemarinhodesouza@gmail.com (J.M.d.S.); terci.bruna@gmail.com (B.T.F.); lais.spoladori@gmail.com (L.F.A.S.); guilhermeferreiracorreia@gmail.com (G.F.C.); isabela.mcastro@uel.br (I.M.d.C.);\n\ntavares.eliandro@uel.br (E.R.T.);\n\nlionilmy@uel.br (L.M.Y.)"
    },
    {
        "id": "doc_886",
        "document": "Faculdade de Ci\u00eancias da Sa\u00fade, Biomedicina, Universidade do Oeste Paulista, Presidente Prudente CEP 19050-920, S\u00e3o Paulo, Brazil\n\n4 Curso de Farm\u00e1cia, Faculdade Dom Bosco, Corn\u00e9lio Proc\u00f3pio CEP 86300-000, Paran\u00e1, Brazil\n\n5 Departamento de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,\n\nCampus Londrina CEP 86067-000, Paran\u00e1, Brazil\n\n* Correspondence: ogatta@uel.br; Tel.: +55-(43)-3371-5503"
    },
    {
        "id": "doc_887",
        "document": "Abstract: Tuberculosis (TB) remains an impactful infectious disease, leading to millions of deaths every year. Mycobacterium tuberculosis causes the formation of granulomas, which will determine, through the host\u2013pathogen relationship, if the infection will remain latent or evolve into active disease. Early TB diagnosis is life-saving, especially among immunocompromised individuals, and leads to proper treatment, preventing transmission. This review addresses different approaches to diagnosing"
    },
    {
        "id": "doc_888",
        "document": "TB, from traditional methods such as sputum smear microscopy to more advanced molecular techniques. Integrating these techniques, such as polymerase chain reaction (PCR) and loop- mediated isothermal amplification (LAMP), has significantly improved the sensitivity and specificity of M. tuberculosis identification. Additionally, exploring novel biomarkers and applying artificial intelligence in radiological imaging contribute to more accurate and rapid diagnosis. Furthermore, we discuss the"
    },
    {
        "id": "doc_889",
        "document": "challenges of existing diagnostic methods, including limitations in resource-limited settings and the emergence of drug-resistant strains. While the primary focus of this review is on TB diagnosis, we also briefly explore the challenges and strategies for diagnosing non-tuberculous mycobacteria (NTM). In conclusion, this review provides an overview of the current landscape of TB diagnostics, emphasizing the need for ongoing research and innovation. As the field evolves, it is crucial to ensure"
    },
    {
        "id": "doc_890",
        "document": "that these advancements are accessible and applicable in diverse healthcare settings to effectively combat tuberculosis worldwide."
    },
    {
        "id": "doc_891",
        "document": "Keywords: pulmonary tuberculosis diagnosis; Mycobacterium tuberculosis; diagnostic techniques; molecular techniques"
    },
    {
        "id": "doc_892",
        "document": "1. Introduction\n\nTuberculosis (TB) is a bacterial disease caused by Mycobacterium tuberculosis (sensu stricto) and other members of the Mycobacterium tuberculosis complex (MTBC) [1,2]. The\n\nDiseases 2024, 12, 202. https://doi.org/10.3390/diseases12090202\n\nhttps://www.mdpi.com/journal/diseases\n\nDiseases 2024, 12, 202\n\n2 of 24\n\ndisease caused 1.3 million deaths in 2022 [3], with over 31 million TB-related deaths estimated for the coming years [4]."
    },
    {
        "id": "doc_893",
        "document": "The lungs are the most commonly affected organs (pulmonary tuberculosis, PTB) [5]. However, the disease can affect other sites, such as pleura, lymph nodes, abdomen, geni- tourinary tract, skin, joints, bones, and meninges, a condition known as extrapulmonary TB [6], which afflicts between 15 and 20% of TB patients, especially HIV-positive individu- als [7]."
    },
    {
        "id": "doc_894",
        "document": "Typical symptoms of PTB include persistent cough, hemoptysis, chest discomfort, fa- tigue, weight loss, night sweats, and fever, although mild or no symptoms may occur in the initial stages [8,9]. Moreover, individuals with latent tuberculosis infection (LTBI) exhibit no active TB signs [10] and constitute a potential source for future active TB cases [11]."
    },
    {
        "id": "doc_895",
        "document": "Transmission, mainly through cough-generated aerosols [12], is influenced by environ- mental conditions, microbial viability, and host immune response [13]. Risk factors include alcohol abuse [14], coinfection with HIV [15], anemia [16], diabetes [17], silicosis [18], smoking and exposure to air pollution [19], homelessness [20], and incarceration [21]."
    },
    {
        "id": "doc_896",
        "document": "Upon infection, M. tuberculosis triggers the formation of granulomas [2,22], after which the pathogen can remain in a latent state or lead to active disease depending on the host\u2019s immune response [2,23]. Since recent studies suggest a potential association between PTB and lung cancer, effective TB control is needed to reduce this risk [24\u201326]."
    },
    {
        "id": "doc_897",
        "document": "The diagnosis of TB encompasses difficulties such as underdiagnosis and limited access to testing [27], a scenario that was worsened by the COVID-19 pandemic, although the last Global Tuberculosis Report signals some progress in reversing its impact on TB control [3]. Additionally, the growing incidence of non-tuberculous mycobacterial (NTM) infections, partially due to the aging of the population, as well as an increase in immunosup- pressed individuals [28], poses challenges for the diagnosis"
    },
    {
        "id": "doc_898",
        "document": "of TB. In fact, non-tuberculous mycobacteria share some features with M. tuberculosis, and non-tuberculous pulmonary disease usually presents with nonspecific signs and radiological findings similar to those caused by the TB causative agent. Therefore, diagnosing non-tuberculous mycobacterial pulmonary disease in regions with high TB prevalence is a complex endeavor. Recent reviews have outlined methods for diagnosing NTM, and the reader is referred to these reviews for a greater understanding"
    },
    {
        "id": "doc_899",
        "document": "of the methods that are used or are being developed for the diagnosis of NTM [29,30]. We briefly summarized the main techniques, and they are shown in Supplementary Table S1 [31\u201345]."
    },
    {
        "id": "doc_900",
        "document": "Early TB diagnosis is critical for global health since it prevents TB transmission [46\u201348] and reduces mortality, especially for people living with HIV [49]. Rapid diagnostic tech- niques enable prompt treatment initiation [50,51], aligning with the End TB Strategy, which emphasizes effective diagnosis and treatment for people with TB [52]."
    },
    {
        "id": "doc_901",
        "document": "Therefore, this non-systematic literature review discusses the diagnosis of tuberculosis, particularly PTB, and identifies future research directions regarding TB diagnostics."
    },
    {
        "id": "doc_902",
        "document": "2. Traditional Diagnostic Methods\n\n2.1. Sputum Smear Microscopy\n\nSputum smear microscopy (SSM) is one of the techniques which has been widely used to diagnose active PTB [53\u201355], identifying acid-fast bacilli through acid-fast stainings such as Ziehl\u2013Neelsen (hot stain) or Kinyoun (cold stain), whose principle involves the binding of carbol fuchsin to the mycobacterial mycolic acids [6]."
    },
    {
        "id": "doc_903",
        "document": "Ziehl\u2013Neelsen staining is cost-effective (mean cost USD 13.31) [56] but may underesti- mate bacterial burden [57,58], as well as presenting variable sensitivity (32% to 89%) [56]. Furthermore, this technique cannot differentiate between dead and live bacteria, drug- susceptible from drug-resistant strains, nor distinguish M. tuberculosis from other mycobac- teria [46], exhibiting compromised sensitivity whenever the bacterial load is less than 10,000 bacilli/mL sputum sample [59]. A study"
    },
    {
        "id": "doc_904",
        "document": "performed by Chopra et al. [60] showed that Kinyoun\u2019s method presented higher sensitivity (98.37%) compared to Ziehl\u2013Neelsen staining (89.25%), indicating it is more effective at detecting tubercle bacilli."
    },
    {
        "id": "doc_905",
        "document": "Diseases 2024, 12, 202\n\n3 of 24\n\nFluorescence or light-emitting diode (LED) microscopy [61\u201363], automated microscopy, and artificial intelligence (AI) [64\u201367] techniques have been employed to improve the performance of SSM."
    },
    {
        "id": "doc_906",
        "document": "Notably, SSM should be combined with other diagnostic tools to enhance the effi- cacy and reliability of TB diagnosis [68]. Despite the diffused employment of molecular approaches, researchers underscore that SSM remains fundamental as the primary diagnos- tic technique for TB globally [69\u201371], with high-burden countries conducting millions of smears annually [72,73].\n\n2.2. Chest Radiography"
    },
    {
        "id": "doc_907",
        "document": "Chest radiography/chest X-ray (CXR) is very useful for TB diagnosis, particularly in resource-limited settings, showing high sensitivity in detecting PTB but limited speci- ficity [74,75]. According to the World Health Organization (WHO) [76], this technique ex- hibits a sensitivity ranging from 87% to 98% and is considered a valuable tool for screening PTB [77]. Moreover, CXR provides diagnostic and prognostic information in children with TB [78] despite its limitations in detecting"
    },
    {
        "id": "doc_908",
        "document": "lymphadenopathy, which requires additional methods [79]. Key radiographic findings frequently observed on CXRs in patients diag- nosed with PTB encompass cavitation, consolidation, masses, pleural effusion, calcification, and nodules [80], with predominant features often comprising cavitation, bronchiectasis, and fibrosis [81]. Due to the overlap of radiographic findings, another limitation of CXR is its inability to differentiate PTB from pulmonary diseases caused by NTM [82,83]."
    },
    {
        "id": "doc_909",
        "document": "CXR as a screening test shortens the period required to diagnose PTB [84]. Further- more, the rise of AI, particularly deep learning algorithms, has revolutionized TB detection, showing superior performance in both screening and diagnosis [85,86]. AI approaches have opened new possibilities for improved accuracy and efficiency in TB diagnosis, aligning with the WHO\u2019s recommendation to use Computer-Aided Detections (CAD) in conjunction with human interpretation for TB screening in individuals"
    },
    {
        "id": "doc_910",
        "document": "aged 15 years or older [87]."
    },
    {
        "id": "doc_911",
        "document": "A notable breakthrough is the deep convolutional neural network (DCNN)-based AI algorithm developed by Nijiati et al. [88], which demonstrated an impressive accuracy of 96.73% in diagnosing TB from CXR, surpassing the performance of other models. Notably, incorporating demographic variables such as age, weight, height, and gender has enhanced the performance of deep learning models [89]. Additionally, Rahman et al. [90] underscored the importance of segmenting lung regions in CXR images before"
    },
    {
        "id": "doc_912",
        "document": "applying deep learning classification. Their study revealed that the DenseNet201 model achieved a higher accuracy of 98.6% when using segmented lung images compared to 96.47% when using whole X-ray images."
    },
    {
        "id": "doc_913",
        "document": "Despite the advancements in CAD for TB detection, concerns persist regarding po- tential biases, limitations in implementation, and challenges in its broader applicability. Ongoing evaluation, consideration of version updates, and a tailored approach to im- plementation that considers local data and patient characteristics are crucial to ensure the effectiveness and safety of CAD software in clinical practice [91]. Challenges include limited disease detection, suboptimal accuracy for specific"
    },
    {
        "id": "doc_914",
        "document": "populations, and the need for validation for pediatric use [92]."
    },
    {
        "id": "doc_915",
        "document": "Currently, 16 CADs for digital chest radiography are planned for WHO policy re- view [93], signaling the collaboration between AI and conventional diagnostic methods.\n\n3. Culture-Based Diagnostic"
    },
    {
        "id": "doc_916",
        "document": "M. tuberculosis is classified as a slow-growing mycobacteria, requiring seven days to six weeks to produce visible colonies on solid media. The procedure for culturing M. tuberculosis must be performed only in Biosafety Level 3 or 4 laboratories due to the high transmissibility of the mycobacteria, which is a limiting diagnostic capacity in many low and middle-income countries. Also, adequate training of laboratory analysts is essential for reducing pre-analytical risks associated with the"
    },
    {
        "id": "doc_917",
        "document": "entire diagnostic process [94]."
    },
    {
        "id": "doc_918",
        "document": "Diseases 2024, 12, 202\n\n4 of 24"
    },
    {
        "id": "doc_919",
        "document": "The use of selective media enhances accuracy compared to non-selective media, as the most frequent sample is sputum, which may carry non-tuberculous bacteria from normal microbiota [3,95]. The Petroff method has been used for the digestion-decontamination of contaminated clinical samples before culturing on solid media. Clinical specimens are incubated with an equal volume of a 2 to 4% NaOH solution for approximately 15 min, fol- lowed by centrifugation, and then inoculated onto solid media"
    },
    {
        "id": "doc_920",
        "document": "[96]. Kudoh and Kudoh [97] proposed a simplified method for the decontamination step and subsequent culturing. The clinical samples are picked up using a sterile cotton swab, which is subsequently immersed into a 4% NaOH solution. After 2 min, the swab is inoculated onto slightly acidified solid media (such as Kudoh\u2013Ogawa medium). This method has been evaluated and has proven to be as effective and sensitive as the Petroff decontamination method for sputum samples [98\u2013100]. It has been used in"
    },
    {
        "id": "doc_921",
        "document": "developing countries [99,101,102], as well as in rural areas without adequate infrastructure for culturing mycobacteria [100]. Additionally, due to its speed, this method is favored in laboratories that handle a high volume of clinical samples [98]."
    },
    {
        "id": "doc_922",
        "document": "Solid media that have been used to cultivate M. tuberculosis involve L\u00f6wenstein\u2013Jensen (LJ), described by Ernest L\u00f6wenstein in 1931 and modified by Kai Adolf Jensen in 1932 [103], and Kudoh\u2013Ogawa (KO), an alternative medium used to grow this bacterium [97]. Both LJ and KO are selective for Mycobacterium species due to the presence of malachite green (a triarylmethane dye) [104]. According to Madeira et al. [102], the growth of M. tuberculosis in these media presents high and similar sensibility"
    },
    {
        "id": "doc_923",
        "document": "and specificity. These researchers observed a lower contamination rate with KO medium (4.1%) compared to LJ medium (9.0%), suggesting a potentially higher risk of false-positive results with LJ due to contamination by NTM or other microorganisms. However, both media are time-consuming, which might lead to delays in the diagnosis of TB [102]."
    },
    {
        "id": "doc_924",
        "document": "Regarding liquid media, Middlebrook is a medium that may vary in composition, resulting in different formulations, such as Middlebrook 7H9, 7H10, and 7H11, which primarily differ in the composition and concentration of organic compounds [105]. Tra- ditionally, Middlebrook medium has been enriched with various compounds to enhance sensitivity [106]. Middlebrook 7H10, in particular, can be supplemented with oleic acid\u2013 albumin\u2013dextrose\u2013catalase. This medium supports faster mycobacteria growth and"
    },
    {
        "id": "doc_925",
        "document": "allows further biofilm studies [107,108]."
    },
    {
        "id": "doc_926",
        "document": "In addressing the limitations of liquid media, Becton Dickinson (BD) introduced the Mycobacteria Growth Indicator Tube (MGIT), combining Middlebrook 7H9 broth with fluorescent compounds metabolized by M. tuberculosis. This method, revealed under ultra- violet (UV) light, shortened incubation time and enhanced detection rates during routine laboratory procedures [109,110]. Some studies have reported that MGIT 960 outperforms the use of LJ to detect M. tuberculosis [111\u2013113]."
    },
    {
        "id": "doc_927",
        "document": "Despite the time-consuming nature of culture, it remains the gold standard for diag- nosing TB (including extrapulmonary infections) and monitoring TB treatment, offering advantages in identifying the pathogen and the antimicrobial susceptibility profile de- termination [114]. Furthermore, culturing mycobacteria is also the gold standard for differentiating between MTBC and NTM [69,115].\n\n4. Molecular Diagnostic Techniques"
    },
    {
        "id": "doc_928",
        "document": "Advances in molecular biology have driven research and development in methods for the rapid and accurate detection of MTBC and NTM and their drug resistance, providing important tools for TB control [116]. In fact, the introduction of molecular tests has sig- nificantly improved TB diagnosis, particularly for cases with negative microscopy [117]. However, the WHO emphasizes that molecular tests are not substitutes for microbiological cultures and phenotypic antimicrobial susceptibility testing"
    },
    {
        "id": "doc_929",
        "document": "[53]."
    },
    {
        "id": "doc_930",
        "document": "Diseases 2024, 12, 202\n\n5 of 24\n\n4.1. Molecular WHO-Recommended Rapid Diagnostic Tests\n\nWHO recommends the use of molecular rapid diagnostic tests to detect M. tuberculosis and resistance to rifampicin (RIF) and fluoroquinolones. These tests are used to diagnose and guide TB treatment, and can also be used to monitor the response to treatment [118]."
    },
    {
        "id": "doc_931",
        "document": "4.1.1. Nucleic-Acid Amplification Tests\n\nMost WHO-recommended rapid diagnostic tests for TB rely on nucleic-acid ampli- fication technology (NAAT) (Table 1) [119]. Critical examples for initial TB diagnosis without antimicrobial resistance assessment include the Loopamp\u2122 MTBC Detection Kit and FluoroType\u00ae MTB [118].\n\nTable 1. Nucleic acid amplification tests (NAATs) recommended by the World Health Organization for tuberculosis diagnosis."
    },
    {
        "id": "doc_932",
        "document": "Test Target LoD CFU/mL Sensitivity (%) Specificity (%) Time to Result (h) RIF/INH Resistance Detection Notes References LoopampTM MTBC 6 6 regions within MTBC DNA N/A ~80.9 ~96.5 <lh No Manual assay [119,120] FluoroType\u00ae MTB VER 1.0 1S6110 30 ~88.1 ~98.9 3h No Uses FluoroType\u00ae technology, manual/ automated DNA extraction [121\u2013123] FluoroType\u00ae MTB VER 2.0 1S6110 26 ~91.6 ~93.8 3h No Uses FluoroType\u00ae technology, manual DNA extraction [121,124]"
    },
    {
        "id": "doc_933",
        "document": "Xpert\u00ae MTB/RIF rpoB 131 ~85 ~98 2h RIF Automated, nested qPCR [69,125,126] Xpert\u00ae MTB/RIF Ultra IS6110, 151081, rpoB 16 ~87.8 ~98.1 <2h RIF Improved version of Xpert\u00ae MTB/RIF [69,127] Truenat\u00ae MTB nrdB 100 ~73.3 ~97.9 <lh No Chip-based qPCR [128] Truenat\u00ae MTB Plus nrdZ, 186110 29 ~91.7 ~97.2 <lh No Chip-based qPCR, higher sensitivity than Truenat\u00ae MTB [129] RealTime MTB 156110, pab 17 93% (culture+), 81% (smear- negative) 97% ~6h No Separate test available for RIF/INH resistance [130,131]"
    },
    {
        "id": "doc_934",
        "document": "RealTime MTB RIF/INH rpoB, inhA promoter, katG 60 94.8 (RIF) 88.3 (INH) 100 (RIF) 94.3 (INH) Additional 45h RIF/INH Carried out upon positive RealTime MTB result [69,132] BD MAX\u2122 MDR-TB IS6110, 151081, rpoB, inhA promoter, katG 0.5 92.6 98.6 <4h RIF/INH Integrated MTBC and RIF/INH detection [133] FluoroType\u00ae MTBDR VER 2.0 1poB, katG, inhA 20 89.8 97.5 25h RIF/INH Integrated MTBC and RIF/INH detection [122,124,134]"
    },
    {
        "id": "doc_935",
        "document": "VER 2.0\n\ndetection\n\nDiseases 2024, 12, 202\n\n6 of 24\n\nTable 1. Cont.\n\nTest cobas\u00ae MTB cobas\u00ae MTB- RIF/INH Target 16S rRNA, esx genes rpoB, katG, inhA promoter LoD CFU/mL Sensitivity (%) Specificity (%) Time to Result (h) RIF/INH Resistance Detection Notes References Different targets 8.8 ~93.5 ~98. 3.5 h No compared to [135,136] other tests 182 (RIF) 27.5 (INH) ~96.7 (RIF) ~97.4 (INH) ~97.9 (RIF) ~99.3 (INH) Additional 3.5 h RIF/INH Carried out upon cobas\u00ae MTB positive result [136,137]"
    },
    {
        "id": "doc_936",
        "document": "LoD: limit of detection; RIF: rifampicin; INH: isoniazid; MTBC: Mycobacterium tuberculosis complex; N/A: not available; SSM: sputum smear microscopy; CFU: colony-forming unit; qPCR: real-time PCR."
    },
    {
        "id": "doc_937",
        "document": "The Loopamp\u2122 MTBC Detection Kit (TB-LAMP; Eiken Chemical, Tokyo, Japan) is a manual assay that provides results in less than one hour. The loop-mediated isothermal amplification (LAMP) technology [138] utilizes four primer sets to amplify six distinct regions within the DNA of MTBC. This process forms stem-loop structures detectable by dyes like SYBR green and calcein [120,139,140]. Nagai et al. [119] reported an approximate sensitivity of 80.9% and specificity of 96.5%. TB-LAMP holds potential"
    },
    {
        "id": "doc_938",
        "document": "as a substitute for SSM in diagnosing PTB in adults with symptoms and as a follow-up test to SSM, especially for further examination of smear-negative samples [120]."
    },
    {
        "id": "doc_939",
        "document": "FluoroType\u00ae MTB VER 1.0 and VER 2.0 (Bruker/Hain Lifescience, Nehren, Germany) utilize FluoroType\u00ae technology for rapid molecular genetic testing, allowing direct detec- tion of MTBC from patient samples. These automated systems deliver results within three hours, using fluorescence-based technology for enhanced reliability and efficiency in TB diagnostics [121]. The assay utilizes high-resolution melt analysis to identify and automati- cally record fluorescence signals linked to probes that"
    },
    {
        "id": "doc_940",
        "document": "target the MTBC insertion element IS6110 [141]. It is important to highlight that a remarkable characteristic of FluoroType\u00ae MTB VER 1.0 relies on its ability to detect clinically relevant NTM species [142]."
    },
    {
        "id": "doc_941",
        "document": "Moreover, WHO has endorsed several mWRD tests for the initial TB diagnosis and the detection of resistance to RIF or the combination RIF/INH [118]. Among these, the Xpert\u00ae MTB/RIF Assay (Cepheid, Sunnyvale, CA, USA) is an automated diagnostic test using nested real-time PCR (qPCR) to detect the MTBC and RIF resistance qualitatively. It amplifies a specific segment of the rpoB gene and distinguishes between wild-type and mutation-associated RIF resistance. The assay is compatible with GeneXpert\u00ae"
    },
    {
        "id": "doc_942",
        "document": "systems and automates sample processing and nucleic acid amplification [125]. Furthermore, the Xpert\u00ae MTB/RIF Ultra assay, also developed by Cepheid, is an improved version of the Xpert\u00ae MTB/RIF test, offering higher sensitivity and reliability for detecting MTBC and RIF resistance. This is achieved through two multicopy amplification targets (IS6110 and IS1081), a larger PCR chamber, and melting curve analysis. Xpert Ultra exhibits a lower LoD (16 CFU/mL) compared to 131 CFU/mL for Xpert\u00ae"
    },
    {
        "id": "doc_943",
        "document": "MTB/RIF) [69]."
    },
    {
        "id": "doc_944",
        "document": "Chip-based qPCR technology is employed by Truenat\u00ae MTB and Truenat\u00ae MTB Plus (Molbio Diagnostics, Goa, India) to detect M. tuberculosis in specimens from pulmonary and extrapulmonary TB [69]. Truenat\u00ae MTB targets the nrdB gene (codes for R2-like ligand binding oxidase) with an LoD of 100 CFU/mL [128]. At the same time, Truenat\u00ae MTB Plus utilizes the nrdZ gene and the IS6110 sequence, offering a significantly lower LoD of 29 CFU/mL [129]. Following a positive Truenat\u2122 MTB Plus test, an aliquot of"
    },
    {
        "id": "doc_945",
        "document": "the extracted DNA undergoes further testing with the Truenat MTB-RIF-Dx assay to detect mutations related to RIF resistance [69]. An important drawback of Truenat\u00ae MTB is its inability to detect mycobacterial species other than M. tuberculosis [128]."
    },
    {
        "id": "doc_946",
        "document": "The RealTime MTB assay (Abbott Molecular, Des Plaines, IL, USA) uses PCR to detect MTBC DNA, exhibiting a sensitivity of 93% in culture-positive samples, 81% in smear- negative culture-positive samples, and a specificity of 97%. With an LoD of 17 CFU/mL, the target regions include IS6110 and pab gene (codes for protein antigen B, Pab) [130]. The RealTime MTB RIF/INH (Abbott Molecular, Des Plaines, IL, USA) assay detects resistance\n\nDiseases 2024, 12, 202\n\n7 of 24"
    },
    {
        "id": "doc_947",
        "document": "to RIF (rpoB gene) and different levels of INH resistance (katG gene and inhA promoter region) [132]. It allows for the identification of MTBC with or without rifampicin-resistant TB (RR-TB), isoniazid-resistant rifampicin-susceptible TB (Hr-TB), or multidrug-resistant TB (MDR-TB) within 10.5 h using raw or processed sputum specimens or DNA eluates from positive samples [69]."
    },
    {
        "id": "doc_948",
        "document": "The BD MAX\u2122 MDR-TB assay (Becton Dickinson, Sparks, MD, USA) integrates MTBC detection and assesses resistance to RIF and INH. The automated process involves specimen treatment with BD MAX STR reagent, transfer to the BD MAX MDR-TB Sample Tube, and utilization of the BD MAX System for DNA extraction, amplification, and detection using qPCR. Targeting IS6110 and IS1081 for MTBC detection (LoD = 0.5 CFU/mL; 92.6% overall sensitivity, and 98.6% overall specificity), the system also identifies"
    },
    {
        "id": "doc_949",
        "document": "resistance, with the rpoB gene for RIF resistance, and the inhA promoter region and katG gene for INH resistance [133]."
    },
    {
        "id": "doc_950",
        "document": "The FluoroType\u00ae MTBDR VER 2.0 (Bruker/Hain Lifescience, Nehren, Germany) is a multiplex qPCR assay for the rapid detection of MTBC and resistance to RIF and INH, based on the LiquidArray\u00ae technology. DNA extraction can be manual (FluoroLyse) or automated (GenoXtract\u00ae X2 cartridge). The targeted sequences include rpoB, katG, and inhA, allowing the identification of mutations associated with RIF and INH resistances [134]."
    },
    {
        "id": "doc_951",
        "document": "The cobas\u00ae MTB test (Roche Molecular Diagnostics, Pleasanton, CA, USA) targets 16S rRNA and esx genes through qPCR (LoD = 8.8 CFU/mL in raw sputum). It is intended for use on the cobas\u00ae 5800/6800/8800 Systems and is an automated, qualitative in vitro diagnostic test. The test can detect MTBC DNA in various human respiratory specimens, including sputum and bronchoalveolar lavage samples [135]. Additionally, the cobas\u00ae MTB-RIF/INH test (Roche Molecular Diagnostics, Pleasanton, CA, USA), also"
    },
    {
        "id": "doc_952",
        "document": "conducted on the cobas\u00ae 5800/6800/8800 Systems, is an automated PCR test designed as a reflex test with cobas\u00ae MTB. It identifies RIF and INH resistance mutations in M. tuberculosis, analyzing eighteen RIF-resistance-associated mutations in the rpoB gene and seven INH- resistance-associated mutations in the katG gene and inhA gene promotor region. The LoD in raw sputum is 182 CFU/mL for RIF-resistant M. tuberculosis and 27.5 CFU/mL for INH-resistant M. tuberculosis [137]."
    },
    {
        "id": "doc_953",
        "document": "The aforementioned Abbott RealTime MTB and Abbott RealTime MTB RIF/INH, BD MAX\u2122 MDR-TB, FluoroType\u00ae MTBDR and FluoroType\u00ae MTB, and cobas\u00ae MTB and cobas MTB-RIF/INH have been classified as Moderate complexity automated (MC-a) NAATs for detection of TB and resistance to RIF and INH [69]. Overall, WHO prioritizes using mWRDs, including MC-aNAATs, as the initial diagnostic test for suspected TB. The use of molecular approaches, in addition to culture methods, offers several advantages, including"
    },
    {
        "id": "doc_954",
        "document": "faster results, improved sensitivity, rifampicin resistance detection, and, ultimately, quicker initiation of appropriate treatment [69]. All the NAATs presented in Table 1 (except for Truenat\u00ae MTB) detect DNA from MTBC but do not differentiate the subspecies, especially Mycobacterium bovis, which is a significant cause of zoonotic TB. This is particularly im- portant as the zoonotic transmission of TB, especially that involving M. bovis, has gained increasing attention globally [143\u2013145]."
    },
    {
        "id": "doc_955",
        "document": "Therefore, because these methods do not differenti- ate between these two species, crucial information about the zoonotic aspect of TB may be overlooked, and a traditional culture-based method must be performed [125,128,129]."
    },
    {
        "id": "doc_956",
        "document": "4.1.2. Line Probe Assays (LPAs)"
    },
    {
        "id": "doc_957",
        "document": "Line-probe assays (LPAs) represent a category of DNA strip-based tests that detect the presence of MTBC and mutations associated with drug resistance. The interpretation of the results involves analyzing a band pattern on the strips, where immobilized probes are bound to MTBC amplicons. The probes are specifically designed to target prevalent mutations linked to resistance against both first- and second-line anti-TB drugs, as well as distinct MTBC wild-type DNA sequences. Two commonly used LPAs,"
    },
    {
        "id": "doc_958",
        "document": "GenoType\u00ae MTBDRplus and GenoType\u00ae MTBDRsl, are recommended by the WHO [146]."
    },
    {
        "id": "doc_959",
        "document": "Diseases 2024, 12, 202\n\n8 of 24"
    },
    {
        "id": "doc_960",
        "document": "GenoType\u00ae MTBDRplus (VER 2.0; Hain Lifescience GmbH, Nehren, Germany) enables the identification of RIF resistance by detecting significant mutations in the rpoB gene. Moreover, it assesses INH resistance through the katG gene and the promoter region of the inhA gene. Benefits include testing from patient specimens or cultures and obtaining results in five hours (compared to 1 to 2 months required by conventional methods) [147]. In a study conducted by Moga et al. [148], GenoType\u00ae MTBDRplus VER"
    },
    {
        "id": "doc_961",
        "document": "2.0 achieved a sensitivity of ~94.3% to detect INH resistance among MDR-TB isolates and a specificity of 100%. Similarly, Stephen et al. [149] reported 100% sensitivity and specificity to detect resistance to both INH and RIF. Furthermore, Tan et al. [150] reported that the test displayed a sensitivity of ~92.7% and a specificity of ~94.5% in diagnosing TB, while Meaza et al. [151] reported a sensitivity and specificity of ~96.4% and 100%, respectively, to detect MDR-TB."
    },
    {
        "id": "doc_962",
        "document": "GenoType\u00ae MTBDRsl (VER 1.0 and VER 2.0; Hain Lifescience GmbH, Nehren, Ger- many) assists in detecting extensively drug-resistant tuberculosis (XDR-TB) by identifying MTBC and its resistance to fluoroquinolones, aminoglycosides/cyclic peptides, second-line injectable drugs (KAN: kanamycin; AMK: amikacin; CAP: capreomycin) and ethambutol (only VER 1.0) [152]. According to Bouzouita et al. [153], GenoType\u00ae MTBDRsl 2.0 pre- sented sensitivities of approximately 92.8% and 80% to detect resistance to"
    },
    {
        "id": "doc_963",
        "document": "fluoroquinolones and second-line injectable drugs (KAN, AMK, and CAP), respectively. Notably, specificity was 100% for the drugs mentioned above."
    },
    {
        "id": "doc_964",
        "document": "Detecting MDR-TB is a notable strength of LPAs. Given that MDR-TB poses a sub- stantial public health risk, timely identification is essential for effectively treating and preventing the spread of the disease [154]. Another advantage is the ability of LPAs to de- tect specific genetic mutations associated with drug resistance. This allows for personalized treatment plans, as different M. tuberculosis strains may respond differently to different drugs [146]."
    },
    {
        "id": "doc_965",
        "document": "However, drawbacks include the potential for false results, reliance on skilled person- nel, and higher costs compared to traditional methods. Despite challenges, line probe assays are crucial in managing MDR-TB due to their ability to identify drug resistance-associated genetic markers [146].\n\n4.2. Sequencing"
    },
    {
        "id": "doc_966",
        "document": "Several studies highlight the impact of sequencing on diagnosing infectious dis- eases [155\u2013157]. In 2018, WHO published one of the first guides concerning the use of whole genome sequencing (WGS) as a tool to study MTBC, particularly the mutations related to drug resistance. The document discussed the use of the sequencing platforms Illumina MiSeqTM (Illumina Inc., San Diego, CA, USA), Ion Personal Genome Machine\u00ae (Thermo Fisher Scientific, Inc., Waltham, MA, USA), Nanopore MinION\u00ae (Oxford"
    },
    {
        "id": "doc_967",
        "document": "Nanopore Tech- nologies, Oxford, UK), and the GeneReader system (Qiagen, Hilden, Germany) [158]. Similarly, in October 2023, WHO published a document to help laboratories implement next-generation sequencing (NGS), also known as high throughput sequencing (HTS), for TB bacteria characterization, focusing on drug resistance mutations to complement existing TB surveillance systems [159]. The study by Vogel et al. [160] demonstrated the technical and financial aspects of implementing WGS in a"
    },
    {
        "id": "doc_968",
        "document": "National Reference Laboratory in Kyrgyzstan. The authors highlighted that implementing WGS for TB diagnostics involves challenges such as higher sequencing costs, extended procurement and capacity building timelines, early consideration of infrastructure requirements, tailored solutions for quality assurance, careful planning for transitioning WGS to routine diagnostics, and the necessity of ongoing support by experienced experts for sustainable success. A review by Ness, DiNardo, and Farhat"
    },
    {
        "id": "doc_969",
        "document": "[161] presents sequencing platforms for NGS of M. tuberculosis, as well as applications of targeted HTS in the context of TB."
    },
    {
        "id": "doc_970",
        "document": "4.3. MALDI-TOF MS\n\nRegarding mass spectrometry, Matrix-Assisted Laser Desorption/Ionization Time- of-Flight Mass Spectrometry (MALDI-TOF MS) is revolutionizing clinical microbiology\n\nDiseases 2024, 12, 202\n\n9 of 24"
    },
    {
        "id": "doc_971",
        "document": "by rapidly and accurately identifying microorganisms in various samples, potentially im- proving patient outcomes, and reducing hospital stays [162]. Alcolea-Medina et al. [163] successfully established a fast and affordable method (MALDI-TOF) for identifying my- cobacteria species in hospitals. It achieved 85% accuracy compared to existing methods, making it an attractive tool for clinical use."
    },
    {
        "id": "doc_972",
        "document": "Some studies present the use of nucleotide MALDI-TOF-MS and MALDI-TOF-MS as promising rapid tools for detecting drug resistance in M. tuberculosis [164\u2013166], as well as the simultaneous detection of MTBC and mutations related to drug resistance [167\u2013169], although these techniques cannot identify de novo drug resistance mutations [164] nor detect mutations related to novel resistance mechanisms [166]."
    },
    {
        "id": "doc_973",
        "document": "MALDI-TOF MS is a rapid and cost-effective method for microbial identification. While molecular-based assays like PCR offer high specificity and sensitivity, they are generally more expensive and time-consuming. In laboratories equipped with MALDI-TOF MS, it is often the preferred method due to its ease of use and speed [163]."
    },
    {
        "id": "doc_974",
        "document": "Although a pure culture enhances the specificity and sensitivity of the technique, some studies have shown that MALDI-TOF MS can be performed on raw specimens such as sputum and bronchoalveolar lavage fluid [167,168,170].\n\n4.4. Biosensors"
    },
    {
        "id": "doc_975",
        "document": "Lastly, biosensors are versatile biomedical diagnostic tools using targeted molecules to detect analytes [171] that usually consist of a biological sensing element along with a physicochemical transducer and a processor [172]. Notably, in TB diagnosis, DNA electrochemical biosensors, usually targeting the IS6110, demonstrate exceptional sensi- tivity, holding potential for drug-resistance identification [173,174]. In addition to DNA, biosensors can target antigens such as CFP-10/ESAT-6, MPT64,"
    },
    {
        "id": "doc_976",
        "document": "and Ag85, as well as anti- bodies, and cytokines [172]. Furthermore, biosensors are categorized based on their sensing technologies. In addition to electrochemical biosensors, there are other types, such as surface plasmon resonance (SPR), optical, mechanical, and quartz crystal microbalance (QCM)-based biosensors [175]."
    },
    {
        "id": "doc_977",
        "document": "5. Immunological Approaches"
    },
    {
        "id": "doc_978",
        "document": "The interaction between M. tuberculosis and the host involves a complex interplay of immune responses, influencing infection outcomes [176]. In TB diagnosis, immunol- ogy relies on important tools to detect adaptive immune responses in humans, such as interferon-gamma release assays (IGRAs) and tuberculin skin tests (TST), which are recom- mended by WHO for detecting LTBI [177]. However, no gold-standard technique exists for diagnosing this form of infection, and neither TST nor IGRAs are"
    },
    {
        "id": "doc_979",
        "document": "entirely accurate in predicting disease risk. Positive results from these tests should be considered alongside other clinical factors [178]."
    },
    {
        "id": "doc_980",
        "document": "A comprehensive review by McIntyre et al. [179] highlighted that no serological tests have yet met WHO criteria for TB diagnosis, underscoring a gap in the understanding of the role of antibodies in TB immunity. Despite ongoing research, this incomplete knowledge complicates the development of effective vaccines, diagnostic tools, and treatments. Recent advances include the introduction of novel M. tuberculosis antigen-based skin tests (TBSTs) since 2022, which aim to enhance diagnostic accuracy"
    },
    {
        "id": "doc_981",
        "document": "alongside IGRAs and TSTs [180]. Additionally, a review by Melkie et al. [181] concluded that antibody tests remain insuffi- ciently reliable for routine TB diagnosis, underscoring the need for further research and development in this area."
    },
    {
        "id": "doc_982",
        "document": "5.1. Interferon-Gamma Release Assays (IGRAs)\n\nInterferon-gamma release assays (IGRAs) are blood-based tests that measure the production of interferon-gamma (IFN-\u03b3) in response to M. tuberculosis antigens [182]. WHO recommends both IGRAs and TST for detecting LTBI [182], but IGRAs offer several\n\nDiseases 2024, 12, 202\n\n10 of 24\n\nadvantages over TST, including a single-visit requirement and no influence by prior Bacille Calmette\u2013Gu\u00e9rin (BCG) vaccination [183]."
    },
    {
        "id": "doc_983",
        "document": "Despite their advantages, IGRAs are more expensive and require specialized laboratory equipment, which may not be readily available in low- and middle-income countries [183]. Furthermore, IGRAs yield indeterminate results in approximately 1 in 26 tests, particularly for immunocompromised individuals and young children [184]."
    },
    {
        "id": "doc_984",
        "document": "Currently, three WHO-recommended IGRAs include:\n\n\u2022 T-SPOT\u00ae.TB (T-Spot; Oxford Immunotec Ltd., Oxford, UK): uses the enzyme-linked immunospot (ELISPOT) method to count M. tuberculosis-sensitized T cells [185];"
    },
    {
        "id": "doc_985",
        "document": "\u2022 QuantiFERON\u00ae-TB Gold Plus (QFT-Plus; Qiagen, Hilden, Germany): a fourth-generation assay that measures the cell-mediated immune response to two specific M. tuberculosis antigens\u2014Early Secreted Antigenic Target 6 (ESAT-6) and Culture Filtrate Protein 10 (CFP-10)\u2014using an ELISA-based approach [186];"
    },
    {
        "id": "doc_986",
        "document": "\u2022 WANTAI TB-IGRA (Beijing Wantai Biological Pharmacy Enterprise Co Ltd., Beijing, China): an ELISA-based IGRA test similar to QFT-Plus, using a recombinant fusion protein of CFP-10 and ESAT-6 antigens [187].\n\nDespite not being usually recommended for the diagnosis of active TB [156], several studies have explored the potential of IGRAs for this purpose [188\u2013192]."
    },
    {
        "id": "doc_987",
        "document": "Three new IGRAs\u2014(1) Advansure TB IGRA (LG Chem, Seoul, Republic of Korea), (2) Lioferon TB/LTBI (LIONEX Diagnostics & Therapeutics GmbH, Braunschweig, Ger- many), and (3) Quantiferon-Diasorin (Stillwater, MN, USA)\u2014are under review for potential WHO policy recommendations [93].\n\n5.2. Tuberculin Skin Test (TST)"
    },
    {
        "id": "doc_988",
        "document": "Tuberculin skin testing (TST), also known as the Mantoux test, involves the intradermal injection of 0.1 mL of tuberculin-purified protein derivative (PPD) into the forearm, creating a 6 to 10 mm wheal [193]. This wheal typically disappears within 15 to 20 min as the liquid is absorbed. The test is evaluated by a healthcare worker 48 to 72 h later by measuring the diameter of the induration (the raised, hardened area) in millimeters, which results from a delayed hypersensitivity reaction. The"
    },
    {
        "id": "doc_989",
        "document": "measurement excludes any surrounding erythema (redness) [194]. A result is considered positive for individuals devoid of risk factors for TB if the induration measures \u226515 mm; however, in immunocompromised patients or those receiving immunosuppressive treatments, a cut-off of \u22655 mm is used [194]. BCG vaccination significantly impacts TST specificity [183]. Nevertheless, BCG history does not interfere with TST results in children over three years old. For those under three, for whom BCG may cause"
    },
    {
        "id": "doc_990",
        "document": "false positives, using IGRAs is recommended. In situations in which IGRAs are unavailable or inconclusive, ignoring the BCG vaccination history is advised [195]."
    },
    {
        "id": "doc_991",
        "document": "Despite limitations, TST remains a valuable tool for LTBI detection due to its cost- effectiveness and field applicability. However, it requires a cold chain for PPD storage and transportation, two healthcare visits, and specific training in intradermal injection, reading, and interpretation [183]. Although PPD requires a cold chain for storage and transportation [183], a study developed by Maes et al. [196] shows that tuberculin is not as heat labile as commonly believed. This finding is"
    },
    {
        "id": "doc_992",
        "document": "crucial since it suggests that tuberculin may be more resilient to temperature fluctuations than previously thought, emphasizing the importance of proper handling while offering reassurance regarding its viability even if cold chain is compromised. In general, TST continues to be clinically significant in both low and high TB-endemic regions until more advanced and widely available tests become accessible [197]."
    },
    {
        "id": "doc_993",
        "document": "5.3. Mycobacterium Tuberculosis Antigen-Based Skin Tests (TBSTs)\n\nEmerging as alternatives to traditional TST, TBSTs like Cy-Tb\u2122 (Serum Institute of India, Pune, India), Diaskintest\u00ae (Generium, Moscow, Russian Federation) and C-TST (Anhui Zhifei Longcom, Chongqing, China) offer improved specificity and sensitivity for TB diagnosis [180]. The tests involve intradermal injections with M. tuberculosis antigen-\n\nDiseases 2024, 12, 202\n\n11 of 24"
    },
    {
        "id": "doc_994",
        "document": "based reagents and assess induration 48\u201372 h later. Cy-Tb\u2122 employs a unique test dose (0.1 mL containing 0.05 \u00b5g each of recombinant dimer ESAT-6 (rdESAT-6) and recombinant CFP-10 (rCFP-10), boasting high accuracy (73.9% sensitivity, 99.3% specificity) [180,198]. Diaskintest\u00ae utilizes recombinant proteins (CFP-10 and ESAT-6), with hyperallergic reac- tions like blistering and necrosis considered rare [180], achieving approximate sensitivity and specificity of 91.18% and 99.15%, respectively"
    },
    {
        "id": "doc_995",
        "document": "[199]. Moreover, C-TST, formerly EC-Test, uses a similar antigen and assessment method [180], reaching 90.6% and 88.2% of sensitivity and specificity, respectively [193]. These TBSTs represent a promising advancement in TB diagnosis, offering improved accuracy and potentially reducing limitations associated with the traditional TST."
    },
    {
        "id": "doc_996",
        "document": "Regarding safety, a systematic review by Hamada et al. [200] found that these TBSTs showed safety profiles similar to TSTs, with mainly mild injection site reactions. This sug- gests their potential as alternatives, especially considering their accuracy near IGRA tests."
    },
    {
        "id": "doc_997",
        "document": "Despite their ease of administration and favorable safety profile, novel TBSTs have not yet surpassed the use of TST and IGRAs in clinical practice [200,201]. However, further data regarding TBSTs are needed, particularly for pregnant women [200]."
    },
    {
        "id": "doc_998",
        "document": "6. Ongoing Research\n\nRecent studies showcase promising advancements in TB diagnostics:\n\n1. Cepheid MTB-HR cartridge: This fingerstick blood test identifies a three-gene tran- scriptomic signature, achieving a sensitivity of 59.8% in distinguishing TB from non-TB cases. Combined with other methods, it identified 71.2% of confirmed TB cases [202]."
    },
    {
        "id": "doc_999",
        "document": "2. Immuno-affinity LC-MS (ILM) assay: This novel approach quantifies peptides from HIV-1 and M. tuberculosis proteins, achieving high sensitivity and specificity for both infections [203]. Additionally, it can differentiate treatment responders from non- responders, providing valuable insights for integrated TB and HIV management [203]."
    },
    {
        "id": "doc_1000",
        "document": "3. CAPTURE-XT technology: This \u201clab-on-a-chip\u201d platform uses dielectrophoresis to isolate M. tuberculosis from sputum, enabling efficient bacterial purification for sub- sequent molecular confirmation. It demonstrated high concordance with culture diagnosis, highlighting its potential as a robust sample preparation tool [204]."
    },
    {
        "id": "doc_1001",
        "document": "Electronic nose (EN): Ketchanji Mougang et al. [205] conducted a study in Douala, Cameroon, assessing an EN for diagnosing PTB in a clinical setting. The EN utilizes eleven quartz microbalance sensors modified with metalloporphyrins and corroles to detect volatile organic compounds (VOCs) present in exhaled breath samples collected using a specialized breath sampler. Breath samples were segregated into alveolar and non-alveolar fractions, with analysis focusing exclusively on the alveolar"
    },
    {
        "id": "doc_1002",
        "document": "portion to minimize external contaminants. The sensors detect changes in frequency resulting from interactions with VOCs, which exhibit unique patterns associated with TB. The EN demonstrated an accuracy of 88.0%, with a sensitivity of 90.8% and specificity of 85.7%, effectively distinguishing between PTB patients and healthy controls. Notably, the sensitivity of the EN was comparable to TB-LAMP and CXR, surpassing SSM."
    },
    {
        "id": "doc_1003",
        "document": "These studies offer hope for improved TB diagnosis, particularly in challenging set- tings. Further research and development are crucial to translate these technologies into practical applications, contributing to global efforts for TB elimination."
    },
    {
        "id": "doc_1004",
        "document": "Tests Undergoing WHO Policy Review\n\nVarious innovative diagnostic tools for TB have emerged, and several of these promis- ing technologies are currently undergoing rigorous evaluation by the WHO to assess their suitability for incorporation into global TB diagnostic guidelines [93]."
    },
    {
        "id": "doc_1005",
        "document": "Concerning the culture-based drug susceptibility testing, Sensititre\u2122 Mycobacterium tuberculosis MYCOTBI AST Plate (Thermo Fisher Scientific, Inc., Waltham, MA, USA) is a manual semiquantitative test whose results can be interpreted visually or with the aid of the ThermoScientific\u2122 Sensititre\u2122 Vizion\u2122 System [206]. The test is based on micro-\n\nDiseases 2024, 12, 202\n\n12 of 24"
    },
    {
        "id": "doc_1006",
        "document": "broth dilution, testing 12 drugs: the first-line antibiotics rifampicin, rifabutin, isoniazid, and ethambutol, as well as the second-line antibiotics ofloxacin, moxifloxacin, amikacin, kanamycin, streptomycin, para-aminosalicylic acid, ethionamide, and cycloserine. Mini- mum inhibitory concentration (MIC) results can be obtained from 7 to 21 days [206]."
    },
    {
        "id": "doc_1007",
        "document": "Fujifilm SILVAMP TB LAM test (FujiLAM; Fujifilm, Tokyo, Japan), like the Abbott LF- LAM, detects lipoarabinomannan in urine samples [207], with 70% and 93% of sensitivity and specificity to detect TB in adults, and 51% and 87% for children [208]. This new point-of-care test has been considered suitable to detect PTB as well as extrapulmonary forms of the disease in patients with HIV [209] and is easy to be performed by any healthcare worker [210]."
    },
    {
        "id": "doc_1008",
        "document": "The three IGRAs currently undergoing WHO policy review involve (1) StandardTM E TB-Feron ELISA (SD Biosensor, Gyeonggi-do, Republic of Korea), (2) STANDARDTM F TB-Feron FIA (SD Biosensor, Gyeonggi-do, Republic of Korea), and (3) VIDAS\u00ae TB- IGRA (bioM\u00e9rieux, France) [93]. The first is not influenced by previous BCG vaccination; results are available in approximately 100 min and present 98.03% and 98.55% sensitivity and specificity, respectively [211]. Concerning the efficacy of StandardTM E"
    },
    {
        "id": "doc_1009",
        "document": "TB-Feron ELISA compared to QFT-Plus, accordance of 92% between the tests has been reported by Yoo et al. [212] and 94% by Jung et al. [213]. STANDARDTM F TB-Feron FIA, in turn, quantifies the IFN-\u03b3 in the blood samples through a fluorescent immunoassay (FIA) technique, delivering results within 15 min [214]. In South America, Saint-Pierre et al. [215] reported a sensitivity of 88.59% and a specificity of 92.5% for this test. Lastly, VIDAS\u00ae TB-IGRA exhibits sensitivity and specificity of 97.5%"
    },
    {
        "id": "doc_1010",
        "document": "and 97.6%, respectively, with results available within 17 h (estimative for one patient) [216]. Petruccioli et al. [217] reported that the test is able to detect the IFN-\u03b3 response in CD4+/CD8+ T-cells for both TB and LTBI. Diagbouga et al. [218] also discussed that the test is promising for both active and latent TB."
    },
    {
        "id": "doc_1011",
        "document": "Low complexity automated NAATs undergoing WHO policy review include the all-in- one cartridges STANDARD\u2122 M10 MDR-TB (SD Biosensor, Gyeonggi-do, Republic of Ko- rea) and IRON-qPCR\u2122 RFIA Kit (Bioneer, Daejeon, Republic of Korea) [93]. STANDARD\u2122 M10 MDR-TB performs the simultaneous detection of M. tuberculosis and resistance to RIF and INH from sputum samples based on qPCR technology, with a turnaround time of 80 min [219]. IRON-qPCR\u2122 RFIA Kit is undergoing a clinical trial estimated to be"
    },
    {
        "id": "doc_1012",
        "document": "completed in 2024. The test detects M. tuberculosis and mutations related to RIF, INH, fluoroquinolones, and aminoglycosides resistance, which is relevant since there are no WHO-endorsed tests to detect resistance to first- and second-line drugs to treat TB [220]."
    },
    {
        "id": "doc_1013",
        "document": "Finally, the DeepChek\u00ae Assay 13-Plex KB Drug Susceptibility Testing (ABL SA, Luxem- bourg, Luxembourg) assesses TB drug resistance through NGS. The test detects resistance- associated mutations in specific M. tuberculosis-targeted genes by sequencing. The key steps involve DNA extraction, multiplex PCR, NGS, and data analysis [221]."
    },
    {
        "id": "doc_1014",
        "document": "7. Final Remarks\n\nIn order to summarize the methods discussed in this review, an overview of the advan- tages and drawbacks of these methods, as well as the main diagnostics approaches used to diagnose pulmonary tuberculosis, can be visualized in Table 2 and Figure 1, respectively."
    },
    {
        "id": "doc_1015",
        "document": "Finally, although the diagnosis of extrapulmonary TB is not the focus of this review, it is important to highlight the clinical relevance of the assessment of adenosine deaminase (ADA), which has been extensively used to diagnose these forms of tuberculosis [222\u2013224]. ADA, an enzyme found in some types of leukocytes and crucial for purine metabolism, is associated with intracellular infections [225]. Elevated pleural fluid ADA levels are a useful marker for diagnosing tuberculous pleurisy (TPE),"
    },
    {
        "id": "doc_1016",
        "document": "especially in high TB burden areas, though they can also be high in other conditions. Low ADA levels can help exclude TPE, prompting further investigation to identify the cause of pleural effusion [224]. ADA is vital for regulating immune, neurological, and vascular functions and aids in lymphocyte development. Elevated serum ADA can indicate various conditions that stimulate the im- mune system, including TB. However, ADA levels alone are not reliable for differentiating PTB from other lung"
    },
    {
        "id": "doc_1017",
        "document": "infections [226]."
    },
    {
        "id": "doc_1018",
        "document": "Diseases 2024, 12, 202\n\n13 of 24\n\nTable 2. Overall advantages and disadvantages of the tests currently used to diagnose tuberculosis addressed in this review."
    },
    {
        "id": "doc_1019",
        "document": "Technique Advantages Disadvantages References Sputum smear microscopy (SSM) Rapid, cost-effective, important primary diagnostic technique Low sensitivity, cannot differentiate between live and dead bacteria, cannot differentiate between Mtb and other mycobacteria [46,53\u201356,69\u201373] Chest radiography (CXR) Cost-effective, shortens the period required to diagnose PTB, high sensitivity, can be enhanced by Al Cannot differentiate between PTB and pulmonary infections caused by NTM [74\u201376,82\u201386]"
    },
    {
        "id": "doc_1020",
        "document": "Culture-based methods Gold standard, identifies the pathogen, differentiates between MTBC and NTM, improved sensitivity with liquid media Time-consuming, requires biosafety level 3 or 4 laboratories, high cost [3,69,94,107,108,114,115]"
    },
    {
        "id": "doc_1021",
        "document": "Nucleic acid amplification tests (NAATSs) Faster results compared to traditional methods, improved sensitivity, certain NAATs can detect antibiotic resistance, many NAATs are automated, lower LoD Most NAATs cannot differentiate between MTBC and NTM, high cost, complexity [69,118\u2013121,125,128,129]"
    },
    {
        "id": "doc_1022",
        "document": "Line-probe assays (LPAs) Rapid results, simultaneous detection of MTBC and drug resistance, high sensitivity and specificity, identify specific genetic mutations Potential for false results, reliance on skilled personnel, high cost [146\u2013153] Sequencing Comprehensive information, improved accuracy, enhanced surveillance, personalized treatment, detection of drug resistance High costs, technical challenges, time consuming, complex infrastructure requirements [155\u2013158,160]"
    },
    {
        "id": "doc_1023",
        "document": "MALDI-TOF MS Rapid and accurate identification, cost-effective, ease of use, potential for detecting drug resistance Lower specificity and sensitivity than PCR-based methods, requires a pure culture for optimal results [162\u2013169] Biosensors Versatility, high sensitivity, potential for drug resistance detection, point-of-care testing Limited commercial availability, potential for interference, need for further development [172,174]"
    },
    {
        "id": "doc_1024",
        "document": "Interferon-gamma release assays (IGRAs) Single visit, no BCG vaccination interference, high sensitivity for LTBI progression More expensive, requires specialized equipment, indeterminate results possible [182\u2013184] Tuberculin skin test (TST) Cost-effective, field-applicable Requires two visits, cold chain for PPD, BCG vaccination affects specificity [183]"
    },
    {
        "id": "doc_1025",
        "document": "Mycobacterium tuberculosis antigen-based skin tests Improved specificity and sensitivity compared to TST, potentially reduce TST limitations Limited safety data for pregnant women [182,193,199]"
    },
    {
        "id": "doc_1026",
        "document": "Mtb: Mycobacterium tuberculosis; PTB: pulmonary tuberculosis; AI: artificial intelligence; NTM: non-tuberculous mycobacteria; MTBC: Mycobacterium tuberculosis complex; LoD: limit of detection; PCR: polymerase chain reaction; BCG: Bacille Calmette\u2013Gu\u00e9rin; LTBI: latent tuberculosis infection; PPD: purified protein derivative.\n\nDiseases 2024, 12, 202\n\n14 of 24"
    },
    {
        "id": "doc_1027",
        "document": "2 - v Sputum smear microscopy \u00a3 / /' Chest radiography \u00a7\u2014 Sputum LS8 VoV L\\ { = Molecular techniques :\\ A (Nucleic-acid amplification tests, LPAs, I MALDI-TOF MS, Biosensors and Sequencing) / Immunological | E\u2014 Culture techniques (IGRAS, TST, TBSTSs)"
    },
    {
        "id": "doc_1028",
        "document": "Figure 1. This figure illustrates relevant diagnostic techniques employed for pulmonary tuberculosis diagnosis. Sputum is collected and examined under a microscope for acid-fast bacilli (AFB). Chest radiography assesses lung abnormalities such as infiltrates, cavities, or pleural effusions. Molecular techniques detect the genetic material of MTBC using methods like NAATs, LAMP, MALDI-TOF MS, biosensors, and sequencing. Immunological tests, such as IGRAs, TST, and TBSTs, measure the body\u2019s"
    },
    {
        "id": "doc_1029",
        "document": "immunity in response to mycobacterial proteins. Culture involves growing the mycobacteria in a laboratory for identification and further antimicrobial susceptibility testing. These techniques collectively aid in the diagnosis of pulmonary tuberculosis. Created with BioRender.com."
    },
    {
        "id": "doc_1030",
        "document": "8. Conclusions"
    },
    {
        "id": "doc_1031",
        "document": "Tuberculosis remains an important cause of death among infectious diseases, with granulomas as the hallmark of its pathophysiology. Since a wide range of the population is estimated to be infected with M. tuberculosis, exhibiting no symptoms, the infection can become active upon a series of factors, including the interaction between the pathogen and the host immune system. An important consequence of tuberculosis reactivation is the significant risk of transmitting M. tuberculosis to other"
    },
    {
        "id": "doc_1032",
        "document": "individuals, which can amplify the spread of the disease within the community."
    },
    {
        "id": "doc_1033",
        "document": "This review addresses the multiple approaches to diagnosing tuberculosis, focusing on pulmonary tuberculosis. Despite the availability of several molecular testing techniques, they are not accessible in various settings, especially in low- and middle-income coun- tries. Here, culture-based methods play a critical role. The culture of M. tuberculosis not only remains the gold standard for diagnosis but also allows for the characterization of the pathogen, including drug susceptibility profile."
    },
    {
        "id": "doc_1034",
        "document": "This is crucial for ensuring effective treatment regimens and controlling the spread of drug-resistant strains. In many resource- limited settings, culture-based methods offer a vital approach to diagnosis where advanced molecular tests may not be feasible."
    },
    {
        "id": "doc_1035",
        "document": "When feasible, the scenario of tuberculosis diagnosis can be improved with molecu- lar testing without neglecting culture-based methods and SSM, thus improving specific identification of the etiological agent and the drug susceptibility testing, along with the use of decentralized and multi-disease testing (especially M. tuberculosis/HIV coinfection). Importantly, the tests should be affordable and favor non-sputum samples, such as oral swabs and urine. These samples are preferable since sputum"
    },
    {
        "id": "doc_1036",
        "document": "samples are more difficult to obtain, making them a critical consideration for improving accessibility and convenience in testing [227]."
    },
    {
        "id": "doc_1037",
        "document": "Supplementary Materials: The following supporting information can be downloaded at: https://ww w.mdpi.com/article/10.3390/diseases12090202/s1, Table S1: Some examples of tests developed for the diagnosis of non-tuberculous mycobacteria (NTM).\n\nDiseases 2024, 12, 202\n\n15 of 24"
    },
    {
        "id": "doc_1038",
        "document": "Author Contributions: All authors listed have made a substantial intellectual contribution to the study. Conceptualization, writing\u2014original draft preparation, review and editing, G.B.-G., M.R.E.P. and S.F.Y.-O.; writing\u2014original draft preparation, J.M.d.S., B.T.F., L.F.A.S., G.F.C., I.M.d.C., P.H.G.B., G.S.-R. and M.P.; writing\u2014review and editing, E.R.T. and L.M.Y. All authors have read and agreed to the published version of the manuscript."
    },
    {
        "id": "doc_1039",
        "document": "Funding: This research was funded by Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES, Financial Code 01).\n\nAcknowledgments: G.B.-G., J.M.d.S., B.T.F., L.F.A.S., G.F.C., P.H.G.B. and G.S.-R. were funded by a graduate scholarship from CAPES. I.M.d.C. was funded by a graduate scholarship from Fun- da\u00e7\u00e3o Arauc\u00e1ria-PR. S.F.Y.-O. was funded by a research fellowship from Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq, 309260/2022-1)."
    },
    {
        "id": "doc_1040",
        "document": "Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results."
    },
    {
        "id": "doc_1041",
        "document": "References\n\n1\n\n2\n\nGagneux, S. Ecology and evolution of Mycobacterium tuberculosis. Nat. Rev. Microbiol. 2018, 16, 202\u2013213. [CrossRef] [PubMed] Pai, M.; Behr, M.A.; Dowdy, D.; Dheda, K.; Divangahi, M.; Boehme, C.C.; Ginsberg, A.; Swaminathan, S.; Spigelman, M.; Getahun, H.; et al. Tuberculosis. Nat. Rev. Dis. Primers 2016, 2, 16076. [CrossRef]"
    },
    {
        "id": "doc_1042",
        "document": "3. World Health Organization. Global Tuberculosis Report 2023. 2023. Available online: https://www.who.int/teams/global-tuber culosis-programme/tb-reports/global-tuberculosis-report-2023 (accessed on 23 June 2024)."
    },
    {
        "id": "doc_1043",
        "document": "Silva, S.; Arinaminpathy, N.; Atun, R.; Goosby, E.; Reid, M. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: A full-income analysis. Lancet Glob. Health 2021, 9, e1372\u2013e1379. [CrossRef] [PubMed]\n\nBhalla, A.S.; Goyal, A.; Guleria, R.; Gupta, A.K. Chest tuberculosis: Radiological review and imaging recommendations. Indian J. Radiol. Imaging 2015, 25, 213\u2013225. [CrossRef]"
    },
    {
        "id": "doc_1044",
        "document": "6. Natarajan, A.; Beena, P.M.; Devnikar, A.V.; Mali, S. A systemic review on tuberculosis. Indian J. Tuberc. 2020, 67, 295\u2013311. [CrossRef]"
    },
    {
        "id": "doc_1045",
        "document": "7. Sharma, S.K.; Mohan, A.; Kohli, M. Extrapulmonary tuberculosis. Expert Rev. Respir. Med. 2021, 15, 931\u2013948. [CrossRef] [PubMed] 8. Htet, K.K.K.; Chongsuvivatwong, V.; Aung, S.T. Sensitivity and specificity of tuberculosis signs and symptoms screening and adjunct role of social pathology characteristics in predicting bacteriologically confirmed tuberculosis in Myanmar. Trop. Med. Health 2021, 49, 3. [CrossRef]"
    },
    {
        "id": "doc_1046",
        "document": "9. Knechel, N.A. Tuberculosis: Pathophysiology, clinical features, and diagnosis. Crit. Care Nurse 2009, 29, 34\u201344. [CrossRef] 10. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. 2015. Available online: https://www.wh o.int/publications/i/item/9789241548908 (accessed on 23 June 2024).\n\n11. Kiazyk, S.; Ball, T.B. Latent tuberculosis infection: An overview. Can. Commun. Dis. Rep. 2017, 43, 62\u201366. [CrossRef]"
    },
    {
        "id": "doc_1047",
        "document": "12. Turner, R.D.; Bothamley, G.H. Cough and the transmission of tuberculosis. J. Infect. Dis. 2015, 211, 1367\u20131372. [CrossRef]\n\n13. Turner, R.D.; Chiu, C.; Churchyard, G.J.; Esmail, H.; Lewinsohn, D.M.; Gandhi, N.R.; Fennelly, K.P. Tuberculosis Infectiousness and Host Susceptibility. J. Infect. Dis. 2017, 216, S636\u2013S643. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1048",
        "document": "Imtiaz, S.; Shield, K.D.; Roerecke, M.; Samokhvalov, A.V.; L\u00f6nnroth, K.; Rehm, J. Alcohol consumption as a risk factor for tuberculosis: Meta-analyses and burden of disease. Eur. Respir. J. 2017, 50, 1700216. [CrossRef] [PubMed]\n\n14\n\n15. Adhikari, N.; Bhattarai, R.B.; Basnet, R.; Joshi, L.R.; Tinkari, B.S.; Thapa, A.; Joshi, B. Prevalence and associated risk factors for\n\ntuberculosis among people living with HIV in Nepal. PLoS ONE 2022, 17, e0262720. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1049",
        "document": "16. Gelaw, Y.; Getaneh, Z.; Melku, M. Anemia as a risk factor for tuberculosis: A systematic review and meta-analysis. Environ. Health Prev. Med. 2021, 26, 13. [CrossRef]\n\n17. Chen, Z.; Liu, Q.; Song, R.; Zhang, W.; Wang, T.; Lian, Z.; Sun, X.; Liu, Y. The association of glycemic level and prevalence of tuberculosis: A meta-analysis. BMC Endocr. Disord. 2021, 16, 123. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1050",
        "document": "18. Ehrlich, R.; Akugizibwe, P.; Siegfried, N.; Rees, D. The association between silica exposure, silicosis and tuberculosis: A systematic review and meta-analysis. BMC Public Health 2021, 21, 953. [CrossRef]\n\n19. Obore, N.; Kawuki, J.; Guan, J.; Papabathini, S.S.; Wang, L. Association between indoor air pollution, tobacco smoke and tuberculosis: An updated systematic review and meta-analysis. Public Health 2020, 187, 24\u201335. [CrossRef]"
    },
    {
        "id": "doc_1051",
        "document": "among the homeless: Should we change the strategy? Int. J. Tuberc. Lung Dis. 2017, 21, 327\u2013332. [CrossRef]\n\n21. Velen, K.; Charalambous, S. Tuberculosis in prisons: An unintended sentence? Lancet Public Health 2021, 6, e263\u2013e264. [CrossRef]\n\n22. Cronan, M.R. In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses. Front. Immunol. 2022, 13, 820134. [CrossRef]\n\nDiseases 2024, 12, 202\n\n16 of 24"
    },
    {
        "id": "doc_1052",
        "document": "23. Alsayed, S.S.; Gunosewoyo, H. Tuberculosis: Pathogenesis, current treatment regimens and new drug targets. Int. J. Mol. Sci. 2023, 24, 5202. [CrossRef] [PubMed]\n\n24. Qin, Y.; Chen, Y.; Chen, J.; Xu, K.; Xu, F.; Shi, J. The relationship between previous pulmonary tuberculosis and risk of lung cancer in the future. Infect. Agents Cancer 2022, 17, 20. [CrossRef]"
    },
    {
        "id": "doc_1053",
        "document": "25. Hwang, S.Y.; Kim, J.Y.; Lee, H.S.; Lee, S.; Kim, D.; Kim, S.; Hyun, J.H.; Shin, J.I.; Lee, K.H.; Han, S.H.; et al. Pulmonary Tuberculosis and Risk of Lung Cancer: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 765. [CrossRef] [PubMed] 26. Ho, L.J.; Yang, H.Y.; Chung, C.H.; Chang, W.C.; Yang, S.S.; Sun, C.A.; Chien, W.C.; Su, R.Y. Increased risk of secondary lung cancer\n\ncohort\n\nwith tuberculosis: A\n\nPLoS ONE"
    },
    {
        "id": "doc_1054",
        "document": "in\n\n\u20ac0250531.\n\n27. MacGregor-Fairlie, M.; Wilkinson, S.; Besra, G.S.; Goldberg Oppenheimer, P. Tuberculosis diagnostics: Overcoming ancient challenges with modern solutions. Emerg. Top. Life Sci. 2020, 4, 423\u2013436. [CrossRef]\n\n28. Ahmed, I.; Tiberi, S.; Farooqi, J.; Jabeen, K.; Yeboah-Manu, D.; Migliori, G.B.; Hasan, R. Non-tuberculous mycobacterial infections-A neglected and emerging problem. Int. J. Infect. Dis. 2020, 92, S46\u2013S50. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1055",
        "document": "29. Ying, C.; Zhang, L.; Jin, X.; Zhu, D.; Wu, W. Advances in diagnosis and treatment of non-tuberculous mycobacterial lung disease. Diagn. Microbiol. Infect. Dis. 2024, 109, 116254. [CrossRef]\n\n30. Chindam, A.; Vengaldas, S.; Srigiri, V.R.; Syed, U.; Kilaru, H.; Chenimilla, N.P.; Kilaru, S.C.; Patil, E. Challenges of diagnosing and treating non-tuberculous mycobacterial pulmonary disease [NTM-PD]: A case series. J. Clin. Tuberc. Other Mycobact. Dis. 2021, 25, 100271. [CrossRef]"
    },
    {
        "id": "doc_1056",
        "document": "31. Zhu, L.; Jiang, G.; Wang, S.; Wang, C.; Li, Q.; Yu, H.; Zhou, Y.; Zhao, B.; Huang, H.; Xing, W.; et al. Biochip system for rapid and\n\naccurate identification of mycobacterial species from isolates and sputum. J. Clin. Microbiol. 2010, 48, 3654\u20133660. [CrossRef] 32. Ramos, A.; Carvalho, T.; Ribeiro, M.; Guimar\u00e3es, J.T. Capilia\u2122 TB-Neo assay: A new tool for rapid distinction between tuberculous and non-tuberculous mycobacteria. Int. J. Tuberc. Lung. Dis. 2016, 20, 753\u2013756. [CrossRef]"
    },
    {
        "id": "doc_1057",
        "document": "Chae, H.; Han, S.J.; Kim, S.Y.; Ki, C.S.; Huh, H.J; Yong, D.; Koh, WJ].; Shin, S.J. Development of a One-Step Multiplex PCR Assay\n\n33\n\nfor Differential Detection of Major Mycobacterium Species. J. Clin. Microbiol. 2017, 55, 2736\u20132751. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1058",
        "document": "34. Shrivastava, K.; Garima, K.; Narang, A.; Bhattacharyya, K.; Vishnoi, E.; Singh, R.K.; Chaudhry, A.; Prasad, R.; Bose, M.; Varma- Basil, M. Rv1458c: A new diagnostic marker for identification of Mycobacterium tuberculosis complex in a novel duplex PCR assay. J. Med. Microbiol. 2017, 66, 371\u2013376. [CrossRef]\n\n35. Singh, S.; Sharma, M.; Modi, M.; Sharma, A.; Singh, R.; Ray, P.; Sharma, K. High-resolution melting curve analysis of heat shock"
    },
    {
        "id": "doc_1059",
        "document": "protein 65 for identification of mycobacterial isolates. Int. J. Tuberc. Lung. Dis. 2018, 22, 1511\u20131513. [CrossRef] [PubMed]\n\n36. Zhang, W.; Shu, Q.; Zhao, Z.; Fan, J.; Lyon, C.J.; Zelazny, A.M.; Hu, Y. Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. Clin. Proteom. 2018, 15, 1. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1060",
        "document": "37. Chuensirikulchai, K.; Laopajon, W.; Phunpae, P.; Apiratmateekul, N.; Surinkaew, S.; Tayapiwatana, C.; Pata, S.; Kasinrerk, W. Sandwich antibody-based biosensor system for identification of Mycobacterium tuberculosis complex and nontuberculous mycobacteria. J. Immunoass. Immunochem. 2019, 40, 590\u2013604. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1061",
        "document": "38. Wood, H.N.; Sidders, A.E.; Brumsey, L.E.; Morozkin, E.S.; Gerasimova, Y.V.; Rohde, K.H. Species Typing of Nontuberculous Mycobacteria by Use of Deoxyribozyme Sensors. Clin. Chem. 2019, 65, 333\u2013341. [CrossRef]"
    },
    {
        "id": "doc_1062",
        "document": "Shin, S.; Yoo, I.Y.; Shim, H.J.; Kang, O.K.; Jhun, B.W.; Koh, W.J.; Huh, H.J.; Lee, N.Y. Diagnostic Performance of the GENEDIA MTB/NTM Detection Kit for Detecting Mycobacterium tuberculosis and Nontuberculous Mycobacteria with Sputum Specimens. Ann. Lab. Med. 2020, 40, 169\u2013173. [CrossRef]"
    },
    {
        "id": "doc_1063",
        "document": "40. Xiao, G.; Zhang, S.; Liang, Z.; Li, G.; Fang, M.; Liu, Y.; Zhang, J.; Ou, M.; He, X.; Zhang, T.; et al. Identification of Mycobacterium abscessus species and subspecies using the Cas12a/sgRNA-based nucleic acid detection platform. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 551\u2013558. [CrossRef]"
    },
    {
        "id": "doc_1064",
        "document": "41. Li, B.; Zhu, C.; Sun, L.; Dong, H.; Sun, Y.; Cao, S.; Zhen, L.; Qi, Q.; Zhang, Q.; Mo, T.; et al. Performance evaluation and clinical validation of optimized nucleotide MALDI-TOF-MS for mycobacterial identification. Front. Cell. Infect. Microbiol. 2022, 12, 1079184. [CrossRef]"
    },
    {
        "id": "doc_1065",
        "document": "42. Fukushima, K.; Matsumoto, Y.; Matsuki, T.; Saito, H.; Motooka, D.; Komukai, S.; Fukui, E.; Yamuchi, J.; Nitta, T.; Niitsu, T.; et al. MGIT-seq for the Identification of Nontuberculous Mycobacteria and Drug Resistance: A Prospective Study. J. Clin. Microbiol. 2023, 61, e0162622. [CrossRef]"
    },
    {
        "id": "doc_1066",
        "document": "43. Uwamino, Y.; Aono, A.; Tomita, Y.; Morimoto, K.; Kawashima, M.; Kamata, H.; Sasaki, Y.; Nagai, H.; Hasegawa, N.; Mitarai, S. Diagnostic Utility of a Mycobacterium Multiplex PCR Detection Panel for Tuberculosis and Nontuberculous Mycobacterial Infections. Microbiol. Spectr. 2023, 11, e0516222. [CrossRef]"
    },
    {
        "id": "doc_1067",
        "document": "44. Wang, J.; Xu, H.; Wang, X.; Lan, J. Rapid diagnosis of non-tuberculous mycobacterial pulmonary diseases by metagenomic next-generation sequencing in non-referral hospitals. Front. Cell. Infect. Microbiol. 2023, 12, 1083497. [CrossRef]"
    },
    {
        "id": "doc_1068",
        "document": "45. Wu, T.; Shen, C.; Zhao, Z.; Lyu, M.; Bai, H.; Hu, X.; Zhao, J.; Zhang, R.; Qian, K.; Xu, G.; et al. Integrating Paper-Based Microfluidics and Lateral Flow Strip into Nucleic Acid Amplification Device toward Rapid, Low-Cost, and Visual Diagnosis of Multiple Mycobacteria. Small Methods 2024, 11, e2400095. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1069",
        "document": "46. Dong, B.; He, Z.; Li, Y.; Xu, X.; Wang, C.; Zeng, J. Improved Conventional and New Approaches in the Diagnosis of Tuberculosis. Front. Microbiol. 2022, 13, 924410. [CrossRef]\n\n47. Filardo, T.D.; Feng, P.J.; Pratt, R.H.; Price, S.F.; Self, J.L. Tuberculosis\u2014United States, 2021. MMWR Morb. Mortal. Wkly. 2022, 71, 441\u2013446. [CrossRef] [PubMed]\n\nDiseases 2024, 12, 202\n\n17 of 24"
    },
    {
        "id": "doc_1070",
        "document": "48. Santos, J.A.; Leite, A.; Soares, P.; Duarte, R.; Nunes, C. Delayed diagnosis of active pulmonary tuberculosis\u2014Potential risk factors for patient and healthcare delays in Portugal. BMC Public Health 2021, 21, 2178. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1071",
        "document": "49. Kraef, C.; Bentzon, A.; Panteleev, A.; Skrahina, A.; Bolokadze, N.; Tetradov, S.; Podlasin, R.; Karpov, I.; Borodulina, E.; Denisova, E.; et al. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: Associated factors and effect on mortality-a multicentre prospective cohort study. BMC Infect. Dis. 2021, 21, 1038. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1072",
        "document": "50. Ershova, J.V.; Volchenkov, G.V.; Somova, T.R.; Kuznetsova, T.A.; Kaunetis, N.V.; Kaminski, D.; Demikhova, O.V.; Chernousova, L.N.; Vasilyeva, I.A.; Kerr, E.M.; et al. Impact of GeneXpert MTB/RIF\u00ae on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia. BMC Infect. Dis. 2020, 20, 543. [CrossRef]"
    },
    {
        "id": "doc_1073",
        "document": "51. Raja, R.; Sreeramulu, P.N.; Dave, P.; Srinivasan, D. GeneXpert assay\u2013A cutting-edge tool for rapid tissue diagnosis of tuberculous lymphadenitis. J. Clin. Tuberc. Other Mycobact. Dis. 2020, 21, 100204. [CrossRef]\n\n52. World Health Organization. Implementing the End TB Strategy: The Essentials, 2022 Update. 2022. Available online: https://www.wh o.int/publications/i/item/9789240065093 (accessed on 23 June 2024)."
    },
    {
        "id": "doc_1074",
        "document": "53. World Health Organization. Global Tuberculosis Report 2022. 2022. Available online: https://www.who.int/teams/global-tuber culosis-programme/tb-reports/global-tuberculosis-report-2022 (accessed on 23 June 2024).\n\n54. Campelo, T.A.; Cardoso de Sousa, P.R.; Nogueira, L.L.; Frota, C.C.; Zuquim Antas, P.R. Revisiting the methods for detecting Mycobacterium tuberculosis: What has the new millennium brought thus far? Access Microbiol. 2021, 3, 000245. [CrossRef]"
    },
    {
        "id": "doc_1075",
        "document": "Seki, M.; Kim, C.K.; Hayakawa, S.; Mitarai, S. Recent advances in tuberculosis diagnostics in resource-limited settings. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 1405\u20131410. [CrossRef] [PubMed]\n\n55"
    },
    {
        "id": "doc_1076",
        "document": "Figueredo, L.J.A.; Miranda, S.S.; Santos, L.B.D.; Manso, C.G.G.; Soares, V.M.; Alves, S.; Vater, M.C.; Kritski, A.L.; Carvalho, W.D.S.; P\u00e1dua, C.M.; et al. Cost analysis of smear microscopy and the Xpert assay for tuberculosis diagnosis: Average turnaround time. Rev. Soc. Bras. Med. Trop. 2020, 53, e20200314. [CrossRef]\n\n56\n\n57. Vilch\u00e8ze, C.; Kremer, L. Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox. Microbiol. Spectr. 2017, 5. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1077",
        "document": "58. Steingart, K.R.; Henry, M.; Ng, V.; Hopewell, P.C.; Ramsay, A.; Cunningham, J.; Urbanczik, R.; Perkins, M.; Aziz, M.A.; Pai, M. Fluorescence versus conventional sputum smear microscopy for tuberculosis: A systematic review. Lancet Infect. Dis. 2006, 6, 570\u2013581. [CrossRef]\n\n59. Desikan, P. Sputum smear microscopy in tuberculosis: Is it still relevant? Indian J. Med. Res. 2013, 137, 442\u2013444."
    },
    {
        "id": "doc_1078",
        "document": "60. Chopra, S.; Mahajan, S.; Singh, Y.; Chopra, M. Comparative evaluation of Ziehl-Neelsen staining and Kinyoun\u2019s staining in the\n\ndiagnosis of clinically suspected cases of tuberculosis. IP Int. J. Med. Microbiol. Trop. Dis. 2022, 8, 149\u2013153. [CrossRef] 61. Zheng, R.; Xu, F.; Huang, X.; Wang, J.; Feng, Y.; Huang, J.; Qin, L. Evaluation of Aptamer Fluorescence Microscopy in the Diagnosis of Pulmonary Tuberculosis. Microbiol. Spectr. 2022, 10, e0260221. [CrossRef]"
    },
    {
        "id": "doc_1079",
        "document": "62. Whitelaw, A.; Peter, J.; Sohn, H.; Viljoen, D.; Theron, G.; Badri, M.; Davids, V.; Pai, M.; Dheda, K. Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients. Eur. Respir. J. 2011, 38, 1393\u20131397. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1080",
        "document": "63. Steingart, K.R.; Ng, V.; Henry, M.; Hopewell, P.C.; Ramsay, A.; Cunningham, J.; Urbanczik, R.; Perkins, M.D.; Aziz, M.A.; Pai, M. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: A systematic review. Lancet Infect. Dis. 2006, 6, 664\u2013674. [CrossRef]\n\n64. Fu, H.T.; Tu, H.Z.; Lee, H.S.; Lin, Y.E.; Lin, C.W. Evaluation of an AI-Based TB AFB Smear Screening System for Laboratory Diagnosis on Routine Practice. Sensors 2022, 22, 8497. [CrossRef]"
    },
    {
        "id": "doc_1081",
        "document": "65. Kotei, E.; Thirunavukarasu, R. Computational techniques for the automated detection of Mycobacterium tuberculosis from digitized sputum smear microscopic images: A systematic review. Prog. Biophys. Mol. Biol. 2022, 171, 4\u201316. [CrossRef] [PubMed] 66. Zingue, D.; Weber, P.; Soltani, F.; Raoult, D.; Drancourt, M. Automatic microscopic detection of mycobacteria in sputum: A\n\nproof-of-concept. Sci. Rep. 2018, 8, 11308. [CrossRef]"
    },
    {
        "id": "doc_1082",
        "document": "67. Panicker, R.O.; Kalmady, K.S.; Rajan, J.; Sabu, M.K. Automatic detection of tuberculosis bacilli from microscopic sputum smear images using deep learning methods. Biocybern. Biomed. Eng. 2018, 38, 691\u2013699. [CrossRef]\n\n68. Van Deun, A.; Tahseen, S.; Affolabi, D.; Hossain, M.A.; Joloba, M.L.; Angra, P.K.; Ridderhof, J.C.; de Jong, B.C.; Rieder, H.L. Sputum smear microscopy in the Xpert\u00ae MTB/RIF era. Int. J. Tuberc. Lung. Dis. 2019, 23, 12\u201318. [CrossRef]"
    },
    {
        "id": "doc_1083",
        "document": "69. World Health Organization. Operational Handbook on Tuberculosis. Module 3: Diagnosis\u2014Rapid Diagnostics for Tuberculosis Detention, 2021 Update. 2021. Available online: https://www.who.int/publications/i/item/9789240030589 (accessed on 23 June 2024).\n\n70. Das, P.K.; Ganguly, S.B.; Mandal, B. Sputum smear microscopy in tuberculosis: It is still relevant in the era of molecular diagnosis when seen from the public health perspective. Biomed. Biotechnol. Res. J. 2019, 3, 77\u201379. [CrossRef]"
    },
    {
        "id": "doc_1084",
        "document": "71. Sohn, H.; Kasaie, P.; Kendall, E.; Gomez, G.B.; Vassall, A.; Pai, M.; Dowdy, D. Informing decision-making for universal access to quality tuberculosis diagnosis in India: An economic-epidemiological model. BMC Med. 2019, 17, 155. [CrossRef] [PubMed] 72. Maheshwari, P.; Chauhan, K.; Kadam, R.; Pujani, A.; Kaur, M.; Chitalia, M.; Dabas, H.; Perkins, M.D.; Boehme, C.C.; Denkinger,"
    },
    {
        "id": "doc_1085",
        "document": "C.M.; et al. Market assessment of tuberculosis diagnostics in India in 2013. Int. J. Tuberc. Lung. Dis. 2016, 20, 304\u2013313. [CrossRef] 73. Kik, S.V.; Denkinger, C.M.; Chedore, P.; Pai, M. Replacing smear microscopy for the diagnosis of tuberculosis: What is the market potential? Eur. Respir. J. 2014, 43, 1793\u20131796. [CrossRef] [PubMed]\n\nDiseases 2024, 12, 202\n\n18 of 24"
    },
    {
        "id": "doc_1086",
        "document": "74. Nachiappan, A.C.; Rahbar, K.; Shi, X.; Guy, E.S.; Mortani Barbosa, E.J., Jr.; Shroff, G.S.; Ocazionez, D.; Schlesinger, A.E.; Katz, S.I.; Hammer, M.M. Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. Radiographics 2017, 37, 52\u201372. [CrossRef]"
    },
    {
        "id": "doc_1087",
        "document": "75. Pinto, L.M.; Pai, M.; Dheda, K.; Schwartzman, K.; Menzies, D.; Steingart, K.R. Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: A systematic review. Eur. Respir. J. 2013, 42, 480\u2013494. [CrossRef]"
    },
    {
        "id": "doc_1088",
        "document": "76. World Health Organization. Chest Radiography in Tuberculosis Detection: Summary of Current WHO Recommendations and Guidance on Programmatic Approaches. 2016. Available online: https://www.who.int/publications/i/item/9789241511506 (accessed on 23 June 2024)."
    },
    {
        "id": "doc_1089",
        "document": "77. Van\u2019t Hoog, A.; Viney, K.; Biermann, O.; Yang, B.; Leeflang, M.M.; Langendam, M.W. Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status. Cochrane Database Syst. Rev. 2022, 3, CD010890. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1090",
        "document": "78. Huang, C.C.; Tan, Q.; Becerra, M.C.; Calderon, R.; Chiang, S.S.; Contreras, C.; Lecca, L.; Jimenez, J.; Perez-Velez, C.M.; Roya-Pabon, C.L.; et al. The Contribution of Chest Radiography to the Clinical Management of Children Exposed to Tuberculosis. Am. J. Respir. Crit. Care Med. 2022, 206, 892\u2013900. [CrossRef]\n\n79. Nel, M.; Franckling-Smith, Z.; Pillay, T.; Andronikou, S.; Zar, H.J. Chest Imaging for Pulmonary TB-An Update. Pathogens 2022, 11, 161. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1091",
        "document": "80. Feyisa, D.W.; Ayano, Y.M.; Debelee, T.G.; Schwenker, F. Weak Localization of Radiographic Manifestations in Pulmonary Tuberculosis from Chest X-ray: A Systematic Review. Sensors 2023, 23, 6781. [CrossRef]\n\n81. Meghji, J.; Simpson, H.; Squire, S.B.; Mortimer, K. A Systematic Review of the Prevalence and Pattern of Imaging Defined Post-TB Lung Disease. PLoS ONE 2016, 11, e0161176. [CrossRef]"
    },
    {
        "id": "doc_1092",
        "document": "82. Park, M.; Lee, Y.; Kim, S.; Kim, Y.J.; Kim, S.Y.; Kim, Y.; Kim, H.M. Distinguishing nontuberculous mycobacterial lung disease and Mycobacterium tuberculosis lung disease on X-ray images using deep transfer learning. BMC Infect. Dis. 2023, 23, 32. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1093",
        "document": "83. Wang, L.; Ding, W.; Mo, Y.; Shi, D.; Zhang, S.; Zhong, L.; Wang, K.; Wang, J.; Huang, C.; Zhang, S.; et al. Distinguishing nontuberculous mycobacteria from Mycobacterium tuberculosis lung disease from CT images using a deep learning framework. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4293\u20134306. [CrossRef]"
    },
    {
        "id": "doc_1094",
        "document": "84. Mohammed, H.; Oljira, L.; Roba, K.T.; Ngadaya, E.; Tesfaye, D.; Manyazewal, T.; Yimer, G. Impact of early chest radiography on delay in pulmonary tuberculosis case notification in Ethiopia. Int. J. Mycobacteriol. 2021, 10, 364\u2013372. [CrossRef]\n\n85. Kulkarni, S.; Jha, S. Artificial intelligence, radiology, and tuberculosis: A review. Acad. Radiol. 2019, 27, 71\u201375. [CrossRef]"
    },
    {
        "id": "doc_1095",
        "document": "86. Harris, M.; Qi, A.; Jeagal, L.; Torabi, N.; Menzies, D.; Korobitsyn, A.; Pai, M.; Nathavitharana, R.R.; Ahmad Khan, F. A systematic review of the diagnostic accuracy of artificial intelligence-based computer programs to analyze chest x-rays for pulmonary tuberculosis. PLoS ONE 2019, 14, e0221339. [CrossRef]"
    },
    {
        "id": "doc_1096",
        "document": "87. World Health Organization. Rapid Communication on Systematic Screening for Tuberculosis. 2020. Available online: https://www.wh o.int/publications/i/item/9789240016552 (accessed on 23 June 2024).\n\n88. Nijiati, M.; Ma, J.; Hu, C.; Tuersun, A.; Abulizi, A.; Kelimu, A.; Zhang, D.; Li, G.; Zou, X. Artificial Intelligence Assisting the Early Detection of Active Pulmonary Tuberculosis from Chest X-Rays: A Population-Based Study. Front. Mol. Biosci. 2022, 9, 874475. [CrossRef]"
    },
    {
        "id": "doc_1097",
        "document": "89. Heo, S.J.; Kim, Y.; Yun, S.; Lim, S.S.; Kim, J.; Nam, C.M.; Park, E.C.; Jung, I.; Yoon, J.H. Deep Learning Algorithms with Demographic Information Help to Detect Tuberculosis in Chest Radiographs in Annual Workers\u2019 Health Examination Data. Int. J. Environ. Res. Public Health 2019, 16, 250. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1098",
        "document": "90. Rahman, T.; Khandakar, A.; Kadir, M.A.; Islam, K.R.; Islam, K.F.; Mazhar, R.; Hamid, T.; Islam, M.T.; Mahbub, Z.B.; Ayari, M.A.; et al. Reliable tuberculosis detection using chest X-ray with deep learning, segmentation and visualization. IEEE Access 2020, 8, 191586\u2013191601. [CrossRef]"
    },
    {
        "id": "doc_1099",
        "document": "91. Qin, Z.Z.; Barrett, R.; Ahmed, S.; Sarker, M.S.; Paul, K.; Adel, A.S.S.; Banu, S.; Creswell, J. Comparing different versions of computer-aided detection products when reading chest X-rays for tuberculosis. PLoS Digit. Health 2022, 1, e0000067. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1100",
        "document": "92. Geric, C.; Qin, Z.Z.; Denkinger, C.M.; Kik, S.V.; Marais, B.; Anjos, A.; David, P.M.; Ahmad Khan, F.; Trajman, A. The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination. Int. J. Tuberc. Lung Dis. 2023, 27, 367\u2013372. [CrossRef]"
    },
    {
        "id": "doc_1101",
        "document": "93. World Health Organization. Global Tuberculosis Report 2023. TB Research and Innovation. 2023. Available online: https://www. who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-research-and-innovation (ac- cessed on 26 December 2023).\n\n94. Xu, Y.; Wang, G.; Xu, M. Biohazard levels and biosafety protection for Mycobacterium tuberculosis strains with different virulence. Biosaf. Health 2020, 2, 135\u2013141. [CrossRef]"
    },
    {
        "id": "doc_1102",
        "document": "95. Drancourt, M.; Carrieri, P.; G\u00e9vaudan, M.J.; Raoult, D. Blood agar and Mycobacterium tuberculosis: The end of a dogma. J. Clin. Microbiol. 2003, 41, 1710\u20131711. [CrossRef]\n\n96. Stop TB Partnership. GLI Mycobacteriology Laboratory Manual. 2014. Available online: https://stoptb.org/wg/gli/assets/doc uments/gli_mycobacteriology_lab_manual_web.pdf (accessed on 21 August 2024).\n\n97. Kudoh, S.; Kudoh, T. A simple technique for culturing tubercle bacilli. Bull. World Health Organ. 1974, 51, 71\u201382."
    },
    {
        "id": "doc_1103",
        "document": "Diseases 2024, 12, 202\n\n19 of 24\n\n98. Franco-Sotomayor, G.; Rivera-Olivero, I.A.; Leon-Benitez, M.; Uruchima-Campoverde, S.E.; Cardenas-Franco, G.; Perdomo- Castro, M.E.; Cardenas-Franco, C.S.; Ortega-Vivanco, J.; Abad-Ruiz, A.S.; de Waard, J.H.; et al. Fast, Simple, and Cheap: The Kudoh-Ogawa Swab Method as an Alternative to the Petroff-Lowenstein-Jensen Method for Culturing of Mycobacterium tuberculosis. J. Clin. Microbiol. 2020, 58, e01424-19. [CrossRef]"
    },
    {
        "id": "doc_1104",
        "document": "99. Costa, R.R.D.; Silva, S.F.D.; Fochat, R.C.; Macedo, R.L.; Pereira, T.V.; Silva, M.R.; Pinto, C.P.G.; Leite, I.C.G. Comparison between Ogawa-Kudoh and modified Petroff techniques for mycobacteria cultivation in the diagnosis of pulmonary tuberculosis. Einstein (S\u00e3o Paulo) 2018, 16, eAO4214. [CrossRef]"
    },
    {
        "id": "doc_1105",
        "document": "100. Jaspe, R.C.; Rojas, Y.M.; Flores, L.A.; Sofia Toro, E.; Takiff, H.; de Waard, J.H. Evaluation of the Kudoh swab method for the culturing of Mycobacterium tuberculosis in rural areas. Trop. Med. Int. Health 2009, 14, 468\u2013471. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1106",
        "document": "101. Jobarteh, T.; Out, J.; Gitteh, E.; Mendy, F.S.; Faal-Jawara, T.I.; Ofori-Anyinam, B.; Sarr, B.; Riley, A.J.; Ayorinde, A.; de Jong, B.C.; et al. The use of Kudoh method for culture of Mycobacterium tuberculosis and Mycobacterium africanum in The Gambia. PLoS ONE 2024, 19, e0300042. [CrossRef]"
    },
    {
        "id": "doc_1107",
        "document": "102. Madeira, C.M.; Azam, K.I.; Sato, D.N.; Khosa, C.; Bhatt, N.; Viegas, S.O. Evaluation of the Ogawa-Kudoh method for tuberculosis isolation in two health units in Mozambique. Afr. J. Lab. Med. 2020, 9, 929. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1108",
        "document": "103. American Society for Microbiology. How TB Diagnostics Have Evolved Since the Second Century. 2021. Available online: https://asm.org/Articles/2021/March/How-TB-Diagnostics-Have-Evolved-Since-the-Second-C (accessed on 15 January 2024). 104. Banaei, N.; Kincaid, E.Z.; Lin, S.Y.; Desmond, E.; Jacobs, W.R., Jr.; Ernst, J.D. Lipoprotein processing is essential for resistance of Mycobacterium tuberculosis to malachite green. Antimicrob. Agents Chemother. 2009, 53, 3799\u20133802. [CrossRef]"
    },
    {
        "id": "doc_1109",
        "document": "105. Sigma Aldrich. Product M0178. Middlebrook 7H9 Broth Base. Available online: https://www.sigmaaldrich.com/BR/pt/p roduct/sial/m0178?utm_source=google&utm_medium=cpc&utm_campaign=19329107722&utm_content=141938264102&gcl id=CjwKCAiA-vOsBhAAEiwAIWR0TU6ck_CPWtIy4WGvax-giogdjnsUXVIiDWGXxJltDfyeCc_KXuKI8xoCFTAQAvD_BwE (accessed on 15 January 2024)."
    },
    {
        "id": "doc_1110",
        "document": "106. Franzblau, S.G.; DeGroote, M.A.; Cho, S.H.; Andries, K.; Nuermberger, E.; Orme, I.M.; Mdluli, K.; Angulo-Barturen, I.; Dick, T.; Dartois, V.; et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 2012, 92, 453\u2013488. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1111",
        "document": "107. Roquet-Ban\u00e8res, F.; Alcaraz, M.; Hamela, C.; Abendroth, J.; Edwards, T.E.; Kremer, L. In vitro and in vivo efficacy of NITD-916 against Mycobacterium fortuitum. Antimicrob. Agents Chemother. 2023, 67, e0160722. [CrossRef]\n\n108. Aguilera-Correa, J.J.; Boudehen, Y.M.; Kremer, L. Characterization of Mycobacterium abscessus colony-biofilms based on bi- dimensional images. Antimicrob. Agents Chemother. 2023, 67, e00402-23. [CrossRef]"
    },
    {
        "id": "doc_1112",
        "document": "109. Pedro, H.D.S.P.; Coelho, A.G.V.; Nardi, S.M.T.; Vilela, G.; Silva, J.O.; Nascimento, A.C.C.; Galle, L.C.; Aily, D.C.G.; Ferro e Silva, R.R.; Shikama, M.L.M.; et al. Performance of liquid culture MGIT after implementation in a network of public laboratories of Sao Paulo state. Rev. Inst. Adolfo Lutz 2017, 76, e1727."
    },
    {
        "id": "doc_1113",
        "document": "110. Palomino, J.C.; Martin, A.; Von Groll, A.; Portaels, F. Rapid culture-based methods for drug-resistance detection in Mycobacterium tuberculosis. J. Microbiol. Methods 2008, 75, 161\u2013166. [CrossRef]\n\n111. Ma, Y.; Fan, J.; Li, S.; Dong, L.; Li, Y.; Wang, F.; Huo, F.; Pang, Y.; Qin, S. Comparison of Lowenstein-Jensen medium and MGIT culture system for recovery of Mycobacterium tuberculosis from abscess samples. Diagn. Microbiol. Infect. Dis. 2020, 96, 114969. [CrossRef]"
    },
    {
        "id": "doc_1114",
        "document": "112. Kumari, P.; Thakur, J.K.; Kumar, P.; Kumar, R.; Parekh, D. Comparison of LJ Medium and BACTEC MGIT 960 Culture System for the Diagnosis of Tuberculosis. J. Clin. Diagn. Res. 2020, 14, DC09\u2013DC13. [CrossRef]"
    },
    {
        "id": "doc_1115",
        "document": "113. Kumar, H.; Singh, V.A.; Mehta, S.; Nagpal, S.; Bala, R.; Biswas, D. Comparative Evaluation of Conventional Media with Bactec MGIT 960 for Detection of Mycobacterium tuberculosis in Clinically Suspected Cases of Pulmonary and Extra-Pulmonary Tuberculosis. Indian J. Public Health 2020, 11, 818\u2013822. [CrossRef]"
    },
    {
        "id": "doc_1116",
        "document": "114. Salam, A.A.; Rehman, S.; Munir, M.K.; Iqbal, R.; Saeed, S.S.; Khan, S.U. Importance of Ziehl-Neelsen smear and culture on Lowenstein Jensen medium in diagnosis of pulmonary tuberculosis. Pak. J. Chest Med. 2014, 20, 1\u20135.\n\n115. Gopalaswamy, R.; Shanmugam, S.; Mondal, R.; Subbian, S. Of tuberculosis and non-tuberculous mycobacterial infections\u2014A comparative analysis of epidemiology, diagnosis and treatment. J. Biomed. Sci. 2020, 27, 74. [CrossRef]"
    },
    {
        "id": "doc_1117",
        "document": "116. MacLean, E.; Kohli, M.; Weber, S.F.; Suresh, A.; Schumacher, S.G.; Denkinger, C.M.; Pai, M. Advances in Molecular Diagnosis of Tuberculosis. J. Clin. Microbiol. 2020, 58, e01582-19. [CrossRef]\n\n117. Acharya, B.; Acharya, A.; Gautam, S.; Ghimire, S.P.; Mishra, G.; Parajuli, N.; Sapkota, B. Advances in diagnosis of Tuberculosis: An update into molecular diagnosis of Mycobacterium tuberculosis. Mol. Biol. Rep. 2020, 47, 4065\u20134075. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1118",
        "document": "118. World Health Organization. Manual for Selection of Molecular WHO-Recommended Rapid Diagnostic Tests for Detection of Tuberculosis and Drug-Resistant Tuberculosis. 2022. Available online: https://www.who.int/publications/i/item/978924004257 5 (accessed on 23 June 2024)."
    },
    {
        "id": "doc_1119",
        "document": "119. Nagai, K.; Horita, N.; Yamamoto, M.; Tsukahara, T.; Nagakura, H.; Tashiro, K.; Shibata, Y.; Watanabe, H.; Nakashima, K.; Ushio, R.; et al. Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: Systematic review and meta-analysis. Sci. Rep. 2016, 6, 39090. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1120",
        "document": "120. World Health Organization. The Use of Loop-Mediated Isothermal Amplification (TB-LAMP) for the Diagnosis of Pulmonary Tuberculosis: Policy Guidance. 2016. Available online: https://iris.who.int/bitstream/handle/10665/249154/9789241511186-e ng.pdf?sequence=1 (accessed on 23 June 2024).\n\nDiseases 2024, 12, 202\n\n20 of 24"
    },
    {
        "id": "doc_1121",
        "document": "121. Hain Lifescience. FluoroType\u00ae MTB. Available online: https://www.hain-lifescience.de/en/products/microbiology/mycobacte ria/tuberculosis/fluorotype-mtb.html (accessed on 2 December 2023)."
    },
    {
        "id": "doc_1122",
        "document": "122. World Health Organization. A2.4 Information Sheet: Practical Considerations for Implementation of the Bruker-Hain Lifesciences FluoroType MTB and FluoroType MTBDR. Available online: https://tbksp.org/en/node/1709 (accessed on 13 December 2023). 123. Hofmann-Thiel, S.; Hoffmann, H. Evaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country. BMC Infect. Dis. 2014, 14, 59. [CrossRef]"
    },
    {
        "id": "doc_1123",
        "document": "124. Dippenaar, A.; Derendinger, B.; Dolby, T.; Beylis, N.; van Helden, P.D.; Theron, G.; Warren, R.M.; de Vos, M. Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. Clin. Microbiol. Infect. 2021, 27, 1351.e1\u20131351.e4. [CrossRef]"
    },
    {
        "id": "doc_1124",
        "document": "125. Cepheid. Xpert MTB/RIF Assay: Package Insert (Rev. G). 2020. Available online: https://www.cepheid.com/content/dam/ww w-cepheid-com/documents/package-insert-files/Xpert-MTB-RIF-PORTUGUESE-Package-Insert-301-1404-PT-Rev-G.pdf (ac- cessed on 9 December 2023)."
    },
    {
        "id": "doc_1125",
        "document": "126. Li, S.; Liu, B.; Peng, M.; Chen, M.; Yin, W.; Tang, H.; Luo, Y.; Hu, P.; Ren, H. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. PLoS ONE 2017, 12, e0180725. [CrossRef]"
    },
    {
        "id": "doc_1126",
        "document": "127. Kaswala, C.; Schmiedel, Y.; Kundu, D.; George, M.M.; Dayanand, D.; Devasagayam, E.; Manesh, S.A.M.; Kumar, S.S.; Michael, J.S.; Ninan, M.M.; et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of tuberculosis in adult patients: A retrospective cohort study. Int. J. Infect. Dis. 2022, 122, 566\u2013568. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1127",
        "document": "128. Molbio Diagnostics. Truenat\u2122 MTB Package Insert [PDF Document]. Available online: https://www.molbiodiagnostics.com/up loads/product_download/20231107.150156~MTB-pack-insert-V-08.pdf (accessed on 23 June 2024).\n\n129. Molbio Diagnostic. Truenat\u2122 MTB Plus Package Insert [PDF Document]. Available online: https://www.molbiodiagnostics.co"
    },
    {
        "id": "doc_1128",
        "document": "130. Abbott. RealTime MTB Assay. Molecular Diagnostics. Available online: https://www.molecular.abbott/int/en/products/infecti ous-disease/realtime-mtb (accessed on 14 December 2023)."
    },
    {
        "id": "doc_1129",
        "document": "131. Chen, J.H.; She, K.K.; Kwong, T.C.; Wong, O.Y.; Siu, G.K.; Leung, C.C.; Chang, K.C.; Tam, C.M.; Ho, P.L.; Cheng, V.C.; et al. Performance of the new automated Abbott RealTime MTB assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimens. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 1827\u20131832. [CrossRef]"
    },
    {
        "id": "doc_1130",
        "document": "132. Abbott. RealTime MTB RIF/INH. Molecular Diagnostics. Available online: https://www.molecular.abbott/int/en/products/inf ectious-disease/realtime-mtb-rif-inh-resistance (accessed on 23 December 2023).\n\n133. BD MAX\u2122 MDR-TB Assay Package Insert; BD Life Sciences: Sparks, MD, USA, 2019. Available online: https://static.bd.com/do cuments/eifu/P0228_ZMG_H_SD_P0228.pdf (accessed on 14 December 2023)."
    },
    {
        "id": "doc_1131",
        "document": "134. Hain Lifescience. FluoroType\u00ae MTBDR VER 2.0\u2014Your Test System for True MDR-TB Testing. Available online: https://www.ha\n\n/"
    },
    {
        "id": "doc_1132",
        "document": "14 December\n\n135. Cobas\u00ae MTB. Roche Diagnostics. Available online: https://diagnostics.roche.com/global/en/products/params/cobas-mtb.html (accessed on 14 December 2023).\n\n136. World Health Organization. Information Sheet: Practical Consideration for Implementation of the Roche Cobas MTB and Cobas MTB-RIF/INH Assays. 2021. Available online: https://www.stoptb.org/file/10477/download (accessed on 23 December 2023)."
    },
    {
        "id": "doc_1133",
        "document": "137. Cobas\u00ae MTB-RIF/INH. Roche Diagnostics. Available online: https://diagnostics.roche.com/global/en/products/params/coba s-mtb-rif-inh.html (accessed on 23 December 2023).\n\n138. Notomi, T.; Okayama, H.; Masubuchi, H.; Yonekawa, T.; Watanabe, K.; Amino, N.; Hase, T. Loop-mediated isothermal amplifica- tion of DNA. Nucleic Acids Res. 2000, 28, E63. [CrossRef]"
    },
    {
        "id": "doc_1134",
        "document": "139. Tomita, N.; Mori, Y.; Kanda, H.; Notomi, T. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products. Nat. Protoc. 2008, 3, 877\u2013882. [CrossRef]\n\n140. Mori, Y.; Nagamine, K.; Tomita, N.; Notomi, T. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem. Biophys. Res. Commun. 2001, 289, 150\u2013154. [CrossRef]"
    },
    {
        "id": "doc_1135",
        "document": "141. World Health Organization. WHO Operational Handbook on Tuberculosis: Module 3: Diagnosis: Rapid Diagnostics for Tuberculosis Detection, 3rd ed.; WHO: Geneva, Switzerland, 2024. Available online: https://iris.who.int/bitstream/handle/10665/376155/978 9240089501-eng.pdf?sequence=1 (accessed on 23 June 2024)."
    },
    {
        "id": "doc_1136",
        "document": "142. Hain Lifescience. FluoroType\u00ae Mycobacteria VER 1.0\u2014Differentiate Nontuberculous Mycobacteria. Available online: https://www. hain-lifescience.de/en/products/microbiology/mycobacteria/ntm/fluorotype-mycobacteria.html (accessed on 20 August 2024)."
    },
    {
        "id": "doc_1137",
        "document": "143. Khairullah, A.R.; Moses, I.B.; Kusala, M.K.J.; Tyasningsih, W.; Ayuti, S.R.; Rantam, F.A.; Fauziah, I.; Silaen, O.S.M.; Puspitasari, Y.; Aryaloka, S.; et al. Unveiling insights into bovine tuberculosis: A comprehensive review. Open. Vet. J. 2024, 14, 1330\u20131344. [CrossRef]"
    },
    {
        "id": "doc_1138",
        "document": "144. Kasir, D.; Osman, N.; Awik, A.; El Ratel, I.; Rafei, R.; Al Kassaa, I.; El Safadi, D.; Salma, R.; El Omari, K.; Cummings, K.J.; et al. Zoonotic Tuberculosis: A Neglected Disease in the Middle East and North Africa (MENA) Region. Diseases 2023, 11, 39. [CrossRef]"
    },
    {
        "id": "doc_1139",
        "document": "145. de Macedo Couto, R.; Santana, G.O.; Ranzani, O.T.; Waldman, E.A. One Health and surveillance of zoonotic tuberculosis in selected low-income, middle-income and high-income countries: A systematic review. PLoS Negl. Trop. Dis. 2022, 16, e0010428. [CrossRef] [PubMed]\n\nDiseases 2024, 12, 202\n\n21 of 24"
    },
    {
        "id": "doc_1140",
        "document": "146. World Health Organization. Line Probe Assays for Detection of Drug-Resistant Tuberculosis: Interpretation and Reporting Manual for Laboratory Staff and Clinicians. 2022. Available online: https://www.who.int/publications/i/item/9789240046665 (accessed on 23 June 2024).\n\n147. Hain Lifescience. GenoType MTBDRplus. Available online: https://www.hain-lifescience.de/en/products/microbiology/myc obacteria/tuberculosis/genotype-mtbdrplus.html (accessed on 3 January 2024)."
    },
    {
        "id": "doc_1141",
        "document": "148. Moga, S.; Bobosha, K.; Fikadu, D.; Zerihun, B.; Diriba, G.; Amare, M.; Kempker, R.R.; Blumberg, H.M.; Abebe, T. Diagnostic performance of the GenoType MTBDRplus VER 2.0 line probe assay for the detection of isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS ONE 2023, 18, e0284737. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1142",
        "document": "149. Stephen, S.; Muzhizhizhi, D.; Dhibi, N.; Chidemo, T.; Samaneka, W.; Matubu, T.A.; Hakim, J.G.; Chirenje, Z.M. Validation of the GenoType\u00ae MTBDRplus Ver 2.0 assay for detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates at UZCHS-CTRC TB research laboratory. Int. J. Mycobacteriol. 2019, 8, 83\u201388. [CrossRef]"
    },
    {
        "id": "doc_1143",
        "document": "150. Tan, Y.; Li, Q.; Wang, Q.; Sun, H.; Chen, J.; Cai, X.; Yao, Y.; Bao, X.; Wang, C.; Liu, Y.; et al. Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China. Sci. Rep. 2017, 7, 3364. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1144",
        "document": "151. Meaza, A.; Kebede, A.; Yaregal, Z.; Dagne, Z.; Moga, S.; Yenew, B.; Diriba, G.; Molalign, H.; Tadesse, M.; Adisse, D.; et al. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect. Dis. 2017, 17, 280. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1145",
        "document": "152. Hain Lifescience. GenoType MTBDRsl. Available online: https://www.hain-lifescience.de/en/products/microbiology/mycobac teria/tuberculosis/genotype-mtbdrsl.html (accessed on 3 January 2024)."
    },
    {
        "id": "doc_1146",
        "document": "153. Bouzouita, I.; Draoui, H.; Cabibbe, A.M.; Essalah, L.; Bejaoui, S.; Trovato, A.; Messadi, F.; Cirillo, D.M.; Slim-Saidi, L. Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia. Res. Microbiol. 2021, 172, 103816. [CrossRef]"
    },
    {
        "id": "doc_1147",
        "document": "154. Nathavitharana, R.R.; Cudahy, P.G.; Schumacher, S.G.; Steingart, K.R.; Pai, M.; Denkinger, C.M. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Eur. Respir. J. 2017, 49, 1601075. [CrossRef]\n\n155. Miller, S.; Chiu, C. The Role of Metagenomics and Next-Generation Sequencing in Infectious Disease Diagnosis. Clin. Chem. 2021, 68, 115\u2013124. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1148",
        "document": "156. Di Resta, C.; Galbiati, S.; Carrera, P.; Ferrari, M. Next-generation sequencing approach for the diagnosis of human diseases: Open challenges and new opportunities. EJIFCC 2018, 29, 4\u201314.\n\n157. Lecuit, M.; Eloit, M. The diagnosis of infectious diseases by whole genome next generation sequencing: A new era is opening. Front. Cell. Infect. Microbiol. 2014, 4, 25. [CrossRef]"
    },
    {
        "id": "doc_1149",
        "document": "158. World Health Organization. The Use of Next-Generation Sequencing Technologies for the Detection of Mutations Associated with Drug Resistance in Mycobacterium tuberculosis Complex: Technical Guide. 2018. Available online: https://apps.who.int/i ris/handle/10665/274443 (accessed on 23 December 2023)."
    },
    {
        "id": "doc_1150",
        "document": "159. World Health Organization. The Use of Next-Generation Sequencing for the Surveillance of Drug-Resistant Tuberculosis: An Implementation Manual. 2023. Available online: https://www.who.int/publications/i/item/9789240078079 (accessed on 23 December 2023)."
    },
    {
        "id": "doc_1151",
        "document": "160. Vogel, M.; Utpatel, C.; Corbett, C.; Kohl, T.A.; Iskakova, A.; Ahmedov, S.; Antonenka, U.; Dreyer, V.; Ibrahimova, A.; Kamarli, C.; et al. Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country. Sci. Rep. 2021, 11, 15333. [CrossRef]\n\n161. Ness, T.E.; DiNardo, A.; Farhat, M.R. High Throughput Sequencing for Clinical Tuberculosis: An Overview. Pathogens 2022, 11, 1343. [CrossRef]"
    },
    {
        "id": "doc_1152",
        "document": "162. Tsuchida, S.; Umemura, H.; Nakayama, T. Current Status of Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology. Molecules 2020, 25, 4775. [CrossRef]"
    },
    {
        "id": "doc_1153",
        "document": "163. Alcolea-Medina, A.; Fernandez, M.T.C.; Montiel, N.; Garc\u00eda, M.P.L.; Sevilla, C.D.; North, N.; Lirola, M.J.M.; Wilks, M. An improved simple method for the identification of Mycobacteria by MALDI-TOF MS (Matrix-Assisted Laser Desorption- Ionization mass spectrometry). Sci. Rep. 2019, 9, 20216. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1154",
        "document": "164. Ou, X.; Song, Z.; Zhao, B.; Pei, S.; Teng, C.; Zheng, H.; He, W.; Xing, R.; Wang, Y.; Wang, S.; et al. Diagnostic efficacy of an optimized nucleotide MALDI-TOF-MS assay for anti-tuberculosis drug resistance detection. Eur. J. Clin. Microbiol. Infect. Dis. 2024, 43, 105\u2013114. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1155",
        "document": "165. Wu, X.; Tan, G.; Yang, J.; Guo, Y.; Huang, C.; Sha, W.; Yu, F. Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS. Int. J. Infect. Dis. 2022, 121, 47\u201354. [CrossRef]"
    },
    {
        "id": "doc_1156",
        "document": "166. Shi, J.; He, G.; Ning, H.; Wu, L.; Wu, Z.; Ye, X.; Qiu, C.; Jiang, X. Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Tuberculosis 2022, 135, 102209. [CrossRef]"
    },
    {
        "id": "doc_1157",
        "document": "167. Wang, Y.; Xu, Q.; Xu, B.; Lin, Y.; Yang, X.; Tong, J.; Huang, C. Clinical performance of nucleotide MALDI-TOF-MS in the rapid diagnosis of pulmonary tuberculosis and drug resistance. Tuberculosis 2023, 143, 102411. [CrossRef]\n\nDiseases 2024, 12, 202\n\n22 of 24"
    },
    {
        "id": "doc_1158",
        "document": "168. Su, K.Y.; Yan, B.S.; Chiu, H.C.; Yu, C.J.; Chang, S.Y.; Jou, R.; Liu, J.L.; Hsueh, P.R.; Yu, S.L. Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS. Sci. Rep. 2017, 7, 41486. [CrossRef]"
    },
    {
        "id": "doc_1159",
        "document": "169. Ceyssens, P.J.; Soetaert, K.; Timke, M.; Van den Bossche, A.; Sparbier, K.; De Cremer, K.; Kostrzewa, M.; Hendrickx, M.; Mathys, V. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria. J. Clin. Microbiol. 2017, 55, 624\u2013634. [CrossRef]"
    },
    {
        "id": "doc_1160",
        "document": "170. Jiang, L.; Xin, J.; Liang, L.; Xia, M.; Li, J.; Tong, J.; Huang, C.; Li, T. Enhanced diagnosis of pulmonary tuberculosis through nucleotide MALDI-TOF MS analysis of BALF: A retrospective clinical study. Sci. Rep. 2024, 14, 18416. [CrossRef] [PubMed]\n\n171. Bhalla, N.; Jolly, P.; Formisano, N.; Estrela, P. Introduction to biosensors. Essays Biochem. 2016, 60, 1\u20138. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1161",
        "document": "172. Yang, X.; Fan, S.; Ma, Y.; Chen, H.; Xu, J.F.; Pi, J.; Wang, W.; Chen, G. Current progress of functional nanobiosensors for potential tuberculosis diagnosis: The novel way for TB control? Front. Bioeng. Biotechnol. 2022, 10, 1036678. [CrossRef]"
    },
    {
        "id": "doc_1162",
        "document": "173. Rizi, K.S.; Hatamluyi, B.; Rezayi, M.; Meshkat, Z.; Sankian, M.; Ghazvini, K.; Farsiani, H.; Aryan, E. Response surface methodology optimized electrochemical DNA biosensor based on HAPNPTs/PPY/MWCNTs nanocomposite for detecting Mycobacterium tuberculosis. Talanta 2021, 226, 122099. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1163",
        "document": "174. Golichenari, B.; Nosrati, R.; Farokhi-Fard, A.; Faal Maleki, M.; Gheibi Hayat, S.M.; Ghazvini, K.; Vaziri, F.; Behravan, J. Electrochemical-based biosensors for detection of Mycobacterium tuberculosis and tuberculosis biomarkers. Crit. Rev. Biotechnol. 2019, 39, 1056\u20131077. [CrossRef]"
    },
    {
        "id": "doc_1164",
        "document": "175. Mobed, A.; Darvishi, M.; Kohansal, F.; Dehfooli, F.M.; Alipourfard, I.; Tahavvori, A.; Ghazi, F. Biosensors; nanomaterial-based methods in diagnosing of Mycobacterium tuberculosis. J. Clin. Tuberc. Other Mycobact. Dis. 2023, 34, 100412. [CrossRef]\n\n176. de Martino, M.; Lodi, L.; Galli, L.; Chiappini, E. Immune Response to Mycobacterium tuberculosis: A Narrative Review. Front. Pediatr. 2019, 7, 350. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1165",
        "document": "177. Scriba, T.J.; Coussens, A.K.; Fletcher, H.A. Human Immunology of Tuberculosis. Microbiol. Spectr. 2017, 5, TBTB2-0016. [CrossRef] [PubMed]\n\n178. Trajman, A.; Steffen, R.E.; Menzies, D. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. Pulm. Med. 2013, 2013, 601737. [CrossRef]"
    },
    {
        "id": "doc_1166",
        "document": "179. McIntyre, S.; Warner, J.; Rush, C.; Vanderven, H.A. Antibodies as clinical tools for tuberculosis. Front. Immunol. 2023, 14, 1278947. [CrossRef]\n\n180. World Health Organization. WHO Operational Handbook on Tuberculosis. Module 3: Diagnosis. Tests for Tuberculosis Infection. 2022. Available online: https://www.who.int/publications/i/item/9789240058347 (accessed on 23 January 2024)."
    },
    {
        "id": "doc_1167",
        "document": "181. Melkie, S.T.; Arias, L.; Farroni, C.; Jankovic Makek, M.; Goletti, D.; Vilaplana, C. The role of antibodies in tuberculosis diagnosis,\n\nprophylaxis and therapy: A review from the ESGMYC study group. Eur. Respir. Rev. 2022, 31, 210218. [CrossRef]\n\n182. World Health Organization. Use of Alternative Interferon-Gamma Release Assays for the Diagnosis of TB Infection: WHO Policy Statement. 2022. Available online: https://www.who.int/publications/i/item/9789240042346 (accessed on 25 January 2024)."
    },
    {
        "id": "doc_1168",
        "document": "183. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 1: Prevention\u2014Tuberculosis Preventive\n\nTreatment. 2020. Available online: https://www.who.int/publications/i/item/9789240001503 (accessed on 26 January 2024)."
    },
    {
        "id": "doc_1169",
        "document": "184. Zhou, G.; Luo, Q.; Luo, S.; Chen, H.; Cai, S.; Guo, X.; He, J.; Xia, Y.; Li, H.; Zhou, Y.; et al. Indeterminate results of interferon gamma release assays in the screening of latent tuberculosis infection: A systematic review and meta-analysis. Front. Immunol. 2023, 14, 1170579. [CrossRef]\n\n185. Oxford Immunotec. T-SPOT.TB [Package Insert]. Available online: https://www.oxfordimmunotec.com/international/wp-conte nt/uploads/sites/3/Final-File-PI-TB-US-V6.pdf (accessed on 16 November 2023)."
    },
    {
        "id": "doc_1170",
        "document": "186. Qiagen. QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert 01/2023. 2023. Available online: https://www.qiagen.com/us/ resources/download.aspx?id=ac068fc7-a994-4443-ac7c-dda43ce2bc5e&lang=en (accessed on 16 November 2023). 187. WANTAI TB-IGRA Package Insert; Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.: Beijing, China, 2022. Available online:\n\nhttps://www.ystwt.cn/wp-content/uploads/2018/04/Wantai-TB-IGRA.pdf (accessed on 16 November 2023)."
    },
    {
        "id": "doc_1171",
        "document": "188. Sun, Y.; Yao, X.; Ni, Y.; Peng, Y.; Shi, G. Diagnostic Efficacy of T-SPOT.TB for Active Tuberculosis in Adult: A Retrospective Study. Infect. Drug Resist. 2022, 15, 7077\u20137093. [CrossRef]"
    },
    {
        "id": "doc_1172",
        "document": "189. Luo, Y.; Tang, G.; Yuan, X.; Lin, Q.; Mao, L.; Song, H.; Xue, Y.; Wu, S.; Ouyang, R.; Hou, H.; et al. Combination of Blood Routine Examination and T-SPOT.TB Assay for Distinguishing Between Active Tuberculosis and Latent Tuberculosis Infection. Front. Cell Infect. Microbiol. 2021, 1, 575650. [CrossRef]"
    },
    {
        "id": "doc_1173",
        "document": "190. Nguyen, D.T.; Phan, H.; Trinh, T.; Nguyen, H.; Doan, H.; Pham, N.; Nguyen, H.; Nguyen, H.; Nguyen, H.V.; Le, H.V.; et al. Sensitivity and characteristics associated with positive QuantiFERON-TB Gold-Plus assay in children with confirmed tuberculosis. PLoS ONE 2019, 14, e0213304. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1174",
        "document": "191. Takasaki, J.; Manabe, T.; Morino, E.; Muto, Y.; Hashimoto, M.; Iikura, M.; Izumi, S.; Sugiyama, H.; Kudo, K. Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. J. Infect. Chemother. 2018, 24, 188\u2013192. [CrossRef]"
    },
    {
        "id": "doc_1175",
        "document": "192. Zhang, L.; Shi, X.; Zhang, Y.; Zhang, Y.; Huo, F.; Zhou, B.; Deng, G.; Liu, X. Analysis of Factors Influencing Diagnostic Accuracy of T-SPOT.TB for Active Tuberculosis in Clinical Practice. Sci. Rep. 2017, 7, 7764. [CrossRef] [PubMed]\n\n193. Hamada, Y.; Cirillo, D.M.; Matteelli, A.; Penn-Nicholson, A.; Rangaka, M.X.; Ruhwald, M. Tests for tuberculosis infection: Landscape analysis. Eur. Respir. J. 2021, 58, 2100167. [CrossRef]\n\nDiseases 2024, 12, 202\n\n23 of 24"
    },
    {
        "id": "doc_1176",
        "document": "194. Centers for Disease Control and Prevention. Tuberculin Skin Testing. CDC. 2020. Available online: https://www.cdc.gov/tb/publica tions/factsheets/testing/Tuberculin_Skin_Testing_Information_for_Health_Care_Providers.pdf (accessed on 16 November 2023).\n\n195 Pifieiro, R.; Mellado, M.J.; Cilleruelo, M.J.; Garcia-Ascaso, M.; Medina-Claros, A.; Garcia-Hortelano, M. Tuberculin skin test in"
    },
    {
        "id": "doc_1177",
        "document": "bacille Calmette-Gu\u00e9rin-vaccinated children: How should we interpret the results? Eur. J. Pediatr. 2012, 171, 1625\u20131632. [CrossRef] 196. Maes, M.; Gim\u00e9nez, J.F.; D\u2019Alessandro, A.; De Waard, J.H. The stability of human, bovine and avian tuberculin purified protein derivative (PPD). J. Infect. Dev. Ctries. 2011, 5, 781\u2013785. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1178",
        "document": "197. Gualano, G.; Mencarini, P.; Lauria, F.N.; Palmieri, F.; Mfinanga, S.; Mwaba, P.; Chakaya, J.; Zumla, A.; Ippolito, G. Tuberculin skin test\u2014Outdated or still useful for Latent TB infection screening? Int. J. Infect. Dis. 2019, 80, S20\u2013S22. [CrossRef] 198. Cy-Tb Package Insert; Serum Institute: Pune, India, 2022."
    },
    {
        "id": "doc_1179",
        "document": "199. Gosc\u00e9, L.; Allel, K.; Hamada, Y.; Korobitsyn, A.; Ismail, N.; Bashir, S.; Denkinger, C.M.; Abubakar, I.; White, P.J.; Rangaka, M.X. Economic evaluation of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: A modelling study. PLoS Glob. Public Health 2023, 3, e0002573. [CrossRef]"
    },
    {
        "id": "doc_1180",
        "document": "200. Hamada, Y.; Kontsevaya, I.; Surkova, E.; Wang, T.T.; Wan-Hsin, L.; Matveev, A.; Ziganshina, L.E.; Denkinger, C.M.; Korobitsyn, A.; Ismail, N.; et al. A Systematic Review on the Safety of Mycobacterium tuberculosis-Specific Antigen-Based Skin Tests for Tuberculosis Infection Compared with Tuberculin Skin Tests. Open Forum Infect. Dis. 2023, 10, ofad228. [CrossRef]"
    },
    {
        "id": "doc_1181",
        "document": "201. To, K.W.; Zhang, R.; Lee, S.S. Is the new tuberculous antigen-based skin test ready for use as an alternative to tuberculin skin test/interferon-gamma release assay for tuberculous diagnosis? A narrative review. Int. J. Infect. Dis. 2024, 141, 106992. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1182",
        "document": "202. Olbrich, L.; Verghese, V.P.; Franckling-Smith, Z.; Sabi, I.; Ntinginya, N.E.; Mfinanga, A.; Banze, D.; Viegas, S.; Khosa, C.; Semphere, R.; et al. Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: A multicentre prospective study in low-income and middle-income countries. Lancet Infect. Dis. 2024, 24, 140\u2013149. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1183",
        "document": "203. Li, L.; Lyon, C.J.; LaCourse, S.M.; Zheng, W.; Stern, J.; Escudero, J.N.; Murithi, W.B.; Njagi, L.; John-Stewart, G.; Hawn, T.R.; et al. Sensitive Blood-Based Detection of HIV-1 and Mycobacterium tuberculosis Peptides for Disease Diagnosis by Immuno-Affinity Liquid Chromatography-Tandem Mass Spectrometry: A Method Development and Proof-of-Concept Study. Clin. Chem. 2023, 69, 1409\u20131419. [CrossRef]"
    },
    {
        "id": "doc_1184",
        "document": "204. Moore, C.M.; Dhillon, J.; Flynn, R.; Gizynski, K.; Adams, C.; Morgan, G.; McGurk, D.; Boada, E.; Shabestary, S.; Peat, J.; et al. A Novel Microfluidic Dielectrophoresis Technology to Enable Rapid Diagnosis of Mycobacterium tuberculosis in Clinical Samples. J. Mol. Diagn. 2023, 25, 513\u2013523. [CrossRef]"
    },
    {
        "id": "doc_1185",
        "document": "205. Ketchanji Mougang, Y.C.; Endale Mangamba, L.M.; Capuano, R.; Ciccacci, F.; Catini, A.; Paolesse, R.; Mbatchou Ngahane, H.B.; Palombi, L.; Di Natale, C. On-Field Test of Tuberculosis Diagnosis through Exhaled Breath Analysis with a Gas Sensor Array. Biosensors 2023, 13, 570. [CrossRef]\n\n206. Thermo Fisher Scientific. Sensititre\u2122 Mycobacterium tuberculosis MYCOTBI AST Plate. Available online: https://www.thermo fisher.com/order/catalog/product/MYCOTBI (accessed on 12 January 2024)."
    },
    {
        "id": "doc_1186",
        "document": "207. Olbrich, L.; Khambati, N.; Bijker, E.M.; Ruhwald, M.; Heinrich, N.; Song, R. FujiLAM for the diagnosis of childhood tuberculosis: A systematic review. BMJ Paediatr. Open 2022, 6, e001447. [CrossRef]\n\n208. Li, Z.; Tong, X.; Liu, S.; Yue, J.; Fan, H. The Value of FujiLAM in the Diagnosis of Tuberculosis: A Systematic Review and Meta-Analysis. Front. Public Health 2021, 9, 757133. [CrossRef]"
    },
    {
        "id": "doc_1187",
        "document": "209. Kerkhoff, A.D.; Sossen, B.; Schutz, C.; Reipold, E.I.; Trollip, A.; Moreau, E.; Schumacher, S.G.; Burton, R.; Ward, A.; Nicol, M.P.; et al. Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV. Eur. Respir. J. 2020, 55, 1901259. [CrossRef] [PubMed]"
    },
    {
        "id": "doc_1188",
        "document": "210. Chenai Mathabire R\u00fccker, S.; Lissouba, P.; Akinyi, M.; Vicent Lubega, A.; Stewart, R.; Tamayo Antabak, N.; Taremwa Mugisha, I.; Ohler, L.; Macu\u00e1cua, H.; Atieno, M.; et al. Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study. J. Clin. Tuberc. Other Mycobact. Dis. 2022, 27, 100316. [CrossRef]"
    },
    {
        "id": "doc_1189",
        "document": "211. SD Biosensor. STANDARD E TB-Feron ELISA. Available online: https://www.sdbiosensor.com/product/product_view?product _no=113 (accessed on 10 January 2024).\n\n212. Yoo, I.Y.; Lee, J.; Choi, A.R.; Jun, Y.H.; Lee, H.Y.; Kang, J.Y.; Park, Y.-J. Comparative Evaluation of Standard E TB-Feron ELISA and QuantiFERON-TB Gold Plus Assays in Patients with Tuberculosis and Healthcare Workers. Diagnostics 2021, 11, 1659. [CrossRef]"
    },
    {
        "id": "doc_1190",
        "document": "213. Jung, J.; Jhun, B.W.; Jeong, M.; Yoon, S.J.; Huh, H.J.; Jung, C.W.; Kim, K.; Park, J.B.; Kim, D.J.; Huh, W.; et al. Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium tuberculosis Infections in Tertiary Care Setting? J. Clin. Med. 2021, 10, 1376. [CrossRef]\n\n214. SD Biosensor. STANDARD F TB-Feron FIA (IFN-Gamma). Available online: https://www.sdbiosensor.com/product/product_ view?product_no=167# (accessed on 10 January 2024)."
    },
    {
        "id": "doc_1191",
        "document": "215. Saint-Pierre, G.; Conei, D.; Cantillana, P.; Raijmakers, M.; Vera, A.; Guti\u00e9rrez, D.; Kennedy, C.; Peralta, P.; Ramonda, P. Comparison of Two Tuberculosis Infection Tests in a South American Tertiary Hospital: STANDARD F TB-Feron FIA vs. QIAreachTM QuantiFERON-TB. Diagnostics 2023, 13, 1162. [CrossRef] [PubMed]\n\n216. bioM\u00e9rieux. VIDAS\u00ae TB-IGRA. bioM\u00e9rieux Diagnostics. Available online: https://www.biomerieux-diagnostics.com/vidasr-tb -igra (accessed on 10 January 2024)."
    },
    {
        "id": "doc_1192",
        "document": "Diseases 2024, 12, 202\n\n24 of 24\n\n217. Petruccioli, E.; Farroni, C.; Cuzzi, G.; Vanini, V.; Palmieri, F.; Vittozzi, P.; Goletti, D. VIDAS\u00ae TB-IGRA reagents induce a CD4+\n\n218. Diagbouga, S.; Djibougou, A.D.; Pease, C.; Alcaide, A.; Berthoux, A.; Bruiners, N.; Cirillo, D.M.; Combary, A.; Falchero, N.; Handler, D.; et al. Preliminary diagnostic performance of the VIDAS\u00ae TB-IGRA for the detection of Mycobacterium tuberculosis infection and disease. medRxiv 2022. [CrossRef]"
    },
    {
        "id": "doc_1193",
        "document": "219. SD Biosensor. STANDARD M M10 MDR-TB. Available online: https://www.sdbiosensor.com/product/product_view?product _no=23007 (accessed on 12 January 2024).\n\n220. ClinicalTrials.gov. Phase II: Multicentre Clinical Study to Assess the Performance of the Bioneer IRONqPCR \u2122 RFIA Kit for INH-, RIF-, FQ- and AG-Resistance Detection (NCT05117788). 2022. Available online: https://clinicaltrials.gov/study/NCT05117788#s tudy-overview (accessed on 12 January 2024)."
    },
    {
        "id": "doc_1194",
        "document": "221. ABL SA. DEEPCHEK\u00ae ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING (CE-IVD). Available online: https://www.ablsa. com/laboratory-applications/bacteriochek-tb-software/ (accessed on 17 January 2024)."
    },
    {
        "id": "doc_1195",
        "document": "222. Zhou, R.; Qiu, X.; Ying, J.; Yue, Y.; Ruan, T.; Yu, L.; Liu, Q.; Sun, X.; Wang, S.; Qu, Y.; et al. Diagnostic performance of adenosine deaminase for abdominal tuberculosis: A systematic review and meta-analysis. Front. Public Health. 2022, 10, 938544. [CrossRef] 223. Gopalaswamy, R.; Dusthackeer, V.A.; Kannayan, S.; Subbian, S. Extrapulmonary tuberculosis\u2014An update on the diagnosis, treatment and drug resistance. J. Respir. 2021, 1, 141\u2013164. [CrossRef]"
    },
    {
        "id": "doc_1196",
        "document": "224. Aggarwal, A.N.; Agarwal, R.; Sehgal, I.S.; Dhooria, S. Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. PLoS ONE 2019, 14, e0213728. [CrossRef]\n\n225. Gao, L.; Wang, W.; Zhang, Y.; Hu, X.; An, J.; Li, Y.; Chen, M.; Shen, Y. Adenosine deaminase-based measurement in the differential"
    },
    {
        "id": "doc_1197",
        "document": "diagnosis of pleural effusion: A multicenter retrospective study. Ther. Adv. Respir. Dis. 2023, 17, 17534666231155747. [CrossRef] 226. Salmanzadeh, S.; Tavakkol, H.; Bavieh, K.; Alavi, S.M. Diagnostic Value of Serum Adenosine Deaminase (ADA) Level for Pulmonary Tuberculosis. Jundishapur J. Microbiol. 2015, 8, e21760. [CrossRef]\n\n227. Pai, M.; Dewan, P.K.; Swaminathan, S. Transforming tuberculosis diagnosis. Nat. Microbiol. 2023, 8, 756\u2013759. [CrossRef]"
    },
    {
        "id": "doc_1198",
        "document": "Disclaimer/Publisher\u2019s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content."
    },
    {
        "id": "doc_1199",
        "document": "Prevalence and associated factors of pneumonia among under-fives with acute respiratory symptoms: a cross sectional study at a Teaching Hospital in Bushenyi District, Western Uganda\n\nGloria Kiconco1, Munanura Turyasiima1, Andrew Ndamira1, 2, Ortiz Arias Yamile1, Walufu Ivan Egesa1, Martin Ndiwimana1, Melvis Bernis Maren1"
    },
    {
        "id": "doc_1200",
        "document": "1. Department of Pediatrics, Kampala International University School of Health Sciences, Western Campus. 2. African Medical and Research Foundation (AMREF) Africa, Mbarara, Uganda."
    },
    {
        "id": "doc_1201",
        "document": "Co-author details:\n\nYamile Arias Ortiz: yariasortiz@gmail.com, Tel: +256701728177; Andrew Ndamira: lionandrew411@gmail.com, Tel:+256772456666; Turyasiima Munanura: tumiek2000@gmail.com, Tel: +256776505193; Walufu Ivan Egesa: wiegesa@gmail.com, Tel: +256789766517; Melvis Bernis Maren: Email address: samuelramirez1201@gmail.com Tel: +256704310238; Martin Nduwimana: Email address: docrmartin@yahoo.frTel: +256750969417"
    },
    {
        "id": "doc_1202",
        "document": "Abstract\n\nObjectives: This study assessed the prevalence and associated factors of pneumonia among children under-five years pre- senting with acute respiratory symptoms."
    },
    {
        "id": "doc_1203",
        "document": "Methodology: This was a cross sectional study at the Pediatric Department of Kampala International University \u2013 Teaching Hospital, from the month of April to August 2019. The study included 336 children aged 2 to 59 months presenting with acute respiratory symptoms to the pediatric clinic. Pneumonia diagnosis was made according to the World Health Organi- zation definition, modified by a chest radiograph. Structured questionnaires were used to collect data on socio-demographic, environmental and"
    },
    {
        "id": "doc_1204",
        "document": "nutrition factors and multivariate logistic regression analysis using STATA version 13.0 was done to assess for the factors independently associated with pneumonia."
    },
    {
        "id": "doc_1205",
        "document": "Results: Of the 336 children with acute respiratory symptoms, eighty-six, 86 (25.6%) had pneumonia. Factors significantly associated with pneumonia included: age below 6 months (OR=3.2, 95%CI=1.17-8.51, p=0.023), rural residence (OR=5.7, 95%CI=2.97-11.05, p <0.001), not up-to-date for age immunization status (OR=2.9, 95%CI=1.05-7.98, p=0.039), severe acute malnutrition (OR=10.8, 95%CI=2.01-58.41, p=0.006), lack of exclusive breastfeeding during the first six months (OR=2.9, 95%CI=1.53-5.53,"
    },
    {
        "id": "doc_1206",
        "document": "p=0.001) and exposure to cigarette smoke (OR=3.0, 95%CI=1.35-6.80, p=0.007). Conclusion: The prevalence of pneumonia in children under-five years was high. Most of the factors associated with pneu-"
    },
    {
        "id": "doc_1207",
        "document": "Keywords: Pneumonia, prevalence, under-fives.\n\nDOI: https://dx.doi.org/10.4314/ahs.v21i4.25\n\nCite as: Kiconco G, Turyasiima M, Ndamira A, Yamile OA, Egesa WI, Ndiwimana M, et al. Prevalence and associated factors of pneu- monia among under-fives with acute respiratory symptoms: a cross sectional study at a Teaching Hospital in Bushenyi District, Western Uganda. Afri Health Sci. 2021;21(4):1701-10. https://dx.doi.org/10.4314/ahs.v21i4.25"
    },
    {
        "id": "doc_1208",
        "document": "Corresponding author: Gloria Kiconco, Pediatrics and child Health (2020), Kampala International University Teaching Hospital Ishaka Bushenyi. Tel: +256779926658. Email Address: littlebabygal@gmail.com"
    },
    {
        "id": "doc_1209",
        "document": "Introduction\n\nPneumonia is the most common infectious cause of death in children accounting for 16% of all deaths of under-fives worldwide, it is most prevalent in south Asia and sub-Saharan Africa 1 and is the second leading cause of under-five in-patient mortality in Uganda 2. System- atic review and meta-analysis of data on pneumonia across East African countries, estimated the average prevalence of pneumonia in under-fives at 34% 3. In"
    },
    {
        "id": "doc_1210",
        "document": "African Health Sciences \u00a9 2021 Kiconco G et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution Li- cense (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\n\nAfrican Health Sciences, Vol 21 Issue 4, December, 2021\n\n1701"
    },
    {
        "id": "doc_1211",
        "document": "Uganda, 80% of children under five years that sought treatment from a health worker had symptoms of an acute respiratory infection 4. A study was done at Mu- lago national Referral Hospital in Uganda and record- ed a prevalence at 53.7% 5. Studies in different African countries have estimated pneumonia prevalence among under-fives between 16% and 33% 6, 7, 8."
    },
    {
        "id": "doc_1212",
        "document": "The leading risk factors that contribute to pneumonia incidence are lack of exclusive breastfeeding, under-nu- trition, indoor air pollution, low birth weight, over crowding lack of immunization and comorbid condi- tions 9,10. Children with compromised immune systems like malnutrition especially in infants not exclusively breastfed are at higher risk of developing pneumonia 1, 9. The burden of child hood Pneumonia has declined but the rate of decline is slow compared to other infec- tious"
    },
    {
        "id": "doc_1213",
        "document": "diseases in children 1."
    },
    {
        "id": "doc_1214",
        "document": "The government of Uganda has implemented the strat- egies adapted from Global Action Plan for Prevention and Control of Pneumonia (GAPP) which includes a combination of interventions to protect, prevent, and to treat pneumonia for example vaccination, encourag- ing exclusive breastfeeding for six months and access to proper pneumonia treatment, however in Uganda we are still below the national targets 4, 11, 12 which has con- tributed to a high Under-five mortality 4. This study de- termined the"
    },
    {
        "id": "doc_1215",
        "document": "prevalence of pneumonia and described factors associated with pneumonia among children be- tween 2 and 59 months with acute respiratory symptoms attending to Kampala International Teaching Hospital (KIU-TH) in Bushenyi district Western Uganda."
    },
    {
        "id": "doc_1216",
        "document": "Methods and materials"
    },
    {
        "id": "doc_1217",
        "document": "Study design and participants: This study was a hospi- tal based descriptive cross sectional and analytical study in the Pediatric Department of Kampala International University Teaching Hospital (KIU-TH), a private ter- tiary hospital located in Ishaka-Bushenyi municipality Bushenyi district Western Uganda. It serves as a refer- ral center for hospitals and health centers around the districts of Bushenyi, Sheema, Buhweju and Mitooma. KIU-TH provides general and specialized services, has"
    },
    {
        "id": "doc_1218",
        "document": "outpatient and inpatient departments for each disci- pline with an emergency wing and intensive care unit. The Pediatric department has five 5 sections: pediat- ric ward, neonatal ward, Pediatric OPD and emergency. The study was conducted in the pediatric ward, pediat- ric OPD and emergency ward. According to KIU T-H"
    },
    {
        "id": "doc_1219",
        "document": "records in 2018, approximately 280 children under five years attend to KIU T-H per month and around 70% present with acute respiratory symptoms and about one child died of pneumonia every month.\n\nThree hundred thirty-six (336) children aged between 2 and 59 months presenting with acute respiratory symp- toms at the pediatric out patient, emergency and pedi- atric ward were consecutively recruited into the study from the months of April to August 2019."
    },
    {
        "id": "doc_1220",
        "document": "Study procedure: All the children aged 2-59 months who attended to KIU-TH with acute respiratory symptoms (running nose, cough, fast breathing and/or difficulty in breathing) during the study period were consecutive- ly recruited for the study. Children with acute respirato- ry symptoms were identified from the presenting com- plaint at outpatient clinic, Emergency ward or in the pediatric ward. Consent ws obtained from the children\u2019s parents/caretakers after the primary reason for seeking"
    },
    {
        "id": "doc_1221",
        "document": "health care had been taken care of and any emergency treatment (if required) given."
    },
    {
        "id": "doc_1222",
        "document": "We excluded children with obvious clinical features of acute aspiration (near drowning and acute foreign body inhalation) since there was a known cause."
    },
    {
        "id": "doc_1223",
        "document": "A structured questionnaire was used to capture com- prehensive data on acute respiratory symptoms, so- cio-demographic information, breast feeding history, birth weight, immunization status, environmental fac- tors and comorbid medical conditions like Human Im- mune Virus infection (HIV), cerebral palsy and heart disease that could be associated with pneumonia. Birth weight was checked from the immunization cards and by direct interview of parents/caretakers for those who did not have the cards"
    },
    {
        "id": "doc_1224",
        "document": "at the time of data collection. Urban residence was referred to as cities, municipali- ties and towns with a population over 2,000 persons 13. Parental smoking as an environmental risk factor for pneumonia applied only when the smoker stays in the same environment with the child."
    },
    {
        "id": "doc_1225",
        "document": "Physical examination was done for every child to docu- ment nutritional status and clinical features of pneumo- nia including: increased respiratory rate (according to age), chest in drawing and crackles or added sounds on chest auscultation. Chest radiographs were only done for children with clinical features of pneumonia based on World Health Organization Cough and/or difficulty in breathing with fast breathing and/or chest in draw- ing).\n\n1702"
    },
    {
        "id": "doc_1226",
        "document": "African Health Sciences, Vol 21 Issue 4, December, 2021"
    },
    {
        "id": "doc_1227",
        "document": "Children presenting Initial history (age and to the hospital presenting complaint) Aged 2-59 mo without acute respiratory symptoms \u2013 managed for their respective conditions Aged 2-59 mo with acute respiratory symptoms \u2013 consent for the study Acute foreign body inhalation or near-drowning - excluded No clinical features of Clinical features of pneumonia Detailed history and pneumonia (WHO criteria) examination (WHO criteria) Managed according to the diagnosis Associated factors for pneumonia"
    },
    {
        "id": "doc_1228",
        "document": "Chest X-ray No chest X-ray findings of pneumonia Chest X-ray features of pneumonia Has identified respiratory focus of infection Has no identified respiratory focus of infection (pharyngitis, tonsillitis, otitis Pneumonia media, etc) Managed for their respective diagnoses"
    },
    {
        "id": "doc_1229",
        "document": "Fig 1: Flow chart showing summery of the study procedure"
    },
    {
        "id": "doc_1230",
        "document": "Pneumonia definition: In this study pneumonia was defined as presence Cough and/or difficulty in breath- ing with fast breathing and/or chest in drawing 14. These symptoms also present in other many acute respiratory conditions. Therefore the definition was modified with presence of positive chest X-ray findings of pneumonia which included one of the following: infiltrates, consol- idation, pleural effusion, and empyema indicated pneu- monia 15"
    },
    {
        "id": "doc_1231",
        "document": "However, children who had clinical features of pneu- monia using WHO/IMCI criteria but with normal chest X-ray and had no other identified respiratory fo- cus of infection like pharyngitis, tonsillitis, and otitis media were considered to have pneumonia. This was because a normal chest X-ray might not rule out pneu- monia since sensitivity is around 83.3% 16. Children with identified respiratory focus of infection and had no fea- tures of pneumonia on chest Radiograph were given other respective"
    },
    {
        "id": "doc_1232",
        "document": "diagnoses according to the examina- tion findings"
    },
    {
        "id": "doc_1233",
        "document": "Severe pneumonia: Was defined as presence of pneu- monia plus one or more of the danger signs (lethar- gy, dehydration, cyanosis, vomiting everything, failure to feed, convulsions, oxygen saturation <90%, axillary temperature > 39.5degrees centigrade, severe chest in-drawing) 14."
    },
    {
        "id": "doc_1234",
        "document": "Nutritional status: Nutritional status was assessed ac- cording to the WHO nutritional charts 17 and classified as normal nutritional status, moderate acute malnutri- tion (MAM) and severe acute malnutrition (SAM). Weight was measured using a weighing scale (salter type baby weighing scale for infants and those who could not stand) and digital electric weighing scale when the child completely undressed and rounded to the nearest 0.1kg. The body length/height was measured using a Stadiometer and"
    },
    {
        "id": "doc_1235",
        "document": "length measuring board and recorded in centimeters, Mid-upper arm circumference (MUAC) was measured using a MUAC tape and recorded in cen- timeters."
    },
    {
        "id": "doc_1236",
        "document": "African Health Sciences, Vol 21 Issue 4, December, 2021\n\n1703\n\nImmunization status: Child health cards were used to assess the immunization status of children. Appro- priate history about immunization using a checklist was used for caretakers who did not have immunization cards at the time of data collection. Children who had not received all vaccinations expected for their age or had never been immunized at all were labeled not up to-date for age."
    },
    {
        "id": "doc_1237",
        "document": "Data management: Data collection tools were pre- tested to ensure reliability and validity, questionnaires were translated into local language (Runyankole). Leg- ibility was ensured by daily auditing of the question- naires. Chest x-rays were taken by a radiologist and interpreted properly. Radiographic films were attached to the respective questionnaires to avoid misplacement. Privacy and confidentiality were ensured by conduct- ing interviews in the closed clinic and all data collected kept in"
    },
    {
        "id": "doc_1238",
        "document": "a lock and password protected computer. After collection, data was arranged, coded and entered into the computer using the EXCEL 2016 then imported to STATA version 13.0 (Statacorp, College station, USA) for analysis."
    },
    {
        "id": "doc_1239",
        "document": "Data analysis: Data was analyzed using STATA ver- sion 13.0 (Statacorp, College station, USA). The prev- alence of pneumonia among children presenting with acute respiratory symptoms was analyzed using fre- quencies, percentages and corresponding 95% confi- dence interval (CI). Factors associated with pneumonia were analyzed using univariate and multivariate logistic regression. Factors with p-value \u22640.2 at univariate anal- ysis qualified to be taken to multivariate analysis. Meas- ures of"
    },
    {
        "id": "doc_1240",
        "document": "effect were reported using odds ratios for both crude and adjusted analysis, followed by corresponding"
    },
    {
        "id": "doc_1241",
        "document": "95% CI and p-value. At multivariate analysis, factors with p-value \u22640.05 were considered statistically signifi- cant. The results were presented in tables.\n\nEthical considerations: Ethical approval was obtained from the research ethics committee (REC) of Kampa- la International University (Nr UG-REC-023/201902). Informed consent was sought from parents/caretakers of children and the purpose of the study well explained before administering the questionnaire."
    },
    {
        "id": "doc_1242",
        "document": "Study limitations: Some parents/caretakers had no immunization cards at the time of recruitment in to the study and were not clear with the information regarding their immunization status and birth weight, however, history on age and site at immunization based on the UNEPI guidelines was used to help them recall though a few of them could not recall at all."
    },
    {
        "id": "doc_1243",
        "document": "Results\n\nParticipants\u2019 socio-demographics characteristics Among the 336 children aged 2 to 59 months present- ing with acute respiratory symptoms; majority were of age category 24-59 months, males were slightly more than females. Most children were of rural residence and their parents/caretakers had attained primary and sec- ondary level of education. This is shown in table 1."
    },
    {
        "id": "doc_1244",
        "document": "Participants\u2019 medical and environmental charac- teristics\n\nMajority of the children had their immunization up- to-date for their age, were exclusively breastfed up to six months, had normal nutritional status, with no co- morbidity and had normal weight at birth. Most of the children came from families that cook from outside the main house using biomass and their parents/caretakers were non-smokers (Table 2).\n\n1704\n\nAfrican Health Sciences, Vol 21 Issue 4, December, 2021"
    },
    {
        "id": "doc_1245",
        "document": "Table 1: Participants\u2019 socio-demographic characteristics"
    },
    {
        "id": "doc_1246",
        "document": "Characteristic Frequency, n ( Age (months) 2-5 54 (16.1) 6-11 69 (20.5) 12-23 39 (11.6) 24-59 74 (51.8) Sex Male 79 (53.3) Female 57 (46.7) Residence Urban 54 (45.8) Rural 182 (54.2) Parental/care taker\u2019s education No education 21 (6.3) Primary 41 (42.0) Secondary 99 (29.5) Tertiary 75 (22.3) Marital status Married 304 (90.5) Single 32 (9.5) Religion Catholic 143 (42.6) Anglican 127 (37.8) Muslim 32 (9.5) Pentecostal 34 (10.1) Tribe Banyonkole/Bakiga 308 (91.7) Baganda 17 (5.1) Others 11 (3.3)"
    },
    {
        "id": "doc_1247",
        "document": "Table 2: Participant\u2019s medical and environmental characteristics\n\n(%)"
    },
    {
        "id": "doc_1248",
        "document": "Characteristic Freguencx, n (%! Medical characteristics Immunization status Up-to-date for age 309 (92.0) Not up-to-date 27 (8.0) Nutritional status Normal nutrition 238 (95.2) Moderate acute malnutrition 10 (4.0) Severe acute malnutrition 2 (0.8) Exclusive breast feeding for 6months No 71 (21.1) Yes 265 (78.9) Comorbidity No 327 (97.3) Yes 9 (2.7) Birth weight 2.5-3.99 251 (74.7) <2.5 15 (4.5) 4+ 27 (8.0) Unknown 43 (12.8) Environmental Characteristics Place of cooking Indoor 112 (33.3)"
    },
    {
        "id": "doc_1249",
        "document": "Outdoor 224 (66.7) Parental/care taker smoking No 301 (89.6) Yes 35 (10.4)"
    },
    {
        "id": "doc_1250",
        "document": "African Health Sciences, Vol 21 Issue 4, December, 2021\n\n1705\n\nPrevalence of pneumonia among children aged 2 to 59 months presenting with acute respiratory symptoms\n\nEighty-six (25.6%) children under-five years had pneu-\n\nmonia; 24 (27.9%) of these had the severe form. Pneu- monia was more prevalent in children below 6 months of age and affected more of males than females (Table 3).\n\nTable 3: Prevalence of pneumonia by age and sex"
    },
    {
        "id": "doc_1251",
        "document": "Prevalence N n % p-value Overall 336 86 25.6 Age specific 0.127 2-5 54 20 37.0 6-11 69 13 18.8 12-23 39 11 28.2 24-59 174 42 24.1 Gender specific 0.767 Male 179 47 26.3 Female 157 39 24.8\n\nFactors associated with pneumonia among chil- dren aged 2 to 59 months presenting with acute respiratory symptoms\n\nAge of the child, place of residence, parental education, religion, parental smoking, immunization status, nutri- tional status, exclusive breast feeding and having co-"
    },
    {
        "id": "doc_1252",
        "document": "morbidity were associated with pneumonia at univariate analysis. After adjusting for confounders at multivari- ate analysis; children who were aged below 6 months, not immunized up-to-date for age, severely malnour- ished, not exclusively breastfed and exposed to cigarette smoke were more likely to suffer from pneumonia (Ta- ble 4).\n\n1706\n\nAfrican Health Sciences, Vol 21 Issue 4, December, 2021\n\nTable 4: Results of bivariate and multivariate analysis for factors associated with pneumonia"
    },
    {
        "id": "doc_1253",
        "document": "Variable No pneumonia n (%) Pneumoni a n (%) Unadjusted OR (95% CI) Adjusted OR (95% cI p-value Age (months) 2-5 34 (13.6) 20 (23.3) 2.5 (1.12-5.74) 3.2 (1.17-8.51) 0.023 6-11 56 (22.4) 13 (15.1) 1.0 1.0 - 12-23 28 (11.2) 11 (12.8) 1.7 (0.67-4.26) 3.0 (0.96-9.54) E)AOSS 0.058 24-59 132 (52.8) 42 (48.8) 1.4 (0.68-2.75) 2.2 (0.91-5.17) 0.081 Sex Male 132 (52.8) 47 (54.6) 1.0 Female 118 (47.2) 39 (45.4) 0.9 (0.57-1.52) Residence Urban 139 (55.6) 15 (17.4) 1.0 1.0 -"
    },
    {
        "id": "doc_1254",
        "document": "Rural 111 (44.44) 71 (82.6) 5.9 (3.22-10.91) 5.7 (2.97-11.05) <0.001 Parental/caretaker ed ucation 12 (4.8) 9 (10.5) 4.4 (1.49-12.79) No education 98 (39.2) 43 (50.0) 2.6 (1.23-5.32) Primary 76 (30.4) 23 (26.7) 1.8 (0.80-3.89) Secondary 64 (25.6) 11 (12.8) 1.0 Tertiary Marital status Married 227 (90.8) 77 (89.5) 1.0 1.2 Single 23 (9.2) 9 (10.5) (0.51-2.60) Religion Catholic 10 (44.0) 33 (38.4) 1.0 Anglican 95 (38.0) 32 (37.2) 1.1 (0.64-1.96) Muslim 28 (11.2) 4 (4.7) 0.5 (1.56-1.46)"
    },
    {
        "id": "doc_1255",
        "document": "Pentecostal 7(6.8) 17 (19.8) 3.3 (1.53-7.25) Tribe Banyankole/B 228 (91.2) 80 (93.0) 1.0 akiga 3(5.2) 4 (4.7) 0.9 (0.28-2.77) Baganda 9 (3.6) 2 (2.3) 0.6 (0.13-2.99) Others Place of cooking Indoor 82 (32.8) 30 (34.9) 1.0 Outdoor 68 (67.2) 56 (65.1) 0.9 (0.54-1.53) Parental/caretaker 231 (92.4) 70 (81.4) 1.0 1.0 smoking E)A007 - No 9(7.6) 16 (18.6) 2.8 (1.36-5.69) 3.0 (1.35-6.80) 0.007 Yes Immunization status 1.0 1.0 235 74 Up-to-date for (94.0) 5(6.0) (86.0) 12 E)A039 -"
    },
    {
        "id": "doc_1256",
        "document": "age (14.0) 2.5 (1.14-5.67) 2.9 (1.05-7.98) Not up-to- 0.039 date for age Exclusive breast feeding 41 (16.4) 30 (34.9) 2.7 (1.57-4.76) 2.9 (1.53-5.53) 0.001 No 209 (83.6) 56 (65.1) 1.0 1.0 - Yes Nutritional status Normal 238 (95.2) 70 (81.4) 1.0 1.0 - nutrition 10 (4.0) 8 (9.3) 2.7 (1.03-7.15) 2.9 (0.99-8.64) E)A052 0.052 MAM SAM 2 (0.8) 8 (9.3) 13.6 (2.82- 65.52) 10.8 (2.01-58.41) 0.006"
    },
    {
        "id": "doc_1257",
        "document": "MAM: moderate acute malnutrition, SAM: severe acute malnutrition\n\nAfrican Health Sciences, Vol 21 Issue 4, December, 2021\n\n1707\n\nDiscussion"
    },
    {
        "id": "doc_1258",
        "document": "The prevalence of pneumonia was at 25.6% in this study. This prevalence is low compared to findings in a study at Mulago National Referral Hospital Uganda which recorded prevalence of pneumonia in under-fives at 53.7% 5. This could be because of the difference in the study setting. Since Mulago Hospital is near the city, children are likely to be affected by environmental pol- lution, overcrowding and exposure to smoke due to in- door cooking with biomass which predispose to pneu- monia with a"
    },
    {
        "id": "doc_1259",
        "document": "high odds of above 1.5 as found in some studies 3, 7,18. Because most children under-five years visit hospitals due to symptoms of acute respiratory infection 3, the prevalence of pneumonia in this study is almost similar to the hospital based studies among all under-fives (33.5%) in Ethiopia 7, 20.2%) in Sudan 19 and (21%) in Kenya 20."
    },
    {
        "id": "doc_1260",
        "document": "Children of rural residence had 5.7 higher odd of having pneumonia in this study compared to the ur- ban residence, findings are comparable with a study in Ethiopia 6 that reported 4.5 higher odds of developing pneumonia among children of rural residence. The dif- ference could be explained by the low socioeconomic status, low education level in rural areas that are associ- ated with an increased risk of pneumonia 21. However, some studies found an opposite with an increased risk of pneumonia in"
    },
    {
        "id": "doc_1261",
        "document": "urban than rural 19 with more children in urban setting suffering from acute respiratory infec- tions compared to those from rural setting 21. This is because of exposure to factors like environmental air pollution and overcrowding in urban areas which have been found to be associated with pneumonia 7,16. Children aged 2-6 months had 3.2 times higher odd of suffering from pneumonia compared to older infants. A study in Ethiopia 7 found that children who were aged 2-12 month were 2.5 times more"
    },
    {
        "id": "doc_1262",
        "document": "likely to develop pneu- monia as compared to children above 12 months. The findings can be attributed to the weak immune system in these young infants that allows progression of upper respiratory infection to the lungs causing pneumonia 8."
    },
    {
        "id": "doc_1263",
        "document": "Children not exclusively breastfeed for six months, not up to date immunized for their age according to nation- al guidelines had almost 3 times odds of having pneu- monia compared to the exclusively breast fed and im- munized. The findings were comparable with what was found in a study in Brazil 22 where the odds of having pneumonia was 2.4 times higher in children not exclu- sively breast fed and 2.5 times among those who lacked immunization compared to their counterparts. Exclu-"
    },
    {
        "id": "doc_1264",
        "document": "sive breast feeding and Immunization protects and prevents children from pneumonia 1, this explains why children who lacked these factors had a high chance of developing pneumonia compared to their counterparts. Children with severe acute malnutrition in this study were 11 times more likely to have pneumonia than chil- dren with good nutritional status. The findings were similar to related studies in southern Ethiopia 23, in dis- trict hospitals of Malawi 24 and in a tertiary Care Centre in"
    },
    {
        "id": "doc_1265",
        "document": "Pradesh India 25. This is because malnutrition weak- ens the immune system and increases the susceptibility of children to acquire pneumonia 9"
    },
    {
        "id": "doc_1266",
        "document": "Having a co-morbidity for example HIV, asthma, cer- ebral palsy and congenital heart disease was associated with an increased odd of having pneumonia at bivar- iate analysis. A case control study in eastern Kenya 26 found 3.8 odd of having pneumonia in children with a comorbid condition. These comorbidities compromise the immunity of children rendering them susceptible to developing pneumonia following an upper respira- tory tract infection. The results at multivariate analy- sis did not show"
    },
    {
        "id": "doc_1267",
        "document": "any statistical significance and this is because the number of children with co-morbidities in this study was small."
    },
    {
        "id": "doc_1268",
        "document": "Children who were exposed to cigarette smoke were found to have 3 times higher odds of acquiring pneu- monia compared to children who stayed in environment free of cigarette smoke. These findings were compara- ble to the study in Ethiopia 7 which found that exposure to cigarette smoke increased the odds of having pneu- monia by 2.8 times. This is because smoke from the cigarette damages the epithelial lining of the respiratory tract and weakens the innate immune system which al- lows easy"
    },
    {
        "id": "doc_1269",
        "document": "colonization by the microorganisms. Howev- er, another study in Ethiopia 6 did not find association between cigarette smoke exposure and pneumonia in children under-five years."
    },
    {
        "id": "doc_1270",
        "document": "Conclusion"
    },
    {
        "id": "doc_1271",
        "document": "The prevalence of pneumonia among children present- ing with acute respiratory symptoms is high at KIU- TH in Bushenyi and most of the factors associated with pneumonia are modifiable and can be prevented. Therefore emphasis should be put on Health Education to sensitize the community about the preventive meas- ures in addition to appropriate antibiotic treatment of children who already have pneumonia. This is achieva- ble when there is District Health Team Support Super- vision to the lower"
    },
    {
        "id": "doc_1272",
        "document": "health facilities and continued sen- sitisation on timely routine immunisation of children,"
    },
    {
        "id": "doc_1273",
        "document": "1708\n\nAfrican Health Sciences, Vol 21 Issue 4, December, 2021\n\navoiding exposure to cigarette smoke, exclusive breast- feeding, good nutrition practices and prompt antibiotic treatment of children diagnosed with pneumonia\n\nAcknowledgement\n\nWe acknowledge the radiology department of Kampa- la International University Teaching Hospital for the good work done in taking and interpretation of the chest radiographs."
    },
    {
        "id": "doc_1274",
        "document": "Conflict of interest\n\nThe authors have no conflict of interest associated with material presented in this paper.\n\nReferences\n\n1 World Health Organization (WHO). (2016). Pneumo- nia Key Facts. Retrieved from www.who.int on 17th March 2019\n\n2 Ministry of Health (MOH). (2015). Health Sec- tor Development Plan 2015/16-2019/20. https://doi. org/10.1093/intimm/dxu005"
    },
    {
        "id": "doc_1275",
        "document": "3 Biruk B, Melaku B, Ayelign M, Mesfin W, Molla A, Bimerew B, A. et al. Prevalenc of pneumonia and its associated factors among under-five children in East Africa: a systematic review and meta-analysis. BMC Pediatr 2020. 20, 254 https://doi.org/10.1186/s12887- 020-02083-z."
    },
    {
        "id": "doc_1276",
        "document": "4 Uganda Bureau of Statistcs (UBOS) and ICF. Uganda Demographic and Health Survey: Key Indicators Re- port. Kampala, Uganda: UBOS, and Rockville, Mar- yland, USA: UBOS and ICF 4 2016. Retrieved from https://dhsprogram.com/pubs/pdf/PR80/PR80.pd- f%0Awww.ubos.org"
    },
    {
        "id": "doc_1277",
        "document": "5 Nantanda R, Tumwine JK, Ndeezi G O M. Asthma and Pneumonia among Children Less Than Five Years with Acute Respiratory Symptoms in Mulago Hospi- tal, Uganda: Evidence of Under-Diagnosis of Asthma. PLoS One 2013;8(11): e81562. Retrieved from https:// doi.org/10.1371/journal.pone.0081562"
    },
    {
        "id": "doc_1278",
        "document": "6 Fekadu G.A, Terefe M.W, Alemie G.A Prevalence of pneumonia among under-fives Children in Este Town and the Sorrounding RuralKebeles, Northwest Ethio- pia; A Community Based Cross Sectional Study. Science Jounal of Public Health 2014; 3(2): 150- 155.\n\n7 Abuka T. Prevalence of pneumonia and factors as- sociated among children 2-59 months old in Wondo Genet district , Sidama zone , SNNPR , Ethiopia. Curr Pediatr Res 2017;21(1): 19\u201325."
    },
    {
        "id": "doc_1279",
        "document": "8 Uwemedimo O, Lewis T, Essien E, Grace J. C, Hum- phreys N, Margaret E.K, et.al. Distribution and Determi- nants of Pneumonia Diagnosis Using Integrated Man-\n\nagement of Childhood Illness Guidelines: A Nationally Representative Study in Malawi. BMJ Glob Health; 2018; 3: E000506. Doi: 10.1136/ Bmjgh-2017-000506"
    },
    {
        "id": "doc_1280",
        "document": "9 Chisti M J, Tebruegge M, La Vincente S, Graham S M, Duke T. Pneumonia in severely malnourished chil- dren in developing countries - Mortality risk, aetiology and validity of WHO clinical signs: A systematic review. Tropical Medicine and International Health 2009;14(10): 1173\u20131189.\n\n10 Rudan I, Boschi-pinto C, Biloglav Z, Mulholland K, Campbell H. WHO | Epidemiology and etiology of childhood pneumonia. Bulletin of the World Health Organization 2010; 22(i): 9\u201311."
    },
    {
        "id": "doc_1281",
        "document": "11 Nabunya P, Mubeezi R, Awor P Prevalence of exclu- sive breastfeeding among mothers in the informal sec- tor, Kampala Uganda. PLoS One 2020; 15(9): e0239062. https://doi.org/\n\n10.1371/journal.pone.0239062\n\n12 Kibuule D, Kagoya H R and Brian G. Antibiotic use in acute respiratory infections in under-fives in Uganda: findings and implications. Expert Review of Anti-infective"
    },
    {
        "id": "doc_1282",
        "document": "13 Uganda Bureau of Statistics (UBOS) and ICF Inter- national Inc. Uganda Demographic and Health Survey 2011. Kampala, Uganda. Retrieved from ICF Interna- tional Inc\n\n14 World Health Organisation/ Intergrated Man- agement of Childhood Illineses last updated in 2016 (WHO/IMCI) https:/www.who.int/maternal-child-ad- olescent/topics/imci/en/ retrived on feb 2019.\n\n15 O\u2019Grady AK, Torzillo PJ, Frawley K, Chang A B. The radiological diagnosis of Pneumonia in children. Pneumonia 2014; 5:38-51"
    },
    {
        "id": "doc_1283",
        "document": "16 Vojko B, Natalija P, Anja P, Matjaz H, Maja T, Brigita K. Sensitivity of chest ultrasound in the detection of pneumonia in children, European Respiratory Journal 2015 46: OA492; DOI: 10.1183/13993003.congress-2015. OA492\n\n17 WHO Child Growth Standards: Lenth/height- for-age, weight-for-age, weight- for length.weight- for- heght and body mass index- for- age: Methods and de- velopment. Geneva:2006."
    },
    {
        "id": "doc_1284",
        "document": "18 Fonseca Lima E J, Mello M J G, Albuquerque M de F P M de, Lopes M I L, Serra G H C, Lima D EP, et al, Risk factors for community-acquired pneumonia in children under five years of age in the post pneumococ- cal conjugate vaccine era in Brazil: A case control study. BMC Pediatrics 2016; 16(1): 1\u20139.\n\n19 Abdelsafi A G, Goaher M A A, Mohammed A E. Childhood Pneumonia at Omdurman Paediatric Hos- pital, Khartoum, Sudan, International Journal of Multi-"
    },
    {
        "id": "doc_1285",
        "document": "African Health Sciences, Vol 21 Issue 4, December, 2021\n\n1709\n\ndisciplinary and Current Research 2014; (2): Available at: http://ijmcr.com\n\n20 Jeffrey A T, Ayub S M, Norbert O, Stewart K, Rob- ert B, Daniel R. F. The Epidemiology of Hospitalized Pneumonia in Rural Kenya: The Potential of Surveil- lance Data in Setting Public Health Priorities. Interna- tional Journal of Infectious Diseases 2007; (11): 536\u2014543. Doi: 10.1016/J.Ijid.2007.03.006. Http://Intl.Elsevier- health.Com/Journals/Ijid"
    },
    {
        "id": "doc_1286",
        "document": "21 Ganesh S K, Veera K, Bijay N N, Kalaiselvi S, Karthik B. Prevalence of acute respiratory infection among under-five children in urban and rural areas of Puducherry, India, J Nat Sci Biol Med. 2015;6(1):3-6. doi: 10.4103/0976- 9668.149069."
    },
    {
        "id": "doc_1287",
        "document": "22 Saha S K L, Farrar J L, Hossain B, Islam M, Naw- shad A S M, Saha S K. Epidemiology and risk factors for pneumonia severity and mortality in Bangladeshi children < 5 years of age before 10-valent pneumococ- cal conjugate vaccine introduction. BMC Public Health 2016;16(1233):1\u201312."
    },
    {
        "id": "doc_1288",
        "document": "23 Yohannes T, Laelago T, Ayele M, Tamrat T. Mor- tality and morbidity trends and predictors of mortality in under-five children with severe acute malnutrition in Hadiya zone, South Ethiopia: a four-year retrospective review of hospital-based records (2012\u20132015). BMC Nutrition 2017; 3(1): 18. https://doi.org/10.1186/ s40795-017-0135-5"
    },
    {
        "id": "doc_1289",
        "document": "24 Enarson P M, Gie R P, Mwansambo C C, Chalira A E. potentially modifiable factors associated with Death of Infants and Children with Severe Pneumonia Rou- tinely Managed in District Hospitals in Malawi. PLoS One 2015; 10(8): 1\u201313.\n\n25 Arpitha G, Rehman G A. Effect of Severity of Mal- nutrition on Pneumonia in Childern Aged 2M-5Y at a Tertiary Care Center in Khammam , Andhra Pradesh : A Clinical Study. Scholars Journal of Applied Medical Scienc- es (SJAMS) 2014; 2(6E): 3199\u20133203."
    },
    {
        "id": "doc_1290",
        "document": "26 Onyango D, Kikuvi G, Amukoye E, Jared O. Risk factors of severe pneumonia among children aged 2-59 months in western Kenya: a case control study. Pan Afr Med J 2012; 8688: 1\u201313.\n\n1710\n\nAfrican Health Sciences, Vol 21 Issue 4, December, 2021\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nDiagnosis and Treatment of Adults with Community-acquired Pneumonia"
    },
    {
        "id": "doc_1291",
        "document": "An Of\ufb01cial Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America\n\nJoshua P. Metlay*, Grant W. Waterer*, Ann C. Long, Antonio Anzueto, Jan Brozek, Kristina Crothers, Laura A. Cooley, Nathan C. Dean, Michael J. Fine, Scott A. Flanders, Marie R. Grif\ufb01n, Mark L. Metersky, Daniel M. Musher, Marcos I. Restrepo, and Cynthia G. Whitney; on behalf of the American Thoracic Society and Infectious Diseases Society of America"
    },
    {
        "id": "doc_1292",
        "document": "THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY MAY 2019 AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA AUGUST 2019\n\nBackground: This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia."
    },
    {
        "id": "doc_1293",
        "document": "Methods: A multidisciplinary panel conducted pragmatic systematic reviews of the relevant research and applied Grading of Recommendations, Assessment, Development, and Evaluation methodology for clinical recommendations.\n\nResults: The panel addressed 16 speci\ufb01c areas for recommendations spanning questions of diagnostic testing, determination of site of care, selection of initial empiric antibiotic therapy, and subsequent"
    },
    {
        "id": "doc_1294",
        "document": "management decisions. Although some recommendations remain unchanged from the 2007 guideline, the availability of results from new therapeutic trials and epidemiological investigations led to revised recommendations for empiric treatment strategies and additional management decisions.\n\nConclusions: The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia."
    },
    {
        "id": "doc_1295",
        "document": "Keywords: community-acquired pneumonia; pneumonia; patient management\n\nContents Question 1: In Adults with CAP, Question 2: In Adults with CAP, Overview Should Gram Stain and Culture Should Blood Cultures Be Introduction of Lower Respiratory Secretions Obtained at the Time of Diagnosis? Methods Be Obtained at the Time of Question 3: In Adults with CAP, Recommendations Diagnosis? Should Legionella and\n\n*Co\u2013\ufb01rst authors.\n\nEndorsed by the Society of Infectious Disease Pharmacists July 2019."
    },
    {
        "id": "doc_1296",
        "document": "ORCID IDs: 0000-0003-2259-6282 (J.P.M.); 0000-0002-7222-8018 (G.W.W.); 0000-0002-7007-588X (A.A.); 0000-0002-3122-0773 (J.B.); 0000-0001-9702-0371 (K.C.); 0000-0002-5127-3442 (L.A.C.); 0000-0002-1996-0533 (N.C.D.); 0000-0003-3470-9846 (M.J.F.); 0000-0002-8634-4909 (S.A.F.); 0000-0001-7114-7614 (M.R.G.); 0000-0003-1968-1400 (M.L.M.); 0000-0002-7571-066X (D.M.M.); 0000-0001-9107-3405 (M.I.R.); 0000-0002-1056-3216 (C.G.W.)."
    },
    {
        "id": "doc_1297",
        "document": "Supported by the American Thoracic Society and Infectious Diseases Society of America.\n\nThe \ufb01ndings and conclusions in this report are those of the authors and do not necessarily represent the of\ufb01cial position of the U.S. CDC.\n\nAn Executive Summary of this document is available at http://www.atsjournals.org/doi/suppl/10.1164/rccm.201908-1581ST."
    },
    {
        "id": "doc_1298",
        "document": "You may print one copy of this document at no charge. However, if you require more than one copy, you must place a reprint order. Domestic reprint orders: amy.schriver@sheridan.com; international reprint orders: louisa.mott@springer.com.\n\nThis article has an online supplement, which is accessible from this issue\u2019s table of contents at www.atsjournals.org."
    },
    {
        "id": "doc_1299",
        "document": "Am J Respir Crit Care Med Vol 200, Iss 7, pp e45\u2013e67, Oct 1, 2019 Copyright \u00a9 2019 by the American Thoracic Society DOI: 10.1164/rccm.201908-1581ST Internet address: www.atsjournals.org\n\nAmerican Thoracic Society Documents\n\ne45\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nPneumococcal"
    },
    {
        "id": "doc_1300",
        "document": "Testing Be Performed at the Time of Diagnosis? Question 4: In Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis? Question 5: In Adults with CAP, Should Serum Procalcitonin plus Clinical Judgment versus Clinical Judgment Alone Be Used to Withhold Initiation of Antibiotic Treatment? Question 6: Should a Clinical Prediction Rule for Prognosis plus Clinical Judgment versus Clinical Judgment Alone Be Used to Determine Inpatient versus Outpatient"
    },
    {
        "id": "doc_1301",
        "document": "Treatment Location for Adults with CAP? Question 7: Should a Clinical Prediction Rule for Prognosis plus Clinical Judgment versus Clinical Judgment Alone Be Used to Determine Inpatient General Medical versus Higher"
    },
    {
        "id": "doc_1302",
        "document": "Overview"
    },
    {
        "id": "doc_1303",
        "document": "In the more than 10 years since the last American Thoracic Society(ATS)/Infectious Diseases Society of America (IDSA) community-acquired pneumonia (CAP) guideline (1), there have been changes in the process for guideline development, as well as generation of new clinical data. ATS and IDSA agreed on moving from the narrative style of previous documents to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) format. We thus developed this updated CAP guideline as a"
    },
    {
        "id": "doc_1304",
        "document": "series of questions answered from available evidence in an \u201cis option A better than option B\u201d format using the Patient or Population, Intervention, Comparison, Outcome (PICO) framework (2)."
    },
    {
        "id": "doc_1305",
        "document": "Given the expansion in information related to the diagnostic, therapeutic, and management decisions for the care of patients with CAP, we have purposely narrowed the scope of this guideline to address decisions from the time of clinical diagnosis of pneumonia (i.e., signs and symptoms of pneumonia with radiographic con\ufb01rmation) to completion of antimicrobial therapy and follow-up chest\n\nLevels of Inpatient Treatment"
    },
    {
        "id": "doc_1306",
        "document": "Telemetry Unit) for Adults with CAP? Question 8: In the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults? Question 9: In the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa? Question 10: In the Inpatient Setting, Should Patients with Suspected Aspiration Pneumonia Receive Additional Anaerobic Coverage beyond Standard Empiric Treatment for CAP? Question"
    },
    {
        "id": "doc_1307",
        "document": "11: In the Inpatient Setting, Should Adults with CAP and Risk Factors for MRSA or P. aeruginosa Be Treated with"
    },
    {
        "id": "doc_1308",
        "document": "imaging. The document does not address either the initial clinical diagnostic criteria or prevention of pneumonia."
    },
    {
        "id": "doc_1309",
        "document": "CAP is an extraordinarily heterogeneous illness, both in the range of responsible pathogens and the host response. Thus, the PICO questions we identi\ufb01ed for this guideline do not represent the full range of relevant questions about the management of CAP but encompass a set of core questions identi\ufb01ed as high priority by the panel. In addition, although each question was addressed using systematic reviews of available high-quality studies, the evidence base was often insuf\ufb01cient, emphasizing the"
    },
    {
        "id": "doc_1310",
        "document": "continued importance of clinical judgment and experience in treating patients with this illness and the need for continued research."
    },
    {
        "id": "doc_1311",
        "document": "Introduction\n\nThis guideline addresses the clinical entity of pneumonia that is acquired outside of the hospital setting. Although we recognize that CAP is frequently diagnosed without the use of a chest radiograph, especially in the ambulatory setting, we have focused on studies that used radiographic criteria for\n\nExtended-Spectrum Antibiotic"
    },
    {
        "id": "doc_1312",
        "document": "Therapy Instead of Standard CAP Regimens? Question 12: In the Inpatient Setting, Should Adults with CAP Be Treated with Corticosteroids? Question 13: In Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antiviral Therapy? Question 14: In Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy? Question 15: In Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of"
    },
    {
        "id": "doc_1313",
        "document": "Antibiotic Treatment? Question 16: In Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained? Conclusions"
    },
    {
        "id": "doc_1314",
        "document": "de\ufb01ning CAP, given the known inaccuracy of clinical signs and symptoms alone for CAP diagnosis (3). This guideline focuses on patients in the United States who have not recently completed foreign travel, especially to regions with emerging respiratory pathogens. This guideline also focuses on adults who do not have an immunocompromising condition, such as inherited or acquired immune de\ufb01ciency or drug-induced neutropenia, including patients actively receiving cancer chemotherapy, patients"
    },
    {
        "id": "doc_1315",
        "document": "infected with HIV with suppressed CD4 counts, and solid organ or bone marrow transplant recipients."
    },
    {
        "id": "doc_1316",
        "document": "Antibiotic recommendations for the empiric treatment of CAP are based on selecting agents effective against the major treatable bacterial causes of CAP. Traditionally, these bacterial pathogens include Streptococcus pneumoniae, Haemophilus in\ufb02uenzae, Mycoplasma pneumoniae, Staphylococcus aureus, Legionella species, Chlamydia pneumoniae, and Moraxella catarrhalis. The microbial etiology of CAP is changing, particularly with the widespread introduction of the pneumococcal conjugate vaccine, and"
    },
    {
        "id": "doc_1317",
        "document": "there is increased recognition of the role of viral"
    },
    {
        "id": "doc_1318",
        "document": "e46\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1319",
        "document": "pathogens. The online supplement contains a more detailed discussion of CAP microbiology. As bacterial pathogens often coexist with viruses and there is no current diagnostic test accurate enough or fast enough to determine that CAP is due solely to a virus at the time of presentation (see below), our recommendations are to initially treat empirically for possible bacterial infection or coinfection. In addition, the emergence of multidrug- resistant pathogens, including methicillin- resistant S."
    },
    {
        "id": "doc_1320",
        "document": "aureus (MRSA) and Pseudomonas aeruginosa, requires separate recommendations when the risk of each of these pathogens is elevated. We acknowledge that other multidrug-resistant Enterobacteriaceae can cause CAP, including organisms producing extended- spectrum b-lactamase, but we do not discuss them separately because they are much less common and are effectively covered by the strategies presented for P. aeruginosa. Therefore, throughout this document when discussing P. aeruginosa we are also"
    },
    {
        "id": "doc_1321",
        "document": "referring to other similar multiresistant gram-negative bacteria."
    },
    {
        "id": "doc_1322",
        "document": "We have maintained the convention of separate recommendations on the basis of the severity of illness. Although historically site of care (outpatient, inpatient general ward, or ICU) has served as a severity surrogate, decisions about site of care may be based on considerations other than severity and can vary widely between hospitals and practice sites. We have therefore chosen to use the IDSA/ATS CAP severity criteria that have been validated and de\ufb01ne severe CAP as present in patients with"
    },
    {
        "id": "doc_1323",
        "document": "either one major criterion or three or more minor criteria. (Table 1)"
    },
    {
        "id": "doc_1324",
        "document": "This guideline reaf\ufb01rms many recommendations from the 2007 statement. However, new evidence and a new process have led to signi\ufb01cant changes, which are summarized in Table 2."
    },
    {
        "id": "doc_1325",
        "document": "Methods\n\nThe guideline development methodology and how con\ufb02ict of interest was managed are presented in the online supplement. In brief, the list of PICO questions was \ufb01nalized based on a prioritization of the most important management decisions balanced against the decision to reduce the overall length of the document and total number of"
    },
    {
        "id": "doc_1326",
        "document": "and usability. We followed the GRADE standards for evaluating the evidence for each PICO and assigned a quality of evidence rating of high, moderate, low, or very low. On the basis of the quality of evidence, recommendations were assigned as strong or conditional. In some cases, strong recommendations were made in the setting of low or very low quality of evidence in accordance with the GRADE rules for when such recommendations are allowable (e.g., when the consequences of the recommendation"
    },
    {
        "id": "doc_1327",
        "document": "were high, such as preventing harm or saving life). In all other cases, recommendations that were based on low or very low quality of evidence and not believed to represent standards of care were labeled as conditional recommendations. Statements in favor of strong recommendations begin with the words \u201cWe recommend . . .\u201d; statements in favor of conditional recommendations begin with the words \u201cWe suggest . . . .\u201d Although we speci\ufb01ed pairwise PICO questions for all antibiotic options in the"
    },
    {
        "id": "doc_1328",
        "document": "outpatient and inpatient settings, we summarized the recommendations using lists of treatment options, in no preferred order, rather than retain the PICO format for this section."
    },
    {
        "id": "doc_1329",
        "document": "Recommendations\n\nQuestion 1: In Adults with CAP, Should Gram Stain and Culture of Lower Respiratory Secretions Be Obtained at the Time of Diagnosis?\n\nRecommendation. We recommend not obtaining sputum Gram stain and culture routinely in adults with CAP managed in the outpatient setting (strong recommendation, very low quality of evidence).\n\nWe recommend obtaining pretreatment Gram stain and culture of respiratory secretions in adults with CAP managed in the hospital setting who:"
    },
    {
        "id": "doc_1330",
        "document": "1. are classi\ufb01ed as severe CAP (see Table 1), especially if they are intubated (strong recommendation, very low quality of evidence); or\n\n2.\n\na. are being empirically treated for MRSA or P. aeruginosa (strong recommendation, very low quality of evidence); or\n\nb. were previously infected with MRSA or P. aeruginosa, especially those with prior respiratory tract infection (conditional recommendation, very low quality of evidence); or"
    },
    {
        "id": "doc_1331",
        "document": "c. were hospitalized and received parenteral antibiotics, whether during the hospitalization event or not, in the last 90 days (conditional recommendation, very low quality of evidence)."
    },
    {
        "id": "doc_1332",
        "document": "Summary of the evidence. Arguments for trying to determine the etiology of CAP are that 1) a resistant pathogen may be identi\ufb01ed; 2) therapy may be narrowed; 3) some pathogens, such as Legionella, have public health implications; 4) therapy may be adjusted when patients fail initial therapy; and 5) the constantly changing epidemiology of CAP requires ongoing evaluation."
    },
    {
        "id": "doc_1333",
        "document": "These arguments stand in contrast to the lack of high-quality evidence demonstrating that routine diagnostic testing improves individual patient outcomes. Studies that speci\ufb01cally evaluated the use of sputum Gram stain and culture alone (4\u20137), or in combination with other microbiological testing (8\u201311), also did not demonstrate better patient outcomes."
    },
    {
        "id": "doc_1334",
        "document": "The overall poor yield of sputum evaluation for detecting organisms causing CAP limits its impact on management and patient outcomes. Obtaining a valid sputum specimen can be challenging because of patient-related characteristics (12\u201317). Performance characteristics of testing also vary by organism, receipt of prior antibiotics, and setting. For example, in patients with bacteremic pneumococcal pneumonia who have not received antibiotics, microscopic examination and culture of a good-quality"
    },
    {
        "id": "doc_1335",
        "document": "sputum sample detects pneumococci in 86% of cases (18)."
    },
    {
        "id": "doc_1336",
        "document": "Rationale for the recommendation. In balancing the lack of evidence supporting routine sputum culture with the desire for improved antimicrobial stewardship, the committee voted to continue the stance of previous guidelines in recommending neither for nor against routinely obtaining sputum Gram stain and culture in all adults with CAP managed in the hospital setting. Whether to culture patients or not should be determined by individual clinicians on the basis of clinical presentation, local"
    },
    {
        "id": "doc_1337",
        "document": "etiological considerations, and local antimicrobial stewardship processes."
    },
    {
        "id": "doc_1338",
        "document": "The committee identi\ufb01ed two situations in which we recommend sputum\n\nAmerican Thoracic Society Documents\n\ne47\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nTable 1. 2007 Infectious Diseases Society of America/American Thoracic Society Criteria for De\ufb01ning Severe Community-acquired Pneumonia\n\nmajor criterion or three or more minor criteria"
    },
    {
        "id": "doc_1339",
        "document": "Minor criteria\n\nRespiratory rate > 30 breaths/min PaO2/FIO2 ratio < 250 Multilobar in\ufb01ltrates Confusion/disorientation Uremia (blood urea nitrogen level > 20 mg/dl) Leukopenia* (white blood cell count , 4,000 cells/ml) Thrombocytopenia (platelet count , 100,000/ml) Hypothermia (core temperature , 368C) Hypotension requiring aggressive \ufb02uid resuscitation\n\nMajor criteria\n\nSeptic shock with need for\n\nvasopressors\n\nRespiratory failure requiring mechanical"
    },
    {
        "id": "doc_1340",
        "document": "ventilation\n\n*Due to infection alone (i.e., not chemotherapy induced)."
    },
    {
        "id": "doc_1341",
        "document": "Gram stain and culture: in hospitalized patients with severe CAP, and when strong risk factors for MRSA and P. aeruginosa are identi\ufb01ed, unless local etiological data have already shown these pathogens are very infrequently identi\ufb01ed in patients with CAP. Patients who have severe CAP requiring intubation should have lower respiratory tract samples, such as endotracheal aspirates, sent for Gram stain and culture promptly after intubation, particularly as these patients may be more likely to have"
    },
    {
        "id": "doc_1342",
        "document": "pneumonia due to MRSA or P. aeruginosa, and endotracheal aspirates have a better yield of microbiological organisms than sputum culture (19)."
    },
    {
        "id": "doc_1343",
        "document": "We recommend obtaining sputum for Gram stain and culture in situations when risk factors for MRSA or P. aeruginosa are present, both when initial empiric therapy is expanded to cover these pathogens and when it is not expanded. In the former case, negative microbiological test results may be used to deescalate therapy, and in the latter case, positive microbiological test results may be used to adjust therapy. As discussed later, although there are numerous studies identifying individual risk"
    },
    {
        "id": "doc_1344",
        "document": "factors for MRSA and P. aeruginosa, many of these associations are weak and vary across sites."
    },
    {
        "id": "doc_1345",
        "document": "The most consistently strong risk factor to consider is prior infection with either MRSA or P. aeruginosa. In addition, hospitalization and treatment with parenteral antibiotics in the last 90 days is associated with an increased risk of these pathogens, and so we recommend sputum culture in this situation. These recommendations are not based on high- grade evidence but re\ufb02ect the committee\u2019s desire to improve antibiotic use as well as improve clinicians\u2019 understanding of their local pathogen"
    },
    {
        "id": "doc_1346",
        "document": "prevalences and resistance patterns, which we believe are key to selecting appropriate empiric antibiotic therapy."
    },
    {
        "id": "doc_1347",
        "document": "Research needed in this area. Rapid, cost-effective, sensitive, and speci\ufb01c diagnostic tests to identify organisms causing CAP have potential to improve routine care by supporting the use of targeted therapy, especially when there are risk factors for antibiotic-resistant pathogens. All new diagnostic tests should be assessed in high-quality research studies that address the impact of testing strategies on treatment decisions and patient outcomes."
    },
    {
        "id": "doc_1348",
        "document": "Question 2: In Adults with CAP, Should Blood Cultures Be Obtained at the Time of Diagnosis?\n\nRecommendation. We recommend not obtaining blood cultures in adults with CAP managed in the outpatient setting (strong recommendation, very low quality of evidence).\n\nWe suggest not routinely obtaining blood cultures in adults with CAP managed in the hospital setting (conditional recommendation, very low quality of evidence)."
    },
    {
        "id": "doc_1349",
        "document": "We recommend obtaining pretreatment blood cultures in adults with CAP managed in the hospital setting who:\n\n1. are classi\ufb01ed as severe CAP (see Table 1) (strong recommendation, very low quality of evidence); or\n\n2.\n\na. are being empirically treated for MRSA or P. aeruginosa (strong recommendation, very low quality of evidence); or"
    },
    {
        "id": "doc_1350",
        "document": "b. were previously infected with MRSA or P. aeruginosa, especially those with prior respiratory tract infection (conditional recommendation, very low quality of evidence); or\n\nc. were hospitalized and received parenteral antibiotics, whether during the hospitalization event or not, in the last 90 days (conditional recommendation, very low quality of evidence)."
    },
    {
        "id": "doc_1351",
        "document": "Summary of the evidence. There are no high-quality studies that speci\ufb01cally compared patient outcomes with and without blood culture testing. One large observational study found lower mortality for hospitalized patients associated with obtaining blood cultures at the time of admission (20). Three subsequent (smaller) observational studies found similar associations between in-hospital mortality and having blood cultures within 24 hours of admission, but the results were not statistically"
    },
    {
        "id": "doc_1352",
        "document": "signi\ufb01cant (8, 21, 22)."
    },
    {
        "id": "doc_1353",
        "document": "The yield of blood cultures in most series of adults with nonsevere CAP is low, ranging from 2% (outpatients) to 9% (inpatients) (14, 21, 23, 24); furthermore, blood cultures rarely result in an appropriate change in empiric therapy (25), and blood specimens that include skin contaminants can generate false-positive test results. Growth of organisms such as coagulase-negative staphylococci, which are not recognized as CAP pathogens (26), may lead to inappropriate antimicrobial use that increases"
    },
    {
        "id": "doc_1354",
        "document": "the risk for adverse drug effects. A study of adults hospitalized with CAP found blood cultures were associated with a signi\ufb01cant increase in length of stay and duration of antibiotic therapy (27). Given the observational nature of these studies, it is unknown whether the associations found with blood cultures and patient outcomes were causal or due to unmeasured confounding factors, including severity of illness."
    },
    {
        "id": "doc_1355",
        "document": "Although additional diagnostic information could improve the quality of treatment decisions, support for routine collection of blood cultures is reduced by the low quality of studies demonstrating clinical bene\ufb01t. Routinely obtaining blood cultures may generate false- positive results that lead to unnecessary antibiotic use and increased length of stay."
    },
    {
        "id": "doc_1356",
        "document": "In severe CAP, delay in covering less- common pathogens can have serious consequences. Therefore, the potential bene\ufb01t of blood cultures is much larger when results can be returned within 24 to 48 hours.\n\nThe rationale for the recommendation for blood cultures in the setting of risk factors for MRSA and P. aeruginosa is the same as for sputum culture.\n\ne48\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1357",
        "document": "Table 2. Differences between the 2019 and 2007 American Thoracic Society/Infectious Diseases Society of America Community-acquired Pneumonia Guidelines"
    },
    {
        "id": "doc_1358",
        "document": "Recommendation 2007 ATS/IDSA Guideline 2019 ATS/IDSA Guideline Sputum culture Primarily recommended in patients with severe disease Now recommended in patients with severe disease as well as in all inpatients empirically treated for MRSA or Pseudomonas aeruginosa Blood culture Primarily recommended in patients with severe disease Now recommended in patients with severe disease as well as in all inpatients empirically treated for MRSA or P. aeruginosa"
    },
    {
        "id": "doc_1359",
        "document": "Macrolide monotherapy Strong recommendation for outpatients Conditional recommendation for outpatients based on resistance levels Use of procalcitonin Not covered Not recommended to determine need for initial antibacterial therapy Use of corticosteroids Not covered Recommended not to use. May be considered in patients with refractory septic shock"
    },
    {
        "id": "doc_1360",
        "document": "Use of healthcare-associated pneumonia category Accepted as introduced in the 2005 ATS/IDSA hospital-acquired and ventilator-associated pneumonia guidelines Recommend abandoning this categorization. Emphasis on local epidemiology and validated risk factors to determine need for MRSA or P. aeruginosa coverage. Increased emphasis on deescalation of treatment if cultures are negative"
    },
    {
        "id": "doc_1361",
        "document": "Standard empiric therapy for severe CAP B-Lactam/macrolide and B-lactam/fluoroquinolone combinations given equal weighting Both accepted but stronger evidence in favor of B-lactam/macrolide combination Routine use of follow-up chest imaging Not addressed Recommended not to obtain. Patients may be eligible for lung cancer screening, which should be performed as clinically indicated"
    },
    {
        "id": "doc_1362",
        "document": "De\ufb01nition of abbreviations: ATS = American Thoracic Society; CAP = community-acquired pneumonia; IDSA = Infectious Diseases Society of America; MRSA = methicillin-resistant Staphylococcus aureus."
    },
    {
        "id": "doc_1363",
        "document": "Question 3: In Adults with CAP, Should Legionella and Pneumococcal Urinary Antigen Testing Be Performed at the Time of Diagnosis?\n\nRecommendation. We suggest not routinely testing urine for pneumococcal antigen in adults with CAP (conditional recommendation, low quality of evidence), except in adults with severe CAP (conditional recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1364",
        "document": "We suggest not routinely testing urine for Legionella antigen in adults with CAP (conditional recommendation, low quality of evidence), except\n\n1. in cases where indicated by epidemiological factors, such as association with a Legionella outbreak or recent travel (conditional recommendation, low quality of evidence); or\n\nin adults with severe CAP (see Table 1) (conditional recommendation, low quality of evidence).\n\n2."
    },
    {
        "id": "doc_1365",
        "document": "We suggest testing for Legionella urinary antigen and collecting lower respiratory tract secretions for Legionella culture on selective media or Legionella nucleic acid ampli\ufb01cation testing in adults with severe CAP (conditional recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1366",
        "document": "Summary of the evidence. Falguera and colleagues (28) randomized 177 patients to pathogen-directed treatment (targeted treatment) on the basis of results of urinary antigen testing for S. pneumoniae and Legionella versus empirical guideline- directed treatment. Of the 88 patients in the targeted treatment arm, 25% had a positive urinary antigen test and received pathogen- directed therapy. There were no statistical differences in death, clinical relapse, ICU admission, length of hospitalization,"
    },
    {
        "id": "doc_1367",
        "document": "or"
    },
    {
        "id": "doc_1368",
        "document": "length of antibiotic treatment (28). A second trial of 262 patients included a broader range of microbiological testing (sputum and blood cultures) and only Legionella urinary antigen testing, but patients receiving pathogen-directed therapy had similar clinical outcomes to patients receiving empirical, guideline- directed therapy, including mortality, rates of clinical failure, and length of hospitalization (10)."
    },
    {
        "id": "doc_1369",
        "document": "One observational study evaluated cost and antibiotic selection in patients during two time periods, with and without pneumococcal urinary antigen testing, but found no differences during the two time periods (29). In contrast, other observational studies that have evaluated the impact of prior CAP guideline concordance (including initial diagnostic testing with urinary antigen tests and blood cultures, along with site of care\n\nAmerican Thoracic Society Documents\n\ne49"
    },
    {
        "id": "doc_1370",
        "document": "AMERICAN THORACIC SOCIETY DOCUMENTS\n\nTable 3. Initial Treatment Strategies for Outpatients with Community-acquired Pneumonia\n\nStandard Regimen No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa* Amoxicillin or doxycycline or macrolide (if local pneumococcal resistance is ,25%)\u2020 With comorbidities\u2021 Combination therapy with amoxicillin/clavulanate or cephalosporin AND macrolide or doxycyclinex OR monotherapy with respiratory \ufb02uoroquinolonejj"
    },
    {
        "id": "doc_1371",
        "document": "De\ufb01nition of abbreviations: ER = extended release; MRSA = methicillin-resistant Staphylococcus aureus.\n\n*Risk factors include prior respiratory isolation of MRSA or P. aeruginosa or recent hospitalization AND receipt of parenteral antibiotics (in the last 90 d)."
    },
    {
        "id": "doc_1372",
        "document": "\u2020Amoxicillin 1 g three times daily, doxycycline 100 mg twice daily, azithromycin 500 mg on \ufb01rst day then 250 mg daily, clarithromycin 500 mg twice daily, or clarithromycin ER 1,000 mg daily. \u2021Comorbidities include chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia."
    },
    {
        "id": "doc_1373",
        "document": "twice daily, 2,000 mg/125 mg twice daily, cefpodoxime 200 mg twice daily, or cefuroxime 500 mg twice daily; AND azithromycin 500 mg on \ufb01rst day then 250 mg daily, clarithromycin 500 mg twice daily, clarithromycin ER 1,000 mg daily, or doxycycline 100 mg twice daily.\n\nILevofloxacin 750 mg daily, moxifloxacin 400 mg daily, or gemifloxacin 320 mg daily."
    },
    {
        "id": "doc_1374",
        "document": "therapy) have reported reduced mortality for patients receiving prior CAP guideline- concordant care, including diagnostic testing. Costantini and colleagues reported a 57% statistically signi\ufb01cant reduced odds of in-hospital mortality for patients receiving pneumococcal and Legionella urinary antigen testing compared with patients not tested, adjusting for baseline demographic and clinical differences (27). Uematsu and colleagues reported 25% reduced odds of 30-day mortality in patients"
    },
    {
        "id": "doc_1375",
        "document": "receiving urinary antigen tests but no impact on length of hospitalizations (7). However, neither study distinguished whether the mortality bene\ufb01ts attributed to testing were a direct consequence of the test results or a marker of other improved processes of care."
    },
    {
        "id": "doc_1376",
        "document": "Randomized trials have failed to identify a bene\ufb01t for urinary antigen testing for S. pneumoniae and Legionella. Concern has also been raised that narrowing therapy in response to positive urinary antigen tests could lead to increased risk of clinical relapse (28). In large observational studies, these diagnostic tests have been associated with reduction in mortality; therefore, we recommend testing in patients with severe"
    },
    {
        "id": "doc_1377",
        "document": "disease. An increase in Legionella infections in the United States in the past decade highlights the importance of this diagnosis especially among severely ill patients, particularly in the setting of potential outbreaks due to a common source, although most cases are not associated with a known outbreak and remain sporadic (30, 31)."
    },
    {
        "id": "doc_1378",
        "document": "Research needed in this area. Newer nucleic acid ampli\ufb01cation systems for sputum, urine, and blood are being developed and require rigorous testing to assess the impact on treatment decisions and clinical outcomes for patients with CAP, as well as the public health bene\ufb01t in terms of prevention of additional cases and informing primary prevention strategies. In particular, we acknowledge the emergence of rapid, low- cost genomic sequence detection assays that have the potential to greatly"
    },
    {
        "id": "doc_1379",
        "document": "improve pathogen-directed therapy and thereby improve antimicrobial stewardship."
    },
    {
        "id": "doc_1380",
        "document": "Question 4: In Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis?\n\nRecommendation. When in\ufb02uenza viruses are circulating in the community, we\n\nrecommend testing for in\ufb02uenza with a rapid in\ufb02uenza molecular assay (i.e., in\ufb02uenza nucleic acid ampli\ufb01cation test), which is preferred over a rapid in\ufb02uenza diagnostic test (i.e., antigen test) (strong recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1381",
        "document": "in\ufb02uenza tests have become increasingly available, moving from earlier antigen-based detection tests to nucleic acid ampli\ufb01cation tests. We were unable to identify any studies that evaluated the impact of in\ufb02uenza testing on outcomes in adults with CAP. In contrast, a substantial literature has evaluated the importance of in\ufb02uenza testing in the general population, speci\ufb01cally among patients with in\ufb02uenza-like illness (32). Our recommendations for in\ufb02uenza testing in adults with CAP are"
    },
    {
        "id": "doc_1382",
        "document": "consistent with testing recommendations for the broader population of adults with suspected in\ufb02uenza, as summarized in the recent IDSA In\ufb02uenza Clinical Practice Guideline (33)."
    },
    {
        "id": "doc_1383",
        "document": "Rationale for the recommendation. The bene\ufb01ts of antiviral therapy support testing of patients during periods of high in\ufb02uenza activity. During periods of low in\ufb02uenza activity, testing can be considered but may not be routinely performed. Of note, this testing recommendation has both therapeutic and infection-control implications in the hospital setting. Updated in\ufb02uenza testing recommendations are also available on the CDC website (https://www.cdc.gov/\ufb02u/professionals/ diagnosis/index.htm)."
    },
    {
        "id": "doc_1384",
        "document": "Question 5: In Adults with CAP, Should Serum Procalcitonin plus Clinical Judgment versus Clinical Judgment Alone Be Used to Withhold Initiation of Antibiotic Treatment?\n\nRecommendation. We recommend that empiric antibiotic therapy should be initiated in adults with clinically suspected and radiographically con\ufb01rmed CAP regardless of initial serum procalcitonin level (strong recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1385",
        "document": "Summary of the evidence. Several studies have assessed the ability of procalcitonin to distinguish acute respiratory infections due to pneumonia (which are of viral or bacterial etiology) from acute bronchitis or upper respiratory tract infections (which are almost\n\ne50\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1386",
        "document": "y l n e c n a t s i d n a n o i t a z i l a t i p s o H t n e c e R d n a s c i t o i b i t n A l a r e t n e r a P k s i R d e t a d i l a V y l l a c o L a s o n i g u r e a . P r o f s r o t c a F e t a i t i n i t u b s e r u t l u c n i a t b O o a s o n i g u r e a . P r o f e g a r e v o c e v i t i s o p e r a s t l u s e r e r u t l u c f i s e R g u r D r o f k s i R d n a y t i r e v d n a n o i t a z i l a t i p s o H t n e c e R d n a s c i t o i b i t n A l a r e t n e r a P k s i"
    },
    {
        "id": "doc_1387",
        "document": "R d e t a d i l a V y l l a c o L A S R M r o f s r o t c a F d l o h h t i w t u b s e r u t l u c n i a t b O s s e l n u e g a r e v o c A S R M f I . e v i t i s o p e r a s t l u s e r e r u t l u c , e l b a l i a v a s i R C P l a s a n d i p a r c i r i p m e l a n o i t i d d a d l o h h t i w d i p a r f i A S R M t s n i a g a y p a r e h t d d a r o e v i t a g e n s i g n i t s e t e v i t i s o p s i R C P f i e g a r e v o c e S f o l e v e L y b a i n o m u e n P d e f o n o i t"
    },
    {
        "id": "doc_1388",
        "document": "a l o s I y r o t a r i p s e R r o i r P a s o n i g u r e a s a n o m o d u e s P j j a s o n i g u r e a . P r o f e g a r e v o c d d A f o n w o o i t l a l a m o r t \ufb01 s e r u t l u n o c r o c n n i a o i t a t b o l a c s d n e e a d y p a r e h t d e u n i t n o c r o f d e e n r i u q c a - y t i n u m m o C h t i w s t n e i n o i t a l o s I y r o t a r i p s e R r o i r P A S R M f o n i a t b o d n a x e g a r e v o c A S R M d d A f o n w o o i t l a l a m o r \ufb01 t R C P n o c r l"
    },
    {
        "id": "doc_1389",
        "document": "o a s a n / s e r u t l u c n o i t a l a c s e e d y p a r e h t d e u n i t n o c r o f d e e n t a p n I r o f s e i g e t a r t S t n e m n e m i g e R d r a d n a t S \u2021 e r o n o l o \u2020 n e i d u i q l o o r r c u a \ufb02 m y 1 r o m a t c a L t a r i p s e r t a - b e r T t n l a e i t i t i n I . 4 e l b a a p n i e r e v e s n o * a i n o m u e n p T N s e r u t l u c n i a t b o d n a j j a s o n i g u r e a . P r o f e g a r e v o c f o n w o o i t l a l a m o r \ufb01 t s e r u t l u n o c r o"
    },
    {
        "id": "doc_1390",
        "document": "c n n i a t b o d o i t a l a c s e y p a r e h t d e u n i t n o c r o f d e d d n a e d e n A n o d n a x e g a r e v o c A S R M d d d n a R C P l a s a n n i a t b o i t a l r o f a c s e e d e e n d w o l l a o t f o n o i t a m r s \ufb01 e n r o u c t l u r o c A j j a f o s o n i g u r e a . P r o f e g a r e v o c d d n w o o i t l a l a m o r t \ufb01 s e r u t l u n o c r o c n n i a o i t a t b o l a c s d n e e a d y p a r e h t d e u n i t n o c r o f d e e n A n i a t b o d n a f o n w o o"
    },
    {
        "id": "doc_1391",
        "document": "i t l a l a m o r \ufb01 t y p a r e h t x e g a r e v o c A S R M d d R C P l a s a n / s e r u t l u c n o c r o n o i t a l a c s e e d d e u n i t n o c r o f d e e n A \u2021 e n r o \u2020 e o l o n i d u q i l o o r r c u a \ufb02 m 1 1 m m a t a c t a c l - a b L - b t n e i t a p n i * a i n o m e r e v e u e n p S y p a r e h t d e u n i t n o c ; a c i r e m A f o y t e i c o S s e s a e s i D s u o i t c e f n I = A S D I ; a i n o m u e n p d e r i u q c a - l a t i p s o h = P A H ; a i n o m u e n p"
    },
    {
        "id": "doc_1392",
        "document": "d e r i u q c a - y t i n u m m o c = P A C ; y t e i c o S c i c a r o h T n a c i r e m A = S T A : s n o i t a i v e r b b a f o n o i t i n \ufb01 e D . a i n o m u e n p d e t a i c o s s a - r o t a l i t n e v = P A V ; s u e r u a s u c c o c o l y h p a t S t n a t s i s e r - n i l l i c i h t e m = A S R M n i c y m o r h t i r a l c r o y l i a d g m 0 0 5 n i c y m o r h t i z a D N A s r u o h 2 1 y r e v e g m 0 0 6 e n i l o r a t f e c r o , y l i a d g 2 \u2013 1 e n o x a i r t f e c ,"
    },
    {
        "id": "doc_1393",
        "document": ". ) 1 s r u e l b a o h 8 T y e e s ( r e v e s g e n 2 \u2013 i l e d i u 1 e m g i x a i r e t i r c y t i r e v a t o f e c , s r u o h e s 6 P A C y r e v e A g S D I / S T A 3 \u2013 5 . 1 m a 7 t c 0 a 0 b 2 l u y s b 1 d e n n \ufb01 e d s A * i l l i c i p m A \u2020 . y l i a d e c i w t g m 0 0 5 m e n e p o r e m e h t n o y l n , ) o h d 6 y e r e r e v e g m d i s n o c e 0 b 0 5 ( d l u m e n e p i m i o h s h c i h w . ) h 2 1 y r , ) h 8 y r e v e , e a e c a i r e t c e v e g m 0 0 6 ( d i l o z e"
    },
    {
        "id": "doc_1394",
        "document": "n i l r o ) s l e v e l n o g 2 ( e m i d a b o r e t n E i z a t f e c g n i c u d , ) h o r p 8 \u2013 e y r e v e s a m a g t c a 2 l - ( b e d e s a b t s u j d a , h 2 1 m i p e f e c , ) h 6 y r e v e m u r t c e p s - d e d n e t x e y r e v e g 5 . 4 ( r o f e g . y l i a d g m 0 0 4 n i c a x o \ufb02 i x o m r o y l i a d g m 0 5 7 n i c a x o \ufb02 o g k / g m 5 1 ( n i c y m o c n a v : s e n i l e d i u g P A V / P A H A S D I / S T A 6 1 0 2 e h t m a t c a b o z a t - n i l l i c a r e p i p :"
    },
    {
        "id": "doc_1395",
        "document": "s e n i l e d i u g P A V / P A H A S D I / S T A 6 1 0 2 e h t a r e v o c e d u l c n i t o n s e o D . ) h 8 y r e v e g 2 ( m a n o e r t z a r o , ) h 8 y r e v e v r r e e e P P L x \u2021 j j g 1 ( . a t a d l a c i g o l o i b o r c i m l a c o l r o t n e i t a p f o s i s a b"
    },
    {
        "id": "doc_1396",
        "document": "American Thoracic Society Documents\n\ne51\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1397",
        "document": "the purposes of this guideline, the question is whether, among patients with clinically con\ufb01rmed CAP, measurement of procalcitonin can distinguish patients with viral versus bacterial etiologies and guide the need for initial antibiotic therapy. Some investigators have suggested that procalcitonin levels of <0.1 mg/L indicate a high likelihood of viral infection, whereas levels >0.25 mg/L indicate a high likelihood of bacterial pneumonia (34\u201336). However, a recent study in hospitalized patients"
    },
    {
        "id": "doc_1398",
        "document": "with CAP failed to identify a procalcitonin threshold that discriminated between viral and bacterial pathogens, although higher procalcitonin strongly correlated with increased probability of a bacterial infection (37). The reported sensitivity of procalcitonin to detect bacterial infection ranges from 38% to 91%, underscoring that this test alone cannot be used to justify withholding antibiotics from patients with CAP (38)."
    },
    {
        "id": "doc_1399",
        "document": "Procalcitonin has been used to guide initiation of antibiotics in patients with lower respiratory infections, but many of these studies are not restricted to patients with radiographically con\ufb01rmed pneumonia. Some patients with low procalcitonin levels have CAP and have been safely treated without antibiotics (35), but these represent small subgroups, raising concerns about the safety of widely using such a strategy."
    },
    {
        "id": "doc_1400",
        "document": "Research needed in this area. Given the epidemiological evidence that viruses are an important cause of CAP, there is a critical need to validate the use of current rapid laboratory tests, including point-of-care tests, to accurately identify situations in which antibacterial therapy can be safely withheld among adults with CAP."
    },
    {
        "id": "doc_1401",
        "document": "Question 6: Should a Clinical Prediction Rule for Prognosis plus Clinical Judgment versus Clinical Judgment Alone Be Used to Determine Inpatient versus Outpatient Treatment Location for Adults with CAP?\n\nRecommendation. In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of"
    },
    {
        "id": "doc_1402",
        "document": "evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP."
    },
    {
        "id": "doc_1403",
        "document": "Summary of the evidence. Both the PSI and CURB-65 were developed as prognostic models in immunocompetent patients with pneumonia, using patient demographic and clinical variables from the time of diagnosis to predict 30-day mortality (39, 40). When compared with CURB-65, PSI identi\ufb01es larger proportions of patients as low risk and has a higher discriminative power in predicting mortality (41)."
    },
    {
        "id": "doc_1404",
        "document": "Two multicenter, cluster-randomized trials demonstrated that use of the PSI safely increases the proportion of patients who can be treated in the outpatient setting (42, 43). These trials and one additional randomized controlled trial (RCT) support the safety of using the PSI to guide the initial site of treatment of patients without worsening mortality or other clinically relevant outcomes (42\u201344). Consistent evidence from three pre\u2013post intervention studies and one prospective controlled"
    },
    {
        "id": "doc_1405",
        "document": "observational study support the effectiveness and safety of using the PSI to guide the initial site of treatment (45\u201348)."
    },
    {
        "id": "doc_1406",
        "document": "Clinical severity is not the only consideration in determining the need for hospital admission (49, 50). Some patients have medical and/or psychosocial contraindications to outpatient therapy, such as inability to maintain oral intake, history of substance abuse, cognitive impairment, severe comorbid illnesses, and impaired functional status."
    },
    {
        "id": "doc_1407",
        "document": "The PSI may underestimate illness severity among younger patients and oversimplify how clinicians interpret continuous variables (e.g., all systolic blood pressures ,90 mm Hg are considered abnormal, regardless of the patient\u2019s baseline and actual measurement). Therefore, when used as a decision aid, the PSI should be used in conjunction with clinical judgment."
    },
    {
        "id": "doc_1408",
        "document": "In comparison to the PSI, there is less evidence that CURB-65 is effective as a decision aid in guiding the initial site of treatment. One pre\u2013post, controlled intervention study using an electronically calculated version of CURB-65, , 300, absence of pleural PaO2/FIO2 effusion, and fewer than three minor ATS severity criteria observed no signi\ufb01cant"
    },
    {
        "id": "doc_1409",
        "document": "increase in the use of outpatient treatment for adults with CAP (51). A randomized trial compared the safety of inpatient versus outpatient treatment of 49 patients with CURB-65 scores of less than 2 (52) but had limited power to detect differences in patient outcomes; furthermore, outpatient treatment included daily nursing visits and parenteral antibiotic therapy that is typically restricted to inpatient care."
    },
    {
        "id": "doc_1410",
        "document": "Rationale for the recommendation. Our recommendation to use the PSI as an adjunct to clinical judgment to guide the initial site of treatment is based on consistent evidence of the effectiveness and safety of this approach. Using a safe and effective decision aid to increase outpatient treatment of patients with CAP has potential to decrease unnecessary variability in admission rates, the high cost of inpatient pneumonia treatment (53, 54), and the risk of hospital-acquired complications."
    },
    {
        "id": "doc_1411",
        "document": "Providing a conditional recommendation to use CURB-65 considers its greater simplicity of use relative to the PSI despite the paucity of evidence regarding its effectiveness or safety."
    },
    {
        "id": "doc_1412",
        "document": "Research needed in this area. It is important to study the effectiveness and safety of using CURB scores or new prediction rules for prognosis as decision aids to guide the initial site of treatment for patients with CAP compared with the PSI. Future studies of prediction rules should also test electronic versions generated in real time from data routinely recorded in the electronic medical record and assess their performance in patient populations excluded from the development of existing"
    },
    {
        "id": "doc_1413",
        "document": "prediction rules (55, 56)."
    },
    {
        "id": "doc_1414",
        "document": "Question 7: Should a Clinical Prediction Rule for Prognosis plus Clinical Judgment versus Clinical Judgment Alone Be Used to Determine Inpatient General Medical versus Higher Levels of Inpatient Treatment Intensity (ICU, Step- Down, or Telemetry Unit) for Adults with CAP?\n\nRecommendation. We recommend direct admission to an ICU for patients with hypotension requiring vasopressors or respiratory failure requiring mechanical ventilation (strong recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1415",
        "document": "For patients not requiring vasopressors or mechanical ventilator support, we suggest\n\ne52\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nusing the IDSA/ATS 2007 minor severity criteria (Table 1) together with clinical judgment to guide the need for higher levels of treatment intensity (conditional recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1416",
        "document": "Summary of the evidence. The PSI and CURB-65 were not designed to help select the level of care needed by a patient who is hospitalized for CAP. Several prognostic models have been designed to predict the need for higher levels of inpatient treatment intensity using severity-of-illness parameters based on patient outcomes (ATS 2001, IDSA/ATS 2007, SMART-COP, and SCAP score). Studies of prognostic models have used different end points, including inpatient mortality (57, 58), ICU admission"
    },
    {
        "id": "doc_1417",
        "document": "(57\u201359), receipt of intensive respiratory or vasopressor support (59, 60), or ICU admission plus receipt of a critical therapy (61). In comparative studies, these prognostic models yield higher overall accuracy than the PSI or CURB-65 when using illness outcomes other than mortality (58, 59, 61)."
    },
    {
        "id": "doc_1418",
        "document": "The 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to de\ufb01ne severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency department settings and are electronically calculable (51, 61). Several groups have validated these criteria in pneumonia cohorts from different countries (57\u201359, 61), with a meta-analysis reporting one major"
    },
    {
        "id": "doc_1419",
        "document": "or three minor criteria had a pooled sensitivity of 84% and a speci\ufb01city of 78% for predicting ICU admission (62). Without the major criteria, a threshold of three or more minor criteria (recommended in the 2007 IDSA/ATS guideline) had a pooled sensitivity of 56% and speci\ufb01city of 91% for predicting ICU admission (63)."
    },
    {
        "id": "doc_1420",
        "document": "SMART-COP is an alternative, validated prediction rule for identifying patients with pneumonia who need vasopressor support and/or mechanical ventilation. The eight SMART-COP criteria and the nine 2007 IDSA/ATS minor criteria have \ufb01ve overlapping elements: hypoxia, confusion, respiratory rate, multilobar radiographic opacities, and low systolic blood pressure. SMART-COP had a pooled sensitivity of 79% and speci\ufb01city of 64% in predicting ICU admission using a threshold of three or more criteria"
    },
    {
        "id": "doc_1421",
        "document": "but uses albumin,"
    },
    {
        "id": "doc_1422",
        "document": "PaO2, and pH, which are not universally available for real-time clinical decision- making (60). For predicting ICU admission, one comparison reported equivalence of the IDSA/ATS minor criteria and SMART- COP (63) and another reported a signi\ufb01cantly greater performance of the IDSA/ATS minor criteria (61). No randomized studies have evaluated the effectiveness or safety of an illness severity tool as a decision aid to guide the intensity of inpatient treatment for patients hospitalized with CAP."
    },
    {
        "id": "doc_1423",
        "document": "Patients transferred to an ICU after admission to a hospital ward experience higher mortality than those directly admitted to the ICU from an emergency department (64\u201367). This higher mortality may in part be attributable to progressive pneumonia, but \u201cmis-triage\u201d of patients with unrecognized severe pneumonia may be a contributing factor (64). It seems unlikely that physician judgment alone would be equivalent to physician judgment together with a severity tool to guide the site-of-care"
    },
    {
        "id": "doc_1424",
        "document": "decision. We recommend the 2007 IDSA/ATS severe CAP criteria over other published scores, because they are composed of readily available severity parameters and are more accurate than the other scores described above."
    },
    {
        "id": "doc_1425",
        "document": "Controlled studies are needed to study the effectiveness and safety of using illness severity tools as decision aids to guide the intensity of treatment in adults hospitalized for pneumonia.\n\nQuestion 8: In the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults?"
    },
    {
        "id": "doc_1426",
        "document": "Recommendation.\n\n1. For healthy outpatient adults without comorbidities listed below or risk factors for antibiotic resistant pathogens, we recommend (Table 3):\n\nd amoxicillin 1 g three times daily (strong recommendation, moderate quality of evidence), or\n\nd doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence), or\n\nd a macrolide (azithromycin 500 mg on \ufb01rst day then 250 mg daily or clarithromycin 500 mg twice daily or"
    },
    {
        "id": "doc_1427",
        "document": "clarithromycin extended release 1,000 mg daily) only in areas with pneumococcal resistance to macrolides ,25% (conditional recommendation, moderate quality of evidence).\n\n2. For outpatient adults with comorbidities such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia we recommend (in no particular order of preference) (Table 3):\n\nd Combination therapy:"
    },
    {
        "id": "doc_1428",
        "document": "B amoxicillin/clavulanate 500 mg/125 mg three times daily, or amoxicillin/ clavulanate 875 mg/125 mg twice daily, or 2,000 mg/125 mg twice daily, or a cephalosporin (cefpodoxime 200 mg twice daily or cefuroxime 500 mg twice daily); AND"
    },
    {
        "id": "doc_1429",
        "document": "B macrolide (azithromycin 500 mg on \ufb01rst day then 250 mg daily, clarithromycin [500 mg twice daily or extended release 1,000 mg once daily]) (strong recommendation, moderate quality of evidence for combination therapy), or doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence for combination therapy); OR\n\nd Monotherapy:"
    },
    {
        "id": "doc_1430",
        "document": "B respiratory \ufb02uoroquinolone (levo\ufb02oxacin 750 mg daily, moxi\ufb02oxacin 400 mg daily, or gemi\ufb02oxacin 320 mg daily) (strong recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1431",
        "document": "Summary of the evidence. RCTs of antibiotic treatment regimens for adults with CAP provide little evidence of either superiority or equivalence of one antibiotic regimen over another, because of small numbers and the rare occurrence of important outcomes such as mortality or treatment failure resulting in hospitalization. Several published trials included comparators that are no longer available (e.g., ketolides). This paucity of data was noted in a 2014 Cochrane review (68)."
    },
    {
        "id": "doc_1432",
        "document": "We identi\ufb01ed 16 relevant RCTs comparing two antibiotic regimens for the treatment of outpatient CAP (69\u201384). Meta- analyses of each of these groups of studies revealed no differences in relevant outcomes between any of the compared regimens. Similar \ufb01ndings have been\n\nAmerican Thoracic Society Documents\n\ne53\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nreported in a 2008 meta-analysis of antibiotic treatment for outpatient CAP (85)."
    },
    {
        "id": "doc_1433",
        "document": "The committee also considered whether to accept data regarding oral antibiotics given to inpatients with CAP. We believed that this evidence, albeit indirect, could be reasonably extended to outpatients, because inpatients are generally higher risk and more severely ill. As observational data suggest that inpatient and outpatient CAP are due to the same pathogens (69, 71\u201373, 82), except for Legionella and gram-negative bacilli, which are rarely documented in outpatient settings, it seems"
    },
    {
        "id": "doc_1434",
        "document": "reasonable that an antibiotic regimen that was effective for inpatients would be effective for outpatients."
    },
    {
        "id": "doc_1435",
        "document": "Studies of high-dose oral amoxicillin have demonstrated ef\ufb01cacy for inpatients with CAP (86\u201388). Similarly, there is evidence supporting amoxicillin-clavulanic acid in outpatient CAP (71, 73) and inpatient CAP (89, 90)."
    },
    {
        "id": "doc_1436",
        "document": "There are limited data regarding oral doxycycline for pneumonia, mostly involving small numbers of patients (81). Intravenous doxycycline 100 mg twice daily compared favorably to intravenous levo\ufb02oxacin 500 mg daily in 65 in patients with CAP (91). In an open-label randomized trial of intravenous doxycycline 100 mg twice daily compared with standard antibiotics, doxycycline was associated with a quicker response and less change in antibiotics (92)."
    },
    {
        "id": "doc_1437",
        "document": "Rationale for the recommendation. Given the paucity of RCT data in the outpatient setting, the committee considered all available evidence. The data included the few RCTs of outpatient CAP, observational studies, RCTs of inpatient CAP treatment, antimicrobial resistance data from surveillance programs, and data regarding antibiotic-related adverse events."
    },
    {
        "id": "doc_1438",
        "document": "For patients without comorbidities that increase the risk for poor outcomes, the panel recommended amoxicillin 1 g every 8 hours or doxycycline 100 mg twice daily. The recommendation for amoxicillin was based on several studies that showed ef\ufb01cacy of this regimen for inpatient CAP despite presumed lack of coverage of this antibiotic for atypical organisms. This treatment also has a long track record of safety. The recommendation for doxycycline was based on limited clinical trial data, but a"
    },
    {
        "id": "doc_1439",
        "document": "broad spectrum of action, including the most common relevant organisms. Some experts recommend that the \ufb01rst dose of oral doxycycline be 200 mg, to achieve adequate serum levels more rapidly. There are no data"
    },
    {
        "id": "doc_1440",
        "document": "assessing whether such an approach is associated with improved outcomes."
    },
    {
        "id": "doc_1441",
        "document": "In a departure from the prior CAP guidelines, the panel did not give a strong recommendation for routine use of a macrolide antibiotic as monotherapy for outpatient CAP, even in patients without comorbidities. This was based on studies of macrolide failures in patients with macrolide-resistant S. pneumoniae (93, 94), in combination with a macrolide resistance rate of .30% among S. pneumoniae isolates in the United States, most of which is high- level resistance (95). However, in settings where"
    },
    {
        "id": "doc_1442",
        "document": "macrolide resistance is documented to be low and there are contraindications to alternative therapies, a macrolide as monotherapy is a treatment option."
    },
    {
        "id": "doc_1443",
        "document": "Patients with comorbidities should receive broader-spectrum treatment for two reasons. First, such patients are likely more vulnerable to poor outcomes if the initial empiric antibiotic regimen is inadequate. Second, many such patients have risk factors for antibiotic resistance by virtue of previous contact with the healthcare system and/or prior antibiotic exposure (see Recommendation 10) and are therefore recommended to receive broader-spectrum therapy to ensure adequate coverage. In addition"
    },
    {
        "id": "doc_1444",
        "document": "to H. in\ufb02uenzae and M. catarrhalis (both of which frequently produce b-lactamase), S. aureus and gram-negative bacilli are more common causes of CAP in patients with comorbidities, such as COPD."
    },
    {
        "id": "doc_1445",
        "document": "Regimens recommended for patients with comorbidities include a b-lactam or cephalosporin in combination with either a macrolide or doxycycline. These combinations should effectively target macrolide- and doxycycline-resistant S. pneumoniae (as b-lactam resistance in S. pneumoniae remains less common), in addition to b-lactamase\u2013producing strains of H. in\ufb02uenzae, many enteric gram- negative bacilli, most methicillin- susceptible S. aureus, and M. pneumoniae and C. pneumoniae. The monotherapies"
    },
    {
        "id": "doc_1446",
        "document": "listed also are effective against most common bacterial pathogens."
    },
    {
        "id": "doc_1447",
        "document": "Both sets of treatment recommendations contain multiple antibiotic options without specifying a preference order. The choice between these options requires a risk\u2013bene\ufb01t assessment for each individual patient, weighing local epidemiological data against speci\ufb01c risk factors that increase the risk of individual choices, such as documented b-lactam or macrolide"
    },
    {
        "id": "doc_1448",
        "document": "allergy, cardiac arrhythmia (macrolides), vascular disease (\ufb02uoroquinolones), and history of infection with Clostridium dif\ufb01cile. In particular, despite the concern regarding adverse events associated with \ufb02uoroquinolones, the panel believed that \ufb02uoroquinolone therapy was justi\ufb01ed for adults with comorbidities and CAP managed in the outpatient setting. Reasons included the performance of \ufb02uoroquinolones in numerous studies of outpatient CAP (70, 72, 75, 77, 80, 83) and inpatient CAP (see"
    },
    {
        "id": "doc_1449",
        "document": "inpatient CAP section), the very low resistance rates in common bacterial causes of CAP, their coverage of both typical and atypical organisms, their oral bioavailability, the convenience of monotherapy, and the relative rarity of serious adverse events related to their use. However, there have been increasing reports of adverse events related to \ufb02uoroquinolone use as summarized on the U.S. Food and Drug Administration website (96)."
    },
    {
        "id": "doc_1450",
        "document": "Of note, we adopt the convention of prior guidelines to recommend that patients with recent exposure to one class of antibiotics recommended above receive treatment with antibiotics from a different class, given increased risk for bacterial resistance to the initial treatment regimen. We also highlight that although patients with signi\ufb01cant risk factors for CAP due to MRSA or P. aeruginosa (see Recommendation 11) are uncommonly managed in the outpatient setting, these patients may require"
    },
    {
        "id": "doc_1451",
        "document": "antibiotics that include coverage for these pathogens."
    },
    {
        "id": "doc_1452",
        "document": "Research needed in this area. There is a need for head-to-head prospective RCTs of outpatient CAP treatment, comparing clinical outcomes, including treatment failure, need for subsequent visits, hospitalization, time to return to usual activities and adverse events. Furthermore, the prevalence of speci\ufb01c pathogens and their antimicrobial susceptibility patterns in outpatients with pneumonia should be monitored. Newer agents, including lefamulin and omadacycline, need further validation in the"
    },
    {
        "id": "doc_1453",
        "document": "outpatient setting."
    },
    {
        "id": "doc_1454",
        "document": "Question 9: In the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa?\n\nRecommendation 9.1. In inpatient adults with nonsevere CAP without risk factors for\n\ne54\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1455",
        "document": "MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):\n\nd combination therapy with a b-lactam (ampicillin 1 sulbactam 1.5\u20133 g every 6 h, cefotaxime 1\u20132 g every 8 h, ceftriaxone 1\u20132 g daily, or ceftaroline 600 mg every 12 h) and a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily) (strong recommendation, high quality of evidence), or"
    },
    {
        "id": "doc_1456",
        "document": "d monotherapy with a respiratory \ufb02uoroquinolone (levo\ufb02oxacin 750 mg daily, moxi\ufb02oxacin 400 mg daily) (strong recommendation, high quality of evidence).\n\nA third option for adults with CAP who have contraindications to both macrolides and \ufb02uoroquinolones is:\n\nd combination therapy with a b-lactam (ampicillin 1 sulbactam, cefotaxime, ceftaroline, or ceftriaxone, doses as above) and doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1457",
        "document": "Summary of the evidence. Most randomized controlled studies of hospitalized adults with CAP comparing b-lactam/macrolide therapy versus \ufb02uoroquinolone monotherapy were designed as noninferiority trials and had limited sample sizes (97\u2013103). These data suggested that patients treated with b-lactam/macrolide therapy have similar clinical outcomes compared with those treated with \ufb02uoroquinolone monotherapy. A systematic review of 16 RCTs in 4,809 patients found \ufb02uoroquinolone monotherapy resulted"
    },
    {
        "id": "doc_1458",
        "document": "in signi\ufb01cantly fewer incidences of clinical failure, treatment discontinuation, and diarrhea than b-lactam/macrolide combination (104). However, mortality rates were low overall, and there were no signi\ufb01cant differences in mortality between groups. Another systematic review of 20 experimental and observational studies in adults hospitalized with radiographically con\ufb01rmed CAP, b-lactam plus macrolide combination therapy, or \ufb02uoroquinolone monotherapy were generally associated with lower"
    },
    {
        "id": "doc_1459",
        "document": "mortality than b-lactam monotherapy (105). Therefore, the panel recommends a b-lactam (ampicillin plus sulbactam, cefotaxime, ceftaroline, or ceftriaxone) plus"
    },
    {
        "id": "doc_1460",
        "document": "macrolide (azithromycin or clarithromycin)"
    },
    {
        "id": "doc_1461",
        "document": "or monotherapy with a respiratory \ufb02uoroquinolone (levo\ufb02oxacin, moxi\ufb02oxacin) for the management of inpatients with nonsevere CAP. (Of note, azithromycin but not clarithromycin is available in parenteral formulation.) In choosing between these two options, clinicians should weigh the risks and bene\ufb01ts of the drugs, particularly in light of individual risk factors, such as a history of C. dif\ufb01cile infection or risk factors related to U.S. Food and Drug Administration warnings (96). The panel"
    },
    {
        "id": "doc_1462",
        "document": "recommends using doxycycline as an alternative to a macrolide in combination with a b- lactam as a third option in the presence of documented allergies or contraindications to macrolides or \ufb02uoroquinolones or clinical failure on one of those agents. Of note, a newer member of the tetracycline class, omadacycline, was recently reported to be equivalent to moxi\ufb02oxacin as monotherapy for adults with nonsevere CAP and is effective in the setting of tetracycline resistance (106). However, as this is"
    },
    {
        "id": "doc_1463",
        "document": "a single published report and the safety information is less well established, the committee decided to not list this new agent as an alternative to the currently recommended treatment options."
    },
    {
        "id": "doc_1464",
        "document": "The panel also considered b-lactam monotherapy as an option for inpatients with nonsevere CAP. An RCT in 580 patients with CAP could not rule out the possibility that b-lactam monotherapy was inferior to b-lactam/macrolide therapy for inpatients with CAP (107). Nie and colleagues identi\ufb01ed several cohort (n = 4) and retrospective observational (n = 12) studies addressing this question and found that b-lactam/macrolide therapy reduced mortality in patients with CAP compared with patients treated"
    },
    {
        "id": "doc_1465",
        "document": "with b-lactam monotherapy (108). Similarly, Horita and colleagues demonstrated that b-lactam/macrolide combinations may decrease all-cause death, but mainly for patients with severe CAP (109). Therefore, we suggest that b-lactam monotherapy should not be routinely used for inpatients with CAP over \ufb02uoroquinolone monotherapy or b-lactam/macrolide combination therapy."
    },
    {
        "id": "doc_1466",
        "document": "Rationale for the recommendation. As summarized in Table 4, the empiric antibiotic coverage recommendations for patients hospitalized with CAP remain aligned to cover the most likely pathogens\n\ncausing CAP. There is a paucity of RCTs to favor the recommendation of combination b-lactam plus macrolide versus monotherapy with a respiratory \ufb02uoroquinolone versus combined therapy with b-lactam plus doxycycline."
    },
    {
        "id": "doc_1467",
        "document": "Research needed in this area. There is a need for higher-quality evidence in support of the use of combination therapy with a b-lactam and doxycycline. Given concerns over increasing drug resistance (macrolides) and safety issues (macrolides, \ufb02uoroquinolones), there is a need for research on new therapeutic agents for adults with CAP including omadacycline (see above) and lefamulin, a new pleuromutilin antibiotic that was recently demonstrated to be noninferior to moxi\ufb02oxacin in hospitalized"
    },
    {
        "id": "doc_1468",
        "document": "adult patients with CAP (110)."
    },
    {
        "id": "doc_1469",
        "document": "Recommendation 9.2. In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, speci\ufb01c agents and doses are the same as 9.1):\n\nd a b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or\n\nd a b-lactam plus a respiratory \ufb02uoroquinolone (strong recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1470",
        "document": "absence of RCTs evaluating therapeutic alternatives in severe CAP, the evidence is from observational studies that used different de\ufb01nitions of illness severity to address this question. Sligl and colleagues found in a meta-analysis of observational studies with almost 10,000 critically ill patients with CAP that macrolide- containing therapies (often in combination with a b-lactam) were associated with a signi\ufb01cant mortality reduction (18% relative risk, 3% absolute risk) compared with"
    },
    {
        "id": "doc_1471",
        "document": "non\u2013macrolide-containing therapies (111). A mortality bene\ufb01t from macrolides has been observed mainly in cohorts with a large number of patients with severe CAP. In a systematic review, Vardakas and colleagues compared a b-lactam/\ufb02uoroquinolone versus a b-lactam/macrolide combination for the treatment of patients with CAP (112). The authors found 17 observational studies and no RCTs addressing this comparison. The combination of b-lactam/\ufb02uoroquinolone"
    },
    {
        "id": "doc_1472",
        "document": "American Thoracic Society Documents\n\ne55\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\ntherapy was associated with higher mortality than b-lactam/macrolide combination therapy, but the overall quality of the studies was judged to be low, precluding a de\ufb01nitive recommendation (112)."
    },
    {
        "id": "doc_1473",
        "document": "the absence of data from clinical trials demonstrating the superiority of any speci\ufb01c regimen for patients with severe CAP, the committee considered epidemiological data for severe CAP pathogens and observational studies comparing different regimens. As a result, we recommend that combination therapy with a b-lactam plus a macrolide or a b- lactam plus a respiratory \ufb02uoroquinolone should be the treatment of choice for patients with severe CAP. Both \ufb02uoroquinolone monotherapy and the combination"
    },
    {
        "id": "doc_1474",
        "document": "of b-lactam plus doxycycline have not been well studied in severe CAP and are not recommended as empiric therapy for adults with severe CAP."
    },
    {
        "id": "doc_1475",
        "document": "Research needed in this area. Future well-designed RCTs should focus on therapies for patients at highest risk of death with severe pneumonia, as these are needed to assess the bene\ufb01ts and risks of combination b-lactam and macrolide therapy compared with b-lactam and respiratory \ufb02uoroquinolone therapy. Studies of \ufb02uoroquinolone monotherapy in severe CAP are also needed."
    },
    {
        "id": "doc_1476",
        "document": "Question 10: In the Inpatient Setting, Should Patients with Suspected Aspiration Pneumonia Receive Additional Anaerobic Coverage beyond Standard Empiric Treatment for CAP?\n\nRecommendation. We suggest not routinely adding anaerobic coverage for suspected aspiration pneumonia unless lung abscess or empyema is suspected (conditional recommendation, very low quality of evidence)."
    },
    {
        "id": "doc_1477",
        "document": "Summary of the evidence. Aspiration is a common event, and as many as half of all adults aspirate during sleep (113). As a result, the true rate of aspiration pneumonia is dif\ufb01cult to quantify, and there is no de\ufb01nition that separates patients with aspiration pneumonia from all others diagnosed with pneumonia. Some have estimated that 5% to 15% of pneumonia"
    },
    {
        "id": "doc_1478",
        "document": "hospitalizations are associated with aspiration (114). Rates are higher in populations admitted from nursing homes or extended care facilities (115).\n\nPatients who aspirate gastric contents are considered to have aspiration pneumonitis. Many of these patients have resolution of symptoms within 24 to 48 hours and require only supportive treatment, without antibiotics (116)."
    },
    {
        "id": "doc_1479",
        "document": "Studies evaluating the microbiology of patients with aspiration pneumonia in the 1970s showed high rates of isolation of anaerobic organisms (117, 118); however, these studies often used trans-tracheal sampling and evaluated patients late in their disease course, two factors that may have contributed to a higher likelihood of identifying anaerobic organisms (114). Several studies of acute aspiration events in hospitalized patients have suggested that anaerobic bacteria do not play a major role"
    },
    {
        "id": "doc_1480",
        "document": "in etiology (119\u2013121)."
    },
    {
        "id": "doc_1481",
        "document": "infections (frequently associated with use of clindamycin), the question of adding empiric anaerobic coverage (clindamycin or b-lactam/b-lactamase inhibitors) in addition to routine CAP treatment in patients with suspected aspiration is an important one. However, there are no clinical trials comparing treatment regimens with and without anaerobic coverage for patients hospitalized with suspected aspiration. Most recent studies are small, retrospective, and provide only observational data on"
    },
    {
        "id": "doc_1482",
        "document": "microbiologic patterns and treatment regimens for patients hospitalized with suspected aspiration pneumonia."
    },
    {
        "id": "doc_1483",
        "document": "Although older studies of patients with aspiration pneumonia showed high isolation rates of anaerobic organisms, more recent studies have shown that anaerobes are uncommon in patients hospitalized with suspected aspiration (119, 120). Increasing prevalence of antibiotic-resistant pathogens and complications of antibiotic use highlight the need for a treatment approach that avoids unnecessary use of antibiotics."
    },
    {
        "id": "doc_1484",
        "document": "Research needed in this area. Clinical trials evaluating diagnostic and treatment strategies in patients with suspected aspiration are needed, especially in terms of the ability to distinguish micro- and macro- aspiration events that lead to lower\n\nrespiratory tract infection from those that do not result in infection."
    },
    {
        "id": "doc_1485",
        "document": "Question 11: In the Inpatient Setting, Should Adults with CAP and Risk Factors for MRSA or P. aeruginosa Be Treated with Extended-Spectrum Antibiotic Therapy Instead of Standard CAP Regimens?\n\nRecommendation. We recommend abandoning use of the prior categorization of healthcare-associated pneumonia (HCAP) to guide selection of extended antibiotic coverage in adults with CAP (strong recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1486",
        "document": "We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present (strong recommendation, moderate quality of evidence). Empiric treatment options for MRSA include vancomycin (15 mg/kg every 12 h, adjust based on levels) or linezolid (600 mg every 12 h). Empiric treatment options for P. aeruginosa include piperacillin-tazobactam (4.5 g every 6 h), cefepime (2 g every 8 h), ceftazidime (2 g every 8 h),"
    },
    {
        "id": "doc_1487",
        "document": "aztreonam (2 g every 8 h), meropenem (1 g every 8 h), or imipenem (500 mg every 6 h)."
    },
    {
        "id": "doc_1488",
        "document": "If clinicians are currently covering empirically for MRSA or P. aeruginosa in adults with CAP on the basis of published risk factors but do not have local etiological data, we recommend continuing empiric coverage while obtaining culture data to establish if these pathogens are present to justify continued treatment for these pathogens after the \ufb01rst few days of empiric treatment (strong recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1489",
        "document": "Summary of the evidence. HCAP, as a distinct clinical entity warranting unique antibiotic treatment, was incorporated into the 2005 ATS/IDSA guidelines for management of hospital-acquired and ventilator-associated pneumonia (122). HCAP was de\ufb01ned for those patients who had any one of several potential risk factors for antibiotic-resistant pathogens, including residence in a nursing home and other long-term care facilities, hospitalization for >2 days in the last 90 days, receipt of home infusion"
    },
    {
        "id": "doc_1490",
        "document": "therapy, chronic dialysis, home wound care, or a family member with a known antibiotic-resistant pathogen. The introduction of HCAP was based on studies identifying a higher prevalence of"
    },
    {
        "id": "doc_1491",
        "document": "e56\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1492",
        "document": "pathogens that are not susceptible to standard \ufb01rst-line antibiotic therapy, in particular MRSA and P. aeruginosa, in some subsets of patients with CAP (123). Since then, many studies have demonstrated that the factors used to de\ufb01ne HCAP do not predict high prevalence of antibiotic-resistant pathogens in most settings. Moreover, a signi\ufb01cant increased use of broad-spectrum antibiotics (especially vancomycin and antipseudomonal b-lactams) has resulted, without any apparent improvement in patient"
    },
    {
        "id": "doc_1493",
        "document": "outcomes (124\u2013133)."
    },
    {
        "id": "doc_1494",
        "document": "Studies have identi\ufb01ed risk factors for antibiotic-resistant pathogens, and in some cases the risk factors are distinct for MRSA versus P. aeruginosa (134\u2013154). However, most of these individual risk factors are weakly associated with these pathogens. The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral"
    },
    {
        "id": "doc_1495",
        "document": "antibiotics (134, 155, 156). Therefore, we have highlighted these individual risk factors to help guide initial microbiological testing and empiric coverage for these pathogens."
    },
    {
        "id": "doc_1496",
        "document": "Unfortunately, no validated scoring systems exist to identify patients with MRSA or P. aeruginosa with suf\ufb01ciently high positive predictive value to determine the need for empiric extended-spectrum antibiotic treatment. Scoring system development and validation are complicated by varying prevalence of MRSA and P. aeruginosa in different study populations. Moreover, no scoring system has been demonstrated to improve patient outcomes or reduce overuse of broad-spectrum antibiotics."
    },
    {
        "id": "doc_1497",
        "document": "Although there is limited evidence to support the use of a speci\ufb01c set of risk factors to identify patients with suf\ufb01ciently high risk of MRSA or P. aeruginosa to warrant extended-spectrum therapy, a stronger evidence base guides deescalation of therapy after extended- spectrum therapy is initially prescribed. Although no randomized prospective studies have been reported, recent observational (157) and retrospective (158\u2013161) studies in patients with CAP provide strong evidence that deescalation"
    },
    {
        "id": "doc_1498",
        "document": "of antibiotic therapy at 48 hours in accord with microbiological results that do not yield MRSA or P. aeruginosa is safe and"
    },
    {
        "id": "doc_1499",
        "document": "reduces duration of antibiotic treatment, length of hospitalization, and complications of broad-spectrum therapy. These results are reinforced by retrospective (162) and prospective and randomized but not blinded (163) studies of patients with severe sepsis, the majority of whom had pneumonia, as well as by a recent meta-analysis of deescalation in adults with sepsis (164)."
    },
    {
        "id": "doc_1500",
        "document": "We propose that clinicians need to obtain local data on whether MRSA or P. aeruginosa is prevalent in patients with CAP and what the risk factors for infection are at a local (i.e., hospital or catchment area) level. We refer to this process as \u201clocal validation.\u201d This recommendation is based on the absence of high-quality outcome studies, the very low prevalence of MRSA or P. aeruginosa in most centers, and signi\ufb01cant increased use of anti-MRSA and antipseudomonal antibiotics for treatment of"
    },
    {
        "id": "doc_1501",
        "document": "CAP (142, 155, 165). Although we acknowledge that centers may not currently have local prevalence data, adopting the recommendations for culture of sputum and blood when risk factors for MRSA or P. aeruginosa are present will enable clinicians to generate these local data over time. We recommend analyzing the frequency of MRSA or P. aeruginosa as a CAP pathogen relative to the number of all cases of CAP, not just those for whom cultures are sent. Finally, routine cultures in patients empirically"
    },
    {
        "id": "doc_1502",
        "document": "treated for MRSA or P. aeruginosa allow deescalation to standard CAP therapy if cultures do not reveal a drug-resistant pathogen and the patient is clinically improving at 48 hours."
    },
    {
        "id": "doc_1503",
        "document": "approach to treating inpatient adults with CAP is summarized in Table 4. Our recommendation against using the former category of HCAP as a basis for selecting extended-spectrum therapy is based on high-quality studies of patient outcomes. Although we understand that clinicians would prefer a simple rule that does not require incorporating site-speci\ufb01c data, the current evidence does not permit endorsement of a simple and accurate rule to determine which patients with CAP should be covered for"
    },
    {
        "id": "doc_1504",
        "document": "MRSA and/or P. aeruginosa. However, the alternative approach to MRSA and P. aeruginosa that we propose as a replacement is not based on high-quality studies, because such studies do not exist. The lack of adequate outcome data and marked variation between sites in prevalence of MRSA and"
    },
    {
        "id": "doc_1505",
        "document": "P. aeruginosa make generalizing any \ufb01ndings extremely dif\ufb01cult. We hope that future research will improve our understanding of this challenging clinical problem.\n\nOur \ufb01rst principle was to maintain the distinction between severe and nonsevere pneumonia as per prior guidelines, because the risk of inadequate empiric antibiotic therapy is much greater in severe CAP. As noted previously, severity is de\ufb01ned by the degree of physiological impairment, as classi\ufb01ed by the IDSA/ATS 2007 criteria."
    },
    {
        "id": "doc_1506",
        "document": "The second principle was that there is suf\ufb01cient evidence that prior identi\ufb01cation of MRSA or P. aeruginosa in the respiratory tract within the prior year predicts a very high risk of these pathogens being identi\ufb01ed in patients presenting with CAP (139, 141, 143, 150, 155, 165), and therefore these were suf\ufb01cient indications to recommend blood and sputum cultures and empiric therapy for these pathogens in patients with CAP in addition to coverage for standard CAP pathogens, with deescalation at"
    },
    {
        "id": "doc_1507",
        "document": "48 hours if cultures are negative. We endorse the empiric treatment recommendations for MRSA and P. aeruginosa provided by the 2016 Clinical Practice Guideline from IDSA and ATS for the management of adults with hospital- acquired and ventilator-associated pneumonia (166)."
    },
    {
        "id": "doc_1508",
        "document": "The major additional risk factors for MRSA and P. aeruginosa identi\ufb01ed in the literature are hospitalization and parenteral antibiotic exposure in the last 90 days (136\u2013138, 140, 142\u2013151, 153). In patients with recent hospitalization and exposure to parenteral antibiotics, we recommend microbiological testing without empiric extended-spectrum therapy for treatment of nonsevere CAP and microbiological testing with extended-spectrum empiric therapy in addition to coverage for standard CAP"
    },
    {
        "id": "doc_1509",
        "document": "pathogens for treatment of severe CAP, with deescalation at 48 hours if cultures are negative and the patient is improving."
    },
    {
        "id": "doc_1510",
        "document": "The data supporting rapid MRSA nasal testing are robust (167, 168), and treatment for MRSA pneumonia can generally be withheld when the nasal swab is negative, especially in nonsevere CAP. However, the positive predictive value is not as high; therefore, when the nasal swab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative. However, this latter strategy of deescalation"
    },
    {
        "id": "doc_1511",
        "document": "American Thoracic Society Documents\n\ne57\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nin the face of a positive nasal swab will vary depending on the severity of CAP and the local prevalence of MRSA as a pathogen."
    },
    {
        "id": "doc_1512",
        "document": "Question 12: In the Inpatient Setting, Should Adults with CAP Be Treated with Corticosteroids?\n\nRecommendation. We recommend not routinely using corticosteroids in adults with nonsevere CAP (strong recommendation, high quality of evidence).\n\nWe suggest not routinely using corticosteroids in adults with severe CAP (conditional recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1513",
        "document": "We suggest not routinely using corticosteroids in adults with severe in\ufb02uenza pneumonia (conditional recommendation, low quality of evidence).\n\nWe endorse the Surviving Sepsis Campaign recommendations on the use of corticosteroids in patients with CAP and refractory septic shock (169)."
    },
    {
        "id": "doc_1514",
        "document": "randomized controlled studies of corticosteroids used for treatment of CAP have shown signi\ufb01cant reductions in mortality, length of stay, and/or organ failure. The \ufb01rst study found a large magnitude of mortality bene\ufb01t that has not been replicated in other studies, raising concerns that the results overestimated the true effect (170). In the second study, there were baseline differences in renal function between groups (171). Other RCTs of corticosteroids in the treatment of CAP have not shown"
    },
    {
        "id": "doc_1515",
        "document": "signi\ufb01cant differences in clinically important endpoints. Differences have been observed in the time to resolution of fever and other features of clinical stability, but these have not translated into differences in mortality, length of stay, or organ failure (172, 173)."
    },
    {
        "id": "doc_1516",
        "document": "Some (174, 175), but not all (176, 177), meta-analyses of published corticosteroid studies have shown a mortality bene\ufb01t in patients with severe CAP, although no consistent de\ufb01nition of disease severity was used. Side effects of corticosteroids (on the order of 240 mg of hydrocortisone per day) include signi\ufb01cant increases in hyperglycemia requiring therapy and possible higher secondary infection rates (178, 179). No reported study has shown excess mortality in the corticosteroid- treated group."
    },
    {
        "id": "doc_1517",
        "document": "In pneumonia due to in\ufb02uenza, a meta- analysis (180) of predominantly small\n\nretrospective studies suggests that mortality may be increased in patients who receive corticosteroids. This \ufb01nding might re\ufb02ect the importance of innate immunity in defense against in\ufb02uenza as opposed to bacterial pneumonia."
    },
    {
        "id": "doc_1518",
        "document": "There are no data suggesting bene\ufb01t of corticosteroids in patients with nonsevere CAP with respect to mortality or organ failure and only limited data in patients with severe CAP. The risk of corticosteroids in the dose range up to 240 mg of hydrocortisone equivalent per day for a maximum of 7 days is predominantly hyperglycemia, although rehospitalization rates may also be higher (176), and more general concerns about greater complications in the following 30 to 90 days have been raised (179)."
    },
    {
        "id": "doc_1519",
        "document": "At least one large trial (clinicaltrials.gov NCT01283009) has been completed but not reported and may further inform which subgroups of patients bene\ufb01t from steroids. We also endorse the Surviving Sepsis Campaign recommendations on the use of steroids in patients with septic shock refractory to adequate \ufb02uid resuscitation and vasopressor support (169)."
    },
    {
        "id": "doc_1520",
        "document": "Of note, there is no intent that our recommendations would override clinically appropriate use of steroids for comorbid diseases, such as chronic obstructive pulmonary disease, asthma, and autoimmune diseases, where corticosteroids are supported as a component of treatment."
    },
    {
        "id": "doc_1521",
        "document": "Research needed in this area. Large, multicenter, randomized trials with well- de\ufb01ned inclusion and exclusion criteria and measurement of multiple relevant clinical outcomes are needed to de\ufb01ne the subsets of patients (if any) who bene\ufb01t or are potentially harmed from corticosteroid therapy. The trial should also make extensive efforts to de\ufb01ne causative pathogens, to de\ufb01ne whether there are clear pathogen-speci\ufb01c indications or contraindications for corticosteroid therapy (especially disease"
    },
    {
        "id": "doc_1522",
        "document": "due to S. pneumoniae and in\ufb02uenza)."
    },
    {
        "id": "doc_1523",
        "document": "Question 13: In Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antiviral Therapy?\n\nRecommendation. We recommend that antiin\ufb02uenza treatment, such as oseltamivir, be prescribed for adults with CAP who test\n\npositive for in\ufb02uenza in the inpatient setting, independent of duration of illness before diagnosis (strong recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1524",
        "document": "We suggest that antiin\ufb02uenza treatment be prescribed for adults with CAP who test positive for in\ufb02uenza in the outpatient setting, independent of duration of illness before diagnosis (conditional recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1525",
        "document": "Summary of the evidence. No clinical trials have evaluated the effect of treatment with antiin\ufb02uenza agents in adults with in\ufb02uenza pneumonia, and data are lacking on the bene\ufb01ts of using antiin\ufb02uenza agents in the outpatient setting for patients with CAP who test positive for in\ufb02uenza virus. Several observational studies suggest that treatment with oseltamivir is associated with reduced risk of death in patients hospitalized for CAP who test positive for in\ufb02uenza virus (181, 182). Treatment"
    },
    {
        "id": "doc_1526",
        "document": "within 2 days of symptom onset or hospitalization may result in the best outcomes (183, 184), although there may be bene\ufb01ts up to 4 or 5 days after symptoms begin (181, 185)."
    },
    {
        "id": "doc_1527",
        "document": "The use of antiin\ufb02uenza agents in the outpatient setting reduces duration of symptoms and the likelihood of lower respiratory tract complications among patients with in\ufb02uenza (186), with most bene\ufb01t if therapy is received within 48 hours after onset of symptoms (187)."
    },
    {
        "id": "doc_1528",
        "document": "For inpatients, a substantial body of observational evidence suggests that giving antiin\ufb02uenza agents reduces mortality risk in adults with in\ufb02uenza infection. Although bene\ufb01ts are strongest when therapy is started within 48 hours of symptom onset, studies also support starting later (185). These data underlie our strong recommendation for using antiin\ufb02uenza agents for patients with CAP and in\ufb02uenza in the inpatient setting, consistent with the recently published IDSA In\ufb02uenza Clinical Practice"
    },
    {
        "id": "doc_1529",
        "document": "Guideline (33)."
    },
    {
        "id": "doc_1530",
        "document": "Although we did not identify studies that speci\ufb01cally evaluated antiin\ufb02uenza agents for treating outpatients with CAP who test positive for in\ufb02uenza, we make the same recommendation as for inpatients, on the basis of the inpatient data and on outpatient data showing better time to resolution of symptoms and prevention of hospitalization among those with in\ufb02uenza but without pneumonia. Our recommendations are consistent with the\n\ne58"
    },
    {
        "id": "doc_1531",
        "document": "American Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nIDSA in\ufb02uenza guidelines, which were recently released (33)."
    },
    {
        "id": "doc_1532",
        "document": "Randomized controlled studies are needed to support the recommendation for use of antiin\ufb02uenza agents to treat for in\ufb02uenza pneumonia in the outpatient setting. In particular, knowing whether therapy is valuable when started more the 48 hours after symptom onset would help guide clinical decision-making."
    },
    {
        "id": "doc_1533",
        "document": "Question 14: In Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy?\n\nRecommendation. We recommend that standard antibacterial treatment be initially prescribed for adults with clinical and radiographic evidence of CAP who test positive for in\ufb02uenza in the inpatient and outpatient settings (strong recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1534",
        "document": "Summary of the evidence. Bacterial pneumonia can occur concurrently with in\ufb02uenza virus infection or present later as a worsening of symptoms in patients who were recovering from their primary in\ufb02uenza virus infection. As many as 10% of patients hospitalized for in\ufb02uenza and bacterial pneumonia die as a result of their infection (188). An autopsy series from the 2009 H1N1 in\ufb02uenza pandemic found evidence of bacterial coinfection in about 30% of deaths (189)."
    },
    {
        "id": "doc_1535",
        "document": "S. aureus is one of the most common bacterial infections associated with in\ufb02uenza pneumonia, followed by S. pneumoniae, H. in\ufb02uenzae, and group A Streptococcus; other bacteria have also been implicated (188, 190\u2013192). Given this spectrum of pathogens, appropriate agents for initial therapy include the same agents generally recommended for CAP. Risk factors and need for empiric coverage for MRSA would follow the guidelines included earlier in this document. Rapidly progressive severe pneumonia"
    },
    {
        "id": "doc_1536",
        "document": "with MRSA has been described in previously healthy young patients, particularly in the setting of prior in\ufb02uenza; however, it is typically readily identi\ufb01ed in the nares or sputum and should be identi\ufb01ed by following the recommendations of earlier recommendations in this guideline."
    },
    {
        "id": "doc_1537",
        "document": "Rationale for the recommendation. The recommendation to routinely prescribe antibacterial agents in patients with in\ufb02uenza virus infection and pneumonia was based on evidence suggesting that"
    },
    {
        "id": "doc_1538",
        "document": "bacterial coinfections are a common and serious complication of in\ufb02uenza, as well as the inability to exclude the presence of bacterial coinfection in a patient with CAP who has a positive test for in\ufb02uenza virus. Although low levels of biomarkers such as procalcitonin decrease the likelihood that patients have bacterial infections, these biomarkers do not completely rule out bacterial pneumonia in an individual patient with suf\ufb01cient accuracy to justify initially withholding antibiotic therapy,"
    },
    {
        "id": "doc_1539",
        "document": "especially among patients with severe CAP (37, 38, 193). We have provided a strong recommendation because of the signi\ufb01cant risk of treatment failure in delaying appropriate antibacterial therapy in patients with CAP. However in patients with CAP, a positive in\ufb02uenza test, no evidence of a bacterial pathogen (including a low procalcitonin level), and early clinical stability, consideration could be given to earlier discontinuation of antibiotic treatment at 48 to 72 hours."
    },
    {
        "id": "doc_1540",
        "document": "Research needed in this area. Randomized controlled studies are needed to establish whether antibacterial therapy can be stopped at 48 hours for patients with CAP who test positive for in\ufb02uenza and have no biomarker (e.g., procalcitonin) or microbiological evidence of a concurrent bacterial infection.\n\nQuestion 15: In Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?"
    },
    {
        "id": "doc_1541",
        "document": "Recommendation. We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence)."
    },
    {
        "id": "doc_1542",
        "document": "Summary of the evidence. A small number of randomized trials address the appropriate duration of antibiotic therapy in CAP, and randomized placebo-controlled trials of high quality are mostly limited to the inpatient setting. In these trials, no difference was observed between 5 additional days of oral amoxicillin compared with placebo in patients who had clinically improved on 3 days of intravenous"
    },
    {
        "id": "doc_1543",
        "document": "amoxicillin (194), or between 2 days of intravenous cefuroxime followed by 5 days versus 8 days of oral cefuroxime (195). Similar results were obtained with 5 days of levo\ufb02oxacin 750 mg daily compared with 10 days of levo\ufb02oxacin 500 mg daily (196) and 5 days of intravenous ceftriaxone compared with 10 days (197). Several recent meta- analyses similarly demonstrate the ef\ufb01cacy of shorter courses of antibiotic therapy of 5 to 7 days (198\u2013200)."
    },
    {
        "id": "doc_1544",
        "document": "Several studies have demonstrated that the duration of antibiotic therapy can be reduced in patients with CAP with the use of a procalcitonin-guided pathway and serial procalcitonin measurement compared with conventional care, but in most cases the average length of treatment was greatly in excess of current U.S. standards of practice as well as the recommendations of these current guidelines. Concern has also been raised that procalcitonin levels may not be elevated when there is concurrent"
    },
    {
        "id": "doc_1545",
        "document": "viral and bacterial infection (201, 202) or with important pathogens such as Legionella and Mycoplasma spp (37, 201, 203). Serial procalcitonin measurement is therefore likely to be useful primarily in settings where the average length of stay for patients with CAP exceeds normal practice (e.g., 5\u20137 d)."
    },
    {
        "id": "doc_1546",
        "document": "It is recognized that some patients do not respond to a standard duration of therapy. A variety of criteria for determining clinical improvement have been developed for patients with CAP and validated in clinical trials, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation (204). Failure to achieve clinical stability within 5 days is associated with higher mortality and worse"
    },
    {
        "id": "doc_1547",
        "document": "clinical outcomes (205\u2013207). Such failure should prompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or in\ufb02ammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice, patients have shorter durations of antibiotic therapy without adverse impact on outcome (210). All clinicians should therefore use an assessment of"
    },
    {
        "id": "doc_1548",
        "document": "clinical stability as part of routine care of patients with CAP."
    },
    {
        "id": "doc_1549",
        "document": "Longer courses of antibiotic therapy are recommended for 1) pneumonia\n\nAmerican Thoracic Society Documents\n\ne59\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\ncomplicated by meningitis, endocarditis, and other deep-seated infection; or 2) infection with other, less-common pathogens not covered in these guidelines (e.g., Burkholderia pseudomallei, Mycobacterium tuberculosis or endemic fungi)."
    },
    {
        "id": "doc_1550",
        "document": "As recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013bene\ufb01t basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the \ufb01rst 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients. In switching from parenteral to oral antibiotics, either the same agent or the same drug class should be used."
    },
    {
        "id": "doc_1551",
        "document": "We acknowledge that most studies in support of 5 days of antibiotic therapy include patients without severe CAP, but we believe these results apply to patients with severe CAP and without infectious complications. We believe that the duration of therapy for CAP due to suspected or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital- acquired pneumonia and ventilator- associated pneumonia guidelines (166)."
    },
    {
        "id": "doc_1552",
        "document": "Research needed in this area. Controlled studies are needed to establish the duration of antibiotic therapy for adults with complications of CAP, including empyema, and adults with prolonged time to achieving clinical stability."
    },
    {
        "id": "doc_1553",
        "document": "Question 16: In Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\n\nRecommendation. In adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence)."
    },
    {
        "id": "doc_1554",
        "document": "Summary of the evidence. There are limited data on the clinical usefulness of reimaging patients with pneumonia. Most available data have evaluated whether reimaging patients detects lung malignancy not recognized at the time of treatment for pneumonia. Reported rates of malignancy in patients recovering from CAP range from 1.3% to 4% (211\u2013214). When unsuspected\n\nnonmaligant pathology is included, the rate of abnormal \ufb01ndings may reach 5%."
    },
    {
        "id": "doc_1555",
        "document": "Almost all patients with malignancy in reported series were smokers or ex-smokers. One longer-term study found 9.2% of CAP survivors in the Veterans Affairs system (with a predominantly male population and high smoking prevalence) had a new diagnosis of cancer, with a mean time to diagnosis of 297 days. However, only 27% were diagnosed within 90 days of discharge from hospital, suggesting the yield of routine follow-up post discharge would be low (215)."
    },
    {
        "id": "doc_1556",
        "document": "Rationale for the recommendation. Available data suggest the positive yield from repeat imaging ranges from 0.2% to 5.0%; however many patients with new abnormalities in these studies meet criteria for lung cancer screening among current or past smokers (216).\n\nResearch needed in this area. Further research may clarify subgroups of patients who may bene\ufb01t from further radiological assessment after initial therapy for pneumonia.\n\nConclusions"
    },
    {
        "id": "doc_1557",
        "document": "Recommendations to help clinicians optimize therapy for their patients with CAP have been revised in light of new data. Methods of quality improvement are critical to the implementation of guideline recommendations. It remains disappointing how few key clinical questions have been studied adequately enough to allow for strong recommendations regarding the standard of care. We hope that the research priorities outlined in this document will prompt new investigations addressing key knowledge gaps."
    },
    {
        "id": "doc_1558",
        "document": "Despite substantial concern over the rise of antibiotic-resistant pathogens, most patients with CAP can be adequately treated with regimens that have been used for multiple decades. It is also true that the subset of patients with CAP who have signi\ufb01cant comorbidities and frequent contact with healthcare settings and antibiotics is increasing, and, in some settings, the rates of infection with MRSA or P. aeruginosa are high enough to warrant empiric treatment."
    },
    {
        "id": "doc_1559",
        "document": "Unfortunately, microbiological testing has yet to deliver fast, accurate, and affordable testing that results in proven bene\ufb01t for patients with CAP in terms of more rapid delivery of targeted therapy or safe deescalation of unnecessary therapy. Exceptions include rapid testing for MRSA and in\ufb02uenza. Until we have such widely available (and affordable) tests, therapy for many or most patients with CAP will remain empiric. Therefore, clinicians need to be aware of the spectrum of local pathogens,"
    },
    {
        "id": "doc_1560",
        "document": "especially if they care for patients at a center where infection with antibiotic-resistant pathogens such as MRSA and P. aeruginosa are more common."
    },
    {
        "id": "doc_1561",
        "document": "previous ones is that we have signi\ufb01cantly increased the proportion of patients in whom we recommend routinely obtaining respiratory tract samples for microbiologic studies. This decision is largely based on a desire to correct the overuse of anti-MRSA and antipseudomonal therapy that has occurred since the introduction of the HCAP classi\ufb01cation (which we recommend abandoning) rather than high-quality evidence. We expect this change will generate signi\ufb01cant research to prove or disprove the"
    },
    {
        "id": "doc_1562",
        "document": "value of this approach. As it is not possible to create a \u201cone size \ufb01ts all\u201d schema for empiric therapy for CAP, clinicians must validate any approach taking into account their local spectrum and frequency of resistant pathogens, which is another driver for recommending increased testing. We similarly expect our move against endorsing monotherapy with macrolides, which is based on population resistance data rather than high-quality clinical studies, will generate future outcomes studies"
    },
    {
        "id": "doc_1563",
        "document": "comparing different treatment strategies."
    },
    {
        "id": "doc_1564",
        "document": "We hope that clinicians and researchers will \ufb01nd this guideline useful, but the recommendations included here do not obviate the need for clinical assessment and knowledge to ensure each individual patient receives appropriate and timely care. However, this guideline delineates minimum clinical standards that are achievable and will help drive the best patient outcomes on the basis of currently available data. n\n\ne60"
    },
    {
        "id": "doc_1565",
        "document": "American Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nThis clinical practice guideline was prepared by an ATS/IDSA ad hoc committee on community-acquired pneumonia in adults.\n\nMembers of the committee are as follows:"
    },
    {
        "id": "doc_1566",
        "document": "JOSHUA P. METLAY, M.D., PH.D. (Co-Chair)1,2 GRANT W. WATERER, M.B. B.S., PH.D. (Co-Chair)3 ANTONIO ANZUETO, M.D.4,5 JAN BROZEK, M.D., PH.D.6* KRISTINA CROTHERS, M.D.7,8 LAURA A. COOLEY, M.D.9 NATHAN C. DEAN, M.D.10,11 MICHAEL J. FINE, M.D., M.SC.12,13 SCOTT A. FLANDERS, M.D.14 MARIE R. GRIFFIN, M.D., M.P.H.15 ANN C. LONG, M.D., M.S.8* MARK L. METERSKY, M.D.16 DANIEL M. MUSHER, M.D.17,18 MARCOS I. RESTREPO, M.D., M.SC., PH.D.4,5 CYNTHIA G. WHITNEY, M.D., M.P.H.9"
    },
    {
        "id": "doc_1567",
        "document": "*Methodologist. 1Massachusetts General Hospital, Boston, Massachusetts; 2Harvard Medical School, Boston, Massachusetts; 3Royal Perth Hospital"
    },
    {
        "id": "doc_1568",
        "document": "and University of Western Australia, Perth, Australia; 4South Texas Veterans Healthcare System, San Antonio, Texas; 5University of Texas Health San Antonio, San Antonio, Texas; 6McMaster University, Hamilton, Ontario, Canada; 7VA Puget Sound Health Care System, Seattle, Washington; 8University of Washington, Seattle, Washington; 9Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; 10Intermountain Medical Center, Salt Lake City, Utah; 11University of Utah,"
    },
    {
        "id": "doc_1569",
        "document": "Salt Lake City, Utah; 12VA Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 13University of Pittsburgh, Pittsburgh, Pennsylvania; 14University of Michigan, Ann Arbor, Michigan; 15Vanderbilt University, Nashville, Tennessee; 16University of Connecticut School of Medicine, Farmington, Connecticut; 17Michael E. DeBakey VA Medical Center, Houston, Texas; and 18Baylor College of Medicine, Houston, Texas"
    },
    {
        "id": "doc_1570",
        "document": "Author Disclosures: A.A. served as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, P\ufb01zer, and Sunovion; served on an"
    },
    {
        "id": "doc_1571",
        "document": "advisory committee for AstraZeneca, Forest, and Novartis; served on a data safety and monitoring board for Bayer; and received research support from GlaxoSmithKline. N.C.D. served as a consultant for Cerexa; served on a data safety and monitoring board for Contrafect and Theravance; and served on an advisory committee for Cempra and Paratek. S.A.F. received research support from the Blue Cross Blue Shield of Michigan; received personal fees for expert testimony related to the practice of"
    },
    {
        "id": "doc_1572",
        "document": "hospital medicine; and received royalties from Wiley Publishing. A.C.L. has ownership or investment interest with Aurora Cannabis, Canopy Growth, and Cronos Group. M.L.M. received research support from Gilead, Insmed, Multiclonal Therapeutics, and Pharmaxis; served as a consultant for Aradigm, Arsanis, Bayer, Insmed, International Biophysics, Savara, Shionogi, and various law \ufb01rms; served as a consultant for EBSCO as a reviewer for DynaMed, a decision support tool; and served on an advisory"
    },
    {
        "id": "doc_1573",
        "document": "committee and as a consultant for Grifols. J.P.M., G.W., J.B., K.C., L.A.C., M.J.F., M.R.G., D.M.M., M.I.R., and C.G.W. reported no relevant commercial relationships."
    },
    {
        "id": "doc_1574",
        "document": "References\n\n1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis 2007;44:S27\u2013S72."
    },
    {
        "id": "doc_1575",
        "document": "2. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395\u2013400.\n\n3. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community- acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440\u20131445."
    },
    {
        "id": "doc_1576",
        "document": "4. Sato T, Aoshima M, Ohmagari N, Tada H, Chohnabayashi N. Usefulness of sputum Gram staining in community-acquired pneumonia [in Japanese]. Nihon Kokyuki Gakkai Zasshi 2002;40:558\u2013563.\n\n5. Shariatzadeh MR, Marrie TJ. Does sputum culture affect the management and/or outcome of community-acquired pneumonia? East Mediterr Health J 2009;15:792\u2013799."
    },
    {
        "id": "doc_1577",
        "document": "6. Signori LG, Ferreira MW, Vieira LC, Muller KR, Mattos WL. Sputum examination in the clinical management of community-acquired pneumonia [in Portuguese]. J Bras Pneumol 2008;34:152\u2013158.\n\n7. Uematsu H, Hashimoto H, Iwamoto T, Horiguchi H, Yasunaga H. Impact of guideline-concordant microbiological testing on outcomes of pneumonia. Int J Qual Health Care 2014;26:100\u2013107."
    },
    {
        "id": "doc_1578",
        "document": "8. Lidman C, Burman LG, Lagergren A, Ortqvist A. Limited value of routine microbiological diagnostics in patients hospitalized for community- acquired pneumonia. Scand J Infect Dis 2002;34:873\u2013879.\n\n9. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346\u2013348."
    },
    {
        "id": "doc_1579",
        "document": "10. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005;60:672\u2013678."
    },
    {
        "id": "doc_1580",
        "document": "11. Ewig S, Torres A, Angeles Marcos M, Angrill J, Ra\u00f1 \u00b4o A, de Roux A, et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002;20: 1254\u20131262.\n\n12. Ewig S, Schlochtermeier M, G \u00a8oke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002;121:1486\u20131492."
    },
    {
        "id": "doc_1581",
        "document": "13. Garc\u00b4\u0131a-V \u00b4azquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004;164:1807\u20131811.\n\n14. L \u00b4evy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988;93:43\u201348."
    },
    {
        "id": "doc_1582",
        "document": "15. Miyashita N, Shimizu H, Ouchi K, Kawasaki K, Kawai Y, Obase Y, et al. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 2008;14:CR171\u2013CR176.\n\n16. Ros \u00b4on B, Carratal `a J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000;31:869\u2013874."
    },
    {
        "id": "doc_1583",
        "document": "17. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Jansen HM, Boersma WG. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241\u2013249.\n\n18. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004;39:165\u2013169."
    },
    {
        "id": "doc_1584",
        "document": "19. McCauley LM, Webb BJ, Sorensen J, Dean NC. Use of tracheal aspirate culture in newly intubated patients with community-onset pneumonia. Ann Am Thorac Soc 2016;13:376\u2013381.\n\n20. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080\u20132084."
    },
    {
        "id": "doc_1585",
        "document": "21. Benenson RS, Kepner AM, Pyle DN II, Cavanaugh S. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007;33:1\u20138.\n\nAmerican Thoracic Society Documents\n\ne61\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\n22. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community- acquired pneumonia at academic hospitals. Arch Intern Med 2001; 161:2099\u20132104."
    },
    {
        "id": "doc_1586",
        "document": "23. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003;123:1142\u20131150.\n\n24. Waterer GW, Wunderink RG. The in\ufb02uence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78\u201382."
    },
    {
        "id": "doc_1587",
        "document": "25. Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999;116:1278\u20131281.\n\n26. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:342\u2013347."
    },
    {
        "id": "doc_1588",
        "document": "27. Costantini E, Allara E, Patrucco F, Faggiano F, Hamid F, Balbo PE. Adherence to guidelines for hospitalized community-acquired pneumonia over time and its impact on health outcomes and mortality. Intern Emerg Med 2016;11:929\u2013940."
    },
    {
        "id": "doc_1589",
        "document": "28. Falguera M, Ruiz-Gonz \u00b4alez A, Schoenenberger JA, Touz \u00b4on C, G \u00b4azquez I, Galindo C, et al. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community- acquired pneumonia. Thorax 2010;65:101\u2013106."
    },
    {
        "id": "doc_1590",
        "document": "29. Piso RJ, Iven-Koller D, Koller MT, Bassetti S. The routine use of urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment. Swiss Med Wkly 2012;142:w13679.\n\n30. Garrison LE, Kunz JM, Cooley LA, Moore MR, Lucas C, Schrag S, et al. Vital signs: de\ufb01ciencies in environmental control identi\ufb01ed in outbreaks of legionnaires\u2019 disease. North America, 2000-2014. MMWR Morb Mortal Wkly Rep 2016;65:576\u2013584."
    },
    {
        "id": "doc_1591",
        "document": "31. Dooling KL, Toews KA, Hicks LA, Garrison LE, Bachaus B, Zansky S, et al. Active bacterial core surveillance for legionellosis: United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2015;64:1190\u20131193.\n\n32. Uyeki TM. Preventing and controlling in\ufb02uenza with available interventions. N Engl J Med 2014;370:789\u2013791."
    },
    {
        "id": "doc_1592",
        "document": "33. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM Jr, Fry AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal in\ufb02uenzaa. Clin Infect Dis 2018;68:e1\u2013e47.\n\n34. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619\u20131628."
    },
    {
        "id": "doc_1593",
        "document": "35. Christ-Crain M, Stolz D, Bingisser R, M \u00a8uller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community- acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84\u201393.\n\n36. Schuetz P, M \u00a8uller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;(9): CD007498."
    },
    {
        "id": "doc_1594",
        "document": "37. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017;65:183\u2013190.\n\n38. Kamat IS, Ramachandran V, Eswaran H, Abers MS, Musher DM. Low procalcitonin, community acquired pneumonia, and antibiotic therapy. Lancet Infect Dis 2018;18:496\u2013497."
    },
    {
        "id": "doc_1595",
        "document": "39. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community- acquired pneumonia. N Engl J Med 1997;336:243\u2013250.\n\n40. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. De\ufb01ning community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377\u2013382."
    },
    {
        "id": "doc_1596",
        "document": "41. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118: 384\u2013392.\n\n42. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG; CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749\u2013755."
    },
    {
        "id": "doc_1597",
        "document": "43. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881\u2013894.\n\n44. Carratal `a J, Fern \u00b4andez-Sab \u00b4e N, Ortega L, Castellsagu \u00b4e X, Ros \u00b4on B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005;142:165\u2013172."
    },
    {
        "id": "doc_1598",
        "document": "45. Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, et al. Safely increasing the proportion of patients with community- acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998;158:1350\u20131356.\n\n46. Jo S, Kim K, Jung K, Rhee JE, Cho IS, Lee CC, et al. The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia. J Emerg Med 2012;42:133\u2013138."
    },
    {
        "id": "doc_1599",
        "document": "47. Juli \u00b4an-Jim \u00b4enez A, Palomo de los Reyes MJ, Parejo Miguez R, La\u00b4\u0131n- Ter \u00b4es N, Cuena-Boy R, Lozano-Anc\u00b4\u0131n A. Improved management of community-acquired pneumonia in the emergency department. Arch Bronconeumol 2013;49:230\u2013240."
    },
    {
        "id": "doc_1600",
        "document": "48. Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, et al.; Pneumocom Study Investigators. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007;44:41\u201349."
    },
    {
        "id": "doc_1601",
        "document": "49. Labarere J, Stone RA, Scott Obrosky D, Yealy DM, Meehan TP, Auble TE, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-\n\n50. Marrie TJ, Huang JQ. Low-risk patients admitted with community- acquired pneumonia. Am J Med 2005;118:1357\u20131363."
    },
    {
        "id": "doc_1602",
        "document": "51. Dean NC, Jones BE, Jones JP, Ferraro JP, Post HB, Aronsky D, et al. Impact of an electronic clinical decision support tool for emergency department patients with pneumonia. Ann Emerg Med 2015;66: 511\u2013520.\n\n52. Richards DA, Toop LJ, Epton MJ, McGeoch GR, Town GI, Wynn-Thomas SM, et al. Home management of mild to moderately severe community-acquired pneumonia: a randomised controlled trial. Med J Aust 2005;183:235\u2013238."
    },
    {
        "id": "doc_1603",
        "document": "53. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004;125:2140\u20132145.\n\n54. Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc 2012;60:2137\u20132143."
    },
    {
        "id": "doc_1604",
        "document": "55. MDCalc. PSI/PORT score: pneumonia severity index for CAP [accessed 2019 Sept 8]. Available from: https://www.mdcalc.com/ psi-port-score-pneumonia-severity-index-cap.\n\n56. Jones BE, Jones J, Bewick T, Lim WS, Aronsky D, Brown SM, et al. CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest 2011;140:156\u2013163."
    },
    {
        "id": "doc_1605",
        "document": "57. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Pi\u00f1er R, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009;48: 377\u2013385.\n\n58. Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009;64:598\u2013603."
    },
    {
        "id": "doc_1606",
        "document": "59. Chalmers JD, Taylor JK, Mandal P, Choudhury G, Singanayagam A, Akram AR, et al. Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011;53:503\u2013511."
    },
    {
        "id": "doc_1607",
        "document": "60. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al.; Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory\n\ne62\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\nor vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375\u2013384."
    },
    {
        "id": "doc_1608",
        "document": "61. Brown SM, Jones BE, Jephson AR, Dean NC; Infectious Disease Society of America/American Thoracic Society 2007. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009;37:3010\u20133016.\n\n62. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012;16:R141."
    },
    {
        "id": "doc_1609",
        "document": "63. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011;37:1409\u20131420.\n\n64. Brown SM, Jones JP, Aronsky D, Jones BE, Lanspa MJ, Dean NC. Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia. Respirology 2012;17:1207\u20131213."
    },
    {
        "id": "doc_1610",
        "document": "65. Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 2010; 36:826\u2013833.\n\n66. Renaud B, Brun-Buisson C, Santin A, Coma E, Noyez C, Fine MJ, et al. Outcomes of early, late, and no admission to the intensive care unit for patients hospitalized with community-acquired pneumonia. Acad Emerg Med 2012;19:294\u2013303."
    },
    {
        "id": "doc_1611",
        "document": "67. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010;137:552\u2013557."
    },
    {
        "id": "doc_1612",
        "document": "68. Pakhale S, Mulpuru S, Verheij T, Kochen M, Rohde G, Bjerre L. Antibiotics for community-acquired pneumonia in adolescent and adult outpatients. 2014 [accessed 2017 Nov 19]. Available from: http://www.cochrane.org/CD002109/ARI_antibiotics-for- community-acquired-pneumonia-in-adolescent-and-adult- outpatients."
    },
    {
        "id": "doc_1613",
        "document": "69. English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu ZQ, Jenta TR, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative ef\ufb01cacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother 2012;56:2037\u20132047."
    },
    {
        "id": "doc_1614",
        "document": "70. Fogarty C, Grossman C, Williams J, Haverstock M, Church D. Ef\ufb01cacy and safety of moxi\ufb02oxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999;16:748\u2013763.\n\n71. Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002;24:1854\u20131870."
    },
    {
        "id": "doc_1615",
        "document": "72. Gotfried MH, Dattani D, Riffer E, Devcich KJ, Busman TA, Notario GF, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levo\ufb02oxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002;24:736\u2013751.\n\n73. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37: 555\u2013564."
    },
    {
        "id": "doc_1616",
        "document": "74. Kohno S, Watanabe A, Aoki N, Niki Y. Clinical evaluation of telithromycin for community-acquired pneumonia phase III double- blind comparative study of telithromycin versus levo\ufb02oxacin. Japanese Journal of Chemotherapy 2003;51:255\u2013278."
    },
    {
        "id": "doc_1617",
        "document": "75. Liu Y, Zhang Y, Wu J, Zhu D, Sun S, Zhao L, et al. A randomized, double-blind, multicenter phase II study comparing the ef\ufb01cacy and safety of oral nemonoxacin with oral levo\ufb02oxacin in the treatment of community- acquired pneumonia. J Microbiol Immunol Infect 2017;50:811\u2013820."
    },
    {
        "id": "doc_1618",
        "document": "76. Bonvehi P, Weber K, Busman T, Shortridge D, Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for community- acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae. Clin Drug Investig 2003;23:491\u2013501."
    },
    {
        "id": "doc_1619",
        "document": "77. D\u2019Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levo\ufb02oxacin therapy for treatment of mild to moderate community- acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49:4035\u20134041.\n\n78. Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with ce\ufb01xime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998;41: 75\u201380."
    },
    {
        "id": "doc_1620",
        "document": "79. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological ef\ufb01cacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54: 515\u2013523."
    },
    {
        "id": "doc_1621",
        "document": "80. van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, et al. Ef\ufb01cacy and safety of nemonoxacin versus levo\ufb02oxacin for community-acquired pneumonia. Antimicrob Agents Chemother 2010;54:4098\u20134106.\n\n81. Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung 1993;43:1014\u20131017."
    },
    {
        "id": "doc_1622",
        "document": "82. Mathers Dunbar L, Hassman J, Tellier G. Ef\ufb01cacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48\u201362."
    },
    {
        "id": "doc_1623",
        "document": "83. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, et al. Randomized, double-blind, multicenter phase 2 study comparing the ef\ufb01cacy and safety of oral solithromycin (CEM-101) to those of oral levo\ufb02oxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013;57:2526\u20132534."
    },
    {
        "id": "doc_1624",
        "document": "84. Rovira E, Martinez-Moragon E, Belda A, Gonzalvo F, Ripolles F, Pascual JM. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration 1999;66: 413\u2013418.\n\n85. Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J 2008;31:1068\u20131076."
    },
    {
        "id": "doc_1625",
        "document": "86. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxi\ufb02oxacin Study Group. Oral moxi\ufb02oxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185\u2013195."
    },
    {
        "id": "doc_1626",
        "document": "87. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB; Spar\ufb02oxacin European Study Group. Once-daily spar\ufb02oxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998;26: 1312\u20131320."
    },
    {
        "id": "doc_1627",
        "document": "88. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Ef\ufb01cacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378\u2013386."
    },
    {
        "id": "doc_1628",
        "document": "89. Siquier B, S \u00b4anchez-Alvarez J, Garc\u00b4\u0131a-Mendez E, Sabri \u00b4a M, Santos J, Pallar \u00b4es R, et al.; 620 Clinical Study Group. Ef\ufb01cacy and safety of twice- daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006;57:536\u2013545."
    },
    {
        "id": "doc_1629",
        "document": "90. Paris R, Confalonieri M, Dal Negro R, Ligia GP, Mos L, Todisco T, et al. Ef\ufb01cacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 2008;20:77\u201386.\n\n91. Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levo\ufb02oxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010;35:195\u2013200."
    },
    {
        "id": "doc_1630",
        "document": "92. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community- acquired pneumonia. Arch Intern Med 1999;159:266\u2013270.\n\n93. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echag \u00a8uen A, Gareen IF, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556\u2013564."
    },
    {
        "id": "doc_1631",
        "document": "94. Daneman N, McGeer A, Green K, Low DE; Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006;43:432\u2013438.\n\nAmerican Thoracic Society Documents\n\ne63\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1632",
        "document": "95. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program Network, Streptococcus pneumoniae, 2016 [accessed 2019 Sept 8]. Available from: https://www.cdc.gov/abcs/reports-\ufb01ndings/survreports/spneu16.pdf.\n\n96. U.S. Food and Drug Administration. Fluoroquinolone antimicrobial drugs information. 2019 [accessed 2019 Mar 8]. Available from: https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm346750.htm."
    },
    {
        "id": "doc_1633",
        "document": "97. Fogarty C, Siami G, Kohler R, File TM, Tennenberg AM, Olson WH, et al. Multicenter, open-label, randomized study to compare the safety and ef\ufb01cacy of levo\ufb02oxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38:S16\u2013S23."
    },
    {
        "id": "doc_1634",
        "document": "98. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levo\ufb02oxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24:1292\u20131308.\n\n99. Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH. High-dose levo\ufb02oxacin in community-acquired pneumonia: a randomized, open-label study. Clin Drug Investig 2012;32:569\u2013576."
    },
    {
        "id": "doc_1635",
        "document": "100. Lin TY, Lin SM, Chen HC, Wang CJ, Wang YM, Chang ML, et al. An open-label, randomized comparison of levo\ufb02oxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007;30:321\u2013332."
    },
    {
        "id": "doc_1636",
        "document": "101. Portier H, Brambilla C, Garre M, Paganin F, Poubeau P, Zuck P. Moxi\ufb02oxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005;24: 367\u2013376.\n\n102. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, et al.; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312\u20131323."
    },
    {
        "id": "doc_1637",
        "document": "103. Xu S, Xiong S, Xu Y, Liu J, Liu H, Zhao J, et al. Ef\ufb01cacy and safety of intravenous moxi\ufb02oxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technolog Med Sci 2006;26:421\u2013424.\n\n104. Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with b-lactams for adults with community- acquired pneumonia: systematic review and meta-analysis. Int J Antimicrob Agents 2015;46:242\u2013248."
    },
    {
        "id": "doc_1638",
        "document": "105. Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 2016;315:593\u2013602.\n\n106. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:517\u2013527."
    },
    {
        "id": "doc_1639",
        "document": "107. Garin N, Genn \u00b4e D, Carballo S, Chuard C, Eich G, Hugli O, et al. b-Lactam monotherapy vs b-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014;174:1894\u20131901.\n\n108. Nie W, Li B, Xiu Q. b-Lactam/macrolide dual therapy versus b-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1441\u20131446."
    },
    {
        "id": "doc_1640",
        "document": "109. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta- analysis. Respirology 2016;21:1193\u20131200."
    },
    {
        "id": "doc_1641",
        "document": "110. File TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Ef\ufb01cacy and safety of iv-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis [online ahead of print] 4 Feb 2019; DOI: 10.1093/cid/ciz090."
    },
    {
        "id": "doc_1642",
        "document": "111. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community- acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014;42:420\u2013432.\n\n112. Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with b-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 2017;23:234\u2013241."
    },
    {
        "id": "doc_1643",
        "document": "113. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997;111:1266\u20131272.\n\n114. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344:665\u2013671.\n\n115. Marrie TJ, Durant H, Kwan C. Nursing home-acquired pneumonia: a case-control study. J Am Geriatr Soc 1986;34:697\u2013702."
    },
    {
        "id": "doc_1644",
        "document": "116. Jaoude P, Badlam J, Anandam A, El-Solh AA. A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia. Intern Emerg Med 2014;9:143\u2013150.\n\n117. Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess: penicillin G vs clindamycin. JAMA 1975;234: 935\u2013937.\n\n118. Cesar L, Gonzalez C, Calia FM. Bacteriologic \ufb02ora of aspiration- induced pulmonary infections. Arch Intern Med 1975;135: 711\u2013714."
    },
    {
        "id": "doc_1645",
        "document": "119. El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003;167:1650\u20131654.\n\n120. Marik PE, Careau P. The role of anaerobes in patients with ventilator- associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999;115:178\u2013183."
    },
    {
        "id": "doc_1646",
        "document": "121. Mier L, Dreyfuss D, Darchy B, Lanore JJ, Djeda\u00a8\u0131ni K, Weber P, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993;19:279\u2013284."
    },
    {
        "id": "doc_1647",
        "document": "122. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388\u2013416.\n\n123. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854\u20133862."
    },
    {
        "id": "doc_1648",
        "document": "124. Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A, et al. Health care-associated pneumonia in the intensive care unit: guideline-concordant antibiotics and outcomes. J Crit Care 2016; 36:265\u2013271.\n\n125. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, et al. Guideline-concordant therapy and outcomes in healthcare- associated pneumonia. Eur Respir J 2011;38:878\u2013887."
    },
    {
        "id": "doc_1649",
        "document": "126. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014;58:330\u2013339."
    },
    {
        "id": "doc_1650",
        "document": "127. Chen JI, Slater LN, Kurdgelashvili G, Husain KO, Gentry CA. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home. Ann Pharmacother 2013;47:9\u201319.\n\n128. Dobler CC, Waterer G. Healthcare-associated pneumonia: a US disease or relevant to the Asia Paci\ufb01c, too? Respirology 2013;18: 923\u2013932."
    },
    {
        "id": "doc_1651",
        "document": "129. Ewig S, Welte T. Adding fuel to the \ufb02ames? It is time to leave HCAP. Respir Med 2012;106:1309\u20131310.\n\n130. Grenier C, P \u00b4epin J, Nault V, Howson J, Fournier X, Poirier MS, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011;66:1617\u20131624."
    },
    {
        "id": "doc_1652",
        "document": "131. Jones BE, Jones MM, Huttner B, Stoddard G, Brown KA, Stevens VW, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized Veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis 2015;61:1403\u20131410.\n\n132. Kamata K, Suzuki H, Kanemoto K, Tokuda Y, Shiotani S, Hirose Y, et al. Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia. J Infect Chemother 2015;21:596\u2013603.\n\ne64"
    },
    {
        "id": "doc_1653",
        "document": "American Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\n133. Rothberg MB, Zilberberg MD, Pekow PS, Priya A, Haessler S, Belforti R, et al. Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia. J Antimicrob Chemother 2015;70:1573\u20131579."
    },
    {
        "id": "doc_1654",
        "document": "134. Webb BJ, Dascomb K, Stenehjem E, Dean N. Predicting risk of drug- resistant organisms in pneumonia: moving beyond the HCAP model. Respir Med 2015;109:1\u201310.\n\n135. Webb BJ, Dascomb K, Stenehjem E, Vikram HR, Agrwal N, Sakata K, et al. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother 2016;60:2652\u20132663."
    },
    {
        "id": "doc_1655",
        "document": "136. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849\u20131858.\n\n137. Cill \u00b4oniz C, Gabarr \u00b4us A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa. Chest 2016;150:415\u2013425."
    },
    {
        "id": "doc_1656",
        "document": "138. Falcone M, Russo A, Giannella M, Cangemi R, Scarpellini MG, Bertazzoni G, et al. Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS One 2015;10: e0119528.\n\n139. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014;58:5262\u20135268."
    },
    {
        "id": "doc_1657",
        "document": "140. Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, et al. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis 2011;11:61.\n\n141. Jung WJ, Kang YA, Park MS, Park SC, Leem AY, Kim EY, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis 2013;13:370."
    },
    {
        "id": "doc_1658",
        "document": "142. Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology 2016;21:157\u2013163.\n\n143. Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment. BMC Infect Dis 2014;14:252."
    },
    {
        "id": "doc_1659",
        "document": "144. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007;101:2139\u20132144.\n\n145. Polverino E, Cilloniz C, Menendez R, Gabarrus A, Rosales-Mayor E, Alcaraz V, et al. Microbiology and outcomes of community acquired pneumonia in non cystic-\ufb01brosis bronchiectasis patients. J Infect 2015;71:28\u201336."
    },
    {
        "id": "doc_1660",
        "document": "146. Prina E, Ranzani OT, Polverino E, Cill \u00b4oniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12:153\u2013160.\n\n147. Rodrigo-Troyano A, Sibila O. The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirology 2017;22: 1288\u20131299."
    },
    {
        "id": "doc_1661",
        "document": "148. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985\u2013995.\n\n149. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013;13:268."
    },
    {
        "id": "doc_1662",
        "document": "150. Torre-Cisneros J, Natera C, Mesa F, Trikic M, Rodriguez-Bano J. Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study. Eur J Clin Microbiol Infect Dis 2018; 37:51\u201356."
    },
    {
        "id": "doc_1663",
        "document": "151. von Baum H, Welte T, Marre R, Suttorp N, Ewig S; CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J 2010;35:598\u2013605.\n\n152. Wang PH, Wang HC, Cheng SL, Chang HT, Laio CH. Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drug- resistant pathogens. J Formos Med Assoc 2016;115:356\u2013363."
    },
    {
        "id": "doc_1664",
        "document": "153. Wooten DA, Winston LG. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospital-onset pneumonia. Respir Med 2013;107:1266\u20131270.\n\n154. Wu HP, Chu CM, Lin CY, Yu CC, Hua CC, Yu TJ, et al. Liver cirrhosis and diabetes mellitus are risk factors for Staphylococcus aureus infection in patients with healthcare-associated or hospital- acquired pneumonia. Pulm Med 2016;2016:4706150."
    },
    {
        "id": "doc_1665",
        "document": "155. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, et al.; GLIMP Investigators. Global initiative for methicillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis 2016;16:1364\u20131376."
    },
    {
        "id": "doc_1666",
        "document": "156. Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al.; GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018;52:1701190.\n\n157. Carugati M, Franzetti F, Wiemken T, Kelley RR, Peyrani P, Blasi F, et al. De-escalation therapy among bacteraemic patients with community-acquired pneumonia. Clin Microbiol Infect 2015;21:936, e11-8."
    },
    {
        "id": "doc_1667",
        "document": "158. Viasus D, Simonetti AF, Garcia-Vidal C, Niubo J, Dorca J, Carratala J. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. J Antimicrob Chemother 2017;72:547\u2013553.\n\n159. Cremers AJ, Sprong T, Schouten JA, Walraven G, Hermans PW, Meis JF, et al. Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. J Antimicrob Chemother 2014;69: 2258\u20132264."
    },
    {
        "id": "doc_1668",
        "document": "160. Yamana H, Matsui H, Tagami T, Hirashima J, Fushimi K, Yasunaga H. De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia. J Infect 2016;73:314\u2013325.\n\n161. Buckel WR, Stenehjem E, Sorensen J, Dean N, Webb B. Broad- versus narrow-spectrum oral antibiotic transition and outcomes in health care-associated pneumonia. Ann Am Thorac Soc 2017;14: 200\u2013205."
    },
    {
        "id": "doc_1669",
        "document": "162. Morel J, Casoetto J, Josp \u00b4e R, Aubert G, Terrana R, Dumont A, et al. De-escalation as part of a global strategy of empiric antibiotherapy management: a retrospective study in a medico-surgical intensive care unit. Crit Care 2010;14:R225."
    },
    {
        "id": "doc_1670",
        "document": "163. Leone M, Bechis C, Baumstarck K, Lefrant JY, Alban `ese J, Jaber S, et al.; AZUREA Network Investigators. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014;40:1399\u20131408."
    },
    {
        "id": "doc_1671",
        "document": "164. Guti \u00b4errez-Pizarraya A, Leone M, Garnacho-Montero J, Martin C, Martin-Loeches I. Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis. Expert Rev Clin Pharmacol 2017;10: 457\u2013465."
    },
    {
        "id": "doc_1672",
        "document": "165. Jones BE, Brown KA, Jones MM, Huttner BD, Greene T, Sauer BC, et al. Variation in empiric coverage versus detection of methicillin- resistant Staphylococcus aureus and Pseudomonas aeruginosa in hospitalizations for community-onset pneumonia across 128 US Veterans Affairs Medical Centers. Infect Control Hosp Epidemiol 2017;38:937\u2013944."
    },
    {
        "id": "doc_1673",
        "document": "166. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61\u2013e111."
    },
    {
        "id": "doc_1674",
        "document": "167. Danger\ufb01eld B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014;58:859\u2013864.\n\n168. Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis 2018;67:1\u20137."
    },
    {
        "id": "doc_1675",
        "document": "American Thoracic Society Documents\n\ne65\n\nAMERICAN THORACIC SOCIETY DOCUMENTS\n\n169. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304\u2013377."
    },
    {
        "id": "doc_1676",
        "document": "170. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242\u2013248.\n\n171. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 2013;62:439\u2013445."
    },
    {
        "id": "doc_1677",
        "document": "172. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo- controlled trial. Lancet 2015;385:1511\u20131518."
    },
    {
        "id": "doc_1678",
        "document": "173. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high in\ufb02ammatory response: a randomized clinical trial. JAMA 2015;313: 677\u2013686."
    },
    {
        "id": "doc_1679",
        "document": "174. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta- analysis 2015 update. Sci Rep 2015;5:14061.\n\n175. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015;163:519\u2013528."
    },
    {
        "id": "doc_1680",
        "document": "176. Briel M, Spoorenberg SMC, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, et al.; Ovidius Study Group; Capisce Study Group; STEP Study Group. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis 2018;66: 346\u2013354."
    },
    {
        "id": "doc_1681",
        "document": "177. Chen LP, Chen JH, Chen Y, Wu C, Yang XH. Ef\ufb01cacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. World J Emerg Med 2015;6:172\u2013178.\n\n178. Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, et al.; SepNet\u2013Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 2016;316:1775\u20131785."
    },
    {
        "id": "doc_1682",
        "document": "179. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017;357:j1415.\n\n180. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of in\ufb02uenza. Cochrane Database Syst Rev 2016;3:CD010406."
    },
    {
        "id": "doc_1683",
        "document": "181. Lee N, Choi KW, Chan PK, Hui DS, Lui GC, Wong BC, et al. Outcomes of adults hospitalised with severe in\ufb02uenza. Thorax 2010;65:510\u2013515.\n\n182. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al.; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of in\ufb02uenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568\u20131575."
    },
    {
        "id": "doc_1684",
        "document": "183. Lee EH, Wu C, Lee EU, Stoute A, Hanson H, Cook HA, et al. Fatalities associated with the 2009 H1N1 in\ufb02uenza A virus in New York city. Clin Infect Dis 2010;50:1498\u20131504.\n\n184. Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al.; Pandemic H1N1 In\ufb02uenza in Pregnancy Working Group. Pandemic 2009 in\ufb02uenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303:1517\u20131525."
    },
    {
        "id": "doc_1685",
        "document": "185. Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, et al. Treatment with neuraminidase inhibitors for critically ill patients with in\ufb02uenza A (H1N1)pdm09. Clin Infect Dis 2012;55:1198\u20131204.\n\n186. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for in\ufb02uenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729\u20131737."
    },
    {
        "id": "doc_1686",
        "document": "187. Venkatesan S, Myles PR, Leonardi-Bee J, Muthuri SG, Al Masri M, Andrews N, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with in\ufb02uenza A(H1N1)pdm09 at high\n\nrisk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis 2017;64:1328\u20131334."
    },
    {
        "id": "doc_1687",
        "document": "188. Metersky ML, Masterton RG, Lode H, File TM, Jr., Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating in\ufb02uenza. Int J Infect Dis 2012; 16:e321\u2013e331.\n\n189. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic in\ufb02uenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010;177:166\u2013175."
    },
    {
        "id": "doc_1688",
        "document": "190. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 in\ufb02uenza season. Emerg Infect Dis 2006;12:894\u2013899.\n\n191. Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F, et al. Invasive group A streptococcal infection concurrent with 2009 H1N1 in\ufb02uenza. Clin Infect Dis 2010;50:e59\u2013e62."
    },
    {
        "id": "doc_1689",
        "document": "192. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon- Carnes M, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal in\ufb02uenza B virus infection. J Infect Dis 2012;205:895\u2013905."
    },
    {
        "id": "doc_1690",
        "document": "193. Rodr\u00b4\u0131guez AH, Avil \u00b4es-Jurado FX, D\u00b4\u0131az E, Schuetz P, Tre\ufb02er SI, Sol \u00b4e- Viol \u00b4an J, et al.; SEMICYUC/GETGAG Working Group. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with in\ufb02uenza: a CHAID decision-tree analysis. J Infect 2016;72:143\u2013151."
    },
    {
        "id": "doc_1691",
        "document": "194. el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate- severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355."
    },
    {
        "id": "doc_1692",
        "document": "195. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 1999;6:217\u2013222.\n\n196. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levo\ufb02oxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752\u2013760."
    },
    {
        "id": "doc_1693",
        "document": "197. Leophonte P, Choutet P, Gaillat J, Petitpretz P, Portier H, Montestruc F, et al. Ef\ufb01cacit \u00b4e compar \u00b4ee de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aigues communautaires de l\u2019adulte hospitalis \u00b4e avec facteur de risque [in French]. Med Mal Infect 2992;32:360\u2013381."
    },
    {
        "id": "doc_1694",
        "document": "198. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. Drugs 2008;68:1841\u20131854.\n\n199. Li JZ, Winston LG, Moore DH, Bent S. Ef\ufb01cacy of short-course antibiotic regimens for community-acquired pneumonia: a meta- analysis. Am J Med 2007;120:783\u2013790."
    },
    {
        "id": "doc_1695",
        "document": "200. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the ef\ufb01cacy of short-course antibiotic treatments for community- acquired pneumonia in adults. Antimicrob Agents Chemother 2018; 62:e00635-18."
    },
    {
        "id": "doc_1696",
        "document": "201. Kr \u00a8uger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, et al.; CAPNETZ Study Group. In\ufb02ammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009;10:65."
    },
    {
        "id": "doc_1697",
        "document": "202. P\ufb01ster R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, Machado MB, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 in\ufb02uenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care 2014; 18:R44.\n\n203. Musher DM, Bebko SP, Roig IL. Serum procalcitonin level, viral polymerase chain reaction analysis, and lower respiratory tract infection. J Infect Dis 2014;209:631\u2013633."
    },
    {
        "id": "doc_1698",
        "document": "204. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452\u20131457.\n\ne66\n\nAmerican Journal of Respiratory and Critical Care Medicine Volume 200 Number 7 | October 1 2019\n\nAMERICAN THORACIC SOCIETY DOCUMENTS"
    },
    {
        "id": "doc_1699",
        "document": "205. Zasowski E, Butter\ufb01eld JM, McNutt LA, Cohen J, Cosler L, Pai MP, et al. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. Antimicrob Agents Chemother 2014;58:3804\u20133813."
    },
    {
        "id": "doc_1700",
        "document": "206. Garin N, Felix G, Chuard C, Genn \u00b4e D, Carballo S, Hugli O, et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia. PLoS One 2016;11:e0157350.\n\n207. Men \u00b4endez R, Torres A, Zalaca\u00b4\u0131n R, Aspa J, Mart\u00b4\u0131n Villasclaras JJ, Border\u00b4\u0131as L, et al.; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960\u2013965."
    },
    {
        "id": "doc_1701",
        "document": "208. Men \u00b4endez R, Torres A, Rodr\u00b4\u0131guez de Castro F, Zalaca\u00b4\u0131n R, Aspa J, Mart\u00b4\u0131n Villasclaras JJ, et al.; Neumofail Group. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783\u20131790."
    },
    {
        "id": "doc_1702",
        "document": "209. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with community- acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154\u2013160.\n\n210. Uranga A, Espa\u00f1a PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 2016;176:1257\u20131265."
    },
    {
        "id": "doc_1703",
        "document": "211. Macdonald C, Jayathissa S, Leadbetter M. Is post-pneumonia chest X-ray for lung malignancy useful? Results of an audit of current practice. Intern Med J 2015;45:329\u2013334.\n\n212. Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up. Scand J Infect Dis 1993;25:93\u2013100."
    },
    {
        "id": "doc_1704",
        "document": "213. Little BP, Gilman MD, Humphrey KL, Alkasab TK, Gibbons FK, Shepard JA, et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. AJR Am J Roentgenol 2014;202:54\u201359.\n\n214. Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med 2011;171:1193\u20131198."
    },
    {
        "id": "doc_1705",
        "document": "215. Mortensen EM, Copeland LA, Pugh MJ, Fine MJ, Nakashima B, Restrepo MI, et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. Am J Med 2010;123:66\u201371.\n\n216. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:330\u2013338.\n\nAmerican Thoracic Society Documents\n\ne67\n\nClinical Infectious Diseases\n\nI D S A G U I D E L I N E"
    },
    {
        "id": "doc_1706",
        "document": "ESTDSA Infectious Diseases Society of America hiv medicine association\n\nOfficial American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children"
    },
    {
        "id": "doc_1707",
        "document": "David M. Lewinsohn,1,a Michael K. Leonard,2,a Philip A. LoBue,3,a David L. Cohn,4 Charles L. Daley,5 Ed Desmond,6 Joseph Keane,7 Deborah A. Lewinsohn,1 Ann M. Loeffler,8 Gerald H. Mazurek,3 Richard J. O\u2019Brien,9 Madhukar Pai,10 Luca Richeldi,11 Max Salfinger,12 Thomas M. Shinnick,3 Timothy R. Sterling,13 David M. Warshauer,14 and Gail L. Woods15"
    },
    {
        "id": "doc_1708",
        "document": "1Oregon Health & Science University, Portland, Oregon, 2Emory University School of Medicine and 3Centers for Disease Control and Prevention, Atlanta, Georgia, 4Denver Public Health Department, Denver, Colorado, 5National Jewish Health and the University of Colorado Denver, and 6California Department of Public Health, Richmond; 7St James\u2019s Hospital, Dublin, Ireland; 8Francis J. Curry International TB Center, San Francisco, California; 9Foundation for Innovative New Diagnostics, Geneva,"
    },
    {
        "id": "doc_1709",
        "document": "Switzerland; 10McGill University and McGill International TB Centre, Montreal, Canada; 11University of Southampton, United Kingdom; 12National Jewish Health, Denver, Colorado, 13Vanderbilt University School of Medicine, Vanderbilt Institute for Global Health, Nashville, Tennessee, 14Wisconsin State Laboratory of Hygiene, Madison, and 15University of Arkansas for Medical Sciences, Little Rock"
    },
    {
        "id": "doc_1710",
        "document": "Background. Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuber- culosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its diagnosis remain."
    },
    {
        "id": "doc_1711",
        "document": "Methods. A task force supported by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America searched, selected, and synthesized relevant evidence. The evidence was then used as the basis for rec- ommendations about the diagnosis of tuberculosis disease and LTBI in adults and children. The recommendations were formulated, written, and graded using the Grading, Recommendations, Assessment, Development and Evaluation (GRADE) approach."
    },
    {
        "id": "doc_1712",
        "document": "Results. Twenty-three evidence-based recommendations about diagnostic testing for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis are provided. Six of the recommendations are strong, whereas the remaining 17 are conditional."
    },
    {
        "id": "doc_1713",
        "document": "Conclusions. These guidelines are not intended to impose a standard of care. They provide the basis for rational decisions in the diagnosis of tuberculosis in the context of the existing evidence. No guidelines can take into account all of the often compelling unique individual clinical circumstances.\n\nEXECUTIVE SUMMARY"
    },
    {
        "id": "doc_1714",
        "document": "Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (TB disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). TB disease is a leading cause of infectious disease morbidity and mortality worldwide, with many diag- nostic uncertainties. A task force supported by the supported by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America appraised the"
    },
    {
        "id": "doc_1715",
        "document": "evidence and derived the following recommen- dations using the Grading, Recommendations, Assessment, Development, and Evaluation (GRADE) approach (Table 1):"
    },
    {
        "id": "doc_1716",
        "document": "Received 4 October 2016; editorial decision 6 October 2016; accepted 14 October 2016. These guidelines were endorsed by the European Respiratory Society on 20 June 2016. aAuthors are co-chairs of this guideline committee.\n\nCorrespondence: D. M. Lewinsohn, Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, OR (lewinsod@ohsu.edu)."
    },
    {
        "id": "doc_1717",
        "document": "Clinical Infectious Diseases\u00ae 2017;64(2):e1\u2013e33\n\n\u00a9 The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com. DOI: 10.1093/cid/ciw694\n\nTesting for LTBI\n\nOur recommendations for diagnostic testing for LTBI are based upon the likelihood of infection with Mtb and the likelihood of progression to TB disease if infected, as illustrated in Figure 1."
    },
    {
        "id": "doc_1718",
        "document": "\u2022 We recommend performing an interferon-\u03b3 release assay (IGRA) rather than a tuberculin skin test (TST) in individuals 5 years or older who meet the following criteria: (1) are likely to be infected with Mtb, (2) have a low or intermediate risk of disease progression, (3) it has been decided that testing for LTBI is warranted, and (4) either have a history of BCG vacci- nation or are unlikely to return to have their TST read (strong recommendation, moderate-quality evidence). Remarks: A TST is"
    },
    {
        "id": "doc_1719",
        "document": "an acceptable alternative, especially in situations where an IGRA is not available, too costly, or too burdensome."
    },
    {
        "id": "doc_1720",
        "document": "\u2022 We suggest performing an IGRA rather than a TST in all other individuals 5 years or older who are likely to be infected with Mtb, who have a low or intermediate risk of disease progression, and in whom it has been decided that testing for LTBI is warranted (conditional recommen- dation, moderate-quality evidence). Remarks: A TST is an\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e1\n\nD"
    },
    {
        "id": "doc_1721",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nTable 1. Interpretation of Strong and Weak (Conditional) Recommendations"
    },
    {
        "id": "doc_1722",
        "document": "Strong Recommendation Weak (Conditional) Recommendation Patients Most individuals in this situation would want the recommended course of action, and only a small proportion would not. The majority of individuals in this situation would want the suggested course of action, but many would not."
    },
    {
        "id": "doc_1723",
        "document": "Clinicians Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or perfor- mance indicator. Formal decision aids are not likely to be needed to help individuals make deci- sions consistent with their values and preferences."
    },
    {
        "id": "doc_1724",
        "document": "Recognize that different choices will be appropri- ate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful in helping individ- uals to make decisions consistent with their values and preferences."
    },
    {
        "id": "doc_1725",
        "document": "Policy makers The recommendation can be adopted as policy in most situations. Policymaking will require substantial debate and involvement of various stakeholders."
    },
    {
        "id": "doc_1726",
        "document": "acceptable alternative, especially in situations where an IGRA is not available, too costly, or too burdensome.\n\n\u2022 There are insufficient data to recommend a preference for either a TST or an IGRA as the first-line diagnostic test in individuals 5 years or older who are likely to be infected with Mtb, who have a high risk of progression to disease, and in whom it has been determined that diagnostic test- ing for LTBI is warranted."
    },
    {
        "id": "doc_1727",
        "document": "\u2022 Guidelines recommend that persons at low risk for Mtb infection and disease progression NOT be tested for Mtb infection. We concur with this recommendation. However, we also recognize that such testing may be obliged by law or credentialing bodies. If diagnostic testing for LTBI is performed in individuals who are unlikely to be infected with Mtb despite guidelines to the contrary:"
    },
    {
        "id": "doc_1728",
        "document": "\u2022 We suggest performing an IGRA instead of a TST in indivduals 5 years or older (conditional recommendation, low-quality evidence). Remarks: A TST is an acceptable alternative in settings where an IGRA is unavailable, too costly, or too burdensome."
    },
    {
        "id": "doc_1729",
        "document": "\u2022 We suggest a second diagnostic test if the initial test is positive in individuals 5 years or older (conditional recommendation, very low-quality evidence). Remarks: The confirmatory test may be either an IGRA or a TST. When such testing is performed, the person is considered infected only if both tests are positive.\n\n\u2022 We suggest performing a TST rather than an IGRA in healthy children <5 years of age for whom it has been decided that diagnostic testing for LTBI is warranted"
    },
    {
        "id": "doc_1730",
        "document": "e2 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\n(conditional recommendation, very low-quality evidence). Remarks: In situations in which an IGRA is deemed the preferred diagnostic test, some experts are willing to use IGRAs in children over 3 years of age."
    },
    {
        "id": "doc_1731",
        "document": "\u2022 The preceding recommendations are summarized in Figure 2. While both IGRA and TST testing provide evidence for infection with Mtb, they cannot distinguish active from latent TB. Therefore, the diagnosis of active TB must be excluded prior to embarking on treatment for LTBI. This is typically done by determining whether or not symptoms suggestive of TB disease are present, performing a chest radiograph and, if radiographic signs of active TB (eg, air- space opacities, pleural effusions,"
    },
    {
        "id": "doc_1732",
        "document": "cavities, or changes on serial radiographs) are seen, then sampling is performed and the patient managed accordingly."
    },
    {
        "id": "doc_1733",
        "document": "Testing for TB Disease"
    },
    {
        "id": "doc_1734",
        "document": "\u2022 We recommend that acid-fast bacilli (AFB) smear micros- copy be performed, rather than no AFB smear microscopy, in all patients suspected of having pulmonary TB (strong recommendation, moderate-quality evidence). Remarks: False-negative results are sufficiently common that a negative AFB smear result does not exclude pulmonary TB. Similarly, false-positive results are sufficiently com- mon that a positive AFB smear result does not confirm pulmonary TB. Testing of 3 specimens is considered the"
    },
    {
        "id": "doc_1735",
        "document": "normative practice in the United States and is strongly recommended by the Centers for Disease Control and Prevention and the National Tuberculosis Controllers Association in order to improve sensitivity given the pervasive issue of poor sample quality. Providers should request a sputum volume of at least 3 mL, but the optimal volume is 5\u201310 mL. Concentrated respiratory specimens and fluorescence microscopy are preferred."
    },
    {
        "id": "doc_1736",
        "document": "\u2022 We suggest that both liquid and solid mycobacterial cultures be performed, rather than either culture method alone, for every specimen obtained from an individual with sus- pected TB disease (conditional recommendation, low-qual- ity evidence). Remarks: The conditional qualifier applies to performance of both liquid and solid culture methods on all specimens. At least liquid culture should be done on all specimens as culture is the gold standard microbiologic test for the diagnosis of TB"
    },
    {
        "id": "doc_1737",
        "document": "disease. The isolate recovered should be identified according to the Clinical and Laboratory Standards Institute guidelines and the American Society for Microbiology Manual of Clinical Microbiology."
    },
    {
        "id": "doc_1738",
        "document": "\u2022 We suggest performing a diagnostic nucleic acid amplifi- cation test (NAAT), rather than not performing a NAAT, on the initial respiratory specimen from patients suspected of having pulmonary TB (conditional recommendation, low-quality evidence). Remarks: In AFB smear-positive\n\nD\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_1739",
        "document": "Groups with Increased Likeli- Benefit of LTBI Testing Strategy hood of Infection with Mtb Therapy Household contact or recent expo- Yes sure of an active case Not demonstrated Mycobacteriology laboratory personnel Immigrants from high burden Not demonstrated countries (20 / 100,000) Risk of Infection Residents and employces of high Yes risk congregate seitings Not demonstrated Infected sk of Developing Tuberculo: Low Intermediate (RR 1.3 -3) High (RR 3-10) No risk factors Clinical predisposition"
    },
    {
        "id": "doc_1740",
        "document": "Children age less Diabetes than 5 Chronic renal failure HIV infection Intravenous drug use Immunosuppres- sive therapy Abnormal CXR consistent with prior TB Silicosis Benefit of Therapy Not demonstrated Yes In developing a diagnostic approach for the evaluation of those with suspected LTBI, we recommend the clinician weigh the likeli- hood of infection, the likelihood of progression to TB if infected, and the bencfit of therapy (Horsburgh, C.R., Jr., and E.J. Rubin. 2011. Clinical practice."
    },
    {
        "id": "doc_1741",
        "document": "Latent tuberculosis infection in the United States. The New England journal of medicine 364:1441-1448). Recom- mendations were formulated for cach of the three groups illustrated above. These groups are concordant with current recommendations for the interpretation of the TST ( 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 49:1-51)."
    },
    {
        "id": "doc_1742",
        "document": "In developing a diagnostic approach for the evaluation of those with suspected LTBI, we recommend the clinician weigh the likeli- hood of infection, the likelihood of progression to TB if infected, and the bencfit of therapy (Horsburgh, C.R., Jr., and E.J. Rubin. 2011. Clinical practice. Latent tuberculosis infection in the United States. The New England journal of medicine 364:1441-1448). Recom- mendations were formulated for cach of the three groups illustrated above. These groups are"
    },
    {
        "id": "doc_1743",
        "document": "concordant with current recommendations for the interpretation of the TST ( 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 49:1-51)."
    },
    {
        "id": "doc_1744",
        "document": "Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and benefit of therapy. In developing a diagnostic approach for the evaluation of those with suspected LTBI, we recommend the clinician weigh the likelihood of infection, the likelihood of progression to tuberculosis if infected, and the benefit of therapy (Horsburgh and Rubin, Clinical practice: latent tuberculosis infection in the United States."
    },
    {
        "id": "doc_1745",
        "document": "N Engl J Med 2011; 364:1441\u20138). Recommendations were formulated for each of the 3 groups illustrated above. These groups are concordant with current recommendations for the interpretation of the tuber- culin skin test (American Thoracic Society, Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49:1\u201351). Abbreviations: CXR, chest radiograph; HIV, human immunodeficiency virus; LTBI, latent tuberculosis infection; Mtb, Mycobacterium tuberculosis; RR,"
    },
    {
        "id": "doc_1746",
        "document": "; TB, tuberculosis; TST, tuberculin skin test."
    },
    {
        "id": "doc_1747",
        "document": "patients, a negative NAAT makes TB disease unlikely. In AFB smear-negative patients with an intermediate to high level of suspicion for disease, a positive NAAT can be used as presumptive evidence of TB disease, but a negative NAAT cannot be used to exclude pulmonary TB. Appropriate NAAT include the Hologic Amplified Mycobacteria Tuberculosis Direct (MTD) test (San Diego, California) and the Cepheid Xpert MTB/Rif test (Sunnyvale, California)."
    },
    {
        "id": "doc_1748",
        "document": "\u2022 We recommend performing rapid molecular drug sus- ceptibility testing for rifampin with or without isoniazid using the respiratory specimens of persons who are either AFB smear positive or Hologic Amplified MTD positive and who meet one of the following criteria: (1) have been treated for tuberculosis in the past, (2) were born in or have lived for at least 1 year in a foreign country with at least a moderate tuberculosis incidence (\u226520 per 100 000) or a high primary multidrug-resistant"
    },
    {
        "id": "doc_1749",
        "document": "tuberculosis prevalence (\u22652%), (3) are contacts of patients with multid- rug-resistant tuberculosis, or (4) are HIV infected (strong"
    },
    {
        "id": "doc_1750",
        "document": "recommendation, moderate-quality evidence). Remarks: This recommendation specifically addresses patients who are Hologic Amplified MTD positive because the Hologic Amplified MTD NAAT only detects TB and not drug resistance; it is not applicable to patients who are positive for types of NAAT that detect drug resistance, including many line probe assays and Cepheid Xpert MTB/RIF."
    },
    {
        "id": "doc_1751",
        "document": "\u2022 We suggest mycobacterial culture of respiratory speci- mens for all children suspected of having pulmonary TB (conditional recommendation, moderate-quality evidence). Remarks: In a low incidence setting like the United States, it is unlikely that a child identified during a recent con- tract investigation of a close adult/adolescent contact with contagious TB was, in fact, infected by a different individual with a strain with a different susceptibility pattern. Therefore, under some"
    },
    {
        "id": "doc_1752",
        "document": "circumstances, microbi- ological confirmation may not be necessary for children with uncomplicated pulmonary TB identified through a recent contact investigation if the source case has drug- susceptible TB."
    },
    {
        "id": "doc_1753",
        "document": "Diagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e3\n\nD\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\ni c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_1754",
        "document": "Group Testing Strategy Considerations Adults Acceptable: IGRA OR TST Consider dual testing where a positive result from either result would be considered positive Children < 5 years of age Preferred: TST Acceptable: IGRA OR TST Consider dual testing where a positive result Prevalence of BCG vaccination from either would be considered positive' Expertise of staff and/or labora- to1 Preferred: IGRA where available Test availability Acceptable: IGRA or TST Patient perceptions Staff perceptions"
    },
    {
        "id": "doc_1755",
        "document": "Programmatic concerns Testing for LTBI is not recommended If necessary: Preferred: IGRA where available. ither IGRA OR TST Acceptabl For serial testing: Acceptable: Either IGRA OR TST Consider repeat o dual testing where a nega- tive result from either would be considered negative\u2019 1 Performing a second diagnostic test when the initial test is negative is a strategy to increase sensitivity. This may reduce specificity, but the panel decided that this is an acceptable tradeoff in situations in"
    },
    {
        "id": "doc_1756",
        "document": "which the consequences of missing LTBI (i.e., not treating individuals who may benefit from therapy) exceed the consequences of inappropriate therapy (i.\u00a2., hepatotoxicity). Performing a confirmatory test following an initial positive result is based upon both the evidence that false-positive results are common among individuals who are unlikely to be infected with Mtb and the committee\u2019s presumption that performing a second test on those whose initial test was positive will help identify"
    },
    {
        "id": "doc_1757",
        "document": "initial false-positive results."
    },
    {
        "id": "doc_1758",
        "document": "1 Performing a second diagnostic test when the initial test is negative is a strategy to increase sensitivity. This may reduce specificity, but the panel decided that this is an acceptable tradeoff in situations in which the consequences of missing LTBI (i.e., not treating individuals who may benefit from therapy) exceed the consequences of inappropriate therapy (i.\u00a2., hepatotoxicity)."
    },
    {
        "id": "doc_1759",
        "document": "Performing a confirmatory test following an initial positive result is based upon both the evidence that false-positive results are common among individuals who are unlikely to be infected with Mtb and the committee\u2019s presumption that performing a second test on those whose initial test was positive will help identify initial false-positive results."
    },
    {
        "id": "doc_1760",
        "document": "Figure 2. Summary of recommendations for testing for latent tuberculosis infection (LTBI). 1Performing a second diagnostic test when the initial test is negative is a strategy to increase sensitivity. This may reduce specificity, but the panel decided that this is an acceptable trade-off in situations in which the consequences of missing LTBI (ie, not treating individuals who may benefit from therapy) exceed the consequences of inappropriate therapy (ie, hepatotoxicity). 2Performing a"
    },
    {
        "id": "doc_1761",
        "document": "confirmatory test following an initial positive result is based upon both the evidence that false-positive results are common among individuals who are unlikely to be infected with Mycobacterium tuberculosis and the committee\u2019s presumption that performing a second test on those patients whose initial test was positive will help identify initial false-positive results. Abbreviations: IGRA, interferon-\u03b3 release assay; LTBI, latent tuberculosis infection; TST, tuberculin skin test."
    },
    {
        "id": "doc_1762",
        "document": "\u2022 We suggest sputum induction rather than flexible broncho- scopic sampling as the initial respiratory sampling method for adults with suspected pulmonary TB who are either unable to expectorate sputum or whose expectorated spu- tum is AFB smear microscopy negative (conditional recom- mendation, low-quality evidence)."
    },
    {
        "id": "doc_1763",
        "document": "\u2022 We suggest flexible bronchoscopic sampling, rather than no bronchoscopic sampling, in adults with suspected pulmonary TB from whom a respiratory sample can- not be obtained via induced sputum (conditional recom- mendation, very low-quality evidence). Remarks: In the committee members\u2019 clinical practices, bronchoalveolar lavage (BAL) plus brushings alone are performed for most patients; however, for patients in whom a rapid diagnosis is essential, transbronchial biopsy is also performed."
    },
    {
        "id": "doc_1764",
        "document": "\u2022 We suggest that postbronchoscopy sputum specimens be collected from all adults with suspected pulmonary TB who undergo bronchoscopy (conditional recommendation, low-quality evidence). Remarks: Postbronchoscopy spu- tum specimens are used to perform AFB smear micros- copy and mycobacterial cultures.\n\n\u2022 We suggest flexible bronchoscopic sampling, rather than no bronchoscopic sampling, in adults with suspected mil- iary TB and no alternative lesions that are accessible for"
    },
    {
        "id": "doc_1765",
        "document": "sampling whose induced sputum is AFB smear micros- copy negative or from whom a respiratory sample cannot be obtained via induced sputum (conditional recommenda- tion, very low-quality evidence). Remarks: Bronchoscopic sampling in patients with suspected miliary TB should include bronchial brushings and/or transbronchial biopsy, as the yield from washings is substantially less and the yield from BAL unknown. For patients in whom it is important to provide a rapid presumptive diagnosis of"
    },
    {
        "id": "doc_1766",
        "document": "tuberculosis (ie, those who are too sick to wait for culture results), trans- bronchial biopsies are both necessary and appropriate."
    },
    {
        "id": "doc_1767",
        "document": "\u2022 We suggest that cell counts and chemistries be performed on amenable fluid specimens collected from sites of sus- pected extrapulmonary TB (conditional recommendation, very low-quality evidence). Remarks: Specimens that are amenable to cell counts and chemistries include pleural, cerebrospinal, ascitic, and joint fluids."
    },
    {
        "id": "doc_1768",
        "document": "\u2022 We suggest that adenosine deaminase levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB, TB meningitis, peritoneal TB, or pericardial TB (conditional recommendation, low- quality evidence).\n\n\u2022 We suggest that free IFN-\u03b3 levels be measured, rather than not measured, on fluid collected from patients with\n\ne4 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\nD"
    },
    {
        "id": "doc_1769",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nsuspected pleural TB or peritoneal TB (conditional recom- mendation, low-quality evidence)."
    },
    {
        "id": "doc_1770",
        "document": "\u2022 We suggest that AFB smear microscopy be performed, rather than not performed, on specimens collected from sites of suspected extrapulmonary TB (conditional recommenda- tion, very low-quality evidence). Remarks: A positive result can be used as evidence of extrapulmonary TB and guide decision making because false-positive results are unlikely. However, a negative result may not be used to exclude TB because false-negative results are exceedingly common."
    },
    {
        "id": "doc_1771",
        "document": "\u2022 We recommend that mycobacterial cultures be performed, rather than not performed, on specimens collected from sites of suspected extrapulmonary TB (strong recommen- dation, low-quality evidence). Remarks: A positive result can be used as evidence of extrapulmonary TB and guide decision making because false-positive results are unlikely. However, a negative result may not be used to exclude TB because false-negative results are exceedingly common."
    },
    {
        "id": "doc_1772",
        "document": "\u2022 We suggest that NAAT be performed, rather than not per- formed, on specimens collected from sites of suspected extrapulmonary TB (conditional recommendation, very low-quality evidence). Remarks: A positive NAAT result can be used as evidence of extrapulmonary TB and guide decision making because false-positive results are unlikely. However, a negative NAAT result may not be used to exclude TB because false-negative results are exceedingly common. At present, NAAT testing on specimens other"
    },
    {
        "id": "doc_1773",
        "document": "than sputum is an off-label use of the test."
    },
    {
        "id": "doc_1774",
        "document": "\u2022 We suggest that histological examination be performed, rather than not performed, on specimens collected from sites of suspected extrapulmonary TB (conditional rec- ommendation, very low-quality evidence). Remarks: Both positive and negative results should be interpreted in the context of the clinical scenario because neither false- positive nor false-negative results are rare."
    },
    {
        "id": "doc_1775",
        "document": "\u2022 We recommend one culture isolate from each mycobac- terial culture-positive patient be submitted to a regional genotyping laboratory for genotyping (strong recommen- dation, very low-quality evidence)."
    },
    {
        "id": "doc_1776",
        "document": "Persons infected with Mycobacterium tuberculosis (Mtb) have a broad array of presentations, ranging from those with clinical, radiographic, and microbiological evidence of tuberculosis (TB disease) to those who are infected with Mtb but have no clini- cal evidence of TB disease (latent tuberculosis infection [LTBI]). Individuals with LTBI who have been recently exposed have an increased risk of developing TB, whereas those with remote exposure have less risk over time unless they develop a"
    },
    {
        "id": "doc_1777",
        "document": "condi- tion that impairs immunity. Operationally, recent exposure can be defined either epidemiologically (ie, as might occur in the set- ting of the household of an infectious case or occupational expo- sure) or immunologically (ie, conversion of a tuberculin skin test or interferon-\u03b3 release assay [IGRA] from negative to positive)."
    },
    {
        "id": "doc_1778",
        "document": "These clinical practice guidelines on the diagnosis and classi- fication of tuberculosis in adults and children were prepared by a task force supported by the American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA). Additionally, Fellows of the American Academy of Pediatrics participated in the development of these guidelines. The specific objectives of these guidelines are as follows:"
    },
    {
        "id": "doc_1779",
        "document": "\u2022 To define high- and low-risk patient populations based upon the results of epidemiological studies.\n\n\u2022 To provide diagnostic recommendations that lead to bene- ficial treatments and favorable clinical outcomes.\n\n\u2022 To describe a classification scheme for tuberculosis that is based on pathogenesis."
    },
    {
        "id": "doc_1780",
        "document": "These guidelines target clinicians in high-resource coun- tries with a low incidence of TB disease and LTBI, such as the United States. The recommendations may be less applicable to medium- and high-tuberculosis incidence countries. For such countries, guidance documents published by the World Health Organization (WHO) may be more suitable.\n\nHOW TO USE THESE GUIDELINES"
    },
    {
        "id": "doc_1781",
        "document": "These guidelines are not intended to impose a standard of care. They provide the basis for rational decisions in the diagnos- tic evaluation of patients with possible LTBI or TB. Clinicians, patients, third-party payers, stakeholders, or the courts should never view the recommendations contained in these guidelines as dictates. Guidelines cannot take into account all of the often compelling unique individual clinical circumstances. Therefore, no one charged with evaluating clinicians\u2019 actions"
    },
    {
        "id": "doc_1782",
        "document": "should attempt to apply the recommendations from these guidelines by rote or in a blanket fashion. Qualifying remarks accompanying each recommendation are its integral parts and serve to facili- tate more accurate interpretation. They should never be omit- ted when quoting or translating recommendations from these guidelines."
    },
    {
        "id": "doc_1783",
        "document": "METHODS\n\nCommittee Selection"
    },
    {
        "id": "doc_1784",
        "document": "The criteria for committee selection were an (1) established track record in the relevant clinical or research area; (2) involvement with the ATS Assembly on Microbiology, Tuberculosis and Pulmonary Infections, the IDSA Tuberculosis Committee, or employment by the United States CDC Division of Tuberculosis Elimination; and (3) absence of disqualifying conflicts of interest. Conflicts of interest were managed according to the policies and procedures agreed upon by the participating organizations"
    },
    {
        "id": "doc_1785",
        "document": "[1]."
    },
    {
        "id": "doc_1786",
        "document": "The committee was divided into subcommittees assigned to develop drafts for each of the following areas: (1) LTBI, (2) clini- cal and radiological aspects of TB diagnosis, (3) microbiological evaluation for TB diagnosis and detection of drug resistance,\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e5\n\nD"
    },
    {
        "id": "doc_1787",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nc . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nand (4) pediatric TB diagnosis. Meetings were held either in-person or via teleconference.\n\nEvidence Synthesis"
    },
    {
        "id": "doc_1788",
        "document": "Each subcommittee identified key diagnostic questions and then performed a pragmatic evidence synthesis for each question, to identify and summarize the related evidence. The subcommit- tees first sought studies comparing one diagnostic intervention with another and measuring clinical outcomes. Such evidence was unavailable, so the subcommittees next sought diagnostic accuracy studies. When published evidence was lacking, the collective clinical experience of the committee was used. The evidence"
    },
    {
        "id": "doc_1789",
        "document": "syntheses were used to inform the recommendations. Though comprehensive, the evidence syntheses should not be considered systematic reviews of the evidence."
    },
    {
        "id": "doc_1790",
        "document": "Developing and Grading Recommendations\n\nRecommendations were formulated and the quality of evidence and strength of each recommendation were rated using the Grading, Recommendations, Assessment, Development and Evaluation (GRADE) approach [2, 3]."
    },
    {
        "id": "doc_1791",
        "document": "The quality of evidence is the extent to which one can be con- fident that the estimated effects are close to the actual effects and was rated as high, moderate, low, or very low. The quality of evidence rating derived from the quality of the accuracy studies that informed the panel\u2019s judgments, as randomized trials and controlled observational studies were lacking. Well-done accu- racy studies that enrolled consecutive patients with legitimate diagnostic uncertainty and used appropriate"
    },
    {
        "id": "doc_1792",
        "document": "reference stand- ards represented high-quality evidence; lack of these charac- teristics constituted reasons to downgrade the quality evidence. Normally, the quality of evidence for first-line therapy would have been factored into such quality of evidence ratings but, in this case, the quality of evidence that treatment of TB disease and LTBI improve outcomes is high quality, so the overall quality of evidence rating was determined entirely by the accuracy study."
    },
    {
        "id": "doc_1793",
        "document": "The decision to recommend for or against an intervention was based upon consideration of the balance of desirable conse- quences (ie, benefits) and undesirable consequences (ie, harms, burdens), quality of the evidence, patient values and preferences, cost, resource use, and feasibility. The subcommittees used open discussion to arrive at a consensus for each of the recommen- dations. An open voting procedure was reserved for situations when the subcommittee could not reach consensus through"
    },
    {
        "id": "doc_1794",
        "document": "discussion, but this was not needed for any recommendation."
    },
    {
        "id": "doc_1795",
        "document": "The strength of a recommendation indicates the committee\u2019s certainty that the desirable consequences of the recommended course of action outweigh the undesirable consequences. A strong recommendation is one for which the subcommittee is certain, whereas a conditional recommendation is one for which the subcommittee is uncertain. Uncertainty may exist if the qual- ity of evidence is poor, there is a fine balance between desirable"
    },
    {
        "id": "doc_1796",
        "document": "and undesirable consequences (ie, the benefits may not be worth the costs or burdens), the balance of desirable and undesirable consequences depends upon the clinical context, or there is variation about how individuals value the outcomes. A strong recommendation should be interpreted as the right thing to do for the vast majority of patients; a weak recommendation should be interpreted as being the right thing to do for the majority of patients, but maybe not for a sizeable minority of"
    },
    {
        "id": "doc_1797",
        "document": "patients."
    },
    {
        "id": "doc_1798",
        "document": "TUBERCULOSIS: EPIDEMIOLOGY, TRANSMISSION, AND PATHOGENESIS"
    },
    {
        "id": "doc_1799",
        "document": "A full discussion of these topics can be found in the Supplementary Materials. TB disease remains one of the major causes of morbidity and mortality in the world. The WHO estimates that 8.6 million new cases of tuberculosis occurred in 2014 and approximately 1.5 million persons died from the disease [4]. The emergence of drug-resistant tuberculosis has become apparent over the past 2 decades, and in particular, mul- tidrug-resistant tuberculosis (MDR-TB; resistant to isoniazid and rifampin) and"
    },
    {
        "id": "doc_1800",
        "document": "extensively drug-resistant tuberculosis (XDR-TB; resistant to isoniazid and rifampin, plus any fluoroquinolone and at least 1 of 3 injectable second-line drugs [ie, amikacin, kanamycin, or capreomycin]), which are more difficult to treat than drug-sus- ceptible disease [5, 6]. The approximate number of cases of MDR-TB in the world is roughly 500 000 reported from at least 127 countries, and XDR-TB has been reported from 105 countries [4]."
    },
    {
        "id": "doc_1801",
        "document": "In the United States, 9412 cases of TB disease were reported in 2014, with a rate of 3.0 cases per 100 000 persons. Sixty-six per- cent of cases were in foreign-born persons; the rate of disease was 13.4 times higher in foreign-born persons than in US- born indi- viduals (15.3 vs 1.1 per 100 000, respectively) [7]. An estimated 11 million persons are infected with Mtb [8]. Thus, although the case rate of TB in the United States has declined during the past several years, there remains a large"
    },
    {
        "id": "doc_1802",
        "document": "reservoir of individuals who are infected with Mtb. Without the application of improved diagnosis and effective treatment for LTBI, new cases of TB will develop from within this group, which is therefore a major focus for the control and elimination of tuberculosis [9]."
    },
    {
        "id": "doc_1803",
        "document": "Mtb is transmitted from person to person via the airborne route [10]. Several factors determine the probability of Mtb transmission: (1) infectiousness of the source patient\u2014a posi- tive sputum smear for acid-fast bacilli (AFB) or a cavity on chest radiograph being strongly associated with infectiousness; (2) host susceptibility of the contact; (3) duration of exposure of the contact to the source patient; (4) the environment in which the exposure takes place (a small, poorly ventilated space"
    },
    {
        "id": "doc_1804",
        "document": "providing the highest risk); and (5) infectiousness of the Mtb strain. In the United States, among contacts of patients with TB disease eval- uated during a contact investigation, about 1% have TB disease themselves and 23% have a positive tuberculin skin test (TST) without evidence of tuberculosis disease and are considered to have LTBI [11]. Those who are household contacts and are"
    },
    {
        "id": "doc_1805",
        "document": "D\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne6 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_1806",
        "document": "exposed to patients who are smear positive have higher rates of both infection and disease [12]. Medical procedures that gener- ate aerosols of respiratory secretions, such as sputum induction and bronchoscopy, entail significant risk for Mtb transmission unless proper precautions are taken [13].\n\nInitial Infection: Acquisition of Latent Mtb Infection"
    },
    {
        "id": "doc_1807",
        "document": "After inhalation, the droplet nucleus is carried down the bron- chial tree and implants in a respiratory bronchiole or alveolus. Whether or not inhaled tubercle bacilli establish an infection depends on both host and microbial factors [14]. It is hypoth- esized that, following infection, but before the development of cellular immunity, tubercle bacilli spread via the lymphatics to the hilar lymph nodes and then through the bloodstream to more distant anatomic sites [15]. The majority of"
    },
    {
        "id": "doc_1808",
        "document": "pulmonary tuberculosis infections are clinically and radiographically unap- parent [16]. A positive TST or IGRA result, most commonly, is the only indication that infection with Mtb has taken place."
    },
    {
        "id": "doc_1809",
        "document": "Those who develop a positive TST are considered to have LTBI. It is estimated that, in the absence of treatment, approx- imately 4%\u20136% of individuals who acquire LTBI will develop active TB disease during their lifetime. The greatest risk of pro- gression is during the first 2 years following exposure [11, 17]. The ability of the host to contain the organism is reduced in young (<4 years) children and by certain diseases such as silico- sis, diabetes mellitus, and diseases associated with"
    },
    {
        "id": "doc_1810",
        "document": "immunosup- pression (eg, human immunodeficiency virus [HIV] infection), as well as by corticosteroids and other immunosuppressive drugs such as tumor necrosis factor alpha (TNF-\u03b1) inhibitors. In these circumstances, the likelihood of progression to TB dis- ease is greater. For example, individuals who have a prior latent infection with Mtb (not treated) and then acquire HIV infection will develop TB disease at an approximate rate of 5%\u201310% per year (in the absence of effective HIV treatment)"
    },
    {
        "id": "doc_1811",
        "document": "[18, 19]."
    },
    {
        "id": "doc_1812",
        "document": "DIAGNOSTIC TESTS FOR LTBI"
    },
    {
        "id": "doc_1813",
        "document": "The aim of testing for LTBI is to identify those who will benefit from prophylactic therapy. At present, the likelihood of complet- ing LTBI treatment is relatively modest. In some reports, only 17%\u201337% of those eligible for LTBI therapy ultimately complete the treatment course, with higher rates of completion associated with shorter courses of therapy [20, 21]. Once therapy has been initiated, completion rates are more favorable [22]. It is hoped that better diagnostic tests, testing"
    },
    {
        "id": "doc_1814",
        "document": "strategies, and treatment reg- imens will allow for resources to be focused on patients who are most deserving of evaluation and treatment of LTBI and, there- fore, result in increased completion of therapy rates."
    },
    {
        "id": "doc_1815",
        "document": "Tuberculin Skin Testing\n\nThe tuberculin skin test (TST) detects cell-mediated immunity to Mtb through a delayed-type hypersensitivity reaction using a\n\nprotein precipitate of heat-inactivated tubercle bacilli (purified protein derivative [PPD]\u2013tuberculin). The TST has been the standard method of diagnosing LTBI."
    },
    {
        "id": "doc_1816",
        "document": "The TST is administered by the intradermal injection of 0.1 mL of PPD (5 TU) into the volar surface of the forearm (Mantoux method) to produce a transient wheal. The test is interpreted at 48\u201372 hours by measuring the transverse diame- ter of the palpable induration. TST interpretation is risk-strat- ified [23]. A reaction of 5 mm or greater is considered positive for close contacts of tuberculosis cases; immunosuppressed persons, in particular persons with HIV infection; individu- als with"
    },
    {
        "id": "doc_1817",
        "document": "clinical or radiographic evidence of current or prior TB; and persons receiving TNF blocking agents. A reaction of \u226510 mm is considered positive for other persons at increased risk of LTBI (eg, persons born in high TB incidence countries and those with at risk of occupational exposure to TB) and for persons with medical risk factors that increase the prob- ability of progression from LTBI to TB (Figure 1). A reaction of 15 mm or greater is considered positive for all other per- sons. Serious"
    },
    {
        "id": "doc_1818",
        "document": "adverse reactions to PPD-tuberculin are rare. However, strong reactions with vesiculation and ulceration may occur."
    },
    {
        "id": "doc_1819",
        "document": "The sensitivity of the TST, as measured in clinically well per- sons with previously treated tuberculosis, is high (95%\u201398%). False-negative reactions occur more frequently in infants and young children, early (<6\u20138 weeks) after infection, in persons having recently received viral vaccination, in persons with clinical conditions associated with immunosuppression (eg, HIV infection) or overwhelming illness (including extensive or disseminated tuberculosis), after recent viral and bacterial"
    },
    {
        "id": "doc_1820",
        "document": "infections, and in association with treatment with immunosup- pressive drugs (eg, high-dose corticosteroids, TNF inhibitors)."
    },
    {
        "id": "doc_1821",
        "document": "Test specificity of the TST is decreased among persons with prior BCG vaccination, especially those vaccinated postinfancy and those with repeat vaccination. Similarly, persons living in areas where nontuberculous mycobacteria are common are at increased risk of having false-positive TST reactions. Repeated administration of TSTs cannot induce reactivity; however, a repeat TST can restore reactivity in persons whose TST reac- tivity has waned over time. Because of this \u201cboosting phenom- enon,\u201d"
    },
    {
        "id": "doc_1822",
        "document": "initial repeat testing is recommended for persons with a negative TST who are to undergo periodic TST screening and who have not been tested with tuberculin recently (eg, 1 year).\u201d This \u201c2-step\u201d testing, with a repeat TST within 1\u20133 weeks after an initial negative TST, is intended to avoid misclassification of subsequent positive TSTs as a TST conversion, indicating recent infection, when they are actually a result of boosting."
    },
    {
        "id": "doc_1823",
        "document": "Benefits and Limitations of the TST\n\nThe benefits of the TST include its simplicity to perform (it does not require a laboratory or equipment and can be done by a trained healthcare worker in remote locations), its low\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e7\n\nD\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\n. o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_1824",
        "document": "cost, no need for phlebotomy, the observation that it reflects a polycellular immune response, and the foundation of well-con- trolled studies that support the use of the TST to detect LTBI and guide the use of prophylactic therapy [24]. In addition, there are well-established definitions of TST conversion, which are particularly helpful when using the TST in the setting of serial testing."
    },
    {
        "id": "doc_1825",
        "document": "Limitations include the need for trained personnel to both administer the intradermal injection and interpret the test, inter- and intrareader variability in interpretation, the need for a return visit to have the test read, false-positive results due to the cross-reactivity of the antigens within the PPD to both BCG and nontuberculous mycobacteria, false-negative results due to infections and other factors, rare adverse effects, and compli- cated interpretation due to boosting, conversions, and"
    },
    {
        "id": "doc_1826",
        "document": "rever- sions [24]."
    },
    {
        "id": "doc_1827",
        "document": "Interferon-Gamma Release Assays\n\nOverview of IGRAs"
    },
    {
        "id": "doc_1828",
        "document": "Until recently, the TST has been the only method to test for latent infection with Mtb. Ideally, an improved diagnostic test would specifically identify those with Mtb infection and would delineate those at risk for disease progression. In this regard, the TST has well-known strengths and limitations [23, 25, 26]. The IGRAs are newer tests to diagnose infection with Mtb. IGRAs are in vitro, T cell\u2013based assays that measure interferon gamma (IFN-\u03b3) release by sensitized T cells in response to"
    },
    {
        "id": "doc_1829",
        "document": "highly spe- cific Mtb antigens."
    },
    {
        "id": "doc_1830",
        "document": "Immune Basis of IGRAs"
    },
    {
        "id": "doc_1831",
        "document": "Like the TST, the IGRA is a reflection of the cellular immune response. The discovery of antigens that have elicited robust immune responses and are relatively specific for infection with Mtb has enabled the development of IGRA assays, which are more specific for Mtb infection than the TST [27], particularly in the setting of BCG vaccination. Of particular interest has been the RD-1 gene segment, a 9.5-kb DNA segment absent from all strains of Mycobacterium bovis BCG but present in wild-type M."
    },
    {
        "id": "doc_1832",
        "document": "bovis and Mtb [28]. This region, containing 11 open reading frames, is responsible for the transcription and translation of a variety of antigenic proteins, including early secretory antigen (ESAT-6) [29\u201333] and culture filtrate protein (CFP-10) [34\u201337]. Both antigens are absent from all attenuated strains of M. bovis (BCG strains) and most nontuberculous mycobacteria with the important exceptions of Mycobacterium kansasii, Mycobacterium szulgai, Mycobacterium marinum [32, 38], and Mycobacterium"
    },
    {
        "id": "doc_1833",
        "document": "leprae [39, 40]."
    },
    {
        "id": "doc_1834",
        "document": "IGRA assays are primarily a reflection of a CD4+ T-cell immune response to these antigens. Immunologic memory is characterized by the clonal expansion of antigen-specific T cells following exposure to an antigen. Effector memory T cells are defined by their capacity to respond rapidly to subsequent\n\ne8 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_1835",
        "document": "antigenic exposure. This response is characterized by the release of cytokines, as well as further expansion of these cells. Responses measured in current short-term IGRA assays reflect the presence of these cells. Although it has been postulated measurement of these short-term effectors might reflect recent infection and/or ongoing bacterial replication, current evidence does not support this hypothesis [41\u201343].\n\nCommercially Available IGRAs"
    },
    {
        "id": "doc_1836",
        "document": "Currently, there are 2 commercially available IGRA platforms that measure interferon-\u03b3 release in response to Mtb-specific antigens: the QuantiFERON TB Gold In Tube (QFT-GIT; Cellestis Limited, Carnegie, Victoria, Australia) and T-SPOT.TB test (T-SPOT, manufactured by Oxford Immunotec Ltd, Abingdon, United Kingdom). The QFT-GIT measures IFN-\u03b3 plasma concentration using an enzyme-linked immunosorbent assay (ELISA), while the T-SPOT assay enumerates T cells releasing IFN-\u03b3 using an enzyme-linked"
    },
    {
        "id": "doc_1837",
        "document": "immunospot (ELISPOT) assay."
    },
    {
        "id": "doc_1838",
        "document": "QuantiFERON Assays"
    },
    {
        "id": "doc_1839",
        "document": "The QFT-GIT method has been approved by the US Food and Drug Administration (FDA) and has replaced the QuantiFERON-TB Gold (QFT-G) test. Whole blood (mini- mum 3 mL) is drawn directly into heparinized tubes coated with lyophilized antigen and agitated. In this case, peptides from ESAT-6, CFP-10, and TB7.7 are found within the same tube. Two additional tubes are drawn as controls (mitogen control and nil control). The mitogen control (phytohemagglutinin [PHA]) stimulates T-cell proliferation and"
    },
    {
        "id": "doc_1840",
        "document": "ensures that viable cells are present. After incubation for 16\u201324 hours at 37\u00b0C, plasma is col- lected from each tube and the concentration of IFN-\u03b3 is deter- mined for each by ELISA. The in-tube methodology requires no additional sample handling. Perhaps because of the nearly immediate exposure of T cells to antigen, as well as the addition of the TB7.7 peptide, the QFT-GIT may be more sensitive than the QFT-G test. Studies reporting the sensitivity and specificity of the QFT-GIT test are"
    },
    {
        "id": "doc_1841",
        "document": "provided in Supplementary Tables 1 and 2, respectively. The next generation of QFT (QFTPlus) has been introduced in Europe and is pending approval in the United States. QFTPlus contains a tube of short peptides derived from CFP-10, which are designed to elicit an enhanced CD8 T-cell response. There is no TB7.7 peptide. No published information is available to evaluate the performance of this test."
    },
    {
        "id": "doc_1842",
        "document": "The QFT-GIT assay is considered positive if the difference between the IFN-\u03b3 concentration in response to the Mtb anti- gens and the IFN-\u03b3 response to the nil control is \u22650.35 IU. In addition, to control for high background in the nil control, the IFN-\u03b3 response to antigen must be 25% greater than the IFN-\u03b3 concentration in the NIL control. An indeterminate response defined as either a lack of response in the PHA control well (IFN-\u03b3 concentration \u22640.5 IU) or a nil control that has a very high"
    },
    {
        "id": "doc_1843",
        "document": "background (IFN-\u03b3 concentration >8 IU)."
    },
    {
        "id": "doc_1844",
        "document": "D\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\no u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nT-SPOT.TB Assays"
    },
    {
        "id": "doc_1845",
        "document": "The T-SPOT.TB assay is currently available in Europe, Canada, and has been approved for use in the United States with revised criteria for test interpretation. For the T-SPOT.TB assay, blood (minimum 2 mL) is drawn into either a heparin or CPT Ficoll tube, and must be processed within 8 hours. More recently, this time has been extended to 32 hours if the \u201cT-cell Xtend\u201d additive is used and the blood kept between 10\u00b0C and 25\u00b0C. Peripheral blood mononuclear cells (PBMCs) are separated using"
    },
    {
        "id": "doc_1846",
        "document": "density gradient centrifugation, enumerated, and then added to microtiter wells at 2.5 \u00d7 105 viable PBMCs per well that have been coated with mon- oclonal antibodies to IFN-\u03b3 (ELISPOT assay). Peptides derived from ESAT-6 and CFP-10 antigens are then added and the plate is developed following overnight (16\u201320 hours) incubation at 37\u00b0C. Cells are then washed away and \u201ccaptured\u201d IFN-\u03b3 is then detected via a sandwich capture technique by conjugation with secondary antibodies hence revealing a"
    },
    {
        "id": "doc_1847",
        "document": "\u201cspot.\u201d These spots are then enumer- ated as \u201cfootprints\u201d [44] of effector T cells [44, 45]."
    },
    {
        "id": "doc_1848",
        "document": "For the T-SPOT.TB assay, a positive response is based on spot-forming units (SFU). Outside of the United States, if the negative control well contains \u22645 SFU and there are >6 SFU above the media nil control in either of the antigen wells, then this is considered positive. If the negative control well has \u22656 SFU, then the antigen wells must be at least 2 times the negative control well for a response to be considered positive. An invalid response is defined as high background in the negative"
    },
    {
        "id": "doc_1849",
        "document": "control well (\u226510 SFU) or if the positive control well is not responsive to mitogen (PHA, <20 SFU). The FDA has published revised criteria for T-SPOT.TB interpretation in the United States, in which a test is considered negative if there are \u22644 spots. Eight spots or greater is considered positive. Five, 6, and 7 spots are considered \u201cborderline\u201d and would be interpreted in conjunc- tion with the subject\u2019s pretest probability of infection with Mtb. Studies reporting the sensitivity and"
    },
    {
        "id": "doc_1850",
        "document": "specificity of the T-SPOT test are provided in Supplementary Tables 3 and 4, respectively."
    },
    {
        "id": "doc_1851",
        "document": "Indeterminate/Invalid IGRA Responses"
    },
    {
        "id": "doc_1852",
        "document": "Unlike the TST, in which the results are interpreted categorically based on the size of the reaction [46], the IGRAs currently have a trichotomous outcome yielding a positive, negative, or inde- terminate result (T-SPOT may also yield a borderline result as described above). As described above, an indeterminate/invalid IGRA can result from either a high background (nil) response or from a poor response to positive control mitogen. Indeterminate IGRA results are associated with immunosuppression"
    },
    {
        "id": "doc_1853",
        "document": "[47\u201349], although they may occur in healthy individuals (studies report- ing the test characteristics of IGRAs in individuals with immu- nosuppression are provided in Supplementary Tables 5 and 6). With regard to those with a poor response to the positive con- trol mitogen, there are at least 2 possibilities. First, the test may not have been correctly performed. For example, errors in spec- imen collection, long delays in specimen processing, incubator"
    },
    {
        "id": "doc_1854",
        "document": "malfunction, or technical errors might result in a poor mito- gen response. Here, it is reasonable to simply repeat the assay. Second, a persistently diminished response to mitogen may be a reflection of anergy. Thus, the reproducibility and details regarding the reason for an indeterminate result may provide clinically useful information.\n\nReproducibility of IGRAs"
    },
    {
        "id": "doc_1855",
        "document": "Because IGRAs are predicated on in vitro release of cytokines from stimulated cells, there is likely to be more variability in these tests than those based on the measurement of a circu- lating substance such as sodium. There are at least 4 sources of variability which are inherent in the IGRA: (1) the type of measurement itself (ie, ELISA or ELISPOT), (2) reproducibility of a complex biological reaction, (3) the natural variability of immune responses, and (4) variability introduced during the"
    },
    {
        "id": "doc_1856",
        "document": "course of test performance or manufacturing variances."
    },
    {
        "id": "doc_1857",
        "document": "Reproducibility has been evaluated for both the QFT and T-SPOT assays. Although published information regarding currently available tests is limited [50, 51] the QFT-IT result was reported to have an 11% variance (http://www.access- data.fda.gov/cdrh_docs/pdf/P010033). Studies on within subject variability of the QFT-IT are limited and most were performed in areas of the world where Mtb is endemic and variability over time due to reinfection would be expected [50, 51]. Recently, intrasubject"
    },
    {
        "id": "doc_1858",
        "document": "variability of QFT-IT was assessed using available plasma, and a discordance rate of 8% between the first and second tests was observed. While the variations were quantitatively modest, results at or near the cutoff resulted in differing test results [52]. This variability might spuriously change the test result (positive to negative or negative to positive). Consequently, values at or near the test cutoff should be interpreted with caution. Variability of the T-SPOT was dependent on the"
    },
    {
        "id": "doc_1859",
        "document": "strength of the response, and varied from 4% in those with robust responses, to 22% in those whose responses were close to the cutoff (http://www. accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma. cfm?num=p070006)."
    },
    {
        "id": "doc_1860",
        "document": "Boosting of IGRAs"
    },
    {
        "id": "doc_1861",
        "document": "Initial studies found that repeat TST testing did not alter the IGRA response [53, 54]. However, more recent evidence [50, 51] suggests that the prior placement of a TST can boost an IGRA, particularly in those individuals who were already IGRA positive to begin with (ie, previously sensitized to Mtb or pos- sibly other mycobacteria). Additionally, it was found that this could be observed in as little as 3 days post-TST administration, and that the boosting effect may wane after several months"
    },
    {
        "id": "doc_1862",
        "document": "[50, 51]. While these data do not detract from the excellent overall agreement that has been reported, they suggest when dual test- ing is to be considered that the IGRA be collected either con- currently or prior to TST placement."
    },
    {
        "id": "doc_1863",
        "document": "Diagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e9\n\nD\n\no\n\nn l o a d e d f r o m h t t p s : / / a c a d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nSpecial Considerations"
    },
    {
        "id": "doc_1864",
        "document": "Because IGRAs rely on a functional assessment of viable lympho- cytes, these tests require special attention to the technical aspects of the test. This includes proper filling of the blood collection tube, proper mixing, timely transport to the laboratory, and timely pro- cessing of the specimen. Additionally, for the laboratory, perfor- mance of cellular assays may pose unique challenges with regard to reagent storage and preparation as well as the separation of viable cells. Finally,"
    },
    {
        "id": "doc_1865",
        "document": "manufacturing problems such as endotoxin contam- ination can confound assays that depend on cellular activation."
    },
    {
        "id": "doc_1866",
        "document": "Benefits and Limitations of IGRAs\n\nThe benefits of IGRAs include the use of antigens that are largely specific for Mtb (ie, no cross-reactivity with BCG and minimal cross-reactivity with nontuberculous mycobacteria), the test can be performed in a single visit, and both the perfor- mance and reporting of results in a laboratory setting fall under the auspices of regulatory certification [24]."
    },
    {
        "id": "doc_1867",
        "document": "Limitations include cost, the need for phlebotomy (which may be particularly challenging in children), complicated inter- pretation due to frequent conversions and reversions and lack of consensus on thresholds, and inconsistent test reproducibility [24]. The reproducibility of results is particularly problematic in the setting of serial testing. While some of this can be attributed to results that fall near the cutoff, this is not always the case, and current data does not provide specific"
    },
    {
        "id": "doc_1868",
        "document": "guidance. Data on the effect of IGRA-guided therapy on prevention of TB disease is limited, although one study demonstrated a roughly 84% reduc- tion in TB disease among household contacts who received IGRA-based preventive therapy [55]. Finally, several studies have reported an increased rate of indeterminate IGRA results in children <5 years of age [47, 56\u201360] and one study described an increased rate of indeterminate IGRA results among individuals with HIV infection and a CD4 count \u2264200"
    },
    {
        "id": "doc_1869",
        "document": "cells/\u00b5L [61]"
    },
    {
        "id": "doc_1870",
        "document": "DIAGNOSTIC APPROACH: TESTING SUSPECTED LTBI FOR\n\nThis section addresses how to test for LTBI. A complementary ATS/CDC/IDSA guideline that addresses who to screen for LTBI and how to treat LTBI is in development and forthcoming."
    },
    {
        "id": "doc_1871",
        "document": "No definitive diagnostic test for LTBI exists. Our recommen- dations for diagnostic testing for LTBI are based upon the likeli- hood of infection with Mtb and the likelihood of progression to TB disease if infected, as illustrated in Figure 1. The recommen- dations are summarized in Figure 2. As our literature searches failed to identify randomized trials or observational studies that directly compared different diagnostic approaches and meas- ured clinical outcomes, our recommendations are"
    },
    {
        "id": "doc_1872",
        "document": "based upon evidence about the accuracy of various tests combined with evi- dence that treatment of LTBI improves clinical outcomes."
    },
    {
        "id": "doc_1873",
        "document": "There are 2 major benefits of treating LTBI: Treating LTBI prevents progression to active TB disease with its attendant\n\ne10 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_1874",
        "document": "morbidities [62] and has public health benefits, as each new case is likely to infect others. The consequences of failing to pre- vent progression to active TB disease may be especially severe in the young or immunocompromised host, in whom the dis- ease is more likely to be disseminated and elude discovery, and has a higher mortality rate. Failure to rapidly diagnose TB dis- ease also poses a risk of widespread transmission in hospitals, homeless shelters, and prisons."
    },
    {
        "id": "doc_1875",
        "document": "Patients with LTBI have a 4%\u20136% lifetime risk of developing TB disease, with approximately half of these cases occurring follow- ing recent exposure [11, 17]. Multiple placebo-controlled trials in adults and children with LTBI have shown that isoniazid reduces the subsequent development of TB disease in patients at high risk of progression. As an example, in a trial of 28 000 individuals with LTBI and radiographic evidence of healed tuberculosis, isonia- zid taken for 52 weeks reduced the"
    },
    {
        "id": "doc_1876",
        "document": "subsequent development of TB disease from 14.3% to 3.6% [62]. Other groups in which the treatment of LTBI has been demonstrated to reduce the incidence of TB disease include household contacts of active TB patients [55, 63], native Alaskan communities [64], residents of mental health facilities [65], persons with HIV infection [66\u201369], and individuals treated with TNF inhibitors [70, 71]. These data can be extrapolated to populations at low risk for progression (ie, no risk factors) and"
    },
    {
        "id": "doc_1877",
        "document": "intermediate risk for progression (ie, diabetes, chronic renal disease, intravenous drug abuse); while the relative benefit of treatment is probably similar in these lower risk popu- lations, the absolute benefit is almost certainly smaller due to the lower baseline risk of progression to TB disease."
    },
    {
        "id": "doc_1878",
        "document": "These studies provide high-quality evidence that treatment of LTBI reduces the incidence of TB disease in populations at high risk for progression. However, they provide only moder- ate-quality evidence that treatment of LTBI reduces the inci- dence of TB disease in populations at low or intermediate risk for progression because the data are from high-risk populations."
    },
    {
        "id": "doc_1879",
        "document": "Our recommendations for the diagnosis of LTBI reflect both the likelihood of infection (either likely or unlikely, based upon studies that used the TST to detect LTBI) and the risk of pro- gression if infected (low; intermediate, RR 1.3\u20133; and high, RR 3\u201310). This paradigm is summarized in Figure 1."
    },
    {
        "id": "doc_1880",
        "document": "Question 1: Should an IGRA or a TST be performed in indi- viduals 5 years or older who are likely to be infected with Mtb, who have a low or intermediate risk of disease progres- sion, and in whom it has been decided that testing for LTBI is warranted?"
    },
    {
        "id": "doc_1881",
        "document": "Evidence\n\nIn individuals who are likely to be infected with Mtb but at low or intermediate risk of disease progression, the sensitivity of IGRAs in the detection of Mtb infection has been consistently reported as either equal (QFT; 81%\u201386%) or superior (T-SPOT; 90%\u201395%) to the sensitivity of the TST (71%\u201382%) [47, 72\u201394]\n\nD\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\np . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_1882",
        "document": "when a final diagnosis of either microbiologically confirmed or clinical TB is used as the reference standard. Individuals who are likely to be infected with Mtb include household contacts (studies reporting the test characteristics of IGRAs in contacts are provided in Supplementary Table 7), recent exposures of an active case, mycobacteriology laboratory personnel, immi- grants from high-burden countries, and residents or employees of high-risk congregate settings. Individuals at low risk of"
    },
    {
        "id": "doc_1883",
        "document": "pro- gression to TB include those with no risk factors, while those at intermediate risk of progression to TB include those with diabe- tes, chronic renal failure, or intravenous drug abuse."
    },
    {
        "id": "doc_1884",
        "document": "In patients who are known to have received vaccination with BCG, the specificity of IGRAs has also been consistently supe- rior to TST testing, presumably because IGRAs rely on responses to antigens absent in BCG and many nontuberculous mycobac- teria. In contrast, among patients who have not received vac- cination with BCG, the specificity of IGRAs and TST appears similar. Meta-analyses estimate that the specificity of QFT\u2013IT to be >95%, whereas the specificity for TST is roughly 97% in those"
    },
    {
        "id": "doc_1885",
        "document": "with no prior exposure to BCG. The specificity is reduced to roughly 60% in those with a history of BCG vaccination [24]. Data for the commercially available T-SPOT are more limited. In German healthcare workers, specificity (using a cutoff of 6 spots) was reported at 97%, whereas in Korean adolescents the specificity was 85% [49]. In Navy recruits, specificity was 99% using the 8-spot cutoff [95]."
    },
    {
        "id": "doc_1886",
        "document": "Our confidence in the estimated test characteristics was moderate because many of the studies did not report whether the subjects were consecutively enrolled."
    },
    {
        "id": "doc_1887",
        "document": "Recommendation 1a: We recommend performing an IGRA rather than a TST in individuals 5 years or older who meet the following criteria: (1) are likely to be infected with Mtb, (2) have a low or intermediate risk of disease progression, (3) it has been decided that testing for LTBI is warranted, and (4) either have a history of BCG vaccination or are unlikely to return to have their TST read (strong recommendation, moderate-quality evi- dence). Remarks: A TST is an acceptable alternative,"
    },
    {
        "id": "doc_1888",
        "document": "especially in situations where an IGRA is not available, too costly, or too burdensome."
    },
    {
        "id": "doc_1889",
        "document": "Recommendation 1b: We suggest performing an IGRA rather than a TST in all other individuals 5 years or older who are likely to be infected with Mtb, who have a low or intermedi- ate risk of disease progression, and in whom it has been decided that testing for LTBI is warranted (conditional recommendation, moderate-quality evidence). Remarks: A TST is an acceptable alternative, especially in situations where an IGRA is not availa- ble, too costly, or too burdensome."
    },
    {
        "id": "doc_1890",
        "document": "Rationale\n\nAccuracy studies indicate that IGRAs are more specific and equally or more sensitive than TST in individuals who have received the BCG vaccination; therefore, false-positive results"
    },
    {
        "id": "doc_1891",
        "document": "are less likely with IGRAs than TST. This is important because false-positive results may lead to unnecessary treatment and its accompanying risks (ie, hepatotoxicity) [96\u201398]. To minimize these risks, the guideline development panel chose to recom- mend IGRA testing for individuals who received the BCG vaccination."
    },
    {
        "id": "doc_1892",
        "document": "In contrast, the accuracy of TST and IGRAs appears similar in those without a history of BCG vaccination. Despite the sim- ilar test characteristics, the guideline development committee chose to suggest IGRA testing over TST testing in such patients because it was concerned about the reliability of a history of having received or not received the BCG vaccination. Because many of the individuals who fall into the likely to be infected with Mtb category are from regions of the world in which the"
    },
    {
        "id": "doc_1893",
        "document": "BCG vaccination is routinely administered, the committee con- cluded that individuals who are likely to be infected with Mtb and provide history of not having received the BCG vaccination should be treated the same as those who provide a history of having received the BCG vaccination, unless there is a reason to choose an alternate approach such as IGRA testing not being available, being too costly, or being too burdensome."
    },
    {
        "id": "doc_1894",
        "document": "The recommendation to perform IGRA testing rather than TST testing is strong for those who have received the BCG vac- cination or who are not likely to return for TST read, reflecting the guideline development committee\u2019s certainty that avoiding the serious consequences of false-positive results and obtaining a result to guide therapy outweigh the additional cost and need to perform phlebotomy for IGRA testing. In contrast, the sug- gestion to perform IGRA testing rather than TST testing on all"
    },
    {
        "id": "doc_1895",
        "document": "other patients who are likely to be infected with Mtb and have a low or moderate risk of progressing to TB disease is conditional, reflecting the committee\u2019s recognition that the choice should depend upon the clinical context as the test characteristics are similar. While the committee concluded that IGRA testing is preferable in most patients, it recognized that TST testing may be more appropriate in a sizeable minority due to availability, feasibility, cost, or burden."
    },
    {
        "id": "doc_1896",
        "document": "Justification for Extending the Recommendation Down to 5 Years of Age"
    },
    {
        "id": "doc_1897",
        "document": "Young children are at increased risk of developing TB following infection and more likely to develop severe disease than older children and adults [99, 100]. This risk is highest in the young- est infants, diminishes with increasing age, and becomes equiv- alent with older children and adults at approximately 5 years of age. Thus, children \u22655 years old have a similar risk of TB as adults and display a similar disease spectrum. With respect to Mtb infection, children aged \u22655 years possess a"
    },
    {
        "id": "doc_1898",
        "document": "functional immune response equivalent to that of adults. In addition, the results of existing studies of IGRA performance in children \u22655 years of age, albeit limited, are consistent with results of stud- ies of IGRA performance in adults. The sensitivity of IGRAs in"
    },
    {
        "id": "doc_1899",
        "document": "Diagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e11\n\nD"
    },
    {
        "id": "doc_1900",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\n. o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nchildren with TB [56, 59, 101\u2013105] and in older children who are household [106, 107] or school [108] contacts and the spec- ificity of IGRAs in children [102, 108] are comparable to those of adults. For these reasons, it seems reasonable to extrapolate the results of studies of IGRA performance in healthy adults to children aged \u22655 years."
    },
    {
        "id": "doc_1901",
        "document": "Cautions and Limitations"
    },
    {
        "id": "doc_1902",
        "document": "While both IGRA and TST testing provide evidence for infec- tion with Mtb, they cannot distinguish active from latent tuber- culosis. Therefore, the diagnosis of active TB must be excluded prior to embarking on treatment for LTBI. This is typically done by determining whether or not symptoms suggestive of TB disease are present, performing a chest radiograph and, if radiographic signs of active tuberculosis (eg, airspace opacities, pleural effusions, cavities, or changes on serial radiographs)"
    },
    {
        "id": "doc_1903",
        "document": "are seen, then sampling is performed and the patient managed accordingly."
    },
    {
        "id": "doc_1904",
        "document": "Quantitative aspects of the tests are poorly understood. With respect to the TST, the result is categorized as positive or nega- tive and quantitative data are of limited utility, with the excep- tion of recognition that a large (>15 mm) skin test reaction is more likely to reflect infection with Mtb [109, 110]. The dichot- omous characterization of the result, coupled with the fact that repeat testing is not recommended in the setting of a prior posi- tive test result, has resulted in a paucity"
    },
    {
        "id": "doc_1905",
        "document": "of information about the variability of the TST result over time. With respect to IGRAs, measurement of IFN-\u03b3 over time may reflect inherent variabil- ity in the test result (the FDA accepts a variance of 11%) or true immunological variation due to alterations in the abundance of Mtb antigens, exposure to other antigens, and/or the health and nutritional status of the host. As an example, it is possible that a rise in IFN-\u03b3 might reflect ongoing exposure and/or growth of the bacteria."
    },
    {
        "id": "doc_1906",
        "document": "Alternatively, a rise in IFN- \u03b3 may reflect var- iability of the test. At present, there are insufficient data upon which to base any recommendations for quantitative interpre- tation of IGRAs beyond those cut-points recommended by the FDA. However, it is important to recognize that the optimal cut-points are controversial and results near the cut-point are less reliable than results far above or below the cut-point. The results of IFN-\u03b3 testing should be reported quantitatively such that these"
    },
    {
        "id": "doc_1907",
        "document": "immune correlates of the natural history of TB can be prospectively discerned and ultimately applied to clinical practice."
    },
    {
        "id": "doc_1908",
        "document": "Discordance between TST and IGRA testing is common. Not surprisingly, TST-positive/IGRA-negative discordance is often seen in persons with prior exposure to BCG. However, TST-positive/IGRA-negative discordant results where the TST is well over 15 mm have also been reported. The reasons for this delayed type hypersensitivity are not understood. It could relate to the possibility that discordance may reflect immune responses that have occurred in the remote past (and where the"
    },
    {
        "id": "doc_1909",
        "document": "e12 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_1910",
        "document": "antigen is currently not available to drive an ongoing response that can be measured by IGRA), may reflect immune differences inherent in a delayed-type hypersensitivity versus blood assay, or may reflect exposures to nontuberculous mycobacteria. In low-risk populations, discordant tests are likely to be false posi- tives [61, 111]. Clearly, more information is desirable regarding which test best reflects productive infection and, therefore, best reflects the likelihood of disease progression."
    },
    {
        "id": "doc_1911",
        "document": "The benefit of targeted testing for LTBI resides not in the test employed, but in its programmatic use. We acknowledge that programmatic considerations such as cost, test availability, prevalence of BCG exposure in the target population, ability to reevaluate the patient 2\u20133 days after testing, and the training and expertise of program staff might all affect the decision to use IGRA- or TST-based evaluations."
    },
    {
        "id": "doc_1912",
        "document": "Question 2: Should an IGRA or a TST be performed in indi- viduals 5 years or older who are likely to be infected with Mtb, who have a high risk of progression to disease, and in whom it has been decided that testing for LTBI is warranted?"
    },
    {
        "id": "doc_1913",
        "document": "Evidence\n\nIndividuals at high risk of progression to TB include those with HIV infection, an abnormal chest radiograph consist- ent with prior TB, or silicosis. It also includes those who are receiving immunosuppressive therapy. Most data about the accuracy of the TST and IGRA are from patients who are immunocompromised."
    },
    {
        "id": "doc_1914",
        "document": "Studies have compared TST and IGRAs in the setting of immunocompromise. Both diagnostic tests have diminished sensitivity in this setting. The sensitivity of IGRAs (QFT-IT and T-SPOT) for detecting LTBI in individuals with HIV infection has been estimated to be from 65% to 100% [112\u2013114], while the sensitivity of TST is only 43% (25,85) when a final diagnosis of either microbiologically confirmed or clinical TB is used as the reference standard. These limited data suggest that IGRAs are at least"
    },
    {
        "id": "doc_1915",
        "document": "as sensitive as TST in the setting of HIV infection. Studies have also compared IGRAs with TST in populations that were heterogeneous with respect to both the type of underlying immunocompromise and the reasons for testing. These stud- ies demonstrated significant discord between TST and IGRA results, but the source of the discordance has not been eluci- dated [61]. The panel\u2019s confidence in the estimated test charac- teristics of IGRA and TST testing was moderate because it was not reported"
    },
    {
        "id": "doc_1916",
        "document": "whether patients were consecutively enrolled or whether there was true diagnostic uncertainty."
    },
    {
        "id": "doc_1917",
        "document": "Recommendation 2: There are insufficient data to recom- mend a preference for either a TST or an IGRA as the first-line diagnostic test in individuals 5 years or older who are likely to be infected with Mtb, who have a high risk of progression to disease, and in whom it has been determined that diagnostic testing for LTBI is warranted.\n\nD"
    },
    {
        "id": "doc_1918",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_1919",
        "document": "Rationale\n\nThe committee judged the body of evidence insufficient to render a recommendation for either IGRA or TST testing in patients likely to be infected with Mtb who are at high risk for progression to disease because the estimated test characteristics were widely variable and derived from only a small subgroup of such patients (ie, immunocompromised patients)."
    },
    {
        "id": "doc_1920",
        "document": "As part of the discussion about which diagnostic test to perform in patients likely to be infected who are at high risk for progression to disease, many committee members acknowledged that they perform a second test in their clinical practices when such patients test negative; specifically, they perform a TST if an initial IGRA is negative or an IGRA if an initial TST is negative. If the second test is positive, they consider this evidence for infection with Mtb. Their practice is not based upon"
    },
    {
        "id": "doc_1921",
        "document": "empirical evidence, but rather, the following clinical rationale. A sensitive diagnostic test is important for individuals who are likely to be infected with Mtb and at high risk of progression, so that such individuals are less likely to receive false-negative results that will result in delayed diagno- sis and treatment. Performing a second diagnostic test when the initial test is negative is one strategy to increase sensitivity. While this strategy to increase sensitivity may reduce the spec-"
    },
    {
        "id": "doc_1922",
        "document": "ificity of diagnostic testing, this may be an acceptable tradeoff in situations in which it is determined that the consequences of missing LTBI (ie, not treating individuals who may benefit from therapy) exceed the consequences of inappropriate ther- apy (ie, hepatotoxicity)."
    },
    {
        "id": "doc_1923",
        "document": "Cautions and Limitations"
    },
    {
        "id": "doc_1924",
        "document": "While both QFT and T-SPOT rely on the release of IFN-\u03b3 in response to RD-1 antigens, limited data have suggested that indeterminate results are more common for QFT-IT when the CD4 count is <200 cells/\u00b5L than T-SPOT [115]. This may be the result of T-SPOT using a defined number of PBMCs, which may better, but not completely, normalize for the lack of CD4+ T cells. By incorporating a measure of anergy into the test (Mitogen control), IGRAs may more accurately allow the clinician to discriminate a"
    },
    {
        "id": "doc_1925",
        "document": "test that is negative from one that is indeterminate (anergic by virtue of inadequate responses to mitogen)."
    },
    {
        "id": "doc_1926",
        "document": "Question 3: Should an IGRA or a TST be performed in indi- viduals 5 years or older who are unlikely to be infected with Mtb, but in whom it has been decided that testing for LTBI is warranted?\n\nEvidence\n\nThere is a lack of direct evidence regarding the relative test characteristics of IGRA and TST testing in individuals who are unlikely to be infected with Mtb. Indirect evidence from individuals likely to be infected with Mtb indicates that IGRA"
    },
    {
        "id": "doc_1927",
        "document": "testing is more specific than TST testing and equally or more sensitive than TST testing. We have no reason to suspect that these relative test characteristics will be different among indi- viduals who are unlikely to be infected with Mtb. However, it is likely that false-positive results are more common for both IGRAs and TST in populations with a lower prevalence of LTBI. This is supported by a study of longitudinal testing of healthcare workers residing in areas of low TB prevalence, which"
    },
    {
        "id": "doc_1928",
        "document": "found that most conversions were false-positive results as evidenced by a negative result on repeat testing [116]."
    },
    {
        "id": "doc_1929",
        "document": "The evidence provides low confidence in the estimated test characteristics in our population of interest because many of the estimates are based upon evidence from patients who are likely to be infected with a high risk for progression rather than patients who are unlikely to be infected, and many of the studies did not report whether subjects were consecutively enrolled."
    },
    {
        "id": "doc_1930",
        "document": "Guidelines recommend that persons at low risk for Mtb infec- tion and disease progression NOT be tested for Mtb infection. We concur with this recommendation. However, we also rec- ognize that such testing may be obliged by law or credentialing bodies. If diagnostic testing for LTBI is performed in individu- als who are unlikely to be infected with Mtb despite guidelines to the contrary."
    },
    {
        "id": "doc_1931",
        "document": "Recommendation 3a: We suggest performing an IGRA instead of a TST in individuals 5 years or older (conditional recommendation, low-quality evidence). Remarks: A TST is an acceptable alternative in settings where an IGRA is unavailable, too costly, or too burdensome."
    },
    {
        "id": "doc_1932",
        "document": "Recommendation 3b: We suggest a second diagnostic test if the initial test is positive in individuals 5 years or older (conditional recommendation, very low-quality evidence). Remarks: The confirmatory test may be either an IGRA or a TST. When such testing is performed, the person is consid- ered infected only if both tests are positive.\n\nRationale"
    },
    {
        "id": "doc_1933",
        "document": "Current ATS/CDC and American Academy of Pediatrics guide- lines recommend that testing for LTBI not be performed in individuals at low risk for infection with Mtb because the risk of isoniazid chemoprophylaxis may outweigh the potential benefit [117]. Despite this, testing is often performed in conjunction with school enrollment, employee health testing, and other institutional settings. In such patients, many conversions are false results, which may lead to unnecessary therapy and, there- fore,"
    },
    {
        "id": "doc_1934",
        "document": "unnecessary and age-related risk of hepatotoxicity."
    },
    {
        "id": "doc_1935",
        "document": "The evidence indicates that false-positive results are frequent (ie, more common than true-positive results) among individ- uals who are unlikely to be infected with Mtb. Use of a more specific test may result in fewer false-positive results and, there- fore, fewer persons receiving unnecessary LTBI treatment and being placed at risk for adverse outcomes. In addition to the risk\n\nD"
    },
    {
        "id": "doc_1936",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e13"
    },
    {
        "id": "doc_1937",
        "document": "associated with isoniazid chemoprophylaxis, those with a posi- tive test for LTBI often undergo additional screening, including a chest radiograph. Avoiding such unnecessary screening has both cost and health benefits. The desire for a more specific test favors IGRA testing over TST, according to evidence described above from patients who are likely to be infected and who have a low or intermediate risk for progression. The notion of per- forming a second, confirmatory test following an initial"
    },
    {
        "id": "doc_1938",
        "document": "posi- tive result is based upon the evidence that false-positive results are common among individuals who are unlikely to be infected with Mtb and the committee\u2019s presumption that performing a second test on those whose initial test was positive will improve specificity."
    },
    {
        "id": "doc_1939",
        "document": "The recommendations are both conditional because the quality of evidence provided the committee with limited confi- dence in the estimated test characteristics of IGRAs and TST in individuals who are unlikely to be infected; therefore, the com- mittee could not be certain that the desirable consequences of performing IGRAs instead of TST, or of performing a second test following a positive result, outweigh the undesirable conse- quences in the vast majority of patients."
    },
    {
        "id": "doc_1940",
        "document": "Traditionally, once an individual has had a positive TST, future use of the TST for screening is not recommended due to the belief that the skin test will remain positive for life. In those who are TST negative, serial testing can be compli- cated by random variability, boosting (ie, increased reactions upon retesting due to immunological memory), conversions (ie, new reactions due to new infection), and reversions (ie, decreased reactions). Criteria for the placement and reading of the TST, as"
    },
    {
        "id": "doc_1941",
        "document": "well as the effect of boosting with PPD, criteria for TST conversion have been established. Receiver operating characteristic (ROC) analysis has been used to establish crite- ria for positive and negative IGRA results in those thought to be unlikely to be infected or those with TB disease. However, IGRAs have not proven to be the solution to the problem of false-positive results associated with serial testing in low risk individuals. At present, there is insufficient information available to"
    },
    {
        "id": "doc_1942",
        "document": "guide the establishment of definitive criteria for the conversion and possible reversion of IGRAs. The issue of interpreting IGRA conversions and reversions in the context of serial testing has proven especially problematic. For exam- ple, in a study of 216 Indian healthcare workers, a QFT con- version rate of 12% and a reversion rate of 24% were observed, with many of these apparent changes occurring near the cutoff values [118]. A longitudinal study involving 2563 in health- care workers"
    },
    {
        "id": "doc_1943",
        "document": "demonstrated an IGRA conversion (6%\u20138%) in those undergoing serial testing [116]. These rates were 6\u20139 times higher than that seen for the TST and were thought to have represent false conversions. Such studies have not yielded useful criteria that can be used to distinguish Mtb infection"
    },
    {
        "id": "doc_1944",
        "document": "from a false-positive result [119]. As discussed above, there are a number of sources of variability in the IGRA assay related to laboratory technique such as sample agitation, time elapsed prior to incubation, duration of incubation, agitation technique, and blood volume that could result in variability around the cutoff value. In this instance, this variability may reflect the inherent variability of a biologic measurement, and is the rationale behind the committee\u2019s recommendation that"
    },
    {
        "id": "doc_1945",
        "document": "quantitative values be reported. The optimal cut-points for IGRA testing are controversial. While results close to the cut- point tend to be less reliable than results substantially above or below the cut-point, this is not absolute; in many instances, positive values well above the threshold were not repro- duced in subsequent testing [116]. It is for this reason that the committee felt that quantitative guidance regarding the interpretations of conversions and reversions in the context of"
    },
    {
        "id": "doc_1946",
        "document": "healthcare worker screening could not be provided. Given the varied sources of IGRA variability [24], the committee thought that a positive test in a low-risk individual was likely to be a false-positive result, and recommended repeat testing."
    },
    {
        "id": "doc_1947",
        "document": "Question 4: Should an IGRA or a TST be performed in healthy children <5 years of age in whom it has been decided that testing for LTBI is warranted?\n\nEvidence\n\nThe body of evidence regarding IGRA performance in young children is limited. Compared with adults, a limited number of children have been enrolled in IGRA studies. Even fewer chil- dren from nonendemic countries have been studied, and many reports do not include a separate analysis of young children."
    },
    {
        "id": "doc_1948",
        "document": "The sensitivity of IGRAs in young children with TB ranges from 52% to 100% when a final diagnosis of either microbio- logically confirmed or clinical TB disease is used as the reference standard, which is comparable to adults [56, 59, 76, 102\u2013105, 120]. The sensitivity of the TST has been reported as equiva- lent or increased compared with IGRAs in children [56, 59, 76, 101\u2013105, 120], with young age associated with decreased IGRA positivity [107]. Important caveats to this comparison, however,"
    },
    {
        "id": "doc_1949",
        "document": "are that some studies used earlier, less sensitive versions of the IGRA and results have been inconsistent. As examples of the inconsistencies, a study using an IGRA similar to a currently available IGRA test demonstrated increased sensitivity of the IGRA compared with TST in children aged <3 years, especially among those coinfected with HIV and/or malnourished [121]. None of these studies were performed in nonendemic countries."
    },
    {
        "id": "doc_1950",
        "document": "The specificity of IGRAs appears to be excellent in children in the range of 90%\u2013100% [122] according to a study conducted in children who had nontuberculous mycobacteria. The study found that IGRAs were more specific than TST in children with nontuberculous mycobacterial disease [102].\n\nOur confidence in the estimated test characteristics of IGRAs and TST in children is very low because most of the studies did\n\nD"
    },
    {
        "id": "doc_1951",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\ne m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne14 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\nnot report whether or not they enrolled consecutive patients, were not performed in nonendemic countries, and have pro- vided inconsistent results."
    },
    {
        "id": "doc_1952",
        "document": "Recommendation: We suggest performing a TST rather than an IGRA in healthy children <5 years of age for whom it has been decided that diagnostic testing for LTBI is warranted (con- ditional recommendation, very low-quality evidence). Remarks: In situations in which an IGRA is deemed the preferred diag- nostic test, some experts are willing to use IGRAs in children over 3 years of age.\n\nRationale"
    },
    {
        "id": "doc_1953",
        "document": "The limited direct evidence described above suggests that the TST might be more sensitive than IGRAs in young children, and IGRAs may be more specific than the TST, particularly in those given BCG. Because young children have a high risk for progression to active TB disease, the committee believed that the sensitivity of the diagnostic test (ie, avoiding false-negative results, missed opportunities to treat) is more important than the specificity of the test (ie, avoiding false-positive results,"
    },
    {
        "id": "doc_1954",
        "document": "unnecessary therapy). This is supported by the observations that the potential consequences of delayed treatment are high, while the risk of hepatotoxicity is greatly reduced in young children. An additional reason to favor TST testing over IGRA testing in young children is that the management of the most at-risk young children (ie, young household contacts) depends upon the results of serial testing for infection, for which there are no data for IGRAs in young children."
    },
    {
        "id": "doc_1955",
        "document": "While there are theoretical benefits from IGRA testing (eg, improved acceptance of LTBI therapy), these benefits have not been proven. Therefore, there is insufficient evidence that the benefits of IGRA testing exceed the well-known limitations of the TST. For these reasons, it is too early to recommend replac- ing the TST with IGRA testing. The recommendation is condi- tional because the quality of evidence provided the committee with limited confidence in the estimated test characteristics of"
    },
    {
        "id": "doc_1956",
        "document": "IGRAs and TSTs in children; therefore, the committee could not be certain that the desirable consequences of performing IGRAs instead of TSTs outweigh the undesirable consequences in the vast majority of patients."
    },
    {
        "id": "doc_1957",
        "document": "Cautions and Limitations"
    },
    {
        "id": "doc_1958",
        "document": "In studies of young children that report rates of indeterminate IGRA results, the frequency ranges from 0 to 35%, which is generally higher than in studies that reported in adults. Several studies have reported an increased rate of indeterminate IGRA results in children <5 years of age [47, 56\u201360]. As phlebotomy is more difficult in young children, inability to perform the IGRA due to insufficient blood volumes represents an additional prac- tical limitation to IGRA testing in young children. A"
    },
    {
        "id": "doc_1959",
        "document": "relatively high incidence of failed phlebotomy has been documented in some studies [106, 123]."
    },
    {
        "id": "doc_1960",
        "document": "DIAGNOSTIC TESTS FOR TB\n\nThe diagnosis and management of TB disease rely on accurate laboratory tests, both for the benefit of individual patients and the control of TB in the community through public health ser- vices. Therefore, laboratory services are an essential component of effective TB control at the local, state, national, and global levels."
    },
    {
        "id": "doc_1961",
        "document": "In the United States, up to 80% of all initial TB-related labora- tory work (eg, AFB smear and culture inoculation) is performed in hospitals, clinics, and independent laboratories outside the public health system, whereas >50% of species identification and drug susceptibility testing (DST) is performed in public health laboratories [124]. Thus, effective TB control requires a network of public and private laboratories to optimize labora- tory testing and the flow of information. Public health"
    },
    {
        "id": "doc_1962",
        "document": "labora- tory workers, as a component of the public health sector with a mandate for TB control, should take a leadership role in devel- oping laboratory networks and in facilitating communication among laboratory workers, clinicians, and TB controllers."
    },
    {
        "id": "doc_1963",
        "document": "Seven types of tests for the diagnosis of TB disease and detec- tion of drug resistance are performed within the tuberculosis laboratory system and recommended for optimal TB control services (Table 2). These laboratory tests should be available to every clinician involved in TB diagnosis and management, and to jurisdictional public health agencies charged with TB control."
    },
    {
        "id": "doc_1964",
        "document": "For suspected cases of pulmonary TB, sputum smears for AFB are correlated with the likelihood of transmission and then, for AFB smear\u2013positive pulmonary cases, a nucleic acid ampli- fication assay provides rapid confirmation that the infecting mycobacteria are from the Mtb complex. Both sputum smears for AFB and nucleic acid amplification tests (NAATs) should be available with rapid turnaround times from specimen collection."
    },
    {
        "id": "doc_1965",
        "document": "Table 2. Essential Laboratory Tests for the Detection of Mycobacterium tuberculosis"
    },
    {
        "id": "doc_1966",
        "document": "Test Time Required 1. Nucleic acid amplification test, detection (NAAT-TB) 1d II. Nucleic acid amplification test, resistance markers (NAAT-R) 1-2d IIl. Acid-fast bacilli microscopy 1d IV. Growth detection Liquid Solid Up to 6-8 wk (average 10-14 d) (average 3-4 wk) V. Identification of Mycobacterium tuberculosis complex by DNA probe or HPLC 1d\u00b0 VI. First-line drug susceptibility testing (liquid medium) 1102 wk? VII. Second-line and novel compound drug susceptibility testing"
    },
    {
        "id": "doc_1967",
        "document": "i. Liquid (broth-based) medium 110 2 wk? ii. Solid (agar- or egg-based) medium 3104wk\u2019"
    },
    {
        "id": "doc_1968",
        "document": "Abbreviation: HPLC, high-performance liquid chromatography.aAfter detection of growth.\n\nD\n\no\n\nn l o a d e d f r o m h t t p s : / / a c a d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e15"
    },
    {
        "id": "doc_1969",
        "document": "These tests facilitate decisions about initiating treatment for TB or a non-TB pulmonary infection, infection control measures (eg, patient isolation), and, if TB is diagnosed, for reporting the case and establishing priority for the contact investigation.\n\nDIAGNOSTIC APPROACH: TESTING FOR SUSPECTED PULMONARY TB"
    },
    {
        "id": "doc_1970",
        "document": "Pulmonary TB is often first suspected on the basis of chest computed tomographic findings (Supplementary Table 8). Randomized trials and controlled observational studies that directly compared diagnostic tests for pulmonary tuberculo- sis and measured patient-important outcomes have not been performed. Therefore, the recommendations in this section are based upon data that describe how accurate a diagnostic test is at confirming or excluding pulmonary TB, coupled with the widely accepted"
    },
    {
        "id": "doc_1971",
        "document": "knowledge that diagnosing pulmonary TB leads to therapy that dramatically improves patient-important outcomes and reduces disease transmission [125, 126]. Finally, it was the consensus of the committee that testing for LTBI (TST or IGRA) cannot be used to exclude a diagnosis of TB and, hence, should not be used in the evaluation of those with suspected TB."
    },
    {
        "id": "doc_1972",
        "document": "Question 5: Should AFB smear microscopy be performed in persons suspected of having pulmonary TB? Evidence"
    },
    {
        "id": "doc_1973",
        "document": "Performing 3 AFB smears confirms pulmonary TB with a sensitivity of approximately 70% when culture-confirmed TB disease is the reference standard. The reason for performing 3 AFB smears is that each specimen increases sensitivity. The sensitivity of the first specimen is 53.8%, which increases by a mean of 11.1% by obtaining a second specimen. Obtaining a third specimen increases the sensitivity by a mean of only 2%\u20135% (ie, false-positive results could exceed the additional true-positive results"
    },
    {
        "id": "doc_1974",
        "document": "obtained from a third specimen)."
    },
    {
        "id": "doc_1975",
        "document": "The sensitivity of a first morning specimen is 12% greater than a single spot specimen [127]. Concentrated specimens have a mean increase in sensitivity of 18% compared with non- concentrated specimens (using culture as the standard) and flu- orescence microscopy is on average 10% more sensitive than conventional microscopy [128, 129]. The specificity of micros- copy is relatively high (\u226590%), but the positive predictive value (PPV) varies (70%\u201390%) depending upon the prevalence of tuberculosis"
    },
    {
        "id": "doc_1976",
        "document": "versus nontuberculous mycobacterial disease [130, 131]. These accuracy studies provide moderate confidence in the estimated test characteristics because many did not report having enrolled consecutive patients."
    },
    {
        "id": "doc_1977",
        "document": "Recommendation 5: We recommend that AFB smear micros- copy be performed, rather than no AFB smear microscopy, in all patients suspected of having pulmonary TB (strong recommen- dation, moderate-quality evidence). Remarks: False-negative results are sufficiently common that a negative AFB smear result"
    },
    {
        "id": "doc_1978",
        "document": "does not exclude pulmonary TB. Similarly, false-positive results are sufficiently common that a positive AFB smear result does not confirm pulmonary TB. Testing of 3 specimens is consid- ered the normative practice in the United States and is strongly recommended by the CDC and the National Tuberculosis Controllers Association to improve sensitivity given the per- vasive issue of poor sample quality. Providers should request a sputum volume of at least 3 mL, but the optimal volume is 5\u201310 mL."
    },
    {
        "id": "doc_1979",
        "document": "Concentrated respiratory specimens and fluorescence microscopy are preferred."
    },
    {
        "id": "doc_1980",
        "document": "Rationale"
    },
    {
        "id": "doc_1981",
        "document": "AFB smear microscopy can be performed in hours, is inex- pensive, and is technically simple. Our committee predeter- mined that AFB smear microscopy would be recommended if false-negative results occur <30% of the time (ie, sensitivity is \u226570%) and false-positive results occur <10% of the time (ie, specificity is \u226590%). The likely outcome of a false-negative result is additional diagnostic testing and/or delayed diagnosis due to the duration required for cultures to become positive, whereas the"
    },
    {
        "id": "doc_1982",
        "document": "likely outcome of a false-positive result is unnec- essary therapy with its associated risk for hepatotoxicity. The different thresholds for false results reflect the committee\u2019s recognition that the consequences of false-negative results are generally transient, whereas the consequences of false-pos- itive results may be long lasting. In this case, the sensitivity and specificity of AFB smear microscopy were approximately 70% and \u226590%, respectively, so AFB smear microscopy is recommended."
    },
    {
        "id": "doc_1983",
        "document": "The recommendation is strong because the quality of evi- dence provided the committee with moderate confidence in the estimated test characteristics of AFB smear microscopy, and the committee therefore felt certain that the desirable consequences of AFB smear microscopy (ie, an early presumptive diagnosis, initiation of therapy, and possibly less transmission) outweigh the undesirable consequences (ie, cost, burden, effects of false results) in the vast majority of patients."
    },
    {
        "id": "doc_1984",
        "document": "Question 6: Should both liquid and solid mycobacterial cul- tures be performed in persons suspected of having pulmo- nary TB?\n\nEvidence"
    },
    {
        "id": "doc_1985",
        "document": "A meta-analysis comparing 2 liquid culture methods with solid cultures found that both liquid culture methods were more sensitive (88% and 90%) than the solid culture method (76%) when a combination of conventional solid media with a broth-based method was the reference standard, and also had a shorter time to detection (13.2 and 15.2 days for liquid cul- ture methods versus 25.8 days for the solid culture method) [132]. The specificity of all 3 methods exceeded 99%. Liquid culture medium has a"
    },
    {
        "id": "doc_1986",
        "document": "higher contamination rate than solid culture medium due to the growth of bacteria other than"
    },
    {
        "id": "doc_1987",
        "document": "D\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\ni c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne16 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_1988",
        "document": "mycobacteria (4%\u20139% in the meta-analysis), which interferes with obtaining a valid culture result. This evidence provides low confidence in the estimated test characteristics for 2 rea- sons. First, there may be selection bias, as many of the stud- ies did not state whether they enrolled consecutive patients. Second, there is indirectness, since the studies address the test characteristics of either test alone but the question is about the tests combined."
    },
    {
        "id": "doc_1989",
        "document": "Recommendation 6: We suggest that both liquid and solid mycobacterial cultures be performed, rather than either cul- ture method alone, for every specimen obtained from an individual with suspected TB disease (conditional recommen- dation, low-quality evidence). Remarks: The conditional qual- ifier applies to performance of both liquid and solid culture methods on all specimens. At least liquid culture should be done on all specimens as culture is the gold standard micro- biologic test for the"
    },
    {
        "id": "doc_1990",
        "document": "diagnosis of TB disease. The isolate recovered should be identified according to the Clinical and Laboratory Standards Institute guidelines and the American Society for Microbiology Manual of Clinical Microbiology [133, 134]."
    },
    {
        "id": "doc_1991",
        "document": "Rationale"
    },
    {
        "id": "doc_1992",
        "document": "Mycobacterial culture is the laboratory gold standard for tuber- culosis diagnosis, but the preferred type of cultures is uncer- tain. Liquid cultures alone are reasonably sensitive and highly specific, but limited by contamination. Solid cultures alone are not sufficiently sensitive to reliably diagnose TB and gen- erally take longer to yield results; however, some Mtb isolates are detected only on solid medium. Performing both liquid and solid cultures likely improves the sensitivity of"
    },
    {
        "id": "doc_1993",
        "document": "mycobacterial cultures, while the liquid cultures provide a more rapid answer and the solid cultures serve as a safeguard against contamina- tion. The recommendation is conditional because the quality of evidence provided the committee with limited confidence in the estimated test characteristics of the culture methods; there- fore, the committee could not be certain that the desirable con- sequences of performing both culture methods instead of only one method outweigh the undesirable"
    },
    {
        "id": "doc_1994",
        "document": "consequences in the vast majority of patients."
    },
    {
        "id": "doc_1995",
        "document": "Question 7: Should NAAT be performed on the initial res- piratory specimen in persons suspected of having pulmonary TB?\n\nTB?"
    },
    {
        "id": "doc_1996",
        "document": "Evidence\n\nThree meta-analyses were identified and reviewed. The first stratified the performance characteristics of NAAT based upon AFB smear results [135]. When AFB smear microscopy was positive, the sensitivity and specificity of NAAT were 96% and 85%, respectively. Most studies used culture as the reference standard. When AFB smear microscopy was negative, the sen- sitivity decreased to 66% and the specificity increased to 98%."
    },
    {
        "id": "doc_1997",
        "document": "When further stratified by whether the patient received treat- ment, the specificity in untreated patients was 97%. The second meta-analysis reported an overall sensitivity of 85% and speci- ficity of 97% and did not stratify according to the results of AFB smear microscopy [136]. There was significant heterogeneity in both meta-analyses. The third meta-analysis stratified the NAAT test characteristics in AFB smear microscopy\u2013negative suspects according to clinical suspicion of tuberculosis"
    },
    {
        "id": "doc_1998",
        "document": "[137]. It found that in AFB smear microscopy\u2013negative individuals, a positive NAAT result is beneficial when the clinical suspicion of tuberculosis was intermediate or high (>30%) and a negative NAAT result is of little use in excluding the presence of Mtb. This evidence provides low confidence in the estimated test characteristics because there may be selection bias since many of the studies did not state whether they enrolled consecutive patients with legitimate diagnostic uncertainty and"
    },
    {
        "id": "doc_1999",
        "document": "there was significant inconsistency in the meta-analyses."
    },
    {
        "id": "doc_2000",
        "document": "Recommendation 7: We suggest performing a diagnostic NAAT, rather than not performing a NAAT, on the initial res- piratory specimen from patients suspected of having pulmo- nary TB (conditional recommendation, low-quality evidence). Remarks: In AFB smear\u2013positive patients, a negative NAAT makes TB disease unlikely. In AFB smear\u2013negative patients with an intermediate to high level of suspicion for disease, a positive NAAT can be used as presumptive evidence of TB disease, but a negative NAAT"
    },
    {
        "id": "doc_2001",
        "document": "cannot be used to exclude pul- monary TB. Appropriate NAATs include the Hologic Amplified Mycobacteria Tuberculosis Direct (MTD) test (San Diego, California) and the Cepheid Xpert MTB/Rif test (Sunnyvale, California)."
    },
    {
        "id": "doc_2002",
        "document": "Rationale"
    },
    {
        "id": "doc_2003",
        "document": "Mycobacterial culture results require at least 1\u20132 weeks; there- fore, rapid diagnostic tests that can be performed within hours are desirable, such as AFB smear microscopy and diagnostic NAAT. Diagnostic NAAT has the added advantage over AFB smear microscopy of being able to distinguish Mtb from nontu- berculous mycobacteria. However, NAAT is appropriate only as an adjunct to mycobacterial culture and AFB smear microscopy. It is used as an adjunct to mycobacterial culture because it is not"
    },
    {
        "id": "doc_2004",
        "document": "sensitive enough to replace mycobacterial culture for diagnosis and does not produce an isolate, which is needed for phenotypic DST. It is used as an adjunct to AFB smear microscopy because the test characteristics of NAAT are highly variable depending upon the AFB smear results and clinical suspicion."
    },
    {
        "id": "doc_2005",
        "document": "In AFB smear\u2013positive patients, NAAT yields false-negative results only 4% of the time, indicating that it is reliable for exclud- ing pulmonary TB. In AFB smear\u2013negative patients, clinical sus- picion needs to be considered. When there is an intermediate to high level of suspicion for disease, NAAT yields sufficiently few false-positive results that a positive NAAT result can be used as presumptive evidence of TB and guide therapeutic decisions;\n\nD"
    },
    {
        "id": "doc_2006",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e17"
    },
    {
        "id": "doc_2007",
        "document": "however, false-negative results are sufficiently common that NAAT cannot be used to exclude pulmonary TB. When the clin- ical suspicion for TB is low, NAAT is generally not performed because false-positive results are unacceptably frequent. An algorithm for interpretation and use of NAAT results in con- junction with AFB smear results has been published [138]."
    },
    {
        "id": "doc_2008",
        "document": "The recommendation is conditional because the quality of evidence provided the committee with limited confidence in the estimated test characteristics of NAAT; therefore, the com- mittee could not be certain that the desirable consequences of performing NAAT (ie, promptly diagnosing TB disease and initiating treatment), instead of not performing NAAT, outweigh the undesirable consequences (ie, cost, false-posi- tive results leading to unnecessary treatment, and false-neg- ative results provided"
    },
    {
        "id": "doc_2009",
        "document": "false reassurance) in the vast majority of patients."
    },
    {
        "id": "doc_2010",
        "document": "Cautions and Limitations"
    },
    {
        "id": "doc_2011",
        "document": "Laboratory-based diagnostic tests are not a replacement for clinical judgment and experience. A diagnosis of pulmonary tuberculosis can be made in the absence of laboratory confir- mation, especially in children [139]. Although there appears to be little increase in accuracy achieved by routinely performing NAAT on multiple specimens rather than on a single speci- men, some clinicians may find it beneficial in the diagnosis of individual patients [140, 141]. As an example, the presence of"
    },
    {
        "id": "doc_2012",
        "document": "inhibitors can cause false-negative results for some NAATs [142] and, therefore, if a specimen has a positive AFB smear result and a negative NAAT result, evaluation of the sample for the presence of inhibitors should be considered if the NAAT being used is subject to inhibition. If inhibitors are detected, collection of a new specimen for NAAT should be considered. The recommendation for use of NAATs is based on stud- ies of commercial test kits. The data on in-house tests show even greater"
    },
    {
        "id": "doc_2013",
        "document": "heterogeneity [143]. If in-house tests are to be used, they should be validated and be shown to have analyti- cal performance accuracy comparable to or better than that of commercial tests."
    },
    {
        "id": "doc_2014",
        "document": "Question 8: Should rapid molecular drug susceptibility test- ing for isoniazid and rifampin be performed as part of the initial diagnostic evaluation for all patients suspected of hav- ing pulmonary TB or only in selected subgroups? Evidence"
    },
    {
        "id": "doc_2015",
        "document": "Rapid molecular DST can be performed via line probe or molecular beacon assays. We evaluated systematic reviews with meta-analyses of 2 line probe assays [144, 145]. Both line probe assays detected rifampin resistance with a sensitivity and specificity of \u226597% and \u226598%, respectively, when conventional, culture-based DST was used as the reference standard. More recently, a molecular-beacon based method for rapid rifampin resistance detection was evaluated in a large international"
    },
    {
        "id": "doc_2016",
        "document": "e18 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\naccuracy study [146]. This assay, Xpert MTB/RIF, was >92% sensitive and >99% specific for detection of rifampin resistance when performed on a single specimen; the sensitivity increased to >97% when performed on 3 specimens [146]. Despite its good sensitivity and specificity, the PPV of rapid molecular DST for the detection of rifampin resistance is low in popula- tions with a low prevalence of drug resistance (Supplementary Table 9) [147]."
    },
    {
        "id": "doc_2017",
        "document": "One of the assays also detects isoniazid resistance. It identi- fied isoniazid resistance with a sensitivity and specificity of 84% and 99%, respectively, when culture-based DST is used as the reference standard. However, when the meta-analysis was per- formed on a subgroup of studies that evaluated a newer version of the assay, the sensitivity increased to approximately 90%. This indicates that in appropriate subgroups of patients, false-posi- tive and false-negative results occur in 1% and 10%"
    },
    {
        "id": "doc_2018",
        "document": "of patients, respectively. In contrast to rifampin resistance, the PPV of a test indicating isoniazid resistance is quite high, a reflection of isoniazid resistance being fairly prevalent in the United States (approximately 8%) [144]."
    },
    {
        "id": "doc_2019",
        "document": "This evidence provides moderate confidence in the estimated sensitivities and specificities among patient subgroups with increased rates of drug resistance. The confidence is moderate instead of high because the absence of reporting that patients were enrolled consecutively suggests that there is a risk of bias."
    },
    {
        "id": "doc_2020",
        "document": "Recommendation 8: We recommend performing rapid molecular DST for rifampin with or without isoniazid using the respiratory specimens of persons who are either AFB smear positive or Hologic Amplified MTD positive and who meet one of the following criteria: (1) have been treated for tuberculosis in the past, (2) were born in or have lived for at least 1 year in a foreign country with at least a moderate tuberculosis inci- dence (\u226520 per 100 000) or a high primary MDR-TB prevalence (\u22652%), (3) are"
    },
    {
        "id": "doc_2021",
        "document": "contacts of patients with MDR-TB, or (4) are HIV infected (strong recommendation, moderate-quality evi- dence). Remarks: This recommendation specifically addresses patients who are Hologic Amplified MTD positive because the Hologic Amplified MTD NAAT only detects TB and not drug resistance; it is not applicable to patients who are positive for types of NAAT that detect drug resistance, including many line probe assays and Cepheid Xpert MTB/RIF."
    },
    {
        "id": "doc_2022",
        "document": "Rationale"
    },
    {
        "id": "doc_2023",
        "document": "Conventional, culture-based DST is the laboratory gold stand- ard [134, 148, 149]. It is performed routinely any time Mtb com- plex is isolated in culture. Drug susceptibility testing is essential because treatment success for patients with MDR-TB (can reach 75% or higher [150, 151]) is dependent upon patients being treated with an effective antimicrobial regimen [152]. An important limitation of culture-based DST, however, is that it can take >2 weeks to grow the isolate that is necessary for"
    },
    {
        "id": "doc_2024",
        "document": "testing."
    },
    {
        "id": "doc_2025",
        "document": "D\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\np . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_2026",
        "document": "Rapid molecular DST addresses this limitation. It can be per- formed within hours, enabling earlier initiation of an appropri- ate antimicrobial regimen. Rapid molecular DST is an adjunct and not a replacement for culture-based DST because it only evaluates susceptibility to rifampin and occasionally isonia- zid. Nonetheless, detection of rifampin resistance is helpful to clinicians because it is a good surrogate for MDR-TB in loca- tions where rifampin monoresistance is uncommon. However, an"
    },
    {
        "id": "doc_2027",
        "document": "important limitation is that the PPV is expected to be lower in the United States than in areas where rifampin resistance is more common [153\u2013155]."
    },
    {
        "id": "doc_2028",
        "document": "The committee recommends rapid molecular DST only for subgroups in which drug resistance is more likely, as the PPV for rifampin resistance testing is low in populations with a low prevalence of drug resistance. Examples of appropriate persons for testing include those who are NAAT or AFB smear positive and meet one of the following criteria: (1) have been treated for tuberculosis in the past, (2) were born in or have lived for at least 1 year in a foreign country with at least a moderate tuber-"
    },
    {
        "id": "doc_2029",
        "document": "culosis incidence (\u226520 per 100 000) or a high primary MDR-TB prevalence (\u2265 2%), (3) are contacts of patients with MDR-TB, or (4) are HIV infected [154, 156\u2013158]."
    },
    {
        "id": "doc_2030",
        "document": "The sensitivity and specificity of rapid molecular DST for detecting rifampin resistance are both >97%, indicating that false-positive and false-negative results occur <3% of the time; thus, rapid molecular DST can be used confirm or exclude rifampin resistance in respiratory specimens. The sensitivity and specificity of rapid molecular DST for detecting isoniazid resist- ance are estimated to be 90% and 99%, respectively, indicating that false-positive and false-negative results occur roughly"
    },
    {
        "id": "doc_2031",
        "document": "1% and 10% of the time, respectively; thus, rapid molecular DST can be used to confirm isoniazid resistance in respiratory spec- imens, but not exclude it."
    },
    {
        "id": "doc_2032",
        "document": "The recommendation is strong because the moderate-quality evidence provided the committee with sufficient confidence in the test characteristics to be certain that the benefits of rapid molecular DST (ie, early identification of possible MDR-TB and initiation of an appropriate antimicrobial regimen) outweigh the costs and burden of testing in the overwhelming majority of patients who have increased risk for drug resistance.\n\nCautions and Limitations"
    },
    {
        "id": "doc_2033",
        "document": "Line probe and molecular beacon assays have not been suffi- ciently validated for use on specimens other than respiratory specimens. The recommendation for line probe assays and molecular beacon on respiratory specimens is based upon studies of commercial test kits, only one of which is currently approved by the FDA: the molecular beacon\u2013based method, Xpert MTB/RIF. It is the only FDA-approved assay and it inte- grates diagnosis of TB and detection of rifampin resistance. If this test is used"
    },
    {
        "id": "doc_2034",
        "document": "for the diagnosis of TB, a rifampin resistance result is automatically provided regardless of patient risk."
    },
    {
        "id": "doc_2035",
        "document": "Other assays for rapid detection of drug resistance using alternative molecular techniques (eg, automated real-time pol- ymerase chain reaction [PCR] with sequencing, loop-mediated isothermal amplification [LAMP]) are being developed. These assays are promising, but are not yet commercially available [146, 159, 160]. The data on in-house tests show substantial het- erogeneity [161]. If in-house tests are to be used, they should be validated and shown to have performance accuracy at least"
    },
    {
        "id": "doc_2036",
        "document": "comparable to that of commercial tests. The same cautions also apply to new commercial assays that may become available in the near future."
    },
    {
        "id": "doc_2037",
        "document": "Some clinicians and health departments may opt for broader use of the molecular detection of drug resistance assays than recommended above, especially in regions where MDR-TB is more common. Because the prevalence of rifampin resistance (and therefore MDR-TB) is low in the United States, the PPV of Xpert MTB/RIF and other assays for rifampin resistance will be lower than in settings where Xpert MTB/RIF has been pre- dominantly studied. Therefore, confirmation of a positive test result for"
    },
    {
        "id": "doc_2038",
        "document": "rifampin resistance has been recommended [147]. To confirm a positive result, genetic loci associated with rifampin resistance (to include rpoB), as well as isoniazid resistance (to include inhA and katG), should be sequenced to assess for MDR-TB. If mutations associated with rifampin resistance are confirmed, rapid molecular testing for other known mutations associated with drug resistance (to first-line and second-line drugs) is needed for healthcare providers to select an opti- mally"
    },
    {
        "id": "doc_2039",
        "document": "effective treatment regimen. All molecular testing should prompt growth-based DST."
    },
    {
        "id": "doc_2040",
        "document": "Alternative methods for rapid molecular DST are being developed and other technologies are likely to become available in the near future (eg, automated real-time PCR with sequenc- ing, LAMP) [162]. It is possible that these techniques will be sufficiently sensitive to be used for AFB smear\u2013negative spec- imens. Laboratories in the United States should only use tests approved by the FDA or tests that have been produced and val- idated in accord with applicable FDA and Clinical Laboratory"
    },
    {
        "id": "doc_2041",
        "document": "Improvement Amendments regulations."
    },
    {
        "id": "doc_2042",
        "document": "Question 9: Should respiratory specimens be collected from children with suspected pulmonary TB disease? Evidence\n\nEvidence"
    },
    {
        "id": "doc_2043",
        "document": "Respiratory specimens that can be collected from children include gastric aspirates; sputum collected by spontaneous expectoration, induction, or nasopharyngeal aspiration; and bronchoalveolar lavage (BAL). Gastric aspirates involve intu- bating the stomach after an overnight fast to collect swallowed sputum before the stomach empties. Collection of specimens on 3 consecutive mornings from patients with suspected pul- monary TB provides a diagnostic yield of up to 40%\u201350%, with higher yields for"
    },
    {
        "id": "doc_2044",
        "document": "infants (up to 90%), symptomatic children, and children with extensive disease (up to 77%), using a clinical"
    },
    {
        "id": "doc_2045",
        "document": "Diagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e19\n\nD\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\n. o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_2046",
        "document": "diagnosis of TB disease in a low prevalence country as criteria for the diagnosis of TB disease [163\u2013165]. Meticulous attention to detail during the collection and processing of the specimen can improve yield (details are provided at http://www.currytb- center.ucsf.edu/pediatric_tb/). Sputum collected from children by nasopharyngeal aspiration or sputum induction with a bron- chodilator has a yield of 20%\u201330% [166], whereas BAL in chil- dren with pulmonary TB has a yield of 10%\u201322% [167]. These"
    },
    {
        "id": "doc_2047",
        "document": "estimates of diagnostic yield are based upon moderate-quality evidence\u2014accuracy studies for which it was not documented whether the subjects were enrolled consecutively."
    },
    {
        "id": "doc_2048",
        "document": "Recommendation 9: We suggest mycobacterial culture of respiratory specimens for all children suspected of having pul- monary TB (conditional recommendation, moderate-quality evidence)."
    },
    {
        "id": "doc_2049",
        "document": "Remarks: In a low incidence setting like the United States, it is unlikely that a child identified during a recent contract inves- tigation of a close adult/adolescent contact with contagious TB was, in fact, infected by a different individual with a strain with a different susceptibility pattern. Therefore, under some circumstances, microbiological confirmation may not be nec- essary for children with uncomplicated pulmonary TB identi- fied through a recent contact investigation if the source"
    },
    {
        "id": "doc_2050",
        "document": "case has drug-susceptible TB."
    },
    {
        "id": "doc_2051",
        "document": "Rationale"
    },
    {
        "id": "doc_2052",
        "document": "Despite the observation that less than half of pediatric spec- imens yield a positive culture, the committee judged that the desirable consequences of mycobacterial cultures of respiratory specimens outweigh the undesirable consequences of specimen collection in children for several reasons. First, a positive myco- bacterial culture is likely to be reassuring to parents and staff that the diagnosis of tuberculosis is correct. Second, cultures are necessary for DST, which is particularly"
    },
    {
        "id": "doc_2053",
        "document": "important in situations in which TB drug resistance is prevalent. Third, suspectibility data are not always available from the presumed source case. Finally, after-the-fact culture collection in the face of treatment failure may have even lower yield than sampling a drug-na- ive child. Specimens that can be used for mycobacterial culture include gastric aspirates, sputum, and BAL; the panel decided that there was insufficient evidence to advocate one collection method over another."
    },
    {
        "id": "doc_2054",
        "document": "With respect to the need for DST, overtreatment for pre- sumed drug-resistant TB may lead to unnecessary toxicities and cost, while undertreatment due to unidentified drug resistance may lead to treatment failure, risk of dissemination, and even death. While it is tempting to avoid culture collection from the child contact when a putative source case is identified (espe- cially when susceptibility results are already available), prior case series indicate that 2%\u201310% of children have"
    },
    {
        "id": "doc_2055",
        "document": "susceptibility patterns that differ from the presumed source case [168] and more recent US studies have found up to 15% discordance of"
    },
    {
        "id": "doc_2056",
        "document": "molecular fingerprinting between the isolates collected from children with culture-proven TB compared to their presumed source case [169, 170]. In contrast, no discordance was found between pediatric TB cases and their presumed source cases from 2000 to 2004 in Houston [171]."
    },
    {
        "id": "doc_2057",
        "document": "The recommendation is conditional because the moderate quality of evidence provided the committee with insufficient confidence in the estimated diagnostic yield; thus, the com- mittee felt uncertain that a diagnosis was rendered frequently enough that the desirable consequences of collecting respira- tory specimens (ie, confirming the diagnosis of TB, obtaining an isolate for DST) outweigh the undesirable consequences (ie, cost, burden, effects of false results) in the vast majority of chil-"
    },
    {
        "id": "doc_2058",
        "document": "dren with suspected pulmonary TB."
    },
    {
        "id": "doc_2059",
        "document": "The highest yields for gastric aspirates are in the youngest infants, in children with extensive or symptomatic disease, and for the first gastric aspirate collected. While there are situations where a presumed source case is not the child\u2019s true source case, in the case of a very recent contact investigation of a house- hold-type contact with pan-susceptible disease, performing only one gastric aspirate or relying on the source case suscep- tibility may be appropriate. For infants,"
    },
    {
        "id": "doc_2060",
        "document": "immunocompromised hosts, children with extensive, disseminated, or extrapulmo- nary disease, exposure to other potential source cases, or risk of drug-resistance, respiratory specimens should be collected. Studies comparing the yield of gastric aspirates to sputum have shown discrepent results. Selection of an appropriate respira- tory specimen (i.e., gastric aspirates, spontaneous or induced sputa, or rarely bronchoalveolar lavage) should be based upon the expertise of the clinic and provider,"
    },
    {
        "id": "doc_2061",
        "document": "the patient\u2019s age and developmental level, and the likelihood of an alternative diagno- sis. Most investigators have not found increased yield for bron- choalveolar lavage compared to gastric aspirates. Bronchoscopy should be reserved for situations where an alternative diagnosis is being considered or when the anatomy is unclear."
    },
    {
        "id": "doc_2062",
        "document": "Cautions and Limitations"
    },
    {
        "id": "doc_2063",
        "document": "Gastric aspirates are rarely AFB smear positive and the yield of cultures is suboptimal in children with pulmonary TB; thus, gastric aspirate culture results are helpful only if they are pos- itive. Negative results should not dissuade the provider from empirically treating tuberculosis in children in the appropriate clinical setting. Gastric aspirate, sputum induction, and naso- pharyngeal aspiration in children are not comfortable and not without financial cost. The procedures have modest risk"
    },
    {
        "id": "doc_2064",
        "document": "(bleed- ing from the nose, bronchospasm, airway intubation)."
    },
    {
        "id": "doc_2065",
        "document": "Question 10: Should sputum induction or flexible broncho- scopic sampling be the initial respiratory sampling method for adults with suspected pulmonary TB who are either una- ble to expectorate sputum or whose expectorated sputum is AFB smear microscopy negative?\n\nD\n\no\n\nn l o a d e d f r o m h t t p s : / / a c a d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne20 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_2066",
        "document": "Evidence"
    },
    {
        "id": "doc_2067",
        "document": "We identified 6 studies [172\u2013177] that compared the diagnostic yield of induced sputum with the yield of specimens obtained by flexible bronchoscopy, using a positive mycobacterial culture or evidence of a response the therapy as criteria for the diag- nosis of pulmonary TB. Five of the 6 studies demonstrated a higher yield from induced sputum than bronchoscopy, with the remaining study [176] demonstrating a similar yield. The diagnostic yield of induced sputum increases with multiple specimens,"
    },
    {
        "id": "doc_2068",
        "document": "with detection rates by AFB smear microscopy of 91%\u201398% and mycobacterial culture of 99%\u2013100% reported when 3 or more specimens are obtained [178]."
    },
    {
        "id": "doc_2069",
        "document": "Two cost-analysis studies favored sputum induction over bronchoscopy [172, 174]. In the first study, direct costs for bronchoscopy measured in Canadian dollars were $187.60, compared with $22.22 for sputum induction [172]. In the sec- ond study, induced sputum was about one-third the cost of flex- ible bronchoscopy, and the most cost-effective strategy was 3 induced sputa without bronchoscopy [174]."
    },
    {
        "id": "doc_2070",
        "document": "Our confidence in the accuracy of the study results is low because there was a risk of bias and indirectness. With respect to risk of bias, most of the studies did not report whether or not consecutive patients were enrolled. Supporting this concern, the variability of prevalence among studies suggests that the degree of diagnostic uncertainty likely differed among studies. With respect to indirectness, there appeared to be indirectness of the intervention because the studies varied in the"
    },
    {
        "id": "doc_2071",
        "document": "number of specimens collected (from 1 to 3 per patient), the concentra- tions of hypertonic saline, the type of nebulizers, and the cul- ture techniques."
    },
    {
        "id": "doc_2072",
        "document": "Recommendation 10: We suggest sputum induction rather than flexible bronchoscopic sampling as the initial respiratory sampling method for adults with suspected pulmonary TB who are either unable to expectorate sputum or whose expectorated sputum is AFB smear microscopy negative (conditional recom- mendation, low-quality evidence).\n\nRationale"
    },
    {
        "id": "doc_2073",
        "document": "Induced sputum has equal or greater diagnostic yield than bronchoscopic sampling, has fewer risks, and is less expensive. These features all favor induced sputum as the initial respira- tory sampling method in patients with suspected pulmonary TB who are either unable to expectorate sputum or whose expectorated sputum is AFB smear microscopy negative. The committee recognizes that a potential advantage of bronchos- copy over sputum induction is the possibility of making a rapid presumptive"
    },
    {
        "id": "doc_2074",
        "document": "diagnosis of tuberculosis by performing biopsies and identifying typical histopathologic findings, but felt that the balance of the upsides to downsides of induced sputum outweighed that of bronchoscopic sampling. The recommen- dation is conditional because the quality of evidence does not provide sufficient confidence in the study results for the"
    },
    {
        "id": "doc_2075",
        "document": "committee to be absolutely certain that the balance of desira- ble to undesirable consequences favors induced sputum over bronchoscopy.\n\nQuestion 11: Should flexible bronchoscopic sampling be per- formed in adults with suspected pulmonary TB from whom a respiratory sample cannot be obtained via induced sputum? Evidence"
    },
    {
        "id": "doc_2076",
        "document": "Numerous studies reported the diagnostic yield of respiratory specimens obtained by flexible bronchoscopy, using a positive mycobacterial culture or evidence of a response the therapy as criteria for the diagnosis of pulmonary TB [172\u2013175, 178\u2013182]. Generally speaking, bronchoscopic sampling appears to have a diagnostic yield of 50%\u2013100% when based on culture in patients suspected of having pulmonary TB. This yield appears unaffected by HIV infection, with bronchoscopy leading to an early pre-"
    },
    {
        "id": "doc_2077",
        "document": "sumptive diagnosis of TB in 34%\u201348% of HIV-infected patients according to 2 studies [183, 184]. In one study, bronchial washings had the same culture yield (95%) as BAL but higher frequency of positive AFB smears (26% vs. 4%) [235]. Bronchoscopic brush- ings yield AFB smear\u2013positive results in 9%\u201356% [180, 185]."
    },
    {
        "id": "doc_2078",
        "document": "Transbronchial biopsy (TBB) provides histopathologic find- ings suggestive of pulmonary TB in 42%\u201363% of specimens from smear-negative HIV-uninfected patients [183, 186]. HIV- infected patients are less likely (9%\u201319%) to demonstrate gran- ulomas on TBB [183, 186], although in 2 studies TBB was the exclusive means of diagnosing pulmonary TB in 10%\u201323% of patients [183, 184]."
    },
    {
        "id": "doc_2079",
        "document": "Our confidence in the accuracy of these estimated diagnostic yields is very low because most of the studies did not report whether or not consecutive patients were enrolled, the range of reported diagnostic yields is wide, and the studies varied in how specimens were collected (bronchial aspirates and/or BAL and/ or bronchial brushings and/or TBB) and the culture techniques."
    },
    {
        "id": "doc_2080",
        "document": "Recommendation 11: We suggest flexible bronchoscopic sampling, rather than no bronchoscopic sampling, in adults with suspected pulmonary TB from whom a respiratory sample cannot be obtained via induced sputum (conditional recommen- dation, very low-quality evidence). Remarks: In the committee members\u2019 clinical practices, BAL plus brushings alone are per- formed for most patients; however, for patients in whom a rapid diagnosis is essential, transbronchial biopsy is also performed."
    },
    {
        "id": "doc_2081",
        "document": "Rationale\n\nThe committee judged that the desirable consequences of bron- choscopic sampling outweigh the undesirable consequences among patients with suspected pulmonary TB from whom respiratory samples could not be obtained noninvasively. The most important reason to perform bronchoscopy in a patient with possible pulmonary TB is to differentiate TB disease from alternative diseases. Another reason to perform bronchoscopy is to obtain specimens for cultures that provide isolates for DST."
    },
    {
        "id": "doc_2082",
        "document": "Diagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e21\n\nD\n\nWoly peapeojumoq\n\no\n\nw\n\nn\n\nl\n\no\n\na\n\nd\n\ne\n\nd\n\nf\n\nr\n\no\n\nm\n\nh\n\nt\n\nt\n\np\n\ns\n\n:\n\n/\n\n/\n\nc a d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_2083",
        "document": "Empiric treatment for presumed drug-resistant TB may lead to unnecessary toxicities and cost if the patient actually has drug-sensitive TB, while empiric treatment for drug-sensitive TB may lead to treatment failure, risk of dissemination, and even death if the patient actually has drug-resistant TB. Moreover, delayed diagnosis of drug resistance will prolong therapy and increase risk of default. Bronchoscopy also provides the oppor- tunity of obtaining a rapid presumptive diagnosis by"
    },
    {
        "id": "doc_2084",
        "document": "identifying histopathologic findings consistent with tuberculosis. These benefits of bronchoscopic sampling were thought to outweigh the risks of bronchoscopy and the accompanying sedation, as well as the costs and burdens."
    },
    {
        "id": "doc_2085",
        "document": "The recommendation is conditional, reflecting the guide- line development committee\u2019s uncertainty that the desirable consequences of bronchoscopy outweigh the undesirable consequences in many situations. Reasons for the commit- tee\u2019s uncertainty included the highly variable estimates of diagnostic yield, the very low quality of evidence, recogni- tion that bronchoscopy is an invasive procedure and the risk of harm varies according to the patient\u2019s clinical condition, and recognition that the"
    },
    {
        "id": "doc_2086",
        "document": "feasibility of timely bronchoscopy varies according to the clinical setting. For example, in the context of a public health clinic, the benefits of obtaining a bronchoscopy may not justify the thousands of dollars that it will cost due to professional fees, hospital charges, pathol- ogy costs, and laboratory fees, or the days to weeks of delays that will be necessary to refer the patient to a pulmonologist for bronchoscopy. In some situations, the potential harm associated with delayed diagnosis"
    },
    {
        "id": "doc_2087",
        "document": "may warrant empiric ini- tiation of therapy based upon a reasonable suspicion of TB disease."
    },
    {
        "id": "doc_2088",
        "document": "Question 12: Should postbronchoscopy sputum specimens be collected from adults with suspected pulmonary TB? Evidence"
    },
    {
        "id": "doc_2089",
        "document": "Postbronchoscopy sputum specimens are typically sent for AFB smear microscopy and mycobacterial culture. Postbronchoscopy AFB smears have a diagnostic yield of 9%\u201373% and postbro- nchoscopy mycobacterial cultures have a yield of 35%\u201371% according to multiple studies [182, 185, 187, 188]. In HIV- infected patients, the yield of postbronchoscopy sputum cul- tures was 80% in a single study [186]. Our confidence in the accuracy of the estimated diagnostic yields is low because most of the studies"
    },
    {
        "id": "doc_2090",
        "document": "did not report whether or not consecutive patients were enrolled and the diagnostic yields reported varied greatly as indicated by the wide ranges described above."
    },
    {
        "id": "doc_2091",
        "document": "Recommendation 12: We suggest that postbronchoscopy sputum specimens be collected from all adults with suspected pulmonary TB who undergo bronchoscopy (conditional recom- mendation, low-quality evidence). Remarks: Postbronchoscopy sputum specimens are used to perform AFB smear microscopy and mycobacterial cultures.\n\ne22 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al"
    },
    {
        "id": "doc_2092",
        "document": "Rationale\n\nThe rationale for postbronchoscopy sputum collection is the same as that described above for the bronchoscopic collection of respiratory specimens.\n\nQuestion 13: Should flexible bronchoscopic sampling be per- formed in adults with suspected miliary TB and no alterna- tive lesions that are accessible for sampling whose induced sputum is AFB smear microscopy negative or from whom a respiratory sample cannot be obtained via induced sputum?\n\nEvidence"
    },
    {
        "id": "doc_2093",
        "document": "Specimens obtained via bronchoscopy can undergo AFB smear microscopy, mycobacterial culture, NAAT, and his- topathological analysis. There is a paucity of evidence regarding the diagnostic characteristics of various types of bronchoscopic specimens (ie, washings, BAL, brushings, TBB) obtained from patients with possible miliary TB. It has been reported that bronchial washings, brushings, and TBB have diagnostic yields of 14% [234], 27%\u201378% [181, 189, 190], and 32%\u201375% [181, 189, 190],"
    },
    {
        "id": "doc_2094",
        "document": "respectively. The diag- nostic yield of BAL has not been reported. Our confidence in the accuracy of the estimated diagnostic yields is very low because most of the studies did not report whether or not consecutive patients were enrolled (the prevalence of miliary TB ranged from 55% to 90% in the studies, suggesting that the degree of diagnostic uncertainty differed among the studies), the ranges of diagnostic yields were wide for both brushings and TBB, reflecting the variable results reported"
    },
    {
        "id": "doc_2095",
        "document": "by the indi- vidual studies, and the studies varied in the technique used to perform the sampling (particularly TBB) and the number of specimens collected."
    },
    {
        "id": "doc_2096",
        "document": "Recommendation 13: We suggest flexible bronchoscopic sampling, rather than no bronchoscopic sampling, in adults with suspected miliary TB and no alternative lesions that are accessible for sampling whose induced sputum is AFB smear microscopy negative or from whom a respiratory sample cannot be obtained via induced sputum (condi- tional recommendation, very low-quality evidence). Remarks: Bronchoscopic sampling in patients with suspected miliary TB should include bronchial brushings and/or TBB,"
    },
    {
        "id": "doc_2097",
        "document": "as the yield from washings is substantially less and the yield from BAL unknown. For patients in whom it is important to pro- vide a rapid presumptive diagnosis of tuberculosis (ie, those who are too sick to wait for culture results), TBB is both nec- essary and appropriate."
    },
    {
        "id": "doc_2098",
        "document": "Rationale\n\nThe rationale for bronchoscopic sampling in individuals with sus- pected miliary TB and no alternative lesions that are accessible for sampling (eg, enlarged lymph nodes or draining lesions) whose induced sputum is AFB smear negative or from whom a respiratory\n\nD\n\nw n l o a d e d f r o m h t t p s : / / a c a d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_2099",
        "document": "sample cannot be obtained via induced sputum is essentially the same as that described above for patients with suspected pulmo- nary TB from whom a respiratory sample cannot be obtained via induced sputum. That is, it is important to differentiate miliary TB from other diseases and also to obtain specimens for mycobacte- rial culture because cultures provide isolates for DST, which may prevent unnecessary drug toxicities and cost, mitigate treatment failure, and reduce the risk of dissemination"
    },
    {
        "id": "doc_2100",
        "document": "and death. Moreover, bronchoscopy also provides the opportunity of obtaining a rapid presumptive diagnosis by identifying histopathologic findings con- sistent with tuberculosis. These benefits outweigh the risks of both bronchoscopy and the accompanying sedation."
    },
    {
        "id": "doc_2101",
        "document": "The recommendation is conditional, reflecting the guide- line development committee\u2019s uncertainty that the desirable consequences of bronchoscopy outweigh the undesirable con- sequences and its recognition that the balance of desirable and undesirable consequences depends upon clinical context. Reasons for the committee\u2019s uncertainty included the variable estimates of the diagnostic yield and very low quality of evi- dence. Clinical considerations that may affect the balance of desirable and"
    },
    {
        "id": "doc_2102",
        "document": "undesirable effects include the patient\u2019s condi- tion (ie, bronchoscopy is an invasive procedure and the risk of harm varies according to the patient\u2019s clinical condition) and the availability, feasibility, and cost of timely bronchoscopy in a particular clinical setting."
    },
    {
        "id": "doc_2103",
        "document": "DIAGNOSTIC APPROACH: TESTING FOR SUSPECTED EXTRAPULMONARY TB"
    },
    {
        "id": "doc_2104",
        "document": "Randomized trials and controlled observational studies that directly compared diagnostic tests or approaches for extrapul- monary TB and measured patient-important outcomes have not been performed. Therefore, the recommendations in this section are based upon data that describe how accurate a diagnostic test is at confirming or excluding extrapulmonary TB, coupled with evidence that the diagnosis of extrapulmonary TB leads to therapy that improves patient-important outcomes. Tests used to"
    },
    {
        "id": "doc_2105",
        "document": "diagnose extrapulmonary TB are described in Supplementary Figure 1."
    },
    {
        "id": "doc_2106",
        "document": "With respect to the evidence that the diagnosis of extrapul- monary TB leads to therapy that improves patient-important outcomes, trials directly comparing treatment with no treat- ment will never be done. However, indirect evidence from patients with pulmonary TB (described above) and evidence from patients with disseminated TB suggests that extrapulmo- nary TB is treatable with high cure rates in most drug-suscepti- ble cases and that untreated extrapulmonary TB has significant morbidity and"
    },
    {
        "id": "doc_2107",
        "document": "mortality, particularly meningeal TB [191]. As an example, an observational study that excluded patients with tuberculous meningitis found that mortality due to dissemi- nated TB fell from 100% to <5% with the introduction of iso- niazid-based antimicrobial regimens [192]. The large mortality reduction in this study would probably have been less dramatic if patients with tuberculous meningitis had been included, as"
    },
    {
        "id": "doc_2108",
        "document": "2 case series that included patients with tuberculous menin- gitis found that mortality due to disseminated tuberculosis is 20% [193, 194]. Nevertheless, mortality is clearly improved with a large magnitude of effect. This evidence constitutes moderate-quality evidence that treatment of extrapulmonary TB improves mortality because there are observational stud- ies with a very large magnitude of effect, but the increase in confidence in the results due to the large magnitude of effect is"
    },
    {
        "id": "doc_2109",
        "document": "mitigated by the indirectness of the population."
    },
    {
        "id": "doc_2110",
        "document": "Question 14: Should cell counts and chemistries be per- formed on amenable (ie, liquid) specimens collected from sites of suspected extrapulmonary TB? Evidence\n\nWe identified no studies that reported the sensitivity and spec- ificity of cell counts and chemistries in the identification of extrapulmonary TB. Therefore, the committee used its collec- tive clinical experience to inform its recommendation. Clinical experience constitutes very low-quality evidence."
    },
    {
        "id": "doc_2111",
        "document": "Recommendation 14: We suggest that cell counts and chem- istries be performed on amenable fluid specimens collected from sites of suspected extrapulmonary TB (conditional rec- ommendation, very low-quality evidence). Remarks: Specimens that are amenable to cell counts and chemistries include pleural, cerebrospinal, ascitic, and joint fluids.\n\nRationale"
    },
    {
        "id": "doc_2112",
        "document": "Cell counts and chemistries can be performed in hours, are inexpensive, and are technically simple. Any risks are related to the sampling procedure. Although their sensitivity and speci- ficity for extrapulmonary TB have not been reported, the com- mittee suspects that the sensitivity is moderate to high and the specificity is poor if interpreted alone, but substantially better if interpreted in the context of the clinical setting, radiographic findings, and other laboratory results. Most"
    },
    {
        "id": "doc_2113",
        "document": "importantly, it is believed that cell counts and chemistries can provide use- ful information to guide the clinician toward either confirm- atory diagnostic testing for tuberculosis or diagnostic testing for alternative etiologies; this alone provides enough benefit to justify the costs of the additional tests. The strength of the recommendation is conditional because it is believed that the balance of the benefits of the additional information versus the cost of the testing may be finely"
    },
    {
        "id": "doc_2114",
        "document": "balanced in some clinical situ- ations, and the quality of evidence provides little confidence in the estimates upon which the committee based its judgments."
    },
    {
        "id": "doc_2115",
        "document": "Question 15: Should adenosine deaminase (ADA) and free IFN-\u03b3 levels be measured on specimens collected from sites of suspected extrapulmonary TB?\n\nEvidence\n\nTest characteristics of ADA in the diagnostic evaluation of meningeal, pleural, peritoneal, and pericardial tuberculosis\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e23\n\nD"
    },
    {
        "id": "doc_2116",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\n. o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4"
    },
    {
        "id": "doc_2117",
        "document": "have been reported in meta-analyses of accuracy studies. Two meta-analyses estimated the sensitivity and specificity of an ele- vated ADA level in the cerebrospinal fluid [195, 196]. The first meta-analysis included 10 studies and found a sensitivity and specificity of 79% and 91%, respectively [195], using final clin- ical diagnosis, consistent pathology/cytology, or microbiologic confirmation as the reference standard. Most of the studies used a threshold of 9 U/L or 10 U/L to define an"
    },
    {
        "id": "doc_2118",
        "document": "elevated ADA. The second meta-analysis included 13 studies and showed that the sensitivity and specificity are exquisitely sensitive to the thresh- old used to define an elevated ADA level [196]. If 4 U/L was used as the threshold, the sensitivity and specificity were >93% and <80%, respectively. In contrast, if 8 U/L was used as the threshold, the sensitivity and specificity were <59% and >96%, respectively."
    },
    {
        "id": "doc_2119",
        "document": "Five meta-analyses that included 9\u201363 studies estimated that the sensitivity and specificity of an elevated ADA level in the pleural fluid are 89%\u201399% and 88%\u201397%, respectively, with all but one of the meta-analyses estimating that the specificity is \u226590% [197\u2013201]. A more recent meta-analysis reported similar sensitivity and specificity [202]. Final clinical diagnosis, con- sistent pathology/cytology, or microbiologic confirmation were used as the reference standard in most studies. Thresholds"
    },
    {
        "id": "doc_2120",
        "document": "used to define an elevated ADA level ranged from 10 U/L to 71 U/L, with most clustering around 40 U/L."
    },
    {
        "id": "doc_2121",
        "document": "A meta-analysis of 31 studies estimated that the sensitivity and specificity of an elevated ADA level in pericardial fluid are 88% and 83%, respectively [203]. The threshold to define an ele- vated ADA level was 40 U/L. Finally, a meta-analysis of 4 studies estimated that the sensitivity and specificity of an elevated ADA level in peritoneal fluid are 100% and 97%, respectively [204]. The threshold used to define an elevated ADA level ranged from 36 U/L to 40 U/L."
    },
    {
        "id": "doc_2122",
        "document": "The test characteristics of free IFN-\u03b3 levels have not been as extensively studied. A meta-analysis of 6 studies estimated that the sensitivity and specificity of an elevated free IFN-\u03b3 level in peritoneal fluid are 93% and 99%, respectively [205]. The threshold used to define an elevated IFN-\u03b3 level ranged from 0.35 U/L to 9 U/L or 20 pg/mL to 112 pg/mL. A meta-analy- sis of 22 studies estimated that the sensitivity and specificity of an elevated free IFN-\u03b3 level in pleural fluid are 89% and"
    },
    {
        "id": "doc_2123",
        "document": "97%, respectively [206]. The threshold used to define an elevated IFN-\u03b3 level ranged from 0.3 U/L to 10 U/L or 12 pg/mL to 300 pg/mL. We did not identify any studies that looked at the test characteristics of free IFN-\u03b3 levels on pericardial fluid or cerebrospinal fluid."
    },
    {
        "id": "doc_2124",
        "document": "No studies were identified that reported the test character- istics of using both ADA and free IFN-\u03b3 to evaluate specimens from patients with suspected extrapulmonary TB. This evidence provides low confidence in the accuracy of the estimated test characteristics for both ADA and free IFN-\u03b3 levels. The studies did not report whether consecutive patients were enrolled (ie,"
    },
    {
        "id": "doc_2125",
        "document": "risk of bias) and the studies reported variable results (ie, incon- sistency), probably due in large part to the different thresholds used to define an elevated level.\n\nRecommendation 15a: We suggest that ADA levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB, TB meningitis, peritoneal TB, or pericardial TB (conditional recommendation, low-qual- ity evidence)."
    },
    {
        "id": "doc_2126",
        "document": "Recommendation 15b: We suggest that free IFN-\u03b3 levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB or peritoneal TB (condi- tional recommendation, low-quality evidence).\n\nRationale"
    },
    {
        "id": "doc_2127",
        "document": "Neither the ADA level nor the IFN-\u03b3 level provide a defin- itive diagnosis of extrapulmonary TB disease; rather, they provide supportive evidence that must be interpreted in the entire clinical context. In any type of diagnostic testing for extrapulmonary TB, both false-negative results and false-pos- itive results have important consequences. False-negative results delay diagnosis and treatment while diagnostic testing continues, whereas false-positive results may lead to unnec- essary therapy"
    },
    {
        "id": "doc_2128",
        "document": "and the associated risks of drug toxicity and cost. Therefore, it is desirable for diagnostic tests to be both sensitive and specific."
    },
    {
        "id": "doc_2129",
        "document": "Our committee made the judgment that measurement of ADA levels and free IFN-\u03b3 levels are indicated if false-neg- ative results occur <30% of the time (ie, sensitivity is \u226570%) and false-positive results occur <20% of the time (ie, specificity is \u226580%). The different thresholds for false results reflect the committee\u2019s recognition that the consequences of false-nega- tive results are generally transient, whereas the consequences of false-positive results may be long lasting. In this case, the"
    },
    {
        "id": "doc_2130",
        "document": "sensitivity and specificity of ADA were \u226579% and \u226583%, respectively, for detecting TB in cerebrospinal fluid, pleural fluid, peritoneal fluid, and pericardial fluid, so ADA measure- ments are recommended in these fluids. Similarly, the sensitiv- ity and specificity of free IFN-\u03b3 measurements were \u226589% and \u226597%, respectively, for detecting TB in pleural fluid and peri- toneal fluid, so free IFN-\u03b3 measurements are recommended in these fluids."
    },
    {
        "id": "doc_2131",
        "document": "The recommendations are conditional because the low qual- ity of evidence does not provide sufficient confidence in the estimated sensitivities and specificities for the committee to be certain that the balance of desirable to undesirable conse- quences favors testing and obtaining the specimens to test usu- ally requires an invasive procedure and, therefore, the balance of benefits versus risks may vary substantially depending upon the clinical condition of the patient. Furthermore, the commit-"
    },
    {
        "id": "doc_2132",
        "document": "tee recognized that these tests often required the services of an off-site laboratory, and that standards were variable across labo- ratories and across published studies."
    },
    {
        "id": "doc_2133",
        "document": "D\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\ni c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne24 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\nQuestion 16: Should AFB smear microscopy be performed on specimens collected from sites of suspected extrapulmo- nary TB?\n\nEvidence"
    },
    {
        "id": "doc_2134",
        "document": "The diagnostic yield and sensitivity of AFB smear micros- copy tend to be lower in extrapulmonary TB than pulmo- nary TB because the former is paucibacillary. Accuracy studies indicate that AFB smear microscopy has a sensitivity of 0\u201310%, 14%\u201339%, 10%\u201330%, <5%, and 0\u201342% in pleural fluid (Supplementary Table 10), pleural tissue (Supplementary Table 10), urine (Supplementary Table 11), cerebrospinal fluid (Supplementary Table 12), peritoneal fluid (Supplementary Table 13), and pericardial fluid"
    },
    {
        "id": "doc_2135",
        "document": "(Supplementary Table 14), respectively [207\u2013218], when final clinical diagnosis, consistent pathology/cytology, or microbiologic confirmation is used as the reference standard. In contrast, the specificity of AFB smear microscopy tends to be quite high as described for pulmonary TB (\u226590%). This evidence provides very low confidence in the estimated test characteristics because many studies do not report enrolling consecutive patients, most studies were small with few samples, and ranges are wide"
    },
    {
        "id": "doc_2136",
        "document": "due to variable results from the individual studies."
    },
    {
        "id": "doc_2137",
        "document": "Recommendation 16: We suggest that AFB smear micros- copy be performed, rather than not performed, on specimens collected from sites of suspected extrapulmonary TB (condi- tional recommendation, very low-quality evidence). Remarks: A positive result can be used as evidence of extrapulmonary TB and guide decision making because false-positive results are unlikely. However, a negative result may not be used to exclude TB because false-negative results are exceedingly common.\n\nRationale"
    },
    {
        "id": "doc_2138",
        "document": "AFB smear microscopy provides the opportunity for early diag- nosis and treatment. The estimated specificity of \u226590% for AFB smear in the diagnosis of extrapulmonary TB indicates that false-positive results occur only \u226410% of the time; thus, if a pos- itive AFB smear result is obtained, it is reasonable to assume that infection is present and to act accordingly. In contrast, the estimated sensitivity of <50% for all specimen types indicates that false-negative results are more common that"
    },
    {
        "id": "doc_2139",
        "document": "true-nega- tive results and, thus, a negative AFB smear result should not be used to exclude extrapulmonary TB; additional diagnostic testing is indicated."
    },
    {
        "id": "doc_2140",
        "document": "Even though a positive AFB smear result is infrequent, the committee judged the benefits of early diagnosis (early initia- tion of treatment, potential to reduce transmission) to outweigh the cost and burden of AFB smear microscopy. The recommen- dation is conditional because the very low quality of evidence does not provide sufficient confidence in the estimated sensi- tivities and specificities for the committee to be certain that the balance of desirable to undesirable consequences favors"
    },
    {
        "id": "doc_2141",
        "document": "testing"
    },
    {
        "id": "doc_2142",
        "document": "and obtaining the specimens to test usually requires an invasive procedure and, therefore, the balance of benefits versus risks may vary substantially depending upon the clinical condition of the patient.\n\nQuestion 17: Should mycobacterial cultures be performed on specimens collected from sites of suspected extrapulmonary TB?\n\nEvidence"
    },
    {
        "id": "doc_2143",
        "document": "Accuracy studies indicate that mycobacterial culture has a sen- sitivity of 23%\u201358%, 40%\u201358%, 80%\u201390%, 45%\u201370%, 45%\u2013 69%, and 50%\u201365% in pleural fluid (Supplementary Table 10), pleural tissue (Supplementary Table 10), urine (Supplementary Table 11), cerebrospinal fluid (Supplementary Table 12), peri- toneal fluid (Supplementary Table 13), and pericardial fluid (Supplementary Table 14), respectively [207, 208, 211, 213\u2013216, 219\u2013223], when final clinical diagnosis, consistent pathology/ cytology,"
    },
    {
        "id": "doc_2144",
        "document": "or microbiologic confirmation is used as the reference standard. The specificity of mycobacterial culture tends to be comparatively higher than the sensitivity (>97%). This evi- dence provides low confidence in the estimated test character- istics because many studies do not report enrolling consecutive patients and most studies were small with few samples."
    },
    {
        "id": "doc_2145",
        "document": "Recommendation 17: We recommend that mycobacterial cultures be performed, rather than not performed, on spec- imens collected from sites of suspected extrapulmonary TB (strong recommendation, low-quality evidence). Remarks: A positive result can be used as evidence of extrapulmonary TB and guide decision making because false-positive results are unlikely. However, a negative result may not be used to exclude TB because false-negative results are exceedingly common.\n\nRationale"
    },
    {
        "id": "doc_2146",
        "document": "The estimated specificity of >97% for mycobacterial cultures in the diagnosis of extrapulmonary TB indicates that false-positive results occur only <3% of the time; thus, a positive mycobac- terial culture is a reliable indicator that infection is present. In contrast, the estimated sensitivity of mycobacterial culture is widely variable depending upon the specimen type. However, even the specimen that provides the highest sensitivity (urine has an 80%\u201390% sensitivity for the diagnosis of"
    },
    {
        "id": "doc_2147",
        "document": "urinary TB) provides false-negative results 10%\u201320% of the time. Such fre- quent false-negative results suggest that mycobacterial cultures should not be used exclude extrapulmonary TB; additional diagnostic testing is indicated."
    },
    {
        "id": "doc_2148",
        "document": "The committee judged the diagnostic yield and benefits of mycobacterial culture sufficient to outweigh the cost and burden. Importantly, positive mycobacterial cultures are the only way to obtain isolates for DST. Empiric treatment for presumed drug-resistant TB may lead to unnecessary toxici- ties and cost if the patient actually has drug-susceptible TB, whereas empiric treatment for drug-susceptible TB may lead\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e25\n\nD"
    },
    {
        "id": "doc_2149",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\ni c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nto treatment failure, risk of dissemination, and even death if the patient actually has drug-resistant TB. Moreover, delayed diagnosis of drug resistance will prolong therapy and increase risk of default."
    },
    {
        "id": "doc_2150",
        "document": "The recommendation is strong despite the low quality of evidence because the committee is certain that the balance of desirable to undesirable consequences favors mycobacterial cul- ture. This certainty reflects the committee\u2019s recognition of the importance of obtaining mycobacterial isolates for DST com- pared with the costs and burdens of performing the cultures, and the belief that additional data would not alter the balance of desirable and undesirable consequences in the overwhelming"
    },
    {
        "id": "doc_2151",
        "document": "majority of patients."
    },
    {
        "id": "doc_2152",
        "document": "Question 18: Should NAAT be performed on specimens col- lected from sites of suspected extrapulmonary TB? Evidence"
    },
    {
        "id": "doc_2153",
        "document": "Meta-analyses have been published for the use of NAAT in suspected pleural and meningeal tuberculosis [224, 225]. Most studies used final clinical diagnosis, consistent pathol- ogy/cytology, or microbiologic confirmation as the reference standard. Nucleic acid amplification performed on pleural fluid and cerebrospinal fluid has a sensitivity of 56% and 62%, respectively, indicating false-negative rates of 44% and 38%, respectively. In contrast, the specificity of NAAT is high for both pleural"
    },
    {
        "id": "doc_2154",
        "document": "fluid and cerebrospinal fluid (98% for both), indi- cating that only about 2% of positive results are false-positives. Individual studies have been published describing the test char- acteristics of nucleic acid amplification on other body fluids and tissues. The studies showed considerable variability in the sensitivity and specificity based upon the disease site; generally speaking, the sensitivity was usually <90%, while the specificity was >95% (Supplementary Table 15) [191, 226]. This"
    },
    {
        "id": "doc_2155",
        "document": "evidence provides very low confidence in the estimated test characteris- tics because many studies do not report enrolling consecutive patients, findings were inconsistent as exemplified by the wide ranges, and the studies were small with few samples."
    },
    {
        "id": "doc_2156",
        "document": "Recommendation 18: We suggest that NAAT be performed, rather than not performed, on specimens collected from sites of suspected extrapulmonary TB (conditional recommendation, very low-quality evidence). Remarks: A positive NAAT result can be used as evidence of extrapulmonary TB and guide decision making because false-positive results are unlikely. However, a negative NAAT result may not be used to exclude TB because false-negative results are exceedingly common."
    },
    {
        "id": "doc_2157",
        "document": "Rationale\n\nNAAT cannot replace mycobacterial culture for diagnosis because it is not sensitive enough and it does not produce an isolate, which is needed for DST. However, NAAT is appropriate as an adjunct to mycobacterial culture because"
    },
    {
        "id": "doc_2158",
        "document": "mycobacterial culture results require at least 1\u20132 weeks, but NAAT can be performed within hours, thereby offer- ing the opportunity for early diagnosis and treatment. The committee felt that NAAT gives positive results frequently enough that the potential benefits outweigh the costs and burden of testing. Moreover, the committee felt that if the test results are applied correctly (ie, a positive NAAT result is considered adequate to confirm extrapulmonary TB, but a negative NAAT result is not"
    },
    {
        "id": "doc_2159",
        "document": "used to exclude extrapulmo- nary TB), then the risks associated with false results are minimal."
    },
    {
        "id": "doc_2160",
        "document": "The recommendation is conditional because the very low quality of evidence does not provide sufficient confidence in the estimated sensitivities and specificities for the committee to be certain that the balance of desirable to undesirable conse- quences favors testing and obtaining the specimens to test usu- ally requires an invasive procedure and, therefore, the balance of benefits versus risks may vary substantially depending upon the clinical condition of the patient."
    },
    {
        "id": "doc_2161",
        "document": "Cautions and Limitations\n\nAt this time there are no FDA-approved NAATs for use with extrapulmonary specimens.\n\nQuestion 19: Should histological examination be performed on specimens collected from sites of suspected extrapulmo- nary TB?\n\nnary TB?\n\nEvidence"
    },
    {
        "id": "doc_2162",
        "document": "Accuracy studies indicate that histological examination has a sensitivity of 69%\u201397%, 86%\u201394%, 60%\u201370%, 79%\u2013 100%, and 73%\u2013100% in pleural tissue (Supplementary Table 10), urologic tissue (Supplementary Table 11), endo- metrial curettage (Supplementary Table 11), peritoneal biopsy (Supplementary Table 13), and pericardial tissue (Supplementary Table 14), respectively, when final clinical diagnosis, consistent pathology/cytology, or microbiologic confirmation is used as the reference standard."
    },
    {
        "id": "doc_2163",
        "document": "The speci- ficity of mycobacterial culture microscopy tends to be low because necrotizing and nonnecrotizing granulomas are seen in other infectious and noninfectious diseases. This evidence provides very low confidence in the estimated test characteristics because many studies do not report enrolling consecutive patients, the wide ranges of sensitivity are due to the variable results of individual studies, and the studies were small with few samples."
    },
    {
        "id": "doc_2164",
        "document": "Recommendation 19: We suggest that histological examina- tion be performed, rather than not performed, on specimens collected from sites of suspected extrapulmonary TB (condi- tional recommendation, very low-quality evidence). Remarks: Both positive and negative results should be interpreted in the context of the clinical scenario because neither false-positive nor false-negative results are rare.\n\nD"
    },
    {
        "id": "doc_2165",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\nd e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne26 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\nRationale"
    },
    {
        "id": "doc_2166",
        "document": "Tissue sampling with histological examination generally occurs after other types of diagnostic testing have failed to identify a definitive diagnosis. Thus, at this stage in the diag- nostic process, the committee thought testing was worthwhile if sensitivity and specificity were both >50%, meaning that true results were more likely than false results. Histological examination surpassed these thresholds and, therefore, is rec- ommended. However, the committee emphasizes the impor- tance of"
    },
    {
        "id": "doc_2167",
        "document": "interpreting the results within the clinical context, to lessen the impact of false results. The recommendation is conditional because the very low quality of evidence does not provide sufficient confidence in the estimated sensitivities and specificities for the committee to be certain that the balance of desirable to undesirable consequences favors testing and obtaining the specimens to test usually requires an invasive procedure and, therefore, the balance of benefits versus risks may vary"
    },
    {
        "id": "doc_2168",
        "document": "substantially depending upon the clinical condition of the patient."
    },
    {
        "id": "doc_2169",
        "document": "GENOTYPING OF M. TUBERCULOSIS"
    },
    {
        "id": "doc_2170",
        "document": "Over the past 2 decades, genotyping of TB strains has been shown to be a valuable tool in TB control. Molecular epidemiology has helped to identify unsuspected transmission, determine likely locations of transmission, measure the extent of transmission, and differentiate reactivation from newly acquired infection [227]. Often traditional contact investigations focus on persons in the household and workplace. Numerous reports describe TB cases linked through genotyping of Mtb isolates, when"
    },
    {
        "id": "doc_2171",
        "document": "detection of transmission was initially missed by conventional contact investigation because the setting was nontraditional. This type of transmission occurs frequently among members of a \u201csocial network\u201d that is centered around a specific activity, including illicit drug use, excess alcohol use, or gambling, or location such as a homeless shelter, adult entertainment club, or HIV residen- tial care facility [228\u2013231]. When genotyping detects previously unrecognized transmission of TB in a"
    },
    {
        "id": "doc_2172",
        "document": "nonconventional setting, public health interventions to contain and subsequently end the outbreak can be redirected to focus on the social network or location associated with transmission."
    },
    {
        "id": "doc_2173",
        "document": "Genotyping or DNA fingerprinting of Mtb can be used for determining the clonality of bacterial cultures. PCR-based, and sometimes Southern blotting, methods are used. The PCR-based methods are mycobacterial interspersed repeti- tive units (MIRU) and spacer oligonucleotide typing (spol- igotyping) [232, 233]. A standardized protocol has been developed to permit comparison of genotypes from different laboratories [232]."
    },
    {
        "id": "doc_2174",
        "document": "Question 20: Should genotyping be performed on a culture isolate from culture-positive patients with TB?\n\nEvidence\n\nWe identified no empirical evidence that estimated the fre- quency with which the availability of genotyped isolates changed public health practices or affected patient outcomes. Therefore, the recommendation is based upon the committee\u2019s collective clinical experience, which constitutes very low-qual- ity evidence."
    },
    {
        "id": "doc_2175",
        "document": "Recommendation 20: We recommend one culture isolate from each mycobacterial culture\u2013positive patient be submitted to a regional genotyping laboratory for genotyping (strong rec- ommendation, very low-quality evidence).\n\nRationale"
    },
    {
        "id": "doc_2176",
        "document": "Genotyping is useful in detecting false-positive results due to confirming laboratory cross-contamination [234, 235], investi- gating outbreaks of TB (both detecting unsuspected outbreaks and confirming suspected outbreaks) [236], evaluating contact investigations [237], and determining whether new episodes of TB are due to reinfection or reactivation [238]. In addition, genotyping is useful for elucidating sites and patterns of Mtb transmission within communities [237, 239]. This information is"
    },
    {
        "id": "doc_2177",
        "document": "used by state and local tuberculosis control programs to focus interventions to interrupt further TB transmission. Genotyping is used to aid public health departments in the control of TB and poses no risk to individual patients."
    },
    {
        "id": "doc_2178",
        "document": "Recently, whole-genome sequencing (WGS) has been applied to investigation of tuberculosis outbreaks [240]. This technique may add discriminatory power to strain identification, but the role of WGS in outbreak investigation is still being determined."
    },
    {
        "id": "doc_2179",
        "document": "In response to nosocomial outbreaks and tuberculosis among HIV-infected patients, the CDC established a national univer- sal tuberculosis genotyping system for the United States. The merger of modern molecular protocols for strain identification at the DNA level and conventional epidemiological methodol- ogies has given birth to an enhanced collaborative strategy to impact tuberculosis control efforts. Regional TB genotyping laboratories can be contacted through the state public health"
    },
    {
        "id": "doc_2180",
        "document": "laboratories or TB control programs."
    },
    {
        "id": "doc_2181",
        "document": "The recommendation is strong because the committee felt certain that the public health benefits of genotyping far outweigh the modest costs and burdens of genotyping. Even though the evidence can provide very little confidence in the magnitude of the benefits, costs, and burdens used by the committee to make its decision, the differences seemed so overwhelming that the committee thought it extraordinarily unlikely that additional data would lead to a judgment that the costs and harms exceed the"
    },
    {
        "id": "doc_2182",
        "document": "benefits."
    },
    {
        "id": "doc_2183",
        "document": "RESEARCH NEEDS\n\nAs described by Abu-Raddad et al [241], improved detection of those with TB and improved identification of those at risk\n\nD\n\ndno-olwspeoe//:sdpy Woly peapeojumoq\n\nm i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e27\n\nto progress once infected have the potential to substantially decrease the prevalence of TB and its associated mortality."
    },
    {
        "id": "doc_2184",
        "document": "Tuberculosis"
    },
    {
        "id": "doc_2185",
        "document": "The ability to rapidly and accurately identify Mtb as well as drug resistance (eg, through NAAT, line probe, molecular bea- con, and Xpert MTB/RIF assays) reflects substantial advances. While rapid tests for TB diagnosis still have a sensitivity of 70%\u201390%, they may fail to detect paucibacillary pulmonary TB. They also remain relatively expensive, making them difficult to implement in high-burden, low-resource settings. Ideally, what is needed is a simple, inexpensive, rapid (ie, hours) test"
    },
    {
        "id": "doc_2186",
        "document": "that is highly accurate (>95% sensitivity and specificity). Rapid tests for detection of drug resistance are approaching the desired level of accuracy, at least for rifampin. However, these tests also are relatively expensive and need to be expanded to allow for detection of resistance to other TB medications. Such expansion is currently limited by gaps in knowledge of the molecular basis of resistance to most first- and second-line drugs. In this regard, improved functional tests for resistance"
    },
    {
        "id": "doc_2187",
        "document": "may prove useful."
    },
    {
        "id": "doc_2188",
        "document": "Other significant gaps remain in the diagnosis of pediatric and extrapulmonary TB. First, the yield of AFB smear and cul- ture in children is low compared to that in adults, which leads to excessive morbidity and mortality due to delayed and missed diagnoses, especially in resource-limited settings. Conversely, the inability to exclude TB results in overtreatment when the diagnosis cannot be excluded. In areas of the world where TB is diagnosed entirely based on smear microscopy, children will"
    },
    {
        "id": "doc_2189",
        "document": "be almost completely neglected and untreated for TB. In areas with greater resources, low yields of microbiologic specimens in chil- dren deter many clinicians from even attempting culture collec- tion. This may result in prolonged treatment with extra TB drugs (in jurisdictions that use 4 drugs for 6 months in patients lack- ing susceptibility data). Alternatively, drug resistance will not be identified and the child could suffer dire consequences receiving inadequate care. Second, similar"
    },
    {
        "id": "doc_2190",
        "document": "challenges exist for the accurate diagnosis of those with extrapulmonary TB. Finally, diagnostic approaches to the identification of those likely to fail TB treat- ment are needed. These limitations in the diagnosis of paucibac- illary TB highlight the need to develop testing strategies based on either host or bacterial markers of infection that can be measured from readily available clinical sources such as plasma or urine."
    },
    {
        "id": "doc_2191",
        "document": "Latent Tuberculosis Infection\n\nIndividuals with immunological evidence of exposure to Mtb antigens, but without evidence of clinical disease are termed \u201clatently\u201d infected. However, it is clear that there is considerable heterogeneity within this classification. As was described previ- ously, those with recent infection (<2 years) are at increased risk for progression to clinical disease, and functionally might be considered acutely infected. Conversely, those more remotely"
    },
    {
        "id": "doc_2192",
        "document": "infected are at substantially lower risk, but remote infection remains difficult to define operationally. Those with nega- tive TSTs or IGRAs are unlikely to progress to TB. However, the PPV of either test is relatively modest, as current estimates would suggest that among household contacts, 20\u201340 peo- ple require treatment to prevent one case. While the number needed to treat based on IGRAs is not known with certainty, early evidence suggests that it is not likely to be dramatically different"
    },
    {
        "id": "doc_2193",
        "document": "[24, 55]. Nonetheless, a careful evaluation of which diagnostic is more closely associated with the development of TB remains a research priority. Given the relatively poor PPVs of current diagnostics for the prediction of progression to TB disease, a diagnostic that can accurately identify those at risk is needed. It should be noted that both QFT and T-SPOT are largely measures of CD4 T-cell immunity, but additional mark- ers of inflammation, cellular, or humoral immunity may prove useful."
    },
    {
        "id": "doc_2194",
        "document": "Clearly, the identification of biomarkers associated with the development of tuberculosis following infection will require carefully performed prospective investigation. In this regard, the prospective evaluation of populations at risk for disease pro- gression, and the use of sophisticated imaging such as positron emission tomography\u2013computed tomography (PET-CT) are likely to further delineate markers associated with either disease progression or subclinical infection."
    },
    {
        "id": "doc_2195",
        "document": "Operationally, the intent of targeted testing is to identify those who would benefit from treatment. While much is now known about the accuracy of both the TST and IGRAs, much less is known about their performance with regard to treatment com- pletion. Additional research on the use of IGRAs with regard to provider and patient perceptions is needed to establish opti- mal diagnostic and treatment strategies. Finally, the literature addressing the performance of IGRAs in children <5 years old is"
    },
    {
        "id": "doc_2196",
        "document": "still limited and studies to inform the appropriate use of these tests to accurately diagnose LTBI in this age group are needed. Studies of young household contacts in low-incidence countries would be especially informative."
    },
    {
        "id": "doc_2197",
        "document": "GUIDELINE STATEMENT"
    },
    {
        "id": "doc_2198",
        "document": "These guidelines are not intended to impose a standard of care. They provide the basis for rational decisions in the diagnostic evaluation of patients with possible latent tuberculosis or tuberculosis. Clinicians, patients, third-party payers, stakeholders, or the courts should never view the recommendations contained in these guidelines as dictates. Guidelines cannot take into account all of the often compelling unique individual clinical circumstances. Therefore, no one charged with evaluating"
    },
    {
        "id": "doc_2199",
        "document": "clinicians\u2019 actions should attempt to apply the recommendations from these guidelines by rote or in a blanket fashion. Qualifying remarks accompanying each recommendation are its integral parts and serve to facilitate more accurate interpretation. They should never be omitted when quoting or translating recommendations from these guidelines."
    },
    {
        "id": "doc_2200",
        "document": "Supplementary Data\n\nSupplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.\n\nD"
    },
    {
        "id": "doc_2201",
        "document": "dno-olwspeoe//:sdpy Woly peapeojumoq\n\ni c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne28 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\nNotes\n\nAcknowledgments. The writing committee thanks Drs Mike Iseman and Jeffrey Starke for their critical examination of the manuscript. The committee is particularly indebted to Kevin Wilson for his patience and his editing skills."
    },
    {
        "id": "doc_2202",
        "document": "Potential conflicts of interest. D. L. C. has received speaking fees from Qiagen. C. L. D. serves on the data and safety monitoring board (DSMB) for Otsuka America Pharmaceutical, Inc, served on a DSMB for Sanofi Pasteur Inc, received research support from Insmed, and received travel support from Qiagen. L. R. serves as a speaker and on an advisory committee for Boehringer Ingelheim and F. Hoffmann-La Roche, serves on an advisory committee and received research support from Biogen Inc, served on"
    },
    {
        "id": "doc_2203",
        "document": "an advisory committee for AstraZeneca, GlaxoSmithKline, and Sanofi Pasteur, served as a consultant for Bayer HealthCare, served as a speaker for Cipla. T.M.S. is employed by the US Centers for Disease Control and Prevention (CDC). T. R. S. serves on a DSMB for Otsuka. P. A. L. is employed by the CDC. All other authors report no potential conflicts. All authors have sub- mitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the"
    },
    {
        "id": "doc_2204",
        "document": "content of the manuscript have been disclosed."
    },
    {
        "id": "doc_2205",
        "document": "References\n\n1. Sch\u00fcnemann HJ, Osborne M, Moss J, et al. ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med 2009; 180:564\u201380.\n\n2. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106\u201310."
    },
    {
        "id": "doc_2206",
        "document": "3. Sch\u00fcnemann HJ, Jaeschke R, Cook DJ, et al. ATS Documents Development and Implementation Committee. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommenda- tions. Am J Respir Crit Care Med 2006; 174:605\u201314.\n\n4. World Health Organization. Global tuberculosis report 2015. Geneva, Switzerland: WHO, 2015."
    },
    {
        "id": "doc_2207",
        "document": "5. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuber- culosis among hospitalized patients with the acquired immunodeficiency syn- drome. N Engl J Med 1992; 326:1514\u201321.\n\n6. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575\u201380."
    },
    {
        "id": "doc_2208",
        "document": "7. Scott C, Kirking HL, Jeffries C, et al. Tuberculosis trends\u2014United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64: 265\u20139.\n\n8. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999\u20132000. Am J Respir Crit Care Med 2008; 177:348\u201355."
    },
    {
        "id": "doc_2209",
        "document": "9. US Institute of Medicine; Committee on the Elimination of Tuberculosis in the United States, Geiter L, ebrary Inc. Ending neglect the elimination of tuberculosis in the United States. Washington, DC: National Academy Press, 2000:xvi, 269 p.\n\n10. Reichman LB, Hershfield ES; ebrary Inc. Tuberculosis: a comprehensive inter- national approach. Lung biology in health and disease v 144. 2nd ed. New York: Dekker, 2000:xxviii, 898 p."
    },
    {
        "id": "doc_2210",
        "document": "11. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1\u201351.\n\n12. Reichler MR, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287:991\u20135."
    },
    {
        "id": "doc_2211",
        "document": "Respir\n\n14. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157:679\u201391.\n\n15. Balasubramanian V, Wiegeshaus EH, Taylor BT, Smith DW. Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 1994; 75:168\u201378.\n\n16. Dannenberg AM Jr. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989; 11 Suppl 2:S369\u201378."
    },
    {
        "id": "doc_2212",
        "document": "17. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060\u20137.\n\n18. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculo- sis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545\u201350."
    },
    {
        "id": "doc_2213",
        "document": "19. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1993; 119:185\u201393.\n\n20. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162:2033\u20138."
    },
    {
        "id": "doc_2214",
        "document": "21. Reichler MR, Reves R, Bur S, et al. Contact Investigation Study Group. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 2002; 95:414\u201320.\n\n22. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008; 12:1235\u201354."
    },
    {
        "id": "doc_2215",
        "document": "23. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17:968\u201375.\n\n24. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detec- tion of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014; 27:3\u201320.\n\n25. Kendig EL Jr, Kirkpatrick BV, Carter WH, Hill FA, Caldwell K, Entwistle M. Underreading of the tuberculin skin test reaction. Chest 1998; 113:1175\u20137."
    },
    {
        "id": "doc_2216",
        "document": "26. Centers for Disease Control and Prevention. Guidelines for preventing the trans- mission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1\u2013141.\n\n27. Black CA. Delayed type hypersensitivity: current theories with an historic per- spective. Dermatol Online J 1999; 5:7.\n\n28. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537\u201344."
    },
    {
        "id": "doc_2217",
        "document": "29. Andersen P, Andersen AB, S\u00f8rensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 1995; 154:3359\u201372.\n\n30. Mustafa AS, Amoudy HA, Wiker HG, et al. Comparison of antigen-specific T-cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis. Scand J Immunol 1998; 48:535\u201343."
    },
    {
        "id": "doc_2218",
        "document": "31. Mustafa AS, Oftung F, Amoudy HA, et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 2000; 30(suppl 3):S201\u20135.\n\n32. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996; 64:16\u201322."
    },
    {
        "id": "doc_2219",
        "document": "33. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178:1274\u201382.\n\n34. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-mo- lecular-mass culture filtrate protein (CFP-10). Microbiology 1998; 144 (pt 11):3195\u2013203."
    },
    {
        "id": "doc_2220",
        "document": "35. Bothamley GH, Rudd RM. Clinical evaluation of a serological assay using a mon- oclonal antibody (TB72) to the 38 kDa antigen of Mycobacterium tuberculosis. Eur Respir J 1994; 7:240\u20136.\n\n36. Colangeli R, Spencer JS, Bifani P, et al. MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hyper- sensitivity in guinea pigs. Infect Immun 2000; 68:990\u20133."
    },
    {
        "id": "doc_2221",
        "document": "37. Dillon DC, Alderson MR, Day CH, et al. Molecular and immunological charac- terization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol 2000; 38:3285\u201390.\n\n38. Arend SM, de Haas P, Leyten E, et al. ESAT-6 and CFP-10 in clinical versus envi- ronmental isolates of Mycobacterium kansasii. J Infect Dis 2005; 191:1301\u201310."
    },
    {
        "id": "doc_2222",
        "document": "39. Geluk A, van Meijgaarden KE, Franken KL, et al. Identification and characteriza- tion of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect Immun 2002; 70:2544\u20138.\n\n40. Geluk A, van Meijgaarden KE, Franken KL, et al. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuber- culosis. Scand J Immunol 2004; 59:66\u201370."
    },
    {
        "id": "doc_2223",
        "document": "41. Millington KA, Gooding S, Hinks TS, Reynolds DJ, Lalvani A. Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis. J Infect Dis 2010; 202:1685\u20139."
    },
    {
        "id": "doc_2224",
        "document": "42. Hinks TS, Dosanjh DP, Innes JA, et al. Frequencies of region of difference 1 antigen-specific but not purified protein derivative-specific gamma interferon- secreting T cells correlate with the presence of tuberculosis disease but do not distinguish recent from remote latent infections. Infect Immun 2009; 77:5486\u201395."
    },
    {
        "id": "doc_2225",
        "document": "43. Kik SV, Franken WP, Arend SM, et al. Interferon-gamma release assays in immi- grant contacts and effect of remote exposure to Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13:820\u20138.\n\n44. Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuber- culosis infection in healthy urban Indians. J Infect Dis 2001; 183:469\u201377."
    },
    {
        "id": "doc_2226",
        "document": "45. T-SPOT.TB: an aid in the diagosis of tuberculosis infection; package insert for in vitro diagnositic use. Abingdon, UK: Oxford Immunotec Ltd.\n\nD\n\nWoly peapeojumoq\n\no\n\nw\n\nn\n\nl\n\no\n\na\n\nd\n\ne\n\nd\n\nf\n\nr\n\no\n\nm\n\nh\n\nt\n\nt\n\np\n\ns\n\n:\n\n/\n\n/\n\na\n\na d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e29"
    },
    {
        "id": "doc_2227",
        "document": "46. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Diseases Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376\u201395."
    },
    {
        "id": "doc_2228",
        "document": "47. Ferrara G, Losi M, D\u2019Amico R, et al. Use in routine clinical practice of two com- mercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367:1328\u201334.\n\n48. Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172:631\u20135."
    },
    {
        "id": "doc_2229",
        "document": "49. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28:24\u201330.\n\n50. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009; 4:e8517."
    },
    {
        "id": "doc_2230",
        "document": "51. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009; 180:49\u201358.\n\n52. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 2013; 187:206\u201311."
    },
    {
        "id": "doc_2231",
        "document": "53. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006; 174:736\u201342.\n\n54. Leyten EM, Prins C, Bossink AW, et al. Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific IFN-{gamma} assay. Eur Respir J 2007; 29:1212\u20136.\n\n55. Zellweger JP, Sotgiu G, Block M, et al. TBNET. Risk assessment of tuberculosis in contacts by IFN-\u03b3 release assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med 2015; 191:1176\u201384."
    },
    {
        "id": "doc_2232",
        "document": "56. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuber- culosis in children. Thorax 2006; 61:616\u201320.\n\n57. Richeldi L, Bergamini BM, Vaienti F. Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts. Eur Respir J 2008; 32:524\u20135."
    },
    {
        "id": "doc_2233",
        "document": "58. Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics 2009; 123:e419\u201324.\n\n59. Kampmann B, Whittaker E, Williams A, et al. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 2009; 33:1374\u201382."
    },
    {
        "id": "doc_2234",
        "document": "60. Lighter J, Rigaud M, Eduardo R, Peng CH, Pollack H. Latent tuberculosis diagno- sis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics 2009; 123:30\u20137.\n\n61. Talati NJ, Seybold U, Humphrey B, et al. Poor concordance between inter- feron-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009; 9:15."
    },
    {
        "id": "doc_2235",
        "document": "62. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60:555\u201364.\n\n63. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962; 85:490\u2013510."
    },
    {
        "id": "doc_2236",
        "document": "64. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95:935\u201343.\n\n65. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88:161\u201375.\n\n66. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophy-\n\nlaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268\u201372."
    },
    {
        "id": "doc_2237",
        "document": "67. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801\u20138.\n\n68. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998; 317:625\u20139."
    },
    {
        "id": "doc_2238",
        "document": "69. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tubercu- losis in adults with HIV infection. N Engl J Med 2011; 365:11\u201320.\n\n70. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766\u201372."
    },
    {
        "id": "doc_2239",
        "document": "71. Perez J, Kupper H, Spencer-Green G. Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64:265.\n\n72. Bartu V, Havelkova M, Kopecka E. QuantiFERON-TB Gold in the diagnosis of active tuberculosis. J Int Med Res 2008; 36:434\u20137.\n\n73. Bosshard V, Roux-Lombard P, Perneger T, et al. Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis? Respir Med 2009; 103:30\u20134."
    },
    {
        "id": "doc_2240",
        "document": "74. Chee CB, Gan SH, Khinmar KW, et al. Comparison of sensitivities of two com- mercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol 2008; 46:1935\u201340.\n\n75. Chou CH, Hsu HL, Lee LN, Hsueh PR, Luh KT. Comparison of 2 interfer- on-gamma assays and Roche Cobas Amplicor Mycobacterium tuberculosis assay for rapid diagnosis of tuberculosis among patients with suspected tuberculosis in Taiwan. J Microbiol Immunol Infect 2009; 42:251\u20137."
    },
    {
        "id": "doc_2241",
        "document": "76. Dom\u00ednguez J, Ruiz-Manzano J, De Souza-Galv\u00e3o M, et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 2008; 15:168\u201371.\n\n77. Dosanjh DP, Hinks TS, Innes JA, et al. Improved diagnostic evaluation of sus- pected tuberculosis. Ann Intern Med 2008; 148:325\u201336.\n\n78. US Food and Drug Administration. Medical devices: T-SPOT-TB\u2014P070006. Silver Spring, MD: FDA, 2008."
    },
    {
        "id": "doc_2242",
        "document": "79. Gerogianni I, Papala M, Klapsa D, Zinzaras E, Petinaki E, Gourgoulianis KI. Whole-blood interferon-gamma assay for the diagnosis of tuberculosis infection in an unselected Greek population. Respirology 2008; 13:270\u20134.\n\n80. Goletti D, Carrara S, Butera O, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET- Study. PLoS One 2008; 3:e3417."
    },
    {
        "id": "doc_2243",
        "document": "81. Harada N, Higuchi K, Yoshiyama T, et al. Comparison of the sensitivity and spec- ificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect 2008; 56:348\u201353.\n\n82. Higuchi K, Kawabe Y, Mitarai S, Yoshiyama T, Harada N, Mori T. Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol 2009; 198:33\u20137."
    },
    {
        "id": "doc_2244",
        "document": "83. Jafari C, Ernst M, Diel R, et al. Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. Am J Respir Crit Care Med 2006; 174:1048\u201354.\n\n84. Janssens JP. Interferon-gamma release assay tests to rule out active tuberculosis. Eur Respir J 2007; 30:183\u20134; author reply 184\u20135."
    },
    {
        "id": "doc_2245",
        "document": "85. Kang YA, Lee HW, Hwang SS, et al. Usefulness of whole-blood interfer- on-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest 2007; 132:959\u201365.\n\n86. Latorre I, De Souza-Galv\u00e3o M, Ruiz-Manzano J, et al. Quantitative evaluation of T-cell response after specific antigen stimulation in active and latent tuberculo- sis infection in adults and children. Diagn Microbiol Infect Dis 2009; 65:236\u201346."
    },
    {
        "id": "doc_2246",
        "document": "87. Leung WL, Law KL, Leung VS, et al. Comparison of intracellular cytokine flow cytometry and an enzyme immunoassay for evaluation of cellular immune response to active tuberculosis. Clin Vaccine Immunol 2009; 16:344\u201351.\n\n88. Liao CH, Lai CC, Tan CK, et al. False-negative results by enzyme-linked immu- nospot assay for interferon-gamma among patients with culture-confirmed tuberculosis. J Infect 2009; 59:421\u20133."
    },
    {
        "id": "doc_2247",
        "document": "89. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diag- nosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005; 24:529\u201336.\n\n90. Palazzo R, Spensieri F, Massari M, et al. Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections. Clin Vaccine Immunol 2008; 15:327\u201337."
    },
    {
        "id": "doc_2248",
        "document": "91. Park SY, Jeon K, Um SW, Kwon OJ, Kang ES, Koh WJ. Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis. Scand J Infect Dis 2009; 41:818\u201322.\n\n92. Ruhwald M, Bodmer T, Maier C, et al. TBNET. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32:1607\u201315."
    },
    {
        "id": "doc_2249",
        "document": "93. Tan CK, Lai CC, Liao CH, et al. Rapid diagnosis of active pulmonary tuberculo- sis in the elderly using enzyme-linked immunospot assay for interferon-gamma. J Am Geriatr Soc 2009; 57:2361\u20132.\n\n94. Wang JY, Chou CH, Lee LN, et al. Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-gamma. Emerg Infect Dis 2007; 13:553\u20138."
    },
    {
        "id": "doc_2250",
        "document": "95. Bienek DR, Chang CK. Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis. Int J Tuberc Lung Dis 2009; 13:1416\u201321.\n\n96. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a pub- lic health clinic. Am J Respir Crit Care Med 2003; 168:443\u20137.\n\nD\n\nWoly peapeojumoq\n\no\n\nw\n\nn\n\nl\n\no\n\na\n\nd\n\ne\n\nd\n\nf\n\nr\n\no\n\nm\n\nh\n\nt\n\nt\n\np\n\ns\n\n:\n\n/\n\n/"
    },
    {
        "id": "doc_2251",
        "document": "a\n\na d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne30 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\n97. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014\u20138."
    },
    {
        "id": "doc_2252",
        "document": "98. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472\u20137.\n\n99. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99:131\u20138."
    },
    {
        "id": "doc_2253",
        "document": "100. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-tho- racic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8:392\u2013402.\n\n101. Connell T, Bar-Zeev N, Curtis N. Early detection of perinatal tuberculosis using a whole blood interferon-gamma release assay. Clin Infect Dis 2006; 42:e82\u20135."
    },
    {
        "id": "doc_2254",
        "document": "102. Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in chil- dren in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45:322\u20138.\n\n103. Dogra S, Narang P, Mendiratta DK, et al. Comparison of a whole blood inter- feron-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. J Infect 2007; 54:267\u201376."
    },
    {
        "id": "doc_2255",
        "document": "104. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PLoS One 2008; 3:e2624.\n\n105. Nicol MP, Davies MA, Wood K, et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tubercu- losis in a community setting. Pediatrics 2009; 123:38\u201343."
    },
    {
        "id": "doc_2256",
        "document": "106. Hesseling AC, Mandalakas AM, Kirchner HL, et al. Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. Thorax 2009; 64:840\u20136.\n\n107. Nakaoka H, Lawson L, Squire SB, et al. Risk for tuberculosis among children. Emerg Infect Dis 2006; 12:1383\u20138.\n\n108. Higuchi K, Harada N, Mori T, Sekiya Y. Use of QuantiFERON-TB Gold to inves- tigate tuberculosis contacts in a high school. Respirology 2007; 12:88\u201392."
    },
    {
        "id": "doc_2257",
        "document": "109. Chee CB, Soh CH, Boudville IC, Chor SS, Wang YT. Interpretation of the tuber- culin skin test in Mycobacterium bovis BCG-vaccinated Singaporean schoolchil- dren. Am J Respir Crit Care Med 2001; 164:958\u201361.\n\n110. Radhakrishna S, Frieden TR, Subramani R; Tuberculosis Research Centre (ICMR). Association of initial tuberculin sensitivity, age and sex with the inci- dence of tuberculosis in south India: a 15-year follow-up. Int J Tuberc Lung Dis 2003; 7:1083\u201391."
    },
    {
        "id": "doc_2258",
        "document": "111. Mancuso JD, Tribble D, Mazurek GH, et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin Infect Dis 2011; 53:234\u201344.\n\n112. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007; 150:238\u201344."
    },
    {
        "id": "doc_2259",
        "document": "113. Sauzullo I, Mengoni F, Lichtner M, et al. QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculo- sis. Diagn Microbiol Infect Dis 2008; 62:395\u2013401."
    },
    {
        "id": "doc_2260",
        "document": "114. Vincenti D, Carrara S, Butera O, et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 2007; 150:91\u20138.\n\n115. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a sys- tematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230\u20138."
    },
    {
        "id": "doc_2261",
        "document": "116. Dorman SE, Belknap R, Graviss EA, et al. Tuberculosis Epidemiologic Studies Consortium. Interferon-\u03b3 release assays and tuberculin skin testing for diagno- sis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014; 189:77\u201387.\n\n117. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15:603\u201322."
    },
    {
        "id": "doc_2262",
        "document": "118. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuber- culosis using interferon-gamma assay. Am J Respir Crit Care Med 2006; 174:349\u201355.\n\n119. Daley CL, Reves RR, Beard MA, et al. A summary of meeting proceedings on addressing variability around the cut point in serial interferon-gamma release assay testing. Infect Control Hosp Epidemiol 2013; 34:625\u201330."
    },
    {
        "id": "doc_2263",
        "document": "120. Okada K, Mao TE, Mori T, et al. Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiol Infect 2007:1\u20139.\n\n121. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004; 364:2196\u2013203."
    },
    {
        "id": "doc_2264",
        "document": "122. Sun L, Xiao J, Miao Q, et al. Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis. FEMS Immunol Med Microbiol 2011; 63:165\u201373.\n\n123. Tsiouris SJ, Austin J, Toro P, et al. Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection. Int J Tuberc Lung Dis 2006; 10:939\u201341."
    },
    {
        "id": "doc_2265",
        "document": "124. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54:1\u201381."
    },
    {
        "id": "doc_2266",
        "document": "125. Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, FitzGerald JM; Canadian Collaborative Group in Nosocomial Transmission of Tuberculosis. Delay in diagnosis among hospitalized patients with active tuberculosis\u2013 predictors and outcomes. Am J Respir Crit Care Med 2002; 165:927\u201333.\n\n126. Golub JE, Bur S, Cronin WA, et al. Delayed tuberculosis diagnosis and tubercu- losis transmission. Int J Tuberc Lung Dis 2006; 10:24\u201330."
    },
    {
        "id": "doc_2267",
        "document": "127. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11:485\u201395.\n\n128. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:664\u201374."
    },
    {
        "id": "doc_2268",
        "document": "129. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:570\u201381.\n\n130. Gordin F, Slutkin G. The validity of acid-fast smears in the diagnosis of pulmo- nary tuberculosis. Arch Pathol Lab Med 1990; 114:1025\u20137."
    },
    {
        "id": "doc_2269",
        "document": "131. Yajko DM, Nassos PS, Sanders CA, Madej JJ, Hadley WK. High predictive value of the acid-fast smear for Mycobacterium tuberculosis despite the high preva- lence of Mycobacterium avium complex in respiratory specimens. Clin Infect Dis 1994; 19:334\u20136.\n\n132. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta- analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 2004; 42:2321\u20135."
    },
    {
        "id": "doc_2270",
        "document": "133. Forbes B, Banaiee N, Beavis K, et al. Laboratory detection and identification of mycobacteria; approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI publication no. M48A), 2008.\n\n134. Woods G, Lin G, Desmond E. Susceptibility test methods: mycobacteria, Nocardia, and other actinomycetes. Washington, DC: ASM Press, 2011.\n\n135. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic accu-"
    },
    {
        "id": "doc_2271",
        "document": "racy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 2006; 61:783\u201390.\n\n136. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2008; 3:e1536."
    },
    {
        "id": "doc_2272",
        "document": "137. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1\u2013196.\n\n138. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7\u201310.\n\n139. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis 2003; 3:624\u201332."
    },
    {
        "id": "doc_2273",
        "document": "140. Moore DF, Guzman JA, Mikhail LT. Reduction in turnaround time for labora- tory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid ampli- fication test. Diagn Microbiol Infect Dis 2005; 52:247\u201354.\n\n141. Campos M, Quartin A, Mendes E, et al. Feasibility of shortening respiratory isolation with a single sputum nucleic acid amplification test. Am J Respir Crit Care Med 2008; 178:300\u20135."
    },
    {
        "id": "doc_2274",
        "document": "142. Sloutsky A, Han LL, Werner BG. Practical strategies for performance optimi- zation of the enhanced Gen-Probe amplified Mycobacterium tuberculosis direct test. J Clin Microbiol 2004; 42:1547\u201351.\n\n143. Flores LL, Pai M, Colford JM Jr, Riley LW. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiol 2005; 5:55."
    },
    {
        "id": "doc_2275",
        "document": "144. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagno- sis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165\u201374.\n\n145. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a system- atic review and meta-analysis. BMC Infect Dis 2005; 5:62.\n\nD\n\nWoly peapeojumoq\n\no\n\nw\n\nn\n\nl\n\no\n\na\n\nd\n\ne\n\nd\n\nf\n\nr\n\no\n\nm\n\nh\n\nt\n\nt\n\np\n\ns\n\n:\n\n/\n\n/\n\na"
    },
    {
        "id": "doc_2276",
        "document": "c\n\na d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e31\n\n146. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuber- culosis and rifampin resistance. N Engl J Med 2010; 363:1005\u201315."
    },
    {
        "id": "doc_2277",
        "document": "147. Centers for Disease Control and Prevention. Availability of an assay for detect- ing Mycobacterium tuberculosis, including rifampin-resistant strains, and con- siderations for its use\u2014United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:821\u20137."
    },
    {
        "id": "doc_2278",
        "document": "148. Woods G, Brown-Elliott B, Conville P, et al. Susceptibility testing of mycobac- teria, nocardiae, and other aerobic actinomycetes; approved standard\u20142nd ed. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI publication no. M24-A2), 2011.\n\n149. Francis J. Curry National Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco, CA: Francis J. Curry National Tuberculosis Center, 2008."
    },
    {
        "id": "doc_2279",
        "document": "150. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169:1103\u20139.\n\n151. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994\u20131997. Chest 2001; 120:343\u20138."
    },
    {
        "id": "doc_2280",
        "document": "152. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuber- culosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149:123\u201334.\n\n153. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse coun- tries by a commercial line probe assay as an initial indicator of multidrug resist- ance. Int J Tuberc Lung Dis 2000; 4:481\u20134."
    },
    {
        "id": "doc_2281",
        "document": "154. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tubercu- losis in the United States, 1993\u20131996. JAMA 1997; 278:833\u20137.\n\n155. LoBue PA, Moser KS. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993\u20132002. Int J Tuberc Lung Dis 2005; 9:501\u20136.\n\n156. Clark CM, Li J, Driver CR, Munsiff SS. Risk factors for drug-resistant tuberculo- sis among non-US-born persons in New York City. Int J Tuberc Lung Dis 2005; 9:964\u20139."
    },
    {
        "id": "doc_2282",
        "document": "157. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994\u20132003. JAMA 2005; 293:2732\u20139.\n\n158. Weiner M, Benator D, Burman W, et al. Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40:1481\u201391."
    },
    {
        "id": "doc_2283",
        "document": "159. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48:229\u201337.\n\n160. Zhu RY, Zhang KX, Zhao MQ, et al. Use of visual loop-mediated isotheral ampli- fication of rimM sequence for rapid detection of Mycobacterium tuberculosis and Mycobacterium bovis. J Microbiol Methods 2009; 78:339\u201343."
    },
    {
        "id": "doc_2284",
        "document": "161. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Geneva, Switzerland: WHO, 2008.\n\n162. Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis 2008; 47:203\u20137. 163. Loeffler AM. Pediatric tuberculosis. Semin Respir Infect 2003; 18:272\u201391."
    },
    {
        "id": "doc_2285",
        "document": "164. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pul- monary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006; 173:1078\u201390.\n\n165. Berggren Palme I, Gudetta B, Bruchfeld J, Eriksson M, Giesecke J. Detection of Mycobacterium tuberculosis in gastric aspirate and sputum collected from Ethiopian HIV-positive and HIV-negative children in a mixed in- and outpa- tient setting. Acta Paediatr 2004; 93:311\u20135."
    },
    {
        "id": "doc_2286",
        "document": "166. Hatherill M, Hawkridge T, Zar HJ, et al. Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary tuberculosis? Arch Dis Child 2009; 94:195\u2013201.\n\n167. Abadco DL, Steiner P. Gastric lavage is better than bronchoalveolar lavage for isolation of Mycobacterium tuberculosis in childhood pulmonary tuberculosis. Pediatr Infect Dis J 1992; 11:735\u20138."
    },
    {
        "id": "doc_2287",
        "document": "168. Steiner M, Zimmerman R, Park BH, Shirali SR, Schmidt H. Primary tuberculo- sis in children. 2. Correlation of susceptibility patterns of M. tuberculosis isolated from children with those isolated from source cases as an index of drug-resistant infection in a community. Am Rev Respir Dis 1968; 98:201\u20139."
    },
    {
        "id": "doc_2288",
        "document": "169. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculo- sis in children. Correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis. Am J Dis Child 1985; 139:780\u20132.\n\n170. Sun SJ, Bennett DE, Flood J, Loeffler AM, Kammerer S, Ellis BA. Identifying the sources of tuberculosis in young children: a multistate investigation. Emerg Infect Dis 2002; 8:1216\u201323."
    },
    {
        "id": "doc_2289",
        "document": "171. Marquez L, Feske ML, Teeter LD, Musser JM, Graviss EA. Pediatric tuberculosis: the litmus test for tuberculosis control. Pediatr Infect Dis J 2012; 31:1144\u20137.\n\n172. Anderson C, Inhaber N, Menzies D. Comparison of sputum induction with fib- er-optic bronchoscopy in the diagnosis of tuberculosis. Am J Respir Crit Care Med 1995; 152(5 pt 1):1570\u20134."
    },
    {
        "id": "doc_2290",
        "document": "173. Conde MB, Soares SL, Mello FC, et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med 2000; 162:2238\u201340.\n\n174. McWilliams T, Wells AU, Harrison AC, Lindstrom S, Cameron RJ, Foskin E. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. Thorax 2002; 57:1010\u20134."
    },
    {
        "id": "doc_2291",
        "document": "175. Saglam L, Akgun M, Aktas E. Usefulness of induced sputum and fibreoptic bronchoscopy specimens in the diagnosis of pulmonary tuberculosis. J Int Med Res 2005; 33:260\u20135.\n\n176. Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diag- nosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis 2007; 44:1415\u201320."
    },
    {
        "id": "doc_2292",
        "document": "177. Al Zahrani K, Al Jahdali H, Poirier L, Ren\u00e9 P, Menzies D. Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pul- monary tuberculosis. Int J Tuberc Lung Dis 2001; 5:855\u201360.\n\n178. Charoenratanakul S, Dejsomritrutai W, Chaiprasert A. Diagnostic role of fiber- optic bronchoscopy in suspected smear negative pulmonary tuberculosis. Respir Med 1995; 89:621\u20133."
    },
    {
        "id": "doc_2293",
        "document": "179. Wongthim S, Udompanich V, Limthongkul S, Charoenlap P, Nuchprayoon C. Fiberoptic bronchoscopy in diagnosis of patients with suspected active pulmo- nary tuberculosis. J Med Assoc Thai 1989; 72:154\u20139.\n\n180. Chawla R, Pant K, Jaggi OP, Chandrashekhar S, Thukral SS. Fibreoptic bron- choscopy in smear-negative pulmonary tuberculosis. Eur Respir J 1988; 1:804\u20136."
    },
    {
        "id": "doc_2294",
        "document": "181. Willcox PA, Benatar SR, Potgieter PD. Use of the flexible fibreoptic broncho- scope in diagnosis of sputum-negative pulmonary tuberculosis. Thorax 1982; 37:598\u2013601.\n\n182. Danek SJ, Bower JS. Diagnosis of pulmonary tuberculosis by flexible fiberoptic bronchoscopy. Am Rev Respir Dis 1979; 119:677\u20139.\n\n183. Miro AM, Gibilara E, Powell S, Kamholz SL. The role of fiberoptic bronchoscopy for diagnosis of pulmonary tuberculosis in patients at risk for AIDS. Chest 1992; 101:1211\u20134."
    },
    {
        "id": "doc_2295",
        "document": "184. Salzman SH, Schindel ML, Aranda CP, Smith RL, Lewis ML. The role of bron- choscopy in the diagnosis of pulmonary tuberculosis in patients at risk for HIV infection. Chest 1992; 102:143\u20136.\n\n185. Wallace JM, Deutsch AL, Harrell JH, Moser KM. Bronchoscopy and transbron- chial biopsy in evaluation of patients with suspected active tuberculosis. Am J Med 1981; 70:1189\u201394."
    },
    {
        "id": "doc_2296",
        "document": "186. Kennedy DJ, Lewis WP, Barnes PF. Yield of bronchoscopy for the diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Chest 1992; 102:1040\u20134.\n\n187. Sarkar SK, Sharma GS, Gupta PR, Sharma RK. Fiberoptic bronchoscopy in the diagnosis of pulmonary tuberculosis. Tubercle 1980; 61:97\u20139."
    },
    {
        "id": "doc_2297",
        "document": "188. Schoch OD, Rieder P, Tueller C, et al. Diagnostic yield of sputum, induced spu- tum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med 2007; 175:80\u20136.\n\n189. Willcox PA, Potgieter PD, Bateman ED, Benatar SR. Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope. Thorax 1986; 41:681\u20134.\n\n190. Pant K, Chawla R, Mann PS, Jaggi OP. Fiberbronchoscopy in smear-negative miliary tuberculosis. Chest 1989; 95:1151\u20132."
    },
    {
        "id": "doc_2298",
        "document": "191. Cheng VC, Yew WW, Yuen KY. Molecular diagnostics in tuberculosis. Eur J Clin Microbiol Infect Dis 2005; 24:711\u201320.\n\n192. Falk A. U.S. veterans administration-armed forces cooperative study on the chemotherapy of tuberculosis. 13. Tuberculous meningitis in adults, with special reference to survival, neurologic residuals, and work status. Am Rev Respir Dis 1965; 91:823\u201331."
    },
    {
        "id": "doc_2299",
        "document": "193. Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89:291\u20136.\n\n194. Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis 1990; 12:583\u201390.\n\nXu HB, Jiang RH, Li L, Sha W, Xiao HP. Diagnostic value of adenosine deam-\n\n195."
    },
    {
        "id": "doc_2300",
        "document": "inase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis. Int J Tuberc Lung Dis 2010; 14:1382\u20137.\n\nD\n\nWoly peapeojumoq\n\no\n\nw\n\nn\n\nl\n\no\n\na\n\nd\n\ne\n\nd\n\nf\n\nr\n\no\n\nm\n\nh\n\nt\n\nt\n\np\n\ns\n\n:\n\n/\n\n/\n\na"
    },
    {
        "id": "doc_2301",
        "document": "c\n\nd e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\ne32 \u2022 CID 2017:64 (15 January) \u2022 Lewinsohn et al\n\n196. Tuon FF, Higashino HR, Lopes MI, et al. Adenosine deaminase and tuberculous meningitis\u2013a systematic review with meta-analysis. Scand J Infect Dis 2010; 42:198\u2013207."
    },
    {
        "id": "doc_2302",
        "document": "197. Morisson P, Neves DD. Evaluation of adenosine deaminase in the diagno- sis of pleural tuberculosis: a Brazilian meta-analysis. J Bras Pneumol 2008; 34:217\u201324.\n\n198. Liang QL, Shi HZ, Wang K, Qin SM, Qin XJ. Diagnostic accuracy of adeno- sine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med 2008; 102:744\u201354."
    },
    {
        "id": "doc_2303",
        "document": "199. Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C. Adenosine deami- nase and interferon gamma measurements for the diagnosis of tuberculous pleu- risy: a meta-analysis. Int J Tuberc Lung Dis 2003; 7:777\u201386.\n\n200. Goto M, Noguchi Y, Koyama H, Hira K, Shimbo T, Fukui T. Diagnostic value of adenosine deaminase in tuberculous pleural effusion: a meta-analysis. Ann Clin Biochem 2003; 40(pt 4):374\u201381."
    },
    {
        "id": "doc_2304",
        "document": "201. Ena J, Valls V, P\u00e9rez de Oteyza C, Enr\u00edquez de Salamanca R. The usefulness and limitations of adenosine deaminase in the diagnosis of tubercular pleurisy. A meta-analytical study [in Spanish]. Med Clin (Barc) 1990; 95:333\u20135.\n\n202. Gui X, Xiao H. Diagnosis of tuberculosis pleurisy with adenosine deaminase (ADA): a systematic review and meta-analysis. Int J Clin Exp Med 2014; 7:3126\u201335."
    },
    {
        "id": "doc_2305",
        "document": "203. Tuon FF, Litvoc MN, Lopes MI. Adenosine deaminase and tuberculous pericar- ditis\u2014a systematic review with meta-analysis. Acta Trop 2006; 99:67\u201374.\n\n204. Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol 2006; 40:705\u201310."
    },
    {
        "id": "doc_2306",
        "document": "205. Su SB, Qin SY, Guo XY, Luo W, Jiang HX. Assessment by meta-analysis of inter- feron-gamma for the diagnosis of tuberculous peritonitis. World J Gastroenterol 2013; 19:1645\u201351.\n\n206. Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ. Diagnostic value of inter- feron-gamma in tuberculous pleurisy: a metaanalysis. Chest 2007; 131:1133\u201341.\n\n207. Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest 1987; 91:106\u20139."
    },
    {
        "id": "doc_2307",
        "document": "208. Chan CH, Arnold M, Chan CY, Mak TW, Hoheisel GB. Clinical and patholog- ical features of tuberculous pleural effusion and its long-term consequences. Respiration 1991; 58(3\u20134):171\u20135.\n\n209. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992; 326:668\u201372.\n\n210. Ogawa SK, Smith MA, Brennessel DJ, Lowy FD. Tuberculous meningitis in an urban medical center. Medicine (Baltimore) 1987; 66:317\u201326."
    },
    {
        "id": "doc_2308",
        "document": "211. Haas EJ, Madhavan T, Quinn EL, Cox F, Fisher E, Burch K. Tuberculous menin- gitis in an urban general hospital. Arch Intern Med 1977; 137:1518\u201321.\n\n212. Monteyne P, Sindic CJ. The diagnosis of tuberculous meningitis. Acta Neurol Belg 1995; 95:80\u20137.\n\n213. Karney WW, O\u2019Donoghue JM, Ostrow JH, Holmes KK, Beaty HN. The spec- trum of tuberculous peritonitis. Chest 1977; 72:310\u20135."
    },
    {
        "id": "doc_2309",
        "document": "214. Shakil AO, Korula J, Kanel GC, Murray NG, Reynolds TB. Diagnostic features of tuberculous peritonitis in the absence and presence of chronic liver disease: a case control study. Am J Med 1996; 100:179\u201385.\n\n215. Sherman S, Rohwedder JJ, Ravikrishnan KP, Weg JG. Tuberculous enteritis and peritonitis. Report of 36 general hospital cases. Arch Intern Med 1980; 140:506\u20138."
    },
    {
        "id": "doc_2310",
        "document": "216. Singh MM, Bhargava AN, Jain KP. Tuberculous peritonitis. An evaluation of pathogenetic mechanisms, diagnostic procedures and therapeutic measures. N Engl J Med 1969; 281:1091\u20134.\n\n217. Quale JM, Lipschik GY, Heurich AE. Management of tuberculous pericarditis. Ann Thorac Surg 1987; 43:653\u20135.\n\n218. Fowler NO, Manitsas GT. Infectious pericarditis. Prog Cardiovasc Dis 1973; 16:323\u201336.\n\n219. Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63:88\u201392."
    },
    {
        "id": "doc_2311",
        "document": "220. Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. Chest 1991; 99:883\u20136.\n\n221. Simon HB, Weinstein AJ, Pasternak MS, Swartz MN, Kunz LJ. Genitourinary tuberculosis. Clinical features in a general hospital population. Am J Med 1977; 63:410\u201320.\n\n222. Christensen WI. Genitourinary tuberculosis: review of 102 cases. Medicine (Baltimore) 1974; 53:377\u201390."
    },
    {
        "id": "doc_2312",
        "document": "223. Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine (Baltimore) 1984; 63:25\u201355.\n\n224. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM Jr. Nucleic acid amplifi- cation tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis 2004; 4:6."
    },
    {
        "id": "doc_2313",
        "document": "225. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. Diagnostic accu- racy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003; 3:633\u201343.\n\n226. Pai M, Ling DI. Rapid diagnosis of extrapulmonary tuberculosis using nucleic acid amplification tests: what is the evidence? Future Microbiol 2008; 3:1\u20134."
    },
    {
        "id": "doc_2314",
        "document": "227. Daley CL, Kawamura LM. The role of molecular epidemiology in contact inves- tigations: a US perspective. Int J Tuberc Lung Dis 2003; 7(12 suppl 3):S458\u201362.\n\n228. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accel- erated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231\u20135."
    },
    {
        "id": "doc_2315",
        "document": "229. Cluster of tuberculosis cases among exotic dancers and their close contacts\u2014 Kansas, 1994\u20132000. MMWR Morb Mortal Wkly Rep 2001; 50:291\u20133.\n\n230. Bock NN, Mallory JP, Mobley N, DeVoe B, Taylor BB. Outbreak of tuberculosis associated with a floating card game in the rural south: lessons for tuberculosis contact investigations. Clin Infect Dis 1998; 27:1221\u20136."
    },
    {
        "id": "doc_2316",
        "document": "231. Increase in African immigrants and refugees with tuberculosis\u2014Seattle-King County, Washington, 1998\u20132001. MMWR Morb Mortal Wkly Rep 2002; 51:882\u20133.\n\n232. Cowan LS, Diem L, Monson T, et al. Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States. J Clin Microbiol 2005; 43:688\u201395."
    },
    {
        "id": "doc_2317",
        "document": "233. Oelemann MC, Diel R, Vatin V, et al. Assessment of an optimized mycobacte- rial interspersed repetitive-unit-variable-number tandem-repeat typing system combined with spoligotyping for population-based molecular epidemiology studies of tuberculosis. J Clin Microbiol 2007; 45:691\u20137.\n\n234. Breese PE, Burman WJ, Hildred M, et al. The effect of changes in laboratory practices on the rate of false-positive cultures for Mycobacterium tuberculosis. Arch Pathol Lab Med 2001; 125:1213\u20136."
    },
    {
        "id": "doc_2318",
        "document": "235. Burman WJ, Reves RR. Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment. Clin Infect Dis 2000; 31:1390\u20135.\n\n236. Daley CL. Molecular epidemiology: a tool for understanding control of tubercu- losis transmission. Clin Chest Med 2005; 26:217\u201331, vi."
    },
    {
        "id": "doc_2319",
        "document": "237. Malakmadze N, Gonz\u00e1lez IM, Oemig T, et al. Unsuspected recent transmission of tuberculosis among high-risk groups: implications of universal tuberculosis genotyping in its detection. Clin Infect Dis 2005; 40:366\u201373.\n\n238. Behr MA, Small PM. Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis 1997; 25:806\u201310."
    },
    {
        "id": "doc_2320",
        "document": "239. Kimerling ME, Benjamin WH, Lok KH, Curtis G, Dunlap NE. Restriction frag- ment length polymorphism screening of Mycobacterium tuberculosis isolates: population surveillance for targeting disease transmission in a community. Int J Tuberc Lung Dis 1998; 2:655\u201362.\n\n240. Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and social- network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364: 730\u20139."
    },
    {
        "id": "doc_2321",
        "document": "241. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 2009; 106:13980\u20135."
    },
    {
        "id": "doc_2322",
        "document": "D\n\no w n l o a d e d f r o m h t t p s : / / a c a d e m i c . o u p . c o m / c i d / a r t i c l e / 6 4 / 2 / e 1 / 2 6 2 9 5 8 3 b y g u e s t o n 0 7 O c t o b e r 2 0 2 4\n\nDiagnosis of TB in Adults and Children \u2022 CID 2017:64 (15 January) \u2022 e33\n\nCochrane\n\nCochrane Database of Systematic Reviews\n\nDiabetes as a risk factor for tuberculosis disease (Review)"
    },
    {
        "id": "doc_2323",
        "document": "Franco JVA, Bongaerts B, Metzendorf MI, Risso A, Guo Y, Pe\u00f1a Silva L, Boeckmann M, Schlesinger S, Damen JAAG, Richter B, Baddeley A, Bastard M, Carlqvist A, Garcia-Casal MN, Hemmingsen B, Mavhunga F, Manne-Goehler J, Viney K"
    },
    {
        "id": "doc_2324",
        "document": "Franco JVA, Bongaerts B, Metzendorf MI, Risso A, Guo Y, Pe\u00f1a Silva L, Boeckmann M, Schlesinger S, Damen JAAG, Richter B, Baddeley A, Bastard M, Carlqvist A, Garcia-Casal MN, Hemmingsen B, Mavhunga F, Manne-Goehler J, Viney K, Lethaby A. Diabetes as a risk factor for tuberculosis disease.\n\nCochrane Database of Systematic Reviews 2024, Issue 8. Art. No.: CD016013.\n\nDOI: 10.1002/14651858.CD016013.pub2."
    },
    {
        "id": "doc_2325",
        "document": "www.cochranelibrary.com\n\nDiabetes as a risk factor for tuberculosis disease (Review)\n\nCopyright \u00a9 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.\n\nWILEY\n\nCochrane Library Trusted evidence. Informed decisions. Better health.\n\nCochrane Database of Systematic Reviews\n\n[Prognosis Review]"
    },
    {
        "id": "doc_2326",
        "document": "Diabetes as a risk factor for tuberculosis disease\n\nJuan VA Franco1, Brenda Bongaerts1, Maria-Inti Metzendorf1, Agostina Risso2, Yang Guo1, Laura Pe\u00f1a Silva1, Melanie Boeckmann3, Sabrina Schlesinger4, Johanna AAG Damen5, Bernd Richter1, Annabel Baddeley6, Mathieu Bastard6, Anna Carlqvist6, Maria Nieves Garcia-Casal7, Bianca Hemmingsen8, Farai Mavhunga6, Jennifer Manne-Goehler9, Kerri Viney6"
    },
    {
        "id": "doc_2327",
        "document": "1Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf, D\u00fcsseldorf, Germany. 2Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 3Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany. 4Institute for Biometrics and Epidemiology, German Diabetes Center (Deutsches Diabetes- Zentrum/DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany."
    },
    {
        "id": "doc_2328",
        "document": "5Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. 6Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland. 7Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland. 8Department of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland. 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA"
    },
    {
        "id": "doc_2329",
        "document": "Contact: Juan VA Franco, juan.franco@med.uni-duesseldorf.de.\n\nEditorial group: Cochrane Central Editorial Service.\n\nPublication status and date: Edited (no change to conclusions), published in Issue 8, 2024."
    },
    {
        "id": "doc_2330",
        "document": "Citation: Franco JVA, Bongaerts B, Metzendorf MI, Risso A, Guo Y, Pe\u00f1a Silva L, Boeckmann M, Schlesinger S, Damen JAAG, Richter B, Baddeley A, Bastard M, Carlqvist A, Garcia-Casal MN, Hemmingsen B, Mavhunga F, Manne-Goehler J, Viney K, Lethaby A. Diabetes as a risk factor for tuberculosis disease. Cochrane Database of Systematic Reviews 2024, Issue 8. Art. No.: CD016013. DOI: 10.1002/14651858.CD016013.pub2."
    },
    {
        "id": "doc_2331",
        "document": "Copyright \u00a9 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence , which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\n\nA B S T R A C T\n\nBackground"
    },
    {
        "id": "doc_2332",
        "document": "Tuberculosis (TB) is amongst the leading causes of death from an infectious disease, with an estimated 1.3 million deaths from TB in 2022. Approximately 25% of the global population is estimated to be infected with the TB bacterium, giving rise to 10.6 million episodes of TB disease in 2022. The prevalence of diabetes influences TB incidence and TB mortality. It is associated not only with an increased risk of TB disease but also death during TB treatment, TB relapse after treatment completion"
    },
    {
        "id": "doc_2333",
        "document": "and multidrug-resistant TB. Since 2011, the World Health Organization (WHO) has recommended collaborative TB and diabetes activities as outlined in the Collaborative Framework for Care and Control of TB and Diabetes."
    },
    {
        "id": "doc_2334",
        "document": "Objectives\n\nTo determine the prognostic value of diabetes mellitus (DM) in the general population of adults, adolescents and children for predicting tuberculosis disease.\n\nSearch methods\n\nWe searched the literature databases MEDLINE (via PubMed) and WHO Global Index Medicus, and the WHO International Clinical Trials Registry Platform (ICTRP) on 3 May 2023 (date of last search for all databases); we placed no restrictions on the language of publication."
    },
    {
        "id": "doc_2335",
        "document": "Selection criteria\n\nWe included retrospective and prospective cohort studies, irrespective of publication status or language. The target population comprised adults, adolescents and children from diverse settings, encompassing outpatient and inpatient cohorts, with varying comorbidities and risk of exposure to tuberculosis.\n\nDiabetes as a risk factor for tuberculosis disease (Review)\n\n1"
    },
    {
        "id": "doc_2336",
        "document": "Copyright \u00a9 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.\n\nCochrane Library\n\nTrusted evidence. Informed decisions. Better health.\n\nCochrane Database of Systematic Reviews\n\nData collection and analysis"
    },
    {
        "id": "doc_2337",
        "document": "We used standard Cochrane methodology and the Quality In Prognosis Studies (QUIPS) tool. Prognostic factors assessed at enrolment/ baseline included diabetes, as defined by the individual studies, encompassing patient-reported status, abstracted from medical records or claims data, or diagnosed by plasma glucose/glycosylated haemoglobin. The primary outcome was the incidence of tuberculosis disease. The secondary outcome was recurrent TB disease. We performed a random-effects meta-analysis for"
    },
    {
        "id": "doc_2338",
        "document": "the adjusted hazard ratios, risk ratios, or odds ratios, employing the restricted maximum likelihood estimation. We rated the certainty of the evidence using the GRADE approach."
    },
    {
        "id": "doc_2339",
        "document": "Main results"
    },
    {
        "id": "doc_2340",
        "document": "We included 48 cohort studies with over 61 million participants from the six WHO regions. However, the representation was variable as eight population-based studies were from South Korea and 19 from China, with overlapping study periods, and only one from the African region (Ethiopia). All studies included adults, and nine studies also included children and adolescents. Most studies diagnosed DM based on clinical records, including fasting blood glucose levels or glucose-lowering treatments. The"
    },
    {
        "id": "doc_2341",
        "document": "studies did not distinguish between type 1 and type 2 DM; only one study focused on type 1 DM. Diagnosis and exclusion of TB were performed using culture or molecular WHO- recommended rapid diagnostic tests (mWRD) in only 12 studies, which could have biassed the effect estimate. The median follow-up time was five years (interquartile range 1.5 to 10, range 1 to 16.9), and the studies primarily reported an adjusted hazard ratio from a multivariable Cox-proportional hazard model."
    },
    {
        "id": "doc_2342",
        "document": "Hazard Ratios (HR)\n\nThe HR estimates represent the highest certainty of the evidence, explored through sensitivity analyses and excluding studies at high risk of bias. We present 95% confidence intervals (CI) and prediction intervals, which show between-study heterogeneity represented in measuring the variability of effect sizes (i.e. the interval within which the effect size of a new study would fall considering the same population of studies included in the meta-analysis)."
    },
    {
        "id": "doc_2343",
        "document": "DM may increase the risk of tuberculosis disease (HR 1.90, 95% CI 1.51 to 2.40; prediction interval 0.83 to 4.39; 10 studies; 11,713,023 participants). The certainty of the evidence is low, due to a moderate risk of bias across studies and inconsistency. Considering a risk without diabetes of 129 cases per 100,000 population, this represents 102 more (59 to 153 more) cases per 100,000."
    },
    {
        "id": "doc_2344",
        "document": "When stratified by follow-up time, the results are more consistent across < 10 years follow-up (HR 1.52, 95% CI 1.47 to 1.57; prediction interval 1.45 to 1.59; 7 studies; 10,380,872 participants). This results in a moderate certainty of the evidence due to a moderate risk of bias across studies."
    },
    {
        "id": "doc_2345",
        "document": "However, at 10 or more years of follow-up, the estimates yield a wider CI and a higher HR (HR 2.44, 95% CI 1.22 to 4.88; prediction interval 0.09 to 69.12; 3 studies; 1,332,151 participants). The certainty of the evidence is low due to the moderate risk of bias and inconsistency."
    },
    {
        "id": "doc_2346",
        "document": "Odds Ratio (OR)\n\nDM may increase the odds of tuberculosis disease (OR 1.61, 95% CI 1.27 to 2.04; prediction interval 0.96 to 2.70; 4 studies; 167,564 participants). Stratification by follow-up time was not possible as all studies had a follow-up < 10 years. The certainty of the evidence is low due to a moderate risk of bias and inconsistency."
    },
    {
        "id": "doc_2347",
        "document": "Risk Ratio (RR)\n\nThe RR estimates represent the highest certainty of the evidence, explored through sensitivity analyses and excluding studies at high risk of bias. DM probably increases the risk of tuberculosis disease (RR 1.60, 95% CI 1.42 to 1.80; prediction interval 1.38 to 1.85; 6 studies; 44,058,675 participants). Stratification by follow-up time was not possible as all studies had a follow-up < 10 years. The certainty of the evidence is moderate due to a moderate risk of bias."
    },
    {
        "id": "doc_2348",
        "document": "Authors' conclusions"
    },
    {
        "id": "doc_2349",
        "document": "Diabetes probably increases the risk of developing TB disease in the short term (< 10 years) and may also increase the risk in the long term (\u2265 10 years). As glycaemic control and access to care may be potential effect modifiers of the association between diabetes and the risk of TB disease, the overall estimates should be interpreted with caution when applied locally. Policies targeted at reducing the burden of diabetes are needed to contribute to the aims of ending TB. Large population-based"
    },
    {
        "id": "doc_2350",
        "document": "cohorts, including those derived from high-quality national registries of exposures (diabetes) and outcomes (TB disease), are needed to provide estimates with a high certainty of evidence of this risk across different settings and populations, including low- and middle-income countries from different WHO regions. Moreover, studies including children and adolescents and currently recommended methods for diagnosing TB would provide more up-to-date information relevant to practice and policy."
    },
    {
        "id": "doc_2351",
        "document": "Funding\n\nWorld Health Organization (203256442)\n\nDiabetes as a risk factor for tuberculosis disease (Review)\n\nCopyright \u00a9 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.\n\n2\n\nCochrane Library Trusted evidence. Informed decisions. Better health.\n\nCochrane Database of Systematic Reviews\n\nRegistration\n\nPROSPERO registration: CRD42023408807\n\nP L A I N L A N G U A G E S U M M A R Y"
    },
    {
        "id": "doc_2352",
        "document": "Does diabetes increase the risk of tuberculosis?\n\nKey messages\n\n\u2022 Having diabetes probably increases the risk of developing tuberculosis disease to about double the population risk (1.5 to 2.4 times increased risk).\n\n\u2022 These results apply to the general adult population; the risk for other groups, such as adolescents and children, is unclear."
    },
    {
        "id": "doc_2353",
        "document": "What is tuberculosis?\n\nTuberculosis (TB) is an infection caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other sites in the body. TB spreads through the air when a person with TB disease coughs or sneezes. Some people do not develop symptoms after infection, while others develop the disease and symptoms, such as persistent cough, weight loss, fever and night sweats. This is called TB disease."
    },
    {
        "id": "doc_2354",
        "document": "The diagnosis of TB disease usually involves the administration of a molecular test or culture that detects the bacteria in a bodily secretion (such as sputum (mucus and saliva)) after consultation with a doctor.\n\nTB is a major health concern globally; over 10 million people develop TB disease, and approximately 1.3 million die from the disease every year.\n\nWhat is diabetes?"
    },
    {
        "id": "doc_2355",
        "document": "Diabetes is a chronic condition characterised by abnormally high blood glucose (sugar) due toinadequate insulin production by the pancreas or the body's inability to properly utilise the insulin it produces, or a combination of both. There are many different types of diabetes; the most frequent is called 'type 2 diabetes mellitus'. Insulin is a hormone that regulates blood sugar. This leads to symptoms such as thirst, frequent urination, tiredness, and slow healing of wounds. Without proper"
    },
    {
        "id": "doc_2356",
        "document": "management, diabetes can lead to complications such as heart disease, kidney damage, nerve problems, and eye issues. Managing diabetes involves healthy eating, staying active, taking medicine, and monitoring health parameters to prevent complications."
    },
    {
        "id": "doc_2357",
        "document": "What did we want to find out?\n\nWe wanted to estimate the risk of developing TB disease for people with diabetes compared to those without diabetes.\n\nWhat did we do?\n\nWe looked at studies that included people with and without diabetes over time and compared how frequently each group developed tuberculosis."
    },
    {
        "id": "doc_2358",
        "document": "What did we find?\n\nWe included 48 studies with over 61 million participants from the six WHO regions. However, the representation was variable as we found eight whole-population studies from South Korea, 19 from China, and only one from the African region (Ethiopia). Most studies were in adults, four in children and three in children and adults. On average, the studies followed people for five years."
    },
    {
        "id": "doc_2359",
        "document": "We found that people with diabetes were at 1.5 to 2.4 times higher risk of developing tuberculosis compared to those without diabetes.\n\nWhat are the limitations of the evidence?"
    },
    {
        "id": "doc_2360",
        "document": "Many of the studies had limitations. One problem was that many of them used sputum microscopy to diagnose TB in people with symptoms which might have missed some diagnoses. More accurate methods, such as culture or rapid diagnostic tests, currently exist and would miss fewer cases of TB. Moreover, well-defined diagnostic criteria for diabetes, including the type of diabetes and how well-controlled the glucose levels are, are needed to estimate the risk associated with the condition accurately."
    },
    {
        "id": "doc_2361",
        "document": "How up-to-date is this review?\n\nThis evidence is up-to-date as of 3 May 2023.\n\nDiabetes as a risk factor for tuberculosis disease (Review)\n\nCopyright \u00a9 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.\n\n3\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\nm Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES"
    },
    {
        "id": "doc_2362",
        "document": "Robert Loddenkemper1, Marc Lipman2, and Alimuddin Zumla3\n\n1Charite\u00b4 Universita\u00a8tsmedizin Berlin, Department of Pneumology, HELIOS-Klinikum Emil von Behring, 14165 Lungenklinik Heckeshorn, Berlin, Germany\n\n2Respiratory & HIV Medicine, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, United Kingdom"
    },
    {
        "id": "doc_2363",
        "document": "3Division of Infection and Immunity, University College London, Consultant Infectious Diseases Physician, University College London Hospitals NHS Foundation Trust, London NW3 2PF, United Kingdom\n\nCorrespondence: rloddenkemper@dgpberlin.de"
    },
    {
        "id": "doc_2364",
        "document": "Tuberculosis (TB) in adults can present in a large number of ways. The lung is the predominant site of TB. Primary pulmonary TB should be distinguished from postprimary pulmonary TB, which is the most frequent TB manifestation in adults (70%\u201380% cases). Cough is common, although the chest radiograph often raises suspicion of disease. Sputum sampling is a key step in the diagnosis of TB, and invasive procedures such as bronchoscopy may be necessary to achieve adequate samples for diagnosis."
    },
    {
        "id": "doc_2365",
        "document": "Extrapulmonary involvement, which may present many years after exposure, occurs in a variable proportion of cases (20%\u201345%). This re\ufb02ects the country of origin of patients and also the frequency of associated human immunode\ufb01- ciency virus (HIV) coinfection. In the latter case, the presentation of TB is often nonspeci\ufb01c, and care needs to be taken to not miss the diagnosis. Anti-TB therapy should be given in line with proven (or assumed) drug resistance. In extrapulmonary TB, adjunctive"
    },
    {
        "id": "doc_2366",
        "document": "therapeutic measures may be indicated; although in all cases, support is often required to ensure that people are able to complete treatment with minimal adverse events and maximal adherence to the prescribed regimen, and so reduce risk of future disease for themselves and others."
    },
    {
        "id": "doc_2367",
        "document": "In parts of the world where tuberculosis (TB) is endemic, symptomatic individuals and their health-care providers are likely to recognize and consider TB early within the diagnostic algo- rithm (A\u0131\u00a8t-Khaled et al. 2010). However, in countries with a declining or low prevalence, the time to diagnosis and starting treatment can be prolonged. This may be attributable to both patient and health system factors (Millen et al. 2008, Migliori et al. 2012) and can be"
    },
    {
        "id": "doc_2368",
        "document": "accentuated by the stigma associated with a po- tential diagnosis of TB (as well as HIV coinfec- tion) (Courtwright and Turner 2010). Hence, education for individuals, communities, and social care providers about TB symptoms, and where and how to get them investigated, is an important part of clinical management (Chowdhury et al. 2013; TB CARE 2014).\n\nConsidering TB as the cause of a person\u2019s symptoms (or new signs in a child with a sig-"
    },
    {
        "id": "doc_2369",
        "document": "Editors: Stefan H.E. Kaufmann, Eric J. Rubin, and Alimuddin Zumla\n\nAdditional Perspectives on Tuberculosis available at www.perspectivesinmedicine.org\n\nCopyright # 2016 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a017848 Cite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n1\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2370",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nni\ufb01cant exposure), making a rapid and accu- rate diagnosis and initiating effective treatment promptly are central to good patient care and public health TB management. Not only does this alleviate symptoms and reduce mortality for the individual, but it also decreases onward transmission to others and hence impacts on the overall burden of TB."
    },
    {
        "id": "doc_2371",
        "document": "TB in adults can present in a variety of ways. The lung is the predominant site of TB as in- fection with Mycobacterium tuberculosis (Mtb) or other members of the TB complex arises almost exclusively from inhaling droplets con- taining the bacilli. This may result in sympto- matic, primary pulmonary TB disease (usually in children) and in adults, after a variable amount of time in a clinically asymptomatic state of latent TB infection (LTBI), generally as postprimary pulmonary TB. Mtb may spread"
    },
    {
        "id": "doc_2372",
        "document": "directly from the lungs, via the lymphatics, or the bloodstream, to other body sites causing the various extrapulmonary TB manifestations de- scribed in this review."
    },
    {
        "id": "doc_2373",
        "document": "The location of disease should be docu- mented in all patients. Given that there may be multiple sites involved, it is recommended that at least two, a major and a minor site, when applicable, be recorded. Here, the de\ufb01nitions used are those proposed by a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting of TB cases (Rieder et al. 1996)."
    },
    {
        "id": "doc_2374",
        "document": "It is important to note that TB can be diag- nosed via a number of different clinical path- ways and settings. In a low incidence country such as Germany, among more than 25,000 TB cases studied between 1996 and 2000, almost 80% were diagnosed through passive case find- ing (~62% had symptoms suggesting TB, 16% were diagnosed during investigations for other medical causes, 1% at autopsy) and 19% by active case finding in high-risk groups, partic- ularly in close contacts of infectious patients"
    },
    {
        "id": "doc_2375",
        "document": "(Forssbohm 2004). This further reinforces the importance of thinking of TB as a possible cause of a patient\u2019s symptoms or signs in clinical prac- tice (Craig et al. 2009)."
    },
    {
        "id": "doc_2376",
        "document": "CLINICAL PRESENTATION AND DIAGNOSIS OF TB\n\nPulmonary TB"
    },
    {
        "id": "doc_2377",
        "document": "Pulmonary TB is de\ufb01ned as tuberculosis of the lung parenchyma and the tracheobronchi- al tree only. Primary pulmonary TB should be distinguished from postprimary pulmonary TB, which is the most frequent TB manifesta- tion in adults. The classic clinical features of pulmonary TB include chronic cough, sputum production, appetite loss, weight loss, fever, night sweats, and hemoptysis (Lawn and Zumla 2011). Someone presenting with any of these symptoms should be suspected of having TB. If they are"
    },
    {
        "id": "doc_2378",
        "document": "or were known to be in contact with infectious TB, they are even more likely to be suffering from TB (Ait-Khaled et al. 2010.)"
    },
    {
        "id": "doc_2379",
        "document": "Primary Pulmonary TB"
    },
    {
        "id": "doc_2380",
        "document": "In countries with a high TB prevalence, primary pulmonary disease occurs usually in childhood, but where TB is less endemic, it occurs fairly often also in adults. It is characterized by local granulomatous in\ufb02ammation, usually in the periphery of the lung (Ghon focus), and may be accompanied by ipsilateral lymph node in- volvement, termed the Ghon complex. The in- fection is usually asymptomatic but can present as an acute lower respiratory tract infection. The most important clue to the"
    },
    {
        "id": "doc_2381",
        "document": "diagnosis is a histo- ry of close contact with an infectious TB case. The diagnosis is suspected when a tuberculin skin test or a blood interferon-g release assay (IGRA) converts to positive, usually 3\u2013 8 wk af- ter infection. The chest radiograph may show the Ghon focus/complex (Fig. 1)."
    },
    {
        "id": "doc_2382",
        "document": "Rare primary sites of TB are the alimentary tract caused by swallowing Mtb, usually Myco- bacterium bovis, present in nonpasteurized milk products (de la Rua-Domenech 2006), or after direct cutaneous infection (usually occurring in laboratory personnel) (Menzies et al. 2003). Intravesical Bacillus Calmette \u2013 Gue\u00b4rin (BCG) vaccination used to treat localized bladder tu- mors may occasionally disseminate and pre- sent as primary BCG disease (Fig. 2) (Lamm 1992).\n\n2"
    },
    {
        "id": "doc_2383",
        "document": "Cite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\n{\u00e9\u2019;\ufb01 Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2384",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nA\n\nFigure 1. Ghon complex. (Figure reprinted from Fuehner et al. 2007, with permission, from Springer, # 2007.)\n\nLocal complications of primary pulmonary TB may result from lymph node enlargement leading to bronchial obstruction. Tuberculous pleurisy can arise early in the course of primary pulmonary TB, either by direct spread from the pulmonary lesion or through hematogenous dissemination."
    },
    {
        "id": "doc_2385",
        "document": "Rare, serious, early systemic complications caused by blood-borne spread of Mtb are mili- ary TB and meningitis. Many years later, TB of\n\nthe skeletal or urogenital system and other or- gans may result (Wallgren 1948)."
    },
    {
        "id": "doc_2386",
        "document": "Postprimary pulmonary TB may follow pri- mary TB. In the generally immunocompetent. there is a lifetime chance of reactivation of the dormant primary complex of 5%\u201410% (Hors- burgh Jr 2004). These estimates were developed before the availability of molecular techniques that can distinguish reactivation from reinfec- tion with another strain of Mtb, and it may be that the overall risk is rather less in most people with latent TB infection not exposed again to Mtb. The first 2 yr following primary"
    },
    {
        "id": "doc_2387",
        "document": "infection are the period of maximal risk of progression. This can be reduced significantly by treating LTBI, which is indicated particularly in high- risk groups (Table 1) (Diel et al. 2013). It is not known why only ~10% of individuals in- fected with Mtb develop active disease. Apart from diverse risk factors such as diabetes, smok- ing, and chronic renal failure (Hu et al. 2014) several genes have been found to be associated with increased susceptibility to, or resistance against, Mtb (Moller"
    },
    {
        "id": "doc_2388",
        "document": "et al. 2010)"
    },
    {
        "id": "doc_2389",
        "document": "Erythema nodosum and other skin condi- tions such as granulomatous panniculitis plus forms of uveitis and polyarthritis (Poncet\u2019s dis- ease) are considered to re\ufb02ect the host immune response to mycobacterial antigen. They can be\n\ni"
    },
    {
        "id": "doc_2390",
        "document": "Figure 2. Disseminated BCG disease. Computed tomography (CT) of the chest showing bilateral patchy ground glass shadowing and consolidation in a patient who developed fevers, cough, and positive blood cultures for BCG following treatment with intravesical BCG for bladder carcinoma. (Figure provided by Marc Lipman.)\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n3\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2391",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nTable 1. Persons at high risk of progressing from latent to active TB\n\nRecent contact with a TB case\n\nPersons with \ufb01brotic changes on chest radiograph consistent with old TB\n\nHIV-infected persons\n\nOrgan transplant recipients\n\nPersons immunosuppressed for other reasons (e.g., taking the equivalent of 15 mg/d of prednisone for .1 mo or taking tumor necrosis factor- a inhibitors)\n\nRecent immigrants (,5 yr) from high prevalence countries"
    },
    {
        "id": "doc_2392",
        "document": "Persons with the following clinical conditions: Diabetes mellitus\n\nChronic renal failure\n\nSome hematologic disorders (e.g., leukemia and lymphomas)\n\nOther speci\ufb01c malignancies (e.g., carcinoma of the head or neck and lung)\n\nGastrectomy and jejunoileal bypass\n\nSilicosis\n\nInjection drug users\n\nTobacco smokers\n\nResidents and employees of high-risk congregate living facilities (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health-care facilities)"
    },
    {
        "id": "doc_2393",
        "document": "Mycobacteriology laboratory personnel\n\nData modi\ufb01ed from Diel et al. 2013."
    },
    {
        "id": "doc_2394",
        "document": "seen both during primary infection and at some time distant from presumed infection (Kroot et al. 2007). The features are often nonspeci\ufb01c, and the key clinical issue here is to consider TB as a possible underlying cause of the presenta- tion. This is generally based on determining whether there is a history of exposure or resi- dence in a TB-endemic area. The increasing numbers of individuals who are immuno- compromised from infections such as HIV or through medical treatments (and are at much"
    },
    {
        "id": "doc_2395",
        "document": "greater risk of developing active TB) make this method of categorization less helpful than pre- viously."
    },
    {
        "id": "doc_2396",
        "document": "Postprimary Pulmonary TB\n\nPostprimary TB of the lungs is the prevailing TB manifestation in adults (in 60% \u2013 80%) (Public\n\nHealth England 2014). It can occur many years after exposure to an individual with infectious TB and may be provoked by temporary or per- manent immunological impairment. Males are more often affected than females (Borgdorff et al. 2000)."
    },
    {
        "id": "doc_2397",
        "document": "The most frequent symptoms of active dis- ease are fever, anorexia or reduced appetite, weight loss, night sweats, anemia, and persistent cough (i.e., lasting .14 d) (TB CARE 2014) usually productive of purulent and/or blood- stained sputum. Occasionally, patients com- plain of localized thoracic pain attributable to accompanying pleural in\ufb02ammation. In exten- sive and long-lasting pulmonary disease, pa- tients may report breathlessness. Hemoptysis is usually the result of cavitating lung"
    },
    {
        "id": "doc_2398",
        "document": "disease caus- ing erosion of pulmonary blood vessels (Fig. 3)."
    },
    {
        "id": "doc_2399",
        "document": "Hoarseness can occur if there is laryngeal involvement. Patients with laryngeal and tra- cheobronchial (Fig. 4) TB may have Mtb in spu- tum despite a normal chest X-ray, although in general, the radiograph will suggest the possible diagnosis (Bhat et al. 2009).\n\nTuberculoma of the lung should be consid- ered as part of the differential diagnosis in mass lesions presenting in individuals with a history of exposure to Mtb (Fig. 5)."
    },
    {
        "id": "doc_2400",
        "document": "The physical signs of TB are not speci\ufb01c. Auscultation often does not show any patho- logical breath sounds or may reveal crackles, wheezing, or bronchial breathing (which is\n\no\n\nFigure 3. Cavitating tuberculosis presenting with he- moptysis (note arrows indicating cavities). (Figure reprinted from Fuehner et al. 2007, with permission, from Springer, # 2007.)\n\n4\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis"
    },
    {
        "id": "doc_2401",
        "document": "www.perspectivesinmedicine.org m Cold Spring Harbor Perspectives in Medicine PERSPECTIVES Voo\u2122\n\nk3 \u00a5 %\n\nFigure 4. TB in the mucosa of the left main bronchus. Histology and culture from biopsy were positive for Mtb. (Figure provided by Robert Loddenkemper.)"
    },
    {
        "id": "doc_2402",
        "document": "termed amphoric when related to the movement of air within a cavity). The radiographic features vary from very discrete in\ufb01ltrates to extensive and bilateral changes with multiple cavities characteristic of TB. Usually, the changes are more pronounced in the upper lobes. The dif- ferential diagnosis of cavitation includes other infections as well as malignant and in\ufb02amma- tory lung diseases (Table 2)."
    },
    {
        "id": "doc_2403",
        "document": "diagnosis of TB. Patients will have a pro\ufb01le that re\ufb02ects their general state of health and nu- trition. They may or may not be anemic and have moderately elevated in\ufb02ammatory mark- ers such as C-reactive protein. However, all of these measures are highly variable (Breen et al. 2008a). The following blood tests are recom- mended generally as baseline assessments rather than for any speci\ufb01c value in TB diagnosis. These include kidney and liver function, blood sugar, hemoglobin, white cell and"
    },
    {
        "id": "doc_2404",
        "document": "differential counts, platelet count, and C-reactive protein (or ESR). It is recommended that routine HIV and hepatitis B and C testing be performed and vitamin D blood levels measured, as pa- tients are invariably de\ufb01cient (Blasi and Mat- teelli 2013)."
    },
    {
        "id": "doc_2405",
        "document": "The presentation of HIV-associated pulmo- nary TB can mimic that seen in the HIV unin- fected. This is generally found in subjects with relatively well-preserved immunity (manifest as blood CD4 counts .350 cells/mL) (Cain et al. 2010). However, the associated immune dysregulation in most individuals with active TB and HIV coinfection means that although symptoms may be similar, patients can also present with very nonspeci\ufb01c although severe systemic features (e.g., weight loss, night sweats, and"
    },
    {
        "id": "doc_2406",
        "document": "fever) and minimal speci\ufb01c respiratory complaints (Breen et al. 2008a)."
    },
    {
        "id": "doc_2407",
        "document": "Figure 5. Lung tuberculoma. Initially thought to be a primary lung cancer, bronchoscopic biopsy showed acid- fast bacilli on smear. Culture grew Mtb. (Figure provided by Marc Lipman.)\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n5\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nTable 2. Differential diagnosis of pulmonary cavitation"
    },
    {
        "id": "doc_2408",
        "document": "cavitation Cause Infection Examples Tuberculosis Acute bacterial, e.g., Staphylococcus aureus, Klebsiella pneumoniae Subacute/chronic bacterial (e.g., Nocardia sp, melidoidosis, actinomycosis) Fungal (e.g., cryptococcosis, coccidiodomycosis) Malignancy Primary lung cancer (e.g., non\u2014 small cell squamous) Pulmonary metastases Inflammatory Sarcoidosis Wegener\u2019s granulomatous angiitis Rheumatoid arthritis Vascular Pulmonary infarct Congenital Sequestered lung; bronchogenic cyst"
    },
    {
        "id": "doc_2409",
        "document": "The radiology of HIV TB is discussed in more detail elsewhere. However, an important point to note is that parenchymal cavitation is less likely in individuals with low blood CD4 counts. Extrapulmonary manifestations (in- cluding mediastinal nodal disease and pleural effusions) are also more common in HIV coin- fection (Lawn and Zumla 2011)."
    },
    {
        "id": "doc_2410",
        "document": "The lack of cavities means that sputum sam- ples in HIV-associated pulmonary TB are of- ten smear-negative. This is despite individuals having in fact a very high mycobacterial burden (Elliott et al. 1993; Crump et al. 2012; Huang et al. 2014). Indeed, sputum cultures are gener- ally positive as frequently in HIV-infected as -uninfected subjects. The importance of obtain- ing samples from other body \ufb02uids and loca- tions cannot be overemphasized. This should include mycobacterial blood and urine"
    },
    {
        "id": "doc_2411",
        "document": "cultures. Given that HIV-associated TB is often multisite, general radiological evaluation (including com- puted tomography [CT] chest, abdomen, and pelvis or equivalent investigations, e.g., abdom- inal ultrasound) may identify other areas of pathology that are amenable to diagnostic aspi- ration or biopsy. The high mycobacterial burden associated with HIV means that often urine an-"
    },
    {
        "id": "doc_2412",
        "document": "tigen tests such as the cell wall component lip- oarabinnoman (available in commercially pro- duced kits) may be positive in patients with very low blood CD4 counts (,100 cells/mL). These offer, therefore, an alternative approach to TB diagnosis in advanced HIV infection (Lawn et al. 2013)."
    },
    {
        "id": "doc_2413",
        "document": "In many clinical settings, HIV is diagnosed at the same time as TB (Rice et al. 2013). This mainly follows the pattern of presentation with clinical TB, which then results in an HIV test. However, the use of antiretroviral therapy in an individual at risk of TB can lead to an un- masking paradoxical reaction (which is part of the immune reconstitution in\ufb02ammatory syndrome, IRIS) (Breen et al. 2005). These are typically highly in\ufb02ammatory presentations, in which individuals develop intense"
    },
    {
        "id": "doc_2414",
        "document": "systemic symptoms and new onset signs and radiological changes within a matter of days."
    },
    {
        "id": "doc_2415",
        "document": "Although the underlying mechanism has not been fully elucidated, it appears to arise as a consequence of a host immune response di- rected against a (generally foreign) persistent antigen. Mycobacteria ful\ufb01ll this role well, al- though so do other chronic intracellular or- ganisms such as fungi. Hence, a presentation of apparent unmasking TB must be investigated comprehensively. Samples should be sent for cy- tology, histology, and bacterial, fungal, and my- cobacterial cultures to avoid"
    },
    {
        "id": "doc_2416",
        "document": "diagnostic confu- sion and inappropriate treatment."
    },
    {
        "id": "doc_2417",
        "document": "Sputum sampling is a key step in the diag- nosis of TB. Attempts should be made to obtain at least two sputum samples from individuals with suspected TB (including extrapulmonary TB, which is often associated with positive spu- tum cultures despite few reported symptoms) (Parimon et al. 2008). Good-quality sputum samples should be obtained. It is standard to ask for three samples, although evidence sug- gests that two may strike a better balance in terms of value (Mase et al. 2007). These are"
    },
    {
        "id": "doc_2418",
        "document": "generally requested to be provided \ufb01rst thing in the morning (i.e., at a time when individuals are most productive). However, in an ambula- tory setting, this can result in delay, and often there is utility in obtaining samples in one day (e.g., in the morning and afternoon)."
    },
    {
        "id": "doc_2419",
        "document": "6\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\nm Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES Voo\u2122"
    },
    {
        "id": "doc_2420",
        "document": "Should an individual be unable to produce sputum spontaneously, many centers will per- form induced sputum using hypertonic saline (generally between 3% and 7% concentration). This technique is quick (in total taking ,1 h), relatively inexpensive, and not as invasive as a bronchoscopy. It also has a good yield (Brown et al. 2007). However, this is operator-depen- dent, and the procedure requires experienced technicians to ensure that optimal samples are obtained."
    },
    {
        "id": "doc_2421",
        "document": "Sputum induction creates a considerable aerosol of potentially infectious material (Doo- ley et al. 1990). It should therefore be performed in a setting where infection control is of a high standard, or there is minimal risk of transmis- sion to others, e.g., induction performed in an open air setting, away from others."
    },
    {
        "id": "doc_2422",
        "document": "Should sputum induction be unavailable or unsuccessful, \ufb02exible bronchoscopy with bron- choalveolar lavage is indicated. This procedure has the advantage of being able to sample spe- ci\ufb01c sites (and hence in theory improve the re- covery from, e.g., localized disease or a cavity) (Schoch et al. 2007). A good-quality sample, which is promptly set up for mycobacterial cul- ture, has a high diagnostic yield (Breen et al. 2008b). This is important because the proce- dure is associated with"
    },
    {
        "id": "doc_2423",
        "document": "signi\ufb01cant up-front cap- ital cost, and potential risk to both patients and health-care workers."
    },
    {
        "id": "doc_2424",
        "document": "Bronchoscopic procedures also enable aspi- ration and biopsies to be performed. This in- cludes both lung tissue (bronchial biopsies) and needle aspiration under either direct vision or using ultrasound (EBUS) (Navani et al. 2011)."
    },
    {
        "id": "doc_2425",
        "document": "Pulmonary samples can be assessed using acid-fast bacilli (AFB) smear, nucleic acid am- plification techniques such as GeneXpert, my- cobacterial culture, or cytological analysis. AFB sputum smear is the most long standing, al- though it is fairly insensitive (requiring at least 5 x 10> bacilli per mL for detection). Molecular diagnostics are equally rapid, more sensitive, and also currently more expensive. They can also detect genetic resistance to antituberculosis drugs (Boehme et al. 2011),"
    },
    {
        "id": "doc_2426",
        "document": "and with modifica- tion they might distinguish between live and dead bacilli (Honeyborne et al. 2011)."
    },
    {
        "id": "doc_2427",
        "document": "Culture techniques are still regarded as the gold standard. Liquid \ufb02uorometric systems are faster than solid media and more sensitive (Dhillon et al. 2014). However, they are also expensive and require skilled personnel to use them. At present, they are not routinely avail- able worldwide for all patient samples that are obtained for suspected TB.\n\nExtrapulmonary Tuberculosis"
    },
    {
        "id": "doc_2428",
        "document": "Extrapulmonary tuberculosis (EPTB) occurs in 10% \u2013 42% of adult TB patients depending on race or ethnic background, age, presence or ab- sence of underlying disease, genotype of the Mtb strain, and immune status (Caws et al. 2008) (Table 3). EPTB is de\ufb01ned as TB affecting any site other than the lung. Sometimes it is accom- panied by pulmonary disease (Public Health England 2014). It can affect any organ in the body and has numerous clinical manifestations, and thus requires a high index of"
    },
    {
        "id": "doc_2429",
        "document": "clinical suspi- cion (Zumla et al. 2013). EPTB can occur many years after exposure. In addition to systemic fea-"
    },
    {
        "id": "doc_2430",
        "document": "Table 3. Frequency of bacteriological culture con\ufb01r- mation of Mtb complex among reported tuberculosis cases by site of disease, Germany, 1996\u20132000"
    },
    {
        "id": "doc_2431",
        "document": "Culture confirmation Total Present Absent Total 18,501 7801 26,302 Pulmonary (70%) 15,134 5493 20,627 (73%) Extrapulmonary 3367 (59%) 2308 5675 Lymphatic, peripheral 859 (51%) 826 1685 Lymphatic, intrathoracic 223 (39%) 352 575 Pleural 579 (55%) 470 1049 Genitourinary 746 (78%) 212 958 Osteoarticular 326 (71%) 131 457 Miliary 126 (69%) 58 184 Meningeal 91 (68%) 42 133 Peritoneal 65 (56%) 51 116 Cutaneous 70 (61%) 45 115 Other 282 (70%) 121 403"
    },
    {
        "id": "doc_2432",
        "document": "1Data modi\ufb01ed from Forssbohm et al. 2008. 2Data are presented as n or n (%).\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n7\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES Voo\u2122"
    },
    {
        "id": "doc_2433",
        "document": "tures, patients with EPTB may complain of symptoms related to the involved site/organ. In contrast to pulmonary TB, females are more often affected (one exception to this being pleu- risy) (Forssbohm et al. 2008) (Fig. 6). The dif- ferences in the proportion of EPTB by area of origin are remarkable. Patients from Africa and Asia are generally far more likely to present with EPTB than those from Germany (Forssbohm et al. 2008); genetic factors may explain some of these differences (Fernando et"
    },
    {
        "id": "doc_2434",
        "document": "al. 2007). HIVand other conditions that markedly impair host immunity have led to an increase in extrap- ulmonary disease. This re\ufb02ects an inability to contain Mtb, and hence dissemination, with positive cultures from a number of body sites, often occurs. The diagnosis can require biopsy and/or surgical removal."
    },
    {
        "id": "doc_2435",
        "document": "Lymph Node TB\n\nIntrathoracic Lymph Node TB\n\nIntrathoracic lymph node TB is relatively more frequent in children than in adults, usually in association with primary pulmonary TB. It may be noted on the chest radiograph as mediastinal enlargement, sometimes associated with calci- \ufb01cation (Fig. 7). The use of CT scanning has\n\nshown the relative insensitivity of chest radio- graphs."
    },
    {
        "id": "doc_2436",
        "document": "Often, enlarged lymph nodes are present only on one side of the mediastinum, although they may be bilateral. The lymph nodes may become so large that they cause bronchial ob- struction and collapse of an adjacent region of the lung. If they perforate into the bronchial tract, this may result in sublobar or lobar pneu- monia (Fig. 8). The differential diagnosis in- cludes other infectious etiologies such as non- tuberculosis mycobacteria (NTM) and fungal infection, malignancy (lymphoma, lung can-"
    },
    {
        "id": "doc_2437",
        "document": "cer), sarcoidosis, and silicosis."
    },
    {
        "id": "doc_2438",
        "document": "The diagnosis can be established by bron- choscopy (Chung and Lee 2000) (Fig. 9), which may be used also as an adjunctive therapeutic measure by removing obstructing intrabron- chial lesions or by placement of an intrabron- chial stent (Lee et al. 2010). If hilar or medi- astinal intrathoracic lymph node involvement is the sole TB manifestation, transbronchial needle aspiration (\u201cblind\u201d TBNA or under ul- trasound guidance as EBUS) or mediastino- scopy may establish the etiology. Rapid molec-"
    },
    {
        "id": "doc_2439",
        "document": "ular diagnostic methods have been successfully applied to EBUS-derived lymph node samples (Dhasmana et al. 2014). This provides the op-"
    },
    {
        "id": "doc_2440",
        "document": "10.0 5.0 2.0 1.0 0.5 0.3 0 15 25 35 45 55 65 Age group (yr)"
    },
    {
        "id": "doc_2441",
        "document": "Figure 6. Age-speci\ufb01c female-to-male odds ratio (OR) of having extrapulmonary TB compared with pulmonary TB by site of extrapulmonary TB, Germany 1996\u20132000. Solid circle, lymphatic, peripheral; open circle, lym- phatic intrathoracic; solid square, pleural; open square, genitourinary; solid triangle, osteoarticular; inverted solid triangle, meningeal; inverted open triangle, peritoneal. (Figure reprinted from Forssbohm et al. 2008, with permission, from the European Respiratory Society, # 2008.)"
    },
    {
        "id": "doc_2442",
        "document": "8\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\n{\u00e9\u2019;\ufb01 Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2443",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\n\u00a5, 2 \u00a5 J\n\nFigure 7. Silicotuberculosis. (Figure reprinted from Fuehner et al. 2007, with permission, from Springer, # 2007.)\n\nportunity to con\ufb01rm clinically suspected dis- ease promptly and also to obtain samples for drug sensitivity testing.\n\ncome \ufb02uctuant, matted together, and in\ufb02amed. If not treated, they may perforate through the skin and create nonhealing \ufb01stulas."
    },
    {
        "id": "doc_2444",
        "document": "Extrathoracic Lymph Node TB\n\nExtrathoracic lymph node TB is one of the most frequent EPTB manifestations in adults. In Ger- many, for example, it accounts for 30% of EPTB (Forssbohm et al. 2008). In most cases, the cer- vical/supraclavicular (Fig. 10), and more rarely the axillary or inguinal, lymph nodes are in- volved.\n\nAt \ufb01rst, the lymph nodes are \ufb01rm, painless, and not warm (Fig. 10), but they may later be-"
    },
    {
        "id": "doc_2445",
        "document": "The differential diagnosis includes other infectious etiologies such as NTM and fungal infection, malignancy (lymphoma, [lung] can- cer), and sarcoidosis. The diagnosis is estab- lished by needle aspiration, occasionally by sur- gical biopsy."
    },
    {
        "id": "doc_2446",
        "document": "Tuberculous Pleurisy\n\nTuberculous pleurisy is one of the most frequent EPTB manifestations. In Germany, it accounts for 19% of EPTB cases (Forssbohm et al. 2008).\n\nP\n\nFigure 8. Pneumonia of left upper lobe (lingula) caused by lymph node perforation. (Figure provided by Robert Loddenkemper.)\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n9\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2447",
        "document": "PERSPECTIVES Booc?\u201d Www.perspectivesinmedicine.org\n\n| o p il f J -\n\nFigure 9. CTof the chest and bronchoscopy showing lymph node perforation, before and after treatment for TB. (Figure provided by Robert Loddenkemper.)"
    },
    {
        "id": "doc_2448",
        "document": "It is more frequent (15% \u2013 90%) in HIV coin- fection, being seen in patients with higher blood CD4 counts (Gopi et al. 2007). As with pulmo- nary TB, and contrary to other forms of EPTB, males are more often affected than females. Usually, it occurs in the young; however, in countries with a low TB incidence, pleural dis- ease may develop at older ages as well."
    },
    {
        "id": "doc_2449",
        "document": "It can present acutely with high fever or as a subacute/chronic illness. Clinical features may start with pleuritic chest pain (dry pleurisy), but the predominant symptom, caused by pleural effusion, is breathlessness. Physical signs of ef- fusion are dullness on percussion and reduced breath sounds at the affected site. The size of the effusion can vary between very small to almost complete involvement of the hemithorax; it is"
    },
    {
        "id": "doc_2450",
        "document": "rarely bilateral (Fig. 11). Pulmonary TB changes are present in the minority, but studies have shown that in up to 20%, Mtb can be found in sputum (Parimon et al. 2008)."
    },
    {
        "id": "doc_2451",
        "document": "The differential diagnosis includes all causes of pleural effusion. The diagnosis is established by investigation of the pleural fluid and/or by pleural biopsies (closed-needle biopsies or thoracoscopic biopsies [Light 2010]). The diag- nosis of pleural TB is hampered by its pauciba- cillary nature (Chegou et al. 2008). Less than 10% of pleural fluids are smear-positive, and culture is positive in only ~30% (20%\u201450%) of cases. However, in HIV-positive patients, the fluid is much more likely to"
    },
    {
        "id": "doc_2452",
        "document": "be smear- and culture-positive for Mtb if the CD4 count is <100 cells/wL (Heydermann etal. 1998). The"
    },
    {
        "id": "doc_2453",
        "document": "Figure 10. Extrathoracic lymph node disease. (Left \ufb01gure, provided by the authors; right \ufb01gure, reprinted from Siemon 2007, with permission, from Springer, # 2007.)\n\n10\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis"
    },
    {
        "id": "doc_2454",
        "document": "www.perspectivesinmedicine.org m Cold Spring Harbor Perspectives in Medicine PERSPECTIVES Voo\u2122\n\nFigure 11. Unilateral large left pleural effusion attrib- utable to tuberculosis. (Figure reprinted from Fuehner et al. 2007 with permission, from Springer, # 2007.)\n\nexudative fluid is, in the majority of cases, pre- dominantly lymphocytic, although in ~10%, mainly polymorphonuclear leukocytes are found (Bielsa et al. 2013)."
    },
    {
        "id": "doc_2455",
        "document": "Several laboratory and microbiological tests have been developed during recent years, in- cluding nucleic acid ampli\ufb01cation and detec-\n\nl\"\\l\n\nFigure 12. Thoracoscopic image of early TB pleural effusion. Following drainage of 800 mL of serous ef- fusion, typical miliary sago-like nodules in all parts of the right parietal pleura can be seen (1) on the dia- phragm and (2) the anterior chest wall. (Figure re- printed from Loddenkemper et al. 2011, with permis- sion, from Thieme, # 2011.)"
    },
    {
        "id": "doc_2456",
        "document": "tion, markers of speci\ufb01c and nonspeci\ufb01c im- mune response such as adenosine deaminase (ADA), and IGRA. These may help in diagnos- ing TB as the cause of pleural effusion and have a reasonable high sensitivity and speci\ufb01city (Trajman et al. 2008; Light 2010). However, at least in countries with a low TB prevalence, the accuracy may not be suf\ufb01cient in individ- ual cases (Hooper et al. 2009, 2010). The diag- nostic yield of closed-needle pleural biopsies, especially under ultrasound guidance, is"
    },
    {
        "id": "doc_2457",
        "document": "up to 80% (Diacon et al. 2003; Koegelenberg et al. 2010)."
    },
    {
        "id": "doc_2458",
        "document": "The accuracy of medical thoracoscopy ( pleuroscopy) is almost 100%, as the patholo- gist is provided with multiple biopsies selected under direct vision (Figs. 12 and 13). Culture is therefore more often positive (78% in one study) (Fig. 14), which in turn enables drug susceptibility testing to be performed (Lod- denkemper 1998; Loddenkemper et al. 2011).\n\nN"
    },
    {
        "id": "doc_2459",
        "document": "Figure 13. Thoracoscopic image of established TB pleural effusion. Following drainage of 2000 mL of serous effusion, in\ufb02amed and hyperemic visceral and parietal pleura covered with \ufb01brinous patches is evi- dent. The posterior costovertebral region is shown with the diaphragm (1) and the chest wall (2). The lung cannot be visualized as it is \ufb01brin-covered. The \ufb01brinous adhesions pull the diaphragm cranially, producing tenting, and show vascularization at their base (arrows). (Figure reprinted"
    },
    {
        "id": "doc_2460",
        "document": "from Loddenkemper et al. 2011, with permission, from Thieme, # 2011.)"
    },
    {
        "id": "doc_2461",
        "document": "Cite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n11\n\nR. Loddenkemper et al.\n\nwww.perspectivesinmedicine.org m Cold Spring Harbor Perspectives in Medicine PERSPECTIVES Voo\u2122\n\nA Needle biopsy Fluid culture Thoracoscopy 51 28 99 61 100 B Needle biopsy Fluid culture Thoracoscopy 25 28 76 39 78"
    },
    {
        "id": "doc_2462",
        "document": "Figure 14. (A) Combined histological and bacteriolo- gical yield (%) of standard techniques in diagnosis of TB-related pleural effusion. (B) Cultural yield (%) of standard techniques in diagnosis of TB-related pleu- ral effusion. (Figure reprinted from Loddenkemper et al. 2011, with permission, from Thieme, # 2011.)"
    },
    {
        "id": "doc_2463",
        "document": "Once again, it cannot be overemphasized that clinicians need to think of TB as a possible cause of pleural effusions\u2014and hence perform appropriate investigations if they wish to make the diagnosis. This is particularly important giv- en that effusions often spontaneously resolve, although the patient is at high risk of recurrence or more widespread disease if they do not receive anti-TB treatment at that stage."
    },
    {
        "id": "doc_2464",
        "document": "Pleural thickening, trapped lung, and chron- ic empyema are potential sequelae of tubercu- lous pleural effusion. However, extensive \ufb01- brous pleural changes and tuberculous empy- ema (Fig. 15) are rare if an early diagnosis is made and appropriate treatment started (Sahn 2002). There are insuf\ufb01cient data to support evidence-based recommendations regarding the use of adjunctive corticosteroids in the treatment of tuberculous pleurisy (Engel et al. 2007; Light 2010). The early removal of pleural"
    },
    {
        "id": "doc_2465",
        "document": "\ufb02uid may also reduce the long-term impact of residual pleural \ufb01brosis (Chung et al. 2008; Light 2010)."
    },
    {
        "id": "doc_2466",
        "document": "Bone/Joints\n\nTB affecting the bones and/or joints is one of the most frequent EPTB manifestations in adults. In Germany, skeletal TB accounts for 8% of EPTB cases (Forssbohm et al. 2008), al- though in high-incidence countries, it is much more common. It presents usually several (5\u2013 7) years after the primary pulmonary infection (Wallgren 1948)."
    },
    {
        "id": "doc_2467",
        "document": "The spine is involved in almost half of skeletal TB cases (Pott\u2019s disease). This starts as in\ufb02ammation of the intervertebral disk, most often in the lower thoracic and upper lumbar vertebrae, and later involves typically two adja-\n\n\u00bb / 4 RN\n\nFigure 15. Tuberculous pleural empyema. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)\n\n12\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis"
    },
    {
        "id": "doc_2468",
        "document": "Medicine\n\nm Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\n\u00bb (AR \u2018:\\ ':I \u00a2\n\nFigure 16. Coronal CT image of young male with back pain, fever, and weight loss with tuberculous paraspinal abscess secondary to vertebral involve- ment. (Figure provided by Marc Lipman.)"
    },
    {
        "id": "doc_2469",
        "document": "cent vertebrae and the intervertebral disk (Jain and Dhammi 2007). The most common \ufb01rst symptom is slowly progressive, often over weeks and months, back pain with occasionally as- sociated abdominal pain. Local tenderness on palpation may be present. At later stages, kypho- scoliosis or even a gibbus may develop. Spinal cord or nerve root compression with sensory or motor symptoms, even paraplegia, can occur. A paraspinal abscess may develop within the psoas muscle and cause pain in the groin,"
    },
    {
        "id": "doc_2470",
        "document": "in particular, on hip \ufb02exion. However, paraspinal collections can be seen at any site within the vertebral column (Fig. 16). Modern imaging techniques such as CT, MRI, and bone scan have considerably enhanced the diagnostic work up. Whole-spine imaging is recommend- ed as multiple vertebral sites are involved in up to 50% of cases (Fig. 17). The differential diag- nosis includes other infectious etiologies such as chronic bacterial infection, NTM, and malig- nancy (lymphoma, [lung] cancer). The"
    },
    {
        "id": "doc_2471",
        "document": "diagno- sis is established by open surgical or needle biopsy for both culture and cytology/histology. Surgical treatment may be indicated (e.g., using external \ufb01xation) if there is clear vertebral col-"
    },
    {
        "id": "doc_2472",
        "document": "lapse or destruction or increasing pain suggest- ing imminent risk of spinal cord or nerve root compression (Fig. 18).\n\nIn other bones and joints, the metaphyses of long bones are the most common sites of TB, but hips, knees, shoulders, elbows (Fig. 19), an- kles, wrists, or any other bone or joint may be involved (Watts and Lifeso 1996). The diagnosis is established by open surgical or needle biopsy with culture and histology.\n\nN i \\ ; PN"
    },
    {
        "id": "doc_2473",
        "document": "Figure 17. Spinal tuberculosis. Whole-spine MRI showing abnormal signal at multiple vertebral levels within cervical, thoracic, and lumbar spine, plus an- terior paraspinal collections at sites of disease. (Fig- ure provided by Marc Lipman.)\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n13\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2474",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nA A\\ g\u2018? e o\n\nFigure 18. Spinal tuberculosis. (A) Destruction of vertebrae after tuberculous spondylitis; (B) treatment with external \ufb01xator. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)\n\nGenitourinary System"
    },
    {
        "id": "doc_2475",
        "document": "Genitourinary system disease includes TB of the kidney, ureter, bladder, and the male and female genital tract (Cek et al. 2005; Kulchavenya 2013). In Germany, it is a frequent extrapulmo- nary manifestation in adults and accounts for 17% of such cases (Forssbohm et al. 2008). This is in marked contrast to the United Kingdom, where it is responsible for ~3% (Public Health England 2014). A variety of local symptoms can develop depending on the involved organ, usually many years after the primary"
    },
    {
        "id": "doc_2476",
        "document": "infection. Systemic symptoms are less common. Many pa- tients are asymptomatic, and TB may only be detected by urinalysis of pyuria with no appar- ent bacterial growth. This occurs in >90% of cases. Around 50% will have evidence of previ- ous or active TB present on the chest radiograph (Wilberschied et al. 1999)."
    },
    {
        "id": "doc_2477",
        "document": "Urological TB can cause destruction of the involved kidney, usually unilateral, perinephric or psoas abscess, and/or may lead to stenosis of the ureter and/or involvement of the bladder with cystitis, often accompanied by hematuria."
    },
    {
        "id": "doc_2478",
        "document": "TB of the female genital system presents as tubal or endometrial involvement (endometri- tis) causing pelvic pain and/or menorrhagia and may cause infertility. The ovaries (adnexi- tis) can be involved also, and this may mimic an ovarian cancer (Fig. 20). The diagnosis is estab- lished by image-guided needle biopsy, laparos- copy, or open surgical biopsy. TB of the vulva is uncommon."
    },
    {
        "id": "doc_2479",
        "document": "TB of the male genital system presents main- ly as involvement of the scrotum (epididymitis, orchitis), but the prostate may be affected as well. The diagnosis is established by image- guided needle biopsy or open surgical biopsy.\n\nIn some patients, mostly caused by late di- agnosis, medical treatment may not result in the resolution of symptoms. Thus, additional sur- gical intervention and reconstruction may be indicated (Kulchavenya 2013)."
    },
    {
        "id": "doc_2480",
        "document": "Abdomen\n\nAbdominal TB includes involvement of the peritoneum with ascites or any intra-abdominal\n\n14\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nf\u00e9\u2019;\ufb01\u2019% Cold Spring Harbor Perspectives in Medicine"
    },
    {
        "id": "doc_2481",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nFigure 19. Tuberculosis of the elbow joint. Bone loss is present at the distal humerus, its epidondyles, and also the olecranon and coronoidal process of the ulna. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)"
    },
    {
        "id": "doc_2482",
        "document": "organ (Tan et al. 2009). This has become rare in low-incidence countries; in Germany, it ac- counts for 2% of EPTB cases (Forssbohm et al. 2008). Although elsewhere, such as the Indian subcontinent and countries (e.g., the United Kingdom) that see TB relatively frequently in these populations, it is more common. In- fection can result from swallowing sputum or nonpasteurized milk (Mycobacterium bovis) or by hematogenous spread. In the gut, TB may occur in any location from the mouth to the anus,"
    },
    {
        "id": "doc_2483",
        "document": "although is most often in the ileum and cecum."
    },
    {
        "id": "doc_2484",
        "document": "Abdominal pain occurs frequently, some- times mimicking acute appendicitis. Other presentations include small bowel obstruction or gastrointestinal bleeding. The liver, spleen (Fig. 21), pancreas, and adrenal glands may all be involved. In the latter case, the presenta- tion can be one of insidious adrenal insuff- iciency, in which patients report lethargy or\n\nare noted to have metabolic derangements on blood testing."
    },
    {
        "id": "doc_2485",
        "document": "The differential diagnosis (Khan et al. 2006) depends on the organs involved and includes other infectious etiologies, malignancy (Fig. 22), and in\ufb02ammatory bowel disease (Almadi et al. 2009). Tuberculous peritonitis with ascites results in abdominal swelling often accompa- nied by acute symptoms of fever, anorexia, and weight loss. The \ufb01nal diagnosis is estab- lished by investigation of the ascitic \ufb02uid, which apart from cytology and mycobacterial smear, molecular diagnostics, and culture, may"
    },
    {
        "id": "doc_2486",
        "document": "be tested for adenosine deaminase (Shen et al. 2013) and using IGRA (Chou et al. 2011). Lap- aroscopy, open surgical biopsy, or colonoscopy (Sanai and Bzeizi 2005) may need to be per- formed, and the diagnosis of TB of other ab- dominal organs is often made following surgical biopsy or tissue sampling guided by ultrasound or CT."
    },
    {
        "id": "doc_2487",
        "document": "Cite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n15\n\nR. Loddenkemper et al.\n\nwww.perspectivesinmedicine.org m Cold Spring Harbor Perspectives in Medicine PERSPECTIVES Voo\u2122\n\n>t . ) o\n\nFigure 20. Coronal MRI showing TB of the left ovary (black arrow from caudal). Right ovary (white arrow from lateral) with cystic enlarged follicles. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)"
    },
    {
        "id": "doc_2488",
        "document": "Central Nervous System\n\nTB of the central nervous system (CNS) includes tuberculous meningitis (TBM) (the most com- mon manifestation) and encephalitis with or without cerebral tuberculomas (Fig. 23). CNS disease is often seen as part of a disseminated"
    },
    {
        "id": "doc_2489",
        "document": "illness, with radiological evidence of, for exam- ple, miliary TB on chest imaging (see below). It has become rare in low-TB-incidence countries, and in Germany, it accounts for 2% of EPTB cases in adults (Forssbohm et al. 2008). Head- ache is the predominant local symptom. Others include a decreased level of consciousness, sei-\n\n\u00a5 \u2018t-.,\u2018a L) > < G o o Ul | O my 5 10\n\nFigure 21. Splenic tuberculomas. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)\n\n16"
    },
    {
        "id": "doc_2490",
        "document": "Cite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2491",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\n- \u201c*-v\\.,.'\n\nFigure 22. Abdominal TB attributable to TB. Pain and weight loss in an Indian male initially considered to result from disseminated abdominal malignancy. CT abdomen: (A) Pretreatment peritoneal and mes- enteric thickening leading to omental \u201ccake\u201d (note oral contrast given); (B) posttreatment normal peri- toneum and mesentery (no oral contrast given). (Fig- ure provided by Marc Lipman.)"
    },
    {
        "id": "doc_2492",
        "document": "zures, neck stiffness, vomiting, and those attrib- utable to involvement of cranial nerves. Spinal meningitis with involvement of the peripheral nerves and even paraplegia can occur (Thwaites et al. 2009). The severity of TBM at presentation is strongly associated with prognosis. Various factors and scoring models have been developed to predict the outcomes of TBM, and these are used in the evaluation of different treatment reg- imens (Chou et al. 2010)."
    },
    {
        "id": "doc_2493",
        "document": "Severe complications include cerebral and spinal cord infarction from granulomatous arteritis, midbrain and the brain stem involve- ment with loss of automatic, involuntary func-"
    },
    {
        "id": "doc_2494",
        "document": "tion, as well as the development of hydrocepha- lus requiring short- and long-term intervention. The pressure effects of an abscess or granuloma in the CNS may be catastrophic. This should be considered during both investigation and sub- sequent treatment of patients with \u201chigh-risk\u201d lesions in, for example, the brain substance or spinal cord (Thwaites et al. 2009)."
    },
    {
        "id": "doc_2495",
        "document": "The differential diagnosis includes other in- fectious etiologies of meningitis. The diagnosis is established by lumbar puncture and investi- gation of the spinal \ufb02uid (Thwaites et al. 2009). Highly suspicious is a cerebrospinal \ufb02uid (CSF) leucocytosis ( predominantly lymphocytes) and raised protein and low-glucose values. The di- agnosis is hampered by its paucibacillary nature, but it may be enhanced by simple modi\ufb01cation of the Ziehl-Neelsen stain and an ESAT-6 intra- cellular stain (Feng et"
    },
    {
        "id": "doc_2496",
        "document": "al. 2014). The sensitivity is improved using the Xpert MTB/RIF (Nhu et al. 2014). Rapid techniques based on nucleic acid ampli\ufb01cation such as polymerase chain reaction (PCR) are more sensitive and speci\ufb01c as they detect speci\ufb01c DNA sequences of the organism (Thwaites et al. 2004a; Galimi 2011; Nhu et al."
    },
    {
        "id": "doc_2497",
        "document": "e,\n\nFigure 23. CNS tuberculoma. MRI brain with con- trast shows enhancing lesion with associated edema and mass effect in a Somali female presenting with headache and a seizure. Biopsy-cultured Mtb (Figure provided by Marc Lipman.)\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n17\n\nR. Loddenkemper et al.\n\nMedicine\n\n{\u00e9\u2019;\ufb01 Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2498",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES Voo\u2122\n\nFigure 24. Retinal tuberculous lesions. (Figure re- printed from Siemon 2007, with permission, from Springer, # 2007.)"
    },
    {
        "id": "doc_2499",
        "document": "2014). CT-guided needle biopsies or open sur- gery may be needed for the diagnosis of tuber- culomas (DeLance et al. 2013). MRI will show generally more lesions than CT (Bernaerts et al. 2003), although in many parts of the world, ac- cess to MRI is restricted and, although there is a greater radiation exposure, CTmay be preferable if serial imaging is required during follow up."
    },
    {
        "id": "doc_2500",
        "document": "Fundoscopic examination of the eye can reveal evidence of both anterior and posterior chamber disease (Gupta et al. 2007). Apart from\n\npresumed in\ufb02ammatory responses to mycobac- terial antigen (e.g., phlyctenular conjunctivitis, episcleritis, and anterior uveitis), papilloedema may be present in patients with CNS involve- ment. Choroidal tubercles can be visualized\u2014 and are helpful in the diagnosis of disseminated TB (Fig. 24)."
    },
    {
        "id": "doc_2501",
        "document": "Apart from speci\ufb01c anti-TB therapy, ad- junctive corticosteroids (either dexamethasone or prednisolone) should be given to all patients with TBM, regardless of disease severity and HIV status (Thwaites et al. 2004b). Surgical shunting should be considered early in the pa- tient with hydrocephalus and symptoms of raised intracranial pressure. Other neurosurgi- cal operations may be indicated in patients with seizures or brain or spinal cord compres- sion (DeLance et al. 2013)."
    },
    {
        "id": "doc_2502",
        "document": "Miliary TB\n\nDisseminated TB can involve any number of organs (Zumla et al. 2013). Hematogenous spread, when it includes the lungs, is often characterized by the radiological feature of a \u201cmiliary\u201d pattern on imaging. This was \ufb01rst described in chest radiographs (where the nu- merous granulomas were felt to resemble millet seed, i.e., 1\u2013 4-mm rounded opacities scattered throughout both lungs), although is also appli- cable to CT imaging (Fig. 25). In Germany, it\n\n- - 4 L S |"
    },
    {
        "id": "doc_2503",
        "document": "Figure 25. Miliary TB on chest radiograph and CT. (Figure reprinted from Fuehner et al. 2007, with permission, from Springer, # 2007.)\n\n18\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nf\u00e9\u2019;\"H\u2018tb Cold Spring Harbor Perspectives in Medicine PERSPECTIVES Yoo Www.perspectivesinmedicine.org\n\naccounts for 3% of EPTB cases (Forssbohm et al. 2008)."
    },
    {
        "id": "doc_2504",
        "document": "The differential diagnosis of this radio- graphic appearance includes other infections (e.g., fungi, nocardia and healed varicella pneu- monia) as well as malignancy (in particular, thyroid, breast, and renal cancers, plus melano- ma and osteosarcoma) and conditions that re- sult in granulomas) (e.g., sarcoidosis). Hence, clinicians must ensure that a diagnosis of mili- ary TB is based on as much laboratory informa- tion as possible (Ray et al. 2013) and that pa- tients who are started on"
    },
    {
        "id": "doc_2505",
        "document": "anti-TB treatment are carefully monitored for response and/or the development of new symptoms and signs. Pa- tients may develop an acute respiratory distress syndrome (ARDS) associated with a high mor- tality despite intensive care (Erbes et al. 2006; Lee et al. 2011). The bene\ufb01t of adjunctive cor- ticosteroid administration in patients with mil- iary TB is unclear (Ray et al. 2013)."
    },
    {
        "id": "doc_2506",
        "document": "OTHER TB MANIFESTATIONS\n\nTB can present at any body site. Therefore, cli- nicians should consider sending samples for mycobacterial molecular analysis, smear, and culture, as well as histo- or cytopathology. This situation occurs most frequently when patients present either with cutaneous disease (typically nonhealing lesions that have been treated for some time with standard antibacterials) (Fig."
    },
    {
        "id": "doc_2507",
        "document": "26) or to breast, or ear, nose, and throat sur- geons. In Germany, other TB manifestations ac- count for 9% of all extrapulmonary TB cases (Forssbohm et al. 2008)."
    },
    {
        "id": "doc_2508",
        "document": "TB pericarditis is a globally important condition with a distinctly poor prognosis if not diagnosed promptly (Fig. 27). It is usually seen as an active acute or subacute condition associated with systemic features plus a pericar- dial effusion, which may lead to tamponade (Syed and Mayosi 2007). Adjunctive treatment with corticosteroids is recommended (Evans 2008). Constrictive pericarditis secondary to pericardial calci\ufb01cation can also occur (Fig. 28). Here, the initial ( primary) infection is"
    },
    {
        "id": "doc_2509",
        "document": "thought to have occurred several years earlier and was often asymptomatic. Over time, the patient notices increasing exercise limitation, yet even then may present to health-care servic- es with apparent acute clinical decompensation."
    },
    {
        "id": "doc_2510",
        "document": "The calci\ufb01cation associated with TB is gen- erally thick, con\ufb02uent, and irregular, although these features cannot be relied on. CT or MRI are useful investigations but should not de- tract from efforts to isolate or detect an organ- ism (which may be from other sites including the lung). This may be unsuccessful ( particu- larly with the chronic presentation). The patient will often have a history of exposure to TB, usually from having spent time as a child in a TB-endemic country. Anti-TB"
    },
    {
        "id": "doc_2511",
        "document": "treatment should be given, in addition to cardiac and sur-"
    },
    {
        "id": "doc_2512",
        "document": "o e b o Pl r A V& o1 2. g <% et {. T\n\nFigure 26. Tracheo-cutaneous \ufb01stula with scrofuloderma. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n19\n\nR. Loddenkemper et al."
    },
    {
        "id": "doc_2513",
        "document": "www.perspectivesinmedicine.org m Cold Spring Harbor Perspectives in Medicine PERSPECTIVES Voo\u2122\n\nA \u2014\u2014\u2014 N o~ ~t % e\n\nFigure 27. Tuberculous pericarditis with bilateral pleural effusions. (A) CT; (B) echocardiography. (Figure reprinted from Siemon 2007, with permission, from Springer, # 2007.)\n\ngical management as needed (Syed and Mayosi 2007)."
    },
    {
        "id": "doc_2514",
        "document": "TREATMENT OF TB\n\nThe diagnosis of active TB (and hence the deci- sion to start anti-TB drug therapy without which the great majority of cases will not be cured) uses information derived from the my-"
    },
    {
        "id": "doc_2515",
        "document": "cobacteria (e.g., positive AFB smear, molecular diagnostic test or culture), a compatible host response (e.g., cavitation on a chest radiograph), and environmental factors (e.g., a history of contact with TB in a person with consistent clinical features, or acquisition of HIV infection leading to altered [and impaired] immunity).\n\nPrompt initiation of treatment will reduce morbidity and mortality for the affected indi-\n\nA e F o4 il r e"
    },
    {
        "id": "doc_2516",
        "document": "Figure 28. Calci\ufb01cation after tuberculous pericarditis. (Figure reprinted from Uehlinger et al. 1959, with permission, from EMH Schweizer A\u00a8 rzteverlag, # 1959.)\n\n20\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\n{\u00e9\u2019;\ufb01 Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES Voo\u2122"
    },
    {
        "id": "doc_2517",
        "document": "vidual and also break the cycle of onward trans- mission that sustains TB. However, treatment is not without its complications. This is most evi- dent in the management of HIV-associated TB (Khan et al. 2010; Schutz et al. 2010), in which there are considerable drug \u2013 drug interactions between antiretrovirals and anti-TB medication, and an increased risk of the intense in\ufb02amma- tory response provoked by concurrent use of these drugs (IRIS) (Meintjes et al. 2008). This means that in practice, the"
    },
    {
        "id": "doc_2518",
        "document": "relative timing of in- troduction of these agents also needs to be fac- tored (Blanc et al. 2011; To\u00a8ro\u00a8k et al. 2011)."
    },
    {
        "id": "doc_2519",
        "document": "Drug treatment is dealt with in more detail in other sections of this book. However, some of the key principles are described in brief here. Effective treatment is one that enables the indi- vidual to complete therapy and results in a very high cure rate and minimal risk of relapse owing to the original infection. Thus, drug therapy needs to be ef\ufb01cacious and have few adverse events (Breen et al. 2006). Both of these will maximize adherence to treatment regimens. However, factors such as"
    },
    {
        "id": "doc_2520",
        "document": "duration of treatment, pill burden, cost of therapy, and even ensuring that the patient can access a sustained and se- cure supply of medication (Capstick et al. 2011) will impact on treatment effectiveness. Hence, at both a personal and a societal level, high- quality treatment programs must ensure that safe and effective drug supplies are available and that a TB service can provide regular mon- itoring with facilities that optimize the patient\u2019s ability to adhere to the prescribed regimen."
    },
    {
        "id": "doc_2521",
        "document": "Therapeutic combinations should, if at all possible, be based on known sensitivity of the organism to the selected drugs (World Health Organization 2011). The increasing prevalence of drug resistance (World Health Organization 2013) and the ease of global travel mean that no longer can clinicians assume that the infecting organism is likely to be drug-sensitive. This em- phasizes the importance of obtaining pretreat- ment samples for rapid molecular diagnostics and culture, both of which can"
    },
    {
        "id": "doc_2522",
        "document": "indicate likely drug sensitivity and hence guide early and on- going treatment (Moureet al. 2011)."
    },
    {
        "id": "doc_2523",
        "document": "In presumed drug-sensitive disease, treat- ment should commence with a minimum of"
    },
    {
        "id": "doc_2524",
        "document": "three effective drugs. In practice, this means a four-drug therapy with a rifamycin plus isonia- zid as well as pyrazinamide and ethambutol for the \ufb01rst 2 mo (by which point, drug susceptibil- ity should be known for any positive Mtb cul- tures). It can never be assumed that prescribing medication equates to the patient actually tak- ing it, and arrangements must be in place to ensure that adequate treatment support and supervision are available for the duration of therapy."
    },
    {
        "id": "doc_2525",
        "document": "On-treatment monitoring of individual response may use strategies such as directly observed therapy (Okanurak et al. 2007), pill counts, and urine tests, plus measures of patient characteristics that re\ufb02ect disease alleviation, e.g., weight gain (Khan et al. 2006) and health status (Kruijshaar et al. 2010)."
    },
    {
        "id": "doc_2526",
        "document": "People on treatment for pulmonary TB can be followed with serial sputum cultures. How- ever, in resource-rich environments, individuals often stop producing sputum within a few weeks of starting an effective treatment regimen (Hales et al. 2013). In cases in which there is doubt regarding adherence with medication or possible treatment failure, it is recommended that the patient be evaluated for therapeutic compliance, pharmacodynamics (e.g., is there any possibility of malabsorption?), drug"
    },
    {
        "id": "doc_2527",
        "document": "resis- tance, or an alternative diagnosis."
    },
    {
        "id": "doc_2528",
        "document": "The importance of close liaison with other experienced clinicians and microbiologists, as well as public health of\ufb01cials within the setting of a multidisciplinary team meeting or through the use of regular cohort reviews (Anderson et al. 2014), cannot be overemphasized. These provide optimal care for the individual and strengthen public health management of TB and are also an excellent method of education and training for all individuals involved in TB care (Migliori et al. 2012)."
    },
    {
        "id": "doc_2529",
        "document": "The diagnosis of TB enables health-care ser- vices to provide more than just treatment for TB. HIV testing should be routinely offered\u2014 with studies showing that \u201copt out\u201d testing in TB clinics is a simple method of achieving this (Roy et al. 2013). Screening for other blood- borne viruses such as hepatitis B and C, as well as assessing nutritional status, blood pres-\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n21\n\nR. Loddenkemper et al."
    },
    {
        "id": "doc_2530",
        "document": "Medicine\n\nm Cold Spring Harbor Perspectives in\n\nwww.perspectivesinmedicine.org PERSPECTIVES\n\nsure, blood sugar, and encouraging smoking cessation, can also be highlighted during clini- cal care as part of a package of person-related health management.\n\nCONCLUSION"
    },
    {
        "id": "doc_2531",
        "document": "Given the generally excellent response to treat- ment if therapy is started early, there is now little excuse for \u201cmissed diagnoses\u201d and \u201clate pre- sentations\u201d of TB. It remains a condition that in many parts of the world is common and hence usually promptly diagnosed. Here, the clinical issues often center on the need to ensure that correct, effective medication is prescribed and adverse events are minimized. However, in environments where TB is less frequently seen, the recognition that it can"
    },
    {
        "id": "doc_2532",
        "document": "present in multiple ways and that TB must be considered early (by both the patient and their health-care provider) within the clinical diagnostic algorithm are of paramount importance. This is made more complex by the increasing numbers of immu- nocompromised individuals (through, e.g., HIV infection and medical treatments) at risk of developing active TB who, by virtue of their altered host response, will often have a modi\ufb01ed presentation of TB disease. Strategies to combat the loss of"
    },
    {
        "id": "doc_2533",
        "document": "familiarity with TB in low TB burden areas include the use of clinical networks and multidisciplinary and multiprofessional team working, plus on-going, relevant education in at-risk communities, the general public, and health-care workers."
    },
    {
        "id": "doc_2534",
        "document": "REFERENCES\n\nA\u0131\u00a8t-Khaled N, Alarco\u00b4 n E, Armengol R, Bissell K, Boillot F, Caminero JA, Chiang C-Y, Clevenbergh P, Dlodlo R, Enarson DA, et al. 2010. Management of tuberculosis: A guide to the essentials of good practice. Paris, France, International Union Against Tuberculosis and Lung Dis- ease (The Union) http://www.theunion.org/what-we- do/publications/technical/english/pub_orange-guide_ eng.pdf"
    },
    {
        "id": "doc_2535",
        "document": "Almadi MA, Ghosh S, Aljebreen AM. 2009. Differentiating intestinal tuberculosis from Crohn\u2019s disease: A diagnostic challenge. Am J Gastroenterol 104: 1003\u20131012.\n\nAnderson C, White J, Abubakar I, Lipman M, Tamne S, Anderson SR, deKoningh J, Dart S. 2014. Raising standards in UK TB control: Introducing cohort review. Thorax 69: 187\u2013189."
    },
    {
        "id": "doc_2536",
        "document": "Bernaerts A, Vanhoenacker FM, Parizel PM, Van Goethem JW, Van Altena R, Laridon A, De Roeck J, Coeman V, De Schepper AM. 2003. Tuberculosis of the central ner- vous system: Overview of neuroradiological \ufb01ndings. Eur Radiol 13: 1876\u2013 1890.\n\nBhat VK, Latha P, Upadhya D, Hegde J. 2009. Clinicopath- ological review of tubercular laryngitis in 32 cases of pulmonary Kochs. Am J Otolaryngol 30: 327\u2013 330."
    },
    {
        "id": "doc_2537",
        "document": "Bielsa S, Palma R, Pardina M, Esquerda A, Light RW, Porcel JM. 2013. Comparison of polymorphonuclear- and lym- phocyte-rich tuberculous pleural effusions. Int J Tuberc Lung Dis 17: 85\u201389.\n\nBlanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, et al. 2011. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365: 1471\u20131481."
    },
    {
        "id": "doc_2538",
        "document": "Blasi F, Matteelli A. 2013. Indicator condition-guided HIV testing in Europe: A step forward to HIV control. Eur Respir J 42: 572\u2013 575.\n\nBoehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Tarcela Gler M, Blakemore R, Worodria W, Gray C, et al. 2011. Feasibility, diagnostic accuracy, and effec- tiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 377: 1495\u2013 1505."
    },
    {
        "id": "doc_2539",
        "document": "Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. 2000. Gender and tuberculosis: A comparison of prevalence surveys with noti\ufb01cation data to explore sex differences in case detection. Int J Tuberc Lung Dis 4: 123\u2013 132.\n\nBreen RAM, Smith CJ, Cropley I, Johnson MA, Lipman MCI. 2005. Does immune reconstitution syndrome pro- mote active tuberculosis in patients receiving HAART? AIDS 19: 1201\u20131206."
    },
    {
        "id": "doc_2540",
        "document": "Breen RAM, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, et al. 2006. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 61: 791\u2013 794."
    },
    {
        "id": "doc_2541",
        "document": "Breen RAM, Leonard O, Perrin FMR, Smith CJ, Bhagani S, Cropley I, Lipman MCI. 2008a. How good are systemic symptoms and blood in\ufb02ammatory markers in detecting individuals with active tuberculosis? A prospective UK cohort study. Int J Tuberc Lung Dis 12: 44\u2013 49."
    },
    {
        "id": "doc_2542",
        "document": "Breen RA, Barry SM, Smith CJ, Shorten RJ, Dilworth JP, Cropley I, McHugh TD, Gillespie SH, Janossy G, Lipman MC. 2008b. Clinical application of a rapid lung-orientat- ed immunoassay in individuals with possible tuberculo- sis. Thorax 63: 67\u2013 71."
    },
    {
        "id": "doc_2543",
        "document": "Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. 2007. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis 44: 1415\u20131420.\n\nCain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasa- neeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, et al. 2010. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 362: 707 \u2013716.\n\n22"
    },
    {
        "id": "doc_2544",
        "document": "Cite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2545",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES\n\nCapstick T, Laycock D, Lipman M. 2011. Treatment inter- ruptions and inconsistent supply of anti-TB drugs in the UK. Int J Tuberc Lung Dis 15: 754\u2013 760.\n\nCaws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, Stepniewska K, Huyen MN, Bang ND, Loc TH, et al. 2008. The in\ufb02uence of host and bacterial genotype on the development of disseminated disease with Mycobacteri- um tuberculosis. PLoS Pathog 4: e1000034."
    },
    {
        "id": "doc_2546",
        "document": "Cek M, Lenk S, Naber KG , Bishop MC, Johansen TE, Botto H, Grabe M, Lobel B, Redorta JP, Tenke P. 2005. Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Of\ufb01ce. EAU guidelines for the management of genitouri- nary tuberculosis. Eur Urol 48: 353\u2013 362."
    },
    {
        "id": "doc_2547",
        "document": "Chegou NN, Walzl G, Bolliger CT, Diacon AH, van den Heuvel MM. 2008. Evaluation of adapted whole-blood interferon-g release assays for the diagnosis of pleural tuberculosis. Respiration 76: 131 \u2013138.\n\nChou CH, Lin GM, Ku CH, Chang FY. 2001. Comparison of the APACHE II, GCS and MRC scores in predicting out- comes in patients with tuberculous meningitis. Int J Tu- berc Lung Dis 14: 86\u201392."
    },
    {
        "id": "doc_2548",
        "document": "Chou OH, Park KH, Park SJ, Kim SM, Park SY, Moon SM, Chong YP, Kim MN, Lee SO, Choi SH, et al. 2011. Rapid diagnosis of tuberculous peritonitis by T cell-based assays on peripheral blood and peritoneal \ufb02uid mononuclear cells. J Infect 62: 462\u2013 471.\n\nChowdhury AM, Bhuiya A, Chowdhury ME, Rasheed S, Hussain Z, Chen LC. 2013. The Bangladesh paradox: Exceptional health achievement despite economic pover- ty. Lancet 382: 1734\u20131745."
    },
    {
        "id": "doc_2549",
        "document": "Chung HS, Lee JH. 2000. Bronchoscopic assessment of the evolution of endobronchial tuberculosis. Chest 117: 385\u2013392.\n\nChung CL, Chen CH, Yeh CY, Sheu JR, Chang SC. 2008. Early effective drainage in the treatment of loculated tu- berculosis pleurisy. Eur Respir J 31: 1261\u20131267.\n\nCourtwright A, Turner AN. 2010. Tuberculosis and stigma- tization: Pathways and interventions. Public Health Rep 125: 434\u2013 442."
    },
    {
        "id": "doc_2550",
        "document": "Craig SE, Bettinson H, Sabin CA, Gillespie SH, Lipman MCI. 2009. Think TB! Is the diagnosis of pulmonary tuberculosis delayed by antibiotics? Int J Tuberc Lung Dis 13: 208\u2013 213.\n\nCrump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang LY, Chow SC, Njau BN, Mushi GS, Maro VP, et al. 2012. Bacteremic disseminated tubercu- losis in sub-Saharan Africa: A prospective cohort study. Clin Infect Dis 55: 242\u2013250."
    },
    {
        "id": "doc_2551",
        "document": "DeLance AR, Safaee M, Oh MC, Clark AJ, Kaur G, Sun MZ, Bollen AW, Phillips JJ, Parsa AT. 2013. Tuberculoma of the central nervous system. J Clin Neurosci 20: 1333\u2013 1341.\n\nde la Rua-Domenech R. 2006. Human Mycobacterium bovis infection in the United Kingdom: Incidence, risks, con- trol measures and review of the zoonotic aspects of bo- vine tuberculosis. Tuberculosis (Edinb) 86: 77\u2013109."
    },
    {
        "id": "doc_2552",
        "document": "Dhasmana DJ, Ross C, Bradley CJ, Connell DW, George PM, Singanayagam A, Jepson A, Craig C, Wright C, Moly- neaux PL, et al. 2014. Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphade- nopathy by endobronchial ultrasound. Ann Am Thorac Soc 11: 392\u2013396.\n\nDhillon J, Fourie PB, Mitchison DA. 2014. Persister popu- lations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media. J Antimi- crob Chemother 69: 437 \u2013440."
    },
    {
        "id": "doc_2553",
        "document": "Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezui- denhout J, Bolliger CT, Walzl G. 2003. Diagnostic tools in tuberculous pleurisy: A direct comparative study. Eur Respir J 22: 589\u2013 591.\n\nDiel R, Loddenkemper R, Zellweger JP, Sotgiu G, D\u2019Ambro- sio L, Centis R, van der Werf MJ, Dara M, Detjen A, Gondrie P, et al. 2013. Old ideas to innovate TB control: Preventive treatment to achieve elimination. Eur Respir J 42: 785\u2013 801."
    },
    {
        "id": "doc_2554",
        "document": "Dooley SW Jr, Castro KG, Hutton MD, Mullan RJ, Polder JA, Snider DE Jr. 1990. Guidelines for preventing the trans- mission of tuberculosis in health-care settings, with spe- cial focus on HIV-related issues. MMWR Recomm Rep 39: 1 \u201329.\n\nElliott AM, Hayes RJ, Halwiindi B, Luo N, Tembo G, Pobee JO, Nunn PP, McAdam KP. 1993. The impact of HIV on infectiousness of pulmonary tuberculosis: A community study in Zambia. AIDS 7: 981\u2013 987."
    },
    {
        "id": "doc_2555",
        "document": "Engel ME, Matchaba PT, Volmink J. 2007. Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 17: CD001876.\n\nErbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-Ioanas M, Lode H. 2006. Characteristics and outcome of pa- tients with active pulmonary tuberculosis requiring in- tensive care. Eur Respir J 27: 1223\u2013 1228."
    },
    {
        "id": "doc_2556",
        "document": "Evans DJ. 2008. The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tubercu- losis: Do they improve outcome? Respir Med 102: 793\u2013 800.\n\nFernando SL, Saunders BM, Sluyter R, Skarratt KK, Gold- berg H, Marks GB, Wiley JS, Britton WJ. 2007. A poly- morphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 175: 360\u2013366."
    },
    {
        "id": "doc_2557",
        "document": "Feng GD, Shi M, Ma L, Chen P, Wang BJ, Zhang M, Chang XL, Su XC, Yang YN, Fan XH, et al. 2014. Diagnostic accuracy of intracellular Mycobacterium tuberculosis de- tection for tuberculous meningitis. Am J Respir Crit Care Med 189: 475\u2013481."
    },
    {
        "id": "doc_2558",
        "document": "Forssbohm M. 2004. Studie des DZK zur Epidemiologie der Tuberkulose. Abschlussbericht 1996\u2013 2000 (22.333 Fa\u00a8lle) [Study of the German Central Committee against Tuber- culosis on the epidemiology of tuberculosis. Final report 1996-2000 (22.333 cases)]. In 28. Informationsbericht des DZK (ed. Loddenkemper R), pp. 66\u2013 78. DZK, Berlin."
    },
    {
        "id": "doc_2559",
        "document": "Forssbohm M, Zwahlen M, Loddenkemper R, Rieder HL. 2008. Demographic characteristics of patients with ex- trapulmonary tuberculosis in Germany. Eur Respir J 31: 99\u2013 105.\n\nFuehner T, Stoll M, Bange FC, Welte T, Pletz MW. 2007. Klinik der Lungentuberkulose. Pneumologe 4: 151\u2013 162.\n\nGalimi R. 2011. Extrapulmonary tuberculosis: Tuberculous meningitis new developments. Eur Rev Med Pharmacol Sci 15: 365\u2013 386."
    },
    {
        "id": "doc_2560",
        "document": "Gopi A, Madhavan SM, Sharma SK, Sahn SA. 2007. Diag- nosis and treatment of tuberculous pleural effusion in 2006. Chest 131: 880\u2013 889.\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n23\n\nR. Loddenkemper et al.\n\nMedicine\n\nm Cold Spring Harbor Perspectives in"
    },
    {
        "id": "doc_2561",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES\n\nGupta V, Gupta A, Rao NA. 2007. Intraocular tuberculo- sis\u2014An update. Surv Ophthalmol 52: 561\u2013 587.\n\nHales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukko- nen J, et al. 2013. The association between symptoms and microbiologically de\ufb01ned response to tuberculosis treat- ment. Ann Am Thorac Soc 10: 18\u2013 25."
    },
    {
        "id": "doc_2562",
        "document": "Heyderman RS, Makunike R, Muza T, Odwee M, Kadzir- ange G, Manyemba J, Muchedzi C, Ndemera B, Gomo ZA, Gwanzura LK, et al. 1998. Pleural tuberculosis in Harare, Zimbabwe: The relationship between human im- munode\ufb01ciency virus, CD4 lymphocyte count, granulo- ma formation and disseminated disease. Trop Med Int Health 3: 14\u201320."
    },
    {
        "id": "doc_2563",
        "document": "Honeyborne I, McHugh TD, Phillips PJ, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, et al. 2011. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quanti\ufb01ca- tion of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol 49: 3905\u2013 3911.\n\nHooper CE, Lee YC, Maskell NA. 2009. Interferon-g release assays for the diagnosis of TB pleural effusions: Hype or real hope? Curr Opin Pulm Med 15: 358\u2013365."
    },
    {
        "id": "doc_2564",
        "document": "Hooper C, Lee YCG, Maskell N, on behalf of the BTS Pleural Guideline Group. 2010. Investigation of a unilateral pleu- ral effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax 65: i4 \u2013ii17.\n\nHorsburgh CR Jr. 2004. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 350: 2060\u20132067."
    },
    {
        "id": "doc_2565",
        "document": "Hu HY, Wu CY, Huang N, Chou YJ, Chang YC, Chu D. 2014. Increased risk of tuberculosis in patients with end-stage renal disease: A population-based cohort study in Tai- wan, a country of high incidence of end-stage renal dis- ease. Epidemiol Infect 142: 191\u2013199."
    },
    {
        "id": "doc_2566",
        "document": "Huang CC, Tchetgen ET, Becerra M, Cohen T, Hughes KC, Zhang Z, Calderon R, Yataco R, Contreras C, Galea J, et al. 2014. The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household con- tacts. Clin Infect Dis 58: 765\u2013 774.\n\nJain AK, Dhammi IK. 2007. Tuberculosis of the spine: A review. Clin Orthop Relat Res 460: 39\u201349."
    },
    {
        "id": "doc_2567",
        "document": "Khan A, Sterling TR, Reves R, Vernon A, Horsburgh CR. 2006. Lack of weight gain and relapse risk in a large tu- berculosis treatment trial. Am J Respir Crit Care Med 174: 344\u2013348.\n\nKhan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. 2010. Treatment of active tuberculosis in HIV-coinfected patients: A systematic review and meta- analysis. Clin Infect Dis 50: 1288\u20131299."
    },
    {
        "id": "doc_2568",
        "document": "Koegelenberg CF, Bollinger CT, Theron, Walzl G, Wright CA, Louw M, Diacon AH. 2010. A direct comparison of the diagnostic yield of ultrasound-assisted Abrams and Tru- Cut needle biopsies for pleural tuberculosis. Thorax 65: 857\u2013862.\n\nKroot EJ, Hazes JM, Colin EM, Dolhain RJ. 2007. Poncet\u2019s disease: Reactive arthritis accompanying tuberculosis. Two case reports and a review of the literature. Rheuma- tology (Oxford) 46: 484 \u2013489."
    },
    {
        "id": "doc_2569",
        "document": "Kruijshaar ME, Lipman M, Essink-Bot ML, Lozewicz S, Creer D, Dart S, Sadler H, Maguire H, Abubakar I.\n\n2010. Health status of UK patients with active tubercu- losis. Int J Tuberc Lung Dis 14: 296\u2013 302.\n\nKulchavenya E. 2013. Best practice in the diagnosis and management of urogenital tuberculosis. Ther Adv Urol 5: 143\u2013 151.\n\nLamm DL. 1992. Complications of bacillus Calmette-Gue- rin immunotherapy. Urol Clin North Am 19: 565 \u2013572.\n\nLawn SD, Zumla AI. 2011. Tuberculosis. Lancet 378: 57\u201372."
    },
    {
        "id": "doc_2570",
        "document": "Lawn SD, Kerkhoff AD, Vogt M, Wood R. 2013. HIV-asso- ciated tuberculosis: Relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC Med 11: 231.\n\nLee JY, Yi CA, Kim TS, Kim H, Kim J, Han J, Kwon OJ, Lee KS, Chung MJ. 2010. CT scan features as predictors of patient outcome after bronchial intervention in endo- bronchial TB. Chest 138: 380\u2013385."
    },
    {
        "id": "doc_2571",
        "document": "Lee K, Kim JH, Lee JH, Lee WY, Park MS, Kim JY, Kim KC, Lee MG, Jung KS, Kim YS, et al. 2011. Acute respiratory distress syndrome caused by miliary tuberculosis: A mul- ticentre survey in South Korea. Int J Tuberc Lung Dis 15: 1099\u20131103.\n\nLight RW. 2010. Update on tuberculous pleural effusion. Respirology 15: 451\u2013 458.\n\nLoddenkemper R. 1998. Thoracoscopy\u2014State of the art. Eur Respir J 11: 213\u2013221."
    },
    {
        "id": "doc_2572",
        "document": "Loddenkemper, Praveen, Noppen, Pyng. 2011. Medical Thoracoscopy/Pleuroscopy: Manual and Atlas. Georg Thieme, New York.\n\nMase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cun- ningham J, Urbanczik R, Perkins MD, Aziz MA, Pai M. 2007. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: A systematic review. Int J Tuberc Lung Dis 11: 485\u2013495."
    },
    {
        "id": "doc_2573",
        "document": "Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, et al. 2008. Tuberculosis-associated immune reconsti- tution in\ufb02ammatory syndrome: Case de\ufb01nitions for use in resource-limited settings. Lancet Infect Dis 8: 516\u2013 523."
    },
    {
        "id": "doc_2574",
        "document": "Menzies D, Fanning A, Yuan L, FitzGerald JM. 2003. Cana- dian Collaborative Group in Nosocomial Transmission of Tuberculosis. Factors associated with tuberculin conver- sion in Canadian microbiologiy and pathology workers. Am J Respir Crit Care Med 167: 599 \u2013602.\n\nMigliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D\u2019Ambrosio L, Centis R, Sotgiu G, Menegale O, et al. 2012. European Union standards for tuberculosis care. Eur Respir J 39: 807\u2013 819."
    },
    {
        "id": "doc_2575",
        "document": "Millen SJ, Uys PW, Hargrove J, van Helden PD, Williams BG. 2008. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS ONE 3: e1933.\n\nMo\u00a8ller M, de Wit E, Hoal EG. 2010. Past, present and future directions in human genetic susceptibility to tuberculo- sis. FEMS Immunol Med Microbiol 58: 3\u2013 26."
    },
    {
        "id": "doc_2576",
        "document": "Moure R, Mun\u02dcoz L, Torres M, Santin M, Mart\u0131\u00b4n R, Alcaide F. 2011. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clin- ical samples by use of an integrated real-time PCR meth- od. J Clin Microbiol 49: 1137\u20131139.\n\nNavani N, Molyneaux PL, Breen RA, Connell DW, Jepson A, Nankivell M, Brown JM, Morris-Jones S, Ng B, Wic-\n\n24\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\nClinical Aspects of Adult Tuberculosis"
    },
    {
        "id": "doc_2577",
        "document": "m Cold Spring Harbor Perspectives in Medicine"
    },
    {
        "id": "doc_2578",
        "document": "www.perspectivesinmedicine.org PERSPECTIVES\n\nkremasinghe M, et al. 2011. Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopa- thy: A multicentre study. Thorax 66: 889 \u2013893.\n\nNhu NT, Heemskerk D, Thu do DA, Chau TT, Mai NT, Nghia HD, Loc PP, Ha DT, Merson L, Thinh TT, et al. 2014 Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. J Clin Microbiol 52: 226 \u2013233."
    },
    {
        "id": "doc_2579",
        "document": "Okanurak K, Kitayaporn D, Wanarangsikul W, Koompong C. 2007. Effectiveness of DOT for tuberculosis treatment outcomes: A prospective cohort study in Bangkok, Thai- land. Int J Tuberc Lung Dis 11: 762\u2013 768.\n\nParimon T, Spitters CE, Muangman N, Euathrongchit J, Oren E, Narita M. 2008. Unexpected pulmonary involve- ment in extrapulmonary tuberculosis patients. Chest 134: 589\u2013594."
    },
    {
        "id": "doc_2580",
        "document": "Public Health England. 2014. http://www.hpa.org.uk/ Topics/InfectiousDiseases/InfectionsAZ/Tuberculosis/ TBUKSurveillanceData/EnhancedTuberculosisSurveill ance/nTBEnhanced11site/ (accessed 18 April 2014).\n\nRay S, Talukdar A, Kundu S, Khanra D, Sonthalia N. 2013. Diagnosis and management of miliary tuberculosis: Cur- rent state and future perspectives. Ther Clin Risk Manag 9: 9 \u201326."
    },
    {
        "id": "doc_2581",
        "document": "Rice B, Elford J, Yin Z, Kruijshaar M, Abubakar I, Lipman M, Pozniak A, Kall M, Delpech V. 2013. Decreasing inci- dence of tuberculosis among HIV diagnosed heterosex- uals in England and Wales. AIDS 27: 1151\u20131157."
    },
    {
        "id": "doc_2582",
        "document": "Rieder HL, Watson JM, Raviglione MC, Forssbohm M, Mi- gliori GB, Schwoebel V, Leitch AG, Zellweger JP. 1996. Surveillance of tuberculosis in Europe. Working Group of the World Health Organization (WHO) and the Eu- ropean Region of the International Union Against Tuber- culosis and Lung Disease (IUATLD) for uniform report- ing on tuberculosis cases. Eur Respir J 9: 1097\u2013 1104."
    },
    {
        "id": "doc_2583",
        "document": "Roy A, Anaraki S, Hardelid P, Catchpole M, Rodrigues LC, Lipman M, Perkins S, Roche A, Stagg H, Figueroa J, Abubakar I. 2013. Implementing universal HIV testing in London tuberculosis clinics: A cluster randomised controlled trial. Eur Respir J 41: 627\u2013634.\n\nSahn SA. 2002. Pleural thickening, trapped lung, and chron- ic empyema as sequelae of tuberculous pleural effusion: Don\u2019t sweat the pleural thickening. Int J Tuberc Lung Dis 6: 461 \u2013464."
    },
    {
        "id": "doc_2584",
        "document": "Sanai FM, Bzeizi KI. 2005. Systematic review: Tuberculous peritonitis\u2014Presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther 22: 685\u2013 700.\n\nSchoch OD, Rieder P, Tueller C, Altpeter E, Zellweger JP, Rieder HL, Krause M, Thurnheer R. 2007. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med 175: 80\u201386."
    },
    {
        "id": "doc_2585",
        "document": "Schutz C, Meintjes G, Almajid F, Wilkinson RJ, Pozniak A. 2010. Clinical management of tuberculosis and HIV-1 co-infection. Eur Respir J 36: 1460\u20131481.\n\nShen YC, Wang T, Chen L, Yang T, Wan C, Hu QJ, Wen FQ. 2013. Diagnostic accuracy of adenosine deaminase for\n\ntuberculous peritonitis: A meta-analysis. Arch Med Sci 9: 601\u2013 607.\n\nSiemon G. 2007. Extrapulmonale tuberkulose. Pneumolog 4: 163 \u2013174."
    },
    {
        "id": "doc_2586",
        "document": "Syed FF, Mayosi BM. 2007. A modern approach to tubercu- lous pericarditis. Prog Cardiovasc Dis 50: 218\u2013 236.\n\nTan KK, Chen K, Sim R. 2009. The spectrum of abdominal tuberculosis in a developed country: A single institution\u2019s experience over 7 years. J Gastrointest Surg 13: 142\u2013 147.\n\nTB CARE I. 2014. International standards for tuberculosis care. 3rd ed. TB CARE I, The Hague, Netherlands."
    },
    {
        "id": "doc_2587",
        "document": "Thwaites GE, Caws M, Chau TT, Dung NT, Campbell JI, Phu NH, Hien TT, White NJ, Farrar JJ. 2004a. Comparison of conventional bacteriology with nucleic acid ampli\ufb01ca- tion (ampli\ufb01ed mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J Clin Microbiol 42: 996\u2013 1002."
    },
    {
        "id": "doc_2588",
        "document": "Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, et al. 2004b. Dexamethasone for the treat- ment of tuberculous meningitis in adolescents and adults. N Engl J Med 351: 1741\u2013 1751.\n\nThwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J, British Infection Society. 2009. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 59: 167\u2013 187."
    },
    {
        "id": "doc_2589",
        "document": "To\u00a8ro\u00a8k ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, Dung NT, Chau NV, Bang ND, Tien NA, et al. 2011. Timing of initiation of antiretroviral therapy in human immunode\ufb01ciency virus (HIV)\u2014Associated tubercu- lous meningitis. Clin Infect Dis 52: 1374\u20131383.\n\nTrajman A, Pai M, Dheda K, van Zyl Smit R, Zwerling AA, Joshi R, Kalantri S, Daley P, Menzies D. 2008. Novel tests for diagnosing tuberculous pleural effusion: What works and what does not? Eur Respir J 31: 1098\u2013 1106"
    },
    {
        "id": "doc_2590",
        "document": "Uehlinger A, Schaub F, Bu\u00a8hlmann A. 1959. Zur klinik und pathophysiologie der pericarditis constrictiva. Schweiz Med Wochenschr 89: 853\u2013862.\n\nWallgren A. 1948. The time-table of tuberculosis. Tubercle 29: 245\u2013 251.\n\nWatts HG, Lifeso RM. 1996. Tuberculosis of bones and joints. J Bone Joint Surg Am 78: 288\u2013298.\n\nWilberschied LA, Kaye K, Fujiwara PI, Frieden TR. 1999. Extrapulmonary tuberculosis among foreign-born pa- tients, New York City, 1995 to 1996. J Immigr Health 1: 65\u2013 75."
    },
    {
        "id": "doc_2591",
        "document": "World Health Organization. 2011. Guidelines for the pro- grammatic management of drug-resistant tuberculosis\u2014 2011 update, 6th ed. WHO/HTM/TB/2011. WHO, Geneva.\n\nWorld Health Organization. 2013. Global tuberculosis report\n\nZumla A, Raviglione M, Hafner R, von Reyn CF. 2013. Tu- berculosis. N Engl J Med 368: 745 \u2013755.\n\nCite this article as Cold Spring Harb Perspect Med 2016;6:a017848\n\n25\n\n686871 GPHXXX10.1177/2333794X16686871Global Pediatric HealthChisti et al"
    },
    {
        "id": "doc_2592",
        "document": "research-article2017\n\n@ Check for updates\n\nOriginal Article\n\nDiagnosis of Tuberculosis Following World Health Organization\u2013 Recommended Criteria in Severely Malnourished Children Presenting With Pneumonia\n\nGlobal Pediatric Health Volume 4: 1 \u20134 \u00a9 The Author(s) 2017 Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/2333794X16686871 https://doi.org/10.1177/2333794X16686871 journals.sagepub.com/home/gph"
    },
    {
        "id": "doc_2593",
        "document": "Mohammod Jobayer Chisti, MBBS, MMed, PhD1, Mohammed Abdus Salam, MBBS1, Abu S. M. S. B. Shahid, MBBS1, K. M. Shahunja, MBBS1, Sumon Kumar Das, MBBS1, Abu Syed Golam Faruque, MBBS, MPH1, Pradip Kumar Bardhan, MBBS, MD1, and Tahmeed Ahmed, MBBS, PhD1\n\nAbstract"
    },
    {
        "id": "doc_2594",
        "document": "Evidences on diagnosis of tuberculosis (TB) following the World Health Organization (WHO) criteria in children with severe acute malnutrition (SAM) are lacking. We sought to evaluate the WHO criteria for the diagnosis of TB in such children. In this prospective study, we enrolled SAM children aged <5 with radiological pneumonia. We collected induced sputum and gastric lavage for smear microscopy, mycobacterial culture, and Xpert MTB/RIF. Using the last 2 methods as the gold standard, we"
    },
    {
        "id": "doc_2595",
        "document": "determined sensitivity, specificity, and positive and negative predictive values of WHO criteria (n = 388). However, Xpert MTB/RIF was performed on the last 214 children. Compared to mycobacterial culture\u2013confirmed TB, sensitivity and specificity (95% confidence interval) of WHO criteria were 40 (14% to 73%) and 84 (80% to 87%), respectively. Compared to culture- and/or Xpert MTB/RIF-confirmed TB, the values were 22% (9% to 43%) and 83 (79% to 87%), respectively. Thus, the good specificity of"
    },
    {
        "id": "doc_2596",
        "document": "the WHO criteria may help minimize overtreatment with anti-TB therapy in SAM children, especially in resource-limited settings."
    },
    {
        "id": "doc_2597",
        "document": "Keywords\n\npneumonia, severely malnourished children, tuberculosis, World Health Organization, children\n\nReceived December 4, 2016. Accepted for publication December 4, 2016.\n\nIntroduction"
    },
    {
        "id": "doc_2598",
        "document": "Recent data suggest that in endemic countries tuberculo- sis (TB) may contribute to 10% to 20% of total deaths in children1,2 under the age of 15 years. The 2015 global TB report of the World Health Organization (WHO), based on vital registration data, indicated that there were 140 000 deaths in children due to TB.3 TB represented 2% of total deaths in children in year 2012.4 However, among the notified new TB cases in Southeast Asia and Sub-Saharan Africa, less than 4% are among children4; the"
    },
    {
        "id": "doc_2599",
        "document": "low rate is likely due to poor case detection. Due to difficulties in diagnosis, the actual burden of childhood TB is likely to be higher than the aforementioned esti- mates. The diagnosis of adult TB is based mainly on the"
    },
    {
        "id": "doc_2600",
        "document": "routine use of sputum microscopy; however, children below the age of 7 years cannot produce sputum. This makes the detection of Mycobacterium tuberculosis and thereby the diagnosis of TB difficult. Additionally, microscopy of induced sputum or gastric lavage, even when possible, often yields negative results due to the\n\n1International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh"
    },
    {
        "id": "doc_2601",
        "document": "Corresponding Author:\n\nMohammod Jobayer Chisti, Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh.\n\nEmail: chisti@icddrb.org"
    },
    {
        "id": "doc_2602",
        "document": "Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non- commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).\n\n2"
    },
    {
        "id": "doc_2603",
        "document": "paucibacillary nature of childhood TB. The conventional culture method for isolating Mycobacterium tuberculosis takes as long as 8 to 12 weeks. In contrast, the Xpert MTB/RIF assay, a highly sensitive real-time polymerase chain reaction (RT-PCR) test, is specific for TB5; how- ever, it requires high-quality samples, is expensive, and is not readily available in resource-poor and TB-endemic countries. This is why clinicians in such places rely mostly on a combination of epidemiology, history of"
    },
    {
        "id": "doc_2604",
        "document": "exposure, clinical features, chest X-rays, and tuberculin skin test (TST) following WHO criteria in making a diagnosis and treating childhood TB.3 However, clinical signs of TB in children, especially those with severe acute malnutrition (SAM), are often subtle,5 and the diagnosis of TB is even more difficult when such chil- dren present with acute pneumonia.5,6 The WHO criteria, which is also endorsed by the Bangladesh National Guideline for the Management of Tuberculosis in Children,7 relies"
    },
    {
        "id": "doc_2605",
        "document": "mainly on clinical data rather than labo- ratory tests.3 This makes it potentially very useful where TB is endemic, childhood malnutrition is common, microscopy is often negative, and Xpert MTB/RIF is unavailable. Dhaka Hospital, part of the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), treats a large number of children suffering from malnutrition and diarrhea8 each year. Some of the chil- dren with SAM also present with pneumonia and may have pulmonary"
    },
    {
        "id": "doc_2606",
        "document": "tuberculosis.5 Within this context, the present study aimed to validate the use of WHO criteria for diagnosing TB in pneumonic SAM children by com- paring it with culture and Xpert MTB/RIF methods."
    },
    {
        "id": "doc_2607",
        "document": "Materials and Methods\n\nEthics Statement\n\nThe study (Protocol Number: PR-10067) was approved by the Research Review Committee and the Ethical Review Committee of the icddr,b. Written informed consent was obtained from parents or guardians of each of the participating children; children whose caregivers did not give consent were not enrolled."
    },
    {
        "id": "doc_2608",
        "document": "Study Setting\n\nThe study was conducted at Dhaka Hospital, part of icddr,b. The description of the study site is available in a recently published article based on the same prospective study.5\n\nStudy Design\n\nWe enrolled all SAM children of either sex, aged 0 to 59 months, who were admitted to the intensive care unit,\n\nGlobal Pediatric Health"
    },
    {
        "id": "doc_2609",
        "document": "high dependency unit, or acute respiratory infection ward between April 2011 and June 2012, with symp- toms of cough and/or respiratory difficulty, and radio- logical pneumonia. We collected induced sputum and gastric lavage fluid for acid-fast bacilli (AFB) micros- copy, mycobacterial culture, and performed RT-PCR by Xpert MTB/RIF whenever the Xpert MTB/RIF facility at icddr,b became available. Using positive diagnosis by mycobacterial culture and/or Xpert MTB/RIF as the gold standard, we"
    },
    {
        "id": "doc_2610",
        "document": "determined sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of the WHO cri- teria (Table 1).3,7 Identification of SAM children, diag- nosis of radiological pneumonia, collection of induced sputum, and Xpert MTB/RIF protocols have been described previously by the authors.5"
    },
    {
        "id": "doc_2611",
        "document": "Patient Management\n\nA description of the management of study participants has been described in a recently published article based on the same study.5\n\nMeasurements\n\nA description of the measurements has also been described in a recently published article based on the same study.5\n\nAnalysis"
    },
    {
        "id": "doc_2612",
        "document": "All data were entered into a personal computer using SPSS for Windows (version 17.0; SPSS Inc, Chicago, IL) and Epi-Info (version 6.0, USD, Stone Mountain, GA). We had evaluated the number of sputum samples that were sent, number of available reports, children with culture- and/or Xpert MTB/RIF-confirmed TB, and children with positive and negative WHO criteria. Using positive diagnosis by mycobacterial culture and/or Xpert MTB/RIF as the gold standard, we had also evalu- ated the sensitivity,"
    },
    {
        "id": "doc_2613",
        "document": "specificity, positive predictive value, negative predictive value, accuracy, and their 95% con- fidence intervals of the WHO criteria (Table 1)3,7 for the diagnosis of TB in severely malnourished children."
    },
    {
        "id": "doc_2614",
        "document": "Results\n\nWe performed tests with regard to the WHO criteria for 388 children, all of whom were also tested by AFB microscopy and mycobacterial culture using induced sputum and gastric lavage fluid. RT-PCR by Xpert MTB/RIF was performed only for the last 214 children. The median (interquartile) age of the children in the\n\nChisti et al\n\nTable 1. World Health Organization Criteria for the Diagnosis of Childhood Tuberculosis (TB)."
    },
    {
        "id": "doc_2615",
        "document": "The presence of 3 or more of the following should strongly suggest a diagnosis of TB"
    },
    {
        "id": "doc_2616",
        "document": "Parameters Definition History A history of recent close contact (within the past 12 months) Symptom criteria suggestive of TB Persistent, nonremitting cough for >2 weeks not responding to conventional antibiotics and/or bronchodilators and/or Persistent documented fever (>38\u00b0C/100\u00b0F) >2 weeks and/or Documented weight loss or not gaining weight during the past 3 months OR severe malnutrition, and/or Fatigue and reduced playfulness"
    },
    {
        "id": "doc_2617",
        "document": "Physical signs highly of suggestive of TB Gibbus, cervical lymphadenopathy, nonpainful pleural/pericardial effusion, meningitis not responding to antibiotics, ascites, nonpainful enlarged joints, phlyctenular conjunctivitis, erythema nodosum A positive tuberculin skin test For children with severe malnutrition or HIV, 5 mm or more; for others, 10 mm or more Chest X-ray suggestive of TB End point consolidation, other infiltrate, hilar or para-tracheal lymphadenopathy"
    },
    {
        "id": "doc_2618",
        "document": "3\n\nTable 2. Summary of WHO Criteria for Diagnosis of TB in Children Under the Age of 5 Years With Pneumonia and Severe Acute Malnutritiona.\n\nNumber of Sputum Culture- and/or Samples (1 Sample per Number of Culture- Xpert MTB/RIF- Positive WHO Negative WHO Parameters Patient) Reports Available Confirmed TB Confirmed TB Criteria (\u22653) (%) Criteria (<3) (%) WHO 388 388 10 27 65 (17) 323 (83)"
    },
    {
        "id": "doc_2619",
        "document": "Abbreviations: WHO, World Health Organization; TB, tuberculosis. aFigures represent percentages, unless specified."
    },
    {
        "id": "doc_2620",
        "document": "Table 3. Validity of WHO Criteriaa.\n\nCompared to Culture Positive TB Compared to Culture and/or Xpert MTB/RIF Positive TB Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV (95% CI) (95% CI) (95% CI) (95% CI) Accuracy (95% CI) (95% CI) (95% CI) (95% CI) Accuracy Parameter (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) WHO 40 (14-73) 84 (80-87) 6 (2-16) 98 (96-99) 83% 22 (9-43) 83 (79-87) 9 (4-20) 93 (90-96) 79% criteria"
    },
    {
        "id": "doc_2621",
        "document": "Abbreviations: WHO, World Health Organization; TB, tuberculosis; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.\n\naFigures represent n (%), unless specified."
    },
    {
        "id": "doc_2622",
        "document": "study was 10 (5, 16) months. TB was confirmed in 27 children (6.8%): 10 by culture, 21 by Xpert MTB/RIF, and 4 by both methods. According to WHO criteria, TB was diagnosed in 65 children (17%; Table 2). Only in 5 children was TB diagnosed by both WHO criteria and the reference methods. Table 3 shows sensitivity, speci- ficity, PPV, NPV, and diagnostic accuracy of the WHO criteria compared with TB cases confirmed by either mycobacterial culture or Xpert MTB/RIF."
    },
    {
        "id": "doc_2623",
        "document": "Discussion\n\nTo our knowledge, this is the first reported study that has evaluated the role of WHO criteria in diagnosing TB"
    },
    {
        "id": "doc_2624",
        "document": "specifically in severely malnourished children. Diagnosis of childhood TB is difficult due largely to issues with the collection of sputum, the paucibacillary nature of childhood TB, and the subtlety of TB symp- toms in SAM children.5,6 To overcome the problem of diagnosis of TB in the large number of SAM children,5 like in other resource-poor settings in Bangladesh, Dhaka Hospital routinely uses WHO criteria (Table 1).3,7 WHO criteria employs simple clinical features and chest X-ray (Table"
    },
    {
        "id": "doc_2625",
        "document": "1).3,7"
    },
    {
        "id": "doc_2626",
        "document": "These include prolonged duration of cough and/or fever, failure to thrive or severe malnutrition, result of TST, suggestive physical findings, and a positive chest X-ray (Table 1).\n\n4"
    },
    {
        "id": "doc_2627",
        "document": "The most important outcome of this study is the rea- sonable performance of WHO criteria in the diagnosis of TB in pneumonic SAM children. The sensitivity of WHO criteria was only 40%, meaning that 60% of TB cases in a population would be missed if these criteria alone were used. However, a specificity of 84% suggests that only around 16% of non-TB children would be inappropriately treated using WHO criteria. TST is the cornerstone of WHO criteria. The high rate of TST false negatives9,10 is"
    },
    {
        "id": "doc_2628",
        "document": "offset by a positive response in this popu- lation, supporting the reliability of WHO criteria. Therefore, clinicians depend heavily on a combination of clinical observations, TST, and chest radiography when applying WHO criteria to diagnose TB. Our find- ings suggest that clinicians in resource-limited settings may apply WHO criteria for diagnosis and initiation of TB treatment in SAM children presenting with pneumo- nia. Dhaka Hospital has been using WHO criteria for diagnosing childhood TB"
    },
    {
        "id": "doc_2629",
        "document": "since the introduction of crite- ria in diagnosing childhood TB by WHO in 2006, and the results of this study justify its use in SAM children."
    },
    {
        "id": "doc_2630",
        "document": "The main limitation of our study was the availability of Xpert MTB/RIF only in the later part of the investigation."
    },
    {
        "id": "doc_2631",
        "document": "In conclusion, our results suggest that, in spite of low sensitivity of WHO criteria based on simple clinical fea- tures and radiologic abnormality for the diagnosis of TB in children with severe pneumonia and severe malnutri- tion, its high specificity and accuracy help minimize and prevent complications arising from inappropriate treat- ments, thereby saving money. Whenever possible, diag- nosis of childhood TB should be confirmed by Xpert MTB/RIF or mycobacterial culture to increase TB case"
    },
    {
        "id": "doc_2632",
        "document": "detection in children as well as minimize potential over- treatment by using the WHO criteria alone."
    },
    {
        "id": "doc_2633",
        "document": "Acknowledgments"
    },
    {
        "id": "doc_2634",
        "document": "We gratefully acknowledge the donors for their support and commitment to icddr,b\u2019s research efforts. We would like to express our sincere thanks to all physicians, clinical fellows, nurses, members of feeding team, and cleaners of the hospital for their invaluable support and contribution during patient enrollment and data collection. We would also like to express our gratitude to caregivers/mothers of the study participants for their consent to enroll their children in the study."
    },
    {
        "id": "doc_2635",
        "document": "Author Contributions\n\nAll the authors contributed in designing the study, carrying it out, analyzing the data, and writing the article. Additionally, MJC led the write-up and finally approved the article.\n\nGlobal Pediatric Health\n\nDeclaration of Conflicting Interests\n\nThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.\n\nFunding"
    },
    {
        "id": "doc_2636",
        "document": "The author(s) disclosed receipt of the following financial sup- port for the research, authorship, and/or publication of this article: This work was funded by icddr,b and its donors, who provide unrestricted support to the institution for its operations and research. Current donors providing unrestricted support include the following: Government of the People\u2019s Republic of Bangladesh, Canadian International Development Agency, Swedish International Development Cooperation Agency, and the"
    },
    {
        "id": "doc_2637",
        "document": "Department for International Development, UK."
    },
    {
        "id": "doc_2638",
        "document": "References\n\n1. Marais BJ, Schaaf HS. Childhood tuberculosis: an emerg- ing and previously neglected problem. Infect Dis Clin North Am. 2010;24:727-749.\n\n2. Winston CA, Menzies HJ. Pediatric and adolescent tuberculosis in the United States, 2008-2010. Pediatrics. 2012;130:e1425-e1432.\n\n3. World Health Organization. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2015."
    },
    {
        "id": "doc_2639",
        "document": "4. Graham SM, Sismanidis C, Menzies HJ, Marais BJ, Detjen AK, Black RE. Importance of tuberculosis control to address child survival. Lancet. 2014;383: 1605-1607.\n\n5. Chisti MJ, Graham SM, Duke T, et al. A prospective study of the prevalence of tuberculosis and bacteraemia in Bangladeshi children with severe malnutrition and pneu- monia including an evaluation of Xpert MTB/RIF assay. PLoS One. 2014;9:e93776."
    },
    {
        "id": "doc_2640",
        "document": "6. Chisti MJ, Ahmed T, Pietroni MAC, et al. Pulmonary tuberculosis in severely-malnourished or HIV-infected children with pneumonia: a review. J Health Popul Nutr. 2013;31:308-313.\n\n7. World Health Organization. National Guideline for the Management of Tuberculosis in Children. 2nd ed. Geneva, Switzerland: World Health Organization; 2013."
    },
    {
        "id": "doc_2641",
        "document": "8. Ahmed T, Ali M, Ullah MM, et al. Mortality in severely malnourished children with diarrhoea and use of a stan- dardised management protocol. Lancet. 1999;353:1919- 1922.\n\n9. Lloyd AV. Tuberculin test in children with malnutrition. Br Med J. 1968;3:529-531.\n\n10. Aref GH, Osman MZ, Zaki A, Amer MA, Hanna SS. Clinical and radiologic study of the frequency and pre- sentation of chest infection in children with severe pro- tein energy malnutrition. J Egypt Public Health Assoc. 1992;67:655-673."
    },
    {
        "id": "doc_2642",
        "document": "Articles\n\nCauses of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study\n\nThe Pneumonia Etiology Research for Child Health (PERCH) Study Group*\n\nSummary\n\nBackground Pneumonia is the leading cause of death among children younger than 5 years. In this study, we estimated causes of pneumonia in young African and Asian children, using novel analytical methods applied to clinical and microbiological findings."
    },
    {
        "id": "doc_2643",
        "document": "Methods We did a multi-site, international case-control study in nine study sites in seven countries: Bangladesh, The Gambia, Kenya, Mali, South Africa, Thailand, and Zambia. All sites enrolled in the study for 24 months. Cases were children aged 1\u201359 months admitted to hospital with severe pneumonia. Controls were age-group-matched children randomly selected from communities surrounding study sites. Nasopharyngeal and oropharyngeal (NP-OP), urine, blood, induced sputum, lung aspirate, pleural"
    },
    {
        "id": "doc_2644",
        "document": "fluid, and gastric aspirates were tested with cultures, multiplex PCR, or both. Primary analyses were restricted to cases without HIV infection and with abnormal chest x-rays and to controls without HIV infection. We applied a Bayesian, partial latent class analysis to estimate probabilities of aetiological agents at the individual and population level, incorporating case and control data."
    },
    {
        "id": "doc_2645",
        "document": "Findings Between Aug 15, 2011, and Jan 30, 2014, we enrolled 4232 cases and 5119 community controls. The primary analysis group was comprised of 1769 (41\u00b78% of 4232) cases without HIV infection and with positive chest x-rays and 5102 (99\u00b77% of 5119) community controls without HIV infection. Wheezing was present in 555 (31\u00b77%) of 1752 cases (range by site 10\u00b76\u201397\u00b73%). 30-day case-fatality ratio was 6\u00b74% (114 of 1769 cases). Blood cultures were positive in 56 (3\u00b72%) of 1749 cases, and"
    },
    {
        "id": "doc_2646",
        "document": "Streptococcus pneumoniae was the most common bacteria isolated (19 [33\u00b79%] of 56). Almost all cases (98\u00b79%) and controls (98\u00b70%) had at least one pathogen detected by PCR in the NP-OP specimen. The detection of respiratory syncytial virus (RSV), parainfluenza virus, human metapneumovirus, influenza virus, S pneumoniae, Haemophilus influenzae type b (Hib), H influenzae non-type b, and Pneumocystis jirovecii in NP-OP specimens was associated with case status. The aetiology analysis estimated that"
    },
    {
        "id": "doc_2647",
        "document": "viruses accounted for 61\u00b74% (95% credible interval [CrI] 57\u00b73\u201365\u00b76) of causes, whereas bacteria accounted for 27\u00b73% (23\u00b73\u201331\u00b76) and Mycobacterium tuberculosis for 5\u00b79% (3\u00b79\u20138\u00b73). Viruses were less common (54\u00b75%, 95% CrI 47\u00b74\u201361\u00b75 vs 68\u00b70%, 62\u00b77\u201372\u00b77) and bacteria more common (33\u00b77%, 27\u00b72\u201340\u00b78 vs 22\u00b78%, 18\u00b73\u201327\u00b76) in very severe pneumonia cases than in severe cases. RSV had the greatest aetiological fraction (31\u00b71%, 95% CrI 28\u00b74\u201334\u00b72) of all pathogens. Human rhinovirus, human metapneumovirus A or"
    },
    {
        "id": "doc_2648",
        "document": "B, human parainfluenza virus, S pneumoniae, M tuberculosis, and H influenzae each accounted for 5% or more of the aetiological distribution. We observed differences in aetiological fraction by age for Bordetella pertussis, parainfluenza types 1 and 3, parechovirus\u2013enterovirus, P jirovecii, RSV, rhinovirus, Staphylococcus aureus, and S pneumoniae, and differences by severity for RSV, S aureus, S pneumoniae, and parainfluenza type 3. The leading ten pathogens of each site accounted for 79% or more"
    },
    {
        "id": "doc_2649",
        "document": "of the site\u2019s aetiological fraction."
    },
    {
        "id": "doc_2650",
        "document": "Interpretation In our study, a small set of pathogens accounted for most cases of pneumonia requiring hospital admission. Preventing and treating a subset of pathogens could substantially affect childhood pneumonia outcomes.\n\nFunding Bill & Melinda Gates Foundation.\n\nCopyright \u00a9 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license."
    },
    {
        "id": "doc_2651",
        "document": "Introduction\n\nPneumonia remains the greatest cause of death globally in children younger than 5 years, accounting for an estimated 12\u00b78% of annual deaths beyond the neonatal period.1 A substantial reduction in the past few decades of estimated pneumonia deaths (0\u00b79 million in 2015 vs 1\u00b77 million deaths in 1990) reflects not only economic development, improved nutrition, and reduced house hold crowding, but also the use of pneumoniaspecific"
    },
    {
        "id": "doc_2652",
        "document": "interventions such as improved case management\u2014 including empirical antibiotic treatment\u2014and effective vaccines against leading pneumonia pathogens.2,3 Despite these advances, continued progress to reduce pneumonia mortality is constrained by the absence of vaccines against the remaining common pathogens.\n\nThe Pneumonia Etiology Research for Child Health (PERCH) study sought to characterise the causes of severe childhood pneumonia requiring hospital admission"
    },
    {
        "id": "doc_2653",
        "document": "@+ CrossMark\n\n=\n\nLancet 2019; 394: 757\u201379 Published Online June 27, 2019 http://dx.doi.org/10.1016/ S0140-6736(19)30721-4\n\nThis online publication has been corrected. The corrected version first appeared at thelancet.com on August 29, 2019\n\nSee Comment page 714\n\n*Study group collaborators listed at the end of the Article"
    },
    {
        "id": "doc_2654",
        "document": "Correspondence to: Dr Katherine L O\u2019Brien, Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA\n\nobrienk@who.int\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n757\n\nArticles\n\nResearch in context\n\nEvidence before this study"
    },
    {
        "id": "doc_2655",
        "document": "Before designing and doing the PERCH study, we did a detailed review to assess the body of evidence on pneumonia aetiology and the epidemiological, laboratory, and analytical methods used to quantify causes of pneumonia in young children. Additionally, we established an expert panel, the Pneumonia Methods Working Group (PMWG), to provide additional advice on the key epidemiological, laboratory, study design, and analytical issues that the PERCH study needed to optimise. The search dates,"
    },
    {
        "id": "doc_2656",
        "document": "databases used, search terms, and restrictions are detailed in a separate publication (Zunera Gilani and colleagues, 2012). The results of our reviews of the pre-existing evidence and the decisions reached by the PMWG have been published in a set of methods papers and in the protocol. Since this review, the descriptive results of three large paediatric pneumonia aetiology studies in children younger than 5 years have been published\u2014from the USA (EPIC), South Africa (Drakenstein), and a"
    },
    {
        "id": "doc_2657",
        "document": "multicountry study (GABRIEL)\u2014and were considered in our analysis."
    },
    {
        "id": "doc_2658",
        "document": "Added value of this study"
    },
    {
        "id": "doc_2659",
        "document": "The PERCH study is a comprehensive, systematic, multisite study of the causes of severe and very severe pneumonia with hospital admission among children aged 1\u201359 months in the context of routine use of Haemophilus influenzae type b and pneumococcal conjugate vaccine. The emphasis on a single protocol with highly standardised implementation and quality control steps throughout the study conduct, the inclusion of diverse sites but with routine implementation of existing pneumonia vaccines, the"
    },
    {
        "id": "doc_2660",
        "document": "duration of enrolment to capture seasonal trends, the use of a 33-target multiplex quantitative PCR, the inclusion of multiple body fluid specimens, the inclusion of an appropriate control group, the adjustment for the sensitivity of the laboratory tests, and the large size of the study all provided strength to the inferential value of the"
    },
    {
        "id": "doc_2661",
        "document": "among children living in highburden, lowresource regions in the era of routine use of vaccines against pertussis, selected pneumococcal serotypes, Haemophilus influenzae type b (Hib), and measles.4 The PERCH study sought to provide rigorous data that would inform future prevention and treatment strategies in lowincome and lowermiddleincome settings and to address challenges faced by previous pneumonia aetiology studies, such as imperfect standardisation of methods and analyses, narrow"
    },
    {
        "id": "doc_2662",
        "document": "generalisability, and absence of an analytical method to provide their primary output of interest, an aetiological distribution.5,6"
    },
    {
        "id": "doc_2663",
        "document": "Here, we report the descriptive clinical and micro bi o logical findings of the PERCH study using a traditional analytical approach, so that results can be compared with those of other pneumonia studies. Acknowledging that aetiology cannot be inferred from these results alone, we also developed a new analytical approach to assess the aetiological distribution of pneumonia.7\u20139 This"
    },
    {
        "id": "doc_2664",
        "document": "results. Our study provides results for over 30 pathogens and allows for cross-site comparisons of aetiological distribution because of its highly standardised methodology. It is the first infectious aetiology study to integrate the results of testing of multiple pathogens from multiple body fluid specimens, by using a range of laboratory assays, and to provide an aetiological distribution of the pathogens, with uncertainty intervals, both by individual and in the population. Our results showed"
    },
    {
        "id": "doc_2665",
        "document": "that ten pathogens were responsible for 79\u201390% of cases with severe pneumonia requiring hospital admission in children younger than 5 years across a wide range of geographical and epidemiological settings. Causes of pneumonia varied by age strata and severity status and, to a lesser degree, by geography."
    },
    {
        "id": "doc_2666",
        "document": "Implications of all the available evidence"
    },
    {
        "id": "doc_2667",
        "document": "From a policy perspective, the low number of pathogens that are common causes of pneumonia requiring hospital admission in children younger than 5 years across all sites could allow for targeted development of pneumonia interventions. Respiratory syncytial virus was the most common cause of disease and should be a primary target for dedicated prevention and treatment efforts, especially for children younger than 6 months. Bacterial pathogens, cumulatively, caused a substantial proportion of"
    },
    {
        "id": "doc_2668",
        "document": "disease and, being treatable and commonly fatal, should remain a target for early access to treatment. Our study clearly shows that the inferential value of nasopharyngeal specimens varies by pathogen, with only a low number of pathogens providing evidence of causality. The PERCH Integrated Analysis shows the value of analytical approaches that account for pathogen prevalence, test performance, multiple specimens, and multiple results for an individual pathogen. The methods developed by the"
    },
    {
        "id": "doc_2669",
        "document": "PERCH study for integrating such data, in a principled approach, offer the opportunity for other aetiology studies to also adapt and use these methods."
    },
    {
        "id": "doc_2670",
        "document": "approach integrates microbiology results from multiple specimens types and multiple results for one pathogen from an individual; this approach also accounts for the sensitivity and specificity of the individual diagnostic tests used. We report the probability distributions of the microbial aetiology in the study population, and in individual cases.\n\nMethods\n\nStudy design and participants"
    },
    {
        "id": "doc_2671",
        "document": "The PERCH casecontrol study design has been previously described.4,10,11 Briefly, we assessed the causes of WHO defined12 severe or very severe pneumonia (pre2013 definitions, originally presented in 2005) among children aged 1\u201359 months presented and admitted to a hospital with this condition. The nine study locations in seven countries (Basse, The Gambia; Bamako, Mali; Lusaka, Zambia; Soweto, South Africa; Kilifi, Kenya; Dhaka and Matlab, Bangladesh; and Nakhon Phanom and Sa Kaeo,\n\n758"
    },
    {
        "id": "doc_2672",
        "document": "www.thelancet.com Vol 394 August 31, 2019\n\nArticles"
    },
    {
        "id": "doc_2673",
        "document": "Thailand) were selected to represent diverse epi demiological conditions through an open call for applications.4 Site characteristics, vacci nation schedules for each country, and screening and enrolment procedures are described in the appendix.4 All sites, except those in Thailand, were routinely using Hib vaccine; pneumococcal conjugate vaccine (PCV) was in routine use in The Gambia, Kenya, Mali, and South Africa and was in routine use in Zambia for the last few months of the PERCH study."
    },
    {
        "id": "doc_2674",
        "document": "Influenza vaccine was not in routine use at any site."
    },
    {
        "id": "doc_2675",
        "document": "Cases were enrolled at the time of presentation to the hospital. Severe pneumonia was defined as cough or difficulty breathing with lower chest wall indrawing; very severe pneumonia was defined as cough or difficulty breathing and at least one of the following signs: central cyanosis, difficulty breastfeeding or drinking, vomiting everything, convulsions, lethargy, unconsciousness, or head nodding.12 Elevated respiratory rate was not part of case definitions (appendix). Exclusion criteria for"
    },
    {
        "id": "doc_2676",
        "document": "cases and controls were hospitalisation within the preceding 14 days, having been discharged as a PERCH case within the preceding 30 days, and residence outside the study catchment area. Cases had the additional exclusion criterion of resolution of lower chest wall indrawing after bronchodilator therapy for children with wheeze. At all sites, case assessment occurred within 24 h of admission. In Bangladesh, children from the Dhaka site that met the case definition were identified at an"
    },
    {
        "id": "doc_2677",
        "document": "outpatient clinic and referred for hospital admission; children whose parents refused hospital admission were still enrolled if they met all other inclusion criteria (n=33). Each site enrolled participants over a 24month period (appendix). Case screening was done 24 h per day and 7 days per week at four sites (Kilifi, Sa Kaeo, Nakhon Phanom, and Matlab), during which all eligible consenting cases were enrolled. At the remaining sites, screening was done during established hours; all eligible"
    },
    {
        "id": "doc_2678",
        "document": "consenting cases presenting during predefined screening hours were enrolled, except for Mali, where a systematic sampling process was used (appendix)."
    },
    {
        "id": "doc_2679",
        "document": "Controls were randomly selected from residents of the same catchment area as cases and frequency matched to cases by age group (1 to <6 months, 6 to <12 months, 12 to <24 months, and 24\u201359 months of age), as previously described.11 Sites aimed to enrol a minimum of 25 con trols monthly or matched to case counts when they had enrolled more than 25 cases in a month. Controls were enrolled regardless of respiratory symptoms to provide the least biased comparison for estimating pneumonia causes, but"
    },
    {
        "id": "doc_2680",
        "document": "were ineligible if they met the PERCH case definition.11,13"
    },
    {
        "id": "doc_2681",
        "document": "All enrolled children were tested for HIV, except those in Bangladesh and controls in The Gambia and Thailand, because these were low HIVprevalence settings. HIV positive controls were oversampled in sites with high HIV prevalence (Zambia and South Africa) by recruitment at HIV treatment clinics.11"
    },
    {
        "id": "doc_2682",
        "document": "The study protocol was approved by the Institutional Review Boards or Ethical Review Committees for each of the seven institutions and at The Johns Hopkins School of Public Health.14 Parents or guardians of participants provided written informed consent. We followed stan dardised procedures for assessment of enrolment criteria, clinical assessment, specimen collection, data collection, and laboratory testing.10,15\u201317 The study protocol, data collection forms, standard operating procedures, and"
    },
    {
        "id": "doc_2683",
        "document": "clinical training videos are publicly available.18"
    },
    {
        "id": "doc_2684",
        "document": "Procedures"
    },
    {
        "id": "doc_2685",
        "document": "Cases underwent clinical examination at admission, at 24 h, and at 48 h (if the child was still hospitalised) including assessments of respiratory signs, anthro po morphic measurements, and peripheral oxygen saturation (on room air whenever possible).15,18 We assessed the vital status of cases during a followup visit or telephone interview done 30 days after admission (with a window of 21\u201390 days). Controls were similarly assessed for clinical findings at enrolment but had no followup"
    },
    {
        "id": "doc_2686",
        "document": "assessment.18 Clinical definitions used in analyses are described in the appendix."
    },
    {
        "id": "doc_2687",
        "document": "At enrolment, we collected nasopharyngeal and oropharyngeal (NPOP), urine, and blood specimens from cases and controls and blood cultures, induced sputum, lung aspirate, pleural fluid, and gastric aspirates from cases only. Results of bacterial and tuberculosis cultures of blood, lung aspirate, and pleural fluid were immediately available to the treating physicians. PCR results were batched and not available for clinical management. Chest xrays were obtained from cases at enrolment and"
    },
    {
        "id": "doc_2688",
        "document": "interpreted by two members of the PERCH Chest Radiograph Reading Panel trained in the WHO method;19 discordant readings were arbitrated as described elsewhere.20 Readers were masked to site and clinical factors. Chest xrays were classified as consoli dation, other infiltrate, both, normal, or uninterpretable by standardised WHO criteria.19\u201321 We defined xrays as abnormal (positive chest xray) if they showed either consolidation, other infiltrate, or both."
    },
    {
        "id": "doc_2689",
        "document": "Specimen collection procedures, laboratory testing methods, and determination of pathogenspecific PCR density thresholds used in analyses have been described separately elsewhere (appendix).17,22\u201328 Briefly, we used a 33pathogen multiplex quantitative PCR (FTD Resp33, Fast Track Diagnostics, Sliema, Malta) and cultures to test NPOP swabs (of cases and controls; cultures were done for Streptococcus pneumoniae alone), induced sputum (of cases), lung aspirates (of eligible cases in The Gambia,"
    },
    {
        "id": "doc_2690",
        "document": "Bangladesh, Mali, and South Africa), and pleural fluid (at the discretion of the treating paediatrician in cases with pleural effusions on chest xray); gastric aspirates from cases were cultured for mycobacteria alone. We tested blood samples for S pneumoniae by PCR for cases and controls and with cultures for cases only. Pleural fluid specimens that signalled positive by"
    },
    {
        "id": "doc_2691",
        "document": "See Online for appendix\n\nFor the study protocol and study materials see https:// www.jhsph.edu/ivac/resources/ perch-background-and- methods/\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n759\n\nArticles\n\nautomated culture but yielded no pathogen on subculture were also tested for pneumococcal antigen (BinaxNOW, Alere, Orlando, FL, USA; appendix). We tested serum specimens from cases and controls for the presence of antimicrobial activity; specimens from cases were also tested for Creactive protein."
    },
    {
        "id": "doc_2692",
        "document": "All pathogens detected by blood culture, except for contaminants, were included as potential pathogens. We excluded PCR results for Klebsiella pneumoniae because of poor assay specificity, which was identified after our testing protocol was established.29 For Moraxella catarrhalis, NPOP PCR results are described in this study, but were excluded from the integrated aetiology analysis; these results did not provide useful diagnostic evidence because control prevalence of M catarrhalis was"
    },
    {
        "id": "doc_2693",
        "document": "substantially higher than case prevalence (appendix). We implemented confirmatory uniplex PCR testing for specimens that tested positive on the multiplex assay for Legionella spp, pertussis, and Hib (appendix). For several pathogens with similar prevalence in cases and controls (ie, S pneumoniae, H influenzae, cytomegalovirus, and P jirovecii from NPOP specimens and S pneumoniae from whole blood specimens),24,25,27 positivity was redefined by use of quantitative PCR density thresholds based on"
    },
    {
        "id": "doc_2694",
        "document": "our analyses. For all remaining pathogens, the standard assay thresholds were used. Blood culture contaminants were defined by standard criteria (appendix) and these results were excluded from the aetiology analysis."
    },
    {
        "id": "doc_2695",
        "document": "We obtained a single induced sputum or gastric aspirate specimen from each case, except in South Africa, where two specimens were routinely collected for increased tuberculosis detection, or at physicians\u2019 discretion for cases with suspected tuberculosis diagnosis. The first specimen alone was used to define a positive result for Mycobacterium tuberculosis to ensure crosssite compa rability; the lower sensitivity of a single specimen was accounted for in the aetiology analysis. With the"
    },
    {
        "id": "doc_2696",
        "document": "exception of tuberculosis, we did not use the induced sputum results in the aetiology analysis because the microbiological findings from sputum culture and PCR did not add information beyond that added by the NPOP specimens, which had the analytical advantage of availability from both cases and controls.30\u201332"
    },
    {
        "id": "doc_2697",
        "document": "Pneumococcal serotypes were assessed by Quellung reaction or PCR; for NPOP specimens that were culture negative but PCR positive and met the density threshold criteria for positivity and adequate specimen volume, we used a microarray assay to assess serotype (n=52; appendix).17,33 These serotypes were grouped into vaccine type or nonvaccine type according to the 13valent PCV (PCV13) formulation. The Gambia, Mali, South Africa, and Zambia (for part of the study period) used PCV13, whereas Kenya"
    },
    {
        "id": "doc_2698",
        "document": "used the tenvalent PCV (PCV10). The multiplex PCR panel included a target for all H influenzae and for H influenzae type b; cultured isolates were serotyped by slide agglutination or PCR. NPOP specimens from cases who met study defined clinical"
    },
    {
        "id": "doc_2699",
        "document": "criteria for measles (n=33) were tested for measles by PCR (appendix). Antibiotic exposure at the time of specimen collection was defined as either documented admin istration of antibiotics in the facility or antibiotic activity in the serum (measured by Staphylococcus aureus bioassay), collected at the same time as the specimen.28"
    },
    {
        "id": "doc_2700",
        "document": "Statistical analysis\n\nData were singledata entered into a centralised electronic data capture system (Emmes Corporation, Rockville, MD, USA);16 the Kenya site extracted data from its existing electronic data capture system, which conformed to the study data entry standards."
    },
    {
        "id": "doc_2701",
        "document": "The number of sites and the number of participants enrolled per site were based on a combination of feasibility within budget and the case prevalence at each site. Site eligibility included, among other criteria, a minimum of 100 cases per year of severe pneumonia requiring hospital admission in children aged 1\u201359 months. Seven sites were selected so that results would represent diverse epidemiological settings in Asia and Africa, and sites were enrolled for 2 years rather than 1 year to enable"
    },
    {
        "id": "doc_2702",
        "document": "asses sment of seasonality, annual variations, and outbreaks in aetiology."
    },
    {
        "id": "doc_2703",
        "document": "Unless otherwise specified, we restricted analyses to cases and controls without HIV infection because the aetiological distribution was expected to vary substantially according to HIV infection status (to be reported in a separate publication). The primary analysis was to esti mate the aetiological fraction of severe and very severe pneumonia among cases with a positive chest xray; cases were restricted to positive results in chest xrays because the analytical method for assessing causes, the"
    },
    {
        "id": "doc_2704",
        "document": "PERCH Integrated Analysis (PIA) model, assumed that all cases had a lung infection. A secondary analysis of all cases without HIV infection, regardless of chest xray, was done and is reported in the appendix.34 Children missing all laboratory measurements used in the integrated aetiology analysis (blood cultures, NPOP PCR, whole blood PCR, and tuberculosis cultures for cases; NPOP PCR and whole blood PCR for controls) were excluded from the analyses. For children with at least one of these"
    },
    {
        "id": "doc_2705",
        "document": "measure ments, any missing data for the other measurements were imputed during model estimation by use of standard Bayesian methods.35"
    },
    {
        "id": "doc_2706",
        "document": "Statistical comparisons of demographic and clinical characteristics between sites and casecontrol groups were done with logistic regression that adjusted for age in months, with or without site as appropriate. We compared the prevalence of organisms measured in both cases and controls using odds ratios (ORs) with 95% CIs calculated by logistic regression, adjusting for site, age in months, and the other pathogens detected (this adjustment for NPOP PCR results alone); we could not adjust for"
    },
    {
        "id": "doc_2707",
        "document": "previous antibiotic use because it was rare among controls. Except for selected sitestratified analyses, results are for all sites combined; comprehensive"
    },
    {
        "id": "doc_2708",
        "document": "760\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles\n\nsitespecific results will be published separately. We used elevated Creactive protein concentrations in the case descriptive analysis, but this was not a variable in the PIA model."
    },
    {
        "id": "doc_2709",
        "document": "We developed and used the PIA model, a novel application of Bayesian latent class analysis that integrates the case and control data across multiple specimens and tests, resulting in an estimate of the aetiology distribution for each individual case and for the population of cases.7\u20139,36 This method assumes that infections at body sites peripheral to the lung are indicative of the cause of the putative lung infection and that measurements are independent of one another. This method was tested"
    },
    {
        "id": "doc_2710",
        "document": "with use of simulated datasets comprising cases with known aetiology who had a mix of measurements that varied in their sensitivity and specificity, which were prespecified, and it was shown to give accurate estimates of the aetiological fraction, even under mild violations of the independence assumption.9 The PIA model uses a Markov Chain Monte Carlo algorithm that, on con vergence, samples from the posterior distribution of the aetiology estimates, given the observed measurements (appendix)."
    },
    {
        "id": "doc_2711",
        "document": "The populationlevel estimate for each pathogen is the average of the individual case probabilities and has a 95% credible interval (95% CrI), the Bayesian analogue of the confidence interval. Sensitivity analyses were done to assess the influence of the values used for aetiology and sensitivity priors (appendix). To allow for the possibility that the pneumonia event was caused by a pathogen not tested for, we included a pathogen category termed not otherwise specified (NOS). Cases who had"
    },
    {
        "id": "doc_2712",
        "document": "negative tests for all pathogens or positive results only in measurements with poor specificity had a higher individuallevel probability to be included in NOS category than other cases."
    },
    {
        "id": "doc_2713",
        "document": "The PIA model assumes that a pneumonia event is caused by a single pathogen. For cases with multiple pathogens detected in silver standard measurements (eg, blood cultures, lung aspirates, or pleural fluid), the model cannot distinguish which one is the dominant cause. For these cases, the model distributes the aetiology probability equally across the pathogens detected. This distribution leads to an underestimation of the contri bution of the true cause of the disease because the sum of the"
    },
    {
        "id": "doc_2714",
        "document": "pathogen probabilities for an individual case in this primary pathogen model must be 100%. For cases who are negative by silver standard measurements, the cause is distributed across multiple pathogens according to the strength of evidence for each pathogen. This evidence includes whether the pathogen was detected in multiple samples from the individual, the pathogen\u2019s prevalence among cases, the pathogen\u2019s odds ratio, and apriori assumptions regarding sensitivity and aetiology."
    },
    {
        "id": "doc_2715",
        "document": "As a Bayesian analysis, we assigned apriori estimates for both the aetiology distribution and the sensitivity of each laboratory measurement. These estimates quantify the preceding uncertainty about the model parameters."
    },
    {
        "id": "doc_2716",
        "document": "The apriori aetiology distribution favoured no pathogen over another (uninformed) because we wanted to estimate the causes using the evidence in the PERCH study alone. The apriori sensitivity distribution, selected by an internal working group using available information external to the PERCH study, varied by laboratory test method and pathogen (table 1, appendix). We classified specimens according to their estimated measurement error as either bronze (ie, imperfect sensitivity and specificity)"
    },
    {
        "id": "doc_2717",
        "document": "or silver standard (ie, imperfect sensitivity, but 100% specificity); no test was categorised as gold standard (ie, 100% sensitivity and specificity; table 1, apriori estimates of measurementspecific sensitivity are detailed in the appendix).9 Measurements designated as silver standard were those of blood cultures, of cultures or PCR of percutaneous lung aspirate and pleural fluid"
    },
    {
        "id": "doc_2718",
        "document": "Base sensitivity priors Reduced sensitivity priors Specificity Blood cultures*t Streptococcus pneumoniae 5-20% 1-13% 100% Haemophilus influenzae 5-20% 1-13% 100% Moraxella catarrhalis 5-15% 1-10% 100% Staphylococcus aureus 5-15% 1-10% 100% Non-fermentative Gram-negative rods 5-15% 1-10% 100% Candida spp 5-15% 1-10% 100% Non-pneumococcal streptococci, including enterococci 5-15% 1-10% 100% Salmonella spp 10-50% 1\u201334% 100% Enterobacteriaceae 10-50% 1\u201334% 100%"
    },
    {
        "id": "doc_2719",
        "document": "Neisseria meningitidis 10-50% 1\u201334% 100% NP-OP PCR S S pneumoniae 50\u201390%\u2020 15-55% 1-control prevalencet H influenzae 50\u201390%\u2020 15-55% 1-control prevalencet Salmonella spp 0-5-90% 0:5-90% 1-control prevalencet Legionella spp 0-5-90% 0:5-90% 1-control prevalencet All other PCR targets 50-90% 50-90% 1-control prevalencet Whole blood PCR S S pneumoniae 12\u201365% 12\u201365% 1-control prevalencet Induced sputum Mycobacterium tuberculosis 10-30% 10-30% 100% Lung aspirate"
    },
    {
        "id": "doc_2720",
        "document": "All pathogens by culture or PCR NA\u00a7 NA\u00a7 100% Plevral fluid All pathogens by culture or PCR NA\u00a7 NA\u00a7 100%"
    },
    {
        "id": "doc_2721",
        "document": "Background information supporting choice of sensitivity priors is provided in the appendix. For base priors, specimens had blood culture volume greater than 1\u00b75 mL (blood culture only) and no evidence of previous antibiotic exposure; for reduced priors, specimens had blood culture volume lower than 1\u00b75 mL or evidence of previous antibiotic exposure. These criteria were not applicable for some pathogen measurements (more details in the appendix). NP-OP=nasopharyngeal and oropharyngeal. NA=Not"
    },
    {
        "id": "doc_2722",
        "document": "applicable. *Direct evidence of the diagnostic sensitivity of blood cultures for S pneumoniae and H influenzae obtained from vaccine probe studies; for all other pathogens, we set the base blood culture sensitivity prior to 5\u201315%, with the exception of Salmonella spp, Enterobacteriaceae, and N meningitidis, for which we selected wider priors (10\u201350%) to reflect their greater uncertainty. \u2020Adjusted (reduced) for previous antibiotic exposure and low blood volume (blood culture only; see appendix"
    },
    {
        "id": "doc_2723",
        "document": "for more details). \u2021See appendix for control prevalence. \u00a7Results of lung aspirate and pleural fluid were used to update the aetiology prior distribution that was applied to cases with similar clinical characteristics."
    },
    {
        "id": "doc_2724",
        "document": "Table 1: Integrated aetiology analysis input values for sensitivity and specificity of laboratory test measures\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n761\n\nArticles"
    },
    {
        "id": "doc_2725",
        "document": "A Cases B Community controls||** 5723 eligible children with severe or very severe pneumonia 8994 eligible children contacted\u2020\u2020\u2021\u2021 1491 not enrolled 3464 declined or did not show to clinic\u2020\u2020 840 refused 531 had no legal guardian 32 died 88 other* 5530 (61\u00b75%) screened 4232 (73\u00b79%) enrolled 52 ineligible 26 admitted to hospital in preceding 14 days 2 PERCH case in past 30 days 10 seriously ill and referred to hospital 251 (5\u00b79%) with HIV infection 1 met case de\ufb01nition 13 none of the above, not"
    },
    {
        "id": "doc_2726",
        "document": "speci\ufb01ed 3981 (94\u00b71% of 4232) without 1769 (41\u00b78% of 4232) without HIV infection\u2020 HIV infection CXR-positive\u2020 5478 (60\u00b79%) eligible Laboratory results available 3926 (98\u00b76%) blood cultures Laboratory results available 1749 (98\u00b79%) blood cultures 359 refused 3910 (98\u00b72%) NP-OP PCR 1733 (98\u00b70%) NP-OP PCR 3922 (98\u00b75%) pneumococcal NP 1748 (98\u00b78%) pneumococcal NP cultures cultures 5119 (56\u00b79%) enrolled 3757 (94\u00b74%) pneumococcal WB PCR 1676 (94\u00b77%) pneumococcal WB PCR 44 (1\u00b71%) LA cultures\u2021 41 (2\u00b73%)"
    },
    {
        "id": "doc_2727",
        "document": "LA cultures\u2021 27 (0\u00b77%) LA PCR\u2021 27 (1\u00b75%) LA PCR\u2021 17 (0\u00b73%) with HIV infection** 16 (0\u00b74%) PF cultures\u2021 15 (0\u00b78%) PF cultures\u2021 13 (0\u00b73%) PF PCR\u2021 12 (0\u00b77%) PF PCR\u2021 3535 (88\u00b78%) tuberculosis IS or GA cultures 1566 (88.5%) tuberculosis IS or GA cultures 5102 (99\u00b77% of 5119) without HIV infection\u2020 30 (0\u00b78%) measles NP-OP PCR\u00a7 10 (0\u00b77%) measles NP-OP PCR\u00a7 3972 (99\u00b78% of 3981) with \u22651 1767 (99\u00b79% of 1769) with \u22651 laboratory result available\u00b6 laboratory result available\u00b6 Laboratory results available"
    },
    {
        "id": "doc_2728",
        "document": "4977 (97\u00b75%) NP-OP PCR 5043 (98\u00b78%) pneumococcal NP cultures 4779 (93\u00b77%) pneumococcal WB PCR 5075 (99\u00b75% of 5102) with \u22651 laboratory results available\u00b6"
    },
    {
        "id": "doc_2729",
        "document": "Figure 1: Case (A) and control (B) enrolment and specimen availability profile\n\nFor JAGS see http://mcmc-jags. sourceforge.net/\n\nFor the Bayesian Analysis Kit for Etiology Research see https://github.com/zhenkewu/ baker"
    },
    {
        "id": "doc_2730",
        "document": "CXR=chest x-ray. NP=nasopharyngeal. OP=oropharyngeal. WB=whole blood. LA=lung aspirate. PF=pleural fluid. IS=induced sputum. GA=gastric aspirate. *Of the 88 children not enrolled because of other reasons, 45 were not enrolled because of an enrolment cap at the Mali site, ten because of political unrest in Bangladesh, and 24 in Kenya and nine in Zambia because of reasons not stated. \u2020Included in clinical descriptive analysis. \u2021Lung aspirate and pleural fluid specimens were collected on a subset"
    },
    {
        "id": "doc_2731",
        "document": "of cases eligible for the procedures; for samples with low volumes, only culture was done. \u00a7Measles testing was done on a subset of cases who met the study defined clinical criteria for measles. \u00b6Included in laboratory descriptive analysis and aetiology analysis; at least one of the following specimens was required for a child to be included in the aetiology analysis: blood culture, NP-OP PCR, WB PCR, or tuberculosis culture for cases; and NP-OP PCR or WB PCR for controls. ||Number contacted,"
    },
    {
        "id": "doc_2732",
        "document": "screened, and eligible includes some extrapolated data for the Zambia and South Africa sites; data were available for 16 of 24 months for Zambia and 10\u00b75 of 24 months for South Africa; for each of these sites, available data were used to extrapolate numbers for the months with missing data assuming that contact, participation, and eligibility rates were constant over time.**Not shown here are an additional 206 controls with HIV infection enrolled from HIV clinics at the South Africa and Zambia"
    },
    {
        "id": "doc_2733",
        "document": "sites to ensure adequate sample size of children with HIV infection; these children will be described in forthcoming manuscripts devoted to the causes of severe and very severe pneumonia in children with HIV infection. \u2020\u2020Data for total number of children contacted and number of children who declined or did not show to clinic were not available for the Mali site. \u2021\u2021Among sites with available data for total number of children contacted (ie, all sites except Mali), 8149 (73\u00b79%) of 11 033 randomly"
    },
    {
        "id": "doc_2734",
        "document": "selected children or households were contacted; the number of children or guardians contacted is used as the denominator for the percentage of children screened, eligible, and enrolled; because the denominator excludes Mali but the numerator does not, the percentages for screened, eligible, and enrolled are overestimated."
    },
    {
        "id": "doc_2735",
        "document": "specimens, and of M tuberculosis cultures of induced sputum (or gastric aspirate). PCR results from the NPOP swab and whole blood (S pneumoniae alone) specimens were included as bronze standard measurements, with controls providing the data to estimate specificity. We reduced the sensitivity for detecting bacterial pathogens in NPOP PCR (S pneumoniae and H influenzae only) and blood culture specimens for individuals whose specimens were collected after documented antibiotic exposure and for"
    },
    {
        "id": "doc_2736",
        "document": "blood culture specimens with low blood volume (appendix)."
    },
    {
        "id": "doc_2737",
        "document": "The PIA model integrated the apriori distributions with the observed data, changing (updating) both the apriori distribution and sensitivity estimates with contributions of the study data, to produce the aetiology estimates.9 The positive lung aspirate results were used to update the apriori aetiology distribution for cases with similar chest xray characteristics (appendix). Intrinsic within the PIA model, the sensitivity of the bronze standard measurements (eg, NPOP) for individual bacteria was"
    },
    {
        "id": "doc_2738",
        "document": "updated by use of the results of cases with positive blood cultures."
    },
    {
        "id": "doc_2739",
        "document": "762\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles"
    },
    {
        "id": "doc_2740",
        "document": "com bined and assumed that the measurement sensi tivities were common across sites, while allowing the aetio logical distributions and control prevalences to vary across sites (appendix). We did analyses stratified by age (<1 year and \u22651 year) and WHO pneumonia severity (severe and very severe). The allsite results were based on cases with a positive chest xray, wherein each case, without regard to site, contributed equally to the estimated aetiology distribution, and based on all controls. To"
    },
    {
        "id": "doc_2741",
        "document": "assess differences in the aetiological distri bution related to site, we standardised the age and severity of case distributions at each site to that of all sites combined (appendix). We compared the age and severitystandardised results across sites for ten focus pathogens (H influenzae, M tuberculosis, S aureus, S pneumoniae, human metapneumovirus [HMPV], influenza, parainfluenza, rhinovirus, respi ratory syncytial virus [RSV], and P jirovecii). We defined focus pathogens on the basis of"
    },
    {
        "id": "doc_2742",
        "document": "results of the allsite aetiological analysis. Focus pathogens were those with aetiology estimates higher than 5% (n=7) or higher than 2% that were of epidemiological interest (defined as treatable by antibiotics [P jirovecii and S aureus] or having an available vaccine [influenza virus]). The 95% CrI around the aetiological fraction of these three pathogens overlap with some nonfocus pathogens; therefore, we used the term focus pathogen rather than labelling these ten as the most common"
    },
    {
        "id": "doc_2743",
        "document": "pathogens. In this study, we also report the list of the sitespecific ten most common pathogens and the overall aetiological fraction of those pathogens (ie, the ten pathogens with the highest aetiological fraction at a given site)."
    },
    {
        "id": "doc_2744",
        "document": "We did statistical analyses with SAS, version 9.4, and with Bayesian inference software JAGS 4.2.0; NPOP PCR figures were created with R, version 3.3.1. The PIA model used an opensource R software package that we developed called the Bayesian Analysis Kit for Etiology Research."
    },
    {
        "id": "doc_2745",
        "document": "Role of the funding source\n\nRepresentatives from the Bill & Melinda Gates Foundation participated in site selection and in Pneumonia Methods Working Group meetings, which informed the study design. They had no role in the data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication."
    },
    {
        "id": "doc_2746",
        "document": "Results\n\nBetween Aug 15, 2011, and Jan 30, 2014, we enrolled 4232 (73\u00b79%) of 5723 eligible children with severe or very severe pneumonia as cases and 5119 (56\u00b79%) of 8994 eligible children in the study catchment areas contacted as community controls; an additional 206 con trols with HIV infection were enrolled from HIV clinics"
    },
    {
        "id": "doc_2747",
        "document": "in South Africa and Zambia for HIVspecific analyses to be reported separately (figure 1). Enrolment of cases and controls varied by season (appendix). Approximately 90% of the planned specimens (ranging from 88\u00b78% for"
    },
    {
        "id": "doc_2748",
        "document": "All cases Cases witha positive x-ray Controls p value Total 3981 1769 5102 \u00b7\u00b7 Age, months \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 <0-0001 28 days\u20135 1619 (407% 691 (39\u00b71%) 1598 (31-3%) \u00b7\u00b7 6-11 908 (22-8%) ) 425 (24:0% ) 1210 (23:7% \u00b7\u00b7 12-23 903 (22:7%, E 436 24-6%) \u00e9 1262 24:7% E ;: \u00b7\u00b7 24-59 551 (13-8% ) 217 (12:3%) 1032 (20-2%, \u00b7\u00b7 Sex Girls. 1684 (423%) 778 (44-0%) 2533 (49:7%) <0-0001 Respiratory tract illness (controls only) \u00b7\u00b7 \u00b7\u00b7 1206 (23-6%) \u00b7\u00b7 Positive malaria smear\u2019 (3:9%) (1:9%) (1:3%) 0\u00b71480 DTP vaccine"
    },
    {
        "id": "doc_2749",
        "document": "Number of doses (regardless of age) \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 <0-0001 [ 480 (12:5%) 201 (11-8%) 249 (5:0%) \u00b7\u00b7 1-2 1086 (28:3%) 484 (28-4%) 1060 (21-1%) \u00b7\u00b7 =3 2267 (59:1%) 1017 (60-0%) 3708 (73-9%) \u00b7\u00b7 Fully vaccinated for aget Age <1year 1724 (70-3%) 751 (69\u00b75%) 2258 (81.0%) <0-0001 Age > 1year 1264 (915%) 566 (911%) 2083 (93-5%) 0-1407 PCvV Number of doses (regardless of \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 0\u00b70014 age) [ 1690 (43-8%) 701 (40-8%) 2404 (47-9%) \u00b7\u00b7 1-2 1021 (26-4%) 480 (28:0%) 1056 (21-0%) \u00b7\u00b7"
    },
    {
        "id": "doc_2750",
        "document": "=3 1151 (29-8%) 536 (31.2%) 1561 (311%) \u00b7\u00b7 Fully vaccinated for aget Age <1year 1226 (49.7%) 566 (52:0%) 1384 (49.6%) 0\u00b70004 Age >1year 640 (45-9%) ) 291 (46-3%; ) 867 (38-8%, ) 07019 Full vaccination for measles\u00a7 1453 86.8%) \u00e9 646 853%) \u00a7 2459 90-6%) \u00e9 00135 Mid-pper arm circumference <11\u00b75 cm\u00b6 171 (7-4%) 8-8%) 0-8%) <0-0001 Weight-for-age Z score <0-0001 \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 Severe (. 3) 631 15:9%, 338 (19-2%) 196 (3-9%) \u00b7\u00b7 Moderate (; 3to<-2) 754 19-0%, e :: 361 (20-5%) EEE % 515 (10-1%, ) E \u00b7\u00b7"
    },
    {
        "id": "doc_2751",
        "document": "Normal (: ) 2584 651% 1062 60-3%, 368 86-0%) \u00b7\u00b7 Antibiotic activity detected in serum 918 =) (24-5%; 425 (25:3%, & 1-8%) <0-0001 Previous exposure to antibiotics|| 1530 (38-9%) 704 (401%) (17%) <0-0001 Median duration of illness (days) 3.0 (20-5:0) 3.0 (20-5:0) \u00b7\u00b7 \u00b7\u00b7 Very severe pneumonia 1279 (32:1%) 519 (29-3%) \u00b7\u00b7 \u00b7\u00b7 Wheeze on auscultation 1340 (33-9% = 555 (31.7%) \u00b7\u00b7 \u00b7\u00b7 Tachypnoea 3256 (82:4%) & 1492 (853% \u00b7\u00b7 \u00b7\u00b7 Hypoxaemia 1423 (35:8% & 748 (423%, ;) \u00b7\u00b7 \u00b7\u00b7"
    },
    {
        "id": "doc_2752",
        "document": "Oxygen use at admission\u2019 1243 (37-4% L 671 43:9%, \u00b7\u00b7 \u00b7\u00b7 Temperature 238.0\u00b0C 1213 (30:5%) \u00e9 591 (33\u00b75%) E \u00b7\u00b7 \u00b7\u00b7 CRP 240 mg/L 925 (27-6%) 526 (34-9% \u00b7\u00b7 \u00b7\u00b7 Elevated WBC count 1620 (43-4%) 793 (47-8 ) \u00b7\u00b7 \u00b7\u00b7"
    },
    {
        "id": "doc_2753",
        "document": "(Table 2 continues on next page)\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n763\n\nArticles"
    },
    {
        "id": "doc_2754",
        "document": "All cases Cases witha positive x-ray Controls p value (Continued from previous page) Chest x-ray findings Positive 1769 (44-4%) 1769 (100%) \u00b7\u00b7 \u00b7\u00b7 Consolidation 841 (21\u00b71%) 841 (47\u00b75%) \u00b7\u00b7 \u00b7\u00b7 Other infiltrate 928 (23-3%) ) % 928 (52:5%) \u00b7\u00b7 \u00b7\u00b7 Negative 1627 40-9%) \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 Uninterpretable 351 (8\u00b78%) \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 Missing 234 (5:9%) \u00b7\u00b7 \u00b7\u00b7 \u00b7\u00b7 Blood culture volume, mLtf 1to<2 1649 (487%) 753 (51-4%) \u00b7\u00b7 \u00b7\u00b7 >2to<3 1313 (38-8%, ) \u00e9 537 (36:7%, ) E \u00b7\u00b7 \u00b7\u00b7 =3 425 12:6%) 175 12.0%) \u00b7\u00b7 \u00b7\u00b7"
    },
    {
        "id": "doc_2755",
        "document": "Died in hospital or within 30 days of admission 292 (7:3%) 114 (6-4%) \u00b7\u00b7 \u00b7\u00b7 Died in hospital 251 (6\u00b73%) (5-4%) \u00b7\u00b7 \u00b7\u00b7 Died post discharge, within 41 %) 9 (1-1%) \u00b7\u00b7 \u00b7\u00b7 30 days of admissiont+ Missing 30-day vital status 346 (87%) 146 (8:3%) \u00b7\u00b7 \u00b7\u00b7"
    },
    {
        "id": "doc_2756",
        "document": "Data are n (%) or median (IQR). Positive cases are those with a positive chest x-ray. p values obtained from logistic regression models adjusted for age in months (all variables expect age category) and site for cases with a positive x-ray versus controls. During the study, pneumococcal conjugate vaccine (PCV) was in routine use in Kenya (introduced February, 2011), The Gambia (August, 2009), Mali (March, 2011), and South Africa (April, 2009); PCV was introduced in Zambia in July, 2013 (Lusaka),"
    },
    {
        "id": "doc_2757",
        "document": "3 months before the end of study enrolment. Duration of illness was defined as duration (in days) of cough, wheeze, fever, or difficulty breathing, whichever was longest. Tachypnoea was defined as 60 or more breaths per min (<2 months), 50 or more breaths per min (2\u201311 months), and 40 or more breaths per min (12\u201359 months). Hypoxaemia was defined as oxygen saturation lower than 92% (or <90% for sites at elevation above 1200 m: Zambia and South Africa), or supplemental oxygen use if a room air"
    },
    {
        "id": "doc_2758",
        "document": "oxygen saturation reading was not available; a room air oxygen saturation reading was available for 3514 (88\u00b73%) children; the South African site, at an altitude of 1600 m above sea level, had a standard clinical practice to administer supplemental oxygen for all children admitted to hospital with a diagnosis of severe pneumonia. Elevated white blood cell (WBC) count was defined as greater than 15 \u00d7 109 cells per L for children aged 1\u201311 months and greater than 13 \u00d7 109 cells per L for children"
    },
    {
        "id": "doc_2759",
        "document": "aged 12\u201359 months. CRP=C-reactive protein. *Restricted to endemic sites (Kenya, Gambia, Mali, and Zambia). \u2020For children younger than 1 year, full vaccination was defined as having received at least one dose and being up to date for age on the basis of the child\u2019s age at enrolment, doses received, and country schedule (allowing a 4-week window for each dose); for children aged 1 year or older, full vaccination was defined as having received three or more doses. \u2021For children younger than 1 year,"
    },
    {
        "id": "doc_2760",
        "document": "full vaccination was defined as having received at least one dose and being up to date for age on the basis of the child\u2019s age at enrolment, doses received, and country schedule (allowing a 4-week window for each dose); for children aged 1 year or older in all sites except Kenya, full vaccination was defined as having received three or more doses; for children older than 1 year in Kenya (which introduced PCV with catch-up campaign), full vaccination was defined as having received three or more"
    },
    {
        "id": "doc_2761",
        "document": "doses, two doses if given at least 8 weeks apart and the child was older than 1 year of age at first dose, and one dose if the child was older than 2 years at any dose or at introduction. \u00a7Data restricted to those age-eligible; at least one dose was restricted to children older than 10 months (>10\u00b75 months in Bangladesh). \u00b6Restricted to children aged 6 months or older. ||Defined as serum bioassay positive (cases and controls), antibiotics administered at the referral facility, or antibiotic"
    },
    {
        "id": "doc_2762",
        "document": "administration before the collection of whole blood specimens at the study facility (cases only); restricted to children with blood culture (cases only) or whole blood (cases or controls) collected. **Data was recorded in the Mali site on the basis of time at presentation, not time at admission, as was done at all other sites; Mali is excluded from the all site summary. \u2020\u202013\u00b77% of cases with a blood culture collected were missing blood culture volume data.29 \u2021\u2021Restricted to children discharged"
    },
    {
        "id": "doc_2763",
        "document": "alive who had vital status data obtained 21 days or longer after admission."
    },
    {
        "id": "doc_2764",
        "document": "Table 2: Demographic and clinical characteristics of cases without HIV infection and controls for all sites"
    },
    {
        "id": "doc_2765",
        "document": "tuberculosis cultures to 98\u00b76% for blood cultures) were collected and tested (figure 1); reasons for missing specimens included specimens not collected because of physician discretion or contraindication (particularly for induced sputum), specimens lost in transport, and parental refusal.16 Cases (251 [5\u00b79%] of 4232) and controls (17 [0\u00b73%] of 5119) with HIV infection were otherwise excluded from analyses in this report, leaving 3981 (94\u00b71%) of 4232 cases and 5102 (99\u00b77%) of"
    },
    {
        "id": "doc_2766",
        "document": "5119 con trols categorised as without HIV infection (figure 1, appendix). The primary analysis further restricted cases to those with positive chest xrays (1769 [52\u00b71%] of 3396 who had an interpretable xray; table 2, 3 appendix). The descriptive laboratory analysis and the primary aetiology analysis excluded an additional two cases and 27 controls missing all microbiology test results. The secondary allcase aetiology analysis (ie, regardless of xray findings) included 3968 cases and 5075"
    },
    {
        "id": "doc_2767",
        "document": "controls with at least one micro biology test result (figure 1); of the 3972 cases with at least one test result, four cases who tested positive for measles by NPOP PCR (all without an infiltrate on their chest xrays) were excluded from the allcase analysis."
    },
    {
        "id": "doc_2768",
        "document": "Demographic and clinical characteristics presented in table 2, table 3, and the appendix. Cases were unevenly distributed across the seven sites; of all cases with a positive chest xray (1769), Thailand made up the lowest percentage (5\u00b75%), whereas South Africa made up the highest (24\u00b76%; appendix) of the seven countries. For every site except Thailand, more than 75% of cases with a positive xray were younger than 24 months, with the majority being younger than 12 months (appendix). Controls"
    },
    {
        "id": "doc_2769",
        "document": "were older than cases in The Gambia, Mali, South Africa, and Dhaka (Bangladesh) sites (p<0\u00b7020; appendix). The proportion of cases with very severe pneumonia was lowest in Bangladesh and The Gambia and highest in Mali and Kenya (p<0\u00b70001; table 2, 3, appendix). 30day case fatality ratio of cases with a positive xray was 6\u00b74% (114 of 1769 cases), which varied markedly by site (p<0\u00b70001) and was higher in cases with very severe pneumonia (13\u00b73% of 519 very severe cases without HIV infection and"
    },
    {
        "id": "doc_2770",
        "document": "with a positive xray; range by site 3\u00b77\u201328\u00b72%) than in cases with severe pneumonia (3\u00b76% of 1250 severe cases without HIV infection and with a positive xray; range by site 0\u00b75\u20139\u00b77%; appendix). are"
    },
    {
        "id": "doc_2771",
        "document": "Clinical characteristics at admission of cases with a positive chest xray varied substantially by site (tables 2, 3, appendix), particularly for wheezing (range by site 10\u00b76\u201397\u00b73%), fever (9\u00b77\u201358\u00b79%), hypoxaemia (10\u00b70\u201375\u00b78%), and oxygen administration (5\u00b75\u201390\u00b71%; p<0\u00b70001 for all). It should be noted that the South African site, at an altitude of 1600 m above sea level, had a standard clinical practice to administer supplemental oxygen at admission and often before recording oxygen saturation"
    },
    {
        "id": "doc_2772",
        "document": "for all children admitted to hospital with a diagnosis of severe pneumonia. Additionally, Mali oxygen administration data were excluded from analysis because of inadequate standardisation of data recording. Tachypnoea was commonly observed at all sites (85\u00b73% of cases). Malnutrition, defined as WHO weightforage Z score37 lower than \u20132, was found in 39\u00b77% of cases with a positive xray and without HIV infection, with significant variability by site (p<0\u00b70001 for all); malnutrition was more common"
    },
    {
        "id": "doc_2773",
        "document": "in cases than in controls at all sites (appendix). The prevalence of any"
    },
    {
        "id": "doc_2774",
        "document": "764\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles\n\nrespiratory symptom among controls without HIV infection was 23\u00b76% (range by site 5\u00b74\u201341\u00b72%, appendix).\n\nPrevious exposure to antibiotics varied by site and case or control status, as did coverage with vaccines against pertussis, Hib, S pneumoniae, and measles (appendix; p<0\u00b7050 for all). Enrolment of cases varied by season at all sites, except in Mali and Zambia (appendix)."
    },
    {
        "id": "doc_2775",
        "document": "Blood cultures were positive for a pathogen in 56 (3\u00b72%) of 1749 cases with positive chest xrays and available blood cultures (percentage range by site 1\u00b70\u20135\u00b70%; figure 2, appendix). Isolation rates did not vary significantly by age strata (p=0\u00b721), but did vary by case severity (p=0\u00b7014) and were 45% lower among cases with previous antibiotic exposure or with blood volume lower than 1\u00b70 mL (appendix).28 The bacterial species most commonly isolated from blood cultures was S pneumoniae (19 [34%]"
    },
    {
        "id": "doc_2776",
        "document": "of 56 positive blood cultures); however, no pneumococcal isolates were cultured from sites in South Africa, Thailand, or Bangladesh. Although not part of the core methods, South Africa had two blood cultures that were flagged as positive and tested positive for pneumococcal antigen, but were negative for pneumococcal culture (appendix)."
    },
    {
        "id": "doc_2777",
        "document": "M tuberculosis was cultured from 24 (1\u00b75%) of 1571 cases with positive xrays (23 from induced sputum and one from gastric aspirate; appendix). 11 (29%) of 37 lung aspirates and 12 (80%) of 15 pleural fluid speci mens tested by culture, PCR, or both were positive for a pathogen; bacterial pathogens (most often S pneumoniae [lung aspirate] and S aureus [pleural fluid]) were more commonly detected (in 23 cases) than viral pathogens (three cases), and all viral pathogens were codetected with"
    },
    {
        "id": "doc_2778",
        "document": "bacteria (table 4, appendix). Multiple pathogens were observed in six (55%) of 11 lung aspirates that yielded at least one pathogen by culture or PCR."
    },
    {
        "id": "doc_2779",
        "document": "None of the ten cases with positive chest xrays who met the clinical screening definition for measles testing were positive for measles (appendix). Legionella longbeachae infection was identified in one case, a 19monthold Zambian child without HIV infection with very severe pneumonia, in both NPOP and induced sputum speci mens by multiplex PCR and confirmatory uniplex PCR."
    },
    {
        "id": "doc_2780",
        "document": "Almost all cases (3867 [98\u00b79%] of 3910) and controls (4886 [98\u00b70%] of 4984) had at least one pathogen detected (ie, ignoring density threshold) by PCR in the NPOP specimen; most cases (2313 [59\u00b72%]) and controls (2667 [53\u00b75%]) had four or more patho gens detected (appendix). The mean number of potential pathogens detected in NPOP specimens was 3\u00b78 (SD 1\u00b75) among cases and 3\u00b76 (SD 1\u00b75) among controls. Among cases with multiple pathogens detected in NPOP specimens, 3219 (88\u00b74%) of 3642 had both"
    },
    {
        "id": "doc_2781",
        "document": "viral and bacterial detections; no pathogen was commonly found alone (appendix). In cases with a positive chest xray, the most common bacteria detected in NPOP specimens were S pneumoniae (1265 [72\u00b78%] of 1737), M catarrhalis (1153 [66\u00b74%]), H influenzae (1004 [57\u00b78%]), and S aureus (268 [15\u00b74%]), whereas cytomegalovirus (890 [51\u00b72%])"
    },
    {
        "id": "doc_2782",
        "document": "and RSV (506 [29\u00b71%]) were the most common viruses (appendix). Influenza virus was rarely detected (influenza A 62 [3\u00b76%]; influenza B 18 [1\u00b70%]; influenza C 10 [0\u00b76%]). S pneumoniae was more commonly detected in controls (3846 [77\u00b72%] of 4984) than in cases with a positive chest xray (p=0\u00b70001). After applying PCR density thresholds that best distinguished cases from controls,24,25 the proportion of positive results in cases with a positive xray changed for S pneumoniae (from 72\u00b78% to 13\u00b75%), H"
    },
    {
        "id": "doc_2783",
        "document": "influenzae (from 57\u00b78% to 29\u00b75%), P jirovecii (from 8\u00b79% to 4\u00b73%), and cytomegalo virus (from 51\u00b72% to 22\u00b77%). This changed the rank order of most commonly detected bacteria in the NPOP specimens to M catarrhalis, H influenzae, S aureus, and S pneumoniae (appendix). Compared with controls, having a positive chest xray in cases was significantly associated with the presence of 15 different pathogens in NPOP specimens (figure 3). The adjusted ORs for NPOP PCR results ranged widely across"
    },
    {
        "id": "doc_2784",
        "document": "pathogens, with RSV (OR 14\u00b70, 95% CI 11\u00b74\u201317\u00b71), parainfluenza 1 (7\u00b77, 4\u00b76\u201313\u00b70), and human meta pneumovirus A or B (6\u00b73, 4\u00b78\u20138\u00b72) having the highest adjusted ORs, followed by influenza A (3\u00b76, 2\u00b74\u20135\u00b73) and Bordetella pertussis (3\u00b73, 1\u00b76\u20137\u00b72); parainfluenza 1, influenza A, and B pertussis were infrequently detected in cases (figure 3, appendix). M catarrhalis was the only pathogen significantly negatively associated with case status (OR 0\u00b76, 95% CI 0\u00b75\u20130\u00b77). We observed only minor changes in the"
    },
    {
        "id": "doc_2785",
        "document": "magnitude and direction of the ORs after removing the adjustment for detection of the other pathogens (appendix)."
    },
    {
        "id": "doc_2786",
        "document": "Whole blood PCR was positive for S pneumoniae in cases with a positive xray (128 [7\u00b76%] of 1676) at nearly the same prevalence as in controls (255 [5\u00b73%] of 4779; OR 1\u00b72, 95% CI 1\u00b70\u20131\u00b76); after applying a PCR density threshold (\u22652\u00b72 log10 copies per mL) to enhance differ entiation of cases and controls,26,27 prevalence was 91 (5\u00b74%) of 1676 cases with a positive chest xray versus 144 (3\u00b70%) of 4779 controls (1\u00b76, 1\u00b72\u20132\u00b71; appendix)."
    },
    {
        "id": "doc_2787",
        "document": "Integrating the microbiology results from the multiple specimens among the 1767 cases with a positive chest xray and the 5075 controls, we estimated that more disease was due to viral pathogens (61\u00b74%, 95% CrI 57\u00b73\u201365\u00b76) than to bacterial pathogens (other than M tuberculosis; 27\u00b73%, 23\u00b73\u201331\u00b76); the remaining aetiological fractions were attributed to M tuberculosis, Candida spp, P jirovecii, and causes not otherwise specified (figure 4A, appendix). RSV was the most common cause (31\u00b71%, 95% CrI"
    },
    {
        "id": "doc_2788",
        "document": "28\u00b74\u201334\u00b72), and other common pathogens (each accounting for 5% or more of the aetiological distribution) included human rhinovirus, HMPV A or B, human parainfluenza virus (types 1\u20134 combined), S pneumoniae, M tuberculosis, and H influenzae. Unknown causes (NOS category) accounted for 1\u00b78% (95% CrI 0\u00b72\u20134\u00b75) of the pneumonia aetiology distribution. The fraction of pneumonia attributable to pathogens targeted by currently licensed vaccines (Hib, vaccineserotype S pneumoniae, pertussis, M"
    },
    {
        "id": "doc_2789",
        "document": "tuberculosis, and influenza A or B) was 14\u00b70% (11\u00b73\u201317\u00b70)."
    },
    {
        "id": "doc_2790",
        "document": "www.thelancet.com Vol 394 August 31, 2019\n\n765"
    },
    {
        "id": "doc_2791",
        "document": "Controls. s l o r t n o C 659 9 6 91 (13-8%) 1 9 ( 153 (232%) 217 3 5 1 ( 7 1 2 (32:9%) 198 ( 8 1 323 (49:0%) 3 2 3 ) ( (38:5%) 4 5 2 ( \u00b7 \u00b7 535 ( 81.7%) 5 5 215 5 1 2 (88:5%) 405 ( 5 0 4 (98:3%) ( 655 (100%) 5 ( (00%) 0 ) ( (0-0%) 0 ) ( 0 (00%) (00%) ) ( 0 ) ( 455 (95-0%) 5 ) ("
    },
    {
        "id": "doc_2792",
        "document": "Thailand d n a l i a h T Cases with apositive h t i w s e s a C s l X-ray. 98 y a r - x 9 18 (18-4%) 8 1 ) 19 (19-4%) 30 9 1 ) ( ) 0 3 (30-6%) 31 1 43 (43:9%) 3 4 ) ( ) \u00b7 \u00b7 ) \u00b7 \u00b7 67 (69:8%) 7 6 ) 23 3 2 (62:2%) 54 4 5 (91:5%) ) ( 95 (99-0%) 5 9 ( ) (00%) 0 ( (1-0%) 1 ( 0 (00%) (17%) 1 ( ( 60 (90-9%) 0 6 ( )"
    },
    {
        "id": "doc_2793",
        "document": "Bangladesh with Controls. apositive o r t n o C h t i w s e 772 y a 2 7 7 9 221 (22-8%) (28-6%) 1 2 2 0 ( 168 (22-8%) (21-8%) 196 8 6 1 0 ( 1 1 (25-4%) 187 ( 1 8 402 (52:1%) 2 0 4 ( ) (@19%) 9 1 \u00b7 \u00b7 ( \u00b7 \u00b7 \u00b7 650 (84:9%) 8 ( 346 3 5 (85:9%) (88-9%) 364 ( 3 4 (95-8%) (96:6%) ( 2 (100%) 2 7 7 8 ( ) (00%) 0 ( 0 (0-0%) 0 ( 0 0 0 (00%) (00%) ( 0 ( 0 384 (80-9%) (88-1%) ( 0"
    },
    {
        "id": "doc_2794",
        "document": "Controls. Cases s a C s l o r t n o C x-ray 828 219 r - x 1 2 8 2 8 320 50 (38-6%) 5 0 2 3 ( 228 50 (27-5%) 148 81 5 8 2 2 ( 8 8 1 (17:9%) (37:0%) 132 38 ( ) 2 1 424 87 (51:2%) (39-7%) 8 4 2 4 ( (5-4%) 5 4 \u00b7 \u00b7 482 178 (59-4%) (817%) 2 ( ) 378 85 8 8 3 (70-0%) 208 114 ( ) 1 1 8 0 2 (76-8%) ( 81 218 (10-0%) (100%) 1 2 1 8 ( 488 (60-2%) (00%) ( 242 (29-8%) (0-0%) ( 2 4 2 431 (79-8%) 1 (00%) 171 (63.1%) (00%) ( ( 1 7 1 345 110 (92-0%) 1 1 ( 5 )"
    },
    {
        "id": "doc_2795",
        "document": "South Africa h t u o S Cases with apositive h t i w s e s a C s l X-ray. 435 y a r - x 5 3 4 219 (50-3%) 9 1 2 ( 111 (255%) 78 1 1 1 ) ( 8 7 (17:9%) 27 ) ( 7 2 222 (51.0%) 2 2 2 ) ( ) \u00b7 \u00b7 \u00b7 \u00b7 166 (40-7%) 6 1 ) ( 189 1 (60-2%) 75 5 7 (79-8%) ) 74 (18-1%) 4 7 252 (61-8%) 2 5 2 82 (201%) 2 8 ) ( 217 (691%) 7 1 2 55 (58:5%) 5 5 106 (841%) 1 )"
    },
    {
        "id": "doc_2796",
        "document": "a i b m a Caseswitha Controls. o r t n o C a h t i w s e s a 601 y a r - 1 0 6 8 0 110 286 (47-6%) 6 8 2 0 1 1 ) 49 150 (25:0%) 37 108 0 5 1 9 4 ( 8 0 1 7 3 (18-0%) 12 57 7 5 2 1 91 300 (49-9%) 0 0 3 1 9 ( (115%) 9 6 \u00b7 \u00b7 ( (0-8%) 5 1 ) ) 98 389 (64.9%) ( 113 368 3 3 1 1 (848%) 40 152 2 5 1 0 4 (92:1%) ( ) 584 (97:2%) 5 9 9 ( 17 (2:8%) 7 1 7 (0-0%) 0 ( 0 15 5 1 6 (3-4%) (00%) ) ( 0 ( 0 42 188 (855%) 8 1 2 4 )"
    },
    {
        "id": "doc_2797",
        "document": "Zambia Z positive C s l o r t X-ray. 208 x 2 (52:9%) ( ) (236%) ) (17:8%) 438%) ) (0-5%) ( (50-8%) ) (74-8%) (95-2%) ( 199 (96:6%) 1 (3-4%) ( ) (0-0%) ( ) (3-8%) (0:0%) ( ) (77-8%) )"
    },
    {
        "id": "doc_2798",
        "document": "Kenya Cases with Controls. apositive n o C h t i w s e s a x-ray 282 863 y a r - 3 8 2 8 2 90 234 (31:9%) (27:1%) 4 3 2 0 9 ( 66 190 (23-4%) (22:0%) 79 247 0 9 1 6 6 ( ) 7 4 2 9 7 (28-0%) (28-6%) 47 192 ( ) 2 1 7 4 130 410 (46-1%) (47-6%) 0 1 4 0 3 1 ( (24-4%) 15 1 1 2 \u00b7 \u00b7 ( (3:2%) (1-8%) 5 1 9 ( ) 212 712 (763%) (84-4%) 2 1 7 2 1 2 ( 133 387 3 3 3 1 (85-8%) (91:5%) 117 405 ( 5 0 4 7 1 1 (95-1%) (96-2%) ( ) 14 34 (50%) (40%) 4 3 4 1 ( 87 236 (311%) (27:9%) 2 ( 8 )"
    },
    {
        "id": "doc_2799",
        "document": "179 575 (63-9%) (68-0%) 5 7 5 ( 9 7 1 136 392 (87:2%) 2 1 (927%) 93 330 (750%) (782%) ( 0 3 ( 3 9 131 458 (90-3%) (92-0%) ( 1 1 )"
    },
    {
        "id": "doc_2800",
        "document": "K Controls. C s l o r t n o 725 x 5 2 247 (341%) 7 4 ( ) 188 (25:9%) 165 8 8 ( ) 5 (22:8%) 125 ( 5 366 (505%) ( (41-2%) 8 9 9 ) (11%) ( ) 521 (71:9%) 1 ( ) 346 (79:5%) 278 ( 8 (95:9%) ( ) 212 (29:3%) 2 1 ( ) 146 (202%) ( 365 (505%) ( 5 332 (76:5%) 2 134 (46-4%) ( ( 326 (881%) ("
    },
    {
        "id": "doc_2801",
        "document": "The Gambia G e h T Caseswith apositive s e s a C x-ray Total 286 y a r - x 6 8 2 l a Age, months 28days-5 106 (37-1%) s m , 6 0 1 ( 6-11 71 (24-8%) 12-23 70 1 7 1 1 \u2013 6 ( 0 7 3 2 \u2013 2 (24-5%) 24-59 39 ( 9 9 Girls 108 (37-8%) 8 1 s l r i x G ( tract only) Pos e malari smear\u2019 \u00b7 \u00b7 s s e n l l i t y r o t a r i p (1:2%) 3 * r a e m s a i r a l a m v i t i s ( 165 (60-2%) Fully vaccinated for 5 3 \u2265 ( r o f d e t a n i c c a v aget 96 Age <1 year 9 r a e y 1 < (56:1%) 97 Age = 1year ( 7 9"
    },
    {
        "id": "doc_2802",
        "document": "(94-2%) PCv ( V Number of doses (regardless of age) 0 48 (17:5%) f o s e s o d r e b m u N ( 1-2 63 (23:0%) 3 6 ( 2 \u2013 1 =3 163 (59-5%) 3 1 ( 3 \u2265 Fully vaccinated for agef Age <1 year 95 (55-6%) 5 9 r o f d e t a n i c c a v r a e y 1 < Age 21 year 94 (91:3%) ( 9 ( r a e y 1 \u2265 vaccination for measles\u00a7 119 (91-5%) 9 1 ( r o f n o i t a n i c c a v l"
    },
    {
        "id": "doc_2803",
        "document": "Thailand\n\nSouth Africa\n\nZambia\n\nMali\n\nThe Gambia\n\n(88:1%) (90-9%) (95-0%) (Table continues on next page)\n\n(\n\n(92:0%) (80-9%)\n\n(\n\n)\n\n(841%)\n\n(\n\n)\n\n(855%)\n\n(\n\n)\n\n(77-8%)\n\n(\n\n)\n\n(92:0%)\n\n%\n\n0\n\n2\n\n9\n\n(\n\n)\n\n(90-3%)\n\n%\n\n3\n\n0\n\n9\n\n(\n\n(881%)\n\n(\n\n)\n\n(78:0%)\n\n(\n\n)\n\n(89:9%)\n\n(\n\n)\n\n(91-5%)\n\n%\n\n5\n\n1\n\n9\n\n(\n\n766\n\nwww.thelancet.com Vol 394 August 31, 2019"
    },
    {
        "id": "doc_2804",
        "document": "Controls. C (00%) 0 ) ( 5 (08%) ( 41 (62%) 1 4 ( 613 (93-0%) 3 6 ) ( 5 (08%) ( \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 on next page) p t x e n n"
    },
    {
        "id": "doc_2805",
        "document": "Thailand d n a l i a h T Cases with apositive x-ray h t i w s e s a C y a r - x 2 (2:5%) ( 18 (18-4%) 8 1 ) ( 16 (16:3%) 6 1 ) ( 64 (65:3%) 6 ( 30 (306%) 0 3 ( 3 (2-4) ( 20 0 2 (20-4%) 38 ( 3 (38:8%) ( 74 (80-4%) 4 7 ( 28 (28:6%) 8 2 ( 36 (36 7%) 3 \u00b7 ( 55 56-1%) 5 5 ( 22 (24:2%) 2 2 ( 48 (49:5%) ( 42 (42-9%) 56 2 4 ) ( 5 (57:1%) ( 37 (37-8%) 42 7 3 ( 2 4 (42:9%) 19 (19-4%) ( 9 1 ) ( 3 continues o s e u n i t n o c"
    },
    {
        "id": "doc_2806",
        "document": "with Controls s l o r t n o C h t i w s e y (0-2%) 1 ( 43 (5:6%) 3 4 ( 138 (17:9%) 8 1 ( ) 591 (76-6%) 1 9 5 ( 10 (1-4%) 0 1 ( \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 ) \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 (Table ("
    },
    {
        "id": "doc_2807",
        "document": "Bangladesh Cases apositive x-ray s a C a a r - x 3 (1-8%) ( 31 (14-2%) 1 3 ( 70 (32:0%) 0 7 ( 118 (53-9%) 8 1 1 ( 52 (24-6%) 2 5 ( 3 (2-5) ( 27 7 2 (123%) 213 ( 3 1 2 (97-3%) ( 210 (95:9%) 0 1 2 ( 22 (10-0%) 2 2 ( 12 (55%) 2 1 ( 38 3 (17-4%) 26 (129%) ( 6 2 ( 123 (60-0%) 3 2 1 ( 58 (26:5%) 161 8 5 ( 1 6 1 (73:5%) ( 90 (427%) 119 0 9 ( 9 1 1 (56-4%) 2 (1:0%) ( ( s l o r t ) \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7"
    },
    {
        "id": "doc_2808",
        "document": "South Africa a c i r f A h t u o S Cases with Controls apositive x-ray n o C h t i w s e s a C y a r - x 9 7 (4-6%) (1:5%) ( ( 81 20 (18-8%) (2:4%) 0 2 ( 1 8 ( 71 31 (16:5%) (38%) 1 3 1 7 ( ( 278 770 (647%) (93-8%) 0 7 7 2 ( ( 249 8 (57-2%) (1:0%) 9 4 2 ( ( 3 (2-5) ) ( 153 3 5 1 (352%) 122 ( 2 2 1 (290%) ( 331 (78:3%) 1 3 3 ( 329 (75:8%) 9 2 3 ( 392 (901%) 2 9 3 ( 42 2 4 (97%) 134 (31:4%) ( 4 3 1 ( 194 (44-7%) 4 9 1 ) ( 250 (57-5%) 185 0 5 2 ( 1 (425%) ( 154 (851%) 19 4 5 1 ( 9 1"
    },
    {
        "id": "doc_2809",
        "document": "(105%) 8 (4-4%) ( ) ("
    },
    {
        "id": "doc_2810",
        "document": "Controls s l o r t n o 9 28 8 2 47 7 4 525 5 2 21 1 2 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 a i b m C a h t i w s e s y a (2:9%) ( 0 (47%) ( 5 (7:8%) 1 ( (87:5%) 5 2 ( ) (3:6%) ( ) 3 0 2 8 7 2 2 1 7 5 ) 3 4 3 3"
    },
    {
        "id": "doc_2811",
        "document": "Zambia a Z Caseswitha positive x-ray a C r - x s l o r t 8 10 (10:3%) 1 ( ) 35 (16-8%) 3 ( 31 (14-9%) 3 ( ) 142 (683%) 4 1 ( 189 (92:2%) 1 1 ( (2-6) \u00b7 \u00b7 ( 70 7 \u00b7 \u00b7 (337%) 22 ( 2 \u00b7 \u00b7 (10-6%) ( 188 (908%) 8 1 \u00b7 \u00b7 ( 97 (46:6%) 9 \u00b7 \u00b7 ( 122 (587%) 2 1 \u00b7 \u00b7 ( 122 (58:9%) 2 1 \u00b7 \u00b7 91 (48-4%) ( 9 \u00b7 \u00b7 ( 97 (47-8%) 9 \u00b7 \u00b7 ( 135 (64-9%) 73 3 1 \u00b7 \u00b7 ( 7 \u00b7 \u00b7 (351%) ( 104 (52:0%) 83 0 1 \u00b7 \u00b7 ( 8 \u00b7 \u00b7 (41:5%) 13 (6:5%) ( 1 \u00b7 \u00b7 ("
    },
    {
        "id": "doc_2812",
        "document": "with Controls n o C h t i w s e s a y a r - 24 (13%) ( 4 2 68 38 (4-4%) 8 3 ( 8 6 ) 65 109 (12:7%) 9 0 1 5 6 ( ) 710 (82:8%) 0 1 7 ( ) 99 21 (26%) 2 9 9 ( 3 4 1 41 1 4 4 2 6 0 75 5 7 8 78 ) 8 7 5 4 9 1 ) 3 82 0 8 2 8 19 9 1"
    },
    {
        "id": "doc_2813",
        "document": "Kenya K Cases apositive x-ray C a x s l o r t n (12:6%) ( 1 (24-4%) ( 7 ) (23:3%) 6 ( 146 (52:3%) 1 8 ( (35:1%) 9 ( (2-4) \u00b7 \u00b7 ( 114 1 \u00b7 \u00b7 (40-4%) ( \u00b7 \u00b7 (14-6%) ( 224 (79-4%) 2 \u00b7 \u00b7 ( 106 (37:7%) 1 \u00b7 \u00b7 ( (26-6%) \u00b7 \u00b7 ( 128 1 \u00b7 \u00b7 (45-4%) (35:9%) ( \u00b7 \u00b7 ( 145 (52:0%) 1 \u00b7 \u00b7 ( 119 (42:2%) 163 1 \u00b7 \u00b7 ( 1 \u00b7 \u00b7 (57-8%) ( 180 (64-1%) 1 \u00b7 \u00b7 ( \u00b7 \u00b7 (29-2%) (6-8%) ( \u00b7 \u00b7 ("
    },
    {
        "id": "doc_2814",
        "document": "Mali i l a M Cases with Controls apositive x-ray o C h t i w s e s a C a y a r - x 36 (25:2%) (0-2%) ( 3 ) ( 71 27 (29-5%) (37%) 2 ( 1 7 ( 44 66 (183%) (9-2%) 6 4 4 ( ( 126 628 (52:3%) (87-1%) 2 6 6 2 1 ( ) ( 54 19 (22:-4%) (26%) 1 4 5 ( ) ( 5 (37) ) ( 96 9 (39-8%) 35 ( 5 3 (14:5%) ( 205 (851%) 5 0 2 ( 133 (55:2%) 3 3 1 ) ( \u00b7 \u00b7 89 (36:9%) 8 89 (43.0%) ( 9 8 ( 86 (35-8%) 8 ( 136 (56-4%) 105 1 ( 5 0 1 (43:6%) ( 87 (36:6%) 73 8 ( 3 7 (30.7%) 78 (32:8%) ( 8 ("
    },
    {
        "id": "doc_2815",
        "document": "The Gambia a i b m a G e h T Caseswith Controls apositive X-ray s l o r t n o C h t i w s e s a y a r - 9 3 (5:0%) (0-7%) ( 34 35 (11:9%) (5-4%) 5 3 ( 4 3 64 83 (22-4%) (12-8%) 3 8 6 ( 188 531 (657%) (81-8%) 1 3 5 8 8 1 ( 30 1 (106%) (0-2%) 0 3 ( 3 (2-4) \u00b7 \u00b7 39 \u00b7 \u00b7 9 3 (136%) 84 \u00b7 \u00b7 8 (29-6%) 260 (90-9%) \u00b7 \u00b7 0 6 2 33 (115%) \u00b7 \u00b7 3 3 34 (119%) \u00b7 \u00b7 4 3 117 \u00b7 \u00b7 7 1 1 (40-9%) 86 (48-9%) ) \u00b7 \u00b7 6 8 100 (49-8%) \u00b7 \u00b7 0 0 1 101 (35:3%) 185 \u00b7 \u00b7 1 0 1 \u00b7 \u00b7 1 (64-7%) 101 (39:5%) 119 \u00b7 \u00b7 1 0 1 \u00b7 \u00b7 9 1 1"
    },
    {
        "id": "doc_2816",
        "document": "(46:5%) 36 (14-1%) \u00b7 \u00b7 )"
    },
    {
        "id": "doc_2817",
        "document": "C a x (Continued from previous page) Mid-upper am circumference <115m Z ( p m f e c n e r e f m u c r i c e r o c s Weight-for-age score Severe (<-3) ( ( e r e v e Moderate (= -3 to <-2) < o t 3 \u2013 ( e t a r e d o M ( Normal (= -2) ) ( l a m r o N ( Previous exposure to antibiotics| | e s u o i v ( Median duration of ess (days) ( s s e n l l i f o n o i t a r u d n a i d ( Very severe pneumonia p e r e v e s Wheeze on auscultation ( n o i t a t l u c s u a n o e z e e ( Tachypnoea ( Hypoxaemia ("
    },
    {
        "id": "doc_2818",
        "document": "Oxygen use at admission** * * n o i s s i m d a t a e s u ( Temperature 238-0 \u00b0C C \u00b0 \u2265 CRP 240 mg/L ( 0 4 \u2265 P ( Elevated WBC count t n u o c C B W d e t a v ( Chestx-ray findings Consoll ation Other infiltrate n o i t a d i l o s n o ( e t a r t l fi n i r e h t O Blood culture volume, mLt+ ( \u2020 \u2020 L m , e r u t l u c d o 1to<2 2to<3 2 < o t ( 3 < o t >3 ( 3 ("
    },
    {
        "id": "doc_2819",
        "document": "www.thelancet.com Vol 394 August 31, 2019\n\n767"
    },
    {
        "id": "doc_2820",
        "document": "Controls s l o r t n o C h t i \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 versus controls. . s l o r t n o c s u s r e v y in breaths per min n i a i b m a Z d e c u South Africa), a standard clinical , h t u o l a c i n i l c d r a d n a t s d and greater r g d n a s h t n at least one dose three or more e s o d e n o t s a e l t a e r o m r o e t 4-week window for was r o f w o d n i w vaccination restricted to those n o i t a n i c e"
    },
    {
        "id": "doc_2821",
        "document": "administered at the recorded in the and were coded as $\u00a7Restricted to e h t t a e h t n i d e d r o c e r s s a d e d o c \u2021 A~ N \u2014~ O"
    },
    {
        "id": "doc_2822",
        "document": "Thailand T Caseswith apositive X-ray w s e s a C s l o r t y a r - x 5 (51%) \u00b7 \u00b7 ( 2 (2:0%) \u00b7 \u00b7 ( 3 \u00b7 \u00b7 (3:2%) 1 ) ( \u00b7 \u00b7 (1:0%) with a positive x-ray ) ( a r - x p h t i PCV wat as 60 or more d o r t n i s P ; ) e r o m 6 m: Zambia and above sea level, had S d n a a i b m a Z : a h , l a e s e v o b a aged 1-11 months o m 1 1 \u2013 1 n e r having received as having received d e v i e c e r s s a (allowing a 4 g n i ( e l campaign), full introduction. \u00a7Data c a v l l f , r a \u00a7 . n"
    },
    {
        "id": "doc_2823",
        "document": "antibiotics collected. **Data was had hypoxaemia South Africa).\u201d a , a w a t a D * * . d e t c e l l d a h h t u o S i % =< O"
    },
    {
        "id": "doc_2824",
        "document": "Bangladesh Cases with Controls apositive x-ray n o C h t i w s e s a C e v i t i s o p a y a r - x 2 (0:9%) ( 0 (00%) ) ( 2 (0:9%) 3 ) ( (1-4%) and site for cases ) ( w e t i s (April, 2009); Tachypnoea was defined 2 , l i ( a c i r f A h t elevation above 1200 altitude of 1600 m 0 0 2 1 e v o b a n o i t a v e 0 1 o e d u t i t l a cells per L for children d l i h c r o f r e p s l l e c 9 nwas defined as vaccination was defined a d e n fi e d s a w n o i t a d s a w n o i t a n i c"
    },
    {
        "id": "doc_2825",
        "document": "and country schedule PCV u d e h c s c d n a with catch-up any dose or at h t i w P i t a r o e d y n a (cases and controls), or controls) oxygen if they Gambi and 59-1% ( o c c r o n e g y x o d e v i e c 1 \u00b7 9 5 d n a , a i b m a G e \u2014+ W W B wn"
    },
    {
        "id": "doc_2826",
        "document": "a Controls s l o r t n o C \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 age category) c e g a t 2011), longest. u o S d n a , ) 2 s for sites at site, at an l e t a s e t i s r o f % n a t a , e t i s n than 15 x 10\u00b0 0 1 5 1 n a h t r full vaccinati or older, full n i c c a v l c a v l l u , r o r o doses received, , d e v i e c e r s e s o d introduced than 2 years at d e c u d o r t n i t a n t"
    },
    {
        "id": "doc_2827",
        "document": "positive whole blood (cases all cf ren received Mali, 7-0% The e ( d o o l b e l o h w r e r n e r d l i h , h T n i % 0 \u00b7 7 , i l a M (=2}"
    },
    {
        "id": "doc_2828",
        "document": "South Africa h S Cases with apositive X-ray h t i w s e s a C y a r - x 18 (41%) 8 1 ( 16 (37%) 6 1 ( 2 (0:5%) 48 ) ( 8 (11.0%) variables expect ) ( e s e l b a i r a v l l (March, whicheverwas , ( i l a M , ) w 92% (or <90% the South African 0 9 < ( % 2 9 n a A h t u o S e h t ; defined as greater g s a d e n fi e d younger than 1year, aged 1 year n at enrolment, , t n e m l o r n e t a e in Kenya (which child was older ( n i r o s l i h"
    },
    {
        "id": "doc_2829",
        "document": "as serum bioassay (cases only) or | care, of Zambia and m u r e s s d e n o o ( e e r a c a c i n i l c d n a a i b m a Z i \u2014_"
    },
    {
        "id": "doc_2830",
        "document": "Controls s l o r t n o C a h t \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 \u00b7 age in months (all ( s h t n o m i e g a (August, 2009), difficulty breathing, 2 , r saturation lower than (88-3%) children; h t r e w o l n o i t a r u t a s c ( 4 (WBC) count was s c ) ( l l ). tFor children dose); for children r o F \u2020 ) a i b c ; h of the child's age older g a s \u2019 d l i h c e h t f o s i s than 1year and one dose if the 1 n a h t n e r d l e f i e d e n o"
    },
    {
        "id": "doc_2831",
        "document": "or older.[|Defined with blood culture a concurrent project 1-8% fi e D | | . r e d l o s h t n r u t l u c d o o l b h t i w n % 8 \u00b7 1 , K n i % 2 \u00b7 Kenya, each PERCH e t i s H C R E P e [t"
    },
    {
        "id": "doc_2832",
        "document": "Zambia a Caseswitha positive X-ray i w s e s a C y a r - x 25 (12:0%) 5 2 ( 23 (11-1%) 3 2 ) ( 1 (1:0%) 82 ( 2 8 (39-4%) models adjusted for ) ( a 2011), Gambia wheeze, fever, or G e h T , ) 2 o , r , e defined as oxygen available for 3514 n e g y x o s a d e n 3 r f e l b a l i a v white blood cell e c d o o l b e t i h w Mali, and Zam| window for each d n a , i l a M e r w w age on the bat a b e h t n o e g a doses; for children at first dose, i h c r f ; s e s o d , e d t t"
    },
    {
        "id": "doc_2833",
        "document": "children aged 6 months restricted to children evidence from and Th ind, 0-2% o m a e r d l i h c t d e t c m o r f e 0 , d n a l i a h T d n controls for r s l o r t n o c I [t"
    },
    {
        "id": "doc_2834",
        "document": "Kenya a Controls Cases with ~ Controls apositive x-ray t n o C h t i w s e s a C s l o r t n y a r - x 17 (6-0%) \u00b7 7 1 \u00b7 \u00b7 17 (6-0%) \u00b7 7 1 \u00b7 \u00b7 0 \u00b7 \u00b7 \u00b7 (0-0%) 2 ) ( \u00b7 \u00b7 \u00b7 (0-7%) obtained from logistic regression ) ( n o i s s e r g e r l m d e n i a t b o Kenya February, defined as duration (in days) of cough, d e c u d o r t n i ( i e s u e n f o ( n d s (12-59 months). Hypoxaemiawas room air oxygen saturation reading . n o i t a r u t a s n e g y x o r i a m o"
    },
    {
        "id": "doc_2835",
        "document": "diagnosis of severe pneumonia. Elevated a v e l E e r e v e s f o to endemic sites (Kenya, The Gambia, and country schedule (allowing a 4-week G e h T ( s c i m e d n e o t d ( e s c least one dose and be g up to date as a d o t p u n i e d n a e s o d e n o t s a e defined having received three or apart and the child was older than 1 year of m r o e e r h t d e v i e c e r o r n r o s a w c"
    },
    {
        "id": "doc_2836",
        "document": "months in Bangladesh). fiRestricted to specimens at the study fa y (cases only); other sites; The Gambia, on the basis culture volume data (0-0% Bangladesh o t d \u00b6 . n i s h ; ( t i l i c a f s a b e h t n o G e h T n i ; s e t i s r i ( a t a d e m u l o v e r u admission. x-ray and without HIV infection n o i t c e f n i V I H d n a D"
    },
    {
        "id": "doc_2837",
        "document": "The Gambia Mali M a G e T Controls Cases apositive x-ray s a C s l o r t n o C o p a a r - x 31 (12:9%) 1 3 \u00b7 \u00b7 25 (10-4%) 5 2 \u00b7 \u00b7 6 \u00b7 \u00b7 (2:9%) 8 ( \u00b7 \u00b7 (3:3%) with a positive chest ( t s e h c e v i t i s o p h t i w conjugate (PCV) enrolment. Duration of ( n i c c a v o n o i t a r u D . and 40 or more breaths reading was not e r b e r o m r o 0 4 d n a , t o n s a w n o i t a admitted to hospital o t d e t t i m d a n e r d"
    },
    {
        "id": "doc_2838",
        "document": "CRP=C-reacti protein. at enrolment, doses e v i t c a e r - C = P R C . s d , e t a e g a was defined as having d e n fi e d s a w n Kenya, full vaccination if given at least 8 weeks i c c a v l l f , K t l t a n e v i g f i older than 10 months collection of whole blood at admission, aswas done collected h t n o m 0 1 n a h t r e d l o o l b e w o n o i t c e l l o c d s a , n o i s s i m d a s s i e r e w d e t c e l l o c e r 21 days or longer of cases with a positive r o 1 2 f o N R \u2014"
    },
    {
        "id": "doc_2839",
        "document": "Cases with apositive X-ray h t i w s e s a C y a r - x (Continued from previous page) Died in hospital or within 30 days of 16 admission (56%) ) s u o i v e r p m ( 6 1 f o r o n i d e i ( n o i s s i m d a Died in hospital 12 (42%) 2 1 i d e i D ) ( Died post-discharge, within 30 4 0 3 n i h t i w , d e i D days of admission+ (1:5%) Mi g 30-day vital status 2 ( \u2021 a f o s u t a t s l a t i n i s s i"
    },
    {
        "id": "doc_2840",
        "document": "(07%) Dataare n (%) or median (IQR). Positive cases are those ) ( e s o h t s e s a c e v i t i s o P . ( n a i d e m ( e r a a t a D During study, pneumococcal July, 2013 (Lusaka), 3 months before the end of study c p e h t g D . a c i r f A h t u o S n i d e s u f o d e e t e b , 3 1 0 2 ,"
    },
    {
        "id": "doc_2841",
        "document": "(<2 months), 50 or more breaths per min (2-11 months), or supplemental oxygen use if a room air oxygen saturation ( n i m r e p s h t a e r b e r o m r o 0 5 , r u t a s n e g y x o r i a m o o r a i e s u n e g y x o r o practice to administer supplemental oxygen for all children l i h c l l a r o f n e g y x o l r e t s i n i m d a"
    },
    {
        "id": "doc_2842",
        "document": "than 13x10\u00b0cells per L for children aged 12-59 months. and being to date for on the basis of the child\u2019s h t n o m 9 5 \u2013 2 1 a r o f r s l l e c 9 0 1 \u00d7 3 1 n a h s c e t o b e t n o e g a r e d o t p u d up age age doses. For chi ren younger than 1year, full vaccination or o i t a n i c c a v l l u f , 1 n e r d l i h c r o F \u2021 . s e s o d"
    },
    {
        "id": "doc_2843",
        "document": "each dose); for children aged 1year older inall sites except defined as having received three or more doses, two doses e s e t i s l l a n i r e d l o r 1 n e r d l i h c r f ; h c a e d o w t , s d e r o m r o e d d"
    },
    {
        "id": "doc_2844",
        "document": "age-eligible; at least one dose was restricted to children referral facility, or antibiotic administration before the Mal ite on the basis of time at presentation, not time such for this study. 1713.7% of with blood culture n e r d l i h c o t d e t c i r t s e r s e s o d e n o t s a e l t a ; e h t e n a c i t o i b i t n a r o , y t i l i c a f l e m i t t o n , n p t a e f o s i s a b e h t n o e t i s i l a M u t l u c d o o l b t i w s e s a c f o \u2020 . s i h t r o f h c u"
    },
    {
        "id": "doc_2845",
        "document": "children discharged alive who had vital status data obtained Table Demographic and clinical characteristics o a d s u t a t s l d o e v i l n c s c i t s i r e t c a r a h c d n a c i : 3 e l b a T f=d (=3} (v} - \u2014 \u2014 \u2014_ a"
    },
    {
        "id": "doc_2846",
        "document": "Some pathogens differed in their aetiological fraction by age strata. B pertussis, parainfluenza type 3, S aureus, P jirovecii, and RSV had a greater aetiological fraction in children younger than 1 year than in those aged 1 year or older, whereas parechovirus\u2013enterovirus, parainfluenza type 1, rhinovirus, and S pneumoniae were more common causes in children aged 1 year or older than in those younger than 1 year (figure 4B; appendix). We found seven pathogens in the top ten pathogens of both age"
    },
    {
        "id": "doc_2847",
        "document": "strata (RSV, rhinovirus, HMPV, parainfluenza, S pneumoniae, M tuberculosis, and H influenzae). The aetiological distribution by finer age strata is provided in the appendix. We observed differences in aetiological fraction by pneumonia severity for RSV, S aureus, S pneumoniae, parainfluenza type 3, and all viral causes combined (figure 4C, appendix)."
    },
    {
        "id": "doc_2848",
        "document": "In analyses of all cases regardless of chest xray findings compared with cases with a positive xray, a greater aetiological fraction was attributed to rhinovirus (11\u00b74% in all cases vs 7\u00b75% in cases with a positive xray), parechovirus\u2013enterovirus (4\u00b76% vs 1\u00b76%) and nonfermenting Gramnegative bacteria (2\u00b78% vs 0\u00b79%) in all cases, but otherwise, the analyses did not differ substantively (appendix). Aetiology by chest xray find ings will be reported in a separate manuscript."
    },
    {
        "id": "doc_2849",
        "document": "The sitespecific aetiology results standardised for age and severity of the ten focus pathogens showed consistency across the sites for most pathogens (figure 5, appendix), including for influenza, which did not exceed 3% in any site except Zambia (6\u00b71%). Exceptions to this consistency included the following: rhinovirus was sub stantially more common in Bangladesh (29\u00b77%) and Kenya (12\u00b79%); H influenzae was extremely uncommon in Bangladesh (0\u00b77%); H influenzae type b in Zambia (3\u00b74%) and Mali"
    },
    {
        "id": "doc_2850",
        "document": "(4\u00b72%) and nontype b H influenzae in South Africa (10\u00b70%) were dispro portionately higher than in other sites; and S pneumoniae, both vaccinetypes and nonvaccinetypes, was higher in The Gambia (15\u00b71%) and Mali (17\u00b74%) than in other sites. The fraction of cases attributed to bacteria was lower in Bangladesh (10\u00b74%) and Kenya (17\u00b75%) than in other sites (range 32\u00b77\u201337\u00b76). M tuberculosis had a larger aetiological fraction in Zambia, The Gambia, Thailand, and South Africa (6\u00b74\u201310\u00b72) than in other"
    },
    {
        "id": "doc_2851",
        "document": "sites (<3%). The NOS contribution was 2% or less in all sites except Thailand (7\u00b74%). The results stan dardised for age and severity (appendix) did not differ from the primary, non standardised, sitespecific results (ie, based on the mix of cases enrolled at each site)."
    },
    {
        "id": "doc_2852",
        "document": "The cumulative aetiological fraction of the standardised and sitespecific ten most common pathogens accounted for between 79\u00b70% and 90\u00b70% of the aetiological fraction at every site (figure 6). By contrast, the cumulative aetiological fraction of the ten focus pathogens ranged by site from 55\u00b71% to 86\u00b76%, reflecting heterogeneity across the sites in the rank order of each pathogen (appendix). The distribution of the individual case aetiological probability\n\n768"
    },
    {
        "id": "doc_2853",
        "document": "www.thelancet.com Vol 394 August 31, 2019\n\nArticles"
    },
    {
        "id": "doc_2854",
        "document": "6 Streptococcus pneumoniae PCV13 serotype S pneumoniae non-PCV13 serotype 5 14 12 Haemophilus influenzae type b H influenzae non-type b Staphylococcus aureus Salmonella spp ) % ( s n e 4 8 Neisseria meningitidis Enterobacteriaceae Moraxella catarrhalis m i c e p s e r 3 56 9 Candida spp Other streptococci and enterococci Mixed u t l u c d o 9 2 o l B 2 2 1 0 All The Gambia Mali Kenya Zambia South Africa Bangladesh Thailand (n=1749) (n=279) (n=241) (n=282) (n=205) (n=433) (n=211) (n=98)"
    },
    {
        "id": "doc_2855",
        "document": "Figure 2: Blood culture results by study site in cases with positive chest x-ray and without HIV infection"
    },
    {
        "id": "doc_2856",
        "document": "Enterobacteriaceae includes Escherichia coli, Enterobacter spp, and Klebsiella spp, excluding mixed Gram-negative rods. Other streptopcocci and enterococci include Streptococcus pyogenes and Enterococcus faecium. Mixed label includes Salmonella spp and other streptopcocci and enterococci. Contaminants, including those organisms deemed to be contaminants after clinical review, were excluded from the analysis. Figure is restricted to cases with available blood culture results. The numbers on the"
    },
    {
        "id": "doc_2857",
        "document": "top of the bars refer to the total number of positive blood cultures. Two of the cases positive for pneumococcus in Kenya were pneumococcal conjugate vaccine (PCV) 13-type but not PCV10-type (serotypes 19A and 6A). Antibiotic pretreatment (defined as having a positive serum bioassay result, antibiotics administered at the referral facility, or antibiotic administration before whole-blood specimen collection at the study facility) varied by site: The Gambia (composite 10\u00b76%, bioassay 7\u00b76%), Mali"
    },
    {
        "id": "doc_2858",
        "document": "(22\u00b74%, 17\u00b71%), Kenya (35\u00b71%, 10\u00b70%), Zambia (92\u00b72%, 25\u00b73%), South Africa (57\u00b72%, 54\u00b72%), Bangladesh (24\u00b76%, 21\u00b76%), and Thailand (30\u00b76%, 19\u00b74%)."
    },
    {
        "id": "doc_2859",
        "document": "for each pathogen, for the casespecific leading pathogen, and for any virus by site are provided in the appendix."
    },
    {
        "id": "doc_2860",
        "document": "Sensitivity analyses were done to assess the effect of the assumptions of PIA model sensitivity and aetiology priors on the aetiology findings. Lowering and narrowing the pneumococcal blood culture sensitivity prior, or increasing its aetiology prior, had little effect on the S pneumoniae aetiology estimate, probably because of the strength of evidence regarding S pneumoniae from the other measurements (NPOP PCR and whole blood PCR; appendix). Increasing the aetiology prior of NOS from 3% (base"
    },
    {
        "id": "doc_2861",
        "document": "case) to 25% resulted in an increase in the NOS aetiology estimate from lower than 8% at all sites to 8\u201325% across sites (appendix)."
    },
    {
        "id": "doc_2862",
        "document": "Discussion"
    },
    {
        "id": "doc_2863",
        "document": "The principal finding of the PERCH study was that, in lowincome and lowmiddleincome settings with wide spread uptake of Hib vaccine and PCV, viruses, especially RSV, were the predominant cause of pneu monia requiring hospital admission in children younger than 5 years at all sites, but bacteria continued to cause from a quarter to a third of all cases. In each site, a small number of pathogens accounted for most cases admitted to hospital with radiographically confirmed pneumonia; the ten most"
    },
    {
        "id": "doc_2864",
        "document": "common pathogens at a given site accounted for 79% or more of cases of disease at that site. Furthermore, most cases at every site were caused by a handful of pathogens that were commonly found in all sites. Nonetheless, the relative contribution of these"
    },
    {
        "id": "doc_2865",
        "document": "pathogens varied by age and, to a lesser degree, by severity of the disease."
    },
    {
        "id": "doc_2866",
        "document": "Approximately half of children admitted to hospital defined by WHO as having severe or very severe pneumonia had an infiltrate on chest xrays, and among these cases, clinical characteristics varied substantially across all sites, including case severity at presentation, presence of wheeze, and casefatality ratios. Nevertheless, we found little variability in the pathogens commonly detected from body fluid specimens of cases across study sites, except for the low recovery of bacteria from blood"
    },
    {
        "id": "doc_2867",
        "document": "specimens in the Asian sites, or the pathogens accounting for the majority of aetiology distribution."
    },
    {
        "id": "doc_2868",
        "document": "RSV was the dominant pathogen in all sites, accounting for 31\u00b71% of the aetiology distribution, more than three times greater than the next leading pathogen. RSV was notable not only for its frequent detection in the NPOP of cases with a positive chest xray, but also for its uncommon detection in controls, making it one of a few pathogens (including parainfluenza 1 and HMPV) for which detection had high predictive value for aetiological attribution. RSV was a common pathogen across age strata"
    },
    {
        "id": "doc_2869",
        "document": "and pneumonia severities, although the aetiological fraction was notably higher in infants than in older children. The predominance of RSV emphasises its importance as a prevention and therapeutic target. In the past decade, pneumonia aetiology studies29,38 in the USA and South Africa and the GABRIEL multisite study39 also identified RSV as an important target."
    },
    {
        "id": "doc_2870",
        "document": "www.thelancet.com Vol 394 August 31, 2019\n\n769\n\nArticles"
    },
    {
        "id": "doc_2871",
        "document": "Culture PCR Culture, PCR, or both Lung aspirate Cases with available results (n) 37 25 37 Any positive\u2122 (13-5%) (36:0%) 11 (29\u00b77%) Streptococcus pneumoniaet (13-5%) 24-0%) 21-6%) Haemophilus influenzae non-b# 1 (2\u00b77%) 16-0%) 10-8%) Chlamydophila pneumoniae 0 (4-0%) 2:7%) Moraxella catarrhalis 0 16-0%) 10-8%) Human metapneumovirus NA (4-0%: ; 2:7%) ii E Adenovirus NA (4-0%: 2:7%) Combinations S pneumoniae + Hinfluenzae (27%)\u00a7 (4-0%: 2:7%) S pneumoniae + M catarrhalis [ 8-0%; 54% )"
    },
    {
        "id": "doc_2872",
        "document": "Adenovirus + C pneumoniae NA 4:0%, % \u00e9 g 2:7%) % E Hinfluenzae + M catarrhalis +S pneumoniae NA 4:0%, 2:7%) ) Hinfluenzae + M catarrhalis + human metapneumovirus NA 1(4 0%, 1 (2\u00b77%) Negative 32 (86\u00b75%) 16 (64-0%) 26 (70-3%) Pleural fluid Cases with available results (n) 15 12 15 Any positive\u2122 60-0% 7 (58\u00b73%) 80-0%) S S pneumoniae\u2020 67% %E (333%) 333%)1 i E Staphylococcus aureus (46:7% (333%) 46:7%) Escherichia coli 67% 0 6.7%) Streptococcus group F 67% 0 7%, Human bocavirus NA 1 (8\u00b73%) 7%,"
    },
    {
        "id": "doc_2873",
        "document": "Combinations E coli + streptococcus group F 1 (6\u00b77%) NA 6.7%) Saureus + human bocavirus NA 1 (8\u00b73%) 6.7%) % S pneumoniae + S aureus [ [ 6.7%) )1 E Negative 6 (40-0%) (41.7%) 3 (20\u00b70%)"
    },
    {
        "id": "doc_2874",
        "document": "Data are n (%). Results were restricted to specimens obtained within 3 days of enrolment and to those pathogens determined by the clinical review team to be non-contaminants. NA=not applicable. *Total number of cases with a positive culture result; does not equal the number of organisms identified because some cases appear in multiple rows (any positive and in combination). \u2020For S pneumoniae in lung aspirates, PCV13 types were identified in three cases, non-PCV13 types were identified in two"
    },
    {
        "id": "doc_2875",
        "document": "cases, and three cases did not have serotyping available (PCR-positive alone); for S pneumoniae in pleural fluid, PCV13 type was identified in one case and four cases did not have serotyping available (positive result only for PCR test, antigen test, or both). \u2021One case positive for H influenzae by lung aspirate was missing serotyping data for the culture isolate but was negative for H influenzae type b by lung aspirate PCR. \u00a7This case was positive for S pneumoniae and H influenzae by lung"
    },
    {
        "id": "doc_2876",
        "document": "aspirate culture and positive for H influenzae, M catarrhalis, and S pneumoniae by lung aspirate PCR; therefore, it is reported twice in this table. \u00b6Three cases were positive in pleural fluid for S pneumoniae by antigen testing; two of these were also positive for S pneumoniae in culture, PCR, or both, and one was positive only for S pneumoniae in antigen testing."
    },
    {
        "id": "doc_2877",
        "document": "Table 4: Organisms identified by culture and PCR of lung aspirate or pleural fluid specimens in cases with a positive chest x-ray and without HIV infection"
    },
    {
        "id": "doc_2878",
        "document": "The contribution of parainfluenza viruses and HMPV to the aetiological distribution varied little by age strata or disease severity but did vary by site. We recorded a low prevalence (<5%) of influenza A or B in all sites and the aetiological contribution of influenza A or B did not exceed 3% in any site except Zambia (6\u00b71%). Influenza circulation varies annually, and the 2 years of enrolment in the PERCH study might have been low circulation years."
    },
    {
        "id": "doc_2879",
        "document": "Of the tested pathogens, human rhinovirus was associated with the most geographical heterogeneity in"
    },
    {
        "id": "doc_2880",
        "document": "aetiological fraction, ranging from 30% in Bangladesh and 13% in Kenya, to less than 2% in Zambia, The Gambia, and Mali. Human rhinovirus predominance in Kenya was not explained by an overrepresentation of respiratory infection seasons (three compared with two seasons in all other African sites; appendix), on the basis of an analysis of the Kenya data that excluded the third respiratory season (data not shown). Although well described as a cause of upper respiratory tract infection, the role of"
    },
    {
        "id": "doc_2881",
        "document": "human rhinovirus as a cause of pneumonia is uncertain.40\u201342 It is possible that human rhinovirus, as several other respiratory viruses, might be incorrectly attributed as the true cause of pneumonia despite all methodological and analytical efforts to address this. This general limitation extends beyond this study to most casecontrol studies for pneumonia aetiology, leading to an exaggeration of the contribution of viruses to pneumonia when the primary specimen used to assess causality is from"
    },
    {
        "id": "doc_2882",
        "document": "the upper respiratory tract. However, the OR and the significant association with wheeze (data not shown) argues against this."
    },
    {
        "id": "doc_2883",
        "document": "For bacteria that commonly colonise the upper respiratory tract, such as S pneumoniae and H influenzae, the inferential role of NPOP PCR for estimating aetiology in a casecontrol study has inherent uncertainties. To mitigate the risk of underestimating the attributable aetiology of these bacterial pathogens, analyses incor porated pathogen density measures from the NPOP specimens to distinguish cases from controls, adjustment for antibiotic exposure that lowers detection in the NPOP PCR, and"
    },
    {
        "id": "doc_2884",
        "document": "blood PCR for S pneumoniae. Additionally, for these and all bacterial pathogens, we directly sampled from the lung (albeit in few cases), optimised and adjusted for the volume of blood for culture, accounted for the effect of previous antibiotic exposure on the sensitivity of bacterial pathogen detection for blood cultures, and accounted for the low sensitivity of blood cultures."
    },
    {
        "id": "doc_2885",
        "document": "About 3% of cases in the PERCH study had a non contaminant organisms isolated from blood culture. S pneumoniae was the most common isolate, consistent with other childhood pneumonia aetiology studies.29,38 Although we attempted to improve identification of cases with true pneumococcal pneumonia using whole blood PCR,26,27 the specificity was poor because prevalence was similar between cases and controls (aOR 1\u00b72); this improved somewhat when bacterial load was considered (aOR 1\u00b76). Perhaps the"
    },
    {
        "id": "doc_2886",
        "document": "poor specificity of blood PCR is due to low level seeding, swallowed sputum, or gastro intestinal tract absorption of pneumococcal antigens from common colonisation with S pneumoniae in the nasopharynx.43 This mechanism is also believed to be the source of poor pneumococcal urine antigen specificity.44 Despite the high prevalence of pneumococcal NPOP colonisation among children in every site,25 the prevalence of positive blood PCR for S pneumoniae was lower in Asian sites26 and in the Zambia"
    },
    {
        "id": "doc_2887",
        "document": "site, which had the highest prevalence of antibiotic pretreatment. Neither"
    },
    {
        "id": "doc_2888",
        "document": "770\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles"
    },
    {
        "id": "doc_2889",
        "document": "Bordetella pertussis Chlamydophila pneumoniae Haemophilus influenzae non-type b* H influenzae type b* a i r Legionella spp e t c Moraxella catarrhalis a B Mycoplasma pneumoniae Staphylococcus aureus Streptococcus pneumoniae non-PCV13 serotype* S pneumoniae PCV13 serotype* Salmonella spp Adenovirus Human bocavirus Cytomegalovirus* In\ufb02uenza virus A In\ufb02uenza virus B s e s u In\ufb02uenza virus C Human metapneumovirus A or B r i V Parain\ufb02uenza virus 1 Parain\ufb02uenza virus 2 Parain\ufb02uenza virus 3"
    },
    {
        "id": "doc_2890",
        "document": "Parain\ufb02uenza virus 4 Parechovirus\u2013enterovirus i g n u Human rhinovirus Respiratory syncytial virus A or B Pneumocystis jirovecii* Controls Cases F 0 20 40 60 0 5 10 15 Prevalence (%) Odds ratio 20"
    },
    {
        "id": "doc_2891",
        "document": "Figure 3: Nasopharyngeal-oropharyngeal (NP-OP) pathogen prevalence* and adjusted odds ratios (OR) in cases with positive chest x-ray and without HIV infection and in controls without\n\nHIV infection"
    },
    {
        "id": "doc_2892",
        "document": "Pathogens are ordered alphabetically among bacteria, followed by viruses and fungi. ORs adjusted for age (months), site, and presence of other pathogens detected by NP-OP PCR, but not adjusted for previous antibiotic use, which is known to influence bacterial positivity. *Prevalence defined by use of NP-OP PCR density thresholds for four pathogens: Pneumocystis jirovecii, 4 log10 copies per mL; Haemophilus influenzae, 5\u00b79 log10 copies per mL; cytomegalovirus, 4\u00b79 log10 copies per mL;"
    },
    {
        "id": "doc_2893",
        "document": "Streptococcus pneumoniae, 6\u00b79 log10 copies per mL; NP-OP PCR results based on positivity are in the appendix. PCV=pneumococcal conjugate vaccine."
    },
    {
        "id": "doc_2894",
        "document": "the Asian sites nor the South Africa site had a positive blood culture for S pneumoniae, unlike the other four African sites. We investigated the site performance of blood collection and culture and found no methodological explanation for the inability to isolate S pneumoniae from blood cultures at these three sites, nor for the lower prevalence of positive pneumococcal results in the Asian sites compared with that of other sites. However, the South Africa site had two blood culture samples that"
    },
    {
        "id": "doc_2895",
        "document": "were alarm positive, culture negative, with pneumococci in chains detected on Gram stain, and Binax positive, and all three sites isolated pneumococci from blood in patients who were not enrolled in the PERCH study during the same period. Antibiotic treatment before specimen collection is known to influence the isolation of bacteria from blood and NP, as we have previously described,25,28 but does not substantially influence pneumococcal detection by whole blood PCR.26,27 The prevalence of"
    },
    {
        "id": "doc_2896",
        "document": "antibiotic pretreatment was particularly high in Zambia (92%), South Africa (57%), and Kenya (35%); this was accounted for, as described previously, by reducing the sensitivity."
    },
    {
        "id": "doc_2897",
        "document": "There were reasons to expect that, in our study, there would be a lower burden of pneumococcal disease than in earlier studies. By design, sites with PCV in routine use were targeted for participation in the PERCH study (all except Zambia, Thailand, and Bangladesh used PCV), which could have reduced the pneumococcal"
    },
    {
        "id": "doc_2898",
        "document": "pneumonia disease burden by approximately 70% at those sites, if the serotype distribution matched that of invasive pneumococcal disease.45 The low pneumococcal aetiological attribution is supported by the low prevalence of radiographic consolidation that has been shown to be associated with bacterial pneumonia,46\u201348 which comprised only 25% of all PERCH cases and half of the cases with a positive chest xray. Furthermore, 60% of cases in the PERCH study were younger than 1 year, with many"
    },
    {
        "id": "doc_2899",
        "document": "younger than 6 months, a group often excluded from the analyses of clinical trials of pneumococcal vaccine that partly formed the basis for our expectations about pneumococcal burden. Economic development and improved access to care might also have reduced hospital admissions for pneumococcal pneumonia through effective early outpatient treatment. In some sites, such as Thailand, the absence of any detected cases of pneumococcal bacteraemia might simply reflect low enrolment numbers, given that"
    },
    {
        "id": "doc_2900",
        "document": "invasive pneumococcal disease has been observed at this site in other studies.49\u201351"
    },
    {
        "id": "doc_2901",
        "document": "Among other vaccinepreventable pathogens, M tuberculosis burden varied by site, accounting for 6\u201310% of the aetiology in four sites (The Gambia, Zambia, South Africa, and Thailand), but less than 3% elsewhere. M tuberculosis was rarely cultured from induced sputum or gastric aspirates and, in the South Africa site, testing more than one specimen increased the yield.52 The sensitivity of M tuberculosis culture is low when testing a\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n771\n\nArticles"
    },
    {
        "id": "doc_2902",
        "document": "A Unstrati\ufb01ed B Strati\ufb01ed by age C Strati\ufb01ed by severity Respiratory syncytial virus A or B Human rhinovirus Human metapneumovirus A or B Parain\ufb02uenza virus 1\u20134 Streptococcus pneumoniae Haemophilus influenzae Mycobacterium tuberculosis Staphylococcus aureus Enterobacteriaceae Other streptococci and enterococci In\ufb02uenza virus A\u2013C Pneumocystis jirovecii Moraxella catarrhalis Parechovirus\u2013enterovirus Salmonella spp Human bocavirus Fungi Adenovirus NFGNR Bordetella pertussis Age \u22651 year Age <1 year"
    },
    {
        "id": "doc_2903",
        "document": "Severe Legionella spp Very severe Cytomegalovirus Bacteria Neisseria meningitidis Viruses NOS Other 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Aetiological fraction (%) Aetiological fraction (%) Aetiological fraction (%)"
    },
    {
        "id": "doc_2904",
        "document": "Figure 4: Aetiological fraction unstratified (A), stratified by age (B), and stratified by severity (C) for cases with a positive chest x-ray and without HIV infection from all PERCH sites combined"
    },
    {
        "id": "doc_2905",
        "document": "Lines represent 95% credible interval; the darker region of the line represents the IQR. The size of the symbol is scaled on the basis of the ratio of the estimated aetiological fraction to its SE. Of two identical aetiological fraction estimates, the estimate associated with a larger symbol is more informed by the data than the priors. Positive chest x-rays defined as consolidation or other infiltrate on the x-ray. The following pathogens contributed less than 1% to the aetiological fraction"
    },
    {
        "id": "doc_2906",
        "document": "(overall and after stratifying by age and severity) and were excluded from the figure: Coronavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Other streptococci and enterococci includes Streptococcus pyogenes and Enterococcus faecium. Non-fermentative Gram-negative rods (NFGNR) includes Acinetobacter spp and Pseudomonas spp. Enterobacteriaceae includes Escherichia coli, Enterobacter spp, and Klebsiella spp, excluding mixed Gram-negative rods. Pathogens that were estimated at the"
    },
    {
        "id": "doc_2907",
        "document": "subspecies level, but grouped to the species level for display include parainfluenza virus type 1, 2, 3 and 4; Streptococcus pneumoniae PCV 13 and S pneumoniae non-PCV 13 types; Haemophilus influenzae type b and H influenzae non-type b; and influenza A, B, and C. Exact figures, including subspecies and serotype disaggregation (eg, PCV13 type and non-PCV13 type), are given in the appendix. NOS=not otherwise specified (ie, pathogens we did not test for)."
    },
    {
        "id": "doc_2908",
        "document": "single induced sputum specimen (30%) and remains low even when multiple samples were taken from children with pulmonary tuberculosis;53 this was accounted for in the aetiology model. Perhaps owing to high vaccination rates, B pertussis was rarely identified but, when present, was most often found in children younger than 12 months. Detection of B pertussis by PCR of NPOP specimens was highly predictive of case status, with very few positives identified in controls.54 We saw few cases that were"
    },
    {
        "id": "doc_2909",
        "document": "clinically compatible with measles, therefore it is unlikely that we missed many measlesrelated cases of pneumonia, highlighting the efforts of measles control at the sites during the study. Hib was an uncommon cause for pneumonia in our study and was less com mon than nontype b H influenzae. The longstanding use of Hib vaccine in several study sites could have accounted for the low contribution of Hib to the aetiological distribution. However, the two sites where the contribution of Hib"
    },
    {
        "id": "doc_2910",
        "document": "exceeded the contribution of nonb H influenzae (Mali and Zambia) did not have the lowest Hib vaccination rates. Thailand was the only site not using Hib vaccine; the reason for the small contribution of Hib to pneumonia aetiology in Thailand is unclear, but might relate to access to outpatient antibiotics."
    },
    {
        "id": "doc_2911",
        "document": "P jirovecii is a prominent cause of pneumonia among children with HIV infection. The PERCH study has shown that it is also a relevant cause of pneumonia in a subset of children without HIV infection. Among cases, those who had P jirovecii detected in the NPOP specimens were more likely than other cases to be younger than 6 months and malnourished. To the best of our knowledge, the single case of legionellosis (in the Zambia site) that we identified is the first reported case of childhood"
    },
    {
        "id": "doc_2912",
        "document": "infection due to L longbeachae in Africa."
    },
    {
        "id": "doc_2913",
        "document": "The aetiological contribution of nontested pathogens (ie, the NOS category) was approximately 2% in the all site analysis. Sensitivity analyses that assumed a higher fraction for the NOS category (aetiology prior set at 25% vs 3%) concluded that the NOS category would probably not account for more than 15% of cases across the sites, except in Thailand (25%). This emphasises that strong evidence exists for the aetiological contribution of pathogens tested for in our study, unless there is"
    },
    {
        "id": "doc_2914",
        "document": "substantial confounding of the true cause by these pathogens. Because the value chosen for the aetiology prior influences the fraction attributed to the NOS category, our analysis cannot be used to estimate precisely the size of the NOS category. However, it does"
    },
    {
        "id": "doc_2915",
        "document": "772\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles"
    },
    {
        "id": "doc_2916",
        "document": "A Respiratory syncytial Human rhinovirus Human metapneumo- Parain\ufb02uenza virus 1\u20134 Streptococcus Haemophilus influenzae virus A or B virus A or B pneumoniae 60 50 ) % ( n o 40 i t c a r f l a 30 c i g o l o i 20 t e A 10 0 Mycobacterium Staphylococcus aureus In\ufb02uenza virus A\u2013C Pneumocystis jirovecii NOS Other pathogens tuberculosis 60 50 ) % ( n o i 40 t c a r f l a c 30 i g o l o i t 20 e A 10 0 The Ga m bia M ali Kenya Za m bia South Africa Bangladesh Thailand The Ga m bia M ali Kenya Za m bia"
    },
    {
        "id": "doc_2917",
        "document": "South Africa Bangladesh Thailand The Ga m bia M ali Kenya Za m bia South Africa Bangladesh Thailand The Ga m bia M ali Kenya Za m bia South Africa Bangladesh Thailand The Ga m bia M ali Kenya Za m bia South Africa Bangladesh Thailand The Ga m bia M ali Kenya Za m bia South Africa Bangladesh Thailand B Viruses Bacteria* 100 ) % ( n 80 o i t c a r f 60 l a c i g 40 o l o i t e A 20 0 The Gambia Mali Kenya Zambia South Africa Bangladesh Thailand The Gambia Mali Kenya Zambia South Africa Bangladesh"
    },
    {
        "id": "doc_2918",
        "document": "Thailand"
    },
    {
        "id": "doc_2919",
        "document": "The size of the symbol is scaled on the basis of the ratio of the estimated aetiological fraction to its SE. Of two identical aetiological fraction estimates, the estimate associated with a larger symbol is more informed by the data than the priors. Positive chest x-rays defined as consolidation or other infiltrate on the x-ray. Graph restricted to the ten focus pathogens from the all-site analysis, which include those with aetiology estimate higher than 5% (n=7) or higher than 2% that were of"
    },
    {
        "id": "doc_2920",
        "document": "epidemiological interest (defined as treatable by antibiotics [Pneumocystis jirovecii and Staphylococcus aureus] or having an available vaccine [influenza virus]). The 95% credibility intervals for the aetiological fractions of these three pathogens overlap with some non-focus pathogens, hence our use of the term focus pathogen rather than labelling these ten as the most common pathogens. Other pathogens category represents the sum of the aetiological fraction for all remaining pathogens tested"
    },
    {
        "id": "doc_2921",
        "document": "for, but not presented in this figure. Site-specific results were standardised to the following case mix: 40% younger than 1 year with severe pneumonia, 20% younger than 1 year with very severe pneumonia, 30% aged 1 year or older with severe pneumonia, and 10% aged 1 year or older with very severe pneumonia. Pathogens estimated at the subspecies level, but grouped to the species level for display include parainfluenza virus types 1, 2, 3, and 4; Streptococcus pneumoniae PCV13 and S pneumoniae"
    },
    {
        "id": "doc_2922",
        "document": "non-PCV13 types; Haemophilus influenzae type b and H influenzae non-type b; and influenza virus A, B, and C. Exact figures are given in the appendix. NOS=not otherwise specified (ie, pathogens we did not test for). *The summary for bacteria excludes Mycobacterium tuberculosis."
    },
    {
        "id": "doc_2923",
        "document": "affirm that NOS accounts for a small fraction of pneumonia causes.\n\nThe contribution of NPOP data for assessing aetiolog ical probability depends on differences in frequency of detection between cases and controls. The validity of NPOP infection as a source of aetiological inference for a selected group of pneumonia pathogens is supported by the finding that clear distinctions in prevalence by case or"
    },
    {
        "id": "doc_2924",
        "document": "control status were found consistently across sites. However, NPOP specimens provide little inferential value to the cause of pneumonia at the individual case level, except for a small group of pathogens, such as RSV and B pertussis. Collection of induced sputum added little value beyond that of the NPOP specimen, despite the high quality of the lower respiratory tract specimens.30,32 For those pathogens with NPOP OR lower than 1, ruling out\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n773"
    },
    {
        "id": "doc_2925",
        "document": "Articles"
    },
    {
        "id": "doc_2926",
        "document": "100 90 80 70 60 50 40 30 The Gambia Mali Kenya 20 Zambia South Africa 10 Bangladesh Thailand 0 1 2 3 4 5 6 7 8 9 10 Rank The Gambia Mali Kenya Zambia South Africa Bangladesh Thailand RSV RSV RSV RSV RSV RSV RSV S pneu S pneu Rhino HMPV H inf Rhino M cat Para HMPV HMPV Mtb Para HMPV Other strep Mtb Para Para Salm sp Mtb Para NOS H inf H inf H inf Entrb S pneu PV\u2013EV Mtb Cand sp S aur S pneu Flu Adeno Entrb H inf HMPV Boca PV\u2013EV H inf Other strep Mtb Rhino M cat Mtb Flu S pneu S aur Boca NFGNR"
    },
    {
        "id": "doc_2927",
        "document": "Entrb Salm sp P jirov S aur Rhino NOS Cand sp S aur P jirov Mtb P jirov HMPV CMV HMPV"
    },
    {
        "id": "doc_2928",
        "document": "Figure 6: Cumulative contribution of site-specific ten most common pathogens in cases with a positive chest x-ray and without HIV infection"
    },
    {
        "id": "doc_2929",
        "document": "Positive chest x-rays defined as consolidation or other infiltrate on the x-ray. Site-specific results were standardised to the following case mix: 40% younger than 1 year with severe pneumonia, 20% younger than 1 year with very severe pneumonia, 30% aged 1 year or older with severe pneumonia, and 10% aged 1 year or older with very severe pneumonia. Ranks correspond to the site-specific rank from the top ten pathogens of each site; the pathogen corresponding to each rank varies by site (see"
    },
    {
        "id": "doc_2930",
        "document": "inset panel). Other strep category includes Streptococcus pyogenes and Enterococcus faecium. Non-fermentative Gram-negative rods (NFGNR) includes Acinetobacter spp and Pseudomonas spp. Enterobacteriaceae category (Entrb) includes Escherichia coli, Enterobacteriaceae spp, and Klebsiella spp, excluding mixed Gram-negative rods. Pathogens estimated at the subspecies level, but grouped to the species level for display include parainfluenza virus types 1, 2, 3, and 4; Streptococcus pneumoniae PCV13"
    },
    {
        "id": "doc_2931",
        "document": "and S pneumoniae non-PCV13 types; Haemophilus influenzae type b and H influenzae non-type b; and influenza virus A, B, and C. Boca=human bocavirus. Cand sp=Candida spp. CMV=cytomegalovirus. Flu=influenza virus A, B and C. H inf=H influenzae. HMPV=human metapneumovirus A or B. Mtb=Mycobacterium tuberculosis. M cat=Moraxella catarrhalis. NOS=not otherwise specified (ie, pathogens we did not test for). P jirov=Pneumocystis jirovecii. Para=parainfluenza virus type 1, 2, 3 and 4."
    },
    {
        "id": "doc_2932",
        "document": "PV-EV=parechovirus\u2013enterovirus. Rhino=human rhinovirus. RSV=respiratory syncytial virus A or B. S aur=Staphylococcus aureus. S pneu=S pneumoniae. Salm sp=Salmonella spp."
    },
    {
        "id": "doc_2933",
        "document": "their role in the causal chain was not possible with this study design; probe or longitudinal study designs are needed to better understand the contribution of these pathogens to pneumonia aetiology and better explore the sequence from NPOP infection to lung infection. Despite their limitations, NPOP specimens remain of substantial importance for pneumonia aetiology studies because they are easily collected, can be subjected to molecular diagnostic testing, and can provide valid information"
    },
    {
        "id": "doc_2934",
        "document": "about infection of certain pathogens in the respiratory tract."
    },
    {
        "id": "doc_2935",
        "document": "Four sites (The Gambia, South Africa, Mali, and Bangladesh) included lung aspirate specimen collection as part of the study protocol. Because of the clinical criteria for specimen collection (ie, cases with anterior, large, and rightsided consolidation), hesitation from clinicians and families, and delays in ethical approvals"
    },
    {
        "id": "doc_2936",
        "document": "and training at some sites, only 37 (6\u00b78%) of 545 cases with radiographic consolidation enrolled at these four sites had a lung aspirate specimen collected. Pathogen detection from lung aspirates was lower (29% overall, 41% when both culture and PCR were undertaken) than that reported in previous studies, possibly because the timing of lung aspirates occurred after antibiotic administration.55 Pleural fluid specimens, included in the study protocol in all sites at the discretion of the treating"
    },
    {
        "id": "doc_2937",
        "document": "clinicians, were only available from 15 (8%) of 180 cases in whom at least one standardised chest xray reader identified pleural fluid; however, a pathogen was detected in 80% of these specimens. Bacteria were more com monly detected on these specimens than viruses, with the most common being S pneumoniae in lung aspirates and S aureus in pleural fluid. These specimens, although most directly reflective of the true cause of pneumonia, were collected in a highly selected group of cases and the"
    },
    {
        "id": "doc_2938",
        "document": "results are unlikely to be generalisable."
    },
    {
        "id": "doc_2939",
        "document": "Clinical characteristics and case outcomes varied substantially by site. The high variation in wheezing prevalence among cases, especially the extremely high prevalence in Bangladesh, might be related to poor air quality, infection, or underlying propensity for bronchospasm in the children presenting for care.56\u201358 Sites also differed in the mix of case severity, which might reflect underlying host factors (eg, nutritional status), other concurrent illnesses (eg, malaria), or patient propensity"
    },
    {
        "id": "doc_2940",
        "document": "for seeking care and ability to access to care. Because pathogen findings differed by case severity, it is possible that the stratification of cases on finer or differently defined severity indicators might control for some confounding by site. Casefatality ratios varied by site, reflecting differences in case severity and clinical care. Among all cases who died in the 30 days after hospital admission, only a small proportion of deaths (41 [14%] of 292) occurred after discharge. This is similar"
    },
    {
        "id": "doc_2941",
        "document": "to the proportion of mortality (16% of deaths) observed to occur after discharge in a study of severe pneumonia requiring hospital admission in children younger than 5 years in Kilifi,59 but contrasts with the substantial proportion of mortality (74% of deaths) observed to occur in the 90 days after enrolment for diarrhoeal illness in the GEMS study,60 although those children were followed for a longer period."
    },
    {
        "id": "doc_2942",
        "document": "We did not obtain chest xrays from a small proportion of cases (6%, n=234), many (33%) because of death soon after enrolment, limiting the representation of microbiological findings in immediately fatal cases in the primary analysis. Among cases with a chest xray, 53% had either a normal or uninterpretable finding; by design, the WHO clinical pneumonia case definitions are highly sensitive, but nonspecific. We focused on the epidemiological and laboratory characteristics of cases with pneumonia"
    },
    {
        "id": "doc_2943",
        "document": "with a positive xray to enhance the specificity of the clinical case definition for pneumonia, recognising that this might introduce bias by excluding"
    },
    {
        "id": "doc_2944",
        "document": "774\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles\n\ncases with pneumonia whose xray findings lagged behind the clinical findings or cases with lower tract disease caused by pathogens who did not have chest xray infiltrates (eg, pertussis). We assessed this bias by providing analyses of all cases, regardless of xray findings, and observed little difference in the findings. Notably, among cases without a positive chest xray, 26% either had a missing or uninterpretable xray."
    },
    {
        "id": "doc_2945",
        "document": "We did the PERCH study over a 24month period at each site to obtain more reliable data on annual seasonality patterns and to increase the probability of detecting pathogens that exhibit multiyear epidemic cycles. We were unlikely to miss seasonal outbreaks; however, some pathogens (eg, B pertussis, influenza subtypes, parainfluenza viruses, and Mycoplasma pneumoniae) have periodicities that are longer than 24 months and, therefore, we might have observed quiescent periods.61\u201364"
    },
    {
        "id": "doc_2946",
        "document": "Among the ten focus pathogens of our study, a subset (HMPV, parainfluenza, S pneumoniae, human rhinovirus, H influenzae, and M tuberculosis) differed in their impor tance across sites. The estimated contributions of some pathogens varied by age strata (RSV, pertussis, parainflu enza types 1 and 3, P jirovecii, S aureus, S pneumoniae, parechovirusenterovirus, and rhinovirus) and by disease severity (all viral causes combined, RSV, S aureus, S pneumoniae, and parainfluenza type 3), which might"
    },
    {
        "id": "doc_2947",
        "document": "have implications for treatment guideline revisions. Because preventive measures against current pathogens are increasingly implemented, the proportional aetiological distribution will continue to change over time."
    },
    {
        "id": "doc_2948",
        "document": "The PERCH study results can be compared with other childhood pneumonia aetiology studies.29,39,65,66 The multisite BOSTID study66,67 from the 1980s, an important historical reference, detected viruses and bacteria from upper respiratory specimens and bacterial antigens from urine specimens and found high prevalence of RSV, S pneumoniae, and Hib. The PERCH study differed substantially from BOSTID in study design through the inclusion of controls, in strict standardisation of case definitions and"
    },
    {
        "id": "doc_2949",
        "document": "methods, and in the breadth and types of laboratory testing. The multicountry GABRIEL pneumonia casecontrol aetiology study,65 done in low income settings and published in 2017, also highlighted RSV as a major causative pathogen. However, the aetiological attribution for RSV was substantially lower in the GABRIEL study than in the PERCH study (18% vs 31%).65 This discordance appears mainly attributable to differences in the prevalence of RSV in GABRIEL (20% of cases) compared with that in the"
    },
    {
        "id": "doc_2950",
        "document": "PERCH study (29% of cases), rather than a result of different analytical approaches. Study design and methodological differences probably affected the rate of RSV detection; specifically, the age distribution of cases enrolled in GABRIEL was older than that of cases in PERCH, and GABRIEL controls were enrolled from facilities, rather than from the community. Although S pneumoniae detection in NP specimens in cases was"
    },
    {
        "id": "doc_2951",
        "document": "similar between the two studies (68% in GABRIEL vs"
    },
    {
        "id": "doc_2952",
        "document": "73% in PERCH [any detection]), the control prevalence was considerably lower in GABRIEL (48% vs 77%), resulting in a high OR and attributable fraction in the GABRIEL study. The difference in pneumococcal findings between the PERCH and GABRIEL studies is unlikely to lie in the case definitions used, which were similar between studies. Instead, notable differences existed in PCV use (nearly absent in GABRIEL, but widely used in PERCH) and in control eligibility (facility based recruitment and no"
    },
    {
        "id": "doc_2953",
        "document": "respiratory symptoms in GABRIEL vs community controls regardless of respi ratory symptoms, if not casedefining, in PERCH). Additionally, the proportion of cases and controls who had detection of both viruses and bacteria was sub stantially higher in PERCH (83\u00b75% cases and 75\u00b78% of controls had mixed bacterialviral detection) than in GABRIEL (59\u00b76% cases and 36\u00b71% controls), suggesting that other differences in the selection of participants or in clinical or laboratory methods might have also"
    },
    {
        "id": "doc_2954",
        "document": "contributed. In the EPIC study38 of childhood pneumonia aetiology from the USA, RSV and human rhinovirus were the most commonly detected pathogens from the upper respiratory tract among young children hospitalised with radiographic pneumonia, and a larger proportion of children had no pathogen detected compared with that of PERCH (18\u00b79% in EPIC vs 0\u00b79% in PERCH). In the South African Drakenstein case control substudy29 of pneumonia aetiology (using the same multiplex PCR assay as PERCH), cases"
    },
    {
        "id": "doc_2955",
        "document": "were predominantly children with nonsevere pneumonia, managed in outpatient settings, and with a median age of 5 months. Nevertheless, a range of pathogens similar to that of the PERCH study was associated with pneumonia case status, but the prevalence of influenza was higher. Unlike the PERCH study of severe pneumonia with hospital admission, the Drakenstein substudy found that cytomegalovirus, bocavirus, and adenovirus were associated with case status.29"
    },
    {
        "id": "doc_2956",
        "document": "Our study has several limitations, particularly related to viral pathogens as confounders of pneumonia aetiology, to the copathogen interpretation, and to bacterial aetiology. Our descriptive analysis underscored limitations inherent to nearly every pneumonia aetiology study\u2014multiple specimens, multiple tests with varying sensitivity and specificity, and the absence of an established and principled method to integrate the results in a single aetiology analysis\u2014and justifies the novel analytical"
    },
    {
        "id": "doc_2957",
        "document": "approach we have taken. As in all casecontrol studies, residual confounding cannot be excluded. Despite matching controls by community of residence, age, and season of cases, there are likely to be factors that influence nasopharyngeal infection and independently influence infection with significant lung pathogens (eg, crowding); this could overestimate the role of viruses and underestimate the role of bacteria. The PIA model integrates the multiple observed laboratory results,"
    },
    {
        "id": "doc_2958",
        "document": "www.thelancet.com Vol 394 August 31, 2019\n\n775\n\nArticles"
    },
    {
        "id": "doc_2959",
        "document": "acknowledging the inherent error in laboratory meas urements, the reduced sensitivity of assays because of previous antibiotic use or low blood culture volume, and the indirect nature of data obtained from sampling body fluids distant from the lung. The model assumes each case has a primary pathogen as the cause and does not attempt to estimate whether specific pathogen combinations are necessary for pneumonia. This approach has been described in detail elsewhere9 and has been contrasted with"
    },
    {
        "id": "doc_2960",
        "document": "the standard attributable fraction method. The PIA model includes assumptions on the sensitivity of laboratory measures and aetiology priors, each with a range provided. The validity of the assumptions regarding sensitivity is limited by the availability of data on diagnostic test performance. Despite the potential misspecification of these assumptions, sensitivity analyses showed that the aetiology results were robust to changes in these values, except the aetiology prior for NOS.9 Furthermore,"
    },
    {
        "id": "doc_2961",
        "document": "the inherent ability of an observational study to accurately define the contribution of bacteria to pneumonia is uncertain. To advance this problem will require better diagnostics (such as discriminating PCR in blood samples or other pathogenspecific, infection specific biomarkers), specimens other than the NPOP swabs (such as lung aspirates, which are very challenging to obtain), and the sampling of patients before they have had antibiotics, which, in the era of community case management, is"
    },
    {
        "id": "doc_2962",
        "document": "increasingly unlikely. A vaccine probe study is the optimal way to reveal the contribution of a pathogen to pneumonia,68 but this can only be undertaken for one or two pathogens at a time. Finally, the allsite PERCH study pneumonia aetiological distribution reflected estimates of the distribution of cases with pneumonia who were admitted to a hospital, outside of the neonatal period, across the PERCH study sites during the period of observation. We recognise that pneumonia is an important"
    },
    {
        "id": "doc_2963",
        "document": "illness in neonates. Because there was a sister study, ANISA,69 assessing the causes of neonatal disease during the same period, the PERCH study focused on children outside the neonatal period."
    },
    {
        "id": "doc_2964",
        "document": "The results from the PERCH study should not be extrapolated as the global aetiological distribution of severe childhood pneumonia or interpreted as the aetio logical distribution at the national level for each of the participating sites. At the time of study initiation (2011), 88% of countries eligible for programmes of Gavi, the Vaccine Alliance, were using Hib vaccine and 21% were using PCV in their routine immunisation programmes.70 However, the PERCH study was intentionally designed to"
    },
    {
        "id": "doc_2965",
        "document": "reflect the aetiology in the setting of high PCV and Hib vaccine use. By 2020, these vaccines are expected to be used in 100% (Hib vaccine) and 93% (PCV vaccine) of Gavieligible countries.70 Furthermore, the aetiological distribution among the cases does not necessarily reflect the aetiological distribution among pneumonia deaths, especially in children who died in the community without the provision of curative care efforts."
    },
    {
        "id": "doc_2966",
        "document": "The PERCH study was designed to update the evidence base on causes of serious pneumonia with use of the most advanced clinical, microbiological, and analytical methods, deployed across geographically and epidemiologically diverse study sites in Africa and south Asia, where the pneumonia burden is greatest. Beyond comparing the clinical and microbiological findings of cases and controls, as has traditionally been done in aetiology studies, we have used a novel analytical method to overcome some"
    },
    {
        "id": "doc_2967",
        "document": "of the limitations of this traditional approach and estimate the aetiology distribution, with 95% CrI, in both the population and each individual. Previously, infectious aetiology studies were unable to integrate the results from multiple specimen types for multiple pathogens."
    },
    {
        "id": "doc_2968",
        "document": "Our results highlight the consistency of the pneumonia aetiology findings across sites, disease severity, and age strata, providing evidence to target the handful of pathogens that are consistently identified as important for prevention and treatment. RSV is the most common cause of serious pneumonia with hospital admission in these settings and should be a target for dedicated prevention and treatment efforts. Bacterial pathogens cumulatively cause a substantial proportion of disease and,"
    },
    {
        "id": "doc_2969",
        "document": "because they are treatable and commonly fatal, should remain as targets for early access to appropriate supportive and curative treatment. The PERCH study estimated that 61% of pneumonia requiring hospital admission in children younger than 5 years and without HIV infection had a primary viral cause; however, we cannot firmly exclude the presence of bacterial co infection, as discussed above. Nevertheless, this finding strengthens the need to adjust pneumonia treatment algorithms to emphasise"
    },
    {
        "id": "doc_2970",
        "document": "supportive care and identify children for whom antibiotics are unlikely to be therapeutic, thereby reducing the pressure for anti microbial resistance. Future pneumonia research needs to address the conundrum of multiple pathogens and the sequence of their role in pneumonia pathogenesis. The findings from the PERCH study should prompt additional investments in pneumonia prevention, testing, triage, and treatment and should encourage the use of innovative design and analyses in aetiology studies,"
    },
    {
        "id": "doc_2971",
        "document": "especially those that can further assess pneumonia as a multipathogen disease."
    },
    {
        "id": "doc_2972",
        "document": "Contributors"
    },
    {
        "id": "doc_2973",
        "document": "KLO, OSL, HCB, WAB, DRF, LLH, SRCH, MDK, KLK, SAMad, DRM, JAGS, DMT, JCh, JCr, AND, AJD, NF, RAK, SAMal, and SLZ designed the study. Principal investigators of the study were KLO and OSL (overall); WAB, DG, and KZ (Bangladesh); SRCH and SMAZ (The Gambia); JAGS and JOA (Kenya); KLK, SOS, and MDT (Mali); SAMad and DPM (South Africa); HCB, SAMal, and PA (Thailand); and DMT, JCh, LM, and PSe (Zambia). Team leads included DRF (clinical and epidemiological), LLH (clinical and epidemiological), MDK"
    },
    {
        "id": "doc_2974",
        "document": "(data analysis), and DRM (laboratory). KLO, OSL, HCB, WAB, DRF, LLH, SRCH, MDK, KLK, SAMad, DRM, JAGS, DMT, PVA, PA, TPA, MA, JOA, VLB, CB, JCh, MJC, JCr, AND, AJD, BEE, HPE, NF, DG, MJG, MMH, LH, YJ, EWK, AK, RAK, SK, NK, LK, GK, EMM, GM, NM, SAMal, JLMc, JLMi, DPM, SCM, AM, LM, JM, MSO, UO, DEP, CP, JR, PSa, PSe, AS, EAFS, SS, SWS, SOS, MS, BT, MDT, ST, AT, NLW, KZ, and SMAZ collected the data. MDK, SLZ, ZW, QS, WF, ML, CP, DEP, MMH, MH, and NLW supervised"
    },
    {
        "id": "doc_2975",
        "document": "776\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles"
    },
    {
        "id": "doc_2976",
        "document": "or did the analysis. KLO, OSL, HCB, WAB, DRF, LLH, SRCH, MDK, KLK, SAMad, DRM, JAGS, DMT, SLZ, ZW, QS, WF, ML, CP, DEP, MMH, MH, NLW interpreted the data. KLO, DRM, MDK, and CP drafted the paper. OSL, HCB, WAB, DRF, LLH, SRCH, KLK, SAMad, JAGS, DMT, SLZ, and ZW provided substantial contributions to the review and revision of the text. CP drafted the descriptive appendix. MDK, SLZ, ZW, CP, and QS drafted the analytical methods appendix. All authors reviewed the draft. KLO had final responsibility"
    },
    {
        "id": "doc_2977",
        "document": "for the decision to submit for publication."
    },
    {
        "id": "doc_2978",
        "document": "The PERCH Study Group"
    },
    {
        "id": "doc_2979",
        "document": "Katherine L O\u2019Brien, Orin S Levine, Maria Deloria Knoll, Daniel R Feikin, Andrea N DeLuca, Amanda J Driscoll, Nicholas Fancourt, Wei Fu, Meredith Haddix, Laura L Hammitt, Melissa M Higdon, E Wangeci Kagucia, Ruth A Karron, Mengying Li, Daniel E Park, Christine Prosperi, Qiyuan Shi, Zhenke Wu, Scott L Zeger, Nora L Watson, Jane Crawley, David R Murdoch, W Abdullah Brooks, Hubert P Endtz, Khalequ Zaman, Doli Goswami, Lokman Hossain, Yasmin Jahan, Mohammod Jobayer Chisti, Stephen R C Howie, Bernard"
    },
    {
        "id": "doc_2980",
        "document": "E Ebruke, Martin Antonio, Jessica L McLellan, Eunice M Machuka, Arifin Shamsul, Syed M A Zaman, Grant Mackenzie, J Anthony G Scott, Juliet O Awori, Susan C Morpeth, Alice Kamau, Sidi Kazungu, Micah Silaba Ominde, Karen L Kotloff, Milagritos D Tapia, Samba O Sow, Mamadou Sylla, Boubou Tamboura, Uma Onwuchekwa, Nana Kourouma, Aliou Toure, Seydou Sissoko, Shabir A Madhi, David P Moore, Peter V Adrian, Vicky L Baillie, Locadiah Kuwanda, Azwifarwi Mudau, Michelle J Groome, Nasreen Mahomed, Eric A F"
    },
    {
        "id": "doc_2981",
        "document": "Sim\u00f5es, Henry C Baggett, Somsak Thamthitiwat, Susan A Maloney, Charatdao Bunthi, Julia Rhodes, Pongpun Sawatwong, Pasakorn Akarasewi, Donald M Thea, Lawrence Mwananyanda, James Chipeta, Phil Seidenberg, James Mwansa, Somwe Wa Somwe, Geoffrey Kwenda, Trevor P Anderson, Joanne L Mitchell."
    },
    {
        "id": "doc_2982",
        "document": "Affiliations"
    },
    {
        "id": "doc_2983",
        "document": "Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA (Katherine L O\u2019Brien, Orin S Levine [currently affiliated with Bill & Melinda Gates Foundation, Seattle, WA, USA], Maria Deloria Knoll, Daniel R Feikin [also affiliated with the US Centers for Disease Control and Prevention, Atlanta, GA, USA], Andrea N DeLuca, Amanda J Driscoll, Nicholas Fancourt, Wei Fu, Meredith Haddix, Laura L Hammitt, Melissa M Higdon, E Wangeci Kagucia, Ruth A Karron, Mengying Li, Daniel E Park, Christine"
    },
    {
        "id": "doc_2984",
        "document": "Prosperi, Qiyuan Shi, Zhenke Wu, and Scott L Zeger); The Emmes Corporation, Rockville, MD, USA (Nora L Watson); Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (Jane Crawley); University of Otago, Christchurch, New Zealand (David R Murdoch); International Centre for Diarrhoeal Disease Research, Bangladesh, (W Abdullah Brooks, Hubert P Endtz, Khalequ Zaman, Doli Goswami, Lokman Hossain, Yasmin Jahan, and Mohammod Jobayer Chisti); Medical Research Council, Basse, The"
    },
    {
        "id": "doc_2985",
        "document": "Gambia (Stephen R C Howie, Bernard E Ebruke, Martin Antonio, Jessica L McLellan, Eunice M Machuka, Arifin Shamsul, Syed M A Zaman, Grant Mackenzie); KEMRI\u2013Wellcome Trust Research Programme, Kilifi, Kenya (J Anthony G Scott [also affiliated with London School of Hygiene and Tropical Medicine, London, UK], Juliet O Awori, Susan C Morpeth, Alice Kamau, Sidi Kazungu, and Micah Silaba Ominde); Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine"
    },
    {
        "id": "doc_2986",
        "document": "Development, University of Maryland School of Medicine, Baltimore, MD, USA (Karen L Kotloff, Milagritos D Tapia, Samba O Sow, Mamadou Sylla, Boubou Tamboura, Uma Onwuchekwa, Nana Kourouma, Aliou Toure, and Seydou Sissoko); Centre pour le D\u00e9veloppement des Vaccins (CVDMali), Bamako, Mali (Karen L Kotloff, Milagritos D Tapia, Samba O Sow, Mamadou Sylla, Boubou Tamboura, Uma Onwuchekwa, Nana Kourouma, Aliou Toure, Seydou Sissoko); Medical Research Council, Respiratory and Meningeal Pathogens"
    },
    {
        "id": "doc_2987",
        "document": "Research Unit and Department of Science and Technology\u2013National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa (Shabir A Madhi, David P Moore, Peter V Adrian, Vicky L Baillie, Locadiah Kuwanda, Azwifarwi Mudau, Michelle J Groome, Nasreen Mahomed, and Eric A F Sim\u00f5es); Thailand"
    },
    {
        "id": "doc_2988",
        "document": "Ministry of Public Health\u2013US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand (Henry C Baggett, Somsak Thamthitiwat, Susan A Maloney, Charatdao Bunthi, Julia Rhodes, Pongpun Sawatwong, and Pasakorn Akarasewi); Boston University School of Public Health, Boston, MA, USA (Donald M Thea, Lawrence Mwananyanda, James Chipeta, Phil Seidenberg, James Mwansa, Somwe Wa Somwe, and Geoffrey Kwenda); University Teaching Hospital, Lusaka, Zambia (Donald M Thea, Lawrence"
    },
    {
        "id": "doc_2989",
        "document": "Mwananyanda, James Chipeta, Phil Seidenberg, James Mwansa, Somwe Wa Somwe, and Geoffrey Kwenda); Canterbury Health Laboratories, Christchurch, New Zealand (Trevor P Anderson and Joanne L Mitchell)."
    },
    {
        "id": "doc_2990",
        "document": "Declaration of interests"
    },
    {
        "id": "doc_2991",
        "document": "KLO has received grant funding from GlaxoSmithKline and Pfizer and participates on technical advisory boards for Merck, SanofiPasteur, PATH, Affinivax, and ClearPath. MDK has received funding for consultancies from Merck, Pfizer, and Novartis and grant funding from Merck. LLH has received grant funding from Pfizer and GlaxoSmithKline. KLK has received grant funding from Merck Sharp & Dohme. SAMad has received honorarium for advisory board from the Bill & Melinda Gates Foundation, Pfizer,"
    },
    {
        "id": "doc_2992",
        "document": "Medimmune, and Novartis; institutional grants from GlaxoSmithKline, Novartis, Pfizer, Minervax, and Bill & Melinda Gates Foundation; and speakers bureau for Sanofi Pasteur and GlaxoSmithKline. WAB reported funding from Sanofi, PATH, Bill & Melinda Gates Foundation, and contributions to contemporaneous studies from Serum Institute of India, Roche, and Sanofi. All other authors declare no competing interests."
    },
    {
        "id": "doc_2993",
        "document": "Data sharing\n\nWe are in the process of making the PERCH dataset publicly available in ClinEpiDB (University of Pennsylvania, PA, USA; https://clinepidb.org; we estimate availability in 2020).\n\nAcknowledgments"
    },
    {
        "id": "doc_2994",
        "document": "The PERCH study was supported by grant 48968 from the Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA). JAGS was supported by a clinical fellowship from the Wellcome Trust (UK; 098532). We gratefully acknowledge the substantial contributions to the design of the study by the Pneumonia Methods Working Group (Zulfiqar A Bhutta, Robert E Black, Harry Campbell, Thomas"
    },
    {
        "id": "doc_2995",
        "document": "Cherian, Derrick Crook, Menno D de Jong, Scott F Dowell, Stephen M Graham, Keith P Klugman, Claudio F Lanata, Shabir A Madhi, Paul Martin, James Nataro, Franco Piazza, Shamim Ahmed Qazi, Heather Zar) and the PERCH Site Selection Committee (David L Blazes, Robert Bollinger, Claire V Broome, John A Crump, Olivier Fontaine, Robert Gie, David Goldblatt, Patrick W Kelley, Sharon J Peacock, Mark S Riddle, Montse SorianoGabarr\u00f3, Annelies Van Rie, Christopher W Woods). The PERCH Expert Group (William C"
    },
    {
        "id": "doc_2996",
        "document": "Blackwelder, Harry Campbell, John A Crump, Menno D de Jong, Adegoke Falade, Claudio F Lanata, Kim Mulholland, Shamim Ahmed Qazi, Cynthia G Whitney) provided valuable advice during the conduct of the study and the analysis of the results for which we are indebted. We also recognise the support provided by the Institutional Review Boards for study oversight. We appreciate the helpful discussions with our many colleagues who were conducting aetiology studies of pneumonia, neonatal sepsis, and"
    },
    {
        "id": "doc_2997",
        "document": "diarrhoea during the same period, including the EPIC study, the GABRIEL study, the ANISA study, and the GEMS study. We acknowledge the work of all PERCH contributors who were involved in data collection at the local sites and central laboratories, members of the PERCH Chest Radiograph Reading Panel (see appendix for the list of members in each group), and Shalika Jayawardena and Rose Watt from Canterbury Health Laboratories. Finally, we gratefully recognise the willingness and confidence in the"
    },
    {
        "id": "doc_2998",
        "document": "study by the parents of the participating children and express our gratitude for their commitment to the advancement of knowledge toward better health for children of their community and those of other communities. This paper is published with the permission of the Director of the Kenya Medical Research Institute."
    },
    {
        "id": "doc_2999",
        "document": "report\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n777\n\nArticles\n\nand do not necessarily represent the official position of the US Centers for Disease Control and Prevention, US Department of Health and Human Services, or the US Government."
    },
    {
        "id": "doc_3000",
        "document": "References\n\n1 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under5 mortality in 2000\u201315: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 2016; 388: 3027\u201335.\n\n2 Feikin D, Flannery B, Hamel M, Stack M, Hansen P. Vaccines for children in low and middleincome countries. In: Disease control priorities: reproductive, maternal, newborn, and child health, 3rd edn. Washington DC: World Bank, 2016: 187\u2013204."
    },
    {
        "id": "doc_3001",
        "document": "3 Lee LA, Franzel L, Atwell J, et al. The estimated mortality impact of vaccinations forecast to be administered during 2011\u20132020 in 73 countries supported by the GAVI Alliance. Vaccine 2013; 31: B61\u201372.\n\nLevine OS, O\u2019Brien KL, DeloriaKnoll M, et al. The Pneumonia Etiology Research for Child Health Project: a 21st century childhood pneumonia etiology study. Clin Infect Dis 2012; 54: S93\u2013101."
    },
    {
        "id": "doc_3002",
        "document": "5 Gilani Z, Kwong YD, Levine OS, et al. A literature review and survey of childhood pneumonia etiology studies: 2000\u20132010. Clin Infect Dis 2012; 54 (suppl 2): S102\u201308.\n\n6 Feikin DR, Hammitt LL, Murdoch DR, O\u2019Brien KL, Scott JAG. The enduring challenge of determining pneumonia etiology in children: considerations for future research priorities. Clin Infect Dis 2017; 64: S188\u201396."
    },
    {
        "id": "doc_3003",
        "document": "7 Wu Z, DeloriaKnoll M, Hammitt LL, Zeger SL. Partially latent class models for casecontrol studies of childhood pneumonia aetiology. J R Stat Soc Ser C Appl Stat 2016; 65: 97\u2013114.\n\n8 Wu Z, DeloriaKnoll M, Zeger S. Nested partiallylatent class models for dependent binary data; estimating disease etiology. Biostatistics 2017; 18: 200\u201313."
    },
    {
        "id": "doc_3004",
        "document": "9 Deloria Knoll M, Fu W, Shi Q, et al. Bayesian estimation of pneumonia etiology: epidemiologic considerations and applications to the Pneumonia Etiology Research for Child Health Study. Clin Infect Dis 2017; 64: S213\u201327.\n\n10 Scott JAG, Wonodi C, Mo\u00efsi JC, et al. The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clin Infect Dis 2012; 54 (suppl 2): S109\u201316."
    },
    {
        "id": "doc_3005",
        "document": "11 DeloriaKnoll M, Feikin DR, Scott JAG, et al. Identification and selection of cases and controls in the Pneumonia Etiology Research for Child Health Project. Clin Infect Dis 2012; 54: S117\u201323.\n\n12 WHO. Pocket book of hospital care for children: guidelines for the management of common illnesses with limited resources. 2005. http://whqlibdoc.who.int/publications/2005/9241546700.pdf. (accessed July 1, 2018)."
    },
    {
        "id": "doc_3006",
        "document": "13 Higdon MM, Hammitt LL, Deloria Knoll M, et al. Should controls with respiratory symptoms be excluded from casecontrol studies of pneumonia etiology? Reflections from the PERCH study. Clin Infect Dis 2017; 64: S205\u201312.\n\n14 DeLuca AN, Regenberg A, Sugarman J, Murdoch DR, Levine O. Bioethical considerations in developing a biorepository for the Pneumonia Etiology Research for Child Health Project. Clin Infect Dis 2012; 54: S172\u201379."
    },
    {
        "id": "doc_3007",
        "document": "15 Crawley J, Prosperi C, Baggett HC, et al. Standardization of clinical assessment and sample collection across all PERCH study sites. Clin Infect Dis 2017; 64: S228\u201337.\n\n16 Watson NL, Prosperi C, Driscoll AJ, et al. Data management and data quality in PERCH, a large international casecontrol study of severe childhood pneumonia. Clin Infect Dis 2017; 64: S238\u201344."
    },
    {
        "id": "doc_3008",
        "document": "17 Driscoll AJ, Karron RA, Morpeth SC, et al. Standardization of laboratory methods for the PERCH study. Clin Infect Dis 2017; 64: S245\u201352.\n\n18 The PERCH Study Group. The Pneumonia Etiology Research for Child Health Project (PERCH) study materials. 2012. https://www. jhsph.edu/ivac/resources/perchbackgroundandmethods/ (accessed Sept 1, 2018)."
    },
    {
        "id": "doc_3009",
        "document": "19 Cherian T, Mulholland EK, Carlin JB, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005; 83: 353\u201359.\n\n20 Fancourt N, Deloria Knoll M, BargerKamate B, et al. Standardized interpretation of chest radiographs in cases of pediatric pneumonia from the PERCH study. Clin Infect Dis 2017; 64: S253\u201361."
    },
    {
        "id": "doc_3010",
        "document": "21 Fancourt N, DeloriaKnoll M, Baggett HC, et al. Chest radiograph findings in childhood pneumonia cases from the multisite PERCH study. Clin Infect Dis 2017; 64 (suppl 3): S262\u201370.\n\n22 Murdoch DR, O\u2019Brien KL, Driscoll AJ, Karron RA, Bhat N. Laboratory methods for determining pneumonia etiology in children. Clin Infect Dis 2012; 54 (suppl 2): S146\u201352."
    },
    {
        "id": "doc_3011",
        "document": "23 Feikin DR, Fu W, Park DE, et al. Is Higher viral load in the upper respiratory tract associated with severe pneumonia? Findings from the PERCH study. Clin Infect Dis 2017; 64: S337\u201346.\n\n24 Park DE, Baggett HC, Howie SRC, et al. Colonization density of the upper respiratory tract as a predictor of pneumonia\u2014 Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Pneumocystis jirovecii. Clin Infect Dis 2017; 64: S328\u201336."
    },
    {
        "id": "doc_3012",
        "document": "25 Baggett HC, Watson NL, Deloria Knoll M, et al. Density of upper respiratory colonization with Streptococcus pneumoniae and its role in the diagnosis of pneumococcal pneumonia among children aged <5 years in the PERCH study. Clin Infect Dis 2017; 64: S317\u201327."
    },
    {
        "id": "doc_3013",
        "document": "26 Morpeth SC, Deloria Knoll M, Scott JAG, et al. Detection of pneumococcal DNA in blood by polymerase chain reaction for diagnosing pneumococcal pneumonia in young children from low and middleincome countries. Clin Infect Dis 2017; 64: S347\u201356.\n\n27 Deloria Knoll M, Morpeth SC, Scott JAG, et al. Evaluation of pneumococcal load in blood by polymerase chain reaction for the diagnosis of pneumococcal pneumonia in young children in the PERCH study. Clin Infect Dis 2017; 64: S357\u201367."
    },
    {
        "id": "doc_3014",
        "document": "28 Driscoll AJ, Deloria Knoll M, Hammitt LL, et al. The effect of antibiotic exposure and specimen volume on the detection of bacterial pathogens in children with pneumonia. Clin Infect Dis 2017; 64: S368\u201377.\n\n29 Zar HJ, Barnett W, Stadler A, GardnerLubbe S, Myer L, Nicol MP. Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested casecontrol study of the Drakenstein Child Health Study. Lancet Respir Med 2016; 4: 463\u201372."
    },
    {
        "id": "doc_3015",
        "document": "30 Murdoch DR, Morpeth SC, Hammitt LL, et al. Microscopic analysis and quality assessment of induced sputum from children with pneumonia in the PERCH study. Clin Infect Dis 2017; 64: S271\u201379.\n\n31 Murdoch DR, Morpeth SC, Hammitt LL, et al. The diagnostic utility of induced sputum microscopy and culture in childhood pneumonia. Clin Infect Dis 2017; 64: S280\u201388."
    },
    {
        "id": "doc_3016",
        "document": "32 Thea DM, Seidenberg P, Park DE, et al. Limited utility of polymerase chain reaction in induced sputum specimens for determining the causes of childhood pneumonia in resourcepoor settings: findings from the Pneumonia Etiology Research for Child Health (PERCH) study. Clin Infect Dis 2017; 64: S289\u2013300."
    },
    {
        "id": "doc_3017",
        "document": "33 Turner P, Hinds J, Turner C, et al. Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. J Clin Microbiol 2011; 49: 1784\u201389.\n\n34 WHO. Technical bases for the WHO recommendations on the management of pneumonia in children at firstlevel health facilities: programme for the control of acute respiratory infections. Geneva: World health Organization, 1991."
    },
    {
        "id": "doc_3018",
        "document": "35 Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis, 3rd edn. Boca Raton, FL: Taylor & Francis Group, 2014.\n\n36 Hammitt LL, Feikin DR, Scott JAG, et al. Addressing the analytic challenges of crosssectional pediatric pneumonia etiology data. Clin Infect Dis 2017; 64: S197\u2013204.\n\n37 WHO. WHO AnthroPlus software. 2009. http://www.who.int/ growthref/tools/en/ (accessed Dec 1, 2017)."
    },
    {
        "id": "doc_3019",
        "document": "38 Jain S, Williams DJ, Arnold SR, et al. Communityacquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372: 835\u201345.\n\n39 B\u00e9net T, Picot VS, Awasthi S, et al. Severity of pneumonia in under 5yearold children from developing countries: a multicenter, prospective, observational study. Am J Trop Med Hyg 2017; 97: 68\u201376."
    },
    {
        "id": "doc_3020",
        "document": "40 Tang JW, Lam TT, Zaraket H, et al. Global epidemiology of noninfluenza RNA respiratory viruses: data gaps and a growing need for surveillance. Lancet Infect Dis 2017; 17: e320\u201326.\n\n778\n\nwww.thelancet.com Vol 394 August 31, 2019\n\nArticles\n\n41 Spichak TV, Yatsyshina SB, Katosova LK, Kim SS, Korppi MO. Is the role of rhinoviruses as causative agents of pediatric communityacquired pneumonia overestimated? Eur J Pediatr 2016; 175: 1951\u201358."
    },
    {
        "id": "doc_3021",
        "document": "42 Pretorius MA, Tempia S, Walaza S, et al. The role of influenza, RSV and other common respiratory viruses in severe acute respiratory infections and influenzalike illness in a population with a high HIV seroprevalence, South Africa 2012\u20132015. J Clin Virol 2016; 75: 21\u201326.\n\n43 Dagan R, Shriker O, Hazan I, et al. Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol 1998; 36: 669\u201373."
    },
    {
        "id": "doc_3022",
        "document": "44 Dowell SF, Garman RL, Liu G, Levine OS, Yang YH. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001; 32: 824\u201325.\n\n45 Johnson HL, DeloriaKnoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7: e1000348."
    },
    {
        "id": "doc_3023",
        "document": "46 Cutts FT, Zaman SMA, Enwere G, et al. Efficacy of ninevalent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, doubleblind, placebocontrolled trial. Lancet 2005; 365: 1139\u201346.\n\n47 Klugman KP, Madhi S a, Huebner R, et al. A trial of a 9valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341\u201348."
    },
    {
        "id": "doc_3024",
        "document": "48 Tregnaghi MW, S\u00e1ezLlorens X, L\u00f3pez P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiDCV) in young Latin American children: a doubleblind randomized controlled trial. PLoS Med 2014; 11: e1001657."
    },
    {
        "id": "doc_3025",
        "document": "49 Piralam B, Tomczyk SM, Rhodes JC, et al. Incidence of\n\npneumococcal pneumonia among adults in rural Thailand, 2006\u20132011: Implications for pneumococcal vaccine considerations. Am J Trop Med Hyg 2015; 93: 1140\u201347.\n\n50 Rhodes J, Dejsirilert S, Maloney SA, et al. Pneumococcal bacteremia requiring hospitalization in rural Thailand: an update on incidence, clinical characteristics, serotype distribution, and antimicrobial susceptibility, 2005\u20132010. PLoS One 2013; 8: e66038."
    },
    {
        "id": "doc_3026",
        "document": "51 Baggett HC, Peruski LF, Olsen SJ, et al. Incidence of pneumococcal bacteremia requiring hospitalization in rural Thailand. Clin Infect Dis 2009; 48: S65\u201374.\n\n52 Moore DP, Higdon MM, Hammitt LL, et al. The incremental value of repeated induced sputum and gastric aspirate samples for the diagnosis of pulmonary tuberculosis in young children with acute communityacquired pneumonia. Clin Infect Dis 2017; 64: S309\u201316."
    },
    {
        "id": "doc_3027",
        "document": "53 Nicol MP, Zar HJ. New specimens and laboratory diagnostics for childhood pulmonary TB: progress and prospects. Paediatr Respir Rev 2011; 12: 16\u201321.\n\n54 BargerKamate B, Deloria Knoll M, Kagucia EW, et al. Pertussisassociated pneumonia in infants and children from low and middleincome countries participating in the PERCH Study. Clin Infect Dis 2016; 63: S187\u201396."
    },
    {
        "id": "doc_3028",
        "document": "55 Ideh RC, Howie SRC, Ebruke B, et al. Transthoracic lung aspiration for the aetiological diagnosis of pneumonia: 25 years of experience from The Gambia. Int J Tuberc Lung Dis 2011; 15: 729\u201335.\n\n56 Dawood FS, Fry AM, Goswami D, et al. Incidence and characteristics of early childhood wheezing, Dhaka, Bangladesh, 2004\u20132010. Pediatr Pulmonol 2016; 51: 588\u201395."
    },
    {
        "id": "doc_3029",
        "document": "57 Murray EL, Brondi L, Kleinbaum D, et al. Cooking fuel type, household ventilation, and the risk of acute lower respiratory illness in urban Bangladeshi children: a longitudinal study. Indoor Air 2012; 22: 132\u201339.\n\n58 Silk BJ, Cohen AL, Abedin J, et al. Household air quality risk factors associated with childhood pneumonia in urban Dhaka, Bangladesh. Am J Trop Med Hyg 2014; 90: 968\u201375."
    },
    {
        "id": "doc_3030",
        "document": "59 Ngari MM, Fegan G, Mwangome MK, et al. Mortality after inpatient treatment for severe pneumonia in children: a cohort study. Paediatr Perinat Epidemiol 2017; 31: 233\u201342.\n\n60 Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, casecontrol study. Lancet 2013; 382: 209\u201322."
    },
    {
        "id": "doc_3031",
        "document": "61 Fry AM, Curns AT, Harbour K, Hutwagner L, Holman RC, Anderson LJ. Seasonal trends of human parainfluenza viral infections: United States, 1990\u20132004. Clin Infect Dis 2006; 43: 1016\u201322.\n\n62 Cox N. Influenza seasonality: timing and formulation of vaccines. Bull World Health Organ 2014; 92: 311\u201311."
    },
    {
        "id": "doc_3032",
        "document": "63 Broutin H, Gu\u00e9gan JF, Elguero E, Simondon F, Cazelles B. Largescale comparative analysis of pertussis population dynamics: periodicity, synchrony, and impact of vaccination. Am J Epidemiol 2005; 161: 1159\u201367.\n\n64 Omori R, Nakata Y, Tessmer HL, Suzuki S, Shibayama K. The determinant of periodicity in Mycoplasma pneumoniae incidence: an insight from mathematical modelling. Sci Rep 2015; 5: 14473."
    },
    {
        "id": "doc_3033",
        "document": "65 B\u00e9net T, S\u00e1nchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, casecontrol study. Clin Infect Dis 2017; 54: S93\u2013101.\n\n66 Selwyn BJ, Coordinated Data Group of BOSTID Researchers. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev Infect Dis 1990; 12: S870\u201388."
    },
    {
        "id": "doc_3034",
        "document": "67 Bale JR. Creation of a research program to determine the etiology and epidemiology of acute respiratory tract infection among children in developing countries. Rev Infect Dis 1990; 12 (suppl 8): S861\u201366.\n\n68 Feikin D, Scott J, Gessner B. Use of vaccines as probes to define disease burden. Lancet 2014; 383: 1762\u201370."
    },
    {
        "id": "doc_3035",
        "document": "69 Saha SK, Schrag SJ, El Arifeen S, et al. Causes and incidence of communityacquired serious infections among young children in south Asia (ANISA): an observational cohort study. Lancet 2018; 392: 145\u201359.\n\n70 International Vaccine Access Center. VIEWhub: Data visualization platform. http://www.viewhub.org (accessed July 1, 2018).\n\nwww.thelancet.com Vol 394 August 31, 2019\n\n779\n\n\\NTIAT/ | N % \u2019\\\u20181 L K&\n\n& OOQ\n\nGlobal Strategy for\n\nUpdated 2023\n\n\u00a9 2023 Global Initiative for Asthma\n\n\\\\\u201cTMT/P wod T"
    },
    {
        "id": "doc_3036",
        "document": "Global Strategy for Asthma Management and Prevention (2023 update)"
    },
    {
        "id": "doc_3037",
        "document": "The reader acknowledges that this report is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessing and treating patients, health professionals are strongly advised to use their own professional judgment, and to take into account local and national regulations and guidelines. GINA cannot be held"
    },
    {
        "id": "doc_3038",
        "document": "liable or responsible for inappropriate healthcare associated with the use of this document, including any use which is not in accordance with applicable local or national regulations or guidelines."
    },
    {
        "id": "doc_3039",
        "document": "Suggested citation: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from: www.ginasthma.org\n\n1\n\nTable of contents"
    },
    {
        "id": "doc_3040",
        "document": "ables and figures reface lembers of GINA committees (2022-23) \\bbreviations 10 lethodology 13 Vhat's NewW in GINA 2023 7........coiiiiiiici s e e e a e eb s e e bR A R AR e d s e b e n s n b 17 TION 1.ADULTS, ADOLESCENTS AND CHILDREN 6 YEARS AND OLDER 21 hapter 1. Definition, description, and diagnosis of asthma 21 Definition of asthma 22 Description of asthma 22 Making the initial diagnosis 23 Confirming the diagnosis of asthma in patients already taking ICS-containing treatment 29"
    },
    {
        "id": "doc_3041",
        "document": "Differential diagnosis 30 How to make the diagnosis of asthma in other contexts 31 \u2018hapter 2. Assessment of asthma 33 Overview 35 Assessing asthma symptom control 36 Assessing future risk of adverse outcomes 40 Role of lung function in assessing asthma control 41 Assessing asthma severity 42 hapter 3. Treating asthma to control symptoms and minimize risk 47 3.1. General principles of asthma management 48 Long-term goals of asthma management 49 The patient-health care provider partnership 49"
    },
    {
        "id": "doc_3042",
        "document": "Personalized control-based asthma management 50 3.2. Medications and strategies for symptom control and risk reduction 53 Asthma medications 55 Asthma treatment steps for adults, adolescents and children 6\u201411 years 68 STEP 1 68 STEP 2 71 STEP 3 74 STEP 4 76 STEP 5 78 Reviewing response and adjusting treatment... 81 Other strategies for adjusting asthma treatment 84"
    },
    {
        "id": "doc_3043",
        "document": "SECTION\n\n2"
    },
    {
        "id": "doc_3044",
        "document": "Treating other modifiable risk factors 84 Other therapies 86 Non-pharmacological strategies 88 Indications for referral for expert advice 97 3.3. Guided asthma self-management education and skills training 98 Skills training for effective use of inhaler devices 98 Shared decision-making for choice of inhaler device 98 Adherence with medications and with other advice 101 Asthma information 102 Training in guided asthma self-management 103"
    },
    {
        "id": "doc_3045",
        "document": "3.4. Managing asthma with multimorbidity and in specific populations 106 Managing multimorbidity 106 Managing asthma during the COVID-19 pandemic 109 Managing asthma in specific populations or settings 112 3.5. Difficult-to-treat and severe asthma in adults and adolescents 120 Definitions: uncontrolled, difficult-to-treat and severe asthma 121 Prevalence: how many people have severe asthmMa? ......cc.cocuiiiiiiiiiii e 121 Importance: the impact of severe asthma 122"
    },
    {
        "id": "doc_3046",
        "document": "Investigate and manage difficult-to-treat asthma in adults and adolescents 127 Assess and treat severe asthma phenotypes 129 Manage and monitor severe asthma treatment 136 apter 4. Management of worsening-asthma and exacerbations 139 Overview 141 Diagnosis of exacerbations 142 Self-management of exacerbations with a written asthma action plan ... 142 Management of asthma exacerbations in primary care (adults, adolescents, chidren 6\u201411 years) 147"
    },
    {
        "id": "doc_3047",
        "document": "Management of asthma exacerbations in the emergency department (adults, adolescents, children 6-11 years)150 Discharge planning and follow-up. 156 apter 5. Diagnosis and initial treatment of adults with features of asthma, COPD or both.... 159 Objectives 161 Background to diagnosing asthma and/or COPD in adult patients 161 Assessment and management of patients with chronic respiratory symptoms 162 Future research 167 [ION 2.CHILDREN 5 YEARS AND YOUNGER 169"
    },
    {
        "id": "doc_3048",
        "document": "apter 6. Diagnosis and management of asthma in children 5 years and younger 169 6.1. Diagnosis 170"
    },
    {
        "id": "doc_3049",
        "document": "3.3.\n\n3.4.\n\n3.5.\n\nChapter\n\nChapter\n\nSECTION\n\nChapter\n\n6.1.\n\n3"
    },
    {
        "id": "doc_3050",
        "document": "Asthma and wheezing in young children 170 Clinical diagnosis of asthma 171 Tests to assist in diagnosis 173 Differential diagnosis 175 6.2. Assessment and management 177 Goals of asthma management 177 Assessment of asthma 177 Medications for symptom control and risk reduction 179 Asthma treatment steps for children aged 5 years and younger 181 Reviewing response and adjusting treatment 184 Choice of inhaler device 184 Asthma self-management education for carers of young children 186"
    },
    {
        "id": "doc_3051",
        "document": "6.3. Management of worsening asthma and exacerbations in children 5 years and younger 187 Diagnosis of exacerbations 187 Initial home management of asthma exacerbations 188 Primary care or hospital management of acute asthma exacerbations in children 5 years or younger 190 hapter 7. Primary prevention of asthma in children 195 Factors contributing to the development of asthma in children 196 Factors associated with increased or decreased risk of asthma in children 196"
    },
    {
        "id": "doc_3052",
        "document": "Advice about primary prevention of asthma 199 CTION 3. TRANSLATION INTO CLINICAL PRACTICE... 201 hapter 8. Implementing asthma management strategies into health systems.. 01 Introduction ... 202 Adapting and implementing asthma clinical practice guidelines 202 Barriers and facilitators 204 Examples of high impact implementation interventions 204 Evaluation of the implementation process 205 How can GINA help with implementation? ............ooo it 205 FERENCES 206"
    },
    {
        "id": "doc_3053",
        "document": "SECTION\n\n4\n\nTables and figures\n\nDIAGNOSIS"
    },
    {
        "id": "doc_3054",
        "document": "Box 1-1 Diagnostic flowchart for clinical practice 24 Box 1-2 Diagnostic criteria for asthma in adults, adolescents, and children 6-11 years 25 Box 1-3 Steps for confirming the diagnosis of asthma in a patient already taking ICS-containing treatment 28 Box 1-4 How to step down ICS-containing treatment to help confirm the diagnosis of asthma 29 Box 1-5 Differential diagnosis of asthma in adults, adolescents and children 6\u201411 years 30 ASSESSMENT"
    },
    {
        "id": "doc_3055",
        "document": "Box 2-1. Assessment of asthma in adults, adolescents, and children 6-11 years 35 Box 2-2. GINA assessment of asthma control in adults, adolescents and children 6-11 years 38 Box 2-3. Specific questions for assessment of asthma in children 6-11 years 39 Box 2-4. Investigating a patient with poor symptom control and/or exacerbations despite treatment 45 ASTHMA MANAGEMENT Box 3-1 Communication strategies for health care providers 49"
    },
    {
        "id": "doc_3056",
        "document": "Box 3-2 The asthma management cycle for personalized asthma care 50 Box 3-3 Population level versus patient level decisions about asthma treatment 52 Box 3-4 Terminology for asthma medications 56 Box 3-5 Asthma treatment tracks for adults and adolescents 58 Initial treatment choices Box 3-6. Initial asthma treatment - recommended options for adults and adolescents 59 Box 3-7. Selecting initial treatment in adults and adolescents with a diagnosis of asthma 60"
    },
    {
        "id": "doc_3057",
        "document": "Box 3-8. Flowchart for initial treatment in adults and adolescents with of asthma 61 selecting a diagnosis Box 3-9. Initial asthma treatment \u2014 recommended options for children aged 6\u201411 years 62 Box 3-10. Selecting initial treatment in children aged 6\u201411 with a diagnosis of asthma 63 years Box 3-11. Flowchart for selecting initial treatment in children aged 6\u201411 years with a diagnosis of asthma 64 Main treatment figures"
    },
    {
        "id": "doc_3058",
        "document": "Box 3-12 Personalized management for adults and adolescents to control symptoms and minimize future risk 65 Box 3-13 Personalized management for children 6\u201411 to control symptoms and minimize future risk 66 years Box 3-14 Low, medium and high daily metered doses of inhaled corticosteroids (alone or with LABA) 67 Box 3-15 Medications and doses for GINA Track 1: anti-inflammatory reliever (AIR)-based therapy 80 Ongoing management"
    },
    {
        "id": "doc_3059",
        "document": "Box 3-16 Options for stepping down treatment in adults and adolescents once asthma is well controlled 83 Box 3-17 Treating potentially modifiable risk factors to reduce exacerbations 85 Box 3-18 Non-pharmacological interventions \u2014 summary 88 Box 3-19 Effectiveness of avoidance measures for indoor allergens 93 Box 3-20 Indications for considering referral for expert advice, where available 97 Box 3-21 Shared decision-making between health professional and patient about choice of inhalers 99"
    },
    {
        "id": "doc_3060",
        "document": "Box 3-22 Choice and effective use of inhaler devices 100 Box 3-23 Poor adherence with prescribed maintenance treatment in asthma 102 Box 3-24 Asthma information 103 Difficult-to-treat and severe asthma Box 3-25 What proportion of adults have difficult-to-treat or severe asthma? 121 Box 3-26 Decision tree \u2014 investigate and manage difficult to treat asthma in adult and adolescent patients 123 Box 3-27 Decision tree \u2014 assess and treat severe asthma phenotypes 124"
    },
    {
        "id": "doc_3061",
        "document": "Box 3-28 Decision tree \u2014 consider add-on biologic Type 2-targeted treatments 125 Box 3-29 Decision tree \u2014 monitor and manage severe asthma treatment 126"
    },
    {
        "id": "doc_3062",
        "document": "5"
    },
    {
        "id": "doc_3063",
        "document": "Box 4-1 Factors that increase the risk of asthma-related death 141 Box 4-2 Self-management of worsening asthma in adults and adolescents with a written asthma action plan 146 Box 4-3 Management of asthma exacerbations in primary care (adults, adolescents, children 6\u201411 years) 148 Box 4-4 Management of asthma exacerbations in acute care facility, e.g. emergency department 152 Box 4-5 Discharge management after hospital or emergency department care for asthma 157 ASTHMA, COPD AND ASTHMA+COPD"
    },
    {
        "id": "doc_3064",
        "document": "Box 5-1. Current definitions of asthma and COPD, and clinical description of asthma-COPD overlap 162 Box 5-2. Approach to initial treatment in patients with asthma and/or COPD 163 Box 5-3. Spirometric measures in asthma and COPD 164 Box 5-4. Specialized investigations sometimes used in patients with features of asthma and COPD 166 CHILDREN 5 YEARS AND YOUNGER Box 6-1 Probability of asthma diagnosis in children 5 years and younger 171"
    },
    {
        "id": "doc_3065",
        "document": "Box 6-2 Features suggesting a diagnosis of asthma in children 5 years and younger 172 Box 6-3 Questions that can be used to elicit features suggestive of asthma 173 Box 6-4 Common differential diagnoses of asthma in children 5 years and younger 175 Box 6-5 GINA assessment of asthma control in children 5 years and younger 178 Box 6-6 Personalized management of asthma in children 5 years and younger 183 Box 6-7 Low daily doses of inhaled corticosteroids for children 5 years and younger 184"
    },
    {
        "id": "doc_3066",
        "document": "Box 6-8 Choosing an inhaler device for children 5 years and younger 185 Box 6-9 Management of acute asthma or wheezing in children 5 years and younger 189 Box 6-10. Initial assessment of acute asthma exacerbations in children 5 years and younger 190 Box 6-11. Indications for immediate transfer to hospital for children 5 years and younger 191 Box 6-12. Initial emergency department management of asthma exacerbations in children 5 years and younger 192 PRIMARY PREVENTION OF ASTHMA IN CHILDREN"
    },
    {
        "id": "doc_3067",
        "document": "Box 7-1. Advice about primary prevention of asthma in children 5 years and younger 199 IMPLEMENTATION STRATEGIES Box 8-1 Approach to implementation of the Global Strategy for Asthma Management and Prevention 203 Box 8-2 Essential elements required to implement a health-related strategy 203 Box 8-3 Examples of barriers to the implementation of evidence-based recommendations 204 Box 8-4 Examples of high-impact implementation interventions in asthma management 204"
    },
    {
        "id": "doc_3068",
        "document": "6\n\nPreface\n\nAsthma is a serious global health problem affecting all age groups. Its prevalence is increasing in many countries, especially among children. Although some countries have seen a decline in hospitalizations and deaths from asthma, asthma still imposes an unacceptable burden on health care systems, and on society through loss of productivity in the workplace and, especially for pediatric asthma, disruption to the family."
    },
    {
        "id": "doc_3069",
        "document": "This year, the Global Initiative for Asthma celebrates 30 years of working to improve the lives of people with asthma by translating medical evidence into better asthma care worldwide. Established in 1993 by the National Heart, Lung, and Blood Institute and the World Health Organization, GINA works with healthcare professionals, researchers, patients and public health officials around the world to reduce asthma prevalence, morbidity and mortality. The Global Strategy for Asthma Management and"
    },
    {
        "id": "doc_3070",
        "document": "Prevention (\u2018GINA Strategy Report\u2019) was first published in 1995, and has been updated annually since 2002 by the GINA Science Committee. It contains guidance for primary care practitioners, specialists and allied health professionals, based on the latest high quality evidence available. More resources and supporting material are provided online at www.ginasthma.org."
    },
    {
        "id": "doc_3071",
        "document": "GINA supports global efforts to achieve environmental sustainability in health care, while ensuring that our guidance reflects an optimal balance between clinical and environmental priorities, with a particular focus on patient safety. GINA also supports efforts to ensure global availability of, and access to, effective quality-assured medications, to reduce the burden of asthma mortality and morbidity. Since 2001, GINA has organized the annual World Asthma Day, a focus for local and national"
    },
    {
        "id": "doc_3072",
        "document": "activities to raise awareness of asthma and educate families and health care professionals about effective asthma care. In 2023, the theme for World Asthma Day is \u2018Asthma Care for All\u2019."
    },
    {
        "id": "doc_3073",
        "document": "GINA is an independent organization funded solely through sale and licensing of its educational publications. Members of the GINA Board of Directors are drawn globally from leaders with an outstanding demonstrated commitment to asthma research, asthma clinical management, public health and patient advocacy. GINA Science Committee members are highly experienced asthma experts from around the world, who continually review and synthesize scientific evidence to provide guidance on asthma prevention,"
    },
    {
        "id": "doc_3074",
        "document": "diagnosis and management. The GINA Dissemination Task Group is responsible for promoting GINA resources throughout the world. Members work with an international network of patient representatives and leaders in asthma care (GINA Advocates), to implement asthma education programs and support evidence-based care. GINA support staff comprise the Executive Director and Project Manager."
    },
    {
        "id": "doc_3075",
        "document": "We acknowledge the superlative work of all who have contributed to the success of the GINA program. In particular, we recognize the outstanding long-term dedication of founding Scientific Director Dr Suzanne Hurd and founding Executive Director Dr Claude Lenfant in fostering GINA\u2019s development until their retirement in 2015. We acknowledge the invaluable commitment and skill of our current Executive Director Ms Rebecca Decker, BS, MSJ. We continue to recognize the contribution of Prof J Mark"
    },
    {
        "id": "doc_3076",
        "document": "FitzGerald to GINA for over 25 years until his passing in 2022. We also thank all members of the Science Committee, who receive no honoraria or reimbursement for their many hours of work in reviewing evidence and attending meetings, and the GINA Dissemination Task Group and Advocates."
    },
    {
        "id": "doc_3077",
        "document": "We hope you find this report to be a useful resource in the management of asthma and that it will help you work with each of your patients to provide the best personalized care,\n\nHelen K Reddel, MBBS PhD Chair, GINA Science Committee\n\nArzu Yorganc\u0131o\u011flu, MD Chair, GINA Board of Directors\n\n7\n\nMembers of GINA committees (2022\u201323)"
    },
    {
        "id": "doc_3078",
        "document": "GINA SCIENTIFIC COMMITTEE\n\nHelen K. Reddel, MBBS PhD, Chair Woolcock Institute of Medical Research, Macquarie University Sydney, Australia\n\nLeonard B. Bacharier, MD Vanderbilt University Medical Center Nashville, TN, USA\n\nEric D. Bateman, MD University of Cape Town Lung Institute Cape Town, South Africa"
    },
    {
        "id": "doc_3079",
        "document": "Matteo Bonini MD, PhD\n\nDepartment of Cardiovascular and Thoracic Sciences, Universit\u00e0 Cattolica del Sacro Cuore Rome, Italy National Heart and Lung Institute (NHLI), Imperial College London, UK\n\nLouis-Philippe Boulet, MD Universit\u00e9 Laval Qu\u00e9bec, QC, Canada\n\nArnaud Bourdin, MD, PhD Department of Respiratory Diseases, University of Montpellier"
    },
    {
        "id": "doc_3080",
        "document": "Montpellier, France\n\nChristopher Brightling, FMedSci, PhD Leicester NIHR Biomedical Research Centre, University of Leicester Leicester, UK\n\nGuy Brusselle, MD, PhD Ghent University Hospital Ghent, Belgium\n\nRoland Buhl, MD PhD Mainz University Hospital Mainz, Germany\n\nJeffrey M. Drazen, MD Brigham and Woman\u2019s Hospital Boston, MA, USA\n\nFrancine Ducharme, MD"
    },
    {
        "id": "doc_3081",
        "document": "Departments of Pediatrics and of Social and Preventive Medicine, Sainte-Justine University Health Centre, University of Montreal Montreal, Quebec, Canada Liesbeth Duijts, MD MSc Phd University Medical Center Rotterdam, The Netherlands Louise Fleming, MBChB MD Royal Brompton Hospital London, United Kingdom Hiromasa Inoue, MD Kagoshima University Kagoshima, Japan Fanny Wai-san Ko, MD The Chinese University of Hong Kong Hong Kong Refiloe Masekela MBBCh, PhD Department of Paediatrics and Child"
    },
    {
        "id": "doc_3082",
        "document": "Health, University of KwaZulu Natal Durban, South Africa Kevin Mortimer, BA/MA, MB/BChir, PhD Liverpool School of Tropical Medicine Liverpool, UK Department of Paediatrics and Child Health, College of Health Sciences, School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa Paulo Pitrez, MD, PhD Hospital Moinhos de Vento Porto Alegre, Brazil Sundeep Salvi MD, PhD Pulmocare Research and Education (PURE) Foundation Pune, India"
    },
    {
        "id": "doc_3083",
        "document": "Aziz Sheikh, BSc, MBBS, MSc, MD The University of Edinburgh Edinburgh, United Kingdom\n\n8\n\nGINA BOARD OF DIRECTORS\n\nArzu Yorgancioglu, MD Chair Celal Bayar University Department of Pulmonology Manisa, Turkey\n\nKeith Allan, CBiol, MRSB Patient Partner University Hospitals of Leicester Leicester, UK\n\nEric D. Bateman, MD University of Cape Town Lung Institute Cape Town, South Africa\n\nGuy Brusselle, MD, PhD Ghent University Hospital Ghent, Belgium"
    },
    {
        "id": "doc_3084",
        "document": "Muhwa Jeremiah Chakaya, MD Respiratory Society of Kenya Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University Nairobi, Kenya\n\nAlvaro A. Cruz, MD Federal University of Bahia Salvador, BA, Brazil\n\nHiromasa Inoue, MD Kagoshima University Kagoshima, Japan\n\nJerry A. Krishnan, MD PhD University of Illinois Hospital & Health Sciences System Chicago, IL, USA\n\nMark L. Levy, MD Locum GP London, UK"
    },
    {
        "id": "doc_3085",
        "document": "Helen K. Reddel, MBBS PhD Woolcock Institute of Medical Research, Macquarie University Sydney, Australia"
    },
    {
        "id": "doc_3086",
        "document": "GINA DISSEMINATION TASK GROUP\n\nMark L. Levy, MD (Chair) Locum GP London, UK\n\nKeith Allan, CBiol, MRSB Patient Partner University Hospitals of Leicester Leicester, UK\n\nHiromasa Inoue, MD Kagoshima University Kagoshima, Japan\n\nHelen K. Reddel, MBBS PhD, Chair Woolcock Institute of Medical Research, Macquarie University Sydney, Australia\n\nArzu Yorgancioglu, MD Celal Bayar University Department of Pulmonology Manisa, Turkey\n\nGINA PROGRAM\n\nRebecca Decker, BS, MSJ\n\nKristi Rurey, AS"
    },
    {
        "id": "doc_3087",
        "document": "EDITORIAL ASSISTANCE\n\nCharu Grover, PhD Jenni Harman, BVSc, BA\n\nGRAPHICS ASSISTANCE\n\nKate Chisnall\n\nINFORMATION DESIGN\n\nTomoko Ichikawa, MS Hugh Musick, MBA Institute for Healthcare Delivery Design University of Illinois, Chicago, USA\n\nDisclosures for members of GINA committees can be found at www.ginasthma.org\n\n9\n\nAbbreviations"
    },
    {
        "id": "doc_3088",
        "document": "ABPA Allergic bronchopulmonary aspergillosis ACE Angiotensin-converting enzyme ACQ Asthma Control Questionnaire ACT Asthma Control Test (see also cACT) AERD Aspirin-exacerbated respiratory disease AIR Anti-inflammatory reliever (see Box 3-4, p.56) ANCA Antineutrophil cytoplasmic antibody Anti-IL4Ra Anti-interleukin 4 receptor alpha (monoclonal antibody) Anti-IL5 Anti-interleukin 5 (monoclonal antibody) Anti-ILSR Anti-interleukin 5 receptor (monoclonal antibody)"
    },
    {
        "id": "doc_3089",
        "document": "Anti-TSLP Anti-thymic stromal lymphopoietin (monoclonal antibody) APGAR Activities, Persistent, triGgers, Asthma medications, Response to ATS/ERS American Thoracic Society and European Respiratory Society BDP Beclometasone dipropionate BD Bronchodilator BMI Body mass index BNP B-type natriuretic peptide bpm Beats per minute BTS British Thoracic Society cACT Childhood Asthma Control Test CBC Complete blood count (also known as full blood count [FBC])"
    },
    {
        "id": "doc_3090",
        "document": "CDC Centers for Disease Control and Prevention [USA] Cl Confidence interval COPD Chronic obstructive pulmonary disease COVID-19 Coronavirus disease 2019 CRP C-reactive protein CRSwWNP Chronic rhinosinusitis with nasal polyps CRSsNP Chronic rhinosinusitis without nasal polyps CT Computerized tomography CXR Chest X-ray DLCO Diffusing capacity in the lung for carbon monoxide DEXA Dual-energy X-ray absorptiometry DPI Dry-powder inhaler ED Emergency department"
    },
    {
        "id": "doc_3091",
        "document": "EGPA Eosinophilic granulomatosis with polyangiitis FeNO Fractional concentration of exhaled nitric oxide EEN/. Earced avniratarvy valiime in 1 ecarand (meaaciirad hyv enircnmaoatrs)"
    },
    {
        "id": "doc_3092",
        "document": "FEV1 Forced expiratory volume in 1 second (measured by spirometry)\n\nto therapy\n\n10\n\nAbbreviations\n\nFVC Forced vital capacity (measured by spirometry)"
    },
    {
        "id": "doc_3093",
        "document": "FVC Forced vital capacity (measured by spirometry) FEV1/FVC Ratio of forced expiratory volume in 1 second to forced vital capacity GERD Gastro-esophageal reflux disease (GORD in some countries) GOLD Global Initiative for Chronic Obstructive Pulmonary Disease GRADE Grading of Recommendations Assessment, Development and Evaluation (an approach to cli practice guideline development) HDM House dust mite HEPA High-efficiency particulate air HFA Hydrofluoroalkane propellant"
    },
    {
        "id": "doc_3094",
        "document": "HIV/AIDS Human immunodeficiency virus/acquired immunodeficiency syndrome ICS Inhaled corticosteroid lg Immunoglobulin IL Interleukin IM Intramuscular ICU Intensive care unit v Intravenous LABA Long-acting-betaz agonist LAMA Long-acting muscarinic antagonist (also called long-acting anticholinergic) LMIC Low- and middle-income countries LTRA Leukotriene receptor antagonist (also called leukotriene modifier)"
    },
    {
        "id": "doc_3095",
        "document": "MART Maintenance-and-reliever therapy (with ICS-formoterol); in some countries called SMART (si inhaler maintenance-and-reliever therapy) n.a Not applicable NSAID Nonsteroidal anti-inflammatory drug NO2 Nitrogen dioxide (air pollutant) 02 Oxygen 0oCs Oral corticosteroids OSA Obstructive sleep apnea PaCO:2 Arterial partial pressure of carbon dioxide PaO2 Arterial partial pressure of oxygen PEF Peak expiratory flow"
    },
    {
        "id": "doc_3096",
        "document": "PM10 Particulate matter with a particle diameter of 10 micrometers or less (air pollution) pMDI Pressurized metered-dose inhaler QTc Corrected QT interval on electrocardiogram RCT Randomized controlled trial SABA Short-acting betaz agonist SC Subcutaneous SCIT Subcutaneous allergen immunotherapy Abbreviatione"
    },
    {
        "id": "doc_3097",
        "document": "Abbreviations\n\nclinical"
    },
    {
        "id": "doc_3098",
        "document": "(single-\n\n11\n\nsIgE Specific immunoglobulin E\n\nSLIT Sublingual immunotherapy\n\nS02 Sulfur dioxide (air pollutant)\n\nT2 Type 2 airway inflammation (an asthma phenotype)\n\nTSLP Thymic stromal lymphopoietin\n\nURTI Upper respiratory tract infection\n\nWHO World Health Organization\n\nVCD Vocal cord dysfunction (included in inducible laryngeal obstruction)\n\nWHO-PEN The World Health Organization Package of Essential Noncommunicable disease interventions for primary care\n\n12\n\nAbbreviations\n\nMethodology"
    },
    {
        "id": "doc_3099",
        "document": "GINA SCIENCE COMMITTEE"
    },
    {
        "id": "doc_3100",
        "document": "The GINA Science Committee was established in 2002 to review published research on asthma management and prevention, to evaluate the impact of this research on recommendations in GINA documents, and to provide yearly updates to these documents. The members are recognized leaders in asthma research and clinical practice, with the scientific expertise to contribute to the task of the Committee. They are invited to serve for a limited period and in a voluntary capacity. The Committee is broadly"
    },
    {
        "id": "doc_3101",
        "document": "representative of adult and pediatric disciplines, and members are drawn from diverse geographic regions. The Science Committee normally meets twice yearly, in conjunction with the American Thoracic Society (ATS) and European Respiratory Society (ERS) international conferences, to review asthma-related scientific literature. During COVID-19, meetings of the Science Committee were held online each month. Statements of interest for Committee members are found on the GINA website www.ginasthma.org."
    },
    {
        "id": "doc_3102",
        "document": "PROCESSES FOR UPDATES AND REVISIONS OF THE GINA STRATEGY REPORT\n\nLiterature search"
    },
    {
        "id": "doc_3103",
        "document": "Details are provided on the GINA website (www.ginasthma.org/about-us/methodology). In summary, two PubMed searches are performed each year, each covering the previous 18 months, using filters established by the Science Committee. The search terms include asthma, all ages, only items with abstracts, clinical trial or meta-analysis or systematic review, and human. The search is not limited to specific PICOT (Population, Intervention, Comparison, Outcomes, Time) questions. The \u2018clinical trial\u2019"
    },
    {
        "id": "doc_3104",
        "document": "publication type includes not only conventional randomized controlled trials, but also pragmatic, real-life and observational studies. The search for systematic reviews includes, but is not limited to, those conducted using GRADE methodology.1 An additional search is conducted for guidelines documents published by other international organizations. The respiratory community is also invited to submit any other fully published peer-reviewed publications for consideration, providing that the full"
    },
    {
        "id": "doc_3105",
        "document": "paper is submitted in (or translated into) English; however, because of the comprehensive process for literature review, such ad hoc submissions have rarely resulted in substantial changes to the report."
    },
    {
        "id": "doc_3106",
        "document": "Systematic reviews"
    },
    {
        "id": "doc_3107",
        "document": "Unique among evidence-based recommendations in asthma, and most other therapeutic areas, GINA conducts an ongoing twice-yearly update of the evidence base for its recommendations. GINA does not carry out or commission its own GRADE-based reviews, because of the current cost of such reviews, the large number of PICOT questions that would be necessary for a comprehensive practical report of this scope, and because it would limit the responsiveness of the GINA Strategy Report to emerging evidence"
    },
    {
        "id": "doc_3108",
        "document": "and new developments in asthma management. However, the Science Committee reviews relevant systematic reviews conducted with GRADE methodology as part of its normal review process, once such reviews are published. GINA recommendations are constantly being reviewed and considered for update as new evidence (including GRADE-based systematic reviews on specific topics) is identified and indicates the need."
    },
    {
        "id": "doc_3109",
        "document": "Literature screening and review"
    },
    {
        "id": "doc_3110",
        "document": "Each article identified by the literature search, after removal of duplicates and those already reviewed, is pre-screened in Covidence for relevance and major quality issues by the Editorial Assistant and by at least two non-conflicted members of the Science Committee. Each publication selected from screening is reviewed for quality and relevance by at least two members of the Science Committee, neither of whom may be an author (or co-author) or declare a conflict of interest in relation to the"
    },
    {
        "id": "doc_3111",
        "document": "publication. Articles that have been accepted for publication and are online in advance of print are eligible for full text review if the approved/corrected copy-edited proof is available. All members receive a copy of all abstracts and full text publications, and non-conflicted members have the opportunity to provide comments during the pre-meeting review period. Members evaluate the abstract and the full text publication, and answer written questions in a review template about whether the"
    },
    {
        "id": "doc_3112",
        "document": "scientific data impact on GINA recommendations, and if so, what specific changes"
    },
    {
        "id": "doc_3113",
        "document": "Methodology\n\n13\n\nshould be made. In 2020, the Critical Appraisal Skills Programme (CASP) checklist2 was provided in the review template to assist in evaluation of systematic reviews. A list of all publications reviewed by the Committee is posted on the GINA website (www.ginasthma.org)."
    },
    {
        "id": "doc_3114",
        "document": "Discussion and decisions during Science Committee meetings\n\nEach publication that is assessed by at least one reviewer to potentially impact on the GINA Strategy Report is discussed in a Science Committee meeting (virtual or face-to-face). This process comprises three parts, as follows:"
    },
    {
        "id": "doc_3115",
        "document": "1. Quality and relevance of original research and systematic review publications. First, the Committee considers the relevance of the publication to the GINA Strategy Report, the quality of the study, the reliability of the findings, and the interpretation of the results, based on the responses from reviewers and discussion by members of the Committee. For systematic reviews, GRADE assessments, if available, are taken into account. However, for any systematic review, GINA members also"
    },
    {
        "id": "doc_3116",
        "document": "independently consider the clinical relevance of the question addressed by the review, and the scientific and clinical validity of the included populations and study design. During this discussion, a member who is an author (or was involved in the study) may be requested to provide clarification or respond to questions about the study, but they may not otherwise take part in this discussion about the quality and relevance of the publication."
    },
    {
        "id": "doc_3117",
        "document": "2. Decision about inclusion of the evidence. During this phase, the Committee decides whether the publication or its findings affect GINA recommendations or statements and should be included in the GINA Strategy Report. These decisions to modify the report or its references are made by consensus by Committee members present and, again, any member with a conflict of interest is excluded from these decisions. If the chair is an author on a publication being reviewed, an alternative chair is"
    },
    {
        "id": "doc_3118",
        "document": "appointed to lead the discussion in part 1 and the decision in part 2 for that publication."
    },
    {
        "id": "doc_3119",
        "document": "3. Discussion about related changes to the GINA Strategy Report. If the committee resolves to include the publication or its findings in the report, an author or conflicted member, if present, is permitted to take part in the subsequent discussions about and decisions on changes to the report, including the positioning of the study findings in the report and the way that they would be integrated with existing (or other new) components of the GINA management strategy. These discussions may take"
    },
    {
        "id": "doc_3120",
        "document": "place immediately, or over the course of the year as new evidence emerges or as other changes to the report are agreed and implemented. The approach to managing conflicts of interest, as described above, also applies to members of the GINA Board who ex-officio attend GINA Science Committee meetings."
    },
    {
        "id": "doc_3121",
        "document": "As with all previous GINA Strategy Reports, levels of evidence are assigned to management recommendations where appropriate. Current criteria (Table A; p.15) are based on those originally developed by the National Heart Lung and Blood Institute. From 2019, GINA has included in \u2018Level A\u2019 strong observational evidence that provides a consistent pattern of findings in the population for which the recommendation is made, and has also described the values and preferences that were taken into account"
    },
    {
        "id": "doc_3122",
        "document": "in making major new recommendations. The table was updated in 2021 to avoid ambiguity about the positioning of observational data and systematic reviews."
    },
    {
        "id": "doc_3123",
        "document": "New therapies and indications\n\nThe GINA Strategy Report is a global strategy document. Since regulatory approvals differ from country to country, and manufacturers do not necessarily make regulatory submissions in all countries, some GINA recommendations are likely to be off-label in some countries. This is a particular issue for pediatrics, where across different diseases, many treatment recommendations for pre-school children and for children aged 6\u201311 years are off-label."
    },
    {
        "id": "doc_3124",
        "document": "For new therapies, GINA\u2019s aim is to provide clinicians with evidence-based guidance about new therapies and their positioning in the overall asthma treatment strategy as soon as possible; otherwise the gap between regulatory approval and the periodic update of many national guidelines is filled only by advertising or educational material produced by the manufacturer or distributor. For new therapies for which the GINA Science Committee considers there is sufficient good- quality evidence for"
    },
    {
        "id": "doc_3125",
        "document": "safety and efficacy or effectiveness in relevant asthma populations, recommendations may be held until after approval for asthma by at least one major regulatory agency (e.g. European Medicines Agency or US Food and Drug Administration), since regulators often receive substantially more safety and/or efficacy data on new medications than are available to GINA through peer-reviewed literature. However, decisions by GINA to make or not make a recommendation about any therapy, or about its use in"
    },
    {
        "id": "doc_3126",
        "document": "any specific population, are based on the best available"
    },
    {
        "id": "doc_3127",
        "document": "14\n\nMethodology\n\npeer-reviewed evidence and not on labeling directives from regulators."
    },
    {
        "id": "doc_3128",
        "document": "For existing therapies with evidence for new regimens or in different populations, the Science Committee may, where relevant, make recommendations that are not necessarily covered by regulatory indications in any country at the time, provided the Committee is satisfied with the available evidence around safety and efficacy/effectiveness. Since the GINA Strategy Report represents a global strategy, the report does not refer to recommendations being \u2018off-label\u2019. However, readers are advised that,"
    },
    {
        "id": "doc_3129",
        "document": "when assessing and treating patients, they should use their own professional judgment and should also take into account local and national guidelines and eligibility criteria, as well as locally licensed drug doses."
    },
    {
        "id": "doc_3130",
        "document": "External review\n\nPrior to publication each year, the GINA Strategy Report undergoes extensive external review by patient advocates and by asthma care experts from primary and specialist care in multiple countries. There is also continuous external review throughout the year in the form of feedback from end-users and stakeholders through the contact form on the GINA website.\n\nTable A. Description of levels of evidence used in this report"
    },
    {
        "id": "doc_3131",
        "document": "Evidence level Sources of evidence Definition A Randomized controlled trials (RCTs), systematic reviews, observational evidence. Rich body of data. Evidence is from endpoints of well-designed RCTs, systematic reviews of relevant studies or observational studies that provide a consistent pattern of findings in the population for which the recommendation is made. Category A requires substantial numbers of studies involving substantial numbers of participants."
    },
    {
        "id": "doc_3132",
        "document": "B Randomized controlled trials and systematic reviews. Limited body of data. Evidence is from endpoints of intervention studies that include only a limited number of patients, post hoc or subgroup analysis of RCTs or systematic reviews of such RCTs. In general, Category B applies when few randomized trials exist, they are small in size, they were undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent."
    },
    {
        "id": "doc_3133",
        "document": "C Nonrandomized trials or observational studies. Evidence is from non-randomized trials or observational studies. D Panel consensus judgment. This category is used only in cases where the provision of some guidance was deemed valuable but the clinical literature addressing the subject was insufficient to justify placement in one of the other categories. The Panel Consensus is based on clinical experience or knowledge that does not meet the above listed criteria."
    },
    {
        "id": "doc_3134",
        "document": "LITERATURE REVIEWED FOR GINA 2023 UPDATE"
    },
    {
        "id": "doc_3135",
        "document": "The GINA Strategy Report has been updated in 2023 following the routine twice-yearly review of the literature by the GINA Science Committee. The literature searches for \u2018clinical trial\u2019 publication types (see above), systematic reviews and guidelines identified a total of 3698 publications, of which 3118 duplicates/animal studies/non-asthma/pilot studies and protocols were removed. A total of 580 publications underwent screening of title and abstract by at least two reviewers, and 491 were"
    },
    {
        "id": "doc_3136",
        "document": "screened out for relevance and/or quality. A total of 89 publications underwent full-text review by at least two members of the Science Committee, and 52 publications were subsequently discussed at meetings of the Science Committee. A list of key changes in GINA 2023 can be found starting on p.17, and a tracked changes copy is archived on the GINA website at www.ginasthma.org/archived-reports/."
    },
    {
        "id": "doc_3137",
        "document": "Methodology\n\n15\n\nFUTURE CHALLENGES"
    },
    {
        "id": "doc_3138",
        "document": "Despite laudable efforts to improve asthma care over the past 30 years, and the availability of effective medications, many patients globally have not benefited from advances in asthma treatment and often lack even the rudiments of care. Many of the world\u2019s population live in areas with inadequate medical facilities and meager financial resources. GINA recognizes that the recommendations found in this report must be adapted to fit local practices and the availability of healthcare resources. To"
    },
    {
        "id": "doc_3139",
        "document": "improve asthma care and patient outcomes, evidence-based recommendations must also be disseminated and implemented nationally and locally, and integrated into health systems and clinical practice. Implementation requires an evidence-based strategy involving professional groups and stakeholders and considering local cultural and socioeconomic conditions. GINA is a partner organization in the Global Alliance against Chronic Respiratory Diseases (GARD). Through the work of GINA, and in cooperation"
    },
    {
        "id": "doc_3140",
        "document": "with GARD and the International Union Against Tuberculosis and Lung Diseases (IUATLD), substantial progress toward better care for all patients with asthma should be achieved in the next decade."
    },
    {
        "id": "doc_3141",
        "document": "At the most fundamental level, patients in many areas do not have access to any inhaled corticosteroid-containing medications, which are the cornerstone of care for asthma patients of all severity. More broadly, medications remain the major contributor to the overall costs of asthma management, so the access to and pricing of high quality asthma medications continues to be an issue of urgent need and a growing area of research interest.3-5 The safest and most effective approach to asthma"
    },
    {
        "id": "doc_3142",
        "document": "treatment in adolescents and adults, which also avoids the consequences of starting treatment with SABA alone, depends on access to ICS\u2013formoterol across all asthma severity levels.6,7 Budesonide- formoterol is included in the World Health Organization (WHO) essential medicines list, so the fundamental changes to treatment of mild asthma first included in the 2019 GINA Strategy Report may provide a feasible solution to reduce the risk of severe exacerbations in low- and middle-income countries.7"
    },
    {
        "id": "doc_3143",
        "document": "The urgent need to ensure access to affordable, quality-assured inhaled asthma medications as part of universal health coverage must now be prioritized by all relevant stakeholders, particularly manufacturers of relevant inhalers. GINA is collaborating with IUATLD and other organizations to work towards a World Health Assembly Resolution to improve equitable access to affordable care, including inhaled medicines, for children, adolescents and adults with asthma.5\n\n16\n\nMethodology"
    },
    {
        "id": "doc_3144",
        "document": "What\u2019s new in GINA 2023?\n\nThe GINA Strategy Report has been updated in 2023 following the routine twice-yearly cumulative review of the literature by the GINA Scientific Committee. A copy showing tracked changes from the GINA 2022 report is archived on the GINA website.\n\nKEY CHANGES"
    },
    {
        "id": "doc_3145",
        "document": "\u2022 Clarification of terminology for asthma medications: a new table (Box 3-4, p.56) has been added to clarify terminology for types of asthma medications, including the different meanings of \u2018maintenance\u2019 and \u2018controller\u2019 medications. The term \u2018controller\u2019 has been replaced where appropriate by \u2018maintenance treatment\u2019 or \u2018ICS-containing treatment\u2019. The term anti-inflammatory reliever (\u2018AIR\u2019), including as-needed ICS-formoterol and as-needed ICS-SABA, reflects the dual purpose of these reliever"
    },
    {
        "id": "doc_3146",
        "document": "inhalers. It is important to distinguish between as-needed use of an anti- inflammatory reliever on its own (\u2018AIR-only\u2019) in Steps 1\u20132, and maintenance and reliever therapy (\u2018MART\u2019) with ICS- formoterol in Steps 3\u20135. We suggest including these definitions in health professional education."
    },
    {
        "id": "doc_3147",
        "document": "\u2022 New commentary explaining the asthma management cycle: Commentary has been added to Box 3-2 (p.50) to assist clinicians to explain the asthma management cycle (assessment \u2013 adjustment \u2013 review) to patients, and to health professionals during education presentations. This figure is repeated in the GINA treatment figures for all age- groups, as a reminder about the key elements of asthma management."
    },
    {
        "id": "doc_3148",
        "document": "\u2022 Addition of as-needed ICS-SABA to GINA 2023 treatment figure for adults and adolescents: The figure (Box 3-12, p.65) has been updated to include as-needed combination ICS-SABA (an anti-inflammatory reliever) in GINA Track 2. This addition was based on a clinical trial in patients taking GINA Steps 3\u20135 maintenance treatment, showing that using budesonide-salbutamol (budesonide-albuterol) as the reliever reduced the risk of severe exacerbations, compared with a salbutamol (albuterol) reliever."
    },
    {
        "id": "doc_3149",
        "document": "Most of the benefit was seen in patients taking Step 3 treatment. Additional details are found on p.74, p.76 and p.78. Only one small randomized controlled trial has examined as- needed-only ICS-SABA for Steps 1\u20132, and more studies are needed in children and adolescents. ICS-SABA is not recommended for regular maintenance therapy, so it cannot be used for maintenance and reliever therapy."
    },
    {
        "id": "doc_3150",
        "document": "Despite the addition of ICS-SABA reliever in Track 2, GINA Track 1 with as-needed ICS-formoterol remains the preferred treatment approach for adults and adolescents (Box 3-12, p.65). The reasons are: (a) the evidence from multiple large randomized controlled trials (RCTs), both highly controlled and pragmatic, that ICS-formoterol reliever is superior to SABA for reducing severe exacerbations. Evidence supporting ICS-SABA is comparatively limited: a single RCT comparing as-needed ICS-SABA and"
    },
    {
        "id": "doc_3151",
        "document": "as-needed SABA in Steps 3\u20135, and a small proof-of-concept study with as- needed-only ICS-SABA in Step 2; (b) the reduction in emergency department visits or hospitalizations with as-needed- only ICS-formoterol in patients previously taking SABA alone, low-dose ICS or LTRA: by 65% compared with SABA alone, and by 37% compared with daily ICS plus as-needed SABA; and (c) the simplicity of the Track 1 approach for patients and clinicians, because the same medication is used for both symptom relief"
    },
    {
        "id": "doc_3152",
        "document": "and, if needed, maintenance treatment. Treatment can be adjusted up or down, when clinically appropriate, by adding/removing maintenance doses, without needing to add a different medication or inhaler device."
    },
    {
        "id": "doc_3153",
        "document": "\u2022 Practical guidance on medications and doses for GINA Track 1: More details have been provided in a new table (Box 3-15, p.80). Details about doses are also included where relevant throughout the report, including in sections on treatment steps (starting on p.68), and asthma action plans (p.142). This information has been added in response to requests by clinicians and academics, and to address incorrect advice about dosage of ICS-formoterol in some commonly used external clinical resources. We"
    },
    {
        "id": "doc_3154",
        "document": "also cite an article written by authors from GINA and the 2020 NAEPP Focused Updates to US asthma guidelines,8 which provides practical advice about MART for clinicians, including a template for a written asthma action plan customized for use with this regimen."
    },
    {
        "id": "doc_3155",
        "document": "\u2022 Update of GINA 2023 treatment figure for children 6\u201311 years (Box 3-13, p.66): Mepolizumab, an anti- interleukin-5 antibody given by subcutaneous injection, has been added to the preferred maintenance treatment options at Step 5 for children with severe eosinophilic asthma, after specialist referral and optimization of treatment. A\n\nWhat\u2019s new in GINA 2023?\n\n17"
    },
    {
        "id": "doc_3156",
        "document": "double-blind RCT in urban children taking high dose ICS or ICS-LABA demonstrated a reduction in severe exacerbations with add-on mepolizumab compared with placebo (p.133).\n\n\u2022 Clarification of GINA 2023 treatment figure for children 5 years and younger (Box 6-6, p.183): To avoid confusion, the Step 1 box for \u2018Preferred controller\u2019 now states that there is \u2018Insufficient evidence for maintenance treatment\u2019."
    },
    {
        "id": "doc_3157",
        "document": "\u2022 Addition of environmental considerations for inhaler choice: The section about choice of inhalers has been expanded, and a new figure added (Box 3-21, p.99), with more details about the issues that should be considered, including the environmental impact of the inhalers themselves. The issues include, first, choosing the most appropriate medication for the patient to reduce exacerbations and control symptoms and then, from the inhalers available for that medication, assessing which inhaler the"
    },
    {
        "id": "doc_3158",
        "document": "patient can use correctly after training; if there is more than one option, which of them has the lowest environmental impact, and whether the patient is satisfied with the inhaler. Reducing the risk of asthma exacerbations is a high-priority objective because of their burden to patients and to the healthcare system; urgent health care also has a high environmental impact. As always, GINA stresses the importance of regularly checking inhaler technique for every patient, and correcting it when"
    },
    {
        "id": "doc_3159",
        "document": "faulty."
    },
    {
        "id": "doc_3160",
        "document": "\u2022 Additional advice on management of asthma in low- and middle-income countries: Advice has been provided about management of asthma in countries that lack access to essential inhaled asthma medications (p.112).9 GINA is actively contributing to international efforts to improve access to affordable essential asthma medications for all.4,5,7,10"
    },
    {
        "id": "doc_3161",
        "document": "\u2022 Updated advice on definition of mild asthma: Further discussion has been added about the limitations of the current retrospective definition of mild asthma, and the contrast between this academic definition and the common usage of \u2018mild asthma\u2019 in respiratory literature and in clinical practice. Interim advice about how to describe asthma severity in various scenarios (clinical practice, education of health professionals, epidemiologic studies and clinical trials) has been expanded and"
    },
    {
        "id": "doc_3162",
        "document": "clarified (p.42). GINA is continuing discussion on this topic with a range of groups, including patients and primary and specialist health professionals."
    },
    {
        "id": "doc_3163",
        "document": "\u2022 Updated guidance on managing severe asthma: This includes clarification that, regardless of regulatory approvals, GINA recommends biologic therapy for asthma only if asthma is severe, and only if existing treatment has been optimized. The sections about classes of biologic therapy in Chapter 3.5 provide a brief summary of the now-extensive evidence base, not a detailed review. Because of the variability between populations, settings and background exacerbation rates in different studies of"
    },
    {
        "id": "doc_3164",
        "document": "biologic therapies, specific results are reported from meta-analyses as a general indication of magnitude of effect, but not from individual studies, with the exception of data on OCS reduction. With expanding indications for biologic therapy, additional non-asthma indications are mentioned only if they are relevant to asthma management, or if the condition is commonly associated with asthma. Other updates in Chapter 3.5 include the recommendation for mepolizumab in children aged \u22656 years with"
    },
    {
        "id": "doc_3165",
        "document": "eosinophilic asthma, noted above; and a double-blind study of withdrawal of mepolizumab in adults with eosinophilic asthma, that found more exacerbations in those who ceased mepolizumab than those who continued treatment (p.136)."
    },
    {
        "id": "doc_3166",
        "document": "\u2022 New practical guide to management of asthma exacerbations: Following multiple requests, additional details have been added about medications and doses for as-needed ICS-formoterol and as-needed ICS-SABA in the section on written asthma action plans, together with a reference for a downloadable action plan customized for maintenance and reliever therapy (MART) with ICS-formoterol (p.142). Information has also been added about studies supporting the use of budesonide-formoterol for acute asthma"
    },
    {
        "id": "doc_3167",
        "document": "in emergency department settings (p.150)."
    },
    {
        "id": "doc_3168",
        "document": "Safety issues\n\n\u2022 Pulse oximetry: the FDA has issued a safety communication about the potential overestimation of oxygen saturation from pulse oximetry in people with dark skin color (p.151)."
    },
    {
        "id": "doc_3169",
        "document": "\u2022 Advice about potential drug interactions between anti-COVID-19 treatment such as ritonavir-boosted nirmatrelvir (NMV/r) and asthma medications including ICS-salmeterol and ICS-vilanterol. This advice is included because several key drug interaction websites recommend that LABAs should be stopped if NMV/r is prescribed, without advising that\n\n18\n\nWhat\u2019s new in GINA 2023?"
    },
    {
        "id": "doc_3170",
        "document": "this could result in an asthma exacerbation. Advice about drug interactions has also been added in the section about management of allergic bronchopulmonary aspergillosis (p.118).\n\nOther changes include the following:\n\no Imaging: a brief section has been added about the role of imaging in the diagnosis of asthma (p.28).\n\no Pertussis has been added as a differential diagnosis for asthma (p.30), and for exacerbations of asthma (p.139)."
    },
    {
        "id": "doc_3171",
        "document": "o Asthma Control Questionnaire (ACQ): GINA again advises use of the 5-item version (ACQ-5), rather than ACQ-6 or ACQ-7 (p.37). Data for ACQ-5, ACQ-6 and ACQ-7 cannot be combined for meta-analysis."
    },
    {
        "id": "doc_3172",
        "document": "o Composite asthma control tools: Because patients with good symptom control can still be at risk of severe exacerbations, and because of the many modifiable risk factors for exacerbations that are independent of symptom control (Box 2-2B, p.38), GINA does not recommend assessment tools that combine symptom control with exacerbation history; both symptom control and individual risk factors should be assessed (p.35)."
    },
    {
        "id": "doc_3173",
        "document": "o Advice about managing asthma during the COVID-19 pandemic: Advice has been added about management of asthma if patients acquire COVID-19, including potential drug interactions (p.118).\n\no FeNO-guided treatment: A well-conducted multinational study in children found that adding FeNO to symptom- guided treatment did not result in fewer exacerbations (p.84). Updates of the 2016 Cochrane reviews on this topic to include additional studies in children and adults are awaited."
    },
    {
        "id": "doc_3174",
        "document": "o Update of evidence on digital interventions for adherence: A Cochrane review found that a variety of digital intervention strategies improved adherence to maintenance asthma medications, reduced exacerbations, and improved asthma control, in studies of up to 2 years\u2019 duration in adults and children. Effective interventions included electronic monitoring of maintenance inhaler use and text messages (p.101)."
    },
    {
        "id": "doc_3175",
        "document": "o Nasal and sinus disease: this material (p.108) has been divided into separate sections about rhinitis and sinusitis, and chronic rhinosinusitis with and without nasal polyps (CRSwNP and CRSsNP respectively).\n\no Transitioning of adolescents from pediatric to adult care: Additional information has been provided about important issues to consider during this vulnerable period, based on new guidelines from the European Academy of Allergy and Clinical Immunology (p.113)"
    },
    {
        "id": "doc_3176",
        "document": "o Fragility fractures: the cumulative adverse effects of exposure to oral corticosteroids include not just osteoporosis, but also fragility fractures, which in the elderly can have serious effects on quality of life, and often require healthcare utilization. The risk of fragility fractures has been included in several places."
    },
    {
        "id": "doc_3177",
        "document": "o Non-pharmacologic strategies: New evidence has been included about the benefit of physical activity in adults with moderate/severe asthma (p.90). A systematic review of comprehensive social risk interventions in the USA found a reduction in emergency room visits. Evidence from other countries and settings is needed (p.95)."
    },
    {
        "id": "doc_3178",
        "document": "o Outdoor air pollution: use of digital monitoring devices identified an impact of higher pollution on asthma medication utilization, with a lag of 0\u20133 days (p.95). This may be useful in predicting need for additional resources at healthcare facilities.\n\no Vaccinations: additional evidence is included about the safety of influenza vaccination in people with asthma. There is insufficient evidence to recommend routine pneumococcal or pertussis vaccination in adults (p.87)."
    },
    {
        "id": "doc_3179",
        "document": "Structure and format\n\n\u2022 Appendix: The Appendix will be replaced by a yearly supplement published after the GINA Strategy Report, explaining the evidence and rationale for recent major changes in more detail than is possible in this \u2018What\u2019s New\u2019 summary. Appendices published up to 2020 are available in the online archive."
    },
    {
        "id": "doc_3180",
        "document": "\u2022 Treatment steps for adults, adolescents and children 6\u201311 years: Information in Chapter 3.2 about new or updated treatment recommendations has been restructured, where possible, to provide details under the headings of population, evidence, other considerations and practice points.\n\nWhat\u2019s new in GINA 2023?\n\n19"
    },
    {
        "id": "doc_3181",
        "document": "\u2022 Boxes and tables: For simplicity, boxes (tables and figures) have been renumbered consecutively within each chapter. Abbreviations have been removed from figures and tables to reduce crowding, and they are now included at the beginning of the report, accessed by a hyperlink from underneath each Box. The publication year has been added to the main treatment figures to help avoid external use of out-of-date versions."
    },
    {
        "id": "doc_3182",
        "document": "\u2022 COVID-19: Given the marked reduction in COVID-19 cases in most countries, the section on management of asthma during the pandemic has been moved to Chapter 3.3 (p.109).\n\n\u2022 Short guide on difficult-to-treat and severe asthma: Chapter 3.5 of the GINA 2023 report about difficult-to-treat and severe asthma, including the decision tree, will be published shortly as a stand-alone resource, now in a larger format than the previous \u2018pocket\u2019 guide, to improve its readability and utility."
    },
    {
        "id": "doc_3183",
        "document": "Topics still under discussion"
    },
    {
        "id": "doc_3184",
        "document": "\u2022 Diagnosis of asthma: Discussion is ongoing about the diagnosis of asthma in adults and in children, following review of recent guidelines on diagnosis of asthma in children aged 5\u201316 years11 and in adults.12 Further work is needed to evaluate the utility for clinical practice of their consensus-based algorithms. Both algorithms recommended FeNO testing instead of bronchodilator responsiveness testing for patients whose prebronchodilator lung function is above specified criteria; this would"
    },
    {
        "id": "doc_3185",
        "document": "require testing on a second day, since FeNO must be performed before spirometry. The ATS/ERS technical standard on interpretive strategies for routine lung function tests13 was also reviewed. The authors recommended a change in the criterion for significant bronchodilator responsiveness in FEV1 or FVC to 10% of the predicted value, but cautioned against over-reliance on strict cut-offs. As bronchodilator responsiveness defined by the conventional criterion of change >12% and >200 mL was used as"
    },
    {
        "id": "doc_3186",
        "document": "a gold standard for the evaluation of diagnostic tests by the above two guidelines groups, it would be helpful for the effect of the proposed new bronchodilator responsiveness criterion on the sensitivity and specificity of these diagnostic tests to be assessed. For the present, no changes have been made to the GINA box about diagnostic investigations (Box 1-2, p.25), except to reverse the order of confirming variability in lung function, and confirming that there is evidence of expiratory"
    },
    {
        "id": "doc_3187",
        "document": "airflow limitation, to address some ambiguity with the previous wording. The GINA diagnostic flow-chart (Box 1-2, p.24) starts by assessing whether the patient or child\u2019s symptoms are typical of asthma or more typical of other conditions, as the latter should prompt alternative investigations rather than necessarily proceeding to spirometry."
    },
    {
        "id": "doc_3188",
        "document": "\u2022 Assessment of symptom control: GINA continues to seek evidence relevant to the assessment of symptom control in patients whose reliever is ICS-formoterol.\n\n\u2022 Allergen immunotherapy: A review of updated evidence on subcutaneous allergen immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for patients with asthma is nearing completion.\n\n\u2022 Severe asthma in children 6\u201311 years: a pocket guide is in development."
    },
    {
        "id": "doc_3189",
        "document": "\u2022 Digital formats for GINA resources: investigation of digital options is ongoing, with the aim of facilitating access to GINA resources on portable devices and smartphones. Presentation of the GINA Strategy Report as an eBook is not feasible at present because bibliographic referencing programs are not yet compatible with any of the current e-Book platforms, so references would need to be re-entered manually every year."
    },
    {
        "id": "doc_3190",
        "document": "\u2022 Advice about COVID-19 will be updated promptly on the GINA website as relevant information becomes available."
    },
    {
        "id": "doc_3191",
        "document": "Note: minor corrections and clarifications 06 July 2023\n\n\u2022 Box 3-9 (p.62): Text corrected: the preferred initial treatment for children 6\u201311 years with infrequent symptoms is ICS taken whenever SABA is taken; the alternative is daily maintenance low-dose ICS plus as-needed SABA.\n\n\u2022 Box 3-12 (p.65): Order of Track 2 reliever options reversed, and footnote edited, to clarify that anti-inflammatory relievers comprise as-needed ICS-formoterol and as-needed ICS-SABA, but not SABA alone."
    },
    {
        "id": "doc_3192",
        "document": "\u2022 Box 3-15 (p.80): Minor reformatting and table and text edits for clarity including that, for children 6\u201311 years, there is no evidence for use of anti-inflammatory reliever alone in Step 1 or for MART in Step 5.\n\n\u2022 A small number of minor corrections have been made to text, reference citation numbers and incomplete citations.\n\n20\n\nWhat\u2019s new in GINA 2023?\n\nSECTION 1. ADULTS, ADOLESCENTS AND CHILDREN 6 YEARS AND OLDER\n\nChapter 1.\n\nDefinition, description, and diagnosis of asthma\n\nKEY POINTS"
    },
    {
        "id": "doc_3193",
        "document": "What is asthma?\n\n\u2022 Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough, that vary over time and in intensity, together with variable expiratory airflow limitation. Airflow limitation may later become persistent."
    },
    {
        "id": "doc_3194",
        "document": "\u2022 Asthma is usually associated with airway hyperresponsiveness and airway inflammation, but these are not necessary or sufficient to make the diagnosis.\n\n\u2022 Recognizable clusters of demographic, clinical and/or pathophysiological characteristics are often called \u2018asthma phenotypes\u2019; however, these do not correlate strongly with specific pathological processes or treatment responses."
    },
    {
        "id": "doc_3195",
        "document": "How is asthma diagnosed?\n\n\u2022 The diagnosis of asthma is based on the history of characteristic symptom patterns and evidence of variable expiratory airflow limitation. This should be documented from bronchodilator reversibility testing or other tests.\n\n\u2022 Test before treating, wherever possible, i.e. document the evidence for the diagnosis of asthma before starting ICS-containing treatment, as it is often more difficult to confirm the diagnosis once asthma control has improved."
    },
    {
        "id": "doc_3196",
        "document": "\u2022 Additional or alternative strategies may be needed to confirm the diagnosis of asthma in particular populations, including patients already on ICS-containing treatment, the elderly, and those in low-resource settings.\n\nDEFINITION OF ASTHMA"
    },
    {
        "id": "doc_3197",
        "document": "DEFINITION OF ASTHMA\n\nAsthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough, that vary over time and in intensity, together with variable expiratory airflow limitation."
    },
    {
        "id": "doc_3198",
        "document": "This definition was reached by consensus, based on consideration of the characteristics that are typical of asthma before ICS-containing treatment is commenced, and that distinguish it from other respiratory conditions. However, airflow limitation may become persistent later in the course of the disease.\n\nDESCRIPTION OF ASTHMA"
    },
    {
        "id": "doc_3199",
        "document": "Asthma is a common, chronic respiratory disease affecting 1\u201329% of the population in different countries.14,15 Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightness and/or cough, and by variable expiratory airflow limitation. Both symptoms and airflow limitation characteristically vary over time and in intensity. These variations are often triggered by factors such as exercise, allergen or irritant exposure, change in weather, or viral respiratory"
    },
    {
        "id": "doc_3200",
        "document": "infections."
    },
    {
        "id": "doc_3201",
        "document": "Symptoms and airflow limitation may resolve spontaneously or in response to medication, and may sometimes be absent for weeks or months at a time. On the other hand, patients can experience episodic flare-ups (exacerbations) of asthma that may be life-threatening and carry a significant burden to patients and the community. The majority of asthma deaths occur in low- and middle-income countries.4 Asthma is usually associated with airway hyperresponsiveness to direct or indirect stimuli, and with"
    },
    {
        "id": "doc_3202",
        "document": "chronic airway inflammation. These features usually persist, even when symptoms are absent or lung function is normal, but may normalize with treatment."
    },
    {
        "id": "doc_3203",
        "document": "Asthma phenotypes\n\nAsthma is a heterogeneous disease, with different underlying disease processes. Recognizable clusters of demographic, clinical and/or pathophysiological characteristics are often called \u2018asthma phenotypes\u2019.16-18 In patients with\n\n22\n\n1. Definition, description and diagnosis of asthma"
    },
    {
        "id": "doc_3204",
        "document": "more severe asthma, some phenotype-guided treatments are available. However, except in patients with severe asthma, no strong relationship has been found between specific pathological features and particular clinical patterns or treatment responses. More research is needed to understand the clinical utility of phenotypic classification in asthma.\n\nMany clinical phenotypes of asthma have been identified.16-18 Some of the most common are:"
    },
    {
        "id": "doc_3205",
        "document": "\u2022 Allergic asthma: this is the most easily recognized asthma phenotype, which often commences in childhood and is associated with a past and/or family history of allergic disease such as eczema, allergic rhinitis, or food or drug allergy. Examination of the induced sputum of these patients before treatment often reveals eosinophilic airway"
    },
    {
        "id": "doc_3206",
        "document": "\u2022 Non-allergic asthma: some patients have asthma that is not associated with allergy. The cellular profile of the sputum of these patients may be neutrophilic, eosinophilic or contain only a few inflammatory cells (paucigranulocytic). Patients with non-allergic asthma often demonstrate a lesser short-term response to ICS."
    },
    {
        "id": "doc_3207",
        "document": "\u2022 Adult-onset (late-onset) asthma: some adults, particularly women, present with asthma for the first time in adult life. These patients tend to be non-allergic, and often require higher doses of ICS or are relatively refractory to corticosteroid treatment. Occupational asthma (i.e. asthma due to exposures at work) should be ruled out in patients presenting with adult-onset asthma."
    },
    {
        "id": "doc_3208",
        "document": "\u2022 Asthma with persistent airflow limitation: some patients with long-standing asthma develop airflow limitation that is persistent or incompletely reversible. This is thought to be due to airway wall remodeling.\n\n\u2022 Asthma with obesity: some obese patients with asthma have prominent respiratory symptoms and little eosinophilic airway inflammation."
    },
    {
        "id": "doc_3209",
        "document": "There is little evidence about the natural history of asthma after diagnosis, but one longitudinal study showed that approximately 16% of adults with recently diagnosed asthma may experience clinical remission (no symptoms or asthma medication for at least 1 year) within 5 years.19\n\nMAKING THE INITIAL DIAGNOSIS"
    },
    {
        "id": "doc_3210",
        "document": "Making the diagnosis of asthma before treatment is started, as shown in Box 1-1 (p.24) is based on identifying both a characteristic pattern of respiratory symptoms such as wheezing, shortness of breath (dyspnea), chest tightness or cough, and variable expiratory airflow limitation.20 The pattern of symptoms is important, as respiratory symptoms may be due to acute or chronic conditions other than asthma (see Box 1-3 (p.30). If possible, the evidence supporting a diagnosis of asthma (Box 1-2,"
    },
    {
        "id": "doc_3211",
        "document": "p.25) should be documented when the patient first presents, as the features that are characteristic of asthma may improve spontaneously or with treatment. As a result, it is often more difficult to confirm a diagnosis of asthma once the patient has been started on ICS-containing treatment, because this reduces variability of both symptoms and lung function."
    },
    {
        "id": "doc_3212",
        "document": "Patterns of respiratory symptoms that are characteristic of asthma\n\nThe following features are typical of asthma and, if present, increase the probability that the patient has asthma:20\n\nRespiratory symptoms of wheeze, shortness of breath, cough and/or chest tightness:\n\n\u2022 Patients (especially adults) experience more than one of these types of symptoms.\n\n\u2022 Symptoms are often worse at night or in the early morning.\n\n\u2022 Symptoms vary over time and in intensity."
    },
    {
        "id": "doc_3213",
        "document": "\u2022 Symptoms are triggered by viral infections (colds), exercise, allergen exposure, changes in weather, laughter, or irritants such as car exhaust fumes, smoke or strong smells.\n\nThe following features decrease the probability that respiratory symptoms are due to asthma:\n\n\u2022 Isolated cough with no other respiratory symptoms (see p.31)\n\n\u2022 Chronic production of sputum\n\n\u2022 Shortness of breath associated with dizziness, light-headedness or peripheral tingling (paresthesia)\n\n\u2022 Chest pain"
    },
    {
        "id": "doc_3214",
        "document": "\u2022 Exercise-induced dyspnea with noisy inspiration.\n\n1. Definition, description and diagnosis of asthma\n\n23\n\nBox 1-1. Diagnostic flowchart for clinical practice"
    },
    {
        "id": "doc_3215",
        "document": "Patient with respiratory symptoms (Box 1-2) Are the symptoms typical of asthma? YES Detailed history/examination for asthma History/examination supports asthma diagnosis? i e NOQ m\u2014 YES Is patient already taking containing treatment? 7 Z. diagno YES i __onics NO . Clinical urgency, and en other diagnoses unlikely Perform spirometry/PEF with reversibility test (Box 1-2) Results support asthma diagnosis? 7 NO - T YES s NO Lz Empiric initial treatment NO YES (Boxes 3-6 to 3-11) YES Review response"
    },
    {
        "id": "doc_3216",
        "document": "\" Co mo 1-3 months (Box 1-2) o I rf 7% Treat for ASTHMA (Boxes 3-6 to 3-11)"
    },
    {
        "id": "doc_3217",
        "document": "PEF: peak expiratory flow (highest of three readings). When measuring PEF, use the same meter each time as the value may vary by up to 20% between different meters; prn: as-needed. See list of abbreviations (p.10)."
    },
    {
        "id": "doc_3218",
        "document": "Bronchodilator responsiveness (reversibility) may be lost during severe exacerbations or viral infections, and in long-standing asthma, and it usually decreases with inhaled corticosteroid treatment. If bronchodilator responsiveness is not found at initial presentation, the next step depends on the availability of tests and the clinical urgency of need for treatment.\n\n24\n\n1. Definition, description and diagnosis of asthma"
    },
    {
        "id": "doc_3219",
        "document": "Box 1-2. Diagnostic criteria for asthma in adults, adolescents, and children 6\u201311 years\n\n1. HISTORY OF TYPICAL VARIABLE RESPIRATORY SYMPTOMS\n\nFeature\n\nWheeze, shortness of breath,\n\nchest tightness and cough\n\n(Descriptors may vary between"
    },
    {
        "id": "doc_3220",
        "document": "cultures and by age)\n\nSymptoms or features that support the diagnosis of asthma\n\n\u2022 More than one type of respiratory symptom (in adults, isolated cough is seldom due to asthma)\n\n\u2022 Symptoms occur variably over time and vary in intensity\n\n\u2022 Symptoms are often worse at night or on waking\n\n\u2022 Symptoms are often triggered by exercise, laughter, allergens, cold air"
    },
    {
        "id": "doc_3221",
        "document": "2. CONFIRMED VARIABLE EXPIRATORY AIRFLOW LIMITATION Feature Considerations, definitions, criteria 1. Documented* excessive variability in lung function (one or more of the following) The greater the variations, or the more occasions excess variation is seen, the more confident the diagnosis. If initially negative, tests can be repeated during symptoms or in the early morning"
    },
    {
        "id": "doc_3222",
        "document": "\u00abPositive bronchodilator (BD) responsiveness (reversibility) test Adults: increase in FEV1 of >12% and >200 mL (greater confidence if increase is >15% and >400 mL). Children: increase in FEV1 from baseline of >12% predicted Measure change 10-15 minutes after 200\u2014400 mcg salbutamol (albuterol) or equivalent, compared with pre-BD readings. Positive test more likely if BD withheld before test: SABA 24 hours, twice-daily LABA 24 hours, once-daily LABA 36 hours"
    },
    {
        "id": "doc_3223",
        "document": "eExcessive variability in twice- daily PEF over 2 weeks Adults: average daily diurnal PEF variability >10% Children: average daily diurnal PEF variability >13% eIncrease in lung function after 4 weeks of treatment Adults: increase in FEV1 by >12% and >200 mL (or PEF' by >20%) from baseline after 4 weeks of ICS-containing treatment, outside respiratory infections"
    },
    {
        "id": "doc_3224",
        "document": "\u00abPositive exercise challenge test Adults: fall in FEV1 of >10% and >200 mL from baseline Children: fall in FEV1 of >12% predicted, or PEF >15% from baseline \u00abPositive bronchial challenge test (usually only for adults) Fall in FEV1 from baseline of 220% with standard doses of methacholine, or 215% with standardized hyperventilation, hypertonic saline or mannitol challenge"
    },
    {
        "id": "doc_3225",
        "document": "eExcessive variation in lung function between visits (good specificity but poor sensitivity) Adults: variation in FEV1 of >12% and >200 mL between visits, outside of respiratory infections. Children: variation in FEV1 of >12% in FEV1 or >15% in PEFT between visits (may include respiratory infections) AND"
    },
    {
        "id": "doc_3226",
        "document": "2 Documented* expiratory airflow limitation At a time when FEV1 is reduced (e.g. during testing above), confirm that FEV1/FVC is also reduced compared with the lower limit of normal (it is usually >0.75-0.80 in adults, >0.90 in children?')"
    },
    {
        "id": "doc_3227",
        "document": "See list of abbreviations (p.10). For bronchodilator responsiveness testing, use either a SABA or a rapid-acting ICS-LABA. See Box 1-3 (p.28) for how to confirm the diagnosis in patients already taking ICS-containing treatment. *Daily diurnal PEF variability is calculated from twice daily PEF as (day\u2019s highest minus day\u2019s lowest) divided by (mean of day\u2019s highest and lowest), averaged over one week. For each PEF measurement, use the highest of 3 readings. \u2020For PEF, use the same meter each time,"
    },
    {
        "id": "doc_3228",
        "document": "as PEF may vary by up to 20% between different meters. BD responsiveness may be lost during severe exacerbations or viral infections,22 and airflow limitation may become persistent over time. If reversibility is not present at initial presentation, the next step depends on the availability of other tests and the urgency of the need for treatment. In a situation of clinical urgency, asthma treatment may be commenced and diagnostic testing arranged within the next few weeks (Box 1-4, p.29), but"
    },
    {
        "id": "doc_3229",
        "document": "other conditions that can mimic asthma (Box 1-5) should be considered, and the diagnosis confirmed as soon as possible."
    },
    {
        "id": "doc_3230",
        "document": "1. Definition, description and diagnosis of asthma\n\n25\n\nWhy is it important to confirm the diagnosis of asthma?"
    },
    {
        "id": "doc_3231",
        "document": "This is important to avoid unnecessary treatment or over-treatment, and to avoid missing other important diagnoses. In adults with an asthma diagnosis in the last 5 years, one-third could not be confirmed as having asthma after repeated testing over 12 months and staged withdrawal of ICS-containing treatment. The diagnosis of asthma was less likely to be confirmed in patients who had not had lung function testing performed at the time of initial diagnosis. Some patients (2%) had serious"
    },
    {
        "id": "doc_3232",
        "document": "cardiorespiratory conditions that had been misdiagnosed as asthma.23"
    },
    {
        "id": "doc_3233",
        "document": "History and family history\n\nCommencement of respiratory symptoms in childhood, a history of allergic rhinitis or eczema, or a family history of asthma or allergy, increases the probability that the respiratory symptoms are due to asthma. However, these features are not specific for asthma and are not seen in all asthma phenotypes. Patients with allergic rhinitis or atopic dermatitis should be asked specifically about respiratory symptoms.\n\nPhysical examination"
    },
    {
        "id": "doc_3234",
        "document": "Physical examination in people with asthma is often normal. The most frequent abnormality is expiratory wheezing (rhonchi) on auscultation, but this may be absent or only heard on forced expiration. Wheezing may also be absent during severe asthma exacerbations, due to severely reduced airflow (so called \u2018silent chest\u2019), but at such times, other physical signs of respiratory failure are usually present. Wheezing may also be heard with inducible laryngeal obstruction, chronic obstructive"
    },
    {
        "id": "doc_3235",
        "document": "pulmonary disease (COPD), respiratory infections, tracheomalacia, or inhaled foreign body. Crackles (crepitations) and inspiratory wheezing are not features of asthma. Examination of the nose may reveal signs of allergic rhinitis or nasal polyps."
    },
    {
        "id": "doc_3236",
        "document": "Lung function testing to document variable expiratory airflow limitation\n\nAsthma is characterized by variable expiratory airflow limitation, i.e., expiratory lung function varies over time, and in magnitude, to a greater extent than in healthy populations. In asthma, lung function may vary between completely normal and severely obstructed in the same patient. Poorly controlled asthma is associated with greater variability in lung function than well-controlled asthma.22"
    },
    {
        "id": "doc_3237",
        "document": "Lung function testing should be carried out by well-trained operators with well-maintained and regularly calibrated equipment,24 with an inline filter to protect against transmission of infection.25 Forced expiratory volume in 1 second (FEV1) from spirometry is more reliable than peak expiratory flow (PEF). If PEF is used, the same meter should be used each time, as measurements may differ from meter to meter by up to 20%.26"
    },
    {
        "id": "doc_3238",
        "document": "A reduced FEV1 may be found with many other lung diseases (or poor spirometric technique), but a reduced ratio of FEV1 to forced vital capacity (FEV1/FVC), compared with the lower limit of normal, indicates expiratory airflow limitation. Many spirometers now include multi-ethnic age-specific predicted values.21"
    },
    {
        "id": "doc_3239",
        "document": "In clinical practice, once an obstructive defect has been confirmed, variation in airflow limitation is generally assessed from variation in FEV1 or PEF. \u2018Variability\u2019 refers to improvement and/or deterioration in symptoms and lung function. Excessive variability may be identified over the course of one day (diurnal variability), from day to day, from visit to visit, or seasonally, or from a reversibility test. \u2018Reversibility\u2019 (now called \u2018responsiveness\u2019)24 generally refers to rapid"
    },
    {
        "id": "doc_3240",
        "document": "improvements in FEV1 (or PEF), measured within minutes after inhalation of a rapid-acting bronchodilator such as 200\u2013400 mcg salbutamol,27 or more sustained improvement over days or weeks after the introduction of treatment such as ICS.27"
    },
    {
        "id": "doc_3241",
        "document": "In a patient with typical respiratory symptoms, obtaining evidence of excessive variability in expiratory lung function is an essential component of the diagnosis of asthma. Some specific examples are:\n\n\u2022 An increase in lung function after administration of a bronchodilator, or after a trial of ICS-containing treatment \u2022 A decrease in lung function after exercise or during a bronchial provocation test"
    },
    {
        "id": "doc_3242",
        "document": "\u2022 Variation in lung function beyond the normal range when it is repeated over time, either on separate visits, or on home monitoring over at least 1\u20132 weeks.\n\n26\n\n1. Definition, description and diagnosis of asthma"
    },
    {
        "id": "doc_3243",
        "document": "Specific criteria for demonstrating excessive variability in expiratory lung function are listed in Box 1-2 (p.25). A decrease in lung function during a respiratory infection, while commonly seen in asthma, does not necessarily indicate that a person has asthma, as it may also be seen in otherwise healthy individuals or people with COPD.\n\nHow much variation in expiratory airflow is consistent with asthma?"
    },
    {
        "id": "doc_3244",
        "document": "There is overlap in bronchodilator reversibility and other measures of variation between health and disease.28 In a patient with respiratory symptoms, the greater the variations in their lung function, or the more times excess variation is seen, the more likely the diagnosis is to be asthma (Box 1-2, p.25). Generally, in adults with respiratory symptoms typical of asthma, an increase or decrease in FEV1 of >12% and >200 mL from baseline, or (if spirometry is not available) a change in PEF of at"
    },
    {
        "id": "doc_3245",
        "document": "least 20%, is accepted as being consistent with asthma."
    },
    {
        "id": "doc_3246",
        "document": "Diurnal PEF variability is calculated from twice daily readings as the daily amplitude percent mean, i.e.:\n\n( [Day\u2019s highest \u2013 day\u2019s lowest] / mean of day\u2019s highest and lowest) x 100"
    },
    {
        "id": "doc_3247",
        "document": "Then the average of each day\u2019s value is calculated over 1\u20132 weeks. The upper 95% confidence limit of diurnal variability (amplitude percent mean) from twice daily readings is 9% in healthy adults,29 and 12.3% in healthy children,30 so in general, diurnal variability >10% for adults and >13% for children is regarded as excessive."
    },
    {
        "id": "doc_3248",
        "document": "If FEV1 is within the predicted normal range when the patient is experiencing symptoms, this reduces the probability that the symptoms are due to asthma. However, patients whose baseline FEV1 is >80% predicted can have a clinically important increase in lung function with bronchodilator or ICS-containing treatment. Predicted normal ranges (especially for PEF) have limitations, so the patient\u2019s own best reading (\u2018personal best\u2019) is recommended as their \u2018normal\u2019 value."
    },
    {
        "id": "doc_3249",
        "document": "When can variable expiratory airflow limitation be documented?"
    },
    {
        "id": "doc_3250",
        "document": "If possible, evidence of variable expiratory airflow limitation should be documented before treatment is started. This is because variability usually decreases with ICS treatment as lung function improves. In addition, any increase in lung function after initiating ICS-containing treatment can help to confirm the diagnosis of asthma. Bronchodilator responsiveness may not be present between symptoms, during viral infections or if the patient has used a beta2-agonist within the previous few hours;"
    },
    {
        "id": "doc_3251",
        "document": "and in some patients, airflow limitation may become persistent or irreversible over time."
    },
    {
        "id": "doc_3252",
        "document": "If spirometry is not available, or variable expiratory airflow limitation is not documented, a decision about whether to investigate further or start ICS-containing treatment immediately depends on clinical urgency and access to other tests. Box 1-3 (p.29) describes how to confirm the diagnosis of asthma in a patient already taking ICS-containing treatment.\n\nOther tests\n\nBronchial provocation tests"
    },
    {
        "id": "doc_3253",
        "document": "One option for documenting variable expiratory airflow limitation is to refer the patient for bronchial provocation testing to assess airway hyperresponsiveness. Challenge agents include inhaled methacholine,31 histamine, exercise, 32 eucapnic voluntary hyperventilation or inhaled mannitol. These tests are moderately sensitive for a diagnosis of asthma but have limited specificity.31,32 For example, airway hyperresponsiveness to inhaled methacholine has been described in patients with allergic"
    },
    {
        "id": "doc_3254",
        "document": "rhinitis,33 cystic fibrosis,34 bronchopulmonary dysplasia35 and COPD.36 This means that a negative test in a patient not taking ICS can help to exclude asthma, but a positive test does not always mean that a patient has asthma \u2013 the pattern of symptoms (Box 1-2, p.25) and other clinical features (Box 1-3, p.28) must also be considered."
    },
    {
        "id": "doc_3255",
        "document": "Allergy tests"
    },
    {
        "id": "doc_3256",
        "document": "The presence of atopy increases the probability that a patient with respiratory symptoms has allergic asthma, but this is not specific for asthma nor is it present in all asthma phenotypes. Atopic status can be identified by skin prick testing or by measuring the level of specific immunoglobulin E (sIgE) in serum. Skin prick testing with common environmental allergens is simple and rapid to perform and, when performed by an experienced tester with standardized extracts, is inexpensive and has a"
    },
    {
        "id": "doc_3257",
        "document": "high sensitivity. Measurement of sIgE is no more reliable than skin tests and is more expensive, but may be preferred for uncooperative patients, those with widespread skin disease, or if the history suggests a risk of"
    },
    {
        "id": "doc_3258",
        "document": "1. Definition, description and diagnosis of asthma\n\n27\n\nanaphylaxis.37 The presence of a positive skin test or positive sIgE, however, does not mean that the allergen is causing symptoms \u2013 the relevance of allergen exposure and its relation to symptoms must be confirmed by the patient\u2019s history.\n\nImaging"
    },
    {
        "id": "doc_3259",
        "document": "Imaging studies are not routinely used in the diagnosis of asthma, but may be useful to investigate the possibility of comorbid conditions or alternative diagnoses in adults with difficult-to-treat asthma. Imaging may also be used to identify congenital abnormalities in infants with asthma-like symptoms, and alternative diagnoses in children with difficult-to-treat asthma. High-resolution computed tomography (CT) of the lungs can identify conditions such as bronchiectasis, emphysema, lung"
    },
    {
        "id": "doc_3260",
        "document": "nodules, airway wall thickening and lung distension, and may assess airway distensibility. The presence of radiographically detected emphysema is considered when differentiating asthma from COPD (Box 5-4, p.166), but there is no accepted threshold and these conditions can coexist. Moreover, air trapping (which may be present in asthma, and is also a feature of ageing) can be difficult to distinguish from emphysema. Chest imaging is not currently recommended to predict treatment outcomes or lung"
    },
    {
        "id": "doc_3261",
        "document": "function decline, or to assess treatment response."
    },
    {
        "id": "doc_3262",
        "document": "CT of the sinuses can identify changes suggestive of chronic rhinosinusitis with or without nasal polyps (p.108), which in patients with severe asthma may help with choice of biologic therapy (see Box 3-28, p.125).\n\nBox 1-3. Steps for confirming the diagnosis of asthma in a patient already taking ICS-containing treatment"
    },
    {
        "id": "doc_3263",
        "document": "Current status Steps to confirm the diagnosis of asthma Variable respiratory symptoms and variable airflow limitation Diagnosis of asthma is confirmed. Assess the level of asthma control (Box 2-2, p.38) and review ICS-containing treatment (Box 3-12, p.65, Box 3-13, p.66)."
    },
    {
        "id": "doc_3264",
        "document": "Variable respiratory symptoms but no variable airflow limitation Consider repeating spirometry after withholding bronchodilator (4 hrs for SABA, 24 hrs for twice- daily ICS-LABA, 36 hrs for once-daily ICS-LABA) or during symptoms. Check between-visit variability of FEV4, and bronchodilator responsiveness. If still normal, consider other diagnoses (Box 1-5, p.30)."
    },
    {
        "id": "doc_3265",
        "document": "If FEVy is >70% predicted: consider stepping down ICS-containing treatment (see Box 1-5) and reassess in 2\u20144 weeks, then consider bronchial provocation test or repeating bronchodilator responsiveness. If FEV; is <70% predicted: consider stepping up ICS-containing treatment for 3 months (Box 3-12, p.65), then reassess symptoms and lung function. If no response, resume previous treatment and referr p\ufb01tient for diagnosis and investigation."
    },
    {
        "id": "doc_3266",
        "document": "Few respiratory symptoms, normal lung function, and no variable airflow limitation"
    },
    {
        "id": "doc_3267",
        "document": "Consider repeating BD responsiveness test again after withholding bronchodilator as above or during symptoms. If normal, consider alternative diagnoses (Box 1-5, p.30). Consider stepping down ICS-containing treatment (see Box 1-5): ) If symptoms emerge and lung function falls: asthma is confirmed. Step up ICS-containing treatment to previous lowest effective dose. ) If no change in symptoms or lung function at lowest controller step: consider ceasing ICS-"
    },
    {
        "id": "doc_3268",
        "document": "containing, and monitor patient closely for at least 12 months (Box 3-16)."
    },
    {
        "id": "doc_3269",
        "document": "Persistent shortness of breath and persistent airflow limitation Consider stepping up ICS-containing treatment for 3 months (Box 3-12, p.65), then reassess symptoms and lung function. If no response, resume previous treatment and refer patient for diagnosis and investigation. Consider asthma\u2014COPD overlap (Chapter 5, p.159)."
    },
    {
        "id": "doc_3270",
        "document": "28\n\n1. Definition, description and diagnosis of asthma\n\nCONFIRMING THE DIAGNOSIS OF ASTHMA IN PATIENTS ALREADY TAKING ICS-CONTAINING TREATMENT\n\nIf the basis of a patient\u2019s diagnosis of asthma has not previously been documented, confirmation with objective testing should be sought. Many patients (25\u201335%) with a diagnosis of asthma in primary care cannot be confirmed as having asthma.23,38-41"
    },
    {
        "id": "doc_3271",
        "document": "The process for confirming the diagnosis in patients already on ICS-containing treatment depends on the patient\u2019s symptoms and lung function (Box 1-3, p.28). In some patients, this may include a trial of either a lower or a higher dose of ICS-containing treatment. If the diagnosis of asthma cannot be confirmed, refer the patient for expert investigation and diagnosis. For some patients, it may be necessary to step down the ICS-containing treatment in order to confirm the diagnosis of asthma. The"
    },
    {
        "id": "doc_3272",
        "document": "process is described in Box 1-4, p.29."
    },
    {
        "id": "doc_3273",
        "document": "Box 1-4. How to step down ICS-containing treatment to help confirm the diagnosis of asthma\n\n1. ASSESS\n\n\u2022 Document the patient\u2019s current status including asthma control (Box 2-2, p.38) and lung function. If the patient has risk factors for asthma exacerbations (Box 2-2B), step down treatment only with close supervision.\n\n\u2022 Choose a suitable time (e.g., no respiratory infection, not going away on vacation, not pregnant)."
    },
    {
        "id": "doc_3274",
        "document": "Provide a written asthma action plan (Box 4-2, p.146) so the patient knows how to recognize and respond if symptoms worsen. Ensure they have enough medication to resume their previous dose if their asthma worsens.\n\n2. ADJUST\n\nShow the patient how to reduce their ICS dose by 25\u201350%, or stop other maintenance medication (e.g., LABA, leukotriene receptor antagonist) if being used. See step-down options in Box 3-16, p.83. Schedule a review visit for 2\u2013 4 weeks."
    },
    {
        "id": "doc_3275",
        "document": "3. REVIEW RESPONSE\n\n\u2022 Repeat assessment of asthma control and lung function tests in 2\u20134 weeks (Box 1-2, p.25).\n\nIf symptoms increase and variable expiratory airflow limitation is confirmed after stepping down treatment, the diagnosis of asthma is confirmed. The patient should be returned to their lowest previous effective treatment."
    },
    {
        "id": "doc_3276",
        "document": "If, after stepping down to a low-dose ICS-containing treatment, symptoms do not worsen and there is still no evidence of variable expiratory airflow limitation, consider ceasing ICS-containing treatment and repeating asthma control assessment and lung function tests in 2\u20133 weeks, but follow the patient for at least 12 months.23\n\nSee list of abbreviations (p.10).\n\n1. Definition, description and diagnosis of asthma\n\n29"
    },
    {
        "id": "doc_3277",
        "document": "DIFFERENTIAL DIAGNOSIS\n\nThe differential diagnosis in a patient with suspected asthma varies with age (Box 1-5). Any of these alternative diagnoses may also be found together with asthma. See Chapter 3.4 (p.106) for management of multimorbidity.\n\nBox 1-5. Differential diagnosis of asthma in adults, adolescents and children 6\u201311 years"
    },
    {
        "id": "doc_3278",
        "document": "Age Symptoms Condition"
    },
    {
        "id": "doc_3279",
        "document": "6-11 years Sneezing, itching, blocked nose, throat-clearing Sudden onset of symptoms, unilateral wheeze Recurrent infections, productive cough Recurrent infections, productive cough, sinusitis Cardiac murmurs Pre-term delivery, symptoms since birth Excessive cough and mucus production, gastrointestinal symptoms Chronic upper airway cough syndrome Inhaled foreign body Bronchiectasis Primary ciliary dyskinesia Congenital heart disease Bronchopulmonary dysplasia Cystic fiprpsis"
    },
    {
        "id": "doc_3280",
        "document": "12-39 years Sneezing, itching, blocked nose, throat-clearing Dyspnea, inspiratory wheezing (stridor) Dizziness, paresthesia, sighing Productive cough, recurrent infections Excessive cough and mucus production Cardiac murmurs Shortness of breath, family history of early emphysema Chronic upper airway cough syndrome Inducible laryngeal obstruction Hyperventilation, dysfunctional breathing Bronchiectasis Cystic fibrosis Congenital heart disease Alphasi-antitrypsin deficiency"
    },
    {
        "id": "doc_3281",
        "document": "Sudden onset of symptoms Inhaled foreign body"
    },
    {
        "id": "doc_3282",
        "document": "All ages Cough, sputum, dyspnea on exertion, smoking or noxious exposure Productive cough, recurrent infections Dyspnea with exertion, nocturnal symptoms, ankle edema Treatment with angiotensin-converting enzyme (ACE) inhibitor Dyspnea with exertion, non-productive cough, finger clubbing Sudden onset of dyspnea, chest pain Dyspnea, unresponsive to bronchodilators Chronic cough, hemoptysis, dyspnea; and/or fatigue, fever, (night) sweats, anorexia, weight loss"
    },
    {
        "id": "doc_3283",
        "document": "COPD* Bronchiectasis Cardiac failure Medication-related cough Parenchymal lung disease Pulmonary embolism Central airway obstruction Tuberculosis"
    },
    {
        "id": "doc_3284",
        "document": "Prolonged paroxysms of coughing, sometimes stridor Pertussis"
    },
    {
        "id": "doc_3285",
        "document": "See list of abbreviations (p.10). *For more detail, see Chapter 5 (p.159). Any of the above conditions may also contribute to respiratory symptoms in patients with confirmed asthma.\n\nWhat is the role of exhaled nitric oxide in the diagnosis of asthma?"
    },
    {
        "id": "doc_3286",
        "document": "The fractional concentration of exhaled nitric oxide (FeNO) is modestly associated with levels of sputum and blood eosinophils.42 FeNO has not been established as useful for ruling in or ruling out a diagnosis of asthma (defined on p.22) because, while FeNO is higher in asthma that is characterized by Type 2 airway inflammation,43 it is also elevated in non-asthma conditions (e.g. eosinophilic bronchitis, atopy, allergic rhinitis, eczema), and it is not elevated in some asthma phenotypes (e.g."
    },
    {
        "id": "doc_3287",
        "document": "neutrophilic asthma). FeNO is lower in smokers and during bronchoconstriction44 and the early phases of allergic response;45 it may be increased or decreased during viral respiratory infections.44 See Chapter 3.2, p.57 for discussion about FeNO in the context of decisions about initial asthma treatment."
    },
    {
        "id": "doc_3288",
        "document": "30\n\n1. Definition, description and diagnosis of asthma\n\nHOW TO MAKE THE DIAGNOSIS OF ASTHMA IN OTHER CONTEXTS\n\nPatients presenting with persistent non-productive cough as the only respiratory symptom"
    },
    {
        "id": "doc_3289",
        "document": "Diagnoses to be considered are chronic upper airway cough syndrome (often called \u2018postnasal drip\u2019), cough induced by angiotensin-converting enzyme (ACE) inhibitors, gastroesophageal reflux, chronic sinusitis, and inducible laryngeal obstruction.46,47 Patients with so-called \u2018cough-variant asthma\u2019 have persistent cough as their principal or only symptom, associated with airway hyperresponsiveness. It is often more problematic at night. Lung function may be normal, and for these patients,"
    },
    {
        "id": "doc_3290",
        "document": "documentation of variability in lung function (Box 1-2, p.25) is important.48 Cough-variant asthma must be distinguished from eosinophilic bronchitis in which patients have cough and sputum eosinophilia but normal spirometry and airway responsiveness.48"
    },
    {
        "id": "doc_3291",
        "document": "Occupational asthma and work-exacerbated asthma\n\nAsthma acquired in the workplace is frequently missed. Asthma may be induced or (more commonly) aggravated by exposure to allergens or other sensitizing agents at work, or sometimes from a single, massive exposure. Occupational rhinitis may precede asthma by up to a year and early diagnosis is essential, as persistent exposure is associated with worse outcomes.49,50"
    },
    {
        "id": "doc_3292",
        "document": "An estimated 5\u201320% of new cases of adult-onset asthma can be attributed to occupational exposure.49 Adult-onset asthma requires a systematic inquiry about work history and exposures, including hobbies. Asking patients whether their symptoms improve when they are away from work (weekends or vacation) is an essential screening question.51 It is important to confirm the diagnosis of occupational asthma objectively as it may lead to the patient changing their occupation, which may have legal and"
    },
    {
        "id": "doc_3293",
        "document": "socioeconomic implications. Specialist referral is usually necessary, and frequent PEF monitoring at and away from work is often used to help confirm the diagnosis. Further information about occupational asthma is found in Chapter 3 (p.116) and in specific guidelines.49"
    },
    {
        "id": "doc_3294",
        "document": "Athletes\n\nThe diagnosis of asthma in athletes should be confirmed by lung function tests, usually with bronchial provocation testing.52 Conditions that may either mimic or be associated with asthma, such as rhinitis, laryngeal disorders (e.g., inducible laryngeal obstruction47), dysfunctional breathing, cardiac conditions and over-training, must be excluded.53"
    },
    {
        "id": "doc_3295",
        "document": "Pregnant women\n\nPregnant women and women planning a pregnancy should be asked whether they have asthma so that appropriate advice about asthma management and medications can be given (see Chapter 3: Managing asthma with multimorbidity and in specific populations, p.114).54 If objective confirmation of the diagnosis is needed, it would not be advisable to carry out a bronchial provocation test or to step down ICS-containing treatment until after delivery.\n\nThe elderly"
    },
    {
        "id": "doc_3296",
        "document": "Asthma is frequently undiagnosed in the elderly,55 due to poor perception of airflow limitation; acceptance of dyspnea as being \u2018normal\u2019 in old age; lack of fitness; and reduced physical activity. The presence of multimorbidity also complicates the diagnosis. In a large population based survey of asthma patients older than 65 years, factors associated with a history of asthma hospitalization included co-diagnosis of COPD, coronary artery disease, depression, diabetes mellitus, and difficulty"
    },
    {
        "id": "doc_3297",
        "document": "accessing medications or clinical care because of cost.56 Symptoms of wheezing, breathlessness and cough that are worse on exercise or at night can also be caused by cardiovascular disease or left ventricular failure, which are common in this age group. A careful history and physical examination, combined with an electrocardiogram and chest X-ray, will assist in the diagnosis.57 Measurement of plasma brain natriuretic polypeptide and assessment of cardiac function with echocardiography may also"
    },
    {
        "id": "doc_3298",
        "document": "be helpful.58 In older people with a history of smoking or biomass fuel exposure, COPD and overlapping asthma and COPD (asthma\u2013COPD overlap) should be considered (Chapter 5, p.159)."
    },
    {
        "id": "doc_3299",
        "document": "1. Definition, description and diagnosis of asthma\n\n31\n\nSmokers and ex-smokers"
    },
    {
        "id": "doc_3300",
        "document": "Asthma and COPD may be difficult to distinguish in clinical practice, particularly in older patients and smokers and ex- smokers, and these conditions may overlap (asthma-COPD overlap). The Global Strategy for Diagnosis, Management and Prevention of COPD (GOLD) 202359 defines COPD on the basis of chronic respiratory symptoms, environmental exposures such as smoking or inhalation of toxic particles or gases, with confirmation by post-bronchodilator FEV1/FVC <0.7. Clinically important"
    },
    {
        "id": "doc_3301",
        "document": "bronchodilator reversibility (>12% and >200 mL) is often found in COPD.60 Low diffusion capacity is more common in COPD than asthma. The history and pattern of symptoms and past records can help to distinguish these patients from those with long-standing asthma who have developed persistent airflow limitation (see Chapter 5, p.159). Uncertainty in the diagnosis should prompt early referral for specialized investigation and treatment recommendations, as patients with asthma-COPD overlap have"
    },
    {
        "id": "doc_3302",
        "document": "worse outcomes than those with asthma or COPD alone.61"
    },
    {
        "id": "doc_3303",
        "document": "Obese patients"
    },
    {
        "id": "doc_3304",
        "document": "While asthma is more common in obese than non-obese people,62 respiratory symptoms associated with obesity can mimic asthma. In obese patients with dyspnea on exertion, it is important to confirm the diagnosis of asthma with objective measurement of variable expiratory airflow limitation. One study found that non-obese patients were just as likely to be over-diagnosed with asthma as obese patients (around 30% in each group).38 Another study found both over- and under-diagnosis of asthma in obese"
    },
    {
        "id": "doc_3305",
        "document": "patients.63"
    },
    {
        "id": "doc_3306",
        "document": "Low- and middle-income countries"
    },
    {
        "id": "doc_3307",
        "document": "As described above, asthma is a clinical diagnosis, based on the history of characteristic symptom patterns and evidence of variable expiratory airflow limitation. However, in low- and middle-income countries (LMICs), access to lung function testing is often very limited, and even when available, may be substantially underused (e.g. unaffordable for the patient or health system,64 too time-consuming in a busy clinic, or impractical because requiring repeated visits of indigent patients.7"
    },
    {
        "id": "doc_3308",
        "document": "In addition, in LMICs, the differential diagnosis of asthma may include other endemic respiratory disease (e.g., tuberculosis, HIV/AIDS-associated lung diseases, and parasitic or fungal lung diseases), so clinicians tend to place greater reliance on clinical findings and often use a syndromic approach to diagnosis and initial management.65 This comes at the cost of precision but is based on the assumption (valid in most LMICs) that under-diagnosis and under-treatment of asthma is more likely66"
    },
    {
        "id": "doc_3309",
        "document": "than the overdiagnosis and overtreatment often seen in high income countries.23,67"
    },
    {
        "id": "doc_3310",
        "document": "While acknowledging that poor access to lung function testing is a common barrier to asthma diagnosis in LMICs, GINA does not recommend that diagnosis should be solely based on syndromic clinical patterns. When spirometry is not available, the presence of variable expiratory airflow limitation (including reversible obstruction) can be confirmed by PEF (Box 1-2, p.25). The World Health Organization (WHO) Package of essential noncommunicable (PEN) disease interventions for primary care68 lists the"
    },
    {
        "id": "doc_3311",
        "document": "PEF meter as an essential tool in the management of chronic respiratory diseases. WHO-PEN proposes use of PEF in support of a clinical diagnosis: a \u226520% improvement in PEF 15 minutes after giving 2 puffs of albuterol increases the likelihood of a diagnosis of asthma versus COPD and other diagnoses.68 GINA also suggests that improvement in symptoms and PEF after a 4-week therapeutic trial with anti-inflammatory therapy, with a 1-week course of oral corticosteroids if necessary, can help to"
    },
    {
        "id": "doc_3312",
        "document": "confirm the diagnosis of asthma (or prompt investigation for alternative diagnoses) before starting long-term ICS-containing treatment."
    },
    {
        "id": "doc_3313",
        "document": "A structured algorithmic approach to patients presenting with respiratory symptoms forms part of several strategies developed for improving respiratory disease management in LMICs.7 These strategies are of particular use in countries where, owing to the high prevalence of tuberculosis, large numbers of patients with respiratory symptoms present for assessment at tuberculosis clinics."
    },
    {
        "id": "doc_3314",
        "document": "There is a pressing need for access to affordable diagnostic tools (peak flow meters and spirometry), and training in their use, to be substantially scaled up in LMICs.9\n\n32\n\n1. Definition, description and diagnosis of asthma\n\nSECTION 1. ADULTS, ADOLESCENTS AND CHILDREN 6 YEARS AND OLDER\n\nChapter 2.\n\nAssessment of asthma\n\nKEY POINTS"
    },
    {
        "id": "doc_3315",
        "document": "Asthma control\n\n\u2022 The level of asthma control is the extent to which the features of asthma can be observed in the patient, or have been reduced or removed by treatment.\n\n\u2022 Asthma control is assessed in two domains: symptom control and risk of adverse outcomes. Poor symptom control is burdensome to patients and increases the risk of exacerbations, but patients with good symptom control can still have severe exacerbations."
    },
    {
        "id": "doc_3316",
        "document": "Asthma severity\n\n\u2022 The current definition of asthma severity is based on retrospective assessment, after at least 2\u20133 months of asthma treatment, from the treatment required to control symptoms and exacerbations."
    },
    {
        "id": "doc_3317",
        "document": "\u2022 This definition is clinically useful for severe asthma, as it identifies patients whose asthma is relatively refractory to conventional treatment with a combination of high-dose inhaled corticosteroid (ICS) and a long- acting beta2 agonist (LABA) and who may benefit from additional treatment such as biologic therapy. It is important to distinguish between severe asthma and asthma that is uncontrolled due to modifiable factors such as incorrect inhaler technique and/or poor adherence."
    },
    {
        "id": "doc_3318",
        "document": "\u2022 However, the clinical utility of a retrospective definition of mild asthma as \u2018easy to treat\u2019 is less clear, as patients with few interval symptoms can have exacerbations triggered by external factors such as viral infections or allergen exposure, and short-acting beta2 agonist (SABA)-only treatment is a significant risk factor for exacerbations."
    },
    {
        "id": "doc_3319",
        "document": "\u2022 In clinical practice and in the general community, the term \u2018mild asthma\u2019 is often used to mean infrequent or mild symptoms, and patients often incorrectly assume that it means they are not at risk and do not need ICS- containing treatment."
    },
    {
        "id": "doc_3320",
        "document": "\u2022 For these reasons, GINA suggests that the term \u2018mild asthma\u2019 should generally be avoided in clinical practice or, if used, qualified with a reminder that patients with infrequent symptoms can still have severe or fatal exacerbations, and that this risk is substantially reduced with ICS-containing treatment."
    },
    {
        "id": "doc_3321",
        "document": "\u2022 GINA is continuing to engage in stakeholder discussions about the definition of mild asthma, to obtain agreement about the implications for clinical practice and clinical research of the changes in knowledge about asthma pathophysiology and treatment since the current definition of asthma severity was published."
    },
    {
        "id": "doc_3322",
        "document": "How to assess a patient with asthma\n\n\u2022 Assess symptom control from the frequency of daytime and night-time asthma symptoms, night waking and activity limitation and, for patients using SABA reliever, their frequency of SABA use. Other symptom control tools include Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ)."
    },
    {
        "id": "doc_3323",
        "document": "\u2022 Also, separately, assess the patient\u2019s risk factors for exacerbations, even if their symptom control is good. Risk factors for exacerbations that are independent of symptom control include not only a history of \u22651 exacerbation in the previous year, but also SABA-only treatment (without any ICS), over-use of SABA, socioeconomic problems, poor adherence, incorrect inhaler technique, low forced expiratory volume in 1 second (FEV1), exposures such as smoking, and blood eosinophilia. To date, there"
    },
    {
        "id": "doc_3324",
        "document": "are no suitable composite tools for assessing exacerbation risk."
    },
    {
        "id": "doc_3325",
        "document": "\u2022 Also assess risk factors for persistent airflow limitation and medication side-effects, treatment issues such as inhaler technique and adherence, and comorbidities, and ask the patient about their asthma goals and treatment preferences.\n\n\u2022 Once the diagnosis of asthma has been made, the main role of lung function testing is in the assessment of future risk. It should be recorded at diagnosis, 3\u20136 months after starting treatment, and periodically thereafter."
    },
    {
        "id": "doc_3326",
        "document": "Investigate for impaired perception of bronchoconstriction if there are few symptoms but low lung function, and investigate for alternative diagnoses if there are frequent symptoms despite good lung function.\n\n34\n\n2. Assessment of asthma"
    },
    {
        "id": "doc_3327",
        "document": "OVERVIEW\n\nFor every patient, assessment of asthma should include the assessment of asthma control (both symptom control and future risk of adverse outcomes), treatment issues particularly inhaler technique and adherence, and any comorbidities that could contribute to symptom burden and poor quality of life (Box 2-1, p.35). Lung function, particularly FEV1 as a percentage of predicted, is an important part of the assessment of future risk."
    },
    {
        "id": "doc_3328",
        "document": "The use of digital technology, telemedicine and telehealthcare in the monitoring of patients with asthma is rapidly increasing, particularly during the COVID-19 pandemic. However, the types of interactions are diverse, and high-quality studies are needed to evaluate their utility and effectiveness.."
    },
    {
        "id": "doc_3329",
        "document": "What is meant by \u2018asthma control\u2019?\n\nThe level of asthma control is the extent to which the manifestations of asthma can be observed in the patient, or have been reduced or removed by treatment.29,69 It is determined by the interaction between the patient\u2019s genetic background, underlying disease processes, the treatment that they are taking, environment, and psychosocial factors.69"
    },
    {
        "id": "doc_3330",
        "document": "Asthma control has two domains: symptom control and future risk of adverse outcomes (Box 2-2, p.38). Both should always be assessed. Lung function is an important part of the assessment of future risk; it should be measured at the start of treatment, after 3\u20136 months of treatment (to identify the patient\u2019s personal best), and periodically thereafter for ongoing risk assessment."
    },
    {
        "id": "doc_3331",
        "document": "How to describe a patient\u2019s asthma control\n\nAsthma control should be described in terms of both symptom control and future risk domains. For example:\n\nMs X has good asthma symptom control, but she is at increased risk of future exacerbations because she has had a severe exacerbation within the last year. Mr Y has poor asthma symptom control. He also has several additional risk factors for future exacerbations including low lung function, current smoking, and poor medication adherence."
    },
    {
        "id": "doc_3332",
        "document": "What does the term \u2018asthma control\u2019 mean to patients?"
    },
    {
        "id": "doc_3333",
        "document": "Many studies describe discordance between the patient\u2019s and health provider\u2019s assessment of the patient\u2019s level of asthma control. This does not necessarily mean that patients \u2018over-estimate\u2019 their level of control or \u2018under-estimate\u2019 its severity, but that patients understand and use the word \u2018control\u2019 differently from health professionals, e.g. based on how quickly their symptoms resolve when they take reliever medication.69,70 If the term \u2018asthma control\u2019 is used with patients, the meaning"
    },
    {
        "id": "doc_3334",
        "document": "should always be explained."
    },
    {
        "id": "doc_3335",
        "document": "Box 2-1. Assessment of asthma in adults, adolescents, and children 6\u201311 years\n\n1. Assess asthma control = symptom control and future risk of adverse outcomes\n\n\u2022 Assess symptom control over the last 4 weeks (Box 2-2A).\n\nIdentify any other risk factors for exacerbations, persistent airflow limitation or side-effects (Box 2-2B).\n\n."
    },
    {
        "id": "doc_3336",
        "document": "\u2022 Measure lung function at diagnosis/start of treatment, 3\u20136 months after starting ICS-containing treatment, then periodically, e.g., at least once every 1\u20132 years, but more often in at-risk patients and those with severe asthma."
    },
    {
        "id": "doc_3337",
        "document": "2. Assess treatment issues\n\n\u2022 Document the patient\u2019s current treatment step (Box 3-12, p.65).\n\n\u2022 Watch inhaler technique (Box 3-22, p.100), assess adherence (Box 3-23, p.102) and side-effects.\n\n\u2022 Check that the patient has a written asthma action plan.\n\n\u2022 Ask about the patient\u2019s attitudes and goals for their asthma and medications."
    },
    {
        "id": "doc_3338",
        "document": "3. Assess multimorbidity\n\n\u2022 Rhinitis, rhinosinusitis, gastroesophageal reflux, obesity, obstructive sleep apnea, depression and anxiety can contribute to symptoms and poor quality of life, and sometimes to poor asthma control (see Chapter 3.4, p.106).\n\n2. Assessment of asthma\n\n35"
    },
    {
        "id": "doc_3339",
        "document": "ASSESSING ASTHMA SYMPTOM CONTROL\n\nAsthma symptoms such as wheeze, chest tightness, shortness of breath and cough typically vary in frequency and intensity, and contribute to the burden of asthma for the patient. Poor symptom control is also strongly associated with an increased risk of asthma exacerbations.71-73"
    },
    {
        "id": "doc_3340",
        "document": "Asthma symptom control should be assessed at every opportunity, including during routine prescribing or dispensing. Directed questioning is important, as the frequency or severity of symptoms that patients regard as unacceptable or bothersome may vary from current recommendations about the goals of asthma treatment, and may differ from patient to patient. For example, despite having low lung function, a person with a sedentary lifestyle may not experience bothersome symptoms and so may appear to"
    },
    {
        "id": "doc_3341",
        "document": "have good symptom control."
    },
    {
        "id": "doc_3342",
        "document": "To assess symptom control (Box 2-2A) ask about the following in the past four weeks: frequency of asthma symptoms (days per week), any night waking due to asthma or limitation of activity and, for patients using a SABA reliever, frequency of its use for relief of symptoms. In general, do not include reliever taken before exercise, because some people take this routinely without knowing whether they need it.\n\nFrequency of reliever use"
    },
    {
        "id": "doc_3343",
        "document": "Historically, frequency of SABA reliever use (<2 or \u22652 days/week) has been included in the composite assessment of symptom control. This distinction was arbitrary, based on the assumption that if SABA was used on >2 days in a week, the patient needed to start maintenance ICS-containing therapy or increase the dose. In addition, higher average use of SABA over a year is associated with a higher risk of severe exacerbations,74,75 and in the shorter term, increasing use of as-needed SABA is"
    },
    {
        "id": "doc_3344",
        "document": "associated with an increased likelihood of a severe exacerbation in subsequent days or weeks.76"
    },
    {
        "id": "doc_3345",
        "document": "However, for patients prescribed an anti-inflammatory reliever (AIR) such as as-needed low-dose ICS-formoterol (GINA Track 1, Box 3-12, p.65), use of this reliever more than 2 days/week is already providing additional ICS therapy, so further dose escalation may not be needed. In addition, increasing use of as-needed ICS-formoterol is associated with a significantly lower risk of severe exacerbation in subsequent days or weeks compared with if the reliever is SABA,77,78 or compared with if the"
    },
    {
        "id": "doc_3346",
        "document": "patient is using SABA alone.79"
    },
    {
        "id": "doc_3347",
        "document": "For these reasons, while the assessment of symptom control in Box 2-2A includes a criterion for SABA reliever use on \u22642 versus >2 days/week, it does not include a similar criterion for an anti-inflammatory reliever such as as-needed ICS- formoterol. However, the patient\u2019s average frequency of as-needed ICS-formoterol use over the past 4 weeks should be assessed, and taken into account when the patient\u2019s maintenance ICS dose (or need for maintenance ICS-formoterol) is reviewed. This issue will be"
    },
    {
        "id": "doc_3348",
        "document": "reviewed again when further data are available."
    },
    {
        "id": "doc_3349",
        "document": "Asthma symptom control tools for adults and adolescents"
    },
    {
        "id": "doc_3350",
        "document": "Simple screening tools: these can be used in primary care to quickly identify patients who need more detailed assessment. Examples include the consensus-based GINA symptom control tool (Part A, Box 2-2A). This classification correlates with assessments made using numerical asthma control scores.80,81 It can be used, together with a risk assessment (Box 2-2B), to guide treatment decisions (Box 3-12, p.65). Other examples are the Primary Care Asthma Control Screening Tool (PACS),82 and the"
    },
    {
        "id": "doc_3351",
        "document": "30-second Asthma Test, which also includes time off work/school.83"
    },
    {
        "id": "doc_3352",
        "document": "Categorical symptom control tools: e.g., the consensus-based \u2018Royal College of Physicians (RCP) Three Questions\u2019 tool,84 which asks about difficulty sleeping, daytime symptoms and activity limitation due to asthma in the previous month. The Asthma APGAR tool includes a patient-completed asthma control assessment covering 5 domains: activity limitations, daytime and nighttime symptom frequency (based on US criteria for frequency of night waking), triggers, adherence, and patient-perceived"
    },
    {
        "id": "doc_3353",
        "document": "response to treatment. This assessment is linked to a care algorithm for identifying problems and adjusting treatment up or down. A study in the US showed that introduction of the Asthma APGAR tools for patients aged 5\u201345 in primary care was associated with improved rates of asthma control; reduced asthma-related urgent care, and hospital visits; and increased practices\u2019 adherence to asthma management guidelines.85"
    },
    {
        "id": "doc_3354",
        "document": "36\n\n2. Assessment of asthma\n\nNumerical \u2018asthma control\u2019 tools: these tools provide scores and cut points to distinguish different levels of symptom control, validated against health care provider assessment. Many translations are available. These scores may be useful for assessing patient progress; they are commonly used in clinical research, but may be subject to copyright restrictions. Numerical asthma control tools are more sensitive to change in symptom control than categorical tools.80"
    },
    {
        "id": "doc_3355",
        "document": "Examples of numerical asthma control tools for assessing symptom control are:"
    },
    {
        "id": "doc_3356",
        "document": "\u2022 Asthma Control Questionnaire (ACQ):86,87 Scores range from 0\u20136 (higher is worse), with scores calculated as the average from all questions. The authors stated that ACQ \u22640.75 indicated a high probability that asthma was well controlled; 0.75\u20131.5 as a \u2018grey zone\u2019; and \u22651.5 a high probability that asthma was poorly controlled, based on concepts of asthma control at the time; they later added that the crossover point between \u2018well-controlled\u2019 and \u2018not well-controlled\u2019 asthma was close to 1.00.88"
    },
    {
        "id": "doc_3357",
        "document": "The 5-item ACQ (ACQ-5), comprises five symptom questions. Two additional versions were published: ACQ-6 includes SABA frequency, and ACQ-7 also includes pre-bronchodilator FEV1 % predicted. The minimum clinically important difference for all three versions of ACQ is 0.5.88 GINA prefers ACQ-5 over ACQ-6 or 7 because the reliever question assumes regular rather than as-needed use of SABA, there is no option between zero SABA use in a week and SABA use every day, and ACQ has not been validated with"
    },
    {
        "id": "doc_3358",
        "document": "ICS- formoterol or ICS-SABA as the reliever. In addition, if ACQ-7 were to be used in adjustment of treatment, the inclusion of FEV1 in the composite score could lead to repeated step-up in ICS dose for patients with persistent airflow limitation. For these reasons, data for ACQ-5, ACQ-6 and ACQ-7 cannot be combined for meta-analysis."
    },
    {
        "id": "doc_3359",
        "document": "\u2022 Asthma Control Test (ACT):81,89,90 Scores range from 5\u201325 (higher is better). Scores of 20\u201325 are classified as well- controlled; 16\u201319 as not well-controlled; and 5\u201315 as very poorly controlled asthma. The ACT has four symptom/ reliever questions plus patient self-assessed control. The minimum clinically important difference is 3 points.90"
    },
    {
        "id": "doc_3360",
        "document": "Because patients with good symptom control can still be at risk of future severe exacerbations or asthma-related death, and because of the many modifiable risk factors for exacerbations that are independent of symptom control (Box 2-2B, p.38), GINA does not recommend assessment tools that combine symptom control with exacerbation history."
    },
    {
        "id": "doc_3361",
        "document": "When different tools are used for assessing asthma symptom control, the results correlate broadly with each other, but are not identical. Respiratory symptoms may be non-specific so, when assessing changes in symptom control, it is important to clarify that symptoms are due to asthma.\n\nAsthma symptom control tools for children aged 6\u201311 years"
    },
    {
        "id": "doc_3362",
        "document": "In children, as in adults, assessment of asthma symptom control is based on symptoms, limitation of activities and use of rescue medication. Careful review of the impact of asthma on a child\u2019s daily activities, including sports, play and social life, and on school absenteeism, is important. Many children with poorly controlled asthma avoid strenuous exercise so their asthma may appear to be well controlled. This may lead to poor fitness and a higher risk of obesity."
    },
    {
        "id": "doc_3363",
        "document": "Children vary considerably in the degree of airflow limitation observed before they complain of dyspnea or use their reliever therapy, and marked reduction in lung function is often seen before it is recognized by the parent or caregiver. They may report irritability, tiredness, and changes in mood in their child as the main problems when the child\u2019s asthma is not controlled. Parents/caregivers have a longer recall period than children, who may recall only the last few days; therefore, it is"
    },
    {
        "id": "doc_3364",
        "document": "important to include information from both the parent/caregiver and the child when the level of symptom control is being assessed."
    },
    {
        "id": "doc_3365",
        "document": "Several numeric asthma control scores have been developed for children. These include:\n\n\u2022 Childhood Asthma Control Test (c-ACT)91 with separate sections for parent/caregiver and child to complete\n\n\u2022 Asthma Control Questionnaire (ACQ)92,93"
    },
    {
        "id": "doc_3366",
        "document": "Some asthma control scores for children include history of exacerbations with symptoms, but these may have the same limitations as described above for adults. They include the Test for Respiratory and Asthma Control in Kids (TRACK)94-96 and the Composite Asthma Severity Index (CASI).97\n\nThe results of these various tests correlate to some extent with each other and with the GINA classification of symptom control. Box 2-3 (p.39) provides more details about assessing asthma control in children."
    },
    {
        "id": "doc_3367",
        "document": "2. Assessment of asthma\n\n37\n\nBox 2-2. GINA assessment of asthma control in adults, adolescents and children 6\u201311 years\n\nA. Asthma symptom control\n\nIn the past 4 weeks, has the patient had: Well controlled Partly controlled Uncontrolled \u2022 Daytime asthma symptoms more than twice/week? Yes No \u2022 Any night waking due to asthma? Yes No None of 1\u20132 of 3\u20134 of \u2022 SABA* reliever for symptoms more than twice/week? Yes No these these these \u2022 Any activity limitation due to asthma? Yes No"
    },
    {
        "id": "doc_3368",
        "document": "B. Risk factors for poor asthma outcomes\n\nAssess risk factors at diagnosis and periodically, particularly for patients experiencing exacerbations.\n\nMeasure FEV1 at start of treatment, after 3\u20136 months of ICS-containing treatment to record the patient\u2019s personal best lung function, then periodically for ongoing risk assessment."
    },
    {
        "id": "doc_3369",
        "document": "a. Risk factors for exacerbations Uncontrolled asthma symptoms Factors that increase the risk of exacerbations even if the patient has few asthma symptoms\u2020 Having uncontrolled asthma symptoms is an important risk factor for exacerbations.% Medications High SABA use (23 x 200-dose canisters/year associated with increased risk of exacerbations, increased mortality particularly if 21 canister per month )74.75.99.100"
    },
    {
        "id": "doc_3370",
        "document": "Inadequate ICS: not prescribed ICS, poor adherence, ' or incorrect inhaler technique102 Other medical conditions Obesity, 93194 chronic rhinosinusitis,\u2019\u00ae* GERD,'** confirmed food allergy,'%\u00ae pregnancy106 Exposures Smoking, 97 e-cigarettes, % allergen exposure if sensitized,? air pollution109-112 Psychosocial Major psychological or socioeconomic problems?13.114 Lung function Low FEV1 (especially <60% predicted),'\u00b0\u201d'5 high bronchodilator responsiveness104,116,117"
    },
    {
        "id": "doc_3371",
        "document": "Type 2 inflammatory markers Higher blood eosinophils,04.118.119 glevated FeNO (in adults with allergic asthma taking ICS)'2\u00b0 Exacerbation history Ever intubated or in intensive care unit for asthma,\u2019?' 21 severe exacerbation in last 12 months'22.123 b. Risk factors for developing persistent airflow limitation History Preterm birth, low birth weight and greater infant weight gain,'* chronic mucus hypersecretion125,126"
    },
    {
        "id": "doc_3372",
        "document": "Medications Lack of ICS treatment in patient with history of severe exacerbation'?\u201d Exposures Tobacco smoke, 25 noxious chemicals; occupational or domestic exposures*\u00ae Investigation findings Low initial FEV','26 sputum or blood eosinophilia'?\u00ae c. Risk factors for medication side-effects Systemic Frequent OCS, long-term, high-dose and/or potent ICS, P450 inhibitors'28 Local High-dose or potent ICS,'28.129 poor inhaler technique'3\u00b0"
    },
    {
        "id": "doc_3373",
        "document": "Local High-dose or potent ICS,128,129 poor inhaler technique130"
    },
    {
        "id": "doc_3374",
        "document": "See list of abbreviations (p.10). *Based on SABA (as-needed ICS-formoterol reliever not included); see page 36; excludes reliever taken before exercise. \u2020\u2018Independent\u2019 risk factors are those that are significant after adjustment for the level of symptom control. Cytochrome P450 inhibitors such as ritonavir, ketoconazole, itraconazole may increase systemic exposure to some types of ICS and some LABAs; see drug interaction websites and p.111 for details. For children 6\u201311 years, also refer to Box"
    },
    {
        "id": "doc_3375",
        "document": "2-3, p.39. See Box 3-17, p.85 for specific risk reduction strategies."
    },
    {
        "id": "doc_3376",
        "document": "of\n\n38\n\n2. Assessment of asthma"
    },
    {
        "id": "doc_3377",
        "document": "Asthma symptom control Day symptoms Ask: How often does the child have cough, wheeze, dyspnea or heavy breathing (number of times per week or day)? What triggers the symptoms? How are symptoms managed? Night symptoms Cough, awakenings, tiredness during the day? (If the only symptom is cough, consider other diagnoses such as rhinitis or gastroesophageal reflux disease)."
    },
    {
        "id": "doc_3378",
        "document": "Reliever use How often is reliever medication used? (check date on inhaler or last prescription) Distinguish between pre-exercise use (sports) and use for relief of symptoms."
    },
    {
        "id": "doc_3379",
        "document": "Level of activity = What sports/hobbies/interests does the child have, at school and in their spare time? How does the child\u2019s level of activity compare with their peers or siblings? How many days is the child absent from school? Try to get an accurate picture of the child\u2019s day from the child without interruption from the parent/caregiver. Risk factors for adverse outcomes"
    },
    {
        "id": "doc_3380",
        "document": "Exacerbations Ask: How do viral infections affect the child\u2019s asthma? Do symptoms interfere with school or sports? How long do the symptoms last? How many episodes have occurred since their last medical review? Any urgent doctor/emergency department visits? Is there a written action plan? Risk factors for exacerbations include a history of exacerbations, poor symptom control, poor adherence and poverty,'2 and persistent bronchodilator reversibility even if the child has few symptoms.\u21227"
    },
    {
        "id": "doc_3381",
        "document": "Lung function Check curves and technique. Main focus is on FEV1 and FEV1/FVC ratio. Plot these values as percent predicted to see trends over time. Side-effects Check the child\u2019s height at least yearly, as poorly controlled asthma can affect growth,'3 and growth velocity may be lower in the first 1-2 years of ICS treatment.'32 Ask about frequency and dose of ICS and OCS. Treatment factors"
    },
    {
        "id": "doc_3382",
        "document": "Inhaler technique Ask the child to show how they use their inhaler. Compare with a device-specific checklist. Adherence Is there any of the child\u2019s brescribed maintenance medication (inhalers and/or tablets) in the home at present? On how many days in a week does the child use it (e.g., 0, 2, 4, 7 days)? Is it easier to remember to use it in the morning or evening? Where is the medication kept \u2014 is it in plain view to"
    },
    {
        "id": "doc_3383",
        "document": "Goals/concerns reduce forgetting? Check date on inhaler. Does the child or their parent or caregiver have any concerns about their asthma (e.g., fear of medication, side-effects, interference with activity)? What are their goals for treatment? Comorbidities Allergic rhinitis Itching, sneezing, nasal obstruction? Can the child breathe through their nose? What medications Eczema are being taken for nasal symptoms? corticosteroids?"
    },
    {
        "id": "doc_3384",
        "document": "Food allergy Sleep disturbance, topical Is the child allergic to any foods? (Confirmed food allergy is a risk factor for asthma-related death.105) Check BMI. Ask about diet and Obesity age-adjusted physical activity. Other investigations 2-week diary (if needed) If no clear assessment can be made based on the above questions, ask the child or parent/caregiver to keep a daily diary of asthma symptoms, reliever use and peak expiratory flow"
    },
    {
        "id": "doc_3385",
        "document": "Exercise (best of three) for 2 weeks. Provides information about airway hyperresponsiveness and fithess (Box 1-2, p.25). Only challenge undertake a challenge if it is otherwise difficult to assess asthma control. (laboratory) See list of abbreviations (p.10)."
    },
    {
        "id": "doc_3386",
        "document": "2. Assessment of asthma\n\n39"
    },
    {
        "id": "doc_3387",
        "document": "ASSESSING FUTURE RISK OF ADVERSE OUTCOMES\n\nThe second component of assessing asthma control (Box 2-2B, p.38) is to identify whether the patient is at risk of adverse asthma outcomes, particularly exacerbations, persistent airflow limitation, and side-effects of medications (Box 2-2B). Asthma symptoms, although an important outcome for patients, and themselves a strong predictor of future risk of exacerbations, are not sufficient on their own for assessing asthma because:"
    },
    {
        "id": "doc_3388",
        "document": "\u2022 Asthma symptoms can be controlled by placebo or sham treatments133,134 or by inappropriate use of long- acting beta2-agonist (LABA) alone,135 which leaves airway inflammation untreated.\n\n\u2022 Respiratory symptoms may be due to other conditions such as lack of fitness, or comorbidities such as inducible laryngeal obstruction.47\n\n\u2022 Anxiety or depression may contribute to symptom reporting."
    },
    {
        "id": "doc_3389",
        "document": "\u2022 Some patients have impaired perception of bronchoconstriction, with few symptoms despite low lung function.136\n\nAsthma symptom control and exacerbation risk should not be simply combined numerically, as poor control of symptoms and of exacerbations may have different causes and may need different treatment approaches.\n\nRisk factors for exacerbations"
    },
    {
        "id": "doc_3390",
        "document": "Poor asthma symptom control itself substantially increases the risk of exacerbations.71-73 However, several additional independent risk factors have been identified, i.e., factors that, when present, increase the patient\u2019s risk of exacerbations even if symptoms are few. These risk factors (Box 2-2B, p.38) include a history of \u22651 exacerbation in the previous year, poor adherence, incorrect inhaler technique, chronic sinusitis and smoking, all of which can be assessed in primary care.137 The risk"
    },
    {
        "id": "doc_3391",
        "document": "of severe exacerbations and mortality increases incrementally with higher SABA use, independent of treatment step.75 Prescribing of three or more 200-dose SABA inhalers in a year, corresponding to more than daily use, is associated with an increased risk of severe exacerbations74,75 and, in one study, increased mortality.75 Risk factors and comorbidities that are modifiable (or potentially modifiable) are sometimes called \u2018treatable traits\u2019.138"
    },
    {
        "id": "doc_3392",
        "document": "In children, the risk of exacerbations is greatly increased if there is a history of previous exacerbations; it is also increased with poor symptom control, suboptimal drug regimen, comorbid allergic disease and poverty.123\n\nRisk factors for development of persistent airflow limitation"
    },
    {
        "id": "doc_3393",
        "document": "The average rate of decline in FEV1 in non-smoking healthy adults is 15\u201320 mL/year.139 People with asthma may have an accelerated decline in lung function and develop airflow limitation that is not fully reversible. This is often associated with more persistent dyspnea. Independent risk factors that have been identified for persistent airflow limitation include exposure to cigarette smoke or noxious agents, chronic mucus hypersecretion, and asthma exacerbations in patients not taking ICS127 (see"
    },
    {
        "id": "doc_3394",
        "document": "Box 2-2B, p.38). Children with persistent asthma may have reduced growth in lung function, and some are at risk of accelerated decline in lung function in early adult life.140"
    },
    {
        "id": "doc_3395",
        "document": "Risk factors for medication side-effects"
    },
    {
        "id": "doc_3396",
        "document": "Choices with any medication are based on the balance of benefit and risk. Most people using asthma medications do not experience any side-effects. The risk of side-effects increases with higher doses of medications, but these are needed in few patients. Systemic side-effects that may be seen with long-term, high-dose ICS include easy bruising, an increase beyond the usual age-related risk of osteoporosis and fragility fractures, cataracts, glaucoma, and adrenal suppression. Local side-effects of"
    },
    {
        "id": "doc_3397",
        "document": "ICS include oral thrush and dysphonia. Patients are at greater risk of ICS side-effects with higher doses or more potent formulations128,129 and, for local side-effects, with incorrect inhaler technique.130"
    },
    {
        "id": "doc_3398",
        "document": "Drug interactions with asthma medications: concomitant treatment with cytochrome P450 inhibitors such as ketoconazole, ritonavir, itraconazole, erythromycin and clarithromycin may increase the risk of ICS adverse effects such as adrenal suppression, and with short-term use, may increase the risk of cardiovascular adverse effects of the LABAs salmeterol and vilanterol (alone or in combination with ICS). Concomitant use of these medications is not recommended (see also p.111).141\n\n40"
    },
    {
        "id": "doc_3399",
        "document": "2. Assessment of asthma\n\nROLE OF LUNG FUNCTION IN ASSESSING ASTHMA CONTROL"
    },
    {
        "id": "doc_3400",
        "document": "Does lung function relate to other asthma control measures?\n\nLung function does not correlate strongly with asthma symptoms in adults142 or children.143 In some asthma control tools, lung function is numerically averaged or added with symptoms,86,144 but if the tool includes several symptom items, these can outweigh clinically important differences in lung function.145 In addition, low FEV1 is a strong independent predictor of risk of exacerbations, even after adjustment for symptom frequency."
    },
    {
        "id": "doc_3401",
        "document": "Lung function should be assessed at diagnosis or start of treatment, after 3\u20136 months of ICS-containing treatment to assess the patient\u2019s personal best FEV1, and periodically thereafter. For example, in most adult patients, lung function should be recorded at least every 1\u20132 years, but more frequently in higher risk patients including those with exacerbations and those at risk of decline in lung function (see Box 2-2B, p.38). Lung function should also be recorded more frequently in children"
    },
    {
        "id": "doc_3402",
        "document": "based on asthma severity and clinical course (Evidence D)."
    },
    {
        "id": "doc_3403",
        "document": "Once the diagnosis of asthma has been confirmed, it is not generally necessary to ask patients to withhold their regular or as-needed medications before visits,29 but preferably the same conditions should apply at each visit."
    },
    {
        "id": "doc_3404",
        "document": "How to interpret lung function test results in asthma\n\nA low FEV1 percent predicted:\n\nIdentifies patients at risk of asthma exacerbations, independent of symptom levels, especially if FEV1 is <60% predicted107,115,146,147\n\nIs a risk factor for lung function decline, independent of symptom levels126\n\n\u2022 If symptoms are few, suggests limitation of lifestyle, or poor perception of airflow limitation,148 which may be due to untreated airway inflammation.136"
    },
    {
        "id": "doc_3405",
        "document": "A \u2018normal\u2019\n\n\u2022 Prompts consideration of alternative causes for the symptoms; e.g., cardiac disease, or cough due to post- nasal drip or gastroesophageal reflux disease (Box 1-3, p.28).\n\nPersistent bronchodilator responsiveness:"
    },
    {
        "id": "doc_3406",
        "document": "\u2022 Finding significant bronchodilator responsiveness (increase in FEV1 >12% and >200 mL from baseline27) in a patient taking ICS-containing treatment, or who has taken a SABA within 4 hours, or a LABA within 12 hours (or 24 hours for a once-daily LABA), suggests uncontrolled asthma.\n\nIn children, spirometry cannot be reliably obtained until age 5 years or more, and it is less useful than in adults. Many children with uncontrolled asthma have normal lung function between flare-ups (exacerbations)."
    },
    {
        "id": "doc_3407",
        "document": "How to interpret changes in lung function in clinical practice\n\nWith regular ICS treatment, FEV1 starts to improve within days, and reaches a plateau after around 2 months.149 The patient\u2019s highest FEV1 reading (personal best) should be documented, as this provides a more useful comparison for clinical practice than FEV1 percent predicted. If predicted values are used in children, measure their height at each visit."
    },
    {
        "id": "doc_3408",
        "document": "Some patients may have a faster than average decrease in lung function, and develop persistent (incompletely reversible) airflow limitation. While a trial of higher dose ICS-LABA and/or systemic corticosteroids may be appropriate to see if FEV1 can be improved, high doses should not be continued if there is no response."
    },
    {
        "id": "doc_3409",
        "document": "The between-visit variability of FEV1 (up to 12% week to week or 15% year to year in healthy individuals27) limits its use in adjusting asthma treatment or identifying accelerated decline in clinical practice. The minimal important difference for improvement and worsening in FEV1 based on patient perception of change has been reported to be about 10%.150,151"
    },
    {
        "id": "doc_3410",
        "document": "The role of short-term and long-term PEF monitoring\n\nOnce the diagnosis of asthma is made, short-term peak expiratory flow (PEF) monitoring may be used to assess response to treatment, to evaluate triggers (including at work) for worsening symptoms, or to establish a baseline for action plans. After starting ICS, personal best PEF (from twice daily readings) is reached on average within\n\n2. Assessment of asthma\n\n41"
    },
    {
        "id": "doc_3411",
        "document": "2 weeks.152 Average PEF continues to increase, and diurnal PEF variability to decrease, for about 3 months.142,152 Excessive variation in PEF suggests suboptimal asthma control, and increases the risk of exacerbations.153\n\nLong-term PEF monitoring is now generally only recommended for patients with severe asthma, or those with impaired perception of airflow limitation.136,154-157 For clinical practice, displaying PEF results on a standardized chart may improve accuracy of interpretation.158"
    },
    {
        "id": "doc_3412",
        "document": "ASSESSING ASTHMA SEVERITY"
    },
    {
        "id": "doc_3413",
        "document": "The current concept of asthma severity is based on \u2018difficulty to treat\u2019\n\nThe current concept of asthma severity, recommended by an ATS/ERS Task Force29,69 and included in most asthma guidelines, is that asthma severity should be assessed retrospectively from how difficult the patient\u2019s asthma is to treat. This is reflected by the level of treatment required to control the patient\u2019s symptoms and exacerbations, i.e., after at least several months of treatment:29,69,159 By this definition:"
    },
    {
        "id": "doc_3414",
        "document": "\u2022 Severe asthma is defined as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA, or that requires high-dose ICS-LABA to prevent it from becoming uncontrolled. Severe asthma must be distinguished from asthma that is difficult to treat due to inadequate or inappropriate treatment, or persistent problems with adherence or comorbidities such as chronic rhinosinusitis or obesity,159 as they need very different treatment compared with if asthma is relatively"
    },
    {
        "id": "doc_3415",
        "document": "refractory to high-dose ICS-LABA or even oral corticosteroids (OCS).159 See Box 2-4 (p.45) for how to distinguish difficult-to-treat and severe asthma, and Chapter 3.5 (p.120) for more detail about assessment, referral and treatment in this population."
    },
    {
        "id": "doc_3416",
        "document": "\u2022 Moderate asthma is currently defined as asthma that is well controlled with Step 3 or Step 4 treatment e.g. with low- or medium-dose ICS-LABA in either treatment track.\n\n\u2022 Mild asthma is currently defined as asthma that is well controlled with low-intensity treatment, i.e., as-needed low-dose ICS-formoterol, or low-dose ICS plus as-needed SABA."
    },
    {
        "id": "doc_3417",
        "document": "By this retrospective definition, asthma severity cannot be assessed unless good asthma control has been achieved and treatment stepped down to find the patient\u2019s minimum effective dose at which their asthma remains well- controlled (p.83), or unless asthma remains uncontrolled despite at least several months of optimized maximal therapy.\n\nThe terms \u2018severe asthma\u2019 and \u2018mild asthma\u2019 are often used with different meanings than this"
    },
    {
        "id": "doc_3418",
        "document": "In the community and in primary care, the terms \u2018severe\u2019 or \u2018mild\u2019 asthma are more commonly based on the frequency or severity of symptoms or exacerbations, irrespective of treatment. For example, asthma is commonly called \u2018severe\u2019 if patients have frequent or troublesome asthma symptoms, regardless of their treatment, and \u2018mild asthma\u2019 is commonly used if patients do not have daily symptoms or if symptoms are quickly relieved."
    },
    {
        "id": "doc_3419",
        "document": "In epidemiological studies, asthma is often classified as \u2018mild\u2019, \u2018moderate\u2019 or \u2018severe\u2019 based only on the prescribed treatment by GINA or BTS Step, regardless of patients\u2019 level of asthma control. This assumes that the prescribed treatment was appropriate for the patient\u2019s needs, whereas asthma is often under-treated or over-treated."
    },
    {
        "id": "doc_3420",
        "document": "Most clinical trials of biologic therapy enroll patients with asthma that is uncontrolled despite taking medium- or high- dose ICS-LABA, but do not assess and treat contributory factors such as incorrect inhaler technique, poor adherence, or comorbidities before considering the patient\u2019s eligibility for enrolment.160,161 Some clinical trial participants may therefore have \u2018difficult-to-treat\u2019, rather than severe asthma."
    },
    {
        "id": "doc_3421",
        "document": "Some guidelines162,163 also retain an older classification of asthma severity based on symptom and SABA frequency, night waking, lung function and exacerbations before ICS-containing treatment is started.29,69 This classification also distinguishes between \u2018intermittent\u2019 and \u2018mild persistent\u2019 asthma, but this historical distinction was arbitrary: it was not evidence-based, but was based on an untested assumption that patients with symptoms \u22642 days/week were not at risk and would not benefit from"
    },
    {
        "id": "doc_3422",
        "document": "ICS, so should be treated with SABA alone. However, it is now known that patients with so-called \u2018intermittent\u2019 asthma can have severe or fatal exacerbations,164,165 and that their risk is substantially reduced by ICS-containing treatment compared with SABA alone.166-168 Although this symptom-based classification is stated to apply to patients not on ICS-containing treatment,162,163 it is often used more broadly. This can cause confusion, as a patient\u2019s asthma may be classified differently, and"
    },
    {
        "id": "doc_3423",
        "document": "they may be prescribed different treatment, depending on which definition the clinician uses."
    },
    {
        "id": "doc_3424",
        "document": "42\n\n2. Assessment of asthma\n\nFor low resource countries without access to effective medications such as ICS, the World Health Organization definition of severe asthma169 includes a category of \u2018untreated severe asthma\u2019. This category corresponds to uncontrolled asthma in patients not taking any ICS-containing treatment.\n\nThe patient\u2019s view of asthma severity"
    },
    {
        "id": "doc_3425",
        "document": "Patients may perceive their asthma as severe if they have intense or frequent symptoms, but this does not necessarily indicate underlying severe disease, as symptoms and lung function can rapidly become well controlled with commencement of ICS-containing treatment, or improved inhaler technique or adherence.29,69 Likewise, patients often perceive their asthma as mild if they have symptoms that are easily relieved by SABA, or that are infrequent.29,69 Of concern, patients often interpret the term"
    },
    {
        "id": "doc_3426",
        "document": "\u2018mild asthma\u2019 to mean that they are not at risk of severe exacerbations and do not need to take ICS-containing treatment. This is often described as patients \u2018underestimating\u2019 their asthma severity, but instead it reflects their different interpretation of the words \u2018severity\u2019 and \u2018mild\u2019 compared with the academic usage of these terms.29,69"
    },
    {
        "id": "doc_3427",
        "document": "How useful is the current retrospective definition of asthma severity?"
    },
    {
        "id": "doc_3428",
        "document": "The retrospective definition of severe asthma based on \u2018difficulty to treat\u2019 has been widely accepted in guidelines and in specialist clinical practice. It has obvious clinical utility as it identifies patients who, because of their burden of disease and incomplete response to optimized conventional ICS-based treatment, may benefit from referral to a respiratory physician (if available) for further investigation, phenotyping, and consideration of additional treatment such as biologic therapy"
    },
    {
        "id": "doc_3429",
        "document": "(See Chapter 3.5, p.120). It is appropriate to classify asthma as \u2018difficult-to-treat\u2019 rather than severe if there are modifiable factors such as incorrect inhaler technique, poor adherence or untreated comorbidities, because asthma may become well controlled when such issues are addressed.29,69,159"
    },
    {
        "id": "doc_3430",
        "document": "By contrast, the clinical utility of the retrospective definition of mild asthma is much less clear. There is substantial variation in opinions about the specific criteria that should be used, for example whether FEV1 should be \u226580% predicted in order for asthma to be considered \u2018mild\u2019, and whether the occurrence of any exacerbation precludes a patient\u2019s asthma being classified as \u2018mild\u2019 for the next 12 months.170 There are too few studies of the underlying pathology to discern whether isolated"
    },
    {
        "id": "doc_3431",
        "document": "exacerbations necessarily imply greater inherent severity, especially given the contribution of external triggers such as viral infections or allergen exposure to sporadic exacerbations."
    },
    {
        "id": "doc_3432",
        "document": "Further, by this definition, asthma can be classified as \u2018mild\u2019 only after several months of ICS-containing treatment, and only if asthma is well-controlled on low-dose ICS or as-needed low-dose ICS-formoterol, so this definition clearly cannot be applied to patients with uncontrolled or partly controlled symptoms who are taking SABA. Finally, retrospective classification of asthma as mild appears of little value in deciding on future treatment. In addition, in the studies of as-needed"
    },
    {
        "id": "doc_3433",
        "document": "ICS-formoterol, baseline patient characteristics such as daily reliever use, lower lung function or history of exacerbations (or even baseline blood eosinophils or FeNO) did not identify patients who should instead be treated with daily ICS.171,172 Instead, decisions about ongoing treatment should be based upon the large evidence base about the efficacy and effectiveness of as-needed ICS-formoterol or daily ICS, together with an individualized assessment of the patient\u2019s symptom control,"
    },
    {
        "id": "doc_3434",
        "document": "exacerbation risk, predictors of response, and patient preferences (see Box 3-2, p.50)."
    },
    {
        "id": "doc_3435",
        "document": "However, the most urgent problem with the term \u2018mild asthma\u2019, regardless of how it is defined, is that it encourages complacency, since both patients and clinicians often interpret \u2018mild asthma\u2019 to mean that the patient is at low risk and does not need ICS-containing treatment. However, up to 30% of asthma exacerbations and deaths occur in people with infrequent symptoms, for example, less than weekly or only on strenuous exercise.164,165\n\nInterim advice about asthma severity descriptors"
    },
    {
        "id": "doc_3436",
        "document": "For clinical practice\n\nGINA continues to support the current definition of severe asthma as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA, or that requires high-dose ICS-LABA to prevent it from becoming uncontrolled, and maintains the clinically important distinction between difficult-to-treat and severe asthma. See Box 2-4 (p.45) and Chapter 3.5 (p.120) for more detail about assessment and treatment of such patients."
    },
    {
        "id": "doc_3437",
        "document": "We suggest that in clinical practice, the term \u2018mild asthma\u2019 should generally be avoided, because of the common but mistaken assumption by patients and clinicians that it equates to low risk. Instead, assess the patient\u2019s symptom control and risk factors on their current treatment (p.35), as well as multimorbidity and patient goals and preferences.\n\n2. Assessment of asthma\n\n43"
    },
    {
        "id": "doc_3438",
        "document": "Explain that patients with infrequent or mild asthma symptoms can still have severe or fatal exacerbations if treated with SABA alone,164,165 and that this risk is reduced by half to two-thirds with low-dose ICS or with as-needed low- dose ICS-formoterol.166,167 Ensure that you prescribe ICS-containing therapy to reduce the patient\u2019s risk of severe exacerbations (Box 3-5, p.58), and treat any modifiable risk factors or comorbidities using pharmacologic or non- pharmacologic strategies (see Box"
    },
    {
        "id": "doc_3439",
        "document": "3-17, p.85 and Box 3-18, p.88)."
    },
    {
        "id": "doc_3440",
        "document": "For health professional education"
    },
    {
        "id": "doc_3441",
        "document": "The term \u2018apparently mild asthma\u2019 may be useful to highlight the discordance between symptoms and risk. However, be aware that in some languages \u2018apparently\u2019 translates to the opposite of the intended meaning. Explain that \u2018asthma control\u2019 tools such as ACQ and ACT assess only one domain of asthma control (p.40), and that patients with infrequent interval symptoms are over-represented in studies of severe, near-fatal and fatal asthma exacerbations.164,165 Always emphasize the need for and"
    },
    {
        "id": "doc_3442",
        "document": "benefit from ICS-containing treatment in patients with asthma, regardless of their symptom frequency, and even if they have no obvious additional risk factors."
    },
    {
        "id": "doc_3443",
        "document": "For epidemiologic studies\n\nIf clinical details are not available, describe the prescribed (or dispensed) treatment, without imputing severity, e.g., \u2018patients prescribed SABA with no ICS\u2019 rather than \u2018mild asthma\u2019. Since treatment options change over time, and may differ between guidelines, state the actual treatment class, rather than a treatment Step (e.g., \u2018low-dose maintenance and reliever therapy with ICS-formoterol\u2019 rather than \u2018Step 3 treatment\u2019)."
    },
    {
        "id": "doc_3444",
        "document": "For clinical trials\n\nDescribe the patient population by their level of asthma control and treatment, e.g., \u2018patients with uncontrolled asthma despite medium-dose ICS-LABA plus as-needed SABA\u2019 rather than \u2018moderate asthma\u2019.\n\nFurther discussion is clearly needed"
    },
    {
        "id": "doc_3445",
        "document": "Given the importance of mild asthma and the discordance between its academic definition and the various ways that the term is used in clinical practice, GINA is continuing to discuss these issues with a wide range of stakeholders. The aim is to obtain agreement among patients, health professionals, researchers, industry and regulators about the implications for clinical practice and clinical research of current knowledge about asthma pathophysiology and treatment,29,69 and whether/how the term"
    },
    {
        "id": "doc_3446",
        "document": "\u2018mild asthma\u2019 should be used in the future. Pending the outcomes of this discussion, no change has been made to use of the term \u2018mild asthma\u2019 elsewhere in this GINA Strategy Report."
    },
    {
        "id": "doc_3447",
        "document": "HOW TO DISTINGUISH BETWEEN UNCONTROLLED ASTHMA AND SEVERE ASTHMA"
    },
    {
        "id": "doc_3448",
        "document": "Although good symptom control and minimal exacerbations can usually be achieved with ICS-containing treatment, some patients will not achieve one or both of these goals even with a long period of high-dose therapy.144,159 In some patients this is due to truly refractory severe asthma, but in many others, it is due to incorrect inhaler technique, poor adherence, over-use of SABA, comorbidities, persistent environmental exposures, or psychosocial factors."
    },
    {
        "id": "doc_3449",
        "document": "It is important to distinguish between severe asthma and uncontrolled asthma, as the latter is a much more common reason for persistent symptoms and exacerbations, and may be more easily improved. Box 2-4 (p.45) shows the initial steps that can be carried out to identify common causes of uncontrolled asthma. More details are given in Section 3.5 (p.120) about investigation and management of difficult-to-treat and severe asthma, including referral to a respiratory physician or severe asthma"
    },
    {
        "id": "doc_3450",
        "document": "clinic where possible, and use of add-on treatment including biologic therapy. The most common problems that need to be excluded before making a diagnosis of severe asthma are:"
    },
    {
        "id": "doc_3451",
        "document": "\u2022 Poor inhaler technique (up to 80% of community patients)102 (Box 3-22, p.100)\n\n\u2022 Poor medication adherence173,174 (Box 3-23, p.102)\n\n\u2022 Incorrect diagnosis of asthma, with symptoms due to alternative conditions such as inducible laryngeal obstruction, cardiac failure or lack of fitness (Box 1-5, p.30)\n\n\u2022 Multimorbidity such as rhinosinusitis, GERD, obesity and obstructive sleep apnea104,175 (Chapter 3.4, p.106)"
    },
    {
        "id": "doc_3452",
        "document": "\u2022 Ongoing exposure to sensitizing or irritant agents in the home or work environment.\n\n44\n\n2. Assessment of asthma\n\nBox 2-4. Investigating a patient with poor symptom control and/or exacerbations despite treatment"
    },
    {
        "id": "doc_3453",
        "document": "Watch patient using Watch patient use their inhaler(s), check against inhaler checklist. Show correct method, and recheck, up to 3 times. Re-check each visit. their inhaler Have empathic discussion to identify poor adherence, e.g. \u2018Many patients don'\u2019t use their Discuss adherence and inhaler as prescribed. In the fast 4 weeks, how many days a week have you takenit?\u201d (0 days, 1, 2, 3 etc) and/or. \u201cDo you find it easier fo remember your infialer in the moring barriers to use or the evening?\u201d Ask"
    },
    {
        "id": "doc_3454",
        "document": "about beliefs, cost of medications, and refill frequency. Confirm the diagnosis If no evidence of variable airflow limitation on spirometry or other festing (Box 1-2), consider halving ICS dose and repeating lung function after 2-3 weeks (Box 1-5); check patient has of asthma action plan. Consider referring for challenge test . For adultsfadolescents, switch to GINA Track 1, if available, to reduce exacerbations and If possible, remove simplify regimen (Box 3-5) potential risk factors Check for"
    },
    {
        "id": "doc_3455",
        "document": "risk factors or inducers such as smoking, beta-blockers o NSAIDS, or occupationa Assess and manage or domestic allergen exposure (Box 2-2). and address as possible{Bax 3-17). Check for and manage comorbidities (e.g. rhinitis, obesity, GERD. obstructive sleep apnea; comorbidities depression/anxiety) that may contribute to symptoms Consider treatment Consider step-up to next freatment level or alternative option on present level (Boxes 3-12, 3-13) step-up Use shared decision-making, and balance"
    },
    {
        "id": "doc_3456",
        "document": "potential benefits and risks If asthma still uncontrolled after 3-6 months on high dose ICS-LABA, or with ongoing Refer to a specialist risk factors, refer to a specialist or severe asthma clinic, if available or severe asthma clinic Refer earlier than 6 months/if asthma very severe or difficult to manage, or if doubts about diagnosis."
    },
    {
        "id": "doc_3457",
        "document": "See list of abbreviations (p.10). See Chapter 3.5 (p.120) for more details about assessment and management of difficult-to-treat and severe asthma.\n\n2. Assessment of asthma\n\n45\n\n\u00ae & O\\\"o & C)OQ O ot & @?\u2018 & X & K\n\n&\n\nSECTION 1. ADULTS, ADOLESCENTS AND CHILDREN 6 YEARS AND OLDER"
    },
    {
        "id": "doc_3458",
        "document": "Chapter 3.\n\nTreating asthma to control symptoms and minimize risk\n\nThis chapter is divided into five parts:\n\n3.1. General principles of asthma management (p.48)\n\n3.2. Medications and strategies for asthma symptom control and risk reduction\n\n\u2022 Medications, including treatment steps (p.53)\n\n\u2022 Treating modifiable risk factors (p.85)\n\n\u2022 Non-pharmacological therapies and strategies (p.88)\n\n3.3. Guided asthma self-management education and skills training (p.98)"
    },
    {
        "id": "doc_3459",
        "document": "\u2022 Information, inhaler choice, inhaler skills, adherence, written asthma action plan, self-monitoring, regular review\n\n3.4. Managing asthma with multimorbidity and in specific populations and contexts, including COVID-19 (p.106)\n\n3.5. Difficult-to-treat and severe asthma in adults and adolescents (including decision tree) (p.120)\n\nManagement of worsening and acute asthma is described in Chapter 4 (p.139).\n\n3.1. GENERAL PRINCIPLES OF ASTHMA MANAGEMENT\n\nKEY POINTS"
    },
    {
        "id": "doc_3460",
        "document": "Goals of asthma management\n\n\u2022 The long-term goals of asthma management are to achieve good symptom control, and to minimize future risk of asthma-related mortality, exacerbations, persistent airflow limitation and side-effects of treatment. The patient\u2019s own goals for their asthma and its treatment should also be identified."
    },
    {
        "id": "doc_3461",
        "document": "The patient-health professional partnership\n\n\u2022 Effective asthma management requires a partnership between the person with asthma (or the parent/caregiver) and their health care providers.\n\n\u2022 Teaching communication skills to health care providers may lead to increased patient satisfaction, better health outcomes, and reduced use of healthcare resources."
    },
    {
        "id": "doc_3462",
        "document": "\u2022 The patient\u2019s \u2018health literacy\u2019 \u2013 that is, the patient\u2019s ability to obtain, process and understand basic health information to make appropriate health decisions \u2013 should be taken into account.\n\nMaking decisions about asthma treatment\n\n\u2022 Asthma treatment is adjusted in a continual cycle of assessment, treatment, and review of the patient\u2019s response in both symptom control and future risk (of exacerbations and side-effects), and of patient preferences."
    },
    {
        "id": "doc_3463",
        "document": "\u2022 For population-level decisions about asthma medications, e.g., choices made by national guidelines, insurers, health maintenance organizations or national formularies, the \u2018preferred\u2019 regimens in Steps 1\u20134 represent the best treatments for most patients, based on evidence from randomized controlled trials, meta-analyses and observational studies about safety, efficacy and effectiveness, with a particular emphasis on symptom burden and exacerbation risk. For Steps 1\u20135, there are different"
    },
    {
        "id": "doc_3464",
        "document": "preferred population-level recommendations for different age-groups (adults/adolescents, children 6\u201311 years, children 5 years and younger). In Step 5, there are also different preferred population-level recommendations depending on the inflammatory phenotype, Type 2 or non- Type 2."
    },
    {
        "id": "doc_3465",
        "document": "\u2022 For individual patients, shared decision-making about treatment should also take into account any patient characteristics or phenotype that predict the patient\u2019s risk of exacerbations or other adverse outcomes, or their likely response to treatment, together with the patient\u2019s goals or concerns and practical issues (inhaler technique, adherence, medication access and cost to the patient).\n\n48\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3466",
        "document": "LONG-TERM GOALS OF ASTHMA MANAGEMENT\n\nThe long-term goals of asthma management from a clinical perspective are:\n\n\u2022 To achieve good control of symptoms and maintain normal activity levels\n\n\u2022 To minimize the risk of asthma-related death, exacerbations, persistent airflow limitation and side-effects."
    },
    {
        "id": "doc_3467",
        "document": "It is also important to elicit the patient\u2019s own goals regarding their asthma, as these may differ from conventional medical goals. Shared goals for asthma management can be achieved in various ways, taking into account differing health care systems, medication availability, and cultural and personal preferences."
    },
    {
        "id": "doc_3468",
        "document": "THE PATIENT-HEALTH CARE PROVIDER PARTNERSHIP\n\nEffective asthma management requires the development of a partnership between the person with asthma (or the parent/caregiver) and health care providers.176 This should enable the person with asthma to gain the knowledge, confidence and skills to assume a major role in the management of their asthma. Self-management education reduces asthma morbidity in both adults177 (Evidence A) and children178 (Evidence A)."
    },
    {
        "id": "doc_3469",
        "document": "There is emerging evidence that shared decision-making is associated with improved outcomes.179 Patients should be encouraged to participate in decisions about their treatment, and given the opportunity to express their expectations and concerns. This partnership needs to be individualized for each patient. A person\u2019s willingness and ability to engage in self-management may vary depending on factors such as ethnicity, literacy, understanding of health concepts (health literacy), numeracy,"
    },
    {
        "id": "doc_3470",
        "document": "beliefs about asthma and medications, desire for autonomy, and the health care system."
    },
    {
        "id": "doc_3471",
        "document": "Good communication"
    },
    {
        "id": "doc_3472",
        "document": "Good communication by health care providers is essential as the basis for good outcomes180-182 (Evidence B). Teaching healthcare providers to improve their communication skills (Box 3-1) can result in increased patient satisfaction, better health outcomes, and reduced use of health care resources180-182 without lengthening consultation times.183 It can also enhance patient adherence.183 Training patients to give information clearly, seek information, and check their understanding of information"
    },
    {
        "id": "doc_3473",
        "document": "provided is also associated with improved adherence with treatment recommendations.183"
    },
    {
        "id": "doc_3474",
        "document": "Box 3-1. Communication strategies for health care providers\n\nKey strategies to facilitate good communication181,182\n\n\u2022 A congenial demeanor (friendliness, humor and attentiveness)\n\n\u2022 Allowing the patient to express their goals, beliefs and concerns\n\n\u2022 Empathy, reassurance, and prompt handling of any concerns\n\n\u2022 Giving encouragement and praise\n\n\u2022 Giving appropriate (personalized) information\n\n\u2022 Providing feedback and review\n\nHow to reduce the impact of low health literacy184"
    },
    {
        "id": "doc_3475",
        "document": "\u2022 Order information from most to least important.\n\n\u2022 Speak slowly and use simple words (avoid medical language, if possible).\n\n\u2022 Simplify numeric concepts (e.g., use numbers instead of percentages).\n\n\u2022 Frame instructions effectively (use illustrative anecdotes, drawings, pictures, table or graphs).\n\n\u2022 Confirm understanding by using the \u2018teach-back\u2019 method (ask patients to repeat instructions).\n\n\u2022 Ask a second person (e.g., nurse, family member) to repeat the main messages."
    },
    {
        "id": "doc_3476",
        "document": "\u2022 Pay attention to non-verbal communication by the patient.\n\n\u2022 Make patients feel comfortable about asking questions.\n\n3. Treating to control symptoms and minimize future risk\n\n49\n\nHealth literacy and asthma"
    },
    {
        "id": "doc_3477",
        "document": "There is increasing recognition of the impact of low health literacy on health outcomes, including in asthma.184,185 Health literacy means much more than the ability to read: it is defined as \u2018the degree to which individuals have the capacity to obtain, process and understand basic health information and services to make appropriate health decisions\u2019.184 Low health literacy is associated with reduced knowledge and worse asthma control.186 In one study, low numeracy among parents of children with"
    },
    {
        "id": "doc_3478",
        "document": "asthma was associated with higher risk of exacerbations.185 Interventions adapted for cultural and ethnicity perspectives have been associated with improved knowledge and significant improvements in inhaler technique.187 Suggested communication strategies for reducing the impact of low health literacy are shown in Box 3-1."
    },
    {
        "id": "doc_3479",
        "document": "PERSONALIZED CONTROL-BASED ASTHMA MANAGEMENT"
    },
    {
        "id": "doc_3480",
        "document": "Asthma control has two domains: symptom control and risk reduction (see Box 2-2, p.38). In control-based asthma management, pharmacological and non-pharmacological treatment is adjusted in a continual cycle that involves assessment, treatment and review by appropriately trained personnel (Box 3-2) in order to achieve the goals of asthma treatment (p.49). Asthma outcomes have been shown to improve after the introduction of control-based guidelines188,189 or practical tools for implementation of"
    },
    {
        "id": "doc_3481",
        "document": "control-based management strategies.179,190"
    },
    {
        "id": "doc_3482",
        "document": "Box 3-2. The asthma management cycle for personalized asthma care"
    },
    {
        "id": "doc_3483",
        "document": "Confirmation of diagnosis if necessary Symptom control & modifiable risk factors (see Box 2-2) Comorbidities Inhaler technique & adherence Patient (and parent/caregiver) preferences and goals Symptoms Exacerbations Side-effects Lung function Comorbidities Treatment of modifiable risk factors Patient (and parent/ and comorbidities caregiver) satisfaction Non-pharmacological strategies Asthma medications (adjust down/up/ between tracks) Education & skills training"
    },
    {
        "id": "doc_3484",
        "document": "Personalized asthma management involves a continual cycle of assessment, adjustment of treatment and review.\n\n\u2022 ASSESS the patient\u2019s symptom control and their risk factors for exacerbations, for decline in lung function and for medication adverse effects (Box 2-2, p.38), with particular attention to inhaler technique and adherence. Assess comorbidities and the patient\u2019s goals and preferences, and confirm the diagnosis of asthma if not yet done."
    },
    {
        "id": "doc_3485",
        "document": "\u2022 ADJUST the patient\u2019s management, based on these assessments. This includes treatment of modifiable risk factors (Box 3-17, p.85) and comorbidities (p.106), relevant non-pharmacologic strategies (Box 3-18, p.88), education and skills training (Chapter 3.3, p.98), and adjustment of medication as required (Chapter 3.2, p.53). For adults and adolescents, the preferred controller and reliever treatment across all steps is with combination ICS-formoterol, as shown in GINA Track 1 (Box 3-12, p.65)."
    },
    {
        "id": "doc_3486",
        "document": "\u2022 REVIEW the patient in line with the goals of treatment (p.49), reassess factors affecting symptoms, risk of adverse outcomes and patient satisfaction, arrange further investigations if needed, and readjust treatment if needed.\n\nSee list of abbreviations (p.10).\n\n50\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3487",
        "document": "The concept of control-based management is also supported by the design of most randomized controlled medication trials, in which patients are identified for a change in asthma treatment on the basis of features of poor symptom control with or without other risk factors such as low lung function or a history of exacerbations. From 2014, GINA asthma management has focused not only on asthma symptom control, but also on personalized management of the patient\u2019s modifiable risk factors for"
    },
    {
        "id": "doc_3488",
        "document": "exacerbations, other adverse outcomes and multimorbidity, and also taking into account the patient\u2019s preferences and goals."
    },
    {
        "id": "doc_3489",
        "document": "For many patients in primary care, achieving good symptom control is a good guide to a reduced risk of exacerbations.191 When inhaled corticosteroids (ICS) were introduced into asthma management, large improvements were observed in symptom control and lung function, and exacerbations and asthma-related mortality also decreased.\n\nHowever, patients with apparently mild asthma and few or intermittent symptoms may be still at risk of severe"
    },
    {
        "id": "doc_3490",
        "document": "exacerbations166 (Box 2-2B, p.38). In addition, some patients continue to have exacerbations despite well-controlled symptoms, and for patients with ongoing symptoms, side-effects may be an issue if ICS doses continue to be stepped up. Therefore, in control-based management, both domains of asthma control (symptom control and future risk \u2013 see Box 2-2, p.38) should be taken into account when choosing asthma treatment and reviewing the response.29,69"
    },
    {
        "id": "doc_3491",
        "document": "Choosing between asthma treatment options\n\nAt each treatment step in asthma management, different medication options are available that, although not of identical efficacy, may be alternatives for controlling asthma. Different considerations apply to recommendations or choices made for broad populations compared with those for individual patients (Box 3-3, p.52), as follows:"
    },
    {
        "id": "doc_3492",
        "document": "\u2022 Population-level medication choices: Population-level medication choices are often applied by bodies such as national formularies or managed care organizations. Population-level recommendations aim to represent the best option for most patients in the particular population. At each treatment step, \u2018preferred\u2019 controller and reliever regimens are recommended that provide the best benefit-to-risk ratio for both symptom control and risk reduction. Choice of the preferred controller and/or"
    },
    {
        "id": "doc_3493",
        "document": "preferred reliever is based on evidence from efficacy studies (highly controlled studies in well-characterized populations) and effectiveness studies (from pragmatically controlled studies, or studies in broader populations, or strong observational data),192 with a particular focus on symptoms and exacerbation risk. Safety and relative cost are also considered. In Step 5, there are different population-level recommendations depending on the inflammatory phenotype, Type 2 or non-Type 2. In the"
    },
    {
        "id": "doc_3494",
        "document": "treatment figure for adults and adolescents (Box 3-12, p.65), the options are shown in two \u2018tracks\u2019. Track 1, with as-needed low-dose ICS-formoterol as the reliever, is the preferred approach for most patients, based on evidence of overall lower exacerbation risk and similar symptom control, and a simpler regimen for stepping treatment up and down as needed, compared with treatments in Track 2 in which the reliever is short-acting beta2 agonist (SABA) or, in some cases, combination ICS-SABA (for"
    },
    {
        "id": "doc_3495",
        "document": "more details, see Chapter 3.2, p.53)."
    },
    {
        "id": "doc_3496",
        "document": "\u2022 Patient-level medication choices: Treatment choices for individual patients also take into account any patient characteristics or phenotype that may predict their risk of exacerbations or other adverse outcomes, or a clinically important difference in their response compared with other patients, together with assessment of multimorbidity, the patient\u2019s goals and preferences, and practical issues such as cost, ability to use the medication and adherence (see Box 3-2, p.50). For factors relating"
    },
    {
        "id": "doc_3497",
        "document": "to the choice of inhaler, see Chapter 3.3 (p.98)."
    },
    {
        "id": "doc_3498",
        "document": "The extent to which asthma treatment can be individualized according to patient characteristics or phenotypes depends on the health system, the clinical context, the potential magnitude of difference in outcomes, cost and available resources. At present, most evidence and research activity about individualized treatment is focused on severe asthma193,194 (see Chapter 3.5, p.120).\n\n3. Treating to control symptoms and minimize future risk\n\n51"
    },
    {
        "id": "doc_3499",
        "document": "Box 3-3. Population level versus patient level decisions about asthma treatment"
    },
    {
        "id": "doc_3500",
        "document": "Choosing between treatment options at a population level\n\n(e.g. national formularies, health maintenance organizations, national guidelines)\n\nThe \u2018preferred\u2019 medication at each step is the best treatment for most patients, based on:\n\n\u2022 Efficacy\n\n\u2022 Effectiveness\n\n|\n\nMainly based on evidence about symptoms and exacerbations (from\n\nrandomized controlled trials, pragmatic studies and strong observational data)\n\n\u2022 Safety\n\n\u2022 Availability and cost at the population level"
    },
    {
        "id": "doc_3501",
        "document": "For Steps 1\u20135, there are different population-level recommendations by age-group (adults/adolescents, children 6\u201311 years, children 5 years and younger). In Step 5, there are also different population-level recommendations depending on the inflammatory phenotype, Type 2 or non-Type 2.\n\nChoosing between controller options for individual patients\n\nUse shared decision-making with the patient or parent/caregiver to discuss the following:"
    },
    {
        "id": "doc_3502",
        "document": "1. Preferred treatment (as above) based on evidence for symptom control and risk reduction\n\n2. Patient characteristics or phenotype\n\n\u2022 Does the patient have any features that predict differences in their future risk or treatment response compared with other patients (e.g., smoker; history of exacerbations, blood eosinophilia)? (see Box 2-2B, p.38)\n\n\u2022 Are there any modifiable risk factors or multimorbidity that may affect treatment outcomes?"
    },
    {
        "id": "doc_3503",
        "document": "3. Patient views\n\n\u2022 What are the patient\u2019s goals, beliefs and concerns about asthma and medications?"
    },
    {
        "id": "doc_3504",
        "document": "4. Practical issues\n\nFor the preferred controller and reliever, which inhaler(s) are available to the patient?\n\nInhaler technique \u2013 can the patient use the inhaler correctly after training?\n\n\u2022 Adherence \u2013 how often is the patient likely to take the medication?\n\n\u2022 Cost to patient \u2013 can the patient afford the medication?\n\n\u2022 Which of the available inhalers has the lowest environmental impact? (see p.98)\n\n52\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3505",
        "document": "3.2. MEDICATIONS AND STRATEGIES FOR SYMPTOM CONTROL AND RISK REDUCTION\n\nKEY POINTS\n\n\u2022 For safety, GINA does not recommend treatment of asthma in adults, adolescents or children 6\u201311 years with SABA alone. Instead, they should receive ICS-containing treatment to reduce their risk of serious exacerbations and to control symptoms."
    },
    {
        "id": "doc_3506",
        "document": "ICS-containing treatment can be delivered either with regular daily treatment or, in adults and adolescents with mild asthma, with as-needed low-dose ICS-formoterol taken whenever needed for symptom relief. For children with mild asthma, ICS can be taken whenever the SABA reliever is taken."
    },
    {
        "id": "doc_3507",
        "document": "\u2022 Reduction in severe exacerbations is a high priority across treatment steps, to reduce the risk and burden to patients and the burden to the health system, and to reduce the need for oral corticosteroids (OCS), which have cumulative long-term adverse effects."
    },
    {
        "id": "doc_3508",
        "document": "Treatment tracks for adults and adolescents\n\n\u2022 For clarity, the treatment figure for adults and adolescents shows two \u2018tracks\u2019, largely based on the choice of reliever. Treatment may be stepped up or down within a track using the same reliever at each step, or treatment may be switched between tracks, according to the individual patient\u2019s needs."
    },
    {
        "id": "doc_3509",
        "document": "\u2022 Track 1, in which the reliever is low-dose ICS-formoterol, is the preferred approach recommended by GINA. When a patient at any step has asthma symptoms, they use low-dose ICS-formoterol as needed for symptom relief. In Steps 3\u20135, they also take ICS-formoterol as regular daily treatment. This approach is preferred because it reduces the risk of severe exacerbations compared with using a SABA reliever, with similar symptom control, and because of the simplicity for patients and clinicians of"
    },
    {
        "id": "doc_3510",
        "document": "needing only a single medication across treatment steps 1\u20134. Medications and doses for Track 1 are explained in Box 3-15, p.80."
    },
    {
        "id": "doc_3511",
        "document": "\u2022 Track 2, in which the reliever is a SABA or ICS-SABA, is an alternative if Track 1 is not possible, or if a patient is stable, with good adherence and no exacerbations in the past year on their current therapy. In Step 1, the patient takes a SABA and a low-dose ICS together for symptom relief (in combination if available, or with the ICS taken immediately after the SABA). In Steps 2\u20135, the reliever is a SABA or combination ICS-SABA. Before considering a SABA reliever, consider whether the"
    },
    {
        "id": "doc_3512",
        "document": "patient is likely to be adherent with their ICS-containing treatment, as otherwise they would be at higher risk of exacerbations."
    },
    {
        "id": "doc_3513",
        "document": "Steps 1 and 2"
    },
    {
        "id": "doc_3514",
        "document": "\u2022 Track 1: In adults and adolescents with mild asthma or who are taking SABA alone, treatment with as-needed-only low-dose ICS-formoterol reduces the risk of severe exacerbations and emergency department visits or hospitalizations by about two-thirds compared with SABA-only treatment. As-needed-only low-dose ICS-formoterol reduces the risk of emergency department visits and hospitalizations compared with daily ICS, with no clinically important difference in symptom control. In patients"
    },
    {
        "id": "doc_3515",
        "document": "previously using SABA alone, as-needed low-dose ICS- formoterol also significantly reduces the risk of severe exacerbations needing OCS, compared with daily ICS."
    },
    {
        "id": "doc_3516",
        "document": "\u2022 Track 2: Treatment with regular daily low-dose ICS plus as-needed SABA is highly effective in reducing asthma symptoms and reducing the risk of asthma-related exacerbations, hospitalization and death. However, adherence with ICS in the community is poor, leaving patients taking SABA alone and at increased risk of exacerbations. While as-needed-only ICS-SABA could be an option at this step, current evidence is limited to small studies that were not powered to detect differences in exacerbation"
    },
    {
        "id": "doc_3517",
        "document": "rates."
    },
    {
        "id": "doc_3518",
        "document": "(continued on next page)\n\n3. Treating to control symptoms and minimize future risk\n\n53\n\nKEY POINTS (continued)\n\nStepping up if asthma remains uncontrolled despite good adherence and inhaler technique\n\n\u2022 Before considering any step up, first confirm that the symptoms are due to asthma and identify and address common problems such as inhaler technique, adherence, allergen exposure and multimorbidity; provide patient education."
    },
    {
        "id": "doc_3519",
        "document": "\u2022 For adults and adolescents, the preferred Step 3 treatment is the Track 1 regimen with low-dose ICS-formoterol as maintenance-and-reliever therapy (MART). This reduces the risk of severe exacerbations, with similar or better symptom control, compared with maintenance treatment using a combination of an ICS and a long-acting beta2 agonist (LABA) as controller, plus as-needed SABA. If needed, the maintenance dose of ICS-formoterol can be increased to medium (i.e. Step 4) by increasing the number"
    },
    {
        "id": "doc_3520",
        "document": "of maintenance inhalations. MART is also a preferred treatment option at Steps 3 and 4 for children 6\u201311 years, with a lower dose ICS-formoterol inhaler."
    },
    {
        "id": "doc_3521",
        "document": "ICS-formoterol should not be used as the reliever for patients taking a different ICS-LABA maintenance treatment, because clinical evidence for safety and efficacy is lacking.\n\n\u2022 Other Step 3 options for adults and adolescents in Track 2, and in children, include maintenance ICS-LABA plus as- needed SABA or plus as-needed ICS-SABA (if available) or, for children 6\u201311 years, medium-dose ICS plus as- needed SABA.\n\n\u2022 For children, try other controller options at the same step before stepping up."
    },
    {
        "id": "doc_3522",
        "document": "Stepping down to find the minimum effective dose\n\n\u2022 Once good asthma control has been achieved and maintained for 2\u20133 months, consider stepping down gradually to find the patient\u2019s lowest treatment that controls both symptoms and exacerbations\n\n\u2022 Provide the patient with a written asthma action plan, monitor closely, and schedule a follow-up visit.\n\n\u2022 Do not completely withdraw ICS unless this is needed temporarily to confirm the diagnosis of asthma."
    },
    {
        "id": "doc_3523",
        "document": "For all patients with asthma, providing asthma education and training in essential skills\n\n\u2022 After choosing the right class of medication for the patient, the choice of inhaler device depends on which inhalers are available for the patient for that medication, which of these inhalers the patient can use correctly after training, and their relative environmental impact. Check inhaler technique frequently."
    },
    {
        "id": "doc_3524",
        "document": "\u2022 Provide inhaler skills training: this is essential for medications to be effective, but technique is often incorrect.\n\n\u2022 Encourage adherence with controller medication, even when symptoms are infrequent.\n\n\u2022 Provide training in asthma self-management (self-monitoring of symptoms and/or peak expiratory flow (PEF), written asthma action plan and regular medical review) to control symptoms and minimize the risk of exacerbations."
    },
    {
        "id": "doc_3525",
        "document": "For patients with one or more risk factors for exacerbations\n\n\u2022 Prescribe ICS-containing medication, preferably from Track 1 options, i.e., with as-needed low-dose ICS-formoterol as reliever; provide a written asthma action plan; and arrange review more frequently than for lower-risk patients.\n\nIdentify and address modifiable risk factors (e.g., smoking, low lung function, over-use of SABA)."
    },
    {
        "id": "doc_3526",
        "document": "\u2022 Consider non-pharmacological strategies and interventions to assist with symptom control and risk reduction, (e.g., smoking cessation advice, breathing exercises, some avoidance strategies).\n\nDifficult-to-treat and severe asthma (see section 3.5, p.120)\n\n\u2022 Patients who have poor symptom control and/or exacerbations, despite medium- or high-dose ICS-LABA treatment, should be assessed for contributing factors, and asthma treatment optimized."
    },
    {
        "id": "doc_3527",
        "document": "\u2022 If the problems continue or diagnosis is uncertain, refer to a specialist center for phenotypic assessment and consideration of add-on therapy including biologics.\n\nFor all patients, use your own professional judgment, and always check local eligibility and payer criteria\n\n54\n\n3. Treating to control symptoms and minimize future risk\n\nASTHMA MEDICATIONS"
    },
    {
        "id": "doc_3528",
        "document": "Categories of asthma medications\n\nThe pharmacological options for long-term treatment of asthma fall into the following main categories (Box 3-4; p.56):"
    },
    {
        "id": "doc_3529",
        "document": "\u2022 Controller medications: in the past, this term mostly referred to medications containing ICS that were used to reduce airway inflammation, control symptoms, and reduce risks such as exacerbations and related decline in lung function.127 In GINA Track 1, controller treatment is delivered through an anti-inflammatory reliever (AIR), low-dose ICS-formoterol, taken when symptoms occur and before exercise or allergen exposure; in Steps 3\u20135, the patient also takes maintenance controller treatment"
    },
    {
        "id": "doc_3530",
        "document": "(daily or twice-daily ICS-formoterol). This is called maintenance-and-reliever therapy (MART). The dose and regimen of controller medications should be optimized to minimize the risk of medication side-effects, including risks of needing OCS."
    },
    {
        "id": "doc_3531",
        "document": "\u2022 Reliever medications: these are provided to all patients for as-needed relief of breakthrough symptoms, including during worsening asthma or exacerbations. They are also recommended for short-term prevention of exercise- induced bronchoconstriction (EIB). Relievers include the anti-inflammatory relievers ICS-formoterol and ICS- SABA, and SABA alone. Over-use of SABA (e.g., dispensing of three or more 200-dose canisters in a year, corresponding to average use more than daily) increases the risk"
    },
    {
        "id": "doc_3532",
        "document": "of asthma exacerbations.74,75"
    },
    {
        "id": "doc_3533",
        "document": "\u2022 Add-on therapies including for patients with severe asthma (Section 3.5, p.120).\n\nWhen compared with medications used for other chronic diseases, most of the medications used for treatment of asthma have very favorable therapeutic ratios.\n\n3. Treating to control symptoms and minimize future risk\n\n55\n\nBox 3-4. Terminology for asthma medications"
    },
    {
        "id": "doc_3534",
        "document": "Term Definition Notes Maintenance treatment Asthma treatment that is prescribed for use every day (or on a regularly scheduled basis) Medications intended to be used continuously, even when the person does not have asthma symptoms. Examples include ICS-containing medications (ICS, ICS-LABA, ICS-LABA-LAMA), as well as LTRA and biologic therapy. The term \u2018maintenance\u2019 describes the prescribed frequency of administration, not a particular class of asthma medicine."
    },
    {
        "id": "doc_3535",
        "document": "Controller Medication targeting both domains of asthma control (symptom control and future risk)"
    },
    {
        "id": "doc_3536",
        "document": "In the past, \u2018controller\u2019 was largely used for ICS-containing medications prescribed for regular daily treatment, so \u2018controller\u2019 and \u2018maintenance\u2019 became almost synonymous. However, this became confusing after the introduction of combination ICS-containing relievers for as-needed use. To avoid confusion, \u2018ICS-containing treatment\u2019 and \u2018maintenance treatment\u2019 have been substituted as appropriate where the intended meaning was unclear."
    },
    {
        "id": "doc_3537",
        "document": "Reliever Asthma inhaler taken as needed, for quick relief of asthma symptoms"
    },
    {
        "id": "doc_3538",
        "document": "Sometimes called rescue ink;arlers. As well as being used for symptom relief, reliever inhalers can also be used before exercise, to prevent exercise-induced asthma symptoms. Includes SABAs (e.g., salbutamol [albuterol], terbutaline, ICS- salbutamol), as-needed ICS-formoterol, and as-needed ICS-SABA. SABA-containing relievers are not intended for regular maintenance use, or to be taken when the person does not have asthma symptoms (except before exercise)."
    },
    {
        "id": "doc_3539",
        "document": "Anti-inflammatory reliever (AIR) Reliever inhaler that contains both a low-dose ICS and a rapid-acting bronchodilator"
    },
    {
        "id": "doc_3540",
        "document": "Includes budesonide-formoterol, beclometasone-formoterol and ICS-salbutamol combinations. Patients can also use them as needed before exercise or allergen exposure to prevent asthma symptoms and bronchoconstriction. Non-formoterol LABAs in combination with ICS cannot be used as relievers. The anti-inflammatory effect of as-needed ICS-formoterol was demonstrated by reduction in FeNO in several studies.!7!172.195 Some anti-inflammatory relievers can be used"
    },
    {
        "id": "doc_3541",
        "document": "as-needed at Steps 1-2 as the person\u2019s sole asthma treatment, without a maintenance treatment (\u2018AlR-only\u2019 treatment). Almost all evidence for this is with ICS-formoterol. Some ICS-formoterol combinations can be used as both maintenance treatment and reliever treatment at Steps 3-5 (see MART, below). For medications and doses see Box 3-15, p.80."
    },
    {
        "id": "doc_3542",
        "document": "Maintenance-and- reliever therapy (MART) Treatment regimen in which the patient uses an ICS-formoterol inhaler every day (maintenance dose), and also uses the same medication as needed for relief of asthma symptoms (reliever doses)"
    },
    {
        "id": "doc_3543",
        "document": "MART (Maintenance And Reliever Therapy) can be used only with combination ICS-formoterol inhalers such as budesonide-formoterol and beclometasone-formoterol. Other ICS-formoterol inhalers can also potentially be used, but combinations of ICS with non-formoterol LABAs, or ICS-SABA, cannot be used for MART. MART is also sometimes called SMART (single-inhaler maintenance and reliever therapy); the meaning is the same. For medications and doses see Box 3-15, p.80."
    },
    {
        "id": "doc_3544",
        "document": "See list of abbreviations (p.10).\n\n56\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3545",
        "document": "Initial asthma treatment in adults, adolescents and children 6\u201311 years\n\nFor the best outcomes, ICS-containing treatment should be initiated when (or as soon as possible after) the diagnosis of asthma is made. All patients should also be provided with a reliever inhaler for quick symptom relief, preferably an anti- inflammatory reliever (AIR).\n\nWhy should ICS-containing medication be commenced from the time of diagnosis?"
    },
    {
        "id": "doc_3546",
        "document": "\u2022 As-needed low-dose ICS-formoterol reduces the risk of severe exacerbations and emergency department visits or hospitalizations by 65% compared with SABA-only treatment.167 This anti-inflammatory reliever regimen (AIR-only) significantly reduces severe exacerbations regardless of the patient\u2019s baseline symptom frequency, lung function, exacerbation history or inflammatory profile (T2-high or T2-low).171,172"
    },
    {
        "id": "doc_3547",
        "document": "\u2022 Starting treatment with SABA alone trains patients to regard it as their main asthma treatment, and increases the risk of poor adherence when daily ICS is subsequently prescribed.\n\n\u2022 Early initiation of low-dose ICS in patients with asthma leads to a greater improvement in lung function than if symptoms have been present for more than 2\u20134 years.196,197 One study showed that after this time, higher ICS doses were required, and lower lung function was achieved.198"
    },
    {
        "id": "doc_3548",
        "document": "\u2022 Patients not taking ICS who experience a severe exacerbation have a greater long-term decline in lung function than those who are taking ICS.127\n\n\u2022 For patients with occupational asthma, early removal from exposure to the sensitizing agent and early ICS- containing treatment increase the probability of resolution of symptoms, and improvement of lung function and airway hyperresponsiveness.49,50"
    },
    {
        "id": "doc_3549",
        "document": "For adults and adolescents, recommended options for initial asthma treatment, based on evidence (where available) and consensus, are listed in Box 3-6 (p.59) and shown in Boxes 3-7 (p.60) and 3-8 (p.60). Treatment for adults and adolescents is shown in two tracks, depending on the reliever inhaler (Box 3-12, p.65)."
    },
    {
        "id": "doc_3550",
        "document": "For children 6\u201311 years, recommendations about initial treatment are on p.62 and p.63. The patient\u2019s response should be reviewed, and treatment stepped down once good control is achieved. Recommendations for a stepwise approach to ongoing treatment are found in Box 3-13 (p.66).\n\nDoes FeNO help in deciding whether to commence ICS?"
    },
    {
        "id": "doc_3551",
        "document": "In studies mainly limited to non-smoking adult patients, fractional concentration of exhaled nitric oxide (FeNO) >50 parts per billion (ppb) was associated with a good short-term (weeks) response to ICS.199,200 However, these studies did not examine the longer-term risk of exacerbations. In two 12-month studies in mild asthma or taking SABA alone, severe exacerbations were reduced with as-needed low-dose ICS-formoterol versus as-needed SABA and versus maintenance ICS, independent of baseline"
    },
    {
        "id": "doc_3552",
        "document": "inflammatory characteristics including FeNO.171,172"
    },
    {
        "id": "doc_3553",
        "document": "Consequently, in patients with a diagnosis or suspected diagnosis of asthma, measurement of FeNO can support the decision to start ICS, but cannot be used to decide against treatment with ICS. Based on past and current evidence, GINA recommends treatment with daily low-dose ICS or as-needed low-dose ICS-formoterol for all adults and adolescents with mild asthma, to reduce the risk of serious exacerbations.171,172,201-203"
    },
    {
        "id": "doc_3554",
        "document": "Adjusting ongoing asthma treatment in adults, adolescents and children 6\u201311 years old"
    },
    {
        "id": "doc_3555",
        "document": "Once asthma treatment has been commenced (Boxes 3-6 to 3-10), ongoing treatment decisions are based on a personalized cycle of assessment, adjustment of treatment, and review of the response. For each patient, in addition to treatment of modifiable risk factors, asthma medication can be adjusted up or down in a stepwise approach (adults and adolescents: Box 3-12, p.65, children 6\u201311 years, Box 3-13, p.66) to achieve good symptom control and minimize future risk of exacerbations, persistent"
    },
    {
        "id": "doc_3556",
        "document": "airflow limitation and medication side-effects. Once good asthma control has been maintained for 2\u20133 months, treatment may be stepped down in order to find the patient\u2019s minimum effective treatment (Box 3-16, p.83)."
    },
    {
        "id": "doc_3557",
        "document": "3. Treating to control symptoms and minimize future risk\n\n57\n\nPeople\u2019s ethnic and racial backgrounds may be associated with different responses to treatment. These are not necessarily associated with genetic differences.204 The contributors are likely to be multifactorial, including differences in exposures, social disadvantage, diet and health-seeking behavior."
    },
    {
        "id": "doc_3558",
        "document": "If a patient has persisting uncontrolled symptoms and/or exacerbations despite 2\u20133 months of ICS-containing treatment, assess and correct the following common problems before considering any step up in treatment:\n\nIncorrect inhaler technique\n\n.\n\n\u2022 Poor adherence\n\n\u2022 Persistent exposure at home/work to agents such as allergens, tobacco smoke, indoor or outdoor air pollution, or to medications such as beta-blockers or (in some patients) nonsteroidal anti-inflammatory drugs (NSAIDs)"
    },
    {
        "id": "doc_3559",
        "document": "\u2022 Comorbidities that may contribute to respiratory symptoms and poor quality of life\n\n\u2022 Incorrect diagnosis.\n\nBox 3-5. Asthma treatment tracks for adults and adolescents"
    },
    {
        "id": "doc_3560",
        "document": "For adults and adolescents, the main treatment figure (Box 3-12, p.65), shows the options for ongoing treatment as two treatment \u2018tracks\u2019, with the key difference being the medication that is used for symptom relief. In Track 1 (preferred), the reliever is as-needed low-dose ICS-formoterol, and in Track 2, the reliever is as-needed SABA or as-needed ICS-SABA. The two tracks show how treatment can be stepped up and down using the same reliever at each step."
    },
    {
        "id": "doc_3561",
        "document": "Track 1: The reliever is as-needed low-dose ICS-formoterol"
    },
    {
        "id": "doc_3562",
        "document": "This is the preferred approach recommended by GINA for adults and adolescents, because of the extensive evidence that using low-dose ICS-formoterol (an anti-inflammatory reliever; AIR) reduces the risk of severe exacerbations compared with using SABA as reliever, with similar symptom control. In addition, the treatment regimen is simpler, with patients using a single medication for reliever and for maintenance treatment if prescribed, across treatment steps."
    },
    {
        "id": "doc_3563",
        "document": "o With this approach, when a patient at any treatment step has asthma symptoms, they use low-dose ICS-formoterol in a single inhaler for symptom relief and to provide anti-inflammatory therapy.\n\no In Steps 3\u20135, patients also take ICS-formoterol as their daily maintenance treatment; together, this is called \u2018maintenance-and-reliever therapy\u2019 (MART).\n\no Medications and doses for GINA Track 1 are shown in Box 3-15, p.80."
    },
    {
        "id": "doc_3564",
        "document": "Track 2: The reliever is as-needed SABA or as-needed ICS-SABA\n\nThis is an alternative approach if Track 1 is not possible, or if a patient\u2019s asthma is stable with good adherence and no exacerbations on their current therapy. However, before prescribing a regimen with SABA-only reliever, consider if the patient is likely to be adherent with their maintenance therapy, as otherwise they will be at higher risk of exacerbations.\n\n."
    },
    {
        "id": "doc_3565",
        "document": "In Step 1, the patient takes a SABA and a low-dose ICS together for symptom relief when symptoms occur (in a combination inhaler, or with the ICS taken immediately after the SABA).\n\nIn Steps 2\u20135, a SABA or combination ICS-SABA is used for symptom relief, and the patient takes maintenance ICS- containing medication regularly every day. If the reliever and maintenance medication are in different devices, make sure that the patient can use each inhaler correctly."
    },
    {
        "id": "doc_3566",
        "document": "Stepping up and down\n\nTreatment can be stepped up or down along one track, using the same reliever at each step, or it can be switched between tracks, according to the individual patient\u2019s needs and preferences. Before stepping up, check for common problems such as incorrect inhaler technique, poor adherence, and environmental exposures, and confirm that the symptoms are due to asthma (Box 2-4, p.45)."
    },
    {
        "id": "doc_3567",
        "document": "The additional controller options, shown below the two treatment tracks, either have limited indications or less evidence for their safety and/or efficacy, compared with the treatments in Tracks 1 and 2.\n\nSee list of abbreviations (p.10).\n\n58\n\n3. Treating to control symptoms and minimize future risk\n\nBox 3-6. Initial asthma treatment - recommended options for adults and adolescents"
    },
    {
        "id": "doc_3568",
        "document": "Presenting symptoms Preferred INITIAL treatment (Track 1) Alternative INITIAL treatment (Track 2) Infrequent asthma symptoms, e.g., less than twice a month and no risk factors for exacerbations, including no exacerbations in the last 12 months (Box 2-2B, p.38) As-needed low-dose ICS- formoterol (Evidence B) Low-dose ICS taken whenever SABA is taken, in combination or separate inhalers (Evidence B)"
    },
    {
        "id": "doc_3569",
        "document": "Asthma symptoms or need for reliever twice a month or more As-needed low-dose ICS- formoterol (Evidence A) Low-dose ICS plus as-needed SABA (Evidence A). Before choosing this option, consider likely adherence with daily ICS."
    },
    {
        "id": "doc_3570",
        "document": "Troublesome asthma symptoms most days (e.g., 4-5 days/week); or waking due to asthma once a week or more, especially if any risk factors exist (Box 2-2B, p.38) Low-dose ICS-formoterol maintenance and reliever therapy (MART) (Evidence A) Low-dose ICS-LABA plus as-needed SABA (Evidence A) or plus as-needed ICS-SABA (Evidence B), OR Medium-dose ICS plus as-needed SABA (Evidence A) or plus as-needed ICS-SABA (Evidence B). Consider likely adherence with daily maintenance treatment."
    },
    {
        "id": "doc_3571",
        "document": "Initial asthma presentation is with severely uncontrolled asthma, or with an acute exacerbation Medium-dose ICS-formoterol maintenance and reliever therapy (MART) (Evidence D). A short course of oral corticosteroids may also be needed."
    },
    {
        "id": "doc_3572",
        "document": "Medium- or high-dose ICS-LABA (Evidence D) plus as-needed SABA or plus as-needed ICS-SABA. Consider likely adherence with daily maintenance treatment. A short course of oral corticosteroids may also be needed. High-dose ICS plus as-needed SABA is another option (Evidence A) but adherence is weak compared with combination ICS-LABA."
    },
    {
        "id": "doc_3573",
        "document": "Before starting initial controller treatment\n\n\u2022 Record evidence for the diagnosis of asthma.\n\n\u2022 Record the patient\u2019s level of symptom control and risk factors, including lung function (Box 2-2, p.38).\n\n\u2022 Consider factors influencing choice between available treatment options (Box 3-3, p.52), including likely adherence with daily ICS-containing treatment, particularly if the reliever is SABA.\n\n\u2022 Choose a suitable inhaler (Box 3-21 p.98) and ensure that the patient can use the inhaler correctly."
    },
    {
        "id": "doc_3574",
        "document": "Schedule an appointment for a follow-up visit.\n\nAfter starting initial controller treatment\n\n\u2022 Review patient\u2019s response (Box 2-2, p.38) after 2\u20133 months, or earlier depending on clinical urgency.\n\n.\n\nSee Box 3-12 (p.65) for recommendations for ongoing treatment and other key management issues.\n\n\u2022 Check adherence and inhaler technique frequently.\n\n\u2022 Step down treatment once good control has been maintained for 3 months (Box 3-16, p.83)."
    },
    {
        "id": "doc_3575",
        "document": "This table is based on evidence from available studies and consensus. Considerations also include cost and likely adherence with ICS-containing treatment. See also Box 3-7 (p.60) for where to start on the main treatment figure for adults and adolescents. See Box 3-14, p.67 for low, medium and high ICS doses for adults and adolescents, and Box 3-15 (p.80) for Track 1 medications and doses. See list of abbreviations (p.10).\n\nD)"
    },
    {
        "id": "doc_3576",
        "document": "of\n\n3. Treating to control symptoms and minimize future risk\n\n59\n\nBox 3-7. Selecting initial treatment in adults and adolescents with a diagnosis of asthma"
    },
    {
        "id": "doc_3577",
        "document": "GINA 2023 \u2014 STARTING TREATMENT in adults and adolescents with a diagnosis of asthma Track 1 using ICS-formoterol reliever is preferred because it reduces the risk of Short course OCS Daily symptoms, or waking with may also be needed asthma once a b.r patients presenting Symptoms most week or more, with severely days, or waking andluu(lung uncontrofled asthma asthma once function than 4-5 days a week or more B B TRACK 1: PREFERRED * Confirm diagnosis CONTROLLER and RELIEVER * Symptom control"
    },
    {
        "id": "doc_3578",
        "document": "reduces the risk of exacerbations Using ICS-formoterol as the reliever* and modifiable risk S factors \u2014 compared with using a SABA reliever, and is a simpler regimen * Comorbidities * Inhaler technique and adherence Daily symptoms, Short course OCS or waking with * Patient preferences asthma once a for patients presenting and goals Symptoms most week or more, with severely qays, or waking lndlw{lung uncontrofled asthma Symptoms twice with asthma once function a month or more, a week or more than"
    },
    {
        "id": "doc_3579",
        "document": "twice but less than 4-5 B days a week TRACK 2: Altemative CONTROLLER and RELIEVER Before considering a regimen with SABA reliever, check if the patient is likely to adhere to = B daily controller treatment RELIEVER: As-needed SABA, or as-needed ICS-SABA* *Anti-inflammatory relievers (AIR)"
    },
    {
        "id": "doc_3580",
        "document": "GINA 2023 \u2014 STARTING TREATMENT\n\nin adults and adolescents with a diagnosis of asthma\n\nTrack 1 using ICS-formoterol reliever is preferred because it reduces the risk of\n\n*Anti-inflammatory relievers (AIR)\n\nSee list of abbreviations (p.10). See Box 3-14, p.67 for low, medium and high ICS doses for adults and adolescents. See Box 3-15, p.80, for Track 1 medications and doses.\n\n60\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3581",
        "document": "Box 3-8. Flowchart for selecting initial treatment in adults and adolescents with a diagnosis of asthma"
    },
    {
        "id": "doc_3582",
        "document": "GINA 2023 \u2014 STARTING TREATMENT in adults and adolescents 12+ years with a diagnosis of asthma FIRST ASSESS: IF: START WITH: TRACK 1 OR TRACK 2 (preferred) Short course OCS may Daily symptoms, waking at also be needed for patients Confirmation night once a week ormore = YES \u2014 STEP 4 presenting with severely of diagnosis and low lung function? uncontrolled asthma 1 NO \\/ Symptom control & modifiable risk factors Symptoms most days, or waking at night once \u2014 YES = STEP 3 a week or more? 1 NO v"
    },
    {
        "id": "doc_3583",
        "document": "Symptoms twice a w\u2014 YES m\u2014fp STEP 2 month or more? Inhaler technique & adherence ICS-containing therapy is recommended even if I as it reduces the risk of \u2018symptoms are infrequent, NO severe exacerbations and need for OCS Patient preferences STEP 1 & goals \u2014 Track 1 is preferred as it reduces the risk of severe exacerbations and need for OCS, and is a simpler regimen"
    },
    {
        "id": "doc_3584",
        "document": "GINA 2023 \u2014 STARTING TREATMENT\n\nin adults and adolescents 12+ years with a diagnosis of asthma\n\nSee list of abbreviations (p.10). See Box 3-14, p.67 for low, medium and high ICS doses for adults and adolescents. See Box 3-15, p.80, for Track 1 medications and doses.\n\n3. Treating to control symptoms and minimize future risk\n\n61\n\nBox 3-9. Initial asthma treatment \u2013 recommended options for children aged 6\u201311 years"
    },
    {
        "id": "doc_3585",
        "document": "Presenting symptoms Preferred INITIAL treatment Infrequent asthma symptoms, e.g., less than twice a month and no risk factors for exacerbations (Box 2-2B, p.38) Low-dose ICS taken whenever SABA is taken (Evidence B) in combination or separate inhalers An alternative option is daily maintenance low-dose ICS with as-needed SABA (Evidence B)."
    },
    {
        "id": "doc_3586",
        "document": "Asthma symptoms or need for reliever twice a month or more, but less than daily Low-dose ICS plus as-needed SABA (Evidence A) Other options include daily LTRA (less effective than ICS, Evidence A), or taking ICS whenever SABA is taken in combination or separate inhalers (Evidence B). Consider likely adherence with maintenance treatment if reliever is SABA."
    },
    {
        "id": "doc_3587",
        "document": "Troublesome asthma symptoms most days (e.g., 4-5 days/week); or waking due to asthma once a week or more, especially if any risk factors exist (Box 2-2B) Low-dose ICS-LABA plus as needed SABA (Evidence A), OR Medium-dose ICS plus as-needed SABA (Evidence A), OR Very-low-dose ICS-formoterol maintenance and reliever (Evidence B) Other options include daily low-dose ICS and LTRA, plus as-needed SABA"
    },
    {
        "id": "doc_3588",
        "document": "Initial asthma presentation is with severely uncontrolled asthma, or with an acute exacerbation Start regular maintenance treatment with medium-dose ICS-LABA plus as-needed SABA or low-dose ICS-formoterol maintenance and reliever (MART). A short course of OCS may also be needed."
    },
    {
        "id": "doc_3589",
        "document": "Before starting initial controller treatment\n\n\u2022 Record evidence for the diagnosis of asthma, if possible.\n\n\u2022 Record the child\u2019s level of symptom control and risk factors, including lung function (Box 2-2, p.38, Box 2-3, p.39).\n\n\u2022 Consider factors influencing choice between available treatment options (Box 3-3, p.52).\n\n\u2022 Choose a suitable inhaler (Box 3-21 p.98) and ensure that the child can use the inhaler correctly.\n\n\u2022 Schedule an appointment for a follow-up visit."
    },
    {
        "id": "doc_3590",
        "document": "After starting initial controller treatment\n\n\u2022 Review child\u2019s response (Box 2-2, p.38) after 2\u20133 months, or earlier depending on clinical urgency.\n\n\u2022 See Box 3-13 (p.66) for recommendations for ongoing treatment and other key management issues.\n\n\u2022 Step down treatment once good control has been maintained for 3 months (Box 3-16, p.83)."
    },
    {
        "id": "doc_3591",
        "document": "This table is based on evidence from available studies and from consensus, including considerations of cost. See also Box 3-4D (p.63) for where to start on the main treatment figure for children 6\u201311 years. See Box 3-14, p.67 for low, medium and high ICS doses in children, and Box 3-15 (p.80) for MART doses in children.. See list of abbreviations (p.10).\n\n62\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3592",
        "document": "Box 3-10. Selecting initial treatment in children aged 6\u201311 years with a diagnosis of asthma"
    },
    {
        "id": "doc_3593",
        "document": "GINA 2023 - STARTING TREATMENT Children 6-11 years with a diagnosis of asthma Confirmation of diagnosis Inhaler technique & adherence Short course OCS Symptom control & modifiable risk factors Child and parent/caregiver preferences may also be needed Comorbidities and goals Symptoms most for patients presenting days, or waking uncontrolled asthma with severely with asthma once a week or Symptoms more, and low most days, or lung function Symptoms waking with twice a month or asthma once a"
    },
    {
        "id": "doc_3594",
        "document": "Symptoms more, but less week or more less than twice than daily a month PREFERRED CONTROLLER to prevent exacerbations and control symptoms e Other controller options (limited indications, or less evidence for efficacy or safety) T T A RELIEVER As-needed SABA (or low dose ICS-formoterol reliever for MART in Steps 3 and 4)"
    },
    {
        "id": "doc_3595",
        "document": "GINA 2023 - STARTING TREATMENT Children 6-11 with a diagnosis of asthma\n\nSee list of abbreviations (p.10). See Box 3-14, p.67 for low, medium and high ICS doses in children. See Box 3-15, p.80 for medications and doses for MART in children.\n\n3. Treating to control symptoms and minimize future risk\n\n63\n\nBox 3-11. Flowchart for selecting initial treatment in children aged 6\u201311 years with a diagnosis of asthma"
    },
    {
        "id": "doc_3596",
        "document": "GINA 2023 \u2014 SUGGESTED INITIAL CONTROLLER TREATMENT in CHILDREN 6-11 years with a diagnosis of asthma FIRST ASSESS: IF: START WITH: Short course OCS may Confirmation Sym) most days, also be needed for patients of diagnosis waking at night 2 once a \u2014 YES - STEP 4 presenting with severely week and low lung function? uncontrolled asthma NIO Symptom control & \\J modifiable risk factors most \u2014 YES s STEP 3 days,or waking at night 2 once a week? NIO \u00a5 Symptoms twice a Inhaler technique month or more?"
    },
    {
        "id": "doc_3597",
        "document": "w\u2014 YES STEP 2 & adherence | NO Child and parent/caregiver preferences and goals | > Take ICS whenever STEP 1 SABA taken MART= maintenance and reliever therapy (ICS-formoterol as both maintenance and reliever)"
    },
    {
        "id": "doc_3598",
        "document": "GINA 2023 \u2014 SUGGESTED INITIAL CONTROLLER TREATMENT\n\nin CHILDREN 6-11 years with a diagnosis of asthma\n\nMART= maintenance and reliever therapy (ICS-formoterol as both maintenance and reliever)\n\nSee list of abbreviations (p.10). See Box 3-14, p.67 for low, medium and high ICS doses in children. See Box 3-15, p.80 for medications and doses for MART in children.\n\n64\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3599",
        "document": "Box 3-12. Personalized management for adults and adolescents to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3600",
        "document": "Confirmation of diagnosis if necessary GINA 2023 - Adults & adolescents Symptom control & modifiable 12+ years risk factors (see Box 2-2) Comorbidities Inhaler technique & adherence Personalized asthma management Patient preferences and goals Assess, Adjust, Review for individual patient needs Symptoms Exacerbations Side-effects Treatment ol difiable risk factors Lung function and comorb) s Comorbidities Patient satisfaction Non-pharmacological strategies Asthma medications (adjust"
    },
    {
        "id": "doc_3601",
        "document": "down/up/between tracks) Education & skills training TRACK 1: PREFERRED CONTROLLER and RELIEVER Using ICS-formoterol as the reliever* reduces the risk of exacerbations compared with = = See GINA using a SABA reliever, and is a VER: As-needed low-dose ICS-formoterol* simpler regimen severe asthma guide TRACK 2: Alternative CONTROLLER and RELIEVER Before considering a regimen with SABA reliever, check if the m. B B patient is likely to adhere to daily controller treatment RELIEVER: as-needed"
    },
    {
        "id": "doc_3602",
        "document": "ICS-SABA*, or as-needed SABA Other controller options (limited Low dose ICS whenever Add LAMA or LTRA or Add azithromycin (adults) or Medium dose ICS, or LTRA. As last resort consider indications, or less evidence for SABA taken*, or daily LTRA, add LTRA, or add HDM SLIT, or switch to adding low dose OCS but efficacy or safety \u2014 see text) or add HDM SLIT HDM SLIT high dose ICS consider side-effects *Anti-inflammatory reliever (AIR)"
    },
    {
        "id": "doc_3603",
        "document": "*Anti-inflammatory reliever (AIR)\n\nSee list of abbreviations (p.10). For recommendations about initial asthma treatment in adults and adolescents, see Box 3-7 (p.59) and 3-8 (p.60). See Box 3-14, p.67 for low, medium and high ICS doses for adults and adolescents. See Box 3-15, p.80, for Track 1 medications and doses.\n\n3. Treating to control symptoms and minimize future risk\n\n65\n\nBox 3-13. Personalized management for children 6\u201311 years to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3604",
        "document": "GINA 2023 - Children 6-11 years Confirmation of diagnosis if necessary Symptom control & modifiable risk factors (see Box 2-2) . biditi Personalized asthma management: Inhaler technique & adherence Child and parent/caregiver preferences and goals Assess, Adjust, Review Symptoms Exacerbations Side-effects Lung function Treatment of modifiable risk factors & comorbidities Child (and parent/ Non-pharmacological strategies caregiver) satisfaction Asthma medications (adjust down or up) Education &"
    },
    {
        "id": "doc_3605",
        "document": "skills training Asthma medication options: Adjust treatment up and down for individual child\u2019s needs PREFERRED CONTROLLER to prevent exacerbations and control symptoms =2k Other controller options (limited indications, or less evidence for efficacy or safety) I RELIEVER As-needed SABA (or ICS-formoterol reliever* in MART in Steps 3 and 4) *Anti-inflammatory refievers (AIR)"
    },
    {
        "id": "doc_3606",
        "document": "RELIEVER\n\nAs-needed SABA (or ICS-formoterol reliever* in MART in Steps 3 and 4)\n\n*Anti-inflammatory refievers (AIR)\n\nSee list of abbreviations (p.10). For initial asthma treatment in children aged 6\u201311 years, see Box 3-4C (p.62) and Box 3-4D (p.63) See Box 3-14, p.67 for low, medium and high ICS doses in children. See Box 3-15 for MART doses for children 6\u201311 years.\n\n66\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3607",
        "document": "Box 3-14. Low, medium and high daily metered doses of inhaled corticosteroids (alone or with LABA)"
    },
    {
        "id": "doc_3608",
        "document": "This is not a table of equivalence, but instead, suggested total daily doses for \u2018low\u2019, \u2018medium\u2019 and \u2018high\u2019 dose ICS options for adults/adolescents (Box 3-12, p.65) and children 6\u201311 years (Box 3-13, p.66), based on product information. Few data are available for comparative potency, and this table does NOT imply potency equivalence. Doses may differ by country, depending on local products, regulatory labelling and clinical guidelines or, for one product, with addition of a LAMA to an"
    },
    {
        "id": "doc_3609",
        "document": "ICS-LABA.205"
    },
    {
        "id": "doc_3610",
        "document": "Low-dose ICS provides most of the clinical benefit of ICS for most patients with asthma. However, ICS responsiveness varies between patients, so some patients may need medium-dose ICS if their asthma is uncontrolled, or they have ongoing exacerbations, despite good adherence and correct technique with low-dose ICS (with or without LABA). High-dose ICS (in combination with LABA or separately) is needed by very few patients, and its long-term use is associated with an increased risk of local and"
    },
    {
        "id": "doc_3611",
        "document": "systemic side-effects, which must be balanced against the potential benefits. For medications and doses of ICS-formoterol for GINA Track 1, see Box 3-15, p.80)."
    },
    {
        "id": "doc_3612",
        "document": "Daily doses in this table are shown as metered doses. See product information for delivered doses.\n\nAdults and adolescents (12 years and older)"
    },
    {
        "id": "doc_3613",
        "document": "Inhaled corticosteroid (alone or in combination with LABA) Total daily ICS Low dose (mcg) \u2014 Medium see notes above High Beclometasone dipropionate (pMDI, standard particle, HFA) 200-500 >500-1000 >1000 Beclometasone dipropionate (DPI or pMDI, extrafine particle, HFA) 100-200 >200-400 >400 Budesonide (DPI, or pMDI, standard particle, HFA) 200-400 >400-800 >800 Ciclesonide (pMDI, extrafine particle, HFA) 80-160 >160-320 >320 Fluticasone furoate (DPI) 100 200"
    },
    {
        "id": "doc_3614",
        "document": "Fluticasone propionate (DPI) 100-250 >250-500 >500 Fluticasone propionate (pMDI, standard particle, HFA) 100-250 >250-500 >500 Mometasone furoate (DPI) Depends on DPI device \u2014 see product information Mometasone furoate (pMDI, standard particle, HFA) 200-400 >400"
    },
    {
        "id": "doc_3615",
        "document": "Children 6\u201311 years \u2013 see notes above (for children 5 years and younger, see Box 6-7, p.184)"
    },
    {
        "id": "doc_3616",
        "document": "Beclometasone dipropionate (pMDI, standard particle, HFA) 100 200 >200-400 >400 Beclometasone dipropionate (pMDI, extrafine particle, HFA) 50-100 >100-200 >200 Budesonide (DPI, or pMDI, standard particle, HFA) 100-200 >200-400 >400 Budesonide (nebules) 250-500 >500-1000 >1000 Ciclesonide (pMDI, extrafine particle*, HFA) 80 >80-160 >160 Fluticasone furoate (DPI) 50 n.a Fluticasone propionate (DPI) 50-100 >100-200 >200 Fluticasone propionate (pMDI, standard particle, HFA) 50-100 >100-200 >200"
    },
    {
        "id": "doc_3617",
        "document": "Mometasone furoate (pMDI, standard particle, HFA) 100 200"
    },
    {
        "id": "doc_3618",
        "document": "See list of abbreviations (p.10). ICS by pMDI should preferably be used with a spacer.\n\nFor new preparations, including generic ICS, the manufacturer\u2019s information should be reviewed carefully, as products containing the same molecule may not be clinically equivalent. Combination inhalers that include a long-acting muscarinic antagonist (LAMA) may have different ICS dosing \u2013 see product information.\n\n3. Treating to control symptoms and minimize future risk\n\n67"
    },
    {
        "id": "doc_3619",
        "document": "Choice of medication, device and dose"
    },
    {
        "id": "doc_3620",
        "document": "In clinical practice, the choice of medication, device and dose for maintenance and for reliever for each individual patient should be based on assessment of symptom control, risk factors, which inhalers are available for the relevant medication class, which of these the patient can use correctly after training, their cost, their environmental impact and the patient\u2019s likely adherence. For more detail about choice of inhaler, see Chapter 3.3 and Box 3-21 (p.99). It is important to monitor the"
    },
    {
        "id": "doc_3621",
        "document": "response to treatment and any side-effects, and to adjust the dose accordingly (Box 3-12, p.65)."
    },
    {
        "id": "doc_3622",
        "document": "Once good symptom control has been maintained for 2\u20133 months, the ICS dose should be carefully back-titrated to the minimum dose that will maintain good symptom control and minimize exacerbation risk, while reducing the potential for side-effects (Box 3-16, p.83). Patients who are being considered for a high daily dose of ICS (except for short periods) should be referred for expert assessment and advice, where possible (Chapter 3.5, p.120). There is currently insufficient good-quality evidence"
    },
    {
        "id": "doc_3623",
        "document": "to support use of extrafine-particle ICS aerosols over others.206"
    },
    {
        "id": "doc_3624",
        "document": "GINA recommends that all adults and adolescents and all children 6\u201311 years should receive ICS-containing medication, incorporated in their maintenance and/or anti-inflammatory reliever treatment as part of personalized asthma management. For adults and adolescents, treatment options are shown in Box 3-12; p.65; and, for children 6\u201311 years, in Box 3-13; p.66. Clinicians should check local eligibility and payer criteria before prescribing."
    },
    {
        "id": "doc_3625",
        "document": "The evidence supporting treatment options at each step is summarized below.\n\nASTHMA TREATMENT STEPS FOR ADULTS, ADOLESCENTS AND CHILDREN 6\u201311 YEARS"
    },
    {
        "id": "doc_3626",
        "document": "The steps below refer to the recommended asthma treatment options shown in Box 3-12, p.65 for adults and adolescents, and in Box 3-13, p.66 for children 6\u201311 years. Treatment recommendations for adults and adolescents are shown in two treatment Tracks (description on p.58), for clarity. Suggested low, medium and high doses for a range of ICS formulations are shown in Box 3-14 (p.67). Medication options and doses for GINA Track 1 are listed in Box 3-15 (p.80)."
    },
    {
        "id": "doc_3627",
        "document": "STEP 1\n\nPreferred Step 1 treatment for adults and adolescents: low-dose combination ICS-formoterol taken as needed for relief of symptoms, and if needed before exercise (Track 1)\n\nPopulation: GINA Step 1 recommendations are for:\n\n\u2022 Initial asthma treatment in patients with symptoms less than twice a month and no exacerbation risk factors, a group that is rarely studied\n\n\u2022 Step-down treatment for patients whose asthma is well controlled on regular ICS or LTRA."
    },
    {
        "id": "doc_3628",
        "document": "In Track 1, the preferred treatment (as-needed ICS-formoterol) is the same for Steps 1 and 2."
    },
    {
        "id": "doc_3629",
        "document": "Evidence: Use of low-dose ICS-formoterol as needed for symptom relief (an anti-inflammatory reliever) in Step 1 for adults and adolescents (Evidence B) is supported by indirect evidence for a reduction in risk of severe exacerbations compared with as-needed SABA alone, from a large double-blind study202 and an open-label study171 in patients who were eligible for Step 2 therapy (see below), and by direct evidence from two studies in patients previously taking Step 2 treatment (maintenance ICS or"
    },
    {
        "id": "doc_3630",
        "document": "LTRA).207"
    },
    {
        "id": "doc_3631",
        "document": "Together, the four large studies showed a similar or greater reduction in severe exacerbations, compared with daily ICS, with no clinically important difference in symptom control or lung function.171,172 For patients previously taking SABA alone, the risk of severe exacerbations was 26% lower with as-needed low-dose ICS-formoterol compared with daily ICS;207 it was also significantly lower than with daily ICS in an open-label study in patients previously taking SABA alone.171\n\n68"
    },
    {
        "id": "doc_3632",
        "document": "3. Treating to control symptoms and minimize future risk\n\nAmong patients stepping down from regular ICS or LTRA, as-needed ICS-formoterol was associated with a similar207 or greater172 reduction in severe exacerbations compared with taking daily ICS. Findings were similar in the adolescent subgroup.208 No new safety signals were seen with as-needed budesonide-formoterol in mild asthma.171,172,202,203,210"
    },
    {
        "id": "doc_3633",
        "document": "Considerations: There were several important considerations for extending the Step 2 recommendation for as-needed- only low-dose ICS-formoterol to Step 1 (i.e., eliminating SABA-only treatment):\n\n\u2022 Patients with few interval asthma symptoms can still have severe or fatal exacerbations.164 GINA recommends assessing and addressing risk factors for exacerbations as well as symptom control (Box 2-2)."
    },
    {
        "id": "doc_3634",
        "document": "\u2022 The historic distinction between so-called \u2018intermittent\u2019 and \u2018mild persistent\u2019 asthma is arbitrary, with no evidence of difference in response to ICS.166 A large reduction in risk of severe exacerbations with as-needed ICS- formoterol, compared with as-needed SABA, was seen even in patients with SABA use twice a week or less at baseline.171"
    },
    {
        "id": "doc_3635",
        "document": "\u2022 A post hoc analysis of one study found that a single day with increased as-needed budesonide-formoterol reduced the short-term (21-day) risk of severe exacerbations compared to as needed SABA alone, suggesting that timing of use of ICS-formoterol is important.79\n\n\u2022 In patients with infrequent symptoms, adherence with prescribed daily ICS is very poor,211 exposing them to risks of SABA-only treatment if they are prescribed daily ICS plus as-needed SABA"
    },
    {
        "id": "doc_3636",
        "document": "\u2022 There is a lack of evidence for the safety or efficacy of SABA-only treatment. Historic recommendations for\n\nSABA-only treatment were based on the assumption that patients with mild asthma would not benefit from ICS\n\n\u2022 Taking SABA regularly for as little as one week significantly increases exercise-induced bronchoconstriction, airway hyperresponsiveness and airway inflammation, and decreases bronchodilator response.212"
    },
    {
        "id": "doc_3637",
        "document": "\u2022 Even modest over-use of SABA (indicated by dispensing of 3 or more 200-dose canisters a year) is associated with increased risk of severe exacerbations74 and, in one study, asthma mortality.75"
    },
    {
        "id": "doc_3638",
        "document": "\u2022 GINA places a high priority on avoiding patients becoming reliant on SABA, and on avoiding conflicting messages in asthma education. Previously, patients were initially provided only with SABA for symptom relief, but later, despite this treatment being effective from the patient\u2019s perspective, they were told that in order to reduce their SABA use, they needed to take a daily maintenance treatment, even when they had no symptoms. Recommending that all patients should be provided with"
    },
    {
        "id": "doc_3639",
        "document": "ICS-containing treatment from the start of therapy (including, in mild asthma, the option of as-needed ICS-formoterol) allows consistent messaging about the need for both symptom relief and risk reduction, and may avoid establishing patient reliance on SABA as their main asthma treatment."
    },
    {
        "id": "doc_3640",
        "document": "Practice points for as-needed-only ICS-formoterol in mild asthma"
    },
    {
        "id": "doc_3641",
        "document": "The usual dose of as-needed budesonide-formoterol in mild asthma is a single inhalation of 200/6 mcg (delivered dose 160/4.5 mcg), taken whenever needed for symptom relief. The maximum recommended dose of as-needed budesonide-formoterol in a single day corresponds to a total of 72 mcg formoterol (54 mcg delivered dose). However, in RCTs in mild asthma, such high usage was rarely seen, with average use around 3\u20134 doses per week.171,202,203 For more details about medications and doses for"
    },
    {
        "id": "doc_3642",
        "document": "as-needed-only ICS-formoterol, see Box 3-15 (p.80)."
    },
    {
        "id": "doc_3643",
        "document": "Rinsing the mouth is not generally needed after as-needed doses of low-dose ICS-formoterol, as this was not required in any of the mild asthma studies (or in MART studies), and there was no increase in risk of oral thrush.210"
    },
    {
        "id": "doc_3644",
        "document": "ICS-formoterol formulations other than budesonide-formoterol have not been studied for as-needed-only use, but beclometasone-formoterol may also be suitable. Both of these medications are well-established for as-needed use within maintenance and reliever therapy in GINA Steps 3\u20135.213 Combination ICS with non-formoterol LABA cannot be used as-needed for symptom relief."
    },
    {
        "id": "doc_3645",
        "document": "For pre-exercise use in patients with mild asthma, one 6-week study showed that use of low-dose budesonide- formoterol for symptom relief and before exercise reduced exercise-induced bronchoconstriction to a similar extent as regular daily low-dose ICS with SABA for symptom relief and before exercise.214 More studies are needed, but this study suggests that patients with mild asthma who are prescribed as-needed low-dose ICS-formoterol to prevent"
    },
    {
        "id": "doc_3646",
        "document": "3. Treating to control symptoms and minimize future risk\n\n69\n\nexacerbations and control symptoms can use the same medication prior to exercise, if needed, and do not need to be prescribed a SABA for pre-exercise use (Evidence B).\n\nAlternative Step 1 treatment options for adults and adolescents (Track 2)"
    },
    {
        "id": "doc_3647",
        "document": "Low-dose ICS taken whenever SABA is taken (Evidence B): For patients with symptoms less than twice a month or eligible to step-down from regular ICS treatment, there is very little evidence about the safety and efficacy of taking ICS whenever SABA is taken (in separate or combination inhalers). However, it may be an option in countries where ICS-formoterol is not available or affordable. In Step 1, the evidence for this strategy is indirect, from small studies with separate or combination ICS"
    },
    {
        "id": "doc_3648",
        "document": "and SABA inhalers in patients eligible for Step 2 treatment (see below).215-218 In making this recommendation, the most important considerations were reducing the risk of severe exacerbations, and the difficulty of achieving good adherence with regularly prescribed ICS in patients with infrequent symptoms. For definitions of low- dose ICS see Box 3-14 (p.67)."
    },
    {
        "id": "doc_3649",
        "document": "Regular daily low-dose ICS has been suggested by GINA since 2014 for consideration as a Step 1 treatment for patients with symptoms less than twice a month, to reduce the risk of exacerbations. This was based on indirect evidence from studies in patients eligible for Step 2 treatment166,209,219 (Evidence B). However, patients with symptoms less than twice a month are extremely unlikely to take ICS regularly even if prescribed, leaving them exposed to the risks of SABA-only treatment, so this"
    },
    {
        "id": "doc_3650",
        "document": "regimen is no longer recommended for general use in such patients."
    },
    {
        "id": "doc_3651",
        "document": "Step 1 treatment options for children 6\u201311 years"
    },
    {
        "id": "doc_3652",
        "document": "For children 6\u201311 years with asthma symptoms less than twice a month, possible treatment options include taking ICS whenever SABA is taken, based on indirect evidence from Step 2 studies with separate inhalers in children and adolescents. One of these studies showed substantially fewer exacerbations compared with SABA-only treatment,216 and another showed similar outcomes as with physician-adjusted treatment and with lower average ICS dose218 (Evidence B). Regular ICS plus as-needed SABA is also"
    },
    {
        "id": "doc_3653",
        "document": "a possible option for this age-group (Evidence B), but the likelihood of poor adherence in children with infrequent symptoms should be taken into account. See Box 3-14 (p.67) for ICS doses."
    },
    {
        "id": "doc_3654",
        "document": "There have been no studies of as needed-only ICS-formoterol in children aged 6\u201311 years. However, concerns around SABA-only treatment are also relevant to children and should be considered when initiating Step 1 treatment (see other controller options for children in Step 2, below).\n\nNot recommended"
    },
    {
        "id": "doc_3655",
        "document": "GINA no longer recommends SABA-only treatment of asthma in adults, adolescents or children 6\u201311 years. Although inhaled SABAs are highly effective for the quick relief of asthma symptoms,220 patients whose asthma is treated with SABA alone (compared with ICS) are at increased risk of asthma-related death (Evidence A)75,221 and urgent asthma-related healthcare (Evidence A),222 even if they have good symptom control.223 The risk of severe exacerbations requiring urgent health care is substantially"
    },
    {
        "id": "doc_3656",
        "document": "reduced in adults and adolescents by either as-needed ICS- formoterol,167 or by regular low-dose ICS with as-needed SABA.219 The risk of asthma exacerbations and mortality increases incrementally with higher SABA use, including in patients treated with SABA alone.75 One long-term study of regular SABA in patients with newly diagnosed asthma showed worse outcomes and lower lung function than in patients who were treated with daily low-dose ICS from the start.224"
    },
    {
        "id": "doc_3657",
        "document": "In adults, inhaled short-acting anticholinergic agents like ipratropium are potential alternatives to SABA for routine relief of asthma symptoms; however, these agents have a slower onset of action than inhaled SABA. Oral SABA and theophylline have a higher risk of side-effects and are not recommended. For clinicians in regions without access to inhaled therapies, advice on minimizing the frequency and dose of these oral medications has been provided elsewhere.9 No long-term safety studies have"
    },
    {
        "id": "doc_3658",
        "document": "been performed to assess the risk of severe exacerbations associated with oral SABA or theophylline use in patients not also taking ICS. Use of long-acting muscarinic antagonists (LAMA) in asthma without concomitant ICS is associated with an increased risk of severe exacerbations.225"
    },
    {
        "id": "doc_3659",
        "document": "70\n\n3. Treating to control symptoms and minimize future risk\n\nThe rapid-onset LABA, formoterol, is as effective as SABA as a reliever medication in adults and children,226 and reduces the risk of severe exacerbations by 15\u201345%, compared with as-needed SABA,227-229 but use of regular or frequent LABA without ICS is strongly discouraged because of the risk of exacerbations135,230 (Evidence A)."
    },
    {
        "id": "doc_3660",
        "document": "STEP 2\n\nPreferred Step 2 treatment for adults and adolescents: low-dose ICS-formoterol, taken as-needed for relief of symptoms and, if needed, before exercise (Track 1)\n\nPopulation: patients enrolled in these studies were considered by their physicians to have mild asthma, with symptoms or SABA use up to twice a day on SABA alone or regular ICS or LTRA plus as-needed SABA.\n\nEvidence: The current evidence for this treatment in Step 2 is with low-dose budesonide-formoterol:"
    },
    {
        "id": "doc_3661",
        "document": "\u2022 A large double-blind study in mild asthma found a 64% reduction in severe exacerbations, compared with SABA-only treatment,202 with a similar finding in an open-label study in patients with mild asthma previously taking SABA alone (Evidence A).171\n\n\u2022 Two large double-blind studies in mild asthma showed as-needed budesonide-formoterol was non-inferior for severe exacerbations, compared with regular ICS.202,203"
    },
    {
        "id": "doc_3662",
        "document": "\u2022 In two open-label randomized controlled trials, representing the way that patients with mild asthma would use as-needed ICS-formoterol in real life, as-needed budesonide-formoterol was superior to maintenance ICS in reducing the risk of severe exacerbations (Evidence A).171,172"
    },
    {
        "id": "doc_3663",
        "document": "\u2022 A Cochrane review provided moderate to high certainty evidence that as-needed ICS-formoterol was clinically effective in adults and adolescents with mild asthma, significantly reducing important clinical outcomes including need for oral corticosteroids, severe exacerbation rates, and emergency department visits or hospital admissions compared with daily ICS plus as-needed SABA (Evidence A).167,210"
    },
    {
        "id": "doc_3664",
        "document": "\u2022 In all four studies, the as-needed low-dose ICS-formoterol strategy was associated with a substantially lower average ICS dose than with maintenance low-dose ICS.171,172,202,203\n\n\u2022 Clinical outcomes with as-needed ICS-formoterol were similar in adolescents as in adults.208"
    },
    {
        "id": "doc_3665",
        "document": "\u2022 A post hoc analysis of one study202 found that a day with >2 doses of as-needed budesonide-formoterol reduced the short-term (21 day) risk of severe exacerbations compared to as needed terbutaline alone, suggesting that timing of use of ICS-formoterol is important.79\n\n\u2022 No new safety signals were seen with as-needed budesonide-formoterol in mild asthma.171,172,202,203,210"
    },
    {
        "id": "doc_3666",
        "document": "Considerations: The most important considerations for GINA in recommending as-needed-only low-dose ICS- formoterol in Step 2 were:\n\n\u2022 The need to prevent severe exacerbations in patients with mild or infrequent symptoms; these can occur with unpredictable triggers such as viral infection, allergen exposure, pollution or stress."
    },
    {
        "id": "doc_3667",
        "document": "\u2022 The desire to avoid the need for daily ICS in patients with mild asthma, who in clinical practice are often poorly adherent with prescribed ICS, leaving them exposed to the risks of SABA-only treatment.219\n\n\u2022 The greater reduction in severe exacerbations with as-needed ICS-formoterol, compared with daily ICS, among patients previously taking SABA alone, with no significant difference for patients with well-controlled asthma on ICS or LTRA at baseline.171,207"
    },
    {
        "id": "doc_3668",
        "document": "\u2022 The very small differences in FEV1, (approximately 30\u201350 mL), symptom control (difference in ACQ-5 of approximately 0.15 versus minimal clinically important difference 0.5), and symptom-free days (mean difference 10.6 days per year)202,203 compared with regular ICS were considered to be less important. These differences did not increase over the 12-month studies. The primary outcome variable of one study202 was \u2018well-controlled asthma weeks\u2019, but this outcome was not considered reliable"
    },
    {
        "id": "doc_3669",
        "document": "because it was based on an earlier concept of asthma control, and was systematically biased against the as-needed ICS-formoterol treatment group because much less ICS was permitted in a week for patients on ICS-formoterol than those on maintenance ICS before the week was classified as not well controlled."
    },
    {
        "id": "doc_3670",
        "document": "3. Treating to control symptoms and minimize future risk\n\n71\n\n\u2022 The similar reduction in FeNO with as-needed budesonide-formoterol as with maintenance ICS, and the lack of significant difference in treatment effect with as-needed budesonide-formoterol by patients\u2019 baseline eosinophils or baseline FeNO.171,172"
    },
    {
        "id": "doc_3671",
        "document": "Anti-inflammatory reliever treatment with as-needed-only ICS-formoterol (\u2018AIR-only\u2019) is the preferred treatment for Steps 1 and 2 in adults/adolescents, so these steps have been combined in the treatment figure (Track 1, Box 3-12, p.65) to avoid confusion."
    },
    {
        "id": "doc_3672",
        "document": "Practice points for as-needed ICS-formoterol in mild asthma\n\nPatient preferences: from qualitative research, the majority of patients in a pragmatic open-label study preferred as- needed ICS-formoterol for ongoing treatment rather than regular daily ICS with a SABA reliever. They reported that shared decision-making would be important in choosing between these treatment options.231"
    },
    {
        "id": "doc_3673",
        "document": "The usual dose of as-needed budesonide-formoterol in mild asthma is a single inhalation of 200/6 mcg (delivered dose 160/4.5 mcg), taken whenever needed for symptom relief. Based on product information, the maximum recommended dose of budesonide-formoterol in a single day is a total of 72 mcg formoterol (54 mcg delivered dose). However, in the randomized controlled trials in mild asthma, such high usage was rarely seen, and average use of as-needed ICS-formoterol was around 3\u20134 doses per"
    },
    {
        "id": "doc_3674",
        "document": "week.171,172,202,203 For more details about medications and doses for as-needed-only ICS-formoterol, see Box 3-15 (p.80)."
    },
    {
        "id": "doc_3675",
        "document": "Rinsing the mouth is not generally needed after as-needed use of low-dose ICS-formoterol, as this was not required in any of the mild asthma studies (or MART studies), and there was no increase in risk of oral thrush."
    },
    {
        "id": "doc_3676",
        "document": "Other ICS-formoterol formulations have not been studied for as-needed-only use, but beclometasone-formoterol may also be suitable. Both of these medications are well established for as-needed use within maintenance and reliever therapy (MART) in GINA Steps 3\u20135.213 No new safety signals were seen in four studies with as-needed budesonide- formoterol in mild asthma.171,172,202,203,210 ICS-LABA combinations with a non-formoterol LABA are not suitable for this regimen."
    },
    {
        "id": "doc_3677",
        "document": "For pre-exercise use in patients with mild asthma, one study showed that budesonide-formoterol taken as-needed and before exercise had similar benefit in reducing exercise-induced bronchoconstriction as daily ICS with SABA as-needed and pre-exercise.214 More studies are needed, but this suggests that patients with mild asthma who are prescribed as- needed low-dose ICS-formoterol to prevent exacerbations and control symptoms can use the same medication prior to exercise, if needed, and do not"
    },
    {
        "id": "doc_3678",
        "document": "need to be prescribed a SABA for pre-exercise use (Evidence B)."
    },
    {
        "id": "doc_3679",
        "document": "Alternative Step 2 treatment for adults and adolescents: daily low-dose ICS plus as-needed SABA (Track 2)\n\nPopulation: Most studies of daily low dose ICS have included patients with symptoms up to most or all days a week."
    },
    {
        "id": "doc_3680",
        "document": "Evidence: regular daily low-dose ICS plus as-needed SABA is a long-established treatment for mild asthma. There is a large body of evidence from RCTs and observational studies showing that the risks of severe exacerbations, hospitalizations and mortality are substantially reduced with regular low-dose ICS; symptoms and exercise-induced bronchoconstriction are also reduced209,219,221,232,233 (Evidence A). Severe exacerbations are halved with low-dose ICS even in patients with symptoms 0\u20131 days a"
    },
    {
        "id": "doc_3681",
        "document": "week.166 In a meta-analysis of long-term longitudinal studies, regular ICS was associated with a very small increase in pre- and post-bronchodilator FEV1 % predicted, in adults but not in children, compared with SABA alone.234"
    },
    {
        "id": "doc_3682",
        "document": "Other considerations: Clinicians should be aware that adherence with maintenance ICS in the community is extremely low. They should consider the likelihood that patients with infrequent symptoms who are prescribed daily ICS plus as-needed SABA will be poorly adherent with the ICS, increasing their risk of severe exacerbations."
    },
    {
        "id": "doc_3683",
        "document": "Over-use of SABA, indicated by dispensing of three or more 200-dose canisters of SABA in a year (i.e. average use more than daily), is associated with an increased risk of severe exacerbations74,75 and, in one study, with increased mortality,75 even in patients also taking ICS-containing treatment.\n\n72\n\n3. Treating to control symptoms and minimize future risk\n\nOther Step 2 treatment options for adults and adolescents"
    },
    {
        "id": "doc_3684",
        "document": "Low-dose ICS taken whenever SABA is used (in combination or separate ICS and SABA inhalers) is another option if as-needed ICS-formoterol is not available, and the patient is unlikely to take regular ICS. The evidence is from two small studies in adults and two small studies in children and adolescents, with separate or combination ICS and SABA inhalers,215-218 showing no difference in exacerbations compared with daily ICS. If combination ICS-SABA is not available, the patient needs to carry"
    },
    {
        "id": "doc_3685",
        "document": "both ICS and SABA inhalers with them for as-needed use. See Box 3-14 (p.67) for ICS doses. There are no studies with daily maintenance ICS plus as-needed combination ICS-SABA."
    },
    {
        "id": "doc_3686",
        "document": "Leukotriene receptor antagonists (LTRA) are less effective than ICS,235 particularly for exacerbations (Evidence A). Before prescribing montelukast, health professionals should consider its benefits and risks, and patients should be counselled about the risk of neuropsychiatric events. In 2020, the US Food and Drug Administration (FDA) required a boxed warning to be added about the risk of serious mental health adverse effects with montelukast.236"
    },
    {
        "id": "doc_3687",
        "document": "Regular daily combination low-dose ICS-LABA as the initial maintenance controller treatment (i.e. in patients previously treated with SABA alone) reduces symptoms and improves lung function, compared with low-dose ICS.237 However, it is more expensive and does not further reduce the risk of exacerbations compared with ICS alone237 (Evidence A)."
    },
    {
        "id": "doc_3688",
        "document": "For patients with purely seasonal allergic asthma, e.g., with birch pollen, with no interval asthma symptoms, regular daily ICS or as-needed low-dose ICS-formoterol should be started immediately symptoms commence, and be continued for four weeks after the relevant pollen season ends (Evidence D)."
    },
    {
        "id": "doc_3689",
        "document": "Preferred Step 2 treatment for children 6\u201311 years\n\nThe preferred controller option for children at Step 2 is regular low-dose ICS plus as-needed SABA (see Box 3-14, p.67 for ICS dose ranges in children). This reduces the risk of serious exacerbations compared with SABA-only treatment.219\n\nAlternative Step 2 treatment for children 6\u201311 years"
    },
    {
        "id": "doc_3690",
        "document": "Another controller option for children is taking low-dose ICS whenever SABA is taken, based on the results of two small studies with separate ICS and SABA inhalers in patients aged between 5 years and 17 or 18 years.216,218 Exacerbations and symptoms were similar with this regimen as with maintenance ICS plus as-needed SABA. Interviews with parents/caregivers indicated that those whose children were randomized to as-needed ICS-SABA felt more in control of their child\u2019s asthma than those whose"
    },
    {
        "id": "doc_3691",
        "document": "children were randomized to physician-based adjustment.218"
    },
    {
        "id": "doc_3692",
        "document": "Another option is daily LTRA, which, overall, is less effective than ICS.235 The FDA warning about montelukast (above) also applies to its use in children.236\n\nNot recommended"
    },
    {
        "id": "doc_3693",
        "document": "Sustained-release theophylline has only weak efficacy in asthma238-240 (Evidence B) and side-effects are common, and may be life-threatening at higher doses.241 Use of long-acting muscarinic antagonists (LAMA) in asthma without concomitant ICS is associated with an increased risk of severe exacerbations.225 Chromones (nedocromil sodium and sodium cromoglycate) have been discontinued globally; these had a favorable safety profile but low efficacy242-244 (Evidence A), and their pMDI inhalers"
    },
    {
        "id": "doc_3694",
        "document": "required burdensome daily washing to avoid blockage."
    },
    {
        "id": "doc_3695",
        "document": "3. Treating to control symptoms and minimize future risk\n\n73\n\nSTEP 3\n\nBefore considering a step up, check for common problems such as incorrect inhaler technique, poor adherence, and environmental exposures, and confirm that the symptoms are due to asthma (Box 2-4, p.45).\n\nPreferred Step 3 treatment for adults and adolescents: low-dose ICS-formoterol maintenance and reliever therapy"
    },
    {
        "id": "doc_3696",
        "document": "For adults and adolescents, the \u2018preferred\u2019 Step 3 option is low-dose ICS-formoterol as both maintenance and reliever treatment (MART). In this regimen, low-dose ICS-formoterol, either budesonide-formoterol or beclometasone-formoterol, is used as both the daily maintenance treatment and as an anti-inflammatory reliever for symptom relief."
    },
    {
        "id": "doc_3697",
        "document": "Population: Double-blind studies included adult and adolescent patients with \u22651 exacerbation in the previous year despite maintenance ICS or ICS-LABA treatment, usually with poor symptom control."
    },
    {
        "id": "doc_3698",
        "document": "Evidence: Low-dose ICS-formoterol maintenance and reliever therapy reduced severe exacerbations and provided similar levels of asthma control at relatively low doses of ICS, compared with a fixed dose of ICS-LABA as maintenance treatment or a higher dose of ICS, both with as-needed SABA245-250 (Evidence A). In a meta-analysis, switching patients with uncontrolled asthma from Step 3 treatment to MART was associated with a 29% reduced risk of severe exacerbation compared with stepping up to Step 4"
    },
    {
        "id": "doc_3699",
        "document": "ICS-LABA maintenance plus SABA reliever, and a 30% reduced risk compared with staying on the same treatment with SABA reliever.251 In open-label studies that did not require a history of severe exacerbations, maintenance and reliever therapy with ICS-formoterol also significantly reduced severe exacerbations, with a lower average dose of ICS.245,252"
    },
    {
        "id": "doc_3700",
        "document": "Other considerations: Use of ICS-formoterol as an anti-inflammatory reliever across treatment steps provides a simple regimen with easy transition if treatment needs to be stepped up (e.g. from Step 2 to Step 3, or Step 3 to Step 4), without the need for an additional medication or different prescription, or a different inhaler type (see Box 3-15, p.80).\n\nPractice points for maintenance and reliever therapy (MART) with low-dose ICS-formoterol"
    },
    {
        "id": "doc_3701",
        "document": "Medications: ICS-formoterol maintenance and reliever therapy for Step 3 treatment can be prescribed with low-dose budesonide-formoterol (\u226512 years) or low-dose beclometasone-formoterol (\u226518 years). The usual dose of budesonide- formoterol for MART is 200/6 mcg metered dose (160/4.5 mcg delivered dose) and the usual dose of beclometasone- formoterol is 100/6 metered dose (87.5/5 mcg), with each of these combinations prescribed as one inhalation twice-daily and one inhalation whenever needed for"
    },
    {
        "id": "doc_3702",
        "document": "symptom relief."
    },
    {
        "id": "doc_3703",
        "document": "Doses: The maximum recommended total dose of formoterol in a single day (total of maintenance and reliever doses, based on product information, is 72 mcg metered dose (54 mcg delivered dose) for budesonide-formoterol and 48 mcg metered dose (36 mcg delivered dose) for beclometasone-formoterol. For a summary of medications and doses, see Box 3-15 (p.80)."
    },
    {
        "id": "doc_3704",
        "document": "ICS-formoterol should not be used as the reliever for patients taking a different ICS-LABA maintenance treatment, since clinical evidence for safety and efficacy is lacking.\n\nRinsing the mouth is not generally needed after as-needed doses of ICS-formoterol, as this was not required in any of the MART studies, and there was no increase in risk of oral thrush.\n\nAdditional practice points can be found in an article describing how to use MART, including a customizable written"
    },
    {
        "id": "doc_3705",
        "document": "Alternative Step 3 treatment for adults and adolescents: maintenance low-dose ICS-LABA plus as-needed SABA or plus as-needed combination ICS-SABA (Track 2)\n\nCurrently approved combination ICS-LABA inhalers for Step 3 maintenance treatment of asthma include low doses of fluticasone propionate-formoterol, fluticasone furoate-vilanterol, fluticasone propionate-salmeterol, beclometasone- formoterol, budesonide-formoterol, mometasone-formoterol, and mometasone-indacaterol (see Box 3-14, p.67).\n\n74"
    },
    {
        "id": "doc_3706",
        "document": "3. Treating to control symptoms and minimize future risk\n\nEffectiveness of fluticasone furoate-vilanterol over usual care was demonstrated for asthma symptom control in a large real-world study, but there was no significant difference in risk of exacerbations.253,254"
    },
    {
        "id": "doc_3707",
        "document": "Maintenance ICS-LABA plus as-needed SABA: This is an alternative approach if MART is not possible, or if a patient\u2019s asthma is stable with good adherence and no exacerbations on their current therapy. For patients taking maintenance ICS, changing to maintenance combination ICS-LABA provides additional improvements in symptoms and lung function with a reduced risk of exacerbations compared with the same dose of ICS (Evidence A),255,256 but there is only a small reduction in reliever use.257,258"
    },
    {
        "id": "doc_3708",
        "document": "In these studies, the reliever was as-needed SABA. However, before prescribing a regimen with SABA reliever, consider whether the patient is likely to be adherent with their ICS-containing treatment, as otherwise they will be at higher risk of exacerbations."
    },
    {
        "id": "doc_3709",
        "document": "Maintenance ICS-LABA plus as-needed combination ICS-SABA (\u226518 years):\n\nPopulation: In the double-blind MANDALA study,259 the population relevant to Step 3 recommendations comprised patients with poor asthma control and a history of severe exacerbations who were taking maintenance low-dose ICS- LABA or medium-dose ICS. In this study, patients were randomized to as-needed ICS-SABA or as-needed SABA, and continued to take their usual maintenance treatment."
    },
    {
        "id": "doc_3710",
        "document": "Evidence: In the sub-population taking Step 3 maintenance treatment, as-needed use of 2 inhalations of budesonide- salbutamol (albuterol) 100/100 mcg metered dose (80/90 mcg delivered dose), taken for symptom relief, increased the time to first severe exacerbation by 41% compared with as-needed salbutamol (hazard ratio 0.59; CI 0.42\u20130.85). The proportion of patients with a clinically important difference in ACQ-5 was slightly higher with the budesonide-salbutamol reliever. A formulation with a"
    },
    {
        "id": "doc_3711",
        "document": "lower ICS dose did not significantly reduce severe exacerbations.259"
    },
    {
        "id": "doc_3712",
        "document": "Other considerations: There are no head-to-head comparisons between this regimen and ICS-formoterol maintenance-and-reliever therapy (MART), both of which include an anti-inflammatory reliever (AIR). However, as ICS- SABA is not recommended for regular use, and its use as the reliever in Steps 3\u20135 requires the patient to have different maintenance and reliever inhalers, this regimen is more complex for patients than GINA Track 1 with ICS-formoterol, in which the same medication is used for both"
    },
    {
        "id": "doc_3713",
        "document": "maintenance and reliever doses. Transition between treatment steps with as-needed ICS-SABA may also be more complex than in GINA Track 1 as there is only one small study of as-needed- only ICS-SABA (beclometasone-salbutamol) as a Step 2 treatment.215"
    },
    {
        "id": "doc_3714",
        "document": "Practice points: A maximum number of 6 as-needed doses (each 2 puffs of 100/100 mcg budesonide-salbutamol [80/90 mcg delivered dose]) can be taken in a day. It is essential to educate patients about the different purpose of their maintenance and reliever inhalers, and to train them in correct inhaler technique with both devices if they are different; this also applies to SABA relievers."
    },
    {
        "id": "doc_3715",
        "document": "Other Step 3 controller options for adults and adolescents\n\nFor adult patients with allergic rhinitis and sensitized to house dust mite, with suboptimally controlled asthma despite low to high-dose ICS, consider adding sublingual allergen immunotherapy (SLIT), provided FEV1 is >70% predicted.260,261 (see p.86)."
    },
    {
        "id": "doc_3716",
        "document": "Another option for adults and adolescents is to increase ICS to medium dose150 (see Box 3-14, p.67) but, at population level, this is less effective than adding a LABA262,263 (Evidence A). Other less efficacious options are low-dose ICS- containing therapy plus either LTRA264 (Evidence A) or low-dose, sustained-release theophylline265 (Evidence B). Note the FDA warning for montelukast.236"
    },
    {
        "id": "doc_3717",
        "document": "Preferred Step 3 treatment for children 6\u201311 years\n\nIn children, after checking inhaler technique and adherence, and treating modifiable risk factors, there are three preferred options at a population level:\n\n.\n\nIncrease ICS to medium dose (see Box 3-14, p.67),266 plus as-needed SABA reliever (Evidence A), or\n\n\u2022 Change to combination low-dose ICS-LABA plus as-needed SABA reliever (Evidence A),267 or"
    },
    {
        "id": "doc_3718",
        "document": "\u2022 Switch to maintenance-and-reliever therapy (MART) with a very low dose of ICS-formoterol (Evidence B).268 For a summary of medications and doses, see Box 3-15 (p.80).\n\n3. Treating to control symptoms and minimize future risk\n\n75"
    },
    {
        "id": "doc_3719",
        "document": "Evidence: In a large study of children aged 4\u201311 years with a history of an exacerbation in the previous year, combination ICS-LABA was non-inferior to the same dose of ICS alone for severe exacerbations, with no difference in symptom control or reliever use.269 In children, a single study of maintenance and reliever therapy with very low-dose budesonide-formoterol (100/6 metered dose, 80/4.5 mcg delivered dose for both maintenance and reliever) showed a large reduction in exacerbations,"
    },
    {
        "id": "doc_3720",
        "document": "compared with the same dose of budesonide-formoterol plus SABA reliever, or compared with higher-dose ICS.268"
    },
    {
        "id": "doc_3721",
        "document": "Individual children\u2019s responses vary, so try the other controller options above before considering Step 4 treatment.270\n\nOther Step 3 treatment options for children 6\u201311 years\n\nIn children, a 2014 systematic review and meta-analysis did not support the addition of LTRA to low-dose ICS.264 The FDA warning about montelukast (above) also applies to its use in children.236"
    },
    {
        "id": "doc_3722",
        "document": "STEP 4\n\nAlthough at a population level most benefit from ICS is obtained at low dose, individual ICS responsiveness varies, and some patients whose asthma is uncontrolled on low-dose ICS-LABA despite good adherence and correct inhaler technique may benefit from increasing the maintenance dose to medium. High-dose ICS is no longer recommended at Step 4."
    },
    {
        "id": "doc_3723",
        "document": "Before stepping up, check for common problems such as incorrect inhaler technique, poor adherence, and environmental exposures, and confirm that the symptoms are due to asthma (Box 2-4, p.45).\n\nPreferred Step 4 treatment for adults and adolescents: medium-dose ICS-formoterol maintenance and reliever therapy (Track 1)"
    },
    {
        "id": "doc_3724",
        "document": "For adult and adolescent patients, combination ICS-formoterol as both maintenance and reliever treatment (MART) is more effective in reducing exacerbations than the same dose of maintenance ICS-LABA or higher doses of ICS249 (Evidence A). The greatest reduction in risk was seen in patients with a history of severe exacerbations,213 but MART was also significantly more effective than conventional best practice with as-needed SABA in open-label studies in which patients were not selected for"
    },
    {
        "id": "doc_3725",
        "document": "greater exacerbation risk.223"
    },
    {
        "id": "doc_3726",
        "document": "In Step 4, the MART regimen can be prescribed with medium-dose maintenance budesonide-formoterol or beclometasone-formoterol treatment, by increasing the twice-daily maintenance dose to 2 inhalations, but the reliever remains 1 inhalation of low-dose ICS-formoterol as needed. The usual dose of budesonide-formoterol for Step 4 MART is 200/6 mcg metered dose (160/4.5 mcg delivered dose) and the usual dose of beclometasone-formoterol is 100/6 metered dose (87.5/5 mcg), with each of these"
    },
    {
        "id": "doc_3727",
        "document": "combinations prescribed as two inhalations twice-daily and one inhalation whenever needed for symptom relief. Based on product information, the maximum recommended total dose of formoterol in a single day is 72 mcg metered dose (54 mcg delivered dose) for budesonide-formoterol and 48 mcg metered dose (36 mcg delivered dose) for beclometasone-formoterol). For practice points, see information for GINA Step 3 and an article for clinicians.8 For a summary of medications and doses, see Box 3-15"
    },
    {
        "id": "doc_3728",
        "document": "(p.80)."
    },
    {
        "id": "doc_3729",
        "document": "Alternative Step 4 treatment for adults and adolescents: medium or high-dose ICS-LABA plus as-needed SABA or as-needed ICS-SABA (Track 2)"
    },
    {
        "id": "doc_3730",
        "document": "Maintenance medium- or high-dose ICS-LABA plus as-needed SABA: This is an alternative approach if MART is not possible, or if a patient\u2019s asthma is stable with good adherence and no exacerbations on their current therapy. As above, individual ICS responsiveness varies, and some patients whose asthma is uncontrolled or who have frequent exacerbations on low-dose ICS-LABA despite good adherence and correct inhaler technique may benefit from maintenance medium-dose ICS-LABA271 (Evidence B) plus"
    },
    {
        "id": "doc_3731",
        "document": "as-needed SABA, if MART is not available. However, before prescribing a regimen with SABA reliever, consider whether the patient is likely to be adherent with their ICS-containing treatment, as otherwise they will be at higher risk of exacerbations. Occasionally, high-dose ICS-LABA may be needed."
    },
    {
        "id": "doc_3732",
        "document": "76\n\n3. Treating to control symptoms and minimize future risk\n\nMaintenance ICS-LABA plus as-needed combination ICS-SABA (\u226518 years):\n\nPopulation: In the double-blind MANDALA study,259 the population relevant to Step 4 recommendations comprised patients with poor asthma control and a history of severe exacerbations who were taking maintenance medium-dose ICS-LABA or high-dose ICS."
    },
    {
        "id": "doc_3733",
        "document": "Evidence: In the sub-population of patients who were taking maintenance medium-dose ICS-LABA or high-dose ICS (Step 4 treatment), there was no significant increase in time to first severe exacerbation with as-needed budesonide- salbutamol (albuterol) 2 inhalations of 100/200 mcg metered dose (80/90 mcg delivered dose), compared with as- needed salbutamol (hazard ratio 0.81; CI 0.61\u20131.07). More studies in this population are needed."
    },
    {
        "id": "doc_3734",
        "document": "Other considerations: There are no head-to-head comparisons between this regimen and ICS-formoterol MART, both of which include an anti-inflammatory reliever. However, as ICS-SABA is not recommended for regular use, and its use as the reliever in Steps 3\u20135 requires the patient to have different maintenance and reliever inhalers, this regimen is more complex for patients than GINA Track 1 with ICS-formoterol in which the same medication is used for both maintenance and reliever doses."
    },
    {
        "id": "doc_3735",
        "document": "Practice points: A maximum number of 6 as-needed doses (each 2 puffs of 100/100 mcg budesonide-salbutamol [80/90 mcg delivered dose]) can be taken in a day. It is essential to educate patients about the different purpose of their maintenance and reliever inhalers, and to train them in correct inhaler technique with both devices if they are different; this also applies to SABA relievers.\n\nOther Step 4 controller options for adults and adolescents"
    },
    {
        "id": "doc_3736",
        "document": "Long-acting muscarinic antagonists: LAMAs may be considered as add-on therapy in a separate inhaler for patients aged \u22656 years (tiotropium), or in a combination (\u2018triple\u2019) inhaler for patients aged \u226518 years (beclometasone-formoterol- glycopyrronium; fluticasone furoate-vilanterol-umeclidinium; mometasone-indacaterol-glycopyrronium) if asthma is persistently uncontrolled despite medium or high-dose ICS-LABA. Adding a LAMA to medium or high-dose ICS-LABA modestly improved lung"
    },
    {
        "id": "doc_3737",
        "document": "function205,272-275,252 (Evidence A) but with no difference in symptoms. In some studies, adding LAMA to ICS-LABA modestly reduced exacerbations, compared with some medium- or high-dose ICS-LABA comparators.205,272,273,276 In a meta-analysis, there was a 17% reduction in risk of severe exacerbations with addition of LAMA to medium- or high-dose ICS-LABA.290"
    },
    {
        "id": "doc_3738",
        "document": "However, for patients experiencing exacerbations despite low-dose ICS-LABA, the ICS dose should be increased to at least medium, or treatment switched to maintenance and reliever therapy with ICS-formoterol, before considering adding a LAMA. In one study, the severe exacerbation rate was lower in patients receiving high-dose fluticasone furoate- vilanterol (ICS-LABA) than with low- to medium-dose fluticasone furoate-vilanterol-umeclidinium (ICS-LABA-LAMA).274 For patients prescribed an"
    },
    {
        "id": "doc_3739",
        "document": "ICS-LABA-LAMA with a non-formoterol LABA, the appropriate reliever is SABA."
    },
    {
        "id": "doc_3740",
        "document": "In Step 4, there is insufficient evidence to support ICS-LAMA over low- or medium-dose ICS-LABA combination; all studies were with ICS and tiotropium in separate inhalers.272 In one analysis, response to adding LAMA to medium-dose ICS, as assessed by FEV1, ACQ, and exacerbations, was not modified by baseline demographics, body-mass index, FEV1, FEV1 reversibility, or smoking status (past smoking versus never).277"
    },
    {
        "id": "doc_3741",
        "document": "Allergen immunotherapy: Consider adding sublingual allergen immunotherapy (SLIT) for adult patients with allergic rhinitis and sensitization to house dust mite, with suboptimally controlled asthma despite low- to high-dose ICS, but only if FEV1 is >70% predicted.260,261 (see p.86)."
    },
    {
        "id": "doc_3742",
        "document": "Other options: For medium- or high-dose budesonide, efficacy may be improved with dosing four times daily278,279 (Evidence B), but adherence may be an issue. For other ICS, twice-daily dosing is appropriate (Evidence D). Other options for adults or adolescents that can be added to a medium or high-dose ICS, but that are less efficacious than adding LABA, include LTRA280-284 (Evidence A), or low-dose sustained-release theophylline239 (Evidence B), but neither of these has been compared with"
    },
    {
        "id": "doc_3743",
        "document": "maintenance and reliever therapy with ICS-formoterol. Note the FDA warning for montelukast.236"
    },
    {
        "id": "doc_3744",
        "document": "3. Treating to control symptoms and minimize future risk\n\n77\n\nPreferred Step 4 treatment for children 6\u201311 years"
    },
    {
        "id": "doc_3745",
        "document": "For children whose asthma is not adequately controlled by low-dose maintenance ICS-LABA with as-needed SABA, treatment may be increased to medium-dose ICS-LABA269 (Evidence B). For maintenance-and-reliever therapy (MART) with budesonide-formoterol, the maintenance dose may be increased to 100/6 mcg twice daily (metered dose; 80/4.5 mcg delivered dose) (Evidence D); this is still a low-dose regimen. For a summary of medications and doses, see Box 3-15 (p.80)."
    },
    {
        "id": "doc_3746",
        "document": "If asthma is not well controlled on medium-dose ICS (Box 3-14B, p.67), refer the child for expert assessment and advice.\n\nOther Step 4 options for children 6\u201311 years"
    },
    {
        "id": "doc_3747",
        "document": "Other controller options include increasing to high pediatric dose ICS-LABA (Box 3-14B, p.67), but adverse effects must be considered. Tiotropium (a long-acting muscarinic antagonist) by mist inhaler may be used as add-on therapy in children aged 6 years and older; it modestly improves lung function and reduces exacerbations (Evidence A),285 largely independent of baseline IgE or blood eosinophils.286 If not trialed before, LTRA could be added (but note the FDA warning about montelukast).236"
    },
    {
        "id": "doc_3748",
        "document": "Add-on theophylline is not recommended for use in children due to lack of efficacy and safety data."
    },
    {
        "id": "doc_3749",
        "document": "STEP 5\n\nPreferred treatment at Step 5 in adults, adolescents and children (Track 1 and Track 2): refer for expert assessment, phenotyping, and add-on therapy\n\nPatients of any age with persistent symptoms or exacerbations despite correct inhaler technique and good adherence with Step 4 treatment and in whom other controller options have been considered, should be referred to a specialist with expertise in investigation and management of severe asthma, if available159 (Evidence D)."
    },
    {
        "id": "doc_3750",
        "document": "In severe asthma, as in mild\u2013moderate asthma,287 participants in randomized controlled trials may not be representative of patients seen in clinical practice. For example, a registry study found that over 80% of patients with severe asthma would have been excluded from major regulatory studies evaluating biologic therapy.288"
    },
    {
        "id": "doc_3751",
        "document": "Recommendations from the GINA Guide and decision tree on Diagnosis and Management of difficult-to-treat and severe asthma in adolescent and adult patients are included in Chapter 3.5 (p.120). These recommendations emphasize the importance of first optimizing existing therapy and treating modifiable risk factors and comorbidities (see Box 3-26, p.123). If the patient still has uncontrolled symptoms and/or exacerbations, additional treatment options that may be considered may include the following"
    },
    {
        "id": "doc_3752",
        "document": "(always check local eligibility and payer criteria):"
    },
    {
        "id": "doc_3753",
        "document": "\u2022 Combination high-dose ICS-LABA may be considered in adults and adolescents, but for most patients, the increase in ICS dose generally provides little additional benefit144,150,263 (Evidence A), and there is an increased risk of side-effects, including adrenal suppression.289 A high dose is recommended only on a trial basis for 3\u20136 months when good asthma control cannot be achieved with medium-dose ICS plus LABA and/or a third controller (e.g. LTRA or sustained-release theophylline239,283"
    },
    {
        "id": "doc_3754",
        "document": "Evidence B)."
    },
    {
        "id": "doc_3755",
        "document": "\u2022 Add-on long-acting muscarinic antagonists (LAMA) can be prescribed in a separate inhaler for patients aged \u22656 years (tiotropium), or in a combination (\u2018triple\u2019) inhaler for patients aged \u226518 years (beclometasone-formoterol- glycopyrronium; fluticasone furoate-vilanterol-umeclidinium; mometasone-indacaterol-glycopyrronium) if asthma is not well controlled with medium or high-dose ICS-LABA. Adding LAMA to ICS-LABA modestly improves lung function (Evidence A),205,272-275,277,285,290 but not"
    },
    {
        "id": "doc_3756",
        "document": "quality of life, with no clinically important change in symptoms.290 Some studies showed a reduction in exacerbation risk; in meta-analysis, overall, there was a 17% reduction in risk of severe exacerbations requiring oral corticosteroids (Evidence A).205,272,273,276,285,290 For patients with exacerbations despite ICS-LABA, it is essential that sufficient ICS is given, i.e., at least medium-dose ICS-LABA,"
    },
    {
        "id": "doc_3757",
        "document": "78\n\n3. Treating to control symptoms and minimize future risk\n\nbefore considering adding a LAMA. For patients prescribed an ICS-LABA-LAMA with a non-formoterol LABA, the appropriate reliever is SABA; patients prescribed ICS-formoterol-LAMA can continue ICS-formoterol reliever."
    },
    {
        "id": "doc_3758",
        "document": "\u2022 Add-on azithromycin (three times a week) can be considered after specialist referral for adult patients with persistent symptomatic asthma despite high-dose ICS-LABA. Before considering add-on azithromycin, sputum should be checked for atypical mycobacteria, ECG should be checked for long QTc (and re-checked after a month on treatment), and the risk of increasing antimicrobial resistance should be considered.291 Diarrhea is more common with azithromycin 500 mg 3 times a week.292 Treatment for"
    },
    {
        "id": "doc_3759",
        "document": "at least 6 months is suggested, as a clear benefit was not seen by 3 months in the clinical trials.292,505 The evidence for this recommendation includes a meta-analysis of two clinical trials292,505 in adults with persistent asthma symptoms that found reduced asthma exacerbations among those taking medium or high-dose ICS-LABA who had either an eosinophilic or non- eosinophilic profile and in those taking high-dose ICS-LABA (Evidence B).293 The option of add-on azithromycin for adults is"
    },
    {
        "id": "doc_3760",
        "document": "recommended only after specialist consultation because of the potential for development of antibiotic resistance at the patient or population level.292"
    },
    {
        "id": "doc_3761",
        "document": "\u2022 Add-on biologic therapy: options recommended by GINA for patients with uncontrolled severe asthma despite optimized maximal therapy (see chapter 3.5 for more details) include:\n\no Add-on anti-immunoglobulin E (anti-IgE) treatment (omalizumab) for patients aged \u22656 years with severe allergic asthma (Evidence A)294"
    },
    {
        "id": "doc_3762",
        "document": "o Add-on anti-interleukin-5/5R treatment (subcutaneous mepolizumab for patients aged \u22656 years; intravenous reslizumab for ages \u226518 years or subcutaneous benralizumab for ages \u226512 years), with severe eosinophilic asthma (Evidence A).294-299\n\no Add-on anti-interleukin-4R\u03b1 treatment (subcutaneous dupilumab) for patients aged \u22656 years with severe eosinophilic/Type 2 asthma,300 or for adults or adolescents requiring treatment with maintenance OCS (Evidence A)301-303"
    },
    {
        "id": "doc_3763",
        "document": "o Add-on anti-thymic stromal lymphopoietin (anti-TSLP) treatment (subcutaneous tezepelumab) for patients aged \u226512 years with severe asthma (Evidence A).304"
    },
    {
        "id": "doc_3764",
        "document": "\u2022 Sputum-guided treatment: for adults with persisting symptoms and/or exacerbations despite high-dose ICS or ICS-LABA, treatment may be adjusted based on eosinophilia (>3%) in induced sputum. In severe asthma, this strategy leads to reduced exacerbations and/or lower doses of ICS (Evidence A),305 but few clinicians currently have access to routine sputum testing."
    },
    {
        "id": "doc_3765",
        "document": "\u2022 Add-on treatment with bronchial thermoplasty may be considered for some adult patients with severe asthma159,306 (Evidence B). Evidence is limited and in selected patients (see p.87). The long-term effects compared with control patients, including for lung function, are not known."
    },
    {
        "id": "doc_3766",
        "document": "\u2022 As a last resort, add-on low-dose oral corticosteroids (\u22647.5 mg/day prednisone equivalent) may be considered for some adults with severe asthma (Evidence D),159 but they are often associated with substantial side effects (Evidence A).307-310 They should only be considered for adults with poor symptom control and/or frequent exacerbations despite good inhaler technique and adherence with Step 5 treatment, and after exclusion of other contributory factors and other add-on treatments including"
    },
    {
        "id": "doc_3767",
        "document": "biologics where available and affordable. Patients should be counseled about potential side-effects.308,310 They should be assessed and monitored for risk of adrenal suppression and corticosteroid-induced osteoporosis, and those expected to be treated for \u22653 months should be provided with relevant lifestyle counseling and prescription of therapy for prevention of osteoporosis and fragility fractures (where appropriate).311"
    },
    {
        "id": "doc_3768",
        "document": "\u2022 Maintenance and reliever therapy (MART) with ICS-formoterol: there is no evidence about initiating MART in patients receiving add-on biologic therapy, but for a patient already taking MART, there is no reason to discontinue this if biologic therapy is added. Studies are needed. For patients receiving triple therapy (ICS-LABA- LAMA) with a non-formoterol LABA, the appropriate reliever is SABA or ICS-SABA.\n\n3. Treating to control symptoms and minimize future risk\n\n79"
    },
    {
        "id": "doc_3769",
        "document": "Box 3-15. Medications and doses for GINA Track 1: anti-inflammatory reliever (AIR)-based therapy"
    },
    {
        "id": "doc_3770",
        "document": "\u2022 In GINA Track 1, the reliever is low dose ICS-formoterol, with or without maintenance ICS-formoterol. This is the preferred treatment approach for adults and adolescents with asthma, because it reduces severe exacerbations across treatment steps compared with using a SABA reliever; it uses a single medication for both reliever and maintenance treatment (less confusing for patients); and a patient\u2019s treatment can be stepped up and down if needed without changing the medication or inhaler"
    },
    {
        "id": "doc_3771",
        "document": "device. This cannot be done with any other ICS-LABA."
    },
    {
        "id": "doc_3772",
        "document": "\u2022 Low dose ICS-formoterol is called an anti-inflammatory reliever (AIR) because it relieves symptoms and reduces inflammation. AIR with ICS-formoterol significantly reduces the risk of severe exacerbations across treatment steps compared with using a SABA reliever, with similar symptom control, lung function and adverse effects"
    },
    {
        "id": "doc_3773",
        "document": "\u2022 Steps 1\u20132 (AIR-only): low dose ICS-formoterol is used as needed for symptom relief without any maintenance treatment. It reduces the risk of severe exacerbations and ED visits/hospitalizations by 65% compared with SABA alone, and reduces ED visits/hospitalizations by 37% compared with daily ICS plus as-needed SABA.167 Starting treatment with as-needed ICS-formoterol avoids training patients to regard SABA as their main asthma treatment."
    },
    {
        "id": "doc_3774",
        "document": "\u2022 Steps 3\u20135 (MART): maintenance-and-reliever therapy with ICS-formoterol reduces the risk of severe exacerbations by 32% compared with the same dose of ICS-LABA,213 by 23% compared with a higher dose of ICS-LABA,213 and by 17% compared with usual care.245 MART is also an option for children 6\u201311 years in Steps 3\u20134.\n\n\u2022 Asthma action plan: Simple action plans for AIR-only and MART are available online.8,312\n\nWhich medications can be used in GINA Track 1, and how often?"
    },
    {
        "id": "doc_3775",
        "document": "\u2022 Most evidence for MART, and all evidence for AIR-only, is with budesonide (BUD)-formoterol DPI, usually 200/6 mcg metered dose (160/4.5 mcg delivered dose) for adults/adolescents, and 100/6 mcg (80/4.5) for MART in children 6\u2013 11 years. Beclometasone (BDP)-formoterol 100/6 mcg (84.6/5.0) is approved for MART in adults. Other low-dose combination ICS-formoterol products may be suitable but have not been studied."
    },
    {
        "id": "doc_3776",
        "document": "\u2022 For as-needed use, patients should take 1 inhalation of ICS-formoterol whenever needed for symptom relief, or before exercise or allergen exposure, instead of a SABA reliever. See doses below."
    },
    {
        "id": "doc_3777",
        "document": "\u2022 Advise patients to take extra inhalations when symptoms persist or recur, but to seek medical care if they need more than the following total inhalations in a single day (as-needed + maintenance): BUD-formoterol adolescents and adults 12* inhalations, children 8* inhalations; BDP-formoterol 8 inhalations. Most patients need far less than this."
    },
    {
        "id": "doc_3778",
        "document": "Step Age (years) Medication and device (check patient can use inhaler) Metered dose (mcg) Delivered dose (mcg) Dosage R (AIR-only) 6-11 (No evidence) - - - S 12-17 18 =i i Budesonide-formoterol DP' 200/6 160/4.5 R 1 inhalation whenever needed Step 3 MART 6-11 Budesonide-formoterol DP 100/6 ES N 80/4.5 1 inhalation once daily, PLUS 1 inhalation whenever needed I 12-17 218 R Budesonide-formoterol DP' 200/6 N 160/4.5 Bl tot ittt et 1 inhalation once or twice daily, PLUS 1 inhalation whenever needed"
    },
    {
        "id": "doc_3779",
        "document": "I 218 R Beclometasone-formoterol pMDI S 100/6 N 84.5/5.0 Step 4 MART 6-11 Budesonide-formoterol DP 100/6 N 80/4.5 1 inhalation twice daily, PLUS 1 inhalation whenever needed 12-17 218 N Budesonide-formoterol DP' 200/6 S 160/4.5 Wit 2 inhalations twice daily, PLUS 1 inhalation whenever needed 218 N Beclometasone-formoterol pMDI N 100/6 HEEEEE\u2014\u2014\u2014\u2014 84.5/5.0 Step 5 MART 6-11 (No evidence) - - - \u2014"
    },
    {
        "id": "doc_3780",
        "document": "12-17; 218 e Budesonide-formoterol DP' 200/6 160/4.5 O 2 inhalations twice daily, PLUS 1 inhalation whenever needed 218 N Beclometasone-formoterol pMDI N 100/6 HEEEEE\u2014\u2014\u2014\u2014 84.5/5.0"
    },
    {
        "id": "doc_3781",
        "document": "*For budesonide-formoterol pMDIs with 3 mcg (2.25 mcg) formoterol, use double the number of inhalations. For abbreviations, see p.10\n\n80\n\n3. Treating to control symptoms and minimize future risk\n\nREVIEWING RESPONSE AND ADJUSTING TREATMENT"
    },
    {
        "id": "doc_3782",
        "document": "How often should asthma be reviewed?\n\nPatients with asthma should be reviewed regularly to monitor their symptom control, risk factors and occurrence of exacerbations, as well as to document the response to any treatment changes. For most controller medications, improvement in symptoms and lung function begins within days of initiating treatment, but the full benefit may only be reached after 3\u20134 months.313 In severe and chronically under-treated disease, it may take longer.314"
    },
    {
        "id": "doc_3783",
        "document": "All health care providers should be encouraged to assess asthma control, adherence and inhaler technique at every visit, not just when the patient presents because of their asthma.315 The frequency of visits depends upon the patient\u2019s initial level of control, their response to treatment, and their level of engagement in self-management."
    },
    {
        "id": "doc_3784",
        "document": "Ideally, patients should be seen 1\u20133 months after starting treatment and every 3\u201312 months thereafter. After an exacerbation, a review visit within 1 week should be scheduled (Evidence D).316\n\nStepping up asthma treatment\n\nAsthma is a variable condition, and adjustments of controller treatment by the clinician and/or the patient may be needed.317\n\n.\n\nreliever\n\nFor\n\nwhose reliever inhaler is"
    },
    {
        "id": "doc_3785",
        "document": "combination budesonide-formoterol or beclometasone-formoterol (with or without maintenance ICS-formoterol), the patient adjusts the number of as-needed doses of ICS-formoterol from day to day according to their symptoms. This strategy reduces the risk of developing a severe exacerbation requiring oral corticosteroids within the next 3\u20134 weeks.77-79 As-needed combination budesonide-salbutamol is an anti-inflammatory reliever option that has been studied in Steps 3\u20135.259"
    },
    {
        "id": "doc_3786",
        "document": "\u2022 Short-term step up (for 1\u20132 weeks): A short-term increase in maintenance ICS dose for 1\u20132 weeks may be necessary; for example, during viral infections or seasonal allergen exposure. This may be initiated by the patient according to their written asthma action plan (Box 4-2, p.61), or by the health care provider."
    },
    {
        "id": "doc_3787",
        "document": "\u2022 Sustained step up (for at least 2\u20133 months): Although at a group level most benefit from ICS is obtained at low dose, individual ICS responsiveness varies, and some patients whose asthma is uncontrolled on low-dose ICS- LABA despite good adherence and correct technique may benefit from increasing the maintenance dose to medium. A step up in treatment may be recommended (Box 3-12, p.65) if it has been confirmed that the symptoms are due to asthma, inhaler technique and adherence are"
    },
    {
        "id": "doc_3788",
        "document": "satisfactory, and modifiable risk factors such as smoking have been addressed (Box 3-17, p.38). Any step-up should be regarded as a therapeutic trial. If there is no response after 2\u20133 months, treatment should be reduced to the previous level, and alternative treatments or referral considered."
    },
    {
        "id": "doc_3789",
        "document": "Stepping down treatment when asthma is well controlled\n\nOnce good asthma control has been achieved and maintained for 2\u20133 months and lung function has reached a plateau, treatment can often be successfully reduced, without loss of asthma control. The aims of stepping down are:\n\n\u2022 To find the patient\u2019s minimum effective treatment, i.e., to maintain good control of symptoms and exacerbations, and to minimize the costs of treatment and potential for side-effects"
    },
    {
        "id": "doc_3790",
        "document": "\u2022 To encourage the patient to continue maintenance treatment. Patients often experiment with intermittent treatment through concern about the risks or costs of daily treatment,318 but this leaves them exposed to the risks of SABA-only treatment. For patients whose asthma is well controlled on maintenance low-dose ICS with as-needed SABA, an alternative is to cease maintenance ICS and switch to as-needed low-dose ICS-formoterol.202,203\n\n3. Treating to control symptoms and minimize future risk\n\n81"
    },
    {
        "id": "doc_3791",
        "document": "Before stepping down"
    },
    {
        "id": "doc_3792",
        "document": "The approach to stepping down will differ from patient to patient depending on their current treatment, risk factors and preferences. There are few data on the optimal timing, sequence and magnitude of treatment reductions in asthma. Factors associated with a greater risk of exacerbation after step-down include a history of exacerbations and/or emergency department visit for asthma in the previous 12 months,319,320 and a low baseline FEV1.320 Other predictors of loss of control during dose"
    },
    {
        "id": "doc_3793",
        "document": "reduction include airway hyperresponsiveness and sputum eosinophilia,321 but these tests are not readily available in primary care."
    },
    {
        "id": "doc_3794",
        "document": "Any treatment step-down should be considered as a therapeutic trial, with the response evaluated in terms of both symptom control and exacerbation frequency. Prior to stepping down, the patient should be provided with a written asthma action plan and instructions for how and when to resume their previous treatment if their symptoms worsen."
    },
    {
        "id": "doc_3795",
        "document": "How to step asthma treatment down\n\nDecisions about treatment step-down should be made on an individual patient level. In one study of patients with well- controlled asthma on medium-dose ICS-LABA, reducing the ICS dose and removing the LABA had similar effects on a composite treatment failure outcome. However, stopping LABA was associated with lower lung function and more hospitalizations; and decreasing the ICS dose was inferior to maintaining a stable dose of ICS-LABA.322"
    },
    {
        "id": "doc_3796",
        "document": "If treatment is stepped down too far or too quickly, exacerbation risk may increase even if symptoms remain reasonably controlled323 (Evidence B). To date, higher baseline FeNO has not been found to be predictive of exacerbation following step-down of ICS dose.324, 325 A meta-analysis suggested that greater reduction in ICS dose may be able to be achieved in patients with baseline FeNO <50 ppb, but the findings point to the need for further research.325 Complete cessation of ICS is associated"
    },
    {
        "id": "doc_3797",
        "document": "with a significantly increased risk of exacerbations326 (Evidence A)."
    },
    {
        "id": "doc_3798",
        "document": "Stepping down from daily low-dose ICS plus as-needed SABA to as-needed-only ICS-formoterol provides similar or greater protection from severe exacerbations and need for urgent health care, with similar symptom control and lung function and a much lower average daily ICS dose, compared with treatment with daily low-dose ICS plus as-needed SABA.167 Step-down strategies for different controller treatments are summarized in Box 3-16, p.83; these are based on current evidence, but more research is"
    },
    {
        "id": "doc_3799",
        "document": "needed. Few step-down studies have been performed in children."
    },
    {
        "id": "doc_3800",
        "document": "82\n\n3. Treating to control symptoms and minimize future risk\n\nBox 3-16. Options for stepping down treatment in adults and adolescents once asthma is well controlled"
    },
    {
        "id": "doc_3801",
        "document": "General principles of stepping down asthma treatment\n\n\u2022 Consider stepping down when asthma symptoms have been well controlled and lung function has been stable for 3 or more months (Evidence D). If the patient has risk factors for exacerbations (Box 2-2, p.38), for example a history of exacerbations in the past year,319 or persistent airflow limitation, step down only with close supervision.\n\n\u2022 Choose an appropriate time (no respiratory infection, patient not travelling, not pregnant)."
    },
    {
        "id": "doc_3802",
        "document": "\u2022 Approach each step as a therapeutic trial: engage the patient in the process, document their asthma status (symptom control, lung function and risk factors, Box 2-2, p.38), provide clear instructions, provide a written asthma action plan (Box 4-2, p.146) and ensure the patient has sufficient medication to resume their previous dose if necessary, monitor symptoms and/or PEF, and schedule a follow-up visit (Evidence D).\n\n."
    },
    {
        "id": "doc_3803",
        "document": "Stepping down ICS doses by 25\u201350% at 3 month intervals is feasible and safe for most patients (Evidence A).327"
    },
    {
        "id": "doc_3804",
        "document": "Current step Current medication and dose Options for stepping down Evidence Step 5 High-dose ICS-LABA plus oral corticosteroids (OCS) Optimize inhaled therapy and reduce OCS dose Use sputum-guided approach to reducing OCS Alternate-day OCS treatment Replace OCS with high-dose ICS If T2 high severe asthma, add biologic therapy and reduce OCS \u2022 \u2022 \u2022 \u2022 > 0 0w O B D High-dose ICS-LABA plus other add-on agents Refer for expert advice \u2022 D"
    },
    {
        "id": "doc_3805",
        "document": "Step 4 Moderate- to high-dose ICS- LABA maintenance treatment Continue combination ICS-LABA with 50% reduction in ICS component, by using available formulations Discontinuing LABA may lead to deterioration328 Switch to maintenance and reliever therapy (MART) with ICS-formoterol, with lower maintenance dose?! \u2022 \u2022 \u2022 B A A Medium-dose ICS-formoterol* as maintenance and reliever Reduce maintenance ICS-formoterol* to low dose, and continue as-needed low-dose ICS-formoterol* reliever \u2022 D"
    },
    {
        "id": "doc_3806",
        "document": "High-dose ICS plus second controller Reduce ICS dose by 50% and continue second controller3?\u201d \u2022 B Step 3 Low-dose ICS-LABA maintenance Reduce ICS-LABA to once daily Discontinuing LABA may lead to deterioration328 \u2022 \u2022 D A Low-dose ICS-formoterol* as maintenance and reliever Reduce maintenance ICS-formoterol* dose to once daily and continue as-needed low-dose ICS-formoterol* reliever Consider stepping down to as-needed-only low-dose ICS-formoterol \u2022 \u2022 (\u00a2} 0O"
    },
    {
        "id": "doc_3807",
        "document": "Medium- or high-dose ICS Reduce ICS dose by 50%3%\" Adding LTRA or LABA may allow ICS dose to be stepped down?\u00ae?\u00ae \u2022 \u2022 W>\u00bb A B Step 2 Low-dose maintenance ICS Once-daily dosing (budesonide, ciclesonide, mometasone)330.331 Switch to as-needed low-dose ICS-formotero|172.202.203.207 Switch to taking ICS whenever SABA is taken?!5216:218 217 \u2022 \u2022 W>\u00bb>\u00bb| A A B"
    },
    {
        "id": "doc_3808",
        "document": "Low-dose maintenance ICS or LTRA Switch to as-needed low-dose ICS formoterol!71:172.202,203.207 Complete cessation of ICS in adults and adolescents is not advised as the risk of exacerbations is increased with SABA-only treatment2%7-326 \u2022 \u2022 > >"
    },
    {
        "id": "doc_3809",
        "document": "See list of abbreviations (p.10). *MART: low-dose budesonide-formoterol or beclometasone-formoterol (p.80). \u2020Note FDA warning about montelukast.236\n\n3. Treating to control symptoms and minimize future risk\n\n83\n\nOTHER STRATEGIES FOR ADJUSTING ASTHMA TREATMENT\n\nSome alternative strategies for adjusting asthma maintenance ICS-containing treatment have been evaluated:"
    },
    {
        "id": "doc_3810",
        "document": "\u2022 Treatment guided by sputum eosinophil count: in adults, this approach, when compared with guidelines-based treatment, leads to a reduced risk of exacerbations and similar levels of symptom control and lung function in patients with frequent exacerbations and moderate-severe asthma.305 However, only a limited number of centers have routine access to induced sputum analysis. There are insufficient data available in children to assess this approach.305 Sputum-guided treatment is recommended for"
    },
    {
        "id": "doc_3811",
        "document": "adult patients with moderate or severe asthma who are managed in (or can be referred to) centers experienced in this technique159,305 (Evidence A)."
    },
    {
        "id": "doc_3812",
        "document": "\u2022 Treatment guided by fractional concentration of exhaled nitric oxide (FeNO): In several studies of FeNO-guided treatment, problems with the design of the intervention and/or control algorithms make comparisons and conclusions difficult.332 Results of FeNO measurement at a single point in time should be interpreted with caution (see p.28).44,199 In a 2016 meta-analysis, FeNO-guided treatment in children and young adults with asthma was associated with a significant reduction in the number of"
    },
    {
        "id": "doc_3813",
        "document": "patients with \u22651 exacerbation (OR 0.67; 95% CI 0.51\u2013 0.90) and in exacerbation rate (mean difference \u20130.27; 95% \u20130.49 to \u20130.06 per year) compared with guidelines- based treatment333 (Evidence A); similar differences were seen in comparisons between FeNO-guided treatment and non-guidelines-based algorithms.333 However, a subsequent good-quality multicenter clinical trial in children with asthma in secondary and primary care centers found that the addition of FeNO to symptom-guided treatment did"
    },
    {
        "id": "doc_3814",
        "document": "not reduce severe exacerbations over 12 months.334 In non-smoking adults with asthma, no significant reduction in risk of exacerbations and in exacerbation rates was observed with FeNO-guided treatment, compared with a treatment strategy similar to that in most guidelines; a difference was seen only in studies with other (non- typical) comparator approaches to adjustment of treatment.335 In adults and in children, no significant differences were seen in symptoms or ICS dose with FeNO-guided"
    },
    {
        "id": "doc_3815",
        "document": "treatment compared with other strategies.333,335"
    },
    {
        "id": "doc_3816",
        "document": "Further studies are needed to identify the populations most likely to benefit from sputum-guided305 or FeNO-guided adjustment of maintenance ICS-containing treatment,333,335 and the optimal frequency of monitoring."
    },
    {
        "id": "doc_3817",
        "document": "There is a need for further evidence-based corticosteroid de-escalation strategies in patients with asthma. In a randomized controlled trial (RCT) of patients taking high-dose ICS-LABA, a strategy based on a composite of Type 2 biomarkers only versus an algorithm based on ACQ-7 and history of recent exacerbation was inconclusive because a substantial proportion of patients did not follow recommendations for treatment change.336 Until more definitive evidence for a specific strategy is available,"
    },
    {
        "id": "doc_3818",
        "document": "GINA continues to recommend a clinical evaluation that includes patient-reported symptoms as well as modifiable risk factors, comorbidities and patient preferences when making treatment decisions. Further evidence on the role of biomarkers in such decisions in Steps 1\u20134 is needed."
    },
    {
        "id": "doc_3819",
        "document": "The assessment of patients with severe asthma includes identification of the inflammatory phenotype, based on blood or sputum eosinophils or FeNO, to assess the patient\u2019s eligibility for various add-on treatments including biologic therapy. A higher baseline blood eosinophil count and/or FeNO predicts a good asthma response to some biologic therapies (see Box 3-27 (p.124) and Box 3-28 (p.125)."
    },
    {
        "id": "doc_3820",
        "document": "TREATING OTHER MODIFIABLE RISK FACTORS\n\nSome patients continue to experience exacerbations even with maximal doses of current treatment. Having even one exacerbation increases the risk that a patient will have another within the next 12 months.122 There is increasing research interest in identifying at-risk patients (Box 2-2B, p.38), and in investigating new strategies to further reduce exacerbation risk."
    },
    {
        "id": "doc_3821",
        "document": "In clinical practice, exacerbation risk can be reduced both by optimizing asthma medications, and by identifying and treating modifiable risk factors (Box 3-17). Not all risk factors require or respond to a step up in controller treatment.\n\n84\n\n3. Treating to control symptoms and minimize future risk\n\nBox 3-17. Treating potentially modifiable risk factors to reduce exacerbations"
    },
    {
        "id": "doc_3822",
        "document": "Risk factor Treatment strategy Evidence"
    },
    {
        "id": "doc_3823",
        "document": "Any patient with 21 risk factor for exacerbations (including poor symptom control)"
    },
    {
        "id": "doc_3824",
        "document": "Ensure patient is prescribed an ICS-containing treatment. . Switch to a regimen with an anti-inflammatory reliever (ICS-formoterol or ICS- SABA) if available, as this reduces the risk of severe exacerbations compared with if the reliever is SABA. Ensure patient has a written action plan appropriate for their health literacy. Review patient more frequently than low-risk patients. Check inhaler technique and adherence frequently; correct as needed. Identify any"
    },
    {
        "id": "doc_3825",
        "document": "modifiable risk factors (Box 2-2, p.38). \u2022 \u2022 \u2022"
    },
    {
        "id": "doc_3826",
        "document": "A A o>\u00bb>> A A A D"
    },
    {
        "id": "doc_3827",
        "document": "21 severe exacerbation in last year Switch to a regimen with an anti-inflammatory reliever (as-needed ICS- formoterol or ICS-SABA) if available, as this reduces the risk of severe exacerbations compared with if the reliever is SABA. Consider stepping up treatment if no modifiable risk factors. Identify any avoidable triggers for exacerbations. \u2022 \u2022 > o> A C"
    },
    {
        "id": "doc_3828",
        "document": "Exposure to tobacco smoke or e-cigarettes Encourage smoking cessation by patient/family; provide advice and resources Consider higher dose of ICS if asthma poorly controlled. \u2022 @ > Low FEV4, especially if <60% predicted Consider trial of 3 months\u2019 treatment with high-dose ICS. Consider 2 weeks\u2019 OCS, but take short- and long-term risks into account Exclude other lung disease, e.g., COPD. Refer for expert advice if no improvement. \u2022 OO0 WmwW B D"
    },
    {
        "id": "doc_3829",
        "document": "Obesity Strategies for weight reduction Distinguish asthma symptoms from symptoms due to deconditioning, \u2022 Ow B D mechanical restriction, and/or sleep apnea. Major psychological problems Arrange mental health assessment. Help patient to distinguish between symptoms of anxiety and asthma; provide advice about management of panic attacks. \u2022 lw) D Major socioeconomic problem . Identify most cost-effective ICS-based regimen. D"
    },
    {
        "id": "doc_3830",
        "document": "Confirmed food allergy Appropriate food avoidance; anaphylaxis action plan; injectable epinephrine; refer for expert advice. A Occupational or domestic exposure to irritants Remove from exposure as soon as possible. Refer for expert advice. A D"
    },
    {
        "id": "doc_3831",
        "document": "Allergen exposure if sensitized Consider trial of simple avoidance strategies; consider cost. Consider step up of asthma treatment. Consider adding SLIT in symptomatic adult HDM-sensitive patients with allergic rhinitis despite ICS, provided FEV1 is >70% predicted. e Ne] D B Sputum eosinophilia despite medium/high ICS (few centers) Increase ICS dose, independent of level of symptom control. \u2022 A*"
    },
    {
        "id": "doc_3832",
        "document": "See list of abbreviations (p.10). * Based on evidence from relatively small studies in selected populations. Also see Box 3-18 and p.88 for non- pharmacological interventions.\n\n3. Treating to control symptoms and minimize future risk\n\n85"
    },
    {
        "id": "doc_3833",
        "document": "Reduce the potential for local and/or systemic side-effects of medications by ensuring correct inhaler technique (Box 3-22, p.100), by reminding patients to rinse and spit out after using ICS, and, after good asthma control has been maintained for 3 months, by finding each patient\u2019s minimum effective dose (the lowest dose that will maintain good symptom control and minimize exacerbations, Box 3-16, p.83). Check for drug interactions particularly with cytochrome P450 inhibitors (see p.40)."
    },
    {
        "id": "doc_3834",
        "document": "OTHER THERAPIES\n\nAllergen immunotherapy"
    },
    {
        "id": "doc_3835",
        "document": "Allergen-specific immunotherapy may be a treatment option where allergy plays a prominent role, including asthma with allergic rhinoconjunctivitis.337,338 There are currently two approaches: subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Few studies in asthma have compared immunotherapy with pharmacological therapy, or used standardized outcomes such as exacerbations, and most studies have been in patients with mild asthma. The allergens most commonly included in allergen"
    },
    {
        "id": "doc_3836",
        "document": "immunotherapy studies have been house dust mite and grass pollens. There is insufficient evidence about safety and efficacy of allergen immunotherapy in patients sensitized to mold.339"
    },
    {
        "id": "doc_3837",
        "document": "GINA is currently reviewing evidence about allergen immunotherapy for asthma, and will update its advice based on the findings.\n\nSubcutaneous immunotherapy (SCIT)"
    },
    {
        "id": "doc_3838",
        "document": "SCIT involves the identification and use of clinically relevant allergens, and administration of extracts in progressively higher doses to induce desensitization and/or tolerance. European physicians tend to favor single allergen immunotherapy whereas Northern American physicians often prescribe multiple allergens for treatment.340 In people with asthma and allergic sensitization, SCIT is associated with a reduction in symptom scores and medication requirements, and improved allergen-specific"
    },
    {
        "id": "doc_3839",
        "document": "and non-specific airway hyperresponsiveness.340"
    },
    {
        "id": "doc_3840",
        "document": "For SCIT, analysis of pooled safety data from clinical trials and post-marketing surveillance in house dust mite allergic respiratory disease suggests the incidence of adverse drug reactions is approximately 0.5%.341 Studies to date suggest that serious adverse effects of SCIT are uncommon, but may include life-threatening anaphylactic reactions."
    },
    {
        "id": "doc_3841",
        "document": "Advice\n\n\u2022 Compared with pharmacological and avoidance options, potential benefits of SCIT must be weighed against the risk of adverse effects and the inconvenience and cost of the prolonged course of therapy, including the minimum half- hour wait required after each injection (Evidence D).\n\nSublingual immunotherapy (SLIT)"
    },
    {
        "id": "doc_3842",
        "document": "Modest effects were identified in a systematic review of SLIT for asthma in adults and children,338,342,343 but there was concern about the design of many of the studies.344 The evidence for important outcomes such as exacerbations and quality of life remains limited.344 There are few studies comparing SLIT with pharmacological therapy for asthma.345 A trial of SLIT for house dust mites (HDM) in patients with asthma and HDM allergic rhinitis demonstrated a modest reduction of ICS with high-dose"
    },
    {
        "id": "doc_3843",
        "document": "SLIT.261 In another study in patients with asthma and HDM allergic rhinitis, SLIT added to low or medium-dose ICS showed increased time to exacerbation during ICS reduction in suboptimally controlled asthma.260"
    },
    {
        "id": "doc_3844",
        "document": "Side effects346-348 from SLIT for inhalant allergens are predominantly limited to oral and gastrointestinal symptoms.338"
    },
    {
        "id": "doc_3845",
        "document": "Advice\n\n\u2022 For adult patients with allergic rhinitis and sensitized to house dust mite, with persisting asthma symptoms despite low- to medium-dose ICS-containing therapy, consider adding SLIT, but only if FEV1 is >70% predicted (Evidence B) \u2022 As for any treatment, potential benefits of SLIT for individual patients should be weighed against the risk of adverse effects, and the cost to the patient and health system.\n\n86\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3846",
        "document": "Vaccinations\n\nInfluenza causes significant morbidity and mortality in the general population, and contributes to some acute asthma exacerbations. In 2020, many countries saw a reduction in influenza-related illness, likely due to the handwashing, masks and social/physical distancing introduced because of the COVID-19 pandemic."
    },
    {
        "id": "doc_3847",
        "document": "The risk of influenza infection itself can be reduced by annual vaccination. A 2013 systematic review of placebo- controlled randomized controlled trials of influenza vaccination showed no reduction in asthma exacerbations,349 but no such studies had been performed since 2001. However, a later systematic review and meta-analysis that included observational studies with a wide range of study designs suggested that influenza vaccination reduced the risk of asthma exacerbations, although for most"
    },
    {
        "id": "doc_3848",
        "document": "of the studies, bias could not be excluded.350 There is no evidence for an increase in asthma exacerbations after influenza vaccination compared to placebo.350 A systematic review of studies in individuals aged 2\u201349 years with mild\u2013moderate asthma found no significant safety concerns or increased risk for asthma-related outcomes after influenza vaccination with live attenuated virus.351"
    },
    {
        "id": "doc_3849",
        "document": "Other vaccines: People with asthma, particularly children and the elderly, are at higher risk of pneumococcal disease.352 There is insufficient evidence to recommend routine pneumococcal vaccination in all adults with asthma.353 For information about COVID-19 vaccines, see p.111."
    },
    {
        "id": "doc_3850",
        "document": "Advice\n\n\u2022 Advise patients with moderate to severe asthma to receive an influenza vaccination every year, or at least when vaccination of the general population is advised (Evidence C). Follow local immunization schedules.\n\n\u2022 There is insufficient evidence to recommend routine pneumococcal or pertussis vaccination in adults with asthma. Follow local immunization schedules.\n\n\u2022 Advice about COVID-19 vaccination is on p.111."
    },
    {
        "id": "doc_3851",
        "document": "\u2022 COVID-19 vaccination and influenza vaccination may be given on the same day.\n\nBronchial thermoplasty"
    },
    {
        "id": "doc_3852",
        "document": "Bronchial thermoplasty is a potential treatment option at Step 5 in some countries for adult patients whose asthma remains uncontrolled despite optimized therapeutic regimens and referral to an asthma specialty center (Evidence B). Bronchial thermoplasty involves treatment of the airways during three separate bronchoscopies with a localized radiofrequency pulse.134 The treatment is associated with a large placebo effect.134 In patients taking high-dose ICS- LABA, bronchial thermoplasty was"
    },
    {
        "id": "doc_3853",
        "document": "associated with an increase in asthma exacerbations during the 3 month treatment period, and a subsequent decrease in exacerbations, but no beneficial effect on lung function or asthma symptoms compared with sham-controlled patients.134 Extended follow-up of some treated patients reported a sustained reduction in exacerbations compared with pre-treatment.354 However, longer-term follow up of larger cohorts comparing effectiveness and safety, including for lung function, in both active and"
    },
    {
        "id": "doc_3854",
        "document": "sham-treated patients is needed."
    },
    {
        "id": "doc_3855",
        "document": "Advice\n\n\u2022 For adult patients whose asthma remains uncontrolled despite optimization of asthma therapy and referral to a severe asthma specialty center, and who do not have access to biologic therapy or are not eligible for it, bronchial thermoplasty is a potential treatment option at Step 5 in some countries (Evidence B)."
    },
    {
        "id": "doc_3856",
        "document": "\u2022 Caution should be used in selecting patients for this procedure. The number of studies is small, people with chronic sinus disease, frequent chest infections or FEV1 <60% predicted were excluded from the pivotal sham-controlled study, and patients did not have their asthma treatment optimized before bronchial thermoplasty was performed."
    },
    {
        "id": "doc_3857",
        "document": "\u2022 Bronchial thermoplasty should be performed in adults with severe asthma only in the context of an independent Institutional Review Board-approved systematic registry or a clinical study, so that further evidence about effectiveness and safety of the procedure can be accumulated.159\n\n3. Treating to control symptoms and minimize future risk\n\n87\n\nVitamin D"
    },
    {
        "id": "doc_3858",
        "document": "Several cross-sectional studies have shown that low serum levels of Vitamin D are linked to impaired lung function, higher exacerbation frequency and reduced corticosteroid response.355 Vitamin D supplementation may reduce the rate of asthma exacerbation requiring treatment with systemic corticosteroids or may improve symptom control in asthma patients with baseline 25(OH)D of less than approximately 25\u201330 nmol/L.356,357 In a meta-analysis, benefit for worsening asthma was seen in some studies,"
    },
    {
        "id": "doc_3859",
        "document": "but to date, there is no good-quality evidence that Vitamin D supplementation leads to improvement in asthma control or reduction in exacerbations.358-360 More studies are needed."
    },
    {
        "id": "doc_3860",
        "document": "NON-PHARMACOLOGICAL STRATEGIES\n\nIn addition to pharmacological treatments, other strategies may be considered where relevant, to assist in improving symptom control and/or reducing future risk. The advice and evidence level are summarized in Box 3-18, with brief text on the following pages."
    },
    {
        "id": "doc_3861",
        "document": "Box 3-18.Non-pharmacological interventions \u2014 summary Intervention Advice/recommendation (continued on next page) Evidence Cessation of smoking, environmental tobacco exposure (ETS) and vaping At every visit, strongly encourage people with asthma who smoke or vape to quit. Provide access to counseling and smoking cessation programs (if availabI?)A A . Advise parents/caregivers of children with asthma not to smoke and not to allow smoking in rooms or cars that their children use. A"
    },
    {
        "id": "doc_3862",
        "document": "Strongly encourage people with asthma to avgiq environmental smoke exposure. B Assess smokers/ex-smokers for COPD or overlapping features of asthma and COPD (asthma+COPD, previously called asthma-COPD overlap or ACO, Chapter 5, p.159), as additional treatment strategies may be requirerdr. D Physical activity Encourage people with asthmg to \u00bbengage in regular physical activity for its general health benefits. A"
    },
    {
        "id": "doc_3863",
        "document": "Provide advice about prevtentipn of exercise-induced bronchoconstriction with regular ICS. > Provide advice about prevention of breakthrough exercise-induced bronchoconstriction with o warm-up before exercise o SABA (or ICS-SABA) before exercise o Iow-dqse ICS-formoterol before exercise (see Box 3-15, p.80). W > > Regular physical activity improves cardiopulmonary fitness, and can have a small benefit for asthma control and lung function, including with swimming in young people with asthma. W"
    },
    {
        "id": "doc_3864",
        "document": "Physical activity interventions in adults with moderate/severe asthma was associated with improved symptoms and quality of life A There is little evidence to recommend one form of physical activity over another. D Avoidance of occupational or domestic exposures to allergens or irritants Ask all patients with adult-onset asthma about their work history and other exposures to irritant gases or particles, including at home. D"
    },
    {
        "id": "doc_3865",
        "document": "In management of occupational asthma, identify and eliminate occupational sensitizers as soon as possible, and remove sensitized patients from any further exposure to these agents. A Patients with suspected or confirmed occupational asthma should be referred promptly for expert assessment and advice, if available. A"
    },
    {
        "id": "doc_3866",
        "document": "88\n\n3. Treating to control symptoms and minimize future risk\n\nBox 3-18 (continued) Non-pharmacological interventions \u2013 Summary"
    },
    {
        "id": "doc_3867",
        "document": "Intervention Advice/recommendation Evidenc D Avoidance of medications that Always ask about asthma before prescribing NSAIDs, and advise patients to stop using them if asthma worsens. may make asthma worse Always ask people with asthma about concomitant medications. D Aspirin and NSAIDs (non-steroidal anti-inflammatory drugs) are not generally contraindicated unless there is a history of previous reactions to these agents (see p.117). A"
    },
    {
        "id": "doc_3868",
        "document": "Decide about prescription of oral or ophthalmic beta-blockers on a case-by-case basis. Initiate treatment under close medical supervision by a specialist. D If cardioselective beta-blockers are indicated for acute coronary events, asthma is not an absolute contra-indication, but the relative risks/benefits should be considered. D Healthy diet Encourage patients with asthma to consume a diet high in fruit and vegetablersrfor its general health benefits. A"
    },
    {
        "id": "doc_3869",
        "document": "Avoidance of indoor allergens Allergen avoidance is not recommended as a general strategy in asth'rT;a;. A For sensitized patients, there is limited evidence of clinical benefit for asthma in most circumstances with single-strategy indoor allergen avoidance. A Remediation of dampness or mold in homes reduces asthma symptoms and medication use in adults. A"
    },
    {
        "id": "doc_3870",
        "document": "For patients sensitized to house dust mite and/or pets, there is limited evidence of clinical benefit for asthma with avoidance strategies (only in children) . B Allergen avoidance strategies are often complicated and expensive, and there are no validated methods for identifying those who Vargrlikely to benefit. D"
    },
    {
        "id": "doc_3871",
        "document": "Weight reduction . Include weight reduction in the treatment plan for obese patients with asthma. For obese adults with asthma a weight reduction program plus twice-weekly aerobic and strength exercises is more e\ufb01ectiygfor symptom control than weight reduction alone. B B Breathing exercises Breathing exercises may be a useful supplement to asthma pharmacotherapy for symptoms and quality of life, but\ufb02th\u2018ey do not reduce exacerbation risk or have consistent effects on lung function. A"
    },
    {
        "id": "doc_3872",
        "document": "Avoidance of indoor air pollution Encourage people with asthma to use non-polluting heating and cooking sources, and for sources of pollutants to be vented outdoors where possible. @ B Avoidance of outdoor allergens For s\u00e9nsitized patients, when pollen and mold counts are highest, closing windows and doors, remaining indoors, and using air conditioning may reduce exposure to outdoor allergens. D"
    },
    {
        "id": "doc_3873",
        "document": "Dealing with emotional stress Encourage patients to identify goals and strategies to deal with emotional stress if it makes their asthma worse. D There is insufficient evidence to support one stress-reduction strategy over another, but relaxation strategies and breathing exercises may be helpful. B Arrange a mental health assessment for patients with symptoms of anxiety or depression. D"
    },
    {
        "id": "doc_3874",
        "document": "Addressing social risk In US studies, comprehensive social risk interventions were associated with reduced emergency department visits and hospitalizations for children. Studies from other countries and settings are needed. A"
    },
    {
        "id": "doc_3875",
        "document": "3. Treating to control symptoms and minimize future risk\n\n89\n\nBox 3-18 (continued) Non-pharmacological interventions \u2013 Summary"
    },
    {
        "id": "doc_3876",
        "document": "ntervention Advice/recommendation Evidence oidance of tdoor air llutants/weather. nditions During unfavorable environmental conditions (very cold weather or high air pollution) it may be helpful, if feasible, to stay indoors in a climate-controlled environment, and to avoid strenuous outdoor physical activity; and to avoid polluted environments during viral infections, if feasible. D"
    },
    {
        "id": "doc_3877",
        "document": "oidance of ds and food Food avoidance should not be recommended unless an allergy or food chemical sensitivity has been clearly demonstrated, usually by carefully supervised oral challenges. D emicals For patients with confirmed food allergy, refer for specialist advice if available D For patients with confirmed food allergy, food allergen avoidance may reduce asthma exacerbations. D"
    },
    {
        "id": "doc_3878",
        "document": "If food chemical sensitivity is confirmed, complete avoidance is not usually necessary, and sensitivity often decreases when asthma control improves. D list of abbreviations (p.10). Interventions with highest level evidence are shown first."
    },
    {
        "id": "doc_3879",
        "document": "outdoor\n\nfoods\n\nSee\n\nCessation of smoking and vaping and avoidance of environmental tobacco smoke\n\nCigarette smoking has multiple deleterious effects in people with established asthma, in addition to its other well-known effects such as increased risk of lung cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease; and, with exposure in pregnancy, increased risk of asthma and lower respiratory infections in children."
    },
    {
        "id": "doc_3880",
        "document": "In people with asthma (children and adults), exposure to environmental tobacco smoke increases the risk of hospitalization and poor asthma control. Active smoking is associated with increased risk of poor asthma control, hospital admissions and, in some studies, death from asthma; increased rate of decline of lung function and may lead to COPD; and reduced the effectiveness of inhaled and oral corticosteroids.361 After smoking cessation, lung function improves and airway inflammation"
    },
    {
        "id": "doc_3881",
        "document": "decreases.362 Reduction of environmental tobacco smoke exposure improves asthma control and reduces hospital admissions in adults and children.363 Use of e-cigarettes (vaping) is associated with an increased risk of asthma symptoms or diagnosis, and an increased risk of asthma exacerbations.108,364"
    },
    {
        "id": "doc_3882",
        "document": "Advice\n\n\u2022 At every visit, strongly encourage people with asthma who smoke to quit. They should be provided with access to counseling and, if available, to smoking cessation programs (Evidence A).\n\n\u2022 Strongly encourage people with asthma who vape to quit.\n\n\u2022 Strongly encourage people with asthma to avoid environmental smoke exposure (Evidence B).\n\n\u2022 Advise parents/caregivers of children with asthma not to smoke and not to allow smoking in rooms or cars that their children use (Evidence A)."
    },
    {
        "id": "doc_3883",
        "document": "\u2022 Assess patients with a >10 pack-year smoking history for COPD or asthma\u2013COPD overlap, as additional treatment strategies may be required (see Chapter 5, p.159).\n\nPhysical activity"
    },
    {
        "id": "doc_3884",
        "document": "For people with asthma, as in the general population, regular moderate physical activity has important health benefits including reduced cardiovascular risk and improved quality of life.365 There is some evidence that aerobic exercise training can have a small beneficial effect on asthma symptom control and lung function, although not airway inflammation.366 In physically inactive adults with moderate/severe asthma, physical activity interventions were associated with reduced symptoms and"
    },
    {
        "id": "doc_3885",
        "document": "improved quality of life.367 Further studies are needed to identify the optimal regimen. Improved cardiopulmonary fitness may reduce the risk of dyspnea unrelated to airflow limitation being mistakenly attributed to asthma. In one study of non-obese patients with asthma, high intensity interval training together"
    },
    {
        "id": "doc_3886",
        "document": "90\n\n3. Treating to control symptoms and minimize future risk\n\nwith a diet with high protein and low glycemic index improved asthma symptom control, although no benefit on lung function was seen.368 In young people with asthma, swimming training is well tolerated and leads to increased lung function and cardio-pulmonary fitness;369 however, there are some concerns about exposure to chlorine and trichloramine with indoor pools.52"
    },
    {
        "id": "doc_3887",
        "document": "Exercise is an important cause of asthma symptoms for many asthma patients, but EIB can usually be reduced with maintenance ICS.52 Breakthrough exercise-related symptoms can be managed with warm-up before exercise,52 and/or by taking SABA52 or low-dose ICS-formoterol214 before or during exercise."
    },
    {
        "id": "doc_3888",
        "document": "Advice\n\n\u2022 Encourage people with asthma to engage in regular physical activity because of its general health benefits (Evidence A). However, regular physical activity confers no specific benefit on lung function or asthma symptoms per se, with the exception of swimming in young people with asthma (Evidence B). There is insufficient evidence to recommend one form of physical activity over another (Evidence D)."
    },
    {
        "id": "doc_3889",
        "document": "\u2022 Provide patients with advice about prevention and management of exercise-induced bronchoconstriction including with daily treatment with ICS (Evidence A) plus SABA as-needed and pre-exercise (Evidence A), or treatment with low-dose ICS-formoterol as-needed and before exercise (Evidence B), with warm-up before exercise if needed (Evidence A). For doses of ICS-formoterol, see Box 3-15, p.80. For patients prescribed as-needed ICS-SABA, this can also be used before exercise."
    },
    {
        "id": "doc_3890",
        "document": "Avoidance of occupational or domestic exposures"
    },
    {
        "id": "doc_3891",
        "document": "Occupational exposures to allergens or sensitizers account for a substantial proportion of the incidence of adult-onset asthma.370 Once a patient has become sensitized to an occupational allergen, the level of exposure necessary to induce symptoms may be extremely low, and resulting exacerbations become increasingly severe. Attempts to reduce occupational exposure have been successful, especially in industrial settings.49 Cost-effective minimization of latex sensitization can be achieved by"
    },
    {
        "id": "doc_3892",
        "document": "using non-powdered low-allergen gloves instead of powdered latex gloves.49"
    },
    {
        "id": "doc_3893",
        "document": "Advice\n\n\u2022 Ask all patients with adult-onset asthma about their work history and other exposures to inhaled allergens or irritants, including at home (Evidence D).\n\nIn management of occupational asthma, identify and eliminate occupational sensitizers as soon as possible, and remove sensitized patients from any further exposure to these agents (Evidence A)."
    },
    {
        "id": "doc_3894",
        "document": "\u2022 Patients with suspected or confirmed occupational asthma should be referred for expert assessment and advice, if available, because of the economic and legal implications of the diagnosis (Evidence A).\n\nAvoidance of medications that may make asthma worse"
    },
    {
        "id": "doc_3895",
        "document": "Aspirin and other NSAIDs can cause severe exacerbations.371 Beta-blocker drugs, including topical ophthalmic preparations, may cause bronchospasm372 and have been implicated in some asthma deaths. However, beta-blockers have a proven benefit in the management of cardiovascular disease. People with asthma who have had an acute coronary event and received beta-blockers within 24 hours of hospital admission have been found to have lower in- hospital mortality rates than those who did not receive"
    },
    {
        "id": "doc_3896",
        "document": "beta-blockers.373"
    },
    {
        "id": "doc_3897",
        "document": "Advice\n\n\u2022 Always ask people with asthma about concomitant medications, including eyedrops (Evidence D).\n\n\u2022 Always ask about asthma and previous reactions before prescribing NSAIDs, and advise patients to stop using these medications if asthma worsens.\n\n\u2022 Aspirin and NSAIDs are not generally contraindicated in asthma unless there is a history of previous reactions to these agents (Evidence A). (See \u2018Aspirin-exacerbated respiratory disease\u2019, p.117)."
    },
    {
        "id": "doc_3898",
        "document": "\u2022 For people with asthma who may benefit from oral or ophthalmic beta-blocker treatment, a decision to prescribe these medications should be made on a case-by-case basis, and treatment should only be initiated under close medical supervision by a specialist (Evidence D).\n\n3. Treating to control symptoms and minimize future risk\n\n91"
    },
    {
        "id": "doc_3899",
        "document": "\u2022 Asthma should not be regarded as an absolute contraindication to use cardioselective beta-blockers when they are indicated for acute coronary events, but the relative risks and benefits should be considered (Evidence D). The prescribing physician and patient should be aware of the risks and benefits of treatment.374"
    },
    {
        "id": "doc_3900",
        "document": "Avoidance of indoor allergens\n\nBecause many asthma patients react to multiple factors that are ubiquitous in the environment, avoiding these factors completely is usually impractical and very burdensome for the patient. Medications to maintain good asthma control have an important role because patients are often less affected by environmental factors when their asthma is well controlled."
    },
    {
        "id": "doc_3901",
        "document": "There is conflicting evidence about whether measures to reduce exposure to indoor allergens are effective at reducing asthma symptoms.375,376 The majority of single interventions have failed to achieve a sufficient reduction in allergen load to lead to clinical improvement.375,377,378 It is likely that no single intervention will achieve sufficient benefits to be cost effective (Box 3-19, p.93). One study of insecticidal bait in homes eradicated cockroaches for a year and led to a significant"
    },
    {
        "id": "doc_3902",
        "document": "decrease in symptoms, improvement in pulmonary function, and less health care use for children with moderate to severe asthma.379"
    },
    {
        "id": "doc_3903",
        "document": "House dust mite: HDM live and thrive in many sites throughout the house, so they are difficult to reduce and impossible to eradicate. A systematic review of multi-component interventions to reduce allergens, including HDM, showed no benefit for asthma in adults and a small benefit for children.380 One study that used a rigorously applied integrated approach to HDM control led to a significant decrease in symptoms, medication use and improvement in pulmonary function for children with HDM"
    },
    {
        "id": "doc_3904",
        "document": "sensitization and asthma.381 However, this approach is complicated and expensive and is not generally recommended. A study in HDM-sensitized children recruited after emergency department presentation showed a decrease in emergency department visits, but not oral corticosteroids, with the use of mite-impermeable encasement of the mattress, pillow and duvet.382"
    },
    {
        "id": "doc_3905",
        "document": "Furred pets: complete avoidance of pet allergens is impossible for sensitized patients as these allergens are ubiquitous outside the home383 in schools,384 public transport, and even cat-free buildings, probably transferred on clothes.384 Although removal of such animals from the home of a sensitized patient is encouraged,385 it can be many months before allergen levels decrease,386 and the clinical effectiveness of this and other interventions remains unproven.387"
    },
    {
        "id": "doc_3906",
        "document": "Pest rodents: symptomatic patients suspected of domestic exposure to pest rodents should be evaluated with skin prick tests or specific IgE, as exposure may not be apparent unless there is an obvious infestation.388 High-level evidence for the effectiveness of removing rodents is lacking, as most integrated pest management interventions also remove other allergen sources;388 one non-sham-controlled study showed comparable clinical improvement with pest reduction education and integrated pest"
    },
    {
        "id": "doc_3907",
        "document": "management.389"
    },
    {
        "id": "doc_3908",
        "document": "Cockroaches: avoidance measures for cockroaches are only partially effective in removing residual allergens390 and evidence of clinical benefit is lacking."
    },
    {
        "id": "doc_3909",
        "document": "Fungi: fungal exposure has been associated with asthma exacerbations. The number of fungal spores can best be reduced by removing or cleaning mold-laden objects.391 Air conditioners and dehumidifiers may be used to reduce humidity to less than 50% and to filter large fungal spores. However, air conditioning and sealing of windows have also been associated with increases in fungal and HDM allergens.392"
    },
    {
        "id": "doc_3910",
        "document": "Advice\n\n\u2022 Allergen avoidance is not recommended as a general strategy for people with asthma (Evidence A).\n\n\u2022 For sensitized patients, although it would seem logical to attempt to avoid allergen exposure in the home, there is some evidence for clinical benefit with single avoidance strategies (Evidence A) and only limited evidence for benefit with multi-component avoidance strategies (in children) (Evidence B)."
    },
    {
        "id": "doc_3911",
        "document": "\u2022 Although allergen avoidance strategies may be beneficial for some sensitized patients (Evidence B), they are often complicated and expensive, and there are no validated methods for identifying those who are likely to benefit (Evidence D).\n\n92\n\n3. Treating to control symptoms and minimize future risk\n\nBox 3-19. Effectiveness of avoidance measures for indoor allergens"
    },
    {
        "id": "doc_3912",
        "document": "Measure Evidence of effect on allergen levels Evidence of clinical benefit House dust mites Encase bedding in impermeable covers Some (A) Adults - none (A) Children - some (A) Wash bedding on hot cycle (65-60\u00b0C) Some (C) (D) Replace carpets with hard flooring Some (B) (D) Acaricides and/or tannic acid Weak (C) (D) Minimize objects that accumulate dust (D) (D) Vacuum cleaners with integral HEPA filter and double- thickness bags Weak (C) (D) Remove, hot wash, or freeze soft toys (D,), None Pets"
    },
    {
        "id": "doc_3913",
        "document": "Remove cat/dog from the home Weak (C) (D Keep pet from the main living areas/bedrooms Weak C) E( (D HEPA-filter air cleaners Some (B) (A) Wash pet Weak (C) (D Replace carpets with hard flooring (D) (D Vacuum cleaners with integral HEPA filter and double- thickness bags (D) (D Cockroaches Bait plus professional extermination of coqkroaches Minimal (D) (D Baits placed in households Some (B) Some (B) Rodents Integrated pest management st[ategies Some (B) Some (B) Fungi"
    },
    {
        "id": "doc_3914",
        "document": "Remediation of dampness or mold in homes A A Air filters, air conditiqnjng Some (B) (D)"
    },
    {
        "id": "doc_3915",
        "document": "See list of abbreviations (p.10). This table is adapted from Custovic et al393"
    },
    {
        "id": "doc_3916",
        "document": "Healthy diet\n\nIn the general population, a diet high in fresh fruit and vegetables has many health benefits, including prevention of many chronic diseases and forms of cancer. Many epidemiological studies report that a high fruit and vegetable diet is associated with a lower risk of asthma and lung function decline. There is some evidence that increasing fruit and vegetable intake leads to an improvement in asthma control and a reduced risk of exacerbations.394"
    },
    {
        "id": "doc_3917",
        "document": "Advice\n\n\u2022 Encourage patients with asthma to consume a diet high in fruit and vegetables for its general health benefits (Evidence A).\n\n3. Treating to control symptoms and minimize future risk\n\n93\n\nWeight reduction for obese patients"
    },
    {
        "id": "doc_3918",
        "document": "Asthma can be more difficult to control in obese patients,395-397 the risk of exacerbations is greater,103,104 and response to ICS may be reduced.398 There is limited evidence about the effect of weight loss on asthma control. Studies have ranged from dietary restriction to multifactorial interventions with exercise training and cognitive behavioral therapy, but populations have generally been small, and interventions and results have been heterogeneous.399 In some studies, weight loss has"
    },
    {
        "id": "doc_3919",
        "document": "improved asthma control, lung function and health status, and reduced medication needs in obese patients with asthma.400,401 The most striking results have been observed after bariatric surgery,402,403 but even 5\u201310% weight loss with diet, with or without exercise, can lead to improved asthma control and quality of life.404"
    },
    {
        "id": "doc_3920",
        "document": "Advice\n\n\u2022 Include weight reduction in the treatment plan for obese patients with asthma (Evidence B). Increased exercise alone appears to be insufficient (Evidence B)."
    },
    {
        "id": "doc_3921",
        "document": "Breathing exercises\n\nA systematic review of studies of breathing and/or relaxation exercises in adults with asthma and/or dysfunctional breathing, including the Buteyko method and the Papworth method, reported improvements in symptoms, quality of life and/or psychological measures, but with no consistent effect on lung function and no reduction in risk of exacerbations.405"
    },
    {
        "id": "doc_3922",
        "document": "Studies of non-pharmacological strategies, such as breathing exercises, can only be considered high quality when control groups are appropriately matched for level of contact with health professionals and for asthma education. A study of two physiologically contrasting breathing exercises, which were matched for contact with health professionals and instructions about rescue inhaler use, showed similar improvements in reliever use and ICS dose after down- titration in both groups.406 This"
    },
    {
        "id": "doc_3923",
        "document": "suggests that perceived improvement with breathing exercises may be largely due to factors such as relaxation, voluntary reduction in use of rescue medication, or engagement of the patient in their care. The cost of some commercial programs may be a potential limitation."
    },
    {
        "id": "doc_3924",
        "document": "Breathing exercises used in some of these studies are available at www.breathestudy.co.uk407 and www.woolcock.org.au/resources/breathing-techniques-asthma.406\n\nAdvice\n\n\u2022 Breathing exercises may be considered as a supplement to conventional asthma management strategies for symptoms and quality of life, but they do not improve lung function or reduce exacerbation risk (Evidence A).\n\nAvoidance of indoor air pollution"
    },
    {
        "id": "doc_3925",
        "document": "In addition to passive and active smoking, other major indoor air pollutants that are known to impact on respiratory health include nitric oxide, nitrogen oxides, carbon monoxide, carbon dioxide, sulfur dioxide, formaldehyde, and biologicals (endotoxin).408,409 Sources include cooking and heating devices using gas and solid biomass fuels, particularly if they are not externally flued (vented). Installation of non-polluting, more effective heating (heat pump, wood pellet burner, flued gas) in the"
    },
    {
        "id": "doc_3926",
        "document": "homes of children with asthma does not significantly improve lung function but significantly reduces symptoms of asthma, days off school, healthcare utilization, and pharmacist visits.410 Air filters can reduce fine particle exposure, but there is no consistent effect on asthma outcomes.411,412"
    },
    {
        "id": "doc_3927",
        "document": "Advice\n\n\u2022 Encourage people with asthma to use non-polluting heating and cooking sources, and for sources of pollutants to be vented outdoors where possible (Evidence B).\n\n94\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3928",
        "document": "Strategies for dealing with emotional stress\n\nEmotional stress may lead to asthma exacerbations in children413 and adults. Hyperventilation associated with laughing, crying, anger, or fear can cause airway narrowing.414,415 Panic attacks have a similar effect.416,417 However, it is important to note that asthma is not primarily a psychosomatic disorder. During stressful times, medication adherence may also decrease."
    },
    {
        "id": "doc_3929",
        "document": "Advice\n\n\u2022 Encourage patients to identify goals and strategies to deal with emotional stress if it makes their asthma worse (Evidence D).\n\n\u2022 There is insufficient evidence to support one strategy over another, but relaxation strategies and breathing exercises may be helpful in reducing asthma symptoms (Evidence B).\n\n\u2022 Arrange a mental health assessment for patients with symptoms of anxiety or depression (Evidence D)."
    },
    {
        "id": "doc_3930",
        "document": "Interventions addressing social risks\n\nA systematic review of social risk intervention studies based in the USA found that interventions that addressed these challenges, including health and health care, neighborhood and built environment, and social and community context, were associated with a marked reduction in pediatric emergency department visits and hospitalizations for asthma.418 Data are needed from studies in other countries and other socioeconomic settings."
    },
    {
        "id": "doc_3931",
        "document": "Avoidance of outdoor allergens\n\nFor patients sensitized to outdoor allergens such as pollens and molds, these are impossible to avoid completely.\n\nAdvice\n\n\u2022 For sensitized patients, closing windows and doors, remaining indoors when pollen and mold counts are highest, and using air conditioning may reduce exposure (Evidence D).\n\n\u2022 The impact of providing information in the media about outdoor allergen levels is difficult to assess.\n\nAvoidance of outdoor air pollution"
    },
    {
        "id": "doc_3932",
        "document": "Meta-analysis of epidemiological studies showed a significant association between air pollutants such as ozone, nitrogen oxides, acidic aerosols, and particulate matter and symptoms or exacerbations of asthma, including emergency department visits and hospitalizations.110 Use of digital monitoring identified a lag of 0\u20133 days between higher levels of multiple pollutants and increased asthma medication use.112 Proximity to main roads at home and school is associated with greater asthma"
    },
    {
        "id": "doc_3933",
        "document": "morbidity.419 Certain weather and atmospheric conditions like thunderstorms420,421 may trigger asthma exacerbations by a variety of mechanisms, including dust and pollution, by increasing the level of respirable allergens, and causing changes in temperature and/or humidity. Reduction of outdoor air pollutants usually requires national or local policy changes. For example, short-term traffic restrictions imposed in Beijing during the 2008 Olympics reduced pollution and was associated with a"
    },
    {
        "id": "doc_3934",
        "document": "significant fall in asthma outpatient visits.422"
    },
    {
        "id": "doc_3935",
        "document": "Advice\n\n\u2022 In general, when asthma is well controlled, there is no need for patients to modify their lifestyle to avoid unfavorable outdoor conditions (air pollutants, weather).\n\n\u2022 It may be helpful, where possible, during unfavorable environmental conditions (very cold weather, low humidity or high air pollution) to avoid strenuous outdoor physical activity and stay indoors in a climate-controlled environment; and to avoid polluted environments during viral infections (Evidence D)."
    },
    {
        "id": "doc_3936",
        "document": "3. Treating to control symptoms and minimize future risk\n\n95\n\nAvoidance of food and food chemicals\n\nFood allergy as an exacerbating factor for asthma is uncommon and occurs primarily in young children. Confirmed food allergy is a risk factor for asthma-related mortality.105"
    },
    {
        "id": "doc_3937",
        "document": "Food chemicals, either naturally occurring or added during processing, may also trigger asthma symptoms especially when asthma is poorly controlled. Sulfites (common food and drug preservatives found in such foods as processed potatoes, shrimp, dried fruits, beer, and wine) have often been implicated in causing severe asthma exacerbations.423 However, the likelihood of a reaction is dependent on the nature of the food, the level and form of residual sulfite, the sensitivity of the patient, and"
    },
    {
        "id": "doc_3938",
        "document": "the mechanism of the sulfite-induced reaction.423 There is little evidence to support any general role for other dietary substances including benzoate, the yellow dye, tartrazine, and monosodium glutamate in worsening asthma."
    },
    {
        "id": "doc_3939",
        "document": "Advice\n\n\u2022 Ask people with asthma about symptoms associated with any specific foods (Evidence D).\n\n\u2022 Food avoidance should not be recommended unless an allergy or food chemical sensitivity has been clearly demonstrated (Evidence D), usually by carefully supervised oral challenges.105\n\n\u2022 Patients with suspected or confirmed food allergy should be referred for expert advice about management of asthma and anaphylaxis (Evidence D)"
    },
    {
        "id": "doc_3940",
        "document": "If food allergy is confirmed, food allergen avoidance can reduce asthma exacerbations (Evidence D).\n\nIf food chemical sensitivity is confirmed, complete avoidance is not usually necessary, and sensitivity often decreases when overall asthma control improves (Evidence D).\n\n96\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3941",
        "document": "INDICATIONS FOR REFERRAL FOR EXPERT ADVICE\n\nFor most patients asthma can usually be managed in primary care, but some clinical situations warrant referral for expert advice regarding diagnosis and/or management (Box 3-20). This list is based on consensus. Indications for referral may vary, because the level at which asthma care is mainly delivered (primary care or specialist care) varies substantially between countries."
    },
    {
        "id": "doc_3942",
        "document": "Box 3-20. Indications for considering referral for expert advice, where available\n\nDifficulty confirming the diagnosis of asthma\n\nPatient has symptoms of chronic infection, or features suggesting a cardiac or other non-pulmonary cause (Box 1-3, p.28) (immediate referral recommended).\n\n.\n\n\u2022 Diagnosis is unclear, even after a trial of therapy with ICS or systemic corticosteroids.\n\nPatient has features of both asthma and COPD, and there is doubt about priorities for treatment."
    },
    {
        "id": "doc_3943",
        "document": "Suspected occupational asthma\n\n\u2022 Refer for confirmatory testing and identification of sensitizing or irritant agent, and specific advice about eliminating exposure and pharmacological treatment. See specific guidelines49 for details.\n\nPersistent or severely uncontrolled asthma or frequent exacerbations"
    },
    {
        "id": "doc_3944",
        "document": "Symptoms remain uncontrolled, or patient has ongoing exacerbations or low lung function despite correct inhaler technique and good adherence with Step 4 treatment (medium-dose ICS-LABA, Box 3-12, p.65). Before referral, depending on the clinical context, identify and treat modifiable risk factors (Box 2-2, p.38; Box 3-17, p.85) and comorbidities (p.106).\n\n.\n\nPatient frequently uses asthma-related health care (e.g., multiple ED visits or urgent primary care visits)."
    },
    {
        "id": "doc_3945",
        "document": "See Section 3.5 (p.120) on difficult-to-treat and severe asthma, including a decision tree.\n\n.\n\nAny risk factors for asthma-related death (see Box 4-1, p.141)\n\n\u2022 Near-fatal asthma attack (ICU admission, or mechanical ventilation for asthma) at any time in the past\n\n\u2022 Suspected or confirmed anaphylaxis or food allergy in a patient with asthma\n\nEvidence of, or risk of, significant treatment side-effects\n\n\u2022 Significant side-effects from treatment\n\n\u2022 Need for long-term oral corticosteroid use"
    },
    {
        "id": "doc_3946",
        "document": "\u2022 Frequent courses of oral corticosteroids (e.g., two or more courses a year)\n\nSymptoms suggesting complications or sub-types of asthma\n\ne.g., aspirin-exacerbated respiratory disease (p.117); allergic bronchopulmonary aspergillosis\n\nAdditional reasons for referral in children 6\u201311 years\n\n\u2022 Doubts about diagnosis of asthma e.g., respiratory symptoms are not responding well to treatment in a child who was born prematurely"
    },
    {
        "id": "doc_3947",
        "document": "Symptoms or exacerbations that remain uncontrolled despite medium-dose ICS (Box 3-14B, p.67) with correct inhaler technique and good adherence\n\n\u2022 Suspected side-effects of treatment (e.g., growth delay)\n\n\u2022 Concerns about the child\u2019s welfare or well-being\n\nSee list of abbreviations (p.10). For indications for referral in children 0-5 years, see p.176.\n\n3. Treating to control symptoms and minimize future risk\n\n97\n\n3.3. GUIDED ASTHMA SELF-MANAGEMENT EDUCATION AND SKILLS TRAINING"
    },
    {
        "id": "doc_3948",
        "document": "KEY POINTS\n\n\u2022 As with other chronic diseases, people with asthma need education and skills training to manage it well. This is most effectively achieved through a partnership between the patient and their health care providers. The essential components for this include:\n\no Choosing the most appropriate inhaler for the patient\u2019s asthma treatment: consider available devices, cost, the ability of the patient to use the inhaler after training, environmental impact, and patient satisfaction"
    },
    {
        "id": "doc_3949",
        "document": "o Skills training to use inhaler devices effectively\n\no Encouraging adherence with medications, appointments and other advice, within an agreed management strategy\n\no Asthma information\n\no Training in guided self-management, with self-monitoring of symptoms or peak flow; a written asthma action plan to show how to recognize and respond to worsening asthma; and regular review by a health care provider or trained health care worker."
    },
    {
        "id": "doc_3950",
        "document": "In developing, customizing and evaluating self-management interventions for different cultures, sociocultural factors should be taken into account.424"
    },
    {
        "id": "doc_3951",
        "document": "SKILLS TRAINING FOR EFFECTIVE USE OF INHALER DEVICES\n\nDelivery of respiratory medications by inhalation achieves a high concentration in the airways, more rapid onset of action, and fewer systemic adverse effects than systemic delivery. However, using an inhaler is a skill that must be learnt and maintained in order for the medication to be delivered effectively."
    },
    {
        "id": "doc_3952",
        "document": "Poor inhaler technique leads to poor asthma control, increased risk of exacerbations and increased adverse effects.102 Most patients (up to 70\u201380%) do not use their inhaler correctly. Unfortunately, many health care providers are unable to correctly demonstrate how to use the inhalers they prescribe.425 Most people with incorrect technique are unaware that they have a problem. There is no \u2018perfect\u2019 inhaler \u2013 patients can have problems using any inhaler device. The several factors that should be"
    },
    {
        "id": "doc_3953",
        "document": "considered in the choice of inhaler device for an individual patient are described below and in Box 3-21 (p.99)."
    },
    {
        "id": "doc_3954",
        "document": "Strategies for ensuring effective use of inhaler devices are summarized in Box 3-22, p.100.426 These principles apply to all types of inhaler devices. For patients prescribed pressurized metered dose inhalers (pMDIs), use of a spacer improves delivery and (for ICS) reduces the potential for local side-effects such as dysphonia and oral candidiasis.427 With ICS, the risk of candidiasis can also be reduced by rinsing and spitting out after use."
    },
    {
        "id": "doc_3955",
        "document": "Checking and correcting inhaler technique using a standardized checklist takes only 2\u20133 minutes and leads to improved asthma control in adults428,429 and older children426 (Evidence A). A physical demonstration is essential to improve inhaler technique.430 This is easiest if the health care provider has placebo inhalers and a spacer. After training, inhaler technique deteriorates with time, so checking and re-training must be repeated regularly. This is particularly important for patients with"
    },
    {
        "id": "doc_3956",
        "document": "poor symptom control or a history of exacerbations. Attaching a pictogram431,432 or a list of inhaler technique steps433 to the inhaler substantially increases the retention of correct technique at follow-up. Pharmacists, nurses and trained lay health workers can provide highly effective inhaler skills training.426,434-436"
    },
    {
        "id": "doc_3957",
        "document": "SHARED DECISION-MAKING FOR CHOICE OF INHALER DEVICE"
    },
    {
        "id": "doc_3958",
        "document": "Globally, multiple different devices are available for delivery of inhaled medication, including pressurized metered-doses inhalers (pMDIs), dry-powder inhalers (DPIs), mist inhalers and nebulizers, although the choice of inhaler device for each medication class in any country is often limited. Reducing the risk of severe exacerbations and asthma deaths is a global priority that is driving initiatives to increase access to ICS-containing inhalers for people with asthma worldwide (see p.112) and,"
    },
    {
        "id": "doc_3959",
        "document": "when these inhalers are available, to ensure that patients are trained in how to use them correctly."
    },
    {
        "id": "doc_3960",
        "document": "98\n\n3. Treating to control symptoms and minimize future risk\n\nThere is also increasing interest in the potential to reduce the impact of asthma and its care (routine and urgent) on the environment, including from the manufacture and potential recycling of inhaler devices, and from the propellants in pMDIs, which are the inhalers most commonly used worldwide.437-439"
    },
    {
        "id": "doc_3961",
        "document": "For all age-groups, selecting the right inhaler for the individual patient is crucial to asthma care, not only to reduce patients\u2019 symptom burden, but also to reduce the need for emergency healthcare and hospitalization, which have even greater environmental impacts than use of pMDIs.440,441\n\nBox 3-21. Shared decision-making between health professional and patient about choice of inhalers\n\nnen OPTIMAL INHALER SELECTION Safest and best for the patient and for the planet"
    },
    {
        "id": "doc_3962",
        "document": "See list of abbreviations (p.10).\n\n3. Treating to control symptoms and minimize future risk\n\n99\n\nBox 3-22. Choice and effective use of inhaler devices"
    },
    {
        "id": "doc_3963",
        "document": "CHOOSE\n\n\u2022 Choose the most appropriate inhaler device for the patient before prescribing. Consider the preferred medication (Box 3-12, p.65; 3-13, p.66), available devices, patient skills, environmental impact and cost (see Box 3-22, p.100).\n\nIf different options are available, encourage the patient to participate in the choice.\n\nFor pMDIs, use of a spacer improves delivery and (with ICS) reduces the potential for side-effects."
    },
    {
        "id": "doc_3964",
        "document": "Ensure that there are no physical barriers, e.g. arthritis, that limit use of the inhaler.\n\nAvoid use of multiple different inhaler types where possible, to avoid confusion.\n\nCHECK\n\n\u2022 Check inhaler technique at every opportunity.\n\nAsk the patient to show you how they use their inhaler (don\u2019t just ask if they know how to use it).\n\n\u2022 Identify any errors using a device-specific checklist."
    },
    {
        "id": "doc_3965",
        "document": "CORRECT\n\nShow the patient how to use the device correctly with a physical demonstration, e.g., using a placebo inhaler.\n\n\u2022 Check technique again, paying attention to problematic steps. You may need to repeat this process 2\u20133 times within the same session for the patient to master the correct technique.428\n\n\u2022 Consider an alternative device only if the patient cannot use the inhaler correctly after several repeats of training."
    },
    {
        "id": "doc_3966",
        "document": "\u2022 Re-check inhaler technique frequently. After initial training, errors often recur within 4\u20136 weeks.442\n\nCONFIRM\n\n\u2022 Clinicians should be able to demonstrate correct technique for each of the inhalers they prescribe.\n\n\u2022 Pharmacists and nurses can provide highly effective inhaler skills training.434,435"
    },
    {
        "id": "doc_3967",
        "document": "See list of abbreviations (p.10).\n\nSeveral factors must be considered in shared decision-making about the choice of inhaler device for the individual patient (Box 3-21, p.99), starting with the choice of the medication itself."
    },
    {
        "id": "doc_3968",
        "document": "\u2022 Which medication class(es) or individual medication(s) does the patient need to relieve and control symptoms and to prevent asthma exacerbations? The approach in GINA Track 1 (Box 3-5, p.58) is preferred, because the use of ICS-formoterol as an anti-inflammatory reliever reduces the risk of severe exacerbations and urgent health care utilization compared with using a SABA reliever. The Track 1 approach also avoids the risks associated with SABA over-use, and allows simple adjustment across"
    },
    {
        "id": "doc_3969",
        "document": "treatment steps with a single medication for both symptom relief and delivery of ICS-containing treatment. Most studies of MART with ICS-formoterol, and all studies of as- needed-only ICS-formoterol have used a DPI."
    },
    {
        "id": "doc_3970",
        "document": "\u2022 Which inhaler devices are available to the patient for these medications? The choice of device for any particular medication class in an individual country is often limited. Consider local availability, access, and cost to the patient. Where more than one medication is needed, a single (combination) inhaler is preferable to multiple inhalers. Also consider the patient\u2019s age, since DPIs are not suitable for most children aged \u22645 years and some elderly patients; pMDIs with spacers remain"
    },
    {
        "id": "doc_3971",
        "document": "essential for such patients."
    },
    {
        "id": "doc_3972",
        "document": "\u2022 Can the patient use the available device(s) correctly after training? This may be determined by factors including physical dexterity, coordination, inspiratory flow, and cognitive status. Different inhaler types require different inhalation techniques, so it is preferable to avoid prescribing a pMDI and DPI for the same patient. Incorrect inhaler technique increases risk of severe asthma exacerbations.\n\n100\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3973",
        "document": "\u2022 What are the environmental implications of the available inhaler(s)? This has become an important part of inhaler selection, particularly with regard to the propellants in pMDIs, but also related to inhaler manufacture and potential recycling. However, clinicians need to be aware of the potential to place an additional burden on patients of so- called \u2018green guilt\u2019, which could impact negatively on adherence and increase the risk of exacerbations."
    },
    {
        "id": "doc_3974",
        "document": "\u2022 Is the patient satisfied with the medication and inhaler? The best inhaler for each patient is likely to be the one that they prefer and are able to use, as this promotes adherence and reduces risk of exacerbations and adverse effects.\n\nIn follow-up, review symptom control, asthma exacerbations and adverse events, and check the patient\u2019s ability to use their inhaler(s) correctly, ideally at each visit.\n\nADHERENCE WITH MEDICATIONS AND WITH OTHER ADVICE"
    },
    {
        "id": "doc_3975",
        "document": "Identifying poor adherence\n\nPoor adherence is defined as the failure of treatment to be taken as agreed upon by the patient and the health care provider. There is increasing awareness of the importance of poor adherence in chronic diseases, and of the potential to develop interventions to improve adherence.443 Approximately 50% of adults and children on long-term therapy for asthma fail to take medications as directed at least part of the time.174"
    },
    {
        "id": "doc_3976",
        "document": "In clinical practice, poor adherence may be identified by an empathic question that acknowledges the likelihood of incomplete adherence and encourages an open discussion. See Box 3-23, p.102 for examples. Checking the date of the last prescription or the date on the inhaler may assist in identifying poor adherence. In some health systems, pharmacists can assist in identifying poorly adherent patients by monitoring dispensing records. Electronic inhaler monitoring has also been used in clinical"
    },
    {
        "id": "doc_3977",
        "document": "practice to identify poor adherence in patients with difficult-to-treat asthma.160,161"
    },
    {
        "id": "doc_3978",
        "document": "In clinical studies, poor adherence may be identified by short adherence behavior questionnaires, or from dispensing records; dose or pill counting; electronic inhaler monitoring;444 and drug assay such as for prednisolone.445\n\nFactors contributing to poor adherence"
    },
    {
        "id": "doc_3979",
        "document": "It is important to elicit patients\u2019 beliefs and concerns about asthma and asthma medications in order to understand the reasons behind their medication-taking behavior. Factors involved in poor adherence are listed in Box 3-23, p.102. They include both intentional and unintentional factors. Issues such as ethnicity,446 health literacy,447,448 and numeracy185 are often overlooked. Patients may be concerned about known side-effects or about perceived harm.318,449"
    },
    {
        "id": "doc_3980",
        "document": "Interventions that improve adherence in asthma\n\nFew adherence interventions have been studied comprehensively in asthma. Some examples of successful interventions have been published:\n\n\u2022 Shared decision-making for medication/dose choice improved adherence and asthma outcomes.176,179\n\n\u2022 Electronic inhaler reminders, either proactively or for missed doses, improved adherence450-452 and possibly reduced exacerbations and oral corticosteroid use.450-453"
    },
    {
        "id": "doc_3981",
        "document": "In a difficult inner-city environment, home visits for a comprehensive asthma program by an asthma nurse led to improved adherence and reduced prednisone courses over the following several months.454\n\n\u2022 Providing adherence information to clinicians did not improve ICS use among patients with asthma unless clinicians chose to view the details of their patients\u2019 medication use.455"
    },
    {
        "id": "doc_3982",
        "document": "In a health maintenance organization, an automated voice recognition program with messages triggered when refills were due or overdue led to improved ICS adherence relative to usual care, but no difference in urgent care visits.456\n\n\u2022 In one study, directly observed administration of maintenance asthma treatment at school, combined with telemedicine oversight, was associated with more symptom-free days and fewer urgent visits than usual care.457"
    },
    {
        "id": "doc_3983",
        "document": "3. Treating to control symptoms and minimize future risk\n\n101"
    },
    {
        "id": "doc_3984",
        "document": "Digital interventions for adherence: A 2022 Cochrane review found that a variety of digital intervention strategies improved adherence to maintenance controller medications, especially in those with poor adherence, reduced exacerbations, and improved asthma control, in studies of up to 2 years\u2019 duration in adults and children.453 Electronic monitoring of maintenance inhaler use and text messages sent to phones appear to be effective. No harms associated with these technologies were reported. The"
    },
    {
        "id": "doc_3985",
        "document": "effects of digital interventions on quality of life, lung function and unscheduled health care utilization are unclear."
    },
    {
        "id": "doc_3986",
        "document": "Improving adherence to maintenance ICS-containing medications may not necessarily translate to improved clinical outcomes.458 Further studies are needed of adherence strategies that are feasible for implementation in primary care.\n\nBox 3-23. Poor adherence with prescribed maintenance treatment in asthma"
    },
    {
        "id": "doc_3987",
        "document": "Factors contributing to poor adherence How to identify poor adherence in clinical practice"
    },
    {
        "id": "doc_3988",
        "document": "Medication/regimen . Difficulties using inhaler device (e.g., arthritis) . Burdensome regimen (e.g., multiple times per day) . Multiple different inhalers Unintentional poor adherence . Misunderstanding about instructions . Forgetfulness . Absence of a daily routine . Cost Intentional poor adherence . Perception that treatment is not necessary . Denial or anger about asthma or its treatment . Inappropriate expectations Concerns about side-effects (real or"
    },
    {
        "id": "doc_3989",
        "document": "perceived) Dissatisfaction with health care providers Stigmatization Cultural or religious issues Cost Examples of successful adherence interventions"
    },
    {
        "id": "doc_3990",
        "document": "patients prescribed treatment, empathic question . Acknowledge the likelihood of incomplete adherence and encourage an open non-judgmental discussion. Examples are: \u2018Many patients don\u2019t use their inhaler as prescribed. In the last 4 weeks, how many days a week have you been taking it \u2014 not at all, 1, 2, 3 or more days a week?'4%\u00b0 \u2018Do you find it easier to remember your inhaler in the morning or the evening?' Check medication usage ) Check the date of the last"
    },
    {
        "id": "doc_3991",
        "document": "prescription . Check the date and dose counter on the inhaler . In some health systems, prescribing and dispensing frequency can be monitored electronically by clinicians and/or pharmacists See review articles for more detail.73:460"
    },
    {
        "id": "doc_3992",
        "document": "Examples of successful adherence interventions\n\n\u2022 Shared decision-making for medication/dose choice176,179\n\nInhaler reminders, either proactively or for missed doses450-452\n\n.\n\n\u2022 Prescribing low-dose ICS once-daily versus twice-daily461\n\n\u2022 Home visits for a comprehensive asthma program by an asthma nurse454"
    },
    {
        "id": "doc_3993",
        "document": "ASTHMA INFORMATION\n\nWhile education is relevant to asthma patients of all ages, the information and skills training required by each person may vary, as will their ability or willingness to take responsibility. All individuals will require certain core information and skills, but most education must be personalized and provided over several sessions or stages."
    },
    {
        "id": "doc_3994",
        "document": "For young children, the focus of asthma education will be on the parent/caregiver, but young children can be taught simple asthma management skills. Adolescents may have unique difficulties with adherence, and peer support group education may help in addition to education provided by the health care provider.462 These are complex interventions,\n\n102\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_3995",
        "document": "and there have been few studies. Regional issues and the adolescent\u2019s developmental stage may affect the outcomes of such programs.463"
    },
    {
        "id": "doc_3996",
        "document": "The key features and components of an asthma education program are provided in Box 3-24. Information alone improves knowledge but does not improve asthma outcomes.464 Social and psychological support may also be required to maintain positive behavioral change, and skills are required for effective medication delivery. At the initial consultation, verbal information should be supplemented with written or pictorial465,466 information about asthma and its treatment. The GINA website"
    },
    {
        "id": "doc_3997",
        "document": "(www.ginasthma.org) contains patient educational materials as well as links to several asthma websites. Patients and their families should be encouraged to make a note of any questions that arise from reading this information or as a result of the consultation, and should be given time to address these during the next consultation."
    },
    {
        "id": "doc_3998",
        "document": "Asthma education and training, for both adults and children, can be delivered effectively by a range of health care providers including pharmacists and nurses (Evidence A).434,435,467,468 Trained lay health workers (also known as community health workers) can deliver discrete areas of respiratory care such as asthma self-management education. Asthma education by trained lay health workers has been found to improve patient outcomes and healthcare utilization compared with usual care,436,469 and"
    },
    {
        "id": "doc_3999",
        "document": "to a similar extent as nurse-led education in primary care470 (Evidence B). These findings suggest the need for additional studies to assess applicability in other settings and populations."
    },
    {
        "id": "doc_4000",
        "document": "Box 3-24. Asthma information\n\nGoal: To provide the person with asthma, their family and other carers with suitable information and training to manage their asthma in partnership with their health care providers"
    },
    {
        "id": "doc_4001",
        "document": "Approach Content . Focus on the development of the partnership. . Asthma diagnosis . Accept that this is a continuing process. . Rationale for treatment, and differences between . Share information. relievers and maintenance treatments (if prescribed) Fully discuss expectations, fears and concerns. anti-inflammatory treatment . Develop shared goals. How to recognize worsening asthma and what actions to take; how and when to seek medical attention Management of comorbidities"
    },
    {
        "id": "doc_4002",
        "document": "TRAINING IN GUIDED ASTHMA SELF-MANAGEMENT"
    },
    {
        "id": "doc_4003",
        "document": "Guided self-management may involve varying degrees of independence, ranging broadly from patient-directed self- management to doctor-directed self-management. With patient-directed self-management patients make changes in accordance with a prior written action plan without needing to first contact their health care provider. With doctor- directed self-management, patients still have a written action plan, but refer most major treatment decisions to their physician at the time of a planned or"
    },
    {
        "id": "doc_4004",
        "document": "unplanned consultation."
    },
    {
        "id": "doc_4005",
        "document": "The essential components of effective guided asthma self-management education are:177\n\n\u2022 Self-monitoring of symptoms and/or peak flow\n\n\u2022 A written asthma action plan to show how to recognize and respond to worsening asthma; and\n\n\u2022 Regular review of asthma control, treatment and skills by a health care provider."
    },
    {
        "id": "doc_4006",
        "document": "Self-management education that includes these components dramatically reduces asthma morbidity, both in adults (Evidence A)177,436,471 and children (Evidence A).178,471 Benefits include reduction of one-third to two-thirds in asthma-\n\n3. Treating to control symptoms and minimize future risk\n\n103"
    },
    {
        "id": "doc_4007",
        "document": "related hospitalizations, emergency department visits and unscheduled doctor or clinic visits, missed work/school days, and nocturnal wakening.177 It has been estimated that the implementation of a self-management program in 20 patients prevents one hospitalization, and successful completion of such a program by 8 patients prevents one emergency department visit.177,472 Less intensive interventions that involve self-management education but not a written action plan are less effective,473 and"
    },
    {
        "id": "doc_4008",
        "document": "information alone is ineffective.464 A systematic meta-review of 270 RCTs on supported self- management for asthma confirmed that it reduces unscheduled healthcare use, improves asthma control, is applicable to a wide range of target groups and clinical settings, and does not increase health care costs (Evidence A).471"
    },
    {
        "id": "doc_4009",
        "document": "Self-monitoring of symptoms and/or peak flow\n\nPatients should be trained to keep track of their symptoms (with or without a diary), and notice and take action, if necessary, when symptoms start to worsen. Peak expiratory flow (PEF) monitoring may sometimes be useful:\n\n\u2022 Short-term monitoring\n\nFollowing an exacerbation, to monitor recovery Following a change in treatment, to help in assessing whether the patient has responded g"
    },
    {
        "id": "doc_4010",
        "document": "If symptoms appear excessive (for objective evidence of degree of lung function impairment)\n\nTo assist in identification of occupational or domestic triggers for worsening asthma control\n\n\u2022 Long-term monitoring\n\no]\n\nFor earlier detection of exacerbations, mainly in patients with poor perception of airflow limitation?36\n\nFor patients with a history of sudden severe exacerbations\n\no For patients who have difficult-to-control or severe asthma"
    },
    {
        "id": "doc_4011",
        "document": "For patients carrying out PEF monitoring, use of a laterally compressed PEF chart (showing 2 months on a landscape format page) allows more accurate identification of worsening asthma than other charts.158 One such chart is available for download from www.woolcock.org.au/resources/asthma-peak-flow-chart.\n\nThere is increasing interest in internet or phone-based monitoring of asthma. Based on existing studies, the main benefit is likely to be for more severe asthma474 (Evidence B)."
    },
    {
        "id": "doc_4012",
        "document": "Written asthma action plans\n\nPersonal written asthma action plans show patients how to make short-term changes to their treatment in response to changes in their symptoms and/or PEF. They also describe how and when to access medical care.475,476 The term \u2018written\u2019 action plan includes printed, digital or pictorial plans, i.e., the patient is given a record of the instructions."
    },
    {
        "id": "doc_4013",
        "document": "The benefits of self-management education for asthma morbidity are greater in adults when the action plans include both a step up in ICS and the addition of OCS, and for PEF-based plans, when they are based on personal best rather than percent predicted PEF476 (Evidence A)."
    },
    {
        "id": "doc_4014",
        "document": "The efficacy of self-management education is similar regardless of whether patients self-adjust their medications according to an individual written plan or whether the medication adjustments are made by a doctor (Evidence A).473 Thus, patients who are unable to undertake guided self-management can still achieve benefit from a structured program of regular medical review."
    },
    {
        "id": "doc_4015",
        "document": "Examples of written asthma action plan templates for asthma treatment with a SABA reliever, including for adult and pediatric patients with low literacy, can be found on several websites (e.g. Asthma UK, www.asthma.org.uk; Asthma Society of Canada, www.asthma.ca; Family Physician Airways Group of Canada, www.fpagc.com; National Asthma Council Australia, www.nationalasthma.org.au) and in research publications.477,478"
    },
    {
        "id": "doc_4016",
        "document": "Action plan for patients using as-needed ICS-formoterol as their reliever\n\nA different type of action plan is needed for patients using as-needed ICS-formoterol as their reliever in GINA Track 1, because the initial \u2018action\u2019 when asthma worsens is for the patient to increase their as-needed doses of ICS-formoterol, rather than taking a SABA and/or increasing their maintenance treatment. An example of such a customized template\n\n104\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4017",
        "document": "can be found in a review article about practical use of maintenance-and reliever-therapy (MART).8 A similar action plan template can be used for patients using as-needed-only ICS-formoterol.312"
    },
    {
        "id": "doc_4018",
        "document": "Health care providers should become familiar with action plans that are relevant to their local health care system, treatment options, and cultural and literacy context. Details of the specific treatment adjustments that can be recommended for written asthma action plans are described in the next chapter (Box 4-2, p.146)."
    },
    {
        "id": "doc_4019",
        "document": "Regular review by a healthcare provider or trained healthcare worker\n\nThe third component of effective asthma self-management education is regular review by a healthcare provider or trained healthcare worker. Follow-up consultations should take place at regular intervals. Regular review should include the following:\n\n\u2022 Ask the patient if they have any questions or concerns."
    },
    {
        "id": "doc_4020",
        "document": "Discuss issues, and provide additional educational messages as necessary; if available, refer the patient to someone trained in asthma education.\n\n\u2022 Assess asthma control, risk factors for exacerbations, and comorbidities.\n\nReview the patient\u2019s level of symptom control and risk factors (Box 2-2, p.38).\n\nAsk about flare-ups to identify contributory factors and whether the patient\u2019s response was appropriate (e.g., was an action plan used?)."
    },
    {
        "id": "doc_4021",
        "document": "Review the patient\u2019s symptom or PEF diary, if they keep one. Assess comorbidities.\n\n\u2022 Assess treatment issues.\n\nWatch the patient use their inhaler, and correct and re-check technique if necessary (Box 3-22 p.100). Assess medication adherence and ask about adherence barriers (Box 3-23, p.102). Ask about adherence with other interventions (e.g., smoking cessation). Review the asthma action plan and update it if level of asthma control or treatment have changed.479"
    },
    {
        "id": "doc_4022",
        "document": "A single page prompt to clinicians has been shown to improve the provision of preventive care to children with asthma during office visits.480 Follow-up by telehealthcare is unlikely to benefit patients with asthma that is well controlled at a low treatment step, but may be of benefit in those with severe disease at risk of hospital admission.474"
    },
    {
        "id": "doc_4023",
        "document": "School-based programs for children\n\nA systematic review found that school-based studies (most conducted in the US and Canada) that included self- management skills for children aged 5\u201318 years was associated with a 30% decrease in emergency department visits, and a significant decrease in hospitalizations and in days of reduced activity.481\n\n3. Treating to control symptoms and minimize future risk\n\n105\n\n3.4. MANAGING ASTHMA WITH MULTIMORBIDITY AND IN SPECIFIC POPULATIONS"
    },
    {
        "id": "doc_4024",
        "document": "KEY POINTS\n\n\u2022 Multimorbidity is common in patients with chronic diseases such as asthma. It is important to identify and manage multimorbidity, as it contributes to impaired quality of life, increased healthcare utilization, and adverse effects of medications. In addition, comorbidities such as rhinosinusitis, obesity and gastro-esophageal reflux disease (GERD) may contribute to respiratory symptoms and some contribute to poor asthma control.\n\n\u2022 For patients with dyspnea or wheezing on exertion:"
    },
    {
        "id": "doc_4025",
        "document": "o Distinguish between exercise-induced bronchoconstriction (EIB) and symptoms that result from obesity or a lack of fitness or are the result of alternative conditions such as inducible laryngeal obstruction.\n\n\u2022 All adolescents and adults with asthma should receive ICS-containing treatment to reduce their risk of severe exacerbations. It should be taken every day or, as an alternative in mild asthma, by as-needed ICS-formoterol for symptom relief."
    },
    {
        "id": "doc_4026",
        "document": "\u2022 Refer patients with difficult-to-treat or severe asthma to a specialist or severe asthma service, after addressing common problems such as incorrect diagnosis, incorrect inhaler technique, ongoing environmental exposures, and poor adherence (see Section 3.5, p.120).\n\nMANAGING MULTIMORBIDITY"
    },
    {
        "id": "doc_4027",
        "document": "Multimorbidity is a common problem in patients with chronic diseases such as asthma. It is associated with worse quality of life, increased healthcare utilization and increased adverse effects of treatment.175 Multimorbidity is particularly common among those with difficult-to-treat or severe asthma.104 Active management of comorbidities such as rhinosinusitis, obesity and GERD is important, as these conditions may also contribute to respiratory symptom burden and lead to medication"
    },
    {
        "id": "doc_4028",
        "document": "interactions. Some comorbidities also contribute to poor asthma control.482"
    },
    {
        "id": "doc_4029",
        "document": "Obesity\n\nClinical features\n\nBeing overweight or obese is a risk factor for childhood asthma and wheeze, particularly in girls.483 Asthma is more difficult to control in obese patients.395-398 This may be due to a different type of airway inflammation, contributory comorbidities such as obstructive sleep apnea and GERD, mechanical factors, or other as yet undefined factors. In addition, lack of fitness and reduction in lung volume due to abdominal fat may contribute to dyspnea."
    },
    {
        "id": "doc_4030",
        "document": "Diagnosis\n\nDocument body-mass index (BMI) for all patients with asthma. Because of other potential contributors to dyspnea and wheeze in obese patients, it is important to confirm the diagnosis of asthma with objective measurement of variable expiratory airflow limitation (Box 1-2, p.25). Asthma is more common in obese than non-obese patients,62 but both over- and under-diagnosis of asthma occur in obesity.38,63\n\nManagement"
    },
    {
        "id": "doc_4031",
        "document": "As for other patients with asthma, ICS are the mainstay of treatment in obese patients (Evidence B), although their response may be reduced.398 Weight reduction should be included in the treatment plan for obese patients with asthma (Evidence B). Increased exercise alone appears to be insufficient (Evidence B).404 Weight loss can improve asthma control, lung function, health status and reduces medication needs in obese patients,400,401 but the studies have generally been small, quality of some"
    },
    {
        "id": "doc_4032",
        "document": "studies is poor, and the interventions and results have been variable.399 The most striking results have been observed after bariatric surgery,402,403,484 but even 5\u201310% weight loss can lead to improved"
    },
    {
        "id": "doc_4033",
        "document": "106\n\n3. Treating to control symptoms and minimize future risk\n\nasthma control and quality of life.404 For patients with comorbid obstructive sleep apnea, one study showed a significant reduction in moderate exacerbations with 6 months of continuous positive airway pressure (CPAP) therapy.485\n\nGastroesophageal reflux disease (GERD)\n\nClinical features"
    },
    {
        "id": "doc_4034",
        "document": "GERD can cause symptoms such as heartburn and epigastric or chest pain, and is also a common cause of dry cough. Symptoms and/or diagnosis of GERD are more common in people with asthma than in the general population,482 but this may be in part due to cough being attributed to asthma; in addition, some asthma medications such as beta2-agonists and theophylline cause relaxation of the lower esophageal sphincter. Asymptomatic gastroesophageal reflux is not a likely cause of poorly controlled"
    },
    {
        "id": "doc_4035",
        "document": "asthma.482"
    },
    {
        "id": "doc_4036",
        "document": "Diagnosis"
    },
    {
        "id": "doc_4037",
        "document": "In patients with confirmed asthma, GERD should be considered as a possible cause of a dry cough; however, there is no value in screening patients with uncontrolled asthma for GERD (Evidence A). For patients with asthma and symptoms suggestive of reflux, an empirical trial of anti-reflux medication, such as a proton pump inhibitor or motility agent, may be considered, as in the general population. If the symptoms do not resolve, specific investigations such as 24-hour pH monitoring or endoscopy"
    },
    {
        "id": "doc_4038",
        "document": "may be considered."
    },
    {
        "id": "doc_4039",
        "document": "Management"
    },
    {
        "id": "doc_4040",
        "document": "Clinical trials of proton pump inhibitors in patients with confirmed asthma, most of whom had a diagnosis of GERD, showed small benefits for lung function, but no significant benefit for other asthma outcomes.486,487 In a study of adult patients with symptomatic asthma but without symptoms of GERD, treatment with high-dose proton pump inhibitors did not reduce asthma symptoms or exacerbations.488 In general, benefits of proton pump inhibitors in asthma appear to be limited to patients with both"
    },
    {
        "id": "doc_4041",
        "document": "symptomatic reflux and night-time respiratory symptoms.489 Other treatment options include motility agents, lifestyle changes and fundoplication. In summary, symptomatic reflux should be treated, but patients with poorly controlled asthma should not be treated with anti-reflux therapy unless they also have symptomatic reflux (Evidence A).487 Few data are available for children with asthma symptoms and symptoms of GERD.490,491"
    },
    {
        "id": "doc_4042",
        "document": "Anxiety and depression\n\nClinical features\n\nAnxiety symptoms and psychiatric disorders, particularly depressive and anxiety disorders, are more prevalent among people with asthma.492,493 Psychiatric comorbidity is also associated with worse asthma symptom control and medication adherence, and worse asthma-related quality of life.494 Anxious and depressive symptoms have been associated with increased asthma-related exacerbations and emergency visits.495 Panic attacks may be mistaken for asthma."
    },
    {
        "id": "doc_4043",
        "document": "Diagnosis"
    },
    {
        "id": "doc_4044",
        "document": "Although several tools are available for screening for anxious and depressive symptomatology in primary care, the majority have not been validated in asthma populations. Difficulties in distinguishing anxiety or depression from asthma symptoms may therefore lead to misdiagnosis. It is important to be alert to possible depression and/or anxiety in people with asthma, particularly when there is a previous history of these conditions. Where appropriate, patients should be referred to psychiatrists"
    },
    {
        "id": "doc_4045",
        "document": "or evaluated with a disease-specific psychiatric diagnostic tool to identify potential cases of depression and/or anxiety."
    },
    {
        "id": "doc_4046",
        "document": "Management"
    },
    {
        "id": "doc_4047",
        "document": "There have been few good quality pharmacological and non-pharmacological treatment trials for anxiety or depression in patients with asthma, and results are inconsistent. A Cochrane review of 15 randomized controlled trials of psychological interventions for adults with asthma included cognitive behavior therapy, psychoeducation, relaxation, and biofeedback.496 Results for anxiety were conflicting, and none of the studies found significant treatment differences for depression. Drug treatments"
    },
    {
        "id": "doc_4048",
        "document": "and cognitive behavior therapy497 have been described as having some potential in"
    },
    {
        "id": "doc_4049",
        "document": "3. Treating to control symptoms and minimize future risk\n\n107\n\npatients with asthma; however, current evidence is limited, with a small number of studies and methodological shortcomings.\n\nFood allergy and anaphylaxis\n\nClinical features"
    },
    {
        "id": "doc_4050",
        "document": "Rarely, food allergy is a trigger for asthma symptoms (<2% of people with asthma). In patients with confirmed food- induced allergic reactions (anaphylaxis), co-existing asthma is a strong risk factor for more severe and even fatal reactions. Food-induced anaphylaxis often presents as life-threatening asthma.105 An analysis of 63 anaphylaxis-related deaths in the United States noted that almost all had a past history of asthma; peanuts and tree nuts were the foods most commonly responsible.498 A"
    },
    {
        "id": "doc_4051",
        "document": "UK study of 48 anaphylaxis-related deaths found that most were regularly treated for asthma, and that in most of these, asthma was poorly controlled.499"
    },
    {
        "id": "doc_4052",
        "document": "Diagnosis\n\nIn patients with confirmed food allergy, it is important to assess for asthma. Children with food allergy have a four-fold increased likelihood of having asthma compared with children without food allergy.500 Refer patients with suspected food allergy or intolerance for specialist allergy assessment. This may include appropriate allergy testing such as skin prick testing and/or blood testing for specific IgE. On occasion, carefully supervised food challenges may be needed.\n\nManagement"
    },
    {
        "id": "doc_4053",
        "document": "Patients who have a confirmed food allergy that puts them at risk for anaphylaxis must have an epinephrine auto-injector available at all times, and be trained how to use it. They, and their family, must be educated in appropriate food avoidance strategies, and in the medical notes, they should be flagged as being at high risk. It is especially important to ensure that their asthma is well controlled, they have a written action plan, understand the difference between asthma and anaphylaxis, and"
    },
    {
        "id": "doc_4054",
        "document": "are reviewed on a regular basis."
    },
    {
        "id": "doc_4055",
        "document": "Rhinitis\n\nClinical features"
    },
    {
        "id": "doc_4056",
        "document": "Evidence clearly supports a link between diseases of the upper and lower airways.501 Most patients with asthma, either allergic or non-allergic, have concurrent rhinitis, and 10\u201340% of patients with allergic rhinitis have asthma.502 Depending on sensitization and exposure, allergic rhinitis may be seasonal (e.g. ragweed or grass pollen), or perennial (e.g., HDM allergens, furred pets in the home), or intermittent (e.g. furred pets at other locations).503 Rhinitis is defined as irritation and"
    },
    {
        "id": "doc_4057",
        "document": "inflammation of the mucous membranes of the nose. Allergic rhinitis may be accompanied by ocular symptoms (conjunctivitis)."
    },
    {
        "id": "doc_4058",
        "document": "Diagnosis\n\nRhinitis can be classified as either allergic or non-allergic depending on whether allergic sensitization is demonstrated. Variation in symptoms by season or with environmental exposure (e.g., furred pets, HDM, molds) suggests allergic rhinitis. Examination of the upper airway should be arranged for patients with severe asthma."
    },
    {
        "id": "doc_4059",
        "document": "Management\n\nEvidence-based guidelines developed by Allergic Rhinitis in Asthma (ARIA)501 recommend intranasal corticosteroids for treatment of allergic rhinitis. In a case-control study, treatment of rhinitis with intranasal corticosteroids was associated with less need for asthma-related hospitalization and emergency department visits,504 but a meta-analysis found improvement in asthma outcomes only in patients not also receiving ICS.505"
    },
    {
        "id": "doc_4060",
        "document": "Chronic rhinosinusitis with and without nasal polyps (CRSwNP and CRSsNP)\n\nRhinosinusitis is defined as inflammation of the nose and paranasal sinuses characterized by more than two symptoms including nasal blockage/obstruction and/or nasal discharge (anterior/posterior nasal drip).506 Other symptoms may\n\n108\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4061",
        "document": "include facial pain/pressure and/or a reduction or loss of smell. Sinusitis rarely occurs in the absence of rhinitis. Rhinosinusitis is defined as acute when symptoms last <12 weeks with complete resolution, and chronic when symptoms occur on most days for at least 12 weeks without complete resolution."
    },
    {
        "id": "doc_4062",
        "document": "Chronic rhinosinusitis is an inflammatory condition of the paranasal sinuses that encompasses two clinically distinct entities: chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP).507 The heterogeneity of chronic rhinosinusitis may explain the wide variation in prevalence rates in the general population ranging from 1\u201310% without polyps and 4% with polyps. Chronic rhinosinusitis is associated with more severe asthma, especially in patients"
    },
    {
        "id": "doc_4063",
        "document": "with nasal polyps.508"
    },
    {
        "id": "doc_4064",
        "document": "Diagnosis\n\nNasendoscopy and/or computed tomography (CT) of the sinuses can identify changes suggestive of chronic rhinosinusitis with or without nasal polyps. In severe asthma, presence of nasal polyps may help with choice of biologic therapy (see Box 3-28, p.125).\n\nManagement"
    },
    {
        "id": "doc_4065",
        "document": "Chronic rhinosinusitis, with or without nasal polyps, has a significant impact on patients\u2019 quality of life. Guidelines about the management of chronic rhinosinusitis with or without nasal polyps have been published.509,510 Few placebo- controlled studies have systematically evaluated the effect of proper treatment and management of chronic rhinosinusitis on asthma control. A placebo-controlled trial of nasal mometasone in adults and children with chronic rhinosinusitis and poorly controlled"
    },
    {
        "id": "doc_4066",
        "document": "asthma showed no benefit for asthma outcomes, suggesting that, while chronic rhinosinusitis can contribute to respiratory symptoms (e.g., chronic cough), its treatment in patients with asthma should be targeted at the symptoms of rhinosinusitis rather than to improve asthma control.511"
    },
    {
        "id": "doc_4067",
        "document": "Biologic therapy targeting T2 inflammation can significantly improve symptoms due to chronic rhinosinusitis with nasal polyps. In patients with chronic rhinosinusitis with nasal polyps, omalizumab,512 mepolizumab513,514 and dupilumab515 improved subjective and objective assessments including nasal symptoms and polyp size, compared with placebo.\n\nMANAGING ASTHMA DURING THE COVID-19 PANDEMIC\n\nAre people with asthma at higher risk of COVID-19 or severe COVID-19?"
    },
    {
        "id": "doc_4068",
        "document": "People with asthma do not appear to be at increased risk of acquiring COVID-19, and systematic reviews have not shown an increased risk of severe COVID-19 in people with well-controlled mild to moderate asthma. Overall, studies to date indicate that people with well-controlled asthma are not at increased risk of COVID-19-related death,516,517 and in one meta-analysis, mortality appeared to be lower than in people without asthma.518 However, the risk of COVID-19 death was increased in people who"
    },
    {
        "id": "doc_4069",
        "document": "had recently needed OCS for their asthma,516,519 and in hospitalized patients with severe asthma.519,520 Therefore, it is important to continue good asthma management (as described in the GINA Strategy Report), with strategies to maintain good symptom control, reduce the risk of severe exacerbations and minimize the need for OCS. In one study of hospitalized patients aged \u226550 years with COVID-19, mortality was lower among those with asthma who were using ICS than in patients without an"
    },
    {
        "id": "doc_4070",
        "document": "underlying respiratory condition.520"
    },
    {
        "id": "doc_4071",
        "document": "In 2020 and 2021, many countries saw a reduction in asthma exacerbations and influenza-related illness. The reasons are not precisely known, but may be due to handwashing, masks and social/physical distancing that reduced the incidence of other respiratory infections, including influenza.521"
    },
    {
        "id": "doc_4072",
        "document": "During the pandemic, advise patients with asthma to continue taking their prescribed asthma medications, particularly inhaled corticosteroid (ICS)-containing medications, and oral corticosteroids (OCS) if prescribed"
    },
    {
        "id": "doc_4073",
        "document": "It is important for patients to continue taking their prescribed asthma medications as usual during the COVID-19 pandemic. This includes ICS-containing medications (alone or in combination with a LABA, and add-on therapy including biologic therapy for severe asthma. Stopping ICS often leads to potentially dangerous worsening of asthma.\n\n3. Treating to control symptoms and minimize future risk\n\n109"
    },
    {
        "id": "doc_4074",
        "document": "See Chapter 3.2 (p.53) for information about asthma medications and regimens and non-pharmacologic strategies, and Chapter 3.3 (p.98) for guided asthma self-management education and skills training."
    },
    {
        "id": "doc_4075",
        "document": "For a small proportion of patients with severe asthma, long-term OCS may sometimes be needed, and it is very dangerous to stop these suddenly. See Chapter 3.5 (p.120) for advice about investigation and management of difficult- to-treat and severe asthma, including addition of biologic therapy for minimizing use of OCS.\n\nAdvise patients to discuss with you before stopping any asthma medication.\n\nMake sure that all patients have a written asthma action plan"
    },
    {
        "id": "doc_4076",
        "document": "A written action plan (printed, digital or pictorial) tells the patient how to recognize worsening asthma, how to increase their reliever and maintenance medications, and when to seek medical help. A short course of OCS may be needed during severe asthma flare-ups (exacerbations). See Box 4-2 (p.146) for more information about specific action plan options for increasing reliever medications (or reliever and maintenance medications), depending on the patient\u2019s usual therapeutic regimen."
    },
    {
        "id": "doc_4077",
        "document": "At present, there is no clear evidence about how to distinguish between worsening asthma due to respiratory viral infections such as rhinovirus and influenza, and COVID-19.\n\nIf local risk of COVID-19 is moderate or high, avoid use of nebulizers where possible due to the risk of transmitting infection to other patients/family and to healthcare workers"
    },
    {
        "id": "doc_4078",
        "document": "Nebulizers can transmit respiratory viral particles across distances of at least 1 m. Use of nebulizers for delivering bronchodilator therapy is mainly restricted to management of life-threatening asthma in acute care settings. Instead, to deliver short-acting beta2-agonist for acute asthma in adults and children, use a pressurized metered-dose inhaler and spacer, with a mouthpiece or tightly fitting face mask, if required. Check the manufacturer\u2019s instructions about whether a spacer can be"
    },
    {
        "id": "doc_4079",
        "document": "autoclaved. If not (as is the case for many types of spacers), or if in doubt, spacers should be restricted to single patient use. If use of a nebulizer is needed in settings where COVID-19 infection is possible, strict infection control procedures should be followed."
    },
    {
        "id": "doc_4080",
        "document": "Remind patients not to share inhaler devices or spacers with family members, to avoid transmitting infection."
    },
    {
        "id": "doc_4081",
        "document": "Avoid spirometry in patients with confirmed/suspected COVID-19\n\nIn healthcare facilities, follow local COVID-19 testing recommendations and infection control procedures if spirometry or peak flow measurement is needed.25 Use of an in-line filter minimizes the risk of transmission during spirometry, but many patients cough after performing spirometry; before performing spirometry, coach the patient to stay on the mouthpiece if they feel the need to cough."
    },
    {
        "id": "doc_4082",
        "document": "The US Centers for Disease Control and Prevention (CDC) recommendations are found here. If spirometry is not available due to local infection control restrictions, and information about lung function is needed, consider asking patients to monitor lung function at home."
    },
    {
        "id": "doc_4083",
        "document": "Follow infection control recommendations if other aerosol-generating procedures are needed\n\nOther aerosol-generating procedures include oxygen therapy (including with nasal prongs), sputum induction, manual ventilation, non-invasive ventilation and intubation. CDC recommendations are found here. Follow local health advice about hygiene strategies and use of personal protective equipment, as new information becomes available in your country or region."
    },
    {
        "id": "doc_4084",
        "document": "The CDC website provides up-to-date information about COVID-19 for health professionals here, and for patients here. The website of the World Health Organization (WHO) provides comprehensive advice for health professionals and health systems about prevention and management of COVID-19 here.\n\n110\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4085",
        "document": "Management of asthma if the patient acquires COVID-19\n\nPeople with asthma who acquire COVID-19 are not at higher risk of severe COVID-19. However, be aware that those with poorly controlled asthma (e.g. recent need for OCS) are at higher risk of hospitalization for severe disease if they acquire COVID-19.516,519,520 Advise patients to continue taking their usual asthma medications. Patients with severe asthma should continue biologic therapy or OCS, if prescribed."
    },
    {
        "id": "doc_4086",
        "document": "To reduce the risk of transmitting infection, as above, avoid use of nebulizers where possible (use pMDI and spacer instead), avoid spirometry, and instruct patients to avoid sharing of inhalers/spacers."
    },
    {
        "id": "doc_4087",
        "document": "Before prescribing antiviral therapies, consult local prescribing guidelines. Check carefully for potential interactions between asthma therapy and COVID-19 therapy. For example, ritonavir-boosted nirmatrelvir (NMV/r) is a potent CYP3A4 inhibitor. While this is unlikely to cause clinically important corticosteroid-related adverse effects, because of the short duration of anti-COVID-19 treatment, be cautious if considering prescribing NMV/r for patients taking ICS- salmeterol or ICS-vilanterol,"
    },
    {
        "id": "doc_4088",
        "document": "as the interaction may increase cardiac toxicity of the LABA.141 Product information indicates that for patients taking ICS-salmeterol or ICS-vilanterol, concomitant treatment with CYP3A4 inhibitors is not recommended. Some drug interaction websites advise stopping ICS-salmeterol or ICS-vilanterol during NMV/r treatment and for a few days afterwards, but this may increase the risk of an asthma exacerbation. Instead, consider prescribing alternative antiviral therapy (if available) or switching"
    },
    {
        "id": "doc_4089",
        "document": "to ICS alone or ICS-formoterol (if available) for the duration of NVM/r therapy and a further 5 days.141 If switching to a different inhaler, remember to teach correct technique with the new inhaler."
    },
    {
        "id": "doc_4090",
        "document": "Advise people with asthma to be up to date with COVID-19 vaccines"
    },
    {
        "id": "doc_4091",
        "document": "Many types of COVID-19 vaccines have been studied and are in use. New evidence about the vaccines, including in people with asthma, will emerge over time. In general, allergic reactions to the vaccines are rare. Patients with a history of severe allergic reaction to a COVID-19 vaccine ingredient (e.g., polyethylene glycol for Pfizer/BioNTech or Moderna, or polysorbate 80 for AstraZeneca or J&J/Janssen) should receive a different COVID-19 vaccine. However, people with anaphylaxis to foods, insect"
    },
    {
        "id": "doc_4092",
        "document": "venom, or other medications can safely receive COVID-19 vaccines. More details from the US Advisory Committee on Immunization Practices (ACIP) are here. As always, patients should speak to their healthcare provider if they have concerns. Follow local advice about monitoring patients after COVID-19 vaccination."
    },
    {
        "id": "doc_4093",
        "document": "Usual vaccine precautions apply. For example, ask if the patient has a history of allergy to any components of the vaccine, and if the patient has a fever or another infection, delay vaccination until they are well.\n\nFor people with severe asthma, GINA suggests that, if possible, the first dose of biologic therapy and COVID-19 vaccine should not be given on the same day, to allow adverse effects of either to be more easily distinguished."
    },
    {
        "id": "doc_4094",
        "document": "Remind people with asthma to have an annual influenza vaccination (p.87). CDC (advice here) now advises that influenza vaccine and COVID-19 vaccine can be given on the same day.\n\nCurrent advice from the CDC is that where there is substantial transmission of COVID-19, people will be better protected, even if they are fully vaccinated, if they wear a mask in indoor public settings. Further details are here."
    },
    {
        "id": "doc_4095",
        "document": "Additional advice about management of asthma in the context of COVID-19 will be posted on the GINA website (www.ginasthma.org) as it becomes available.\n\n3. Treating to control symptoms and minimize future risk\n\n111"
    },
    {
        "id": "doc_4096",
        "document": "MANAGING ASTHMA IN SPECIFIC POPULATIONS OR SETTINGS\n\nThis section includes brief advice about managing asthma in specific populations or settings in which the usual treatment approach may need to be modified. Also refer to the Diagnosis of respiratory symptoms in other settings section of Chapter 1 (p.30).\n\nLow- and middle-income countries"
    },
    {
        "id": "doc_4097",
        "document": "Clinical features\n\nIn 2019, 96% of asthma deaths and 84% of disability-adjusted life years (DALYs) were in low- and middle-income countries (LMICs).4 Symptoms of asthma are similar world-wide, but patient language may differ, and comorbidities may vary depending on environmental exposures such as smoking and biomass fuel exposure and incidence of chronic respiratory infections from tuberculosis and HIV/AIDS."
    },
    {
        "id": "doc_4098",
        "document": "Management\n\nThe fundamental principles and aims of asthma treatment are the same in LMICs as in high-income countries, but common barriers to effective long-term asthma care include the lack of availability and affordability of inhaled medicines, and prioritization of acute care over chronic care by healthcare systems.4,7"
    },
    {
        "id": "doc_4099",
        "document": "Recommendations by WHO and the International Union Against Tuberculosis and Lung Disease (The Union)522 form the basis of treatments offered in many LMICs.7 The WHO Model List of Essential Medicines523 includes ICS, combination ICS-formoterol, and bronchodilators. Spacers are included in the WHO list of essential technology but are rarely available due to obstacles to their manufacture or purchase, practical issues of cleaning, and inconvenience for ambulatory use. Effective spacers can be made"
    },
    {
        "id": "doc_4100",
        "document": "at no cost from plastic drink bottles.524"
    },
    {
        "id": "doc_4101",
        "document": "Medicines selected as \u2018essential\u2019 are not necessarily the most effective or convenient, particularly for patients with more severe disease, and a limited choice does not allow for consideration of patient preferences and likelihood of adherence. However, ICS-containing medications, when provided for large populations, have achieved impressive reductions in mortality and morbidity,525 including in LMICs. In Brazil, government policy ensuring nationwide easy access to ICS, at no cost to patients,"
    },
    {
        "id": "doc_4102",
        "document": "was associated with a 34% reduction in hospitalizations for asthma.168 Prescribing ICS-formoterol as the symptom reliever, with (GINA Steps 3\u20135) or without (Steps 1\u20132) maintenance ICS-formoterol, provides the safest and most effective asthma treatment for adolescents and adults,167,213 and avoids the behavioral consequences of starting treatment with SABA alone."
    },
    {
        "id": "doc_4103",
        "document": "Inclusion of essential asthma medicines in formularies and guidelines does not assure sustained and equitable supply to patients. The supply of medicines in many LMICs tends to be sporadic for a wide variety of reasons, sometimes determined by the ability of governments to pay for supplies, issues relating to procurement, poor administration and record keeping, and problems in the supply chain, particularly to remote dispensaries.5,7"
    },
    {
        "id": "doc_4104",
        "document": "Availability of asthma medicines varies widely between LMICs, with some having only oral bronchodilators (salbutamol and theophylline tablets/solutions) supplemented from time to time with oral corticosteroids.9 Oral bronchodilators have a slow onset of action and more adverse effects than inhaled SABA, and even occasional courses of OCS are associated with a significant risk of short-term adverse effects such as pneumonia and sepsis,526 and, in adults, with long-term adverse effects including"
    },
    {
        "id": "doc_4105",
        "document": "osteoporosis and fragility fractures, cataract and diabetes.309 The largest (52 countries) survey of the accessibility and affordability of inhaled asthma medicines, conducted in 2011, reported that salbutamol was available in only half of public hospitals; ICS was available in fewer than one in five public pharmacies and not at all in 14 countries.527"
    },
    {
        "id": "doc_4106",
        "document": "Obtaining asthma medicines often represents a catastrophic household expense. A recent systematic review of published data on the availability, cost and affordability of essential medicines for asthma and COPD in LMICs found these to be largely unavailable and unaffordable particularly for ICS and combination ICS-LABA.528 This means that the\n\n112\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4107",
        "document": "essential cornerstone of treatment that achieves substantial reductions in morbidity and mortality is out of reach for the great majority of the world\u2019s children, adolescents and adults living with asthma."
    },
    {
        "id": "doc_4108",
        "document": "It is not acceptable in 2023 for clinicians to have to manage asthma with SABAs and oral corticosteroids instead of preventive ICS-containing treatments. The research community must develop and evaluate approaches designed to obviate barriers to care in resource-constrained settings. A World Health Assembly Resolution on equitable access to affordable care, including inhaled medicines, for children, adolescents and adults with asthma, wherever they live in the world, would be a valuable step"
    },
    {
        "id": "doc_4109",
        "document": "forward \u2013 as was recently achieved for the supply of insulin for diabetes.529 GINA strongly supports this initiative.5"
    },
    {
        "id": "doc_4110",
        "document": "In the meantime, in general, Track 2 treatment, although less effective in reducing asthma exacerbations, may be considered preferable in settings where current availability or affordability constrains the ability to implement Track 1 treatment. The \u201cother controller options\u201d in Box 3-12, though potentially less costly, may be considerably less effective (e.g., LTRAs) or more harmful (e.g., maintenance OCS), or not well supported by evidence especially in the low- resource setting (e.g., use of"
    },
    {
        "id": "doc_4111",
        "document": "a low-dose ICS inhaler whenever a SABA is taken for symptom relief). Of these three other controller options, the third would be closest to the preferred recommendations in Tracks 1 and 2, as it would ensure that an ICS was provided, at least during symptomatic periods.9"
    },
    {
        "id": "doc_4112",
        "document": "Adolescents\n\nClinical features\n\nCare of teenagers with asthma should take into account the rapid physical, emotional, cognitive and social changes that occur during adolescence. Asthma control may improve or worsen, although remission of asthma is seen more commonly in males than females.530 Exploratory and risk-taking behaviors such as smoking occur at a higher rate in adolescents with chronic diseases than in healthy adolescents."
    },
    {
        "id": "doc_4113",
        "document": "In a large meta-analysis of adherence with ICS by adolescents and young adults,174 overall adherence was 28%, and slightly higher in those <18 years (36%). However, pharmacy refill data provided lower estimates of adherence than self- report measures. Predictors of adherence included personality, illness perceptions, and treatment beliefs.\n\nManagement"
    },
    {
        "id": "doc_4114",
        "document": "General principles for managing chronic disease in adolescents have been published by WHO.531 Adolescents and their parent/caregivers should be encouraged in the transition towards asthma self-management by the adolescent.532 This may involve the transition from a pediatric to an adult health care facility. Transitioning should not be based on chronological age but on developmental stage and readiness, using formal tools to assess readiness at around 11\u2013 13 years (ideal timing/age not based on"
    },
    {
        "id": "doc_4115",
        "document": "evidence). Clinicians should aim to increase self-management, focusing consultations on areas in which the young person is not confident. Consider using technology to assist with adherence and guide young people to web-based apps and tools to improve knowledge of asthma. Awareness of asthma should be promoted to communities and peers."
    },
    {
        "id": "doc_4116",
        "document": "During consultations, the adolescent should be seen separately from the parent/caregiver so that sensitive issues such as smoking, adherence and mental health can be discussed privately, and confidentiality agreed. Information and self- management strategies should be tailored to the patient\u2019s stage of psychosocial development and desire for autonomy; adolescents are often focused on short-term rather than long-term outcomes. An empathic approach should be used to identify beliefs and behaviors"
    },
    {
        "id": "doc_4117",
        "document": "that may be barriers to optimal treatment; for example, adolescents may be concerned about the impact of treatment on their physical or sexual capabilities."
    },
    {
        "id": "doc_4118",
        "document": "Medication regimens should be tailored to the adolescent\u2019s needs and lifestyle, and reviews arranged regularly so that the medication regimen can be adjusted for changing needs. Information about local youth-friendly resources and support services should be provided, where available. In adolescents with mild asthma, use of as-needed low-dose ICS-formoterol reduced risk of severe exacerbations compared with SABA alone, and without the need for daily treatment. Change in height from baseline in"
    },
    {
        "id": "doc_4119",
        "document": "younger adolescents was significantly greater with as-needed ICS- formoterol than with daily low-dose ICS plus as-needed SABA.208"
    },
    {
        "id": "doc_4120",
        "document": "3. Treating to control symptoms and minimize future risk\n\n113\n\nExercise-induced bronchoconstriction (EIB)\n\nClinical features\n\nPhysical activity is an important stimulus for asthma symptoms for many patients, with symptoms and bronchoconstriction typically worsening after cessation of exercise. However, shortness of breath or wheezing during exercise may also relate to obesity or a lack of fitness, or to comorbid or alternative conditions such as inducible laryngeal obstruction.47,52\n\nManagement"
    },
    {
        "id": "doc_4121",
        "document": "Regular treatment with ICS significantly reduces EIB52 (Evidence A). Training and sufficient warm-up reduce the incidence and severity of EIB52 (Evidence A). Taking SABAs, LABAs or chromones prior to exercise prevents EIB (Evidence A), but tolerance to the protective effects of SABAs and LABAs against EIB develops with regular (more than once-daily) use (Evidence A).52 However, in a 6-week study in patients with mild asthma, low-dose budesonide- formoterol, taken as needed for relief of symptoms"
    },
    {
        "id": "doc_4122",
        "document": "and before exercise, was non-inferior for reducing EIB to regular daily ICS with as-needed SABA.214 More studies are needed, but this suggests that patients with mild asthma who are prescribed as-needed low-dose ICS-formoterol to prevent exacerbations and control symptoms can use the same medication prior to exercise, if needed, and do not need to be prescribed a SABA for pre-exercise use (Evidence B). Chromone pMDIs have been discontinued globally."
    },
    {
        "id": "doc_4123",
        "document": "Breakthrough EIB often indicates poorly controlled asthma, and stepping up ICS-containing treatment (after checking inhaler technique and adherence) generally results in the reduction of exercise-related symptoms.\n\nAthletes\n\nClinical features"
    },
    {
        "id": "doc_4124",
        "document": "Athletes, particularly those competing at a high level, have an increased prevalence of various respiratory conditions compared to non-athletes. They experience a higher prevalence of asthma, EIB, allergic or non-allergic rhinitis, chronic cough, inducible laryngeal obstruction, and recurrent respiratory infections. Airway hyperresponsiveness is common in elite athletes, often without reported symptoms. Asthma in elite athletes is commonly characterized by less correlation between symptoms and"
    },
    {
        "id": "doc_4125",
        "document": "pulmonary function; higher lung volumes and expiratory flows; less eosinophilic airway inflammation; more difficulty in controlling symptoms; and some improvement in airway dysfunction after cessation of training."
    },
    {
        "id": "doc_4126",
        "document": "Management"
    },
    {
        "id": "doc_4127",
        "document": "Preventative measures to avoid high exposure to air pollutants, allergens (if sensitized) and chlorine levels in pools, particularly during training periods, should be discussed with the athlete. They should avoid training in extreme cold or pollution (Evidence C), and the effects of any therapeutic trials of asthma medications should be documented. Adequate anti-inflammatory therapy, especially ICS, is advised; minimization of use of beta2-agonists will help to avoid the development of"
    },
    {
        "id": "doc_4128",
        "document": "tolerance.52 Information on treatment of exercise-induced asthma in athletes can be found in a Joint Task Force Report prepared by the European Respiratory Society, the European Academy of Allergy and Clinical Immunology, and Global Allergy and Asthma European Network (GA(2)LEN)533 and on the World Anti-Doping Agency website (www.wada-ama.org)."
    },
    {
        "id": "doc_4129",
        "document": "Pregnancy\n\nClinical features\n\nAsthma control often changes during pregnancy; in approximately one-third of women asthma symptoms worsen, in one-third they improve, and in the remaining one-third they remain unchanged.534 Exacerbations are common in pregnancy, particularly in the second trimester.106 Exacerbations and poor asthma control during pregnancy may be due to mechanical or hormonal changes, or to cessation or reduction of asthma medications due to concerns by the mother\n\n114"
    },
    {
        "id": "doc_4130",
        "document": "3. Treating to control symptoms and minimize future risk\n\nand/or the health care provider. Pregnant women appear to be particularly susceptible to the effects of viral respiratory infections,535 including influenza."
    },
    {
        "id": "doc_4131",
        "document": "Exacerbations and poor symptom control are associated with worse outcomes for both the baby (pre-term delivery, low birth weight, increased perinatal mortality) and the mother (pre-eclampsia).106 Risk factors for asthma exacerbations during pregnancy include severe asthma, multiparity, black ethnicity, depression and anxiety, current smoking, age >35 years and obesity. Addressing these risk factors may not only reduce the risk of exacerbations, but also the risk of adverse perinatal outcomes.536"
    },
    {
        "id": "doc_4132",
        "document": "If asthma is well controlled throughout pregnancy there is little or no increased risk of adverse maternal or fetal complications.54"
    },
    {
        "id": "doc_4133",
        "document": "Management"
    },
    {
        "id": "doc_4134",
        "document": "Although there is a general concern about any medication use in pregnancy, the advantages of actively treating asthma in pregnancy markedly outweigh any potential risks of usual asthma medications54 (Evidence A). For this reason, using medications to achieve good symptom control and prevent exacerbations is justified even when their safety in pregnancy has not been unequivocally proven. Use of ICS, beta2-agonists, montelukast or theophylline is not associated with an increased incidence of fetal"
    },
    {
        "id": "doc_4135",
        "document": "abnormalities.537"
    },
    {
        "id": "doc_4136",
        "document": "Importantly, ICS reduce the risk of exacerbations of asthma during pregnancy54,538,539 (Evidence A), and cessation of ICS during pregnancy is a significant risk factor for exacerbations106 (Evidence A). A study using administrative data reported that uncontrolled maternal asthma increased the risk of early-onset asthma in the offspring.540 One study reported that a treatment algorithm in non-smoking pregnant women based on monthly FeNO and ACQ was associated with significantly fewer"
    },
    {
        "id": "doc_4137",
        "document": "exacerbations and better fetal outcomes than an algorithm based only on ACQ.541 However, the ACQ-only algorithm did not reflect current clinical recommendations, as LABA was introduced only after ICS had been increased to medium dose, and ICS could be stopped; 58% of women in the ACQ-only group were being treated without ICS by the end of pregnancy. In a follow-up study after 4-6 years, the prevalence of asthma was over 50% lower both in children of women in the FeNO group and in children of"
    },
    {
        "id": "doc_4138",
        "document": "women receiving ICS in the ACQ group, compared with women in the clinical group who did not receive ICS.542 Use of ICS in early pregnancy (before randomization at weeks 12\u201320) also appeared to be protective for asthma in the child.542"
    },
    {
        "id": "doc_4139",
        "document": "On balance, given the evidence in pregnancy and infancy for adverse outcomes from exacerbations during pregnancy (Evidence A),54 including due to lack of ICS or poor adherence,106 and evidence for safety of usual doses of ICS and LABA (Evidence A),537 a low priority should be placed on stepping down treatment (however guided) until after delivery (Evidence D), and ICS should not be stopped in preparation for pregnancy or during pregnancy (Evidence C)."
    },
    {
        "id": "doc_4140",
        "document": "Despite lack of evidence for adverse effects of asthma treatment in pregnancy, many women and doctors remain concerned.543 Pregnant patients with asthma should be advised that poorly controlled asthma, and exacerbations, provide a much greater risk to their baby than do current asthma treatments. Educational resources about asthma management during pregnancy may provide additional reassurance.544 During pregnancy, monthly monitoring of asthma is recommended.544 It is feasible for this to be"
    },
    {
        "id": "doc_4141",
        "document": "achieved by pharmacist-clinician collaboration, with monthly telephone monitoring of asthma symptom control.545 One observational study found that pregnant women whose asthma was well controlled without controller therapy and who had no history of previous exacerbations were at low risk for exacerbations during pregnancy.546 However, such women should still be closely monitored."
    },
    {
        "id": "doc_4142",
        "document": "For women with severe asthma, evidence on use of biologic therapies during pregnancy is scarce.547 A registry study found no evidence of an increased risk of major congenital malformations when mothers received omalizumab during pregnancy. Women should be counselled that the potential risks associated with biologic exposure during pregnancy need to be balanced against the risks for themselves and their children caused by uncontrolled asthma.548"
    },
    {
        "id": "doc_4143",
        "document": "Respiratory infections should be monitored and managed appropriately during pregnancy.535 During acute asthma exacerbations, pregnant women may be less likely to be treated appropriately than non-pregnant patients.106 To avoid fetal hypoxia, it is important to manage acute asthma exacerbations during pregnancy aggressively with SABA, oxygen, and early administration of systemic corticosteroids.\n\n3. Treating to control symptoms and minimize future risk\n\n115"
    },
    {
        "id": "doc_4144",
        "document": "During labor and delivery, usual maintenance medications should be taken, with reliever if needed. Acute exacerbations during labor and delivery are uncommon, but bronchoconstriction may be induced by hyperventilation during labor, and should be managed with SABA. Neonatal hypoglycemia may be seen, especially in preterm babies, when high doses of beta-agonists have been given within the last 48 hours prior to delivery. If high doses of SABA have been given during labor and delivery, blood"
    },
    {
        "id": "doc_4145",
        "document": "glucose levels should be monitored in the baby (especially if preterm) for the first 24 hours.549"
    },
    {
        "id": "doc_4146",
        "document": "A review of asthma guidelines for the management of asthma during pregnancy highlighted the need for greater clarity in current recommendations and the need for more RCTs among pregnant asthma patients.550\n\nWomen \u2013 perimenstrual asthma (catamenial asthma)"
    },
    {
        "id": "doc_4147",
        "document": "Clinical features\n\nIn approximately 20% of women, asthma is worse in the premenstrual phase. These women tend to be older, have more severe asthma, a higher BMI, a longer duration of asthma, and a greater likelihood of aspirin-exacerbated respiratory disease (AERD). They more often have dysmenorrhea, premenstrual syndrome, shorter menstrual cycles, and longer menstrual bleeding. The role of hormone levels and systemic inflammation remains unclear.551"
    },
    {
        "id": "doc_4148",
        "document": "Management\n\nIn addition to the usual strategies for management of asthma, oral contraceptives and/or leukotriene receptor antagonists may be helpful (Evidence D).551 Further research is needed.\n\nOccupational asthma"
    },
    {
        "id": "doc_4149",
        "document": "Clinical features\n\nIn the occupational setting, rhinitis often precedes the development of asthma (see p.30 regarding diagnosis of occupational asthma). Once a patient has become sensitized to an occupational allergen, the level of exposure necessary to induce symptoms may be extremely low; resulting exacerbations become increasingly severe, and with continued exposure, persistent symptoms and irreversible airflow limitation may result.49\n\nManagement"
    },
    {
        "id": "doc_4150",
        "document": "Detailed information is available in evidence-based guidelines about management of occupational asthma.49 All patients with adult-onset asthma should be asked about their work history and other exposures (Evidence A). The early identification and elimination of occupational sensitizers and the removal of sensitized patients from any further exposure are important aspects of the management of occupational asthma (Evidence A). Attempts to reduce occupational exposure have been successful,"
    },
    {
        "id": "doc_4151",
        "document": "especially in industrial settings.49 Cost-effective minimization of latex sensitization can be achieved by using non-powdered low-allergen gloves instead of powdered latex gloves.49 Patients with suspected or confirmed occupational asthma should be referred for expert assessment and advice, if this is available, because of the economic and legal implications of the diagnosis (Evidence A)."
    },
    {
        "id": "doc_4152",
        "document": "The elderly\n\nClinical features"
    },
    {
        "id": "doc_4153",
        "document": "Lung function generally decreases with longer duration of asthma and increasing age, due to stiffness of the chest wall, reduced respiratory muscle function, loss of elastic recoil and airway wall remodeling. Older patients may not report asthma symptoms, and may attribute breathlessness to normal aging or comorbidities such as cardiovascular disease and obesity.552-554 Among the elderly, there is no increased risk of cardiovascular disease among those with asthma, compared with those without"
    },
    {
        "id": "doc_4154",
        "document": "asthma, except in current or former smokers.555 Comorbid arthritis may contribute to reduced exercise capacity and lack of fitness, and make inhaler device use difficult. Asthma costs may be higher amongst older patients, because of higher hospitalization rates and medication costs.553"
    },
    {
        "id": "doc_4155",
        "document": "116\n\n3. Treating to control symptoms and minimize future risk\n\nManagement"
    },
    {
        "id": "doc_4156",
        "document": "Decisions about management of asthma in older people with asthma need to take into account both the usual goals of symptom control and risk minimization and the impact of comorbidities, concurrent treatments and lack of self- management skills.552,553 Data on efficacy of asthma medications in the elderly are limited because these patients are often excluded from major clinical trials. Side-effects of beta2-agonists such as cardiotoxicity, and corticosteroid side- effects such as skin bruising,"
    },
    {
        "id": "doc_4157",
        "document": "osteoporosis and fragility fractures,556 and cataracts, are more common in the elderly than in younger adults.552 Clearance of theophylline is also reduced.552 Elderly patients should be asked about all of the other medications they are taking, including eye-drops, and potential drug interactions should be considered. Factors such as arthritis, muscle weakness, impaired vision and inspiratory flow should be considered when choosing inhaler devices for older patients,553,557 and inhaler technique"
    },
    {
        "id": "doc_4158",
        "document": "should be checked at each visit. Older patients may have difficulties with complex medication regimens, and prescribing of multiple inhaler devices should be avoided if possible. Large print versions may be needed for written information such as asthma action plans. Patients with cognitive impairment may require a carer to help them use their asthma medications. For diagnosis and initial management of patients with asthma-COPD overlap, see Chapter 5, p.159."
    },
    {
        "id": "doc_4159",
        "document": "Aspirin-exacerbated respiratory disease (AERD)\n\nClinical features"
    },
    {
        "id": "doc_4160",
        "document": "The clinical picture and course of AERD (previously called aspirin-induced asthma) are well established.371 It starts with nasal congestion and anosmia, and progresses to chronic rhinosinusitis with nasal polyps that re-grow rapidly after surgery. Asthma and hypersensitivity to aspirin and NSAIDs develop subsequently. Following ingestion of aspirin or NSAIDs, an acute asthma attack develops within minutes to 1\u20132 hours. It is usually accompanied by rhinorrhea, nasal obstruction, conjunctival"
    },
    {
        "id": "doc_4161",
        "document": "irritation, and scarlet flush of the head and neck, and may sometimes progress to severe bronchospasm, shock, loss of consciousness, and respiratory arrest.558,559 AERD is more likely to be associated with low lung function and severe asthma,560,561 and with increased need for emergency care.561 The prevalence of AERD is 7% in general adult asthma populations, and 15% in severe asthma.561,562"
    },
    {
        "id": "doc_4162",
        "document": "Diagnosis"
    },
    {
        "id": "doc_4163",
        "document": "A history of exacerbation following ingestion of aspirin or other NSAIDs is highly suggestive of AERD. Aspirin challenge (oral, bronchial or nasal) is the gold standard for diagnosis563,564 as there are no reliable in vitro tests, but oral aspirin challenge tests must only be conducted in a specialized center with cardiopulmonary resuscitation capabilities because of the high risk of severe reactions.563,564 Bronchial (inhalational) and nasal challenges with lysine aspirin are safer than oral"
    },
    {
        "id": "doc_4164",
        "document": "challenges and may be safely performed in allergy centers.564,565"
    },
    {
        "id": "doc_4165",
        "document": "Management"
    },
    {
        "id": "doc_4166",
        "document": "Patients with AERD should avoid aspirin or NSAID-containing products and other medications that inhibit cyclooxygenase-1 (COX-1), but this does not prevent progression of the disease. Where an NSAID is indicated for other medical conditions, a COX-2 inhibitor (e.g. celecoxib or etoricoxib), or paracetamol (acetaminophen), may be considered566,567 with appropriate health care provider supervision and observation for at least 2 hours after administration568 (Evidence B). ICS are the mainstay of"
    },
    {
        "id": "doc_4167",
        "document": "asthma therapy in AERD, but OCS are sometimes required; LTRA may also be useful559,568 (Evidence B), but note the 2020 FDA warning about adverse effects with montelukast.236 See Chapter 3.5 (p.120) for treatment options for patients with severe asthma. An additional option is aspirin desensitization, which may be conducted under specialist care in a clinic or hospital.569 Desensitization to aspirin followed by daily aspirin treatment can significantly improve upper respiratory symptoms and"
    },
    {
        "id": "doc_4168",
        "document": "overall quality of life, decrease recurrence of nasal polyps, reduce the need for OCS and sinus surgery, and improve nasal and asthma scores, but few double-blind studies have examined asthma outcomes.564,570,571 Aspirin desensitization is associated with a significantly increased risk of adverse effects such as gastritis and gastrointestinal bleeding.571"
    },
    {
        "id": "doc_4169",
        "document": "3. Treating to control symptoms and minimize future risk\n\n117\n\nAllergic bronchopulmonary aspergillosis (ABPA)"
    },
    {
        "id": "doc_4170",
        "document": "Clinical features\n\nAllergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disease characterized by repeated episodes of wheezing, fleeting pulmonary opacities and development of bronchiectasis, sometimes with malaise, weight loss and hemoptysis. Some patients expectorate brownish sputum plugs. ABPA is most commonly diagnosed in people with asthma or cystic fibrosis, due to a hypersensitivity response to Aspergillus fumigatus, a common indoor and outdoor mold."
    },
    {
        "id": "doc_4171",
        "document": "Diagnosis\n\nDiagnosis of ABPA is based on composite criteria including immediate hypersensitivity reaction to A. fumigatus, total serum IgE, specific IgG to A. fumigatus, radiological features and blood eosinophils.572 Sensitization to fungal allergens, without the full picture of ABPA, is often found in asthma, particularly in severe asthma, where it is sometimes called \u2018severe asthma with fungal sensitization\u2019.\n\nManagement"
    },
    {
        "id": "doc_4172",
        "document": "Current first-line therapy is with oral corticosteroids (e.g., a 4-month tapering course), with itraconazole reserved for those with exacerbations or requiring long-term OCS.573,574 575 Clinicians should be aware of the potential for drug interactions between itraconazole (a cytochrome P450 inhibitor) and asthma medications. These interactions may lead to increased risk of ICS adverse effects such as adrenal suppression and Cushing\u2019s syndrome, and may increase the risk of cardiovascular adverse"
    },
    {
        "id": "doc_4173",
        "document": "effects of some LABAs (salmeterol and vilanterol).141 Concomitant use is not recommended, so it may be appropriate to switch ICS-LABA treatment to an alternative product such as budesonide- formoterol or mometasone-formoterol for the duration of treatment with itraconazole.141"
    },
    {
        "id": "doc_4174",
        "document": "A randomized double-blind placebo-controlled study in patients with severe asthma and ABPA found significantly fewer exacerbations with omalizumab (anti-IgE) than placebo.576 There have also been case series reports of treatment of ABPA with benralizumab, dupilumab and mepolizumab.\n\nIn patients with ABPA and bronchiectasis, regular physiotherapy and daily drainage are recommended. Patients should be referred for specialist investigation and care if available."
    },
    {
        "id": "doc_4175",
        "document": "Difficult-to-treat and severe asthma are covered in the next section, Chapter 3.5.\n\nSurgery and asthma\n\nClinical features\n\nThere is no evidence of increased peri-operative risk for the general asthma population.577 However, there is an increased risk for patients with COPD,577 and this may also apply to asthma patients with reduced FEV1. The incidence of severe peri-operative bronchospasm in people with asthma is low, but it may be life threatening.578\n\nManagement"
    },
    {
        "id": "doc_4176",
        "document": "For elective surgery, meticulous attention should be paid pre-operatively to achieving good asthma control, as detailed elsewhere in this chapter, especially for patients with more severe asthma, uncontrolled symptoms, exacerbation history, or persistent airflow limitation (Evidence B).578 For patients requiring emergency surgery, the risks of proceeding without first achieving good asthma control should be weighed against the need for immediate surgery. Patients taking long-term high-dose ICS"
    },
    {
        "id": "doc_4177",
        "document": "or who have received OCS for more than 2 weeks during the previous 6 months should receive hydrocortisone peri-operatively as they are at risk of adrenal crisis in the context of surgery (Evidence B).579 More immediate intra-operative issues relating to asthma management are reviewed in detail elsewhere.578 For all patients, maintaining their prescribed ICS-containing therapy throughout the peri-operative period is important."
    },
    {
        "id": "doc_4178",
        "document": "118\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4179",
        "document": "Air travel and asthma\n\nPractical advice for air travel by people with respiratory disease was published by the British Thoracic Society (BTS) in 2022.580 The advice for people with asthma included pre-flight optimization of treatment, carrying all asthma medications and spacer (if used) in the cabin to allow immediate access during the flight (and in case checked luggage is mislaid), and carrying a copy of the patient\u2019s asthma action plan."
    },
    {
        "id": "doc_4180",
        "document": "3. Treating to control symptoms and minimize future risk\n\n119\n\n3.5. DIFFICULT-TO-TREAT AND SEVERE ASTHMA IN ADULTS AND ADOLESCENTS\n\nKEY POINTS\n\nWhat are difficult to treat and severe asthma?\n\n\u2022 Difficult-to-treat asthma is asthma that is uncontrolled despite prescribing of medium or high-dose ICS-LABA treatment or that requires high-dose ICS-LABA treatment to maintain good symptom control and reduce exacerbations. It does not mean a \u2018difficult patient\u2019."
    },
    {
        "id": "doc_4181",
        "document": "\u2022 Severe asthma is asthma that is uncontrolled despite adherence with optimized high-dose ICS-LABA therapy and treatment of contributory factors, or that worsens when high-dose treatment is decreased. Approximately 3\u201310% of people with asthma have severe asthma.\n\n\u2022 Severe asthma places a large physical, mental, emotional, social and economic burden on patients. It is often associated with multimorbidity."
    },
    {
        "id": "doc_4182",
        "document": "How should these patients be assessed?\n\n\u2022 Assess all patients with difficult-to-treat asthma to confirm the diagnosis of asthma, and to identify and manage factors that may be contributing to symptoms, poor quality of life, or exacerbations.\n\n\u2022 Refer for expert advice at any stage, or if asthma does not improve in response to optimizing treatment."
    },
    {
        "id": "doc_4183",
        "document": "\u2022 For patients with persistent symptoms and/or exacerbations despite high-dose ICS, the clinical or inflammatory phenotype should be assessed, as this may guide the selection of add-on treatment."
    },
    {
        "id": "doc_4184",
        "document": "Management of severe asthma\n\n\u2022 Depending on the inflammatory phenotype and other clinical features, add-on treatments for severe asthma include LAMA, LTRA, low-dose azithromycin (adults), and biologic agents for severe asthma.\n\n\u2022 Low-dose maintenance OCS should be considered only as a last resort if no other options are available, because of their serious long-term side-effects.\n\n\u2022 Assess the response to any add-on treatment, stop ineffective treatments, and consider other options."
    },
    {
        "id": "doc_4185",
        "document": "\u2022 Utilize specialist multidisciplinary team care for severe asthma, if available.\n\n\u2022 For patients with severe asthma, continue to optimize patient care in collaboration with the primary care clinician, and taking into account the patient\u2019s social and emotional needs.\n\n\u2022 Invite patients with severe asthma to enroll in a registry or clinical trial, if available and relevant, to help fill evidence gaps.\n\nSee Boxes 3-26 to 3-29 (starting on p.123) for the GINA severe asthma decision tree."
    },
    {
        "id": "doc_4186",
        "document": "Although the majority of patients can achieve the goal of well controlled asthma, some patients\u2019 asthma will not be well controlled even with optimal therapy. This section is also published separately as a GINA short guide for health professionals: Difficult-to-Treat and Severe Asthma in Adolescent and Adult Patients. Diagnosis and Management. V4.0, 2023 (the Severe Asthma Guide), available to download or order from the GINA website (www.ginasthma.org)."
    },
    {
        "id": "doc_4187",
        "document": "Other resources about severe asthma include an online toolkit published by the Australian Centre of Excellence in Severe Asthma (www.toolkit.severeasthma.org.au).\n\n120\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4188",
        "document": "DEFINITIONS: UNCONTROLLED, DIFFICULT-TO-TREAT AND SEVERE ASTHMA\n\nUnderstanding the definitions of difficult-to-treat and severe asthma starts with the concept of uncontrolled asthma.\n\nUncontrolled asthma includes one or both of the following:\n\n\u2022 Poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma)\n\nFrequent exacerbations (\u22652/year) requiring OCS, or serious exacerbations (\u22651/year) requiring hospitalization."
    },
    {
        "id": "doc_4189",
        "document": "Difficult-to-treat asthma159 is asthma that is uncontrolled despite prescribing of medium- or high-dose ICS with a second controller (usually a LABA) or with maintenance OCS, or that requires high-dose treatment to maintain good symptom control and reduce the risk of exacerbations.159 It does not mean a \u2018difficult patient\u2019. In many cases, asthma may appear to be difficult to treat because of modifiable factors such as incorrect inhaler technique, poor adherence, smoking or comorbidities, or"
    },
    {
        "id": "doc_4190",
        "document": "because the diagnosis is incorrect."
    },
    {
        "id": "doc_4191",
        "document": "Severe asthma159 is a subset of difficult-to-treat asthma (Box 3-15). It means asthma that is uncontrolled despite adherence with maximal optimized high-dose ICS-LABA treatment and management of contributory factors, or that worsens when high-dose treatment is decreased.159 At present, therefore, \u2018severe asthma\u2019 is a retrospective label. It is sometimes called \u2018severe refractory asthma\u2019159 since it is defined by being relatively refractory to high-dose inhaled therapy. However, with the advent"
    },
    {
        "id": "doc_4192",
        "document": "of biologic therapies, the word \u2018refractory\u2019 is no longer appropriate."
    },
    {
        "id": "doc_4193",
        "document": "Asthma is not classified as severe if it markedly improves when contributory factors such as inhaler technique and adherence are addressed.159"
    },
    {
        "id": "doc_4194",
        "document": "PREVALENCE: HOW MANY PEOPLE HAVE SEVERE ASTHMA?\n\nA study in the Netherlands estimated that around 3.7% of asthma patients have severe asthma, based on the number of patients prescribed high-dose ICS-LABA, or medium or high-dose ICS-LABA plus long-term OCS, who had poor symptom control (by Asthma Control Questionnaire) and had good adherence and inhaler technique (Box 3-15).581\n\nBox 3-25. What proportion of adults have difficult-to-treat or severe asthma?"
    },
    {
        "id": "doc_4195",
        "document": "00000 00000 000000 000000 000000 0000800 | 24% 17% 3.7% High intensity \u00a9 difficult-to-treat asthma @\u00ae severe asthma treatment = high intensity treatment = high intensity treatment = high dose ICS-LABA + poor symptom control + poor symptom control or medium dose + good adherence and ICS-LABA + OCS) inhaler technique\n\nSee list of abbreviations (p.10). Data from the Netherlands, reported by Hekking et al (2015)581\n\n3. Treating to control symptoms and minimize future risk\n\n121"
    },
    {
        "id": "doc_4196",
        "document": "IMPORTANCE: THE IMPACT OF SEVERE ASTHMA\n\nThe patient perspective\n\nPatients with severe asthma experience a heavy burden of symptoms, exacerbations and medication side-effects. Frequent shortness of breath, wheeze, chest tightness and cough interfere with day-to-day living, sleeping, and physical activity, and patients often have frightening or unpredictable exacerbations (also called attacks or severe flare-ups)."
    },
    {
        "id": "doc_4197",
        "document": "Medication side-effects are particularly common and problematic with OCS,308 which in the past were a mainstay of treatment for severe asthma. Adverse effects of long-term or frequent OCS include obesity, diabetes, osteoporosis and fragility fractures,556 cataracts, hypertension and adrenal suppression; psychological side-effects such as depression and anxiety are particularly concerning for patients.582 Even short-term use of OCS is associated with sleep disturbance, and increased risk of"
    },
    {
        "id": "doc_4198",
        "document": "infection, fracture and thromboembolism.526 Strategies to minimize need for OCS are therefore a high priority."
    },
    {
        "id": "doc_4199",
        "document": "Severe asthma often interferes with family, social and working life, limits career choices and vacation options, and affects emotional and mental health. Patients with severe asthma often feel alone and misunderstood, as their experience is so different from that of most people with asthma.582\n\nAdolescents with severe asthma"
    },
    {
        "id": "doc_4200",
        "document": "The teenage years are a time of great psychological and physiological development which can impact on asthma management. It is vital to ensure that the young person has a good understanding of their condition and treatment and appropriate knowledge to enable supported self-management. The process of transition from pediatric to adult care should help support the young person in gaining greater autonomy and responsibility for their own health and wellbeing. Severe asthma may improve over 3 years"
    },
    {
        "id": "doc_4201",
        "document": "in approximately 30% of male and female adolescents; the only predictor of asthma becoming non-severe was higher baseline blood eosinophils.583 Studies with longer follow-up time are needed."
    },
    {
        "id": "doc_4202",
        "document": "Healthcare utilization and costs\n\nSevere asthma has very high healthcare costs due to medications, physician visits, hospitalizations, and the costs of OCS side-effects. In a UK study, healthcare costs per patient were higher than for type 2 diabetes, stroke, or COPD.584 In a Canadian study, severe uncontrolled asthma was estimated to account for more than 60% of asthma costs.585"
    },
    {
        "id": "doc_4203",
        "document": "Patients with severe asthma and their families also bear a significant financial burden, not only for medical care and medications, but also through lost earnings and career choices."
    },
    {
        "id": "doc_4204",
        "document": "ASSESSMENT AND MANAGEMENT OF DIFFICULT-TO-TREAT AND SEVERE ASTHMA\n\nThe clinical decision tree starting on page 123, provides brief information about what should be considered in each phase of diagnosis and management of difficult-to-treat and severe asthma. The decision tree is divided into three broad areas:\n\n\u2022 Sections 1\u20134 (green) are for use in primary care and/or specialist care.\n\n\u2022 Sections 5\u20138 (blue) are mainly relevant to respiratory specialists."
    },
    {
        "id": "doc_4205",
        "document": "\u2022 Sections 9\u201310 (brown) are about maintaining ongoing collaborative care between the patient, primary care physician, specialist and other health professionals."
    },
    {
        "id": "doc_4206",
        "document": "Development of the Severe Asthma Guide and decision tree included extensive collaboration with experts in human- centered design to enhance the utility of these resources for end-users. This included translating existing high-level flowcharts and text-based information to a more detailed visual format, and applying information architecture and diagramming principles.\n\nThe decision tree is followed by more detailed information on each stage of assessment and management.\n\n122"
    },
    {
        "id": "doc_4207",
        "document": "3. Treating to control symptoms and minimize future risk\n\nBox 3-26. Decision tree \u2013 investigate and manage difficult to treat asthma in adult and adolescent patients"
    },
    {
        "id": "doc_4208",
        "document": "GP OR SPECIALIST CARE icult-to-treat asthma in adults and adolescents Investigate and manage \u2018Consider referring to specialist or severe asthma clinic at any stage DAGNOSIS: \u201cDifficult- to-treat T contiem e diagnoss \u2014L) 3 optimize management, \u2014L) 4 Review response atter >3 months asthma\u2122 (asthma/differential including: diagnoses) = Asthma education For adolescents and 2 Look for factors DIAGNOSS: adults with symptoms: = Optimize treatment (e.g. check and \u201cSevere If not done by now. refer to"
    },
    {
        "id": "doc_4209",
        "document": "andior exacerbations contributing to symptoms, cormect inhaler technique and e asthma\u2122 a specialist, if possible exacerbations and poor \u2018adherence; switch to ICS-formoterol dpqtmu\ufb01lnw quality of life: maintenance and reliever therapy, high dose ICS-LABA, i available) OQ\u2018 or taking maintenance - Incorrect inhaler technique = Consider - Suboptimal adherence interventions (e.g. smoking \u2018cessation, exercise, weight loss, mucus clearance, influenza and COVID-19 vaccination) i = Modifiable risk"
    },
    {
        "id": "doc_4210",
        "document": "factors and - Treat comorbidities and triggers at home or work, including modifiable risk factors \u2018Consider stepping down Restore previous dose mewn (if sensitzed); - Consider non-biologic add-on (ifused) \u2018medications such as beta-blockers. therapy (e.g. LABA. LAMA, and NSAIDs LMILTRA, if not used) = Consider trial of high dose ICS- \u00bb Overuse of SABA relievers LABA, if not used asthma become = Medication side effects uncontrolled when treatment is stepped difficulties Continue optimizing"
    },
    {
        "id": "doc_4211",
        "document": "GP OR SPECIALIST CARE\n\nSee list of abbreviations (p.10).\n\n3. Treating to control symptoms and minimize future risk\n\n123\n\nBox 3-27. Decision tree \u2013 assess and treat severe asthma phenotypes"
    },
    {
        "id": "doc_4212",
        "document": "SPECIALIST CARE; SEVERE ASTHMA CLINIC IF AVAILABLE Assess and treat severe asthma phenotypes Continue to optimize management as in section 3 (including inhaler technique, adherence, comorbidities, non-pharmacologic strategies) + P | L 5 Investigate further and \u2014L) 6 Assess the severe asthma phenotype \u2014L) 7 Consider other treatments \u2014%) provide patient support & Iz add-on Investigate for comorbidities/differential Could patient Type 2 biologic e yes diagnoses and treatirefer as appropriate have"
    },
    {
        "id": "doc_4213",
        "document": "Type 2 sirway Type 2 airway inflammafion therapy available/ Consider: CBC. CRF. IgG, IgA. IgM. inflammation? affordable? IgE. fungal precipitins; CXR and/or Consider adherence tests HRCT chest; DLCO; DEXA scan Consider increasing the ICS dose for 3-6 months = Consider add-on non-biclogic treatment for - Skin prick testing or specific IgE for =_T mmmsam specific Type 2 diinical phenotypes, .g. AERD. lm relevant allergens, if not already done 'ABPA. chronic rhinosinusitis, nasal polyposis. -"
    },
    {
        "id": "doc_4214",
        "document": "Consider screening for adrenal If add-on Type 2-targeted biologic therapy is insufficiency in patients taking Fmommm I atopic dermatitis maintenance OCS or high dose ICS \u2018Sputum eosinophils 22%. and/or Consider higher dose ICS, if not used - If blood eosinophils 2300/, look for \u2018Asthma is clinically allergen- Consider other add-on therapy and treat non-asthma causes, includ- (e-g- LAMA, LMALTRA, low dose azithromycin) ing parasites (e.g. Strongyloides = As last resort, consider add-on low dose"
    },
    {
        "id": "doc_4215",
        "document": "OCS, but (Repeat blood eosinophils and serology. or stool examination) FeNO up to 3x, at least 1-2 implement strategies to minimize side-effects - If hypereosinophilia e.g. 21500/ul, weeks after OCS or on lowest Stop ineffective add-on therapies consider causes such as EGPA possible OCS dose) Other directed testing (e.g. ANCA, CT Go to section 10 sinuses, BNP, echocardiogram) Note: these are not the criterta for based on clinical suspicion \u2018ado-on dioiogic therapy (see 8) _{Numd'lyplmm \u2018Consider"
    },
    {
        "id": "doc_4216",
        "document": "need for social/psychological Review the basics: differential diagnosis, inhaler technique. adherence, support Involve multidiscipiinary team care Avoid exposures (tobacco smoke, allergens, irritants) i available) Consider investigations (if available and not done) Invite patient to enroll in registry (if available) or clinical trial (if appropriate) \u2018Sputum induction - High resolution chest CT Bronchoscopy for altemative/additional diagnoses Consider trial of add-on treatments (if available and"
    },
    {
        "id": "doc_4217",
        "document": "not already tried) - LAMA Not currently eligible - Low dose azithromycin for T2-targeted biologic - Anti-IL4Re if taking maintenance OCS therapy - Anti-TSLP (but insufficient evidence in patients on maintenance OCS) - As last resort, consider add-on low dose OCS, but implement strategies \\ to minimize side-effects. Consider bronchial thermoplasty (+ registry) \u2018Stop ineffective add-on therapies Go to section 10 Check local eligibility criteria for specific biologic therapies as these may vary"
    },
    {
        "id": "doc_4218",
        "document": "from those listed"
    },
    {
        "id": "doc_4219",
        "document": "SPECIALIST CARE; SEVERE ASTHMA CLINIC IF AVAILABLE\n\nSee list of abbreviations (p.10).\n\n124\n\n3. Treating to control symptoms and minimize future risk\n\nBox 3-28. Decision tree \u2013 consider add-on biologic Type 2-targeted treatments"
    },
    {
        "id": "doc_4220",
        "document": "SPECIALIST CARE; SEVERE ASTHMA CLINIC IF AVAILABLE Assess and treat severe asthma phenotypes cont'd Continue to optimize management as in section 3 (including inhaler technique. adherence, comorbidities. non-pharmacologic strategies) 9 8 Consider add-on biologic Type 2-targeted treatments Eligibility Predictors of asthma response Anti-IgE (omaizumab) . - Consider add-on Type 2- What factors may predict good Extend trial to \u2018targeted biologic therapy hhmmh\u201chmmm' asthma response fo anti-IgE? 8-12"
    },
    {
        "id": "doc_4221",
        "document": "months\u2122 for patients with \u00ab Sensitization on skin prick testing or specific IgE - Blood eosinophils 2260/l ++ \u2018exacerbations or poor = Total serum IgE and weight within dosage range - FeNO 220 ppb + 'symptom control on high - Exacerbations in last year - Allergen-driven symptoms + 'dose ICS-LABA, who have T\"\"'*' + Childhood-onset asthma + Choose one if eligible\u2122 \u00ab Consider local payer trial for at least * Anti-IL5/ Anti-ILSR penralizumab, mepolizumab, reslizumab) 4 months and response?\u201d Good"
    },
    {
        "id": "doc_4222",
        "document": "response \u2018comorbidities and What factors may predict good to T24argeted therapy predictors of response Is kp\ufb01l\ufb02h\ufb02lmhmmm' \u2018asthma response to anti-IL5/5R? assess response when choosing between - Exacerbations in last year \u2018available therapies - Blood eosinophils, .g. 2150/l or 2300/l = More exacerbations in previous year +++ \u00ab Also consider cost, dosing = Adult-onset of asthma ++ frequency. route (SC or IV), STOP add-on patient preference = Nasal polyposis ++ \u2018Consider switching to a different"
    },
    {
        "id": "doc_4223",
        "document": "Type Anti-IL4Rx (dupilumab) What factors may predict good I3 the patient eligible for anti-IL4R\u00abx for severe eosinophilic/Type 2 asthma?\u2122 \u2018asthma response fo anti-IL4R\u00ab? if eligible\u2122 - Higher blood ecsinophils +++ - Exacerbations in last year no - Blood eosinophils 2150 and 1500/, or FeNO 225 ppb. - Higher FeNO +++ Which biologic \u2018or taking maintenance OCS is appropriate fo start first? Littiaino rssponse to T24argeted therapy Anti-TSLP (tezepelumab) \u2018What factors may predict good Is the patient"
    },
    {
        "id": "doc_4224",
        "document": "eligible for anti-TSLP for severe asthma?\" asthma response fo anti-TSLP? - Exacerbations in last year - Higher blood eosinophils +++ - Higher FeNO +++ S Ea\u2014 o evidence of Type 2 aiway inflammation \u2018No evidence of Type 2 airway inflammation. Go fo section 10 * Check local eligibilty crieria for specific biologic therapies as these may vary from those listed"
    },
    {
        "id": "doc_4225",
        "document": "SPECIALIST CARE; SEVERE ASTHMA CLINIC IF AVAILABLE\n\nevidence of Type 2 aiway inflammation\n\nSee list of abbreviations (p.10).\n\n3. Treating to control symptoms and minimize future risk\n\n125\n\nBox 3-29. Decision tree \u2013 monitor and manage severe asthma treatment"
    },
    {
        "id": "doc_4226",
        "document": "SPECIALIST AND PRIMARY CARE IN COLLABORATION Monitor / M ge severe asthma treatment \u2018Continue to optimize management \u00e9 g Review response \u2014 1 0 Continue to optimize management as in section 3, including: = Type 2 comorbidities e.g. nasal polyposis, atopic dermatitis. - Inhaler technique + Adherence - Patient satisfaction - Comorbidity management - Non-pharmacologic strategies + Patients\u2019 sociallemotional needs If good response to Type 2-targeted therapy - Re-evaluate the patient every 3-8 months\u2122"
    },
    {
        "id": "doc_4227",
        "document": "- Two-way communication with GP for ongoing care yes, continue at least moderate dose ICS-LABA Notes: \u00ab Order of reduction of treatments based on observed benefit, potential side-effects, cost and patient preference If no good response to Type 2-targeted therapy adherence, comorbidities, side-effects, emotional support - Consider high resolution chest CT (if not done) - Reassess phenotype and treatment options \u2122. induced sputum (\u00a5 available) - Consider add-on low dose azithromycin - Consider"
    },
    {
        "id": "doc_4228",
        "document": "bronchoscopy for altemative/additional diagnoses - As last resort, consider add-on low dose OCS, but implement - Consider bronchial thermoplasty (+ registry) = Do not stop ICS > No evidence of Type 2 ainway inflammation. Go to section 10 * Check local eligibiity criteria for specific biologic therapies as these may vary from those listed"
    },
    {
        "id": "doc_4229",
        "document": "SPECIALIST AND PRIMARY CARE IN COLLABORATION\n\nCheck local eligibiity criteria for specific biologic therapies as these may vary from those listed\n\nSee list of abbreviations (p.10).\n\n126\n\n3. Treating to control symptoms and minimize future risk\n\nINVESTIGATE AND MANAGE DIFFICULT-TO-TREAT ASTHMA IN ADULTS AND ADOLESCENTS\n\n1. CONFIRM THE DIAGNOSIS (ASTHMA OR DIFFERENTIAL DIAGNOSES)"
    },
    {
        "id": "doc_4230",
        "document": "Stages 1\u20135 can be carried out in primary or specialist care. A patient is classified as having difficult-to-treat asthma if they patient have persistent asthma symptoms and/or exacerbations despite prescribing of medium or high-dose ICS with another controller such as LABA, or maintenance OCS, or require high-dose ICS-LABA treatment to maintain good symptom control and prevent exacerbations. Difficult-to-treat asthma does not mean a \u2018difficult patient\u2019."
    },
    {
        "id": "doc_4231",
        "document": "Consider referral to a specialist or severe asthma clinic at any stage, particularly if:\n\n\u2022 There is difficulty confirming the diagnosis of asthma\n\n\u2022 Patient has frequent urgent healthcare utilization\n\n\u2022 Patient needs frequent or maintenance OCS\n\n\u2022 Occupational asthma is suspected\n\n\u2022 Food allergy or anaphylaxis, as this increases the risk of death\n\n\u2022 Symptoms are suggestive of infective or cardiac cause\n\n\u2022 Symptoms are suggestive of complications such as bronchiectasis"
    },
    {
        "id": "doc_4232",
        "document": "\u2022 Patient has multimorbidity."
    },
    {
        "id": "doc_4233",
        "document": "Are the symptoms due to asthma?\n\nPerform a careful history and physical examination to identify whether symptoms are typical of asthma, or are more likely due to an alternative diagnosis or comorbidity:\n\n\u2022 Dyspnea: COPD, obesity, cardiac disease, deconditioning\n\n\u2022 Cough: inducible laryngeal obstruction (also called vocal cord dysfunction, VCD), upper airway cough syndrome (also called post-nasal drip), gastro-esophageal reflux disease (GERD), bronchiectasis, ACE inhibitors"
    },
    {
        "id": "doc_4234",
        "document": "\u2022 Wheeze: obesity, COPD, tracheobronchomalacia, VCD.\n\nInvestigate according to clinical suspicion and age (see Box 1-5, p.30).\n\nHow can the diagnosis of asthma be confirmed?"
    },
    {
        "id": "doc_4235",
        "document": "Confirmation of the diagnosis is important, because in 12\u201350% of people assumed to have severe asthma, asthma is not found to be the correct diagnosis.586 Perform spirometry, before and after bronchodilator, to assess baseline lung function and seek objective evidence of variable expiratory airflow limitation. If initial bronchodilator responsiveness testing is negative (\u2264200 mL or \u226412% increase in FEV1), consider repeating after withholding bronchodilators or when symptomatic, or consider"
    },
    {
        "id": "doc_4236",
        "document": "stepping controller treatment up or down before further investigations such as bronchial provocation testing (see Box 1-3, p.28). Check full flow-volume curve to assess for upper airway obstruction. If spirometry is normal or is not available, provide the patient with a peak flow meter and diary for assessing variability; consider bronchial provocation testing if patient is able to withhold bronchodilators (SABA for at least 6 hours, LABA for up to 2 days depending on duration of action).32"
    },
    {
        "id": "doc_4237",
        "document": "Strategies for confirming the diagnosis of asthma in patients already taking ICS-containing treatment are shown in Box 1-3 (p.28)."
    },
    {
        "id": "doc_4238",
        "document": "Airflow limitation may be persistent in patients with long-standing asthma, due to remodeling of the airway walls, or limited lung development in childhood. It is important to document lung function when the diagnosis of asthma is first made. Specialist advice should be obtained if the history is suggestive of asthma but the diagnosis cannot be confirmed by spirometry.\n\n3. Treating to control symptoms and minimize future risk\n\n127"
    },
    {
        "id": "doc_4239",
        "document": "2. LOOK FOR FACTORS CONTRIBUTING TO SYMPTOMS AND EXACERBATIONS\n\nSystematically consider factors that may be contributing to uncontrolled symptoms or exacerbations, or poor quality of life, and that can be treated. The most important modifiable factors include:\n\nIncorrect inhaler technique (seen in up to 80% patients): ask the patient to show you how they use their inhaler; compare with a checklist or video.\n\n)"
    },
    {
        "id": "doc_4240",
        "document": "\u2022 Suboptimal adherence (up to 75% asthma patients): ask empathically about frequency of use (e.g., \u2018Many patients don\u2019t use their inhaler as prescribed. In the last 4 weeks, how many days a week have you been taking it \u2013 not at all, 1 day a week, 2, 3 or more?\u2019 or, \u2018Do you find it easier to remember your inhaler in the morning or the evening?\u2019 (see Box 3-23, p.102). Ask about barriers to medication use, including cost, and concerns about necessity or side-effects. Check dates on inhalers and"
    },
    {
        "id": "doc_4241",
        "document": "view dispensing data, if available. Electronic inhaler monitoring, if available, can be helpful in screening for poor adherence."
    },
    {
        "id": "doc_4242",
        "document": "\u2022 Comorbidities: review history and examination for comorbidities that can contribute to respiratory symptoms, exacerbations, or poor quality of life. These include anxiety and depression, obesity, deconditioning, chronic rhinosinusitis, inducible laryngeal obstruction, GERD, COPD, obstructive sleep apnea, bronchiectasis, cardiac disease, and kyphosis due to osteoporosis. Investigate according to clinical suspicion."
    },
    {
        "id": "doc_4243",
        "document": "\u2022 Modifiable risk factors and triggers: identify factors that increase the risk of exacerbations, e.g., smoking, environmental tobacco exposure, other environmental exposures at home or work including allergens (if sensitized), indoor and outdoor air pollution, molds and noxious chemicals, and medications such as beta- blockers or non-steroidal anti-inflammatory drugs (NSAIDs). For allergens, check for sensitization using skin prick testing or specific IgE."
    },
    {
        "id": "doc_4244",
        "document": "\u2022 Regular or over-use of SABAs: regular SABA use causes beta-receptor down-regulation and reduction in response,587 leading in turn to greater use. Over-use may also be habitual. Dispensing of \u22653 SABA canisters per year (corresponding to average use more than daily) is associated with increased risk of emergency department visit or hospitalization independent of severity,74,75 and dispensing of \u226512 canisters per year (one a month) is associated with substantially increased risk of death.75,100"
    },
    {
        "id": "doc_4245",
        "document": "Risks are higher with nebulized SABA.588"
    },
    {
        "id": "doc_4246",
        "document": "\u2022 Anxiety, depression and social and economic problems: these are very common in asthma, particularly in difficult asthma582 and contribute to symptoms, impaired quality of life, and poor adherence."
    },
    {
        "id": "doc_4247",
        "document": "\u2022 Medication side-effects: systemic effects, particularly with frequent or continuous OCS, or long-term high-dose ICS may contribute to poor quality of life and increase the likelihood of poor adherence. Local side-effects of dysphonia or thrush may occur with high-dose or potent ICS, especially if inhaler technique is poor. Consider drug interactions including risk of adrenal suppression with use of P450 inhibitors such as itraconazole."
    },
    {
        "id": "doc_4248",
        "document": "3. REVIEW AND OPTIMIZE MANAGEMENT\n\nReview and optimize treatment for asthma, and for comorbidities and risk factors identified in Section 2. For more details, see Chapter 3.4, p.106.\n\n\u2022 Provide asthma self-management education, and confirm that patient has (and knows how to use) a personalized written or electronic asthma action plan. Refer to an asthma educator if available."
    },
    {
        "id": "doc_4249",
        "document": "\u2022 Optimize asthma medications: confirm that the inhaler is suitable for the patient; check and correct inhaler technique with a physical demonstration and teach-back method, check inhaler technique again at each visit.589 Address suboptimal adherence, both intentional and unintentional.458 Switch to ICS-formoterol maintenance and reliever regimen if available, to reduce the risk of exacerbations.213"
    },
    {
        "id": "doc_4250",
        "document": "\u2022 Consider non-pharmacologic add-on therapy, e.g., smoking cessation, physical exercise,367 healthy diet, weight loss, mucus clearance strategies, influenza vaccination, breathing exercises, allergen avoidance, if feasible, for patients who are sensitized and exposed. For details see text following Box 3-18, p.88.\n\n128\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4251",
        "document": "\u2022 Treat comorbidities and modifiable risk factors identified in Section 2 of the decision tree, where there is evidence for benefit; however, there is no evidence to support routine treatment of asymptomatic GERD (see p.107). Avoid medications that make asthma worse (beta-blockers including eye-drops; aspirin and other NSAIDs in patients with aspirin-exacerbated respiratory disease, p.117). Refer for management of mental health problems if relevant."
    },
    {
        "id": "doc_4252",
        "document": "\u2022 Consider trial of non-biologic medication added to medium/high dose ICS, e.g., LABA, LAMA, LTRA if not already tried. Note FDA boxed warning about potential neuropsychiatric effects with LTRAs.236\n\n\u2022 Consider trial of high-dose ICS-LABA if not currently used."
    },
    {
        "id": "doc_4253",
        "document": "4. REVIEW RESPONSE AFTER APPROXIMATELY 3\u20136 MONTHS\n\nSchedule a review visit to assess the response to the above interventions. Timing of the review visit depends on clinical urgency and what changes to treatment have been made.\n\nWhen assessing the response to treatment, specifically review:\n\n\u2022 Symptom control (symptom frequency, SABA reliever use, night waking due to asthma, activity limitation)\n\n\u2022 Exacerbations since previous visit, and how they were managed\n\n\u2022 Medication side-effects"
    },
    {
        "id": "doc_4254",
        "document": "\u2022 Inhaler technique and adherence\n\n\u2022 Lung function\n\n\u2022 Patient satisfaction and concerns.\n\nIs asthma still uncontrolled, despite optimized therapy?\n\nYES: if asthma is still uncontrolled, the diagnosis of severe asthma has been confirmed. If not done by now, refer the patient to a specialist or severe asthma clinic if possible."
    },
    {
        "id": "doc_4255",
        "document": "NO: if asthma is now well controlled, consider stepping down treatment. Start by decreasing/ceasing OCS first (if used), checking for adrenal insufficiency, then remove other add-on therapy, then decrease ICS dose, but do not stop ICS. See Box 3-16 (p.83) for how to gradually down-titrate treatment intensity.\n\nDoes asthma become uncontrolled when treatment is stepped down?"
    },
    {
        "id": "doc_4256",
        "document": "YES: if asthma symptoms become uncontrolled or an exacerbation occurs when high-dose treatment is stepped down, the diagnosis of severe asthma has been confirmed. Restore the patient's previous dose to regain good asthma control, and refer to a specialist or severe asthma clinic if possible, if not done already.\n\nNO: if symptoms and exacerbations remain well controlled despite treatment being stepped down, the patient does not have severe asthma. Continue optimizing management."
    },
    {
        "id": "doc_4257",
        "document": "ASSESS AND TREAT SEVERE ASTHMA PHENOTYPES\n\n5. INVESTIGATE FURTHER AND PROVIDE PATIENT SUPPORT\n\nFurther assessment and management should be by a specialist, preferably in a multidisciplinary severe asthma clinic if available. The team may include a certified asthma educator and health professionals from fields such as speech pathology, otorhinolaryngology, social work and mental health."
    },
    {
        "id": "doc_4258",
        "document": "What other tests may be considered at the specialist level?\n\nAdditional investigations may be appropriate for identifying less-common comorbidities and differential diagnoses contributing to symptoms and/or exacerbations. Tests should be based on clinical suspicion, and may include:\n\n\u2022 Blood tests: complete blood count, CRP, IgG, IgA, IgM, IgE, fungal precipitins including Aspergillus\n\n3. Treating to control symptoms and minimize future risk\n\n129"
    },
    {
        "id": "doc_4259",
        "document": "\u2022 Allergy testing for clinically relevant allergens: skin prick test or specific IgE, if not already done\n\n\u2022 Other pulmonary investigations: DLCO; CXR or high-resolution chest CT\n\n\u2022 Bone density scan, because of risk of osteoporosis with maintenance or frequent OCS or long-term high-dose ICS311\n\n\u2022 Other directed testing, e.g., ANCA, CT sinuses, BNP, echocardiogram, based on clinical suspicion"
    },
    {
        "id": "doc_4260",
        "document": "If blood eosinophils are \u2265300/\u00b5L, look for and treat non-asthma causes, including parasites (e.g., Strongyloides serology or stool examination), because parasitic infection may be the cause of the blood eosinophilia, and because OCS or biologic therapy in a patient with untreated parasitic infection could potentially lead to disseminated disease. Strongyloides infection is usually asymptomatic.590"
    },
    {
        "id": "doc_4261",
        "document": "If hypereosinophilia is found, e.g., blood eosinophils \u22651500/\u00b5L, consider causes such as eosinophilic granulomatosis with polyangiitis (EGPA)."
    },
    {
        "id": "doc_4262",
        "document": "Consider need for social/psychological support\n\nRefer patients to support services, where available, to help them deal with the emotional, social and financial burden of asthma and its treatment, including during and after severe exacerbations.582 Consider the need for psychological or psychiatric referral, including for patients with anxiety and/or depression."
    },
    {
        "id": "doc_4263",
        "document": "Involve multidisciplinary team care (if available)\n\nMultidisciplinary assessment and treatment of patients with severe asthma increases the identification of comorbidities, and improves outcomes.591\n\nInvite patient to enroll in a registry (if available) or clinical trial (if appropriate)"
    },
    {
        "id": "doc_4264",
        "document": "Systematic collection of data will help in understanding the mechanisms and burden of severe asthma. There is a need for pragmatic clinical trials in severe asthma, including studies comparing two or more active treatments. Participants in randomized controlled trials designed for regulatory purposes may not necessarily be representative of patients seen in clinical practice. For example, a registry study found that over 80% of patients with severe asthma would have been excluded from key"
    },
    {
        "id": "doc_4265",
        "document": "studies evaluating biologic therapy.288"
    },
    {
        "id": "doc_4266",
        "document": "6 ASSESS THE SEVERE ASTHMA PHENOTYPE\n\nThe next step is to assess the patient\u2019s inflammatory phenotype \u2013 is it Type 2 high or low?\n\nWhat is Type 2 inflammation?"
    },
    {
        "id": "doc_4267",
        "document": "Type 2 inflammation is found in the majority of people with severe asthma. It is characterized by cytokines such as interleukin (IL)-4, IL-5 and IL-13, which are often produced by the adaptive immune system on recognition of allergens. It may also be activated by viruses, bacteria and irritants that stimulate the innate immune system via production of IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) by epithelial cells. Type 2 inflammation is often characterized by elevated eosinophils or"
    },
    {
        "id": "doc_4268",
        "document": "increased FeNO, and it may be accompanied by atopy and elevated IgE, whereas non-Type 2 inflammation is often characterized by increased neutrophils.592"
    },
    {
        "id": "doc_4269",
        "document": "In many patients with asthma, Type 2 inflammation rapidly improves when ICS are taken regularly and correctly; this is classified as mild or moderate asthma. In severe asthma, Type 2 inflammation may be relatively refractory to high-dose ICS. It may respond to OCS but their serious adverse effects308,309 mean that alternative treatments should be sought."
    },
    {
        "id": "doc_4270",
        "document": "In adult patients with uncontrolled asthma despite medium- or high-dose ICS plus LABA or other controllers, a history of exacerbations in the previous year, higher blood eosinophil counts and higher FeNO levels are associated with a greater risk of severe exacerbations.593\n\n130\n\n3. Treating to control symptoms and minimize future risk"
    },
    {
        "id": "doc_4271",
        "document": "Could the patient have refractory or underlying Type 2 inflammation?\n\nThe possibility of refractory Type 2 inflammation should be considered if any of the following are found while the patient is taking high-dose ICS or daily OCS:\n\n\u2022 Blood eosinophils \u2265150/\u03bcl, and/or\n\n\u2022 FeNO \u226520 ppb, and/or\n\n\u2022 Sputum eosinophils \u22652%, and/or\n\n\u2022 Asthma is clinically allergen-driven"
    },
    {
        "id": "doc_4272",
        "document": "Patients requiring maintenance OCS may also have underlying Type 2 inflammation. However, biomarkers of Type 2 inflammation (blood eosinophils, sputum eosinophils and FeNO) are often suppressed by OCS. If possible, therefore, these tests should be performed before starting OCS (a short course, or maintenance treatment), or at least 1\u20132 weeks after a course of OCS, or on the lowest possible OCS dose."
    },
    {
        "id": "doc_4273",
        "document": "The above criteria are suggested for initial assessment; those for blood eosinophils and FeNO are based on the lowest levels associated with response to some biologics. They are not the criteria for eligibility for Type 2-targeted biologic therapy, which may differ \u2013 see section 8 and local criteria."
    },
    {
        "id": "doc_4274",
        "document": "Consider repeating blood eosinophils and FeNO up to 3 times (e.g., when asthma worsens, before giving OCS, or at least 1\u20132 weeks after a course of OCS, or on the lowest possible OCS dose), before assuming asthma is non-Type 2. One study of patients with uncontrolled asthma taking medium- to high-dose ICS-LABA found that 65% had a shift in their blood eosinophil category over 48\u201356 weeks.594"
    },
    {
        "id": "doc_4275",
        "document": "Why is the inflammatory phenotype assessed on high-dose ICS?\n\n\u2022 Most RCT evidence about Type 2 targeted biologics is in such patients.\n\n\u2022 Modifiable ICS treatment problems such as poor adherence and incorrect inhaler technique are common causes of uncontrolled Type 2 inflammation"
    },
    {
        "id": "doc_4276",
        "document": "\u2022 Currently, the high cost of biologic therapies generally precludes their widespread clinical use in patients whose symptoms or exacerbations and Type 2 biomarkers are found to respond to ICS when it is taken correctly.\n\n7.1. CONSIDER OTHER TREATMENTS IF THERE IS NO EVIDENCE OF TYPE 2 INFLAMMATION\n\nIf the patient has no evidence of persistent Type 2 inflammation (section 6):"
    },
    {
        "id": "doc_4277",
        "document": "\u2022 Review the basics for factors that may be contributing to symptoms or exacerbations: differential diagnosis, inhaler technique, adherence, comorbidities, medication side-effects (Section 2).\n\n\u2022 Recommend avoidance of relevant exposures (tobacco smoke, pollution, allergens if sensitized and there is evidence of benefit from withdrawal, irritants, infections). Ask about exposures at home and at work."
    },
    {
        "id": "doc_4278",
        "document": "\u2022 Consider additional diagnostic investigations (if available and not already done): sputum induction to confirm inflammatory phenotype, high resolution chest CT, bronchoscopy to exclude unusual comorbidities or alternative diagnoses such as tracheobronchomalacia or sub-glottic stenosis; functional laryngoscopy for inducible laryngeal obstruction."
    },
    {
        "id": "doc_4279",
        "document": "\u2022 Consider a trial of add-on treatment if available and not already tried (but check local eligibility and payer criteria for specific therapies as they may vary from those listed):\n\n\u2013 LAMA272\n\n\u2013 Low-dose azithromycin (adults),292,595 but first check sputum for atypical mycobacteria, check ECG for long QTc (and re-check after a month on treatment), and consider potential for antibiotic resistance.\n\n\u2013 Anti-IL4R\u03b1 if taking maintenance OCS (see section 8 for more details)"
    },
    {
        "id": "doc_4280",
        "document": "\u2013 Anti-TSLP (thymic stromal lymphopoietin) (but insufficient evidence in patients taking maintenance OCS; see section 8 for more details)\n\n3. Treating to control symptoms and minimize future risk\n\n131\n\nAs a last resort, consider add-on low-dose OCS, but implement strategies such as alternate-day treatment to minimize side-effects.\n\n\u2022 Consider bronchial thermoplasty, with registry enrollment. However, the evidence for efficacy and long-term safety is limited.134,354"
    },
    {
        "id": "doc_4281",
        "document": "\u2022 Stop ineffective add-on therapies.\n\n\u2022 Continue to optimize treatment, including inhaler technique, adherence, non-pharmacologic strategies and treating comorbidities (see sections 3 and 10).\n\n7.2 CONSIDER NON-BIOLOGIC OPTIONS IF THERE IS EVIDENCE OF TYPE 2 INFLAMMATION\n\nFor patients with elevated Type 2 biomarkers despite high-dose ICS (see section 5), consider non-biologic options first, given the current high cost of biologic therapy:"
    },
    {
        "id": "doc_4282",
        "document": "\u2022 Assess adherence objectively by monitoring of prescribing or dispensing records, blood prednisone levels,596 or electronic inhaler monitoring.444 In one study, suppression of high FeNO after 5 days of directly observed therapy was an indicator of past poor adherence.597\n\n\u2022 Consider increasing the ICS dose for 3\u20136 months, and review again."
    },
    {
        "id": "doc_4283",
        "document": "\u2022 Consider add-on non-biologic treatment for specific Type 2 clinical phenotypes (see Chapter 3.4, p.106). For example, for aspirin-exacerbated respiratory disease (AERD), consider add-on LTRA and possibly aspirin desensitization (p.117). For allergic bronchopulmonary aspergillosis (ABPA), consider add-on OCS \u00b1 anti-fungal agent (p.118). For chronic rhinosinusitis with or without nasal polyps, consider intensive intranasal corticosteroids; surgical advice may be needed (p.108). For patients with"
    },
    {
        "id": "doc_4284",
        "document": "atopic dermatitis, topical steroidal or non-steroidal therapy may be helpful."
    },
    {
        "id": "doc_4285",
        "document": "7.3 IS TYPE 2-TARGETED BIOLOGIC THERAPY AVAILABLE AND AFFORDABLE?\n\nIf NOT:\n\n\u2022 Consider higher dose ICS-LABA, if not used\n\n\u2022 Consider other add-on therapy, e.g., LAMA, LTRA, low-dose azithromycin if not used\n\n\u2022 As last resort, consider add-on low-dose OCS, but implement strategies to minimize side-effects\n\n\u2022 Stop ineffective add-on therapies\n\n\u2022 Continue to optimize treatment, including inhaler technique, adherence, non-pharmacologic strategies and treating comorbidities (see sections 3 and 10)."
    },
    {
        "id": "doc_4286",
        "document": "8 CONSIDER ADD-ON BIOLOGIC TYPE 2-TARGETED TREATMENTS\n\nIf available and affordable, consider an add-on Type 2 targeted biologic for patients with exacerbations and/or poor symptom control despite taking at least high-dose ICS-LABA, and who have allergic or eosinophilic biomarkers or need maintenance OCS. Where relevant, test for parasitic infection, and treat if present, before commencing treatment (see section 5)."
    },
    {
        "id": "doc_4287",
        "document": "Consider whether to start first with anti-IgE, anti-IL5/5R, anti-IL4R\u03b1 or anti-TSLP. When choosing between available therapies, consider the following:\n\n\u2022 Does the patient satisfy local payer eligibility criteria?\n\n\u2022 Type 2 comorbidities such as atopic dermatitis, nasal polyps\n\n\u2022 Predictors of asthma response (see below)\n\n\u2022 Cost\n\n\u2022 Dosing frequency\n\n132\n\n3. Treating to control symptoms and minimize future risk\n\n\u2022 Delivery route (IV or SC; potential for self-administration)\n\n\u2022 Patient preference."
    },
    {
        "id": "doc_4288",
        "document": "Always check local payer eligibility criteria for biologic therapy, as they may vary substantially. However, GINA recommends the use of biologic therapy only for patients with severe asthma, and only after treatment has been optimized. For any biologic therapy, ensure that the manufacturer\u2019s and/or regulator\u2019s instructions for storage, administration and the duration of monitoring post-administration are followed."
    },
    {
        "id": "doc_4289",
        "document": "Provide the patient with advice about what to do if they experience any adverse effects, including hypersensitivity reactions. GINA suggests that the first dose of asthma biologic therapy should not be given on the same day as a COVID-19 vaccine, so that adverse effects of either can be more easily distinguished.\n\nThere is an urgent need for head-to-head comparisons of different biologics in patients eligible for more than one biologic."
    },
    {
        "id": "doc_4290",
        "document": "Add-on anti-IgE for severe allergic asthma\n\nRegulatory approvals may include: omalizumab for ages \u22656 years, given by SC injection every 2\u20134 weeks, with dose based on weight and serum IgE. May also be indicated for nasal polyps and chronic spontaneous (idiopathic) urticaria. Self-administration may be an option. Check local regulatory and payer criteria, as they may differ from these."
    },
    {
        "id": "doc_4291",
        "document": "Mechanism: binds to Fc part of free IgE, preventing binding of IgE to Fc\u0190R1 receptors, reducing free IgE and down- regulating receptor expression.\n\nEligibility criteria (in addition to criteria for severe asthma) vary between payers, but usually include:\n\n\u2022 Sensitization to inhaled allergen(s) on skin prick testing or specific IgE, and\n\n\u2022 Total serum IgE and body weight within local dosing range, and\n\n\u2022 More than a specified number of exacerbations within the last year."
    },
    {
        "id": "doc_4292",
        "document": "Outcomes: Meta-analysis of RCTs in severe allergic asthma: 44% decrease in severe exacerbations; improved quality of life.294 No double-blind randomized controlled trials of OCS-sparing effect. In a meta-analysis of observational studies in patients with severe allergic asthma, there was a 59% reduction in exacerbation rate, a 41% reduction in the proportion of patients receiving maintenance OCS, and a significant improvement in symptom control.598 In patients with nasal polyps, omalizumab"
    },
    {
        "id": "doc_4293",
        "document": "improved subjective and objective outcomes.512 Additional details about treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) are found on p.108. A registry study of omalizumab in pregnancy found no increased risk of congenital malformations.548"
    },
    {
        "id": "doc_4294",
        "document": "Potential predictors of good asthma response to omalizumab:\n\n\u2022 Baseline IgE level does not predict likelihood of response599"
    },
    {
        "id": "doc_4295",
        "document": "\u2022 In a post-hoc analysis of one clinical trial, a greater decrease in exacerbations was observed (cf. placebo) with blood eosinophils \u2265260/\u03bcl600,601 or FeNO \u226519.5 ppb600 (these criteria representing their median value in that study) but in two large observational studies, exacerbations were reduced with both low or high blood eosinophils602-604 or with both low or high FeNO.604\n\n\u2022 Childhood-onset asthma\n\n\u2022 Clinical history suggesting allergen-driven symptoms."
    },
    {
        "id": "doc_4296",
        "document": "Adverse effects: injection site reactions; anaphylaxis in approximately 0.2% patients605\n\nSuggested initial trial: at least 4 months\n\nAdd-on anti-IL5 or anti-IL5R for severe eosinophilic asthma\n\nRegulatory approvals may include: For ages \u226512 years: mepolizumab (anti-IL5), 100 mg by SC injection every 4 weeks, or benralizumab (anti-IL5 receptor \u03b1), 30 mg by SC injection every 4 weeks for 3 doses then every 8 weeks. For ages\n\n3. Treating to control symptoms and minimize future risk\n\n133"
    },
    {
        "id": "doc_4297",
        "document": "\u226518 years: reslizumab (anti-IL5), 3 mg/kg by IV infusion every 4 weeks. For ages 6\u201311 years, mepolizumab (anti-IL5), 40 mg by SC injection every 4 weeks. Mepolizumab may also be indicated for eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome and chronic rhinosinusitis with nasal polyps. Self-administration may be an option. Check local regulatory and payer criteria, as they may differ from these."
    },
    {
        "id": "doc_4298",
        "document": "Mechanism: mepolizumab and reslizumab bind circulating IL-5; benralizumab binds to IL-5 receptor alpha subunit leading to apoptosis (cell death) of eosinophils.\n\nEligibility criteria (in addition to criteria for severe asthma): these vary by product and between payers, but usually include:\n\n\u2022 More than a specified number of severe exacerbations in the last year, and"
    },
    {
        "id": "doc_4299",
        "document": "\u2022 Blood eosinophils above locally specified level (e.g., \u2265150 or \u2265300/\u03bcl). There is sometimes a different eosinophil cut-point for patients taking OCS."
    },
    {
        "id": "doc_4300",
        "document": "Outcomes: Meta-analysis of RCTs in severe asthma patients with exacerbations in the last year, with varying eosinophil criteria: anti-IL5 and anti-IL5R led to 47\u201354% reduction in severe exacerbations. Improvements in quality of life, lung function and symptom control were significant,294 but less than the clinically important difference. All reduced blood eosinophils; almost completely with benralizumab.606 In post hoc analyses, clinical outcomes with mepolizumab or benralizumab were similar in"
    },
    {
        "id": "doc_4301",
        "document": "patients with and without an allergic phenotype.607,608 In patients taking OCS, median OCS dose was able to be reduced by approximately 50% with mepolizumab609 or benralizumab297 compared with placebo. . In urban children aged 6 years and older with eosinophilic exacerbation-prone asthma, an RCT showed a reduction in the number of exacerbations with subcutaneous mepolizumab versus placebo.298 No differences were seen in lung function, a composite asthma score (CASI), or physician\u2013patient global"
    },
    {
        "id": "doc_4302",
        "document": "assessment.298 In patients with nasal polyps, mepolizumab improved subjective and objective outcomes and reduced the need for surgery,513,514 and in patients with nasal polyps and severe eosinophilic asthma, benralizumab improved subjective outcomes for both conditions and improved quality of life.610 Additional details about treatment of nasal polyps are found on p.108."
    },
    {
        "id": "doc_4303",
        "document": "Potential predictors of good asthma response to anti-IL5 or anti-IL5R:\n\n\u2022 Higher blood eosinophils (strongly predictive)611\n\n\u2022 Higher number of severe exacerbations in previous year (strongly predictive)611\n\n\u2022 Adult-onset asthma612\n\n\u2022 Nasal polyps608\n\n\u2022 Maintenance OCS at baseline608\n\n\u2022 Low lung function (FEV1 <65% predicted in one study).613"
    },
    {
        "id": "doc_4304",
        "document": "Adverse effects: In adults, injection site reactions; anaphylaxis rare; adverse events generally similar between active and placebo. In children, more skin/subcutaneous tissue and nervous system disorders (e.g., headache, dizziness, syncope) were seen with mepolizumab than placebo.298\n\nSuggested initial trial: at least 4 months\n\nAdd-on anti-IL4R\u03b1 for severe eosinophilic/Type 2 asthma or patients requiring maintenance OCS"
    },
    {
        "id": "doc_4305",
        "document": "Regulatory approvals may include: For ages \u226512 years: dupilumab (anti-IL4 receptor \u03b1), 200 mg or 300 mg by SC injection every 2 weeks for severe eosinophilic/Type 2 asthma; 300 mg by SC injection every 2 weeks for OCS- dependent severe asthma or if there is concomitant moderate/severe atopic dermatitis. For children 6\u201311 years with severe eosinophilic/Type 2 asthma by SC injection with dose and frequency depending on weight. May also be indicated for treatment of skin conditions including"
    },
    {
        "id": "doc_4306",
        "document": "moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis. Self-administration may be an option. Check local regulatory and payer criteria, as they may differ from these."
    },
    {
        "id": "doc_4307",
        "document": "Mechanism: binds to interleukin-4 (IL-4) receptor alpha, blocking both IL-4 and IL-13 signaling\n\n134\n\n3. Treating to control symptoms and minimize future risk\n\nEligibility criteria (in addition to criteria for severe asthma): these vary between payers, but usually include:\n\n\u2022 More than a specified number of severe exacerbations in the last year, and\n\n\u2022 Type 2 biomarkers above a specified level (e.g., blood eosinophils \u2265150/\u03bcl and \u22641500/\u03bcl; or FeNO \u226525 ppb); OR requirement for maintenance OCS"
    },
    {
        "id": "doc_4308",
        "document": "Outcomes: Meta-analysis of RCTs in patients with uncontrolled severe asthma (ACQ-5 \u22651.5) and at least one exacerbation in the last year: anti-IL4R\u03b1 led to 56% reduction in severe exacerbations; improvements in quality of life, symptom control and lung function were significant,303 but less than the clinically important difference. In a post hoc analysis, clinical outcomes were similar in patients with allergic and non-allergic phenotype at baseline.614 In patients with OCS-dependent severe"
    },
    {
        "id": "doc_4309",
        "document": "asthma, without minimum requirements for blood eosinophil count or FeNO, the median reduction in OCS dose with anti-IL4R\u03b1 versus placebo was 50%.615 In follow-up, changes were maintained through 2 years of follow-up.616 In children 6\u201311 years with eosinophilic/Type 2 asthma, dupilumab reduced severe exacerbation rate and increased lung function; children taking maintenance OCS were excluded.300 In patients with chronic rhinosinusitis with nasal polyps, dupilumab reduced the size of nasal polyps,"
    },
    {
        "id": "doc_4310",
        "document": "improved nasal symptoms and reduced the need for OCS or sinus surgery.515,617 Additional details about nasal polyps are found on p.108."
    },
    {
        "id": "doc_4311",
        "document": "Potential predictors of good asthma response to dupilumab:\n\n\u2022 Higher blood eosinophils (strongly predictive)301\n\n\u2022 Higher FeNO (strongly predictive)301\n\nAdverse effects: injection-site reactions; transient blood eosinophilia; rare cases of eosinophilic granulomatosis with polyangiitis (EGPA). Anti-IL4R\u03b1 is not suggested for patients with baseline or historic blood eosinophils >1,500 cells/\u00b5L because of limited evidence (such patients were excluded from Phase III trials)."
    },
    {
        "id": "doc_4312",
        "document": "Suggested initial trial: at least 4 months\n\nAdd-on anti-TSLP for severe asthma\n\nRegulatory approvals may include: For ages \u226512 years: tezepelumab (anti-TSLP), 210 mg by SC injection every 4 weeks. Self-administration may be an option. Check local regulatory and payer criteria, as they may differ from these.\n\nMechanism: tezepelumab binds circulating TSLP, a bronchial epithelial cell-derived alarmin implicated in multiple downstream processes involved in asthma pathophysiology."
    },
    {
        "id": "doc_4313",
        "document": "Eligibility criteria (in addition to criteria for severe asthma): these vary between payers, but usually include:\n\n\u2022 Severe exacerbations in the last year.\n\nAnti-TSLP may also be considered in patients with no elevated T2 markers (section 7.1)"
    },
    {
        "id": "doc_4314",
        "document": "Outcomes: In two RCTs in severe asthma patients with severe exacerbations in the last year, anti-TSLP led to 30\u201370% reduction in severe exacerbations, and improved quality of life, lung function and symptom control, irrespective of allergic status.304,618 There was a clear correlation between higher baseline blood eosinophils or FeNO and better clinical outcomes.618 In patients taking maintenance OCS, anti-TSLP did not lead to a reduced OCS dose compared with placebo.619"
    },
    {
        "id": "doc_4315",
        "document": "Potential predictors of good asthma response to anti-TSLP:\n\n\u2022 Higher blood eosinophils (strongly predictive)\n\n\u2022 Higher FeNO levels (strongly predictive)\n\nAdverse effects: injection site reactions; anaphylaxis is rare; adverse events generally similar between active and placebo groups\n\nSuggested initial trial: at least 4 months\n\n3. Treating to control symptoms and minimize future risk\n\n135"
    },
    {
        "id": "doc_4316",
        "document": "Review response to an initial trial of add-on Type 2-targeted therapy\n\n\u2022 At present, there are no well-defined criteria for a good response, but consider exacerbations, symptom control, lung function, side-effects, treatment intensity (including OCS dose), and patient satisfaction\n\nIf the response is unclear, consider extending the trial to 6\u201312 months"
    },
    {
        "id": "doc_4317",
        "document": "\u2022 If there is no response, stop the biologic therapy, and consider switching to a trial of a different Type 2-targeted therapy, if available and the patient is eligible. Also consider the patient\u2019s biomarkers (interval and during exacerbations, if available), and response of any comorbid Type 2 conditions (atopic dermatitis, nasal polyps etc). Review response as above.\n\nMANAGE AND MONITOR SEVERE ASTHMA TREATMENT"
    },
    {
        "id": "doc_4318",
        "document": "9. REVIEW RESPONSE AND IMPLICATIONS FOR TREATMENT\n\nReview response to add-on biologic therapy after 3\u20134 months, and every 3\u20136 months for ongoing care, including:\n\n\u2022 Asthma: symptom control, e.g., Asthma Control Test, Asthma Control Questionnaire (ACQ-5); frequency and severity of exacerbations (e.g., whether OCS were needed), lung function\n\n\u2022 Type 2 comorbidities, e.g. nasal polyps, atopic dermatitis\n\n\u2022 Medications: treatment intensity, including dose of OCS, side-effects, affordability"
    },
    {
        "id": "doc_4319",
        "document": "\u2022 Patient satisfaction\n\nIf the patient has had a good response to Type 2 targeted therapy:\n\nRe-evaluate the need for each asthma medication every 3\u20136 months, but do not completely stop inhaled therapy. Base the order of reduction or cessation of add-on treatments on the observed benefit when they were started, patient risk factors, medication side-effects, cost, and patient satisfaction."
    },
    {
        "id": "doc_4320",
        "document": "For oral treatments, consider gradually decreasing or stopping OCS first, because of their significant adverse effects. Tapering in severe asthma may be supported by internet-based monitoring of symptom control and FeNO.620 Monitor patients for risk of adrenal insufficiency, and provide patient and primary care physician with advice about the need for extra corticosteroid doses during injury, illness or surgery for up to 6 months after cessation of long-term OCS. Continue to assess for presence"
    },
    {
        "id": "doc_4321",
        "document": "of osteoporosis, and review need for preventative strategies including bisphosphonates.311"
    },
    {
        "id": "doc_4322",
        "document": "For inhaled treatments, consider reducing the ICS dose after 3\u20136 months, but do not completely stop inhaled therapy. Current consensus advice is to continue at least medium-dose ICS. Patients should be reminded of the importance of continuing their ICS-containing treatment."
    },
    {
        "id": "doc_4323",
        "document": "For biologic treatments, current consensus advice is that, generally, for a patient with a good response, a trial of withdrawal of the biologic should not be considered until after at least 12 months of treatment, and only if asthma remains well controlled on medium-dose ICS therapy, and (for allergic asthma) there is no further exposure to a previous well-documented allergic trigger. There are few studies of cessation of biologic therapy,621,622 in these studies, symptom control worsened and/or"
    },
    {
        "id": "doc_4324",
        "document": "exacerbations recurred for many (but not all) patients after cessation of the biologic. For example, in a double-blind randomized controlled trial, significantly more patients who stopped mepolizumab experienced a severe exacerbation within 12 months compared with those who continued treatment. There was a small increase in ACQ-5 but no significant difference between groups.623 Long-term safety of several biologics has been reported up to 5 or more years.624-626"
    },
    {
        "id": "doc_4325",
        "document": "If the patient has NOT had a good response to any Type 2-targeted therapy:"
    },
    {
        "id": "doc_4326",
        "document": "Stop the biologic therapy\n\nReview the basics for factors contributing to symptoms, exacerbations and poor quality of life (see Section 2): diagnosis/differential diagnosis, inhaler technique, adherence, modifiable risk factors and triggers including smoking and\n\n136\n\n3. Treating to control symptoms and minimize future risk\n\nother environmental exposures at home or work, comorbidities including obesity, medication side-effects or drug interactions, socio-economic and mental health issues."
    },
    {
        "id": "doc_4327",
        "document": "Consider additional investigations (if not already done): high resolution chest CT; induced sputum to confirm inflammatory phenotype, consider bronchoscopy for alternative or additional diagnoses, consider referral if available, including for diagnosis of alternative conditions.\n\nReassess treatment options (if not already done), such as:"
    },
    {
        "id": "doc_4328",
        "document": "\u2022 Add-on low-dose azithromycin292,595 (adults only; first check sputum for atypical mycobacteria and check ECG for long QTc (and re-check after a month on treatment); consider potential for antibiotic resistance)\n\n\u2022 As last resort, consider add-on low-dose maintenance OCS, but implement strategies such as alternate-day therapy and add-on bisphosphonates to minimize side-effects,311 and alert patient to the need for additional corticosteroid therapy during illness or surgery."
    },
    {
        "id": "doc_4329",
        "document": "\u2022 Consider bronchial thermoplasty (+ registry).\n\nStop ineffective add-on therapies, but do not completely stop ICS"
    },
    {
        "id": "doc_4330",
        "document": "10. CONTINUE COLLABORATIVE OPTIMIZATION OF PATIENT CARE\n\nOngoing management of a patient with severe asthma involves a collaboration between the patient, the primary care physician, specialist(s), and other health professionals, to optimize clinical outcomes and patient satisfaction.\n\nContinue to review the patient every 3\u20136 months including:\n\n\u2022 Clinical asthma measures (symptom control; exacerbations; lung function)\n\n\u2022 Comorbidities\n\n\u2022 The patient's risk factors for exacerbations"
    },
    {
        "id": "doc_4331",
        "document": "\u2022 Treatments (check inhaler technique and adherence; review need for add- on treatments; assess side-effects including of OCS; optimize comorbidity management and non-pharmacologic strategies)\n\n\u2022 The patient\u2019s social and emotional needs."
    },
    {
        "id": "doc_4332",
        "document": "The optimal frequency and location of review (primary care physician or specialist) will depend on the patient\u2019s asthma control, risk factors and comorbidities, and their confidence in self-management, and may depend on local payer requirements and availability of specialist physicians.\n\nCommunicate regularly about:\n\n\u2022 Outcome of review visits (as above)\n\n\u2022 Patient concerns\n\n\u2022 Action plan for worsening asthma or other risks"
    },
    {
        "id": "doc_4333",
        "document": "\u2022 Changes to medications (asthma and non-asthma); potential side-effects\n\n\u2022 Indications and contact details for expedited review.\n\n3. Treating to control symptoms and minimize future risk\n\n137\n\n\u00ae & O\\\"o & C)OQ O ot & @?\u2018 & X & K\n\n&\n\nSECTION 1. ADULTS, ADOLESCENTS AND CHILDREN 6 YEARS AND OLDER\n\nChapter 4.\n\nManagement of worsening asthma and exacerbations\n\nKEY POINTS"
    },
    {
        "id": "doc_4334",
        "document": "Terminology\n\n\u2022 Exacerbations represent an acute or sub-acute worsening in symptoms and lung function from the patient\u2019s usual status, or in some cases, a patient may present for the first time during an exacerbation.\n\n\u2022 The terms \u2018episodes\u2019, \u2018attacks\u2019 and \u2018acute severe asthma\u2019 are also often used, but they have variable meanings. The term \u2018flare-up\u2019 is preferable for use in discussions with most patients."
    },
    {
        "id": "doc_4335",
        "document": "\u2022 Patients who are at increased risk of asthma-related death should be identified, and flagged for more frequent review."
    },
    {
        "id": "doc_4336",
        "document": "Written asthma action plans\n\n\u2022 All patients should be provided with a written (i.e., printed, digital or pictorial) asthma action plan appropriate for their age, their current treatment regimen and their reliever inhaler (short-acting beta2 agonist [SABA] or combination inhaled corticosteroids [ICS]-formoterol), their level of asthma control, and their health literacy, so they know how to recognize and respond to worsening asthma."
    },
    {
        "id": "doc_4337",
        "document": "\u2022 On the action plan, state when and how to change reliever and/or maintenance medications, use oral corticosteroids (OCS) if needed, and access medical care if symptoms fail to respond to treatment.\n\n\u2022 Advise patients who have a history of rapid deterioration to go to an acute care facility or see their doctor immediately their asthma starts to worsen.\n\n\u2022 Base the action plan on changes in symptoms or (only in adults) peak expiratory flow (PEF)."
    },
    {
        "id": "doc_4338",
        "document": "Management of exacerbations in a primary care or acute care facility\n\n\u2022 Assess exacerbation severity from the degree of dyspnea, respiratory rate, pulse rate, oxygen saturation and lung function, while starting SABA and oxygen therapy. Infection control procedures should be followed."
    },
    {
        "id": "doc_4339",
        "document": "\u2022 Arrange immediate transfer to an acute care facility if there are signs of severe exacerbation, or to intensive care if the patient is drowsy, confused, or has a silent chest. During transfer, give inhaled SABA and ipratropium bromide, controlled oxygen and systemic corticosteroids."
    },
    {
        "id": "doc_4340",
        "document": "\u2022 Start treatment with repeated administration of SABA (in most patients, by pressurized metered-dose inhaler [pMDI] and spacer), early introduction of oral corticosteroids, and controlled flow oxygen if available. Review response of symptoms, oxygen saturation and lung function after 1 hour. Give ipratropium bromide only for severe exacerbations. Consider intravenous magnesium sulfate for patients with severe exacerbations not responding to initial treatment."
    },
    {
        "id": "doc_4341",
        "document": "\u2022 Do not routinely request a chest X-ray, and do not routinely prescribe antibiotics for asthma exacerbations.\n\n\u2022 Decide about hospitalization based on the patient\u2019s clinical status, lung function, response to treatment, recent and past history of exacerbations, and ability to manage at home."
    },
    {
        "id": "doc_4342",
        "document": "Discharge management\n\n\u2022 Arrange ongoing treatment before the patient goes home. This should include starting ICS-containing controller treatment or stepping up the dose of existing ICS-containing treatment for 2\u20134 weeks, and reducing reliever medication to as-needed use.\n\n\u2022 Arrange early follow-up after any exacerbation, regardless of where it was managed. At follow-up:\n\no Review the patient\u2019s symptom control and risk factors for further exacerbations."
    },
    {
        "id": "doc_4343",
        "document": "o Prescribe ICS-containing controller therapy to reduce the risk of further exacerbations. If already taking ICS-containing therapy, continue increased doses for 2\u20134 weeks.\n\no Provide a written asthma action plan and, where relevant, advice about avoiding exacerbation triggers\n\n\u2022 Check inhaler technique and adherence.\n\nFor management of asthma exacerbations in children 5 years and younger, see Chapter 6, p.187.\n\n140\n\n4. Management of worsening asthma and exacerbations\n\nOVERVIEW"
    },
    {
        "id": "doc_4344",
        "document": "Definition of asthma exacerbations\n\nExacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient\u2019s usual status that is sufficient to require a change in treatment.29 Exacerbations may occur in patients with a pre- existing diagnosis of asthma or, occasionally, as the first presentation of asthma."
    },
    {
        "id": "doc_4345",
        "document": "What triggers asthma exacerbations?"
    },
    {
        "id": "doc_4346",
        "document": "Exacerbations usually occur in response to exposure to an external agent (e.g. viral upper respiratory tract infection, pollen or pollution) and/or poor adherence with ICS-containing medication; however, a subset of patients present more acutely and without exposure to known risk factors.627,628 Severe exacerbations can occur in patients with mild or well- controlled asthma symptoms.22,219 Box 2-2B (p.38) lists factors that increase a patient\u2019s risk of exacerbations, independent of their level"
    },
    {
        "id": "doc_4347",
        "document": "of symptom control."
    },
    {
        "id": "doc_4348",
        "document": "Common exacerbation triggers include:\n\nViral respiratory infections, 629 e.g. rhinovirus, influenza, adenovirus, pertussis, respiratory syncytial virus\n\nAllergen exposure e.g., grass pollen,630 soybean dust,631 fungal spores\n\n\u2022 Food allergy105\n\n\u2022 Outdoor air pollution111,112,632\n\nSeasonal changes and/or returning to school in fall (autumn)633\n\n\u2022 Poor adherence with ICS634"
    },
    {
        "id": "doc_4349",
        "document": "\u2022 Epidemics of severe asthma exacerbations may occur suddenly, putting high pressure on local health system responses. Such epidemics have been reported in association with springtime thunderstorms and either rye grass pollen or fungal spores,635 and with environmental exposure to soy bean dust.631"
    },
    {
        "id": "doc_4350",
        "document": "Identifying patients at risk of asthma-related death\n\nIn addition to factors known to increase the risk of asthma exacerbations (Box 2-2, p.38), some features are specifically associated with an increase in the risk of asthma-related death (Box 4-1). The presence of one or more of these risk factors should be quickly identifiable in the clinical notes, and these patients should be encouraged to seek urgent medical care early in the course of an exacerbation."
    },
    {
        "id": "doc_4351",
        "document": "Box 4-1. Factors that increase the risk of asthma-related death\n\nA history of near-fatal asthma requiring intubation and mechanical ventilation636\n\n\u2022 Hospitalization636,637 or emergency care visit for asthma in the past year\n\n\u2022 Currently using or having recently stopped using oral corticosteroids (a marker of event severity)636\n\n\u2022 Not currently using inhaled corticosteroids101,636"
    },
    {
        "id": "doc_4352",
        "document": "\u2022 Over-use of short-acting beta2-agonists (SABAs), especially use of more than one canister of salbutamol (or equivalent) monthly75,121,638\n\nPoor adherence with ICS-containing medications and/or poor adherence with (or lack of) a written asthma action plan113\n\nA history of psychiatric disease or psychosocial problems113\n\nFood allergy in a patient with asthma499,639"
    },
    {
        "id": "doc_4353",
        "document": "\u2022 Several comorbidities including pneumonia, diabetes and arrhythmias were independently associated with an increased risk of death after hospitalization for an asthma exacerbation.637\n\nSee list of abbreviations (p.10).\n\n4. Management of worsening asthma and exacerbations\n\n141\n\nTerminology about exacerbations"
    },
    {
        "id": "doc_4354",
        "document": "The academic term \u2018exacerbation\u2019 is commonly used in scientific and clinical literature, although hospital-based studies more often refer to \u2018acute severe asthma\u2019. However, the term \u2018exacerbation\u2019 is not suitable for use in clinical practice, as it is difficult for many patients to pronounce and remember.640,641 The term \u2018flare-up\u2019 is simpler, and conveys the sense that asthma is present even when symptoms are absent. The term \u2018attack\u2019 is used by many patients and health care providers but with"
    },
    {
        "id": "doc_4355",
        "document": "widely varying meanings, and it may not be perceived as including gradual worsening.640,641 In pediatric literature, the term \u2018episode\u2019 is commonly used, but understanding of this term by parent/caregivers is not known."
    },
    {
        "id": "doc_4356",
        "document": "DIAGNOSIS OF EXACERBATIONS"
    },
    {
        "id": "doc_4357",
        "document": "Exacerbations represent a change in symptoms and lung function from the patient\u2019s usual status.29 The decrease in expiratory airflow can be quantified by lung function measurements such as PEF or forced expiratory volume in 1 second (FEV1),642 compared with the patient\u2019s previous lung function or predicted values. In the acute setting, these measurements are more reliable indicators of the severity of the exacerbation than symptoms. The frequency of symptoms may, however, be a more sensitive"
    },
    {
        "id": "doc_4358",
        "document": "measure of the onset of an exacerbation than PEF.643 Consider the possibility of pertussis in a patient with an atypical exacerbation presentation, with predominant cough."
    },
    {
        "id": "doc_4359",
        "document": "A minority of patients perceive airflow limitation poorly and can experience a significant decline in lung function without a change in symptoms.136,148,156 This especially affects patients with a history of near-fatal asthma and also appears to be more common in males. Regular PEF monitoring may be considered for such patients."
    },
    {
        "id": "doc_4360",
        "document": "Severe exacerbations are potentially life-threatening and their treatment requires careful assessment and close monitoring. Patients with severe exacerbations should be advised to see their health care provider promptly or, depending on the organization of local health services, to proceed to the nearest facility that provides emergency access for patients with acute asthma.\n\nSELF-MANAGEMENT OF EXACERBATIONS WITH A WRITTEN ASTHMA ACTION PLAN"
    },
    {
        "id": "doc_4361",
        "document": "All patients with asthma, and parents/caregivers of children with asthma, should be provided with guided self- management education as described in Chapter 3.3 (p.98). The definition of guided self-management education includes monitoring of symptoms and/or lung function, a written asthma action plan, and regular review by a health professional.471 (For children 5 years and younger, see Chapter 6, p.169). A written (i.e., documented) asthma action plan may be printed, digital, or pictorial, to"
    },
    {
        "id": "doc_4362",
        "document": "suit the patient\u2019s needs and literacy."
    },
    {
        "id": "doc_4363",
        "document": "A written asthma action plan helps patients to recognize and respond appropriately to worsening asthma. It should include specific instructions for the patient about changes to reliever and/or maintenance medications, when and how to use OCS if needed (Box 4-2) and when and how to access medical care."
    },
    {
        "id": "doc_4364",
        "document": "The criteria for initiating an increase in maintenance medication will vary from patient to patient. In studies that evaluated an increase in maintenance ICS-containing treatment, this was usually initiated when there was a clinically important change from the patient\u2019s usual level of asthma control, for example, if asthma symptoms were interfering with normal activities, or PEF had fallen by >20% for more than 2 days.476"
    },
    {
        "id": "doc_4365",
        "document": "For patients prescribed an anti-inflammatory reliever (as-needed combination ICS-formoterol or ICS-SABA), this provides a small extra dose of ICS as well as a rapid-acting bronchodilator without delay whenever the reliever is used, as the first step in the patient\u2019s action plan; this approach reduces the risk of progressing to severe exacerbation and need for oral corticosteroids. In the case of as-needed ICS-formoterol, both the ICS and the formoterol appear to contribute to the reduction in"
    },
    {
        "id": "doc_4366",
        "document": "severe exacerbations compared with using a SABA reliever.229 See Box 3-15 (p.80) for more details about as-needed ICS-formoterol, including medications and dosages."
    },
    {
        "id": "doc_4367",
        "document": "A specific action plan template is available for patients prescribed maintenance and reliever therapy with ICS- formoterol;8 it can also be modified for patients prescribed as-needed-only ICS-formoterol.\n\n142\n\n4. Management of worsening asthma and exacerbations\n\nTreatment options for written asthma action plans \u2013 relievers\n\nInhaled combination ICS-formoterol reliever"
    },
    {
        "id": "doc_4368",
        "document": "In adults and adolescents, use of as-needed combination low-dose ICS-formoterol for symptom relief (without maintenance treatment) reduced the risk of severe exacerbations requiring OCS or requiring emergency department visit or hospitalization by 65% compared with SABA-only treatment,167. It also reduced the risk of needing an emergency department visit or hospitalization by 37% compared with daily ICS plus as-needed SABA.167 After a day of even small increased doses of ICS-formoterol, the risk"
    },
    {
        "id": "doc_4369",
        "document": "of severe exacerbation in the following 3 weeks was reduced compared with using the same doses of SABA alone.79 Details about the evidence are found on p.68 and p.71."
    },
    {
        "id": "doc_4370",
        "document": "In adults, adolescents and children 6\u201311 years, maintenance-and-reliever therapy (MART) with ICS-formoterol reduced the risk of severe exacerbations compared with the same or higher dose of ICS or ICS-LABA, with similar symptom control.213,245,268 Details about the evidence are found on p.74 and p.76."
    },
    {
        "id": "doc_4371",
        "document": "Information about medications and doses for use of as-needed ICS-formoterol is summarized in Box 3-15, p.80. For adults and adolescents, the evidence is with use of budesonide-formoterol 200/6 mcg metered dose (160/4.5 mcg delievered dose) by dry powder inhaler and, for children aged 6\u201311 prescribed MART, budesonide-formoterol 100/6 mcg metered dose (80/4.5 mcg delivered dose) by dry powder inhaler. Patients prescribed ICS-formoterol as their reliever (with or without maintenance ICS-formoterol)"
    },
    {
        "id": "doc_4372",
        "document": "should take 1 inhalation of their ICS-formoterol reliever whenever needed for symptom relief. If necessary, an extra dose can be taken a few minutes later. Additional doses are taken when symptoms recur, even if this is within 4 hours, but the maximum total recommended dose in any single day for adults and adolescents is 12 inhalations for budesonide-formoterol (total 72 mcg formoterol [54 mcg delivered dose]) and 8 inhalations for budesonide-formoterol in children and for"
    },
    {
        "id": "doc_4373",
        "document": "beclometasone-formoterol in adults (48 mcg formoterol [36 mcg delivered dose]). This is the maximum total of as-needed doses and maintenance doses, if used."
    },
    {
        "id": "doc_4374",
        "document": "If the patient is rapidly worsening, or has failed to respond to an increase in as-needed doses of ICS-formoterol over 2\u20133 days, they should contact their healthcare provider or seek medical assistance.\n\nInhaled combination ICS-SABA reliever"
    },
    {
        "id": "doc_4375",
        "document": "For adults prescribed as-needed combination ICS-SABA reliever with maintenance ICS-containing therapy, the recommended dose is 2 inhalations of budesonide-salbutamol [albuterol] 100/100 mcg metered dose (80/90 mcg delivered dose) as needed, a maximum of 6 times in a day. Overall, in patients on Step 3\u20135 therapy, this reduced the risk of severe exacerbations by 26% compared with using a SABA reliever, with the greatest benefit seen in patients taking maintenance low dose ICS-LABA or medium-dose"
    },
    {
        "id": "doc_4376",
        "document": "ICS.259 There is only limited evidence about use of as-needed ICS-SABA alone, i.e. without maintenance ICS or ICS-LABA (see p.73)."
    },
    {
        "id": "doc_4377",
        "document": "If the patient is rapidly worsening, or is needing repeated doses of as-needed ICS-SABA reliever over 1\u20132 days, they should contact their healthcare provider or seek medical assistance.\n\nInhaled SABA reliever"
    },
    {
        "id": "doc_4378",
        "document": "For patients prescribed a SABA bronchodilator reliever, repeated dosing provides temporary relief until the cause of the worsening symptoms passes or increased ICS-containing treatment has had time to take effect. However, use of SABA reliever is less effective in preventing progression to severe exacerbation requiring OCS than use of low-dose ICS-formoterol reliever, either with213 or without202,203 daily maintenance ICS-containing treatment, or than combination ICS-SABA reliever (see Chapter"
    },
    {
        "id": "doc_4379",
        "document": "3)."
    },
    {
        "id": "doc_4380",
        "document": "The need for repeated doses of SABA over more than 1\u20132 days signals the need to review, and possibly increase, ICS-containing treatment if this has not already been done. This is particularly important if there has been a lack of response.\n\n4. Management of worsening asthma and exacerbations\n\n143\n\nTreatment options for written asthma action plans \u2013 maintenance medications\n\nMaintenance and reliever therapy (MART) with combination low-dose ICS-formoterol"
    },
    {
        "id": "doc_4381",
        "document": "In adults and adolescents, the combination of a rapid-onset LABA (formoterol) and low-dose ICS (budesonide or beclometasone) in a single inhaler as both the maintenance and the reliever medication was effective in improving asthma symptom control,644 and it reduced exacerbations requiring OCS, and hospitalizations213,245-248 compared with the same or higher dose of ICS or ICS-LABA with as-needed SABA reliever (Evidence A). This regimen was also effective in reducing exacerbations in children"
    },
    {
        "id": "doc_4382",
        "document": "aged 4\u201311 years (Evidence B).268"
    },
    {
        "id": "doc_4383",
        "document": "For adults and adolescents prescribed MART, the recommended maximum total dose of formoterol in 24 hours with budesonide-formoterol is 72 mcg (delivered dose 54 mcg) and with beclometasone-formoterol is 48 mcg (delivered dose 36 mcg) (See Box 3-15, p.80). This approach should not be attempted with other combination ICS-LABA medications with a slower-onset LABA, or that lack evidence of efficacy and safety with a maintenance and reliever regimen."
    },
    {
        "id": "doc_4384",
        "document": "The benefit of the MART regimen in reducing the risk of severe exacerbations requiring OCS appears to be due to the increase in doses of both the ICS and the formoterol at a very early stage of worsening asthma.77-79"
    },
    {
        "id": "doc_4385",
        "document": "In an action plan for patients prescribed maintenance and reliever therapy with ICS-formoterol, the maintenance dose does not normally need to be increased. Instead, the patient increases their as-needed doses of ICS-formoterol. More details of medications and doses for different age-groups are available in Box 3-15, p.80. Examples of action plans customized for MART are available online.8,312\n\nOther ICS and ICS-LABA maintenance treatment regimens plus as-needed SABA"
    },
    {
        "id": "doc_4386",
        "document": "In a systematic review, self-management studies in which the ICS dose was at least doubled were associated with improved asthma outcomes and reduced health care utilization (Evidence A).476 In placebo-controlled trials, temporarily doubling the dose of ICS was not effective (Evidence A);645 however, the delay before increasing the ICS dose (mean 5\u2013 7 days646,647) may have contributed. Some studies in adults648 and young children649 have reported that higher ICS doses might help prevent worsening"
    },
    {
        "id": "doc_4387",
        "document": "asthma progressing to a severe exacerbation. In a randomized controlled trial in primary care with patients aged \u226516 years, those who quadrupled their ICS dose (to average of 2000 mcg/day beclometasone dipropionate (BDP) equivalent) after their PEF fell were significantly less likely to require OCS.650 In an open-label primary care randomized controlled trial of adult and adolescent patients using ICS with or without LABA, early quadrupling of ICS dose (to average 3200 mcg/day BDP equivalent)"
    },
    {
        "id": "doc_4388",
        "document": "was associated with a modest reduction in prescribing of OCS.651 However, a double-blind placebo-controlled study in children 5\u201311 years with high adherence to low-dose ICS found no difference in the rate of severe exacerbations requiring OCS if maintenance ICS was quintupled (to 1600 mcg BDP equivalent) versus continuing maintenance low-dose therapy.652 Given the shape of the ICS dose- response curve, little benefit may be seen from increasing maintenance ICS when background adherence is high,"
    },
    {
        "id": "doc_4389",
        "document": "as in this study."
    },
    {
        "id": "doc_4390",
        "document": "In addition, in several of the studies evaluating ICS increases,646,647,652 a pre-specified level of deterioration in symptoms (\u00b1 lung function) had to be reached before the extra ICS could be started. This may help to explain the greater reduction in severe exacerbations seen with maintenance and reliever therapy with ICS-formoterol, where there is no lag before the doses of both ICS and formoterol are increased."
    },
    {
        "id": "doc_4391",
        "document": "In adult with an acute deterioration, high-dose ICS for 7\u201314 days (500\u20131600 mcg BDP-HFA equivalent) had an equivalent benefit to a short course of OCS (Evidence A).648 For adults taking combination ICS-LABA with as-needed SABA, the ICS dose may be increased by adding a separate ICS inhaler (Evidence D).648,651"
    },
    {
        "id": "doc_4392",
        "document": "Leukotriene receptor antagonists\n\nFor patients with mild asthma using a leukotriene receptor antagonist (LTRA) as their controller, there are no specific studies about how to manage worsening asthma. Clinicians\u2019 judgment should be used (Evidence D).\n\n144\n\n4. Management of worsening asthma and exacerbations"
    },
    {
        "id": "doc_4393",
        "document": "Oral corticosteroids\n\nFor most patients, the written asthma action plan should provide instructions for when and how to commence OCS. Typically, a short course of OCS is used (e.g. for adults, 40\u201350 mg/day usually for 5\u20137 days,648 Evidence B) for patients who:\n\n\u2022 Fail to respond to an increase in reliever and ICS-containing maintenance medication for 2\u20133 days\n\n\u2022 Deteriorate rapidly or who have a PEF or FEV1 <60% of their personal best or predicted value"
    },
    {
        "id": "doc_4394",
        "document": "\u2022 Have worsening asthma and a history of sudden severe exacerbations.\n\nFor children 6\u201311 years, the recommended dose of prednisone is 1\u20132 mg/kg/day to a maximum of 40 mg/day (Evidence B), usually for 3\u20135 days. Patients should be advised about common side-effects, including sleep disturbance, increased appetite, reflux, and mood changes.653 Patients should contact their doctor if they start taking OCS (Evidence D)."
    },
    {
        "id": "doc_4395",
        "document": "Optimize asthma treatment to minimize the risk of exacerbations and the adverse effects of OCS\n\n\u2022 OCS can be life-saving during severe asthma exacerbations, but there is increasing awareness of the risks of repeated courses.\n\n\u2022 In adults, short-term adverse effects of OCS include sleep disturbance, increased appetite, reflux, mood changes,653 sepsis, pneumonia, and thromboembolism.526"
    },
    {
        "id": "doc_4396",
        "document": "\u2022 In adults, even 4\u20135 lifetime courses of OCS are associated with a significantly increased dose-dependent risk of diabetes, cataract, heart failure, osteoporosis and several other conditions.309\n\n\u2022 The need for OCS can be reduced by optimizing inhaled therapy, including attention to inhaler technique and adherence."
    },
    {
        "id": "doc_4397",
        "document": "\u2022 For adults and adolescents, GINA Track 1 with ICS-formoterol as anti-inflammatory reliever reduces the risk of severe exacerbations requiring OCS compared with using a SABA reliever (see Box 3-12, p.65).\n\nReviewing response\n\nPatients should see their doctor immediately or go to an acute care unit if their asthma continues to deteriorate despite following their written asthma action plan, or if their asthma suddenly worsens.\n\nFollow up after a self-managed exacerbation"
    },
    {
        "id": "doc_4398",
        "document": "After a self-managed exacerbation, patients should see their primary care health care provider for a semi-urgent review (e.g. within 1\u20132 weeks, but preferably before ceasing oral corticosteroids if prescribed), for assessment of symptom control and additional risk factors for exacerbations (Box 2-2, p.38), and to identify the potential cause of the exacerbation. This visit provides an opportunity for additional asthma education by a trained asthma educator or trained lay healthcare worker."
    },
    {
        "id": "doc_4399",
        "document": "The written asthma action plan should be reviewed to see if it met the patient\u2019s needs. Maintenance asthma treatment can generally be reduced to previous levels 2\u20134 weeks after the exacerbation (Evidence D), unless the history suggests that the exacerbation occurred on a background of long-term poorly controlled asthma. In this situation, provided inhaler technique and adherence have been checked, a step up in treatment may be indicated (Box 3-12, p.65)."
    },
    {
        "id": "doc_4400",
        "document": "Patients with more than 1\u20132 exacerbations per year despite Step 4\u20135 therapy (or Step 4 therapy in children 6\u201311 years), or with several emergency department visits, should be referred to a specialist center, if available, for assessment and strategies to reduce their risk of future exacerbations and their risk of exposure to OCS. See decision tree for difficult-to- treat and severe asthma in Chapter 3.5, p.120.\n\n4. Management of worsening asthma and exacerbations\n\n145"
    },
    {
        "id": "doc_4401",
        "document": "Box 4-2. Self-management of worsening asthma in adults and adolescents with a written asthma action plan"
    },
    {
        "id": "doc_4402",
        "document": "\u00ab Self-monitoring of symptoms and/or lung function \u00ab Written asthma action plan \u00bb Regular medical review All patients Increase reliever Early increase in controller as below Review response EARLY OR MILD LATE OR SEVERE Medication Short-term change (1-2 weeks) for Evidence level worsening asthma"
    },
    {
        "id": "doc_4403",
        "document": "Increase usual reliever: Low-dose ICS-formoterol Increase frequency of as-needed low-dose prescribed this as-needed only, or with maintenance See Box 3-15 for details of medications and ICS-formoterol (for patients ICS-formoterol). t doses. A (p.80) Short-acting betaz-agonist (SABA) Increase frequency of SABA use For pMDI, add spacer > > Combination ICS-SABA Increase frequency of as-needed ICS-SABA* (see p.143) ah B"
    },
    {
        "id": "doc_4404",
        "document": "Increase usual maintenance treatment: Maintenance and reliever ICS- Continue usual maintenance dose of ICS-formoterol and increase reliever needed.t A formoterol (MART)t Maintenance ICS ICS-formoterol as See Box 3-15 (p.80) Consider quadrupling ICS dose. for details. B with SABA as reliever Maintenance ICS-formoterol Consider maintenance ICS-formoterol.t with SABA as reliever quadrupling B"
    },
    {
        "id": "doc_4405",
        "document": "Maintenance ICS plus other LABA with SABA as reliever Step up to higher dose formulation of ICS plus In adults, consider adding a separate ICS inhaler other LABA, if available to quadruple ICS dose. B D Add oral corticosteroids (OCS) and contact doctor; review before ceasing"
    },
    {
        "id": "doc_4406",
        "document": "OCS (prednisone or prednisolone) Add OCS for severe exacerbations (e.g., PEF or or predicted), or patient not responding to started, morning dosing is preferable. Adults: prednisolone* 40-50 mg/day, usually for is not needed if OCS are for FEV1 <60% personal best treatment over 48 hours. Once 5-7 days. less than 2 weeks. B A D Tapering prescribed 1"
    },
    {
        "id": "doc_4407",
        "document": "for\n\nof\n\n(delivered dose 80/90 mcg) maximum 6 times in a day.259 See text for action plan options in children.\n\na\n\n146\n\n4. Management of worsening asthma and exacerbations\n\nMANAGEMENT OF ASTHMA EXACERBATIONS IN PRIMARY CARE (ADULTS, ADOLESCENTS, CHLDREN 6\u201311 YEARS)\n\nAssessing exacerbation severity"
    },
    {
        "id": "doc_4408",
        "document": "A brief focused history and relevant physical examination should be conducted concurrently with the prompt initiation of therapy, and findings documented in the notes. If the patient shows signs of a severe or life-threatening exacerbation, treatment with SABA, controlled oxygen and systemic corticosteroids should be initiated while arranging for the patient\u2019s urgent transfer to an acute care facility where monitoring and expertise are more readily available. Milder exacerbations can usually be"
    },
    {
        "id": "doc_4409",
        "document": "treated in a primary care setting, depending on resources and expertise."
    },
    {
        "id": "doc_4410",
        "document": "History\n\nThe history should include:\n\n\u2022 Timing of onset and cause (if known) of the present exacerbation\n\n\u2022 Severity of asthma symptoms, including any limiting exercise or disturbing sleep\n\n\u2022 Any symptoms of anaphylaxis\n\n\u2022 Any risk factors for asthma-related death (Box 4-1, p.141)\n\n\u2022 All current reliever and maintenance medications, including doses and devices prescribed, adherence pattern, any recent dose changes, and response to current therapy."
    },
    {
        "id": "doc_4411",
        "document": "Physical examination\n\nThe physical examination should assess:\n\n\u2022 Signs of exacerbation severity (Box 4-3, p.148) and vital signs (e.g., level of consciousness, temperature, pulse rate, respiratory rate, blood pressure, ability to complete sentences, use of accessory muscles, wheeze).\n\n\u2022 Complicating factors (e.g., anaphylaxis, pneumonia, pneumothorax)"
    },
    {
        "id": "doc_4412",
        "document": "\u2022 Signs of alternative conditions that could explain acute breathlessness (e.g., cardiac failure, inducible laryngeal obstruction, inhaled foreign body or pulmonary embolism)."
    },
    {
        "id": "doc_4413",
        "document": "Objective measurements\n\n\u2022 Pulse oximetry. Saturation levels <90% in children or adults signal the need for aggressive therapy. The FDA has issued a safety communication alerting healthcare professionals to the fact that, under conditions of hypoxemia, oxygen saturation may be over-estimated by pulse oximeters in people with dark skin color.654\n\n\u2022 PEF in patients older than 5 years (Box 4-3, p.148)"
    },
    {
        "id": "doc_4414",
        "document": "Treating exacerbations in primary care\n\nThe main initial therapies include repetitive administration of rapid-acting inhaled bronchodilators, early introduction of systemic corticosteroids, and controlled flow oxygen supplementation.642 The aim is to rapidly relieve airflow obstruction and hypoxemia, address the underlying inflammatory pathophysiology, and prevent relapse. Infection control procedures should be followed.\n\nInhaled short-acting beta2-agonists"
    },
    {
        "id": "doc_4415",
        "document": "Currently, inhaled salbutamol (albuterol) is the usual bronchodilator for acute asthma management. For mild to moderate exacerbations, repeated administration of inhaled SABA (up to 4\u201310 puffs every 20 minutes for the first hour) is an effective and efficient way to achieve rapid reversal of airflow limitation655 (Evidence A). After the first hour, the dose of SABA required varies from 4\u201310 puffs every 3\u20134 hours up to 6\u201310 puffs every 1\u20132 hours, or more often. No additional SABA is needed if"
    },
    {
        "id": "doc_4416",
        "document": "there is a good response to initial treatment (e.g. PEF >60\u201380% of predicted or personal best for 3\u20134 hours)."
    },
    {
        "id": "doc_4417",
        "document": "4. Management of worsening asthma and exacerbations\n\n147\n\nBox 4-3. Management of asthma exacerbations in primary care (adults, adolescents, children 6\u201311 years)"
    },
    {
        "id": "doc_4418",
        "document": "PRIMARY CARE Patient presents with acute or sub-acute asthma exacerbation Is it asthma? ASSESS the PATIENT Factors for asthma-related death? Severity of exacerbation? (consider worst feature) MILD or MODERATE SEVERE Talks in phrases, prefers Talks in words, sits hunched sitting to lying, not agitated forwards, agitated Respiratory rate increased Respiratory rate >30/min Accessory muscles not used Accessory muscles in use Z Pulse rate 100-120 bpm Pulse rate >120 bpm 0, saturation (on air) 90-95%"
    },
    {
        "id": "doc_4419",
        "document": "0, saturation (on air) <90% URGENT PEF >50% predicted or best PEF =50% predicted or best START TREATMENT _ Z R/ SABA 4-10 puffs by pMDI + spacer, repeat every 20 minutes for 1 hour Prednisolone: adults 40-50 mg, WORSENING i Z children 1-2 mg/kg, max. 40 mg Controlled oxygen (if available): target %, % saturation 93-95% (children: 94-98%) a ,SABA as needed CONTINUE TREATMENT = WORSENING ASSESS RESPONSE HOUR (or earlier) IMPROVING ASSESS FOR DISCHARGE ARRANGE at DISCHARGE Symptoms impr , not"
    },
    {
        "id": "doc_4420",
        "document": "needing SABA Reliever: continue as needed PEF improving, and >60-\u00a2 of personal Controller: start, or step up. best or predicted Check inhaler technique, adherence Oxygen saturation >94% room air Prednisolone: continue, usually for 5-7 days Resources at home adequate (3-5 days for children) Follow l.l within 2-7 days (1-2 days for children) FOLLOW UuP Review symptoms and signs: Is the exacerbation resolving? Should prednisone be continued? Reliever: reduce to as-needed. Controller:"
    },
    {
        "id": "doc_4421",
        "document": "om\ufb01m{ehigherdosefurdmm\ufb02\u2014zm)ormm (3 months), depending on background to exacerbation Risk factors: check and comrect modifiable risk factors that may have contributed to exacerbation, including inhaler technique and adherence. Refer if >1-2 exacerbations in a year. Action plan: Is it understood? Was it used appropriately? Does it need modification?"
    },
    {
        "id": "doc_4422",
        "document": "Reliever: reduce to as-needed. Controller: om\ufb01m{ehigherdosefurdmm\ufb02\u2014zm)ormm (3 months), depending on background to exacerbation\n\nRisk factors: check and comrect modifiable risk factors that may have contributed to exacerbation, including inhaler technique and adherence. Refer if >1-2 exacerbations in a year.\n\nAction plan: Is it understood? Was it used appropriately? Does it need modification?\n\nSee list of abbreviations (p.10).\n\n148\n\n4. Management of worsening asthma and exacerbations"
    },
    {
        "id": "doc_4423",
        "document": "Delivery of SABA via a pMDI and spacer or a DPI leads to a similar improvement in lung function as delivery via nebulizer (Evidence A);655,656 however, patients with acute severe asthma were not included in these studies. The most cost-effective route of delivery is pMDI and spacer,657 provided the patient can use this device. Because of static charge, some spacers require pre-washing with detergent before use. The manufacturer\u2019s advice should be followed."
    },
    {
        "id": "doc_4424",
        "document": "Combination ICS-formoterol in management of acute asthma exacerbations"
    },
    {
        "id": "doc_4425",
        "document": "Combination ICS-formoterol (budesonide-formoterol or beclometasone-formoterol) is now widely used as an anti-inflammatory reliever as part of routine asthma management in adults and adolescents, because it reduces the risk of severe exacerbations and exposure to OCS compared with use of a SABA reliever (GINA Track 1, p.58). Up to 12 inhalations of budesonide-formoterol 200/6 mcg (or 8 inhalations of beclometasone-formoterol 100/6) can be taken in a single day if needed (see Box 3-15, p.80 for"
    },
    {
        "id": "doc_4426",
        "document": "details of medications and doses)."
    },
    {
        "id": "doc_4427",
        "document": "In emergency departments, a randomized controlled trial in adult and adolescent patients with average FEV1 42\u201345% predicted compared the effect of 2 doses of budesonide-formoterol 400/12 mcg (delivered dose 320/9 mcg) versus 8 doses of salbutamol (albuterol) 100 mcg (delivered dose 90 mcg), with these doses repeated again after 5 minutes; all patients received OCS. Lung function was similar over 3 hours, but pulse rate was higher in the SABA group658. A meta- analysis of earlier RCTs found that"
    },
    {
        "id": "doc_4428",
        "document": "the efficacy and safety of formoterol itself was similar to that of salbutamol [albuterol] in management of acute asthma.659 Formoterol is no longer used for this purpose, but there is no evidence that budesonide-formoterol would be less effective in management of asthma exacerbations.659 More studies are needed. There are no published data on use of combination ICS-SABA in an emergency department setting."
    },
    {
        "id": "doc_4429",
        "document": "Controlled oxygen therapy (if available)"
    },
    {
        "id": "doc_4430",
        "document": "Oxygen therapy should be titrated against pulse oximetry (if available) to maintain oxygen saturation at 93\u201395% (94\u2013 98% for children 6\u201311 years); note the FDA caution above about potential overestimation of saturation in people with dark skin color (p.147). In hospitalized asthma patients, controlled or titrated oxygen therapy is associated with lower mortality and better outcomes than high concentration (100%) oxygen therapy660-663 (Evidence A). Oxygen should not be withheld if oximetry is not"
    },
    {
        "id": "doc_4431",
        "document": "available, but the patient should be monitored for deterioration, somnolence or fatigue because of the risk of hypercapnia and respiratory failure.660-663 If supplemental oxygen is administered, oxygen saturation should be maintained no higher than 96% in adults.664"
    },
    {
        "id": "doc_4432",
        "document": "Systemic corticosteroids"
    },
    {
        "id": "doc_4433",
        "document": "OCS should be given promptly, especially if the patient is deteriorating, or had already increased their reliever and maintenance ICS-containing medications before presenting (Evidence B). The recommended dose of prednisolone for adults is 1 mg/kg/day or equivalent up to a maximum of 50 mg/day, and 1\u20132 mg/kg/day for children 6\u201311 years up to a maximum of 40 mg/day). OCS should usually be continued for 5\u20137 days in adults665,666 and 3-5 days in children667 (Evidence B). Patients should be advised"
    },
    {
        "id": "doc_4434",
        "document": "about common short-term side-effects, including sleep disturbance, increased appetite, reflux and mood changes.653 In adults, the risk of sepsis and thromboembolism is also increased after a short course of OCS.526 While OCS are life-saving for acute severe asthma, use of 4\u20135 lifetime courses in adults is associated with a dose-dependent increased risk of long-term adverse effects such as osteoporosis, fractures, diabetes, heart failure and cataract.309 This emphasizes the importance of"
    },
    {
        "id": "doc_4435",
        "document": "optimizing asthma management after any severe exacerbation to reduce the risk of further exacerbations (see Chapter 3.2, p.53)."
    },
    {
        "id": "doc_4436",
        "document": "Maintenance ICS-containing medication"
    },
    {
        "id": "doc_4437",
        "document": "Patients already prescribed maintenance ICS-containing medication should be provided with advice about increasing the dose for the next 2\u20134 weeks, as summarized in Box 4-2 (p.146). Patients not currently taking controller medication should be commenced on ICS-containing therapy, as SABA-only treatment of asthma is no longer recommended. An exacerbation requiring medical care indicates that the patient is at increased risk of future exacerbations (Box 2-2, p.38)."
    },
    {
        "id": "doc_4438",
        "document": "Antibiotics (not recommended)\n\nEvidence does not support routine use of antibiotics in the treatment of acute asthma exacerbations unless there is strong evidence of lung infection (e.g. fever and purulent sputum or radiographic evidence of pneumonia).668\n\n4. Management of worsening asthma and exacerbations\n\n149"
    },
    {
        "id": "doc_4439",
        "document": "Reviewing response\n\nDuring treatment, patients should be closely monitored, and treatment titrated according to their response. Patients who present with signs of a severe or life-threatening exacerbation (Box 4-3, p.148), who fail to respond to treatment, or who continue to deteriorate should be transferred immediately to an acute care facility. Patients with little or slow response to SABA treatment should be closely monitored."
    },
    {
        "id": "doc_4440",
        "document": "For many patients, lung function can be monitored after SABA therapy is initiated. Additional treatment should continue until PEF or FEV1 reaches a plateau or (ideally) returns to the patient\u2019s previous best. A decision can then be made whether to send the patient home or transfer them to an acute care facility.\n\nFollow up"
    },
    {
        "id": "doc_4441",
        "document": "Discharge medications should include regular maintenance ICS-containing treatment (see Box 3-15, p.80 and Box 4-5, p.157), as-needed reliever medication (low-dose ICS-formoterol, ICS-SABA or SABA) and a short course of OCS. SABA-only treatment is not recommended. Inhaler technique and adherence should be reviewed before discharge. Patients should be advised to use their reliever inhaler only as-needed, rather than routinely. A follow-up appointment should be arranged for about 2\u20137 days later,"
    },
    {
        "id": "doc_4442",
        "document": "depending on the clinical and social context."
    },
    {
        "id": "doc_4443",
        "document": "At the review visit the health care provider should assess whether the flare-up has resolved, and whether OCS can be ceased. They should assess the patient\u2019s level of symptom control and risk factors; explore the potential cause of the exacerbation; and review the written asthma action plan (or provide one if the patient does not already have one). Maintenance ICS-containing treatment can generally be stepped back to pre-exacerbation levels 2\u20134 weeks after the exacerbation. However, if the"
    },
    {
        "id": "doc_4444",
        "document": "exacerbation was preceded by symptoms suggestive of chronically poorly controlled asthma, and inhaler technique and adherence are good, a step up in treatment (Box 3-12, p.65) may be indicated."
    },
    {
        "id": "doc_4445",
        "document": "MANAGEMENT OF ASTHMA EXACERBATIONS IN THE EMERGENCY DEPARTMENT (ADULTS, ADOLESCENTS, CHILDREN 6\u201311 YEARS)\n\nSevere exacerbations of asthma are life-threatening medical emergencies, which are most safely managed in an acute care setting e.g., emergency department (Box 4-4). Infection control procedures should be followed. Management of asthma in the intensive care unit is beyond the scope of this report and readers are referred to a comprehensive review.669\n\nAssessment"
    },
    {
        "id": "doc_4446",
        "document": "History\n\nA brief history and physical examination should be conducted concurrently with the prompt initiation of therapy. Include:\n\n\u2022 Time of onset and cause (if known) of the present exacerbation\n\n\u2022 Severity of asthma symptoms, including any limiting exercise or disturbing sleep\n\n\u2022 Any symptoms of anaphylaxis\n\n\u2022 Risk factors for asthma-related death (Box 4-1, p.141)"
    },
    {
        "id": "doc_4447",
        "document": "\u2022 All current reliever and maintenance medications, including doses and devices prescribed, adherence pattern, any recent dose changes, and response to current therapy."
    },
    {
        "id": "doc_4448",
        "document": "Physical examination\n\nThe physical examination should assess:\n\n\u2022 Signs of exacerbation severity (Box 4-4), including vital signs (e.g., level of consciousness, temperature, pulse rate, respiratory rate, blood pressure, ability to complete sentences, use of accessory muscles)\n\n\u2022 Complicating factors (e.g., anaphylaxis, pneumonia, atelectasis, pneumothorax or pneumomediastinum)"
    },
    {
        "id": "doc_4449",
        "document": "\u2022 Signs of alternative conditions that could explain acute breathlessness (e.g., cardiac failure, inducible laryngeal obstruction, inhaled foreign body or pulmonary embolism).\n\n150\n\n4. Management of worsening asthma and exacerbations\n\nObjective assessments\n\nObjective assessments are also needed as the physical examination alone may not indicate the severity of the exacerbation.670,671 However, patients, and not their laboratory values, should be the focus of treatment."
    },
    {
        "id": "doc_4450",
        "document": "\u2022 Measurement of lung function: this is strongly recommended. If possible, and without unduly delaying treatment, PEF or FEV1 should be recorded before treatment is initiated, although spirometry may not be possible in children with acute asthma. Lung function should be monitored at one hour and at intervals until a clear response to treatment has occurred or a plateau is reached."
    },
    {
        "id": "doc_4451",
        "document": "\u2022 Oxygen saturation: this should be closely monitored, preferably by pulse oximetry. In children, oxygen saturation is normally \u226595% when breathing room air at sea level, and saturation <92% is a predictor of the need for hospitalization (Evidence C).672 Saturation levels <90% in children or adults signal the need for aggressive therapy. Subject to clinical urgency, saturation should be assessed before oxygen is commenced, or 5 minutes after oxygen is removed or when saturation stabilizes. The"
    },
    {
        "id": "doc_4452",
        "document": "FDA has issued a safety communication alerting healthcare professionals to the fact that, under conditions of hypoxemia, oxygen saturation may be over-estimated by pulse oximeters in people with dark skin color.654"
    },
    {
        "id": "doc_4453",
        "document": "\u2022 Arterial blood gas measurements are not routinely required:673 They should be considered for patients with PEF or FEV1 <50% predicted,674 or for those who do not respond to initial treatment or are deteriorating. Supplemental controlled oxygen should be continued while blood gases are obtained. During an asthma exacerbation PaCO2 is often below normal (<40 mmHg). Fatigue and somnolence suggest that pCO2 may be increasing and airway intervention may be needed. PaO2<60 mmHg (8 kPa) and normal or"
    },
    {
        "id": "doc_4454",
        "document": "increased PaCO2 (especially >45 mmHg, 6 kPa) indicate respiratory failure."
    },
    {
        "id": "doc_4455",
        "document": "\u2022 Chest X-ray (CXR) is not routinely recommended: In adults, CXR should be considered if a complicating or alternative cardiopulmonary process is suspected (especially in older patients), or for patients who are not responding to treatment where a pneumothorax may be difficult to diagnose clinically.675 Similarly, in children, routine CXR is not recommended unless there are physical signs suggestive of pneumothorax, parenchymal disease or an inhaled foreign body. Features associated with"
    },
    {
        "id": "doc_4456",
        "document": "positive CXR findings in children include fever, no family history of asthma, and localized lung examination findings.676"
    },
    {
        "id": "doc_4457",
        "document": "Treatment in acute care settings such as the emergency department\n\nThe following treatments are usually administered concurrently to achieve rapid improvement.677\n\nOxygen"
    },
    {
        "id": "doc_4458",
        "document": "To achieve arterial oxygen saturation of 93\u201395% (94\u201398% for children 6\u201311 years), oxygen should be administered by nasal cannulae or mask. Note the FDA caution above about potential overestimation of saturation in people with dark skin color (p.151). In severe exacerbations, controlled low flow oxygen therapy using pulse oximetry to maintain saturation at 93\u201395% is associated with better physiological outcomes than with high concentration (100%) oxygen therapy660-662 (Evidence B). However,"
    },
    {
        "id": "doc_4459",
        "document": "oxygen therapy should not be withheld if pulse oximetry is not available (Evidence D). Once the patient has stabilized, consider weaning them off oxygen using oximetry to guide the need for ongoing oxygen therapy."
    },
    {
        "id": "doc_4460",
        "document": "Inhaled short-acting beta2-agonists"
    },
    {
        "id": "doc_4461",
        "document": "Inhaled short-acting beta2-agonist (SABA) therapy such as salbutamol [albuterol] should be administered frequently for patients presenting with acute asthma. The most cost-effective and efficient delivery is by pMDI with a spacer655,657 (Evidence A). Evidence is less robust in severe and near-fatal asthma. Systematic reviews of intermittent versus continuous SABA in acute asthma, which mostly used nebulized SABA, provide conflicting results. Use of nebulizers can disseminate aerosols and"
    },
    {
        "id": "doc_4462",
        "document": "potentially contribute to spread of respiratory viral infections.678"
    },
    {
        "id": "doc_4463",
        "document": "Current evidence does not support the routine use of intravenous beta2-agonists in patients with severe asthma exacerbations (Evidence A).679\n\n4. Management of worsening asthma and exacerbations\n\n151\n\nBox 4-4. Management of asthma exacerbations in acute care facility, e.g. emergency department"
    },
    {
        "id": "doc_4464",
        "document": "INITIAL ASSESSMENT A: airway B: breathing C: circulation YES 2 Further TRIAGE BY CLINICAL STATUS 7/ G according to worst feature W MILD or MODERATE SEVERE Talks in phrases Talks in words Sits hunched forwards Prefers sitting to lying Not agitated Agitated Respiratory rate increased Respiratory rate - 'min Accessory muscles not used Accessory muscles being used Pulse rate 100-120 bpm Pulse rate >120 bpm O, saturation (on air) < 90% O, saturation (on air) 90-95% PEF > % predicted or best ="
    },
    {
        "id": "doc_4465",
        "document": "predicted or best Short-acting beta,-agonists Short-acting beta,-agonists Consider ipratropium bromide Ipratropium bromide Controlled O, to maintain Controlled O, to maintain saturation 93-95% (children saturation 93-95% (children 94-98%) Oral corticosteroids Oral or IV corticosteroids Consider IV magnesium Consider high dose ICS /// // ASSESS CLINICAL PROGRESS FREQUENTLY MEASURE LUNG FUNCTION in all patients one hour after initial treatment FEV, or PEF 60-80% of predicted or FEV; or PEF <60% of"
    },
    {
        "id": "doc_4466",
        "document": "predicted or personal best and symptoms improved personal best,or lack of clinical response SEVERE MODERATE Continue treatment as above andreassas(rgmetw"
    },
    {
        "id": "doc_4467",
        "document": "See list of abbreviations (p.10).\n\n152\n\n4. Management of worsening asthma and exacerbations\n\nCombination ICS-formoterol as an alternative to high dose SABA"
    },
    {
        "id": "doc_4468",
        "document": "Currently, inhaled salbutamol (albuterol) is the usual bronchodilator in acute asthma management. Similar efficacy and safety have been reported from emergency department studies with formoterol,659 and in one study with budesonide- formoterol.658 This study showed that high-dose budesonide-formoterol had similar efficacy and safety profile to high dose SABA.658 In this study, patients received 2 doses of budesonide-formoterol 400/12 mcg (delivered dose 320/9 mcg) or 8 doses of salbutamol"
    },
    {
        "id": "doc_4469",
        "document": "(albuterol) 100 mcg (delivered dose 90 mcg), repeated once after 5 minutes; all patients received OCS.658 While more studies are needed, meta-analysis of data from earlier studies comparing high- dose formoterol with high dose salbutamol (albuterol) for treatment of acute asthma in the ED setting suggest that budesonide-formoterol would also be effective.659 Formoterol alone is no longer used for this purpose."
    },
    {
        "id": "doc_4470",
        "document": "Epinephrine (for anaphylaxis)\n\nIntramuscular epinephrine (adrenaline) is indicated in addition to standard therapy for acute asthma associated with anaphylaxis and angioedema. It is not routinely indicated for other asthma exacerbations."
    },
    {
        "id": "doc_4471",
        "document": "Systemic corticosteroids\n\nSystemic corticosteroids speed resolution of exacerbations and prevent relapse, and in acute care settings should be utilized in all but the mildest exacerbations in adults, adolescents and children 6\u201311 years.680,681 (Evidence A). Where possible, systemic corticosteroids should be administered to the patient within 1 hour of presentation.680,682 Use of systemic corticosteroids is particularly important in the emergency department if:"
    },
    {
        "id": "doc_4472",
        "document": "Initial SABA treatment fails to achieve lasting improvement in symptoms\n\n\u2022 The exacerbation developed while the patient was taking OCS\n\n\u2022 The patient has a history of previous exacerbations requiring OCS."
    },
    {
        "id": "doc_4473",
        "document": "Route of delivery: oral administration is as effective as intravenous. The oral route is preferred because it is quicker, less invasive and less expensive.683,684 For children, a liquid formulation is preferred to tablets. OCS require at least 4 hours to produce a clinical improvement. Intravenous corticosteroids can be administered when patients are too dyspneic to swallow; if the patient is vomiting; or when patients require non-invasive ventilation or intubation. Evidence does not demonstrate"
    },
    {
        "id": "doc_4474",
        "document": "a benefit of intramuscular corticosteroids over oral corticosteroids.681"
    },
    {
        "id": "doc_4475",
        "document": "Dosage: daily doses of OCS equivalent to 50 mg prednisolone as a single morning dose, or 200 mg hydrocortisone in divided doses, are typically used for adults. For children, a prednisolone dose of 1\u20132 mg/kg up to a maximum of 40 mg/day is suggested.685"
    },
    {
        "id": "doc_4476",
        "document": "Duration: 5- and 7-day courses in adults have been found to be as effective as 10- and 14-day courses respectively (Evidence B),665,666 and a 3\u20135-day course in children is usually considered sufficient for most. A small number of studies examined oral dexamethasone 0.6 mg/kg, given once daily for 1-2 days in children and adults; the relapse rate was similar to that with prednisolone for 3\u20135 days, with a lower risk of vomiting.686-688 Oral dexamethasone should not be continued beyond 2 days"
    },
    {
        "id": "doc_4477",
        "document": "because of concerns about metabolic side-effects. If there is a failure of resolution, or relapse of symptoms, consideration should be given to switching to prednisolone. Evidence from studies in which all patients were taking maintenance ICS after discharge suggests that there is no benefit in tapering the dose of OCS, either in the short term689 or over several weeks690 (Evidence B)."
    },
    {
        "id": "doc_4478",
        "document": "Inhaled corticosteroids"
    },
    {
        "id": "doc_4479",
        "document": "Within the emergency department: high-dose ICS given within the first hour after presentation reduces the need for hospitalization in patients not receiving systemic corticosteroids (Evidence A).682 When added to systemic corticosteroids, evidence is conflicting in adults.691 In children, administration of ICS with or without concomitant systemic corticosteroids within the first hours of attendance to the emergency department might reduce the risk of hospital admission and need for systemic"
    },
    {
        "id": "doc_4480",
        "document": "corticosteroids (Evidence B).692 Overall, add-on ICS are well tolerated; however, cost may be a significant factor, and the agent, dose and duration of treatment with ICS in the management of asthma in the emergency department remain unclear. Patients admitted to hospital for an asthma exacerbation should continue on, or be prescribed, ICS-containing therapy."
    },
    {
        "id": "doc_4481",
        "document": "4. Management of worsening asthma and exacerbations\n\n153"
    },
    {
        "id": "doc_4482",
        "document": "On discharge home: patients should be prescribed ongoing ICS-containing treatment since the occurrence of a severe exacerbation is a risk factor for future exacerbations (Evidence B) (Box 2-2, p.38), and ICS-containing medications significantly reduce the risk of asthma-related death or hospitalization (Evidence A).221 SABA-only treatment of asthma is no longer recommended. For short-term outcomes such as relapse requiring admission, symptoms, and quality of life, a systematic review found no"
    },
    {
        "id": "doc_4483",
        "document": "significant differences when ICS were added to systemic corticosteroids after discharge.693 There was some evidence, however, that post-discharge ICS were as effective as systemic corticosteroids for milder exacerbations, but the confidence limits were wide (Evidence B).693 Cost may be a significant factor for patients in the use of high-dose ICS, and further studies are required to establish their role.693"
    },
    {
        "id": "doc_4484",
        "document": "After an ED presentation or hospitalization, the preferred ongoing treatment is maintenance-and-reliver therapy (MART) with ICS-formoterol. In patients with a history of \u22651 severe exacerbations, MART reduces the risk of another severe exacerbation in the next 12 months by 32% compared with same dose ICS or ICS-LABA plus as-needed SABA, and by 23% compared with higher dose ICS-LABA plus as-needed SABA.213 See Box 3-15 (p.80) for medications and doses.\n\nOther treatments\n\nIpratropium bromide"
    },
    {
        "id": "doc_4485",
        "document": "For adults and children with moderate-severe exacerbations, treatment in the emergency department with both SABA and ipratropium, a short-acting anticholinergic, was associated with fewer hospitalizations (Evidence A694 for adults; Evidence B695 for adolescents/children) and greater improvement in PEF and FEV1 compared with SABA alone (Evidence A, adults/adolescents).694-696 For children hospitalized for acute asthma, no benefits were seen from adding ipratropium to SABA, including no reduction"
    },
    {
        "id": "doc_4486",
        "document": "in length of stay,695 but the risk of nausea and tremor was reduced.695"
    },
    {
        "id": "doc_4487",
        "document": "Aminophylline and theophylline (not recommended)"
    },
    {
        "id": "doc_4488",
        "document": "Intravenous aminophylline and theophylline should not be used in the management of asthma exacerbations, in view of their poor efficacy and safety profile, and the greater effectiveness and relative safety of SABA.697 Nausea and/or vomiting are more common with aminophylline.695,697 The use of intravenous aminophylline is associated with severe and potentially fatal side-effects, particularly in patients already treated with sustained-release theophylline. In adults with severe asthma"
    },
    {
        "id": "doc_4489",
        "document": "exacerbations, add-on treatment with aminophylline does not improve outcomes compared with SABA alone.697"
    },
    {
        "id": "doc_4490",
        "document": "Magnesium"
    },
    {
        "id": "doc_4491",
        "document": "Intravenous magnesium sulfate is not recommended for routine use in asthma exacerbations; however, when administered as a single 2 g infusion over 20 minutes, it reduces hospital admissions in some patients, including adults with FEV1 <25\u201330% predicted at presentation; adults and children who fail to respond to initial treatment and have persistent hypoxemia; and children whose FEV1 fails to reach 60% predicted after 1 hour of care (Evidence A).698-700 Randomized, controlled trials that excluded"
    },
    {
        "id": "doc_4492",
        "document": "patients with more severe asthma showed no benefit with the addition of intravenous or nebulized magnesium compared with placebo in the routine care of asthma exacerbations in adults and adolescents701-703 or children702,704 (Evidence B)."
    },
    {
        "id": "doc_4493",
        "document": "Helium oxygen therapy\n\nA systematic review of studies comparing helium\u2013oxygen with air\u2013oxygen suggests there is no role for this intervention in routine care (Evidence B), but it may be considered for patients who do not respond to standard therapy; however, availability, cost and technical issues should be considered.705\n\nLeukotriene receptor antagonists (LTRAs)"
    },
    {
        "id": "doc_4494",
        "document": "There is limited evidence to support a role for oral or intravenous LTRAs in acute asthma. Small studies have demonstrated improvement in lung function706,707 but the clinical role and safety of these agents requires more study.\n\nAntibiotics (not recommended)\n\nEvidence does not support the routine use of antibiotics in the treatment of acute asthma exacerbations unless there is strong evidence of lung infection (e.g. fever or purulent sputum or radiographic evidence of pneumonia).668\n\n154"
    },
    {
        "id": "doc_4495",
        "document": "4. Management of worsening asthma and exacerbations\n\nNon-invasive ventilation (NIV)"
    },
    {
        "id": "doc_4496",
        "document": "The evidence regarding the role of NIV in asthma is weak. A systematic review identified five studies involving 206 participants with acute severe asthma treated with NIV or placebo.708 Two studies found no difference in need for endotracheal intubation but one study identified fewer admissions in the NIV group. No deaths were reported in either study. Given the small size of the studies, no recommendation is offered. If NIV is tried, the patient should be monitored closely (Evidence D). It"
    },
    {
        "id": "doc_4497",
        "document": "should not be attempted in agitated patients, and patients should not be sedated in order to receive NIV (Evidence D)."
    },
    {
        "id": "doc_4498",
        "document": "Sedatives (MUST BE AVOIDED)\n\nSedation should be strictly avoided during exacerbations of asthma because of the respiratory depressant effect of anxiolytic and hypnotic drugs. An association between the use of these drugs and avoidable asthma deaths has been reported.709,710"
    },
    {
        "id": "doc_4499",
        "document": "Reviewing response\n\nClinical status and oxygen saturation should be re-assessed frequently, with further treatment titrated according to the patient\u2019s response (Box 4-4, p.152). Lung function should be measured after one hour, i.e., after the first three bronchodilator treatments, and patients who deteriorate despite intensive bronchodilator and corticosteroid treatment should be re-evaluated for transfer to the intensive care unit."
    },
    {
        "id": "doc_4500",
        "document": "Criteria for hospitalization versus discharge from the emergency department\n\nFrom retrospective analyses, clinical status (including the ability to lie flat) and lung function 1 hour after commencement of treatment are more reliable predictors of the need for hospitalization than the patient\u2019s status on arrival.711,712\n\nSpirometric criteria proposed for consideration for admission or discharge from the emergency department include:713"
    },
    {
        "id": "doc_4501",
        "document": "If pre-treatment FEV1 or PEF is <25% predicted or personal best, or post-treatment FEV1 or PEF is <40% predicted or personal best, hospitalization is recommended.\n\n.\n\nIf post-treatment lung function is 40\u201360% predicted, discharge may be possible after considering the patient\u2019s risk factors (Box 4-1, p.141) and availability of follow-up care."
    },
    {
        "id": "doc_4502",
        "document": "\u2022 If post-treatment lung function is >60% predicted or personal best, discharge is recommended after considering risk factors and availability of follow-up care.\n\nOther factors associated with increased likelihood of need for admission include:714-716\n\n\u2022 Female sex, older age and non-white race\n\n\u2022 Use of more than eight beta2-agonist puffs in the previous 24 hours"
    },
    {
        "id": "doc_4503",
        "document": "\u2022 Severity of the exacerbation (e.g., need for resuscitation or rapid medical intervention on arrival, respiratory rate >22 breaths/minute, oxygen saturation <95%, final PEF <50% predicted)\n\n\u2022 Past history of severe exacerbations (e.g., intubations, asthma admissions)\n\n\u2022 Previous unscheduled office and emergency department visits requiring use of OCS."
    },
    {
        "id": "doc_4504",
        "document": "Overall, these risk factors should be considered by clinicians when making decisions on admission/discharge for patients with asthma managed in the acute care setting. The patient\u2019s social circumstances should also be considered.\n\n4. Management of worsening asthma and exacerbations\n\n155"
    },
    {
        "id": "doc_4505",
        "document": "DISCHARGE PLANNING AND FOLLOW-UP\n\nPrior to discharge from the emergency department or hospital to home, arrangements should be made for a follow-up appointment within 2\u20137 days (1\u20132 days for children), and strategies to improve asthma management including medications, inhaler skills and written asthma action plan, should be addressed (Box 4-5).316"
    },
    {
        "id": "doc_4506",
        "document": "All patients should be prescribed ongoing ICS-containing treatment to reduce the risk of further exacerbations. For adults and adolescents, the preferred regimen after discharge is maintenance-and-reliever therapy (MART) with the anti- inflammatory reliever ICS-formoterol, because this will reduce the risk of future severe exacerbations and reduce the need for OCS compared with a regimen with a SABA reliever. In the context of a recent ED visit or hospitalization, it would be appropriate to"
    },
    {
        "id": "doc_4507",
        "document": "commence treatment with ICS-formoterol in adults and adolescents at Step 4. For medications and doses, see Box 3-15 (p.80), The maintenance dose can be stepped down later, once the patient has fully recovered and asthma has remained stable for 2\u20133 months (see Box 3-16, p.83)."
    },
    {
        "id": "doc_4508",
        "document": "Follow up after emergency department presentation or hospitalization for asthma\n\nFollowing discharge, the patient should be reviewed by their health care provider regularly over subsequent weeks until good symptom control is achieved and personal best lung function is reached or surpassed. Incentives such as free transport and telephone reminders improve primary care follow up but have shown no effect on long-term outcomes.316"
    },
    {
        "id": "doc_4509",
        "document": "At follow-up, again ensure that the patient\u2019s treatment has been optimized to reduce the risk of future exacerbations. Consider switching to GINA Track 1 with the anti-inflammatory reliever ICS-formoterol, if not already prescribed. See Box 3-15 (p.80) for medications and doses. Check and correct inhaler technique and adherence."
    },
    {
        "id": "doc_4510",
        "document": "Patients discharged following an emergency department presentation or hospitalization for asthma should be especially targeted for an asthma education program, if one is available. Patients who were hospitalized may be particularly receptive to information and advice about their illness. Health care providers should take the opportunity to review:\n\n\u2022 The patient\u2019s understanding of the cause of their asthma exacerbation"
    },
    {
        "id": "doc_4511",
        "document": "\u2022 Modifiable risk factors for exacerbations (including, where relevant, smoking) (Box 3-17, p.85)\n\n\u2022 The patient\u2019s understanding of the purposes and correct uses of medications, including ICS-containing maintenance treatment and anti-inflammatory reliever, if prescribed\n\n\u2022 The actions the patient needs to take to respond to worsening symptoms or peak flows."
    },
    {
        "id": "doc_4512",
        "document": "After an emergency department presentation, comprehensive intervention programs that include optimization of asthma treatment, inhaler technique, and elements of self-management education (self-monitoring, written action plan and regular review177) are cost effective and have shown significant improvement in asthma outcomes316 (Evidence B)."
    },
    {
        "id": "doc_4513",
        "document": "Referral for expert advice should be considered for patients who have been hospitalized for asthma, or who have had several presentations to an acute care setting despite having a primary care provider. Follow-up by a specialist is associated with fewer subsequent emergency department visits or hospitalizations and better asthma control.316"
    },
    {
        "id": "doc_4514",
        "document": "Optimize asthma treatment to minimize the risk of exacerbations and the adverse effects of OCS\n\n\u2022 OCS can be life-saving during severe asthma exacerbations, but there is increasing awareness of the risks of repeated courses.\n\n\u2022 In adults, short-term adverse effects of OCS include sleep disturbance, increased appetite, reflux, mood changes,653 sepsis, pneumonia, and thromboembolism.526"
    },
    {
        "id": "doc_4515",
        "document": "In adults, even 4\u20135 lifetime courses of OCS are associated with a significantly increased dose-dependent risk of diabetes, cataract, heart failure, osteoporosis and several other conditions.309\n\n\u2022 The need for OCS can be reduced by optimizing inhaled therapy, including attention to inhaler technique and adherence."
    },
    {
        "id": "doc_4516",
        "document": "\u2022 For adults and adolescents, GINA Track 1 with ICS-formoterol as anti-inflammatory reliever reduces the risk of severe exacerbations requiring OCS compared with using a SABA reliever (see Box 3-12, p.65).\n\n156\n\n4. Management of worsening asthma and exacerbations\n\nBox 4-5. Discharge management after hospital or emergency department care for asthma\n\nMedications\n\nInhaled corticosteroid (ICS)-containing therapy"
    },
    {
        "id": "doc_4517",
        "document": "Initiate ICS prior to discharge, if not previously prescribed. Maintenance-and-reliever therapy with ICS-formoterol (MART) is preferred as it reduces risk of future exacerbations compared with using a SABA reliever (see Box 3-15, p.80). For adults/adolescents, start at MART at Step 4 on discharge (Box 3-16, Box 3-15). If prescribing an ICS regimen with SABA reliever, step maintenance dose up for 2\u20134 weeks (Box 4-2, p.146). Emphasize good adherence."
    },
    {
        "id": "doc_4518",
        "document": "Oral corticosteroids (OCS)\n\nTo reduce the risk of relapse, prescribe at least a 5\u20137 day course of OCS for adults (prednisolone or equivalent 40\u201350 mg/day) and 3\u20135 days for children (1\u20132 mg/kg/day to a maximum of 40 mg/day)717 (Evidence A). Review progress before ceasing OCS. If the OCS is dexamethasone, treatment is only for total 1\u20132 days,686 but if there is failure of resolution, or relapse of symptoms, consider switching to prednisolone."
    },
    {
        "id": "doc_4519",
        "document": "Reliever medication \u2013 return to as-needed rather than regular use"
    },
    {
        "id": "doc_4520",
        "document": "Transfer patients back to as-needed rather than regular reliever medication use, with frequency based on symptomatic and objective improvement. Regular use of SABA for even 1\u20132 weeks leads to beta-receptor down- regulation, increased airway hyperresponsiveness and increased eosinophilic inflammation, with reduced bronchodilator response.587,718 Ipratropium bromide, if used in the ED or hospital, may be quickly discontinued as it is unlikely to provide ongoing benefit. Patients prescribed"
    },
    {
        "id": "doc_4521",
        "document": "ICS\u2013formoterol as their reliever should return to this on discharge if SABA was substituted in ED or hospital."
    },
    {
        "id": "doc_4522",
        "document": "Risk factors and triggers that contributed to the exacerbation"
    },
    {
        "id": "doc_4523",
        "document": "Identify factors that may have contributed to the exacerbation, and implement strategies to reduce modifiable risk factors (Box 3-17, p.85). These may include irritant or allergen exposure, viral respiratory infections, inadequate long- term ICS treatment, problems with adherence, and/or lack of a written asthma action plan. Handwashing, masks and social/physical distancing may reduce the risk of acquiring viral respiratory infections, including influenza. Self-management skills and written"
    },
    {
        "id": "doc_4524",
        "document": "asthma action plan"
    },
    {
        "id": "doc_4525",
        "document": "\u2022 Review inhaler technique (Box 3-22, p.100).\n\nProvide a written asthma action plan (Box 4-2, p.146) or review the patient\u2019s existing plan, either at discharge or as soon as possible afterwards. Patients discharged from the ED with an action plan and PEF meter have better outcomes than patients discharged without these resources.719 For patients prescribed ICS-formoterol reliever, use an action plan template customized for this treatment.8 Review technique with PEF meter if used.\n\n)"
    },
    {
        "id": "doc_4526",
        "document": "Evaluate the patient\u2019s response as the exacerbation was developing. If it was inadequate, review the action plan and provide further written guidance to assist if asthma worsens again.719,720"
    },
    {
        "id": "doc_4527",
        "document": "\u2022 Review the patient\u2019s use of medications before and during the exacerbation. Was ICS-containing treatment increased promptly and by how much? Was ICS-formoterol reliever (if prescribed) increased in response to symptoms? If OCS were indicated, were they taken; did the patient experience adverse effects? If the patient is provided with a prescription for OCS to be on hand for subsequent exacerbations, beware of inappropriate use, as even 4\u20135 lifetime courses of OCS in adults increase the risk of"
    },
    {
        "id": "doc_4528",
        "document": "serious adverse effects.309"
    },
    {
        "id": "doc_4529",
        "document": "Follow up communication and appointment\n\nInform the patient\u2019s usual health care provider about their ED presentation/admission, instructions given on discharge, and any treatment changes.\n\n\u2022 Make a follow-up appointment within 2\u20137 days of discharge (1\u20132 days for children) to ensure that treatment is continued. The patient should be followed to ensure that asthma symptoms return to well controlled, and that their lung function returns to their personal best (if known)."
    },
    {
        "id": "doc_4530",
        "document": "See list of abbreviations (p.10).\n\n4. Management of worsening asthma and exacerbations\n\n157\n\n\u00ae & O\\\"o & C)OQ O ot & @?\u2018 & X & K\n\n&\n\nChapter 5.\n\nDiagnosis and initial treatment of adults with features of asthma, COPD or both"
    },
    {
        "id": "doc_4531",
        "document": "KEY POINTS\n\nAsthma and chronic obstructive pulmonary disease (COPD) are heterogeneous and overlapping conditions\n\n\u2022 \u2018Asthma\u2019 and \u2018COPD\u2019 are umbrella labels for heterogeneous conditions characterized by chronic airway and/or lung disease. Asthma and COPD each include several different clinical phenotypes, and are likely to have several different underlying mechanisms, some of which may be common to both asthma and COPD."
    },
    {
        "id": "doc_4532",
        "document": "\u2022 Symptoms of asthma and COPD may be similar, and the diagnostic criteria overlap."
    },
    {
        "id": "doc_4533",
        "document": "Why are the labels \u2018asthma\u2019 and \u2018COPD\u2019 still important?\n\n\u2022 There are extremely important differences in evidence-based treatment recommendations for asthma and COPD: treatment with a long-acting beta2 agonist (LABA) and/or long-acting muscarinic antagonist (LAMA) alone (i.e., without inhaled corticosteroids [ICS]) is recommended as initial treatment in COPD but contraindicated in asthma due to the risk of severe exacerbations and death."
    },
    {
        "id": "doc_4534",
        "document": "\u2022 These risks are also seen in patients who have diagnoses of both asthma and COPD, making it important to identify adult patients who, for safety, should not be treated with long-acting bronchodilators alone.\n\n\u2022 In COPD, high-dose ICS should not be used because of the risk of pneumonia."
    },
    {
        "id": "doc_4535",
        "document": "Many patients have features of both asthma and COPD\n\n\u2022 Distinguishing asthma from COPD can be difficult, particularly in smokers and older adults, and some patients may have features of both asthma and COPD.\n\n\u2022 The terms \u2018asthma-COPD overlap\u2019 (ACO) or \u2018asthma+COPD\u2019 are simple descriptors for patients who have features of both asthma and COPD."
    },
    {
        "id": "doc_4536",
        "document": "\u2022 These terms do not refer to a single disease entity. They include patients with several clinical phenotypes that are likely caused by a range of different underlying mechanisms.\n\n\u2022 More research is needed to better define these phenotypes and mechanisms, but in the meantime, safety of pharmacologic treatment is a high priority."
    },
    {
        "id": "doc_4537",
        "document": "Diagnosis\n\n\u2022 Diagnosis in patients with chronic respiratory symptoms involves a stepwise approach, first recognizing that the patient is likely to have chronic airways disease, then syndromic categorization as characteristic asthma, characteristic COPD, with features of both or having other conditions such as bronchiectasis."
    },
    {
        "id": "doc_4538",
        "document": "\u2022 Lung function testing is essential for confirming persistent airflow limitation, but variable airflow obstruction can be detected with serial peak flow measurements and/or measurements before and after bronchodilator."
    },
    {
        "id": "doc_4539",
        "document": "Initial treatment for safety and clinical efficacy\n\n\u2022 For asthma: ICS are essential either alone or in combination with a long-acting bronchodilator (LABA), to reduce the risk of severe exacerbations and death. Do not treat with LABA and/or LAMA alone, without ICS.\n\n\u2022 For patients with features of both asthma and COPD, treat as asthma. ICS-containing therapy is important to reduce the risk of severe exacerbations and death. Do not give LABA and/or LAMA alone without ICS."
    },
    {
        "id": "doc_4540",
        "document": "\u2022 For COPD: Treat according to current GOLD 202359 recommendations, i.e. initial treatment with LAMA and LABA, plus as-needed SABA; with ICS for patients with any hospitalizations, \u22652 exacerbations/year requiring OCS, or blood eosinophils \u2265300/\u00b5l."
    },
    {
        "id": "doc_4541",
        "document": "\u2022 All patients: provide structured education especially focusing on inhaler technique and adherence; assess for, and treat, other clinical problems, including advice about smoking cessation, immunizations, physical activity, and management of multimorbidity.\n\nSpecialist referral for additional investigations in patients with asthma+COPD is encouraged, as they often have worse outcomes than patients with asthma or COPD alone.\n\n160"
    },
    {
        "id": "doc_4542",
        "document": "5. Diagnosis and initial treatment of adults with features of asthma, COPD or both"
    },
    {
        "id": "doc_4543",
        "document": "OBJECTIVES\n\nThe objectives of this section of the GINA Strategy Report are:\n\n\u2022 To assist primary care clinicians to identify typical asthma and typical COPD and to recognize when patients have features of both. This is particularly relevant in older patients (40 years or above)\n\n\u2022 To provide advice about safe and effective initial treatment\n\n\u2022 To provide guidance on indications for referral for specialist assessment.\n\nBACKGROUND TO DIAGNOSING ASTHMA AND/OR COPD IN ADULT PATIENTS"
    },
    {
        "id": "doc_4544",
        "document": "Why are the labels \u2018asthma\u2019 and \u2018COPD\u2019 still important?\n\nAsthma and COPD are heterogeneous conditions characterized by airway obstruction. Each of these \u2018umbrella\u2019 labels includes several different patterns of clinical features (phenotypes) that may overlap. Each may also include different inflammatory patterns and different underlying mechanisms, some of which may be common to both asthma and COPD.722"
    },
    {
        "id": "doc_4545",
        "document": "The most easily recognized phenotypes of asthma and COPD such as allergic asthma in children/young adults and emphysema in older smokers are clearly distinguishable. Regulatory studies of pharmacotherapy in asthma and COPD are largely restricted to patients with very clearly defined asthma or COPD. However, in the community, the features of asthma and COPD may overlap, especially in older adults."
    },
    {
        "id": "doc_4546",
        "document": "There are extremely important differences in treatment recommendations for asthma and COPD. In particular, treatment with long-acting bronchodilators alone (i.e. without ICS) is recommended for initial treatment in COPD59 but is contraindicated in asthma due to the risk of severe exacerbations and death.135,230,723,724 Several studies have also shown that patients with diagnoses of both asthma and COPD are at increased risk of hospitalization or death if they are treated with LABA or LABA-LAMA"
    },
    {
        "id": "doc_4547",
        "document": "compared with ICS-LABA (or ICS-LABA-LAMA).725-727"
    },
    {
        "id": "doc_4548",
        "document": "Challenges in clinical diagnosis of asthma and COPD\n\nAlthough asthma is characterized by variable expiratory airflow limitation, at least initially (Box 1-2, p.25), and COPD is characterized by persistent airflow limitation,59 the definitions of asthma and COPD are not mutually exclusive (Box 5-1, p.162). This means that clinical features are also important in making a diagnosis and treating appropriately."
    },
    {
        "id": "doc_4549",
        "document": "In children and young adults with chronic or recurrent respiratory symptoms, the differential diagnosis is different from that in older adults (see Box 1-5, p.30). Once infectious disease and nonpulmonary conditions (e.g., congenital heart disease, inducible laryngeal obstruction) have been excluded, the most likely chronic airway disease in children and young adults is asthma."
    },
    {
        "id": "doc_4550",
        "document": "However, in adults with a history of long-standing asthma,728,729 persistent airflow limitation may be found 730-734 Distinguishing this from COPD is problematic, especially if they are smokers or have other risk factors for COPD.735-738 On the other hand, patients with COPD may show evidence of reversible airflow obstruction when a rapid-acting bronchodilator is administered, a feature more strongly associated with asthma. In medical records, such patients often are assigned both"
    },
    {
        "id": "doc_4551",
        "document": "diagnoses.61,739"
    },
    {
        "id": "doc_4552",
        "document": "In keeping with common usage of the term \u201coverlap\u201d in other contexts, e.g. for the association between COPD with sleep disorders, and in overlap syndromes of collagen vascular disease, the descriptive term \u2018asthma-COPD overlap\u2019 is often used. Another common descriptor is \u2018asthma+COPD\u2019.\n\n\u2018Asthma-COPD overlap\u2019 is a descriptor for patients often seen in clinical practice, who comprise a heterogeneous group. It does not mean a single disease entity."
    },
    {
        "id": "doc_4553",
        "document": "5. Diagnosis and initial treatment of adults with features of asthma, COPD or both\n\n161\n\nPrevalence and morbidity of asthma-COPD overlap\n\nIn epidemiological studies, reported prevalence rates for asthma+COPD have ranged between 9% and 55% of those with either diagnosis, with variation by gender and age;733,740-742 the wide range reflects the different criteria that have been used by different investigators. Concurrent doctor-diagnosed asthma and COPD has been reported in between 15"
    },
    {
        "id": "doc_4554",
        "document": "There is broad agreement that patients with features of both asthma and COPD have a greater burden of symptoms,745 experience frequent exacerbations,61,731,745 have poor quality of life,61,740,745 a more rapid decline in lung function,745 higher mortality,731,739 and greater use of healthcare resources61,746 compared with patients with asthma or COPD alone.\n\nBox 5-1. Current definitions of asthma and COPD, and clinical description of asthma-COPD overlap"
    },
    {
        "id": "doc_4555",
        "document": "Asthma\n\nAsthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. [GINA 2023]"
    },
    {
        "id": "doc_4556",
        "document": "COPD\n\nChronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. [GOLD 2023]59"
    },
    {
        "id": "doc_4557",
        "document": "Asthma+COPD, also called asthma-COPD overlap\n\n\u2018Asthma-COPD overlap\u2019 and \u2018asthma +COPD\u2019 are terms used to collectively describe patients who have persistent airflow limitation together with clinical features that are consistent with both asthma and COPD.\n\nThis is not a definition of a single disease entity, but a descriptive term for clinical use that includes several different clinical phenotypes reflecting different underlying mechanisms.\n\nSee list of abbreviations (p.10)."
    },
    {
        "id": "doc_4558",
        "document": "ASSESSMENT AND MANAGEMENT OF PATIENTS WITH CHRONIC RESPIRATORY SYMPTOMS\n\n1: History and clinical assessment to establish the following:\n\nThe nature and pattern of respiratory symptoms (variable and/or persistent)\n\n\u2022 History of asthma diagnosis; childhood and/or current\n\n\u2022 Exposure history: smoking and/or other exposures to risk factors for COPD."
    },
    {
        "id": "doc_4559",
        "document": "The features that are most helpful in identifying and distinguishing asthma from COPD, and the features that should prompt a patient to be treated as asthma to reduce the risk of severe exacerbations and death, are shown in Box 5-2."
    },
    {
        "id": "doc_4560",
        "document": "Caution: Consider alternative diagnoses: Other airways diseases, such as bronchiectasis and chronic bronchitis, and other forms of lung disease such as interstitial lung disease may present with some of the above features. The approach to diagnosis provided here does not replace the need for a full assessment of patients presenting with respiratory symptoms, to first exclude non-respiratory diagnoses such as heart failure.20 Physical examination may provide supportive information.\n\n162"
    },
    {
        "id": "doc_4561",
        "document": "5. Diagnosis and initial treatment of adults with features of asthma, COPD or both\n\nBox 5-2. Approach to initial treatment in patients with asthma and/or COPD"
    },
    {
        "id": "doc_4562",
        "document": "HIGHLY LIKELY TO BE ASTHMA if several of the following features TREAT AS ASTHMA FEATURES OF BO | AST! CO \u2018A & 77 s TREAT \\ST] . % ///// Y 4////// /77 //// ///// 7 Il Yytrainiply . ///////// ///// . = o // //////////// P ="
    },
    {
        "id": "doc_4563",
        "document": "HISTORY \u00ab Symptoms vary over time and in intensity - Triggers may include laughter, exercise, allergens, seasonal - Onset before age 40 years - Symptoms improve spontaneously or with bronchodilators (minutes) or ICS (days to weeks)"
    },
    {
        "id": "doc_4564",
        "document": "HISTORY + Symptoms intermittent or episodic May have started before or after age 40 . May have a history of smoking and/or other toxic exposures, or history of low birth weight or respiratory illness such as tuberculosis Any of asthma features at left (e.g. common triggers; symptoms improve spontaneously or"
    },
    {
        "id": "doc_4565",
        "document": "HISTORY + Dyspnea persistent (most days) - Onset after age 40 years - Limitation of physical activity - May have been preceded by cough/sputum - Bronchodilator provides only limited relief History of smoking and/or other toxic exposure, or history of low birth weight or respiratory iliness"
    },
    {
        "id": "doc_4566",
        "document": "\u00ab Current asthma diagnosis, or asthma diagnosis in childhood LUNG FUNCTION \u00ab Variable expiratory airflow limitation \u00ab Persistent airflow limitation may be present with bronchodilators or ICS; current asthma diagnosis or asthma diagnosis in childhood) LUNG FUNCTION \u00ab Persistent expiratory airflow limitation + With or without bronchodilator reversibility ."
    },
    {
        "id": "doc_4567",
        "document": "such as tuberculosis + No past or current diagnosis of asthma LUNG FUNCTION \u00ab Persistent expiratory airflow limitation \u00ab With or without bronchodilator reversibility"
    },
    {
        "id": "doc_4568",
        "document": "INITIAL PHARMACOLOGICAL TREATMENT (as well as treating comorbidities and risk factors. See Box 3-12)"
    },
    {
        "id": "doc_4569",
        "document": "to reduce risk of severe exacerbations and death. - GINA Track 1 with ICS-formoterol as See Box 3-12 and Box 3-15 reliever is the preferred regimen DO NOT GIVE LABA and/or LAMA without ICS Maintenance OCS only as last resort to reduce risk of severe exacerbations and death Add-on LABA and/or LAMA usually also needed Additional COPD treatments as per GOLD DO NOT GIVE LABA and/or LAMA without ICS Maintenance OCS only as last resort"
    },
    {
        "id": "doc_4570",
        "document": "(see report) - Initially maintenance LABA-LAMA - Add ICS as per GOLD for patients with hospitalizations, =2 e: requiring OCS, or blood eosinophils 2300/pl . Avoid high dose ICS, avoid maintenance OCS Reliever containing ICS is not recommended"
    },
    {
        "id": "doc_4571",
        "document": "See list of abbreviations (p.10.\n\n5. Diagnosis and initial treatment of adults with features of asthma, COPD or both\n\n163\n\n2: Lung function testing is essential to confirm the following:\n\n\u2022 The presence of persistent expiratory airflow limitation\n\n\u2022 Variable expiratory airflow limitation."
    },
    {
        "id": "doc_4572",
        "document": "Spirometry is preferably performed at the initial assessment. In cases of clinical urgency it may be delayed to a subsequent visit, but confirmation of diagnosis may be more difficult once patients are started on ICS-containing therapy (see Box 1-3, p.28). Early confirmation (or exclusion) of the presence of persistent expiratory airflow limitation may avoid needless trials of therapy, or delays in initiating other investigations. Spirometry can confirm both persistent airflow limitation and"
    },
    {
        "id": "doc_4573",
        "document": "reversibility (Box 5-2, p.163, Box 5-3, p.164)."
    },
    {
        "id": "doc_4574",
        "document": "Measurement of peak expiratory flow (PEF), if performed repeatedly on the same meter over a period of 1\u20132 weeks, may help to confirm reversible airflow limitation and the diagnosis of asthma by demonstrating excessive variability (Box 1-2, p.25). However, PEF is not as reliable as spirometry, and a normal PEF does not rule out either asthma or COPD.\n\nBox 5-3. Spirometric measures in asthma and COPD"
    },
    {
        "id": "doc_4575",
        "document": "Spirometric variable Asthma COPD Asthma+COPD Normal FEV1/FVC pre- or post BD Compatible with asthma. If patient is symptomatic at a time when lung function is normal, consider alternative diagnosis. Not compatible with COPD Not compatible Reduced post-BD FEV1/FVC (< lower limit of normal, or <0.7 (GOLD)) Indicates airflow limitation but may improve spontaneously or on treatment Required for diagnosis of COPD Required for diagnosis of asthma+COPD"
    },
    {
        "id": "doc_4576",
        "document": "Post-BD FEV1280% predicted Compatible with diagnosis of asthma (good asthma control or interval between symptoms) <y Compatible with mild persistent airflow limitation if post-BD FEV4/FVC is reduced Compatible with mild persistent airflow limitation if post-BD FEV4/FVC is reduced"
    },
    {
        "id": "doc_4577",
        "document": "Post-BD FEV1 <80% predicted Compatible with diagnosis of asthma. Risk factor for asthma exacerbations An indicator of severity of airflow limitation and risk of future events (e.g., mortality and COPD exacerbations) As for COPD and asthma"
    },
    {
        "id": "doc_4578",
        "document": "Post-BD increase in FEV1 212% and 200 mL from baseline (reversible airflow limitation). Usual at some time in course of asthma, but may not be present when well controlled or on ICS-containing therapy Common and more likely when FEV1 is low Common and more likely when FEV1 is low Post-BD increase in FEV1 >12% and 400 mL from baseline (marked reversibility) High probability of asthma Unusual in COPD Compatible with asthma+COPD"
    },
    {
        "id": "doc_4579",
        "document": "See list of abbreviations (p.10).\n\n164\n\n5. Diagnosis and initial treatment of adults with features of asthma, COPD or both\n\n3: Selecting initial treatment (See Box 5-2, p.163)\n\nFor asthma"
    },
    {
        "id": "doc_4580",
        "document": "Commence treatment as described in Chapter 3 (Box 3-4,A-D, p.59\u2013p.63). Pharmacotherapy is based on ICS to reduce the risk of severe exacerbations and death and to improve symptom control, with add-on treatment as required, e.g., add-on LABA and/or LAMA. As-needed low-dose ICS-formoterol may be used as the reliever, on its own in mild asthma or in addition to maintenance ICS-formoterol in patients with moderate-severe asthma prescribed maintenance and reliever therapy (see Box 3-12, p.65)."
    },
    {
        "id": "doc_4581",
        "document": "Inhaled therapy should be optimized to minimize the need for oral corticosteroids (OCS)."
    },
    {
        "id": "doc_4582",
        "document": "For COPD"
    },
    {
        "id": "doc_4583",
        "document": "Commence treatment as in the current GOLD strategy report.59 Pharmacotherapy starts with symptomatic treatment with long-acting bronchodilators (LABA and LAMA). ICS may be added as per GOLD for patients with hospitalizations in the last year, \u22652 exacerbations/year requiring OCS, or blood eosinophils \u2265300/\u00b5L, but is not used alone as monotherapy without LABA and/or LAMA. Inhaled therapy should be optimized to reduce the need for OCS. In patients with features of COPD, high-dose ICS should be"
    },
    {
        "id": "doc_4584",
        "document": "avoided because of the risk of pneumonia.747,748"
    },
    {
        "id": "doc_4585",
        "document": "For patients with features of asthma and COPD\n\nStart treatment as for asthma (Box 3-4,A-D, p.59\u2013p.63) until further investigations have been performed."
    },
    {
        "id": "doc_4586",
        "document": "ICS play a pivotal role in preventing morbidity and even death in patients with uncontrolled asthma symptoms, for whom even seemingly \u2018mild\u2019 symptoms (compared to those of moderate or severe COPD) might indicate significant risk of a life-threatening attack.749 For patients with asthma+COPD, ICS should be used initially in a low or medium dose (see Box 3-14, p.67), depending on level of symptoms and risk of adverse effects, including pneumonia."
    },
    {
        "id": "doc_4587",
        "document": "Patients with features or diagnosis of both asthma and COPD will usually also require add-on treatment with LABA and/or LAMA to provide adequate symptom control."
    },
    {
        "id": "doc_4588",
        "document": "Patients with any features of asthma should not be treated with LABA and/or LAMA alone, without ICS. A large case-control study in community patients with newly diagnosed COPD found that those who also had a diagnosis of asthma had a lower risk of COPD hospitalizations and death if treated with combination ICS-LABA than with LABA alone.725 In another large retrospective longitudinal population cohort study of patients aged \u226566 years, those recorded as having asthma with COPD had lower morbidity"
    },
    {
        "id": "doc_4589",
        "document": "and hospitalizations if they received ICS treatment; a similar benefit was seen in those with COPD plus concurrent asthma.727"
    },
    {
        "id": "doc_4590",
        "document": "All patients with chronic airflow limitation\n\nProvide advice, as described in the GINA and GOLD reports, about:\n\n\u2022 Treatment of modifiable risk factors including advice about smoking cessation\n\n\u2022 Treatment of comorbidities\n\n\u2022 Non-pharmacological strategies including physical activity, and, for COPD or asthma-COPD overlap, pulmonary rehabilitation and vaccinations\n\n\u2022 Appropriate self-management strategies\n\n\u2022 Regular follow-up."
    },
    {
        "id": "doc_4591",
        "document": "In a majority of patients, the initial management of asthma and COPD can be satisfactorily carried out at primary care level. However, both the GINA and GOLD strategy reports recommend referral for further diagnostic procedures at relevant points in patient management (see below). This may be particularly important for patients with features of both asthma and COPD, given that this is associated with worse outcomes and greater health care utilization."
    },
    {
        "id": "doc_4592",
        "document": "5. Diagnosis and initial treatment of adults with features of asthma, COPD or both\n\n165\n\n4: Referral for specialized investigations (if necessary)\n\nReferral for expert advice and further diagnostic evaluation is advised in the following contexts:\n\n\u2022 Patients with persistent symptoms and/or exacerbations despite treatment."
    },
    {
        "id": "doc_4593",
        "document": "\u2022 Diagnostic uncertainty, especially if an alternative diagnosis (e.g., bronchiectasis, post-tuberculous scarring, bronchiolitis, pulmonary fibrosis, pulmonary hypertension, cardiovascular diseases and other causes of respiratory symptoms) needs to be investigated."
    },
    {
        "id": "doc_4594",
        "document": "\u2022 Patients with suspected asthma or COPD in whom atypical or additional symptoms or signs (e.g., hemoptysis, significant weight loss, night sweats, fever, signs of bronchiectasis or other structural lung disease) suggest an additional pulmonary diagnosis. This should prompt early referral, without waiting for a trial of treatment for asthma or COPD.\n\n\u2022 When chronic airways disease is suspected but syndromic features of either asthma or COPD are few."
    },
    {
        "id": "doc_4595",
        "document": "\u2022 Patients with comorbidities that may interfere with the assessment and management of their airways disease, particularly cardiovascular disease.\n\n\u2022 Referral may also be appropriate for issues arising during ongoing management of asthma, COPD or asthma- COPD overlap, as outlined in the GINA and GOLD strategy reports.\n\nBox 5-4 (p.166) summarizes specialized investigations that are sometimes used to distinguish asthma and COPD."
    },
    {
        "id": "doc_4596",
        "document": "Box 5-4. Specialized investigations sometimes used in patients with features of asthma and COPD"
    },
    {
        "id": "doc_4597",
        "document": "Asthma COoPD Lung function tests DLCO Normal (or slightly elevated) Often reduced Arterial blood gases Normal between exacerba\ufb01ons May be chronically abnormal between exacerbations in more severe forms of COPD Airway hyperresponsiveness (AHR) Not useful on its own in distinguishing asthma from COPD, but higher levels of AHR favor asthma Imaging"
    },
    {
        "id": "doc_4598",
        "document": "High resolution CT Scan Usually normal but air trapping and increased bronchial wall thickness may be observed. Low attenuation areas denoting either air trapping or emphysematous change can be quantitated; bronchial wall thickening and features of pulmonary hypertension may be seen. Inflammatory biomarkers"
    },
    {
        "id": "doc_4599",
        "document": "A positive test for atopy (specific IgE and/or skin prick test to aeroallergens) Increases probability of allergic asthma; not essential for diagnosis of asthma Conforms to background prevalence; does not rule out COPD FeNO A high level (>50 ppb) in non- smokers is moderately associated with eosinophilic airway inflammation. Usually normal Low in current smokers Blood eosinophilia Supports diagnosis of eosinophilic airway inflammation May be present in COPD including during exacerbations"
    },
    {
        "id": "doc_4600",
        "document": "Sputum inflammatory cell analysis Role in differential diagnosis is not established in large populations."
    },
    {
        "id": "doc_4601",
        "document": "See list of abbreviations (p.10).\n\n166\n\n5. Diagnosis and initial treatment of adults with features of asthma, COPD or both"
    },
    {
        "id": "doc_4602",
        "document": "FUTURE RESEARCH\n\nThere is an urgent need for more research on this topic, in order to guide better recognition and safe and effective treatment. Patients who do not have \u2018classical\u2019 features of asthma or of COPD, or who have features of both, have generally been excluded from randomized controlled trials of most therapeutic interventions for airways disease, and from many mechanistic studies."
    },
    {
        "id": "doc_4603",
        "document": "Future research should include study of clinical and physiological characteristics, biomarkers, outcomes and underlying mechanisms, among broad populations of patients with respiratory symptoms or with chronic airflow limitation. In the meantime, the present chapter provides interim advice about diagnosis and initial treatment, from the perspective of clinicians, particularly those in primary care and nonpulmonary specialties. Further research is needed to inform evidence-based definitions and a"
    },
    {
        "id": "doc_4604",
        "document": "more detailed classification of patients who present overlapping features of asthma and COPD, and to encourage the development of specific interventions for clinical use."
    },
    {
        "id": "doc_4605",
        "document": "5. Diagnosis and initial treatment of adults with features of asthma, COPD or both\n\n167\n\n\u00ae & O\\\"o & C)OQ O ot & @?\u2018 & X & K\n\n&\n\nSECTION 2. CHILDREN 5 YEARS AND YOUNGER\n\nChapter 6.\n\nDiagnosis and management of asthma in children 5 years and younger\n\n6.1. DIAGNOSIS\n\nKEY POINTS\n\n\u2022 Recurrent wheezing occurs in a large proportion of children 5 years and younger, typically with viral upper respiratory tract infections. It is difficult to discern when this is the initial presentation of asthma."
    },
    {
        "id": "doc_4606",
        "document": "\u2022 Previous classifications of wheezing phenotypes (episodic wheeze and multiple-trigger wheeze; or transient wheeze, persistent wheeze and late-onset wheeze) do not appear to identify stable phenotypes, and their clinical usefulness is uncertain. However, emerging research suggest that more clinically relevant phenotypes will be described and phenotype-directed therapy possible."
    },
    {
        "id": "doc_4607",
        "document": "\u2022 A diagnosis of asthma in young children with a history of wheezing is more likely if they have: o Wheezing or coughing that occurs with exercise, laughing or crying, or in the absence of an apparent respiratory infection\n\no A history of other allergic disease (eczema or allergic rhinitis), allergen sensitization or asthma in first-degree relatives"
    },
    {
        "id": "doc_4608",
        "document": "o Clinical improvement during 2\u20133 months of low-dose inhaled corticosteroid (ICS) treatment plus as-needed short-acting beta2 agonist (SABA) reliever, and worsening after cessation."
    },
    {
        "id": "doc_4609",
        "document": "ASTHMA AND WHEEZING IN YOUNG CHILDREN\n\nAsthma is the most common chronic disease of childhood and the leading cause of childhood morbidity from chronic disease as measured by school absences, emergency department visits and hospitalizations.750 Asthma often begins in early childhood; in up to half of people with asthma, symptoms commence during childhood.751 Onset of asthma is earlier in males than females.752-754"
    },
    {
        "id": "doc_4610",
        "document": "No intervention has yet been shown to prevent the development of asthma or modify its long-term natural course. Atopy is present in the majority of children with asthma who are over 3 years old, and allergen-specific sensitization (and particularly multiple early-life sensitizations) is one of the most important risk factors for the development of asthma.755\n\nViral-induced wheezing"
    },
    {
        "id": "doc_4611",
        "document": "Recurrent wheezing occurs in a large proportion of children aged 5 years or younger. It is typically associated with upper respiratory tract infections (URTI), which occur in this age group around 6\u20138 times per year.756 Some viral infections (respiratory syncytial virus and rhinovirus) are associated with recurrent wheeze throughout childhood. Wheezing in this age group is a highly heterogeneous condition, and not all wheezing indicates asthma. A large proportion of wheezing episodes in young"
    },
    {
        "id": "doc_4612",
        "document": "children is virally induced whether the child has asthma or not. Therefore, deciding when wheezing with a respiratory infection is truly an isolated event or represents a recurrent clinical presentation of childhood asthma may be difficult.754,757 In children aged under 1 year, bronchiolitis may present with wheeze. It is usually accompanied by other chest signs such as crackles on auscultation."
    },
    {
        "id": "doc_4613",
        "document": "Wheezing phenotypes\n\nIn the past, two main classifications of wheezing (called \u2018wheezing phenotypes\u2019) were proposed:\n\n\u2022 Symptom-based classification:758 this was based on whether the child had only episodic wheeze (wheezing during discrete time periods, often in association with URTI, with symptoms absent between episodes) or multiple-trigger wheeze (episodic wheezing with symptoms also occurring between these episodes, e.g., during sleep or with triggers such as activity, laughing, or crying)."
    },
    {
        "id": "doc_4614",
        "document": "\u2022 Time trend-based classification: this system was initially based on retrospective analysis of data from a cohort study.754 It included transient wheeze (symptoms began and ended before the age of 3 years); persistent wheeze (symptoms began before the age of 3 years and continued beyond the age of 6 years), and late-onset wheeze (symptoms began after the age of 3 years). These general patterns have been confirmed in subsequent studies using unsupervised statistical approaches.759,760\n\n170"
    },
    {
        "id": "doc_4615",
        "document": "6. Diagnosis and management of asthma in children 5 years and younger"
    },
    {
        "id": "doc_4616",
        "document": "However, prospective allocation of individual children to these phenotypes has been challenging in \u2018real-life\u2019 clinical situations, and the clinical usefulness of these, and other, classification and asthma prediction systems remain a subject of active investigation. For example, one study conducted in a research setting with high medication adherence found that daily ICS treatment reduced exacerbations in pre-school children characterized as \u2018sensitization with indoor pet exposure\u2019 or \u2018multiple"
    },
    {
        "id": "doc_4617",
        "document": "sensitization with eczema\u2019, but not among those characterized as \u2018minimal sensitization\u2019 or \u2018sensitization with tobacco smoke exposure\u2019.761"
    },
    {
        "id": "doc_4618",
        "document": "CLINICAL DIAGNOSIS OF ASTHMA"
    },
    {
        "id": "doc_4619",
        "document": "It may be challenging to make a confident diagnosis of asthma in children 5 years and younger, because episodic respiratory symptoms such as wheezing and cough are also common in children without asthma, particularly in those aged 0\u20132 years,762,763 and it is not possible to routinely assess airflow limitation or bronchodilator responsiveness in this age group. A probability-based approach, based on the pattern of symptoms during and between viral respiratory infections,764 may be helpful for"
    },
    {
        "id": "doc_4620",
        "document": "discussion with parents/caregivers (Box 6-1 & 2). This allows individual decisions to be made about whether to give a trial of controller treatment. It is important to make decisions for each child individually, to avoid either over- or under-treatment."
    },
    {
        "id": "doc_4621",
        "document": "Box 6-1. Probability of asthma diagnosis in children 5 years and younger\n\nSYMPTOM PATTERN (may change over time) 7 ~S\u2014 oYyl C( gl ol 7 h, \\ Z 7 7, COU( bre \u201cOUg 72 a) 27 Z O lin 4 % ning) . ing) 10 7 ng Ip 7 uring 7 >10d 7 to 7 il ato nfec 0 T ni 7 7 7 7 7 _ 7 . . . . 7 7 r . 7 epi 2 3 7/ D ;ng\u2018 ep 77 i 7 .7 7 7 77 ms i et = le _ No /7 7 na et 7 ~chil /h CCi has ou 0% Ze - co h, w or | 77 4\\{?' ; 7 ;/ 7 i 7 > , & / titi o 7 7 2 7 7 IS tory 2 @) Yz 3 i & Z % W"
    },
    {
        "id": "doc_4622",
        "document": "Symptoms suggestive of asthma in children 5 years and younger\n\nAs shown in Boxes 6-1, 6-2 and 6-3, an asthma diagnosis in children 5 years and younger can often be based on:\n\n\u2022 Symptom patterns (recurrent episodes of wheeze, cough, breathlessness (typically manifested by activity limitation), and nocturnal symptoms or awakenings)"
    },
    {
        "id": "doc_4623",
        "document": "\u2022 Presence of risk factors for development of asthma, such as family history of atopy, allergic sensitization, allergy or asthma, or a personal history of food allergy or atopic dermatitis\n\n\u2022 Therapeutic response to controller treatment.\n\n\u2022 Exclusion of alternate diagnoses.\n\n6. Diagnosis and Management of asthma in children 5 years and younger\n\n171"
    },
    {
        "id": "doc_4624",
        "document": "Box 6-1 is a schematic figure showing the estimated probability of an asthma diagnosis765,766 in children aged 5 years or younger who have viral-induced cough, wheeze or heavy breathing, based on the pattern of symptoms."
    },
    {
        "id": "doc_4625",
        "document": "Many young children wheeze with viral infections; it may be difficult to decide when a child should be given controller treatment. The frequency and severity of wheezing episodes and the temporal pattern of symptoms (only with viral colds or also in response to other triggers) should be taken into account. Any controller treatment should be viewed as a treatment trial, with follow up scheduled after 2\u20133 months to review the response. Review is also important since the pattern of symptoms tends"
    },
    {
        "id": "doc_4626",
        "document": "to change over time in a large proportion of children."
    },
    {
        "id": "doc_4627",
        "document": "A diagnosis of asthma in young children is therefore based largely on recurrent symptom patterns combined with a careful clinical assessment of family history and physical findings with careful consideration of the differential diagnostic possibilities. A positive family history of allergic disorders, or the presence of atopy or allergic sensitization provide additional predictive support, as early allergic sensitization increases the likelihood that a wheezing child will develop persistent"
    },
    {
        "id": "doc_4628",
        "document": "asthma.755"
    },
    {
        "id": "doc_4629",
        "document": "Box 6-2. Features suggesting a diagnosis of asthma in children 5 years and younger"
    },
    {
        "id": "doc_4630",
        "document": "Feature Characteristics suggesting asthma Cough Recurrent or persistent non-productive cough that may be worse at night or accompanied by wheezing and breathing difficulties Cough occurring with exercise, laughing, crying or exposure to tobacco smoke, particularly in the absence of an apparent respiratory infection Wheezing Recurrent wheezing, including during sleep or with triggers such as activity laughing, crying or exposure to tobacco smoke or air pollution"
    },
    {
        "id": "doc_4631",
        "document": "Difficult or heavy breathing or shortness of breath Occurring with exercise, laughing, or crying Reduced activity Not running, playing or laughing at the same intensity as other children; tires earlier during walks (wants to be carried) Past or family history Other allergic disease (atopic dermatitis or allergic rhinitis, food allergy). Asthma in first-degree relative(s)"
    },
    {
        "id": "doc_4632",
        "document": "Therapeutic trial with low-dose ICS (Box 6-6, p.183) plus as-needed SABA Clinical improvement during 2\u20143 months of low-dose ICS treatment and worsening when treatment is stopped"
    },
    {
        "id": "doc_4633",
        "document": "See list of abbreviations (p.10).\n\nWheeze\n\nWheeze is the most common and specific symptom associated with asthma in children 5 years and younger. Wheezing occurs in several different patterns, but a wheeze that occurs recurrently, during sleep, or with triggers such as activity, laughing, or crying, is consistent with a diagnosis of asthma. Clinician confirmation is important, as parents/caregivers may describe any noisy breathing as \u2018wheezing\u2019.767 Some cultures do not have a word for wheeze."
    },
    {
        "id": "doc_4634",
        "document": "Wheezing may be interpreted differently based on:\n\n\u2022 Who observes it (e.g., parent/caregiver versus the health care provider)\n\nThe environmental context (e.g,. high income countries versus areas with a high prevalence of parasites that involve the lung)\n\n)\n\nThe cultural context (e.g., the relative importance of certain symptoms can differ between cultures, as can the diagnosis and treatment of respiratory tract diseases in general).\n\n172"
    },
    {
        "id": "doc_4635",
        "document": "6. Diagnosis and management of asthma in children 5 years and younger\n\nBox 6-3. Questions that can be used to elicit features suggestive of asthma\n\n\u2022 Does your child have wheezing? Wheezing is a high-pitched noise which comes from the chest and not the throat. Use of a video questionnaire,768 or asking a parent/caregiver to record an episode on a smartphone if available can help to confirm the presence of wheeze and differentiate from upper airway abnormalities."
    },
    {
        "id": "doc_4636",
        "document": "\u2022 Does your child wake up at night because of coughing, wheezing, or difficult breathing, heavy breathing, or breathlessness?\n\n\u2022 Does your child have to stop running, or play less hard, because of coughing, wheezing or difficult breathing, heavy breathing, or shortness of breath?\n\n\u2022 Does your child cough, wheeze or get difficult breathing, heavy breathing, or shortness of breath when laughing, crying, playing with animals, or when exposed to strong smells or smoke?"
    },
    {
        "id": "doc_4637",
        "document": "In children with respiratory symptoms, additional features may help to support the diagnosis of asthma\n\n\u2022 Has your child ever had eczema, or been diagnosed with allergy to foods?\n\n\u2022 Has anyone in your family had asthma, hay fever, food allergy, eczema, or any other disease with breathing problems?\n\nCough"
    },
    {
        "id": "doc_4638",
        "document": "Cough due to asthma is generally non-productive, recurrent and/or persistent, and is usually accompanied by wheezing episodes and breathing difficulties. Allergic rhinitis may be associated with cough in the absence of asthma. A nocturnal cough (when the child is asleep) or a cough that occurs with exercise, laughing or crying, in the absence of an apparent respiratory infection, supports a diagnosis of asthma. The common cold and other respiratory illnesses including pertussis are also"
    },
    {
        "id": "doc_4639",
        "document": "associated with coughing. Prolonged cough in infancy, and cough without cold symptoms, are associated with later parent/caregiver-reported physician-diagnosed asthma, independent of infant wheeze. Characteristics of cough in infancy may be early markers of asthma susceptibility, particularly among children with maternal asthma.769"
    },
    {
        "id": "doc_4640",
        "document": "Breathlessness\n\nParents/caregivers may also use terms such as \u2018difficult breathing\u2019, \u2018heavy breathing\u2019, or \u2018shortness of breath\u2019. Breathlessness that occurs during exercise and is recurrent increases the likelihood of the diagnosis of asthma. In infants and toddlers, crying and laughing are equivalent to exercise in older children.\n\nActivity and social behavior"
    },
    {
        "id": "doc_4641",
        "document": "Physical activity is an important trigger of asthma symptoms in young children. Young children with poorly controlled asthma often abstain from strenuous play or exercise to avoid symptoms, but many parents/caregivers are unaware of such changes in their children\u2019s lifestyle. Engaging in play is important for a child\u2019s normal social and physical development. For this reason, careful review of the child\u2019s daily activities, including their willingness to walk and play, is important when assessing"
    },
    {
        "id": "doc_4642",
        "document": "a potential asthma diagnosis in a young child. Parents/caregivers may report irritability, tiredness and mood changes in their child as the main problems when asthma is not well controlled."
    },
    {
        "id": "doc_4643",
        "document": "TESTS TO ASSIST IN DIAGNOSIS\n\nWhile no tests specifically and definitively diagnose asthma with certainty, in children 5 years and younger, the following are useful adjuncts."
    },
    {
        "id": "doc_4644",
        "document": "Therapeutic trial\n\nA trial of treatment for at least 2\u20133 months with as-needed SABA and regular low-dose ICS may provide some guidance about the diagnosis of asthma (Evidence D). Response should be evaluated by symptom control (daytime and night- time), and the frequency of wheezing episodes and exacerbations. Marked clinical improvement during treatment, and\n\n6. Diagnosis and Management of asthma in children 5 years and younger\n\n173"
    },
    {
        "id": "doc_4645",
        "document": "deterioration when treatment is stopped, support a diagnosis of asthma. Due to the variable nature of asthma in young children, a therapeutic trial may need to be repeated in order to be certain of the diagnosis."
    },
    {
        "id": "doc_4646",
        "document": "Tests for allergic sensitization\n\nSensitization to allergens can be assessed using either skin prick testing or allergen-specific immunoglobulin E. Allergic sensitization is present in the majority of children with asthma once they are over 3 years of age; however, absence of sensitization to common aeroallergens does not rule out a diagnosis of asthma. Allergic sensitization is the best predictor for development of persistent asthma.770"
    },
    {
        "id": "doc_4647",
        "document": "Chest X-ray\n\nRadiographs are rarely indicated; however, if there is doubt about the diagnosis of asthma in a wheezing or coughing child, a plain chest X-ray may help to exclude structural abnormalities (e.g., congenital lobar emphysema, vascular ring) chronic infections such as tuberculosis, an inhaled foreign body, or other diagnoses. Other imaging investigations may be appropriate, depending on the condition being considered."
    },
    {
        "id": "doc_4648",
        "document": "Lung function testing\n\nDue to the inability of most children 5 years and younger to perform reproducible expiratory maneuvers, lung function testing, bronchial provocation testing, and other physiological tests do not have a major role in the diagnosis of asthma at this age. However, by 5 years of age, many children are capable of performing reproducible spirometry if coached by an experienced technician and with visual incentives.\n\nExhaled nitric oxide"
    },
    {
        "id": "doc_4649",
        "document": "Measurement of fractional concentration of exhaled nitric oxide (FeNO) is not widely available for most children in this age group and currently remains primarily a research tool. FeNO can be measured in young children with tidal breathing, and normal reference values have been published for children aged 1\u20135 years.771 In pre-school children with recurrent coughing and wheezing, an elevated FeNO recorded 4 weeks from any URTI predicted physician-diagnosed asthma at school age,772 and increased"
    },
    {
        "id": "doc_4650",
        "document": "the odds for wheezing, asthma and ICS use by school age, independent of clinical history and presence of specific IgE.773"
    },
    {
        "id": "doc_4651",
        "document": "Risk profiles"
    },
    {
        "id": "doc_4652",
        "document": "A number of risk profile tools aimed at identifying which wheezing children aged 5 years and younger are at high risk of developing persistent asthma symptoms have been evaluated for use in clinical practice. However, these tools have shown limited performance for clinical practice. Only three prediction tools have been externally validated (Asthma Predictive Index774 from Tucson, USA, Prevention and Incidence of Asthma and Mite Allergy (PIAMA) index675 from the Netherlands, and Leicester"
    },
    {
        "id": "doc_4653",
        "document": "tool775 from the UK), and a systematic review has shown that these tools have poor predictive accuracy, with variation in sensitivity and positive predictive value.776 Larger predictive studies using more advanced statistical methods, and with objective measurements for asthma diagnosis, are probably needed to propose a practical tool in clinical care to predict persistent asthma in recurrent wheezers in infancy and pre-school age. The role of these tools is to help identify children at greater"
    },
    {
        "id": "doc_4654",
        "document": "risk of developing persistent asthma symptoms, not as criteria for the diagnosis of asthma in young children. Each tool demonstrates different performance characteristics with varying criteria used to identify risk.777"
    },
    {
        "id": "doc_4655",
        "document": "174\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\nDIFFERENTIAL DIAGNOSIS\n\nA definite diagnosis of asthma in this young age group is challenging but has important clinical consequences. It is particularly important in this age group to consider and exclude alternative causes that can lead to symptoms of wheeze, cough, and breathlessness before confirming an asthma diagnosis (Box 6-4).762\n\nBox 6-4. Common differential diagnoses of asthma in children 5 years and younger"
    },
    {
        "id": "doc_4656",
        "document": "Condition Typical features Recurrent viral respiratory tract infections Mainly cough, runny congested nose for <10 days; no symptoms between infections Gastroesophageal reflux Cough when feeding; recurrent chest infections; vomits easily especially after large feeds; poor response to asthma medications Foreign body aspiration Episode of abrupt, severe cough and/or stridor during eating or play; recurrent chest infections and cough; focal lung signs"
    },
    {
        "id": "doc_4657",
        "document": "Pertussis Protracted paroxysms of coughing, often with stridor and vomiting Persistent bacterial bronchitis Persistent wet cough; poor response to asthma medications Tracheomalacia Noisy breathing when crying or eating, or during upper airway infections (noisy inspiration if extrathoracic or expiration if intrathoracic); harsh cough; inspiratory or expiratory retraction; symptoms often present since birth; poor response to asthma medications"
    },
    {
        "id": "doc_4658",
        "document": "Tuberculosis Persistent noisy respirations and cough; fever unresponsive to normal antibiotics; enlarged lymph nodes; poor response to bronchodilators or inhaled corticosteroids; contact with someone who has tuberculosis Congenital heart disease Cardiac murmur; cyanosis when eating; failure to thrive; tachycardia; tachypnea or hepatomegaly; poor response to asthma medications"
    },
    {
        "id": "doc_4659",
        "document": "Cystic fibrosis Cough starting shortly after birth; recurrent chest infections; failure to thrive (malabsorption); loose greasy bulky stools Primary ciliary dyskinesia Cough and recurrent chest infections; neonatal respiratory distress, chronic ear infections and persistent nasal discharge from birth; poor response to asthma medications; situs inversus occurs in about 50% of children with this condition Vascular ring Persistently noisy breathing; poor response to asthma medications"
    },
    {
        "id": "doc_4660",
        "document": "Bronchopulmonary dysplasia Infant born prematurely; very low birth weight; needed prolonged mechanical ventilation or supplemental oxygen; difficulty with breathing present from birth Immune deficiency Recurrent fever and infections (including non-respiratory); failure to thrive"
    },
    {
        "id": "doc_4661",
        "document": "6. Diagnosis and Management of asthma in children 5 years and younger\n\n175\n\nKey indications for referral of a child 5 years or younger for further diagnostic investigations or therapeutic decisions\n\nAny of the following features suggest an alternative diagnosis and indicate the need for further investigations:\n\n\u2022 Failure to thrive\n\n\u2022 Neonatal or very early onset of symptoms (especially if associated with failure to thrive)\n\n\u2022 Vomiting associated with respiratory symptoms\n\n\u2022 Continuous wheezing"
    },
    {
        "id": "doc_4662",
        "document": "\u2022 Failure to respond to asthma medications (inhaled ICS, oral steroids or SABA)\n\n\u2022 No association of symptoms with typical triggers, such as viral URTI\n\n\u2022 Focal lung or cardiovascular signs, or finger clubbing\n\n\u2022 Hypoxemia outside context of viral illness.\n\n176\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n6.2. ASSESSMENT AND MANAGEMENT"
    },
    {
        "id": "doc_4663",
        "document": "KEY POINTS\n\n\u2022 The goals of asthma management in young children are similar to those in older patients:\n\no To achieve good control of symptoms and maintain normal activity levels\n\no To minimize the risk of asthma flare-ups, impaired lung development and medication side-effects."
    },
    {
        "id": "doc_4664",
        "document": "\u2022 Wheezing episodes in young children should be treated initially with inhaled SABA, regardless of whether the diagnosis of asthma has been made. However, for initial episodes of wheeze in children <1 year in the setting of infectious bronchiolitis, SABAs are generally ineffective."
    },
    {
        "id": "doc_4665",
        "document": "\u2022 A trial of low-dose ICS treatment should be given if the symptom pattern suggests asthma, alternative diagnoses have been excluded and respiratory symptoms are uncontrolled and/or wheezing episodes are frequent or severe.\n\n\u2022 Response to treatment should be reviewed before deciding whether to continue it. If the response is absent or incomplete, reconsider alternative diagnoses."
    },
    {
        "id": "doc_4666",
        "document": "\u2022 The choice of inhaler device should be based on the child\u2019s age and capability. The preferred device is a pressurized metered dose inhaler and spacer, with face mask for <3 years and mouthpiece for most children aged 3\u20135 years. Children should be switched from a face mask to mouthpiece as soon as they are able to demonstrate good technique.\n\n\u2022 Review the need for asthma treatment frequently, as asthma-like symptoms remit in many young children."
    },
    {
        "id": "doc_4667",
        "document": "GOALS OF ASTHMA MANAGEMENT\n\nAs with other age groups, the goals of asthma management in young children are:\n\n\u2022 To achieve good control of symptoms and maintain normal activity levels\n\n\u2022 To minimize future risk; that is to reduce the risk of flare-ups, maintain lung function and lung development as close to normal as possible, and minimize medication side-effects."
    },
    {
        "id": "doc_4668",
        "document": "Maintaining normal activity levels is particularly important in young children because engaging in play is important for their normal social and physical development. It is important to also elicit the goals of the parent/caregiver, as these may differ from conventional medical goals.\n\nThe goals of asthma management are achieved through a partnership between the parent/caregiver and the health professional team, with a cycle of:"
    },
    {
        "id": "doc_4669",
        "document": "\u2022 Assess (diagnosis, symptom control, risk factors, inhaler technique, adherence, parent preference)\n\n\u2022 Adjust treatment (medications, non-pharmacological strategies, and treatment of modifiable risk factors)\n\n\u2022 Review response including medication effectiveness and side-effects. This is carried out in combination with:\n\nEducation of parent/caregiver, and child (depending on the child\u2019s age)\n\n\u2022 Skills training for effective use of inhaler devices and encouragement of good adherence"
    },
    {
        "id": "doc_4670",
        "document": "\u2022 Monitoring of symptoms by parent/caregiver\n\n\u2022 A written personalized asthma action plan.\n\nASSESSMENT OF ASTHMA"
    },
    {
        "id": "doc_4671",
        "document": "What does \u2018asthma control\u2019 mean?\n\nAsthma control means the extent to which the manifestations of asthma are controlled, with or without treatment.29,69 It has two components (Box 6-5, p.178): the child\u2019s asthma status over the previous four weeks (current symptom control), and how asthma may affect them in the future (future risk). In young children, as in older patients, both symptom control\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n177"
    },
    {
        "id": "doc_4672",
        "document": "and future risk should be monitored (Evidence D). The rationale for this is described on p.40.\n\nAssessing asthma symptom control"
    },
    {
        "id": "doc_4673",
        "document": "Defining satisfactory symptom control in children 5 years and younger depends on information derived from family members and carers, who may be unaware either of how often the child has experienced asthma symptoms, or that their respiratory symptoms represent uncontrolled asthma. Few objective measures to assess symptom control have been validated for children <4 years. The Childhood Asthma Control Test can be used for children aged 4\u201311 years.91 The Test for Respiratory and Asthma Control in"
    },
    {
        "id": "doc_4674",
        "document": "Kids (TRACK) is a validated questionnaire for parent/caregiver completion for preschool-aged children with symptoms consistent with asthma; it includes both symptom control and courses of systemic corticosteroids in the previous year.95 However, children with no interval symptoms can still be at risk of exacerbations."
    },
    {
        "id": "doc_4675",
        "document": "Box 6-5 shows a working schema for assessing asthma control in children \u22645 years, based on current expert opinion. It incorporates assessment of symptoms; the child\u2019s level of activity and their need for reliever/rescue treatment; and assessment of risk factors for adverse outcomes (Evidence D).\n\nBox 6-5. GINA assessment of asthma control in children 5 years and younger"
    },
    {
        "id": "doc_4676",
        "document": "A. Symptom control In the past 4 weeks, has the child had: Level of asthma symptom control Well controlled Partly controlled Uncontrolled Daytime asthma symptoms for more than a few minutes, YesO NoO more than once a week? Any activity limitation due to asthma? (Runs/plays less than other children, tires easily during walks/playing?) None 1-2 3-4 SABA reliever medication needed* more than once a week?Yesd of these of these of these Any night waking or night coughing due to asthma?"
    },
    {
        "id": "doc_4677",
        "document": "B. Future risk for poor asthma outcomes\n\nRisk factors for asthma exacerbations within the next few months\n\n\u2022 Uncontrolled asthma symptoms\n\n\u2022 One or more severe exacerbations (ED attendance, hospitalization, or course of OCS) in previous year\n\nThe start of the child\u2019s usual \u2018flare-up\u2019 season (especially if autumn/fall)\n\n.\n\nExposures: tobacco smoke; indoor or outdoor air pollution; indoor allergens (e.g., house dust mite, cockroach, pets, mold), especially in combination with viral infection778"
    },
    {
        "id": "doc_4678",
        "document": "\u2022 Major psychological or socio-economic problems for child or family\n\nPoor adherence with ICS medication, or incorrect inhaler technique\n\n\u2022 Outdoor pollution (NO2 and particles)111\n\nRisk factors for persistent airflow limitation\n\nSevere asthma with several hospitalizations\n\n\u2022 History of bronchiolitis"
    },
    {
        "id": "doc_4679",
        "document": "Risk factors for medication side-effects\n\nSystemic: Frequent courses of OCS, high-dose and/or potent ICS (see Box 6-7, p.184\n\n\u2022 Local: moderate-to high-dose or potent ICS; incorrect inhaler technique; failure to protect skin or eyes when using ICS by nebulizer or spacer with face mask"
    },
    {
        "id": "doc_4680",
        "document": "See list of abbreviations (p.10). * Excludes reliever taken before exercise. Before stepping up treatment, ensure that the child\u2019s symptoms are due to asthma, and that the child has good inhaler technique and good adherence to existing treatment.\n\n178\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\nAssessing future risk of adverse outcomes"
    },
    {
        "id": "doc_4681",
        "document": "The relationship between symptom control and future risk of adverse outcomes, such as exacerbations (Box 6-5, p.178), has not been sufficiently studied in young children. Although exacerbations may occur in children after months of apparently good symptom control, the risk is greater if current symptom control is poor. Preschool children at high risk of asthma (based on modified API) who were treated with daily low-dose ICS experienced fewer days with asthma symptoms and a reduced risk of"
    },
    {
        "id": "doc_4682",
        "document": "exacerbations than those receiving placebo.779"
    },
    {
        "id": "doc_4683",
        "document": "The future risk of harm due to excessive doses of inhaled or systemic corticosteroids must also be avoided. This can be minimized by ensuring that the prescribed treatment is appropriate and reduced to the lowest dose that maintains satisfactory symptom control and minimizes exacerbations. The child\u2019s height should be measured and recorded at least yearly, as growth velocity may be lower in the first 1\u20132 years of ICS treatment,132 and poorly controlled asthma can affect growth.131 The minimum"
    },
    {
        "id": "doc_4684",
        "document": "effective dose of ICS to maintain good asthma control should be used. If decreased growth velocity is seen, other factors should be considered, including poorly controlled asthma, frequent use of oral corticosteroids (OCS), and poor nutrition, and referral should be considered."
    },
    {
        "id": "doc_4685",
        "document": "If ICS is delivered through a face-mask or nebulizer, the skin on the nose and around the mouth should be cleaned shortly after inhalation in order to avoid local side-effects such as steroid rash (reddening and atrophy).\n\nMEDICATIONS FOR SYMPTOM CONTROL AND RISK REDUCTION\n\nChoosing medications for children 5 years and younger"
    },
    {
        "id": "doc_4686",
        "document": "Good control of asthma can be achieved in the overwhelming majority of young children with a pharmacological intervention strategy.780 This should be developed in a partnership between the family/carer and the health care provider. As with older children and adults, medications comprise only one component of asthma management in young children; other key components include education, skills training for inhaler devices and adherence, non-pharmacological strategies including environmental control"
    },
    {
        "id": "doc_4687",
        "document": "where appropriate, regular monitoring, and clinical review (see later sections in this chapter)."
    },
    {
        "id": "doc_4688",
        "document": "When recommending treatment for a young child, both general and individual questions apply (Box 3-3, p.52)."
    },
    {
        "id": "doc_4689",
        "document": "\u2022 What is the \u2018preferred\u2019 medication option at each treatment step to control asthma symptoms and minimize future risk? These decisions are based on data for efficacy, effectiveness and safety from clinical trials, and on observational data. Studies suggest that consideration of factors such as allergic sensitization and/or peripheral blood count may help to better identify which children are more likely to have a short-term response to ICS.781 However, further studies are needed to assess the"
    },
    {
        "id": "doc_4690",
        "document": "applicability of these findings in a wider range of settings, particularly in areas where blood eosinophilia may reflect helminth infection rather than asthma or atopy."
    },
    {
        "id": "doc_4691",
        "document": "\u2022 How does this individual child differ from other children with asthma, in terms of:\n\no Response to previous treatment\n\no Preferences of the parent/caregiver (goals, beliefs and concerns about medications)"
    },
    {
        "id": "doc_4692",
        "document": "o Practical issues (cost, inhaler technique and adherence)?\n\nThe following treatment recommendations for children of 5 years of age or younger are based on the available evidence and on expert opinion. Although the evidence is expanding it is still rather limited as most clinical trials in this age group have not characterized participants with respect to their symptom pattern, and different studies have used different outcomes and different definitions of exacerbations."
    },
    {
        "id": "doc_4693",
        "document": "A stepwise treatment approach is recommended (Box 6-6, p.183), based on symptom patterns, risk of exacerbations and side-effects, and response to initial treatment. Generally, treatment includes the daily, long-term use of low-dose ICS treatment to keep asthma well controlled, and reliever medications for as-needed symptom relief. The choice of inhaler device is also an important consideration (Box 6-8, p.185).\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n179"
    },
    {
        "id": "doc_4694",
        "document": "Which children should be prescribed regular controller treatment?"
    },
    {
        "id": "doc_4695",
        "document": "Intermittent or episodic wheezing of any severity may represent an isolated viral-induced wheezing episode, an episode of seasonal or allergen-induced asthma, or unrecognized uncontrolled asthma. The initial treatment of wheezing is identical for all of these \u2013 a SABA every 4\u20136 hours as needed until symptoms disappear, usually within 1 to 7 days. Further treatment of the acute wheezing episodes themselves is described below (see Acute asthma exacerbations in children 5 years and younger, p.187)."
    },
    {
        "id": "doc_4696",
        "document": "However, uncertainty surrounds the addition of other medications in these children, especially when the nature of the episode is unclear. In general, the following principles apply."
    },
    {
        "id": "doc_4697",
        "document": "\u2022 If the history and symptom pattern suggest a diagnosis of asthma (Box 6-2, p.172; Box 6-3, p.173) and respiratory symptoms are uncontrolled (Box 6-5, p.178) and/or wheezing episodes are frequent (e.g., three or more episodes in a season), regular controller treatment (usually maintenance low-dose ICS) should be initiated (Step 2, Box 6-6, p.183) and the response evaluated (Evidence D). Regular ICS treatment may also be indicated in a child with less frequent, but more severe episodes of viral-"
    },
    {
        "id": "doc_4698",
        "document": "induced wheeze (Evidence D)."
    },
    {
        "id": "doc_4699",
        "document": "\u2022 If the diagnosis of asthma is in doubt, and inhaled SABA therapy or courses of antibiotics need to be repeated frequently, e.g., more than every 6\u20138 weeks, a trial of regular ICS treatment should be considered to confirm whether the symptoms are due to asthma (Evidence D). Referral for specialist opinion should also be considered at this stage."
    },
    {
        "id": "doc_4700",
        "document": "It is important to discuss the decision to prescribe controller treatment and the choice of treatment with the child\u2019s parents or caregivers. They should be aware of both the relative benefits and risks of the treatments, and the importance of maintaining normal activity levels for their child\u2019s normal physical and social development. Although effects of ICS on growth velocity are seen in pre-pubertal children in the first 1\u20132 years of treatment, this is not progressive or cumulative, and the"
    },
    {
        "id": "doc_4701",
        "document": "one study that examined long-term outcomes showed a difference of only 0.7% in adult height.132,782 Poorly controlled asthma itself adversely affects adult height.131"
    },
    {
        "id": "doc_4702",
        "document": "Treatment steps to control asthma symptoms and minimize future risk for children 5 years and younger\n\nAsthma treatment in young children follows a stepwise approach (Box 6-6), with medication adjusted up or down to achieve good symptom control and minimize future risk of exacerbations and medication side-effects. The need for controller treatment should be re-assessed regularly."
    },
    {
        "id": "doc_4703",
        "document": "Before considering a step-up of controller treatment\n\nIf symptom control is poor and/or exacerbations persist despite 3 months of adequate controller therapy, check the following before any step up in treatment is considered.\n\n\u2022 Confirm that the symptoms are due to asthma rather than a concomitant or alternative condition (Box 6-4, p.176). Refer for expert assessment if the diagnosis is in doubt.\n\n\u2022 Check and correct inhaler technique.\n\n\u2022 Confirm good adherence with the prescribed dose."
    },
    {
        "id": "doc_4704",
        "document": "\u2022 Consider trial of one of the other treatment options for that step, as many children may respond to one of the options.\n\n\u2022 Enquire about risk factors such as allergen or tobacco smoke exposure (Box 6-5, p.178).\n\n180\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\nASTHMA TREATMENT STEPS FOR CHILDREN AGED 5 YEARS AND YOUNGER\n\nSTEP 1: As-needed inhaled short-acting beta2-agonist (SABA)\n\nPreferred option: as-needed inhaled short-acting beta2-agonist (SABA)"
    },
    {
        "id": "doc_4705",
        "document": "All children who experience wheezing episodes should be provided with inhaled SABA for relief of symptoms (Evidence D), although it is not effective in all children. See Box 6-8 (p.185) for choice of inhaler device. Use of SABA for the relief of symptoms on average more than twice a week over a 1-month period indicates the need for a trial of low-dose ICS treatment. Initial episodes of wheeze in children <1 year often occur in the setting of infectious bronchiolitis, and this should be managed"
    },
    {
        "id": "doc_4706",
        "document": "according to local bronchiolitis guidelines. SABAs are generally ineffective for bronchiolitis.783"
    },
    {
        "id": "doc_4707",
        "document": "Other options\n\nOral bronchodilator therapy is not recommended due to its slower onset of action and higher rate of side-effects, compared with inhaled SABA (Evidence D)."
    },
    {
        "id": "doc_4708",
        "document": "For children with intermittent viral-induced wheeze and no interval symptoms, particularly those with underlying atopy (positive for modified API) in whom inhaled SABA medication is not sufficient, intermittent high-dose ICS may be considered649,784,785 (see Management of worsening asthma and exacerbations, p.187), but because of the risk of side- effects, this should only be considered if the physician is confident that the treatment will be used appropriately."
    },
    {
        "id": "doc_4709",
        "document": "STEP 2: Initial controller treatment plus as-needed SABA\n\nPreferred option: regular daily low-dose ICS plus as-needed SABA\n\nRegular daily, low-dose ICS (Box 6-7, p.184) is recommended as the preferred initial treatment to control asthma in children 5 years and younger (Evidence A).779,786-788 This initial treatment should be given for at least 3 months to establish its effectiveness in achieving good asthma control.\n\nOther options"
    },
    {
        "id": "doc_4710",
        "document": "In young children with persistent asthma, regular treatment with a leukotriene receptor antagonist (LTRA) modestly reduces symptoms and need for oral corticosteroids compared with placebo.789 However, for young children with recurrent viral- induced wheezing, a review concluded that neither regular nor intermittent LTRA reduces OCS-requiring exacerbations (Evidence A).790 A further systematic review found that in preschool children with asthma or recurrent wheezing, daily ICS was more effective"
    },
    {
        "id": "doc_4711",
        "document": "in improving symptom control and reducing exacerbations than regular LTRA monotherapy.791 Parents/caregivers should be counselled about the potential adverse effects of montelukast on sleep and behavior, and health professionals should consider the benefits and risks of side effects before prescribing; the FDA has required a boxed warning about these problems.236"
    },
    {
        "id": "doc_4712",
        "document": "For preschool children with asthma characterized by frequent viral-induced wheezing and interval asthma symptoms, as- needed (prn)792 or episodic ICS793 may be considered, but a trial of regular daily low-dose ICS should be undertaken first. The effect on exacerbation risk seems similar for regular daily low-dose and episodic high-dose ICS.788 See also Initial home management of asthma exacerbations, p.188."
    },
    {
        "id": "doc_4713",
        "document": "If good asthma control is not achieved with a given therapy, trials of the alternative Step 2 therapies are recommended prior to moving to Step 3.781\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n181\n\nSTEP 3: Additional controller treatment, plus as-needed SABA and consider specialist referral"
    },
    {
        "id": "doc_4714",
        "document": "If 3 months of initial therapy with a low-dose ICS fails to control symptoms, or if exacerbations continue to occur, check the following before any step up in treatment is considered.\n\n\u2022 Confirm that the symptoms are due to asthma rather than a concomitant or alternative condition (Box 6-4, p.176).\n\n\u2022 Check and correct inhaler technique. Consider alternative delivery systems if indicated.\n\n\u2022 Confirm good adherence with the prescribed dose."
    },
    {
        "id": "doc_4715",
        "document": "\u2022 Enquire about risk factors, such as exposure to allergens or tobacco smoke (Box 6-5, p.178).\n\nPreferred option: medium-dose ICS (double the \u2018low\u2019 daily dose)\n\nDoubling the initial low dose of ICS may be the best option (Evidence C). Assess response after 3 months. The child should be referred for expert assessment if symptom control remains poor and/or flare-ups persist, or if side-effects of treatment are observed or suspected."
    },
    {
        "id": "doc_4716",
        "document": "Other options\n\nAddition of a LTRA to low-dose ICS may be considered, based on data from older children (Evidence D). The relative cost of different treatment options in some countries may be relevant to controller choices for children. See note above about the FDA warning for montelukast.236"
    },
    {
        "id": "doc_4717",
        "document": "Not recommended\n\nThere are insufficient data about the efficacy and safety of ICS-LABA in children <4 years old to recommend their use. A short-term (8 week) placebo-controlled study did not show any significant difference in symptoms between combination fluticasone propionate-salmeterol versus fluticasone propionate alone; no additional safety signals were noted in the group receiving LABA.794\n\nSTEP 4: Continue controller treatment and refer for expert assessment"
    },
    {
        "id": "doc_4718",
        "document": "Preferred option: refer the child for expert advice and further investigation (Evidence D).\n\nIf doubling the initial dose of ICS fails to achieve and maintain good asthma control, carefully reassess inhaler technique and medication adherence as these are common problems in this age group. In addition, reassess and address control of environmental factors where relevant, and reconsider the asthma diagnosis."
    },
    {
        "id": "doc_4719",
        "document": "Other options\n\nThe best treatment for this population has not been established. If the diagnosis of asthma has been confirmed, options to consider, with specialist advice, are:\n\n\u2022 Further increase the dose of ICS for a few weeks until the control of the child\u2019s asthma improves (Evidence D). Monitor for side-effects.\n\n\u2022 Add LTRA (data based on studies in older children, Evidence D). Benefits, and risks of side effects, should be considered, as described previously.236"
    },
    {
        "id": "doc_4720",
        "document": "\u2022 Add long-acting beta agonist (LABA) in combination with ICS; data based on studies in children \u22654 years of age\n\n\u2022 Add a low dose of oral corticosteroid (for a few weeks only) until asthma control improves (Evidence D); monitor for side-effects.\n\n\u2022 Add intermittent high-dose ICS at onset of respiratory illnesses to the regular daily ICS if exacerbations are the main problem (Evidence D)."
    },
    {
        "id": "doc_4721",
        "document": "The need for additional controller treatment should be re-evaluated at each visit and maintained for as short a period as possible, taking into account potential risks and benefits. Treatment goals and their feasibility should be reconsidered and discussed with the child\u2019s family/carer.\n\n182\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\nBox 6-6. Personalized management of asthma in children 5 years and younger"
    },
    {
        "id": "doc_4722",
        "document": "Exclude alternative diagnoses GINA 2023 - Children 5 years and younger Symptom control & modifiable risk Inhaler technigue & adherence Personalized asthma management: Caregiver preferences and goals Assess, Adjust, Review response Symptoms E{(acelbations Side-effects Risk factors Treat modifiable risk factors and comorbidities Non-pharmacological strategies Asthma medications Education & skills training Asthma medication options: Adjust treatment up and down for individual child's needs"
    },
    {
        "id": "doc_4723",
        "document": "PREFERRED STEP 1 CONTROLLER (Insufficient evidence for daily CHOICE controller) Epen | 75 Other controller options (limited indications, or less evidence for efficacy or safety) s RELIEVER As-needed short-acting beta--agonist CONSIDER Infrequent viral Symptom pattemn not consistent with asthma but wheezing Asthma diagnosis, and Asthma not THIS STEP FOR asthma not well-controlied well-controlled CHILDREN WITH: wheezing and no episodes requiring SABA occur frequently, e.g. =3 per year. or few"
    },
    {
        "id": "doc_4724",
        "document": "interval Give diagnostic trial for 3 months. Consider specialist referral. on low dose ICS on double ICS symptoms Symptom pattem consistent with asthma, and asthma symptoms not well-controlled or 23 exacerbations per year. Before stepping up, check for altemative diagnosis, check inhaler skills, review adherence and exposures"
    },
    {
        "id": "doc_4725",
        "document": "See list of abbreviations (p.10). For ICS doses in children, see Box 6-7, p.184\n\nt\n\nBox 6-7. Low daily doses of inhaled corticosteroids for children 5 years and younger"
    },
    {
        "id": "doc_4726",
        "document": "This is not a table of equivalence, but instead, suggestions for \u2018low\u2019 total daily doses for the ICS treatment recommendations for children aged 5 years and younger in Box 6-6 (p.183), based on available studies and product information. Data on comparative potency are not readily available, particularly for children, and this table does NOT imply potency equivalence. The doses listed here are the lowest approved doses for which safety and effectiveness have been adequately studied in this age"
    },
    {
        "id": "doc_4727",
        "document": "group."
    },
    {
        "id": "doc_4728",
        "document": "Low-dose ICS provides most of the clinical benefit for most children with asthma. Higher doses are associated with an increased risk of local and systemic side-effects, which must be balanced against potential benefits."
    },
    {
        "id": "doc_4729",
        "document": "Inhaled corticosteroid Lvow tot'al daily dose (mcg) (age-group with adequate safety and effectiveness data) BDP (pMDI, standard particle, HFA) 100 (ages 5 years and older) BDP (pMDI, extrafine particle, HFA) 50 (ages 5 years and older) Budesonide nebulized 500 (ages 1 year and older) Fluticasone propionate (pMDI, standard particle, HFA) 50 (ages 4 years and older) Fluticasone furoate (DPI) Not sufficiently studied in children 5 years and younger)"
    },
    {
        "id": "doc_4730",
        "document": "Mometasone furoate (pMDI, standard particle, HFA) 100 (ages 5 years and older) Ciclesonide (pMDI, extrafine particle, HFA) Not sufficiently studied in children 5 years and younger"
    },
    {
        "id": "doc_4731",
        "document": "BDP : beclometasone dipropionate. For other abbreviations see p.10. In children, pMDI should always be used with a spacer\n\nREVIEWING RESPONSE AND ADJUSTING TREATMENT"
    },
    {
        "id": "doc_4732",
        "document": "Assessment at every visit should include asthma symptom control and risk factors (Box 6-5, p.178), and side-effects. The child\u2019s height should be measured every year, or more often. Asthma-like symptoms remit in a substantial proportion of children of 5 years or younger,795-797 so the need for continued controller treatment should be regularly assessed (e.g,. every 3\u20136 months) (Evidence D). If therapy is stepped-down or discontinued, schedule a follow-up visit 3\u20136 weeks later to check whether"
    },
    {
        "id": "doc_4733",
        "document": "symptoms have recurred, as therapy may need to be stepped-up or reinstituted (Evidence D)."
    },
    {
        "id": "doc_4734",
        "document": "Marked seasonal variations may be seen in symptoms and exacerbations in this age-group. For children with seasonal symptoms whose daily long-term controller treatment is to be discontinued (e.g., 4 weeks after their season ends), the parent/caregiver should be provided with a written asthma action plan detailing specific signs of worsening asthma, the medications that should be initiated to treat it, and when and how to contact medical care.\n\nCHOICE OF INHALER DEVICE"
    },
    {
        "id": "doc_4735",
        "document": "Inhaled therapy constitutes the cornerstone of asthma treatment in children 5 years and younger. General information about inhaler devices, and the issues that should be considered, are found in Chapter 3.3 (p.98) and in Box 3-21 (p.99). These include, first, choosing the right medication(s) for the child to control symptoms, allow normal activity, and reduce the risk of severe exacerbations; considering which delivery device is available; whether they can use it correctly after training; and,"
    },
    {
        "id": "doc_4736",
        "document": "if more than one type of inhaler device is available, their relative environmental impact."
    },
    {
        "id": "doc_4737",
        "document": "For children aged 5 years and younger, a pressurized metered-dose inhaler (pMDI) with a valved spacer (with or without a face mask, depending on the child\u2019s age) is the preferred delivery system798 (Box 6-8, p.185) (Evidence A). This recommendation is based on studies with beta2-agonists. The spacer device should have documented efficacy in young children. The dose delivered may vary considerably between spacers, so consider this if changing from one spacer to another."
    },
    {
        "id": "doc_4738",
        "document": "The only possible inhalation technique in young children is tidal breathing. The optimal number of breaths required to empty the spacer depends on the child\u2019s tidal volume, and the dead space and volume of the spacer. Generally, 5\u201310 breaths will be sufficient per actuation. The way a spacer is used can markedly affect the amount of drug delivered:\n\n184\n\n6. Diagnosis and management of asthma in children 5 years and younger"
    },
    {
        "id": "doc_4739",
        "document": "\u2022 Spacer size may affect the amount of drug available for inhalation in a complex way depending on the drug prescribed and the pMDI used. Young children can use spacers of all sizes, but theoretically a lower volume spacer (<350 mL) is advantageous in very young children.\n\n\u2022 A single pMDI actuation should be delivered at a time, with the inhaler shaken in between. Multiple actuations into the spacer before inhalation may markedly reduce the amount of drug inhaled."
    },
    {
        "id": "doc_4740",
        "document": "\u2022 Delay between actuating the pMDI into the spacer and inhalation may reduce the amount of drug available. This varies between spacers, but to maximize drug delivery, inhalation should start as soon as possible after actuation. If a health care provider or a carer is giving the medication to the child, they should actuate the pMDI only when the child is ready and the spacer is in the child\u2019s mouth."
    },
    {
        "id": "doc_4741",
        "document": "If a face mask is used it must be fitted tightly around the child\u2019s mouth and nose, to avoid loss of drug.\n\n\u2022 Ensure that the valve is moving while the child is breathing through the spacer."
    },
    {
        "id": "doc_4742",
        "document": "\u2022 Static charge may accumulate on some plastic spacers, attracting drug particles and reducing lung delivery. This charge can be reduced by washing the spacer with detergent (without rinsing) and allowing it to air dry, but it may re-accumulate over time. Spacers made of anti-static materials or metals are less subject to this problem. If a patient or health care provider carries a new plastic spacer for emergency use, it should be regularly washed with detergent (e.g., monthly) to reduce static"
    },
    {
        "id": "doc_4743",
        "document": "charge."
    },
    {
        "id": "doc_4744",
        "document": "\u2022 Nebulizers, the only viable alternative delivery systems in children, are reserved for the minority of children who cannot be taught effective use of a spacer device. If a nebulizer is used for delivery of ICS, it should be used with a mouthpiece to avoid the medication reaching the eyes. If a nebulizer is used, follow local infection control procedures.\n\nBox 6-8. Choosing an inhaler device for children 5 years and younger"
    },
    {
        "id": "doc_4745",
        "document": "Age Preferred device Alternate device 0\u20133 years Pressurized metered dose inhaler plus Nebulizer with face mask dedicated spacer with face mask 4\u20135 years Pressurized metered dose inhaler plus Pressurized metered dose inhaler plus dedicated spacer dedicated spacer with mouthpiece with face mask or nebulizer with mouthpiece or face mask\n\nSee list of abbreviations (p.10).\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n185"
    },
    {
        "id": "doc_4746",
        "document": "ASTHMA SELF-MANAGEMENT EDUCATION FOR CARERS OF YOUNG CHILDREN\n\nAsthma self-management education should be provided to family members and carers of wheezy children 5 years and younger when wheeze is suspected to be caused by asthma. An educational program should contain:\n\n\u2022 A basic explanation about asthma and the factors that influence it\n\n\u2022 Training about correct inhalation technique\n\n.\n\nInformation on the importance of the child\u2019s adherence to the prescribed medication regimen"
    },
    {
        "id": "doc_4747",
        "document": "\u2022 A written asthma action plan.\n\nCrucial to a successful asthma education program are a partnership between patient/carer and health care providers, with a high level of agreement regarding the goals of treatment for the child, and intensive follow-up (Evidence D).30"
    },
    {
        "id": "doc_4748",
        "document": "Written asthma action plans\n\nAsthma action plans should be provided for the family/carers of all children with asthma, including those aged 5 years and younger (Evidence D). Action plans, developed through collaboration between an asthma educator, the health care provider and the family, have been shown to be of value in older children,799 although they have not been extensively studied in children of 5 years and younger. A written asthma action plan includes:"
    },
    {
        "id": "doc_4749",
        "document": "\u2022 A description of how the parent or caregiver can recognize when symptom control is deteriorating\n\n\u2022 The medications to administer"
    },
    {
        "id": "doc_4750",
        "document": "\u2022 When and how to obtain medical care, including telephone numbers of services available for emergencies (e.g., doctors\u2019 offices, emergency departments and hospitals, ambulance services and emergency pharmacies). Details of treatments that can be initiated at home are provided in the following section, Part C: Management of worsening asthma and exacerbations in children 5 years and younger, p.187.\n\n186\n\n6. Diagnosis and management of asthma in children 5 years and younger"
    },
    {
        "id": "doc_4751",
        "document": "6.3. MANAGEMENT OF WORSENING ASTHMA AND EXACERBATIONS IN CHILDREN 5 YEARS AND YOUNGER\n\nKEY POINTS\n\nSymptoms of exacerbation in young children\n\n\u2022 Early symptoms of exacerbations in young children may include increased symptoms; increased coughing, especially at night; lethargy or reduced exercise tolerance; impaired daily activities including feeding; and a poor response to reliever medication.\n\nHome management in a written asthma action plan"
    },
    {
        "id": "doc_4752",
        "document": "\u2022 Give a written asthma action plan to parents/caregivers of young children with asthma so they can recognize an impending severe attack, start treatment, and identify when urgent hospital treatment is required.\n\nInitial treatment at home is with inhaled short-acting beta2-agonist (SABA), with review after 1 hour or earlier."
    },
    {
        "id": "doc_4753",
        "document": "\u2022 Parents/caregivers should seek urgent medical care if the child is acutely distressed, lethargic, fails to respond to initial bronchodilator therapy, or is worsening, especially in children <1 year of age.\n\n\u2022 Medical attention should be sought on the same day if inhaled SABA is needed more often than 3-hourly or for more than 24 hours.\n\n\u2022 There is no compelling evidence to support parent/caregiver-initiated oral corticosteroids."
    },
    {
        "id": "doc_4754",
        "document": "Management of exacerbations in primary care or acute care facility\n\n\u2022 Assess severity of the exacerbation while initiating treatment with SABA (2\u20136 puffs every 20 minutes for first hour) and oxygen (to maintain saturation 94\u201398%)."
    },
    {
        "id": "doc_4755",
        "document": "\u2022 Recommend immediate transfer to hospital if there is no response to inhaled SABA within 1\u20132 hours; if the child is unable to speak or drink, has a respiratory rate >40/minute or is cyanosed, if resources are lacking in the home, or if oxygen saturation is <92% on room air."
    },
    {
        "id": "doc_4756",
        "document": "\u2022 Consider oral prednisone/prednisolone 1\u20132 mg/kg/day for children attending an Emergency Department (ED) or admitted to hospital, up to a maximum of 20 mg/day for children aged 0\u20132 years, and 30 mg/day for children aged 3\u20135 years, for up to 5 days; or dexamethasone 0.6 mg/kg/day for 2 days. If there is failure of resolution, or relapse of symptoms with dexamethasone, consideration should be given to switching to prednisolone."
    },
    {
        "id": "doc_4757",
        "document": "Arrange early follow-up after an exacerbation\n\n\u2022 Children who have experienced an asthma exacerbation are at risk of further exacerbations. Arrange follow-up within 1\u20132 days of an exacerbation and again 1\u20132 months later to plan ongoing asthma management."
    },
    {
        "id": "doc_4758",
        "document": "DIAGNOSIS OF EXACERBATIONS\n\nA flare-up or exacerbation of asthma in children 5 years and younger is defined as an acute or sub-acute deterioration in symptom control that is sufficient to cause distress or risk to health, and necessitates a visit to a health care provider or requires treatment with systemic corticosteroids. In pediatric literature, the term \u2018episode\u2019 is commonly used, but understanding of this term by parents/caregivers is not known"
    },
    {
        "id": "doc_4759",
        "document": "Early symptoms of an exacerbation may include any of the following:\n\n\u2022 Onset of symptoms of respiratory tract infection\n\n\u2022 An acute or sub-acute increase in wheeze and shortness of breath\n\n\u2022 An increase in coughing, especially while the child is asleep\n\n\u2022 Lethargy or reduced exercise tolerance\n\nImpairment of daily activities, including feeding\n\n\u2022 A poor response to reliever medication.\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n187"
    },
    {
        "id": "doc_4760",
        "document": "In a study of children aged 2\u20135 years, the combination of increased daytime cough, daytime wheeze, and night-time beta2-agonist use was a strong predictor at a group level of an imminent exacerbation (1 day later). This combination predicted around 70% of exacerbations, with a low false positive rate of 14%. In contrast, no individual symptom was predictive of an imminent asthma exacerbation.800"
    },
    {
        "id": "doc_4761",
        "document": "Upper respiratory symptoms frequently precede the onset of an asthma exacerbation, indicating the important role of viral URTI in precipitating exacerbations in many, although not all, children with asthma. In a randomized controlled trial of acetaminophen versus ibuprofen, given for pain or fever in children with mild persistent asthma, there was no evidence of a difference in the subsequent risk of flare-ups or poor symptom control.781"
    },
    {
        "id": "doc_4762",
        "document": "INITIAL HOME MANAGEMENT OF ASTHMA EXACERBATIONS\n\nInitial management includes an action plan to enable the child\u2019s family members and carers to recognize worsening asthma and initiate treatment, recognize when it is severe, identify when urgent hospital treatment is necessary, and provide recommendations for follow up (Evidence D). The action plan should include specific information about medications and dosages and when and how to access medical care."
    },
    {
        "id": "doc_4763",
        "document": "Need for urgent medical attention\n\nParents/caregivers should be advised to seek medical attention immediately if:\n\n\u2022 The child is acutely distressed\n\n\u2022 The child\u2019s symptoms are not relieved promptly by inhaled bronchodilator\n\n\u2022 The period of relief after doses of SABA becomes progressively shorter\n\n\u2022 A child younger than 1 year requires repeated inhaled SABA over several hours.\n\nInitial treatment at home\n\nInhaled SABA via a mask or spacer, and review response"
    },
    {
        "id": "doc_4764",
        "document": "The parent/caregiver should initiate treatment with two puffs of inhaled SABA (200 mcg salbutamol [albuterol] or equivalent), given one puff at a time via a spacer device with or without a facemask (Evidence D). This may be repeated a further two times at 20-minute intervals, if needed. The child should be observed by the family/carer and, if improving, maintained in a restful and reassuring atmosphere for an hour or more. Medical attention should be sought urgently if any of the features listed"
    },
    {
        "id": "doc_4765",
        "document": "above apply; or on the same day if more than 6 puffs of inhaled SABA are required for symptom relief within the first 2 hours, or if the child has not recovered after 24 hours."
    },
    {
        "id": "doc_4766",
        "document": "Family/carer-initiated corticosteroids"
    },
    {
        "id": "doc_4767",
        "document": "Although practiced in some parts of the world, the evidence to support the initiation of oral corticosteroid (OCS) treatment by family/carers in the home management of asthma exacerbations in children is weak.801-805 Preemptive episodic high-dose nebulized ICS may reduce exacerbations in children with intermittent viral triggered wheezing.788 However, because of the high potential for side-effects, especially if the treatment is continued inappropriately or is given frequently,"
    },
    {
        "id": "doc_4768",
        "document": "family-administered high-dose ICS should be considered only where the health care provider is confident that the medications will be used appropriately, and the child is closely monitored for side-effects (see p.191)."
    },
    {
        "id": "doc_4769",
        "document": "Leukotriene receptor antagonists"
    },
    {
        "id": "doc_4770",
        "document": "In children aged 2\u20135 years with intermittent viral wheezing, one study found that a short course of an oral LTRA (for 7\u2013 20 days, commenced at the start of an URTI or the first sign of asthma symptoms) reduced symptoms, health care utilization and time off work for the carer.806 In contrast another study found no significant effect with LTRA vs placebo on episode-free days (primary outcome), OCS use, health care utilization, quality of life or hospitalization in children with or without a"
    },
    {
        "id": "doc_4771",
        "document": "positive Asthma Predictive Index (API). However, activity limitation and a symptom trouble score were significantly improved, particularly in children with a positive API.807 Parents/caregivers should be counseled about the FDA warning about risk of adverse effects on sleep and behavior with montelukast.236"
    },
    {
        "id": "doc_4772",
        "document": "188\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\nBox 6-9. Management of acute asthma or wheezing in children 5 years and younger"
    },
    {
        "id": "doc_4773",
        "document": "years younger RIMARY CARE ng ep: diagnose: ASSESS the CHILD isk ation MILD or MODERATE Brea s, ag ed Pulse r: 80 rs) or <150 bpm ( n s, 7 G . START TREATMENT Salbutamol 100 mcg two puffs by pMDI + spacer or G 2.5mg by Ay Repeat every 20 min for the first hour if needed Controlled oxygen (if needed and available): target Z saturation 04-88% camdtrad&upmmpun 1-2 pufis URGENT CLOSELY for 1-2 hours ansf MOl\"lIT\u2018OR are if an, \" ol 2 hrs Worsening. or Any ns of exa lack of -~ wy improvement Z In rate"
    },
    {
        "id": "doc_4774",
        "document": "s sin n saturation Liaid 7% IMPROVING CONTINUE TREATMENT IF NEE 724 Q i\\@'\\ \u2018Worsening, Monitor closely as above N or failure to If symptoms recur within 3-4 hrs & v respond to W) \u00ab Give extra salbutamol 2-3 puffs per hour 10 puffs \u00ab Give prednisolone 2mg/kg (max. 2 N g for <2 yrs: over 3-4 hrs max,mbr\ufb01yls)ual/\u2018y, IMPROVING DISCHARGE/FOLLOW-UP PLANNING Ensure that resources at home are adequate. Reliever: continue as needed Controller: consider need for, or adjustment of, regular controller"
    },
    {
        "id": "doc_4775",
        "document": "Check inhaler technigue and adherence Follow up: within 1-2 working days; prednisone for 23-5 days Provide and explain action plan FOLLOW UP VISITS Review symptoms and signs: |s the exacerbation resolving? Should prednisone be continued? Reliever: Reduce to as-needed Controller: Continue or adjust depending on cause of exacerbation, and duration of need for extra salbutamol Risk factors: Check and correct modifiable risk factors that may have contributed to exacerbation, including inhaler"
    },
    {
        "id": "doc_4776",
        "document": "technique and adherence Action plan: Is it understood? Was it used appropriately? Does it need modification? Schedule next follow up visit"
    },
    {
        "id": "doc_4777",
        "document": "See list of abbreviations (p.10).\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n189\n\nPRIMARY CARE OR HOSPITAL MANAGEMENT OF ACUTE ASTHMA EXACERBATIONS IN CHILDREN 5 YEARS OR YOUNGER\n\nAssessment of exacerbation severity"
    },
    {
        "id": "doc_4778",
        "document": "Conduct a brief history and examination concurrently with the initiation of therapy (Box 6-9, p.189). The presence of any of the features of a severe exacerbation listed in Box 6-10 are an indication of the need for urgent treatment and immediate transfer to hospital (Evidence D). Oxygen saturation from pulse oximetry of <92% on presentation (before oxygen or bronchodilator treatment) is associated with high morbidity and likely need for hospitalization; saturation of 92\u201395% is also associated"
    },
    {
        "id": "doc_4779",
        "document": "with higher risk.672 The FDA has issued a caution about potential overestimation of oxygen saturation by pulse oximetry in people with dark skin color.654 Agitation, drowsiness and confusion are features of cerebral hypoxemia. A quiet chest on auscultation indicates minimal ventilation, insufficient to produce a wheeze."
    },
    {
        "id": "doc_4780",
        "document": "Several clinical scoring systems such as PRAM (Preschool Respiratory Assessment Measure) and PASS (Pediatric Asthma Severity Score) have been developed for assessing the severity of acute asthma exacerbations in children.808"
    },
    {
        "id": "doc_4781",
        "document": "Box 6-10. Initial assessment of acute asthma exacerbations in children 5 years and younger\n\nSymptoms Mild Severe* Altered consciousness No Agitated, confused or drowsy Oximetry on presentation (SaO2)** >95% <92% Speech\u2020 Sentences Words Pulse rate <100 beats/minute >180 beats/minute (0\u20133 years) >150 beats/minute (4\u20135 years) Respiratory rate \u226440/minute >40/minute Central cyanosis Absent Likely to be present Wheeze intensity Variable Chest may be quiet"
    },
    {
        "id": "doc_4782",
        "document": "See list of abbreviations (p.10). *Any of these features indicates a severe asthma exacerbation. **Oximetry before treatment with oxygen or bronchodilator. Note FDA caution about potential overestimation of oxygen saturation with pulse oximetry in people with dark skin color.654 \u2020\n\nIndications for immediate transfer to hospital"
    },
    {
        "id": "doc_4783",
        "document": "Children with features of a severe exacerbation that fail to resolve within 1\u20132 hours despite repeated dosing with inhaled SABA must be referred to hospital for observation and further treatment (Evidence D). Other indications are respiratory arrest or impending arrest; lack of supervision in the home or doctor\u2019s office; and recurrence of signs of a severe exacerbation within 48 hours (particularly if treatment with OCS has already been given). In addition, early medical attention should be"
    },
    {
        "id": "doc_4784",
        "document": "sought for children with a history of severe life-threatening exacerbations, and those aged less than 2 years, as the risk of dehydration and respiratory fatigue is increased (Box 6-12, p.191)."
    },
    {
        "id": "doc_4785",
        "document": "190\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\nEmergency treatment and initial pharmacotherapy\n\nOxygen"
    },
    {
        "id": "doc_4786",
        "document": "Treat hypoxemia urgently with oxygen by face mask to achieve and maintain percutaneous oxygen saturation 94\u201398% (Evidence A). Note the FDA caution above about potential overestimation of oxygen saturation in people with dark skin color. To avoid hypoxemia during changes in treatment, children who are acutely distressed should be treated immediately with oxygen and SABA (2.5 mg of salbutamol or equivalent diluted in 3 mL of sterile normal saline) delivered by an oxygen-driven nebulizer (if"
    },
    {
        "id": "doc_4787",
        "document": "available). This treatment should not be delayed, and may be given before the full assessment is completed. Transient hypoxemia due to ventilation/perfusion mismatch may occur during treatment with SABAs."
    },
    {
        "id": "doc_4788",
        "document": "Box 6-11. Indications for immediate transfer to hospital for children 5 years and younger"
    },
    {
        "id": "doc_4789",
        "document": "Immediate transfer to hospital is indicated if a child \u22645 years with asthma has ANY of the following:\n\nAt initial or subsequent assessment\n\n.\n\nChild is unable to speak or drink\n\nCyanosis\n\nRespiratory rate >40 per minute\n\nOxygen saturation <92% when breathing room air\n\nSilent chest on auscultation\n\nLack of response to initial bronchodilator treatment\n\no Lack of response to 6 puffs of inhaled salbutamol [albuterol] (2 separate puffs, repeated 3 times) over 1\u20132 hours"
    },
    {
        "id": "doc_4790",
        "document": "o Persisting tachypnea* despite three administrations of inhaled SABA, even if the child shows other clinical signs of improvement\n\nSocial environment that limits delivery of acute treatment, or parent/caregiver unable to manage acute asthma at home\n\nDuring transfer to hospital, continue to give inhaled SABA, oxygen (if available) to maintain saturation 94\u201398%, and give systemic corticosteroids (see Box 6-9, p.189)"
    },
    {
        "id": "doc_4791",
        "document": "See list of abbreviations (p.10). *Normal respiratory rates: <60 breaths/minute in children 0\u20132 months; <50 breaths/minute in children 2\u201312 months; <40 breaths/minute in children 1\u20135 years.\n\nInhaled bronchodilator therapy"
    },
    {
        "id": "doc_4792",
        "document": "The initial dose of inhaled SABA may be given by a pMDI with spacer and mask or mouthpiece or an air-driven nebulizer; or, if oxygen saturation is low, by an oxygen-driven nebulizer (as described above). For most children, pMDI plus spacer is favored as it is more efficient than a nebulizer for bronchodilator delivery809 (Evidence A), and nebulizers can spread infectious particles. The initial dose of SABA is two puffs of salbutamol (100 mcg per puff) or equivalent, except in acute, severe"
    },
    {
        "id": "doc_4793",
        "document": "asthma when six puffs should be given. When a nebulizer is used, a dose of 2.5 mg salbutamol solution is recommended, and infection control procedures should be followed. The frequency of dosing depends on the response observed over 1\u20132 hours (see below)."
    },
    {
        "id": "doc_4794",
        "document": "For children with moderate-severe exacerbations and a poor response to initial SABA, nebulized ipratropium bromide may be added every 20 minutes for 1 hour only.809"
    },
    {
        "id": "doc_4795",
        "document": "Magnesium sulfate\n\nThe role of magnesium sulfate is not established for children 5 years and younger, because there are few studies in this age group. Nebulized isotonic magnesium sulfate may be considered as an adjuvant to standard treatment with nebulized salbutamol and ipratropium in the first hour of treatment for children \u22652 years old with acute severe asthma\n\n6. Diagnosis and management of asthma in children 5 years and younger\n\n191"
    },
    {
        "id": "doc_4796",
        "document": "(e.g. oxygen saturation <92%, Box 6-10, p.190), particularly those with symptoms lasting <6 hours.810 Intravenous magnesium sulfate in a single dose of 40\u201350 mg/kg (maximum 2 g) by slow infusion (20\u201360 minutes) has also been used.811\n\nAssessment of response and additional bronchodilator treatment\n\nChildren with a severe asthma exacerbation must be observed for at least 1 hour after initiation of treatment, at which time further treatment can be planned."
    },
    {
        "id": "doc_4797",
        "document": "\u2022 If symptoms persist after initial bronchodilator: a further 2\u20136 puffs of salbutamol (depending on severity) may be given 20 minutes after the first dose and repeated at 20-minute intervals for an hour. Consider adding 1\u20132 puffs of ipratropium. Failure to respond at 1 hour, or earlier deterioration, should prompt urgent admission to hospital, addition of nebulized ipratropium, and a short-course of oral corticosteroids (Evidence D)."
    },
    {
        "id": "doc_4798",
        "document": "\u2022 If symptoms have improved by 1 hour but recur within 3\u20134 hours: the child may be given more frequent doses of bronchodilator (2\u20133 puffs each hour), and oral corticosteroids should be given. The child may need to remain in the emergency department, or, if at home, should be observed by the family/carer and have ready access to emergency care. Children who fail to respond to 10 puffs of inhaled SABA within a 3\u20134 hour period should be referred immediately to hospital (Evidence D)."
    },
    {
        "id": "doc_4799",
        "document": "\u2022 If symptoms resolve rapidly after initial bronchodilator and do not recur for 1\u20132 hours: no further treatment may be required. Further SABA may be given every 3\u20134 hours (up to a total of 10 puffs/24 hours) and, if symptoms persist beyond 1 day, other treatments including inhaled and/or oral corticosteroids are indicated (Evidence D), as outlined below.\n\nBox 6-12.Initial emergency department management of asthma exacerbations in children 5 years and younger"
    },
    {
        "id": "doc_4800",
        "document": "Therapy Dose and administration Supplemental oxygen Delivered by face nasal prongs or mask, as indicated to maintain oxygen saturation at 94\u2014 98% Short-acting betaz- agonist (SABA) 4 2-6 puffs of salbutamol [albuterol] by spacer, or 2.5 mg by nebulizer, every 20 minutes for first hour\u2019, then reassess severity. If symptoms persist or recur, give an additional 2\u20143 puffs per hour. Admnt to hospital if >10 puffs required in 3\u20144 hours."
    },
    {
        "id": "doc_4801",
        "document": "Systemic corticosteroids Give initial dose of oral prednisolone (1-2 mg/kg up to @ maximum 20 mg for children <2 years old; 30 mg for children 2-5 years) OR, intravenous methylprednisolone 1 mg/kg 6-hourly on day 1 Additional options in the first hour of treatment"
    },
    {
        "id": "doc_4802",
        "document": "Ipratropium bromide Consider adding 1-2 puffs of ipratropium bromide by pMDI and spacer For children with moderate-severe exacerbations with a poor response to initial SABA, give nebulized ipratropium bromide 250 mcg every 20 minutes for 1 hour only Magnesium sulfate Consider nebulized isotonic magnesium sulfate (150 mg) 3 doses in the first hour of treatment for children aged 22 years with severe exacerbation (Box 6-10, p.190)"
    },
    {
        "id": "doc_4803",
        "document": "See list of abbreviations (p.10). *If inhalation is not possible an intravenous bolus of terbutaline 2 mcg/kg may be given over 5 minutes, followed by continuous infusion of 5 mcg/kg/hour812 (Evidence C). The child should be closely monitored, and the dose should be adjusted according to clinical improvement and side-effects. See below for additional and ongoing treatment, including maintenance ICS. If a nebulizer is used, follow infection control procedures.\n\n192"
    },
    {
        "id": "doc_4804",
        "document": "6. Diagnosis and management of asthma in children 5 years and younger\n\nAdditional treatment\n\nWhen treatment in addition to SABA is required for an exacerbation, the options available for children in this age group include ICS; a short course of oral corticosteroid; and/or LTRA (see p.188). However, the clinical benefit of these interventions \u2013 particularly on endpoints such as hospitalizations and longer-term outcomes \u2013 has not been impressive."
    },
    {
        "id": "doc_4805",
        "document": "Maintain current controller treatment (if prescribed)\n\nChildren who have been prescribed maintenance therapy with ICS, LTRA or both should continue to take the prescribed dose during and after an exacerbation (Evidence D).\n\nInhaled corticosteroids"
    },
    {
        "id": "doc_4806",
        "document": "For children not previously on ICS, an initial dose of ICS twice the low daily dose indicated in Box 6-7 (p.184) may be given and continued for a few weeks or months (Evidence D). Some studies have used high-dose ICS (1600 mcg/day, preferably divided into four doses over the day and given for 5\u201310 days) as this may reduce the need for OCS.649,784,785,813,814 Addition of ICS to standard care (including OCS) does not reduce risk of hospitalization but reduces length of stay and acute asthma scores"
    },
    {
        "id": "doc_4807",
        "document": "in children in the emergency department.815 However, the potential for side- effects with high-dose ICS should be taken into account, especially if used repeatedly, and the child should be monitored closely. For those children already on ICS, doubling the dose was not effective in a small study of mild- moderate exacerbations in children aged 6\u201314 years,816 nor was quintupling the dose in children aged 5\u201311 years with good adherence. This approach should be reserved mainly for individual cases,"
    },
    {
        "id": "doc_4808",
        "document": "and should always involve regular follow-up and monitoring of adverse effects (Evidence D)."
    },
    {
        "id": "doc_4809",
        "document": "Oral corticosteroids"
    },
    {
        "id": "doc_4810",
        "document": "For children with severe exacerbations, a dose of OCS equivalent to prednisolone 1\u20132 mg/kg/day, with a maximum of 20 mg/day for children under 2 years of age and 30 mg/day for children aged 2\u20135 years, is currently recommended (Evidence A),817 although several studies have failed to show any benefits when given earlier (e.g. by parents or caregivers) during periods of worsening wheeze managed in an outpatient setting (Evidence D).801-804,818,819 A meta- analysis demonstrated a reduced risk of"
    },
    {
        "id": "doc_4811",
        "document": "hospitalization when oral corticosteroids were administered in the emergency department, but no clear benefit in risk of hospitalization when given in the outpatient setting.820 A course of 3\u20135 days is sufficient in most children of this age, and can be stopped without tapering (Evidence D), but the child must be reviewed after discharge (as below) to confirm they are recovering."
    },
    {
        "id": "doc_4812",
        "document": "In children discharged from the emergency department, an intramuscular corticosteroid may be an alternative to a course of OCS for preventing relapse,681 but the risk of long-term adverse effects must be considered. There is insufficient evidence to recommend intramuscular over oral corticosteroids.681"
    },
    {
        "id": "doc_4813",
        "document": "Regardless of treatment, the severity of the child\u2019s symptoms must be carefully monitored. The sooner therapy is started in relation to the onset of symptoms, the more likely it is that the impending exacerbation may be clinically attenuated or prevented."
    },
    {
        "id": "doc_4814",
        "document": "Discharge and follow up after an exacerbation\n\nBefore discharge, the condition of the child should be stable (e.g., he/she should be out of bed and able to eat and drink without problems).\n\nChildren who have recently had an asthma exacerbation are at risk of further exacerbations and require follow up. The purpose is to ensure complete recovery, to establish the cause of the exacerbation, and, when necessary, to establish appropriate maintenance treatment and adherence (Evidence D)."
    },
    {
        "id": "doc_4815",
        "document": "6. Diagnosis and management of asthma in children 5 years and younger\n\n193\n\nPrior to discharge from the emergency department or hospital, family/carers should receive the following advice and information (all are Evidence D).\n\n\u2022 Instruction on recognition of signs of recurrence and worsening of asthma. The factors that precipitated the exacerbation should be identified, and strategies for future avoidance of these factors implemented."
    },
    {
        "id": "doc_4816",
        "document": "\u2022 A written, individualized action plan, including details of accessible emergency services\n\n\u2022 Careful review of inhaler technique\n\n\u2022 Further treatment advice explaining that:\n\no SABAs should be used on an as-needed basis, but the daily requirement should be recorded to ensure it is being decreased over time to pre-exacerbation levels."
    },
    {
        "id": "doc_4817",
        "document": "o ICS has been initiated where appropriate (at twice the low initial dose in Box 6-7 (p.184) for the first month after discharge, then adjusted as needed) or continued, for those previously prescribed controller medication.\n\n\u2022 A supply of SABA and, where applicable, the remainder of the course of oral corticosteroid, ICS or LTRA\n\n\u2022 A follow-up appointment within 1\u20132 days and another within 1\u20132 months, depending on the clinical, social and practical context of the exacerbation.\n\n194"
    },
    {
        "id": "doc_4818",
        "document": "6. Diagnosis and management of asthma in children 5 years and younger\n\nSECTION 2. CHILDREN 5 YEARS AND YOUNGER\n\nChapter 7.\n\nPrimary prevention of asthma in children"
    },
    {
        "id": "doc_4819",
        "document": "KEY POINTS\n\n\u2022 The development and persistence of asthma are driven by gene\u2013environment interactions. For children, a \u2018window of opportunity\u2019 to prevent asthma exists in utero and in early life, but intervention studies are limited.\n\n\u2022 With regard to allergen avoidance strategies aimed at preventing asthma in children:\n\no Strategies directed at a single allergen have not been effective in reducing the incidence of asthma"
    },
    {
        "id": "doc_4820",
        "document": "o Multifaceted strategies may be effective, but the essential components have not been identified.\n\n\u2022 Current recommendations for preventing asthma in children, based on high-quality evidence or consensus, include: o Avoid exposure to environmental tobacco smoke during pregnancy and the first year of life. o Encourage vaginal delivery.\n\no Where possible, avoid use of broad-spectrum antibiotics during the first year of life."
    },
    {
        "id": "doc_4821",
        "document": "\u2022 Breast-feeding is advised, not for prevention of allergy and asthma, but for its other positive health benefits).\n\nFACTORS CONTRIBUTING TO THE DEVELOPMENT OF ASTHMA IN CHILDREN"
    },
    {
        "id": "doc_4822",
        "document": "Asthma is a heterogeneous disease whose inception and persistence are driven by gene\u2013environment interactions that are not yet fully understood. The most important of these interactions may occur in early life and even in utero. There is consensus that a \u2018window of opportunity\u2019 exists during pregnancy and early in life when environmental factors may influence asthma development. Multiple environmental factors, both biological and sociological, may be important in the development of asthma. Data"
    },
    {
        "id": "doc_4823",
        "document": "from studies investigating the role of environmental risk factors for the development of asthma support further research on prevention strategies focusing on nutrition, allergens (both inhaled and ingested), pollutants (particularly environmental tobacco smoke), microbes, and psychosocial factors."
    },
    {
        "id": "doc_4824",
        "document": "\u2018Primary prevention\u2019 refers to preventing the onset of disease. This chapter focuses on primary prevention in children. See p.116 and review articles49 for strategies for preventing occupational asthma.\n\nFACTORS ASSOCIATED WITH INCREASED OR DECREASED RISK OF ASTHMA IN CHILDREN\n\nNutrition of mother and baby\n\nMaternal diet"
    },
    {
        "id": "doc_4825",
        "document": "A large body of research investigating the development of allergy and asthma in children has focused on the mother\u2019s diet during pregnancy. Current evidence does not clearly demonstrate that ingestion of any specific foods during pregnancy increases the risk for asthma. However, a study of a pre-birth cohort observed that maternal intake of foods commonly considered allergenic (peanut and milk) was associated with a decrease in allergy and asthma in the offspring.821 Similar data have been shown"
    },
    {
        "id": "doc_4826",
        "document": "in a very large Danish National birth cohort, with an association between ingestion of peanuts, tree nuts and/or fish during pregnancy and a decreased risk of asthma in the offspring.822,823 Epidemiological studies and randomized controlled trials on maternal dietary intake of fish or long-chain polyunsaturated fatty acids during pregnancy showed no consistent effects on the risk of wheeze, asthma or atopy in the child.824-827 Dietary changes during pregnancy are therefore not recommended for"
    },
    {
        "id": "doc_4827",
        "document": "prevention of allergies or asthma."
    },
    {
        "id": "doc_4828",
        "document": "Maternal obesity and weight gain during pregnancy"
    },
    {
        "id": "doc_4829",
        "document": "Data suggest that maternal obesity and weight gain during pregnancy pose an increased risk for asthma in children. A meta-analysis828 showed that maternal obesity in pregnancy was associated with higher odds of ever asthma or wheeze or current asthma or wheeze; each 1 kg/m2 increase in maternal body-mass index (BMI) was associated with a 2% to 3% increase in the odd of childhood asthma. High gestational weight gain was associated with higher odds of ever asthma or wheeze. However, no"
    },
    {
        "id": "doc_4830",
        "document": "recommendations can be made at present, as unguided weight loss in pregnancy should not be encouraged."
    },
    {
        "id": "doc_4831",
        "document": "196\n\n7. Primary prevention of asthma\n\nBreastfeeding"
    },
    {
        "id": "doc_4832",
        "document": "Despite the existence of many studies reporting a beneficial effect of breastfeeding on asthma prevention, results are conflicting,829 and caution should be taken in advising families that breastfeeding will prevent asthma.830 Breastfeeding decreases wheezing episodes in early life; however, it may not prevent development of persistent asthma (Evidence D). Regardless of any effect on development of asthma, breastfeeding should be encouraged for all of its other positive benefits (Evidence A)."
    },
    {
        "id": "doc_4833",
        "document": "Timing of introduction of solids\n\nBeginning in the 1990s, many national pediatric agencies and societies recommended delay of introduction of solid food, especially for children at a high risk for developing allergy. However, meta-analyses have found no evidence that this practice reduces the risk of allergic disease (including asthma).831 In the case of peanuts, early introduction may prevent peanut allergy in high risk infants.831\n\nDietary supplements for mothers and/or babies\n\nVitamin D"
    },
    {
        "id": "doc_4834",
        "document": "Intake of vitamin D may be through diet, dietary supplementation or sunlight. A systematic review of cohort, case control and cross-sectional studies concluded that maternal dietary intake of vitamin D, and of vitamin E was associated with lower risk of wheezing illnesses in children.832 This was not confirmed in two randomized controlled trials (RCTs) of vitamin D supplementation in pregnancy, which compared standard-dose with high-dose vitamin D; however, a significant effect was not"
    },
    {
        "id": "doc_4835",
        "document": "disproven.833,834 When the results from these two trials were combined, there was a 25% reduction of risk of asthma/recurrent wheeze at ages 0\u20133 years.835 The effect was greatest among women who maintained 25(OH)vitamin D levels of at least 30 ng/mL from the time of study entry through delivery, suggesting that sufficient levels of Vitamin D during early pregnancy may be important in decreasing risk for early life wheezing episodes,835 although in both trials, no effects of vitamin D"
    },
    {
        "id": "doc_4836",
        "document": "supplementation on the development of asthma and recurrent wheeze were evident at the age of 6 years.836"
    },
    {
        "id": "doc_4837",
        "document": "Fish oil and long-chain polyunsaturated fatty acids"
    },
    {
        "id": "doc_4838",
        "document": "Systematic reviews of cohort studies about maternal dietary intake of fish or seafood during pregnancy824,837 and of RCTs on maternal dietary intake of fish or long-chained polyunsaturated fatty acids during pregnancy824 showed no consistent effects on the risk of wheeze, asthma or atopy in the child. One study demonstrated decreased wheeze/asthma in preschool children at high risk for asthma when mothers were given a high-dose fish oil supplement in the third trimester;838 however \u2018fish oil\u2019 is"
    },
    {
        "id": "doc_4839",
        "document": "not well defined, and the optimal dosing regimen has not been established."
    },
    {
        "id": "doc_4840",
        "document": "Probiotics\n\nA meta-analysis provided insufficient evidence to recommend probiotics for the prevention of allergic disease (asthma, rhinitis, eczema or food allergy).839\n\nInhalant allergens"
    },
    {
        "id": "doc_4841",
        "document": "Sensitization to indoor, inhaled aeroallergens is generally more important than sensitization to outdoor allergens for the presence of, and/or development of, asthma. While there appears to be a linear relationship between exposure and sensitization to house dust mite,840,841 the relationship for animal allergen appears to be more complex.829 Some studies have found that exposure to pet allergens is associated with increased risk of sensitization to these allergens,842,843 and of asthma and"
    },
    {
        "id": "doc_4842",
        "document": "wheezing.844,845 By contrast, other studies have demonstrated a decreased risk of developing allergy with exposure to pets.846,847 Analyses of data from large populations of school-age children from birth cohorts in Europe have found no association between pets in the homes early in life and higher or lower prevalence of asthma in children.848,849 For children at risk of asthma, dampness, visible mold and mold odor in the home environment are associated with increased risk of developing"
    },
    {
        "id": "doc_4843",
        "document": "asthma.850 Overall, there are insufficient data to recommend efforts to either reduce or increase pre-natal or early-life exposure to common sensitizing allergens, including pets, for the prevention of allergies and asthma."
    },
    {
        "id": "doc_4844",
        "document": "7. Primary prevention of asthma\n\n197"
    },
    {
        "id": "doc_4845",
        "document": "Birth cohort studies provide some evidence for consideration. A meta-analysis found that studies of interventions focused on reducing exposure to a single allergen did not significantly affect asthma development, but that multifaceted interventions such as in the Isle of Wight study,851 the Canadian Asthma Primary Prevention Study,852 and the Prevention of Asthma in Children study853 were associated with lower risk of asthma diagnosis in children younger than 5 years.854 Two multifaceted studies"
    },
    {
        "id": "doc_4846",
        "document": "that followed children beyond 5 years of age demonstrated a significant protective effect both before and after the age of 5 years.851,855 The Isle of Wight study has shown a continuing positive benefit for early-life intervention through to 18 years of age;856 however, it remains unclear which components of the intervention contributed to the effects reported, and the precise mechanism of these effects."
    },
    {
        "id": "doc_4847",
        "document": "Treatment with grass pollen sublingual allergen immunotherapy (SLIT) for 3 years did not reduce the incidence of asthma diagnosis (primary outcome) in a large randomized double-blind placebo-controlled trial in children aged 5\u201312 years with grass-allergic rhinoconjunctivitis, but asthma symptoms and asthma medication use were reduced. At present, SLIT for children with grass allergic rhinoconjunctivitis is not recommended for asthma prevention.857 Additional studies are needed.\n\nPollutants"
    },
    {
        "id": "doc_4848",
        "document": "Maternal smoking during pregnancy is the most direct route of pre-natal environmental tobacco smoke exposure.858 A meta-analysis concluded that prenatal smoking had its strongest effect on young children, whereas postnatal maternal smoking appeared only to affect asthma development in older children.859 Exposure to outdoor pollutants, such as living near a main road, is associated with increased risk of asthma.860,861 A 2019 study suggested that up to 4 million new pediatric asthma cases (13% of"
    },
    {
        "id": "doc_4849",
        "document": "the global incidence) may be attributable to exposure to traffic-related air pollution.862 Prenatal NO2, SO2, and PM10 exposures are associated with an increased risk of asthma in childhood,863 but it is difficult to separate effects of prenatal and postnatal exposure."
    },
    {
        "id": "doc_4850",
        "document": "Microbial effects"
    },
    {
        "id": "doc_4851",
        "document": "The \u2018hygiene hypothesis\u2019, and the more recently coined \u2018microflora hypothesis\u2019 and \u2018biodiversity hypothesis\u2019,864 suggest that human interaction with microbiota may be beneficial in preventing asthma. For example, there is a lower risk of asthma among children raised on farms with exposure to stables and consumption of raw farm milk than among children of non-farmers.865 The risk of asthma is also reduced in children whose bedrooms have high levels of bacterial-derived lipopolysaccharide"
    },
    {
        "id": "doc_4852",
        "document": "endotoxin.866,867 Similarly, children in homes with \u22652 dogs or cats are less likely to be allergic than those in homes without dogs or cats.847 Exposure of an infant to the mother\u2019s vaginal microflora through vaginal delivery may also be beneficial; the prevalence of asthma is higher in children born by cesarean section than those born vaginally.868,869 This may relate to differences in the infant gut microbiota according to their mode of delivery.870"
    },
    {
        "id": "doc_4853",
        "document": "Respiratory syncytial virus infection is associated with subsequent recurrent wheeze, and preventative treatment of premature infants with monthly injections of the monoclonal antibody, palivizumab, (prescribed for prophylaxis of respiratory syncytial virus) is associated with a reduction in recurrent wheezing in the first year of life.871 However, a sustained effect has not been definitively demonstrated. Although the risk of parent-reported asthma with infrequent wheeze was reduced at 6 years,"
    },
    {
        "id": "doc_4854",
        "document": "there was no impact on doctor-diagnosed asthma or lung function.872 Thus, the long- term effect of palivizumab in the prevention of asthma remains uncertain."
    },
    {
        "id": "doc_4855",
        "document": "Medications and other factors"
    },
    {
        "id": "doc_4856",
        "document": "Antibiotic use during pregnancy and in infants and toddlers has been associated with the development of asthma later in life,873 although not all studies have shown this association.874 Intake of the analgesic, paracetamol (acetaminophen), may be associated with an increased risk of asthma in both children and adults,875 although exposure during infancy may be confounded by use of paracetamol for respiratory tract infections.875 Frequent use of paracetamol by pregnant women has been associated"
    },
    {
        "id": "doc_4857",
        "document": "with increased risk of asthma in their children.876"
    },
    {
        "id": "doc_4858",
        "document": "There is no evidence that vaccinations increase a child\u2019s risk of developing asthma.\n\n198\n\n7. Primary prevention of asthma\n\nPsychosocial factors\n\nThe social environment to which children are exposed may also contribute to the development and severity of asthma. Maternal distress during pregnancy877 or during the child\u2019s early years878 has been associated with an increased risk of the child developing asthma."
    },
    {
        "id": "doc_4859",
        "document": "Obesity\n\nA meta-analysis of 18 studies found that being either overweight or obese was a risk factor for childhood asthma and wheeze, particularly in girls.483 In adults, there is evidence suggesting that obesity affects the risk of asthma, but that asthma does not affect the risk of obesity.879,880"
    },
    {
        "id": "doc_4860",
        "document": "ADVICE ABOUT PRIMARY PREVENTION OF ASTHMA\n\nBased on the results of cohort and observational studies,881 and a GRADE-based analysis conducted for the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines,829 parents/caregivers enquiring about how to reduce the risk of their children developing asthma can be provided with the advice summarized in Box 7-1."
    },
    {
        "id": "doc_4861",
        "document": "Possibly the most important factor is the need to provide a positive, supportive environment for discussion that decreases stress, and which encourages families to make choices with which they feel comfortable."
    },
    {
        "id": "doc_4862",
        "document": "Box 7-1. Advice about primary prevention of asthma in children 5 years and younger\n\nParents/caregivers enquiring about how to reduce the risk of their child developing asthma can be provided with the following advice:\n\n\u2022 Children should not be exposed to environmental tobacco smoke during pregnancy or after birth.\n\n\u2022 Identification and correction of Vitamin D insufficiency in women with asthma who are pregnant, or planning pregnancy, may reduce the risk of early life wheezing episodes."
    },
    {
        "id": "doc_4863",
        "document": "\u2022 Vaginal delivery should be encouraged where possible.\n\n\u2022 The use of broad-spectrum antibiotics during the first year of life should be discouraged.\n\nBreastfeeding is advised, not for prevention of allergy or asthma, but for its other positive health benefits.\n\n7. Primary prevention of asthma\n\n199\n\n\u00ae & O\\\"o & C)OQ O ot & @?\u2018 & X & K\n\n&\n\nSECTION 3. TRANSLATION INTO CLINICAL PRACTICE\n\nChapter 8.\n\nImplementing asthma management strategies into health systems"
    },
    {
        "id": "doc_4864",
        "document": "KEY POINTS\n\nIn order to improve asthma care and patient outcomes, evidence-based recommendations must not only be developed, but also disseminated and implemented at a national and local level, and integrated into clinical practice.\n\n\u2022 Recommendations for implementing asthma care strategies are based on many successful programs worldwide."
    },
    {
        "id": "doc_4865",
        "document": "Implementation requires an evidence-based strategy involving professional groups and stakeholders, and should take into account local cultural and socioeconomic conditions.\n\n\u2022 Cost-effectiveness of implementation programs should be assessed so a decision can be made to pursue or modify them.\n\n\u2022 Local adaptation and implementation of asthma care strategies is aided by the use of tools developed for this purpose.\n\nINTRODUCTION"
    },
    {
        "id": "doc_4866",
        "document": "Due to the exponential increase in medical research publications, practical syntheses are needed to guide policy makers and healthcare professionals in delivering evidence-based care. When asthma care is consistent with evidence-based recommendations, outcomes improve.188,882,883 This Strategy Report is a resource document for healthcare professionals, intended to set out the main goals of asthma treatment and the actions required to ensure their fulfilment, as well as to facilitate the"
    },
    {
        "id": "doc_4867",
        "document": "achievement of standards for quality asthma care. These objectives can only be realized through local implementation in each country, region and healthcare organization."
    },
    {
        "id": "doc_4868",
        "document": "The use of rigorous methodologies such as GRADE1 for the development of clinical practice recommendations, and of ADAPTE884 and similar approaches for assisting the adaptation of recommendations for local country and regional conditions, has assisted in reducing biased opinion as the basis for asthma programs worldwide. Adaptation of clinical practice recommendations to local conditions using the GRADE method is costly, and often requires expertise that is not available locally; in addition,"
    },
    {
        "id": "doc_4869",
        "document": "regular revision is required to remain abreast of developments, including drug availability and new evidence, and this is not easily achieved.885 Further, there is generally very limited high quality evidence addressing the many decision nodes in comprehensive clinical practice guidelines, particularly in developing countries."
    },
    {
        "id": "doc_4870",
        "document": "The GINA annual report is not a formal guideline but an evidence-based strategy, updated yearly from a review of the evidence published in the last 18 months. Each year\u2019s report is an update on the entire strategy, so it does not use individual PICOT questions and GRADE, but the review process includes systematic reviews using these methodologies. (See section on methodology at www.ginasthma.org). As with other evidence-based clinical recommendations, the GINA strategy must be adapted to the"
    },
    {
        "id": "doc_4871",
        "document": "local context for implementation in clinical practice."
    },
    {
        "id": "doc_4872",
        "document": "ADAPTING AND IMPLEMENTING ASTHMA CLINICAL PRACTICE GUIDELINES"
    },
    {
        "id": "doc_4873",
        "document": "Implementation of asthma management strategies may be carried out at a national, regional or local level.886 Ideally, implementation should be a multidisciplinary effort involving many stakeholders, and using cost-effective methods of knowledge translation.886-888 Each implementation initiative needs to consider the nature of the local health system and its resources, including human resources, infrastructure, and available treatments (Box 8-1). Moreover, goals and implementation strategies will"
    },
    {
        "id": "doc_4874",
        "document": "need to vary from country to country and within countries, based on economics, culture and the physical and social environment. Priority should be given to high-impact interventions."
    },
    {
        "id": "doc_4875",
        "document": "Specific steps need to be followed before clinical practice recommendations can be embedded into local clinical practice and become the standard of care, particularly in low resource settings. The individual steps are summarized in Box 8-2.\n\n202\n\n8. Implementing asthma management strategies in health systems\n\nBox 8-1. Approach to implementation of the Global Strategy for Asthma Management and Prevention"
    },
    {
        "id": "doc_4876",
        "document": "L i/ GLOBAL | | LOCAL \u00e9 :: cesees ................. Geeecscecscacaccecetestesesscecsctescsesssssstsesssssesstacsnans\n\nBox 8-2. Essential elements required to implement a health-related strategy\n\nSteps in implementing an asthma strategy into a health system\n\n1. Develop a multidisciplinary working group.\n\n2. Assess the current status of asthma care delivery, outcomes e.g., exacerbations, admissions, deaths, care gaps and current needs."
    },
    {
        "id": "doc_4877",
        "document": "3. Select the material to be implemented, agree on main goals, identify key recommendations for diagnosis and treatment, and adapt them to the local context or environment.\n\n\u2022 In treatment recommendations, consider environmental issues (planetary health) in addition to patient health\n\n4. Identify barriers to, and facilitators of, implementation.\n\n5. Select an implementation framework and its component strategies.\n\n6. Develop a step-by-step implementation plan:"
    },
    {
        "id": "doc_4878",
        "document": "\u2022 Select target populations and evaluable outcomes, and specify data coding requirements (if relevant).\n\n\u2022 Identify local resources to support implementation.\n\n\u2022 Set timelines.\n\n\u2022 Distribute tasks to members.\n\n\u2022 Evaluate outcomes.\n\n7. Continually review progress and results to determine if the strategy requires modification.\n\n8. Implementing asthma management strategies in health systems\n\n203"
    },
    {
        "id": "doc_4879",
        "document": "BARRIERS AND FACILITATORS\n\nMany barriers to, and facilitators of, implementation procedures have been described.888-891 Some of the barriers to implementation of evidence-based asthma management relate to the delivery of care, while others occur at individual or community level (see Box 8-3). Cultural and economic barriers can particularly affect the application of recommendations.\n\nBox 8-3. Examples of barriers to the implementation of evidence-based recommendations"
    },
    {
        "id": "doc_4880",
        "document": "Health care providers Patients Insufficient knowledge of recommendations Low health literacy Lack of agreement with recommendations or Insufficient understanding of asthma and its expectation that they will be effective management Resistance to change Lack of agreement with recommendations External barriers (organizational, health policies, Cultural and economic barriers financial constraints) Peer influence"
    },
    {
        "id": "doc_4881",
        "document": "Lack of time and resources Medico-legal issues Attitudes, beliefs, preferences, fears and misconceptions Lack of accurate coding (diagnosis, exacerbations, ED and hospital admissions and deaths) list of abbreviations (p.10)."
    },
    {
        "id": "doc_4882",
        "document": "See list of abbreviations (p.10)."
    },
    {
        "id": "doc_4883",
        "document": "EXAMPLES OF HIGH IMPACT IMPLEMENTATION INTERVENTIONS\n\nIdeally, interventions should be applied at the level of both the patient and the health care provider and, where relevant, the health system. Studies of the most effective means of medical education show that it may be difficult to change clinical practice. Examples of highly effective implementation interventions are shown in Box 8-4.\n\nBox 8-4. Examples of high-impact implementation interventions in asthma management"
    },
    {
        "id": "doc_4884",
        "document": "Free inhaled corticosteroids (ICS) for patients with a recent hospital admission and/or severe asthma892\n\nEarly treatment with ICS, guided self-management, reduction in exposure to tobacco smoke, improved access to asthma education188\n\n\u2022 Checklist memory aid for primary care, prompting assessment of asthma control and treatment strategies893\n\n\u2022 Use of individualized written asthma action plans as part of self-management education476"
    },
    {
        "id": "doc_4885",
        "document": "An evidence-based care process model for acute and chronic pediatric asthma management, implemented at multiple hospitals894\n\nSee list of abbreviations (p.10).\n\n204\n\n8. Implementing asthma management strategies in health systems"
    },
    {
        "id": "doc_4886",
        "document": "EVALUATION OF THE IMPLEMENTATION PROCESS\n\nAn important part of the implementation process is to establish a means of evaluating the effectiveness of the program and any improvements in quality of care. The Cochrane Effective Practice and Organisation of Care Group (EPOC) offers suggestions on how to assess the effectiveness of interventions.895"
    },
    {
        "id": "doc_4887",
        "document": "Evaluation involves surveillance of traditional epidemiological parameters, such as morbidity and mortality, as well as specific audits of both process and outcome within different sectors of the health care system. Each country should determine its own minimum sets of data to audit health outcomes."
    },
    {
        "id": "doc_4888",
        "document": "HOW CAN GINA HELP WITH IMPLEMENTATION?\n\nThe GINA Strategy Report provides an annually updated summary of evidence relevant to asthma diagnosis, management and prevention that may be used in the formulation and adaptation of local guidelines; where evidence is lacking, the report provides approaches for consideration. The GINA Dissemination Task Group assists in the dissemination of the recommendations in the Strategy Report."
    },
    {
        "id": "doc_4889",
        "document": "A web-based implementation \u2018toolkit\u2019 will provide a template and guide to local adaptation and implementation of these recommendations, together with materials and advice from successful examples of asthma clinical practice guideline development and implementation in different settings.\n\nEducational materials and tools based on this Strategy Report are available from the GINA Website (www.ginasthma.org).\n\nGINA can be contacted via the website (www.ginasthma.org/contact-us)."
    },
    {
        "id": "doc_4890",
        "document": "8. Implementing asthma management strategies in health systems\n\n205\n\nREFERENCES"
    },
    {
        "id": "doc_4891",
        "document": "1. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-614. 2. Critical Appraisal Skills Programme. CASP Checklist: 10 questions to help you make sense of a systematic review: CASP; 2018. Available from: https://casp-uk.net/images/checklist/documents/CASP-Systematic-Review-Checklist/CASP- Systematic-Review-Checklist_2018.pdf."
    },
    {
        "id": "doc_4892",
        "document": "3. Asher I, Bissell K, Chiang CY, et al. Calling time on asthma deaths in tropical regions-how much longer must people wait for essential medicines? Lancet Respir Med 2019; 7: 13-15.\n\n4. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 2021; 397: 928-940."
    },
    {
        "id": "doc_4893",
        "document": "5. Stolbrink M, Chinouya MJ, Jayasooriya S, et al. Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries. Int J Tuberc Lung Dis 2022; 26: 1023-1032.\n\n6. Chiang CY, Ait-Khaled N, Bissell K, et al. Management of asthma in resource-limited settings: role of low-cost corticosteroid/beta-agonist combination inhaler. Int J Tuberc Lung Dis 2015; 19: 129-136."
    },
    {
        "id": "doc_4894",
        "document": "7. Mortimer K, Reddel HK, Pitrez PM, et al. Asthma management in low- and middle-income countries: case for change. Eur Respir J 2022.\n\n8. Reddel HK, Bateman ED, Schatz M, et al. A practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract 2022; 10: S31-s38.\n\n9. Mortimer K, Masekela R, Ozoh O, et al. The reality of managing asthma in sub-Saharan Africa \u2013 Priorities and strategies for improving care. J Pan Afr Thorac Soc 2022; 3: 105-120."
    },
    {
        "id": "doc_4895",
        "document": "Global Asthma Network. The Global Asthma Report 2022. Int J Tuberc Lung Dis 2022; 26: S1-S102.\n\n10\n\n11. Gaillard EA, Kuehni CE, Turner S, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years. Eur Respir J 2021; 58: 2004173.\n\n12. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. Eur Respir J 2022: 2101585."
    },
    {
        "id": "doc_4896",
        "document": "13. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022; 60.\n\n14. Mortimer K, Lesosky M, Garc\u00eda-Marcos L, et al. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur Respir J 2022.\n\n15. Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school-aged"
    },
    {
        "id": "doc_4897",
        "document": "children: Global Asthma Network Phase | cross-sectional study. Lancet 2021; 398: 1569-1580.\n\nBel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med 2004; 10: 44-50.\n\n16\n\n17. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-323.\n\n18. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine 2012; 18: 716-725."
    },
    {
        "id": "doc_4898",
        "document": "19. Westerhof GA, Coumou H, de Nijs SB, et al. Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol 2018; 141: 104-109.e103.\n\n20. Levy ML, Fletcher M, Price DB, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J 2006; 15: 20-34."
    },
    {
        "id": "doc_4899",
        "document": "21. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324-1343.\n\n22. Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control [erratum in Lancet 1999;353:758]. Lancet 1999; 353: 364-369."
    },
    {
        "id": "doc_4900",
        "document": "23. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317: 269-279.\n\n206\n\nReferences"
    },
    {
        "id": "doc_4901",
        "document": "24. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019; 200: e70-e88. 25. Virant FS, Randolph C, Nanda A, et al. Pulmonary procedures during the COVD-19 pandemic: a Workgroup Report of the American Academy of Allergy, Asthma, and Immunology (AAAAI) Asthma Diagnosis and Treatment (ADT) Interest Section. J Allergy Clin Immunol Pract 2022."
    },
    {
        "id": "doc_4902",
        "document": "26. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. 27. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.\n\n28. Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax 2012; 67: 718-726."
    },
    {
        "id": "doc_4903",
        "document": "29. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.\n\n30. Brouwer AF, Brand PL. Asthma education and monitoring: what has been shown to work. Paediatr Respir Rev 2008; 9: 193-199."
    },
    {
        "id": "doc_4904",
        "document": "31. Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49.\n\n32. Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J 2018; 52."
    },
    {
        "id": "doc_4905",
        "document": "33. Ramsdale EH, Morris MM, Roberts RS, et al. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 1985; 75: 573-577."
    },
    {
        "id": "doc_4906",
        "document": "34. van Haren EH, Lammers JW, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89: 209-214. 35. Joshi S, Powell T, Watkins WJ, et al. Exercise-induced bronchoconstriction in school-aged children who had chronic lung disease in infancy. [Erratum in J Pediatr. 2013 Jun;162(6):1298]. J Pediatr 2013; 162: 813-818.e811. 36. Ramsdale EH, Morris MM, Roberts RS, et al."
    },
    {
        "id": "doc_4907",
        "document": "Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 1984; 39: 912-918."
    },
    {
        "id": "doc_4908",
        "document": "37. Ahlstedt S, Murray CS. In vitro diagnosis of allergy: how to interpret IgE antibody results in clinical practice. Prim Care Respir J 2006; 15: 228-236.\n\n38. Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008; 179: 1121-1131.\n\n39. Lucas AE, Smeenk FW, Smeele IJ, et al. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Family practice 2008; 25: 86-91."
    },
    {
        "id": "doc_4909",
        "document": "40. Marklund B, Tunsater A, Bengtsson C. How often is the diagnosis bronchial asthma correct? Fam Pract 1999; 16: 112-116.\n\n41. Montnemery P, Hansson L, Lanke J, et al. Accuracy of a first diagnosis of asthma in primary health care. Fam Pract 2002; 19: 365-368.\n\n42. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med 2015; 3: 290-300."
    },
    {
        "id": "doc_4910",
        "document": "Fahy JV. Type 2 inflammation in asthma \u2014 present in most, absent in many. Nat Rev Immunol 2015; 15: 57-65.\n\n43\n\n44. American Thoracic Society, European Respiratory Society. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930."
    },
    {
        "id": "doc_4911",
        "document": "45. Haccuria A, Michils A, Michiels S, et al. Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes. J Allergy Clin Immunol 2014; 134: 554-559.\n\n46. Gibson PG, Chang AB, Glasgow NJ, et al. CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian cough guidelines summary statement. Med J Aust 2010; 192: 265-271."
    },
    {
        "id": "doc_4912",
        "document": "47. Halvorsen T, Walsted ES, Bucca C, et al. Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement. Eur Respir J 2017; 50.\n\nReferences\n\n207\n\n48. Desai D, Brightling C. Cough due to asthma, cough-variant asthma and non-asthmatic eosinophilic bronchitis. Otolaryngol Clin North Am 2010; 43: 123-130."
    },
    {
        "id": "doc_4913",
        "document": "49. Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma.[Erratum appears in Eur Respir J. 2012 Jun;39(6):1553]. Eur Respir J 2012; 39: 529-545.\n\n50. Henneberger PK, Patel JR, de Groene GJ, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2019; 10: CD006308.\n\n51. Levy ML, Nicholson PJ. Occupational asthma case finding: a role for primary care. Br J Gen Pract 2004; 54: 731- 733."
    },
    {
        "id": "doc_4914",
        "document": "52. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187: 1016-1027."
    },
    {
        "id": "doc_4915",
        "document": "53. Carlsen KH, Anderson SD, Bjermer L, et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 2008; 63: 387-403.\n\nMurphy VE, Gibson PG. Asthma in pregnancy. Clinics in chest medicine 2011; 32: 93-110, ix.\n\n54"
    },
    {
        "id": "doc_4916",
        "document": "55. Adams RJ, Wilson DH, Appleton S, et al. Underdiagnosed asthma in South Australia. Thorax 2003; 58: 846-850. 56. Hsu J, Chen J, Mirabelli MC. Asthma morbidity, comorbidities, and modifiable factors among older adults. J Allergy Clin Immunol Pract 2018; 6: 236-243.e237."
    },
    {
        "id": "doc_4917",
        "document": "57. Parshall MB, Schwartzstein RM, Adams L, et al. An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. Am J Respir Crit Care Med 2012; 185: 435-452. 58. Januzzi JL, Jr., Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948-954."
    },
    {
        "id": "doc_4918",
        "document": "59. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of chronic obstructive lung disease (2023 Report): GOLD; 2023. Available from: https://goldcopd.org.\n\n60. Hanania NA, Celli BR, Donohue JF, et al. Bronchodilator reversibility in COPD. Chest 2011; 140: 1055-1063. 61. Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis. PLoS One 2015; 10: e0136065."
    },
    {
        "id": "doc_4919",
        "document": "62. Boulet LP. Asthma and obesity. Clin Exp Allergy 2013; 43: 8-21.\n\n63. van Huisstede A, Castro Cabezas M, van de Geijn GJ, et al. Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respir Med 2013; 107: 1356-1364.\n\n64. Masekela R, Zurba L, Gray D. Dealing with access to spirometry in Africa: a commentary on challenges and solutions. Int J Environ Res Public Health 2018; 16: 62."
    },
    {
        "id": "doc_4920",
        "document": "65. Global Asthma Network. The global asthma report 2018. Auckland, New Zealand: Global Asthma Network; 2018. Available from: http://globalasthmareport.org.\n\n66. Huang WC, Fox GJ, Pham NY, et al. A syndromic approach to assess diagnosis and management of patients presenting with respiratory symptoms to healthcare facilities in Vietnam. ERJ Open Res 2021; 7.\n\n67. Aaron S, Boulet L, Reddel H, et al. Underdiagnosis and overdiagnosis of asthma. Am J Respir Crit Care Med 2018; 198: 1012-1020."
    },
    {
        "id": "doc_4921",
        "document": "68. World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/who-package-of-essential- noncommunicable-(pen)-disease-interventions-for-primary-health-care.\n\n69. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-554."
    },
    {
        "id": "doc_4922",
        "document": "70. Aroni R, Goeman D, Stewart K, et al. Enhancing validity: what counts as an asthma attack? J Asthma 2004; 41: 729-737.\n\n71. McCoy K, Shade DM, Irvin CG, et al. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol 2006; 118: 1226-1233.\n\n72. Meltzer EO, Busse WW, Wenzel SE, et al. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 2011; 127: 167-172.\n\n208\n\nReferences"
    },
    {
        "id": "doc_4923",
        "document": "73. Schatz M, Zeiger RS, Yang SJ, et al. The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest 2012; 141: 66-72. 74. Stanford RH, Shah MB, D\u2019Souza AO, et al. Short-acting \u03b2-agonist use and its ability to predict future asthma- related outcomes. Ann Allergy Asthma Immunol 2012; 109: 403-407. 75. Nwaru BI, Ekstrom M, Hasvold P, et al. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and"
    },
    {
        "id": "doc_4924",
        "document": "mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020; 55: 1901872. 76. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160: 594-599. 77. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007; 101: 2437-2446. 78."
    },
    {
        "id": "doc_4925",
        "document": "Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res 2012; 13: 59. 79. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide- formoterol use on short-term risk of severe exacerbations in patients with mild"
    },
    {
        "id": "doc_4926",
        "document": "asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med 2021; 9: 149-158. 80. O'Byrne PM, Reddel HK, Eriksson G, et al. Measuring asthma control: a comparison of three classification systems. Eur Respir J 2010; 36: 269-276. 81. Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009; 18: 41-49. 82. LeMay KS, Armour CL, Reddel HK. Performance of a"
    },
    {
        "id": "doc_4927",
        "document": "brief asthma control screening tool in community pharmacy: a cross-sectional and prospective longitudinal analysis. Prim Care Respir J 2014; 23: 79-84. 83. Ahmed S, Ernst P, Tamblyn R, et al. Validation of The 30 Second Asthma Test as a measure of asthma control. Can Respir J 2007; 14: 105-109. 84. Pinnock H, Burton C, Campbell S, et al. Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study. Prim Care Respir J 2012; 21:"
    },
    {
        "id": "doc_4928",
        "document": "288-294. 85. Yawn BP, Wollan PC, Rank MA, et al. Use of Asthma APGAR Tools in primary care practices: a cluster-randomized controlled trial. Ann Fam Med 2018; 16: 100-110. 86. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907. 87. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99:"
    },
    {
        "id": "doc_4929",
        "document": "553-558. 88. Juniper EF, Bousquet J, Abetz L, et al. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616-621. 89. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59-65. 90. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009; 124:"
    },
    {
        "id": "doc_4930",
        "document": "719-723 e711. 91. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119: 817-825. 92. Juniper EF, Gruffydd-Jones K, Ward S, et al. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J 2010; 36: 1410-1416. 93. Nguyen JM, Holbrook JT, Wei CY, et al. Validation and psychometric properties of the Asthma Control Questionnaire among children. J Allergy"
    },
    {
        "id": "doc_4931",
        "document": "Clin Immunol 2014; 133: 91-97.e91-96. 94. Chipps B, Zeiger RS, Murphy K, et al. Longitudinal validation of the Test for Respiratory and Asthma Control in Kids in pediatric practices. Pediatrics 2011; 127: e737-747. 95. Murphy KR, Zeiger RS, Kosinski M, et al. Test for respiratory and asthma control in kids (TRACK): a caregiver- completed questionnaire for preschool-aged children. J Allergy Clin Immunol 2009; 123: 833-839 e839."
    },
    {
        "id": "doc_4932",
        "document": "References\n\n209\n\n96. Zeiger RS, Mellon M, Chipps B, et al. Test for Respiratory and Asthma Control in Kids (TRACK): clinically meaningful changes in score. J Allergy Clin Immunol 2011; 128: 983-988."
    },
    {
        "id": "doc_4933",
        "document": "97. Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index-- an outcome measure for use in children and adolescents. J Allergy Clin Immunol 2012; 129: 694-701. 98. Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and"
    },
    {
        "id": "doc_4934",
        "document": "Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009; 124: 895-902.e891-894."
    },
    {
        "id": "doc_4935",
        "document": "99. Patel M, Pilcher J, Reddel HK, et al. Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy 2013; 43: 1144-1151.\n\n100. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta- agonists. Am J Respir Crit Care Med 1994; 149: 604-610.\n\n101. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268: 3462-3464."
    },
    {
        "id": "doc_4936",
        "document": "102. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930-938.\n\n103. Fitzpatrick S, Joks R, Silverberg JI. Obesity is associated with increased asthma severity and exacerbations, and increased serum immunoglobulin E in inner-city adults. Clin Exp Allergy 2012; 42: 747-759."
    },
    {
        "id": "doc_4937",
        "document": "104. Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2017; 195: 302-313.\n\nBurks AW, Tang M, Sicherer S, et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129: 906-920.\n\n105\n\n106. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax 2006; 61: 169-176."
    },
    {
        "id": "doc_4938",
        "document": "107. Osborne ML, Pedula KL, O'Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007; 132: 1151-1161. 108. Cho JH, Paik SY. Association between electronic cigarette use and asthma among high school students in South Korea. PLoS One 2016; 11: e0151022."
    },
    {
        "id": "doc_4939",
        "document": "109. Lim H, Kwon HJ, Lim JA, et al. Short-term effect of fine particulate matter on children's hospital admissions and emergency department visits for asthma: A systematic review and meta-analysis. J Prev Med Public Health 2016; 49: 205-219."
    },
    {
        "id": "doc_4940",
        "document": "110. Zheng XY, Ding H, Jiang LN, et al. Association between air pollutants and asthma emergency room visits and hospital admissions in time series studies: A systematic review and meta-analysis. PLoS One 2015; 10: e0138146. 111. Mazenq J, Dubus JC, Gaudart J, et al. City housing atmospheric pollutant impact on emergency visit for asthma: A classification and regression tree approach. Respir Med 2017; 132: 1-8."
    },
    {
        "id": "doc_4941",
        "document": "112. Su JG, Barrett MA, Combs V, et al. Identifying impacts of air pollution on subacute asthma symptoms using digital medication sensors. Int J Epidemiol 2022; 51: 213-224.\n\n113. Sturdy PM, Victor CR, Anderson HR, et al. Psychological, social and health behaviour risk factors for deaths certified as asthma: a national case-control study. Thorax 2002; 57: 1034-1039."
    },
    {
        "id": "doc_4942",
        "document": "114. Redmond C, Akinoso-Imran AQ, Heaney LG, et al. Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: A systematic review and meta-analysis. J Allergy Clin Immunol 2022; 149: 1617-1627. 115. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107: 61-67."
    },
    {
        "id": "doc_4943",
        "document": "116. Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy 1995; 25: 820-827.\n\n117. Pongracic JA, Krouse RZ, Babineau DC, et al. Distinguishing characteristics of difficult-to-control asthma in inner- city children and adolescents. J Allergy Clin Immunol 2016; 138: 1030-1041."
    },
    {
        "id": "doc_4944",
        "document": "118. Belda J, Giner J, Casan P, et al. Mild exacerbations and eosinophilic inflammation in patients with stable, well- controlled asthma after 1 year of follow-up. Chest 2001; 119: 1011-1017.\n\n210\n\nReferences\n\n119. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest 1995; 108: 10-15."
    },
    {
        "id": "doc_4945",
        "document": "120. Zeiger RS, Schatz M, Zhang F, et al. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol 2011; 128: 412-414.\n\n121. Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998; 157: 1804-1809."
    },
    {
        "id": "doc_4946",
        "document": "122. Miller MK, Lee JH, Miller DP, et al. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007; 101: 481-489.\n\n123. Buelo A, McLean S, Julious S, et al. At-risk children with asthma (ARC): a systematic review. Thorax 2018; 73: 813- 824."
    },
    {
        "id": "doc_4947",
        "document": "124. den Dekker HT, Sonnenschein-van der Voort AMM, de Jongste JC, et al. Early growth characteristics and the risk of reduced lung function and asthma: A meta-analysis of 25,000 children. J Allergy Clin Immunol 2016; 137: 1026-1035. 125. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-1200."
    },
    {
        "id": "doc_4948",
        "document": "126. Ulrik CS. Outcome of asthma: longitudinal changes in lung function. Eur Respir J 1999; 13: 904-918. 127. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179: 19-24.\n\n128. Raissy HH, Kelly HW, Harkins M, et al. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013; 187: 798-803."
    },
    {
        "id": "doc_4949",
        "document": "129. Foster JM, Aucott L, van der Werf RH, et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. Respir Med 2006; 100: 1318-1336. 130. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: 213-219."
    },
    {
        "id": "doc_4950",
        "document": "131. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 2001; 164: 521-535. 132. Loke YK, Blanco P, Thavarajah M, et al. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One 2015; 10: e0133428.\n\n133. Wechsler ME, Kelley JM, Boyd IO, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365: 119-126."
    },
    {
        "id": "doc_4951",
        "document": "134. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116-124."
    },
    {
        "id": "doc_4952",
        "document": "135. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583-2593. 136. Barnes PJ, Szefler SJ, Reddel HK, et al. Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. J Allergy Clin Immunol 2019; 144: 1180-1186. 137. Loymans RJ, Honkoop PJ, Termeer EH, et al."
    },
    {
        "id": "doc_4953",
        "document": "Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. Thorax 2016; 71: 838-846. 138. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419."
    },
    {
        "id": "doc_4954",
        "document": "139. Kohansal R, Martinez-Camblor P, Agusti A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180: 3-10.\n\n140. McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med 2016; 374: 1842-1852."
    },
    {
        "id": "doc_4955",
        "document": "141. Carr TF, Fajt ML, Kraft M, et al. Treating asthma in the time of COVID. J Allergy Clin Immunol 2023; 151: 809-817. 142. Kerstjens HA, Brand PL, de Jong PM, et al. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. Thorax 1994; 49: 1109-1115."
    },
    {
        "id": "doc_4956",
        "document": "143. Brand PL, Duiverman EJ, Waalkens HJ, et al. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999; 54: 103-107.\n\nReferences\n\n211\n\n144. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844."
    },
    {
        "id": "doc_4957",
        "document": "145. Jenkins CR, Thien FC, Wheatley JR, et al. Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 2005; 26: 36-44.\n\n146. Li D, German D, Lulla S, et al. Prospective study of hospitalization for asthma. A preliminary risk factor model. Am J Respir Crit Care Med 1995; 151: 647-655.\n\n147. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long- term follow-up. Chest 2004; 126: 1875-1882."
    },
    {
        "id": "doc_4958",
        "document": "148. Killian KJ, Watson R, Otis J, et al. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000; 162: 490-496.\n\n149. Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226-235.\n\n150. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410-418."
    },
    {
        "id": "doc_4959",
        "document": "151. Santanello NC, Zhang J, Seidenberg B, et al. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999; 14: 23-27.\n\n152. Reddel HK, Marks GB, Jenkins CR. When can personal best peak flow be determined for asthma action plans? Thorax 2004; 59: 922-924.\n\n153. Frey U, Brodbeck T, Majumdar A, et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature 2005; 438: 667-670."
    },
    {
        "id": "doc_4960",
        "document": "154. Julius SM, Davenport KL, Davenport PW. Perception of intrinsic and extrinsic respiratory loads in children with life-threatening asthma. Pediatr Pulmonol 2002; 34: 425-433.\n\n155. Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330: 1329-1334."
    },
    {
        "id": "doc_4961",
        "document": "156. Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121: 329-333.\n\n157. Nuijsink M, Hop WC, Jongste JC, et al. Perception of bronchoconstriction: a complementary disease marker in children with asthma. J Asthma 2013; 50: 560-564."
    },
    {
        "id": "doc_4962",
        "document": "158. Jansen J, McCaffery KJ, Hayen A, et al. Impact of graphic format on perception of change in biological data: implications for health monitoring in conditions such as asthma. Prim Care Respir J 2012; 21: 94-100.\n\n159. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373."
    },
    {
        "id": "doc_4963",
        "document": "160. Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J 2018; 51.\n\n161. Lee J, Tay TR, Radhakrishna N, et al. Nonadherence in the era of severe asthma biologics and thermoplasty. Eur Respir J 2018; 51."
    },
    {
        "id": "doc_4964",
        "document": "162. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120: S94-138.\n\n163. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146: 1217-1270."
    },
    {
        "id": "doc_4965",
        "document": "164. Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007; 62: 591-604.\n\n165. Bergstr\u00f6m SE, Boman G, Eriksson L, et al. Asthma mortality among Swedish children and young adults, a 10-year study. Respir Med 2008; 102: 1335-1341."
    },
    {
        "id": "doc_4966",
        "document": "166. Reddel HK, Busse WW, Pedersen S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 2017; 389: 157-166.\n\n212\n\nReferences"
    },
    {
        "id": "doc_4967",
        "document": "167. Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev 2021; 5: CD013518. 168. Comaru T, Pitrez PM, Friedrich FO, et al. Free asthma medications reduces hospital admissions in Brazil (Free asthma drugs reduces hospitalizations in Brazil). Respir Med 2016; 121: 21-25."
    },
    {
        "id": "doc_4968",
        "document": "169. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-938.\n\n170. FitzGerald JM, Barnes PJ, Chipps BE, et al. The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res 2020; 6: 00359-02019."
    },
    {
        "id": "doc_4969",
        "document": "171. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019; 380: 2020-2030.\n\n172. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019; 394: 919-928."
    },
    {
        "id": "doc_4970",
        "document": "173. Boulet L-P, Vervloet D, Magar Y, et al. Adherence: the goal to control asthma. Clin Chest Med 2012; 33: 405-417. 174. Murphy J, McSharry J, Hynes L, et al. Prevalence and predictors of adherence to inhaled corticosteroids in young adults (15-30 years) with asthma: a systematic review and meta-analysis. J Asthma 2020: 1-23."
    },
    {
        "id": "doc_4971",
        "document": "175. Wilson KC, Gould MK, Krishnan JA, et al. An Official American Thoracic Society Workshop Report. A framework for addressing multimorbidity in clinical practice guidelines for pulmonary disease, critical Illness, and sleep disorders. Ann Am Thorac Soc 2016; 13: S12-21.\n\n176. Taylor YJ, Tapp H, Shade LE, et al. Impact of shared decision making on asthma quality of life and asthma control among children. J Asthma 2018; 55: 675-683."
    },
    {
        "id": "doc_4972",
        "document": "177. Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003: CD001117.\n\n178. Guevara JP, Wolf FM, Grum CM, et al. Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis. BMJ 2003; 326: 1308-1309."
    },
    {
        "id": "doc_4973",
        "document": "179. Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566-577.\n\n180. Cabana MD, Slish KK, Evans D, et al. Impact of physician asthma care education on patient outcomes. Pediatrics 2006; 117: 2149-2157."
    },
    {
        "id": "doc_4974",
        "document": "181. Partridge MR, Hill SR. Enhancing care for people with asthma: the role of communication, education, training and self-management. 1998 World Asthma Meeting Education and Delivery of Care Working Group. Eur Respir J 2000; 16: 333-348."
    },
    {
        "id": "doc_4975",
        "document": "182. Maguire P, Pitceathly C. Key communication skills and how to acquire them. BMJ 2002; 325: 697-700. 183. Clark NM, Cabana MD, Nan B, et al. The clinician-patient partnership paradigm: outcomes associated with physician communication behavior. Clin Pediatr (Phila) 2008; 47: 49-57."
    },
    {
        "id": "doc_4976",
        "document": "184. Rosas-Salazar C, Apter AJ, Canino G, et al. Health literacy and asthma. J Allergy Clin Immunol 2012; 129: 935-942. 185. Rosas-Salazar C, Ramratnam SK, Brehm JM, et al. Parental numeracy and asthma exacerbations in Puerto Rican children. Chest 2013; 144: 92-98.\n\n186. Apter AJ, Wan F, Reisine S, et al. The association of health literacy with adherence and outcomes in moderate- severe asthma. J Allergy Clin Immunol 2013; 132: 321-327."
    },
    {
        "id": "doc_4977",
        "document": "187. Poureslami I, Nimmon L, Doyle-Waters M, et al. Effectiveness of educational interventions on asthma self- management in Punjabi and Chinese asthma patients: a randomized controlled trial. J Asthma 2012; 49: 542-551. 188. Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663-670."
    },
    {
        "id": "doc_4978",
        "document": "189. Ait-Khaled N, Enarson DA, Bencharif N, et al. Implementation of asthma guidelines in health centres of several developing countries. Int J Tuberc Lung Dis 2006; 10: 104-109.\n\nReferences\n\n213\n\n190. Plaza V, Cobos A, Ignacio-Garcia JM, et al. [Cost-effectiveness of an intervention based on the Global INitiative for Asthma (GINA) recommendations using a computerized clinical decision support system: a physicians randomized trial]. Medicina clinica 2005; 124: 201-206."
    },
    {
        "id": "doc_4979",
        "document": "191. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.\n\n192. Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013; 1: e29-e30.\n\n193. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013; 1: 639-652."
    },
    {
        "id": "doc_4980",
        "document": "194. Drazen JM. Asthma: the paradox of heterogeneity. J Allergy Clin Immunol 2012; 129: 1200-1201. 195. Haahtela T, Tamminen K, Malmberg LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir J 2006; 28: 748-755. 196. Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with"
    },
    {
        "id": "doc_4981",
        "document": "budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121: 1167-1174."
    },
    {
        "id": "doc_4982",
        "document": "197. Selroos O, Pietinalho A, Lofroos AB, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-1234.\n\n198. Selroos O. Effect of disease duration on dose-response of inhaled budesonide in asthma. Respir Med 2008; 102: 1065-1072.\n\n199. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-615."
    },
    {
        "id": "doc_4983",
        "document": "200. Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2018; 6: 29-39."
    },
    {
        "id": "doc_4984",
        "document": "201. Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53: 1901046.\n\n202. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018; 378: 1865-1876."
    },
    {
        "id": "doc_4985",
        "document": "203. Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378: 1877-1887.\n\n204. Wechsler ME, Szefler SJ, Ortega VE, et al. Step-up therapy in black children and adults with poorly controlled asthma. N Engl J Med 2019; 381: 1227-1239."
    },
    {
        "id": "doc_4986",
        "document": "205. Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol- glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med 2020; 8: 1000- 1012."
    },
    {
        "id": "doc_4987",
        "document": "206. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med 2017; 17: 31. 207. Bateman ED, O'Byrne PM, FitzGerald JM, et al. Positioning as-needed budesonide-formoterol for mild asthma: effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. Ann Am Thorac Soc 2021; 18: 2007-2017. 208. Reddel HK, O'Byrne PM, FitzGerald JM, et al."
    },
    {
        "id": "doc_4988",
        "document": "Efficacy and safety of as-needed budesonide-formoterol in adolescents with mild asthma. J Allergy Clin Immunol Pract 2021; 9: 3069-3077.e3066."
    },
    {
        "id": "doc_4989",
        "document": "209. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8 Pt 1): 1392-1397.\n\n210. FitzGerald JM, O'Byrne PM, Bateman ED, et al. Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies. Drug Saf 2021; 44: 467-478."
    },
    {
        "id": "doc_4990",
        "document": "211. Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60.\n\n214\n\nReferences"
    },
    {
        "id": "doc_4991",
        "document": "Hancox RJ. Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis. Clin Rev Allergy Immunol 2006; 31: 279-288. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review meta-analysis. JAMA 2018; 319: 1485-1496. 308: 987-997."
    },
    {
        "id": "doc_4992",
        "document": "Sumino K, Bacharier LB, Taylor J, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African- American children with mild asthma. J Allergy Clin Immunol Pract 2020; 8: 176-185.e172. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J 2006; 15: 326-"
    },
    {
        "id": "doc_4993",
        "document": "Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. Med 2000; 343: 332-336. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880-884. Reddel HK, Ampon RD, Sawyer SM, et al. Risks associated with managing asthma without a preventer: urgent"
    },
    {
        "id": "doc_4994",
        "document": "healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open e016688. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a b2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392. Baan EJ, Hoeve CE, De Ridder M, et al. The ALPACA study: (In)Appropriate LAMA prescribing in asthma: A cohort Pulm Pharmacol Ther 2021; 71: 102074."
    },
    {
        "id": "doc_4995",
        "document": "Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for adults and children with Cochrane Database Syst Rev 2010: CD008418. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787-794. exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753."
    },
    {
        "id": "doc_4996",
        "document": "Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting beta agonists for the treatment of asthma: clearing the air 2012; 67: 342-349. Adams NP, Bestall JB, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005: CD002738. Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008: CD003135."
    },
    {
        "id": "doc_4997",
        "document": "References\n\n215\n\n234. Tan DJ, Bui DS, Dai X, et al. Does the use of inhaled corticosteroids in asthma benefit lung function in the long- term? A systematic review and meta-analysis. Eur Respir Rev 2021; 30."
    },
    {
        "id": "doc_4998",
        "document": "235. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; 5: CD002314. 236. U.S. Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. FDA; 2020 [updated 13 March 2020; cited 2023 April]. 3-4-2020 FDA Drug Safety"
    },
    {
        "id": "doc_4999",
        "document": "Communication]. Available from: https://www.fda.gov/drugs/drug- safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug. 237. Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009: CD005307."
    },
    {
        "id": "doc_5000",
        "document": "238. Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 2002; 96: 432-438.\n\n239.\n\nRivington RN, Boulet LP, Cote J, et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic\n\npatients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995; 151: 325-332.\n\n240."
    },
    {
        "id": "doc_5001",
        "document": "American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and\n\nmontelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175: 235-242.\n\n241.\n\nTsiu SJ, Self TH, Burns R. Theophylline toxicity: update. Ann Allergy 1990; 64: 241-257.\n\n242. Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006: CD003558."
    },
    {
        "id": "doc_5002",
        "document": "243. Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006: CD004108.\n\n244. van der Wouden JC, Uijen JH, Bernsen RM, et al. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev 2008: CD002173."
    },
    {
        "id": "doc_5003",
        "document": "245. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 4: CD007313."
    },
    {
        "id": "doc_5004",
        "document": "246. Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 12: CD009019.\n\n247. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone\u2013formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 23-31."
    },
    {
        "id": "doc_5005",
        "document": "248. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide/formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1: 32-42."
    },
    {
        "id": "doc_5006",
        "document": "249. Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory research 2011; 12: 38. 250. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J 2018; 51."
    },
    {
        "id": "doc_5007",
        "document": "251. Beasley R, Harrison T, Peterson S, et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e220615.\n\n252. Demoly P, Louis R, S\u00f8es-Petersen U, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 2009; 103: 1623-1632."
    },
    {
        "id": "doc_5008",
        "document": "253. Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet 2017; 390: 2247-2255. 254. Svedsater H, Jones R, Bosanquet N, et al. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir Med 2018; 141: 198-206.\n\n216\n\nReferences"
    },
    {
        "id": "doc_5009",
        "document": "255. Cates CJ, Schmidt S, Ferrer M, et al. Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cochrane Database Syst Rev 2018; 12: CD006922.\n\n256. Busse WW, Bateman ED, Caplan AL, et al. Combined analysis of asthma safety trials of long-acting beta2- agonists. N Engl J Med 2018; 378: 2497-2505.\n\n257. Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med 2016; 375: 850-860."
    },
    {
        "id": "doc_5010",
        "document": "258. Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016; 374: 1822-1830.\n\n259. Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med 2022; 386: 2071-2083."
    },
    {
        "id": "doc_5011",
        "document": "260. Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA 2016; 315: 1715-1725.\n\n261. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014; 134: 568-575.e567."
    },
    {
        "id": "doc_5012",
        "document": "262. Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010: CD005533.\n\n263. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223-225."
    },
    {
        "id": "doc_5013",
        "document": "264. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti- leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014; 1: CD003137.\n\n265. Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high- dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-1418."
    },
    {
        "id": "doc_5014",
        "document": "266. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006; 100: 1297-1306.\n\ndoubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010; 182: 1221-1227.\n\n268. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130: 1733-1743."
    },
    {
        "id": "doc_5015",
        "document": "269. Stempel DA, Szefler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med 2016; 375: 840-849.\n\n270. Lemanske R, Mauger D, Sorkness C, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975-985."
    },
    {
        "id": "doc_5016",
        "document": "271. O'Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest 2008; 134: 1192-1199.\n\n272. Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta- analysis. JAMA 2018; 319: 1473-1484."
    },
    {
        "id": "doc_5017",
        "document": "273. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019; 394: 1737-1749. 274. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021; 9: 69-84."
    },
    {
        "id": "doc_5018",
        "document": "275. Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med 2020; 170: 106021.\n\nReferences\n\n217"
    },
    {
        "id": "doc_5019",
        "document": "276. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016: Cd011721.\n\n277. Casale TB, Aalbers R, Bleecker ER, et al. Tiotropium Respimat(R) add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. Respir Med 2019; 158: 97-109."
    },
    {
        "id": "doc_5020",
        "document": "278. Malo JL, Cartier A, Ghezzo H, et al. Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir Med 1995; 89: 537-543. 279. Toogood JH, Baskerville JC, Jennings B, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982; 70: 288-298. 280. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised,"
    },
    {
        "id": "doc_5021",
        "document": "placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90. 281. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-216. 282. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to"
    },
    {
        "id": "doc_5022",
        "document": "moderate asthma. Thorax 2003; 58: 204-210."
    },
    {
        "id": "doc_5023",
        "document": "283. Virchow JC, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162: 578-585.\n\n284. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155: 1235-1240.\n\n285."
    },
    {
        "id": "doc_5024",
        "document": "Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe\n\nsymptomatic asthma: A systematic review. Pediatr Allergy Immunol 2017; 28: 573-578.\n\n286.\n\nSzefler SJ, Vogelberg C, Bernstein JA, et al. Tiotropium Is Efficacious in 6- to 17-Year-Olds with Asthma,\n\nIndependent of T2 Phenotype. J Allergy Clin Immunol Pract 2019; 7: 2286-2295 e2284."
    },
    {
        "id": "doc_5025",
        "document": "287. Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219-223.\n\n288. Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J 2018; 52."
    },
    {
        "id": "doc_5026",
        "document": "289. Broersen LH, Pereira AM, Jorgensen JO, et al. Adrenal insufficiency in corticosteroids use: Systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100: 2171-2180.\n\n290. Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA 2021; 325: 2466-2479."
    },
    {
        "id": "doc_5027",
        "document": "291. Taylor SL, Leong LEX, Mobegi FM, et al. Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med 2019; 200: 309-317.\n\n292. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 659-668."
    },
    {
        "id": "doc_5028",
        "document": "293. Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J 2019; 54.\n\n294. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines \u2013 recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1043-1057."
    },
    {
        "id": "doc_5029",
        "document": "295. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.\n\n296. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355-366.\n\n218\n\nReferences"
    },
    {
        "id": "doc_5030",
        "document": "297. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376: 2448-2458.\n\n298. Jackson DJ, Bacharier LB, Gergen PJ, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022; 400: 502-511."
    },
    {
        "id": "doc_5031",
        "document": "299. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1023-1042.\n\n300. Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med 2021; 385: 2230-2240."
    },
    {
        "id": "doc_5032",
        "document": "301. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486-2496.\n\n302. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388: 31-44."
    },
    {
        "id": "doc_5033",
        "document": "303. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1058- 1068.\n\n304. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017; 377: 936-946."
    },
    {
        "id": "doc_5034",
        "document": "305. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2017; 8: CD005603."
    },
    {
        "id": "doc_5035",
        "document": "306. Chupp G, Laviolette M, Cohn L, et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J 2017; 50. 307. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56: 279-284."
    },
    {
        "id": "doc_5036",
        "document": "308. Lefebvre P, Duh MS, Lafeuille M-H, et al. Acute and chronic systemic corticosteroid\u2013related complications in patients with severe asthma. J Allergy Clin Immunol 2015; 136: 1488-1495.\n\n309. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018; 11: 193-204."
    },
    {
        "id": "doc_5037",
        "document": "310. Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med 2020; 201: 276-293."
    },
    {
        "id": "doc_5038",
        "document": "311. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2017; 69: 1095-1110. 312. National Asthma Council Australia. Asthma action plan library. [web page]: National Asthma Council Australia; [cited 2023 April]. Available from: https://www.nationalasthma.org.au/health-professionals/asthma-action- plans/asthma-action-plan-library."
    },
    {
        "id": "doc_5039",
        "document": "313. Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007; 29: 56-62.\n\n314. Sont JK. How do we monitor asthma control? Allergy 1999; 54 Suppl 49: 68-73.\n\n315. Mintz M, Gilsenan AW, Bui CL, et al. Assessment of asthma control in primary care. Curr Med Res Opin 2009; 25: 2523-2531."
    },
    {
        "id": "doc_5040",
        "document": "316. Schatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes: what improves future outcomes? Proc Am Thorac Soc 2009; 6: 386-393.\n\n317. Thomas A, Lemanske RF, Jr., Jackson DJ. Approaches to stepping up and stepping down care in asthmatic patients. J Allergy Clin Immunol 2011; 128: 915-924.\n\n318. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113: 587-592.\n\nReferences\n\n219"
    },
    {
        "id": "doc_5041",
        "document": "319. Usmani OS, Kemppinen A, Gardener E, et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract 2017; 5: 1378-1387.e1375.\n\n320. DiMango E, Rogers L, Reibman J, et al. Risk factors for asthma exacerbation and treatment failure in adults and adolescents with well-controlled asthma during continuation and step-down therapy. Ann Am Thorac Soc 2018; 15: 955- 961."
    },
    {
        "id": "doc_5042",
        "document": "321. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406-412."
    },
    {
        "id": "doc_5043",
        "document": "322. Rogers L, Sugar EA, Blake K, et al. Step-down therapy for asthma well controlled on inhaled corticosteroid and long-acting beta-agonist: A randomized clinical trial. J Allergy Clin Immunol Pract 2018; 6: 633-643.e631. 323. FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in"
    },
    {
        "id": "doc_5044",
        "document": "adults with persistent asthma. Clinical Therapeutics 2005; 27: 393-406."
    },
    {
        "id": "doc_5045",
        "document": "324. Bose S, Bime C, Henderson RJ, et al. Biomarkers of Type 2 airway inflammation as predictors of loss of Aathma control during step-down therapy for well-controlled disease: the Long-Acting Beta-Agonist Step-Down Study (LASST). J Allergy Clin Immunol Pract 2020; 8: 3474-3481."
    },
    {
        "id": "doc_5046",
        "document": "325. Wang K, Verbakel JY, Oke J, et al. Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. Eur Respir J 2020; 55.\n\n326.\n\nRank MA, Hagan JB, Park MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled\n\ncorticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131: 724-729."
    },
    {
        "id": "doc_5047",
        "document": "327. Hagan JB, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Allergy 2014; 69: 510-516. 328. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev 2015: Cd011306. 329. Rank MA, Gionfriddo MR, Pongdee T, et al. Stepping down from inhaled"
    },
    {
        "id": "doc_5048",
        "document": "corticosteroids with leukotriene inhibitors in asthma: a systematic review and meta-analysis. Allergy Asthma Proc 2015; 36: 200-205. 330. Masoli M, Weatherall M, Holt S, et al. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004; 9: 528-534."
    },
    {
        "id": "doc_5049",
        "document": "331. Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006; 100: 785-794.\n\n332. Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy 2009; 39: 478-490."
    },
    {
        "id": "doc_5050",
        "document": "333. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev 2016; 11: CD011439.\n\n334. Turner S, Cotton S, Wood J, et al. Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial. Lancet Respir Med 2022; 10: 584-592."
    },
    {
        "id": "doc_5051",
        "document": "335. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev 2016; 9: CD011440.\n\n336. Heaney LG, Busby J, Hanratty CE, et al. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med 2021; 9: 57-68."
    },
    {
        "id": "doc_5052",
        "document": "337. Rice JL, Diette GB, Suarez-Cuervo C, et al. Allergen-specific immunotherapy in the treatment of pediatric asthma: A systematic review. Pediatrics 2018; 141.\n\n338. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013; 309: 1278-1288."
    },
    {
        "id": "doc_5053",
        "document": "339. Di Bona D, Frisenda F, Albanesi M, et al. Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review. Clin Exp Allergy 2018; 48: 1391-1401.\n\n220\n\nReferences\n\n340. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010: CD001186."
    },
    {
        "id": "doc_5054",
        "document": "341. Klimek L, Fox GC, Thum-Oltmer S. SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups. Allergo J Int 2018; 27: 131-139.\n\n342. Xu K, Deng Z, Li D, et al. Efficacy of add-on sublingual immunotherapy for adults with asthma: A meta-analysis and systematic review. Ann Allergy Asthma Immunol 2018; 121: 186-194."
    },
    {
        "id": "doc_5055",
        "document": "343. Calamita Z, Saconato H, Pela AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61: 1162-1172.\n\n344. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2020; 9: CD011293."
    },
    {
        "id": "doc_5056",
        "document": "345. Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009; 102: 69-75. 346. Baena-Cagnani CE, Larenas-Linnemann D, Teijeiro A, et al. Will sublingual immunotherapy offer benefit for asthma? Curr Allergy Asthma Rep 2013."
    },
    {
        "id": "doc_5057",
        "document": "347. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131: 1288-1296.e1283.\n\n348. Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic\n\nrhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013; 131: 1361-1366."
    },
    {
        "id": "doc_5058",
        "document": "349. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013; 2: CD000364.\n\n350. Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis 2017; 65: 1388-1395."
    },
    {
        "id": "doc_5059",
        "document": "351. Bandell A, Ambrose CS, Maniaci J, et al. Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis. Expert Rev Vaccines 2021; 20: 717-728. 352. Li L, Cheng Y, Tu X, et al. Association between asthma and invasive pneumococcal disease risk: a systematic review and meta-analysis. Allergy Asthma Clin Immunol 2020; 16: 94."
    },
    {
        "id": "doc_5060",
        "document": "353. Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database Syst Rev 2002: CD002165. 354. Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med 2021; 9: 457-466.\n\n355. Cassim R, Russell MA, Lodge CJ, et al. The role of circulating 25 hydroxyvitamin D in asthma: a systematic review. Allergy 2015; 70: 339-354."
    },
    {
        "id": "doc_5061",
        "document": "356. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med 2017; 5: 881-890. 357. And\u00fajar-Espinosa R, Salinero-Gonz\u00e1lez L, Ill\u00e1n-G\u00f3mez F, et al. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. Thorax 2021; 76: 126-133. 358. Riverin BD, Maguire JL, Li P. Vitamin D supplementation"
    },
    {
        "id": "doc_5062",
        "document": "for childhood asthma: A systematic review and meta- analysis. PLoS One 2015; 10: e0136841."
    },
    {
        "id": "doc_5063",
        "document": "359. Pojsupap S, Iliriani K, Sampaio TZ, et al. Efficacy of high-dose vitamin D in pediatric asthma: a systematic review and meta-analysis. J Asthma 2015; 52: 382-390."
    },
    {
        "id": "doc_5064",
        "document": "360. Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 2014; 311: 2083-2091. 361. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175: 783-790."
    },
    {
        "id": "doc_5065",
        "document": "362. Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174: 127-133.\n\nReferences\n\n221\n\n363. Rayens MK, Burkhart PV, Zhang M, et al. Reduction in asthma-related emergency department visits after implementation of a smoke-free law. J Allergy Clin Immunol 2008; 122: 537-541."
    },
    {
        "id": "doc_5066",
        "document": "364. Wills TA, Soneji SS, Choi K, et al. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J 2021; 57.\n\n365. Valkenborghs SR, Anderson SL, Scott HA, et al. Exercise training programs improve cardiorespiratory and functional fitness in adults with asthma: a systematic review and meta-analysis. J Cardiopulm Rehabil Prev 2022; 42: 423- 433."
    },
    {
        "id": "doc_5067",
        "document": "366. Hansen ESH, Pitzner-Fabricius A, Toennesen LL, et al. Effect of aerobic exercise training on asthma in adults: a systematic review and meta-analysis. Eur Respir J 2020; 56.\n\n367. McLoughlin RF, Clark VL, Urroz PD, et al. Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur Respir J 2022; 60: 2200546."
    },
    {
        "id": "doc_5068",
        "document": "368. Toennesen LL, Meteran H, Hostrup M, et al. Effects of exercise and diet in nonobese asthma patients-a randomized controlled trial. J Allergy Clin Immunol Pract 2018; 6: 803-811.\n\n369. Beggs S, Foong YC, Le HC, et al. Swimming training for asthma in children and adolescents aged 18 years and under. Cochrane Database Syst Rev 2013; 4: CD009607."
    },
    {
        "id": "doc_5069",
        "document": "370. Kogevinas M, Zock JP, Jarvis D, et al. Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II). Lancet 2007; 370: 336-341.\n\nSzczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators.\n\n371\n\nEuropean Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16: 432-436."
    },
    {
        "id": "doc_5070",
        "document": "372. Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. Immunol Allergy Clin North Am 2005; 25: 169-190.\n\n373. Olenchock BA, Fonarow GG, Pan W, et al. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009; 103: 295-300."
    },
    {
        "id": "doc_5071",
        "document": "374. Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute beta-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014; 145: 779-786.\n\n375. Gotzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008: CD001187."
    },
    {
        "id": "doc_5072",
        "document": "376. Leas BF, D'Anci KE, Apter AJ, et al. Effectiveness of indoor allergen reduction in asthma management: A systematic review. J Allergy Clin Immunol 2018; 141: 1854-1869.\n\nSheffer AL. Allergen avoidance to reduce asthma-related morbidity. N Engl J Med 2004; 351: 1134-1136."
    },
    {
        "id": "doc_5073",
        "document": "378. Platts-Mills TA. Allergen avoidance in the treatment of asthma and rhinitis. N Engl J Med 2003; 349: 207-208. 379. Rabito FA, Carlson JC, He H, et al. A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children. J Allergy Clin Immunol 2017; 140: 565-570."
    },
    {
        "id": "doc_5074",
        "document": "380. Crocker DD, Kinyota S, Dumitru GG, et al. Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthma morbidity: a community guide systematic review. Am J Prev Med 2011; 41: S5-32.\n\n381. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004; 351: 1068-1080."
    },
    {
        "id": "doc_5075",
        "document": "382. Murray CS, Foden P, Sumner H, et al. Preventing severe asthma exacerbations in children. A randomized trial of mite-impermeable bedcovers. Am J Respir Crit Care Med 2017; 196: 150-158.\n\n383. Custovic A, Green R, Taggart SC, et al. Domestic allergens in public places. II: Dog (Can f1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings. Clin Exp Allergy 1996; 26: 1246- 1252."
    },
    {
        "id": "doc_5076",
        "document": "384. Almqvist C, Larsson PH, Egmar AC, et al. School as a risk environment for children allergic to cats and a site for transfer of cat allergen to homes. J Allergy Clin Immunol 1999; 103: 1012-1017.\n\n385. Shirai T, Matsui T, Suzuki K, et al. Effect of pet removal on pet allergic asthma. Chest 2005; 127: 1565-1571. 386. Wood RA, Chapman MD, Adkinson NF, Jr., et al. The effect of cat removal on allergen content in household-dust samples. J Allergy Clin Immunol 1989; 83: 730-734."
    },
    {
        "id": "doc_5077",
        "document": "Erwin EA, Woodfolk JA, Custis N, et al. Animal danders. Immunol Allergy Clin North Am 2003; 23: 469-481.\n\n222\n\nReferences\n\n388. Phipatanakul W, Matsui E, Portnoy J, et al. Environmental assessment and exposure reduction of rodents: a practice parameter. Ann Allergy Asthma Immunol 2012; 109: 375-387."
    },
    {
        "id": "doc_5078",
        "document": "389. Matsui EC, Perzanowski M, Peng RD, et al. Effect of an integrated pest management intervention on asthma symptoms among mouse-sensitized children and adolescents with asthma: A randomized clinical trial. JAMA 2017; 317: 1027-1036.\n\n390. Eggleston PA, Wood RA, Rand C, et al. Removal of cockroach allergen from inner-city homes. J Allergy Clin Immunol 1999; 104: 842-846."
    },
    {
        "id": "doc_5079",
        "document": "391. Denning DW, O'Driscoll B R, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27: 615-626.\n\n392. Hirsch T, Hering M, Burkner K, et al. House-dust-mite allergen concentrations (Der f 1) and mold spores in apartment bedrooms before and after installation of insulated windows and central heating systems. Allergy 2000; 55: 79-83."
    },
    {
        "id": "doc_5080",
        "document": "393. Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy 2005; 60: 1112-1115. 394. Wood LG, Garg ML, Smart JM, et al. Manipulating antioxidant intake in asthma: a randomized controlled trial. AM J Clin Nutr 2012; 96: 534-543."
    },
    {
        "id": "doc_5081",
        "document": "395. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007; 101: 2240-2247.\n\n396. Lavoie KL, Bacon SL, Labrecque M, et al. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2006; 100: 648-657.\n\n397. Saint-Pierre P, Bourdin A, Chanez P, et al. Are overweight asthmatics more difficult to control? Allergy 2006; 61: 79-84."
    },
    {
        "id": "doc_5082",
        "document": "398. Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178: 682-687.\n\n399. Okoniewski W, Lu KD, Forno E. Weight Loss for Children and Adults with Obesity and Asthma. A Systematic Review of Randomized Controlled Trials. Ann Am Thorac Soc 2019; 16: 613-625.\n\nAdeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012; 7:"
    },
    {
        "id": "doc_5083",
        "document": "401. Moreira A, Bonini M, Garcia-Larsen V, et al. Weight loss interventions in asthma: EAACI Evidence-Based Clinical Practice Guideline (Part I). Allergy 2013; 68: 425-439.\n\n402. Boulet LP, Turcotte H, Martin J, et al. Effect of bariatric surgery on airway response and lung function in obese subjects with asthma. Respir Med 2012; 106: 651-660."
    },
    {
        "id": "doc_5084",
        "document": "403. Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128: 508-515 e501-502.\n\n404. Scott HA, Gibson PG, Garg ML, et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy 2013; 43: 36-49."
    },
    {
        "id": "doc_5085",
        "document": "405. Santino TA, Chaves GS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev 2020; 3: CD001277.\n\n406. Slader CA, Reddel HK, Spencer LM, et al. Double blind randomised controlled trial of two different breathing techniques in the management of asthma. Thorax 2006; 61: 651-656.\n\n407. Bruton A, Lee A, Yardley L, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. Lancet Respir Med 2018; 6: 19-28."
    },
    {
        "id": "doc_5086",
        "document": "408. Upham JW, Holt PG. Environment and development of atopy. Curr Opin Allergy Clin Immunol 2005; 5: 167-172. 409. Belanger K, Holford TR, Gent JF, et al. Household levels of nitrogen dioxide and pediatric asthma severity. Epidemiology 2013; 24: 320-330.\n\n410. Howden-Chapman P, Pierse N, Nicholls S, et al. Effects of improved home heating on asthma in community dwelling children: randomised controlled trial. BMJ 2008; 337: a1411."
    },
    {
        "id": "doc_5087",
        "document": "411. Park HJ, Lee HY, Suh CH, et al. The effect of particulate matter reduction by indoor air filter use on respiratory symptoms and lung function: a systematic review and meta-analysis. Allergy Asthma Immunol Res 2021; 13: 719-732.\n\nReferences\n\n223"
    },
    {
        "id": "doc_5088",
        "document": "412. Phipatanakul W, Koutrakis P, Coull BA, et al. Effect of school integrated pest management or classroom air filter purifiers on asthma symptoms in students with active asthma: a randomized clinical trial. JAMA 2021; 326: 839-850. 413. Tibosch MM, Verhaak CM, Merkus PJ. Psychological characteristics associated with the onset and course of asthma in children and adolescents: a systematic review of longitudinal effects. Patient Educ Couns 2011; 82: 11-19."
    },
    {
        "id": "doc_5089",
        "document": "414. Rietveld S, van Beest I, Everaerd W. Stress-induced breathlessness in asthma. Psychol Med 1999; 29: 1359-1366. 415. Sandberg S, Paton JY, Ahola S, et al. The role of acute and chronic stress in asthma attacks in children. Lancet 2000; 356: 982-987.\n\nLehrer PM, Isenberg S, Hochron SM. Asthma and emotion: a review. J Asthma 1993; 30: 5-21."
    },
    {
        "id": "doc_5090",
        "document": "417. Nouwen A, Freeston MH, Labbe R, et al. Psychological factors associated with emergency room visits among asthmatic patients. Behav Modif 1999; 23: 217-233.\n\n418. Tyris J, Keller S, Parikh K. Social risk interventions and health care utilization for pediatric asthma: a systematic review and meta-analysis. JAMA Pediatr 2022; 176: e215103."
    },
    {
        "id": "doc_5091",
        "document": "419. Hauptman M, Gaffin JM, Petty CR, et al. Proximity to major roadways and asthma symptoms in the School Inner- City Asthma Study. J Allergy Clin Immunol 2020; 145: 119-126 e114.\n\n420. Newson R, Strachan D, Archibald E, et al. Acute asthma epidemics, weather and pollen in England, 1987-1994. Eur Respir J 1998; 11: 694-701."
    },
    {
        "id": "doc_5092",
        "document": "421. Thien F, Beggs PJ, Csutoros D, et al. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planet Health 2018; 2: e255-e263. 422. Li Y, Wang W, Wang J, et al. Impact of air pollution control measures and weather conditions on asthma during the 2008 Summer Olympic Games in Beijing. Int J Biometeorol 2011; 55: 547-554."
    },
    {
        "id": "doc_5093",
        "document": "423. Taylor SL, Bush RK, Selner JC, et al. Sensitivity to sulfited foods among sulfite-sensitive subjects with asthma. J Allergy Clin Immunol 1988; 81: 1159-1167."
    },
    {
        "id": "doc_5094",
        "document": "424. Ahmed S, Steed L, Harris K, et al. Interventions to enhance the adoption of asthma self-management behaviour in the South Asian and African American population: a systematic review. NPJ Prim Care Respir Med 2018; 28: 5. 425. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir care 2005; 50: 1360-1374; discussion 1374-1365."
    },
    {
        "id": "doc_5095",
        "document": "426. Klijn SL, Hiligsmann M, Evers S, et al. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir Med 2017; 27: 24.\n\n427. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43: 349-360.\n\n428. Basheti IA, Reddel HK, Armour CL, et al. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol 2007; 119: 1537-1538."
    },
    {
        "id": "doc_5096",
        "document": "429. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharmacists. Respir Med 2011; 105: 1815-1822.\n\n430. van der Palen J, Klein JJ, Kerkhoff AH, et al. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Educ Couns 1997; 32: S87-95.\n\nAlmomani BA, Mokhemer E, Al-Sawalha NA, et al. A novel approach of using educational pharmaceutical"
    },
    {
        "id": "doc_5097",
        "document": "pictogram for improving inhaler techniques in patients with asthma. Respir Med 2018; 143: 103-108.\n\n432. Basheti I, Mahboub B, Salameh L, et al. Assessment of novel inhaler technique reminder labels in image format on the correct demonstration of inhaler technique skills in asthma: a single-blinded randomized controlled trial. Pharmaceuticals (Basel) 2021; 14: 150."
    },
    {
        "id": "doc_5098",
        "document": "433. Basheti IA, Obeidat NM, Reddel HK. Effect of novel inhaler technique reminder labels on the retention of inhaler technique skills in asthma: a single-blind randomized controlled trial. NPJ Prim Care Respir Med 2017; 27: 9. 434. Armour CL, Reddel HK, LeMay KS, et al. Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomized trial. J Asthma 2013; 50: 302-309. 435. Kuethe MC, Vaessen-Verberne AA, Elbers RG, et al. Nurse"
    },
    {
        "id": "doc_5099",
        "document": "versus physician-led care for the management of asthma. Cochrane Database Syst Rev 2013; 2: CD009296."
    },
    {
        "id": "doc_5100",
        "document": "436. Federman AD, O'Conor R, Mindlis I, et al. Effect of a self-management support intervention on asthma outcomes in older adults: The SAMBA study randomized clinical trial. JAMA Intern Med 2019.\n\n224\n\nReferences"
    },
    {
        "id": "doc_5101",
        "document": "437. Panigone S, Sandri F, Ferri R, et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res 2020; 7. 438. Janson C, Henderson R, L\u00f6fdahl M, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax 2020; 75: 82-84. 439. Carroll WD, Gilchrist FJ, Horne R. Saving our planet one puff at a time. Lancet Respir Med 2022; 10: e44-e45. 440. Kponee-Shovein K, Marvel J,"
    },
    {
        "id": "doc_5102",
        "document": "Ishikawa R, et al. Carbon footprint and associated costs of asthma exacerbation care among UK adults. J Med Econ 2022; 25: 524-531. 441. Tennison I, Roschnik S, Ashby B, et al. Health care's response to climate change: a carbon footprint assessment of the NHS in England. Lancet Planet Health 2021; 5: e84-e92. 442. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med 2006; 100:"
    },
    {
        "id": "doc_5103",
        "document": "1479-1494. 443. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012; 157: 785-795. 444. Chan AH, Harrison J, Black PN, et al. Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract 2015; 3: 335-349.e331-335. 445. Cohen JL, Mann DM, Wisnivesky JP, et al. Assessing the validity of"
    },
    {
        "id": "doc_5104",
        "document": "self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol 2009; 103: 325-331. 446. Poureslami IM, Rootman I, Balka E, et al. A systematic review of asthma and health literacy: a cultural-ethnic perspective in Canada. MedGenMed 2007; 9: 40. 447. Berkman ND, Sheridan SL, Donahue KE, et al. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med 2011; 155: 97-107. 448. Zeni MB."
    },
    {
        "id": "doc_5105",
        "document": "Systematic review of health literacy in Cochrane database studies on paediatric asthma educational interventions: searching beyond rigorous design. Int J Evid Based Health Care 2012; 10: 3-8. 449. Partridge MR, Dal Negro RW, Olivieri D. Understanding patients with asthma and COPD: insights from a European study. Prim Care Respir J 2011; 20: 315-323, 317 p following 323. 450. Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care"
    },
    {
        "id": "doc_5106",
        "document": "patients with asthma. J Allergy Clin Immunol 2014; 134: 1260-1268. 451. Chan AH, Stewart AW, Harrison J, et al. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir Med 2015; 3: 210-219. 452. Morton RW, Elphick HE, Rigby AS, et al. STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to"
    },
    {
        "id": "doc_5107",
        "document": "improve clinical outcomes for children with asthma. Thorax 2017; 72: 347-354. 453. Chan A, De Simoni A, Wileman V, et al. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev 2022; 6: CD013030. 454. Otsuki M, Eakin MN, Rand CS, et al. Adherence feedback to improve asthma outcomes among inner-city children: a randomized trial. Pediatrics 2009; 124: 1513-1521. 455. Williams LK, Peterson EL, Wells K, et al. A cluster-randomized trial to provide"
    },
    {
        "id": "doc_5108",
        "document": "clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol 2010; 126: 225-231, 231 e221-224. 456. Bender BG, Cvietusa PJ, Goodrich GK, et al. Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment: a randomized clinical trial. JAMA Pediatr 2015; 169: 317-323. 457. Halterman JS, Fagnano M, Tajon RS, et al. Effect of the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) program on asthma"
    },
    {
        "id": "doc_5109",
        "document": "morbidity: A randomized clinical trial. JAMA Pediatr 2018; 172: e174938. 458. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev 2017; 4: CD012226. 459. Foster JM, Smith L, Bosnic-Anticevich SZ, et al. Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. Intern Med J 2012; 42: e136-144. 460. Ulrik CS, Backer V, Soes-Petersen U, et al. The patient's perspective: adherence or"
    },
    {
        "id": "doc_5110",
        "document": "non-adherence to asthma"
    },
    {
        "id": "doc_5111",
        "document": "References\n\n225\n\n461. Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulmonary Medicine 2010; 10: 1.\n\n462. Kew KM, Carr R, Crossingham I. Lay-led and peer support interventions for adolescents with asthma. Cochrane Database Syst Rev 2017; 4: CD012331."
    },
    {
        "id": "doc_5112",
        "document": "463. Clark NM, Shah S, Dodge JA, et al. An evaluation of asthma interventions for preteen students. J Sch Health 2010; 80: 80-87.\n\n464. Gibson PG, Powell H, Coughlan J, et al. Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev 2002: CD001005.\n\n465. Houts PS, Bachrach R, Witmer JT, et al. Using pictographs to enhance recall of spoken medical instructions. Patient Educ Couns 1998; 35: 83-88."
    },
    {
        "id": "doc_5113",
        "document": "466. Meade CD, McKinney WP, Barnas GP. Educating patients with limited literacy skills: the effectiveness of printed and videotaped materials about colon cancer. Am J Public Health 1994; 84: 119-121."
    },
    {
        "id": "doc_5114",
        "document": "467. Manfrin A, Tinelli M, Thomas T, et al. A cluster randomised control trial to evaluate the effectiveness and cost- effectiveness of the Italian medicines use review (I-MUR) for asthma patients. BMC Health Serv Res 2017; 17: 300. 468. Gao G, Liao Y, Mo L, et al. A randomized controlled trial of a nurse-led education pathway for asthmatic children from outpatient to home. Int J Nurs Pract 2020; 26: e12823."
    },
    {
        "id": "doc_5115",
        "document": "469. Campbell JD, Brooks M, Hosokawa P, et al. Community health worker home visits for medicaid-enrolled children with asthma: Effects on asthma outcomes and costs. Am J Public Health 2015; 105: 2366-2372.\n\n470. Partridge MR, Caress AL, Brown C, et al. Can lay people deliver asthma self-management education as effectively as primary care based practice nurses? Thorax 2008; 63: 778-783."
    },
    {
        "id": "doc_5116",
        "document": "471. Pinnock H, Parke HL, Panagioti M, et al. Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Med 2017; 15: 64.\n\n472. Boyd M, Lasserson TJ, McKean MC, et al. Interventions for educating children who are at risk of asthma-related emergency department attendance. Cochrane Database Syst Rev 2009: CD001290.\n\n473. Powell H, Gibson PG. Options for self-management education for adults with asthma. Cochrane Database Syst Rev 2003: CD004107."
    },
    {
        "id": "doc_5117",
        "document": "474. McLean S, Chandler D, Nurmatov U, et al. Telehealthcare for asthma. Cochrane Database Syst Rev 2010: CD007717.\n\n475. Fishwick D, D'Souza W, Beasley R. The asthma self-management plan system of care: what does it mean, how is it done, does it work, what models are available, what do patients want and who needs it? Patient Educ Couns 1997; 32: S21-33.\n\n476. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004; 59: 94-99."
    },
    {
        "id": "doc_5118",
        "document": "477. Holt S, Masoli M, Beasley R. The use of the self-management plan system of care in adult asthma. Prim Care Respir J 2004; 13: 19-27.\n\n478. Roberts NJ, Evans G, Blenkhorn P, et al. Development of an electronic pictorial asthma action plan and its use in primary care. Patient Educ Couns 2010; 80: 141-146.\n\n479. Ring N, Malcolm C, Wyke S, et al. Promoting the use of Personal Asthma Action Plans: a systematic review. Prim Care Respir J 2007; 16: 271-283."
    },
    {
        "id": "doc_5119",
        "document": "480. Halterman JS, Fisher S, Conn KM, et al. Improved preventive care for asthma: a randomized trial of clinician prompting in pediatric offices. Arch Pediatr Adolesc Med 2006; 160: 1018-1025.\n\n481. Kneale D, Harris K, McDonald VM, et al. Effectiveness of school-based self-management interventions for asthma among children and adolescents: findings from a Cochrane systematic review and meta-analysis. Thorax 2019; 74: 432- 438."
    },
    {
        "id": "doc_5120",
        "document": "482. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J 2009; 33: 897-906. 483. Deng X, Ma J, Yuan Y, et al. Association between overweight or obesity and the risk for childhood asthma and wheeze: An updated meta-analysis on 18 articles and 73 252 children. Pediatr Obes 2019; 14: e12532.\n\n226\n\nReferences"
    },
    {
        "id": "doc_5121",
        "document": "Upala S, Thavaraputta S, Sanguankeo A. Improvement in pulmonary function in asthmatic patients after bariatric Ye G, Baldwin DS, Hou R. Anxiety in asthma: a systematic review and meta-analysis. Psychol Med 2021; 51: 11- Lavoie KL, Cartier A, Labrecque M, et al. Are psychiatric disorders associated with worse asthma control and of life in asthma patients? Respir Med 2005; 99: 1249-1257. Ahmedani BK, Peterson EL, Wells KE, et al. Examining the relationship between depression and asthma"
    },
    {
        "id": "doc_5122",
        "document": "exacerbations in a prospective follow-up study. Psychosomatic Medicine 2013; 75: 305-310. Yorke J, Fleming SL, Shuldham C. Psychological interventions for adults with asthma. Cochrane Database Syst Rev Moore et al. behavioural intervention for adults with Parry GD, Cooper CL, JM, Cognitive anxiety complications asthma: prospective randomised trial. Respiratory medicine 2012; 106: 802-810."
    },
    {
        "id": "doc_5123",
        "document": "Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. Allergy Clin Immunol 2007; 119: 1016-1018. Pumphrey RSH, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Immunol 2007; 119: 1018-1019."
    },
    {
        "id": "doc_5124",
        "document": "Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2010; 126: 798-806.e713. Brozek JL, Bousquet J, Agache |, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017; 140: 950-958. update, in collaboration with GA(2)LEN. Allergy 2007; 62 Suppl 84: 1-41."
    },
    {
        "id": "doc_5125",
        "document": "Bousquet J, Schunemann HJ, Samolinski B, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements years and future needs. J Allergy Clin Immunol 2012; 130: 1049-1062. Corren J, Manning BE, Thompson SF, et al. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004; 113: 415-419. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a"
    },
    {
        "id": "doc_5126",
        "document": "meta-analysis. Allergy 2013; 68: 569-579. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps"
    },
    {
        "id": "doc_5127",
        "document": "506. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50: 1-12.\n\nReferences\n\n227\n\n507. Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013; 131: 1350-1360.\n\n508. Hamilos DL. Chronic rhinosinusitis: epidemiology and medical management. J Allergy Clin Immunol 2011; 128: 693-707."
    },
    {
        "id": "doc_5128",
        "document": "509. Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol 2021; 147: 29-36."
    },
    {
        "id": "doc_5129",
        "document": "510. Rank M, Mullol J. Chronic rhinosinusitis: Forward! J Allergy Clin Immunol Pract 2022; 10: 1472-1473. 511. Dixon AE, Castro M, Cohen RI, et al. Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. J Allergy Clin Immunol 2015; 135: 701-709.e705. 512. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146: 595-605."
    },
    {
        "id": "doc_5130",
        "document": "513. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128: 989-995.e988.\n\n514. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol 2017; 140: 1024-1031.e1014.\n\n515. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic"
    },
    {
        "id": "doc_5131",
        "document": "rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre,\n\nrandomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-1650.\n\n516. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436."
    },
    {
        "id": "doc_5132",
        "document": "517. Liu S, Cao Y, Du T, et al. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021; 9: 693-701.\n\n518. Hou H, Xu J, Li Y, et al. The association of asthma with COVID-19 mortality: an updated meta-analysis based on adjusted effect estimates. J Allergy Clin Immunol Pract 2021; 9: 3944-3968.e3945."
    },
    {
        "id": "doc_5133",
        "document": "519. Shi T, Pan J, Katikireddi SV, et al. Risk of COVID-19 hospital admission among children aged 5-17 years with asthma in Scotland: a national incident cohort study. Lancet Respir Med 2022; 10: 191-198."
    },
    {
        "id": "doc_5134",
        "document": "520. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med 2021: 9:699-711."
    },
    {
        "id": "doc_5135",
        "document": "521. Davies GA, Alsallakh MA, Sivakumaran S, et al. Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales. Thorax 2021; 76: 867-873. 522. International Union Against Tuberculosis and Lung Disease. International Union Against Tuberculosis and Lung Disease strategic plan for lung health 2020\u20132025. International Union Against Tuberculosis and Lung Disease; [cited 2021 October]. Available from:"
    },
    {
        "id": "doc_5136",
        "document": "https://theunion.org/our-work/lung-health-ncds/asthma."
    },
    {
        "id": "doc_5137",
        "document": "523. World Health Organization. WHO Model Lists of Essential Medicines. [web page]: WHO; 2021 [cited 2022 April]. Available from: https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential- medicines-lists.\n\n524. Zar HJ, Asmus MJ, Weinberg EG. A 500-ml plastic bottle: an effective spacer for children with asthma. Pediatr Allergy Immunol 2002; 13: 217-222."
    },
    {
        "id": "doc_5138",
        "document": "525. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107: 937-944.\n\n526. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017; 357: j1415."
    },
    {
        "id": "doc_5139",
        "document": "527. Babar ZU, Lessing C, Mace C, et al. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. Pharmacoeconomics 2013; 31: 1063-1082.\n\n528. Stolbrink M, Thomson H, Hadfield R, et al. The availability, cost and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. Lancet 2022; 10: e1423-e1442.\n\n228\n\nReferences"
    },
    {
        "id": "doc_5140",
        "document": "529. Organization WH. New WHA Resolution to bring much needed boost to diabetes prevention and control efforts. WHO; 2021 [updated 27 May 2021; cited 2021 December]. Available from: https://www.who.int/news/item/27-05- 2021-new-wha-resolution-to-bring-much-needed-boost-to-diabetes-prevention-and-control-efforts.\n\n530\n\nPatton GC, Viner R. Pubertal transitions in health. Lancet 2007; 369: 1130-1139."
    },
    {
        "id": "doc_5141",
        "document": "531. Michaud P-A, Suris JC, Viner R. The adolescent with a chronic condition : epidemiology, developmental issues and health care provision. Geneva: WHO; 2007. Available from:\n\nhttp://whqlibdoc.who.int/publications/2007/9789241595704_eng.pdf.\n\n532. Roberts G, Vazquez-Ortiz M, Knibb R, et al. EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy 2020; 75: 2734-2752."
    },
    {
        "id": "doc_5142",
        "document": "533. Carlsen KH, Anderson SD, Bjermer L, et al. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN. Allergy 2008; 63: 492-505.\n\n534. Gluck JC, Gluck PA. The effect of pregnancy on the course of asthma. Immunol Allergy Clin North Am 2006; 26: 63-80."
    },
    {
        "id": "doc_5143",
        "document": "535. Murphy VE, Powell H, Wark PA, et al. A prospective study of respiratory viral infection in pregnant women with and without asthma. Chest 2013; 144: 420-427.\n\n536. Robijn AL, Bokern MP, Jensen ME, et al. Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis. Eur Respir Rev 2022; 31: 220039."
    },
    {
        "id": "doc_5144",
        "document": "537. Lim A, Stewart K, Konig K, et al. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother 2011; 45: 931-945.\n\n538. Wendel PJ, Ramin SM, Barnett-Hamm C, et al. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol 1996; 175: 150-154.\n\n539. Schatz M, Leibman C. Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol 2005; 95: 234-238."
    },
    {
        "id": "doc_5145",
        "document": "540. Liu X, Agerbo E, Schlunssen V, et al. Maternal asthma severity and control during pregnancy and risk of offspring asthma. J Allergy Clin Immunol 2018; 141: 886-892 e883.\n\n541. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983-990."
    },
    {
        "id": "doc_5146",
        "document": "542. Morten M, Collison A, Murphy VE, et al. Managing Asthma in Pregnancy (MAP) trial: FENO levels and childhood asthma. J Allergy Clin Immunol 2018; 142: 1765-1772.e1764.\n\n543. Lim AS, Stewart K, Abramson MJ, et al. Asthma during pregnancy: the experiences, concerns and views of pregnant women with asthma. J Asthma 2012; 49: 474-479."
    },
    {
        "id": "doc_5147",
        "document": "544. National Heart Lung and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 2005; 115: 34-46.\n\n545. Lim AS, Stewart K, Abramson MJ, et al. Multidisciplinary Approach to Management of Maternal Asthma (MAMMA): a randomized controlled trial. Chest 2014; 145: 1046-1054."
    },
    {
        "id": "doc_5148",
        "document": "546. Ali Z, Nilas L, Ulrik CS. Determinants of low risk of asthma exacerbation during pregnancy. Clin Exp Allergy 2018; 48: 23-28.\n\n547. Pfaller B, Jos\u00e9 Yepes-Nu\u00f1ez J, Agache I, et al. Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy 2021; 76: 71-89.\n\n548. Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015; 135: 407-412."
    },
    {
        "id": "doc_5149",
        "document": "549. Nelson-Piercy C. Asthma in pregnancy. Thorax 2001; 56: 325-328.\n\n550. McLaughlin K, Foureur M, Jensen ME, et al. Review and appraisal of guidelines for the management of asthma during pregnancy. Women Birth 2018; 31: e349-e357.\n\n551. Sanchez-Ramos JL, Pereira-Vega AR, Alvarado-Gomez F, et al. Risk factors for premenstrual asthma: a systematic review and meta-analysis. Expert Rev Respir Med 2017; 11: 57-72.\n\nReferences\n\n229"
    },
    {
        "id": "doc_5150",
        "document": "552. Reed CE. Asthma in the elderly: diagnosis and management. J Allergy Clin Immunol 2010; 126: 681-687."
    },
    {
        "id": "doc_5151",
        "document": "554. Slavin RG, Haselkorn T, Lee JH, et al. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol 2006; 96: 406-414. 555. \u00c7olak Y, Afzal S, Nordestgaard BG, et al. Characteristics and Prognosis of Never-Smokers and Smokers with Asthma in the Copenhagen General Population Study. A Prospective Cohort Study. Am J Respir Crit Care Med 2015; 192: 172-181."
    },
    {
        "id": "doc_5152",
        "document": "556. Chalitsios CV, McKeever TM, Shaw DE. Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study. Eur Respir J 2021; 57.\n\n557. Vincken W, Dekhuijzen PR, Barnes P, et al. The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010; 19: 10-20."
    },
    {
        "id": "doc_5153",
        "document": "558. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti- inflammatory drugs. J Allergy Clin Immunol 1984; 74: 617-622.\n\n559. Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, et al. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 2004; 10: 51-56."
    },
    {
        "id": "doc_5154",
        "document": "560. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116: 970-975. 561. Morales DR, Guthrie B, Lipworth BJ, et al. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy 2015; 70: 828-835. 562. Rajan JP, Wineinger NE, Stevenson DD, et al."
    },
    {
        "id": "doc_5155",
        "document": "Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol 2015; 135: 676-681.e671. 563. Nizankowska E, Bestynska-Krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15: 863-869."
    },
    {
        "id": "doc_5156",
        "document": "564. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5-13.\n\n565. Milewski M, Mastalerz L, Nizankowska E, et al. Nasal provocation test with lysine-aspirin for diagnosis of aspirin- sensitive asthma. J Allergy Clin Immunol 1998; 101: 581-586."
    },
    {
        "id": "doc_5157",
        "document": "566. El Miedany Y, Youssef S, Ahmed I, et al. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006; 97: 105-109."
    },
    {
        "id": "doc_5158",
        "document": "567. Morales DR, Lipworth BJ, Guthrie B, et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014; 134: 40-45."
    },
    {
        "id": "doc_5159",
        "document": "568. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 9-14. 569. Pleskow WW, Stevenson DD, Mathison DA, et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982; 69: 11-19. 570. Swierczynska-Krepa M, Sanak M,"
    },
    {
        "id": "doc_5160",
        "document": "Bochenek G, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol 2014; 134: 883-890. 571. Chu DK, Lee DJ, Lee KM, et al. Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis. Int Forum Allergy Rhinol 2019; 9: 1409-1419. 572. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and"
    },
    {
        "id": "doc_5161",
        "document": "proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-873. 573. Agarwal R, Sehgal IS, Dhooria S, et al. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med 2016; 10: 1317-1334."
    },
    {
        "id": "doc_5162",
        "document": "574. Agarwal R, Muthu V, Sehgal IS, et al. A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 2022; 59: 2101787. 575. Agarwal R, Dhooria S, Singh Sehgal I, et al. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest 2018; 153: 656-664.\n\n230\n\nReferences"
    },
    {
        "id": "doc_5163",
        "document": "576. Voskamp AL, Gillman A, Symons K, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2015; 3: 192-199.\n\n577. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Annals Int Med 2006; 144: 581-595."
    },
    {
        "id": "doc_5164",
        "document": "578. Woods BD, Sladen RN. Perioperative considerations for the patient with asthma and bronchospasm. Br J Anaesth 2009; 103 Suppl 1: i57-65.\n\n579. Wakim JH, Sledge KC. Anesthetic implications for patients receiving exogenous corticosteroids. AANA Journal 2006; 74: 133-139.\n\n580. Coker RK, Armstrong A, Church AC, et al. BTS Clinical Statement on air travel for passengers with respiratory disease. Thorax 2022; 77: 329-350."
    },
    {
        "id": "doc_5165",
        "document": "581. Hekking P, Wener R, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135: 896-902.\n\n582. Foster JM, McDonald VM, Guo M, et al. \u201cI have lost in every facet of my life\u201d: the hidden burden of severe asthma. Eur Respir J 2017; 50: 1700765.\n\n583. Ross KR, Gupta R, DeBoer MD, et al. Severe asthma during childhood and adolescence: A longitudinal study. J Allergy Clin Immunol 2020; 145: 140-146 e149."
    },
    {
        "id": "doc_5166",
        "document": "584. O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015; 70: 376-378.\n\n585. Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 2010; 17: 74-80.\n\n586 Hashimoto Bel EH. Current treatment of"
    },
    {
        "id": "doc_5167",
        "document": "asthma. Clin\n\n42: 693-705.\n\n587. Hancox RJ, Cowan JO, Flannery EM, et al. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med 2000; 94: 767-771.\n\n588. Paris J, Peterson EL, Wells K, et al. Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol 2008; 101: 482-487."
    },
    {
        "id": "doc_5168",
        "document": "589. Basheti IA, Armour CL, Bosnic-Anticevich SZ, et al. Evaluation of a novel educational strategy, including inhaler- based reminder labels, to improve asthma inhaler technique Patient Educ Couns 2008; 72: 26-33.\n\n590. Centers for Disease Control and Prevention. Parasites - Stronglyoides. [web page]: U.S. Department of Health & Human Services; 2018 [updated 31 December 2018; cited 2022 April]. Available from: https://www.cdc.gov/parasites/strongyloides/."
    },
    {
        "id": "doc_5169",
        "document": "591. Clark VL, Gibson PG, Genn G, et al. Multidimensional assessment of severe asthma: A systematic review and meta-analysis. Respirology 2017; 22: 1262-1275."
    },
    {
        "id": "doc_5170",
        "document": "592. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med 2017; 377: 965-976. 593. Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med 2021; 9: 1165-1173."
    },
    {
        "id": "doc_5171",
        "document": "594. Lugogo NL, Kreindler JL, Martin UJ, et al. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol 2020; 125: 171-176.\n\n595. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322-329."
    },
    {
        "id": "doc_5172",
        "document": "596. Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817-822."
    },
    {
        "id": "doc_5173",
        "document": "597. McNicholl DM, Stevenson M, McGarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186: 1102-1108. 598. Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract 2021; 9: 2702-2714. 599. Brusselle G, Michils A, Louis R, et al. \"Real-life\" effectiveness of"
    },
    {
        "id": "doc_5174",
        "document": "omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103: 1633-1642."
    },
    {
        "id": "doc_5175",
        "document": "References\n\n231\n\n600. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-811.\n\n601. Casale TB, Chipps BE, Rosen K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy 2018; 73: 490-497."
    },
    {
        "id": "doc_5176",
        "document": "602. Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 2018; 51.\n\n603. Busse WW. Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no! Eur Respir J 2018; 51: 1800730."
    },
    {
        "id": "doc_5177",
        "document": "604. Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 2019; 7: 156-164 e151. 605. Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.\n\n606. Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev 2022; 7: CD010834."
    },
    {
        "id": "doc_5178",
        "document": "Lemiere C, Taill\u00e9 C, Lee JK, et al. Impact of baseline clinical asthma characteristics on the response to\n\nmepolizumab: a post hoc meta-analysis of two Phase III trials. Respir Res 2021; 22: 184."
    },
    {
        "id": "doc_5179",
        "document": "608. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 2018; 6: 51-64. 609. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189-1197."
    },
    {
        "id": "doc_5180",
        "document": "610. Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy 2022; 77: 150-161.\n\n611. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. The Lancet Respiratory medicine 2016; 4: 549-556."
    },
    {
        "id": "doc_5181",
        "document": "612. Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther 2017; 43: 39-45.\n\n613. Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J 2018; 52."
    },
    {
        "id": "doc_5182",
        "document": "614. Corren J, Castro M, O'Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract 2020; 8: 516-526.\n\n615. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475-2485."
    },
    {
        "id": "doc_5183",
        "document": "616. Sher LD, Wechsler ME, Rabe KF, et al. Dupilumab reduces oral corticosteroid use in patients with corticosteroid- dependent severe asthma: an analysis of the phase 3, open-label extension TRAVERSE trial. Chest 2022; 162: 46-55. 617. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA 2016; 315: 469-479."
    },
    {
        "id": "doc_5184",
        "document": "618. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2021; 384: 1800-1809.\n\n619. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med 2022; 10: 650-660."
    },
    {
        "id": "doc_5185",
        "document": "620. Hashimoto S, Brinke AT, Roldaan AC, et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011; 66: 514-520."
    },
    {
        "id": "doc_5186",
        "document": "621. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 2014; 133: 921-923. 622. Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol 2017; 140: 162-169.e162.\n\n232\n\nReferences"
    },
    {
        "id": "doc_5187",
        "document": "623. Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J 2022; 59.\n\n624. Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract 2021; 9: 4381-4392.e4384."
    },
    {
        "id": "doc_5188",
        "document": "625. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2019; 143: 1742-1751.e1747. 626. Zazzali JL, Raimundo KP, Trzaskoma B, et al. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc 2015; 36: 283-292."
    },
    {
        "id": "doc_5189",
        "document": "627. Ramnath VR, Clark S, Camargo CA, Jr. Multicenter study of clinical features of sudden-onset versus slower-onset asthma exacerbations requiring hospitalization. Respir Care 2007; 52: 1013-1020.\n\n628. Zheng XY, Orellano P, Lin HL, et al. Short-term exposure to ozone, nitrogen dioxide, and sulphur dioxide and emergency department visits and hospital admissions due to asthma: A systematic review and meta-analysis. Environ Int 2021; 150: 106435."
    },
    {
        "id": "doc_5190",
        "document": "629. Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 2010; 125: 1178-1187.\n\n630. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger of child and adolescent asthma emergency department presentations: A systematic review and meta-analysis. Allergy 2018; 73: 1632-1641.\n\n631. Anto JM, Sunyer J, Reed CE, et al. Preventing asthma epidemics due to soybeans by dust-control measures. N Engl J Med 1993; 329: 1760-1763."
    },
    {
        "id": "doc_5191",
        "document": "632. Orellano P, Quaranta N, Reynoso J, et al. Effect of outdoor air pollution on asthma exacerbations in children and adults: Systematic review and multilevel meta-analysis. PLoS One 2017; 12: e0174050.\n\n633. Pike KC, Akhbari M, Kneale D, et al. Interventions for autumn exacerbations of asthma in children. Cochrane Database Syst Rev 2018; 3: CD012393."
    },
    {
        "id": "doc_5192",
        "document": "634. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128: 1185-1191.e1182.\n\n635. Andrew E, Nehme Z, Bernard S, et al. Stormy weather: a retrospective analysis of demand for emergency medical services during epidemic thunderstorm asthma. BMJ 2017; 359: j5636."
    },
    {
        "id": "doc_5193",
        "document": "636. Alvarez GG, Schulzer M, Jung D, et al. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J 2005; 12: 265-270.\n\n637. Chang YL, Ko HK, Lu MS, et al. Independent risk factors for death in patients admitted for asthma exacerbation in Taiwan. NPJ Prim Care Respir Med 2020; 30: 7.\n\n638. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near- fatal asthma. Eur Respir J 1994; 7: 1602-1609."
    },
    {
        "id": "doc_5194",
        "document": "639. Roberts G, Patel N, Levi-Schaffer F, et al. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. J Allergy Clin Immunol 2003; 112: 168-174.\n\n640. Blaiss MS, Nathan RA, Stoloff SW, et al. Patient and physician asthma deterioration terminology: results from the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 2012; 33: 47-53."
    },
    {
        "id": "doc_5195",
        "document": "641. Vincent SD, Toelle BG, Aroni RA, et al. \"Exasperations\" of asthma. A qualitative study of patient language about worsening asthma. Med J Aust 2006; 184: 451-454.\n\n642. FitzGerald JM, Grunfeld A. Status asthmaticus. In: Lichtenstein LM, Fauci AS, editors. Current therapy in allergy, immunology, and rheumatology. 5th ed. St. Louis, MO: Mosby; 1996. p. p. 63-67."
    },
    {
        "id": "doc_5196",
        "document": "643. Chan-Yeung M, Chang JH, Manfreda J, et al. Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma. Am J Respir Crit Care Med 1996; 154: 889-893.\n\n644. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600-608."
    },
    {
        "id": "doc_5197",
        "document": "645. Kew KM, Flemyng E, Quon BS, et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2022; 9: CD007524.\n\n646. FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-556.\n\nReferences\n\n233"
    },
    {
        "id": "doc_5198",
        "document": "647. Harrison TW, Oborne J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-275.\n\n648. Reddel HK, Barnes DJ. Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J 2006; 28: 182-199.\n\n649. Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360: 339-353."
    },
    {
        "id": "doc_5199",
        "document": "650. Oborne J, Mortimer K, Hubbard RB, et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009; 180: 598-602.\n\n651. McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med 2018; 378: 902-910."
    },
    {
        "id": "doc_5200",
        "document": "652. Jackson DJ, Bacharier LB, Mauger DT, et al. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. N Engl J Med 2018; 378: 891-901."
    },
    {
        "id": "doc_5201",
        "document": "653. Richards RN. Side effects of short-term oral corticosteroids. J Cutan Med Surg 2008; 12: 77-81. 654. U.S. Food and Drug Administration. Pulse oximeter accuracy and limitations: FDA Safety Communication. FDA; 2022 [updated 7 November 2022; cited 2023 April]. Available from: https://www.fda.gov/medical-devices/safety- communications/pulse-oximeter-accuracy-and-limitations-fda-safety-communication."
    },
    {
        "id": "doc_5202",
        "document": "655. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013.\n\n656. Selroos O. Dry-powder inhalers in acute asthma. Ther Deliv 2014; 5: 69-81.\n\n657. Newman KB, Milne S, Hamilton C, et al. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest 2002; 121: 1036-1041."
    },
    {
        "id": "doc_5203",
        "document": "658. Balanag VM, Yunus F, Yang PC, et al. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2006; 19: 139-147.\n\nRodrigo G, Neffen H, Colodenco F, et al. Formoterol for acute asthma in the emergency department: a\n\n659\n\nsystematic review with meta-analysis. Ann Allergy Asthma Immunol 2010; 104: 247-252."
    },
    {
        "id": "doc_5204",
        "document": "660. Chien JW, Ciufo R, Novak R, et al. Uncontrolled oxygen administration and respiratory failure in acute asthma. Chest 2000; 117: 728-733.\n\n661. Rodrigo GJ, Rodriquez Verde M, Peregalli V, et al. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003; 124: 1312-1317."
    },
    {
        "id": "doc_5205",
        "document": "662. Perrin K, Wijesinghe M, Healy B, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax 2011; 66: 937-941.\n\n663. Patel B, Khine H, Shah A, et al. Randomized clinical trial of high concentration versus titrated oxygen use in pediatric asthma. Pediatr Pulmonol 2019; 54: 970-976."
    },
    {
        "id": "doc_5206",
        "document": "664. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ 2018; 363: k4169.\n\n665. Hasegawa T, Ishihara K, Takakura S, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med 2000; 39: 794-797.\n\n666. Jones AM, Munavvar M, Vail A, et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med 2002; 96: 950-954."
    },
    {
        "id": "doc_5207",
        "document": "667. Chang AB, Clark R, Sloots TP, et al. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. Med J Aust 2008; 189: 306-310. 668. Normansell R, Sayer B, Waterson S, et al. Antibiotics for exacerbations of asthma. Cochrane Database Syst Rev 2018; 6: CD002741.\n\n669. Leatherman J. Mechanical ventilation for severe asthma. Chest 2015; 147: 1671-1680."
    },
    {
        "id": "doc_5208",
        "document": "670. Shim CS, Williams MH, Jr. Evaluation of the severity of asthma: patients versus physicians. Am J Med 1980; 68: 11-13.\n\n234\n\nReferences\n\n671. Atta JA, Nunes MP, Fonseca-Guedes CH, et al. Patient and physician evaluation of the severity of acute asthma exacerbations. Braz J Med Biol Res 2004; 37: 1321-1330.\n\n672. Geelhoed GC, Landau LI, Le Souef PN. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med 1994; 23: 1236-1241."
    },
    {
        "id": "doc_5209",
        "document": "673. Nowak RM, Tomlanovich MC, Sarkar DD, et al. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. JAMA 1983; 249: 2043-2046.\n\n674. Carruthers DM, Harrison BD. Arterial blood gas analysis or oxygen saturation in the assessment of acute asthma? Thorax 1995; 50: 186-188.\n\n675. White CS, Cole RP, Lubetsky HW, et al. Acute asthma. Admission chest radiography in hospitalized adult patients. Chest 1991; 100: 14-16."
    },
    {
        "id": "doc_5210",
        "document": "676. Roback MG, Dreitlein DA. Chest radiograph in the evaluation of first time wheezing episodes: review of current clinical practice and efficacy. Pediatr Emerg Care 1998; 14: 181-184.\n\nCates C, FitzGerald JM, O'Byrne PM. Asthma. Clin Evidence 2000; 3: 686-700.\n\n678. Hui DS, Chow BK, Chu LC, et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009; 135: 648-654."
    },
    {
        "id": "doc_5211",
        "document": "679. Travers AH, Milan SJ, Jones AP, et al. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 2012; 12: CD010179.\n\n680. Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007: CD000195."
    },
    {
        "id": "doc_5212",
        "document": "681. Kirkland SW, Cross E, Campbell S, et al. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Cochrane Database Syst Rev 2018; 6: CD012629. 682. Edmonds ML, Milan SJ, Camargo CA, Jr., et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2012; 12: CD002308."
    },
    {
        "id": "doc_5213",
        "document": "683. Ratto D, Alfaro C, Sipsey J, et al. Are intravenous corticosteroids required in status asthmaticus? JAMA 1988; 260: 527-529.\n\n684. Harrison BD, Stokes TC, Hart GJ, et al. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet 1986; 1: 181-184."
    },
    {
        "id": "doc_5214",
        "document": "685. Kayani S, Shannon DC. Adverse behavioral effects of treatment for acute exacerbation of asthma in children: a comparison of two doses of oral steroids. Chest 2002; 122: 624-628.\n\n686. Keeney GE, Gray MP, Morrison AK, et al. Dexamethasone for acute asthma exacerbations in children: a meta- analysis. Pediatrics 2014; 133: 493-499."
    },
    {
        "id": "doc_5215",
        "document": "687. Kravitz J, Dominici P, Ufberg J, et al. Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial. Ann Emerg Med 2011; 58: 200-204.\n\n688. Cronin JJ, McCoy S, Kennedy U, et al. A randomized trial of single-dose oral dexamethasone versus multidose prednisolone for acute exacerbations of asthma in children who attend the emergency department. Ann Emerg Med 2016; 67: 593-601.e593."
    },
    {
        "id": "doc_5216",
        "document": "689. O'Driscoll BR, Kalra S, Wilson M, et al. Double-blind trial of steroid tapering in acute asthma. Lancet 1993; 341: 324-327.\n\n690. Lederle FA, Pluhar RE, Joseph AM, et al. Tapering of corticosteroid therapy following exacerbation of asthma. A randomized, double-blind, placebo-controlled trial. Arch Intern Med 1987; 147: 2201-2203."
    },
    {
        "id": "doc_5217",
        "document": "691. Kearns N, Maijers I, Harper J, et al. Inhaled corticosteroids in acute asthma: a systemic review and meta-analysis. J Allergy Clin Immunol Pract 2020; 8: 605-617 e606.\n\n692. Li CY, Liu Z. Effect of budesonide on hospitalization rates among children with acute asthma attending paediatric emergency department: a systematic review and meta-analysis. World J Pediatr 2021; 17: 152-163."
    },
    {
        "id": "doc_5218",
        "document": "693. Edmonds ML, Milan SJ, Brenner BE, et al. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev 2012; 12: CD002316.\n\n694. Kirkland SW, Vandenberghe C, Voaklander B, et al. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev 2017; 1: CD001284.\n\nReferences\n\n235"
    },
    {
        "id": "doc_5219",
        "document": "695. Craig SS, Dalziel SR, Powell CV, et al. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2020; 8: CD012977.\n\n696. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60: 740-746."
    },
    {
        "id": "doc_5220",
        "document": "697. Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma. Cochrane Database Syst Rev 2012; 12: CD002742.\n\n698. Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000; 2.\n\n699. FitzGerald JM. Magnesium sulfate is effective for severe acute asthma treated in the emergency department. West J Med 2000; 172: 96."
    },
    {
        "id": "doc_5221",
        "document": "700. Gallegos-Solorzano MC, Perez-Padilla R, Hernandez-Zenteno RJ. Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department. Pulm Pharmacol Ther 2010; 23: 432-437. 701. Goodacre S, Cohen J, Bradburn M, et al. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 293-300. 702. Griffiths B, Kew KM. Intravenous"
    },
    {
        "id": "doc_5222",
        "document": "magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database Syst Rev 2016; 4: CD011050."
    },
    {
        "id": "doc_5223",
        "document": "703. Knightly R, Milan SJ, Hughes R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2017; 11: CD003898."
    },
    {
        "id": "doc_5224",
        "document": "704. Turker S, Dogru M, Yildiz F, et al. The effect of nebulised magnesium sulphate in the management of childhood moderate asthma exacerbations as adjuvant treatment. Allergol Immunopathol (Madr) 2017; 45: 115-120. 705. Rodrigo GJ, Castro-Rodriguez JA. Heliox-driven beta2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2014; 112: 29-34."
    },
    {
        "id": "doc_5225",
        "document": "706. Ramsay CF, Pearson D, Mildenhall S, et al. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax 2011; 66: 7-11.\n\n707. Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev 2012; 5: CD006100."
    },
    {
        "id": "doc_5226",
        "document": "708. Lim WJ, Mohammed Akram R, Carson KV, et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev 2012; 12: CD004360. 709. Joseph KS, Blais L, Ernst P, et al. Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. BMJ 1996; 312: 79-82.\n\n710. FitzGerald JM, Macklem P. Fatal asthma. Annu Rev Med 1996; 47: 161-168."
    },
    {
        "id": "doc_5227",
        "document": "711. Kelly A-M, Kerr D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma? Respir Med 2004; 98: 777-781.\n\n712. Wilson MM, Irwin RS, Connolly AE, et al. A prospective evaluation of the 1-hour decision point for admission versus discharge in acute asthma. J Intensive Care Med 2003; 18: 275-285."
    },
    {
        "id": "doc_5228",
        "document": "713. Grunfeld A, FitzGerald J. Discharge considerations for adult asthmatic patients treated in emergency departments. Can Respir J 1996; 3: 322-327.\n\n714. Pollack CV, Jr., Pollack ES, Baren JM, et al. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Arch Pediatr Adolesc Med 2002; 156: 934-940."
    },
    {
        "id": "doc_5229",
        "document": "715. Rowe BH, Villa-Roel C, Abu-Laban RB, et al. Admissions to Canadian hospitals for acute asthma: a prospective, multicentre study. Can Respir J 2010; 17: 25-30.\n\n716. Weber EJ, Silverman RA, Callaham ML, et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 2002; 113: 371-378."
    },
    {
        "id": "doc_5230",
        "document": "717. Kirkland SW, Vandermeer B, Campbell S, et al. Evaluating the effectiveness of systemic corticosteroids to mitigate relapse in children assessed and treated for acute asthma: A network meta-analysis. J Asthma 2018: 1-12. 718. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833-837.\n\n236\n\nReferences"
    },
    {
        "id": "doc_5231",
        "document": "719. Cowie RL, Revitt SG, Underwood MF, et al. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997; 112: 1534-1538.\n\n720. Ducharme FM, Zemek RL, Chalut D, et al. Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control. Am J Respir Crit Care Med 2011; 183: 195-203."
    },
    {
        "id": "doc_5232",
        "document": "721. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2021 Report. Fontana, WI, USA: GOLD; 2021 [For GOLD 2023 see reference 59]."
    },
    {
        "id": "doc_5233",
        "document": "722. Postma DS, Rabe KF. The Asthma-COPD Overlap Syndrome. N Engl J Med 2015; 373: 1241-1249. 723. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26. 724. McMahon AW, Levenson MS, McEvoy BW, et al. Age and risks of FDA-approved long-acting 2-adrenergic receptor agonists. Pediatrics 2011; 128: e1147-1154."
    },
    {
        "id": "doc_5234",
        "document": "725. Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting \u03b2-agonists and inhaled corticosteroids compared with long-acting \u03b2-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312: 1114-1121.\n\n726. Suissa S, Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: Lessons learned. Chest 2018; 154: 257-265."
    },
    {
        "id": "doc_5235",
        "document": "727. Kendzerska T, Aaron SD, To T, et al. Effectiveness and safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or asthma. A population study. Ann Am Thorac Soc 2019; 16: 1252-1262. 728. Vonk JM, Jongepier H, Panhuysen CIM, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58: 322-327. 729. Lange P, Celli B, Agusti"
    },
    {
        "id": "doc_5236",
        "document": "A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373: 111-122."
    },
    {
        "id": "doc_5237",
        "document": "730. Abramson MJ, Schattner RL, Sulaiman ND, et al. Accuracy of asthma and COPD diagnosis in Australian general practice: a mixed methods study. Prim Care Respir J 2012; 21: 167-173.\n\n731. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728-735."
    },
    {
        "id": "doc_5238",
        "document": "732. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med 2000; 160: 1683-1689. 733. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761-\n\n767"
    },
    {
        "id": "doc_5239",
        "document": "734. Shirtcliffe P, Marsh S, Travers J, et al. Childhood asthma and GOLD-defined chronic obstructive pulmonary disease. Int Med J 2012; 42: 83-88.\n\n735. Guerra S, Sherrill DL, Kurzius-Spencer M, et al. The course of persistent airflow limitation in subjects with and without asthma. Respir Med 2008; 102: 1473-1482.\n\n736. Silva GE, Sherrill DL, Guerra S, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59- 65."
    },
    {
        "id": "doc_5240",
        "document": "737. van Schayck CP, Levy ML, Chen JC, et al. Coordinated diagnostic approach for adult obstructive lung disease in primary care. Prim Care Respir J 2004; 13: 218-221.\n\n738. Zeki AA, Schivo M, Chan A, et al. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo) 2011; 2011: 861926."
    },
    {
        "id": "doc_5241",
        "document": "739. Kendzerska T, Sadatsafavi M, Aaron SD, et al. Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality. PLoS One 2017; 12: e0173830.\n\n740. Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011; 48: 279-285."
    },
    {
        "id": "doc_5242",
        "document": "741. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34: 812-818.\n\n742. Inoue H, Nagase T, Morita S, et al. Prevalence and characteristics of asthma-COPD overlap syndrome identified by a stepwise approach. Int J Chron Obstruct Pulmon Dis 2017; 12: 1803-1810.\n\nReferences\n\n237"
    },
    {
        "id": "doc_5243",
        "document": "743. Uchida A, Sakaue K, Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int 2018; 67: 165-171.\n\n744. Krishnan JA, Nibber A, Chisholm A, et al. Prevalence and characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in routine primary care practices. Ann Am Thorac Soc 2019; 16: 1143-1150."
    },
    {
        "id": "doc_5244",
        "document": "745. Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SM, et al. Identification and definition of asthma-COPD overlap: The CanCOLD study. Respirology 2020; 25: 836-849.\n\n746. Andersen H, Lampela P, Nevanlinna A, et al. High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J 2013; 7: 342-346.\n\n747. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3: CD010115."
    },
    {
        "id": "doc_5245",
        "document": "748. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.\n\n749. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Exp Rev Respir Pharmacol 2013; 6: 197-219.\n\n750. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478."
    },
    {
        "id": "doc_5246",
        "document": "751. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J Royal Soc Med 2010; 103: 98-106.\n\n752. Bisgaard H, Szefler S. Prevalence of asthma-like symptoms in young children. Pediatr Pulmonol 2007; 42: 723- 728.\n\n753. Kuehni CE, Strippoli MP, Low N, et al. Wheeze and asthma prevalence and related health-service use in white and south Asian pre-schoolchildren in the United Kingdom. Clin Exp Allergy 2007; 37: 1738-1746."
    },
    {
        "id": "doc_5247",
        "document": "754. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332: 133-138.\n\n755. Sly PD, Boner AL, Bj\u00f6rksten B, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet 2008; 372: 1100-1106.\n\nHeikkinen T, Jarvinen A. The common cold. Lancet 2003; 361: 51-59.\n\n756"
    },
    {
        "id": "doc_5248",
        "document": "757. Caudri D, Wijga A, CM AS, et al. Predicting the long-term prognosis of children with symptoms suggestive of asthma at preschool age. J Allergy Clin Immunol 2009; 124: 903-910 e901-907.\n\n758. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096-1110."
    },
    {
        "id": "doc_5249",
        "document": "759. Belgrave DCM, Simpson A, Semic-Jusufagic A, et al. Joint modeling of parentally reported and physician- confirmed wheeze identifies children with persistent troublesome wheezing. J Allergy Clin Immunol 2013; 132: 575- 583.e512.\n\n760. Savenije OE, Kerkhof M, Koppelman GH, et al. Predicting who will have asthma at school age among preschool children. J Allergy Clin Immunol 2012; 130: 325-331."
    },
    {
        "id": "doc_5250",
        "document": "761. Fitzpatrick AM, Bacharier LB, Guilbert TW, et al. Phenotypes of recurrent wheezing in preschool children: identification by latent class analysis and utility in prediction of future exacerbation. J Allergy Clin Immunol Pract 2019; 7: 915-924 e917.\n\n762. Doherty G, Bush A. Diagnosing respiratory problems in young children. The Practitioner 2007; 251: 20, 22-25. 763. Pedersen S. Preschool asthma--not so easy to diagnose. Prim Care Respir J 2007; 16: 4-6."
    },
    {
        "id": "doc_5251",
        "document": "764. Brand PL, Caudri D, Eber E, et al. Classification and pharmacological treatment of preschool wheezing: changes since 2008. Eur Respir J 2014; 43: 1172-1177.\n\n765. Cano Garcinuno A, Mora Gandarillas I, Group SS. Early patterns of wheezing in asthmatic and nonasthmatic children. Eur Respir J 2013; 42: 1020-1028."
    },
    {
        "id": "doc_5252",
        "document": "766. Just J, Saint-Pierre P, Gouvis-Echraghi R, et al. Wheeze phenotypes in young children have different courses during the preschool period. Ann Allergy Asthma Immunol 2013; 111: 256-261.e251.\n\nMellis C. Respiratory noises: how useful are they clinically? Pediatr Clin North Am 2009; 56: 1-17, ix.\n\n767\n\n238\n\nReferences"
    },
    {
        "id": "doc_5253",
        "document": "768. Saglani S, McKenzie SA, Bush A, et al. A video questionnaire identifies upper airway abnormalities in preschool children with reported wheeze. Arch Dis Child 2005; 90: 961-964.\n\n769. Oren E, Rothers J, Stern DA, et al. Cough during infancy and subsequent childhood asthma. Clin Exp Allergy 2015; 45: 1439-1446.\n\n770. Azad MB, Chan-Yeung M, Chan ES, et al. Wheezing patterns in early childhood and the risk of respiratory and allergic disease in adolescence. JAMA Pediatr 2016; 170: 393-395."
    },
    {
        "id": "doc_5254",
        "document": "771. Van Der Heijden HH, Brouwer ML, Hoekstra F, et al. Reference values of exhaled nitric oxide in healthy children 1-5 years using off-line tidal breathing. Pediatric Pulmonology 2014; 49: 291-295.\n\n772. Singer F, Luchsinger I, Inci D, et al. Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy 2013; 68: 531-538."
    },
    {
        "id": "doc_5255",
        "document": "773. Caudri D, Wijga AH, Hoekstra MO, et al. Prediction of asthma in symptomatic preschool children using exhaled nitric oxide, Rint and specific IgE. Thorax 2010; 65: 801-807.\n\n774. Castro-Rodr\u00edguez JA, Holberg CJ, Wright AL, et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162: 1403-1406."
    },
    {
        "id": "doc_5256",
        "document": "775. Pescatore AM, Dogaru CM, Duembgen L, et al. A simple asthma prediction tool for preschool children with wheeze or cough. J Allergy Clin Immunol 2014; 133: 111-118.e111-113.\n\n776. Colicino S, Munblit D, Minelli C, et al. Validation of childhood asthma predictive tools: A systematic review. Clin Exp Allergy 2019; 49: 410-418.\n\n777. Bacharier LB. The recurrently wheezing preschool child-benign or asthma in the making? Ann Allergy Asthma Immunol 2015; 115: 463-470."
    },
    {
        "id": "doc_5257",
        "document": "778. Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006; 61: 376-382. 779. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354: 1985-1997."
    },
    {
        "id": "doc_5258",
        "document": "780. Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113: e87-94.\n\n781. Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol 2016; 138: 1608-1618.e1612."
    },
    {
        "id": "doc_5259",
        "document": "782. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367: 904-912.\n\n783. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2014; 6: CD001266. 784. Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354: 1998-2005."
    },
    {
        "id": "doc_5260",
        "document": "785. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65: 407-410."
    },
    {
        "id": "doc_5261",
        "document": "786. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med 2000; 162: 1500-1506. 787. Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120: 1043-1050."
    },
    {
        "id": "doc_5262",
        "document": "788. Kaiser SV, Huynh T, Bacharier LB, et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta- analysis. Pediatrics 2016; 137.\n\n789. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108: E48."
    },
    {
        "id": "doc_5263",
        "document": "790. Brodlie M, Gupta A, Rodriguez-Martinez CE, et al. Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children. Cochrane Database Syst Rev 2015: Cd008202. 791. Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol 2018; 53: 1670-1677. 792. Papi A, Nicolini G, Baraldi E, et al. Regular vs prn nebulized"
    },
    {
        "id": "doc_5264",
        "document": "treatment in wheeze preschool children. Allergy 2009; 64: 1463-1471."
    },
    {
        "id": "doc_5265",
        "document": "References\n\n239"
    },
    {
        "id": "doc_5266",
        "document": "793. Zeiger RS, Mauger D, Bacharier LB, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365: 1990-2001. 794. Yoshihara S, Tsubaki T, Ikeda M, et al. The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. Pediatr Allergy Immunol 2019; 30: 195-203. 795. Piippo-Savolainen E, Remes S, Kannisto S, et al. Asthma and lung function 20 years after wheezing in infancy: results from a"
    },
    {
        "id": "doc_5267",
        "document": "prospective follow-up study. Arch Pediatr Adolesc Med 2004; 158: 1070-1076. 796. Wennergren G, Hansson S, Engstrom I, et al. Characteristics and prognosis of hospital-treated obstructive bronchitis in children aged less than two years. Acta Paediatrica 1992; 81: 40-45. 797. Goksor E, Amark M, Alm B, et al. Asthma symptoms in early childhood--what happens then? Acta Paediatrica 2006; 95: 471-478. 798. Castro-Rodriguez JA, Rodrigo GJ. Beta-agonists through metered-dose inhaler with valved holding"
    },
    {
        "id": "doc_5268",
        "document": "chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. Journal of Pediatrics 2004; 145: 172-177. 799. Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: what is the plan? Arch Pediatr Adolesc Med 2008; 162: 157-163. 800. Swern AS, Tozzi CA, Knorr B, et al. Predicting an asthma exacerbation in children 2 to 5 years of age. Ann"
    },
    {
        "id": "doc_5269",
        "document": "Allergy Asthma Immunol 2008; 101: 626-630. 801. Brunette MG, Lands L, Thibodeau LP. Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. Pediatrics 1988; 81: 624-629. 802. Fox GF, Marsh MJ, Milner AD. Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Eur J Pediatr 1996; 155: 512-516. 803. Grant CC, Duggan AK, DeAngelis C. Independent parental administration of prednisone in acute"
    },
    {
        "id": "doc_5270",
        "document": "asthma: a double-blind, placebo-controlled, crossover study. Pediatrics 1995; 96: 224-229. 804. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362: 1433-1438. 805. Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database Syst Rev 2006: CD005311. 806. Robertson CF, Price D,"
    },
    {
        "id": "doc_5271",
        "document": "Henry R, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175: 323-329. 807. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122: 1127-1135 e1128. 808. Gouin S, Robidas I, Gravel J, et al. Prospective evaluation of two clinical scores for acute"
    },
    {
        "id": "doc_5272",
        "document": "asthma in children 18 months to 7 years of age. Acad Emerg Med 2010; 17: 598-603. 809. Pollock M, Sinha IP, Hartling L, et al. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. Allergy 2017; 72: 183-200. 810. Powell C, Kolamunnage-Dona R, Lowe J, et al. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respir Med 2013; 1: 301-308. 811. Pruikkonen H, Tapiainen T, Kallio M, et al."
    },
    {
        "id": "doc_5273",
        "document": "Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial. Eur Respir J 2018; 51. 812. Fuglsang G, Pedersen S, Borgstrom L. Dose-response relationships of intravenously administered terbutaline in children with asthma. Journal of Pediatrics 1989; 114: 315-320. 813. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child 1993; 68: 85-87. 814. Svedmyr J, Nyberg E, Thunqvist P, et al. Prophylactic"
    },
    {
        "id": "doc_5274",
        "document": "intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr 1999; 88: 42-47. 815. Cai KJ, Su SQ, Wang YG, et al. Dexamethasone versus prednisone or prednisolone for acute pediatric asthma"
    },
    {
        "id": "doc_5275",
        "document": "exacerbations in the emergency department: a meta-analysis. Pediatr Emerg Care 2020.\n\n240\n\nReferences\n\n816. Garrett J, Williams S, Wong C, et al. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998; 79: 12-17.\n\n817. Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001: CD002178."
    },
    {
        "id": "doc_5276",
        "document": "818. Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med 2009; 360: 329-338.\n\n819. Webb MS, Henry RL, Milner AD. Oral corticosteroids for wheezing attacks under 18 months. Arch Dis Child 1986; 61: 15-19."
    },
    {
        "id": "doc_5277",
        "document": "820. Castro-Rodriguez JA, Beckhaus AA, Forno E. Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: Systematic review with meta-analysis. Pediatr Pulmonol 2016; 51: 868-876. 821. Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, et al. Peanut, milk, and wheat intake during pregnancy is associated with reduced allergy and asthma in children. J Allergy Clin Immunol 2014; 133: 1373-1382. 822. Maslova E, Granstrom C, Hansen S, et al. Peanut and tree"
    },
    {
        "id": "doc_5278",
        "document": "nut consumption during pregnancy and allergic disease in children-should mothers decrease their intake? Longitudinal evidence from the Danish National Birth Cohort. J Allergy Clin Immunol 2012; 130: 724-732."
    },
    {
        "id": "doc_5279",
        "document": "823. Maslova E, Strom M, Oken E, et al. Fish intake during pregnancy and the risk of child asthma and allergic rhinitis - longitudinal evidence from the Danish National Birth Cohort. Br J Nutr 2013; 110: 1313-1325.\n\n824. Best KP, Gold M, Kennedy D, et al. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr 2016; 103: 128-143."
    },
    {
        "id": "doc_5280",
        "document": "825. Best KP, Sullivan T, Palmer D, et al. Prenatal fish oil supplementation and allergy: 6-year follow-up of a randomized controlled trial. Pediatrics 2016; 137.\n\n826. Hansen S, Strom M, Maslova E, et al. Fish oil supplementation during pregnancy and allergic respiratory disease in the adult offspring. J Allergy Clin Immunol 2017; 139: 104-111.e104."
    },
    {
        "id": "doc_5281",
        "document": "827. Best KP, Sullivan TR, Palmer DJ, et al. Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood - a longitudinal analysis of long-term follow-up of a randomized controlled trial. World Allergy Organ J 2018; 11: 10.\n\n828. Forno E, Young OM, Kumar R, et al. Maternal obesity in pregnancy, gestational weight gain, and risk of childhood asthma. Pediatrics 2014; 134: e535-546."
    },
    {
        "id": "doc_5282",
        "document": "829. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.\n\n830. Chan-Yeung M, Becker A. Primary prevention of childhood asthma and allergic disorders. Curr Opin Allergy Clin Immunol 2006; 6: 146-151."
    },
    {
        "id": "doc_5283",
        "document": "831. Greer FR, Sicherer SH, Burks AW. The effects of early nutritional interventions on the development of atopic disease in infants and children: The role of maternal dietary restriction, breastfeeding, hydrolyzed formulas, and timing of introduction of allergenic complementary foods. Pediatrics 2019; 143."
    },
    {
        "id": "doc_5284",
        "document": "832. Nurmatov U, Devereux G, Sheikh A. Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis. J Allergy Clin Immunol 2011; 127: 724-733.e721-730.\n\n833. Chawes BL, Bonnelykke K, Stokholm J, et al. Effect of vitamin D3 supplementation during pregnancy on risk of persistent wheeze in the offspring: a randomized clinical trial. JAMA 2016; 315: 353-361."
    },
    {
        "id": "doc_5285",
        "document": "834. Litonjua AA, Carey VJ, Laranjo N, et al. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. JAMA 2016; 315: 362-370. 835. Wolsk HM, Harshfield BJ, Laranjo N, et al. Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial. J Allergy Clin Immunol 2017; 140:"
    },
    {
        "id": "doc_5286",
        "document": "1423-1429.e1425."
    },
    {
        "id": "doc_5287",
        "document": "836. Litonjua AA, Carey VJ, Laranjo N, et al. Six-year follow-up of a trial of antenatal vitamin D for asthma reduction. N Engl J Med 2020; 382: 525-533.\n\nReferences\n\n241\n\n837. Stratakis N, Roumeliotaki T, Oken E, et al. Fish and seafood consumption during pregnancy and the risk of asthma and allergic rhinitis in childhood: a pooled analysis of 18 European and US birth cohorts. Int J Epidemiol 2017; 46: 1465-1477."
    },
    {
        "id": "doc_5288",
        "document": "838. Bisgaard H, Stokholm J, Chawes BL, et al. Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring. N Engl J Med 2016; 375: 2530-2539.\n\n839. Azad MB, Coneys JG, Kozyrskyj AL, et al. Probiotic supplementation during pregnancy or infancy for the\n\nprevention of asthma and wheeze: systematic review and meta-analysis. BMJ 2013; 347: f6471."
    },
    {
        "id": "doc_5289",
        "document": "840. Celedon JC, Milton DK, Ramsey CD, et al. Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood. J Allergy Clin Immunol 2007; 120: 144-149.\n\n841. Lodge CJ, Lowe AJ, Gurrin LC, et al. House dust mite sensitization in toddlers predicts current wheeze at age 12 years. J Allergy Clin Immunol 2011; 128: 782-788.e789."
    },
    {
        "id": "doc_5290",
        "document": "842. Custovic A, Simpson BM, Simpson A, et al. Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial. Lancet 2001; 358: 188-193. 843. Perzanowski MS, Chew GL, Divjan A, et al. Cat ownership is a risk factor for the development of anti-cat IgE but not current wheeze at age 5 years in an inner-city cohort. J Allergy Clin Immunol 2008; 121: 1047-1052. 844. Melen E, Wickman M, Nordvall SL, et al. Influence of"
    },
    {
        "id": "doc_5291",
        "document": "early and current environmental exposure factors on sensitization and outcome of asthma in pre-school children. Allergy 2001; 56: 646-652."
    },
    {
        "id": "doc_5292",
        "document": "845. Takkouche B, Gonzalez-Barcala FJ, Etminan M, et al. Exposure to furry pets and the risk of asthma and allergic rhinitis: a meta-analysis. Allergy 2008; 63: 857-864.\n\n846. Bufford JD, Gern JE. Early exposure to pets: good or bad? Curr Allergy Asthma Rep 2007; 7: 375-382. 847. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 2002; 288: 963-972."
    },
    {
        "id": "doc_5293",
        "document": "848. Lodrup Carlsen KC, Roll S, Carlsen KH, et al. Does pet ownership in infancy lead to asthma or allergy at school age? Pooled analysis of individual participant data from 11 European birth cohorts. PloS one 2012; 7: e43214. 849. Pinot de Moira A, Strandberg-Larsen K, Bishop T, et al. Associations of early-life pet ownership with asthma and allergic sensitization: A meta-analysis of more than 77,000 children from the EU Child Cohort Network. J Allergy Clin Immunol 2022; 150: 82-92."
    },
    {
        "id": "doc_5294",
        "document": "850. Quansah R, Jaakkola MS, Hugg TT, et al. Residential dampness and molds and the risk of developing asthma: a systematic review and meta-analysis. PLoS ONE 2012; 7: e47526.\n\n851. Arshad SH, Bateman B, Matthews SM. Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study. Thorax 2003; 58: 489-493."
    },
    {
        "id": "doc_5295",
        "document": "852. Becker A, Watson W, Ferguson A, et al. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol 2004; 113: 650-656.\n\n853. Schonberger HJAM, Dompeling E, Knottnerus JA, et al. The PREVASC study: the clinical effect of a multifaceted educational intervention to prevent childhood asthma. Eur Respir J 2005; 25: 660-670."
    },
    {
        "id": "doc_5296",
        "document": "854. van Schayck OCP, Maas T, Kaper J, et al. Is there any role for allergen avoidance in the primary prevention of childhood asthma? J Allergy Clin Immunol 2007; 119: 1323-1328.\n\n855. Chan-Yeung M, Ferguson A, Watson W, et al. The Canadian Childhood Asthma Primary Prevention Study: outcomes at 7 years of age. J Allergy Clin Immunol 2005; 116: 49-55."
    },
    {
        "id": "doc_5297",
        "document": "856. Scott M, Roberts G, Kurukulaaratchy RJ, et al. Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. Thorax 2012; 67: 1046-1051."
    },
    {
        "id": "doc_5298",
        "document": "857. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018; 141: 529-538.e513. 858. Wongtrakool C, Wang N, Hyde DM, et al. Prenatal nicotine exposure alters lung function and airway geometry through 7 nicotinic receptors. Am J Respir Cell Mol Biol 2012; 46: 695-702."
    },
    {
        "id": "doc_5299",
        "document": "859. Burke H, Leonardi-Bee J, Hashim A, et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. Pediatrics 2012; 129: 735-744.\n\n860. Bowatte G, Lodge C, Lowe AJ, et al. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. Allergy 2015; 70: 245-256.\n\n242\n\nReferences"
    },
    {
        "id": "doc_5300",
        "document": "861. Khreis H, Kelly C, Tate J, et al. Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis. Environ Int 2017; 100: 1-31. 862. Achakulwisut P, Brauer M, Hystad P, et al. Global, national, and urban burdens of paediatric asthma incidence attributable to ambient NO2 pollution: estimates from global datasets. Lancet Planet Health 2019; 3: e166-e178. 863. Hehua Z, Qing C, Shanyan G, et al. The impact of prenatal exposure to air"
    },
    {
        "id": "doc_5301",
        "document": "pollution on childhood wheezing and asthma: A systematic review. Environ Res 2017; 159: 519-530. 864. Haahtela T, Holgate S, Pawankar R, et al. The biodiversity hypothesis and allergic disease: world allergy organization position statement. World Allergy Organ 2013; 6: 3. 865. Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001; 358: 1129-1133. 866. Braun-Fahrlander C, Riedler J, Herz U, et"
    },
    {
        "id": "doc_5302",
        "document": "al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347: 869-877. 867. Karvonen AM, Hyvarinen A, Gehring U, et al. Exposure to microbial agents in house dust and wheezing, atopic dermatitis and atopic sensitization in early childhood: a birth cohort study in rural areas. Clin Exp Allergy 2012; 42: 1246- 1256. 868. Huang L, Chen Q, Zhao Y, et al. Is elective cesarean section associated with a higher risk of asthma? A meta- analysis. J"
    },
    {
        "id": "doc_5303",
        "document": "Asthma 2015; 52: 16-25. 869. Keag OE, Norman JE, Stock SJ. Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: Systematic review and meta-analysis. PLoS Med 2018; 15: e1002494. 870. Azad MB, Konya T, Maughan H, et al. Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. CMAJ 2013; 185: 385-394. 871. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze"
    },
    {
        "id": "doc_5304",
        "document": "in healthy preterm infants. N Engl J Med 2013; 368: 1791-1799. 872. Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir Med 2018; 6: 257-264. 873. Baron R, Taye M, der Vaart IB, et al. The relationship of prenatal antibiotic exposure and infant antibiotic administration with childhood allergies: a systematic review. BMC Pediatr 2020; 20: 312. 874. Celedon JC, Fuhlbrigge A,"
    },
    {
        "id": "doc_5305",
        "document": "Rifas-Shiman S, et al. Antibiotic use in the first year of life and asthma in early childhood. Clin Exp Allergy 2004; 34: 1011-1016. 875. Cheelo M, Lodge CJ, Dharmage SC, et al. Paracetamol exposure in pregnancy and early childhood and development of childhood asthma: a systematic review and meta-analysis. Arch Dis Child 2015; 100: 81-89. 876. Eyers S, Weatherall M, Jefferies S, et al. Paracetamol in pregnancy and the risk of wheezing in offspring: a systematic review and meta-analysis. Clin Exp"
    },
    {
        "id": "doc_5306",
        "document": "Allergy 2011; 41: 482-489. 877. Flanigan C, Sheikh A, DunnGalvin A, et al. Prenatal maternal psychosocial stress and offspring's asthma and allergic disease: A systematic review and meta-analysis. Clin Exp Allergy 2018; 48: 403-414. 878. Kozyrskyj AL, Mai XM, McGrath P, et al. Continued exposure to maternal distress in early life is associated with an increased risk of childhood asthma. Am J Respir Crit Care Med 2008; 177: 142-147. 879. Xu S, Gilliland FD, Conti DV. Elucidation of causal"
    },
    {
        "id": "doc_5307",
        "document": "direction between asthma and obesity: a bi-directional Mendelian randomization study. Int J Epidemiol 2019. 880. Sun YQ, Brumpton BM, Langhammer A, et al. Adiposity and asthma in adults: a bidirectional Mendelian randomisation analysis of The HUNT Study. Thorax 2020; 75: 202-208. 881. Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? Lancet 2015; 386: 1075-1085. 882. Burgers J, Eccles M. Clinical guidelines as a tool for implementing change in patient care."
    },
    {
        "id": "doc_5308",
        "document": "Oxford: Butterworth- Heinemann; 2005. 883. Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical"
    },
    {
        "id": "doc_5309",
        "document": "guidelines. 1999;\n\n884. The ADAPTE Collaboration. The ADAPTE process: resource toolkit for guideline adaptation. Version 2.0: Guideline International Network; 2009. Available from: https://g-i-n.net/wp-content/uploads/2021/03/ADAPTE-Resource-toolkit- March-2010.pdf.\n\nReferences\n\n243\n\n885. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839-842."
    },
    {
        "id": "doc_5310",
        "document": "886. Boulet LP, FitzGerald JM, Levy ML, et al. A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. Eur Respir J 2012; 39: 1220-1229."
    },
    {
        "id": "doc_5311",
        "document": "887. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997; 157: 408-416. 888. Harrison MB, Legare F, Graham ID, et al. Adapting clinical practice guidelines to local context and assessing barriers to their use. CMAJ 2010; 182: E78-84."
    },
    {
        "id": "doc_5312",
        "document": "889. Partridge MR. Translating research into practice: how are guidelines implemented? Eur Respir J Suppl 2003; 39: 23s-29s.\n\n890. Baiardini I, Braido F, Bonini M, et al. Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol 2009; 9: 228-233."
    },
    {
        "id": "doc_5313",
        "document": "891. Boulet LP, Becker A, Bowie D, et al. Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. Can Respir J 2006; 13 Suppl A: 5-47. 892. Franco R, Santos AC, do Nascimento HF, et al. Cost-effectiveness analysis of a state funded programme for control of severe asthma. BMC Public Health 2007; 7: 82."
    },
    {
        "id": "doc_5314",
        "document": "893. Renzi PM, Ghezzo H, Goulet S, et al. Paper stamp checklist tool enhances asthma guidelines knowledge and implementation by primary care physicians. Can Respir J 2006; 13: 193-197.\n\n894. Nkoy F, Fassl B, Stone B, et al. Improving pediatric asthma care and outcomes across multiple hospitals. Pediatrics 2015; 136: e1602-1610.\n\n895. Cochrane Effective Practice and Organisation of Care (EPOC). Cochrane Effective Practice and Organisation of Care. 2013. Available from: http://epoc.cochrane.org."
    },
    {
        "id": "doc_5315",
        "document": "244\n\nReferences\n\n\\\\\\\\\\TIAT/,/& K/ 40 457N\n\n457N\n\nVisit the GINA website at www.ginasthma.org \u00a9 2023 Global Initiative for Asthma\n\nFarina et al. Italian Journal of Pediatrics (2022) 48:90 https://doi.org/10.1186/s13052-022-01288-5\n\nItalian Journal of Pediatrics\n\nRESEARCH\n\nOpen Access"
    },
    {
        "id": "doc_5316",
        "document": "Alert sign and symptoms for the early diagnosis of pulmonary tuberculosis: analysis of patients followed by a tertiary pediatric hospital\n\n\u00ae Check for updates.\n\nElisa Farina1, Carmen D\u2019Amore2, Laura Lancella3, Elena Boccuzzi4, Marta Luisa Ciofi degli Atti2, Antonino Reale4, Paolo Rossi5, Alberto Villani4, Massimiliano Raponi5 and Umberto Raucci4*"
    },
    {
        "id": "doc_5317",
        "document": "Abstract\n\nBackground: Intercepting earlier suspected TB (Tuberculosis) cases clinically is necessary to reduce TB incidence, so we described signs and symptoms of retrospective cases of pulmonary TB and tried to evaluate which could be early warning signs."
    },
    {
        "id": "doc_5318",
        "document": "Methods: We conducted a retrospective descriptive study of pulmonary TB cases in children in years 2005\u20132017; in years 2018\u20132020 we conducted a cohort prospective study enrolling patients < 18 years accessed to Emergency Department (ED) with signs/symptoms suggestive of pulmonary TB."
    },
    {
        "id": "doc_5319",
        "document": "Results: In the retrospective analysis, 226 patients with pulmonary TB were studied. The most frequently described items were contact history (53.5%) and having parents from countries at risk (60.2%). Cough was referred in 49.5% of patients at onset, fever in 46%; these symptoms were persistent (lasting 10 days) in about 20%. Lymphadenopathy is \u2265 described in 15.9%. The prospective study enrolled 85 patients of whom 14 (16.5%) were confirmed to be TB patients and 71 (83.5%) were non-TB cases."
    },
    {
        "id": "doc_5320",
        "document": "Lymphadenopathy and contact history were the most correlated variables. Fever and cough lasting 10 days were less frequently described in TB cases compared to non-TB patients (p < 0.05)."
    },
    {
        "id": "doc_5321",
        "document": "Conclusions: In low TB endemic countries, pulmonary TB at onset is characterized by different symptoms, i.e. per- sistent fever and cough are less described, while more relevant are contact history and lymphadenopathy. It was not possible to create a score because signs/symptoms usually suggestive of pulmonary TB (considered in the question- naire) were not significant risk factors in our reality, a low TB country.\n\nKeywords: Children, Tuberculosis, Early diagnosis, Emergency"
    },
    {
        "id": "doc_5322",
        "document": "Background\n\nTuberculosis (TB) is one of the top 10 causes of death worldwide [1]. It typically affects lungs (80% are pulmo- nary TB) but can also affect other sites (extrapulmonary\n\n*Correspondence: umberto.raucci@opbg.net\n\n4 Department of Emergency and Clinical Pediatrics, Bambino Ges\u00f9 Children\u2019s Hospital IRCCS, Rome, Italy"
    },
    {
        "id": "doc_5323",
        "document": "TB 15\u201320%). In order to contain epidemic and achieve the END TB strategy (TB elimination), defined by WHO [2] new strategies are needed, such as screen- ing programs, contact tracing [3\u20135], early detection of suspected cases and preventive therapy to reduce dis- ease progression in infected patients (treating latent TB) [6, 7]. Childhood disease is often acquired follow- ing close contact with an infectious adult case, and in 30\u201340% involves household contacts [8, 9]. The risk of"
    },
    {
        "id": "doc_5324",
        "document": "Full list of author information is available at the end of the article\n\nB BMC"
    },
    {
        "id": "doc_5325",
        "document": "\u00a9 The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article\u2019s Creative Commons licence,"
    },
    {
        "id": "doc_5326",
        "document": "unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/)"
    },
    {
        "id": "doc_5327",
        "document": "applies to the data made available in this article, unless otherwise stated in a credit line to the data."
    },
    {
        "id": "doc_5328",
        "document": "Farina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 2 of 8"
    },
    {
        "id": "doc_5329",
        "document": "progression is higher (40\u201350%) in children < 5 years espe- cially in the first 12 months after infection [10, 11], and severe TB disease, including TB meningitis, is highest in infants (< 2 years) and usually occurs within few months of primary infection [9, 12]. Adult risk of progression is lower, only 5% of patients infected develop active disease. Diagnosis of TB in children is often challenging because it\u2019s paucisyntomatic at onset; gold standard in diagno- sis remains culture of bacteria,"
    },
    {
        "id": "doc_5330",
        "document": "but as it can take up to 8 weeks, and considering the paucibacillary nature of childhood lung disease, microbiological confirmation is possible in 35\u201340% of children [13]. In these cases diag- nosis is based on the triad: clinical findings, risk factors and radiographic pattern (Table 1) [14\u201318]."
    },
    {
        "id": "doc_5331",
        "document": "The most frequently reported symptoms in literature are unremitting cough (\u2265 2 weeks duration) and per- sistent fever (> 2\u20133 weeks) [4, 19\u201322]. Considering that most studies have been conducted in high prevalence countries [19, 23\u201326], we analyzed children\u2019s signs/symp- toms, risk factors and anamnestic data of TB at onset in a low prevalence setting. So far several attempts have been made to validate clinical scores for the early diagnosis of pulmonary TB [24, 27\u201329], but none of them have been"
    },
    {
        "id": "doc_5332",
        "document": "internationally validated and in most cases without a control group [30]. The aim of the study was to describe signs and symptoms of retrospective cases of patients with pulmonary TB and to evaluate alerts that could intercept earlier suspected TB cases in emergency setting [31, 32]."
    },
    {
        "id": "doc_5333",
        "document": "Methods\n\nThe study was conducted at the Bambino Ges\u00f9 Pediatric IRCCS in Rome, a tertiary urban pediatric hospital. The study was approved by the Ethics Committee of our Chil- dren\u2019s Hospital according to the Declaration of Helsinki."
    },
    {
        "id": "doc_5334",
        "document": "Retrospective study\n\nThe retrospective study included children \u2264 18 years through the electronic health records with diagnosis of pulmonary TB between 2005\u20132017 years, admitted to Hospital. The extracted data included age, sex, signs and symptoms at onset, risk factors, anamnestic data, diagnostic laboratory and imaging exams. Analyzing lit- erature and our center\u2019s experience we created a ques-\n\npresentation and risk factors, in order to create a clinical score.\n\nProspective study"
    },
    {
        "id": "doc_5335",
        "document": "We analyzed patients conducted in the emergency department (ED) between 2018\u20132020 with symptoms suggestive of pulmonary TB. Children < 18 years of age who arrived in the ED with one or more of the following inclusion criteria were recruited: Fever lasting \u2265 10 days; Cough lasting \u2265 10 days; Idiopathic weight loss in the past 3 months; Positive Mantoux and/or Interferon gamma release assay (IGRA/Quantiferon); Chest X-Ray suggestive for TB; History of contact with TB patient. Once recruited a"
    },
    {
        "id": "doc_5336",
        "document": "questionnaire was administered to par- ents, assessing signs/symptoms and anamnestic data, and a written consent was obtained. Exclusion criteria were represented by chronic lung disease (like cystic fibrosis, patients with tracheostomy), infectious diseases (like Chickenpox, measles) or not giving written consent. Patients were followed up to the diagnostic definition (TB or other diagnosis) by monitoring the data obtained from the electronic health records. Mantoux was read after 48\u201372 h after"
    },
    {
        "id": "doc_5337",
        "document": "injection and considered positive according to national guidelines [20]."
    },
    {
        "id": "doc_5338",
        "document": "Statistical analysis"
    },
    {
        "id": "doc_5339",
        "document": "Patients were characterized according to demographic and clinical characteristics. We compared signs and symptoms of TB patients identified in the retrospec- tive studies with those of the prospective one; moreover, TB-patients and non-TB patients were compared in the prospective study. Results were summarized as numbers and percentages (categorical variables) and as mean and standard deviation (SD)(continuous variables). Categori- cal variables were compared with \u03c72 or Fisher\u2019s 2-tailed exact"
    },
    {
        "id": "doc_5340",
        "document": "test in a contingency table r x c; a Fisher test was used when the value in any of the cells of the contin- gency table was below five. Continuous variables were compared with a Student\u2019s t-test. Unadjusted odds ratios (ORs) and confidence intervals (CIs) were computed through logistic regression modelling. A forward step- wise logistic regression analysis was used to determine the effect of independent risk factors for TB; those vari- ables with p less than 0.20 were included in the multi-"
    },
    {
        "id": "doc_5341",
        "document": "Table 1 Characteristic triad for the diagnosis of tubercolosis\n\n1) Hystory of recent contact with Tubercolosis\n\n2) Positive Mantoux and/or IGRA (Interferon Gamma Release Assay)\n\n3) Signs and symptoms typical of TB and/or. persistent fever, unremitting cough, night sweats, fatigue, weight loss, hemoptysis, chest pain Suggestive radiologic patterns consolidations, pleural effusion, cavitation, miliary pattern, hilar adenopathy with or without airway compression"
    },
    {
        "id": "doc_5342",
        "document": "Farina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 3 of 8\n\nvalue and negative predictive value were calculated for the identified risk factors. The statistical analysis was performed with STATA, statistical software version 13 (StataCorp, College Station, TX, USA).\n\nResults\n\nRetrospective Study\n\nThe retrospective study included 226 pediatric patients with a final diagnosis of pulmonary TB between 2005\u2013 2017. Mean age was about 5.6 years (\u00b1 5.2), most fre-"
    },
    {
        "id": "doc_5343",
        "document": "Parents came from high risk countries in 136 cases (60.2%); contact history was referred in 121 patients (53.5%). Antibiotic therapy has been administered to 40.7% (n = 92) of patients, and 98.9% (n = 91) of them referred no benefit. Patients with positive Mantoux and/ or IGRA before admission were 41.6% (n = 94) and 16.4% (n = 37), respectively; 29 patients (12.8%) were born in high-risk countries and 11 had history of travel to high- risk countries (4.9%). Few patients were immunosup- pressed"
    },
    {
        "id": "doc_5344",
        "document": "or received immunosuppressive therapy (n = 4;"
    },
    {
        "id": "doc_5345",
        "document": "Cough was the most reported symptom at onset in 49.6% (n = 112) of cases; persistent cough last- ing \u2265 10 days was referred in 21.7% (n = 49) of patients (Table 2). Fever occurred in 46% of patients (n = 104) and in 19.4% of patients (n = 44) it lasted \u2265 10 days. Other less frequently reported symptoms were lymphadenopa- thy (n = 36; 15.9%), asthenia (n = 35; 15.5%), weight loss (n = 22; 9.7%), chest pain (n = 16; 7.1%), hemoptysis"
    },
    {
        "id": "doc_5346",
        "document": "The diagnostic tools used in our retrospective patients were IGRA, Mantoux and microbiological tests (culture, bacterioscopic and PCR). The latter were performed by collecting 3 gastric aspirate samples on 3 consecu- tive days. Mantoux and IGRA were positive in 92.9% (n = 210) and 95.6% (n = 216) of cases, respectively; 86 patients (42.2%) had positive results to microbiological cultures, 79 (37.6%) had positive PCR and 40 (18.0%) had positive results to bacterioscopic.\n\nProspective study"
    },
    {
        "id": "doc_5347",
        "document": "The prospective study includes 85 patients includ- ing 14 with TB (16.5%) and 71 non-TB patients (83.5%) (Table 3). Patients with TB were older than non-TB patients (9.6 \u00b1 5.7 versus 5.9 \u00b1 4.5, respectively; p = 0.01); no significant differences between the two groups were observed by sex. Persistent cough lasting \u2265 10 days, is more frequently reported in non-TB patients (67.6% versus 21.4% of TB patients, p = 0.002;). Chest pain was described in 33.3% of TB patients with cough, com- pared to"
    },
    {
        "id": "doc_5348",
        "document": "22.9% of non-TB cases (p = 0.6); hemoptysis is"
    },
    {
        "id": "doc_5349",
        "document": "Table 2 Demographic characteristics, risk factors and reported symptoms at onset in the retrospective population group"
    },
    {
        "id": "doc_5350",
        "document": "VARIABLES N=226 N = % Mean age (years) = standard deviation (SD) 56+\u00a352 5.6 5.2 Sex \u00b1 \u00b1 M 118 522 F 108 478 RISK FACTORS/ANAMNESTIC DATA History of Contact 121 535 Travel in high risk countries Ial 49 Born in high risk country 29 128 Parents origin's from high risk countries 136 60.2 Immunosuppression or immunosuppressive therapy 4 18 Antibiotic therapy 92 407 - With no benefit 91 98.9 Positive Quantiferon (analyzed before hospitalization) 37 164"
    },
    {
        "id": "doc_5351",
        "document": "Positive Mantoux (analyzed before hospitalization) 94 416 SIGNS/SYMPTOMS Cough 112 496 Cough lasting > 10 days 49 217 Fever \u2265 104 46.0 Fever lasting > 10 days 44 194 Lymphadenopathy \u2265 36 159 Asthenia 35 155 Weight loss 22 9.7 Chest pain 16 7.1 Hemoptysis 6 26 Night sweats 4 18 DIAGNOSTICTOOLS Mantoux: positive (+) (=5 mm) ) ( 210 929 QTF+ QTF + \u2265 216 95.6 Culture+ + 86 422 PCR+ + PCR 79 376 Bacterioscopic + + 40 180"
    },
    {
        "id": "doc_5352",
        "document": "QTF Quantiferon, PCR Polymerase Chain Reaction"
    },
    {
        "id": "doc_5353",
        "document": "Fever lasting \u2265 10 days was reported in 40.8% of non- TB patients compared to 7.1% of TB patients (p = 0.02). Lymphadenopathy was most frequently reported in TB patients (n = 6; 42.9%), compared to 15.5% (n = 11) of non-TB cases (p = 0.03). Night sweats were reported in 33.8% (n = 24) of non-TB patients (p = 0.008). Antibi- otic therapy was administered to 69% of non-TB patients (n = 49) and to 21.4% (n = 3) of TB patients (p = 0.002); patients receiving antibiotic therapy without improve- ment"
    },
    {
        "id": "doc_5354",
        "document": "were 77.5% (n = 38) in non-TB patients and 100% (n = 3) in TB patients (p = 0.3). Contact history was reported in 50% of patients with TB and in 7% of non-TB cases (p < 0.001). No statistical differences between the two groups were observed for other anamnestic factors"
    },
    {
        "id": "doc_5355",
        "document": "Farina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 4 of 8\n\nTable 3 Demographic characteristics, risk factors and reported symptoms at onset of the prospective study"
    },
    {
        "id": "doc_5356",
        "document": "Variables in the Prospective study TBcasesN=14 TB cases N = 14 % NonTB casesN=71 = 71 % Pvalue Sex Male 5 357 39 549 02 Female 9 64.3 32 45.1 Age (in years) Mean =+ (SD) 96+\u00a357 9.6 5.7 59+\u00a345 5.9 4.5 001 RISK FACTORS/ANAMNESTIC DATA/SYMPTOMS \u00b1 \u00b1 \u00b1 Fever> 10 days \u2014 7.1 29 408 002 Cough > 10 days \u2265 w 214 48 67.6 0.002 -chest pain \u2265 = 333 n 229 06 -hemoptysis 00 1 21 09 Asthenia WNO 500 43 60.0 05 Weight loss 3 214 14 197 09 Lymphadenopathy O 429 n 155 0.03 Night sweats WO 00 24 338 0.008"
    },
    {
        "id": "doc_5357",
        "document": "History of contact 7 500 5 70 <0001 Travel in high risk countries 1 7.1 7 99 08 Antibiotic therapy W= 3 214 49 69.0 0.002 - no benefit W 100 38 775 03 Born in high risk country 143 5 7.1 04 Immunosuppression or immunosuppres- sive therapy ON 0 00 0 00 -"
    },
    {
        "id": "doc_5358",
        "document": "TB tubercolosis, SD Standard Deviation\n\nas: born in high risk countries (14.3% TB cases versus 7.1% non-TB cases, p = 0.4), travel in high risk coun- tries (7.1% TB cases versus 9.9% non-TB cases, p = 0.8), fatigue/asthenia (50% TB cases versus 60% non-TB cases, p = 0.5) and weight loss (21.4% TB cases versus 19.7% non-TB cases, p = 0.9). None of the included patients was immunosuppressed or received immunosuppressive therapy."
    },
    {
        "id": "doc_5359",
        "document": "Persistent cough lasting \u2265 10 days was present in 21.7% of TB patients analyzed retrospectively and in 21.4% of TB cases in the prospective study; persistent fever\n\nlasting \u2265 10 days was present in 19.0% of retrospective\n\nThe multivariate analysis identified history of contact and lymphadenopathy as risk factors for pulmonary TB (Table 5)."
    },
    {
        "id": "doc_5360",
        "document": "Discussion\n\nTB diagnosis in children is often delayed because clini- cal presentation at onset is non-specific and there isn\u2019t always a history of contact/exposure to a TB case. Fur- thermore, diagnostic methods available often don\u2019t\n\nTable 4 Duration of cough and fever, comparison between retrospective and prospective studies Retrospective study"
    },
    {
        "id": "doc_5361",
        "document": "Cough Cases in which duration Mean duration in days Min Max Prevalence of cases is specified (range min\u2013max) with symptom lasting \u2265 10 days Days 84 20 (1\u2013171) 1 171 49 (21.7%) Fever Days 92 12 (1\u201390) 1 90 43 (19.0%) Prospective study Variable N\u00b0 patients TB cases 14 Cases with symtpom lasting \u2265 10 days With Cough 3 (21.4%) With Fever 1 (7.1%)\n\nTB tubercolosis\n\nFarina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 5 of 8"
    },
    {
        "id": "doc_5362",
        "document": "Table 5 Risk factors for pulmonary tubercolosis: multivariate analysis\n\nVariables prospective Crude OR (IC 95%) Adjusted a OR (IC95%) study Fever 10 days \u2265 Cough 10 days \u2265 Lymphoadenopathy 0.11 (0.01\u20130.9) 0.13 (0.03\u20130.5) 4.1 (1.2\u201314.1) 0.03 (0.001\u20131.0) 0.05 (0.003\u20130.7) 28.6 (2.1\u2013391.2) History of contact 13.2 (3.3\u201352.8) 19.8 (1.4\u2013287.0) Weight loss 1.1 (0.3\u20134.5) 6.9 (0.4\u2013117.5)\n\na adjusted for fever \u2265 contact and weight loss 10 days, cough \u2265 10 days, lymphadenopathy, history of"
    },
    {
        "id": "doc_5363",
        "document": "give immediate confirmation [33]. The two cohorts analyzed (retrospective and prospective) allowed us to extrapolate signs/symptoms at onset and anamnes- tic data (including risk factors), in order to evaluate whether there\u2019s a different clinical presentation and/or different risk factors in low a prevalence country com- pared to what is described in literature. In the prospec- tive study a questionnaire was administered to parents, assessing clinical symptoms and anamnestic data. So far most"
    },
    {
        "id": "doc_5364",
        "document": "studies have been conducted in high TB inci- dence countries [19, 23\u201326, 34]. In these countries, the correlation between respiratory symptoms and TB may be different than in low endemic countries. In addition, risk factors may also have a different weight, for exam- ple contact with a TB case may be a less discriminating factor as frequently present in anamnesis, meanwhile in low-endemic countries it assumes a greater weight."
    },
    {
        "id": "doc_5365",
        "document": "Contact is one of the most significantly correlated risk factor, described in 53.5% of patients with TB in the retrospective study and in 50% of cases in the pro- spective study, while only 7% among non-TB patients (prospective study). The OR (adjusted 19.8) confirms the correlation between contact and TB, as in other studies where contact is a frequently described risk fac- tor (53.2\u201365.2% of patients) [20, 29, 35]. Therefore this data will certainly have a relevant weight in a clinical score."
    },
    {
        "id": "doc_5366",
        "document": "Unfortunately, a child is often just a sentinel case"
    },
    {
        "id": "doc_5367",
        "document": "Another important risk factor is having parents from countries at risk, as highlighted in our retrospective series in 60.2% of cases and confirmed in other stud- ies [20, 37, 38]. In the prospective study parents didn\u2019t declare on the questionnaire their citizenship/native country, so we don\u2019t have this data (question to add to\n\nBeing born in countries at risk is infrequent in our cohorts (12.8% of retrospective cases, 14.3% of pro- spective). This obviously depends on the country in"
    },
    {
        "id": "doc_5368",
        "document": "higher percentage is described (31% of children with"
    },
    {
        "id": "doc_5369",
        "document": "Another variable investigated is use of antibiotic ther- apy and whether with or no benefit. In our study almost all of our TB patients treated previously with first-line antibiotics had no benefit: in the retrospective cohort 91/92 (98.9%) referred no benefit; in the prospective study 3/3 (100%). Comparing the prospective TB and non-TB cases (Table 4), antibiotic therapy was mostly prescribed in non-TB cases (69% vs 21.4%) and this prob- ably correlates with higher frequency in this group of"
    },
    {
        "id": "doc_5370",
        "document": "fever and persistent cough, and consequently prescrip- tion of first-line therapy. In the non-TB group 77.5% of children referred poor response to antibiotic therapy, not so striking as in the TB patients, but expected because if they improved they wouldn\u2019t have come to the ED. To date various studies identified poor response to first-line therapy as an element of suspicion [4, 20, 28, 39, 40], however a large-scale comparison between positive and negative cases is not reported, but necessary to"
    },
    {
        "id": "doc_5371",
        "document": "confirm"
    },
    {
        "id": "doc_5372",
        "document": "Immunosuppression or the intake of immunosuppres- sive drugs is not significant in our cohorts, in which there"
    },
    {
        "id": "doc_5373",
        "document": "Focusing on symptoms at onset, in low income coun- tries patients often present to healthcare facilities in advanced stages of the disease [41], while in high income countries physicians are questioned almost immediately, so diagnosis is often made in a subclinical phase, before symptoms becoming persistent. A symptom frequently reported in literature as suggestive and associated with TB is cough, considered of strong suspicion especially if lasting > 2 weeks(15\u201317) and described in 44\u201352% of"
    },
    {
        "id": "doc_5374",
        "document": "chil- dren at onset [42\u201344]. Unlike what is described in inter- national literature, in our retrospective population 49.6% of cases referred cough, but persistent only in 21.7%, and the same result emerged among TB-cases of the prospec- tive study with persistent cough in 21.4% of patients, sim- ilarly to previous Italian studies (28.7%) [20]."
    },
    {
        "id": "doc_5375",
        "document": "Another symptom referred is fever which occurs in 46% of retrospective cases, but lasting \u2265 10 days in only 19%, while there are few cases with persistent fever at onset in the prospective cohort (7.1%). These data differs from the 35\u201347% frequency described in literature, both in italian studies/low prevalence countries [20, 29], and internationally [22, 45]. Comparing duration of cough and fever in the two cohorts (retrospective and prospec- tive, Tables 3, 4 and 5), although with different"
    },
    {
        "id": "doc_5376",
        "document": "propor- tions of patients analyzed, it seems that persistent cough and fever (lasting \u2265 10 days) is not so strongly suggestive of TB diagnosis in our Italian reality. The prospective study, comparing cases with and without TB, allowed us to evaluate the correlation between fever and persistent"
    },
    {
        "id": "doc_5377",
        "document": "Farina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 6 of 8"
    },
    {
        "id": "doc_5378",
        "document": "cough with the diagnosis of TB, and it seems to confirm this poor correlation. In the multivariate analysis the OR with a value of 0.03 for fever \u2265 10 days, and 0.05 for cough \u2265 10 days shows an almost protective effect for TB, so they seem more related to other diagnoses. These find- ings can have 2 different explanations: on one hand, diag- nosis is often made in a subclinical phase, and this allows treatment in early stages of the disease; on the other hand, the low prevalence determines a"
    },
    {
        "id": "doc_5379",
        "document": "lower probability that a child with a persistent cough and fever will have"
    },
    {
        "id": "doc_5380",
        "document": "Another variable analyzed is lymphadenopathy, which is not always a symptom that lead to suspect TB, but if persistent despite first-line therapies and isolated symp- tom, needs to exclude Non-Tuberculous Mycobacterium infection. In clinical scores proposed for the diagnosis of TB lymphadenopathy is usually included, and fre- quency at onset is described (19.8\u201323.8%) [29, 46]. In our retrospective analysis 15.9% of cases had lymphnode involvement at onset, while in the prospective cohort"
    },
    {
        "id": "doc_5381",
        "document": "lymphadenopathy was referred in 42.9% of TB cases compared to 15.5% of non-TB, with an OR of 28.6 (95%CI 2.1\u2013391.2), so probably it\u2019s a symptom that could have a greater weight in our population and is likely underesti- mated. The very large CI95% is related to the low sample size and less accurate estimate."
    },
    {
        "id": "doc_5382",
        "document": "Weight loss, which international studies reported in 22.6\u201327% of cases [29, 42], was reported in 9.7% of patients in the retrospective analysis, similarly to what is described in low prevalence countries like Italy (9.9% of cases) [20]. The prospective analysis, on the other hand, highlights a higher frequency (21.4% in TB cases, 19.7% non-TB cases). However it\u2019s not a discriminating factor for diagnosis, therefore in our screening process it won\u2019t have a significant weight."
    },
    {
        "id": "doc_5383",
        "document": "Another symptom usually associated with TB is asthenia, in some studies in 36.6% of patients [29, 41], while from our retrospective cohort it seems less fre- quent(15.5% of cases). In the prospective study instead it\u2019s equally described both in patients with (50%) and without (60%) TB, therefore it doesn\u2019t discriminate posi- tive patients from negative ones. This higher frequency may be related to the questionnaire submitted to parents, which points out a less alarming symptom compared to others"
    },
    {
        "id": "doc_5384",
        "document": "(such as fever, cough, lymphadenopathy)."
    },
    {
        "id": "doc_5385",
        "document": "Chest pain is another symptom typically associated with pleuritic involvement [17], mostly described in older children, as the ability to express this symptom is differ- ent [19]. Our retrospective case study with 7.1% of cases confirms the incidence described in the national studies (5%) [20]. In the prospective study 1/14 (7%) TB patients presented chest pain at onset, 11/71 (15%) non TB"
    },
    {
        "id": "doc_5386",
        "document": "questionnaire it was associated with cough symptom, but as these symptoms aren\u2019t always related, it will be better to separate them (proposed questionnaire in Additional"
    },
    {
        "id": "doc_5387",
        "document": "Hemoptysis and night sweats are rarely reported symp- toms in our retrospective cohort (2.6% and 1.8% of cases respectively), similarly to other italian studies (haemop- tysis 2.7%, night sweats 1% cases) [20] and international ones [10, 47]. In the prospective cohort night sweats are never described in TB cases, and described in 33.8% of non-TB cases, probably linked to fever symptom. There- fore, these variables are not clinically relevant for early"
    },
    {
        "id": "doc_5388",
        "document": "We finally analyzed diagnostic tests performed, con- sidering retrospective data (larger sample with 226 patients). Both Mantoux and IGRA were positive in most patients (92.9% and 95.6% respectively), while only 42.2% were culture positive. Although culture is gold stand- ard for active TB diagnosis, it\u2019s lack of positivity must not delay the diagnostic-therapeutic process, consider- ing children\u2019s higher risk of progression to disease after infection [7, 8, 29, 48\u201351]. Low sensitivity and"
    },
    {
        "id": "doc_5389",
        "document": "specific- ity of microbiological tests is related to the paucibacillary nature of pediatric TB, with only 20\u201350% of pulmonary TB cases being culture positive [52]. Bacterioscopic test was positive only in 18% of cases, compatible with it\u2019s low described sensitivity (60%)(45), while PCR was positive in 37.6% of our patients, similarly to other studies reports (30.4\u201332%) [20, 35]."
    },
    {
        "id": "doc_5390",
        "document": "Conclusion"
    },
    {
        "id": "doc_5391",
        "document": "Our study highlighted that in our country, at low TB prevalence, pulmonary TB has a different clinical pattern. Persistent cough and fever are less frequently reported in our patients, while significant risk factors pointed out are contact history with TB case and lymphadenopathy. Another element of suspicion, although not statistically significant in our study because of small sample size, is poor response to antibiotic therapy in TB patients. Anamnestic data like child\u2019s and parents\u2019 origins"
    },
    {
        "id": "doc_5392",
        "document": "are also crucial. In order to validate a clinical score for pulmonary TB in a low prevalence country like Italy, it\u2019s necessary to review risk factors that must guide the diagnostic- therapeutic workup. In our population with low HIV and TB prevalence, the most correct inclusion criteria could be the following: Fever lasting \u2265 10 days; Cough last- ing \u2265 10 days; Poor response to antibiotic therapy; Lym- phadenopathy; Mantoux and/or IGRA positive; Chest X-ray suspected for TB; History of contact"
    },
    {
        "id": "doc_5393",
        "document": "with TB case."
    },
    {
        "id": "doc_5394",
        "document": "It\u2019s necessary to increase sample involving more Centers in order to validate a clinical score that allows a promptly diagnosis, limiting the number of diagnos-\n\nFarina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 7 of 8\n\nanalysis, its feasibility emerged, albeit with some varia- tions both in terms of the inclusion criteria, and on the"
    },
    {
        "id": "doc_5395",
        "document": "Finally, only the comparison between cases with and without TB on a larger sample will be able to confirm or highlight the red flags that must lead us to suspect TB in order to avoid unnecessary risks of interpersonal transmission, particularly in overcrowded places like\n\nAbbreviations\n\nED: Emergency Department; IGRA : Interferon-gamma release assay; IRCCS: Isti- tuto di Ricovero e Cura a Carattere Scientifico (Scientific Institute for Research, Hospitalization and Healthcare); TB: Tuberculosis."
    },
    {
        "id": "doc_5396",
        "document": "Supplementary Information\n\nThe online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13052- 022- 01288-5.\n\nAdditional file 1: Anamnestic questionnaire proposed in our study.\n\n.\n\nAcknowledgements\n\nNot applicable\n\nAuthors\u2019 contributions"
    },
    {
        "id": "doc_5397",
        "document": "EF and UR conceptualized and designed the study, coordinated and super- vised data collection, interpreted data, drafted the initial manuscript, provided critical review and revision of the manuscript, and wrote the final manuscript; CDA performed statistical analysis, interpreted data, contributed to concep- tualizing the study and participated in the design of the study, drafted with EF and UR the initial manuscript, reviewed and revised the initial manuscript; LL and EB contributed to"
    },
    {
        "id": "doc_5398",
        "document": "conceptualizing the study and participated in the design of the study, collected the data, reviewed and revised the initial manu- script; MLCA, AR, PR, AV, and MR contributed to conceptualizing the study, provided study supervision, reviewed and revised the initial manuscript. All authors read and approved the final manuscript."
    },
    {
        "id": "doc_5399",
        "document": "Funding\n\nNo external funding for this manuscript was received. All phases of this study were supported by Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy.\n\nAvailability of data and materials\n\nThe datasets generated and analysed during the current study are not publicly available due privacy protection but are available from the corresponding author on reasonable request and subject to the permission being obtained from Ospedale Pediatrico Bambino Ges\u00f9, IRCCS, Rome.\n\nDeclarations"
    },
    {
        "id": "doc_5400",
        "document": "Ethics approval and consent to participate"
    },
    {
        "id": "doc_5401",
        "document": "The study was approved by the institutional ethics committee of the Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy. All methods were carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. In the prospective study a written informed consent was obtained from all partici- pants or from a parent and/or legal guardian for participants under 16. In the retrospective study patients accessing"
    },
    {
        "id": "doc_5402",
        "document": "in the Emergency Department sign their consent to the processing of personal data also for scientific purposes."
    },
    {
        "id": "doc_5403",
        "document": "Consent for publication\n\nNot applicable.\n\nCompeting interests\n\nThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n\nAuthor details"
    },
    {
        "id": "doc_5404",
        "document": "1 Unit of Internal Medicine, Celio Military Hospital, Rome, Italy. 2 Clinical Path- ways and Epidemiology Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy. 3 Division of Immunology and Infectious Diseases, Department (DPUO), University-Hospital Pediatric, Bambino Ges\u00f9 Children\u2019s Hospital, IRCSS, Rome, Italy. 4 Department of Emergency and Clinical Pediatrics, Bambino Ges\u00f9 Chil- dren\u2019s Hospital IRCCS, Rome, Italy. 5 Medical Direction, Bambino Ges\u00f9 Children\u2019s Hospital, IRCSS, Rome, Italy."
    },
    {
        "id": "doc_5405",
        "document": "Received: 24 February 2022 Accepted: 27 May 2022\n\nReferences\n\n1. WHO. Global Tubercolosis Report. 2020. [WHO web site] https:// www. who. int/ publi catio ns/i/ item/ 97892 40013 131. Accessed 2021 22 October.\n\n2. WHO Implementing the End TB Strategy: The essentials. 2015. [WHO web site] https:// www. who. int/ tb/ publi catio ns/ 2015/ end_ tb_ essen tial. pdf. Accessed 2021 22 October."
    },
    {
        "id": "doc_5406",
        "document": "3. D Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. Lancet Glob Health. 2018;6(12):e1329-e1338. http://doi.org/https:// doi. org/ 10. 1016/ S2214- 109X(18) 30401-7."
    },
    {
        "id": "doc_5407",
        "document": "4. Vessi\u00e8re A, Font H, Gabillard D, Adonis-Koffi L, Borand L, Chabala C, et al. Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial. BMC Pediatr. 2021;21(1):136. https:// doi. org/ 10. 1186/ s12887- 021- 02576-5."
    },
    {
        "id": "doc_5408",
        "document": "5. Sayedi SM, Seddiq MK, Rashidi MK, Qader G, Ikram N, Melese M, et al. Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan. PLoS ONE. 2020;15(10): e0240031. https:// doi. org/ 10. 1371/ journ al. pone. 02400 31.\n\nFox GJ, Dodd PJ, Marais BJ. Household contact investigation to improve tuberculosis control. Lancet Infect Dis. 2019;19:235\u20137. https:// doi. org/ 10. 1016/ S1473- 3099(19) 30061-1."
    },
    {
        "id": "doc_5409",
        "document": "7. Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med. 2021;385(24):2271\u201380.\n\nSchaaf HS, Michaelis IA, Richardson M, Booysen CN, Gie RP, Warren R, et al. Adult-to-child transmission of tuberculosis: household or community contact?. Int J Tuberc Lung Dis. 2003;7:426\u201331."
    },
    {
        "id": "doc_5410",
        "document": "9. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:392\u2013402.\n\n10. Cruz AT, Starke JR. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev. 2007;8(2):107\u201317. https:// doi. org/ 10. 1016/j. prrv. 2007. 04. 008."
    },
    {
        "id": "doc_5411",
        "document": "11. Chan PC, Shinn-Forng Peng S, Chiou MY, Ling DL, Chang LY, et al. Risk for tuberculosis in child contacts. Development and validation of a predic- tive score. Am J Respir Crit Care Med. 2014;189(2):203\u201313. http://doi. org/https:// doi. org/ 10. 1164/ rccm. 201305- 0863OC.\n\n12. Nolt D, Starke JR. Tuberculosis Infection in Children and Adolescents: Test- ing and Treatment. Pediatrics. 2021;148(6): e2021054663. https:// doi. org/ 10. 1542/ peds. 2021- 054663."
    },
    {
        "id": "doc_5412",
        "document": "13. Tuberculosis in: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. American Academy of Pediatrics 31st; ed.; 2018: pag 829- 53.\n\n14. Lighter J, Rigaud M. Diagnosing childhood tuberculosis: traditional and innovative modalities. Curr Probl Pediatr Adolesc Health Care. 2009;39:61\u201388. https:// doi. org/ 10. 1016/j. cppeds. 2008. 12. 003.\n\nFarina et al. Italian Journal of Pediatrics (2022) 48:90\n\nPage 8 of 8"
    },
    {
        "id": "doc_5413",
        "document": "15. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099\u2013104. https:// doi. org/ 10. 1016/ s0140- 6736(00) 02742-2.\n\n16. Mandalakas AM, Starke JR. Current concepts of childhood tuberculosis. Semin Pediatr Infect Dis. 2005;16:93\u2013104. https:// doi. org/ 10. 1053/j. spid. 2005. 01. 001.\n\n17. Starke JR. New concepts in childhood tuberculosis. Curr Opin Pediatr. 2007;19:306\u201313. https:// doi. org/ 10. 1097/ MOP. 0b013 e3281 4b164a."
    },
    {
        "id": "doc_5414",
        "document": "18. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis. 2003;3:624\u201332. https:// doi. org/ 10. 1016/ s1473- 3099(03) 00771-0.\n\n19. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics. 2006;118(5):e1350\u20139. https:// doi. org/ 10. 1542/ peds. 2006- 0519."
    },
    {
        "id": "doc_5415",
        "document": "20. Chiappini E, Lo Vecchio A, Garazzino S, Marseglia GL, Bernardi F, Castagnola E, et al. Italian Pediatric TB Study Group. Recommenda- tions for the diagnosis of pediatric tuberculosis. Eur J Clin Microbiol Infect Dis. 2016;35(1):1\u201318. http://doi.org/https:// doi. org/ 10. 1007/ s10096- 015- 2507-6"
    },
    {
        "id": "doc_5416",
        "document": "21. Wong KS, Huang YC, Lai SH, Chiu CY, Huang YH, Lin TY. Validity of symp- toms and radiographic features in predicting positive AFB smears in adolescents with tuberculosis. Int J Tuberc Lung Dis. 2010;14(2):155\u20139."
    },
    {
        "id": "doc_5417",
        "document": "22. Marais BJ, Obihara CC, Gie RP, Schaaf HS, Hesseling AC, Lombard C, et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. Arch Dis Child. 2005;90(11):1166\u201370. https:// doi. org/ 10. 1136/ adc. 2004. 060640."
    },
    {
        "id": "doc_5418",
        "document": "23. English RG, Bachmann MO, Bateman ED, Zwarenstein MF, Fairall LR, Bheekie A, et al. Diagnostic accuracy of an integrated respiratory guide- line in identifying patients with respiratory symptoms requiring screen- ing for pulmonary tuberculosis: a cross-sectional study. BMC Pulm Med. 2006;25(6):22. https:// doi. org/ 10. 1186/ 1471- 2466-6- 22."
    },
    {
        "id": "doc_5419",
        "document": "24. Egere U, Togun T, Sillah A, Mendy F, Otu J, Hoelscher M, et al. Identifying children with tuberculosis among household contacts in The Gambia. Int J Tuberc Lung Dis. 2017;21(1):46\u201352. https:// doi. org/ 10. 5588/ ijtld. 16. 0289.\n\n25. Jain SK, Ordonez A, Kinikar A, Gupte N, Thakar M, Mave V, et al. Pediatric tuberculosis in young children in India: a prospective study. Biomed Res Int. 2013;2013: 783698. https:// doi. org/ 10. 1155/ 2013/ 783698."
    },
    {
        "id": "doc_5420",
        "document": "26. Osborne CM. The challenge of diagnosing childhood tuberculosis in a developing country. Arch Dis Child. 1995;72(4):369\u201374. https:// doi. org/ 10. 1136/ adc. 72.4. 369.\n\n27. Bonnet M, Kyakwera C, Kyomugasho N, Atwine D, Mugabe F, Nansumba M, et al. Prospective cohort study of the feasibility and yield of household child tuberculosis contact screening in Uganda. Int J Tuberc Lung Dis. 2017;21(8):862\u20138. https:// doi. org/ 10. 5588/ ijtld. 16. 0889."
    },
    {
        "id": "doc_5421",
        "document": "28. Graham SM. The use of diagnostic systems for tuberculosis in chil- dren. Indian J Pediatr. 2011;78:334\u20139. https:// doi. org/ 10. 1007/ s12098- 010- 0307-7.\n\n29. Fourie PB, Becker PJ, Festenstein F, Migliori GB, Alcaide J, Antunes M, et al. Procedures for developing a simple scoring method based on unsophis- ticated criteria for screening children for tuberculosis. Int J Tuberc Lung Dis. 1998;2:116\u201323."
    },
    {
        "id": "doc_5422",
        "document": "30. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis. 2002;6:1038\u201345.\n\n31. Migliori GB, Borghesi A, Rossanigo P, Adriko C, Neri M, Santini S, et al. Proposal of an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. Tuber Lung Dis. 1992;73(3):145\u20139. https:// doi. org/ 10. 1016/ 0962- 8479(92) 90148-D."
    },
    {
        "id": "doc_5423",
        "document": "32. Roya-Pabon CL, Perez-Velez CM. Tuberculosis exposure, infection and dis- ease in children: a systematic diagnostic approach. Pneumonia (Nathan). 2016;8:23. https:// doi. org/ 10. 1186/ s41479- 016- 0023-9.\n\n33. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet. 2016;387:(10024):1211\u201326.1211\u201326, http://doi.org/https:// doi. org/ 10. 1016/ S0140- 6736(15) 00151-8."
    },
    {
        "id": "doc_5424",
        "document": "34. Kruk A, Gie RP, Schaaf HS, Marais BJ. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited set- tings. Pediatrics. 2008;121(6):e1646\u201352. https:// doi. org/ 10. 1542/ peds. 2007- 3138.\n\n35. Romano A, Di Carlo P, Abbagnato L, Salsa L, Mazzola A, Maggio MC, et al. Pulmonary tuberculosis in Italian children by age at presentation. Minerva Pediatr. 2004;56:189\u201395."
    },
    {
        "id": "doc_5425",
        "document": "36. Ho J, Fox GJ, Marais BJ. Passive case finding for tuberculosis is not enough. Int J Mycobacteriol. 2016;5(4):374\u20138. https:// doi. org/ 10. 1016/j. ijmyco. 2016. 09. 023.\n\n37. Froehlich H, Ackerson LM, Morozumi PA; Pediatric Tuberculosis Study Group of Kaiser Permanente, Northern California. Targeted testing of children for tuberculosis: validation of a risk assessment questionnaire. Pediatrics. 2001;107(4):E54. http://doi.org/https:// doi. org/ 10. 1542/ peds. 107.4. e54."
    },
    {
        "id": "doc_5426",
        "document": "38. Winston CA, Menzies HJ. Pediatric and adolescent tuberculosis in the United States, 2008\u20132010. Pediatrics. 2012;130(6):e1425\u201332. https:// doi. org/ 10. 1542/ peds. 2012- 1057.\n\n39. Donald PR. Childhood tuberculosis. Curr Opin Pulm Med. 2000;6(3):187\u2013 92. https:// doi. org/ 10. 1097/ 00063 198- 20000 5000- 00004."
    },
    {
        "id": "doc_5427",
        "document": "40. Weismuller MM, Graham SM, Claessens NJ, Meijnen S, Salaniponi FM, Harries AD. Diagnosis of childhood tuberculosis in Malawi: an audit of hospital practice. Int J Tuberc Lung Dis. 2002;6:432\u20138.\n\n41. Marais BJ. Childhood tuberculosis: epidemiology and natural history of disease. Indian J Pediatr. 2011;78:321\u20137. https:// doi. org/ 10. 1007/ s12098- 010- 0353-1."
    },
    {
        "id": "doc_5428",
        "document": "42. Marais BJ, Gie RP, Obihara CC, Hesseling AC, Schaaf HS, Beyers N. Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis. Arch Dis Child. 2005;90(11):1162\u20135. https:// doi. org/ 10. 1136/ adc. 2004. 070797."
    },
    {
        "id": "doc_5429",
        "document": "43. Oberhelman RA, Soto-Castellares G, Gilman RH, Caviedes L, Castillo ME, Kolevic L, et al. Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study. Lancet Infect Dis. 2010;10(9):612\u201320. https:// doi. org/ 10. 1016/ S1473- 3099(10) 70141-9."
    },
    {
        "id": "doc_5430",
        "document": "44. Triasih R, Robertson CF, Duke T, Graham SM. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis. 2015;60(1):12\u20138. https:// doi. org/ 10. 1093/ cid/ ciu748."
    },
    {
        "id": "doc_5431",
        "document": "45. Frigati L, Maskew M, Workman L, Munro J, Andronikou S, Nicol MP, et al. Clinical Predictors of Culture-confirmed Pulmonary Tuberculosis in Chil- dren in a High Tuberculosis and HIV Prevalence Area. Pediatr Infect Dis J. 2015;34(9):e206\u201310. https:// doi. org/ 10. 1097/ INF. 00000 00000 000792.\n\n46. Khatami A, Britton PN, Marais BJ. Management of Children with Tuber- culosis. Clin Chest Med. 2019;40:797\u2013810. https:// doi. org/ 10. 1016/j. ccm. 2019. 08. 003."
    },
    {
        "id": "doc_5432",
        "document": "47. Lighter J, Rigaud M. Diagnosing childhood tuberculosis: traditional and innovative modalities. Curr Probl Pediatr Adolesc Health Care. 2009;39(3):61\u201388. https:// doi. org/ 10. 1016/j. cppeds. 2008. 12. 003.\n\n48. Piccini P, Chiappini E, Tortoli E, de Martino M, Galli L. Clinical peculiarities of tuberculosis. BMC Infect Dis. 2014;14 Suppl 1(Suppl 1):S4. http://doi. org/https:// doi. org/ 10. 1186/ 1471- 2334- 14- S1- S4."
    },
    {
        "id": "doc_5433",
        "document": "49. Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S, et al. Accuracy of Xpert Mtb/Rif Ultra for the Diagnosis of Pulmonary Tubercu- losis in Children. Pediatr Infect Dis J. 2018;37(10):e261\u20133. https:// doi. org/ 10. 1097/ INF. 00000 00000 001960.\n\n50. Thomas TA. Tuberculosis in Children. Pediatr Clin North Am. 2017;64:893\u2013 909. https:// doi. org/ 10. 1016/j. pcl. 2017. 03. 010."
    },
    {
        "id": "doc_5434",
        "document": "51. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med. 2012;367:348\u201361. https:// doi. org/ 10. 1056/ NEJMr a1008 049.\n\n52. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus state- ment. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Pro- ject. JAMA. 1999;282(7):677\u201386. http://doi.org/https:// doi. org/ 10. 1001/ jama. 282.7. 677."
    },
    {
        "id": "doc_5435",
        "document": "Publisher\u2019s Note\n\nSpringer Nature remains neutral with regard to jurisdictional claims in pub- lished maps and institutional affiliations.\n\n\u00a3207 S2UII3PIND (21Ul epuebn\n\nsasesas|g A103e1ds oy 1\u00a7 WALAVHD\n\n5\n\nRespiratory Diseases\n\n5.1 NON-INFECTIOUS RESPIRATORY DISEASES\n\n5.1.1"
    },
    {
        "id": "doc_5436",
        "document": "ICD10 CODE: J45\n\nA chronic inflammatory disease of the airways which leads to muscle spasm, mucus plugging and oedema. It results in recurrent wheezing, cough, breathlessness and chest tightness.\n\nAcute attacks may be precipitated by upper respiratory tract infections (e.g., flu) and exposure to irritant substances (e.g. dust, exercise, and cold)."
    },
    {
        "id": "doc_5437",
        "document": "Causes\n\n~ Not known but associated with allergies, inherited and en- vironmental factors\n\nClinical features\n\n~ No fever (if fever present, refer to pneumonia)\n\n~ Difficulty in breathing (usually recurrent attacks) with chest tightness, with or without use of accessory muscles. Pa- tients may not appear very distressed despite a severe at- tack\n\n~ Wheezing, rhonchi\n\n~ Cough \u2013 usually dry, may be intermittent, persistent, or acute, especially at night"
    },
    {
        "id": "doc_5438",
        "document": "Severe forms: failure to complete sentences, darkening of lips, oral mucosa and extremities (cyanosis)\n\n328\n\nDifferential diagnosis\n\n~ Heart failure\n\n~ Other causes of chronic cough\n\n~ Bronchiolitis\n\n~ Bronchiectasis\n\nInvestigations\n\nDiagnosis is mainly by clinical features\n\nSpecialised investigations\n\nPeak flow rate: the peak flow rate increases to about 200 ml following administration of a bronchodilator\n\nSpirometry (an increase in Forced Expiratory Volume (FEV) of >12% after bronchodilation)"
    },
    {
        "id": "doc_5439",
        "document": "Sputum: for eosinophilia\n\nIf evidence of bacterial infection\n\nChest X-ray\n\nBlood: complete blood count"
    },
    {
        "id": "doc_5440",
        "document": "General principles of management\n\nThe four essential components of Asthma Management: Patient edu- cation, control of asthma triggers, monitoring for changes in symptoms or lung function, and pharmacologic therapy.\n\n~ Inhalation route is always preferred as it delivers the med- icines directly to the airways; the dose required is smaller, the side-effects are reduced\n\nE.g., nebuliser solutions for acute severe asthma are given\n\nover 5-10 minutes, usually driven by oxygen in hospital"
    },
    {
        "id": "doc_5441",
        "document": "epuebn -\n\n\u00a320Z S3UIIBPIND [ed1Ul])\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n329\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\nIn children having acute attacks, use spacers to administer inhaler puffs\n\n~ Oral route may be used if inhalation is not possible but sys- temic side-effects occur more frequently, onset of action is slower and dose required is higher\n\n~ Parenteral route is used only in very severe cases when nebulisation is not adequate."
    },
    {
        "id": "doc_5442",
        "document": "5.1.1.1 Acute Asthma\n\nAsthma attack is a substantial worsening of asthma symptoms. The severity and duration of attacks are variable and unpredictable. Most attacks are triggered by viral infections. Assess severity using the following table:\n\nNot all features may be present. If the patient says they feel very unwell, listen to them!"
    },
    {
        "id": "doc_5443",
        "document": "Children Below 12 Years Adults And Children >12 Yrs Mild to moderate ~ Able to talk in setenc- ~ Able to talk es ~ Peak flow is 50% of ~ Pulse < 110 bpm predicted or best ~ Respiratory rate < 25 ~ Pulse (beats/minute) Child > 5 years: 125 bpm Child < 5 ~ Peak flow >50% of predicted or best years: 140 bpm ~ SpO2 92% ~ Respiratory rate ~ Child > 5 years: 30 ~ Child < 5 years: 40 ~ SpO2 92%\n\n330"
    },
    {
        "id": "doc_5444",
        "document": "Children Below 12 Years Adults >12 And Children Yrs Severe Cannot complete sentences in one breath or, too breath- less to talk or feed \u00ae Cannot complete sentences in one breath Pulse 2 110 bpm Peak flow < 50% of [ONONO} Respiratory rate >25 predicted or best Pulse Peak flow <50% of (beats/minute) Child > 5 years: > 125 bpm Child <5 > 140 bpm predicted or best SpO2 > 92% Respiratory rate [ONONOXO] Child > 5 years: > 30 Child < 5 years: >40 Use of accessory muscles for breathing (young children)"
    },
    {
        "id": "doc_5445",
        "document": "] SpO2 < 92%"
    },
    {
        "id": "doc_5446",
        "document": "Life threatening (Adults and Children)\n\n~ Silent chest, feeble respiratory effort, cyanosis\n\n~ Hypotension, bradycardia or exhaustion, agitation\n\n(ONOJONOXO]\n\n~ Reduced level of consciousness\n\n~ Peak flow < 33% of predicted or best\n\n~ Arterial oxygen saturation < 92%"
    },
    {
        "id": "doc_5447",
        "document": "Management of asthma attacks\n\nTREATMENT Mild to moderate Treat as an out-patient Reassure patient; place him in a \u00bd sitting position Give salbutamol - Inhaler 2-10 puffs via a large volume spacer LOC HC3 HC3 HC3\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n331\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n332\n\nManagement of asthma attacks"
    },
    {
        "id": "doc_5448",
        "document": "TREATMENT LOC Mild to moderate HC3 - - Q Or 5 mg (2.5 mg in children) nebulisation Repeat every 20-30 min if necessary Prednisolone 50 for HC3 mg (1 mg/kg children) Monitor response for 30-60 min. If not improving or relapse in 3-4 hours HC3 O Refer to higher level HC3 If improving, send home with Q Prednisolone 50 mg (1 mg/kg for children) once a day or 5 days (3 days for children) O Institute or step up chronic treatment (see section 5.1.1.2) = Follow after 1-2 weeks"
    },
    {
        "id": "doc_5449",
        "document": "Q up nstruct the patients on self-treatment and when to HC3 come back O Review in 48 hours = Do not give routine antibiotics unless there are clear signs of bacterial infection Severe HC4 or Patients with severe asthma need to be referred to HC4 hospital after initial treatment HC4 Q Admit patient; place him in a Y% sitting position Q Give high flow oxygen continuously, at least 5 litres/ minute, to maintain the SpO2 > 94% if available"
    },
    {
        "id": "doc_5450",
        "document": "Q - - - Give salbutamol Inhaler 2-10 puffs via a large volume spacer Or 5 mg (2.5 mg in children) nebulisation Repeat every 20-30 min if necessary during the 1st hour HC4"
    },
    {
        "id": "doc_5451",
        "document": "TREATMENT LOC Q Prednisolone 50 mg (1 mg/kg for children) or f Or hy- drocortisone 100 mg (children 4 mg/kg max 100 mg) [V every 6 hours until patient can take oral prednisolone HC4 O Monitor response after nebulisation If response poor Q pratropium bromide nebuliser 500 micrograms (250 microgram in children below 12) every 20- 30 min for he first 2 hours then every 4-6 hours HC4 HC4 O Or aminophylline 250 mg slow IV bolus (child 5 mg/ q) if patient is not taking an oral theophylline"
    },
    {
        "id": "doc_5452",
        "document": "pulse Alternatively, if symptoms have improved, respiration and settling, and peak flow >50% O Step up the usual treatment O And continue with prednisolone to complete 5 days of treatment O Review within 24 hours - - Monitor symptoms and peak flow Arrange self-management plan Life threatening O Arrange for immediate hospital referral and admission HC4 First aid Q Admit patient; place him in a Yz sitting position"
    },
    {
        "id": "doc_5453",
        "document": "Q Give high flow oxygen continuously, at least 5 litres/ minute, to maintain the SpO2 > 94% if available Q - - - Give salbutamol Inhaler 2-10 puffs via a large volume spacer Or 5 mg (2.5 mg in children) nebulisation Repeat every 20 min for 1 hour HC4"
    },
    {
        "id": "doc_5454",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n333\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD"
    },
    {
        "id": "doc_5455",
        "document": "Life threatening Hydrocortisone 100 mg (children 4 mg/kg max 100 mg) IV stat or prednisolone 50 mg (1 mg/kg for children) Ipratropium bromide nebuliser 500 micrograms (250 microgram in children below 12) every 20- 30 minutes for the first 2 hours then every 4-6 hours Monitor response for 15-30 minutes If response is poor Aminophylline 250 mg slow IV bolus (child 5 mg/kg) if patient is not taking an oral theophylline HC4 HC4 HC4"
    },
    {
        "id": "doc_5456",
        "document": "The use of aminophylline and theophylline in the management of asthma exacerbations is discouraged because of their poor efficacy and poor safety profile\n\n334\n\nPRIMARY CARE - Patient presents with\n\nacute or sub-acute asthma exacerbation"
    },
    {
        "id": "doc_5457",
        "document": "ASSESS the PATIENT - Is it asthma? Risk factor for asthma related death? Severity of exacerbation MILD OR MODER- ATE Talks in phrases, sits prefers sitting not lying, not agitated. Respiratory rate increased Accessory muscles not used SEVERE Talks in words, hunched forwards, agitated Respiratory rate >30/min Accessory muscles in use Pulse rate >120 bpm LIFE THREAT- ENING Cyanosis, drowsy, confused or silent chest"
    },
    {
        "id": "doc_5458",
        "document": "WORSENING CONTINUE TREATMENT with salbutamol as needed ASSESS FOR RESPONSE AT 1 HOUR (or earlier) IMPROVING ASSESS FOR DISCHARGE ARRANGE AT DISCHARGE Symptoms improved, not need- ing salbutamol PEF improving, and> 60-80% of personal inhaler or predicted Oxygen saturation >94% room air Reliever: continue as needed Controller: start or step up, check best techniques, adherence Predniso- lone: continue usually for 5 days"
    },
    {
        "id": "doc_5459",
        "document": "FOLLOW UP Reliever: reduce to as needed Controller: continue higher dose for short term (3 months), depending on back- ground to exacerb tion Risk factor: check and correct modifiable risk factors that may have contributed to exacerbation, including inhaler technique and adherence.\n\nAdapted with modification GINA Pocket Guide for Health Professionals 2016\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n335\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsasess|g A103e1dsay 1\u00a7 WALAVHD\n\n336"
    },
    {
        "id": "doc_5460",
        "document": "5.1.1.2 Chronic Asthma\n\nGeneral principles of management\n\n~ Follow a stepped approach\n\nBefore initiating a new drug, check that diagnosis is correct, compli- ance and inhaler technique are correct and eliminate trigger factors for acute exacerbations\n\n~ Start at the step most appropriate to initial severity\n\n~ Rescue course\n\nGive a 3-5 days \u201crescue course\u201d of prednisolone at any step and at any time as required to control acute exacerbations of asthma at a dose of:"
    },
    {
        "id": "doc_5461",
        "document": "Child < 1 year: 1-2 mg/kg daily; 1-5 years: up to 20 mg daily; 5-15 years: Up to 40 mg daily; adult: 40-60 mg daily for up to 3-5 days.\n\n~ Stepping down\n\nReview treatment every 3-6 months\n\nIf control is achieved, stepwise reduction may be possible\n\nIf treatment started recently at Step 4 (or contained corticosteroid tablets, see below), reduction may take place after a short interval; in other patients 1-3 months or longer of stability may be needed before stepwise reduction can be done"
    },
    {
        "id": "doc_5462",
        "document": "TREATMENT LOC STEP 1: Intermittent asthma ~ Intermittent symptoms (< once/week) HC3 ~ Night time symptoms < twice/month ~ Normal physical activity Occasional relief bronchodilator Inhaled short-acting beta2 agonist e.g. salbutamol inhaler 1-2 puffs (100-200 micrograms)"
    },
    {
        "id": "doc_5463",
        "document": "TREATMENT LOC 1-2 puffs (100-200 micrograms) Use with spacer for children Move to Step 2 if use of salbutamol needed more than twice a week or if there are night-time symptoms at least once a week HC3 STEP 2: Mild persistent asthma Symptoms > once/week, but < once/day Night time symptoms > twice/month Symptoms may affect activity HC3 Regular inhaled preventer therapy HC4 Salbutamol inhaler 1-2 puffs prn Plus regular standard-dose inhaled"
    },
    {
        "id": "doc_5464",
        "document": "corticosteroid, e.g. beclomethasone 100-400 micrograms every 12 hours (children: 100-200 micrograms every 12 hours) Assess after 1 month and adjust the dose prn Higher dose may be needed initially to gain control Doubling of the regular dose may be useful to cover exacerbations STEP 3: Moderate persistent asthma HC4 Daily symptoms Symptoms affect activity Night time symptoms > once/week Daily use of salbutamol Children below 5 years: refer to specialist Regular high-dose inhaled corticosteroids"
    },
    {
        "id": "doc_5465",
        "document": "\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD\n\n337\n\n\u00a320Z S3UIIBPIND [ed1Ul]) epuebn\n\nsaseasiq A103e1d50Y 1\u00a7 YILAVHD"
    },
    {
        "id": "doc_5466",
        "document": "TREATMENT LOC Q Salbutamol inhaler 1-2 puffs prn up to 2-3 hourly Usu- ally 4-12 hourly Q PLUS beclomethasone inhaler 400-1000 micrograms every 12 hours (In child 5-12 years: 100-400 micro- grams every 12 hours) In adults, also consider 6-week trial with O Aminophylline 200 mg every 12 hours STEP 4: Severe persistent asthma \u00ae Daily symptoms \u00ae Frequent night time symptoms \u00ae Daily use of salbutamol Refer to specialist clinic especially children <12 RR plus years Regular corticosteroid tablets"
    },
    {
        "id": "doc_5467",
        "document": "O Regular high-dose (as Step 3) Plus regular prednisolone 10-20 mg daily after breakfast \u00ae= Caution Do not give medicines such as morphine, propranolol, other B-blockers to patients with asthma as they worsen or"
    },
    {
        "id": "doc_5468",
        "document": "Do not give medicines such as morphine, propranolol, or other B-blockers to patients with asthma as they worsen respiratory problems\n\nDo not give sedatives to children with asthma, even if they are restless\n\n338\n\nPrevention\n\n~ Avoid precipitating factors e.g.\n\nCigarette smoking"
    },
    {
        "id": "doc_5469",
        "document": "miy =y\n\nAcetylsalicylic acid\n\nKnown allergens such as dust, pollens, animal skins\n\nExposure to cold air\n\n~ Exercise can precipitate asthma in children, advise them to keep an inhaler handy during sports and play\n\n~ Effectively treat respiratory infections\n\nepuebn -\n\n\u00a320Z S3UIIBPIND [ed1Ul])"
    },
    {
        "id": "doc_5470",
        "document": "5.1.2 Chronic Obstructive Pulmonary Disease (COPD) ICD10 CODE: J42-44\n\nChronic obstructive pulmonary disease (COPD) is a lung disease charac- terized by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible.\n\n- The more familiar terms \u2018chronic bronchitis\u2019 and \u2018emphysema\u2019 are no longer used, but are now included within the COPD diagnosis.\n\n- Such a diagnosis should be considered in any patient who"
    },
    {
        "id": "doc_5471",
        "document": "- has symptoms of cough, sputum production, or dyspnea (difficult or labored breathing), and/or a history of exposure to risk factors for the disease.\n\nA COPD exacerbation is an acute worsening of the patient\u2019s respiratory symptoms needing a change in medications."
    },
    {
        "id": "doc_5472",
        "document": "Causes and predisposing factors\n\n~ Tobacco smoking is the commonest cause\n\n~ Indoor air pollution: Biomass fuel smoke (firewood, char- coal and cow dung) exposure in poorly ventilated kitchens\n\n~ Exposure to occupational dust and chemicals (cement, paint, saw dust, fumes) without adequate protection\n\n~ It may frequently follow TB disease (residual symptoms)\n\nsaseasiq A1o3eJ1dsay :\u00a7 YyILdAVHD\n\n339"
    }
]